{"patient_id":"ANODE_551499","record_id":"REC_0000001","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":1.5,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":2,"smoking_pack_years":49,"primary_tumor_size_cm":5.8,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":29.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.823002+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_342890","record_id":"REC_0000002","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":3,"smoking_pack_years":16,"primary_tumor_size_cm":6.0,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.823622+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_108519","record_id":"REC_0000003","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":14.6,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":6.5,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":7.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.824171+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_504292","record_id":"REC_0000004","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":6.0,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":21.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.824584+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_741181","record_id":"REC_0000005","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.5,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.824987+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_120501","record_id":"REC_0000006","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":19,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":51,"sex":"male","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":5.3,"metastatic_sites_count":8,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.825399+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_444069","record_id":"REC_0000007","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":33,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":37,"primary_tumor_size_cm":5.5,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":7.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.825738+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_270361","record_id":"REC_0000008","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":6.4,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":19.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.826078+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_937907","record_id":"REC_0000009","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":26,"primary_tumor_size_cm":5.3,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":57.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.826395+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_827417","record_id":"REC_0000010","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":19,"tmb_mutations_per_mb":4.3,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":66,"primary_tumor_size_cm":7.0,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":19.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.826688+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_152339","record_id":"REC_0000011","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":17.8,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":24,"primary_tumor_size_cm":4.2,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.826969+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_547820","record_id":"REC_0000012","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":62,"primary_tumor_size_cm":3.8,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.827288+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_547326","record_id":"REC_0000013","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":10.5,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":5.2,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.827575+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_275341","record_id":"REC_0000014","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":6.4,"age_at_diagnosis":77,"sex":"male","ecog_performance_status":2,"smoking_pack_years":40,"primary_tumor_size_cm":6.7,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":20.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.828029+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_448140","record_id":"REC_0000015","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":14.5,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":5.5,"metastatic_sites_count":9,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.828441+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_616364","record_id":"REC_0000016","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":5.8,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.828763+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_637469","record_id":"REC_0000017","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":83,"sex":"female","ecog_performance_status":4,"smoking_pack_years":30,"primary_tumor_size_cm":6.2,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.829039+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_690426","record_id":"REC_0000018","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":0,"smoking_pack_years":4,"primary_tumor_size_cm":3.5,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":36.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.829298+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_518751","record_id":"REC_0000019","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":46,"sex":"male","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":5.1,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":21.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.829559+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_966331","record_id":"REC_0000020","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":82,"sex":"male","ecog_performance_status":2,"smoking_pack_years":29,"primary_tumor_size_cm":3.6,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":22.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.829799+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_117747","record_id":"REC_0000021","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":3.6,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.830038+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_815454","record_id":"REC_0000022","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":1.9,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":48,"primary_tumor_size_cm":3.9,"metastatic_sites_count":3,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.830271+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_384426","record_id":"REC_0000023","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":8.4,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":45,"primary_tumor_size_cm":6.1,"metastatic_sites_count":8,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.830509+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_817151","record_id":"REC_0000024","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":16.8,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":3.8,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.830748+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_786237","record_id":"REC_0000025","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":53,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":5.2,"metastatic_sites_count":8,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.830980+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_960232","record_id":"REC_0000026","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None","pd_l1_tps_percent":30,"tmb_mutations_per_mb":4.3,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":4.0,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":46.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.831216+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_626713","record_id":"REC_0000027","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":16,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":4.8,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.831599+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_876716","record_id":"REC_0000028","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":37,"primary_tumor_size_cm":5.0,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.831933+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_318844","record_id":"REC_0000029","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":5.1,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":17.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.832418+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_461611","record_id":"REC_0000030","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":33,"tmb_mutations_per_mb":8.3,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":4.7,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":23.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.832811+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_368013","record_id":"REC_0000031","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":18,"tmb_mutations_per_mb":1.6,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":0,"smoking_pack_years":31,"primary_tumor_size_cm":6.1,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":17.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.833185+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_334354","record_id":"REC_0000032","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":6,"primary_tumor_size_cm":6.1,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.833566+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_300178","record_id":"REC_0000033","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":13.1,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":3.4,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.834006+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_772619","record_id":"REC_0000034","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":6.1,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":18.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.834409+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_351480","record_id":"REC_0000035","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":9.9,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":6.7,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.834844+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_372546","record_id":"REC_0000036","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":8.9,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":1,"primary_tumor_size_cm":6.2,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":6.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.835225+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_511458","record_id":"REC_0000037","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":5.5,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":0,"smoking_pack_years":45,"primary_tumor_size_cm":8.7,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":18.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.835596+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_381340","record_id":"REC_0000038","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":13.5,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":4,"smoking_pack_years":18,"primary_tumor_size_cm":5.8,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.835979+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_615294","record_id":"REC_0000039","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":6.1,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":6.2,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.836423+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_620719","record_id":"REC_0000040","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":15.1,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":6.9,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.837041+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_653341","record_id":"REC_0000041","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":3.0,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":60,"primary_tumor_size_cm":7.0,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":19.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.837472+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_113576","record_id":"REC_0000042","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":9.8,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":6.0,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":18.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.837818+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_934874","record_id":"REC_0000043","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":4.3,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.838142+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_380114","record_id":"REC_0000044","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":18,"tmb_mutations_per_mb":13.1,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":5.4,"metastatic_sites_count":3,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.838462+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_964800","record_id":"REC_0000045","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":4.9,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":17.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.838764+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_676820","record_id":"REC_0000046","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":6.8,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":16.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.839086+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_922889","record_id":"REC_0000047","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":5.5,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":24.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.839414+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_997233","record_id":"REC_0000048","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":19,"tmb_mutations_per_mb":7.4,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":0,"smoking_pack_years":66,"primary_tumor_size_cm":5.3,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.839749+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_808682","record_id":"REC_0000049","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":51,"sex":"male","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":5.7,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":54.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.840164+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_802689","record_id":"REC_0000050","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":2,"smoking_pack_years":30,"primary_tumor_size_cm":2.0,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":24.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.840538+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_865154","record_id":"REC_0000051","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":9.0,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":5.9,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.840870+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_378114","record_id":"REC_0000052","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":16.9,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":4.0,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":17.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.841195+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_927515","record_id":"REC_0000053","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":18.9,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":32,"primary_tumor_size_cm":4.5,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.841595+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_401580","record_id":"REC_0000054","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":31,"tmb_mutations_per_mb":6.1,"age_at_diagnosis":54,"sex":"male","ecog_performance_status":0,"smoking_pack_years":47,"primary_tumor_size_cm":4.5,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":25.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.841856+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_601006","record_id":"REC_0000055","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":17.9,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":2.8,"metastatic_sites_count":3,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.842100+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_747593","record_id":"REC_0000056","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":11.1,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":6.5,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.842346+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_316930","record_id":"REC_0000057","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":6.8,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.842607+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_682060","record_id":"REC_0000058","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":16.5,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":20,"primary_tumor_size_cm":5.8,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.842899+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_532523","record_id":"REC_0000059","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":17.7,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":7.1,"metastatic_sites_count":8,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":6.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.843175+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_949900","record_id":"REC_0000060","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":22,"primary_tumor_size_cm":4.2,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":5.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.843433+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_613503","record_id":"REC_0000061","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":10.3,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":21,"primary_tumor_size_cm":5.4,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.843671+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_683637","record_id":"REC_0000062","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":19,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":6.2,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":17.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.843911+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_402727","record_id":"REC_0000063","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":15.8,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":4.7,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.844195+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_893393","record_id":"REC_0000064","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":17.0,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":21,"primary_tumor_size_cm":5.0,"metastatic_sites_count":8,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.844443+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_496857","record_id":"REC_0000065","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":84,"sex":"male","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":6.3,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.844681+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_671230","record_id":"REC_0000066","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":18,"tmb_mutations_per_mb":5.7,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":26,"primary_tumor_size_cm":6.0,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.845007+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_647840","record_id":"REC_0000067","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":21.4,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":5.2,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":21.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.845248+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_931371","record_id":"REC_0000068","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":13.5,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":3.8,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":22.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.845487+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_559788","record_id":"REC_0000069","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":48,"sex":"male","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":6.1,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.845721+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_170136","record_id":"REC_0000070","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":3.6,"metastatic_sites_count":3,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.845951+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_895721","record_id":"REC_0000071","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":6.9,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":27,"primary_tumor_size_cm":7.0,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":17.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.846184+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_880270","record_id":"REC_0000072","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":8.4,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":5.8,"metastatic_sites_count":3,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.846422+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_665298","record_id":"REC_0000073","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":17.6,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":6.4,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":17.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.846656+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_182781","record_id":"REC_0000074","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":80,"sex":"male","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":6.1,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":47.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.846891+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_908058","record_id":"REC_0000075","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":3.4,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":1,"smoking_pack_years":51,"primary_tumor_size_cm":6.5,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.847125+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_354716","record_id":"REC_0000076","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":24,"primary_tumor_size_cm":7.3,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":18.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.847360+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_121016","record_id":"REC_0000077","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":13.1,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":2,"primary_tumor_size_cm":5.6,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.847594+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_176396","record_id":"REC_0000078","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":47,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":5.8,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.847829+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_738160","record_id":"REC_0000079","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":5.2,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":6.4,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.848309+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_808279","record_id":"REC_0000080","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":16.4,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":5.3,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.848733+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_167673","record_id":"REC_0000081","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":31,"tmb_mutations_per_mb":9.8,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":5.8,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.849110+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_422291","record_id":"REC_0000082","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":5.5,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.1,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.849477+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_210028","record_id":"REC_0000083","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":34,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":79,"sex":"male","ecog_performance_status":2,"smoking_pack_years":21,"primary_tumor_size_cm":7.3,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.849846+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_359788","record_id":"REC_0000084","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":5.3,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":5.2,"metastatic_sites_count":3,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.850168+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_509644","record_id":"REC_0000085","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":6.3,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.850452+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_199692","record_id":"REC_0000086","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":16,"tmb_mutations_per_mb":4.1,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":54,"primary_tumor_size_cm":6.3,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":19.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.850708+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_633195","record_id":"REC_0000087","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":6.9,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.850985+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_590496","record_id":"REC_0000088","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":16.9,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":5.6,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.851277+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_795703","record_id":"REC_0000089","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":15.3,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":6.6,"metastatic_sites_count":3,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":4.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.851568+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_680113","record_id":"REC_0000090","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":17.0,"age_at_diagnosis":75,"sex":"male","ecog_performance_status":2,"smoking_pack_years":22,"primary_tumor_size_cm":5.2,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.851862+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_512814","record_id":"REC_0000091","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":19.0,"age_at_diagnosis":86,"sex":"male","ecog_performance_status":2,"smoking_pack_years":20,"primary_tumor_size_cm":7.1,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.852219+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_641445","record_id":"REC_0000092","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":32,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":6.5,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":5.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.852665+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_940532","record_id":"REC_0000093","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":8.3,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":1,"primary_tumor_size_cm":5.3,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.852970+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_286822","record_id":"REC_0000094","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":15.7,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":25,"primary_tumor_size_cm":6.2,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":19.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.853234+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_400252","record_id":"REC_0000095","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":13.1,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":3.6,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.853480+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_647930","record_id":"REC_0000096","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":19,"tmb_mutations_per_mb":14.1,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":6.1,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.853727+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_307184","record_id":"REC_0000097","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":1,"smoking_pack_years":52,"primary_tumor_size_cm":2.9,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":32.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.853974+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_621594","record_id":"REC_0000098","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":54,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":4.7,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":16.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.854229+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_385761","record_id":"REC_0000099","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":32,"tmb_mutations_per_mb":4.2,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":0,"smoking_pack_years":63,"primary_tumor_size_cm":6.3,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.854485+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_976965","record_id":"REC_0000100","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":17.2,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":4.3,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.854772+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_797360","record_id":"REC_0000101","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":15.6,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":6.2,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.855027+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_741786","record_id":"REC_0000102","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":8.1,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":5.0,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":18.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.855279+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_218660","record_id":"REC_0000103","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":4.8,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":6.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.855523+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_514932","record_id":"REC_0000104","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":4.9,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":47,"primary_tumor_size_cm":4.2,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":55.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.855757+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_952815","record_id":"REC_0000105","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":4.5,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":25,"primary_tumor_size_cm":5.7,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":24.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.856159+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_163962","record_id":"REC_0000106","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":13.5,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":1,"smoking_pack_years":1,"primary_tumor_size_cm":5.0,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":29.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.856452+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_269769","record_id":"REC_0000107","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":6.0,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":6.1,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":43.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.856716+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_427640","record_id":"REC_0000108","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":13.1,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":7.8,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.856964+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_960105","record_id":"REC_0000109","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":4,"primary_tumor_size_cm":6.5,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.857201+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_578037","record_id":"REC_0000110","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":5.7,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.857437+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_732152","record_id":"REC_0000111","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":4.8,"age_at_diagnosis":46,"sex":"female","ecog_performance_status":0,"smoking_pack_years":42,"primary_tumor_size_cm":5.6,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":21.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.857680+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_246493","record_id":"REC_0000112","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":13.3,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":6.4,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.857921+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_330368","record_id":"REC_0000113","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":0,"smoking_pack_years":37,"primary_tumor_size_cm":6.7,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.858156+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_687973","record_id":"REC_0000114","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":10.0,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":2,"smoking_pack_years":28,"primary_tumor_size_cm":4.6,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.858393+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_182589","record_id":"REC_0000115","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":6.1,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":19.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.858632+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_852302","record_id":"REC_0000116","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":10.1,"age_at_diagnosis":52,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":5.9,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":20.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.858884+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_711026","record_id":"REC_0000117","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":4.7,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.859138+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_537571","record_id":"REC_0000118","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":6.8,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.859508+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_732553","record_id":"REC_0000119","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":14.8,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.3,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":17.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.859775+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_485977","record_id":"REC_0000120","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":16,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":51,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":5.8,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.860014+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_640510","record_id":"REC_0000121","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":16.2,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":4.4,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.860324+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_191945","record_id":"REC_0000122","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":16,"tmb_mutations_per_mb":16.8,"age_at_diagnosis":52,"sex":"female","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":5.6,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.860565+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_841627","record_id":"REC_0000123","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":9.0,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":4.3,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.860800+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_577238","record_id":"REC_0000124","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":5.0,"age_at_diagnosis":76,"sex":"male","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":6.7,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.861033+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_614847","record_id":"REC_0000125","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":15.4,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":7.3,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.861270+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_378935","record_id":"REC_0000126","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":13.8,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":5.3,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":16.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.861506+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_933655","record_id":"REC_0000127","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":75,"sex":"male","ecog_performance_status":1,"smoking_pack_years":25,"primary_tumor_size_cm":5.9,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.861744+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_977270","record_id":"REC_0000128","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":44,"sex":"male","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":6.8,"metastatic_sites_count":10,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":6.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.861977+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_662537","record_id":"REC_0000129","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":16.6,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":4.9,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.862214+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_592105","record_id":"REC_0000130","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":8.7,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":24,"primary_tumor_size_cm":3.8,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":18.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.862441+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_137941","record_id":"REC_0000131","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":34,"tmb_mutations_per_mb":7.9,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":56,"primary_tumor_size_cm":2.8,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":7.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.862741+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_458075","record_id":"REC_0000132","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":7.4,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.862980+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_167873","record_id":"REC_0000133","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":35,"tmb_mutations_per_mb":11.5,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":5.6,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":4.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.863218+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_601656","record_id":"REC_0000134","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":13,"tmb_mutations_per_mb":16.2,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":7.5,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.863477+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_341646","record_id":"REC_0000135","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":5.2,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":25.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.863718+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_429254","record_id":"REC_0000136","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":14,"tmb_mutations_per_mb":10.1,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":2,"smoking_pack_years":20,"primary_tumor_size_cm":5.0,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":5.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.863954+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_444686","record_id":"REC_0000137","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":7.3,"age_at_diagnosis":84,"sex":"female","ecog_performance_status":2,"smoking_pack_years":8,"primary_tumor_size_cm":5.5,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.864212+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_213856","record_id":"REC_0000138","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":55,"primary_tumor_size_cm":7.2,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":18.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.864454+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_119828","record_id":"REC_0000139","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":8.5,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":7.3,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.864734+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_391909","record_id":"REC_0000140","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":4.8,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":4.4,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.865001+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_372018","record_id":"REC_0000141","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":5.3,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":17.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.865288+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_578656","record_id":"REC_0000142","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":15.6,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.1,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.865557+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_361601","record_id":"REC_0000143","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":6.1,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.865812+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_934190","record_id":"REC_0000144","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":84,"sex":"female","ecog_performance_status":1,"smoking_pack_years":44,"primary_tumor_size_cm":6.2,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":17.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.866159+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_948554","record_id":"REC_0000145","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":16,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":4,"primary_tumor_size_cm":5.0,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.866405+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_837970","record_id":"REC_0000146","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":11.5,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":6.9,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":18.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.866655+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_893477","record_id":"REC_0000147","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":17.1,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":7.1,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":18.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.866926+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_644483","record_id":"REC_0000148","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":15.5,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":2.0,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.867222+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_253934","record_id":"REC_0000149","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":9.5,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":0,"smoking_pack_years":54,"primary_tumor_size_cm":4.7,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.867490+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_596876","record_id":"REC_0000150","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":8.0,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":3.7,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.867752+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_356381","record_id":"REC_0000151","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":41,"primary_tumor_size_cm":4.5,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.868002+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_838093","record_id":"REC_0000152","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":3.4,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":3.2,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.868315+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_926957","record_id":"REC_0000153","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":4.5,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":55,"primary_tumor_size_cm":5.8,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.868593+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_807988","record_id":"REC_0000154","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":15.5,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":8.4,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.868884+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_893380","record_id":"REC_0000155","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":30,"tmb_mutations_per_mb":9.7,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":7.7,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":6.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.869174+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_686770","record_id":"REC_0000156","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":8.0,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":0,"smoking_pack_years":58,"primary_tumor_size_cm":5.3,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":6.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.869469+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_560069","record_id":"REC_0000157","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":13.3,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":5.4,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":6.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.869933+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_465315","record_id":"REC_0000158","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":26,"primary_tumor_size_cm":4.3,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.870271+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_611507","record_id":"REC_0000159","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":5.6,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":0,"smoking_pack_years":70,"primary_tumor_size_cm":2.0,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":50.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.870558+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_311925","record_id":"REC_0000160","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":13.8,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":6.6,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.870845+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_464643","record_id":"REC_0000161","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":8.1,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":5.2,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":7.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.871093+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_301485","record_id":"REC_0000162","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":17,"tmb_mutations_per_mb":5.7,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":5,"primary_tumor_size_cm":3.7,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":16.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.871324+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_814314","record_id":"REC_0000163","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":13.6,"age_at_diagnosis":83,"sex":"female","ecog_performance_status":2,"smoking_pack_years":0,"primary_tumor_size_cm":5.3,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.871561+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_370502","record_id":"REC_0000164","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":14.3,"age_at_diagnosis":78,"sex":"male","ecog_performance_status":2,"smoking_pack_years":20,"primary_tumor_size_cm":4.8,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.871799+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_684341","record_id":"REC_0000165","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":14.7,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":6.2,"metastatic_sites_count":3,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.872033+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_393968","record_id":"REC_0000166","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None","pd_l1_tps_percent":32,"tmb_mutations_per_mb":3.1,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":44,"primary_tumor_size_cm":4.8,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":52.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.872333+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_606734","record_id":"REC_0000167","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":3.8,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.872582+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_740536","record_id":"REC_0000168","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":5.9,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.872819+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_448290","record_id":"REC_0000169","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":9.7,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":5.2,"metastatic_sites_count":3,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.873049+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_920869","record_id":"REC_0000170","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":31,"tmb_mutations_per_mb":4.8,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":3.9,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.873367+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_303027","record_id":"REC_0000171","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":5.5,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":6.9,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":7.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.873608+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_907514","record_id":"REC_0000172","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":10.1,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":3,"smoking_pack_years":8,"primary_tumor_size_cm":5.5,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.873843+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_738414","record_id":"REC_0000173","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":4.7,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.874077+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_197190","record_id":"REC_0000174","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":0,"smoking_pack_years":25,"primary_tumor_size_cm":7.3,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":6.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.874311+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_583269","record_id":"REC_0000175","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":17.3,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":5.7,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":23.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.874544+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_610479","record_id":"REC_0000176","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":84,"sex":"female","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":6.4,"metastatic_sites_count":8,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":5.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.874775+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_401383","record_id":"REC_0000177","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":9.8,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":2.9,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.875004+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_925053","record_id":"REC_0000178","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":6.0,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.875235+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_664640","record_id":"REC_0000179","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":33,"tmb_mutations_per_mb":5.2,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":6.7,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.875467+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_998257","record_id":"REC_0000180","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":4.3,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":5.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.875698+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_189778","record_id":"REC_0000181","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":28,"primary_tumor_size_cm":2.6,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.875929+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_322334","record_id":"REC_0000182","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":10.0,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":4.6,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.876246+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_864025","record_id":"REC_0000183","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":36,"tmb_mutations_per_mb":10.1,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":5.3,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.876543+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_345923","record_id":"REC_0000184","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":8.4,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":3.3,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":5.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.876781+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_201113","record_id":"REC_0000185","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":34,"primary_tumor_size_cm":5.3,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.877012+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_840781","record_id":"REC_0000186","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":14.4,"age_at_diagnosis":75,"sex":"male","ecog_performance_status":2,"smoking_pack_years":10,"primary_tumor_size_cm":5.2,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.877251+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_328494","record_id":"REC_0000187","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":5.0,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":7.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.877482+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_188645","record_id":"REC_0000188","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":30,"tmb_mutations_per_mb":8.4,"age_at_diagnosis":77,"sex":"male","ecog_performance_status":3,"smoking_pack_years":56,"primary_tumor_size_cm":4.8,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":7.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.877714+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_222349","record_id":"REC_0000189","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":4.3,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":6.3,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.877946+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_228252","record_id":"REC_0000190","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":5.8,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.878177+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_962275","record_id":"REC_0000191","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":5.9,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":6.6,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.878415+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_442070","record_id":"REC_0000192","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":15.7,"age_at_diagnosis":81,"sex":"male","ecog_performance_status":3,"smoking_pack_years":11,"primary_tumor_size_cm":4.0,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.878654+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_895088","record_id":"REC_0000193","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":4.3,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.878897+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_851463","record_id":"REC_0000194","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":11.0,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":3,"smoking_pack_years":20,"primary_tumor_size_cm":4.0,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.879144+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_290905","record_id":"REC_0000195","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":4.4,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":6.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.879395+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_452302","record_id":"REC_0000196","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":16,"tmb_mutations_per_mb":11.1,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":5,"primary_tumor_size_cm":4.6,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.879737+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_485106","record_id":"REC_0000197","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":7.0,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.879980+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_898759","record_id":"REC_0000198","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":49,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":6.0,"metastatic_sites_count":8,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.880289+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_992449","record_id":"REC_0000199","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":6.2,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":23.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.880536+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_904985","record_id":"REC_0000200","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":7.4,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":6.5,"metastatic_sites_count":8,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.880788+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_613732","record_id":"REC_0000201","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":14.1,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":3.5,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.881040+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_894421","record_id":"REC_0000202","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":16.9,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":3.4,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.881296+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_991206","record_id":"REC_0000203","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":48,"sex":"male","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":7.5,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.881542+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_647096","record_id":"REC_0000204","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":3.9,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":24.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.881780+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_696611","record_id":"REC_0000205","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":14.5,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":0,"smoking_pack_years":0,"primary_tumor_size_cm":4.5,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.882016+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_905984","record_id":"REC_0000206","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":10.5,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.9,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.882257+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_865585","record_id":"REC_0000207","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":33,"tmb_mutations_per_mb":8.4,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":52,"primary_tumor_size_cm":3.6,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":7.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.882492+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_529696","record_id":"REC_0000208","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":20,"tmb_mutations_per_mb":5.3,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":0,"smoking_pack_years":39,"primary_tumor_size_cm":3.8,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":22.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.882730+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_789766","record_id":"REC_0000209","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":3.6,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":62,"primary_tumor_size_cm":2.8,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.883061+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_243627","record_id":"REC_0000210","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":53,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":4.6,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.883300+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_577795","record_id":"REC_0000211","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":9.8,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":4.8,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":19.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.883529+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_687344","record_id":"REC_0000212","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":1,"smoking_pack_years":28,"primary_tumor_size_cm":7.1,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":29.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.883762+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_281799","record_id":"REC_0000213","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":14,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":3.4,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.883993+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_423633","record_id":"REC_0000214","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":4.9,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":63,"primary_tumor_size_cm":6.6,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.884306+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_973193","record_id":"REC_0000215","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":36,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":6.0,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.884548+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_356542","record_id":"REC_0000216","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":3.7,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.884787+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_877768","record_id":"REC_0000217","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":10,"primary_tumor_size_cm":6.5,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.885023+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_898995","record_id":"REC_0000218","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":54,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":6.8,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.885261+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_506766","record_id":"REC_0000219","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":16.4,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":3.4,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.885497+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_688137","record_id":"REC_0000220","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":15.3,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":4.1,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.885727+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_350770","record_id":"REC_0000221","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":16.9,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":6.0,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.885957+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_217916","record_id":"REC_0000222","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":7.9,"age_at_diagnosis":83,"sex":"male","ecog_performance_status":1,"smoking_pack_years":74,"primary_tumor_size_cm":4.8,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":6.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.886251+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_761429","record_id":"REC_0000223","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":7.2,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":18.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.886490+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_924585","record_id":"REC_0000224","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":7.3,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":1,"smoking_pack_years":37,"primary_tumor_size_cm":6.5,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.886723+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_851159","record_id":"REC_0000225","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":9.8,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":5,"primary_tumor_size_cm":3.1,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":27.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.886956+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_336473","record_id":"REC_0000226","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":4.5,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":23.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.887192+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_672942","record_id":"REC_0000227","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":14.9,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":4.3,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":17.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.887424+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_665617","record_id":"REC_0000228","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":13.1,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":2,"smoking_pack_years":6,"primary_tumor_size_cm":4.1,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.887655+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_914743","record_id":"REC_0000229","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":30,"tmb_mutations_per_mb":13.5,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":7.7,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":6.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.887887+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_400894","record_id":"REC_0000230","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":7.9,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":4.6,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.888227+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_886573","record_id":"REC_0000231","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":15.7,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":7.0,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":21.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.888476+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_925950","record_id":"REC_0000232","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":17.2,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":6.2,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":17.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.888709+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_928788","record_id":"REC_0000233","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":10.3,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":1,"primary_tumor_size_cm":5.4,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":20.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.888946+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_601118","record_id":"REC_0000234","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":34,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":5.1,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.889177+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_979655","record_id":"REC_0000235","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":4.4,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.889482+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_233540","record_id":"REC_0000236","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":7.9,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":8.7,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.889719+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_588433","record_id":"REC_0000237","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":19,"tmb_mutations_per_mb":8.0,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":0,"smoking_pack_years":32,"primary_tumor_size_cm":5.6,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":16.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.889952+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_228679","record_id":"REC_0000238","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":13.8,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":7.5,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.890186+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_409733","record_id":"REC_0000239","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":9.8,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":3,"smoking_pack_years":11,"primary_tumor_size_cm":5.2,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.890417+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_467262","record_id":"REC_0000240","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":14.5,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":4.8,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.890654+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_997753","record_id":"REC_0000241","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":18,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":74,"sex":"male","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":6.3,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":19.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.890886+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_341820","record_id":"REC_0000242","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":30,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":4,"primary_tumor_size_cm":5.3,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.891121+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_817461","record_id":"REC_0000243","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":15.3,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":7.7,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":6.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.891355+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_811921","record_id":"REC_0000244","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":76,"sex":"male","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":4.3,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.891592+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_739776","record_id":"REC_0000245","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":32,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":5.9,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.891826+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_987495","record_id":"REC_0000246","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":15.3,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":5.2,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.892063+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_692856","record_id":"REC_0000247","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":6.7,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.892351+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_857491","record_id":"REC_0000248","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":9.0,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":6.4,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.892667+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_415657","record_id":"REC_0000249","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":16.9,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":4.8,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":22.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.892913+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_174381","record_id":"REC_0000250","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":19.1,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":5.2,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.893150+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_295825","record_id":"REC_0000251","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":13,"tmb_mutations_per_mb":15.1,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.9,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.893387+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_937443","record_id":"REC_0000252","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":9.0,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":35,"primary_tumor_size_cm":5.0,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.893618+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_451737","record_id":"REC_0000253","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":50,"primary_tumor_size_cm":4.8,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":6.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.893846+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_129478","record_id":"REC_0000254","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":17.0,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":24,"primary_tumor_size_cm":4.6,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.894078+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_504870","record_id":"REC_0000255","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":18.0,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":6.4,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.894315+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_469114","record_id":"REC_0000256","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":4.1,"age_at_diagnosis":79,"sex":"male","ecog_performance_status":2,"smoking_pack_years":61,"primary_tumor_size_cm":8.4,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.894545+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_216369","record_id":"REC_0000257","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":30,"tmb_mutations_per_mb":5.9,"age_at_diagnosis":53,"sex":"male","ecog_performance_status":0,"smoking_pack_years":61,"primary_tumor_size_cm":6.1,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.894779+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_978908","record_id":"REC_0000258","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":7.9,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":4.9,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.895011+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_380592","record_id":"REC_0000259","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":3.0,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.895239+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_625792","record_id":"REC_0000260","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":1,"smoking_pack_years":5,"primary_tumor_size_cm":7.1,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":18.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.895470+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_812208","record_id":"REC_0000261","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":5.9,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":5.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.895758+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_198521","record_id":"REC_0000262","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":20,"tmb_mutations_per_mb":5.0,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":38,"primary_tumor_size_cm":3.9,"metastatic_sites_count":3,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":22.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.895998+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_646756","record_id":"REC_0000263","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":13.3,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":4.7,"metastatic_sites_count":3,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":7.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.896325+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_199624","record_id":"REC_0000264","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":4.8,"metastatic_sites_count":8,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":16.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.896577+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_484508","record_id":"REC_0000265","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":68,"primary_tumor_size_cm":4.7,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.896828+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_547087","record_id":"REC_0000266","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":15.6,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":5.0,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":16.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.897060+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_266546","record_id":"REC_0000267","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":27,"primary_tumor_size_cm":6.6,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":17.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.897297+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_427042","record_id":"REC_0000268","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":15.4,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":3,"primary_tumor_size_cm":3.2,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.897532+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_176614","record_id":"REC_0000269","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":4.5,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":3,"smoking_pack_years":19,"primary_tumor_size_cm":6.3,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":5.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.897760+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_937779","record_id":"REC_0000270","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":15.1,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":4.9,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.897990+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_254213","record_id":"REC_0000271","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":4,"primary_tumor_size_cm":6.5,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.898226+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_177376","record_id":"REC_0000272","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":9.8,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":2,"smoking_pack_years":9,"primary_tumor_size_cm":7.7,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.898456+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_405001","record_id":"REC_0000273","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":5.2,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":21.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.898697+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_294978","record_id":"REC_0000274","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":2.8,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":74,"primary_tumor_size_cm":4.0,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.899017+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_732840","record_id":"REC_0000275","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":14.7,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":0,"smoking_pack_years":5,"primary_tumor_size_cm":5.3,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":16.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.899275+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_367489","record_id":"REC_0000276","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":4.7,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":2,"smoking_pack_years":32,"primary_tumor_size_cm":5.9,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":7.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.899526+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_333868","record_id":"REC_0000277","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":11.5,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":7.1,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.899773+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_203918","record_id":"REC_0000278","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":4.9,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":17.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.900008+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_637417","record_id":"REC_0000279","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":14.4,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":4.1,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":24.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.900330+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_545486","record_id":"REC_0000280","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":15.9,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":4,"primary_tumor_size_cm":5.0,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":21.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.900568+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_940887","record_id":"REC_0000281","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":5.7,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.900801+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_548885","record_id":"REC_0000282","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":14.6,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":5.6,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.901034+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_419973","record_id":"REC_0000283","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":6.2,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.901271+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_182877","record_id":"REC_0000284","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":13.8,"age_at_diagnosis":52,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":5.1,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.901512+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_243102","record_id":"REC_0000285","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":14.4,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":7.5,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.901748+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_330517","record_id":"REC_0000286","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":14.0,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":4.7,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.901982+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_321690","record_id":"REC_0000287","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":5.2,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.902297+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_910403","record_id":"REC_0000288","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":8.9,"age_at_diagnosis":53,"sex":"female","ecog_performance_status":0,"smoking_pack_years":0,"primary_tumor_size_cm":7.0,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":21.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.902541+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_385787","record_id":"REC_0000289","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":6.9,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.902772+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_755536","record_id":"REC_0000290","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":13,"tmb_mutations_per_mb":15.5,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":6.2,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":5.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.903005+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_982376","record_id":"REC_0000291","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":19,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":64,"primary_tumor_size_cm":4.2,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":16.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.903239+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_511041","record_id":"REC_0000292","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":54,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":5.2,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.903473+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_393835","record_id":"REC_0000293","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":8.9,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.903706+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_223089","record_id":"REC_0000294","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":30,"tmb_mutations_per_mb":5.5,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":6.0,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.903982+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_129561","record_id":"REC_0000295","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":15.2,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":5.6,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.904280+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_518131","record_id":"REC_0000296","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":4.8,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":16.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.904534+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_303982","record_id":"REC_0000297","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":4.9,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":4.2,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":46.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.904788+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_676630","record_id":"REC_0000298","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":15.8,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":6.5,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":18.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.905054+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_761189","record_id":"REC_0000299","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":17.1,"age_at_diagnosis":79,"sex":"male","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":4.0,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":6.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.905325+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_146711","record_id":"REC_0000300","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":5.7,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":4.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.905697+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_408239","record_id":"REC_0000301","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":30,"tmb_mutations_per_mb":5.2,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":4.7,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.905950+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_469226","record_id":"REC_0000302","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":3.3,"age_at_diagnosis":77,"sex":"male","ecog_performance_status":2,"smoking_pack_years":7,"primary_tumor_size_cm":5.9,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.906189+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_643606","record_id":"REC_0000303","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":11.5,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":9,"primary_tumor_size_cm":6.1,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.906428+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_272906","record_id":"REC_0000304","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":4.3,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":17.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.906667+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_247798","record_id":"REC_0000305","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":9.0,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":6.5,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":22.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.906898+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_327135","record_id":"REC_0000306","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":34,"tmb_mutations_per_mb":17.3,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":3.4,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.907130+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_673820","record_id":"REC_0000307","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":5.9,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":28.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.907365+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_294137","record_id":"REC_0000308","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":29,"primary_tumor_size_cm":6.3,"metastatic_sites_count":8,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":6.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.907593+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_461746","record_id":"REC_0000309","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":70,"primary_tumor_size_cm":4.0,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.907822+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_871603","record_id":"REC_0000310","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":4.9,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":5.3,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.908052+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_569456","record_id":"REC_0000311","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":4,"primary_tumor_size_cm":5.6,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.908369+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_289721","record_id":"REC_0000312","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.8,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.908612+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_667565","record_id":"REC_0000313","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":6.0,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.908919+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_367900","record_id":"REC_0000314","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":11.0,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":2,"smoking_pack_years":6,"primary_tumor_size_cm":3.9,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.909154+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_150436","record_id":"REC_0000315","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":2,"smoking_pack_years":22,"primary_tumor_size_cm":6.2,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":31.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.909392+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_832582","record_id":"REC_0000316","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":65,"primary_tumor_size_cm":6.8,"metastatic_sites_count":9,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.909624+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_253968","record_id":"REC_0000317","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":17.3,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":4.5,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":6.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.909857+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_698268","record_id":"REC_0000318","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":88,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.8,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.910091+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_604799","record_id":"REC_0000319","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":35,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":6.1,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":18.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.910326+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_350416","record_id":"REC_0000320","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":30,"tmb_mutations_per_mb":5.0,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":6.7,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":21.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.910557+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_323869","record_id":"REC_0000321","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":6.1,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":1,"smoking_pack_years":24,"primary_tumor_size_cm":4.5,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":17.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.910788+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_281105","record_id":"REC_0000322","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":15.6,"age_at_diagnosis":83,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":7.3,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.911021+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_948230","record_id":"REC_0000323","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":3.4,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.911252+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_349223","record_id":"REC_0000324","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":7.9,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":58,"primary_tumor_size_cm":3.5,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.911484+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_973928","record_id":"REC_0000325","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":4.7,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":35,"primary_tumor_size_cm":7.0,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.911717+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_714627","record_id":"REC_0000326","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":46,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":6.7,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.912015+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_237064","record_id":"REC_0000327","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":8.5,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":3.8,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.912321+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_226469","record_id":"REC_0000328","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.4,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.912560+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_684011","record_id":"REC_0000329","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":8,"primary_tumor_size_cm":8.0,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.912797+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_323974","record_id":"REC_0000330","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":34,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":25,"primary_tumor_size_cm":5.3,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.913028+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_361149","record_id":"REC_0000331","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":30,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":85,"sex":"female","ecog_performance_status":1,"smoking_pack_years":49,"primary_tumor_size_cm":6.0,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.913258+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_218815","record_id":"REC_0000332","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":13,"tmb_mutations_per_mb":5.1,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":29,"primary_tumor_size_cm":6.0,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.913493+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_362989","record_id":"REC_0000333","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":4.1,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":6.8,"metastatic_sites_count":8,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":4.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.913722+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_988774","record_id":"REC_0000334","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":5.2,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":27,"primary_tumor_size_cm":4.5,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.913954+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_300943","record_id":"REC_0000335","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":19,"tmb_mutations_per_mb":8.4,"age_at_diagnosis":85,"sex":"female","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":4.0,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":38.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.914196+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_936814","record_id":"REC_0000336","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":2,"primary_tumor_size_cm":6.4,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.914448+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_902078","record_id":"REC_0000337","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":0,"smoking_pack_years":49,"primary_tumor_size_cm":5.8,"metastatic_sites_count":8,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":6.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.914683+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_405949","record_id":"REC_0000338","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":19.4,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":5.4,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.914921+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_907088","record_id":"REC_0000339","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":15.0,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":8,"primary_tumor_size_cm":5.8,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":21.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.915253+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_747917","record_id":"REC_0000340","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":4.9,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":31,"primary_tumor_size_cm":5.3,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":22.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.915488+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_155984","record_id":"REC_0000341","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":20,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":38,"primary_tumor_size_cm":3.8,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.915717+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_258832","record_id":"REC_0000342","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":33,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":85,"sex":"male","ecog_performance_status":1,"smoking_pack_years":27,"primary_tumor_size_cm":7.2,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.915961+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_416676","record_id":"REC_0000343","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":13.8,"age_at_diagnosis":84,"sex":"female","ecog_performance_status":3,"smoking_pack_years":12,"primary_tumor_size_cm":5.5,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.916259+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_632291","record_id":"REC_0000344","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":5.3,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":0,"smoking_pack_years":60,"primary_tumor_size_cm":5.2,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.916501+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_275952","record_id":"REC_0000345","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":3.1,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.916739+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_998350","record_id":"REC_0000346","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":31,"tmb_mutations_per_mb":4.4,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":7.2,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.916972+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_170054","record_id":"REC_0000347","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":88,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":6.6,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.917202+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_544321","record_id":"REC_0000348","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":17,"tmb_mutations_per_mb":6.9,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":33,"primary_tumor_size_cm":5.7,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":20.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.917431+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_363510","record_id":"REC_0000349","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":13.6,"age_at_diagnosis":78,"sex":"male","ecog_performance_status":2,"smoking_pack_years":2,"primary_tumor_size_cm":5.8,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":37.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.917669+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_395726","record_id":"REC_0000350","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":3,"smoking_pack_years":10,"primary_tumor_size_cm":4.8,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.917907+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_341980","record_id":"REC_0000351","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":13.1,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":25,"primary_tumor_size_cm":5.4,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.918138+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_945792","record_id":"REC_0000352","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":0,"smoking_pack_years":35,"primary_tumor_size_cm":5.0,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":31.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.918435+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_369910","record_id":"REC_0000353","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":52,"sex":"male","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":5.0,"metastatic_sites_count":8,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.918681+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_712503","record_id":"REC_0000354","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":10.5,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":7.3,"metastatic_sites_count":9,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.918928+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_433523","record_id":"REC_0000355","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":2.5,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":10,"primary_tumor_size_cm":7.1,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":17.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.919163+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_183386","record_id":"REC_0000356","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":5.9,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.919395+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_475920","record_id":"REC_0000357","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":30,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":6.3,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":24.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.919632+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_648333","record_id":"REC_0000358","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":13.5,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":4.3,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.919864+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_182233","record_id":"REC_0000359","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":5.2,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":1,"smoking_pack_years":49,"primary_tumor_size_cm":6.3,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":4.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.920266+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_635487","record_id":"REC_0000360","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":15.2,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":0,"smoking_pack_years":25,"primary_tumor_size_cm":6.0,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":23.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.920577+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_226279","record_id":"REC_0000361","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":4.7,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":1,"smoking_pack_years":66,"primary_tumor_size_cm":5.5,"metastatic_sites_count":8,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.920832+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_793205","record_id":"REC_0000362","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":5.6,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":63,"primary_tumor_size_cm":3.9,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.921071+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_544327","record_id":"REC_0000363","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":6.1,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.921309+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_183026","record_id":"REC_0000364","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":3.9,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.921549+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_397309","record_id":"REC_0000365","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":3.9,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":49,"primary_tumor_size_cm":5.9,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":33.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.921887+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_840908","record_id":"REC_0000366","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":8.5,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":30,"primary_tumor_size_cm":3.3,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.922129+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_463590","record_id":"REC_0000367","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":16.5,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":4.3,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":7.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.922366+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_360781","record_id":"REC_0000368","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":3.3,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.922603+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_139262","record_id":"REC_0000369","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":88,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":3.5,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.922840+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_747942","record_id":"REC_0000370","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":7.3,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":5.7,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":5.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.923076+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_980758","record_id":"REC_0000371","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":17,"tmb_mutations_per_mb":5.9,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":0,"smoking_pack_years":68,"primary_tumor_size_cm":7.3,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.923312+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_573542","record_id":"REC_0000372","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":11.1,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":5.0,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.923602+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_869194","record_id":"REC_0000373","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":34,"primary_tumor_size_cm":5.2,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.923887+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_899555","record_id":"REC_0000374","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":21.0,"age_at_diagnosis":76,"sex":"male","ecog_performance_status":3,"smoking_pack_years":13,"primary_tumor_size_cm":8.8,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":22.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.924246+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_467836","record_id":"REC_0000375","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":5.6,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":5.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.924500+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_218610","record_id":"REC_0000376","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":5.8,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.924855+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_972527","record_id":"REC_0000377","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":30,"tmb_mutations_per_mb":6.1,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":56,"primary_tumor_size_cm":7.3,"metastatic_sites_count":3,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":17.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.925087+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_156583","record_id":"REC_0000378","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":33,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":7.2,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.925378+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_206850","record_id":"REC_0000379","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":6.2,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.925640+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_726068","record_id":"REC_0000380","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":30,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":53,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":6.3,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.925891+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_263618","record_id":"REC_0000381","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":10.5,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":5.3,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":18.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.926321+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_291228","record_id":"REC_0000382","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":34,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":4.9,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.926559+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_938219","record_id":"REC_0000383","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":30,"tmb_mutations_per_mb":16.3,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":6.6,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":22.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.926798+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_963183","record_id":"REC_0000384","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":15.8,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":6.3,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":21.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.927067+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_824708","record_id":"REC_0000385","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":6.8,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":18.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.927304+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_891145","record_id":"REC_0000386","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":4.8,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":25.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.927542+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_962265","record_id":"REC_0000387","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":2.6,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":39,"primary_tumor_size_cm":7.5,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.927837+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_908366","record_id":"REC_0000388","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":8.1,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":8.1,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.928069+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_952993","record_id":"REC_0000389","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":1,"smoking_pack_years":40,"primary_tumor_size_cm":3.8,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.928364+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_578652","record_id":"REC_0000390","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":6.5,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.928603+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_728808","record_id":"REC_0000391","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":8.7,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":5.5,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.928929+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_205247","record_id":"REC_0000392","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":8.3,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":4.7,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":6.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.929193+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_315936","record_id":"REC_0000393","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.8,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.929482+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_896258","record_id":"REC_0000394","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":74,"sex":"male","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":5.5,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.929733+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_227518","record_id":"REC_0000395","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":2,"smoking_pack_years":4,"primary_tumor_size_cm":4.3,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.929970+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_225104","record_id":"REC_0000396","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":5.6,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":3.7,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.930227+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_173423","record_id":"REC_0000397","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":4.7,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":19.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.930463+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_650853","record_id":"REC_0000398","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":5.5,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":26,"primary_tumor_size_cm":4.9,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":17.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.930700+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_381602","record_id":"REC_0000399","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":4.6,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.930939+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_478396","record_id":"REC_0000400","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":15.5,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":3,"smoking_pack_years":12,"primary_tumor_size_cm":7.4,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.931173+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_673904","record_id":"REC_0000401","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":15.5,"age_at_diagnosis":75,"sex":"male","ecog_performance_status":2,"smoking_pack_years":20,"primary_tumor_size_cm":5.0,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":17.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.931411+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_283785","record_id":"REC_0000402","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":31,"tmb_mutations_per_mb":16.8,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":10,"primary_tumor_size_cm":6.3,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.931642+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_702797","record_id":"REC_0000403","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":7.0,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":24.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.931880+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_745897","record_id":"REC_0000404","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":10.0,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":24,"primary_tumor_size_cm":5.5,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.932344+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_183033","record_id":"REC_0000405","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":9.7,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":7.3,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.932653+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_556631","record_id":"REC_0000406","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":20,"tmb_mutations_per_mb":7.9,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":1,"smoking_pack_years":56,"primary_tumor_size_cm":5.2,"metastatic_sites_count":8,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":7.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.932896+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_524206","record_id":"REC_0000407","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":80,"sex":"male","ecog_performance_status":3,"smoking_pack_years":11,"primary_tumor_size_cm":3.7,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":36.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.933152+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_901879","record_id":"REC_0000408","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":17.5,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":7.2,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.933390+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_442097","record_id":"REC_0000409","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":9.1,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":26,"primary_tumor_size_cm":4.8,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.933628+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_754257","record_id":"REC_0000410","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":18.1,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":1,"primary_tumor_size_cm":8.3,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.933890+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_535758","record_id":"REC_0000411","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":4.5,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":5.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.934151+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_568645","record_id":"REC_0000412","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":1,"smoking_pack_years":25,"primary_tumor_size_cm":5.0,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.934417+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_227165","record_id":"REC_0000413","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":5.3,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.934674+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_847002","record_id":"REC_0000414","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":16,"tmb_mutations_per_mb":3.7,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":30,"primary_tumor_size_cm":2.9,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":18.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.934979+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_448190","record_id":"REC_0000415","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":6.4,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":32,"primary_tumor_size_cm":5.3,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":4.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.935318+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_275189","record_id":"REC_0000416","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":8.5,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":38,"primary_tumor_size_cm":4.2,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.935562+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_523972","record_id":"REC_0000417","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":18,"tmb_mutations_per_mb":9.7,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":27,"primary_tumor_size_cm":3.4,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":5.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.935944+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_573573","record_id":"REC_0000418","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":53,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":5.0,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":31.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.936351+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_439570","record_id":"REC_0000419","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":18,"tmb_mutations_per_mb":15.1,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":5,"primary_tumor_size_cm":6.2,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.936631+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_513734","record_id":"REC_0000420","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.0,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":6.9,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.936885+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_888463","record_id":"REC_0000421","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":3.4,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":22.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.937126+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_824790","record_id":"REC_0000422","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":7.4,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":5.8,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":18.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.937361+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_105900","record_id":"REC_0000423","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":16,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":20,"primary_tumor_size_cm":3.9,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":18.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.937600+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_987199","record_id":"REC_0000424","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":17.8,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":4.4,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.937840+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_902862","record_id":"REC_0000425","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":13.6,"age_at_diagnosis":52,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":5.9,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.938078+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_990588","record_id":"REC_0000426","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":17,"tmb_mutations_per_mb":5.0,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":25,"primary_tumor_size_cm":6.6,"metastatic_sites_count":3,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":19.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.938306+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_101865","record_id":"REC_0000427","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":13.3,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":6.0,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.938540+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_540018","record_id":"REC_0000428","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":14.4,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":6.3,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.938787+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_832159","record_id":"REC_0000429","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":6.6,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":8.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.939041+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_372184","record_id":"REC_0000430","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":16,"tmb_mutations_per_mb":15.0,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":8,"primary_tumor_size_cm":5.1,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.939489+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_641910","record_id":"REC_0000431","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":15.7,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":4.6,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":4.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.939828+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_763467","record_id":"REC_0000432","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":17,"tmb_mutations_per_mb":7.4,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":1,"smoking_pack_years":73,"primary_tumor_size_cm":7.1,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.940170+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_304265","record_id":"REC_0000433","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":21,"primary_tumor_size_cm":5.5,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":26.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.940415+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_937400","record_id":"REC_0000434","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":6.0,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.940692+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_234133","record_id":"REC_0000435","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":5.0,"age_at_diagnosis":51,"sex":"male","ecog_performance_status":0,"smoking_pack_years":47,"primary_tumor_size_cm":4.3,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":16.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.940977+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_691408","record_id":"REC_0000436","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":4.2,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":56,"primary_tumor_size_cm":5.5,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":6.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.941233+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_234359","record_id":"REC_0000437","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":13.6,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":7.1,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.941486+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_630322","record_id":"REC_0000438","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":2.1,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":46,"primary_tumor_size_cm":4.4,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.941716+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_543574","record_id":"REC_0000439","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":5.1,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":24,"primary_tumor_size_cm":5.8,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":43.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.941949+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_193090","record_id":"REC_0000440","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":31,"tmb_mutations_per_mb":10.3,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.3,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.942199+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_113253","record_id":"REC_0000441","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":15,"tmb_mutations_per_mb":14.1,"age_at_diagnosis":54,"sex":"female","ecog_performance_status":0,"smoking_pack_years":4,"primary_tumor_size_cm":5.5,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.942443+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_704826","record_id":"REC_0000442","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":4.1,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.942683+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_241491","record_id":"REC_0000443","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":10.0,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":5.8,"metastatic_sites_count":8,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.943021+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_981126","record_id":"REC_0000444","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":5.7,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.943258+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_963033","record_id":"REC_0000445","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":5.0,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":1,"smoking_pack_years":48,"primary_tumor_size_cm":5.8,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":16.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.943493+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_246538","record_id":"REC_0000446","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":1,"smoking_pack_years":87,"primary_tumor_size_cm":2.5,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":22.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.943727+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_271898","record_id":"REC_0000447","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":20,"tmb_mutations_per_mb":4.5,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":75,"primary_tumor_size_cm":5.5,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":16.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.943961+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_947278","record_id":"REC_0000448","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":35,"tmb_mutations_per_mb":4.3,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":43,"primary_tumor_size_cm":5.9,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.944353+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_731658","record_id":"REC_0000449","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":3.9,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":19.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.944645+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_319624","record_id":"REC_0000450","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":16.3,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":5.3,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.944912+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_731594","record_id":"REC_0000451","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":9.8,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":5.0,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.945154+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_126363","record_id":"REC_0000452","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":8.6,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":0,"smoking_pack_years":49,"primary_tumor_size_cm":3.9,"metastatic_sites_count":8,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.945416+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_132367","record_id":"REC_0000453","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":15,"tmb_mutations_per_mb":16.5,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":4.7,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":22.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.945652+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_743409","record_id":"REC_0000454","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":48,"sex":"male","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":4.2,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.945889+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_319366","record_id":"REC_0000455","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":5.3,"age_at_diagnosis":48,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":6.2,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":38.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.946126+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_573596","record_id":"REC_0000456","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":5.8,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.946421+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_456876","record_id":"REC_0000457","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":7.6,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":0,"smoking_pack_years":62,"primary_tumor_size_cm":4.8,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":58.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.946655+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_292645","record_id":"REC_0000458","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":7.4,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":3.7,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":31.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.946887+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_364867","record_id":"REC_0000459","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":4.6,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":5.5,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":4.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.947122+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_732204","record_id":"REC_0000460","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":8.9,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":24,"primary_tumor_size_cm":5.5,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.947352+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_756273","record_id":"REC_0000461","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":5.4,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":6.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.947589+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_641721","record_id":"REC_0000462","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":16,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":26,"primary_tumor_size_cm":5.0,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.947824+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_954237","record_id":"REC_0000463","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":4.3,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.948055+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_127060","record_id":"REC_0000464","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":17,"tmb_mutations_per_mb":7.6,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":0,"smoking_pack_years":39,"primary_tumor_size_cm":6.8,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":6.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.948453+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_383683","record_id":"REC_0000465","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":4,"primary_tumor_size_cm":5.7,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.948697+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_408673","record_id":"REC_0000466","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":54,"sex":"male","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":2.9,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.948962+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_305999","record_id":"REC_0000467","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":5.9,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":6.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.949231+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_903561","record_id":"REC_0000468","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":31,"tmb_mutations_per_mb":13.1,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":7.1,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.949475+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_723522","record_id":"REC_0000469","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":7.3,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":7.7,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.949796+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_991069","record_id":"REC_0000470","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":4.3,"age_at_diagnosis":50,"sex":"male","ecog_performance_status":0,"smoking_pack_years":49,"primary_tumor_size_cm":4.4,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.950049+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_844410","record_id":"REC_0000471","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":18,"tmb_mutations_per_mb":11.5,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":7.0,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.950292+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_614127","record_id":"REC_0000472","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":13.3,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":3,"smoking_pack_years":19,"primary_tumor_size_cm":5.3,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.950536+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_713061","record_id":"REC_0000473","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":5.5,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":2.0,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":6.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.950779+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_271333","record_id":"REC_0000474","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":9.9,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":7.7,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":25.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.951011+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_467011","record_id":"REC_0000475","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":19,"tmb_mutations_per_mb":6.7,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":1,"smoking_pack_years":36,"primary_tumor_size_cm":4.7,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":21.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.951245+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_252659","record_id":"REC_0000476","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":2.6,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":44,"primary_tumor_size_cm":5.7,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":7.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.951474+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_688304","record_id":"REC_0000477","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":3,"smoking_pack_years":22,"primary_tumor_size_cm":5.0,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":20.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.951712+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_167780","record_id":"REC_0000478","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":17.7,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":4.2,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.951954+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_893992","record_id":"REC_0000479","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":84,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":2.8,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.952235+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_812791","record_id":"REC_0000480","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":14.4,"age_at_diagnosis":54,"sex":"male","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":5.6,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":23.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.952481+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_120884","record_id":"REC_0000481","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":6.3,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":6.3,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":55.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.952715+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_909518","record_id":"REC_0000482","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":5.6,"metastatic_sites_count":3,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.953033+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_746853","record_id":"REC_0000483","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":4.9,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":26.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.953274+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_661456","record_id":"REC_0000484","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":31,"tmb_mutations_per_mb":3.2,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":2,"smoking_pack_years":63,"primary_tumor_size_cm":5.0,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.953511+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_291757","record_id":"REC_0000485","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":10.1,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":7.1,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.953743+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_366661","record_id":"REC_0000486","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":13.3,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":0,"smoking_pack_years":6,"primary_tumor_size_cm":6.9,"metastatic_sites_count":9,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.953974+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_386730","record_id":"REC_0000487","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":9.1,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":4.6,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.954209+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_343640","record_id":"REC_0000488","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":5.0,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.954444+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_564873","record_id":"REC_0000489","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":13.1,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":5.0,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":4.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.954685+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_773571","record_id":"REC_0000490","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":15.4,"age_at_diagnosis":83,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":5.5,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":30.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.954922+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_835579","record_id":"REC_0000491","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":53,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":6.2,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.955162+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_487853","record_id":"REC_0000492","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":8.2,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":17.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.955418+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_904363","record_id":"REC_0000493","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":13.3,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":7.2,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":17.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.955682+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_760013","record_id":"REC_0000494","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":6.1,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.955930+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_258985","record_id":"REC_0000495","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":8.1,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":5.1,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":21.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.956379+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_476043","record_id":"REC_0000496","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":18,"tmb_mutations_per_mb":15.9,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":4.8,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.956631+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_974995","record_id":"REC_0000497","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":6.9,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":16.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.956867+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_296052","record_id":"REC_0000498","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":4.8,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.957100+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_109344","record_id":"REC_0000499","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":90,"sex":"female","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":6.2,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":24.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.957327+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_900671","record_id":"REC_0000500","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":4.9,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":25,"primary_tumor_size_cm":5.6,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.957556+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_701741","record_id":"REC_0000501","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":3.6,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":62,"primary_tumor_size_cm":6.0,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.957787+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_115168","record_id":"REC_0000502","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":25,"primary_tumor_size_cm":5.9,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.958025+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_457889","record_id":"REC_0000503","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":8.1,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":42,"primary_tumor_size_cm":3.9,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":16.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.958261+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_160209","record_id":"REC_0000504","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":4.7,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.958499+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_798095","record_id":"REC_0000505","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":4.2,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":2.8,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":5.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.958802+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_334395","record_id":"REC_0000506","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":84,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":4.2,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":34.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.959055+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_258386","record_id":"REC_0000507","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":5.2,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.959310+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_538417","record_id":"REC_0000508","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":4.1,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.959737+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_767066","record_id":"REC_0000509","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":15,"tmb_mutations_per_mb":4.7,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":3.7,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.959992+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_785761","record_id":"REC_0000510","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":4.1,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.960310+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_382700","record_id":"REC_0000511","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.1,"age_at_diagnosis":52,"sex":"male","ecog_performance_status":0,"smoking_pack_years":27,"primary_tumor_size_cm":5.4,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.960578+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_124911","record_id":"REC_0000512","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":5.1,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":26.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.960845+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_521002","record_id":"REC_0000513","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":16.8,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":27,"primary_tumor_size_cm":4.3,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.961098+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_340888","record_id":"REC_0000514","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":2.6,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":1,"smoking_pack_years":76,"primary_tumor_size_cm":3.4,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.961334+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_764756","record_id":"REC_0000515","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":3.9,"age_at_diagnosis":52,"sex":"female","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":5.9,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":19.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.961569+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_183091","record_id":"REC_0000516","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":8.1,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":6.9,"metastatic_sites_count":3,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.961805+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_348794","record_id":"REC_0000517","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":22,"primary_tumor_size_cm":5.3,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.962046+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_545731","record_id":"REC_0000518","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":6.7,"age_at_diagnosis":85,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":5.7,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.962277+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_783970","record_id":"REC_0000519","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":17,"tmb_mutations_per_mb":5.3,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":2,"smoking_pack_years":20,"primary_tumor_size_cm":6.7,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.962512+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_696956","record_id":"REC_0000520","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":14.9,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":4.4,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":20.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.962751+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_753701","record_id":"REC_0000521","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":9.7,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":5.4,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":7.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.963084+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_425124","record_id":"REC_0000522","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":8.0,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":0,"smoking_pack_years":72,"primary_tumor_size_cm":4.7,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.963323+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_649752","record_id":"REC_0000523","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":13.8,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":6.5,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.963572+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_608199","record_id":"REC_0000524","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":13.6,"age_at_diagnosis":51,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":6.2,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.963807+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_752396","record_id":"REC_0000525","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":6.0,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":75,"primary_tumor_size_cm":6.5,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.964037+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_755928","record_id":"REC_0000526","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":13.3,"age_at_diagnosis":79,"sex":"male","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":7.0,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.964337+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_784691","record_id":"REC_0000527","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":31,"tmb_mutations_per_mb":16.1,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":7.2,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.964580+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_993415","record_id":"REC_0000528","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":23.7,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":5.1,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":7.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.964822+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_321908","record_id":"REC_0000529","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":9.5,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":7.2,"metastatic_sites_count":3,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":7.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.965076+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_599797","record_id":"REC_0000530","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":3.1,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":5.9,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.965326+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_323072","record_id":"REC_0000531","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":6.5,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.965566+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_699012","record_id":"REC_0000532","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":52,"sex":"male","ecog_performance_status":0,"smoking_pack_years":36,"primary_tumor_size_cm":5.2,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":23.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.965797+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_690978","record_id":"REC_0000533","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":6.1,"age_at_diagnosis":83,"sex":"female","ecog_performance_status":3,"smoking_pack_years":11,"primary_tumor_size_cm":4.7,"metastatic_sites_count":8,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":17.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.966027+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_340999","record_id":"REC_0000534","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":4.7,"age_at_diagnosis":54,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":4.4,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":25.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.966370+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_665351","record_id":"REC_0000535","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":4.5,"age_at_diagnosis":52,"sex":"male","ecog_performance_status":0,"smoking_pack_years":33,"primary_tumor_size_cm":6.4,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":16.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.966635+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_397180","record_id":"REC_0000536","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":6.4,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":5.6,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.966881+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_418053","record_id":"REC_0000537","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":8.9,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":5,"primary_tumor_size_cm":6.3,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":32.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.967121+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_291808","record_id":"REC_0000538","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":34,"tmb_mutations_per_mb":18.3,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":5.8,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.967380+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_340192","record_id":"REC_0000539","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":9.1,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":6.5,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.967637+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_821276","record_id":"REC_0000540","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":0,"smoking_pack_years":51,"primary_tumor_size_cm":5.2,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.967989+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_228037","record_id":"REC_0000541","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":7.9,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":0,"smoking_pack_years":40,"primary_tumor_size_cm":4.3,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.968347+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_354649","record_id":"REC_0000542","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":5.0,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":5.5,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.968647+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_725307","record_id":"REC_0000543","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":6.3,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":46,"primary_tumor_size_cm":7.8,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":5.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.968901+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_155256","record_id":"REC_0000544","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":1,"smoking_pack_years":24,"primary_tumor_size_cm":6.2,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.969199+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_672887","record_id":"REC_0000545","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":5.8,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":23.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.969441+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_160035","record_id":"REC_0000546","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":8.3,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":4.9,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.969673+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_887447","record_id":"REC_0000547","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":7.6,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.970035+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_787773","record_id":"REC_0000548","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":6.3,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":0,"smoking_pack_years":30,"primary_tumor_size_cm":7.2,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.970284+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_233786","record_id":"REC_0000549","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":17.6,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":4.2,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.970527+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_412220","record_id":"REC_0000550","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":3.2,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.970768+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_634353","record_id":"REC_0000551","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":5,"primary_tumor_size_cm":6.8,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":21.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.971016+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_256926","record_id":"REC_0000552","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":8,"primary_tumor_size_cm":5.3,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":31.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.971250+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_465918","record_id":"REC_0000553","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":86,"sex":"female","ecog_performance_status":2,"smoking_pack_years":23,"primary_tumor_size_cm":6.6,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.971483+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_144821","record_id":"REC_0000554","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":15.9,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":4.9,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.971715+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_448727","record_id":"REC_0000555","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":66,"primary_tumor_size_cm":4.7,"metastatic_sites_count":9,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":7.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.971950+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_106590","record_id":"REC_0000556","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":34,"tmb_mutations_per_mb":9.8,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":5.0,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.972242+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_314012","record_id":"REC_0000557","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":6.2,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":6.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.972553+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_332515","record_id":"REC_0000558","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":4.4,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":16.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.972870+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_485780","record_id":"REC_0000559","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":2.9,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.973150+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_600497","record_id":"REC_0000560","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":19.0,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":6.2,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.973486+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_849031","record_id":"REC_0000561","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":27,"primary_tumor_size_cm":6.2,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.973731+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_326549","record_id":"REC_0000562","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":84,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":5.5,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.974000+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_952454","record_id":"REC_0000563","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":12,"tmb_mutations_per_mb":5.2,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":1,"smoking_pack_years":48,"primary_tumor_size_cm":4.9,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":6.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.974272+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_255350","record_id":"REC_0000564","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":16.6,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":5.2,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.974511+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_576164","record_id":"REC_0000565","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":11.0,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":5.0,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.974748+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_937941","record_id":"REC_0000566","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":13.1,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":4.9,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.974981+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_845801","record_id":"REC_0000567","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":53,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":7.9,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.975217+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_167926","record_id":"REC_0000568","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":3.3,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":46,"primary_tumor_size_cm":5.8,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":18.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.975450+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_240979","record_id":"REC_0000569","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":15,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":4.8,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":28.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.975683+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_447103","record_id":"REC_0000570","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":6.8,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.975915+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_144944","record_id":"REC_0000571","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":5.6,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.976191+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_408574","record_id":"REC_0000572","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":13.1,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":24,"primary_tumor_size_cm":4.1,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":4.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.976428+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_473201","record_id":"REC_0000573","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":14,"tmb_mutations_per_mb":13.6,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":7.6,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":21.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.976740+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_790567","record_id":"REC_0000574","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":8.0,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":5.9,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":23.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.976976+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_262284","record_id":"REC_0000575","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":32,"tmb_mutations_per_mb":18.4,"age_at_diagnosis":83,"sex":"female","ecog_performance_status":3,"smoking_pack_years":20,"primary_tumor_size_cm":5.0,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.977213+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_407879","record_id":"REC_0000576","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":1,"smoking_pack_years":24,"primary_tumor_size_cm":6.4,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":19.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.977447+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_259771","record_id":"REC_0000577","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":8.2,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.977680+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_846433","record_id":"REC_0000578","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":4.7,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.977916+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_908195","record_id":"REC_0000579","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":5.1,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.978152+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_327786","record_id":"REC_0000580","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":2.2,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":29,"primary_tumor_size_cm":6.4,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.978379+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_634367","record_id":"REC_0000581","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":5.0,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.978620+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_236204","record_id":"REC_0000582","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":3.3,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.978865+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_802844","record_id":"REC_0000583","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":31,"tmb_mutations_per_mb":4.0,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":47,"primary_tumor_size_cm":6.6,"metastatic_sites_count":8,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":19.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.979113+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_235280","record_id":"REC_0000584","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":6.7,"age_at_diagnosis":75,"sex":"male","ecog_performance_status":1,"smoking_pack_years":33,"primary_tumor_size_cm":4.6,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.979358+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_690851","record_id":"REC_0000585","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":4.5,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.979605+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_472431","record_id":"REC_0000586","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":4.1,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":4.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.979939+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_560658","record_id":"REC_0000587","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":4.8,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":7.1,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.980299+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_410081","record_id":"REC_0000588","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":8.6,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":3,"smoking_pack_years":19,"primary_tumor_size_cm":4.0,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.980557+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_774287","record_id":"REC_0000589","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":5.0,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":26,"primary_tumor_size_cm":5.5,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.980791+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_483506","record_id":"REC_0000590","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":8.0,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":3,"smoking_pack_years":20,"primary_tumor_size_cm":3.6,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":6.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.981048+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_413100","record_id":"REC_0000591","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":15.7,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":20,"primary_tumor_size_cm":5.8,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.981319+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_167433","record_id":"REC_0000592","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":15.4,"age_at_diagnosis":86,"sex":"female","ecog_performance_status":2,"smoking_pack_years":23,"primary_tumor_size_cm":3.2,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.981589+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_241540","record_id":"REC_0000593","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":8.6,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":6.3,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":51.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.981827+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_998077","record_id":"REC_0000594","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":5.2,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":52,"primary_tumor_size_cm":5.1,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.982091+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_826412","record_id":"REC_0000595","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":16,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":73,"primary_tumor_size_cm":6.8,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":19.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.982322+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_808744","record_id":"REC_0000596","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":8.9,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":4.8,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.982558+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_973107","record_id":"REC_0000597","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":5.1,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.982802+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_143450","record_id":"REC_0000598","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":30,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":7.1,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":17.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.983048+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_245986","record_id":"REC_0000599","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":17.8,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":8.0,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":7.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.983413+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_444726","record_id":"REC_0000600","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":14.3,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":6.2,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.983658+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_908235","record_id":"REC_0000601","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.4,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.983892+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_353828","record_id":"REC_0000602","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":4.5,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":3.5,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.984257+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_976641","record_id":"REC_0000603","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":6.3,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":24,"primary_tumor_size_cm":7.4,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":43.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.984511+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_480445","record_id":"REC_0000604","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":15.1,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.4,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.984754+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_438995","record_id":"REC_0000605","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":7.6,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.3,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":6.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.984988+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_954552","record_id":"REC_0000606","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":14.5,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":25,"primary_tumor_size_cm":4.8,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.985221+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_730343","record_id":"REC_0000607","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":15.0,"age_at_diagnosis":83,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":8.5,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.985455+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_975887","record_id":"REC_0000608","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":5.8,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.985685+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_784478","record_id":"REC_0000609","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":5.7,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":79,"primary_tumor_size_cm":5.7,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":19.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.985913+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_693645","record_id":"REC_0000610","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":9.7,"age_at_diagnosis":50,"sex":"male","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":6.1,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":38.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.986148+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_244233","record_id":"REC_0000611","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":6.6,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.986383+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_918738","record_id":"REC_0000612","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":13.6,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":7.0,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.986743+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_711509","record_id":"REC_0000613","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":15.9,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":4.5,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":20.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.987034+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_668015","record_id":"REC_0000614","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":6.2,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.987273+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_159809","record_id":"REC_0000615","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":11.5,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":26,"primary_tumor_size_cm":5.9,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":22.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.987542+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_561297","record_id":"REC_0000616","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":4.2,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.987806+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_611942","record_id":"REC_0000617","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":8.5,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":5.1,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.988042+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_748722","record_id":"REC_0000618","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":6.2,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":16.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.988330+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_441663","record_id":"REC_0000619","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":7.4,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":6.8,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.988566+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_576806","record_id":"REC_0000620","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":20,"tmb_mutations_per_mb":6.7,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":66,"primary_tumor_size_cm":5.3,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":24.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.988797+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_920759","record_id":"REC_0000621","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":9.0,"age_at_diagnosis":80,"sex":"male","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":6.1,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.989032+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_504653","record_id":"REC_0000622","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":17.1,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":6.1,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.989261+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_217215","record_id":"REC_0000623","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":13.8,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":33,"primary_tumor_size_cm":5.6,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.989501+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_234457","record_id":"REC_0000624","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":11.1,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":6.0,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.989731+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_293786","record_id":"REC_0000625","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":16,"tmb_mutations_per_mb":13.6,"age_at_diagnosis":52,"sex":"female","ecog_performance_status":0,"smoking_pack_years":27,"primary_tumor_size_cm":5.4,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":21.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.990029+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_262645","record_id":"REC_0000626","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":20,"tmb_mutations_per_mb":6.9,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":6.5,"metastatic_sites_count":8,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":17.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.990266+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_629374","record_id":"REC_0000627","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":30,"tmb_mutations_per_mb":6.1,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":4.4,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":5.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.990499+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_780162","record_id":"REC_0000628","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":21.8,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":5.4,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":20.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.990737+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_362214","record_id":"REC_0000629","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.2,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.991030+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_417914","record_id":"REC_0000630","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":20,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":71,"primary_tumor_size_cm":6.3,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.991263+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_346270","record_id":"REC_0000631","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":4.0,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":8.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.991531+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_284926","record_id":"REC_0000632","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":6.1,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":1,"smoking_pack_years":37,"primary_tumor_size_cm":5.8,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.991766+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_844004","record_id":"REC_0000633","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":34,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":2,"smoking_pack_years":40,"primary_tumor_size_cm":6.6,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.992037+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_580611","record_id":"REC_0000634","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":8.0,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":5.5,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.992322+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_153088","record_id":"REC_0000635","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":3.5,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":42,"primary_tumor_size_cm":5.1,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":7.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.992566+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_280810","record_id":"REC_0000636","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":4.7,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":0,"primary_tumor_size_cm":6.1,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.992802+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_420120","record_id":"REC_0000637","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":6.7,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":35,"primary_tumor_size_cm":6.5,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.993038+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_472045","record_id":"REC_0000638","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":24,"primary_tumor_size_cm":6.8,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.993380+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_373568","record_id":"REC_0000639","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":30,"tmb_mutations_per_mb":6.0,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":57,"primary_tumor_size_cm":6.3,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.993626+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_118118","record_id":"REC_0000640","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":13.3,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":7.0,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.993862+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_201122","record_id":"REC_0000641","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":1,"smoking_pack_years":55,"primary_tumor_size_cm":2.1,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":19.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.994091+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_437521","record_id":"REC_0000642","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":8.0,"age_at_diagnosis":53,"sex":"male","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":4.5,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.994323+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_253609","record_id":"REC_0000643","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":5.6,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":4.8,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.994551+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_123977","record_id":"REC_0000644","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":18.5,"age_at_diagnosis":86,"sex":"female","ecog_performance_status":1,"smoking_pack_years":4,"primary_tumor_size_cm":5.8,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.994782+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_353744","record_id":"REC_0000645","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":8.1,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":0,"smoking_pack_years":5,"primary_tumor_size_cm":6.6,"metastatic_sites_count":11,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.995010+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_441052","record_id":"REC_0000646","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":1,"smoking_pack_years":54,"primary_tumor_size_cm":3.4,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.995241+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_910340","record_id":"REC_0000647","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":28,"primary_tumor_size_cm":7.5,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.995484+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_194282","record_id":"REC_0000648","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":17.3,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":5.3,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.995719+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_284384","record_id":"REC_0000649","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":6.2,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.995956+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_538750","record_id":"REC_0000650","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":5.9,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.996292+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_896012","record_id":"REC_0000651","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":31,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":79,"sex":"male","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":4.1,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.996621+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_768181","record_id":"REC_0000652","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":17,"tmb_mutations_per_mb":15.7,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":2,"smoking_pack_years":6,"primary_tumor_size_cm":5.1,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.996863+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_729416","record_id":"REC_0000653","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":5.0,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":22.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.997093+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_286167","record_id":"REC_0000654","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":31,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":6.8,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":18.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.997327+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_986963","record_id":"REC_0000655","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":11,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.8,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.997562+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_882963","record_id":"REC_0000656","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":24,"primary_tumor_size_cm":4.4,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":21.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.997790+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_490896","record_id":"REC_0000657","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":11.1,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":5.6,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":33.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.998024+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_864066","record_id":"REC_0000658","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":20,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":0,"primary_tumor_size_cm":5.6,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":26.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.998253+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_144396","record_id":"REC_0000659","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ALK fusion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":3.9,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":26.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.998484+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_484947","record_id":"REC_0000660","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":30,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":37,"primary_tumor_size_cm":5.5,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.998723+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_796892","record_id":"REC_0000661","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":31,"tmb_mutations_per_mb":6.3,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":2,"smoking_pack_years":34,"primary_tumor_size_cm":5.3,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.998973+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_187013","record_id":"REC_0000662","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":13.5,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":9.6,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:56.999224+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_876415","record_id":"REC_0000663","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":17.6,"age_at_diagnosis":79,"sex":"male","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":5.8,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.999482+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_751184","record_id":"REC_0000664","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":19,"tmb_mutations_per_mb":8.7,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":3.2,"metastatic_sites_count":3,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":21.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:56.999853+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_469814","record_id":"REC_0000665","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":16.5,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":8.2,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":24.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.000180+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_930467","record_id":"REC_0000666","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":11.5,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":4.9,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.000436+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_356945","record_id":"REC_0000667","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":3.9,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.000677+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_637858","record_id":"REC_0000668","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":0,"primary_tumor_size_cm":2.5,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.000915+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_810584","record_id":"REC_0000669","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":3.2,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.001148+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_253763","record_id":"REC_0000670","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":14.6,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":5.7,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.001380+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_125984","record_id":"REC_0000671","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":17,"tmb_mutations_per_mb":3.6,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":4.4,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.001619+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_820966","record_id":"REC_0000672","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":6.2,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":6.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.001906+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_580031","record_id":"REC_0000673","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":9.9,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":0,"smoking_pack_years":24,"primary_tumor_size_cm":7.3,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.002146+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_867672","record_id":"REC_0000674","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":5.1,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":47,"primary_tumor_size_cm":6.4,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.002379+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_671734","record_id":"REC_0000675","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":22,"primary_tumor_size_cm":4.2,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.002613+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_921449","record_id":"REC_0000676","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":4.8,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":54,"primary_tumor_size_cm":7.2,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":41.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.002845+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_101326","record_id":"REC_0000677","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":16,"tmb_mutations_per_mb":3.3,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":1,"smoking_pack_years":32,"primary_tumor_size_cm":4.9,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.003161+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_152383","record_id":"REC_0000678","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":31,"tmb_mutations_per_mb":9.8,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":2,"smoking_pack_years":9,"primary_tumor_size_cm":6.0,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.003396+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_527355","record_id":"REC_0000679","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":14.5,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":6.2,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.003636+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_829046","record_id":"REC_0000680","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":6.1,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.003868+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_507866","record_id":"REC_0000681","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":5.5,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.004186+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_590155","record_id":"REC_0000682","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":15.8,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":6,"primary_tumor_size_cm":6.7,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.004435+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_890448","record_id":"REC_0000683","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":9.7,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":7.7,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":23.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.004672+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_753878","record_id":"REC_0000684","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":10.5,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":26,"primary_tumor_size_cm":4.8,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.004908+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_384845","record_id":"REC_0000685","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":4.6,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":59,"primary_tumor_size_cm":4.2,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.005143+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_462903","record_id":"REC_0000686","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":14.6,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":24,"primary_tumor_size_cm":6.8,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.005377+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_846364","record_id":"REC_0000687","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":5.5,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":22.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.005608+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_426166","record_id":"REC_0000688","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":14.9,"age_at_diagnosis":43,"sex":"male","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":5.1,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.005844+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_552099","record_id":"REC_0000689","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":4.7,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":5.8,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":5.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.006072+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_533752","record_id":"REC_0000690","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":5.9,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.006373+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_101040","record_id":"REC_0000691","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":25,"primary_tumor_size_cm":2.5,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.006615+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_334642","record_id":"REC_0000692","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":5.7,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.006852+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_798667","record_id":"REC_0000693","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":5.6,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":1,"smoking_pack_years":57,"primary_tumor_size_cm":5.8,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.007087+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_360704","record_id":"REC_0000694","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":16.3,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":7.7,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.007321+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_710750","record_id":"REC_0000695","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":17,"tmb_mutations_per_mb":3.9,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":58,"primary_tumor_size_cm":6.9,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.007549+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_971515","record_id":"REC_0000696","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":15.2,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":7.5,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.007787+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_413860","record_id":"REC_0000697","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":13.1,"age_at_diagnosis":48,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":4.7,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.008023+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_703472","record_id":"REC_0000698","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":15.8,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":4.0,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.008308+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_280602","record_id":"REC_0000699","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":21.7,"age_at_diagnosis":51,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":4.3,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.008545+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_115514","record_id":"REC_0000700","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":15.9,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":6.2,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":5.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.008779+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_547503","record_id":"REC_0000701","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":19,"tmb_mutations_per_mb":4.8,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":42,"primary_tumor_size_cm":8.4,"metastatic_sites_count":8,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.009007+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_772372","record_id":"REC_0000702","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":4.3,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":3.6,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.009240+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_394459","record_id":"REC_0000703","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":32,"tmb_mutations_per_mb":10.1,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":6.1,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.009530+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_743253","record_id":"REC_0000704","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":86,"sex":"male","ecog_performance_status":2,"smoking_pack_years":48,"primary_tumor_size_cm":5.4,"metastatic_sites_count":8,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":18.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.009764+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_372464","record_id":"REC_0000705","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":16.1,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":6.6,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.009996+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_779076","record_id":"REC_0000706","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":18.5,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":5.3,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.010227+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_214205","record_id":"REC_0000707","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":36,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":0,"smoking_pack_years":25,"primary_tumor_size_cm":6.5,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":18.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.010464+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_614615","record_id":"REC_0000708","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":30,"tmb_mutations_per_mb":8.3,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":4.5,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":21.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.010698+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_849578","record_id":"REC_0000709","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":5.6,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":1,"smoking_pack_years":1,"primary_tumor_size_cm":5.2,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.010931+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_801336","record_id":"REC_0000710","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":5.2,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.011162+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_725114","record_id":"REC_0000711","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":20,"tmb_mutations_per_mb":14.6,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.3,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.011395+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_925602","record_id":"REC_0000712","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":14.4,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":3,"smoking_pack_years":19,"primary_tumor_size_cm":6.3,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":17.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.011667+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_890524","record_id":"REC_0000713","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.1,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":4.6,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.011909+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_169173","record_id":"REC_0000714","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.1,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.3,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.012193+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_448495","record_id":"REC_0000715","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":4.1,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":6,"primary_tumor_size_cm":3.1,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.012437+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_955055","record_id":"REC_0000716","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":16.2,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":3.5,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.012750+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_191289","record_id":"REC_0000717","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":4.9,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.012990+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_802831","record_id":"REC_0000718","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":6.0,"age_at_diagnosis":52,"sex":"female","ecog_performance_status":0,"smoking_pack_years":6,"primary_tumor_size_cm":4.8,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":23.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.013222+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_705293","record_id":"REC_0000719","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":32,"tmb_mutations_per_mb":13.1,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":6.2,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.013461+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_946282","record_id":"REC_0000720","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":5.6,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":18.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.013697+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_870021","record_id":"REC_0000721","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":18.3,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":6.5,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.013934+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_723724","record_id":"REC_0000722","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":6.7,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.014164+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_849022","record_id":"REC_0000723","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":16.6,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":4.0,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.014426+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_543007","record_id":"REC_0000724","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":11.5,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":4.8,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":7.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.014674+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_709671","record_id":"REC_0000725","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":4.2,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.015003+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_918853","record_id":"REC_0000726","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":34,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":3.8,"metastatic_sites_count":8,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.015243+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_707843","record_id":"REC_0000727","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":5.5,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":1,"smoking_pack_years":40,"primary_tumor_size_cm":5.6,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":5.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.015521+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_110201","record_id":"REC_0000728","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":17.2,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":23,"primary_tumor_size_cm":5.6,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.015762+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_696028","record_id":"REC_0000729","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":20,"tmb_mutations_per_mb":14.5,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":3,"smoking_pack_years":18,"primary_tumor_size_cm":5.1,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":20.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.016284+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_531628","record_id":"REC_0000730","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":15.2,"age_at_diagnosis":52,"sex":"male","ecog_performance_status":0,"smoking_pack_years":6,"primary_tumor_size_cm":3.8,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":19.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.016570+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_527719","record_id":"REC_0000731","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.7,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.016825+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_189876","record_id":"REC_0000732","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":32,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":7.1,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.017081+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_363029","record_id":"REC_0000733","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":6.4,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.017339+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_295391","record_id":"REC_0000734","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":6.7,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":6.7,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":7.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.017602+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_248162","record_id":"REC_0000735","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":13.1,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":5.8,"metastatic_sites_count":9,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.017861+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_286978","record_id":"REC_0000736","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":8.0,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":6.5,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":24.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.018097+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_970651","record_id":"REC_0000737","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":16,"tmb_mutations_per_mb":5.3,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":69,"primary_tumor_size_cm":5.2,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.018337+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_820896","record_id":"REC_0000738","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":6.3,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":5.0,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.018576+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_538851","record_id":"REC_0000739","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":4.8,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.018824+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_795215","record_id":"REC_0000740","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":0,"smoking_pack_years":38,"primary_tumor_size_cm":6.5,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":6.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.019075+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_617162","record_id":"REC_0000741","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":14.1,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":6.3,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.019335+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_679125","record_id":"REC_0000742","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":7.6,"age_at_diagnosis":89,"sex":"female","ecog_performance_status":0,"smoking_pack_years":37,"primary_tumor_size_cm":7.3,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":16.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.019772+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_396761","record_id":"REC_0000743","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":6.7,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":4.8,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":6.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.020062+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_318229","record_id":"REC_0000744","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":16.4,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":3,"smoking_pack_years":16,"primary_tumor_size_cm":5.8,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.020383+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_504247","record_id":"REC_0000745","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":2.8,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":1,"smoking_pack_years":49,"primary_tumor_size_cm":6.9,"metastatic_sites_count":8,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.020632+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_649795","record_id":"REC_0000746","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":5.3,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":0,"smoking_pack_years":31,"primary_tumor_size_cm":4.3,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.020867+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_889411","record_id":"REC_0000747","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":9.8,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":2,"smoking_pack_years":8,"primary_tumor_size_cm":6.2,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.021099+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_765388","record_id":"REC_0000748","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":45,"primary_tumor_size_cm":5.2,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.021334+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_828854","record_id":"REC_0000749","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":4.5,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.021571+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_690209","record_id":"REC_0000750","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":16.7,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":6.9,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.021805+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_934702","record_id":"REC_0000751","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":5.8,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.022043+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_681432","record_id":"REC_0000752","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":14.6,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":6.0,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":4.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.022286+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_836661","record_id":"REC_0000753","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":14.8,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":3.7,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":19.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.022533+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_429088","record_id":"REC_0000754","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":6.5,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.022770+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_659474","record_id":"REC_0000755","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":34,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":3,"primary_tumor_size_cm":5.1,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.023152+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_353607","record_id":"REC_0000756","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":5.7,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":6.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.023427+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_533468","record_id":"REC_0000757","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":8.3,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":6.0,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.023691+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_958724","record_id":"REC_0000758","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":37,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":3.5,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":18.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.023958+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_667337","record_id":"REC_0000759","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":31,"tmb_mutations_per_mb":8.5,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":4.4,"metastatic_sites_count":3,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":6.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.024283+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_969134","record_id":"REC_0000760","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":14.4,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":4.5,"metastatic_sites_count":3,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":4.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.024567+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_553107","record_id":"REC_0000761","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":6.4,"age_at_diagnosis":87,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":5.0,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":21.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.024836+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_784258","record_id":"REC_0000762","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":17.8,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":6.7,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.025104+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_741054","record_id":"REC_0000763","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":4.2,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.025360+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_200565","record_id":"REC_0000764","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":4.6,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.025603+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_375238","record_id":"REC_0000765","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":15.8,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":6.1,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.025844+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_639803","record_id":"REC_0000766","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":8.4,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":6.6,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.026085+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_747129","record_id":"REC_0000767","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":4.5,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.026330+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_967554","record_id":"REC_0000768","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":30,"tmb_mutations_per_mb":10.0,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":5.5,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":25.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.026723+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_188200","record_id":"REC_0000769","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":14.3,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":3,"primary_tumor_size_cm":5.8,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":6.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.026980+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_705956","record_id":"REC_0000770","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":15.8,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":4.9,"metastatic_sites_count":8,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":5.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.027237+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_411843","record_id":"REC_0000771","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":4.8,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.027504+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_843610","record_id":"REC_0000772","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":5.4,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.027800+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_467348","record_id":"REC_0000773","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":3,"smoking_pack_years":9,"primary_tumor_size_cm":7.3,"metastatic_sites_count":3,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.028121+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_794676","record_id":"REC_0000774","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":7.4,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.028431+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_757480","record_id":"REC_0000775","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":20,"tmb_mutations_per_mb":4.3,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":8.1,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":24.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.028717+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_262941","record_id":"REC_0000776","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":6.0,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.028987+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_535361","record_id":"REC_0000777","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":15.1,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":8.2,"metastatic_sites_count":9,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.029233+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_466225","record_id":"REC_0000778","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":5.7,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":27.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.029480+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_389538","record_id":"REC_0000779","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":2.9,"age_at_diagnosis":79,"sex":"male","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":6.9,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.029722+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_164341","record_id":"REC_0000780","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ALK fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":9.5,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":4,"primary_tumor_size_cm":4.8,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":23.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.029967+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_467106","record_id":"REC_0000781","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":2.3,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.030310+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_692650","record_id":"REC_0000782","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":15.5,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":4.8,"metastatic_sites_count":8,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.030557+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_811153","record_id":"REC_0000783","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":13.5,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":5.8,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.030799+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_627155","record_id":"REC_0000784","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":7.1,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.031046+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_461406","record_id":"REC_0000785","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":4.8,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.031291+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_216014","record_id":"REC_0000786","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":7.3,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.031530+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_402687","record_id":"REC_0000787","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":8.9,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":7.6,"metastatic_sites_count":8,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.031769+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_843333","record_id":"REC_0000788","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":47,"sex":"female","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":6.2,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":5.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.032006+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_976163","record_id":"REC_0000789","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":17.9,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":26,"primary_tumor_size_cm":6.4,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":25.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.032305+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_546756","record_id":"REC_0000790","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":14.4,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":1,"smoking_pack_years":2,"primary_tumor_size_cm":4.9,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.032563+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_619234","record_id":"REC_0000791","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":4.6,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":34,"primary_tumor_size_cm":6.9,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":7.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.032809+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_166568","record_id":"REC_0000792","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":5.1,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.033057+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_512888","record_id":"REC_0000793","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":7.4,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.033299+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_307312","record_id":"REC_0000794","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":0,"smoking_pack_years":51,"primary_tumor_size_cm":3.1,"metastatic_sites_count":8,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.033639+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_527428","record_id":"REC_0000795","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":38,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":29,"primary_tumor_size_cm":6.5,"metastatic_sites_count":8,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.033887+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_275226","record_id":"REC_0000796","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":5.3,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":26.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.034122+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_412148","record_id":"REC_0000797","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":16.2,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":6.7,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.034362+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_487481","record_id":"REC_0000798","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":19,"tmb_mutations_per_mb":3.2,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":40,"primary_tumor_size_cm":6.5,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":23.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.034596+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_661881","record_id":"REC_0000799","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.0,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.034836+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_207148","record_id":"REC_0000800","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":24,"primary_tumor_size_cm":4.4,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":25.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.035072+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_826183","record_id":"REC_0000801","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":3.8,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":18.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.035308+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_292950","record_id":"REC_0000802","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":4.7,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.035551+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_722881","record_id":"REC_0000803","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":13.8,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":5.0,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.035793+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_644842","record_id":"REC_0000804","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":17.4,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":7.0,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.036032+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_621134","record_id":"REC_0000805","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":6.9,"metastatic_sites_count":8,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.036323+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_151292","record_id":"REC_0000806","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":5.9,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":6.8,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.036569+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_601013","record_id":"REC_0000807","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":5.3,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":16.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.036912+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_617390","record_id":"REC_0000808","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":9.5,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":5.2,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.037161+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_201539","record_id":"REC_0000809","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":0,"smoking_pack_years":36,"primary_tumor_size_cm":5.9,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.037402+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_592417","record_id":"REC_0000810","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":34,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":5.5,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":6.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.037646+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_197392","record_id":"REC_0000811","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":35,"tmb_mutations_per_mb":6.3,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":38,"primary_tumor_size_cm":4.3,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":25.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.037892+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_912570","record_id":"REC_0000812","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":17.3,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":4.7,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.038135+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_762624","record_id":"REC_0000813","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":6.1,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":20.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.038376+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_474953","record_id":"REC_0000814","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":8,"primary_tumor_size_cm":3.9,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.038611+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_567763","record_id":"REC_0000815","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":2,"smoking_pack_years":0,"primary_tumor_size_cm":6.4,"metastatic_sites_count":3,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.038866+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_733230","record_id":"REC_0000816","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":3,"smoking_pack_years":21,"primary_tumor_size_cm":6.4,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.039121+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_837978","record_id":"REC_0000817","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":33,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":4.3,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.039381+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_204025","record_id":"REC_0000818","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":3.5,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":8.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.039643+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_255864","record_id":"REC_0000819","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":11.1,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":4.5,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.039918+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_193613","record_id":"REC_0000820","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":7.3,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":6.0,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":21.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.040369+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_109134","record_id":"REC_0000821","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":8.0,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":5.8,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.040683+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_132975","record_id":"REC_0000822","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":15.2,"age_at_diagnosis":53,"sex":"male","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":4.4,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":30.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.040972+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_413165","record_id":"REC_0000823","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":1,"smoking_pack_years":26,"primary_tumor_size_cm":5.9,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.041238+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_150904","record_id":"REC_0000824","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":14.3,"age_at_diagnosis":75,"sex":"male","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":6.2,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":25.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.041501+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_984173","record_id":"REC_0000825","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":5.5,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.0,"metastatic_sites_count":3,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.041787+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_767127","record_id":"REC_0000826","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":18,"tmb_mutations_per_mb":15.0,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":5.9,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.042119+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_191918","record_id":"REC_0000827","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":32,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.4,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.042407+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_706626","record_id":"REC_0000828","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":9.5,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":5.6,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.042683+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_483571","record_id":"REC_0000829","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":77,"sex":"male","ecog_performance_status":3,"smoking_pack_years":13,"primary_tumor_size_cm":4.7,"metastatic_sites_count":8,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.042959+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_288606","record_id":"REC_0000830","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":3.8,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":18.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.043224+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_628403","record_id":"REC_0000831","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":30,"tmb_mutations_per_mb":4.9,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":43,"primary_tumor_size_cm":5.5,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.043481+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_150723","record_id":"REC_0000832","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":18,"tmb_mutations_per_mb":13.8,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":5.1,"metastatic_sites_count":8,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":7.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.043735+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_614910","record_id":"REC_0000833","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":6.2,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.044161+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_712037","record_id":"REC_0000834","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":32,"tmb_mutations_per_mb":16.1,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.4,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.044485+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_466107","record_id":"REC_0000835","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":5.1,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":74,"primary_tumor_size_cm":6.3,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.044758+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_221794","record_id":"REC_0000836","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":6.5,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":5.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.045020+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_246816","record_id":"REC_0000837","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":5.9,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.045327+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_926197","record_id":"REC_0000838","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":24,"primary_tumor_size_cm":4.7,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":33.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.045601+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_541099","record_id":"REC_0000839","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":19,"tmb_mutations_per_mb":4.8,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":5.5,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":17.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.045868+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_506517","record_id":"REC_0000840","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":84,"sex":"male","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":4.0,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.046137+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_798374","record_id":"REC_0000841","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":8.0,"age_at_diagnosis":46,"sex":"male","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":6.1,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":19.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.046402+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_302865","record_id":"REC_0000842","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":10.1,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":32,"primary_tumor_size_cm":6.2,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":17.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.046679+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_190171","record_id":"REC_0000843","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":19.5,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":6.4,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":28.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.046967+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_744028","record_id":"REC_0000844","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":8.4,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":6.6,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":16.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.047226+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_279721","record_id":"REC_0000845","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":14.0,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":5.4,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":22.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.047489+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_343067","record_id":"REC_0000846","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":16.2,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":4.8,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":23.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.047843+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_608188","record_id":"REC_0000847","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":30,"tmb_mutations_per_mb":14.4,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":5.7,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":20.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.048138+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_843969","record_id":"REC_0000848","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":32,"tmb_mutations_per_mb":1.9,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":47,"primary_tumor_size_cm":5.0,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.048403+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_732052","record_id":"REC_0000849","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":11.5,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":4.2,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":24.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.048667+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_556010","record_id":"REC_0000850","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":2,"smoking_pack_years":25,"primary_tumor_size_cm":4.1,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.048903+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_916334","record_id":"REC_0000851","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":32,"tmb_mutations_per_mb":17.4,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":6.0,"metastatic_sites_count":8,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.049148+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_184513","record_id":"REC_0000852","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":16.1,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":9,"primary_tumor_size_cm":6.5,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.049391+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_950732","record_id":"REC_0000853","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":1,"smoking_pack_years":41,"primary_tumor_size_cm":5.9,"metastatic_sites_count":8,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":6.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.049631+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_255756","record_id":"REC_0000854","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":13.1,"age_at_diagnosis":74,"sex":"male","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.9,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":21.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.049875+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_210195","record_id":"REC_0000855","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":6.7,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.050125+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_534598","record_id":"REC_0000856","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":30,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":78,"sex":"male","ecog_performance_status":1,"smoking_pack_years":28,"primary_tumor_size_cm":4.2,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.050368+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_527328","record_id":"REC_0000857","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":3,"smoking_pack_years":11,"primary_tumor_size_cm":6.2,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":19.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.050615+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_359871","record_id":"REC_0000858","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":15.3,"age_at_diagnosis":52,"sex":"male","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":4.5,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.050861+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_137118","record_id":"REC_0000859","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":17,"tmb_mutations_per_mb":6.0,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":1,"smoking_pack_years":47,"primary_tumor_size_cm":4.8,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":20.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.051220+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_922331","record_id":"REC_0000860","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":1,"smoking_pack_years":26,"primary_tumor_size_cm":4.7,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.051467+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_350271","record_id":"REC_0000861","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.2,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.051716+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_656667","record_id":"REC_0000862","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":19,"tmb_mutations_per_mb":7.6,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":4.8,"metastatic_sites_count":3,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.051958+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_281480","record_id":"REC_0000863","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":36,"tmb_mutations_per_mb":6.9,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":48,"primary_tumor_size_cm":6.7,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":22.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.052247+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_926724","record_id":"REC_0000864","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":4.8,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.052509+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_929084","record_id":"REC_0000865","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":36,"primary_tumor_size_cm":7.7,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":41.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.052755+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_428237","record_id":"REC_0000866","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":7.0,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.053002+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_643857","record_id":"REC_0000867","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":19,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":3.7,"metastatic_sites_count":3,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.053248+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_189627","record_id":"REC_0000868","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":10.0,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":4.2,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.053503+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_359286","record_id":"REC_0000869","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":18,"tmb_mutations_per_mb":5.1,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":1,"smoking_pack_years":46,"primary_tumor_size_cm":4.4,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":4.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.053747+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_914629","record_id":"REC_0000870","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":20.3,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":3,"smoking_pack_years":17,"primary_tumor_size_cm":6.5,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.054005+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_581811","record_id":"REC_0000871","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":5.8,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":43.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.054270+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_144338","record_id":"REC_0000872","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":17.0,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":6.7,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.054644+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_359966","record_id":"REC_0000873","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":30,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":76,"sex":"male","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":7.2,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.054923+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_449769","record_id":"REC_0000874","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":14,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":84,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":4.7,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":17.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.055194+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_698882","record_id":"REC_0000875","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":6.0,"metastatic_sites_count":3,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":5.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.055470+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_671920","record_id":"REC_0000876","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":17,"tmb_mutations_per_mb":21.0,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":5.9,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.055766+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_749492","record_id":"REC_0000877","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":19.4,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":0,"smoking_pack_years":2,"primary_tumor_size_cm":6.9,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.056038+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_495748","record_id":"REC_0000878","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":7.9,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":2,"primary_tumor_size_cm":6.9,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.056361+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_430034","record_id":"REC_0000879","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":32,"tmb_mutations_per_mb":4.7,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":60,"primary_tumor_size_cm":5.5,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.056624+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_303514","record_id":"REC_0000880","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":2.1,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.056890+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_535423","record_id":"REC_0000881","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":18.5,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":6.0,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.057154+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_990034","record_id":"REC_0000882","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":33,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":6.0,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":27.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.057406+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_265251","record_id":"REC_0000883","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":0,"smoking_pack_years":45,"primary_tumor_size_cm":5.5,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.057653+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_989392","record_id":"REC_0000884","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":14,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":54,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":4.7,"metastatic_sites_count":8,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":7.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.057901+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_142842","record_id":"REC_0000885","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":20.5,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":1,"smoking_pack_years":24,"primary_tumor_size_cm":6.6,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.058266+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_259490","record_id":"REC_0000886","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":31,"tmb_mutations_per_mb":2.5,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":55,"primary_tumor_size_cm":7.8,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":17.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.058538+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_196417","record_id":"REC_0000887","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":10.5,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":7.0,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.058824+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_648307","record_id":"REC_0000888","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":6.8,"metastatic_sites_count":9,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.059160+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_758408","record_id":"REC_0000889","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":4.9,"age_at_diagnosis":81,"sex":"male","ecog_performance_status":2,"smoking_pack_years":22,"primary_tumor_size_cm":3.1,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":22.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.059485+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_951038","record_id":"REC_0000890","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":28,"primary_tumor_size_cm":4.9,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.059785+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_984584","record_id":"REC_0000891","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":5.3,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":25.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.060131+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_476429","record_id":"REC_0000892","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":5.5,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.060452+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_349432","record_id":"REC_0000893","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":30,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":5.9,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.060728+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_931895","record_id":"REC_0000894","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":28,"primary_tumor_size_cm":4.5,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.060978+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_452161","record_id":"REC_0000895","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":5.0,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.061217+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_959234","record_id":"REC_0000896","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":18.6,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":6.6,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.061457+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_412859","record_id":"REC_0000897","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":14.4,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":7.2,"metastatic_sites_count":3,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.061700+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_536377","record_id":"REC_0000898","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":15.2,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":5.4,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.062057+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_932211","record_id":"REC_0000899","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":18.4,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":3.8,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.062305+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_148650","record_id":"REC_0000900","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":6.9,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":1,"smoking_pack_years":66,"primary_tumor_size_cm":5.6,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":4.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.062547+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_563346","record_id":"REC_0000901","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":7.4,"age_at_diagnosis":54,"sex":"female","ecog_performance_status":0,"smoking_pack_years":77,"primary_tumor_size_cm":5.5,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":22.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.062793+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_437752","record_id":"REC_0000902","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":3.8,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":7.3,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.063034+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_817113","record_id":"REC_0000903","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":15.4,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":6.3,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":42.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.063284+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_370856","record_id":"REC_0000904","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":50,"sex":"male","ecog_performance_status":0,"smoking_pack_years":59,"primary_tumor_size_cm":4.7,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.063524+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_300825","record_id":"REC_0000905","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":6.3,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":34,"primary_tumor_size_cm":8.0,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.063795+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_333548","record_id":"REC_0000906","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":9.9,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":25,"primary_tumor_size_cm":3.3,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.064107+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_119351","record_id":"REC_0000907","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":8.0,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.064443+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_786353","record_id":"REC_0000908","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":3.2,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":0,"smoking_pack_years":36,"primary_tumor_size_cm":4.8,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.064742+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_160461","record_id":"REC_0000909","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":9.0,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":6.4,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.065015+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_644025","record_id":"REC_0000910","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":84,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":6.1,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.065265+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_568388","record_id":"REC_0000911","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":13.1,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":5.0,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.065641+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_421411","record_id":"REC_0000912","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":10.3,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":3,"primary_tumor_size_cm":4.0,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.065918+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_894655","record_id":"REC_0000913","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":19,"tmb_mutations_per_mb":9.0,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":8.6,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.066177+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_937356","record_id":"REC_0000914","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.2,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":22.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.066420+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_861712","record_id":"REC_0000915","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":77,"sex":"male","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":5.1,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.066663+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_426849","record_id":"REC_0000916","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":5.8,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.066904+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_593008","record_id":"REC_0000917","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":4.9,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.067148+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_593282","record_id":"REC_0000918","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":13.5,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":7.0,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.067393+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_877356","record_id":"REC_0000919","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":3,"smoking_pack_years":11,"primary_tumor_size_cm":5.5,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":18.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.067638+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_330016","record_id":"REC_0000920","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":15.3,"age_at_diagnosis":74,"sex":"male","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":2.7,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.067879+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_744313","record_id":"REC_0000921","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":6.7,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":5.7,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":18.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.068160+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_646722","record_id":"REC_0000922","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":14.1,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":0,"smoking_pack_years":5,"primary_tumor_size_cm":5.0,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.068420+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_866765","record_id":"REC_0000923","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":15,"tmb_mutations_per_mb":17.8,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":26,"primary_tumor_size_cm":4.5,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":27.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.068682+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_269946","record_id":"REC_0000924","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":9.0,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":1,"smoking_pack_years":42,"primary_tumor_size_cm":6.6,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":17.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.069121+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_436257","record_id":"REC_0000925","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":32,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":78,"sex":"male","ecog_performance_status":2,"smoking_pack_years":20,"primary_tumor_size_cm":5.2,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.069436+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_383926","record_id":"REC_0000926","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":33,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":7.0,"metastatic_sites_count":3,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":8.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.069720+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_703771","record_id":"REC_0000927","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":9.8,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":6.3,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.069997+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_719476","record_id":"REC_0000928","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.8,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":6.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.070294+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_801450","record_id":"REC_0000929","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":20,"tmb_mutations_per_mb":6.4,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":3.4,"metastatic_sites_count":8,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.070558+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_187056","record_id":"REC_0000930","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":15.4,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":5.3,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.070802+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_875573","record_id":"REC_0000931","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":5.1,"metastatic_sites_count":8,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":19.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.071041+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_846536","record_id":"REC_0000932","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":4.5,"age_at_diagnosis":54,"sex":"female","ecog_performance_status":0,"smoking_pack_years":24,"primary_tumor_size_cm":4.9,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.071276+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_846137","record_id":"REC_0000933","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":4.8,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.071520+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_877975","record_id":"REC_0000934","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":18,"tmb_mutations_per_mb":1.5,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":2.9,"metastatic_sites_count":8,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.071759+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_690215","record_id":"REC_0000935","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":17,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.2,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.071992+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_567007","record_id":"REC_0000936","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":37,"tmb_mutations_per_mb":7.3,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":1,"smoking_pack_years":0,"primary_tumor_size_cm":4.7,"metastatic_sites_count":3,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.072283+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_452904","record_id":"REC_0000937","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":11.1,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":4,"smoking_pack_years":15,"primary_tumor_size_cm":5.0,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":5.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.072652+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_768488","record_id":"REC_0000938","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":4.8,"age_at_diagnosis":48,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":4.8,"metastatic_sites_count":3,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.072915+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_625959","record_id":"REC_0000939","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":14.8,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":4.8,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.073157+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_257020","record_id":"REC_0000940","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":8.3,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":99,"primary_tumor_size_cm":6.0,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.073395+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_858423","record_id":"REC_0000941","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":1,"smoking_pack_years":0,"primary_tumor_size_cm":4.7,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.073632+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_112004","record_id":"REC_0000942","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":4.5,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":59,"primary_tumor_size_cm":6.1,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":18.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.073862+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_202336","record_id":"REC_0000943","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":19.2,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":6.1,"metastatic_sites_count":9,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.074104+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_284098","record_id":"REC_0000944","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":30,"tmb_mutations_per_mb":6.3,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":4.6,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":17.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.074340+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_230155","record_id":"REC_0000945","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":3,"smoking_pack_years":49,"primary_tumor_size_cm":3.5,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.074577+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_325514","record_id":"REC_0000946","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":34,"tmb_mutations_per_mb":5.9,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":31,"primary_tumor_size_cm":7.8,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.074813+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_968435","record_id":"REC_0000947","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":3.8,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.075050+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_429778","record_id":"REC_0000948","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":13,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":6.0,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":18.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.075286+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_260059","record_id":"REC_0000949","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":5,"primary_tumor_size_cm":3.7,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.075525+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_568042","record_id":"REC_0000950","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":10.5,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":1,"primary_tumor_size_cm":5.3,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.075853+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_119726","record_id":"REC_0000951","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":78,"sex":"male","ecog_performance_status":2,"smoking_pack_years":23,"primary_tumor_size_cm":6.5,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.076159+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_705206","record_id":"REC_0000952","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":3,"smoking_pack_years":20,"primary_tumor_size_cm":6.0,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.076436+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_980094","record_id":"REC_0000953","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":83,"sex":"female","ecog_performance_status":3,"smoking_pack_years":11,"primary_tumor_size_cm":6.8,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":7.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.076752+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_763782","record_id":"REC_0000954","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":81,"primary_tumor_size_cm":5.4,"metastatic_sites_count":9,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":17.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.077018+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_472184","record_id":"REC_0000955","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":3,"smoking_pack_years":21,"primary_tumor_size_cm":5.6,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":21.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.077256+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_807795","record_id":"REC_0000956","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":6.8,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":5.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.077499+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_306192","record_id":"REC_0000957","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":16.7,"age_at_diagnosis":54,"sex":"male","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":4.3,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.077752+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_166999","record_id":"REC_0000958","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":4.1,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.078009+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_963015","record_id":"REC_0000959","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":32,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":2,"smoking_pack_years":57,"primary_tumor_size_cm":3.5,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.078275+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_157942","record_id":"REC_0000960","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":83,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":6.3,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.078560+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_491488","record_id":"REC_0000961","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":2.8,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":5.2,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.078873+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_179211","record_id":"REC_0000962","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":9.7,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":7.2,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.079163+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_715257","record_id":"REC_0000963","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":45,"primary_tumor_size_cm":7.2,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.079553+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_598885","record_id":"REC_0000964","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":7.6,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":76,"primary_tumor_size_cm":5.7,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":18.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.079832+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_522525","record_id":"REC_0000965","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":6.4,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":2,"smoking_pack_years":4,"primary_tumor_size_cm":5.1,"metastatic_sites_count":8,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.080162+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_927589","record_id":"REC_0000966","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":10.5,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":5.1,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":27.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.080438+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_503430","record_id":"REC_0000967","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":1,"primary_tumor_size_cm":4.8,"metastatic_sites_count":8,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":7.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.080682+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_496877","record_id":"REC_0000968","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":33,"tmb_mutations_per_mb":15.8,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":4.6,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.080920+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_503340","record_id":"REC_0000969","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":23,"primary_tumor_size_cm":5.4,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":7.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.081155+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_934002","record_id":"REC_0000970","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":16,"tmb_mutations_per_mb":5.1,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":5.6,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.081385+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_826459","record_id":"REC_0000971","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":6.1,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":19.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.081614+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_936645","record_id":"REC_0000972","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":78,"sex":"male","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":5.4,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":4.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.081849+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_569222","record_id":"REC_0000973","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":16.1,"age_at_diagnosis":78,"sex":"male","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":6.2,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.082088+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_558868","record_id":"REC_0000974","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":6.4,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":61,"primary_tumor_size_cm":5.5,"metastatic_sites_count":3,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.082317+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_779307","record_id":"REC_0000975","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":2.5,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":45,"primary_tumor_size_cm":3.8,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":27.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.082553+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_664801","record_id":"REC_0000976","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":5.6,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":51,"primary_tumor_size_cm":6.3,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.082865+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_973378","record_id":"REC_0000977","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":8.9,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":44,"primary_tumor_size_cm":6.8,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.083105+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_808461","record_id":"REC_0000978","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":5.0,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":37,"primary_tumor_size_cm":5.4,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.083341+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_529239","record_id":"REC_0000979","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":4.8,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":0,"smoking_pack_years":53,"primary_tumor_size_cm":4.0,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.083577+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_294789","record_id":"REC_0000980","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":3.2,"metastatic_sites_count":3,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.083812+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_608601","record_id":"REC_0000981","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":18.2,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":4.4,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":6.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.084048+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_667665","record_id":"REC_0000982","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":0,"smoking_pack_years":25,"primary_tumor_size_cm":5.3,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":18.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.084321+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_600161","record_id":"REC_0000983","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":4.5,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.084562+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_697416","record_id":"REC_0000984","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":18.2,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":7.8,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.084802+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_263062","record_id":"REC_0000985","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":6.1,"age_at_diagnosis":83,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":6.7,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":7.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.085029+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_421187","record_id":"REC_0000986","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":15.3,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":6.3,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":20.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.085264+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_697087","record_id":"REC_0000987","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":6.5,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.085497+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_739945","record_id":"REC_0000988","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":3.4,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":18.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.085733+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_913262","record_id":"REC_0000989","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":15.9,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":7.2,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":6.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.086018+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_664050","record_id":"REC_0000990","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":6.2,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.086253+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_752284","record_id":"REC_0000991","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":5.5,"age_at_diagnosis":85,"sex":"female","ecog_performance_status":1,"smoking_pack_years":50,"primary_tumor_size_cm":6.7,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.086483+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_255599","record_id":"REC_0000992","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":6.8,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":25.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.086722+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_221841","record_id":"REC_0000993","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":19,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":42,"primary_tumor_size_cm":5.4,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.086949+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_417875","record_id":"REC_0000994","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":17.1,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":5.6,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":7.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.087182+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_322442","record_id":"REC_0000995","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":15.0,"age_at_diagnosis":88,"sex":"male","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":6.1,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":20.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.087416+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_407970","record_id":"REC_0000996","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":14.8,"age_at_diagnosis":54,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":4.4,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.087649+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_872599","record_id":"REC_0000997","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":6.4,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":52,"primary_tumor_size_cm":3.7,"metastatic_sites_count":3,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":16.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.087880+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_606800","record_id":"REC_0000998","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":9.8,"age_at_diagnosis":53,"sex":"male","ecog_performance_status":0,"smoking_pack_years":5,"primary_tumor_size_cm":6.0,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":21.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.088156+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_550060","record_id":"REC_0000999","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":6.9,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":47,"primary_tumor_size_cm":7.0,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":16.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.088402+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_947221","record_id":"REC_0001000","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":83,"sex":"female","ecog_performance_status":3,"smoking_pack_years":19,"primary_tumor_size_cm":5.3,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.088633+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_443742","record_id":"REC_0001001","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.7,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":7.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.088876+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_418434","record_id":"REC_0001002","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":14.9,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":7.4,"metastatic_sites_count":8,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.089191+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_141213","record_id":"REC_0001003","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":31,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":4,"smoking_pack_years":18,"primary_tumor_size_cm":7.1,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.089471+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_467760","record_id":"REC_0001004","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":5.3,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":6.5,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.089722+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_280726","record_id":"REC_0001005","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":7.3,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":51,"primary_tumor_size_cm":5.6,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":20.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.089964+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_918916","record_id":"REC_0001006","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":8.6,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":5.9,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":6.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.090202+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_408730","record_id":"REC_0001007","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":81,"sex":"male","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":5.5,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":6.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.090438+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_490850","record_id":"REC_0001008","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":15.1,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":8.0,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.090672+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_217675","record_id":"REC_0001009","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":17.7,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":4.9,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":17.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.090909+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_348564","record_id":"REC_0001010","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":13.5,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":6.5,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.091145+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_382659","record_id":"REC_0001011","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":20,"tmb_mutations_per_mb":5.2,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":87,"primary_tumor_size_cm":4.6,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":17.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.091378+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_791611","record_id":"REC_0001012","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":5.4,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.091611+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_980762","record_id":"REC_0001013","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":4.7,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.091844+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_531674","record_id":"REC_0001014","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":14.5,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":2.0,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.092152+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_367560","record_id":"REC_0001015","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":17.4,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":6.8,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.092511+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_242553","record_id":"REC_0001016","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":15.1,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":4.0,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":17.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.092765+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_403507","record_id":"REC_0001017","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":44,"primary_tumor_size_cm":7.0,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.093000+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_624704","record_id":"REC_0001018","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":10.1,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":4.6,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":5.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.093232+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_690572","record_id":"REC_0001019","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":49,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":5.6,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.093467+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_536557","record_id":"REC_0001020","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":29,"primary_tumor_size_cm":6.5,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":47.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.093707+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_714871","record_id":"REC_0001021","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":9.1,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":6.8,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":5.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.093944+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_342056","record_id":"REC_0001022","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":31,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":4.9,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":28.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.094179+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_938829","record_id":"REC_0001023","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":9.0,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":4.7,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.094409+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_850705","record_id":"REC_0001024","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":16.1,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":20,"primary_tumor_size_cm":4.1,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.094643+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_434353","record_id":"REC_0001025","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":6.6,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":58.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.094877+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_307322","record_id":"REC_0001026","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":18.7,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":3,"smoking_pack_years":22,"primary_tumor_size_cm":5.4,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":19.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.095111+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_698625","record_id":"REC_0001027","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":19,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":5.9,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":21.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.095343+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_492298","record_id":"REC_0001028","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":17,"tmb_mutations_per_mb":18.9,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":26,"primary_tumor_size_cm":4.1,"metastatic_sites_count":3,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":8.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.095652+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_693179","record_id":"REC_0001029","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":4.5,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":19.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.095895+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_916769","record_id":"REC_0001030","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":4.6,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":2,"smoking_pack_years":22,"primary_tumor_size_cm":4.5,"metastatic_sites_count":3,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":16.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.096171+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_965225","record_id":"REC_0001031","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":16.7,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":3.6,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":26.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.096421+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_550087","record_id":"REC_0001032","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":5.7,"metastatic_sites_count":9,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.096700+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_725638","record_id":"REC_0001033","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":32,"tmb_mutations_per_mb":6.9,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":7,"primary_tumor_size_cm":6.0,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.096941+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_785639","record_id":"REC_0001034","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":5.2,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":2,"smoking_pack_years":23,"primary_tumor_size_cm":8.5,"metastatic_sites_count":8,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":16.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.097172+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_454772","record_id":"REC_0001035","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":15.1,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":6.2,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.097405+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_519792","record_id":"REC_0001036","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":17,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":0,"smoking_pack_years":6,"primary_tumor_size_cm":5.5,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.097634+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_887589","record_id":"REC_0001037","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":15.4,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":5.6,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":36.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.097875+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_550494","record_id":"REC_0001038","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":15.7,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":4.8,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.098111+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_929906","record_id":"REC_0001039","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":5.1,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":32.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.098349+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_888998","record_id":"REC_0001040","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":54,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":6.4,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.098585+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_323989","record_id":"REC_0001041","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":6.2,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":17.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.098922+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_482120","record_id":"REC_0001042","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":54,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":6.5,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":7.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.099188+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_264124","record_id":"REC_0001043","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":18,"tmb_mutations_per_mb":4.5,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":7.6,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":6.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.099443+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_346611","record_id":"REC_0001044","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":50,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":5.1,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":30.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.099699+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_623457","record_id":"REC_0001045","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":14.4,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":5.6,"metastatic_sites_count":3,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":26.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.099941+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_634600","record_id":"REC_0001046","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":33,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":8,"primary_tumor_size_cm":6.0,"metastatic_sites_count":8,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.100258+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_165681","record_id":"REC_0001047","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":8.3,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":39,"primary_tumor_size_cm":4.6,"metastatic_sites_count":8,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.100513+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_367235","record_id":"REC_0001048","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":5.8,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":43.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.100761+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_795523","record_id":"REC_0001049","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":14.5,"age_at_diagnosis":52,"sex":"male","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":6.3,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.101003+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_609091","record_id":"REC_0001050","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":14.5,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":5.1,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":5.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.101243+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_969277","record_id":"REC_0001051","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":5.1,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":7.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.101481+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_155629","record_id":"REC_0001052","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None","pd_l1_tps_percent":19,"tmb_mutations_per_mb":4.2,"age_at_diagnosis":80,"sex":"male","ecog_performance_status":1,"smoking_pack_years":50,"primary_tumor_size_cm":4.7,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":41.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.101721+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_955410","record_id":"REC_0001053","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":20.5,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":6.8,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":23.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.101960+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_572365","record_id":"REC_0001054","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":37,"tmb_mutations_per_mb":4.8,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":33,"primary_tumor_size_cm":5.1,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.102283+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_309908","record_id":"REC_0001055","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":2,"smoking_pack_years":24,"primary_tumor_size_cm":7.0,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":7.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.102521+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_370610","record_id":"REC_0001056","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":15.8,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":5.4,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.102757+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_999520","record_id":"REC_0001057","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":4.9,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":40.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.102991+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_876951","record_id":"REC_0001058","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":12,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":6.0,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.103224+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_273234","record_id":"REC_0001059","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":7.3,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":7.0,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.103455+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_264323","record_id":"REC_0001060","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":16.7,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":5.5,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":5.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.103705+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_520448","record_id":"REC_0001061","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":14.1,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":5.0,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.103950+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_677661","record_id":"REC_0001062","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ALK fusion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":15.2,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":5.7,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":26.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.104278+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_902286","record_id":"REC_0001063","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":4.4,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.104549+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_916920","record_id":"REC_0001064","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":30,"tmb_mutations_per_mb":6.9,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":4.2,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":23.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.104809+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_823859","record_id":"REC_0001065","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":45,"primary_tumor_size_cm":8.6,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.105079+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_507001","record_id":"REC_0001066","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":14.4,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":6.0,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.105341+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_915094","record_id":"REC_0001067","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":5.6,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.105701+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_949181","record_id":"REC_0001068","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":14.9,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":4.6,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":4.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.105952+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_879407","record_id":"REC_0001069","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":18,"tmb_mutations_per_mb":16.9,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":5.8,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":33.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.106191+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_338216","record_id":"REC_0001070","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":10.3,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":8,"primary_tumor_size_cm":4.5,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.106425+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_350468","record_id":"REC_0001071","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":16.8,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":24,"primary_tumor_size_cm":5.0,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.106659+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_402239","record_id":"REC_0001072","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":6.9,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.106893+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_615633","record_id":"REC_0001073","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":53,"primary_tumor_size_cm":4.9,"metastatic_sites_count":8,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":17.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.107122+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_260860","record_id":"REC_0001074","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":4.8,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.107354+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_738246","record_id":"REC_0001075","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":15.7,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":3.3,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.107590+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_634442","record_id":"REC_0001076","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":1,"smoking_pack_years":34,"primary_tumor_size_cm":5.6,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":7.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.107836+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_558484","record_id":"REC_0001077","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":3.0,"metastatic_sites_count":3,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.108128+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_406021","record_id":"REC_0001078","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":5.9,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":16.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.108390+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_901049","record_id":"REC_0001079","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":85,"sex":"female","ecog_performance_status":1,"smoking_pack_years":64,"primary_tumor_size_cm":4.9,"metastatic_sites_count":8,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.108643+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_260502","record_id":"REC_0001080","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":19.7,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":6.9,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.108974+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_121503","record_id":"REC_0001081","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":75,"sex":"male","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":7.2,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.109219+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_482816","record_id":"REC_0001082","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":36,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":5.7,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.109456+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_588459","record_id":"REC_0001083","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":15,"tmb_mutations_per_mb":16.1,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":6.9,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":6.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.109691+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_572452","record_id":"REC_0001084","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":10.3,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":3,"smoking_pack_years":13,"primary_tumor_size_cm":5.5,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.109927+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_820629","record_id":"REC_0001085","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":20,"tmb_mutations_per_mb":4.4,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":1,"smoking_pack_years":27,"primary_tumor_size_cm":4.0,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":20.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.110161+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_503558","record_id":"REC_0001086","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":8.5,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":7.9,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.110392+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_855318","record_id":"REC_0001087","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":14.8,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":6.1,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":18.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.110630+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_532051","record_id":"REC_0001088","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.4,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.110865+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_331012","record_id":"REC_0001089","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":3.0,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.111096+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_752500","record_id":"REC_0001090","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":3.6,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.111327+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_165656","record_id":"REC_0001091","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":5.5,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.111557+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_422598","record_id":"REC_0001092","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":3.8,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":3.6,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":5.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.111823+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_880724","record_id":"REC_0001093","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":5.2,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.112212+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_838620","record_id":"REC_0001094","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":20,"tmb_mutations_per_mb":5.0,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":61,"primary_tumor_size_cm":4.3,"metastatic_sites_count":3,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":21.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.112467+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_451086","record_id":"REC_0001095","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":4.3,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":3,"smoking_pack_years":11,"primary_tumor_size_cm":6.2,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":20.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.112705+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_676431","record_id":"REC_0001096","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":15.1,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":6.5,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":16.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.112941+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_190989","record_id":"REC_0001097","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":5.7,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":7,"primary_tumor_size_cm":4.3,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":27.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.113171+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_739540","record_id":"REC_0001098","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":7.9,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":3,"smoking_pack_years":13,"primary_tumor_size_cm":8.8,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.113405+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_579548","record_id":"REC_0001099","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":15.5,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":6.7,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.113641+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_828067","record_id":"REC_0001100","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":5.6,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":23.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.113885+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_862258","record_id":"REC_0001101","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":13.6,"age_at_diagnosis":51,"sex":"male","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":4.5,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":48.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.114121+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_133116","record_id":"REC_0001102","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":18.1,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":7.0,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.114356+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_598559","record_id":"REC_0001103","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":10.5,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":1,"smoking_pack_years":4,"primary_tumor_size_cm":5.5,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.114587+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_811953","record_id":"REC_0001104","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":31,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":7.1,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.114818+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_380412","record_id":"REC_0001105","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":14.1,"age_at_diagnosis":85,"sex":"female","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":6.2,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.115055+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_680911","record_id":"REC_0001106","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":0,"primary_tumor_size_cm":4.8,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":6.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.115336+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_745280","record_id":"REC_0001107","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":3.8,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.115573+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_277444","record_id":"REC_0001108","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":9.9,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":25,"primary_tumor_size_cm":5.7,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.115803+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_796353","record_id":"REC_0001109","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":10.1,"age_at_diagnosis":87,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":4.5,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":18.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.116035+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_891768","record_id":"REC_0001110","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ALK fusion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":16.8,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":25,"primary_tumor_size_cm":3.3,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":54.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.116345+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_805467","record_id":"REC_0001111","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":34,"tmb_mutations_per_mb":5.1,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":27,"primary_tumor_size_cm":5.8,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.116582+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_420697","record_id":"REC_0001112","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":5.0,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":19.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.116814+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_169588","record_id":"REC_0001113","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":5.6,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.117050+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_825774","record_id":"REC_0001114","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":6.5,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.117288+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_349249","record_id":"REC_0001115","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":7.4,"age_at_diagnosis":51,"sex":"male","ecog_performance_status":0,"smoking_pack_years":46,"primary_tumor_size_cm":5.0,"metastatic_sites_count":3,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.117521+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_476040","record_id":"REC_0001116","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":5,"primary_tumor_size_cm":5.4,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.117752+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_600026","record_id":"REC_0001117","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":13.5,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":5.2,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.117988+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_166314","record_id":"REC_0001118","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":4.9,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":54,"primary_tumor_size_cm":4.7,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":21.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.118219+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_591466","record_id":"REC_0001119","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":0,"smoking_pack_years":24,"primary_tumor_size_cm":5.5,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.118509+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_757971","record_id":"REC_0001120","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":14.9,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":6.3,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.118754+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_891197","record_id":"REC_0001121","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":5.8,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.119016+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_452793","record_id":"REC_0001122","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":5.0,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.119272+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_507829","record_id":"REC_0001123","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":6.4,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":4.6,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.119523+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_201416","record_id":"REC_0001124","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":6.8,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.119778+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_701483","record_id":"REC_0001125","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":36,"tmb_mutations_per_mb":8.9,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":9,"primary_tumor_size_cm":5.4,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.120020+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_498900","record_id":"REC_0001126","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":4.2,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.120316+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_884587","record_id":"REC_0001127","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":14.7,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":4.8,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.120569+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_326234","record_id":"REC_0001128","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":7.3,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":7.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.120811+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_237528","record_id":"REC_0001129","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":8.9,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":6.8,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.121047+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_116832","record_id":"REC_0001130","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":8.3,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":35,"primary_tumor_size_cm":7.3,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.121280+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_527458","record_id":"REC_0001131","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":48,"primary_tumor_size_cm":5.0,"metastatic_sites_count":3,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.121514+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_519272","record_id":"REC_0001132","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":6.9,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":5.0,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.121845+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_555768","record_id":"REC_0001133","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":17.9,"age_at_diagnosis":75,"sex":"male","ecog_performance_status":1,"smoking_pack_years":27,"primary_tumor_size_cm":3.3,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.122089+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_290541","record_id":"REC_0001134","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":4.1,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.122322+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_937339","record_id":"REC_0001135","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":50,"sex":"male","ecog_performance_status":0,"smoking_pack_years":27,"primary_tumor_size_cm":3.5,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.122557+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_199694","record_id":"REC_0001136","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":7.9,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":3.8,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":22.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.122788+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_511815","record_id":"REC_0001137","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":20,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":2,"smoking_pack_years":61,"primary_tumor_size_cm":3.6,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":17.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.123023+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_797150","record_id":"REC_0001138","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":13.3,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":4.7,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":6.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.123258+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_981168","record_id":"REC_0001139","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":6.8,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":21.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.123494+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_586399","record_id":"REC_0001140","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":5.7,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":40,"primary_tumor_size_cm":5.6,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.123726+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_132670","record_id":"REC_0001141","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":6.0,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":5.1,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":26.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.123958+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_404633","record_id":"REC_0001142","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":13,"tmb_mutations_per_mb":7.9,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":2,"smoking_pack_years":49,"primary_tumor_size_cm":5.4,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":19.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.124243+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_869702","record_id":"REC_0001143","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":16,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":77,"sex":"male","ecog_performance_status":1,"smoking_pack_years":0,"primary_tumor_size_cm":4.2,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.124483+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_100078","record_id":"REC_0001144","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":6.2,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.124716+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_567340","record_id":"REC_0001145","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":4.4,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":4.7,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":20.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.125005+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_575751","record_id":"REC_0001146","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":11.1,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":3.9,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":27.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.125243+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_174271","record_id":"REC_0001147","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":15.7,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":3,"smoking_pack_years":25,"primary_tumor_size_cm":6.1,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.125481+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_287540","record_id":"REC_0001148","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":4.4,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":52,"primary_tumor_size_cm":5.1,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.125716+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_604832","record_id":"REC_0001149","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ALK fusion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":9,"primary_tumor_size_cm":7.2,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":31.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.125949+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_119701","record_id":"REC_0001150","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":5.1,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":5.2,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":22.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.126179+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_185239","record_id":"REC_0001151","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":54,"sex":"male","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":5.3,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":27.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.126413+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_578707","record_id":"REC_0001152","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":21.3,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":20,"primary_tumor_size_cm":5.6,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.126644+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_826839","record_id":"REC_0001153","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.6,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.126875+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_154055","record_id":"REC_0001154","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":6.6,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.127107+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_543100","record_id":"REC_0001155","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":17,"tmb_mutations_per_mb":15.4,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":6.3,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.127339+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_640214","record_id":"REC_0001156","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":2,"primary_tumor_size_cm":5.9,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.127574+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_119432","record_id":"REC_0001157","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.5,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.127809+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_655659","record_id":"REC_0001158","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":15.2,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":6.2,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":24.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.128132+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_804353","record_id":"REC_0001159","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":5.5,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.128378+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_733018","record_id":"REC_0001160","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":20,"tmb_mutations_per_mb":5.2,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":0,"smoking_pack_years":25,"primary_tumor_size_cm":5.4,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.128611+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_313847","record_id":"REC_0001161","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":6.2,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":16.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.128845+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_509327","record_id":"REC_0001162","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":19,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":1,"smoking_pack_years":44,"primary_tumor_size_cm":3.5,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.129077+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_797686","record_id":"REC_0001163","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":23,"primary_tumor_size_cm":4.7,"metastatic_sites_count":8,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.129313+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_397699","record_id":"REC_0001164","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":13.3,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":1,"smoking_pack_years":24,"primary_tumor_size_cm":6.3,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.129546+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_310607","record_id":"REC_0001165","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":1,"smoking_pack_years":38,"primary_tumor_size_cm":4.7,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.129777+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_511157","record_id":"REC_0001166","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":6.0,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":26.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.130014+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_516987","record_id":"REC_0001167","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":20.4,"age_at_diagnosis":54,"sex":"male","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":5.6,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.130251+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_449370","record_id":"REC_0001168","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":10.1,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":4.2,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":8.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.130487+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_855540","record_id":"REC_0001169","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":51,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":4.5,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.130723+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_590046","record_id":"REC_0001170","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":4.1,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.130960+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_442461","record_id":"REC_0001171","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":5.3,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":28.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.131241+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_667674","record_id":"REC_0001172","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":5.9,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.131474+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_649881","record_id":"REC_0001173","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":11,"tmb_mutations_per_mb":20.1,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":3.9,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":18.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.131709+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_703778","record_id":"REC_0001174","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":4.6,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":19.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.131942+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_614949","record_id":"REC_0001175","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":19,"tmb_mutations_per_mb":16.0,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":4.6,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.132203+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_510270","record_id":"REC_0001176","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":32,"tmb_mutations_per_mb":1.9,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":30,"primary_tumor_size_cm":7.0,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.132433+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_175503","record_id":"REC_0001177","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":9.5,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":58,"primary_tumor_size_cm":7.0,"metastatic_sites_count":8,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.132665+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_900954","record_id":"REC_0001178","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":19,"tmb_mutations_per_mb":14.6,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":5.4,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.132898+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_639613","record_id":"REC_0001179","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":7.4,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":49,"primary_tumor_size_cm":5.4,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.133125+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_410110","record_id":"REC_0001180","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":4.0,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":21.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.133365+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_622182","record_id":"REC_0001181","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":4.5,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.133595+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_454395","record_id":"REC_0001182","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":19,"tmb_mutations_per_mb":5.2,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":5.7,"metastatic_sites_count":3,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":17.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.133822+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_788124","record_id":"REC_0001183","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":7.9,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":22.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.134054+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_319799","record_id":"REC_0001184","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":4.3,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":74,"primary_tumor_size_cm":6.4,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.134322+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_546383","record_id":"REC_0001185","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":3,"primary_tumor_size_cm":4.0,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.134560+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_187530","record_id":"REC_0001186","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":7.9,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":3.8,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":5.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.134791+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_782568","record_id":"REC_0001187","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":4.7,"metastatic_sites_count":8,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.135024+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_244194","record_id":"REC_0001188","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":9.7,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":4.8,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.135250+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_222994","record_id":"REC_0001189","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":4.1,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.135479+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_294651","record_id":"REC_0001190","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":15.6,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":3.7,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.135715+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_789030","record_id":"REC_0001191","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":32,"tmb_mutations_per_mb":5.5,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":2,"smoking_pack_years":44,"primary_tumor_size_cm":5.2,"metastatic_sites_count":3,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.135946+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_533320","record_id":"REC_0001192","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":31,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":0,"smoking_pack_years":0,"primary_tumor_size_cm":6.8,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.136285+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_747725","record_id":"REC_0001193","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":74,"sex":"male","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":6.4,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.136536+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_470270","record_id":"REC_0001194","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":6.2,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":31.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.136765+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_584984","record_id":"REC_0001195","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":9.5,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":48,"primary_tumor_size_cm":4.7,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":5.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.136994+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_693188","record_id":"REC_0001196","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":30,"tmb_mutations_per_mb":10.1,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":4.7,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.137229+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_235460","record_id":"REC_0001197","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":9.1,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":6.3,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.137509+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_785782","record_id":"REC_0001198","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":7.2,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.137743+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_501444","record_id":"REC_0001199","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":18.4,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":3.3,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.137980+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_918552","record_id":"REC_0001200","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":8.3,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":4.2,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.138208+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_840444","record_id":"REC_0001201","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":13.6,"age_at_diagnosis":81,"sex":"male","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":3.5,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.138446+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_107170","record_id":"REC_0001202","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":32,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":6,"primary_tumor_size_cm":4.6,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":18.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.138686+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_967498","record_id":"REC_0001203","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":6.9,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":8.3,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":16.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.138931+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_969372","record_id":"REC_0001204","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":30,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":52,"sex":"male","ecog_performance_status":0,"smoking_pack_years":51,"primary_tumor_size_cm":4.5,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":5.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.139186+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_834233","record_id":"REC_0001205","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":36,"tmb_mutations_per_mb":16.7,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":6,"primary_tumor_size_cm":5.7,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.139439+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_410217","record_id":"REC_0001206","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":5.2,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":0,"smoking_pack_years":46,"primary_tumor_size_cm":4.6,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.139699+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_544579","record_id":"REC_0001207","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":19,"tmb_mutations_per_mb":14.3,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":6.0,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.139943+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_499842","record_id":"REC_0001208","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":10.5,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":27,"primary_tumor_size_cm":7.0,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":43.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.140253+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_530391","record_id":"REC_0001209","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":6.4,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.140499+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_180049","record_id":"REC_0001210","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":10.3,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":6.7,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.140851+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_786485","record_id":"REC_0001211","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":20,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":76,"sex":"male","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":4.8,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.141097+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_166100","record_id":"REC_0001212","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":14.4,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":4.9,"metastatic_sites_count":8,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.141340+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_412204","record_id":"REC_0001213","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":5.3,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.141576+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_210274","record_id":"REC_0001214","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":33,"tmb_mutations_per_mb":4.9,"age_at_diagnosis":54,"sex":"female","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":5.0,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.141806+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_707446","record_id":"REC_0001215","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":15.5,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":1,"smoking_pack_years":4,"primary_tumor_size_cm":7.3,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.142043+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_826462","record_id":"REC_0001216","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":33,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":4.1,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.142274+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_690283","record_id":"REC_0001217","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":8.3,"age_at_diagnosis":75,"sex":"male","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":6.0,"metastatic_sites_count":3,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.142504+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_493344","record_id":"REC_0001218","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":16.4,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":5.8,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":21.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.142737+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_555560","record_id":"REC_0001219","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":8.4,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":4.2,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":8.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.142980+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_139902","record_id":"REC_0001220","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":16.9,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":5.7,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.143220+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_104734","record_id":"REC_0001221","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":6.5,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.143451+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_342776","record_id":"REC_0001222","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":6.5,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.143686+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_460037","record_id":"REC_0001223","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":15.3,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":6.5,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":22.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.143979+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_417407","record_id":"REC_0001224","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":15.7,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":10,"primary_tumor_size_cm":5.8,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":8.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.144322+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_965535","record_id":"REC_0001225","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":5.9,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":4.9,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":5.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.144564+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_321905","record_id":"REC_0001226","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":36,"primary_tumor_size_cm":4.7,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.144797+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_811633","record_id":"REC_0001227","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":8.6,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":5.7,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.145032+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_912901","record_id":"REC_0001228","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":14,"tmb_mutations_per_mb":9.9,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":50,"primary_tumor_size_cm":5.9,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.145262+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_236316","record_id":"REC_0001229","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":74,"sex":"male","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":5.4,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.145500+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_174158","record_id":"REC_0001230","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":89,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":5.7,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.145735+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_356385","record_id":"REC_0001231","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":19.6,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":4.8,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.145969+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_806269","record_id":"REC_0001232","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":6.1,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":8.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.146202+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_877479","record_id":"REC_0001233","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":4.2,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.146436+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_415696","record_id":"REC_0001234","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":9.9,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":2.9,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.146666+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_651668","record_id":"REC_0001235","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":8.3,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":0,"smoking_pack_years":70,"primary_tumor_size_cm":5.2,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.146897+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_524911","record_id":"REC_0001236","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":27,"primary_tumor_size_cm":4.6,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.147187+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_613585","record_id":"REC_0001237","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":15.4,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":1,"smoking_pack_years":26,"primary_tumor_size_cm":5.3,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.147428+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_286159","record_id":"REC_0001238","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":6.9,"age_at_diagnosis":80,"sex":"male","ecog_performance_status":2,"smoking_pack_years":41,"primary_tumor_size_cm":5.5,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.147661+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_341829","record_id":"REC_0001239","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":5.7,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":19.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.147897+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_428138","record_id":"REC_0001240","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":19,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":31,"primary_tumor_size_cm":5.9,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.148187+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_930223","record_id":"REC_0001241","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":5.6,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.148432+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_314293","record_id":"REC_0001242","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":16,"tmb_mutations_per_mb":9.9,"age_at_diagnosis":53,"sex":"male","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":6.3,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.148665+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_187532","record_id":"REC_0001243","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":2,"smoking_pack_years":5,"primary_tumor_size_cm":5.9,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":7.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.148902+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_817138","record_id":"REC_0001244","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":32,"tmb_mutations_per_mb":20.4,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":6.1,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":23.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.149143+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_786863","record_id":"REC_0001245","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":4.8,"age_at_diagnosis":50,"sex":"female","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":4.0,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.149376+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_747559","record_id":"REC_0001246","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":4.4,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":0,"smoking_pack_years":73,"primary_tumor_size_cm":7.9,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":22.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.149607+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_196742","record_id":"REC_0001247","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":6.1,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":24.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.149840+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_846418","record_id":"REC_0001248","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":52,"sex":"male","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":8.2,"metastatic_sites_count":8,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.150074+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_452676","record_id":"REC_0001249","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":9.1,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":5.1,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":8.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.150349+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_383033","record_id":"REC_0001250","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":14.4,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":2,"smoking_pack_years":22,"primary_tumor_size_cm":5.1,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.150588+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_687963","record_id":"REC_0001251","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":20.9,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":6.0,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.150825+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_170635","record_id":"REC_0001252","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":8.4,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":0,"smoking_pack_years":56,"primary_tumor_size_cm":5.2,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":16.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.151056+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_715098","record_id":"REC_0001253","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":25,"primary_tumor_size_cm":4.1,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.151291+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_999245","record_id":"REC_0001254","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":10.5,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":25,"primary_tumor_size_cm":5.8,"metastatic_sites_count":3,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.151526+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_759486","record_id":"REC_0001255","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":10.1,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":4.4,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.151759+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_437280","record_id":"REC_0001256","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":16.9,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":5.8,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.151992+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_777019","record_id":"REC_0001257","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":20,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":46,"primary_tumor_size_cm":6.4,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.152295+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_279490","record_id":"REC_0001258","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":4.9,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.152539+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_402833","record_id":"REC_0001259","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":17.0,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.5,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.152781+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_910198","record_id":"REC_0001260","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":30,"tmb_mutations_per_mb":18.1,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.5,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.153016+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_940919","record_id":"REC_0001261","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":2.6,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.153250+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_352209","record_id":"REC_0001262","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":14.1,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":6.1,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.153543+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_889656","record_id":"REC_0001263","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":20,"primary_tumor_size_cm":3.9,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.153784+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_428589","record_id":"REC_0001264","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":10.3,"age_at_diagnosis":82,"sex":"male","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.8,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.154020+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_726492","record_id":"REC_0001265","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":32,"tmb_mutations_per_mb":17.2,"age_at_diagnosis":81,"sex":"male","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":5.9,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.154255+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_561681","record_id":"REC_0001266","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":35,"tmb_mutations_per_mb":7.3,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":6.5,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.154486+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_457190","record_id":"REC_0001267","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":28,"primary_tumor_size_cm":4.4,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":8.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.154735+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_973604","record_id":"REC_0001268","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":30,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":45,"primary_tumor_size_cm":5.3,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":34.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.154985+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_877202","record_id":"REC_0001269","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":32,"tmb_mutations_per_mb":6.4,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":31,"primary_tumor_size_cm":6.5,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.155227+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_410753","record_id":"REC_0001270","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":15.8,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.8,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.155481+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_919047","record_id":"REC_0001271","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":4.4,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":3.4,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.155730+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_682151","record_id":"REC_0001272","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":5.6,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.155960+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_161816","record_id":"REC_0001273","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":14.5,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":5.7,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.156278+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_302311","record_id":"REC_0001274","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":16,"tmb_mutations_per_mb":3.4,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":46,"primary_tumor_size_cm":4.1,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.156558+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_222419","record_id":"REC_0001275","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":19,"tmb_mutations_per_mb":14.8,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":5.5,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.156966+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_858724","record_id":"REC_0001276","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":13.1,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":4.5,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.157290+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_368273","record_id":"REC_0001277","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":6.9,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":5.7,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.157583+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_494696","record_id":"REC_0001278","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":4.3,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":22.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.157848+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_318523","record_id":"REC_0001279","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":11.0,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":3.9,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":24.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.158099+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_515265","record_id":"REC_0001280","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":4.3,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":3,"smoking_pack_years":30,"primary_tumor_size_cm":2.7,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":18.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.158335+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_877925","record_id":"REC_0001281","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":15,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":4.6,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.158574+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_609639","record_id":"REC_0001282","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":5.7,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":29,"primary_tumor_size_cm":7.0,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":20.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.158817+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_155222","record_id":"REC_0001283","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":9.5,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":10,"primary_tumor_size_cm":5.8,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.159065+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_915833","record_id":"REC_0001284","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":22,"primary_tumor_size_cm":4.3,"metastatic_sites_count":8,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.159326+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_758967","record_id":"REC_0001285","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":76,"sex":"male","ecog_performance_status":2,"smoking_pack_years":10,"primary_tumor_size_cm":7.2,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":17.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.159589+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_410945","record_id":"REC_0001286","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":3,"smoking_pack_years":15,"primary_tumor_size_cm":4.4,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.159842+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_978534","record_id":"REC_0001287","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":46,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":7.4,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.160151+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_480099","record_id":"REC_0001288","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":4.8,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":31.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.160564+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_459849","record_id":"REC_0001289","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":8.1,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":75,"primary_tumor_size_cm":6.8,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.160817+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_226040","record_id":"REC_0001290","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":9.8,"age_at_diagnosis":78,"sex":"male","ecog_performance_status":2,"smoking_pack_years":10,"primary_tumor_size_cm":5.4,"metastatic_sites_count":8,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.161053+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_783551","record_id":"REC_0001291","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":4.9,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.161296+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_217564","record_id":"REC_0001292","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":5.3,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.161539+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_112097","record_id":"REC_0001293","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":5.0,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":6.0,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.161772+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_361101","record_id":"REC_0001294","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":16.3,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":6.7,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.162003+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_644063","record_id":"REC_0001295","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":5.6,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":2.8,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.162239+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_132811","record_id":"REC_0001296","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":17.3,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":7.6,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":24.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.162470+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_309855","record_id":"REC_0001297","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":11.5,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":0,"smoking_pack_years":6,"primary_tumor_size_cm":6.4,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.162709+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_468491","record_id":"REC_0001298","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":6.1,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.162941+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_390960","record_id":"REC_0001299","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":6.1,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.163175+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_427058","record_id":"REC_0001300","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":5.5,"metastatic_sites_count":8,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.163409+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_493816","record_id":"REC_0001301","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":8.5,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.2,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.163705+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_176667","record_id":"REC_0001302","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":4.8,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":17.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.163947+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_932207","record_id":"REC_0001303","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":8.3,"age_at_diagnosis":78,"sex":"male","ecog_performance_status":1,"smoking_pack_years":31,"primary_tumor_size_cm":5.9,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.164228+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_552828","record_id":"REC_0001304","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":14.7,"age_at_diagnosis":54,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":5.5,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.164477+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_393976","record_id":"REC_0001305","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":4.8,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":8.3,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.164709+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_748647","record_id":"REC_0001306","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":3.9,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":25.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.164960+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_197219","record_id":"REC_0001307","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":4.5,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.165203+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_506162","record_id":"REC_0001308","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":5.3,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":5.2,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.165449+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_390663","record_id":"REC_0001309","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":18.6,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":6.1,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.165698+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_217331","record_id":"REC_0001310","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":15.9,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":25,"primary_tumor_size_cm":4.3,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.165952+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_460935","record_id":"REC_0001311","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":5.6,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.166228+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_438903","record_id":"REC_0001312","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":7.6,"age_at_diagnosis":87,"sex":"female","ecog_performance_status":3,"smoking_pack_years":19,"primary_tumor_size_cm":5.7,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.166503+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_464473","record_id":"REC_0001313","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":11.5,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":0,"smoking_pack_years":27,"primary_tumor_size_cm":3.8,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.166774+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_935210","record_id":"REC_0001314","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":14.8,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":7.3,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.167215+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_245541","record_id":"REC_0001315","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":9.5,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":4.4,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.167542+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_111531","record_id":"REC_0001316","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":17.0,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":1,"smoking_pack_years":3,"primary_tumor_size_cm":6.6,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":4.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.167880+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_269058","record_id":"REC_0001317","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":5.2,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":6.1,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":46.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.168230+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_859066","record_id":"REC_0001318","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":5.4,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.168530+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_757007","record_id":"REC_0001319","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":6.0,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":5.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.168796+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_531220","record_id":"REC_0001320","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":3.7,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":4.2,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.169039+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_865106","record_id":"REC_0001321","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":32,"tmb_mutations_per_mb":8.5,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":5.0,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.169279+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_983415","record_id":"REC_0001322","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":15.5,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":3,"smoking_pack_years":11,"primary_tumor_size_cm":5.5,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":16.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.169523+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_645542","record_id":"REC_0001323","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":3.8,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.169763+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_577207","record_id":"REC_0001324","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":14.3,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":6.7,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.170007+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_308608","record_id":"REC_0001325","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":7.4,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":5.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.170246+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_645354","record_id":"REC_0001326","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":0,"smoking_pack_years":37,"primary_tumor_size_cm":4.4,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":6.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.170480+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_734969","record_id":"REC_0001327","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":18.1,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":2,"primary_tumor_size_cm":5.3,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":20.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.170823+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_589096","record_id":"REC_0001328","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":5.8,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.171070+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_173452","record_id":"REC_0001329","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":74,"sex":"male","ecog_performance_status":2,"smoking_pack_years":0,"primary_tumor_size_cm":6.8,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.171307+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_269990","record_id":"REC_0001330","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":15.8,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":5.9,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.171545+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_863909","record_id":"REC_0001331","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":10.1,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":5,"primary_tumor_size_cm":5.0,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.171782+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_757679","record_id":"REC_0001332","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":54,"sex":"male","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":7.5,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.172015+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_662521","record_id":"REC_0001333","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":15.7,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":5.4,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.172320+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_146369","record_id":"REC_0001334","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":10.1,"age_at_diagnosis":75,"sex":"male","ecog_performance_status":2,"smoking_pack_years":70,"primary_tumor_size_cm":4.4,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.172563+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_925464","record_id":"REC_0001335","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":34,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":74,"sex":"male","ecog_performance_status":2,"smoking_pack_years":20,"primary_tumor_size_cm":5.6,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.172808+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_338512","record_id":"REC_0001336","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":16.4,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":3.6,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":5.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.173041+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_415257","record_id":"REC_0001337","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":32,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":58,"primary_tumor_size_cm":5.2,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":17.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.173273+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_475798","record_id":"REC_0001338","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":6,"primary_tumor_size_cm":5.7,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.173509+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_707552","record_id":"REC_0001339","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":18.8,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":5.8,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.173746+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_146263","record_id":"REC_0001340","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":30,"tmb_mutations_per_mb":10.5,"age_at_diagnosis":85,"sex":"male","ecog_performance_status":0,"smoking_pack_years":29,"primary_tumor_size_cm":8.2,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.174041+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_621101","record_id":"REC_0001341","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":3.5,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.9,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.174273+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_747307","record_id":"REC_0001342","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":83,"sex":"female","ecog_performance_status":2,"smoking_pack_years":8,"primary_tumor_size_cm":6.2,"metastatic_sites_count":8,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.174505+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_317362","record_id":"REC_0001343","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":6.0,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.174740+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_950402","record_id":"REC_0001344","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":17.1,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":8.1,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.174971+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_888852","record_id":"REC_0001345","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":8.7,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":58,"primary_tumor_size_cm":6.6,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":17.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.175202+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_543471","record_id":"REC_0001346","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":17,"tmb_mutations_per_mb":7.6,"age_at_diagnosis":86,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":5.0,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.175430+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_363729","record_id":"REC_0001347","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":5.0,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":3.6,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.175661+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_351361","record_id":"REC_0001348","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":15.2,"age_at_diagnosis":49,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":2.9,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.175893+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_571048","record_id":"REC_0001349","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":15.6,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":2,"smoking_pack_years":4,"primary_tumor_size_cm":7.8,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.176247+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_131391","record_id":"REC_0001350","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":17.6,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":4.7,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.176493+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_933295","record_id":"REC_0001351","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":15.4,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":5,"primary_tumor_size_cm":7.0,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.176734+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_435609","record_id":"REC_0001352","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":8.9,"age_at_diagnosis":75,"sex":"male","ecog_performance_status":3,"smoking_pack_years":16,"primary_tumor_size_cm":5.2,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.176970+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_933587","record_id":"REC_0001353","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":5.3,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.177261+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_529378","record_id":"REC_0001354","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":9.8,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":6.6,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.177493+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_880625","record_id":"REC_0001355","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":11.5,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":4,"primary_tumor_size_cm":5.5,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.177729+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_398198","record_id":"REC_0001356","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":4.2,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":6.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.177958+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_871848","record_id":"REC_0001357","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":14.0,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":4.8,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.178193+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_365027","record_id":"REC_0001358","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":6.7,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":17.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.178428+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_403979","record_id":"REC_0001359","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":30,"tmb_mutations_per_mb":7.4,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":0,"smoking_pack_years":52,"primary_tumor_size_cm":6.4,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":25.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.178664+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_668288","record_id":"REC_0001360","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":18.4,"age_at_diagnosis":87,"sex":"female","ecog_performance_status":2,"smoking_pack_years":20,"primary_tumor_size_cm":6.0,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.178916+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_230316","record_id":"REC_0001361","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":33,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":0,"smoking_pack_years":27,"primary_tumor_size_cm":6.4,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":6.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.179181+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_349365","record_id":"REC_0001362","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":16.1,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":8,"primary_tumor_size_cm":4.7,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.179434+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_559462","record_id":"REC_0001363","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":4.7,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.179675+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_179034","record_id":"REC_0001364","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":17.9,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":21,"primary_tumor_size_cm":4.1,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":18.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.179924+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_427406","record_id":"REC_0001365","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":6.3,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.180207+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_256472","record_id":"REC_0001366","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":1,"primary_tumor_size_cm":8.5,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":24.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.180543+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_552648","record_id":"REC_0001367","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":4.2,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":5.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.180790+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_560431","record_id":"REC_0001368","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":6.4,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.181021+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_249080","record_id":"REC_0001369","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":32,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":6.0,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.181256+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_206120","record_id":"REC_0001370","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":4.9,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":6.1,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.181499+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_189465","record_id":"REC_0001371","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":16.7,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":4.5,"metastatic_sites_count":3,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.181759+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_836242","record_id":"REC_0001372","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":14.4,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":7.8,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":23.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.182023+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_846809","record_id":"REC_0001373","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":54,"sex":"female","ecog_performance_status":0,"smoking_pack_years":1,"primary_tumor_size_cm":3.3,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":18.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.182273+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_612335","record_id":"REC_0001374","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":7.4,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.1,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.182507+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_385382","record_id":"REC_0001375","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":53,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":7.4,"metastatic_sites_count":3,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":6.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.182743+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_621959","record_id":"REC_0001376","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":4.9,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":2,"primary_tumor_size_cm":6.0,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.182976+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_856098","record_id":"REC_0001377","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":30,"tmb_mutations_per_mb":8.0,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":28,"primary_tumor_size_cm":7.4,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":7.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.183209+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_158523","record_id":"REC_0001378","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":15.0,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.9,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.183441+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_670322","record_id":"REC_0001379","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":2.1,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":3.1,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":16.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.183772+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_214877","record_id":"REC_0001380","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":10.1,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":3.5,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":16.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.184029+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_894984","record_id":"REC_0001381","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":5.9,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.184421+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_539108","record_id":"REC_0001382","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":18,"tmb_mutations_per_mb":20.1,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.0,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":6.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.184680+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_432087","record_id":"REC_0001383","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":2.9,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.184924+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_816189","record_id":"REC_0001384","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":30,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":4.5,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.185177+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_879887","record_id":"REC_0001385","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":3.5,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":67,"primary_tumor_size_cm":6.3,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":24.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.185414+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_119532","record_id":"REC_0001386","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":6.1,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.185658+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_907926","record_id":"REC_0001387","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":6.1,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":2,"smoking_pack_years":22,"primary_tumor_size_cm":3.0,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":4.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.185897+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_650286","record_id":"REC_0001388","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":14.8,"age_at_diagnosis":84,"sex":"female","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":6.7,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.186142+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_499917","record_id":"REC_0001389","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":77,"sex":"male","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":6.5,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.186383+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_511730","record_id":"REC_0001390","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":6.6,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.186623+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_513899","record_id":"REC_0001391","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":4.3,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.186863+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_901116","record_id":"REC_0001392","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":3.7,"age_at_diagnosis":88,"sex":"female","ecog_performance_status":2,"smoking_pack_years":28,"primary_tumor_size_cm":6.1,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.187199+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_324133","record_id":"REC_0001393","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":10.3,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":1,"smoking_pack_years":24,"primary_tumor_size_cm":5.3,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":4.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.187446+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_108374","record_id":"REC_0001394","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":5.0,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":5.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.187679+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_881889","record_id":"REC_0001395","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":5.2,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.187911+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_411428","record_id":"REC_0001396","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":53,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":5.1,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":16.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.188208+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_491814","record_id":"REC_0001397","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":21.0,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":5.1,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.188464+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_912254","record_id":"REC_0001398","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":13.5,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":7.1,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":21.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.188702+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_957364","record_id":"REC_0001399","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":6.7,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":17.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.188939+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_272400","record_id":"REC_0001400","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":34,"primary_tumor_size_cm":5.8,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.189173+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_491517","record_id":"REC_0001401","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":4.4,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":23.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.189405+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_503808","record_id":"REC_0001402","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":15.9,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":0,"smoking_pack_years":5,"primary_tumor_size_cm":5.9,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.189638+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_550534","record_id":"REC_0001403","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":4.4,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":4.4,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.189869+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_982088","record_id":"REC_0001404","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":5.8,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":20.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.190102+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_489816","record_id":"REC_0001405","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":8.5,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":0,"smoking_pack_years":6,"primary_tumor_size_cm":5.4,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":24.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.190407+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_447830","record_id":"REC_0001406","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":16.9,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":6,"primary_tumor_size_cm":4.3,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.190649+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_434125","record_id":"REC_0001407","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":21,"primary_tumor_size_cm":5.2,"metastatic_sites_count":8,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":6.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.190879+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_567594","record_id":"REC_0001408","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":4.8,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.191114+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_449201","record_id":"REC_0001409","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":48,"sex":"male","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":4.5,"metastatic_sites_count":8,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":6.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.191345+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_304370","record_id":"REC_0001410","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":3.6,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":6.6,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":28.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.191572+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_636046","record_id":"REC_0001411","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":15.0,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":4.7,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":23.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.191808+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_475483","record_id":"REC_0001412","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":8.3,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":58,"primary_tumor_size_cm":4.6,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.192042+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_978430","record_id":"REC_0001413","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":31,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":6.8,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.192308+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_623000","record_id":"REC_0001414","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":3.9,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":7.0,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.192545+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_728298","record_id":"REC_0001415","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":9.9,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":5.2,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.192779+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_374246","record_id":"REC_0001416","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":3.3,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":55,"primary_tumor_size_cm":6.4,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.193012+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_706944","record_id":"REC_0001417","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":14.5,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":5.3,"metastatic_sites_count":3,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":8.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.193246+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_684796","record_id":"REC_0001418","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":19.9,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":7.6,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":27.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.193536+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_437129","record_id":"REC_0001419","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":19,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":6.3,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":19.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.193776+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_628614","record_id":"REC_0001420","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":19.9,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":3.6,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":17.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.194010+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_105612","record_id":"REC_0001421","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":7.4,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":6.0,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.194242+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_577380","record_id":"REC_0001422","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":32,"tmb_mutations_per_mb":3.5,"age_at_diagnosis":85,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":3.4,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.194472+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_289036","record_id":"REC_0001423","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":8.7,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":7.8,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.194707+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_136645","record_id":"REC_0001424","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":5.2,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":6.4,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.194938+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_162441","record_id":"REC_0001425","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":14.9,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":7.6,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.195174+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_608595","record_id":"REC_0001426","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":14.3,"age_at_diagnosis":53,"sex":"male","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":8.5,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.195405+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_220023","record_id":"REC_0001427","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":16.1,"age_at_diagnosis":50,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":6.7,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.195641+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_295098","record_id":"REC_0001428","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":13.5,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":5.8,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":23.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.195875+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_969373","record_id":"REC_0001429","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":3.4,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":54,"primary_tumor_size_cm":3.6,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":19.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.196282+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_263064","record_id":"REC_0001430","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":17.7,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":6.6,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":35.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.196568+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_904847","record_id":"REC_0001431","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":20.2,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":5.0,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":21.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.196913+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_826686","record_id":"REC_0001432","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":8.6,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":52,"primary_tumor_size_cm":5.2,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.197160+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_391859","record_id":"REC_0001433","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":13.1,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":7.7,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.197398+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_142393","record_id":"REC_0001434","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":13.3,"age_at_diagnosis":90,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":6.2,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.197635+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_677639","record_id":"REC_0001435","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":31,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":35,"primary_tumor_size_cm":5.8,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.197870+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_349822","record_id":"REC_0001436","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":19.8,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":31,"primary_tumor_size_cm":5.4,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.198112+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_619796","record_id":"REC_0001437","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":13.1,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":2,"smoking_pack_years":10,"primary_tumor_size_cm":4.8,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.198351+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_274644","record_id":"REC_0001438","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":0,"primary_tumor_size_cm":5.5,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.198591+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_775295","record_id":"REC_0001439","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":16.4,"age_at_diagnosis":47,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":3.7,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":23.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.198844+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_931568","record_id":"REC_0001440","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":18.7,"age_at_diagnosis":52,"sex":"female","ecog_performance_status":0,"smoking_pack_years":24,"primary_tumor_size_cm":5.7,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.199093+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_347290","record_id":"REC_0001441","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":6.0,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.199343+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_799553","record_id":"REC_0001442","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":18.1,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":5.0,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.199594+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_437532","record_id":"REC_0001443","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":20,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":84,"sex":"female","ecog_performance_status":1,"smoking_pack_years":3,"primary_tumor_size_cm":4.5,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.199843+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_964399","record_id":"REC_0001444","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":6.7,"age_at_diagnosis":52,"sex":"male","ecog_performance_status":0,"smoking_pack_years":27,"primary_tumor_size_cm":3.3,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":26.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.200267+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_434409","record_id":"REC_0001445","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":17,"tmb_mutations_per_mb":7.3,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":7.7,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":23.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.200530+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_524285","record_id":"REC_0001446","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":16.9,"age_at_diagnosis":76,"sex":"male","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":4.6,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.200782+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_861014","record_id":"REC_0001447","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":4.8,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":1,"smoking_pack_years":37,"primary_tumor_size_cm":5.4,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.201020+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_449418","record_id":"REC_0001448","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":15.7,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":5.0,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.201257+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_645770","record_id":"REC_0001449","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":11.5,"age_at_diagnosis":75,"sex":"male","ecog_performance_status":3,"smoking_pack_years":24,"primary_tumor_size_cm":4.6,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.201494+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_637887","record_id":"REC_0001450","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":4.7,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":5.5,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.201729+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_737678","record_id":"REC_0001451","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":6.0,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.201970+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_940716","record_id":"REC_0001452","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":8.6,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":4.7,"metastatic_sites_count":3,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.202204+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_478406","record_id":"REC_0001453","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":16,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":6.8,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":18.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.202440+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_708472","record_id":"REC_0001454","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":5.5,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":5.7,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":19.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.202673+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_300619","record_id":"REC_0001455","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":30,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":4.7,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":24.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.202903+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_666746","record_id":"REC_0001456","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":6.1,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":6.6,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.203136+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_633440","record_id":"REC_0001457","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":13.1,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":6.7,"metastatic_sites_count":3,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":5.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.203440+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_889272","record_id":"REC_0001458","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":18.2,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":5.0,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.203684+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_321122","record_id":"REC_0001459","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":10.3,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":5.3,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.203938+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_664402","record_id":"REC_0001460","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":18.4,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":2,"primary_tumor_size_cm":7.9,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.204247+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_326333","record_id":"REC_0001461","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":32,"tmb_mutations_per_mb":14.1,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":5.1,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.204518+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_549325","record_id":"REC_0001462","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":7.2,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.204782+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_581976","record_id":"REC_0001463","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":9.8,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":2.4,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.205033+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_106121","record_id":"REC_0001464","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":5.9,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":20.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.205285+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_999024","record_id":"REC_0001465","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":14.1,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":4.4,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.205545+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_761828","record_id":"REC_0001466","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":3.5,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":0,"smoking_pack_years":51,"primary_tumor_size_cm":3.5,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.205804+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_344520","record_id":"REC_0001467","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":6.7,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.206057+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_459624","record_id":"REC_0001468","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":3.2,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.206316+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_926277","record_id":"REC_0001469","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":17.9,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":6.1,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":17.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.206566+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_635308","record_id":"REC_0001470","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":16.8,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":4.4,"metastatic_sites_count":9,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":17.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.206932+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_325628","record_id":"REC_0001471","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":6.5,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":25.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.207184+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_151091","record_id":"REC_0001472","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.2,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.207416+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_125566","record_id":"REC_0001473","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":20.7,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":6.9,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.207654+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_871580","record_id":"REC_0001474","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":5.6,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.207886+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_169252","record_id":"REC_0001475","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":4.4,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.208274+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_721651","record_id":"REC_0001476","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":3.9,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.208536+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_973912","record_id":"REC_0001477","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.0,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":5,"primary_tumor_size_cm":5.9,"metastatic_sites_count":8,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.208771+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_408109","record_id":"REC_0001478","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":11.0,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":3.5,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.209010+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_195940","record_id":"REC_0001479","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":18,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":6.1,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.209247+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_675595","record_id":"REC_0001480","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":13.6,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":6.9,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.209484+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_723882","record_id":"REC_0001481","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":8.5,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":4.9,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.209718+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_393191","record_id":"REC_0001482","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":4.8,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.209952+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_970762","record_id":"REC_0001483","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":35,"tmb_mutations_per_mb":13.8,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":5.6,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":43.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.210261+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_986474","record_id":"REC_0001484","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":15.3,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":5.8,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.210503+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_594134","record_id":"REC_0001485","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":14,"tmb_mutations_per_mb":11.0,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":5.4,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.210742+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_450043","record_id":"REC_0001486","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":14.4,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":4.4,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.210974+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_146313","record_id":"REC_0001487","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":2.2,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":8,"primary_tumor_size_cm":7.7,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":22.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.211203+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_981688","record_id":"REC_0001488","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":15.9,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":21,"primary_tumor_size_cm":5.2,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.211437+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_207530","record_id":"REC_0001489","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":14.1,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":6.8,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.211672+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_328245","record_id":"REC_0001490","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":3.8,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":28.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.211904+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_874025","record_id":"REC_0001491","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":31,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":84,"sex":"female","ecog_performance_status":2,"smoking_pack_years":3,"primary_tumor_size_cm":4.4,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":17.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.212197+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_210115","record_id":"REC_0001492","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":4.2,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":16.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.212447+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_295204","record_id":"REC_0001493","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":4.0,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":60,"primary_tumor_size_cm":6.0,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":17.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.212684+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_707211","record_id":"REC_0001494","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":14.0,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":8.2,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":17.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.212918+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_776075","record_id":"REC_0001495","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":3.3,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":18.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.213151+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_865280","record_id":"REC_0001496","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":19.2,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":6.2,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.213432+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_417611","record_id":"REC_0001497","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":90,"sex":"female","ecog_performance_status":2,"smoking_pack_years":24,"primary_tumor_size_cm":5.5,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.213663+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_719483","record_id":"REC_0001498","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":52,"sex":"male","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":7.2,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.213896+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_184789","record_id":"REC_0001499","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":6.4,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":8.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.214128+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_515288","record_id":"REC_0001500","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":0,"smoking_pack_years":24,"primary_tumor_size_cm":7.3,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.214363+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_194536","record_id":"REC_0001501","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":6.3,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.214598+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_722672","record_id":"REC_0001502","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":4.1,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":6.6,"metastatic_sites_count":3,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.214828+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_499965","record_id":"REC_0001503","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":20.5,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":6.2,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.215066+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_968304","record_id":"REC_0001504","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":7.6,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":5.6,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.215298+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_210492","record_id":"REC_0001505","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":2.0,"age_at_diagnosis":51,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":6.5,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.215528+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_480505","record_id":"REC_0001506","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":5.1,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":0,"smoking_pack_years":52,"primary_tumor_size_cm":3.8,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":16.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.215759+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_807436","record_id":"REC_0001507","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":18.7,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":6.7,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.215998+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_378988","record_id":"REC_0001508","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":31,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":26,"primary_tumor_size_cm":3.9,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.216261+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_369506","record_id":"REC_0001509","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":7.4,"age_at_diagnosis":86,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":6.2,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.216542+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_622299","record_id":"REC_0001510","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":54,"sex":"male","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":4.0,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.216782+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_525154","record_id":"REC_0001511","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":4.4,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":22.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.217017+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_868147","record_id":"REC_0001512","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":4.7,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.217248+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_849994","record_id":"REC_0001513","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":14.3,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":5.8,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.217478+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_719871","record_id":"REC_0001514","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":5.8,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.217709+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_849501","record_id":"REC_0001515","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":8.1,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":5.0,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.217936+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_377999","record_id":"REC_0001516","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":4.0,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.218166+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_247431","record_id":"REC_0001517","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":5.2,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":7.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.218400+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_443460","record_id":"REC_0001518","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":9.9,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.1,"metastatic_sites_count":8,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":6.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.218635+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_660033","record_id":"REC_0001519","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":14.3,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":5.1,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.218884+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_408543","record_id":"REC_0001520","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":15,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":6.3,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.219138+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_287087","record_id":"REC_0001521","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":19.4,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":5.4,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.219386+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_132098","record_id":"REC_0001522","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":18.1,"age_at_diagnosis":50,"sex":"male","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":6.1,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.219730+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_254481","record_id":"REC_0001523","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":16.5,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":4.6,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.219981+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_126427","record_id":"REC_0001524","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":8.1,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":0,"smoking_pack_years":6,"primary_tumor_size_cm":5.8,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.220291+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_407942","record_id":"REC_0001525","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":5.8,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":21.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.220540+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_912106","record_id":"REC_0001526","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":19,"tmb_mutations_per_mb":8.6,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":6.6,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.220772+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_460041","record_id":"REC_0001527","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":12,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":7.3,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":25.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.221013+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_411827","record_id":"REC_0001528","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":9.9,"age_at_diagnosis":54,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":6.1,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.221246+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_601814","record_id":"REC_0001529","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":14.6,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":5.3,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.221482+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_352251","record_id":"REC_0001530","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":15.1,"age_at_diagnosis":46,"sex":"male","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":5.7,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.221717+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_464784","record_id":"REC_0001531","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":30,"tmb_mutations_per_mb":14.6,"age_at_diagnosis":79,"sex":"male","ecog_performance_status":1,"smoking_pack_years":26,"primary_tumor_size_cm":4.3,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.221959+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_210156","record_id":"REC_0001532","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":17.5,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":0,"smoking_pack_years":3,"primary_tumor_size_cm":7.3,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.222196+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_974120","record_id":"REC_0001533","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":14.9,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":3,"smoking_pack_years":10,"primary_tumor_size_cm":5.9,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":49.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.222429+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_547885","record_id":"REC_0001534","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":21.7,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":6.5,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.222661+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_461694","record_id":"REC_0001535","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":5.5,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":6.3,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":16.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.222970+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_519144","record_id":"REC_0001536","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":31,"tmb_mutations_per_mb":3.6,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":0,"smoking_pack_years":67,"primary_tumor_size_cm":5.5,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":20.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.223202+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_411106","record_id":"REC_0001537","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":5.5,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.223439+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_860683","record_id":"REC_0001538","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":15.6,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":7.3,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.223676+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_518691","record_id":"REC_0001539","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":8.6,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.223909+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_220723","record_id":"REC_0001540","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":4.9,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":23.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.224187+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_359508","record_id":"REC_0001541","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":49,"primary_tumor_size_cm":4.6,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.224426+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_682959","record_id":"REC_0001542","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":4.4,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":22.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.224666+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_692917","record_id":"REC_0001543","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":31,"tmb_mutations_per_mb":5.3,"age_at_diagnosis":47,"sex":"female","ecog_performance_status":0,"smoking_pack_years":41,"primary_tumor_size_cm":6.4,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":28.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.224898+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_310887","record_id":"REC_0001544","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":18,"tmb_mutations_per_mb":4.4,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":45,"primary_tumor_size_cm":4.7,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.225131+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_425574","record_id":"REC_0001545","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":3.7,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.225365+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_506172","record_id":"REC_0001546","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":8.4,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":4,"primary_tumor_size_cm":5.3,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.225592+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_638365","record_id":"REC_0001547","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":5.4,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.225827+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_664346","record_id":"REC_0001548","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":32,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":45,"sex":"male","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":6.2,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.226114+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_647469","record_id":"REC_0001549","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":32,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":25,"primary_tumor_size_cm":5.5,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.226350+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_359296","record_id":"REC_0001550","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":8.7,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":6.4,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.226578+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_746097","record_id":"REC_0001551","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":33,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":24,"primary_tumor_size_cm":5.3,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.226811+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_986527","record_id":"REC_0001552","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":15,"tmb_mutations_per_mb":6.1,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":80,"primary_tumor_size_cm":5.2,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.227043+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_867612","record_id":"REC_0001553","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":8.1,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.6,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.227272+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_789878","record_id":"REC_0001554","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":17,"tmb_mutations_per_mb":18.1,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":3,"smoking_pack_years":20,"primary_tumor_size_cm":5.3,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":35.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.227506+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_288461","record_id":"REC_0001555","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":25,"primary_tumor_size_cm":6.0,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.227736+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_387374","record_id":"REC_0001556","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":15.7,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":20,"primary_tumor_size_cm":4.0,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.227972+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_766676","record_id":"REC_0001557","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":16.8,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":6.5,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.228235+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_358220","record_id":"REC_0001558","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":6.2,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":6.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.228472+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_418230","record_id":"REC_0001559","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":6.7,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.228705+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_827924","record_id":"REC_0001560","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":10.1,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":3.9,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.228940+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_947229","record_id":"REC_0001561","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":4.3,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":1,"smoking_pack_years":85,"primary_tumor_size_cm":6.0,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.229214+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_382641","record_id":"REC_0001562","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":16.6,"age_at_diagnosis":51,"sex":"female","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":7.5,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.229452+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_379907","record_id":"REC_0001563","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":5.7,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":5.2,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.229684+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_153725","record_id":"REC_0001564","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":4.6,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":30,"primary_tumor_size_cm":5.7,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":27.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.229918+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_302995","record_id":"REC_0001565","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":19.1,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":6.1,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.230155+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_818836","record_id":"REC_0001566","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":5.2,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":3,"smoking_pack_years":50,"primary_tumor_size_cm":4.4,"metastatic_sites_count":3,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.230387+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_449759","record_id":"REC_0001567","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":21.8,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":5,"primary_tumor_size_cm":4.0,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.230624+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_100161","record_id":"REC_0001568","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":31,"tmb_mutations_per_mb":14.1,"age_at_diagnosis":85,"sex":"male","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":7.2,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.230858+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_200535","record_id":"REC_0001569","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":2.9,"age_at_diagnosis":52,"sex":"male","ecog_performance_status":0,"smoking_pack_years":35,"primary_tumor_size_cm":7.2,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.231087+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_660607","record_id":"REC_0001570","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":3,"smoking_pack_years":13,"primary_tumor_size_cm":6.9,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":30.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.231319+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_646512","record_id":"REC_0001571","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":16,"tmb_mutations_per_mb":20.8,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":5.7,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.231550+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_722784","record_id":"REC_0001572","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":4.4,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":6.3,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.231782+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_140340","record_id":"REC_0001573","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":14.0,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":4.5,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":19.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.232019+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_842085","record_id":"REC_0001574","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":8.9,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":0,"smoking_pack_years":89,"primary_tumor_size_cm":8.0,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.232343+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_305175","record_id":"REC_0001575","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":8.4,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":5.2,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.232587+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_418760","record_id":"REC_0001576","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":5.3,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.232821+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_396142","record_id":"REC_0001577","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":31,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":7.0,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.233057+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_343955","record_id":"REC_0001578","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":15.2,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":5.9,"metastatic_sites_count":9,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.233292+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_781671","record_id":"REC_0001579","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":74,"sex":"male","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":5.7,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.233531+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_330819","record_id":"REC_0001580","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":8.6,"age_at_diagnosis":76,"sex":"male","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":6.7,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.233764+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_942565","record_id":"REC_0001581","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":18,"tmb_mutations_per_mb":8.0,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":1,"smoking_pack_years":27,"primary_tumor_size_cm":3.8,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.233995+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_991380","record_id":"REC_0001582","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":5.0,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":4.5,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.234222+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_714560","record_id":"REC_0001583","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":0,"smoking_pack_years":5,"primary_tumor_size_cm":5.9,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.234453+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_518497","record_id":"REC_0001584","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":14,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":2,"smoking_pack_years":20,"primary_tumor_size_cm":4.9,"metastatic_sites_count":8,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.234679+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_967548","record_id":"REC_0001585","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":4.9,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":5.2,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":29.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.234912+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_748696","record_id":"REC_0001586","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":1,"smoking_pack_years":2,"primary_tumor_size_cm":6.0,"metastatic_sites_count":8,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.235147+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_925843","record_id":"REC_0001587","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":4.8,"age_at_diagnosis":54,"sex":"male","ecog_performance_status":0,"smoking_pack_years":71,"primary_tumor_size_cm":6.3,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":21.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.235422+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_159859","record_id":"REC_0001588","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":15.3,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":3.1,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":4.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.235661+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_241174","record_id":"REC_0001589","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":17.1,"age_at_diagnosis":88,"sex":"male","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":5.2,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.235901+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_298857","record_id":"REC_0001590","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":18.6,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":7.3,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.236229+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_573144","record_id":"REC_0001591","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":19,"tmb_mutations_per_mb":3.4,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":2,"smoking_pack_years":50,"primary_tumor_size_cm":8.7,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.236474+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_179945","record_id":"REC_0001592","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":3.9,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":23.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.236715+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_307785","record_id":"REC_0001593","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":31,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":4,"primary_tumor_size_cm":4.3,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.236953+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_142390","record_id":"REC_0001594","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":30,"tmb_mutations_per_mb":4.9,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":1,"smoking_pack_years":24,"primary_tumor_size_cm":4.2,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":18.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.237181+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_892361","record_id":"REC_0001595","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":4.7,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":36.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.237413+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_957838","record_id":"REC_0001596","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":14,"tmb_mutations_per_mb":4.3,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":5.2,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.237645+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_246128","record_id":"REC_0001597","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":14.4,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":6.1,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.237876+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_597448","record_id":"REC_0001598","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":19,"tmb_mutations_per_mb":4.9,"age_at_diagnosis":90,"sex":"female","ecog_performance_status":2,"smoking_pack_years":0,"primary_tumor_size_cm":6.0,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.238103+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_768015","record_id":"REC_0001599","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":4.9,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.238330+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_857566","record_id":"REC_0001600","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":0,"smoking_pack_years":6,"primary_tumor_size_cm":4.2,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":7.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.238609+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_324492","record_id":"REC_0001601","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":19.8,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":0,"primary_tumor_size_cm":4.9,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.238868+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_938402","record_id":"REC_0001602","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":10.1,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":4.6,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":30.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.239122+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_551747","record_id":"REC_0001603","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":3.3,"age_at_diagnosis":88,"sex":"female","ecog_performance_status":1,"smoking_pack_years":24,"primary_tumor_size_cm":4.8,"metastatic_sites_count":8,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":5.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.239377+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_887914","record_id":"REC_0001604","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":8.5,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":4.4,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":6.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.239627+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_361011","record_id":"REC_0001605","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":15,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":4.4,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":17.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.239867+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_301556","record_id":"REC_0001606","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":36,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":3.5,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.240226+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_845758","record_id":"REC_0001607","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":7.6,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":5.7,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":23.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.240477+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_142464","record_id":"REC_0001608","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":34,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":54,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":6.7,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":31.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.240714+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_983840","record_id":"REC_0001609","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":7.0,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.240957+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_506845","record_id":"REC_0001610","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":6.9,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":6.5,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":7.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.241188+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_323675","record_id":"REC_0001611","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":17,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":6.1,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.241423+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_658361","record_id":"REC_0001612","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":1,"smoking_pack_years":25,"primary_tumor_size_cm":3.3,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.241659+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_165178","record_id":"REC_0001613","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":15.9,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":5.8,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.242006+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_868787","record_id":"REC_0001614","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":9.0,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":4.9,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.242239+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_340179","record_id":"REC_0001615","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":11.0,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":3.1,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.242476+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_678322","record_id":"REC_0001616","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":32,"tmb_mutations_per_mb":4.8,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":6.0,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.242705+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_311683","record_id":"REC_0001617","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":17.5,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":5.4,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":5.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.242941+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_649190","record_id":"REC_0001618","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":35,"tmb_mutations_per_mb":8.0,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":2,"smoking_pack_years":6,"primary_tumor_size_cm":6.4,"metastatic_sites_count":3,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":4.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.243179+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_949599","record_id":"REC_0001619","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":6.0,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":17.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.243421+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_636832","record_id":"REC_0001620","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":32,"tmb_mutations_per_mb":17.3,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":4.0,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.243652+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_114902","record_id":"REC_0001621","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":18.0,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":5.5,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.243882+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_449897","record_id":"REC_0001622","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":19,"tmb_mutations_per_mb":14.3,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":5.8,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.244180+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_250007","record_id":"REC_0001623","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":8.9,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":4.0,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.244423+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_921718","record_id":"REC_0001624","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":14.3,"age_at_diagnosis":41,"sex":"male","ecog_performance_status":0,"smoking_pack_years":26,"primary_tumor_size_cm":5.0,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.244661+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_362282","record_id":"REC_0001625","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":4.5,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":39,"primary_tumor_size_cm":5.7,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":17.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.244889+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_199376","record_id":"REC_0001626","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":34,"tmb_mutations_per_mb":6.9,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":22,"primary_tumor_size_cm":3.9,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.245183+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_960990","record_id":"REC_0001627","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":6.8,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.245427+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_628235","record_id":"REC_0001628","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":5.2,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":5.7,"metastatic_sites_count":3,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":7.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.245655+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_815680","record_id":"REC_0001629","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":3,"smoking_pack_years":23,"primary_tumor_size_cm":6.2,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.245890+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_843884","record_id":"REC_0001630","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":31,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":0,"smoking_pack_years":35,"primary_tumor_size_cm":4.3,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.246118+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_638099","record_id":"REC_0001631","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":15,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":4.5,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":25.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.246357+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_740856","record_id":"REC_0001632","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":74,"sex":"male","ecog_performance_status":2,"smoking_pack_years":8,"primary_tumor_size_cm":5.0,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.246590+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_235512","record_id":"REC_0001633","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":4.3,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.246821+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_311095","record_id":"REC_0001634","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":13.1,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":5.7,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.247056+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_157906","record_id":"REC_0001635","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":33,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":3,"primary_tumor_size_cm":4.8,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.247285+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_968773","record_id":"REC_0001636","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":4.8,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.247516+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_468545","record_id":"REC_0001637","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":17.3,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":2,"smoking_pack_years":10,"primary_tumor_size_cm":6.5,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.247750+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_350950","record_id":"REC_0001638","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":13.8,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":1,"smoking_pack_years":29,"primary_tumor_size_cm":3.6,"metastatic_sites_count":3,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":28.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.247984+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_411963","record_id":"REC_0001639","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":13.5,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":7.5,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.248381+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_569102","record_id":"REC_0001640","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":4.2,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":20.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.248647+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_248188","record_id":"REC_0001641","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":5.2,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":66,"primary_tumor_size_cm":4.5,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":23.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.248899+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_956513","record_id":"REC_0001642","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":30,"tmb_mutations_per_mb":2.6,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":1,"smoking_pack_years":52,"primary_tumor_size_cm":4.4,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.249145+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_671862","record_id":"REC_0001643","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":8.0,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":3.9,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":43.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.249409+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_342126","record_id":"REC_0001644","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":54,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":5.5,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":7.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.249679+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_122457","record_id":"REC_0001645","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":6.4,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":0,"smoking_pack_years":51,"primary_tumor_size_cm":4.1,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.249940+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_762900","record_id":"REC_0001646","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":18.5,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":4.5,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.250190+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_485362","record_id":"REC_0001647","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":5.1,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":32.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.250429+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_457509","record_id":"REC_0001648","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":13.1,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":5.1,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.250665+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_341997","record_id":"REC_0001649","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":6.7,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.250908+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_488822","record_id":"REC_0001650","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":3.9,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":5.5,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.251139+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_602454","record_id":"REC_0001651","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":4.8,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.251379+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_673485","record_id":"REC_0001652","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":7.3,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":3,"smoking_pack_years":23,"primary_tumor_size_cm":6.0,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":22.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.251720+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_781411","record_id":"REC_0001653","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":6.4,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":6.7,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.251962+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_106569","record_id":"REC_0001654","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":21.4,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":30,"primary_tumor_size_cm":3.7,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":40.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.252269+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_874539","record_id":"REC_0001655","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":8.6,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":0,"smoking_pack_years":25,"primary_tumor_size_cm":6.7,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.252513+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_601370","record_id":"REC_0001656","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":6.4,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":22.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.252747+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_317176","record_id":"REC_0001657","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":31,"tmb_mutations_per_mb":5.6,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":5.8,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.252982+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_977577","record_id":"REC_0001658","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":15.0,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":3,"primary_tumor_size_cm":7.7,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.253215+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_920394","record_id":"REC_0001659","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":15.3,"age_at_diagnosis":77,"sex":"male","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":4.2,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.253454+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_614283","record_id":"REC_0001660","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":31,"tmb_mutations_per_mb":7.4,"age_at_diagnosis":88,"sex":"female","ecog_performance_status":3,"smoking_pack_years":44,"primary_tumor_size_cm":5.2,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":22.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.253686+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_374919","record_id":"REC_0001661","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":16.2,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":5.5,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":16.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.253919+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_298451","record_id":"REC_0001662","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":5.8,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":21.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.254157+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_842017","record_id":"REC_0001663","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":8.4,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":19.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.254392+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_830937","record_id":"REC_0001664","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":8.1,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":6.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.254622+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_459042","record_id":"REC_0001665","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":16.2,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":5.2,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.254910+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_516779","record_id":"REC_0001666","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":14.8,"age_at_diagnosis":83,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":7.0,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.255147+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_964404","record_id":"REC_0001667","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":9.5,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":6.2,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":27.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.255380+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_458715","record_id":"REC_0001668","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":5.7,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":4.6,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":6.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.255612+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_157024","record_id":"REC_0001669","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":18,"tmb_mutations_per_mb":5.9,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":46,"primary_tumor_size_cm":6.8,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.255843+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_822440","record_id":"REC_0001670","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":6.6,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.256197+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_632527","record_id":"REC_0001671","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":7.9,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":5.8,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.256465+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_458134","record_id":"REC_0001672","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":14.4,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":4.2,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.256705+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_689706","record_id":"REC_0001673","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":20,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":42,"primary_tumor_size_cm":5.2,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.256939+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_454923","record_id":"REC_0001674","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":51,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":5.1,"metastatic_sites_count":3,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":7.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.257174+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_507636","record_id":"REC_0001675","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":35,"tmb_mutations_per_mb":8.9,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":3,"smoking_pack_years":21,"primary_tumor_size_cm":5.2,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":21.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.257411+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_439869","record_id":"REC_0001676","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":8.3,"age_at_diagnosis":86,"sex":"female","ecog_performance_status":1,"smoking_pack_years":69,"primary_tumor_size_cm":7.0,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.257642+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_649153","record_id":"REC_0001677","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":3,"smoking_pack_years":10,"primary_tumor_size_cm":6.0,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.257874+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_212127","record_id":"REC_0001678","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":4.7,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":3,"primary_tumor_size_cm":8.0,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.258160+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_680649","record_id":"REC_0001679","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":17.6,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":6.2,"metastatic_sites_count":3,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.258401+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_356554","record_id":"REC_0001680","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":16.0,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":7.0,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.258640+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_744384","record_id":"REC_0001681","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":11.1,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":7.6,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.258890+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_762757","record_id":"REC_0001682","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":20,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":5.0,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.259134+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_714139","record_id":"REC_0001683","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":16.4,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":3.4,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":23.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.259386+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_645252","record_id":"REC_0001684","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":18.0,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":3.6,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.259641+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_714033","record_id":"REC_0001685","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":6.3,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":7.2,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.259885+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_271283","record_id":"REC_0001686","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":14.1,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":4.5,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":25.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.260205+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_498967","record_id":"REC_0001687","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":4.7,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":5.6,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":6.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.260452+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_138305","record_id":"REC_0001688","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":30,"primary_tumor_size_cm":6.3,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.260691+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_437345","record_id":"REC_0001689","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":5.7,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":22.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.260924+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_896877","record_id":"REC_0001690","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":17.1,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":6.3,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.261161+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_148331","record_id":"REC_0001691","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":10.3,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":5.6,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":6.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.261510+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_340286","record_id":"REC_0001692","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":14.8,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":5,"primary_tumor_size_cm":5.3,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.261748+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_367460","record_id":"REC_0001693","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":83,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":6.0,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.261982+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_930208","record_id":"REC_0001694","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":8.9,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":5.8,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":4.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.262215+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_575419","record_id":"REC_0001695","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":6.5,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":46.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.262454+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_759391","record_id":"REC_0001696","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":14.3,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":4.0,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":21.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.262691+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_295654","record_id":"REC_0001697","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":6.1,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.262925+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_180016","record_id":"REC_0001698","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":14.8,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":27,"primary_tumor_size_cm":4.8,"metastatic_sites_count":3,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.263157+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_625483","record_id":"REC_0001699","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":8.5,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":7.0,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.263388+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_683563","record_id":"REC_0001700","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":3.1,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":51,"primary_tumor_size_cm":7.1,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.263614+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_983531","record_id":"REC_0001701","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":5.6,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":23.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.263846+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_971662","record_id":"REC_0001702","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":22.8,"age_at_diagnosis":47,"sex":"male","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":5.2,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.264115+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_899127","record_id":"REC_0001703","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":30,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":5.2,"metastatic_sites_count":3,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.264363+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_317470","record_id":"REC_0001704","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":15.2,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":5.8,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":25.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.264656+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_852359","record_id":"REC_0001705","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":4.4,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":47,"primary_tumor_size_cm":5.0,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":19.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.264892+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_356050","record_id":"REC_0001706","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":9.7,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":3.5,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.265125+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_139112","record_id":"REC_0001707","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":14,"tmb_mutations_per_mb":4.0,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":36,"primary_tumor_size_cm":6.4,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":16.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.265359+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_133703","record_id":"REC_0001708","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":0,"primary_tumor_size_cm":8.0,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":17.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.265591+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_372342","record_id":"REC_0001709","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":30,"tmb_mutations_per_mb":8.0,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":6.0,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.265819+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_459004","record_id":"REC_0001710","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":8.9,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":5.4,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.266043+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_973768","record_id":"REC_0001711","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":7.0,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":21.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.266278+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_895718","record_id":"REC_0001712","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":14,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":5.8,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.266509+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_307983","record_id":"REC_0001713","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":17.4,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":6.2,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.266743+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_761941","record_id":"REC_0001714","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":4.6,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.266973+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_987376","record_id":"REC_0001715","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":5.9,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":6,"primary_tumor_size_cm":7.8,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":4.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.267201+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_864050","record_id":"REC_0001716","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":15.3,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":4,"primary_tumor_size_cm":6.2,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.267431+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_411667","record_id":"REC_0001717","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":5.7,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.267709+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_542584","record_id":"REC_0001718","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":31,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":6.8,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":22.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.267949+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_502624","record_id":"REC_0001719","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":5.9,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":0,"smoking_pack_years":47,"primary_tumor_size_cm":7.4,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.268233+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_414937","record_id":"REC_0001720","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":53,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":5.4,"metastatic_sites_count":8,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.268477+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_373692","record_id":"REC_0001721","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":20,"primary_tumor_size_cm":3.5,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.268713+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_824571","record_id":"REC_0001722","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":26,"primary_tumor_size_cm":4.3,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":20.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.268952+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_259077","record_id":"REC_0001723","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":15.8,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":2.8,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.269186+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_237599","record_id":"REC_0001724","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":33,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":6.4,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":30.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.269417+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_281609","record_id":"REC_0001725","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":3,"primary_tumor_size_cm":3.2,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":18.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.269648+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_122416","record_id":"REC_0001726","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":61,"primary_tumor_size_cm":4.6,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.269877+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_285425","record_id":"REC_0001727","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":6.3,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.270108+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_904879","record_id":"REC_0001728","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":15,"tmb_mutations_per_mb":16.9,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":4.2,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.270340+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_992954","record_id":"REC_0001729","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":78,"sex":"male","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":7.5,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.270575+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_901459","record_id":"REC_0001730","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":7.8,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.270859+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_522204","record_id":"REC_0001731","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":16.6,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":7.4,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":21.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.271098+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_741390","record_id":"REC_0001732","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":27,"primary_tumor_size_cm":3.9,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.271328+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_848423","record_id":"REC_0001733","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":6.4,"age_at_diagnosis":90,"sex":"male","ecog_performance_status":2,"smoking_pack_years":20,"primary_tumor_size_cm":5.9,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.271562+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_163608","record_id":"REC_0001734","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":32,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":1,"smoking_pack_years":24,"primary_tumor_size_cm":5.5,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.271793+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_722658","record_id":"REC_0001735","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":3,"smoking_pack_years":10,"primary_tumor_size_cm":7.5,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.272029+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_622287","record_id":"REC_0001736","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":6.6,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":26.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.272307+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_515526","record_id":"REC_0001737","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":10.0,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":24,"primary_tumor_size_cm":6.2,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.272549+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_405163","record_id":"REC_0001738","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":6.6,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.272777+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_863542","record_id":"REC_0001739","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":31,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":54,"sex":"male","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":3.5,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.273013+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_254638","record_id":"REC_0001740","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":9.0,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":4.5,"metastatic_sites_count":9,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.273239+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_650190","record_id":"REC_0001741","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":40,"primary_tumor_size_cm":3.3,"metastatic_sites_count":8,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":4.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.273469+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_894077","record_id":"REC_0001742","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ALK fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":17.4,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":7.0,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":53.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.273706+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_690493","record_id":"REC_0001743","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":15.7,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":6.2,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":23.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.273985+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_973018","record_id":"REC_0001744","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":4.3,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":16.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.274219+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_584692","record_id":"REC_0001745","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":18,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.0,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":25.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.274447+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_174489","record_id":"REC_0001746","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":5.1,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":1,"smoking_pack_years":54,"primary_tumor_size_cm":4.7,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":45.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.274677+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_284927","record_id":"REC_0001747","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":3.9,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":48,"primary_tumor_size_cm":4.3,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":17.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.274910+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_511160","record_id":"REC_0001748","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":18,"tmb_mutations_per_mb":8.0,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":4.7,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.275137+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_582975","record_id":"REC_0001749","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":3.1,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":29.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.275372+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_262207","record_id":"REC_0001750","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":6.2,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.275605+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_982952","record_id":"REC_0001751","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":81,"sex":"male","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":5.4,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":23.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.275836+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_165081","record_id":"REC_0001752","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":7.4,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":54,"primary_tumor_size_cm":5.4,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.276062+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_589945","record_id":"REC_0001753","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":30,"tmb_mutations_per_mb":16.9,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":5.8,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.276333+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_103089","record_id":"REC_0001754","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":6.5,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.276577+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_411702","record_id":"REC_0001755","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":48,"sex":"male","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":6.0,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.276820+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_288259","record_id":"REC_0001756","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":3.4,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.277109+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_553743","record_id":"REC_0001757","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":6.6,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":6.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.277339+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_582377","record_id":"REC_0001758","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":7.3,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":74,"primary_tumor_size_cm":5.4,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.277573+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_293703","record_id":"REC_0001759","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":7.2,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":29.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.277808+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_916722","record_id":"REC_0001760","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":10.3,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":5.1,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":26.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.278042+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_283394","record_id":"REC_0001761","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":8.3,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":0,"smoking_pack_years":5,"primary_tumor_size_cm":5.7,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.278274+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_224564","record_id":"REC_0001762","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":6.3,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.278509+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_547731","record_id":"REC_0001763","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":18,"tmb_mutations_per_mb":10.5,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":5.1,"metastatic_sites_count":3,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.278751+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_199423","record_id":"REC_0001764","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":0,"smoking_pack_years":1,"primary_tumor_size_cm":7.2,"metastatic_sites_count":9,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.278998+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_918140","record_id":"REC_0001765","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":15.2,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":7.2,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.279257+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_549211","record_id":"REC_0001766","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":4.9,"age_at_diagnosis":76,"sex":"male","ecog_performance_status":0,"smoking_pack_years":32,"primary_tumor_size_cm":5.8,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":35.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.279508+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_979199","record_id":"REC_0001767","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":76,"sex":"male","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":5.8,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.279763+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_762548","record_id":"REC_0001768","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":15.3,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":7.8,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":33.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.280006+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_760689","record_id":"REC_0001769","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":9.7,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":0,"primary_tumor_size_cm":6.5,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":34.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.280449+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_239808","record_id":"REC_0001770","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":14.7,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":5.5,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.280701+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_385636","record_id":"REC_0001771","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":52,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":3.8,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":4.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.280949+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_267779","record_id":"REC_0001772","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":6.4,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":4.3,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":21.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.281179+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_175947","record_id":"REC_0001773","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":30,"tmb_mutations_per_mb":11.1,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":6.3,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":21.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.281425+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_328466","record_id":"REC_0001774","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":20,"tmb_mutations_per_mb":14.5,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":4.2,"metastatic_sites_count":8,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.281679+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_638637","record_id":"REC_0001775","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":11.5,"age_at_diagnosis":84,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":3.5,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":21.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.281933+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_200906","record_id":"REC_0001776","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":7.2,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.282179+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_867302","record_id":"REC_0001777","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":0,"smoking_pack_years":28,"primary_tumor_size_cm":6.3,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":20.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.282419+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_848592","record_id":"REC_0001778","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":33,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":0,"smoking_pack_years":36,"primary_tumor_size_cm":6.9,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":20.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.282654+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_554896","record_id":"REC_0001779","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":13.6,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":1,"smoking_pack_years":1,"primary_tumor_size_cm":4.7,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.282891+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_591884","record_id":"REC_0001780","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":3.5,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":54,"primary_tumor_size_cm":6.4,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":6.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.283118+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_164423","record_id":"REC_0001781","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":14.8,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":5.2,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.283367+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_322293","record_id":"REC_0001782","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":31,"tmb_mutations_per_mb":9.8,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":24,"primary_tumor_size_cm":6.2,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.283745+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_438339","record_id":"REC_0001783","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":27,"primary_tumor_size_cm":6.0,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":18.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.284010+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_970599","record_id":"REC_0001784","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":19,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":5.0,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":21.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.284386+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_236436","record_id":"REC_0001785","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":8.1,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":27,"primary_tumor_size_cm":5.3,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.284669+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_461632","record_id":"REC_0001786","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":5.2,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.284940+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_543003","record_id":"REC_0001787","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":32,"tmb_mutations_per_mb":10.0,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":4.6,"metastatic_sites_count":3,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":5.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.285223+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_714155","record_id":"REC_0001788","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":6.8,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.285479+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_428175","record_id":"REC_0001789","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":4.3,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.285720+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_195788","record_id":"REC_0001790","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":4.5,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.285967+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_778234","record_id":"REC_0001791","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":14.4,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":4.7,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.286223+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_824311","record_id":"REC_0001792","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":15.2,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":0,"smoking_pack_years":3,"primary_tumor_size_cm":4.3,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":16.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.286484+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_121437","record_id":"REC_0001793","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":30,"tmb_mutations_per_mb":14.8,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":7.0,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.286732+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_108390","record_id":"REC_0001794","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":18,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":7.6,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":45.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.286970+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_973761","record_id":"REC_0001795","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":4.4,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.287359+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_396645","record_id":"REC_0001796","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":14.3,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":7.7,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":22.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.287610+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_554788","record_id":"REC_0001797","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":6.3,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.287848+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_292478","record_id":"REC_0001798","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":9.0,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":29,"primary_tumor_size_cm":5.8,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":5.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.288129+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_464220","record_id":"REC_0001799","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":53,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":5.0,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.288379+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_657379","record_id":"REC_0001800","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":5.1,"metastatic_sites_count":8,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":20.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.288615+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_627716","record_id":"REC_0001801","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ALK fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":18.7,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":3.7,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":35.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.288847+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_519184","record_id":"REC_0001802","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":5.5,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":5.6,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.289076+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_648227","record_id":"REC_0001803","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":18.8,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":4.1,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.289308+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_940510","record_id":"REC_0001804","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":18,"tmb_mutations_per_mb":20.0,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":6.0,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.289544+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_257637","record_id":"REC_0001805","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":5,"primary_tumor_size_cm":4.6,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.289776+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_844618","record_id":"REC_0001806","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":14.0,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":4.5,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":46.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.290018+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_379429","record_id":"REC_0001807","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":3.5,"age_at_diagnosis":85,"sex":"female","ecog_performance_status":2,"smoking_pack_years":85,"primary_tumor_size_cm":5.4,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.290254+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_210992","record_id":"REC_0001808","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":5.2,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.290575+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_525029","record_id":"REC_0001809","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":30,"tmb_mutations_per_mb":5.5,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":1,"smoking_pack_years":24,"primary_tumor_size_cm":2.9,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":6.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.290810+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_961621","record_id":"REC_0001810","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":2.6,"age_at_diagnosis":78,"sex":"male","ecog_performance_status":1,"smoking_pack_years":4,"primary_tumor_size_cm":6.2,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.291041+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_683434","record_id":"REC_0001811","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":5.2,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":33,"primary_tumor_size_cm":6.4,"metastatic_sites_count":8,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.291278+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_728477","record_id":"REC_0001812","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":16.8,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":5.3,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":7.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.291513+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_944386","record_id":"REC_0001813","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":1,"smoking_pack_years":26,"primary_tumor_size_cm":7.0,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":25.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.291747+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_588123","record_id":"REC_0001814","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":5.7,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.291982+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_771195","record_id":"REC_0001815","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":5.1,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":70,"primary_tumor_size_cm":5.9,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":5.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.292281+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_824773","record_id":"REC_0001816","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":10.3,"age_at_diagnosis":83,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":6.0,"metastatic_sites_count":8,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.292534+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_695152","record_id":"REC_0001817","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":34,"tmb_mutations_per_mb":17.5,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":2,"smoking_pack_years":20,"primary_tumor_size_cm":6.1,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.292770+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_489090","record_id":"REC_0001818","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":14,"tmb_mutations_per_mb":9.0,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":7.8,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":4.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.293003+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_847062","record_id":"REC_0001819","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":72,"primary_tumor_size_cm":6.0,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.293238+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_279836","record_id":"REC_0001820","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":5.9,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":4.5,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.293470+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_459118","record_id":"REC_0001821","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":18,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":4.3,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.293775+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_540217","record_id":"REC_0001822","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":5.7,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.294011+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_743881","record_id":"REC_0001823","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":10.3,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":6.3,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.294247+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_570707","record_id":"REC_0001824","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":19,"tmb_mutations_per_mb":15.6,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":25,"primary_tumor_size_cm":3.2,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.294482+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_807828","record_id":"REC_0001825","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":34,"primary_tumor_size_cm":4.3,"metastatic_sites_count":3,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.294715+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_697184","record_id":"REC_0001826","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":14.5,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":6.2,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.294950+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_599362","record_id":"REC_0001827","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":5.3,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":0,"smoking_pack_years":68,"primary_tumor_size_cm":3.9,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":5.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.295180+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_506605","record_id":"REC_0001828","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":4.8,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.295416+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_260532","record_id":"REC_0001829","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":30,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":24,"primary_tumor_size_cm":5.0,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.295646+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_731870","record_id":"REC_0001830","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":52,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":5.4,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.295881+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_846617","record_id":"REC_0001831","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":75,"sex":"male","ecog_performance_status":3,"smoking_pack_years":17,"primary_tumor_size_cm":6.3,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":19.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.296192+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_143364","record_id":"REC_0001832","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":19,"tmb_mutations_per_mb":5.0,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":7.4,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":20.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.296439+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_915093","record_id":"REC_0001833","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":15.5,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":6.0,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":4.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.296680+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_431423","record_id":"REC_0001834","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":50,"primary_tumor_size_cm":4.3,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":7.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.296981+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_546852","record_id":"REC_0001835","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":4.1,"age_at_diagnosis":48,"sex":"male","ecog_performance_status":0,"smoking_pack_years":71,"primary_tumor_size_cm":3.4,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.297223+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_875623","record_id":"REC_0001836","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":6.4,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":24.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.297460+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_354645","record_id":"REC_0001837","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":6.9,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":4.8,"metastatic_sites_count":9,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.297688+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_481619","record_id":"REC_0001838","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":6.7,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.297915+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_676289","record_id":"REC_0001839","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":6.1,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":17.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.298153+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_871479","record_id":"REC_0001840","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":31,"tmb_mutations_per_mb":11.0,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":5.9,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.298383+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_359761","record_id":"REC_0001841","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":1,"smoking_pack_years":25,"primary_tumor_size_cm":4.5,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":6.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.298618+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_244562","record_id":"REC_0001842","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":3.7,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.298861+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_283635","record_id":"REC_0001843","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":8.9,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":6.8,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":19.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.299110+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_955285","record_id":"REC_0001844","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":14.0,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":6.6,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":7.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.299360+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_822332","record_id":"REC_0001845","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":16,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":6.7,"metastatic_sites_count":9,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.299607+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_914696","record_id":"REC_0001846","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":33,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":55,"primary_tumor_size_cm":4.7,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.299842+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_985236","record_id":"REC_0001847","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":8.4,"age_at_diagnosis":78,"sex":"male","ecog_performance_status":3,"smoking_pack_years":17,"primary_tumor_size_cm":7.5,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":26.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.300222+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_191185","record_id":"REC_0001848","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":11.1,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":6.7,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":16.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.300477+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_109696","record_id":"REC_0001849","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":14.0,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":5.3,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":29.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.300712+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_530978","record_id":"REC_0001850","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":8.4,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":39,"primary_tumor_size_cm":5.5,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.300942+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_750495","record_id":"REC_0001851","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":18,"tmb_mutations_per_mb":13.1,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":25,"primary_tumor_size_cm":5.3,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":28.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.301181+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_917923","record_id":"REC_0001852","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.0,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":7.5,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":25.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.301416+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_956976","record_id":"REC_0001853","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":5.9,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.301655+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_558842","record_id":"REC_0001854","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.5,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.301890+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_988899","record_id":"REC_0001855","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":4.0,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":6.6,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":7.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.302126+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_547534","record_id":"REC_0001856","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":4.6,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.302362+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_948248","record_id":"REC_0001857","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":6.3,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":44,"primary_tumor_size_cm":5.1,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":20.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.302593+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_650152","record_id":"REC_0001858","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":32,"tmb_mutations_per_mb":5.1,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":0,"smoking_pack_years":51,"primary_tumor_size_cm":4.8,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.302826+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_489115","record_id":"REC_0001859","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":4.7,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.303056+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_847978","record_id":"REC_0001860","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":18.7,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":5.4,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.303344+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_170216","record_id":"REC_0001861","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":14.6,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":4.5,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":37.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.303584+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_108903","record_id":"REC_0001862","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":18,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":5.8,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":19.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.303823+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_451753","record_id":"REC_0001863","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":31,"tmb_mutations_per_mb":4.8,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":1,"smoking_pack_years":32,"primary_tumor_size_cm":6.4,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":17.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.304164+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_696315","record_id":"REC_0001864","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":7.9,"age_at_diagnosis":54,"sex":"female","ecog_performance_status":0,"smoking_pack_years":37,"primary_tumor_size_cm":6.0,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.304463+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_676909","record_id":"REC_0001865","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":24,"primary_tumor_size_cm":4.5,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.304731+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_900896","record_id":"REC_0001866","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":5.4,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":21.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.305010+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_354262","record_id":"REC_0001867","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":54,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":5.0,"metastatic_sites_count":8,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.305299+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_281965","record_id":"REC_0001868","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":13.5,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":4.9,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.305558+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_827947","record_id":"REC_0001869","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":25,"primary_tumor_size_cm":4.9,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":6.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.305798+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_591458","record_id":"REC_0001870","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":20,"tmb_mutations_per_mb":5.6,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":1,"smoking_pack_years":33,"primary_tumor_size_cm":5.4,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.306037+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_995138","record_id":"REC_0001871","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":5.4,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.306279+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_308696","record_id":"REC_0001872","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":8,"primary_tumor_size_cm":5.0,"metastatic_sites_count":8,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.306518+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_239786","record_id":"REC_0001873","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":5.3,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.306882+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_986308","record_id":"REC_0001874","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":9.5,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":6.6,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":20.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.307123+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_550477","record_id":"REC_0001875","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":19,"tmb_mutations_per_mb":8.4,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":51,"primary_tumor_size_cm":4.6,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.307356+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_941082","record_id":"REC_0001876","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":6.3,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":70,"primary_tumor_size_cm":6.4,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.307585+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_842511","record_id":"REC_0001877","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":8.7,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":5.0,"metastatic_sites_count":3,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.307818+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_305868","record_id":"REC_0001878","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":16.7,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":4.6,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.308049+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_954558","record_id":"REC_0001879","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":5.3,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":22.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.308354+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_940550","record_id":"REC_0001880","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":3,"smoking_pack_years":12,"primary_tumor_size_cm":6.7,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.308593+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_257748","record_id":"REC_0001881","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":10.1,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":5.6,"metastatic_sites_count":3,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":7.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.308829+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_225886","record_id":"REC_0001882","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":18.8,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":4.8,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":44.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.309064+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_720640","record_id":"REC_0001883","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":16.9,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":6.3,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.309297+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_298494","record_id":"REC_0001884","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":32,"tmb_mutations_per_mb":6.7,"age_at_diagnosis":76,"sex":"male","ecog_performance_status":2,"smoking_pack_years":37,"primary_tumor_size_cm":6.5,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.309527+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_711846","record_id":"REC_0001885","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":0,"smoking_pack_years":5,"primary_tumor_size_cm":4.5,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.309761+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_302185","record_id":"REC_0001886","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":4.9,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.310066+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_639316","record_id":"REC_0001887","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":7.3,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":5.1,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.310304+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_319004","record_id":"REC_0001888","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":8.6,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":6.2,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":19.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.310536+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_411834","record_id":"REC_0001889","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":3.7,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.310767+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_482488","record_id":"REC_0001890","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":18.5,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":7.5,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.311005+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_360991","record_id":"REC_0001891","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":4.5,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":5.1,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":25.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.311234+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_278974","record_id":"REC_0001892","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":10.1,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":7.2,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.311462+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_394087","record_id":"REC_0001893","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":6.5,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":5.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.311691+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_346752","record_id":"REC_0001894","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":4.5,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":70,"primary_tumor_size_cm":7.8,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.311919+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_490777","record_id":"REC_0001895","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":17.1,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":9,"primary_tumor_size_cm":6.9,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.312187+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_748712","record_id":"REC_0001896","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":16.3,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":5.5,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":16.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.312427+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_414744","record_id":"REC_0001897","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":20,"tmb_mutations_per_mb":1.6,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":0,"smoking_pack_years":29,"primary_tumor_size_cm":7.3,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":20.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.312662+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_935101","record_id":"REC_0001898","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":14.3,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":26,"primary_tumor_size_cm":7.8,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":21.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.312899+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_457689","record_id":"REC_0001899","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":4.2,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":34.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.313186+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_141592","record_id":"REC_0001900","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":30,"tmb_mutations_per_mb":14.5,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.5,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":18.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.313423+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_168761","record_id":"REC_0001901","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":30,"tmb_mutations_per_mb":8.1,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":33,"primary_tumor_size_cm":5.2,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":16.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.313654+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_293432","record_id":"REC_0001902","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":3.5,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.313887+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_874276","record_id":"REC_0001903","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":11.1,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":5.0,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.314121+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_481744","record_id":"REC_0001904","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":16.6,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":5,"primary_tumor_size_cm":4.8,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":23.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.314354+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_311388","record_id":"REC_0001905","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":8.7,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":0,"smoking_pack_years":6,"primary_tumor_size_cm":6.5,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.314587+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_848445","record_id":"REC_0001906","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":9.8,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":5.3,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.314820+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_752884","record_id":"REC_0001907","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":5.3,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":7.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.315056+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_729580","record_id":"REC_0001908","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":30,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":5.7,"metastatic_sites_count":8,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.315287+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_623138","record_id":"REC_0001909","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":14.3,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":8.0,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":19.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.315519+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_647979","record_id":"REC_0001910","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":17.5,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":23,"primary_tumor_size_cm":3.6,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.315751+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_518863","record_id":"REC_0001911","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":48,"sex":"male","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":8.0,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.315982+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_531182","record_id":"REC_0001912","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":31,"tmb_mutations_per_mb":8.4,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":22,"primary_tumor_size_cm":4.9,"metastatic_sites_count":8,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.316355+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_583920","record_id":"REC_0001913","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":6.1,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":85,"primary_tumor_size_cm":5.1,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.316592+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_187419","record_id":"REC_0001914","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":3.6,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":26.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.316833+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_357955","record_id":"REC_0001915","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":7.9,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":6.7,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":22.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.317067+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_410273","record_id":"REC_0001916","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":8.7,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":6.0,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.317295+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_173007","record_id":"REC_0001917","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":36,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":6.0,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.317524+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_272298","record_id":"REC_0001918","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":4.2,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.317759+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_132557","record_id":"REC_0001919","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":7.3,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":16.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.317996+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_294092","record_id":"REC_0001920","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":14.1,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":25,"primary_tumor_size_cm":6.5,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.318229+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_689954","record_id":"REC_0001921","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":21.3,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":6.1,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.318460+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_449255","record_id":"REC_0001922","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":17,"tmb_mutations_per_mb":6.4,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":4.7,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":22.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.318695+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_927119","record_id":"REC_0001923","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":18,"tmb_mutations_per_mb":6.0,"age_at_diagnosis":81,"sex":"male","ecog_performance_status":0,"smoking_pack_years":40,"primary_tumor_size_cm":5.2,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":7.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.318944+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_884564","record_id":"REC_0001924","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":5.1,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":21.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.319195+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_167568","record_id":"REC_0001925","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":31,"tmb_mutations_per_mb":14.4,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":5.9,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":28.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.319549+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_286473","record_id":"REC_0001926","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":4.5,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":24,"primary_tumor_size_cm":6.3,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.319812+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_842848","record_id":"REC_0001927","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":8.5,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":24,"primary_tumor_size_cm":4.1,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":18.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.320055+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_556304","record_id":"REC_0001928","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":2.3,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":4.8,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":24.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.320435+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_970701","record_id":"REC_0001929","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":22.1,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":3.9,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.320680+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_665791","record_id":"REC_0001930","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":30,"tmb_mutations_per_mb":14.0,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":6.4,"metastatic_sites_count":3,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":17.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.320915+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_936856","record_id":"REC_0001931","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":5.2,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":66,"primary_tumor_size_cm":5.5,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.321149+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_441940","record_id":"REC_0001932","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":19,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":5.7,"metastatic_sites_count":8,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.321385+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_277251","record_id":"REC_0001933","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":10.3,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":0,"smoking_pack_years":6,"primary_tumor_size_cm":5.6,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.321621+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_942283","record_id":"REC_0001934","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":35,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":3.2,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.321856+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_893583","record_id":"REC_0001935","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":19,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":4.9,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":54.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.322094+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_689676","record_id":"REC_0001936","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":8.3,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":4.5,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":24.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.322327+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_980918","record_id":"REC_0001937","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":19.2,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":4.6,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.322563+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_474474","record_id":"REC_0001938","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":17.1,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.2,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.322882+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_434825","record_id":"REC_0001939","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":6.4,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.323122+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_321529","record_id":"REC_0001940","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":19.7,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":5.4,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.323357+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_812162","record_id":"REC_0001941","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":25,"primary_tumor_size_cm":6.0,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.323594+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_952919","record_id":"REC_0001942","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":45,"sex":"female","ecog_performance_status":0,"smoking_pack_years":35,"primary_tumor_size_cm":5.7,"metastatic_sites_count":3,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.323827+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_358592","record_id":"REC_0001943","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":17,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":6.1,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.324063+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_823057","record_id":"REC_0001944","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":5.5,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":8.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.324351+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_739332","record_id":"REC_0001945","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":2,"smoking_pack_years":62,"primary_tumor_size_cm":4.9,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.324582+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_542287","record_id":"REC_0001946","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":3,"smoking_pack_years":9,"primary_tumor_size_cm":4.0,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.324818+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_664807","record_id":"REC_0001947","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":7.1,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":25.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.325050+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_291850","record_id":"REC_0001948","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":5.5,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":7.8,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.325281+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_592078","record_id":"REC_0001949","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":4.8,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.325512+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_977538","record_id":"REC_0001950","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":5.9,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":86,"primary_tumor_size_cm":3.3,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.325742+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_850967","record_id":"REC_0001951","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":2,"smoking_pack_years":10,"primary_tumor_size_cm":5.4,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.326023+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_497724","record_id":"REC_0001952","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":5.1,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":3,"primary_tumor_size_cm":6.8,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.326259+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_427102","record_id":"REC_0001953","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":14.6,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":2,"smoking_pack_years":0,"primary_tumor_size_cm":4.5,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.326495+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_112246","record_id":"REC_0001954","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":6.2,"metastatic_sites_count":8,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":19.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.326733+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_168578","record_id":"REC_0001955","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":6.8,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.326967+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_242757","record_id":"REC_0001956","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":17,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":4.0,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.327202+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_854040","record_id":"REC_0001957","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":7.5,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":22.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.327433+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_758116","record_id":"REC_0001958","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":10.0,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":5.1,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":22.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.327665+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_595660","record_id":"REC_0001959","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":20,"tmb_mutations_per_mb":3.4,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":4.7,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":27.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.327898+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_404765","record_id":"REC_0001960","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":5.7,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":3.3,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.328178+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_129699","record_id":"REC_0001961","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":10.1,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":7,"primary_tumor_size_cm":5.1,"metastatic_sites_count":3,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.328416+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_718449","record_id":"REC_0001962","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":4.6,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.328651+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_709866","record_id":"REC_0001963","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":51,"sex":"female","ecog_performance_status":0,"smoking_pack_years":44,"primary_tumor_size_cm":7.5,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":5.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.328883+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_968802","record_id":"REC_0001964","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":36,"primary_tumor_size_cm":5.6,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.329158+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_769597","record_id":"REC_0001965","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":20,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":6.6,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":32.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.329393+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_980506","record_id":"REC_0001966","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":5.7,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":1,"smoking_pack_years":33,"primary_tumor_size_cm":7.2,"metastatic_sites_count":8,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.329624+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_317568","record_id":"REC_0001967","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":53,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":6.2,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.329861+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_325279","record_id":"REC_0001968","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":26,"primary_tumor_size_cm":4.6,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.330093+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_666838","record_id":"REC_0001969","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":18,"tmb_mutations_per_mb":4.7,"age_at_diagnosis":85,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":5.6,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.330321+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_757143","record_id":"REC_0001970","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":5.3,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":22.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.330552+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_562085","record_id":"REC_0001971","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":16.0,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":6.2,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.330786+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_986014","record_id":"REC_0001972","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":78,"sex":"male","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":5.0,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.331019+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_722792","record_id":"REC_0001973","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":15.8,"age_at_diagnosis":85,"sex":"male","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":4.2,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.331256+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_673045","record_id":"REC_0001974","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":17.8,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":30,"primary_tumor_size_cm":3.7,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.331486+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_247174","record_id":"REC_0001975","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":56,"primary_tumor_size_cm":6.0,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.331718+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_699420","record_id":"REC_0001976","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":7.3,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.331947+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_598633","record_id":"REC_0001977","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":15.1,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":3.0,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.332276+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_840510","record_id":"REC_0001978","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":24,"primary_tumor_size_cm":6.5,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":8.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.332519+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_487525","record_id":"REC_0001979","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":1,"smoking_pack_years":25,"primary_tumor_size_cm":4.3,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.332753+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_601068","record_id":"REC_0001980","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":3.0,"metastatic_sites_count":8,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.332988+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_307320","record_id":"REC_0001981","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":7.3,"age_at_diagnosis":40,"sex":"male","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":5.2,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.333217+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_430076","record_id":"REC_0001982","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":8.9,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":5.6,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.333447+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_411182","record_id":"REC_0001983","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":17,"tmb_mutations_per_mb":3.1,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":0,"smoking_pack_years":27,"primary_tumor_size_cm":5.5,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":17.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.333680+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_571106","record_id":"REC_0001984","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":8.3,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":6.5,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.333913+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_700238","record_id":"REC_0001985","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":4.1,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.8,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.334145+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_120387","record_id":"REC_0001986","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":7.6,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":20,"primary_tumor_size_cm":8.0,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.334379+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_802945","record_id":"REC_0001987","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":1,"smoking_pack_years":62,"primary_tumor_size_cm":4.2,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.334606+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_150710","record_id":"REC_0001988","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":53,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":6.0,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.334836+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_754496","record_id":"REC_0001989","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":17.2,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":7.3,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":5.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.335073+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_694251","record_id":"REC_0001990","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":9.5,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":1,"smoking_pack_years":5,"primary_tumor_size_cm":5.1,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":6.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.335349+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_944107","record_id":"REC_0001991","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":19.7,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":2,"primary_tumor_size_cm":6.9,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":7.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.335589+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_868546","record_id":"REC_0001992","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":10.0,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":4.1,"metastatic_sites_count":8,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.335826+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_661905","record_id":"REC_0001993","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":15.3,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.8,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":16.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.336058+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_707286","record_id":"REC_0001994","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":2.1,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":17.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.336369+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_617328","record_id":"REC_0001995","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":4.2,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.336605+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_280228","record_id":"REC_0001996","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":15.8,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":3.2,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.336843+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_276018","record_id":"REC_0001997","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":13.1,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.0,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.337076+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_808336","record_id":"REC_0001998","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":0,"smoking_pack_years":5,"primary_tumor_size_cm":3.3,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.337309+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_654578","record_id":"REC_0001999","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":36,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.4,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":21.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.337547+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_301648","record_id":"REC_0002000","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":4.8,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.337778+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_875419","record_id":"REC_0002001","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":14.5,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":5.0,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.338009+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_283064","record_id":"REC_0002002","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":51,"primary_tumor_size_cm":4.7,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.338236+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_255533","record_id":"REC_0002003","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":10.0,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":5.3,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.338519+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_142439","record_id":"REC_0002004","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":3.4,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":4.8,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.338759+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_480207","record_id":"REC_0002005","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":8.5,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":6.3,"metastatic_sites_count":3,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.339011+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_103771","record_id":"REC_0002006","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":10,"primary_tumor_size_cm":6.4,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.339257+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_686097","record_id":"REC_0002007","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":5.8,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.339507+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_285110","record_id":"REC_0002008","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":7.1,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":5.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.339756+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_207042","record_id":"REC_0002009","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":34,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":6.7,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.339994+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_709843","record_id":"REC_0002010","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":4.9,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":69,"primary_tumor_size_cm":4.7,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":17.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.340312+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_690590","record_id":"REC_0002011","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":13.6,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":6.5,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.340558+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_608353","record_id":"REC_0002012","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":4.9,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":26.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.340797+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_765419","record_id":"REC_0002013","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":16,"tmb_mutations_per_mb":5.1,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":4.6,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.341028+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_885590","record_id":"REC_0002014","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":7.3,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.341266+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_936218","record_id":"REC_0002015","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":4.3,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.341505+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_648054","record_id":"REC_0002016","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":18,"tmb_mutations_per_mb":4.6,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":2,"smoking_pack_years":8,"primary_tumor_size_cm":6.8,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":5.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.341835+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_271888","record_id":"REC_0002017","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":7.0,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.342076+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_747923","record_id":"REC_0002018","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":10.1,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":3,"smoking_pack_years":3,"primary_tumor_size_cm":5.5,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.342306+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_190599","record_id":"REC_0002019","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":65,"primary_tumor_size_cm":3.8,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.342541+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_683818","record_id":"REC_0002020","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":13,"tmb_mutations_per_mb":14.3,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":6.2,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.342784+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_132702","record_id":"REC_0002021","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":16,"tmb_mutations_per_mb":5.0,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":3.9,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.343011+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_912691","record_id":"REC_0002022","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":16.6,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":6.7,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.343245+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_783774","record_id":"REC_0002023","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":6.4,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.343473+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_799276","record_id":"REC_0002024","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":13.5,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":6.2,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":22.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.343707+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_421979","record_id":"REC_0002025","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":6.9,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.343942+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_819706","record_id":"REC_0002026","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.5,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":26,"primary_tumor_size_cm":6.3,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":22.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.344221+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_645385","record_id":"REC_0002027","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":30,"primary_tumor_size_cm":6.7,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.344456+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_285063","record_id":"REC_0002028","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":5.2,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":39,"primary_tumor_size_cm":5.6,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":21.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.344692+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_740219","record_id":"REC_0002029","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":6.4,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.344982+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_899017","record_id":"REC_0002030","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":7.3,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.345223+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_851264","record_id":"REC_0002031","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":14.4,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":4.3,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":28.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.345461+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_905327","record_id":"REC_0002032","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":16,"tmb_mutations_per_mb":4.9,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":1,"smoking_pack_years":24,"primary_tumor_size_cm":7.1,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.345692+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_731766","record_id":"REC_0002033","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":7.6,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":5.5,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.345925+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_907463","record_id":"REC_0002034","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":5.2,"age_at_diagnosis":75,"sex":"male","ecog_performance_status":2,"smoking_pack_years":33,"primary_tumor_size_cm":3.3,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.346159+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_234765","record_id":"REC_0002035","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":33,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":90,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":6.0,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.346393+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_673187","record_id":"REC_0002036","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":7.2,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.346626+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_122887","record_id":"REC_0002037","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":9.0,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":3,"smoking_pack_years":10,"primary_tumor_size_cm":3.9,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.346863+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_734539","record_id":"REC_0002038","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.3,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.347090+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_967678","record_id":"REC_0002039","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":9,"primary_tumor_size_cm":6.1,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":17.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.347321+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_379512","record_id":"REC_0002040","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":5.6,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":8,"primary_tumor_size_cm":4.0,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.347548+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_351802","record_id":"REC_0002041","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":4.6,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":38.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.347781+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_704647","record_id":"REC_0002042","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":6.3,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.348051+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_862196","record_id":"REC_0002043","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":9.1,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":3.5,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":23.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.348330+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_856595","record_id":"REC_0002044","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":14.4,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":4.4,"metastatic_sites_count":8,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.348572+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_473792","record_id":"REC_0002045","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":6.6,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":17.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.348809+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_699289","record_id":"REC_0002046","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.1,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":27.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.349042+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_627427","record_id":"REC_0002047","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":34,"tmb_mutations_per_mb":8.1,"age_at_diagnosis":77,"sex":"male","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":5.7,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.349276+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_363144","record_id":"REC_0002048","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":8.5,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":6.4,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":4.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.349505+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_224531","record_id":"REC_0002049","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":14.1,"age_at_diagnosis":52,"sex":"female","ecog_performance_status":0,"smoking_pack_years":27,"primary_tumor_size_cm":5.9,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.349739+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_954693","record_id":"REC_0002050","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":8.4,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":6.5,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.349967+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_216808","record_id":"REC_0002051","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":6.6,"metastatic_sites_count":3,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.350201+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_299683","record_id":"REC_0002052","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":4.2,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":5.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.350429+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_142956","record_id":"REC_0002053","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":27,"primary_tumor_size_cm":6.9,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.350658+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_501058","record_id":"REC_0002054","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":5.8,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.350886+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_253143","record_id":"REC_0002055","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":17.2,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":2.4,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":7.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.351166+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_295829","record_id":"REC_0002056","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":4.3,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":18.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.351400+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_138322","record_id":"REC_0002057","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":3.4,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":3,"smoking_pack_years":17,"primary_tumor_size_cm":6.0,"metastatic_sites_count":3,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.351628+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_885069","record_id":"REC_0002058","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":30,"tmb_mutations_per_mb":17.5,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":5.8,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":33.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.351862+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_960163","record_id":"REC_0002059","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":5.8,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.352142+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_884411","record_id":"REC_0002060","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":14.9,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":2,"smoking_pack_years":21,"primary_tumor_size_cm":4.2,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.352388+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_459040","record_id":"REC_0002061","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":19,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":4.2,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.352623+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_502680","record_id":"REC_0002062","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":9.8,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":3.6,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.352851+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_996078","record_id":"REC_0002063","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":2.9,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":5.3,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.353084+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_360016","record_id":"REC_0002064","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":17.2,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":5.8,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":25.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.353321+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_998762","record_id":"REC_0002065","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":17,"tmb_mutations_per_mb":15.8,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":6.1,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.353557+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_342027","record_id":"REC_0002066","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":68,"primary_tumor_size_cm":4.5,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.353818+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_116336","record_id":"REC_0002067","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":16.6,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":5.3,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.354066+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_682613","record_id":"REC_0002068","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":34,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":52,"sex":"male","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":5.0,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.354415+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_748544","record_id":"REC_0002069","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":45,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":4.8,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.354688+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_845496","record_id":"REC_0002070","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":6.1,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":57,"primary_tumor_size_cm":8.4,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":29.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.354941+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_236101","record_id":"REC_0002071","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":6.9,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":33,"primary_tumor_size_cm":6.2,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":44.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.355200+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_273602","record_id":"REC_0002072","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":18,"tmb_mutations_per_mb":1.5,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":5.8,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":24.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.355458+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_401592","record_id":"REC_0002073","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":20,"tmb_mutations_per_mb":4.8,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":69,"primary_tumor_size_cm":6.4,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.355708+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_476630","record_id":"REC_0002074","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.7,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.355972+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_769181","record_id":"REC_0002075","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":17,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":30,"primary_tumor_size_cm":4.8,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":4.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.356366+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_445690","record_id":"REC_0002076","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":15.1,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":4.7,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.356627+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_553083","record_id":"REC_0002077","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":1,"smoking_pack_years":25,"primary_tumor_size_cm":6.8,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.356876+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_312671","record_id":"REC_0002078","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":8.3,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":6.0,"metastatic_sites_count":3,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.357113+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_540502","record_id":"REC_0002079","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":1.8,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":2,"smoking_pack_years":40,"primary_tumor_size_cm":4.0,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":22.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.357349+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_539098","record_id":"REC_0002080","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":8.1,"age_at_diagnosis":88,"sex":"female","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":5.2,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.357583+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_378908","record_id":"REC_0002081","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":7.1,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":20.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.357947+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_352471","record_id":"REC_0002082","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":4.0,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.358188+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_577768","record_id":"REC_0002083","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":30,"primary_tumor_size_cm":7.5,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.358423+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_823108","record_id":"REC_0002084","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":8.7,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":49,"primary_tumor_size_cm":4.2,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.358656+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_237903","record_id":"REC_0002085","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":13.1,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":4.3,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.358912+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_169689","record_id":"REC_0002086","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":5.0,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":23.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.359167+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_787899","record_id":"REC_0002087","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":14.4,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":4.4,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":27.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.359414+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_373030","record_id":"REC_0002088","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":19,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":47,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":5.1,"metastatic_sites_count":3,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":7.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.359663+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_560504","record_id":"REC_0002089","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":90,"sex":"female","ecog_performance_status":2,"smoking_pack_years":4,"primary_tumor_size_cm":2.9,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":26.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.359900+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_932421","record_id":"REC_0002090","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":15.0,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":6.3,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":24.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.360198+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_940569","record_id":"REC_0002091","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":31,"tmb_mutations_per_mb":7.4,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":3.6,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.360443+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_577767","record_id":"REC_0002092","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":6.3,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":8,"primary_tumor_size_cm":7.0,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.360676+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_616147","record_id":"REC_0002093","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":5.3,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":4.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.360917+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_182163","record_id":"REC_0002094","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":6.1,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.361270+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_922962","record_id":"REC_0002095","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":15.2,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":6.2,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":18.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.361514+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_288697","record_id":"REC_0002096","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":52,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":5.3,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.361752+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_917101","record_id":"REC_0002097","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":17.7,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":7.2,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.361984+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_748084","record_id":"REC_0002098","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":1,"smoking_pack_years":26,"primary_tumor_size_cm":4.6,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.362214+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_960710","record_id":"REC_0002099","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":5.7,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":4.6,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":28.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.362448+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_621154","record_id":"REC_0002100","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":9.8,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":4.1,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.362679+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_907560","record_id":"REC_0002101","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":36,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":3.9,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.362915+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_377581","record_id":"REC_0002102","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":6.4,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":5.7,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":7.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.363145+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_658941","record_id":"REC_0002103","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":5.7,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":5.5,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":27.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.363374+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_753973","record_id":"REC_0002104","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":16.7,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":5.8,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.363611+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_498355","record_id":"REC_0002105","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":7.3,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":28.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.363848+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_140428","record_id":"REC_0002106","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":8.5,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":0,"smoking_pack_years":0,"primary_tumor_size_cm":6.8,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.364123+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_236983","record_id":"REC_0002107","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":1,"smoking_pack_years":59,"primary_tumor_size_cm":5.4,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.364438+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_309335","record_id":"REC_0002108","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":4.0,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.364679+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_843973","record_id":"REC_0002109","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":8,"primary_tumor_size_cm":7.0,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.364912+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_930251","record_id":"REC_0002110","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":32,"tmb_mutations_per_mb":13.1,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":6.2,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.365148+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_611855","record_id":"REC_0002111","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":14.1,"age_at_diagnosis":52,"sex":"male","ecog_performance_status":0,"smoking_pack_years":5,"primary_tumor_size_cm":3.7,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.365387+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_866439","record_id":"REC_0002112","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":7.3,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":86,"primary_tumor_size_cm":7.2,"metastatic_sites_count":3,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.365620+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_945235","record_id":"REC_0002113","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":8.1,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.365852+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_475315","record_id":"REC_0002114","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":16.4,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.8,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.366087+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_886720","record_id":"REC_0002115","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":4.1,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":0,"smoking_pack_years":32,"primary_tumor_size_cm":8.0,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.366320+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_375242","record_id":"REC_0002116","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":6.4,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":47.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.366553+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_652044","record_id":"REC_0002117","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":5.3,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.366788+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_144409","record_id":"REC_0002118","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":24,"primary_tumor_size_cm":4.2,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":23.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.367020+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_510525","record_id":"REC_0002119","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":14.5,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":4.6,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.367252+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_582982","record_id":"REC_0002120","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":10.5,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":3.8,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":19.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.367532+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_881271","record_id":"REC_0002121","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":32,"tmb_mutations_per_mb":6.4,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":1,"smoking_pack_years":48,"primary_tumor_size_cm":7.7,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":19.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.367762+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_829588","record_id":"REC_0002122","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":17.9,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":2,"primary_tumor_size_cm":7.0,"metastatic_sites_count":3,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":17.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.367997+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_970484","record_id":"REC_0002123","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":30,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":84,"sex":"male","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":5.8,"metastatic_sites_count":9,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.368371+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_974778","record_id":"REC_0002124","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":7.0,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.368630+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_577581","record_id":"REC_0002125","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":74,"sex":"male","ecog_performance_status":0,"smoking_pack_years":48,"primary_tumor_size_cm":4.6,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.368873+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_262796","record_id":"REC_0002126","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":81,"primary_tumor_size_cm":6.3,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.369114+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_314285","record_id":"REC_0002127","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":4.9,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.369354+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_453962","record_id":"REC_0002128","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":9.9,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":4.4,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.369594+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_795008","record_id":"REC_0002129","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":0,"smoking_pack_years":3,"primary_tumor_size_cm":4.6,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":5.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.369833+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_413022","record_id":"REC_0002130","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":3.7,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":42,"primary_tumor_size_cm":6.0,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":47.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.370072+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_578211","record_id":"REC_0002131","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":7.7,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.370312+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_250705","record_id":"REC_0002132","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":4.4,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":6.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.370549+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_411992","record_id":"REC_0002133","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":14.3,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":6.9,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.370861+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_680692","record_id":"REC_0002134","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":3,"smoking_pack_years":15,"primary_tumor_size_cm":3.8,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.371101+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_524402","record_id":"REC_0002135","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":17,"tmb_mutations_per_mb":18.4,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":6.8,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.371338+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_976683","record_id":"REC_0002136","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":30,"tmb_mutations_per_mb":8.5,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":8.1,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.371571+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_931816","record_id":"REC_0002137","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":18.2,"age_at_diagnosis":48,"sex":"male","ecog_performance_status":0,"smoking_pack_years":30,"primary_tumor_size_cm":5.3,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.371809+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_787465","record_id":"REC_0002138","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":34,"tmb_mutations_per_mb":7.3,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":4.2,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.372043+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_994887","record_id":"REC_0002139","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":19,"tmb_mutations_per_mb":15.8,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":6.8,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.372327+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_961726","record_id":"REC_0002140","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":11.1,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":4.5,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.372562+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_355256","record_id":"REC_0002141","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":9.0,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":4.3,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":5.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.372797+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_232651","record_id":"REC_0002142","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":4.1,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":6.0,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.373025+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_650495","record_id":"REC_0002143","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":51,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":4.7,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":8.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.373260+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_399456","record_id":"REC_0002144","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":8.5,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":1,"smoking_pack_years":25,"primary_tumor_size_cm":3.8,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.373493+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_261884","record_id":"REC_0002145","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":16.2,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":6.0,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.373729+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_255908","record_id":"REC_0002146","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":4.4,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.374011+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_378965","record_id":"REC_0002147","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":4.1,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":4.8,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":29.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.374243+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_469175","record_id":"REC_0002148","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":7.9,"age_at_diagnosis":53,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":5.7,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.374477+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_193035","record_id":"REC_0002149","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":52,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":6.3,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":17.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.374710+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_120297","record_id":"REC_0002150","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":15.3,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":4.5,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.374945+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_919925","record_id":"REC_0002151","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":82,"sex":"male","ecog_performance_status":2,"smoking_pack_years":8,"primary_tumor_size_cm":5.0,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":7.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.375179+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_719639","record_id":"REC_0002152","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":4.6,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":5.2,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":24.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.375407+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_303108","record_id":"REC_0002153","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":13.5,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":5.4,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":5.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.375639+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_323260","record_id":"REC_0002154","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":20.4,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":4.2,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":39.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.375877+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_504831","record_id":"REC_0002155","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":8.9,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":4.3,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.376202+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_240857","record_id":"REC_0002156","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":6.7,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":6.5,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.376439+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_229596","record_id":"REC_0002157","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":2.9,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":1,"smoking_pack_years":35,"primary_tumor_size_cm":5.5,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.376674+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_787799","record_id":"REC_0002158","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":31,"tmb_mutations_per_mb":8.3,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":61,"primary_tumor_size_cm":4.1,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.376904+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_418481","record_id":"REC_0002159","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":10.1,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":5.4,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.377190+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_395169","record_id":"REC_0002160","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":13.3,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.3,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":20.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.377428+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_151686","record_id":"REC_0002161","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":7.4,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":49,"primary_tumor_size_cm":4.8,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":16.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.377662+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_764056","record_id":"REC_0002162","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":2,"smoking_pack_years":10,"primary_tumor_size_cm":5.9,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.377895+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_537205","record_id":"REC_0002163","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":16.8,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":6.0,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":7.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.378131+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_889182","record_id":"REC_0002164","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":8.7,"age_at_diagnosis":81,"sex":"male","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":4.8,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":23.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.378364+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_321628","record_id":"REC_0002165","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":18,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":3.5,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.378592+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_109913","record_id":"REC_0002166","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":9.7,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":6.2,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":16.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.378832+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_489575","record_id":"REC_0002167","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":4.0,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":34,"primary_tumor_size_cm":4.8,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":17.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.379088+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_362017","record_id":"REC_0002168","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":5.4,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.379343+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_319323","record_id":"REC_0002169","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":17.2,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":6.4,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.379600+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_549771","record_id":"REC_0002170","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":14.1,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":5.9,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.379844+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_754358","record_id":"REC_0002171","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":6.4,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.380151+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_383229","record_id":"REC_0002172","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":18,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":3.9,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.380509+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_146189","record_id":"REC_0002173","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":2,"smoking_pack_years":67,"primary_tumor_size_cm":4.3,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":19.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.380758+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_719004","record_id":"REC_0002174","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.2,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":32.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.381003+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_553029","record_id":"REC_0002175","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":0,"primary_tumor_size_cm":3.5,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.381241+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_263471","record_id":"REC_0002176","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":5.0,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.381474+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_337459","record_id":"REC_0002177","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":16.1,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":5.7,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.381706+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_155443","record_id":"REC_0002178","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":13.3,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":26,"primary_tumor_size_cm":3.3,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.381947+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_937031","record_id":"REC_0002179","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":16.1,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":6.8,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":21.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.382185+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_568703","record_id":"REC_0002180","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":31,"tmb_mutations_per_mb":5.1,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":73,"primary_tumor_size_cm":4.1,"metastatic_sites_count":3,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.382418+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_732309","record_id":"REC_0002181","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":20,"tmb_mutations_per_mb":5.7,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":5.0,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.382647+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_464704","record_id":"REC_0002182","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":7.3,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.382877+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_849219","record_id":"REC_0002183","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":1,"smoking_pack_years":56,"primary_tumor_size_cm":6.6,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.383111+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_150557","record_id":"REC_0002184","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":6.3,"age_at_diagnosis":77,"sex":"male","ecog_performance_status":1,"smoking_pack_years":51,"primary_tumor_size_cm":6.3,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.383343+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_327018","record_id":"REC_0002185","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":52,"sex":"male","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":3.8,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.383627+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_401150","record_id":"REC_0002186","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":2.8,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":6.4,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":24.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.383858+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_423056","record_id":"REC_0002187","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":33,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":5.6,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.384133+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_637777","record_id":"REC_0002188","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":74,"sex":"male","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":3.8,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.384375+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_212457","record_id":"REC_0002189","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":15.1,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":9,"primary_tumor_size_cm":4.3,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":17.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.384611+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_842314","record_id":"REC_0002190","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":8.0,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":0,"smoking_pack_years":2,"primary_tumor_size_cm":3.1,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.384843+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_295984","record_id":"REC_0002191","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":3,"smoking_pack_years":7,"primary_tumor_size_cm":5.1,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":33.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.385072+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_139010","record_id":"REC_0002192","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":5.1,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":5.5,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.385298+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_690539","record_id":"REC_0002193","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":6.0,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.385534+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_551594","record_id":"REC_0002194","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":1,"smoking_pack_years":44,"primary_tumor_size_cm":4.7,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.385760+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_101584","record_id":"REC_0002195","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":14.3,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":7.6,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":22.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.385997+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_694320","record_id":"REC_0002196","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":81,"sex":"male","ecog_performance_status":2,"smoking_pack_years":8,"primary_tumor_size_cm":4.6,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.386229+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_226988","record_id":"REC_0002197","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":30,"tmb_mutations_per_mb":13.3,"age_at_diagnosis":80,"sex":"male","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":6.6,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":5.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.386466+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_935599","record_id":"REC_0002198","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":30,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":74,"sex":"male","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":5.7,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":16.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.386758+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_973327","record_id":"REC_0002199","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":3.5,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":75,"primary_tumor_size_cm":8.6,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":17.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.386997+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_220058","record_id":"REC_0002200","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":10.0,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":4.1,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":18.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.387233+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_848609","record_id":"REC_0002201","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":13.3,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":3.9,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.387471+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_520681","record_id":"REC_0002202","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":78,"sex":"male","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":5.9,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.387706+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_112953","record_id":"REC_0002203","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":11,"tmb_mutations_per_mb":16.8,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":3.2,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.387941+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_318331","record_id":"REC_0002204","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":8.0,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":44,"primary_tumor_size_cm":4.7,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":18.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.388227+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_730258","record_id":"REC_0002205","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":34,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":6.2,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.388470+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_368098","record_id":"REC_0002206","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":18,"tmb_mutations_per_mb":16.0,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":4.5,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.388703+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_635728","record_id":"REC_0002207","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":15.2,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":0,"smoking_pack_years":26,"primary_tumor_size_cm":5.6,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.388939+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_850455","record_id":"REC_0002208","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":16.4,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":4.8,"metastatic_sites_count":3,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.389173+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_433678","record_id":"REC_0002209","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":9.1,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":7.4,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.389405+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_304492","record_id":"REC_0002210","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":34,"tmb_mutations_per_mb":9.5,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":5.5,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.389637+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_640534","record_id":"REC_0002211","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":4.3,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.3,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":7.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.389920+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_157343","record_id":"REC_0002212","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":9.0,"age_at_diagnosis":54,"sex":"female","ecog_performance_status":0,"smoking_pack_years":24,"primary_tumor_size_cm":4.9,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.390156+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_992182","record_id":"REC_0002213","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":16,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":4.2,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":25.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.390384+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_649608","record_id":"REC_0002214","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":17.2,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":7.3,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":4.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.390621+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_563574","record_id":"REC_0002215","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":1,"smoking_pack_years":61,"primary_tumor_size_cm":6.8,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":7.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.390853+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_413825","record_id":"REC_0002216","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":7.6,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":24,"primary_tumor_size_cm":5.8,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.391084+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_889562","record_id":"REC_0002217","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":4.4,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.391313+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_456635","record_id":"REC_0002218","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":20.7,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":7.1,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.391543+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_772564","record_id":"REC_0002219","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":6.0,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.391775+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_634525","record_id":"REC_0002220","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":20,"tmb_mutations_per_mb":3.5,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":32,"primary_tumor_size_cm":7.5,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":16.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.392001+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_720875","record_id":"REC_0002221","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":14.3,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":6.1,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.392276+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_343524","record_id":"REC_0002222","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":15.2,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.7,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.392516+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_928602","record_id":"REC_0002223","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":15.7,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":6.3,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.392754+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_362723","record_id":"REC_0002224","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":61,"primary_tumor_size_cm":5.5,"metastatic_sites_count":8,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":7.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.393043+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_162757","record_id":"REC_0002225","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":1,"smoking_pack_years":31,"primary_tumor_size_cm":4.5,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":16.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.393287+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_529152","record_id":"REC_0002226","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":3.7,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":25.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.393524+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_153935","record_id":"REC_0002227","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":18.4,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":5.5,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.393763+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_558302","record_id":"REC_0002228","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.5,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":23,"primary_tumor_size_cm":4.4,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.393996+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_513689","record_id":"REC_0002229","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":3,"smoking_pack_years":3,"primary_tumor_size_cm":7.7,"metastatic_sites_count":9,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.394228+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_589722","record_id":"REC_0002230","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":19,"tmb_mutations_per_mb":5.0,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":0,"smoking_pack_years":56,"primary_tumor_size_cm":5.5,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":25.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.394456+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_438468","record_id":"REC_0002231","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":16,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":51,"primary_tumor_size_cm":5.2,"metastatic_sites_count":8,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":16.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.394686+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_421029","record_id":"REC_0002232","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":19,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":4.8,"metastatic_sites_count":3,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.394925+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_371682","record_id":"REC_0002233","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":5,"primary_tumor_size_cm":5.7,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.395165+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_412169","record_id":"REC_0002234","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":9.0,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":2,"smoking_pack_years":10,"primary_tumor_size_cm":6.0,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.395398+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_165024","record_id":"REC_0002235","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":17.7,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":4.3,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.395628+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_301635","record_id":"REC_0002236","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":17.1,"age_at_diagnosis":76,"sex":"male","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":6.1,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.395871+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_105330","record_id":"REC_0002237","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":8.3,"age_at_diagnosis":48,"sex":"male","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":5.0,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.396216+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_843902","record_id":"REC_0002238","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":6.6,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.396462+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_340774","record_id":"REC_0002239","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":19,"tmb_mutations_per_mb":2.1,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":1,"smoking_pack_years":4,"primary_tumor_size_cm":5.2,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":21.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.396699+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_783626","record_id":"REC_0002240","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":19,"tmb_mutations_per_mb":4.9,"age_at_diagnosis":52,"sex":"male","ecog_performance_status":0,"smoking_pack_years":44,"primary_tumor_size_cm":5.0,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":28.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.396935+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_293094","record_id":"REC_0002241","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":5.3,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":31.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.397171+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_902936","record_id":"REC_0002242","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":8.6,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":36,"primary_tumor_size_cm":6.2,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.397403+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_213893","record_id":"REC_0002243","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":16.2,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":5.8,"metastatic_sites_count":9,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":8.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.397636+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_960569","record_id":"REC_0002244","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":6.7,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.397868+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_727990","record_id":"REC_0002245","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":8.6,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":4.1,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.398096+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_872875","record_id":"REC_0002246","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":15,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":43,"primary_tumor_size_cm":7.3,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.398330+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_106797","record_id":"REC_0002247","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":22.1,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":0,"smoking_pack_years":24,"primary_tumor_size_cm":6.4,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.398566+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_331447","record_id":"REC_0002248","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":49,"sex":"male","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":4.8,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.398807+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_698399","record_id":"REC_0002249","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":4.6,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.399060+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_774327","record_id":"REC_0002250","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":6.0,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":68,"primary_tumor_size_cm":4.3,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":29.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.399416+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_650375","record_id":"REC_0002251","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":10,"primary_tumor_size_cm":5.1,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.399695+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_503733","record_id":"REC_0002252","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":15,"tmb_mutations_per_mb":5.7,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":2,"smoking_pack_years":74,"primary_tumor_size_cm":7.1,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":25.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.399932+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_637678","record_id":"REC_0002253","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":32,"tmb_mutations_per_mb":14.4,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":7.5,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":18.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.400317+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_628457","record_id":"REC_0002254","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":0,"smoking_pack_years":56,"primary_tumor_size_cm":6.8,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.400576+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_660626","record_id":"REC_0002255","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":4.2,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":24.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.400825+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_221471","record_id":"REC_0002256","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":22,"primary_tumor_size_cm":6.0,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":20.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.401059+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_484467","record_id":"REC_0002257","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":7.2,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":18.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.401302+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_247797","record_id":"REC_0002258","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":15.4,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":6.4,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":17.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.401537+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_274834","record_id":"REC_0002259","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":33,"tmb_mutations_per_mb":13.5,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":5.6,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":8.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.401778+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_988813","record_id":"REC_0002260","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":9.5,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":4.2,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.402010+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_397126","record_id":"REC_0002261","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":5.9,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.402250+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_930540","record_id":"REC_0002262","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":14.3,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":4.5,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":6.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.402486+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_533798","record_id":"REC_0002263","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":8.6,"age_at_diagnosis":51,"sex":"female","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":6.3,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.402819+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_392833","record_id":"REC_0002264","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":4.8,"age_at_diagnosis":53,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":5.6,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.403060+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_651764","record_id":"REC_0002265","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":32,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":3,"smoking_pack_years":38,"primary_tumor_size_cm":5.2,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.403289+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_201233","record_id":"REC_0002266","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":5.9,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":4.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.403526+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_570643","record_id":"REC_0002267","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":3,"smoking_pack_years":12,"primary_tumor_size_cm":5.4,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.403755+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_251651","record_id":"REC_0002268","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":5.9,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":19.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.403991+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_479897","record_id":"REC_0002269","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":3.8,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":21.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.404281+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_340555","record_id":"REC_0002270","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":7.0,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.404522+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_547707","record_id":"REC_0002271","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":84,"sex":"female","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":6.0,"metastatic_sites_count":8,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.404766+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_376105","record_id":"REC_0002272","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":5.7,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":34,"primary_tumor_size_cm":7.5,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.404998+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_152499","record_id":"REC_0002273","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":17.8,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":7.5,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.405242+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_831561","record_id":"REC_0002274","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":13.1,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":5.5,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.405482+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_116887","record_id":"REC_0002275","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":8.4,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":4.1,"metastatic_sites_count":10,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.405710+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_600672","record_id":"REC_0002276","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":3,"smoking_pack_years":3,"primary_tumor_size_cm":5.6,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.406017+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_194633","record_id":"REC_0002277","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":6.4,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":5.2,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":25.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.406255+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_485263","record_id":"REC_0002278","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":83,"sex":"female","ecog_performance_status":2,"smoking_pack_years":0,"primary_tumor_size_cm":5.8,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.406484+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_544621","record_id":"REC_0002279","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":21.8,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":6.1,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.406721+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_756398","record_id":"REC_0002280","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":5.5,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":1,"smoking_pack_years":70,"primary_tumor_size_cm":6.2,"metastatic_sites_count":8,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.406956+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_222726","record_id":"REC_0002281","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":20,"tmb_mutations_per_mb":9.5,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":5.9,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.407193+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_428929","record_id":"REC_0002282","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":15.0,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":5.6,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.407434+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_412867","record_id":"REC_0002283","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":17.6,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":6.0,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":5.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.407669+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_712682","record_id":"REC_0002284","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":3.9,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":6.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.407904+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_768992","record_id":"REC_0002285","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":16,"tmb_mutations_per_mb":8.1,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":73,"primary_tumor_size_cm":6.5,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.408182+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_242557","record_id":"REC_0002286","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":5.0,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":6.6,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":7.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.408425+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_881163","record_id":"REC_0002287","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":7.8,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.408660+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_590057","record_id":"REC_0002288","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":5.3,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":6.2,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":26.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.408891+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_771973","record_id":"REC_0002289","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.6,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.409210+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_518745","record_id":"REC_0002290","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":88,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":5.2,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":23.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.409505+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_807536","record_id":"REC_0002291","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":18,"tmb_mutations_per_mb":8.7,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":6.3,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.409772+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_875943","record_id":"REC_0002292","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":15.8,"age_at_diagnosis":54,"sex":"male","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":5.0,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.410018+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_329955","record_id":"REC_0002293","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":15.2,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":24,"primary_tumor_size_cm":6.0,"metastatic_sites_count":3,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.410253+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_850584","record_id":"REC_0002294","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":7.0,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.410486+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_386452","record_id":"REC_0002295","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":15.0,"age_at_diagnosis":85,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":3.4,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.410718+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_196734","record_id":"REC_0002296","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":11,"tmb_mutations_per_mb":15.7,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":7.3,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.410950+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_504976","record_id":"REC_0002297","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":8.4,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":4.5,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.411179+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_257714","record_id":"REC_0002298","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":6.3,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.411420+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_888376","record_id":"REC_0002299","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":26,"primary_tumor_size_cm":6.2,"metastatic_sites_count":8,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.411649+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_293418","record_id":"REC_0002300","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":45,"primary_tumor_size_cm":6.6,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":17.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.411881+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_734306","record_id":"REC_0002301","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":4.2,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.412190+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_648602","record_id":"REC_0002302","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":37,"tmb_mutations_per_mb":4.5,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":7.2,"metastatic_sites_count":9,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.412558+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_522449","record_id":"REC_0002303","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":7.6,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":25,"primary_tumor_size_cm":5.0,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.412811+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_330247","record_id":"REC_0002304","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":35,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":6.1,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.413048+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_254523","record_id":"REC_0002305","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":19,"tmb_mutations_per_mb":6.4,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":4.5,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.413283+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_923449","record_id":"REC_0002306","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":4.4,"age_at_diagnosis":53,"sex":"female","ecog_performance_status":0,"smoking_pack_years":43,"primary_tumor_size_cm":7.7,"metastatic_sites_count":8,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.413516+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_940211","record_id":"REC_0002307","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":30,"tmb_mutations_per_mb":14.3,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":4.5,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.413752+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_361016","record_id":"REC_0002308","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":14.7,"age_at_diagnosis":47,"sex":"male","ecog_performance_status":0,"smoking_pack_years":3,"primary_tumor_size_cm":6.2,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":6.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.413989+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_558793","record_id":"REC_0002309","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":19,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":3.5,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":23.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.414220+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_475336","record_id":"REC_0002310","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":8.7,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":5.5,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":6.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.414453+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_858079","record_id":"REC_0002311","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":6.5,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.414689+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_493269","record_id":"REC_0002312","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":10.5,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":6.8,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.414923+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_712037","record_id":"REC_0002313","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":16,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":4.6,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":22.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.415166+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_816594","record_id":"REC_0002314","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":4.8,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.415403+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_809959","record_id":"REC_0002315","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":3.9,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":54,"primary_tumor_size_cm":6.4,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.415691+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_602758","record_id":"REC_0002316","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":14.8,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.4,"metastatic_sites_count":9,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":19.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.415935+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_244214","record_id":"REC_0002317","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":14.4,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":4.7,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.416266+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_646340","record_id":"REC_0002318","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.6,"metastatic_sites_count":8,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":7.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.416510+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_209086","record_id":"REC_0002319","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":8.4,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":4.7,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":26.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.416747+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_539655","record_id":"REC_0002320","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":15.3,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":5.7,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":25.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.416981+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_552643","record_id":"REC_0002321","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":31,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":7.0,"metastatic_sites_count":3,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":6.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.417222+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_947284","record_id":"REC_0002322","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":14,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":50,"primary_tumor_size_cm":7.8,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":21.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.417452+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_201362","record_id":"REC_0002323","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":14.3,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":26,"primary_tumor_size_cm":5.7,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.417685+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_486266","record_id":"REC_0002324","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":10.3,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":5.7,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.417923+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_784741","record_id":"REC_0002325","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":32,"tmb_mutations_per_mb":8.5,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":40,"primary_tumor_size_cm":5.8,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.418152+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_396591","record_id":"REC_0002326","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":5.5,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":0,"smoking_pack_years":31,"primary_tumor_size_cm":5.1,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":16.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.418379+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_784058","record_id":"REC_0002327","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":31,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":87,"sex":"female","ecog_performance_status":2,"smoking_pack_years":50,"primary_tumor_size_cm":5.2,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":16.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.418609+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_195216","record_id":"REC_0002328","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":5.7,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.418941+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_737553","record_id":"REC_0002329","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":3.8,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.419208+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_619508","record_id":"REC_0002330","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":54,"primary_tumor_size_cm":5.1,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.419477+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_246240","record_id":"REC_0002331","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":14.7,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":3,"smoking_pack_years":11,"primary_tumor_size_cm":5.6,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":18.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.419740+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_676601","record_id":"REC_0002332","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":28,"primary_tumor_size_cm":5.2,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.419979+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_493798","record_id":"REC_0002333","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":22,"primary_tumor_size_cm":4.8,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.420276+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_393310","record_id":"REC_0002334","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":5.7,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":4.3,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":59.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.420524+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_493481","record_id":"REC_0002335","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":15.0,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":5.7,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.420765+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_984318","record_id":"REC_0002336","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":4.7,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.420999+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_764987","record_id":"REC_0002337","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":85,"sex":"female","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":5.2,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.421231+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_957939","record_id":"REC_0002338","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":5.2,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":16.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.421468+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_224034","record_id":"REC_0002339","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":5.5,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":20.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.421703+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_435721","record_id":"REC_0002340","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":24,"primary_tumor_size_cm":7.3,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.421935+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_766917","record_id":"REC_0002341","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":5.1,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":23,"primary_tumor_size_cm":5.0,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.422276+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_649807","record_id":"REC_0002342","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":4.7,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":31.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.422522+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_162770","record_id":"REC_0002343","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":9.1,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":5.7,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.422753+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_501925","record_id":"REC_0002344","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":5.8,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.422989+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_244505","record_id":"REC_0002345","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":16.6,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":4.9,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.423222+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_289143","record_id":"REC_0002346","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":18,"tmb_mutations_per_mb":6.1,"age_at_diagnosis":51,"sex":"female","ecog_performance_status":0,"smoking_pack_years":39,"primary_tumor_size_cm":5.2,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.423456+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_665390","record_id":"REC_0002347","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":14.8,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":5.6,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.423691+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_510430","record_id":"REC_0002348","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":4.9,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":7.0,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.423919+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_911801","record_id":"REC_0002349","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":14.5,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":5.6,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":20.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.424213+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_978906","record_id":"REC_0002350","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":6.2,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":25.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.424458+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_673016","record_id":"REC_0002351","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":5.5,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.424695+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_959028","record_id":"REC_0002352","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":5.1,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.424932+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_914365","record_id":"REC_0002353","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":7.1,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.425165+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_412801","record_id":"REC_0002354","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":5.1,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":0,"primary_tumor_size_cm":6.5,"metastatic_sites_count":8,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.425445+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_387925","record_id":"REC_0002355","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":6.0,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":26,"primary_tumor_size_cm":7.6,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":44.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.425679+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_426916","record_id":"REC_0002356","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":8.9,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":5.2,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.425909+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_372916","record_id":"REC_0002357","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":0,"smoking_pack_years":4,"primary_tumor_size_cm":4.4,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":8.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.426142+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_416344","record_id":"REC_0002358","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":30,"tmb_mutations_per_mb":15.8,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":7.1,"metastatic_sites_count":8,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.426377+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_842184","record_id":"REC_0002359","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":17.3,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":1,"smoking_pack_years":2,"primary_tumor_size_cm":3.1,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.426615+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_274423","record_id":"REC_0002360","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":6.7,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.426849+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_115168","record_id":"REC_0002361","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":16.7,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":24,"primary_tumor_size_cm":4.4,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.427083+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_609272","record_id":"REC_0002362","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":14.6,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":6.9,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.427318+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_826128","record_id":"REC_0002363","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":9.7,"age_at_diagnosis":53,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":5.1,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.427548+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_800673","record_id":"REC_0002364","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":14,"tmb_mutations_per_mb":4.3,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":0,"smoking_pack_years":48,"primary_tumor_size_cm":4.8,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":7.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.427778+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_533731","record_id":"REC_0002365","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":31,"tmb_mutations_per_mb":11.5,"age_at_diagnosis":76,"sex":"male","ecog_performance_status":1,"smoking_pack_years":24,"primary_tumor_size_cm":3.6,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":7.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.428013+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_374286","record_id":"REC_0002366","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":5.7,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.428288+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_191926","record_id":"REC_0002367","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":4.3,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":26,"primary_tumor_size_cm":5.4,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.428570+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_952501","record_id":"REC_0002368","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":33,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":84,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":5.6,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.428804+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_539649","record_id":"REC_0002369","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":18.6,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":6.0,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.429042+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_763501","record_id":"REC_0002370","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":13.8,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":3.7,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.429280+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_888730","record_id":"REC_0002371","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":4.6,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":66,"primary_tumor_size_cm":5.2,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.429512+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_316900","record_id":"REC_0002372","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.0,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":6.0,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.429748+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_809972","record_id":"REC_0002373","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":5.6,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":5.4,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":23.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.429978+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_838261","record_id":"REC_0002374","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":18,"tmb_mutations_per_mb":8.9,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":2,"smoking_pack_years":20,"primary_tumor_size_cm":4.7,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":21.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.430208+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_548580","record_id":"REC_0002375","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":21,"primary_tumor_size_cm":4.8,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.430441+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_140877","record_id":"REC_0002376","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":14.4,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":6.3,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.430677+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_624748","record_id":"REC_0002377","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":15.2,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":6.7,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.430910+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_513137","record_id":"REC_0002378","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":17.6,"age_at_diagnosis":54,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":6.5,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":23.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.431143+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_106636","record_id":"REC_0002379","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":6.1,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":4.1,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.431373+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_890788","record_id":"REC_0002380","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":6.0,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":2,"smoking_pack_years":3,"primary_tumor_size_cm":4.8,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.431665+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_783422","record_id":"REC_0002381","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":14.1,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":4.5,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":22.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.431903+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_267008","record_id":"REC_0002382","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":2.5,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":7.6,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":30.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.432223+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_929360","record_id":"REC_0002383","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":53,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":6.8,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":49.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.432479+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_162709","record_id":"REC_0002384","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":13.8,"age_at_diagnosis":83,"sex":"female","ecog_performance_status":1,"smoking_pack_years":28,"primary_tumor_size_cm":5.8,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":22.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.432712+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_791778","record_id":"REC_0002385","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":18.4,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":3.4,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.432950+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_725193","record_id":"REC_0002386","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":39,"tmb_mutations_per_mb":3.6,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":6.7,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":23.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.433182+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_340083","record_id":"REC_0002387","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":16,"tmb_mutations_per_mb":16.0,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":5.4,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.433415+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_988286","record_id":"REC_0002388","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":13.6,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":28,"primary_tumor_size_cm":5.0,"metastatic_sites_count":3,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.433645+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_211921","record_id":"REC_0002389","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":17.4,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":5,"primary_tumor_size_cm":4.2,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.433877+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_425025","record_id":"REC_0002390","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":48,"sex":"female","ecog_performance_status":0,"smoking_pack_years":27,"primary_tumor_size_cm":4.8,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.434106+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_751759","record_id":"REC_0002391","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":6.0,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":6.6,"metastatic_sites_count":3,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.434339+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_344570","record_id":"REC_0002392","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":5.7,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":5.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.434573+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_916671","record_id":"REC_0002393","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":13.1,"age_at_diagnosis":76,"sex":"male","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":5.2,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.434863+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_126422","record_id":"REC_0002394","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":14.6,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":5.3,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":24.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.435106+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_436342","record_id":"REC_0002395","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":5.3,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":4.5,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.435339+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_147701","record_id":"REC_0002396","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":8.6,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":5.2,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":24.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.435567+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_450593","record_id":"REC_0002397","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":30,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":87,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":5.3,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":6.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.435792+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_109253","record_id":"REC_0002398","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":14.8,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":3.9,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.436026+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_787721","record_id":"REC_0002399","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":44,"primary_tumor_size_cm":7.2,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":24.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.436363+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_230956","record_id":"REC_0002400","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":75,"sex":"male","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":6.5,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":21.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.436604+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_284639","record_id":"REC_0002401","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":5.2,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":5.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.436837+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_664728","record_id":"REC_0002402","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":4.5,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.437073+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_240049","record_id":"REC_0002403","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":5.4,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":4.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.437306+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_185247","record_id":"REC_0002404","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":5.5,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":46,"primary_tumor_size_cm":6.5,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":16.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.437537+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_564410","record_id":"REC_0002405","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":9.5,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":7.3,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.437765+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_941025","record_id":"REC_0002406","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":9.5,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":5.5,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.438042+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_715769","record_id":"REC_0002407","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":5.7,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.438282+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_611754","record_id":"REC_0002408","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":3,"primary_tumor_size_cm":6.4,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":16.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.438516+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_507614","record_id":"REC_0002409","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":5.0,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":4.6,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.438754+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_602080","record_id":"REC_0002410","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":18,"tmb_mutations_per_mb":1.5,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":65,"primary_tumor_size_cm":4.7,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.438996+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_430002","record_id":"REC_0002411","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":19.1,"age_at_diagnosis":53,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":4.2,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":17.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.439257+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_504022","record_id":"REC_0002412","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":4.7,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":27,"primary_tumor_size_cm":4.4,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":27.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.439504+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_756703","record_id":"REC_0002413","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":15.6,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":6.8,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":35.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.439745+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_691924","record_id":"REC_0002414","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":19.4,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":6.2,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.439988+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_562115","record_id":"REC_0002415","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":4.9,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":27,"primary_tumor_size_cm":6.3,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.440300+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_999573","record_id":"REC_0002416","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":14.1,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":1,"smoking_pack_years":27,"primary_tumor_size_cm":7.6,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":33.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.440546+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_791027","record_id":"REC_0002417","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":18.0,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":5.2,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":22.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.440786+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_278192","record_id":"REC_0002418","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":4.8,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":27.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.441023+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_608619","record_id":"REC_0002419","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":5.2,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.441362+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_295779","record_id":"REC_0002420","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":15.2,"age_at_diagnosis":83,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":3.7,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.441600+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_175688","record_id":"REC_0002421","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":43,"primary_tumor_size_cm":5.0,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.441835+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_397759","record_id":"REC_0002422","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":14.1,"age_at_diagnosis":74,"sex":"male","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":3.2,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.442070+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_458721","record_id":"REC_0002423","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":11.0,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":4.6,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.442307+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_271053","record_id":"REC_0002424","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":14.7,"age_at_diagnosis":76,"sex":"male","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":7.2,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":17.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.442544+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_959986","record_id":"REC_0002425","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":31,"tmb_mutations_per_mb":7.9,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":5.3,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.442771+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_817154","record_id":"REC_0002426","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":16.0,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":3.6,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":5.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.443008+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_116510","record_id":"REC_0002427","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":31,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":0,"smoking_pack_years":39,"primary_tumor_size_cm":6.7,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":4.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.443240+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_873208","record_id":"REC_0002428","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":14.8,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":3.1,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.443479+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_186631","record_id":"REC_0002429","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ALK fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.8,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":31.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.443728+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_593128","record_id":"REC_0002430","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":14.3,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":7.3,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.443980+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_531451","record_id":"REC_0002431","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":30,"tmb_mutations_per_mb":4.7,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":1,"smoking_pack_years":5,"primary_tumor_size_cm":4.5,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.444393+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_279939","record_id":"REC_0002432","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":15.5,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":4.6,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.444763+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_269590","record_id":"REC_0002433","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":8.4,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":5.3,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":17.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.445011+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_190428","record_id":"REC_0002434","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":9.8,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":5.2,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":27.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.445249+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_541584","record_id":"REC_0002435","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":10.0,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":6.3,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.445491+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_250786","record_id":"REC_0002436","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":5.0,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.445726+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_438249","record_id":"REC_0002437","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":32,"tmb_mutations_per_mb":14.3,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":5.7,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":6.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.445962+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_713029","record_id":"REC_0002438","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":9.7,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":3,"smoking_pack_years":6,"primary_tumor_size_cm":7.2,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.446197+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_467095","record_id":"REC_0002439","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":5.2,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":25.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.446432+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_834210","record_id":"REC_0002440","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":14,"tmb_mutations_per_mb":8.3,"age_at_diagnosis":77,"sex":"male","ecog_performance_status":2,"smoking_pack_years":24,"primary_tumor_size_cm":4.0,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.446665+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_307590","record_id":"REC_0002441","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.6,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":5.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.446897+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_378292","record_id":"REC_0002442","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":4.2,"age_at_diagnosis":85,"sex":"female","ecog_performance_status":2,"smoking_pack_years":44,"primary_tumor_size_cm":7.8,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":21.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.447132+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_401433","record_id":"REC_0002443","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":4.6,"metastatic_sites_count":3,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":16.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.447373+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_696333","record_id":"REC_0002444","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":8.5,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":5.8,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":4.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.447605+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_389482","record_id":"REC_0002445","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":5.9,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":6.0,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":16.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.447888+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_687346","record_id":"REC_0002446","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":16,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":2,"smoking_pack_years":8,"primary_tumor_size_cm":6.2,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.448221+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_626111","record_id":"REC_0002447","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":6.7,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":4,"primary_tumor_size_cm":8.0,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":6.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.448472+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_550304","record_id":"REC_0002448","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":6.5,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.448704+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_967036","record_id":"REC_0002449","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":90,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":5.0,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.448939+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_359131","record_id":"REC_0002450","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":5.3,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":3.9,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":16.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.449170+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_972917","record_id":"REC_0002451","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":14.3,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":4.6,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.449402+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_962067","record_id":"REC_0002452","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":5.9,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.449638+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_227088","record_id":"REC_0002453","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":6.0,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.449871+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_287299","record_id":"REC_0002454","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":6.1,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.450101+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_193044","record_id":"REC_0002455","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":5.6,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":17.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.450333+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_599630","record_id":"REC_0002456","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":10,"primary_tumor_size_cm":6.0,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":17.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.450563+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_812858","record_id":"REC_0002457","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":18.9,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":1,"smoking_pack_years":25,"primary_tumor_size_cm":7.0,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.450798+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_678671","record_id":"REC_0002458","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":4.9,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":39,"primary_tumor_size_cm":6.9,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":19.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.451086+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_669979","record_id":"REC_0002459","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":19,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":6.1,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.451328+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_814982","record_id":"REC_0002460","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":8.2,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":27.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.451564+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_971064","record_id":"REC_0002461","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":4.8,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":6.3,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":32.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.451795+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_645114","record_id":"REC_0002462","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":3.9,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":5.3,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.452026+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_480589","record_id":"REC_0002463","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":20,"tmb_mutations_per_mb":4.4,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":1,"smoking_pack_years":41,"primary_tumor_size_cm":7.0,"metastatic_sites_count":9,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":5.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.452306+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_451447","record_id":"REC_0002464","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":33,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":84,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":6.7,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.452544+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_701158","record_id":"REC_0002465","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":16,"tmb_mutations_per_mb":14.1,"age_at_diagnosis":51,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":7.1,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.452779+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_833735","record_id":"REC_0002466","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":5.7,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":5.6,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.453011+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_743595","record_id":"REC_0002467","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":9.7,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":5.4,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":24.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.453238+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_556484","record_id":"REC_0002468","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":5.5,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":2,"smoking_pack_years":45,"primary_tumor_size_cm":4.1,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.453466+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_422996","record_id":"REC_0002469","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":5.2,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":29.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.453698+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_372695","record_id":"REC_0002470","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":9.7,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":3.9,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.453927+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_154787","record_id":"REC_0002471","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":18,"tmb_mutations_per_mb":5.6,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":46,"primary_tumor_size_cm":7.0,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.454200+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_872440","record_id":"REC_0002472","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":6.3,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":4.5,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.454433+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_194688","record_id":"REC_0002473","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":14.0,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":4.8,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":25.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.454673+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_843227","record_id":"REC_0002474","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":18,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":4.6,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.454907+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_606132","record_id":"REC_0002475","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":3.2,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":56,"primary_tumor_size_cm":5.3,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.455136+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_521817","record_id":"REC_0002476","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":37,"tmb_mutations_per_mb":6.7,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":0,"smoking_pack_years":38,"primary_tumor_size_cm":7.1,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.455368+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_912628","record_id":"REC_0002477","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.0,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.455602+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_283414","record_id":"REC_0002478","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":5.7,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":84,"primary_tumor_size_cm":7.1,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":16.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.455833+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_944760","record_id":"REC_0002479","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":14.6,"age_at_diagnosis":78,"sex":"male","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":4.1,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.456069+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_957595","record_id":"REC_0002480","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":3.8,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":6.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.456401+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_637118","record_id":"REC_0002481","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":16,"tmb_mutations_per_mb":11.5,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":4.3,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.456642+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_687859","record_id":"REC_0002482","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":34,"tmb_mutations_per_mb":5.7,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":3,"smoking_pack_years":59,"primary_tumor_size_cm":4.3,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.456871+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_738914","record_id":"REC_0002483","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":5.0,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.457107+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_301606","record_id":"REC_0002484","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":17.7,"age_at_diagnosis":54,"sex":"female","ecog_performance_status":0,"smoking_pack_years":25,"primary_tumor_size_cm":6.8,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.457389+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_992849","record_id":"REC_0002485","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":36,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":43,"primary_tumor_size_cm":6.0,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.457625+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_213951","record_id":"REC_0002486","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":19,"tmb_mutations_per_mb":7.9,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":5.8,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":45.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.457863+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_235033","record_id":"REC_0002487","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":27,"primary_tumor_size_cm":4.9,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.458096+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_312191","record_id":"REC_0002488","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":74,"primary_tumor_size_cm":7.0,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":32.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.458324+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_822681","record_id":"REC_0002489","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":14.9,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":5.7,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.458558+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_468123","record_id":"REC_0002490","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":1,"smoking_pack_years":27,"primary_tumor_size_cm":4.8,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.458798+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_567700","record_id":"REC_0002491","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":6.1,"age_at_diagnosis":48,"sex":"male","ecog_performance_status":0,"smoking_pack_years":35,"primary_tumor_size_cm":5.6,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":16.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.459047+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_593238","record_id":"REC_0002492","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":5.2,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":7.6,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.459295+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_383749","record_id":"REC_0002493","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":8.3,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":1,"smoking_pack_years":32,"primary_tumor_size_cm":3.6,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":16.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.459544+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_493689","record_id":"REC_0002494","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":17,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":6.0,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.459796+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_431171","record_id":"REC_0002495","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None","pd_l1_tps_percent":19,"tmb_mutations_per_mb":6.0,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":53,"primary_tumor_size_cm":7.4,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":55.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.460030+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_233897","record_id":"REC_0002496","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":1,"smoking_pack_years":58,"primary_tumor_size_cm":5.9,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.460355+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_941041","record_id":"REC_0002497","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":24,"primary_tumor_size_cm":5.2,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.460716+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_135949","record_id":"REC_0002498","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":30,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.7,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.460955+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_448575","record_id":"REC_0002499","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":18,"tmb_mutations_per_mb":4.7,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":45,"primary_tumor_size_cm":6.9,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":5.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.461192+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_626714","record_id":"REC_0002500","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":17.1,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":4,"primary_tumor_size_cm":7.5,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":23.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.461432+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_866372","record_id":"REC_0002501","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":15,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":26,"primary_tumor_size_cm":8.0,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.461669+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_851305","record_id":"REC_0002502","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":15.7,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":24,"primary_tumor_size_cm":4.1,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.461901+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_279713","record_id":"REC_0002503","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":33,"tmb_mutations_per_mb":6.1,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":6.4,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.462134+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_133534","record_id":"REC_0002504","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":14.4,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":3.5,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":18.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.462368+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_374612","record_id":"REC_0002505","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":6.6,"metastatic_sites_count":10,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.462605+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_175475","record_id":"REC_0002506","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":4.2,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":0,"smoking_pack_years":2,"primary_tumor_size_cm":4.3,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.462837+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_776042","record_id":"REC_0002507","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":1.5,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":0,"smoking_pack_years":48,"primary_tumor_size_cm":5.4,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":18.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.463069+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_181178","record_id":"REC_0002508","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":17.2,"age_at_diagnosis":79,"sex":"male","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":5.9,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.463307+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_704819","record_id":"REC_0002509","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":14.0,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":6.5,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.463543+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_867716","record_id":"REC_0002510","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":1.5,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":4,"primary_tumor_size_cm":5.7,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.463824+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_559006","record_id":"REC_0002511","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":6.3,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.464063+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_229624","record_id":"REC_0002512","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":30,"tmb_mutations_per_mb":4.8,"age_at_diagnosis":90,"sex":"female","ecog_performance_status":1,"smoking_pack_years":31,"primary_tumor_size_cm":5.0,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.464415+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_181568","record_id":"REC_0002513","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":19.7,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":5.3,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.464653+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_664107","record_id":"REC_0002514","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":0,"smoking_pack_years":4,"primary_tumor_size_cm":6.4,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":56.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.464887+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_295188","record_id":"REC_0002515","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":14.6,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":5.9,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.465125+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_524333","record_id":"REC_0002516","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":32,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":7.1,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.465352+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_940870","record_id":"REC_0002517","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":6.0,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":6.7,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.465584+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_996170","record_id":"REC_0002518","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":5.2,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":6.7,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":7.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.465816+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_917822","record_id":"REC_0002519","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":5.2,"metastatic_sites_count":8,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.466045+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_194925","record_id":"REC_0002520","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":9.3,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.466280+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_721381","record_id":"REC_0002521","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":4.6,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":17.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.466515+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_575244","record_id":"REC_0002522","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":5.2,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":4.5,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":16.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.466746+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_778204","record_id":"REC_0002523","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":6.3,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.467035+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_602647","record_id":"REC_0002524","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":19.0,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":6.3,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.467274+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_357548","record_id":"REC_0002525","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":19,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":3,"primary_tumor_size_cm":5.5,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":23.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.467505+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_324481","record_id":"REC_0002526","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":15.5,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":6.5,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":16.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.467738+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_140863","record_id":"REC_0002527","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":18,"tmb_mutations_per_mb":5.2,"age_at_diagnosis":78,"sex":"male","ecog_performance_status":1,"smoking_pack_years":46,"primary_tumor_size_cm":6.8,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.467970+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_298796","record_id":"REC_0002528","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":21.0,"age_at_diagnosis":77,"sex":"male","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":7.3,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":5.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.468234+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_427407","record_id":"REC_0002529","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":6.9,"age_at_diagnosis":86,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":7.3,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.468466+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_757614","record_id":"REC_0002530","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":4.9,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.468703+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_707944","record_id":"REC_0002531","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":17.0,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":4.7,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.468935+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_524297","record_id":"REC_0002532","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":7,"primary_tumor_size_cm":5.3,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.469167+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_450188","record_id":"REC_0002533","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":32,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":4.9,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.469402+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_767956","record_id":"REC_0002534","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":17,"tmb_mutations_per_mb":9.7,"age_at_diagnosis":75,"sex":"male","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":4.2,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.469633+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_482198","record_id":"REC_0002535","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":6.1,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.469870+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_983028","record_id":"REC_0002536","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":19,"tmb_mutations_per_mb":15.7,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":7.9,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":25.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.470145+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_826549","record_id":"REC_0002537","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":14.8,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":4.3,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":24.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.470384+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_419746","record_id":"REC_0002538","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":30,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":4.0,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.470619+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_982639","record_id":"REC_0002539","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":4.7,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.470855+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_748096","record_id":"REC_0002540","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":3,"smoking_pack_years":21,"primary_tumor_size_cm":3.8,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.471088+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_671738","record_id":"REC_0002541","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.5,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.471319+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_883005","record_id":"REC_0002542","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":0,"smoking_pack_years":26,"primary_tumor_size_cm":6.3,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.471548+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_393901","record_id":"REC_0002543","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":17,"tmb_mutations_per_mb":6.1,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":43,"primary_tumor_size_cm":6.0,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":23.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.471775+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_704660","record_id":"REC_0002544","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":3.6,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":36,"primary_tumor_size_cm":3.5,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.472005+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_664256","record_id":"REC_0002545","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":30,"tmb_mutations_per_mb":8.1,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":5.3,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.472287+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_236209","record_id":"REC_0002546","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":33,"tmb_mutations_per_mb":4.5,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":3.3,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.472522+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_508868","record_id":"REC_0002547","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":80,"sex":"male","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":7.0,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.472760+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_976358","record_id":"REC_0002548","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":6.5,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.472991+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_344817","record_id":"REC_0002549","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":4.5,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":24,"primary_tumor_size_cm":4.5,"metastatic_sites_count":8,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":5.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.473269+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_811893","record_id":"REC_0002550","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.4,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.473511+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_146904","record_id":"REC_0002551","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":18,"tmb_mutations_per_mb":14.4,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":10,"primary_tumor_size_cm":7.9,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.473748+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_149535","record_id":"REC_0002552","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":14.8,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":3,"smoking_pack_years":11,"primary_tumor_size_cm":3.4,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.473983+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_935732","record_id":"REC_0002553","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":11.5,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":4.6,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.474215+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_629300","record_id":"REC_0002554","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":7.7,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.474448+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_540145","record_id":"REC_0002555","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":3.8,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":41,"primary_tumor_size_cm":7.7,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.474680+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_581298","record_id":"REC_0002556","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":15.0,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":2,"smoking_pack_years":7,"primary_tumor_size_cm":3.4,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.474916+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_843720","record_id":"REC_0002557","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":16.0,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":5.8,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":27.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.475144+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_574248","record_id":"REC_0002558","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":3.4,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":7.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.475381+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_927109","record_id":"REC_0002559","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":5.9,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":70,"primary_tumor_size_cm":6.9,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":40.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.475609+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_302463","record_id":"REC_0002560","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":18,"tmb_mutations_per_mb":8.5,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":7.2,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.475842+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_934913","record_id":"REC_0002561","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":6.4,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.476153+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_444647","record_id":"REC_0002562","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":8.0,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":5.4,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.476454+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_714909","record_id":"REC_0002563","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":13.1,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":5.4,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":24.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.476697+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_593403","record_id":"REC_0002564","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":14.3,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":7.2,"metastatic_sites_count":3,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.476935+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_124009","record_id":"REC_0002565","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":2.0,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.477174+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_417493","record_id":"REC_0002566","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":4.0,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":32,"primary_tumor_size_cm":6.0,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.477403+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_356450","record_id":"REC_0002567","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":5.2,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":3,"smoking_pack_years":10,"primary_tumor_size_cm":5.6,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.477632+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_376674","record_id":"REC_0002568","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":14,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":6.8,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":5.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.477865+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_770557","record_id":"REC_0002569","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":19,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":5.0,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.478098+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_495080","record_id":"REC_0002570","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":4.3,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.478330+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_620235","record_id":"REC_0002571","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":6.5,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.478566+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_651970","record_id":"REC_0002572","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":14.1,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":0,"smoking_pack_years":5,"primary_tumor_size_cm":4.8,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.478810+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_841557","record_id":"REC_0002573","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":4.9,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":22.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.479060+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_878515","record_id":"REC_0002574","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":4.3,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.479318+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_554236","record_id":"REC_0002575","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":33,"tmb_mutations_per_mb":6.7,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":5,"primary_tumor_size_cm":4.8,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":23.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.479678+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_423600","record_id":"REC_0002576","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":7.0,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.479926+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_463639","record_id":"REC_0002577","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":8.7,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":6.0,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.480214+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_884742","record_id":"REC_0002578","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":17,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.4,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":17.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.480457+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_690121","record_id":"REC_0002579","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":5.0,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":33,"primary_tumor_size_cm":6.6,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.480688+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_442844","record_id":"REC_0002580","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":74,"primary_tumor_size_cm":6.1,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.480922+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_537337","record_id":"REC_0002581","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":17,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":6.4,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.481154+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_292075","record_id":"REC_0002582","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":13.8,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":6.5,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.481385+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_717491","record_id":"REC_0002583","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":13.3,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":28,"primary_tumor_size_cm":3.5,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.481622+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_903686","record_id":"REC_0002584","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":3,"smoking_pack_years":14,"primary_tumor_size_cm":6.9,"metastatic_sites_count":3,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":18.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.481860+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_517971","record_id":"REC_0002585","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":20,"tmb_mutations_per_mb":4.7,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.2,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":20.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.482092+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_669676","record_id":"REC_0002586","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":5.3,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":4.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.482327+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_242379","record_id":"REC_0002587","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":82,"sex":"male","ecog_performance_status":2,"smoking_pack_years":10,"primary_tumor_size_cm":4.1,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.482568+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_136421","record_id":"REC_0002588","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":15.3,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":5.2,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":21.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.482858+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_930834","record_id":"REC_0002589","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":15.2,"age_at_diagnosis":75,"sex":"male","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":6.4,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.483097+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_242458","record_id":"REC_0002590","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":30,"tmb_mutations_per_mb":2.8,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":44,"primary_tumor_size_cm":6.3,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":21.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.483329+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_557397","record_id":"REC_0002591","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":6.0,"age_at_diagnosis":74,"sex":"male","ecog_performance_status":1,"smoking_pack_years":45,"primary_tumor_size_cm":3.4,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":18.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.483564+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_932386","record_id":"REC_0002592","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":17.7,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":1,"smoking_pack_years":4,"primary_tumor_size_cm":2.0,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.483795+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_378815","record_id":"REC_0002593","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":9.8,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":4.8,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.484025+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_943334","record_id":"REC_0002594","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":7.9,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":39,"primary_tumor_size_cm":6.5,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.484316+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_600500","record_id":"REC_0002595","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":85,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":6.0,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.484550+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_811448","record_id":"REC_0002596","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":15.8,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":4,"primary_tumor_size_cm":5.6,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.484782+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_239304","record_id":"REC_0002597","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":4.6,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.485019+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_185634","record_id":"REC_0002598","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":32,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":6.3,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":23.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.485254+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_805089","record_id":"REC_0002599","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":24,"primary_tumor_size_cm":2.9,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.485486+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_322332","record_id":"REC_0002600","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":1,"smoking_pack_years":4,"primary_tumor_size_cm":5.1,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":19.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.485720+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_335505","record_id":"REC_0002601","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":15.0,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":7.5,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":23.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.486004+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_503213","record_id":"REC_0002602","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":17.9,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":5.1,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.486237+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_651530","record_id":"REC_0002603","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":33,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":5.5,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":22.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.486475+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_739746","record_id":"REC_0002604","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":6.9,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":4.2,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.486704+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_995605","record_id":"REC_0002605","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":13.3,"age_at_diagnosis":74,"sex":"male","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":7.5,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":20.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.486939+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_274837","record_id":"REC_0002606","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":4.4,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":21.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.487172+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_260568","record_id":"REC_0002607","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":32,"tmb_mutations_per_mb":10.1,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":7.1,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.487407+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_159686","record_id":"REC_0002608","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":5.3,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.487642+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_173394","record_id":"REC_0002609","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":16,"tmb_mutations_per_mb":11.1,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":6.0,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.487877+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_493192","record_id":"REC_0002610","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":8.3,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":5.3,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.488149+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_535886","record_id":"REC_0002611","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":6.8,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.488390+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_794171","record_id":"REC_0002612","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":5.0,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":26,"primary_tumor_size_cm":4.5,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":24.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.488621+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_365938","record_id":"REC_0002613","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":20,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":8.0,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.488853+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_452246","record_id":"REC_0002614","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":3.8,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":8.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.489126+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_881905","record_id":"REC_0002615","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":6.2,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.489364+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_770105","record_id":"REC_0002616","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":6.3,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.489596+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_723765","record_id":"REC_0002617","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":9.1,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":6.2,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":24.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.489830+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_857756","record_id":"REC_0002618","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":17,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":3.6,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.490063+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_148278","record_id":"REC_0002619","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":14.0,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":4.0,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.490299+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_333399","record_id":"REC_0002620","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":15.0,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":5.8,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":19.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.490531+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_123739","record_id":"REC_0002621","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":15.3,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":4.3,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.490765+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_872956","record_id":"REC_0002622","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":14.6,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":7.2,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.490999+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_425501","record_id":"REC_0002623","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":10.0,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.1,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.491234+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_138335","record_id":"REC_0002624","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":14.7,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":6.4,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":6.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.491467+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_937049","record_id":"REC_0002625","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":2,"smoking_pack_years":34,"primary_tumor_size_cm":2.8,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":29.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.491698+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_811586","record_id":"REC_0002626","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.0,"age_at_diagnosis":76,"sex":"male","ecog_performance_status":3,"smoking_pack_years":16,"primary_tumor_size_cm":5.1,"metastatic_sites_count":8,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.491932+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_813447","record_id":"REC_0002627","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":0,"primary_tumor_size_cm":3.0,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":6.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.492227+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_747389","record_id":"REC_0002628","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":5.6,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":22.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.492466+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_111983","record_id":"REC_0002629","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":86,"sex":"female","ecog_performance_status":2,"smoking_pack_years":21,"primary_tumor_size_cm":6.7,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.492694+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_300532","record_id":"REC_0002630","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":5.0,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":7.8,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.492927+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_262639","record_id":"REC_0002631","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":18.2,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":7.7,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.493171+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_702580","record_id":"REC_0002632","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":5.6,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":0,"primary_tumor_size_cm":3.6,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":17.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.493403+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_791091","record_id":"REC_0002633","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":15.2,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":4.9,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.493635+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_118389","record_id":"REC_0002634","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":15,"tmb_mutations_per_mb":24.8,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":8,"primary_tumor_size_cm":3.8,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":25.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.493867+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_347248","record_id":"REC_0002635","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":9.9,"age_at_diagnosis":54,"sex":"male","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":6.0,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.494096+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_394702","record_id":"REC_0002636","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":4.4,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":25.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.494328+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_669955","record_id":"REC_0002637","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":14.8,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":7.3,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":30.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.494561+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_834647","record_id":"REC_0002638","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":14.6,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":7.5,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.494797+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_903941","record_id":"REC_0002639","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":8.3,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":2,"smoking_pack_years":7,"primary_tumor_size_cm":5.4,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.495024+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_544377","record_id":"REC_0002640","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":9.5,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":4.5,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.495298+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_375666","record_id":"REC_0002641","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":30,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":68,"primary_tumor_size_cm":5.8,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.495529+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_840465","record_id":"REC_0002642","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":3.8,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":6.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.495764+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_309042","record_id":"REC_0002643","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":15.7,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":4.9,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":29.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.496001+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_968478","record_id":"REC_0002644","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":4.7,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.496396+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_776259","record_id":"REC_0002645","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":2.8,"age_at_diagnosis":74,"sex":"male","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":6.1,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":19.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.496638+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_773244","record_id":"REC_0002646","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":7.3,"metastatic_sites_count":8,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.496872+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_396673","record_id":"REC_0002647","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":6.3,"age_at_diagnosis":54,"sex":"female","ecog_performance_status":0,"smoking_pack_years":54,"primary_tumor_size_cm":5.4,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":6.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.497107+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_366871","record_id":"REC_0002648","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":79,"sex":"male","ecog_performance_status":1,"smoking_pack_years":26,"primary_tumor_size_cm":5.0,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":21.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.497345+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_181014","record_id":"REC_0002649","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":16.2,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":4.7,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.497577+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_499227","record_id":"REC_0002650","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":14,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":48,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":6.5,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":16.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.497812+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_263616","record_id":"REC_0002651","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":13.5,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":9,"primary_tumor_size_cm":6.4,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.498044+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_509422","record_id":"REC_0002652","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.6,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.498277+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_623403","record_id":"REC_0002653","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":18.8,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":7.4,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.498569+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_681346","record_id":"REC_0002654","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":14.6,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":1,"smoking_pack_years":5,"primary_tumor_size_cm":7.9,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.498821+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_296835","record_id":"REC_0002655","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":16.8,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":6.7,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.499079+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_160337","record_id":"REC_0002656","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":3.1,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":75,"primary_tumor_size_cm":6.3,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":19.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.499339+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_670063","record_id":"REC_0002657","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":8.7,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":8.2,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":22.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.499586+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_874900","record_id":"REC_0002658","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":8.1,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":7.7,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.499822+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_908508","record_id":"REC_0002659","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":18.6,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":3.5,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":26.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.500065+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_689555","record_id":"REC_0002660","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":10.3,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":4.6,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.500373+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_743382","record_id":"REC_0002661","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":8.0,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":5.8,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.500608+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_376233","record_id":"REC_0002662","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":5.5,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.500851+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_751593","record_id":"REC_0002663","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":5.1,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.501088+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_349231","record_id":"REC_0002664","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":9.9,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.4,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.501321+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_640496","record_id":"REC_0002665","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":30,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":4,"primary_tumor_size_cm":6.2,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.501558+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_326745","record_id":"REC_0002666","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":4.4,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":1,"smoking_pack_years":36,"primary_tumor_size_cm":5.3,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":21.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.501894+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_568520","record_id":"REC_0002667","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":13.1,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":29,"primary_tumor_size_cm":6.9,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":18.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.502141+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_191889","record_id":"REC_0002668","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":15.8,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":4.2,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.502375+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_240724","record_id":"REC_0002669","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":5.6,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":26.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.502613+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_551330","record_id":"REC_0002670","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":20,"tmb_mutations_per_mb":2.6,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":4.5,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":7.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.502845+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_435786","record_id":"REC_0002671","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":7.6,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":1,"smoking_pack_years":0,"primary_tumor_size_cm":3.8,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.503075+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_679392","record_id":"REC_0002672","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":18,"tmb_mutations_per_mb":18.5,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":2,"smoking_pack_years":9,"primary_tumor_size_cm":4.7,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":40.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.503305+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_844765","record_id":"REC_0002673","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":19,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":6.1,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":27.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.503585+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_774443","record_id":"REC_0002674","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":0,"primary_tumor_size_cm":5.6,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":23.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.503832+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_602194","record_id":"REC_0002675","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":4.1,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.504127+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_637505","record_id":"REC_0002676","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":15.7,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":5.0,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.504387+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_182180","record_id":"REC_0002677","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":7.4,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.504638+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_500126","record_id":"REC_0002678","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":18,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":26,"primary_tumor_size_cm":6.1,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.504903+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_315781","record_id":"REC_0002679","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":3,"smoking_pack_years":22,"primary_tumor_size_cm":6.4,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.505333+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_395006","record_id":"REC_0002680","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":32,"tmb_mutations_per_mb":17.2,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":5.1,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.505604+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_730827","record_id":"REC_0002681","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":16.6,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":3.9,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":22.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.505846+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_769211","record_id":"REC_0002682","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":30,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":64,"primary_tumor_size_cm":4.0,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.506085+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_350297","record_id":"REC_0002683","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":16.4,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":3,"smoking_pack_years":8,"primary_tumor_size_cm":4.4,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.506333+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_843491","record_id":"REC_0002684","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":7.3,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":2,"smoking_pack_years":26,"primary_tumor_size_cm":5.5,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.506564+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_339808","record_id":"REC_0002685","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":15.3,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":8.1,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.506802+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_319178","record_id":"REC_0002686","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":13.6,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":4.7,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.507037+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_885721","record_id":"REC_0002687","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":4.9,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.507271+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_857885","record_id":"REC_0002688","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":14.1,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":4.7,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":24.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.507509+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_178319","record_id":"REC_0002689","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":6.0,"metastatic_sites_count":9,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.507742+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_764511","record_id":"REC_0002690","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":31,"tmb_mutations_per_mb":13.5,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.5,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.507977+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_441693","record_id":"REC_0002691","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":7.5,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":18.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.508286+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_343721","record_id":"REC_0002692","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":9.1,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":6.0,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":4.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.508605+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_346168","record_id":"REC_0002693","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":4.3,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.508845+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_940055","record_id":"REC_0002694","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":17.2,"age_at_diagnosis":87,"sex":"male","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":5.6,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.509085+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_589212","record_id":"REC_0002695","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":6.7,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":6.7,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.509316+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_789452","record_id":"REC_0002696","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":5,"primary_tumor_size_cm":4.2,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.509551+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_274787","record_id":"REC_0002697","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":13.1,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":10,"primary_tumor_size_cm":4.5,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":33.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.509783+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_847907","record_id":"REC_0002698","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":4.4,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.510020+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_308029","record_id":"REC_0002699","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":8.1,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":3,"smoking_pack_years":11,"primary_tumor_size_cm":4.5,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":22.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.510251+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_624571","record_id":"REC_0002700","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":19,"tmb_mutations_per_mb":5.6,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":0,"smoking_pack_years":60,"primary_tumor_size_cm":6.2,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.510480+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_884968","record_id":"REC_0002701","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":19,"tmb_mutations_per_mb":16.3,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.2,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":23.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.510717+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_525666","record_id":"REC_0002702","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":6.1,"age_at_diagnosis":46,"sex":"male","ecog_performance_status":0,"smoking_pack_years":49,"primary_tumor_size_cm":5.3,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":16.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.510949+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_398052","record_id":"REC_0002703","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":7.3,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.511187+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_644237","record_id":"REC_0002704","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":31,"tmb_mutations_per_mb":9.0,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":3.6,"metastatic_sites_count":8,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":16.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.511418+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_701252","record_id":"REC_0002705","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.5,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.3,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.511700+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_931779","record_id":"REC_0002706","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":8.3,"age_at_diagnosis":46,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":5.5,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":18.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.511934+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_246452","record_id":"REC_0002707","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":18.1,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":6.0,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.512218+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_800830","record_id":"REC_0002708","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":10.0,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":24,"primary_tumor_size_cm":5.5,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":7.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.512463+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_397263","record_id":"REC_0002709","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":19,"tmb_mutations_per_mb":8.0,"age_at_diagnosis":86,"sex":"female","ecog_performance_status":2,"smoking_pack_years":41,"primary_tumor_size_cm":5.6,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.512697+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_742776","record_id":"REC_0002710","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":17,"tmb_mutations_per_mb":8.0,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":4.8,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.512928+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_653078","record_id":"REC_0002711","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":84,"sex":"female","ecog_performance_status":3,"smoking_pack_years":6,"primary_tumor_size_cm":5.8,"metastatic_sites_count":3,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.513162+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_404502","record_id":"REC_0002712","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":22.3,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":5.2,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.513400+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_265675","record_id":"REC_0002713","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":58,"primary_tumor_size_cm":5.1,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.513628+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_537455","record_id":"REC_0002714","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":3.1,"metastatic_sites_count":8,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.513861+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_131964","record_id":"REC_0002715","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":14.7,"age_at_diagnosis":50,"sex":"male","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":7.9,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":16.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.514093+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_634245","record_id":"REC_0002716","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":10.5,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":5.2,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":27.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.514327+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_856014","record_id":"REC_0002717","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":16.3,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":4,"smoking_pack_years":13,"primary_tumor_size_cm":4.5,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.514558+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_498637","record_id":"REC_0002718","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":14.3,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":4.5,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.514842+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_728259","record_id":"REC_0002719","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":6.8,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.515082+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_442931","record_id":"REC_0002720","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":4.3,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":7.6,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":7.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.515317+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_956509","record_id":"REC_0002721","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":15.4,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":5.5,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":23.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.515551+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_363315","record_id":"REC_0002722","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":3.0,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":30.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.515782+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_965606","record_id":"REC_0002723","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":6.8,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.516008+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_607746","record_id":"REC_0002724","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":4.9,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":30.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.516331+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_750301","record_id":"REC_0002725","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":6.1,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":6.2,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.516567+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_521550","record_id":"REC_0002726","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":32,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":2,"smoking_pack_years":23,"primary_tumor_size_cm":5.1,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.516795+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_387438","record_id":"REC_0002727","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":16.2,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":5.1,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":6.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.517032+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_304957","record_id":"REC_0002728","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":6.9,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.517259+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_535685","record_id":"REC_0002729","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":28,"primary_tumor_size_cm":5.9,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.517496+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_584484","record_id":"REC_0002730","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":3.7,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":5.5,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.517727+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_160402","record_id":"REC_0002731","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":14.9,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":25,"primary_tumor_size_cm":5.6,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.518006+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_512799","record_id":"REC_0002732","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":20,"tmb_mutations_per_mb":7.4,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":5.6,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":26.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.518236+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_780402","record_id":"REC_0002733","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":4.0,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.518466+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_510628","record_id":"REC_0002734","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":4.0,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":26.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.518699+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_519753","record_id":"REC_0002735","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":3.0,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.518956+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_153809","record_id":"REC_0002736","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":3,"smoking_pack_years":16,"primary_tumor_size_cm":5.4,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.519208+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_941406","record_id":"REC_0002737","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":75,"sex":"male","ecog_performance_status":3,"smoking_pack_years":14,"primary_tumor_size_cm":6.3,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":20.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.519469+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_356124","record_id":"REC_0002738","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":18.1,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":5.8,"metastatic_sites_count":8,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":6.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.519727+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_276352","record_id":"REC_0002739","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":7.3,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.519966+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_487828","record_id":"REC_0002740","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":14.8,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":7.3,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.520285+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_394020","record_id":"REC_0002741","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":4,"primary_tumor_size_cm":6.4,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.520537+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_119051","record_id":"REC_0002742","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":4.6,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":6.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.520776+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_673375","record_id":"REC_0002743","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":5.4,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":27.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.521013+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_560560","record_id":"REC_0002744","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":50,"sex":"female","ecog_performance_status":0,"smoking_pack_years":53,"primary_tumor_size_cm":7.6,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.521364+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_378447","record_id":"REC_0002745","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":10,"primary_tumor_size_cm":6.1,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.521613+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_438184","record_id":"REC_0002746","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":31,"tmb_mutations_per_mb":5.2,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":7.6,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":45.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.521844+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_517232","record_id":"REC_0002747","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":17.2,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":25,"primary_tumor_size_cm":6.3,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.522082+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_317928","record_id":"REC_0002748","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":6.8,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.522315+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_449562","record_id":"REC_0002749","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":4.9,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.522553+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_233334","record_id":"REC_0002750","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":16.5,"age_at_diagnosis":54,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":4.2,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":5.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.522788+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_166906","record_id":"REC_0002751","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":14.9,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":6.0,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.523020+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_525534","record_id":"REC_0002752","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":48,"sex":"female","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":6.1,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":21.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.523254+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_548522","record_id":"REC_0002753","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":16,"tmb_mutations_per_mb":8.3,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":2,"primary_tumor_size_cm":6.3,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.523484+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_536489","record_id":"REC_0002754","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":13,"tmb_mutations_per_mb":19.1,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":5.8,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.523719+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_842085","record_id":"REC_0002755","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":50,"sex":"male","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":4.7,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.523951+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_430300","record_id":"REC_0002756","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":6.9,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":32,"primary_tumor_size_cm":7.2,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.524228+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_591608","record_id":"REC_0002757","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":14.4,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":10,"primary_tumor_size_cm":4.4,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":18.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.524517+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_198628","record_id":"REC_0002758","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":14.9,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":10,"primary_tumor_size_cm":4.5,"metastatic_sites_count":8,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.524754+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_250372","record_id":"REC_0002759","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":4.9,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":38,"primary_tumor_size_cm":6.3,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.524989+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_446164","record_id":"REC_0002760","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":10.1,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":5.0,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.525224+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_960973","record_id":"REC_0002761","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":8.4,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":47,"primary_tumor_size_cm":5.9,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.525456+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_770309","record_id":"REC_0002762","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":22.2,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":4,"primary_tumor_size_cm":6.7,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":19.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.525692+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_492552","record_id":"REC_0002763","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":17,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":4.1,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.525937+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_938564","record_id":"REC_0002764","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":19,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":0,"smoking_pack_years":5,"primary_tumor_size_cm":6.0,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.526170+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_139712","record_id":"REC_0002765","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":3.1,"age_at_diagnosis":51,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":6.1,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":18.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.526401+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_596087","record_id":"REC_0002766","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":5,"primary_tumor_size_cm":5.0,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":49.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.526635+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_149863","record_id":"REC_0002767","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":4.2,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.526872+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_250779","record_id":"REC_0002768","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":4.9,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.527104+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_244836","record_id":"REC_0002769","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":5.5,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":39,"primary_tumor_size_cm":7.4,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":6.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.527337+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_849545","record_id":"REC_0002770","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":0,"smoking_pack_years":42,"primary_tumor_size_cm":4.9,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":7.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.527614+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_594297","record_id":"REC_0002771","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":20,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":24,"primary_tumor_size_cm":5.6,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.527847+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_990354","record_id":"REC_0002772","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":6.1,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":5.5,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":24.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.528165+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_715812","record_id":"REC_0002773","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":5.5,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":25.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.528412+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_752446","record_id":"REC_0002774","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":6.0,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":1,"smoking_pack_years":42,"primary_tumor_size_cm":6.6,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.528647+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_586161","record_id":"REC_0002775","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":0,"smoking_pack_years":3,"primary_tumor_size_cm":4.1,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.528883+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_577755","record_id":"REC_0002776","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":30,"tmb_mutations_per_mb":15.1,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":5.6,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":20.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.529121+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_996991","record_id":"REC_0002777","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":14.1,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":7.0,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.529355+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_811147","record_id":"REC_0002778","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":11.0,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":5.3,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":22.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.529590+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_414499","record_id":"REC_0002779","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":18,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":63,"primary_tumor_size_cm":6.3,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":7.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.529824+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_137397","record_id":"REC_0002780","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":8.5,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":3.5,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":26.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.530053+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_877332","record_id":"REC_0002781","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":0,"smoking_pack_years":79,"primary_tumor_size_cm":7.0,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.530285+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_380023","record_id":"REC_0002782","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":30,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":1,"smoking_pack_years":66,"primary_tumor_size_cm":5.5,"metastatic_sites_count":8,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.530512+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_876362","record_id":"REC_0002783","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":18.1,"age_at_diagnosis":54,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":4.8,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.530820+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_787202","record_id":"REC_0002784","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":10.5,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":4.8,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.531059+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_667986","record_id":"REC_0002785","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":7.3,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":28.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.531294+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_470118","record_id":"REC_0002786","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":16.0,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":6.4,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":16.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.531528+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_407448","record_id":"REC_0002787","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":5.7,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":23.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.531763+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_660471","record_id":"REC_0002788","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":8.3,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":5.8,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.531994+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_253628","record_id":"REC_0002789","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":5.9,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.532290+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_763421","record_id":"REC_0002790","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":13.6,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":7.9,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":8.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.532532+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_750914","record_id":"REC_0002791","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":13.5,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":5.5,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.532771+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_809528","record_id":"REC_0002792","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":23.2,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":6.8,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":30.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.533010+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_514682","record_id":"REC_0002793","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":40,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":4.6,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":18.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.533244+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_356008","record_id":"REC_0002794","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":4.8,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":21.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.533474+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_150174","record_id":"REC_0002795","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":35,"tmb_mutations_per_mb":20.4,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":6.2,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":7.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.533707+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_606128","record_id":"REC_0002796","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":14.1,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":4.8,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.533987+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_685970","record_id":"REC_0002797","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":22,"primary_tumor_size_cm":5.5,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.534223+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_842223","record_id":"REC_0002798","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":9.9,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":5.7,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":27.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.534454+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_931759","record_id":"REC_0002799","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":3.9,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.534690+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_644599","record_id":"REC_0002800","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":53,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":5.3,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.534923+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_652584","record_id":"REC_0002801","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":13.6,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":5.6,"metastatic_sites_count":8,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.535153+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_496363","record_id":"REC_0002802","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":5.9,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":30,"primary_tumor_size_cm":5.6,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":4.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.535382+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_533911","record_id":"REC_0002803","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":14.7,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":4.9,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.535614+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_240968","record_id":"REC_0002804","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":9,"primary_tumor_size_cm":5.5,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.535848+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_509417","record_id":"REC_0002805","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":7.3,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":6.7,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.536153+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_649567","record_id":"REC_0002806","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":14.1,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":5.9,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":45.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.536402+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_273411","record_id":"REC_0002807","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":18,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":0,"smoking_pack_years":56,"primary_tumor_size_cm":5.2,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.536634+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_710862","record_id":"REC_0002808","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":7.6,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":6.3,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.536867+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_210478","record_id":"REC_0002809","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":31,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":7.2,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.537149+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_207847","record_id":"REC_0002810","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":4.6,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.537386+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_620879","record_id":"REC_0002811","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":16.6,"age_at_diagnosis":49,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":4.8,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":34.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.537623+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_256287","record_id":"REC_0002812","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":14.0,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":24,"primary_tumor_size_cm":5.2,"metastatic_sites_count":9,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.537853+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_598373","record_id":"REC_0002813","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":9.7,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":6.0,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":21.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.538080+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_312922","record_id":"REC_0002814","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":74,"sex":"male","ecog_performance_status":1,"smoking_pack_years":24,"primary_tumor_size_cm":5.9,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.538314+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_377585","record_id":"REC_0002815","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":3.0,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":46,"primary_tumor_size_cm":6.0,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.538551+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_363840","record_id":"REC_0002816","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":5.0,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.538797+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_941473","record_id":"REC_0002817","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.5,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":7.0,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.539057+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_691540","record_id":"REC_0002818","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":6.1,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":6.6,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.539307+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_775673","record_id":"REC_0002819","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":5.6,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":32,"primary_tumor_size_cm":7.1,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.539556+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_402314","record_id":"REC_0002820","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":15.1,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":4.0,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.539801+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_547381","record_id":"REC_0002821","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":13.5,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":5.8,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":18.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.540032+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_475224","record_id":"REC_0002822","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":11.0,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":3.9,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.540418+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_909390","record_id":"REC_0002823","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":20,"primary_tumor_size_cm":5.3,"metastatic_sites_count":3,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.540661+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_334293","record_id":"REC_0002824","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":4.4,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":32.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.540900+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_584327","record_id":"REC_0002825","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":20,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":0,"smoking_pack_years":27,"primary_tumor_size_cm":4.7,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":23.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.541132+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_502891","record_id":"REC_0002826","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":15.6,"age_at_diagnosis":84,"sex":"female","ecog_performance_status":2,"smoking_pack_years":6,"primary_tumor_size_cm":5.9,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.541367+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_288363","record_id":"REC_0002827","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.3,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.541604+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_128674","record_id":"REC_0002828","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":15,"tmb_mutations_per_mb":11.1,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":4.5,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":20.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.541837+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_163417","record_id":"REC_0002829","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":16.3,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":6.1,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.542071+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_649299","record_id":"REC_0002830","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":5.9,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":24,"primary_tumor_size_cm":6.3,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":6.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.542302+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_918542","record_id":"REC_0002831","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":75,"sex":"male","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":7.0,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":16.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.542538+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_635537","record_id":"REC_0002832","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":8.6,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":6.0,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":7.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.542763+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_971627","record_id":"REC_0002833","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":6.2,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":17.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.542993+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_950628","record_id":"REC_0002834","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":14.3,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":6.7,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":17.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.543231+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_755065","record_id":"REC_0002835","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":7.9,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":6.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.543539+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_617677","record_id":"REC_0002836","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":5.5,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":3.0,"metastatic_sites_count":8,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.543772+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_116366","record_id":"REC_0002837","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":19,"tmb_mutations_per_mb":5.2,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":49,"primary_tumor_size_cm":6.0,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.544003+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_476762","record_id":"REC_0002838","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":5.7,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":24.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.544301+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_894818","record_id":"REC_0002839","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":14.4,"age_at_diagnosis":51,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":5.8,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.544541+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_885270","record_id":"REC_0002840","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":47,"sex":"female","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":5.8,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.544776+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_287640","record_id":"REC_0002841","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":4.7,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.545012+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_609671","record_id":"REC_0002842","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":21,"primary_tumor_size_cm":7.6,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.545243+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_722311","record_id":"REC_0002843","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":5.6,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.545473+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_560614","record_id":"REC_0002844","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":34,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":2.1,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":27.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.545702+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_486733","record_id":"REC_0002845","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":15.2,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":3.5,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.545939+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_986838","record_id":"REC_0002846","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":33,"tmb_mutations_per_mb":9.7,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":2,"smoking_pack_years":4,"primary_tumor_size_cm":3.7,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":21.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.546167+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_800902","record_id":"REC_0002847","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":30,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":3.1,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.546402+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_483475","record_id":"REC_0002848","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":32,"tmb_mutations_per_mb":11.1,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":4.9,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.546684+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_533260","record_id":"REC_0002849","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":6.2,"metastatic_sites_count":8,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.546922+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_606936","record_id":"REC_0002850","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":11.5,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":25,"primary_tumor_size_cm":7.6,"metastatic_sites_count":9,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":19.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.547154+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_622007","record_id":"REC_0002851","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":14.7,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":30,"primary_tumor_size_cm":3.6,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.547392+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_528365","record_id":"REC_0002852","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":16,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":51,"sex":"male","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":5.5,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.547627+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_165238","record_id":"REC_0002853","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":18,"tmb_mutations_per_mb":3.5,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":1,"smoking_pack_years":29,"primary_tumor_size_cm":5.3,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":19.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.547855+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_971722","record_id":"REC_0002854","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":18,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.8,"metastatic_sites_count":8,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.548124+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_928832","record_id":"REC_0002855","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":7.6,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":4.8,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.548367+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_885050","record_id":"REC_0002856","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":33,"tmb_mutations_per_mb":3.0,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":1,"smoking_pack_years":39,"primary_tumor_size_cm":5.4,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":19.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.548601+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_529802","record_id":"REC_0002857","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":13,"tmb_mutations_per_mb":14.6,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.5,"metastatic_sites_count":10,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.548835+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_575012","record_id":"REC_0002858","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":19,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":77,"sex":"male","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":5.8,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.549071+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_147948","record_id":"REC_0002859","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":4.7,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":4.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.549303+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_261471","record_id":"REC_0002860","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":13.1,"age_at_diagnosis":88,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":4.5,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.549534+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_917167","record_id":"REC_0002861","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":85,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":6.5,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":25.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.549812+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_971948","record_id":"REC_0002862","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":18,"tmb_mutations_per_mb":4.1,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":26,"primary_tumor_size_cm":5.2,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":17.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.550050+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_570704","record_id":"REC_0002863","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":15.4,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":5.4,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.550289+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_551283","record_id":"REC_0002864","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":20,"tmb_mutations_per_mb":4.9,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":36,"primary_tumor_size_cm":4.4,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":7.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.550516+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_267483","record_id":"REC_0002865","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":16,"tmb_mutations_per_mb":3.1,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":4.6,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.550747+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_974114","record_id":"REC_0002866","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":16.8,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":4.5,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":18.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.550983+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_714611","record_id":"REC_0002867","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":3.6,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":8.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.551216+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_601719","record_id":"REC_0002868","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":16.3,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":6.0,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.551445+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_674647","record_id":"REC_0002869","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":38,"primary_tumor_size_cm":5.5,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.551674+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_374120","record_id":"REC_0002870","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.0,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.4,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.551906+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_165691","record_id":"REC_0002871","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":6.1,"metastatic_sites_count":8,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.552164+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_430190","record_id":"REC_0002872","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":7.6,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":6.3,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":5.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.552397+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_261826","record_id":"REC_0002873","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":8.7,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":1,"smoking_pack_years":5,"primary_tumor_size_cm":4.7,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.552631+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_354385","record_id":"REC_0002874","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":34,"tmb_mutations_per_mb":14.1,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":0,"smoking_pack_years":26,"primary_tumor_size_cm":7.0,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":29.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.552911+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_205245","record_id":"REC_0002875","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":6.6,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":6.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.553144+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_535935","record_id":"REC_0002876","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":11.0,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":5.4,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":33.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.553382+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_836352","record_id":"REC_0002877","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":17.1,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":8.1,"metastatic_sites_count":10,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.553617+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_125456","record_id":"REC_0002878","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":15.6,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":4.1,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":6.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.553850+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_799859","record_id":"REC_0002879","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":2.5,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":6.3,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.554083+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_989450","record_id":"REC_0002880","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":7.3,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":38,"primary_tumor_size_cm":4.8,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":24.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.554311+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_278717","record_id":"REC_0002881","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":17.1,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":6.0,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":16.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.554543+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_717628","record_id":"REC_0002882","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":5.8,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":23.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.554772+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_980526","record_id":"REC_0002883","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":19,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":1,"smoking_pack_years":56,"primary_tumor_size_cm":6.4,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":5.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.555004+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_931943","record_id":"REC_0002884","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":7.6,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":1,"smoking_pack_years":4,"primary_tumor_size_cm":4.7,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":33.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.555235+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_569049","record_id":"REC_0002885","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":5.5,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.555469+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_161662","record_id":"REC_0002886","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":5.0,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":1,"smoking_pack_years":4,"primary_tumor_size_cm":5.9,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":25.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.555701+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_962745","record_id":"REC_0002887","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":13,"tmb_mutations_per_mb":8.7,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":0,"smoking_pack_years":4,"primary_tumor_size_cm":4.3,"metastatic_sites_count":3,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":21.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.555972+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_670289","record_id":"REC_0002888","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":18.1,"age_at_diagnosis":80,"sex":"male","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":7.4,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.556306+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_752558","record_id":"REC_0002889","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":10.5,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":4.8,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.556546+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_556947","record_id":"REC_0002890","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":27,"primary_tumor_size_cm":4.1,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.556783+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_390805","record_id":"REC_0002891","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":5.7,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":18.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.557015+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_519403","record_id":"REC_0002892","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":1,"primary_tumor_size_cm":6.8,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.557253+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_128220","record_id":"REC_0002893","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":8.1,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":4.8,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":20.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.557485+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_763821","record_id":"REC_0002894","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":32,"primary_tumor_size_cm":6.0,"metastatic_sites_count":9,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.557718+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_330333","record_id":"REC_0002895","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":8.9,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":5.0,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":20.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.557946+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_318709","record_id":"REC_0002896","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":8.1,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":44,"primary_tumor_size_cm":7.6,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":6.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.558177+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_585057","record_id":"REC_0002897","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":30,"tmb_mutations_per_mb":3.8,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":58,"primary_tumor_size_cm":6.5,"metastatic_sites_count":8,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.558405+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_976145","record_id":"REC_0002898","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":15,"tmb_mutations_per_mb":4.3,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":5.4,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":21.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.558637+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_793816","record_id":"REC_0002899","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":5.5,"metastatic_sites_count":8,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.558892+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_162703","record_id":"REC_0002900","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":20,"primary_tumor_size_cm":3.7,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.559229+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_734592","record_id":"REC_0002901","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":4.2,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.559491+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_394856","record_id":"REC_0002902","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":20,"tmb_mutations_per_mb":5.3,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":5.2,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":59.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.559733+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_214004","record_id":"REC_0002903","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":16.8,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":2,"smoking_pack_years":10,"primary_tumor_size_cm":4.3,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":18.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.559977+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_244355","record_id":"REC_0002904","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":17.8,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":5.9,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.560388+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_503054","record_id":"REC_0002905","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":15,"tmb_mutations_per_mb":16.1,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":5.5,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":42.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.560653+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_306746","record_id":"REC_0002906","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":0,"smoking_pack_years":0,"primary_tumor_size_cm":6.3,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":7.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.560891+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_637046","record_id":"REC_0002907","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":11.1,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":4.3,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.561134+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_955742","record_id":"REC_0002908","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":5.9,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":44,"primary_tumor_size_cm":4.7,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":18.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.561368+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_256503","record_id":"REC_0002909","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":20,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":53,"sex":"female","ecog_performance_status":0,"smoking_pack_years":48,"primary_tumor_size_cm":7.7,"metastatic_sites_count":9,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.561603+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_267527","record_id":"REC_0002910","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":19.6,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":0,"smoking_pack_years":26,"primary_tumor_size_cm":5.7,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.561839+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_230506","record_id":"REC_0002911","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":30,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":6.7,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.562075+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_114056","record_id":"REC_0002912","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":7.9,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":6.0,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.562307+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_899113","record_id":"REC_0002913","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":50,"primary_tumor_size_cm":6.3,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":25.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.562640+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_268382","record_id":"REC_0002914","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":18,"tmb_mutations_per_mb":7.4,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":55,"primary_tumor_size_cm":4.9,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":33.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.562874+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_553295","record_id":"REC_0002915","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":3.9,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":49,"primary_tumor_size_cm":6.3,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":5.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.563107+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_833811","record_id":"REC_0002916","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":15.9,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":5.0,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.563343+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_671369","record_id":"REC_0002917","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":14.6,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":4.7,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.563575+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_201225","record_id":"REC_0002918","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":6.6,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.563814+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_496067","record_id":"REC_0002919","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":20,"tmb_mutations_per_mb":6.3,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":6.8,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":26.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.564049+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_393056","record_id":"REC_0002920","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":9.8,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":5.6,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.564329+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_742246","record_id":"REC_0002921","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":16.2,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":6.0,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.564570+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_395681","record_id":"REC_0002922","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":14,"tmb_mutations_per_mb":9.5,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":3,"primary_tumor_size_cm":3.8,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.564800+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_441154","record_id":"REC_0002923","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":7.3,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":4.6,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.565037+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_324980","record_id":"REC_0002924","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":4.0,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.565274+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_265025","record_id":"REC_0002925","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":5.0,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":60,"primary_tumor_size_cm":5.0,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":23.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.565503+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_131102","record_id":"REC_0002926","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":5.5,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":48,"primary_tumor_size_cm":6.3,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":21.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.565786+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_449316","record_id":"REC_0002927","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":18.2,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":4.8,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.566027+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_800974","record_id":"REC_0002928","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":30,"tmb_mutations_per_mb":19.1,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":3.8,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.566262+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_784369","record_id":"REC_0002929","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":4.0,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":4.1,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.566493+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_415350","record_id":"REC_0002930","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":9.5,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":1,"smoking_pack_years":52,"primary_tumor_size_cm":6.5,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":6.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.566719+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_280938","record_id":"REC_0002931","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":5.5,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.566952+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_470693","record_id":"REC_0002932","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":7.6,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":5.2,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":5.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.567179+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_862726","record_id":"REC_0002933","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":8.1,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":5.5,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.567413+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_946873","record_id":"REC_0002934","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":16.8,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":7.2,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.567647+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_882648","record_id":"REC_0002935","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":2,"primary_tumor_size_cm":6.2,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.567878+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_176404","record_id":"REC_0002936","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":18.5,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":2.7,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.568207+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_646007","record_id":"REC_0002937","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":16,"tmb_mutations_per_mb":8.5,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":7.0,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.568455+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_179538","record_id":"REC_0002938","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":34,"tmb_mutations_per_mb":4.0,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":5.1,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.568686+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_958898","record_id":"REC_0002939","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":21.1,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":2.0,"metastatic_sites_count":8,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":20.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.568983+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_562535","record_id":"REC_0002940","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":15.1,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":5.3,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.569239+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_508349","record_id":"REC_0002941","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.2,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":34.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.569527+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_217659","record_id":"REC_0002942","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":16.7,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":7.8,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.569801+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_753693","record_id":"REC_0002943","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":35,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":3.8,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.570050+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_315901","record_id":"REC_0002944","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":0,"smoking_pack_years":60,"primary_tumor_size_cm":6.5,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":26.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.570290+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_754514","record_id":"REC_0002945","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":4.8,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":43,"primary_tumor_size_cm":5.7,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":21.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.570534+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_516801","record_id":"REC_0002946","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":0,"smoking_pack_years":25,"primary_tumor_size_cm":3.7,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":28.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.570771+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_176541","record_id":"REC_0002947","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":14.8,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":5.0,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.571008+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_191488","record_id":"REC_0002948","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":19.3,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":5.9,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.571247+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_313498","record_id":"REC_0002949","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":16.3,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":5.6,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.571484+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_976301","record_id":"REC_0002950","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":16.1,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":3.0,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.571717+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_949662","record_id":"REC_0002951","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":3.6,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.571950+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_688727","record_id":"REC_0002952","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":11.5,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":6.1,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.572374+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_514425","record_id":"REC_0002953","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":15.6,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":5.4,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.572623+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_865576","record_id":"REC_0002954","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":7.9,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":3.8,"metastatic_sites_count":3,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.572854+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_581821","record_id":"REC_0002955","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":19,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":21,"primary_tumor_size_cm":7.6,"metastatic_sites_count":8,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":7.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.573089+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_920720","record_id":"REC_0002956","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":19,"tmb_mutations_per_mb":17.4,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":3,"primary_tumor_size_cm":6.1,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.573318+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_239636","record_id":"REC_0002957","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":45,"primary_tumor_size_cm":5.2,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":17.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.573547+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_224450","record_id":"REC_0002958","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":14.8,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":5.7,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.573781+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_282845","record_id":"REC_0002959","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":17,"tmb_mutations_per_mb":18.0,"age_at_diagnosis":50,"sex":"male","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":6.3,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.574018+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_965092","record_id":"REC_0002960","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":8.7,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":6.1,"metastatic_sites_count":9,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.574248+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_188555","record_id":"REC_0002961","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":4.8,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.574483+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_114939","record_id":"REC_0002962","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":2,"smoking_pack_years":22,"primary_tumor_size_cm":4.4,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":50.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.574718+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_657530","record_id":"REC_0002963","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":15.2,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":6.5,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.574955+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_325894","record_id":"REC_0002964","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":17.5,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":3.0,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.575191+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_515340","record_id":"REC_0002965","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":37,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":4.6,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.575482+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_424630","record_id":"REC_0002966","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":14.5,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":2,"smoking_pack_years":8,"primary_tumor_size_cm":4.8,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":24.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.575719+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_739722","record_id":"REC_0002967","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":16.3,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":5.3,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.575957+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_109021","record_id":"REC_0002968","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None","pd_l1_tps_percent":15,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":4.7,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":34.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.576283+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_450002","record_id":"REC_0002969","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":6.0,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":45.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.576524+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_244968","record_id":"REC_0002970","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":6.4,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":38.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.576758+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_268020","record_id":"REC_0002971","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":4.4,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.576994+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_167851","record_id":"REC_0002972","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":7.3,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":1,"smoking_pack_years":67,"primary_tumor_size_cm":5.0,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":20.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.577229+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_973516","record_id":"REC_0002973","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":50,"primary_tumor_size_cm":3.8,"metastatic_sites_count":3,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":18.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.577458+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_858920","record_id":"REC_0002974","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":1,"smoking_pack_years":26,"primary_tumor_size_cm":5.6,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":16.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.577692+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_536260","record_id":"REC_0002975","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":15.2,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":9,"primary_tumor_size_cm":4.1,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.577924+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_755373","record_id":"REC_0002976","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":6.9,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":47,"primary_tumor_size_cm":6.3,"metastatic_sites_count":3,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.578152+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_434434","record_id":"REC_0002977","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":14.0,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":5.0,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":53.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.578384+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_340340","record_id":"REC_0002978","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":4.5,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.578665+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_984611","record_id":"REC_0002979","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":24,"primary_tumor_size_cm":5.9,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.578908+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_656523","record_id":"REC_0002980","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":15.5,"age_at_diagnosis":50,"sex":"male","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":5.4,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":18.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.579160+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_667493","record_id":"REC_0002981","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":1,"smoking_pack_years":47,"primary_tumor_size_cm":4.2,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":5.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.579416+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_949476","record_id":"REC_0002982","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":5.5,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":50,"primary_tumor_size_cm":4.5,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.579671+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_141597","record_id":"REC_0002983","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":6.0,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.579920+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_743314","record_id":"REC_0002984","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":10.5,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":7.3,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.580241+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_842518","record_id":"REC_0002985","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":2.9,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.580492+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_979943","record_id":"REC_0002986","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":4.4,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.580735+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_313511","record_id":"REC_0002987","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":31,"tmb_mutations_per_mb":3.7,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.6,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.580976+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_841176","record_id":"REC_0002988","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":83,"sex":"female","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":6.1,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.581215+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_138584","record_id":"REC_0002989","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":31,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":60,"primary_tumor_size_cm":3.0,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.581445+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_868030","record_id":"REC_0002990","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":15.1,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":5.2,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.581682+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_801153","record_id":"REC_0002991","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":15.9,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":1,"primary_tumor_size_cm":5.0,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.582034+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_247262","record_id":"REC_0002992","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":6.6,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.582267+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_732453","record_id":"REC_0002993","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":33,"tmb_mutations_per_mb":5.5,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":58,"primary_tumor_size_cm":4.5,"metastatic_sites_count":8,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":18.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.582501+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_990067","record_id":"REC_0002994","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":34,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":75,"sex":"male","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":7.2,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":19.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.582739+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_563800","record_id":"REC_0002995","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":20.6,"age_at_diagnosis":90,"sex":"female","ecog_performance_status":2,"smoking_pack_years":22,"primary_tumor_size_cm":6.6,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":21.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.582974+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_664146","record_id":"REC_0002996","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":10.3,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":3.6,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.583211+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_418221","record_id":"REC_0002997","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":5.9,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":24.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.583447+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_795167","record_id":"REC_0002998","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":20.5,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":4.9,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.583697+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_177900","record_id":"REC_0002999","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":14.4,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":3.7,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":17.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.583954+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_477126","record_id":"REC_0003000","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":16.1,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":6.2,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":22.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.584259+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_836840","record_id":"REC_0003001","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":19.2,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":5.0,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":16.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.584508+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_686111","record_id":"REC_0003002","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":2.1,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":4.4,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.584744+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_468222","record_id":"REC_0003003","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":6.9,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":4.6,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.584976+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_770563","record_id":"REC_0003004","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":15.9,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":7.3,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.585305+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_966613","record_id":"REC_0003005","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":18,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":6.5,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.585550+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_792296","record_id":"REC_0003006","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":9.0,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":7.1,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":27.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.585784+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_830837","record_id":"REC_0003007","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":6.3,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":27,"primary_tumor_size_cm":5.6,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.586014+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_906762","record_id":"REC_0003008","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":49,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":4.5,"metastatic_sites_count":3,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.586252+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_848772","record_id":"REC_0003009","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":4.6,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":5.2,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":6.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.586481+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_123696","record_id":"REC_0003010","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":19,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":53,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":8.8,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.586719+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_456846","record_id":"REC_0003011","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":6.1,"age_at_diagnosis":53,"sex":"male","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":7.5,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":23.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.586951+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_854151","record_id":"REC_0003012","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":8.4,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":6.7,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":16.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.587183+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_462501","record_id":"REC_0003013","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":13.6,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":5.7,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":21.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.587417+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_480149","record_id":"REC_0003014","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":31,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":45,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":7.4,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.587652+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_229708","record_id":"REC_0003015","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":8.3,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":30,"primary_tumor_size_cm":6.5,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.587884+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_609671","record_id":"REC_0003016","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":16.4,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":6.7,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.588153+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_563773","record_id":"REC_0003017","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":8.1,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":6.9,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":24.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.588445+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_409303","record_id":"REC_0003018","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":17.3,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":4.9,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.588688+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_249513","record_id":"REC_0003019","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":17.3,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.6,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.588924+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_833849","record_id":"REC_0003020","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":14,"tmb_mutations_per_mb":3.2,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":4.6,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.589158+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_592047","record_id":"REC_0003021","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":16.6,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":5.4,"metastatic_sites_count":3,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.589390+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_583463","record_id":"REC_0003022","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":7.3,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":6,"primary_tumor_size_cm":7.3,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.589621+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_864736","record_id":"REC_0003023","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":10.3,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":6.3,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.589852+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_993449","record_id":"REC_0003024","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":20,"tmb_mutations_per_mb":4.4,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":4.1,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":42.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.590086+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_932139","record_id":"REC_0003025","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":30,"tmb_mutations_per_mb":18.3,"age_at_diagnosis":53,"sex":"male","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":4.4,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.590320+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_407278","record_id":"REC_0003026","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":16.3,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":3,"primary_tumor_size_cm":6.0,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":17.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.590554+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_551981","record_id":"REC_0003027","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":30,"tmb_mutations_per_mb":6.0,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":6.6,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.590787+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_556876","record_id":"REC_0003028","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":16.0,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":7.2,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":22.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.591018+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_495860","record_id":"REC_0003029","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":20,"tmb_mutations_per_mb":6.7,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":7.2,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":40.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.591249+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_885109","record_id":"REC_0003030","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":3,"smoking_pack_years":10,"primary_tumor_size_cm":6.9,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.591529+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_658883","record_id":"REC_0003031","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":14.7,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":5.5,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":23.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.591769+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_132180","record_id":"REC_0003032","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":14.9,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":7.1,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.592003+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_934460","record_id":"REC_0003033","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":6.7,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":7.5,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":18.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.592405+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_932937","record_id":"REC_0003034","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":3,"primary_tumor_size_cm":3.7,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":26.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.592665+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_958088","record_id":"REC_0003035","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":3.0,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":16.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.592905+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_563218","record_id":"REC_0003036","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.0,"age_at_diagnosis":79,"sex":"male","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":4.7,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.593139+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_548133","record_id":"REC_0003037","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":16.4,"age_at_diagnosis":47,"sex":"male","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":6.0,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":16.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.593374+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_878428","record_id":"REC_0003038","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":34,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":3.7,"metastatic_sites_count":3,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.593605+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_907262","record_id":"REC_0003039","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":22.8,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":5.5,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.593839+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_288399","record_id":"REC_0003040","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":44,"primary_tumor_size_cm":4.5,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":18.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.594067+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_539217","record_id":"REC_0003041","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":4.4,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":8.0,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":5.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.594301+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_548516","record_id":"REC_0003042","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":2.9,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":0,"smoking_pack_years":24,"primary_tumor_size_cm":5.5,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":17.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.594532+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_786583","record_id":"REC_0003043","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":8.5,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":5.3,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.594828+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_750147","record_id":"REC_0003044","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":8.5,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":5.5,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":26.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.595069+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_562660","record_id":"REC_0003045","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":15.8,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":4.1,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.595302+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_161659","record_id":"REC_0003046","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":33,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":6.1,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":27.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.595539+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_380399","record_id":"REC_0003047","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":31,"tmb_mutations_per_mb":4.1,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":43,"primary_tumor_size_cm":5.7,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":19.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.595773+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_156377","record_id":"REC_0003048","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":5.5,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":2,"smoking_pack_years":70,"primary_tumor_size_cm":6.0,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":48.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.596009+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_701103","record_id":"REC_0003049","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":17.3,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":4.4,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":5.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.596425+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_709634","record_id":"REC_0003050","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":4.8,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.596726+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_638232","record_id":"REC_0003051","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":19,"tmb_mutations_per_mb":18.8,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":4.5,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":43.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.597028+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_926899","record_id":"REC_0003052","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":7.3,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":3.4,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.597284+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_819467","record_id":"REC_0003053","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":1,"primary_tumor_size_cm":4.9,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":20.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.597532+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_453321","record_id":"REC_0003054","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":4.8,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.597775+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_151292","record_id":"REC_0003055","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":15.1,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":6.1,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":5.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.598020+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_810932","record_id":"REC_0003056","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":11,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":54,"primary_tumor_size_cm":5.7,"metastatic_sites_count":3,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":18.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.598374+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_730345","record_id":"REC_0003057","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.1,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":27,"primary_tumor_size_cm":7.5,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.598630+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_638026","record_id":"REC_0003058","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":14.0,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":4.9,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.598868+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_343378","record_id":"REC_0003059","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":8.7,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":4.8,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.599102+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_540966","record_id":"REC_0003060","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":23,"primary_tumor_size_cm":7.2,"metastatic_sites_count":9,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":5.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.599335+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_882426","record_id":"REC_0003061","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.3,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":17.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.599569+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_871837","record_id":"REC_0003062","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":33,"tmb_mutations_per_mb":3.5,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":3,"smoking_pack_years":7,"primary_tumor_size_cm":3.9,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":27.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.599812+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_429481","record_id":"REC_0003063","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":13,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":3,"smoking_pack_years":15,"primary_tumor_size_cm":6.1,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.600056+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_603025","record_id":"REC_0003064","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":15.8,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":4.5,"metastatic_sites_count":8,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.600379+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_496108","record_id":"REC_0003065","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":5.0,"age_at_diagnosis":45,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":5.9,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.600621+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_560646","record_id":"REC_0003066","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":79,"sex":"male","ecog_performance_status":1,"smoking_pack_years":31,"primary_tumor_size_cm":2.9,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.600869+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_171067","record_id":"REC_0003067","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":7.5,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":60.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.601135+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_606546","record_id":"REC_0003068","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":5.9,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":28.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.601396+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_593890","record_id":"REC_0003069","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":68,"primary_tumor_size_cm":6.2,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.601775+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_893513","record_id":"REC_0003070","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.0,"age_at_diagnosis":52,"sex":"male","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":5.3,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.602045+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_885313","record_id":"REC_0003071","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":6.2,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":17.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.602285+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_430384","record_id":"REC_0003072","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":74,"sex":"male","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.3,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.602528+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_985868","record_id":"REC_0003073","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":6.5,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.602768+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_624536","record_id":"REC_0003074","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":10.3,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":5.9,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.603007+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_524278","record_id":"REC_0003075","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":16,"tmb_mutations_per_mb":13.8,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":7.2,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.603245+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_949462","record_id":"REC_0003076","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":7.2,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":17.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.603485+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_269199","record_id":"REC_0003077","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":5.6,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.603720+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_622005","record_id":"REC_0003078","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":8.3,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":4.8,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.603954+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_933888","record_id":"REC_0003079","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":5.2,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":24.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.604270+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_512714","record_id":"REC_0003080","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":4.9,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":24,"primary_tumor_size_cm":6.6,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.604525+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_657624","record_id":"REC_0003081","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":31,"tmb_mutations_per_mb":6.0,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":59,"primary_tumor_size_cm":4.7,"metastatic_sites_count":3,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":25.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.604766+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_877149","record_id":"REC_0003082","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":5.5,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":7.4,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":38.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.605109+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_676979","record_id":"REC_0003083","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":22,"primary_tumor_size_cm":4.2,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.605354+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_331495","record_id":"REC_0003084","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":18,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":4.3,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.605590+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_787929","record_id":"REC_0003085","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":15.9,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":5.7,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.605828+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_807163","record_id":"REC_0003086","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":13.8,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":4.6,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.606063+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_494934","record_id":"REC_0003087","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":51,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":5.3,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":17.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.606295+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_733032","record_id":"REC_0003088","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":4.7,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":47.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.606530+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_309169","record_id":"REC_0003089","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":3,"smoking_pack_years":3,"primary_tumor_size_cm":6.5,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":17.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.606768+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_904774","record_id":"REC_0003090","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":8.6,"age_at_diagnosis":75,"sex":"male","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":5.9,"metastatic_sites_count":8,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.607001+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_613449","record_id":"REC_0003091","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":4.0,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.607235+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_413830","record_id":"REC_0003092","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":16.0,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":5.0,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":8.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.607468+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_883422","record_id":"REC_0003093","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":15.5,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":3,"smoking_pack_years":17,"primary_tumor_size_cm":5.9,"metastatic_sites_count":8,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":19.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.607698+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_675014","record_id":"REC_0003094","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":53,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":7.2,"metastatic_sites_count":8,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.607931+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_632071","record_id":"REC_0003095","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":52,"sex":"male","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":6.4,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":6.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.608272+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_127486","record_id":"REC_0003096","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":5.0,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":4.6,"metastatic_sites_count":8,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.608517+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_743376","record_id":"REC_0003097","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":17.5,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":6.5,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.608756+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_519161","record_id":"REC_0003098","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":13,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":0,"primary_tumor_size_cm":5.9,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.608986+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_888297","record_id":"REC_0003099","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":48,"primary_tumor_size_cm":5.3,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.609215+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_687765","record_id":"REC_0003100","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":10.1,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":3,"smoking_pack_years":12,"primary_tumor_size_cm":5.4,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.609448+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_899768","record_id":"REC_0003101","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":0,"primary_tumor_size_cm":6.1,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.609679+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_719823","record_id":"REC_0003102","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None","pd_l1_tps_percent":17,"tmb_mutations_per_mb":1.7,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":84,"primary_tumor_size_cm":5.2,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":40.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.609912+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_792155","record_id":"REC_0003103","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":17.9,"age_at_diagnosis":50,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":4.6,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.610148+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_640672","record_id":"REC_0003104","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":13.1,"age_at_diagnosis":54,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":3.8,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.610382+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_314927","record_id":"REC_0003105","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":16,"tmb_mutations_per_mb":21.5,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":7.0,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":7.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.610619+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_510344","record_id":"REC_0003106","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":74,"sex":"male","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":4.8,"metastatic_sites_count":9,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.610852+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_147928","record_id":"REC_0003107","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":5.0,"age_at_diagnosis":54,"sex":"female","ecog_performance_status":0,"smoking_pack_years":50,"primary_tumor_size_cm":6.9,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.611082+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_650842","record_id":"REC_0003108","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":18.7,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":4.9,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.611370+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_781919","record_id":"REC_0003109","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":32,"tmb_mutations_per_mb":5.5,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":6.4,"metastatic_sites_count":8,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":6.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.611603+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_349637","record_id":"REC_0003110","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":3.6,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":64,"primary_tumor_size_cm":3.3,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.611833+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_938376","record_id":"REC_0003111","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":5.4,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":23.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.612064+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_693861","record_id":"REC_0003112","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":10.0,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":26,"primary_tumor_size_cm":3.9,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.612336+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_378397","record_id":"REC_0003113","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":8.0,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":3,"smoking_pack_years":30,"primary_tumor_size_cm":4.3,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.612573+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_358175","record_id":"REC_0003114","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":19.8,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":5.8,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":7.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.612818+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_647220","record_id":"REC_0003115","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":6.4,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":21.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.613062+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_164079","record_id":"REC_0003116","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":31,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":70,"primary_tumor_size_cm":5.2,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":17.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.613295+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_253739","record_id":"REC_0003117","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":30,"tmb_mutations_per_mb":5.9,"age_at_diagnosis":87,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.8,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":17.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.613524+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_367792","record_id":"REC_0003118","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":0,"smoking_pack_years":27,"primary_tumor_size_cm":5.5,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":7.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.613759+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_208846","record_id":"REC_0003119","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":41,"primary_tumor_size_cm":7.9,"metastatic_sites_count":3,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.613989+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_932421","record_id":"REC_0003120","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":31,"primary_tumor_size_cm":5.0,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.614222+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_729658","record_id":"REC_0003121","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":1,"smoking_pack_years":56,"primary_tumor_size_cm":4.8,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.614523+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_577152","record_id":"REC_0003122","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":10.3,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":25,"primary_tumor_size_cm":4.7,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.614762+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_529865","record_id":"REC_0003123","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":8.0,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":4.6,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":6.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.614991+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_762727","record_id":"REC_0003124","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":6.7,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":6.0,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.615223+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_879863","record_id":"REC_0003125","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":6.4,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":7,"primary_tumor_size_cm":5.2,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.615454+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_826042","record_id":"REC_0003126","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":3.8,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":5.2,"metastatic_sites_count":9,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.615681+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_380461","record_id":"REC_0003127","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":33,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":1,"smoking_pack_years":59,"primary_tumor_size_cm":7.6,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":6.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.615914+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_767989","record_id":"REC_0003128","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":4.5,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":0,"smoking_pack_years":32,"primary_tumor_size_cm":6.3,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":25.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.616239+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_130993","record_id":"REC_0003129","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":8.9,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":7.4,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.616489+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_762218","record_id":"REC_0003130","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":6.3,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":7.1,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.616727+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_323105","record_id":"REC_0003131","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":24,"primary_tumor_size_cm":4.0,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.616967+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_149250","record_id":"REC_0003132","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":33,"tmb_mutations_per_mb":6.4,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":0,"smoking_pack_years":43,"primary_tumor_size_cm":4.4,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":18.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.617200+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_522518","record_id":"REC_0003133","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":13.5,"age_at_diagnosis":83,"sex":"male","ecog_performance_status":1,"smoking_pack_years":27,"primary_tumor_size_cm":5.2,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.617437+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_704225","record_id":"REC_0003134","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":35,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":27,"primary_tumor_size_cm":6.0,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.617739+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_709288","record_id":"REC_0003135","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":8.1,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":7.0,"metastatic_sites_count":8,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.617980+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_701323","record_id":"REC_0003136","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":49,"sex":"female","ecog_performance_status":0,"smoking_pack_years":0,"primary_tumor_size_cm":5.4,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":23.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.618219+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_775353","record_id":"REC_0003137","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":13.8,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":6.5,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":45.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.618457+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_227073","record_id":"REC_0003138","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":5.3,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":18.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.618693+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_863389","record_id":"REC_0003139","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":7.0,"metastatic_sites_count":10,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":6.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.618931+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_446362","record_id":"REC_0003140","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":6.3,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.619164+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_540311","record_id":"REC_0003141","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":7.0,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.619404+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_774653","record_id":"REC_0003142","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":14.4,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":4.2,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.619646+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_578229","record_id":"REC_0003143","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":32,"tmb_mutations_per_mb":8.4,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":0,"smoking_pack_years":44,"primary_tumor_size_cm":6.2,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":6.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.619882+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_829391","record_id":"REC_0003144","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":14.0,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.0,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.620189+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_704652","record_id":"REC_0003145","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":5.2,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":24,"primary_tumor_size_cm":5.6,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":5.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.620442+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_707464","record_id":"REC_0003146","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":5.0,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":37,"primary_tumor_size_cm":5.2,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":5.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.620689+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_571380","record_id":"REC_0003147","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":7.5,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":8.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.621063+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_158239","record_id":"REC_0003148","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":0,"smoking_pack_years":60,"primary_tumor_size_cm":8.2,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.621315+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_161659","record_id":"REC_0003149","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":21,"primary_tumor_size_cm":3.7,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":4.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.621556+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_282827","record_id":"REC_0003150","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":16.9,"age_at_diagnosis":87,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":7.9,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.621797+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_181751","record_id":"REC_0003151","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":34,"primary_tumor_size_cm":6.4,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":28.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.622045+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_563318","record_id":"REC_0003152","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":30,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":2,"smoking_pack_years":32,"primary_tumor_size_cm":5.4,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":22.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.622299+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_516327","record_id":"REC_0003153","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":7.9,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":3.4,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.622542+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_648499","record_id":"REC_0003154","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":7.9,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":4.3,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":30.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.622776+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_991613","record_id":"REC_0003155","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":32,"tmb_mutations_per_mb":9.0,"age_at_diagnosis":50,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":3.6,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":19.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.623012+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_173971","record_id":"REC_0003156","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":18,"tmb_mutations_per_mb":5.2,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":6.3,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.623247+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_760929","record_id":"REC_0003157","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":14.1,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":2,"primary_tumor_size_cm":3.4,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":26.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.623485+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_985640","record_id":"REC_0003158","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":13.6,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":6.9,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":28.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.623723+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_700002","record_id":"REC_0003159","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":4.6,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.623958+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_507657","record_id":"REC_0003160","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":10.1,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":5.4,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":7.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.624403+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_826787","record_id":"REC_0003161","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":15,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":50,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":6.2,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.624656+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_763793","record_id":"REC_0003162","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":6.8,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":6.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.624897+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_726834","record_id":"REC_0003163","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":5.0,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.625138+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_475364","record_id":"REC_0003164","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":32,"tmb_mutations_per_mb":6.0,"age_at_diagnosis":83,"sex":"female","ecog_performance_status":1,"smoking_pack_years":28,"primary_tumor_size_cm":4.5,"metastatic_sites_count":3,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.625369+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_587699","record_id":"REC_0003165","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":31,"tmb_mutations_per_mb":4.2,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":0,"smoking_pack_years":66,"primary_tumor_size_cm":4.8,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.625605+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_760342","record_id":"REC_0003166","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":13.1,"age_at_diagnosis":84,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":4.9,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.625838+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_806481","record_id":"REC_0003167","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":20,"tmb_mutations_per_mb":8.1,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":1,"smoking_pack_years":45,"primary_tumor_size_cm":5.7,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.626070+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_406562","record_id":"REC_0003168","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":13.3,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.0,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":22.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.626302+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_912965","record_id":"REC_0003169","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None","pd_l1_tps_percent":32,"tmb_mutations_per_mb":4.2,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":51,"primary_tumor_size_cm":5.1,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":37.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.626531+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_721019","record_id":"REC_0003170","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":7.6,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.626764+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_293075","record_id":"REC_0003171","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":4.2,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":28.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.627002+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_722524","record_id":"REC_0003172","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":13,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":80,"sex":"male","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":5.5,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.627238+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_565721","record_id":"REC_0003173","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":32,"tmb_mutations_per_mb":17.5,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":2.7,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":21.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.627550+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_997025","record_id":"REC_0003174","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":13,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":0,"smoking_pack_years":66,"primary_tumor_size_cm":5.0,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":22.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.627788+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_499585","record_id":"REC_0003175","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":14.8,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":2,"smoking_pack_years":3,"primary_tumor_size_cm":7.1,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.628022+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_972227","record_id":"REC_0003176","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":15.2,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":4.2,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.628325+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_420037","record_id":"REC_0003177","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":8.6,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":7.1,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":27.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.628570+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_514757","record_id":"REC_0003178","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":6.6,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":28.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.628811+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_334637","record_id":"REC_0003179","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":51,"primary_tumor_size_cm":6.7,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.629043+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_201111","record_id":"REC_0003180","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":13.1,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":26,"primary_tumor_size_cm":5.3,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":17.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.629284+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_927863","record_id":"REC_0003181","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":31,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":1,"smoking_pack_years":54,"primary_tumor_size_cm":7.0,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":20.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.629515+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_467405","record_id":"REC_0003182","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":15.8,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":6.2,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.629750+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_394862","record_id":"REC_0003183","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":4.9,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.629986+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_817666","record_id":"REC_0003184","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":36,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":5.0,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.630218+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_690807","record_id":"REC_0003185","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":24,"primary_tumor_size_cm":2.9,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.630449+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_188612","record_id":"REC_0003186","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":8.9,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":5.3,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.630750+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_906783","record_id":"REC_0003187","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":1,"smoking_pack_years":27,"primary_tumor_size_cm":6.6,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.630995+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_515630","record_id":"REC_0003188","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":7.6,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":4.5,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.631224+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_458657","record_id":"REC_0003189","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":35,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":7.3,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":19.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.631463+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_114847","record_id":"REC_0003190","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":55,"primary_tumor_size_cm":5.8,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.631691+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_989662","record_id":"REC_0003191","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":44,"sex":"male","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":5.2,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.631930+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_846681","record_id":"REC_0003192","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":8.4,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.0,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.632212+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_944507","record_id":"REC_0003193","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":7.8,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.632447+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_718125","record_id":"REC_0003194","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":4.4,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.632682+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_400824","record_id":"REC_0003195","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":18,"tmb_mutations_per_mb":4.4,"age_at_diagnosis":51,"sex":"male","ecog_performance_status":0,"smoking_pack_years":35,"primary_tumor_size_cm":4.0,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":6.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.632916+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_690039","record_id":"REC_0003196","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":19,"tmb_mutations_per_mb":13.6,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":5.1,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.633151+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_560398","record_id":"REC_0003197","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":9.5,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":3.9,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.633383+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_570635","record_id":"REC_0003198","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":30,"tmb_mutations_per_mb":11.0,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":6.1,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.633615+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_982601","record_id":"REC_0003199","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":87,"sex":"female","ecog_performance_status":2,"smoking_pack_years":0,"primary_tumor_size_cm":3.9,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.633916+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_417038","record_id":"REC_0003200","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":5,"primary_tumor_size_cm":4.8,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":27.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.634159+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_773266","record_id":"REC_0003201","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":31,"tmb_mutations_per_mb":7.4,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":65,"primary_tumor_size_cm":5.8,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.634390+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_202935","record_id":"REC_0003202","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":9.7,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":4.2,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":19.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.634625+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_730348","record_id":"REC_0003203","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":14.3,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":4.4,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":20.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.634862+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_237487","record_id":"REC_0003204","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":30,"tmb_mutations_per_mb":8.7,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":0,"smoking_pack_years":44,"primary_tumor_size_cm":6.0,"metastatic_sites_count":8,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.635095+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_758240","record_id":"REC_0003205","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":30,"tmb_mutations_per_mb":15.5,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":6.4,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":22.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.635325+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_491258","record_id":"REC_0003206","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":16.8,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":6.7,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":24.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.635561+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_346767","record_id":"REC_0003207","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":10.3,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":5.7,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.635791+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_477740","record_id":"REC_0003208","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":9.5,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":5.3,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.636017+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_998292","record_id":"REC_0003209","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":5.2,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":46,"primary_tumor_size_cm":5.5,"metastatic_sites_count":3,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.636345+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_726020","record_id":"REC_0003210","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":16.5,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":5.4,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.636584+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_290877","record_id":"REC_0003211","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":6.8,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.636822+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_130134","record_id":"REC_0003212","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":6.3,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":52,"primary_tumor_size_cm":3.7,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.637113+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_676936","record_id":"REC_0003213","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":7.3,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":4.5,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":38.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.637352+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_919348","record_id":"REC_0003214","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":49,"primary_tumor_size_cm":4.8,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":6.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.637579+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_529100","record_id":"REC_0003215","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":18.1,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":5.3,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":4.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.637820+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_182284","record_id":"REC_0003216","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":4.7,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":26.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.638054+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_296502","record_id":"REC_0003217","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":5.3,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":0,"smoking_pack_years":51,"primary_tumor_size_cm":4.7,"metastatic_sites_count":8,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.638288+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_706909","record_id":"REC_0003218","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":10.1,"age_at_diagnosis":52,"sex":"female","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":5.2,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.638522+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_504560","record_id":"REC_0003219","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":31,"tmb_mutations_per_mb":11.5,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":8.2,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":20.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.638756+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_284353","record_id":"REC_0003220","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":5.2,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.638990+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_122978","record_id":"REC_0003221","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":3.8,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":39.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.639226+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_926245","record_id":"REC_0003222","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":11.5,"age_at_diagnosis":50,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":4.3,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.639464+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_659209","record_id":"REC_0003223","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":13.6,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":2.7,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.639708+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_185444","record_id":"REC_0003224","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":16.3,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":7.3,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.639949+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_543898","record_id":"REC_0003225","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":5.8,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.640331+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_468332","record_id":"REC_0003226","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":3.9,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":2,"smoking_pack_years":40,"primary_tumor_size_cm":6.0,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.640604+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_180694","record_id":"REC_0003227","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":2.0,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":45,"primary_tumor_size_cm":7.7,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.640860+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_692250","record_id":"REC_0003228","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":18.1,"age_at_diagnosis":53,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":3.3,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.641104+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_692617","record_id":"REC_0003229","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":15.6,"age_at_diagnosis":54,"sex":"male","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":2.6,"metastatic_sites_count":8,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.641353+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_909320","record_id":"REC_0003230","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":5.0,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.641605+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_102243","record_id":"REC_0003231","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":7.4,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":1,"smoking_pack_years":25,"primary_tumor_size_cm":6.4,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.641845+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_978915","record_id":"REC_0003232","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":5.4,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.642092+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_680275","record_id":"REC_0003233","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":5.7,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.642333+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_298051","record_id":"REC_0003234","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":19,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":64,"primary_tumor_size_cm":6.7,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":24.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.642574+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_921305","record_id":"REC_0003235","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":4.0,"age_at_diagnosis":54,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":3.8,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.642817+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_235746","record_id":"REC_0003236","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":13.5,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":1,"smoking_pack_years":27,"primary_tumor_size_cm":4.6,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":4.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.643056+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_728745","record_id":"REC_0003237","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":8.6,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.643306+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_624140","record_id":"REC_0003238","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":23,"primary_tumor_size_cm":5.7,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":27.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.643702+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_172313","record_id":"REC_0003239","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":3,"smoking_pack_years":17,"primary_tumor_size_cm":6.6,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.643968+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_385128","record_id":"REC_0003240","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":13.3,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":0,"smoking_pack_years":4,"primary_tumor_size_cm":5.3,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.644296+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_469883","record_id":"REC_0003241","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":0,"smoking_pack_years":25,"primary_tumor_size_cm":5.7,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":23.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.644566+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_774768","record_id":"REC_0003242","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":7.9,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":6.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.644820+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_258930","record_id":"REC_0003243","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":32,"tmb_mutations_per_mb":5.0,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":1,"smoking_pack_years":0,"primary_tumor_size_cm":4.6,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":16.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.645062+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_100870","record_id":"REC_0003244","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":4.5,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":19.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.645308+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_646056","record_id":"REC_0003245","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":13.5,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":5.7,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":23.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.645558+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_819847","record_id":"REC_0003246","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":6.4,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.645820+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_776781","record_id":"REC_0003247","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":7.4,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.646084+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_473522","record_id":"REC_0003248","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":8.4,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":3.8,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":5.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.646348+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_144642","record_id":"REC_0003249","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":18,"tmb_mutations_per_mb":11.5,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":2.7,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.646605+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_955921","record_id":"REC_0003250","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":3.4,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":42,"primary_tumor_size_cm":6.4,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.646856+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_196651","record_id":"REC_0003251","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":4.8,"age_at_diagnosis":75,"sex":"male","ecog_performance_status":2,"smoking_pack_years":21,"primary_tumor_size_cm":5.6,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.647241+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_419513","record_id":"REC_0003252","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":9.8,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":3.6,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.647489+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_224121","record_id":"REC_0003253","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":15,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":3,"smoking_pack_years":10,"primary_tumor_size_cm":5.7,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":33.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.647730+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_690384","record_id":"REC_0003254","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":31,"tmb_mutations_per_mb":5.1,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":65,"primary_tumor_size_cm":4.8,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":25.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.647969+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_519481","record_id":"REC_0003255","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":14.1,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":6.9,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.648286+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_181692","record_id":"REC_0003256","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":15.3,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":4.1,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.648534+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_569672","record_id":"REC_0003257","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":4.8,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.648783+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_355078","record_id":"REC_0003258","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":14.9,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":5.8,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":17.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.649032+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_168849","record_id":"REC_0003259","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":20.4,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":6.3,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.649272+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_353504","record_id":"REC_0003260","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.7,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":30.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.649507+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_212621","record_id":"REC_0003261","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":19,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":35,"primary_tumor_size_cm":6.6,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.649741+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_839793","record_id":"REC_0003262","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":14.3,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":3.4,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.649977+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_982820","record_id":"REC_0003263","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":25,"primary_tumor_size_cm":5.5,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":4.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.650210+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_876067","record_id":"REC_0003264","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":5.0,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":5.0,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.650524+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_841415","record_id":"REC_0003265","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":19.7,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":3.8,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.650771+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_332296","record_id":"REC_0003266","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":15.9,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.6,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.651003+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_385570","record_id":"REC_0003267","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":33,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":31,"primary_tumor_size_cm":6.8,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.651239+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_876787","record_id":"REC_0003268","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":32,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":5.0,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.651474+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_722022","record_id":"REC_0003269","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":31,"tmb_mutations_per_mb":8.3,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":3,"smoking_pack_years":20,"primary_tumor_size_cm":5.7,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":52.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.651705+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_169146","record_id":"REC_0003270","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":16.2,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":5.2,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":21.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.651940+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_974728","record_id":"REC_0003271","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":4,"primary_tumor_size_cm":5.0,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":16.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.652233+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_269595","record_id":"REC_0003272","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":3,"smoking_pack_years":43,"primary_tumor_size_cm":6.5,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.652481+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_493464","record_id":"REC_0003273","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":6.1,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.652745+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_653396","record_id":"REC_0003274","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":4.6,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.652986+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_313523","record_id":"REC_0003275","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":4.2,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":27,"primary_tumor_size_cm":5.9,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":21.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.653224+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_525111","record_id":"REC_0003276","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":9.8,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":5.3,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.653461+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_975252","record_id":"REC_0003277","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":31,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":35,"primary_tumor_size_cm":5.3,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.653792+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_323759","record_id":"REC_0003278","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":6.8,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.654034+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_163165","record_id":"REC_0003279","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":4.1,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":1,"smoking_pack_years":29,"primary_tumor_size_cm":8.3,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":4.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.654263+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_478575","record_id":"REC_0003280","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":7.1,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.654501+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_222545","record_id":"REC_0003281","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":32,"tmb_mutations_per_mb":5.1,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":60,"primary_tumor_size_cm":3.8,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.654737+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_609233","record_id":"REC_0003282","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":20.3,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":25,"primary_tumor_size_cm":3.9,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.654976+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_489133","record_id":"REC_0003283","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":6.3,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":24,"primary_tumor_size_cm":4.6,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.655205+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_687954","record_id":"REC_0003284","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":48,"primary_tumor_size_cm":6.6,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.655440+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_152119","record_id":"REC_0003285","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":5.5,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":59,"primary_tumor_size_cm":4.8,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.655679+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_766012","record_id":"REC_0003286","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":19,"tmb_mutations_per_mb":19.6,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":6.9,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":17.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.655921+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_818411","record_id":"REC_0003287","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":3.5,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":4.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.656365+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_208445","record_id":"REC_0003288","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":15.5,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":4.4,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":22.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.656688+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_344928","record_id":"REC_0003289","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":5.0,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.656963+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_428481","record_id":"REC_0003290","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":18.5,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":5.5,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":26.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.657301+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_736648","record_id":"REC_0003291","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":2.9,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":31,"primary_tumor_size_cm":5.9,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.657545+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_735544","record_id":"REC_0003292","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":5.9,"metastatic_sites_count":8,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":7.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.657781+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_726767","record_id":"REC_0003293","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":1,"smoking_pack_years":51,"primary_tumor_size_cm":3.3,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.658017+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_373947","record_id":"REC_0003294","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":3.4,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":0,"smoking_pack_years":49,"primary_tumor_size_cm":6.1,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":19.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.658272+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_349989","record_id":"REC_0003295","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":4.8,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":21.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.658519+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_852515","record_id":"REC_0003296","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":17.5,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":1,"smoking_pack_years":26,"primary_tumor_size_cm":5.8,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.658789+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_720310","record_id":"REC_0003297","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":4.4,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":7.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.659068+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_869682","record_id":"REC_0003298","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":1,"smoking_pack_years":25,"primary_tumor_size_cm":5.6,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.659347+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_561123","record_id":"REC_0003299","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":13.5,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":6.1,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.659621+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_396191","record_id":"REC_0003300","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":4.4,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":17.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.659877+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_721758","record_id":"REC_0003301","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":4.6,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":5.1,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.660167+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_671200","record_id":"REC_0003302","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":14.5,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":6.1,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":5.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.660425+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_409527","record_id":"REC_0003303","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":5.4,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":29.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.660796+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_371368","record_id":"REC_0003304","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":20,"tmb_mutations_per_mb":3.0,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":38,"primary_tumor_size_cm":5.8,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.661036+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_514933","record_id":"REC_0003305","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":47,"primary_tumor_size_cm":4.7,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":16.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.661271+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_946563","record_id":"REC_0003306","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":76,"sex":"male","ecog_performance_status":3,"smoking_pack_years":14,"primary_tumor_size_cm":7.2,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":23.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.661514+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_965392","record_id":"REC_0003307","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":5.3,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.661751+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_534397","record_id":"REC_0003308","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":8.6,"age_at_diagnosis":79,"sex":"male","ecog_performance_status":0,"smoking_pack_years":58,"primary_tumor_size_cm":5.9,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.661984+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_826517","record_id":"REC_0003309","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":13.8,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":3.9,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":7.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.662223+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_846790","record_id":"REC_0003310","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":6.5,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.662458+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_270220","record_id":"REC_0003311","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":8,"primary_tumor_size_cm":4.4,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.662689+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_826642","record_id":"REC_0003312","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":13,"tmb_mutations_per_mb":11.5,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":5.5,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.662923+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_963721","record_id":"REC_0003313","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":15.5,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":4.8,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.663157+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_336793","record_id":"REC_0003314","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":15.9,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":3,"smoking_pack_years":21,"primary_tumor_size_cm":4.0,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.663388+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_850872","record_id":"REC_0003315","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":10.0,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":6.1,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.663616+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_895826","record_id":"REC_0003316","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":3.7,"age_at_diagnosis":86,"sex":"female","ecog_performance_status":1,"smoking_pack_years":34,"primary_tumor_size_cm":6.1,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.663886+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_721501","record_id":"REC_0003317","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":8.7,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":7.7,"metastatic_sites_count":8,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.664178+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_931140","record_id":"REC_0003318","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":5.9,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":5.1,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":7.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.664429+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_284104","record_id":"REC_0003319","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":5.0,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":92,"primary_tumor_size_cm":6.4,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":19.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.664677+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_171471","record_id":"REC_0003320","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":19,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":89,"sex":"male","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.0,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.664923+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_251348","record_id":"REC_0003321","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":14.3,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":5.2,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.665158+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_949721","record_id":"REC_0003322","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":8.1,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":6,"primary_tumor_size_cm":4.8,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.665390+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_946092","record_id":"REC_0003323","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":4.3,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":28.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.665627+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_583054","record_id":"REC_0003324","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":3.9,"age_at_diagnosis":50,"sex":"female","ecog_performance_status":0,"smoking_pack_years":26,"primary_tumor_size_cm":4.3,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":5.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.665859+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_422275","record_id":"REC_0003325","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":20.1,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":5.2,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.666094+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_142480","record_id":"REC_0003326","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":17,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":5.8,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.666327+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_852597","record_id":"REC_0003327","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":6.7,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.666560+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_985132","record_id":"REC_0003328","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":19.2,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":6.1,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.666795+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_326225","record_id":"REC_0003329","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":32,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":6.3,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.667097+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_592991","record_id":"REC_0003330","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":13.1,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":25,"primary_tumor_size_cm":6.6,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.667337+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_556558","record_id":"REC_0003331","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":8.3,"age_at_diagnosis":52,"sex":"male","ecog_performance_status":0,"smoking_pack_years":72,"primary_tumor_size_cm":6.7,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":16.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.667570+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_380788","record_id":"REC_0003332","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":5.9,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":7.0,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.667801+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_981113","record_id":"REC_0003333","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":81,"sex":"male","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":3.9,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.668035+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_768470","record_id":"REC_0003334","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":52,"sex":"female","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":5.6,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.668314+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_909717","record_id":"REC_0003335","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":13.6,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":6.9,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.668563+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_484315","record_id":"REC_0003336","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":18.9,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":5.0,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.668813+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_707292","record_id":"REC_0003337","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":6.8,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":5.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.669055+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_147262","record_id":"REC_0003338","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":32,"tmb_mutations_per_mb":6.9,"age_at_diagnosis":85,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":5.2,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.669288+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_382483","record_id":"REC_0003339","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":15.1,"age_at_diagnosis":84,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":6.3,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":7.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.669525+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_334615","record_id":"REC_0003340","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":15,"tmb_mutations_per_mb":5.3,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":31,"primary_tumor_size_cm":4.2,"metastatic_sites_count":3,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":26.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.669758+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_799815","record_id":"REC_0003341","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":50,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":5.6,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.669998+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_149033","record_id":"REC_0003342","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":7.9,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":2.2,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":5.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.670303+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_470119","record_id":"REC_0003343","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":2,"smoking_pack_years":23,"primary_tumor_size_cm":5.2,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.670545+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_964871","record_id":"REC_0003344","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":1,"smoking_pack_years":76,"primary_tumor_size_cm":5.2,"metastatic_sites_count":9,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.670775+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_814235","record_id":"REC_0003345","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":3.9,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":7.6,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.671016+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_633985","record_id":"REC_0003346","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":6.6,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.671250+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_995451","record_id":"REC_0003347","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":18,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":58,"primary_tumor_size_cm":3.7,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.671483+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_133881","record_id":"REC_0003348","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":3.1,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.671712+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_824564","record_id":"REC_0003349","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":4.1,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":7.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.671941+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_454644","record_id":"REC_0003350","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":8.3,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":6.5,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.672213+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_813741","record_id":"REC_0003351","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":15.4,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":4.5,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.672458+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_542217","record_id":"REC_0003352","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":1,"smoking_pack_years":61,"primary_tumor_size_cm":5.2,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.672692+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_278371","record_id":"REC_0003353","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":10,"primary_tumor_size_cm":6.9,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":51.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.672931+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_425957","record_id":"REC_0003354","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":9,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":7.5,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":25.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.673164+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_214210","record_id":"REC_0003355","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":5.7,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.673467+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_929124","record_id":"REC_0003356","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":65,"primary_tumor_size_cm":7.3,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":7.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.673710+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_546591","record_id":"REC_0003357","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":17.6,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":7,"primary_tumor_size_cm":2.5,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":7.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.673942+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_391283","record_id":"REC_0003358","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":34,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":49,"primary_tumor_size_cm":6.4,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":18.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.674170+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_505184","record_id":"REC_0003359","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":15.4,"age_at_diagnosis":52,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":6.4,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":46.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.674406+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_836103","record_id":"REC_0003360","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":4.3,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":4.4,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":18.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.674640+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_723517","record_id":"REC_0003361","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":84,"sex":"female","ecog_performance_status":2,"smoking_pack_years":10,"primary_tumor_size_cm":5.8,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":30.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.674875+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_700674","record_id":"REC_0003362","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":6.9,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.675106+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_830149","record_id":"REC_0003363","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":38,"tmb_mutations_per_mb":14.8,"age_at_diagnosis":54,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":4.9,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.675340+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_644066","record_id":"REC_0003364","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":4.0,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.675574+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_738880","record_id":"REC_0003365","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":19.2,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":7.8,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":17.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.675812+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_752369","record_id":"REC_0003366","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":5.5,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.676048+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_248686","record_id":"REC_0003367","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":6.3,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.676394+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_263567","record_id":"REC_0003368","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":30,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":38,"primary_tumor_size_cm":4.0,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.676743+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_634343","record_id":"REC_0003369","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":20,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":5.1,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":19.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.677023+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_683779","record_id":"REC_0003370","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":16.0,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":7.8,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.677287+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_325370","record_id":"REC_0003371","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":19,"tmb_mutations_per_mb":6.3,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":5.6,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":19.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.677526+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_847728","record_id":"REC_0003372","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":34,"tmb_mutations_per_mb":9.8,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":5.6,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.677765+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_291298","record_id":"REC_0003373","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":5.2,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.678007+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_607056","record_id":"REC_0003374","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":1,"smoking_pack_years":0,"primary_tumor_size_cm":3.0,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":37.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.678246+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_322731","record_id":"REC_0003375","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":16.3,"age_at_diagnosis":53,"sex":"male","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":7.7,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.678480+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_926317","record_id":"REC_0003376","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":8.9,"age_at_diagnosis":90,"sex":"female","ecog_performance_status":0,"smoking_pack_years":6,"primary_tumor_size_cm":6.9,"metastatic_sites_count":9,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.678711+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_555695","record_id":"REC_0003377","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":6.1,"age_at_diagnosis":74,"sex":"male","ecog_performance_status":2,"smoking_pack_years":2,"primary_tumor_size_cm":6.2,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":28.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.678944+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_575732","record_id":"REC_0003378","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":20,"tmb_mutations_per_mb":6.1,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":39,"primary_tumor_size_cm":7.1,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.679178+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_321597","record_id":"REC_0003379","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":17.6,"age_at_diagnosis":84,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":4.9,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":50.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.679420+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_974636","record_id":"REC_0003380","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":7.2,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.679666+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_899038","record_id":"REC_0003381","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":17.0,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":5.1,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.680013+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_804278","record_id":"REC_0003382","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":5.6,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":25,"primary_tumor_size_cm":7.0,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.680348+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_728861","record_id":"REC_0003383","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":6.1,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":7.7,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.680609+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_370667","record_id":"REC_0003384","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":1,"smoking_pack_years":24,"primary_tumor_size_cm":8.2,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":16.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.680854+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_751032","record_id":"REC_0003385","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":5.5,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":6.5,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.681090+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_445610","record_id":"REC_0003386","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":4.4,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":5.2,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.681329+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_344652","record_id":"REC_0003387","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":6.6,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.681587+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_338370","record_id":"REC_0003388","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":7.9,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":4.7,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.681839+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_694243","record_id":"REC_0003389","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":7.3,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":2,"smoking_pack_years":9,"primary_tumor_size_cm":6.4,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.682098+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_396740","record_id":"REC_0003390","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":10.0,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":2,"smoking_pack_years":9,"primary_tumor_size_cm":4.2,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":6.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.682350+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_532652","record_id":"REC_0003391","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":13.5,"age_at_diagnosis":88,"sex":"male","ecog_performance_status":2,"smoking_pack_years":4,"primary_tumor_size_cm":4.7,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":29.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.682591+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_330936","record_id":"REC_0003392","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":6.9,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":4.7,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.682825+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_626722","record_id":"REC_0003393","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":13.6,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":7.2,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.683063+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_551037","record_id":"REC_0003394","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":18,"tmb_mutations_per_mb":6.4,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":5.5,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":33.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.683429+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_474257","record_id":"REC_0003395","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":1,"smoking_pack_years":25,"primary_tumor_size_cm":7.5,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.683670+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_873973","record_id":"REC_0003396","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":13.6,"age_at_diagnosis":86,"sex":"female","ecog_performance_status":2,"smoking_pack_years":8,"primary_tumor_size_cm":5.0,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.683907+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_466643","record_id":"REC_0003397","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":8.0,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.684207+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_453025","record_id":"REC_0003398","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":1.5,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":3.1,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.684446+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_856473","record_id":"REC_0003399","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":3,"primary_tumor_size_cm":6.2,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":19.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.684686+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_105889","record_id":"REC_0003400","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":5.9,"metastatic_sites_count":3,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":17.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.684915+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_500550","record_id":"REC_0003401","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":15.5,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":7.3,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":59.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.685151+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_470897","record_id":"REC_0003402","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":4.1,"metastatic_sites_count":9,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.685386+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_116926","record_id":"REC_0003403","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":14.3,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":3.6,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":7.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.685622+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_124073","record_id":"REC_0003404","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":5.7,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":18.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.685852+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_566633","record_id":"REC_0003405","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":8.5,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":4.7,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":22.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.686088+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_486879","record_id":"REC_0003406","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":4.3,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":7.1,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.686317+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_830520","record_id":"REC_0003407","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":32,"tmb_mutations_per_mb":3.9,"age_at_diagnosis":84,"sex":"female","ecog_performance_status":2,"smoking_pack_years":50,"primary_tumor_size_cm":6.0,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.686607+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_813826","record_id":"REC_0003408","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":15.3,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":6.3,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":22.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.686848+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_285321","record_id":"REC_0003409","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":8.7,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":3.3,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.687081+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_546165","record_id":"REC_0003410","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":8.9,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":6.0,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.687311+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_835612","record_id":"REC_0003411","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":10.0,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":6.9,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":21.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.687543+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_536060","record_id":"REC_0003412","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":18.0,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":5.6,"metastatic_sites_count":8,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":4.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.687772+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_797310","record_id":"REC_0003413","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":3.4,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":48,"primary_tumor_size_cm":5.7,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.688003+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_805275","record_id":"REC_0003414","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":9.9,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":5.8,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.688370+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_795272","record_id":"REC_0003415","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":5.1,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":21.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.688619+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_850461","record_id":"REC_0003416","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":30,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":5.6,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":18.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.688858+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_614494","record_id":"REC_0003417","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":5.3,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":22.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.689097+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_837544","record_id":"REC_0003418","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":16,"tmb_mutations_per_mb":21.7,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":3,"smoking_pack_years":19,"primary_tumor_size_cm":4.2,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":22.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.689330+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_560570","record_id":"REC_0003419","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":61,"primary_tumor_size_cm":5.9,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":24.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.689559+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_288428","record_id":"REC_0003420","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":35,"tmb_mutations_per_mb":6.4,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":6.7,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.689848+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_536984","record_id":"REC_0003421","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":33,"tmb_mutations_per_mb":6.3,"age_at_diagnosis":79,"sex":"male","ecog_performance_status":2,"smoking_pack_years":55,"primary_tumor_size_cm":6.0,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.690083+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_324097","record_id":"REC_0003422","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":8.0,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":64,"primary_tumor_size_cm":5.7,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":28.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.690316+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_525292","record_id":"REC_0003423","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":6.2,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.690550+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_766433","record_id":"REC_0003424","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":15.7,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":6.0,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.690780+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_818231","record_id":"REC_0003425","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":3.8,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":0,"smoking_pack_years":66,"primary_tumor_size_cm":6.6,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.691012+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_771189","record_id":"REC_0003426","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":5.6,"age_at_diagnosis":53,"sex":"male","ecog_performance_status":0,"smoking_pack_years":45,"primary_tumor_size_cm":6.3,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":17.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.691247+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_309993","record_id":"REC_0003427","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":3.6,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":4.4,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.691478+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_512789","record_id":"REC_0003428","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":17.3,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":5.4,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.691714+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_755711","record_id":"REC_0003429","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":14,"tmb_mutations_per_mb":4.3,"age_at_diagnosis":50,"sex":"male","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":5.3,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":5.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.691946+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_357597","record_id":"REC_0003430","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":30,"tmb_mutations_per_mb":9.7,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":4.6,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.692257+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_557668","record_id":"REC_0003431","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":16.6,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":3.5,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.692503+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_526038","record_id":"REC_0003432","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":15.3,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":6.1,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.692743+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_466713","record_id":"REC_0003433","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":10.1,"age_at_diagnosis":75,"sex":"male","ecog_performance_status":2,"smoking_pack_years":25,"primary_tumor_size_cm":6.4,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.693037+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_644240","record_id":"REC_0003434","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":3.2,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":5.6,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":5.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.693275+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_116978","record_id":"REC_0003435","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":4.0,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":19.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.693519+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_687386","record_id":"REC_0003436","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":16,"tmb_mutations_per_mb":3.0,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":3,"smoking_pack_years":47,"primary_tumor_size_cm":6.5,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":18.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.693752+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_745161","record_id":"REC_0003437","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":6.9,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":60.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.693987+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_505215","record_id":"REC_0003438","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":4.9,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":29.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.694223+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_528768","record_id":"REC_0003439","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":8.6,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":4.8,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.694461+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_592863","record_id":"REC_0003440","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":5.7,"age_at_diagnosis":53,"sex":"male","ecog_performance_status":0,"smoking_pack_years":67,"primary_tumor_size_cm":5.7,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.694691+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_611812","record_id":"REC_0003441","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":6.9,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.694929+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_177596","record_id":"REC_0003442","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":5.7,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.695162+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_389657","record_id":"REC_0003443","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":18,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":6.6,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":20.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.695398+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_148696","record_id":"REC_0003444","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":9.7,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":31,"primary_tumor_size_cm":3.8,"metastatic_sites_count":3,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.695629+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_771100","record_id":"REC_0003445","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":14.4,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":1,"smoking_pack_years":25,"primary_tumor_size_cm":5.6,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":18.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.695866+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_306048","record_id":"REC_0003446","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":54,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":4.8,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.696244+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_882289","record_id":"REC_0003447","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":9.1,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":1,"primary_tumor_size_cm":4.5,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":7.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.696489+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_872388","record_id":"REC_0003448","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":7.4,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":39,"primary_tumor_size_cm":6.2,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":49.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.696727+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_129064","record_id":"REC_0003449","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":15,"tmb_mutations_per_mb":11.1,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":5.2,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.696962+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_591160","record_id":"REC_0003450","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":8.9,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":6.3,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":16.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.697199+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_309485","record_id":"REC_0003451","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":6.9,"age_at_diagnosis":88,"sex":"female","ecog_performance_status":2,"smoking_pack_years":22,"primary_tumor_size_cm":6.1,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":16.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.697432+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_351627","record_id":"REC_0003452","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":6.4,"age_at_diagnosis":40,"sex":"male","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":5.4,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.697662+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_333429","record_id":"REC_0003453","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":24,"primary_tumor_size_cm":4.2,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":56.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.697895+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_610082","record_id":"REC_0003454","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":4.1,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":56,"primary_tumor_size_cm":6.4,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.698122+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_782117","record_id":"REC_0003455","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":19.9,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":4.7,"metastatic_sites_count":3,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.698361+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_749050","record_id":"REC_0003456","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":89,"sex":"female","ecog_performance_status":3,"smoking_pack_years":3,"primary_tumor_size_cm":4.8,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.698588+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_513176","record_id":"REC_0003457","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":14.1,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":30,"primary_tumor_size_cm":3.5,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.698823+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_593976","record_id":"REC_0003458","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":14.4,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":7.2,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.699052+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_362455","record_id":"REC_0003459","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":67,"primary_tumor_size_cm":3.9,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.699336+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_913623","record_id":"REC_0003460","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":14.3,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":5.5,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":26.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.699590+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_500770","record_id":"REC_0003461","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":19,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":1,"smoking_pack_years":5,"primary_tumor_size_cm":4.8,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.699828+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_417957","record_id":"REC_0003462","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":6.2,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":22.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.700065+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_468648","record_id":"REC_0003463","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":34,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":5.4,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":18.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.700378+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_226572","record_id":"REC_0003464","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":4.5,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.700645+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_902703","record_id":"REC_0003465","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":15.2,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":6.0,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.700896+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_585229","record_id":"REC_0003466","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":8.3,"age_at_diagnosis":88,"sex":"male","ecog_performance_status":1,"smoking_pack_years":59,"primary_tumor_size_cm":4.5,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":22.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.701135+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_867308","record_id":"REC_0003467","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":16.0,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":5.8,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.701383+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_518203","record_id":"REC_0003468","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":4.7,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":39,"primary_tumor_size_cm":4.3,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.701633+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_689294","record_id":"REC_0003469","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":8.7,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":1,"smoking_pack_years":29,"primary_tumor_size_cm":7.1,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.701885+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_345682","record_id":"REC_0003470","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":44,"primary_tumor_size_cm":5.1,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":28.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.702134+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_596360","record_id":"REC_0003471","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":17,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":4.5,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.702386+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_811934","record_id":"REC_0003472","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":17,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":3.5,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.702759+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_369022","record_id":"REC_0003473","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":18,"tmb_mutations_per_mb":16.0,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":4.0,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":24.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.703006+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_546564","record_id":"REC_0003474","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":18.4,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":4.7,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":5.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.703251+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_872862","record_id":"REC_0003475","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":7.6,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":6.7,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.703485+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_792268","record_id":"REC_0003476","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":9.5,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":4.9,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.703720+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_174630","record_id":"REC_0003477","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":14.5,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":5.5,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.703961+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_930586","record_id":"REC_0003478","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":5.1,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":7.9,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.704277+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_443301","record_id":"REC_0003479","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":6.4,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.704544+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_378998","record_id":"REC_0003480","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":5.6,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":49,"primary_tumor_size_cm":6.1,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.704813+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_238235","record_id":"REC_0003481","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":34,"tmb_mutations_per_mb":7.6,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":4.9,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.705075+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_394089","record_id":"REC_0003482","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.6,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":19.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.705334+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_583883","record_id":"REC_0003483","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":6.9,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":34,"primary_tumor_size_cm":6.2,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.705595+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_208964","record_id":"REC_0003484","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":90,"sex":"female","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":7.9,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":53.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.705862+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_784716","record_id":"REC_0003485","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":17.7,"age_at_diagnosis":81,"sex":"male","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":6.2,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.706261+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_966249","record_id":"REC_0003486","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":3.9,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":19.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.706515+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_970752","record_id":"REC_0003487","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":5.0,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.706763+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_342598","record_id":"REC_0003488","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":9.0,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":6.3,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":17.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.706997+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_919079","record_id":"REC_0003489","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":8.5,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":7.0,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":7.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.707228+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_280912","record_id":"REC_0003490","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":1,"smoking_pack_years":31,"primary_tumor_size_cm":6.3,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.707463+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_906802","record_id":"REC_0003491","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":5.6,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":26.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.707692+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_471366","record_id":"REC_0003492","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":1,"smoking_pack_years":55,"primary_tumor_size_cm":5.6,"metastatic_sites_count":8,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.707924+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_648533","record_id":"REC_0003493","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":13.5,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":5.6,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":7.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.708219+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_529815","record_id":"REC_0003494","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":6.2,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.708462+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_480015","record_id":"REC_0003495","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":18,"tmb_mutations_per_mb":15.4,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":4.0,"metastatic_sites_count":3,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.708701+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_995157","record_id":"REC_0003496","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":5.3,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":6.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.708936+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_697554","record_id":"REC_0003497","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":3.8,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":6.0,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.709168+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_442544","record_id":"REC_0003498","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":34,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":5.8,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":24.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.709470+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_823396","record_id":"REC_0003499","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":16.4,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":5.0,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.709711+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_677210","record_id":"REC_0003500","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":34,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.3,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.709945+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_616299","record_id":"REC_0003501","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":14.4,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":4.9,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":20.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.710181+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_103937","record_id":"REC_0003502","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":6.1,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.710415+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_924714","record_id":"REC_0003503","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":13.1,"age_at_diagnosis":74,"sex":"male","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":4.9,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.710651+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_792556","record_id":"REC_0003504","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":14.6,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":3,"smoking_pack_years":15,"primary_tumor_size_cm":6.5,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.710880+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_156337","record_id":"REC_0003505","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":13,"tmb_mutations_per_mb":13.6,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":4.8,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.711113+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_873084","record_id":"REC_0003506","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":30,"tmb_mutations_per_mb":6.9,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":87,"primary_tumor_size_cm":5.2,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.711343+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_160408","record_id":"REC_0003507","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":5.4,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.711571+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_744345","record_id":"REC_0003508","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":19,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":1,"smoking_pack_years":59,"primary_tumor_size_cm":3.1,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.711800+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_246392","record_id":"REC_0003509","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":13.8,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":7.4,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.712035+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_740208","record_id":"REC_0003510","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":5.6,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.712326+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_669610","record_id":"REC_0003511","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":10.3,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":6.8,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.712629+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_538471","record_id":"REC_0003512","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":0,"smoking_pack_years":45,"primary_tumor_size_cm":6.7,"metastatic_sites_count":8,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.712876+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_596710","record_id":"REC_0003513","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":16,"tmb_mutations_per_mb":6.4,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":59,"primary_tumor_size_cm":5.3,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":28.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.713115+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_861983","record_id":"REC_0003514","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":9.7,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":4.9,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":21.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.713353+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_290915","record_id":"REC_0003515","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":14.9,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":6.0,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.713592+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_316994","record_id":"REC_0003516","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":19,"tmb_mutations_per_mb":8.5,"age_at_diagnosis":90,"sex":"female","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":6.8,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.713818+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_850256","record_id":"REC_0003517","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":3.1,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":5.9,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.714054+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_847914","record_id":"REC_0003518","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":1,"primary_tumor_size_cm":4.4,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.714293+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_891459","record_id":"REC_0003519","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":8.1,"age_at_diagnosis":54,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":3.9,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.714530+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_809724","record_id":"REC_0003520","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":14.6,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":6,"primary_tumor_size_cm":7.2,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.714765+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_840054","record_id":"REC_0003521","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":4.5,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.714997+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_887664","record_id":"REC_0003522","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":15,"tmb_mutations_per_mb":2.5,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":35,"primary_tumor_size_cm":6.0,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":7.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.715230+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_765934","record_id":"REC_0003523","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":15.7,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":6.1,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.715468+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_865895","record_id":"REC_0003524","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":30,"tmb_mutations_per_mb":17.2,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":5.0,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.715764+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_346435","record_id":"REC_0003525","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":9.8,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":4.7,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":28.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.716001+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_788633","record_id":"REC_0003526","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":8.1,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":3.0,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.716337+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_890634","record_id":"REC_0003527","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":13,"tmb_mutations_per_mb":4.9,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":46,"primary_tumor_size_cm":5.5,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":7.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.716576+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_154941","record_id":"REC_0003528","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":9.1,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":6.6,"metastatic_sites_count":8,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.716813+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_275195","record_id":"REC_0003529","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":8.0,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":2,"smoking_pack_years":22,"primary_tumor_size_cm":3.9,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.717050+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_707653","record_id":"REC_0003530","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":5.5,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.717278+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_791279","record_id":"REC_0003531","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":0,"smoking_pack_years":27,"primary_tumor_size_cm":3.1,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.717509+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_943797","record_id":"REC_0003532","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":25,"primary_tumor_size_cm":8.2,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":4.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.717741+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_189429","record_id":"REC_0003533","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":16,"tmb_mutations_per_mb":14.9,"age_at_diagnosis":45,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":3.9,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.717975+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_218892","record_id":"REC_0003534","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":16,"tmb_mutations_per_mb":4.1,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":65,"primary_tumor_size_cm":5.4,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":16.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.718204+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_892634","record_id":"REC_0003535","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":34,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":2.7,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.718437+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_311649","record_id":"REC_0003536","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":5.0,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":61,"primary_tumor_size_cm":6.4,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":6.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.718666+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_348423","record_id":"REC_0003537","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":5.3,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":5.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.718965+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_698250","record_id":"REC_0003538","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":4.3,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.719206+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_559731","record_id":"REC_0003539","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":14.5,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":7.4,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":24.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.719455+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_596234","record_id":"REC_0003540","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":30,"tmb_mutations_per_mb":9.1,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":2,"smoking_pack_years":49,"primary_tumor_size_cm":8.4,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.719693+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_572463","record_id":"REC_0003541","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":13,"tmb_mutations_per_mb":14.4,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":4.1,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.719939+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_115977","record_id":"REC_0003542","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":30,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":48,"primary_tumor_size_cm":5.7,"metastatic_sites_count":9,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":16.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.720274+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_762029","record_id":"REC_0003543","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":4.7,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.720535+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_712837","record_id":"REC_0003544","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":13.5,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":26,"primary_tumor_size_cm":6.0,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.720801+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_283889","record_id":"REC_0003545","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":3.9,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.721061+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_147627","record_id":"REC_0003546","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":9.1,"age_at_diagnosis":53,"sex":"female","ecog_performance_status":0,"smoking_pack_years":26,"primary_tumor_size_cm":6.2,"metastatic_sites_count":9,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":6.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.721307+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_982593","record_id":"REC_0003547","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":15.9,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":25,"primary_tumor_size_cm":7.8,"metastatic_sites_count":8,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.721543+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_620404","record_id":"REC_0003548","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":3.1,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.1,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.721779+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_849582","record_id":"REC_0003549","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":19,"tmb_mutations_per_mb":6.9,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":2.2,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.722013+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_804551","record_id":"REC_0003550","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":13.5,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.2,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.722349+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_134605","record_id":"REC_0003551","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":16.5,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":5.8,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.722595+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_628864","record_id":"REC_0003552","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":83,"sex":"female","ecog_performance_status":3,"smoking_pack_years":8,"primary_tumor_size_cm":5.4,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":39.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.722830+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_706866","record_id":"REC_0003553","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":10,"primary_tumor_size_cm":6.1,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":34.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.723060+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_888405","record_id":"REC_0003554","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":5.0,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.723290+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_282571","record_id":"REC_0003555","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":6.6,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.723521+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_968173","record_id":"REC_0003556","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":8.5,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":6.3,"metastatic_sites_count":8,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.723751+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_175213","record_id":"REC_0003557","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":13.5,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":0,"smoking_pack_years":24,"primary_tumor_size_cm":4.8,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":41.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.723986+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_602698","record_id":"REC_0003558","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":11,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":40,"primary_tumor_size_cm":7.7,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.724275+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_792202","record_id":"REC_0003559","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":4.3,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":7.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.724533+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_780210","record_id":"REC_0003560","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":3.7,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":6.1,"metastatic_sites_count":3,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":22.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.724767+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_741249","record_id":"REC_0003561","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":27,"primary_tumor_size_cm":5.1,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.725002+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_397762","record_id":"REC_0003562","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":15.2,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":27,"primary_tumor_size_cm":6.8,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.725235+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_417448","record_id":"REC_0003563","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":50,"sex":"male","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":6.1,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.725548+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_585214","record_id":"REC_0003564","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":1,"smoking_pack_years":24,"primary_tumor_size_cm":6.6,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":7.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.725790+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_541027","record_id":"REC_0003565","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":21,"primary_tumor_size_cm":6.0,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":42.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.726033+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_204835","record_id":"REC_0003566","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":3.5,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":6.3,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.726262+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_359399","record_id":"REC_0003567","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":3.0,"age_at_diagnosis":74,"sex":"male","ecog_performance_status":3,"smoking_pack_years":12,"primary_tumor_size_cm":2.7,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":18.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.726495+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_116079","record_id":"REC_0003568","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":14.3,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":3.8,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":17.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.726725+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_691889","record_id":"REC_0003569","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":5.5,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":25,"primary_tumor_size_cm":7.0,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.726960+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_516017","record_id":"REC_0003570","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":5.0,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":18.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.727192+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_248673","record_id":"REC_0003571","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":30,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.1,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.727427+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_366240","record_id":"REC_0003572","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":15.1,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":3.8,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.727664+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_838138","record_id":"REC_0003573","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":32,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":48,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":4.5,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":6.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.727894+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_239509","record_id":"REC_0003574","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":4.5,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":1,"smoking_pack_years":40,"primary_tumor_size_cm":2.9,"metastatic_sites_count":8,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.728173+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_871571","record_id":"REC_0003575","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":13.6,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":3.7,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.728417+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_670810","record_id":"REC_0003576","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":14.4,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":6.5,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":22.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.728720+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_272592","record_id":"REC_0003577","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":13.6,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":7.4,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.728959+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_979824","record_id":"REC_0003578","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":15.8,"age_at_diagnosis":53,"sex":"male","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":3.6,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":22.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.729198+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_887883","record_id":"REC_0003579","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":4.9,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.729436+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_857591","record_id":"REC_0003580","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":32,"tmb_mutations_per_mb":3.9,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":2.2,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.729665+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_540098","record_id":"REC_0003581","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":20,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":6.0,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":6.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.729902+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_249796","record_id":"REC_0003582","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":10.1,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":4.9,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":21.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.730140+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_616001","record_id":"REC_0003583","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":17.5,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":3.2,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.730383+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_245274","record_id":"REC_0003584","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":10.3,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":5.7,"metastatic_sites_count":9,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":6.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.730666+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_364465","record_id":"REC_0003585","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":52,"sex":"male","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":3.8,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.730940+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_895821","record_id":"REC_0003586","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":5.2,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.731183+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_689554","record_id":"REC_0003587","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":3,"smoking_pack_years":13,"primary_tumor_size_cm":5.3,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.731423+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_268608","record_id":"REC_0003588","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":49,"sex":"male","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":5.6,"metastatic_sites_count":8,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.731659+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_965695","record_id":"REC_0003589","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":18,"tmb_mutations_per_mb":17.5,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":4.6,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":27.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.732018+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_854708","record_id":"REC_0003590","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":30,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":79,"sex":"male","ecog_performance_status":1,"smoking_pack_years":39,"primary_tumor_size_cm":8.1,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.732331+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_832025","record_id":"REC_0003591","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":16.1,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":6.5,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":27.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.732569+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_525727","record_id":"REC_0003592","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":14.5,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":6.2,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":7.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.732804+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_466392","record_id":"REC_0003593","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":11,"tmb_mutations_per_mb":9.8,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":0,"smoking_pack_years":71,"primary_tumor_size_cm":4.1,"metastatic_sites_count":9,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.733043+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_362514","record_id":"REC_0003594","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":6.7,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":8.4,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.733272+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_900320","record_id":"REC_0003595","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":4.0,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":25.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.733499+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_219793","record_id":"REC_0003596","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":4.4,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.733732+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_676550","record_id":"REC_0003597","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":8.7,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":6.8,"metastatic_sites_count":3,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.733967+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_703420","record_id":"REC_0003598","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":13.1,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":26,"primary_tumor_size_cm":8.0,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.734202+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_101098","record_id":"REC_0003599","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":32,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":6.0,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.734437+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_158294","record_id":"REC_0003600","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":4.2,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.734669+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_385046","record_id":"REC_0003601","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":6.3,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":6.4,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":6.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.734898+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_518009","record_id":"REC_0003602","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":7.0,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.735183+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_175384","record_id":"REC_0003603","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":19,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":5.0,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.735419+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_272946","record_id":"REC_0003604","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":14.4,"age_at_diagnosis":53,"sex":"male","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":2.9,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.735655+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_103329","record_id":"REC_0003605","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":5.8,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.735888+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_553299","record_id":"REC_0003606","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":14.7,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":6.7,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":28.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.736233+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_334859","record_id":"REC_0003607","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":16.3,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":6.0,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":19.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.736494+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_415795","record_id":"REC_0003608","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":5.9,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":8.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.736736+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_312740","record_id":"REC_0003609","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":16.4,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":6.2,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":4.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.736976+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_223527","record_id":"REC_0003610","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":35,"tmb_mutations_per_mb":11.1,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":6.8,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":49.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.737207+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_218637","record_id":"REC_0003611","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":3.0,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.737442+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_391920","record_id":"REC_0003612","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":8.1,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":16.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.737670+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_458712","record_id":"REC_0003613","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":1,"smoking_pack_years":32,"primary_tumor_size_cm":5.3,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.737905+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_663938","record_id":"REC_0003614","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":24,"primary_tumor_size_cm":4.8,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":20.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.738138+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_790630","record_id":"REC_0003615","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":11.0,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":10,"primary_tumor_size_cm":5.3,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.738429+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_564684","record_id":"REC_0003616","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":45,"sex":"male","ecog_performance_status":0,"smoking_pack_years":6,"primary_tumor_size_cm":3.5,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.738665+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_863561","record_id":"REC_0003617","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":13.6,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":28,"primary_tumor_size_cm":3.2,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":4.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.738902+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_964885","record_id":"REC_0003618","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None","pd_l1_tps_percent":18,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":33,"primary_tumor_size_cm":6.6,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":41.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.739138+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_826202","record_id":"REC_0003619","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":8.7,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.8,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.739374+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_640346","record_id":"REC_0003620","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":6.4,"age_at_diagnosis":49,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":4.9,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.739614+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_933617","record_id":"REC_0003621","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":5.0,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.739859+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_127400","record_id":"REC_0003622","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":6.1,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.740156+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_877524","record_id":"REC_0003623","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":75,"primary_tumor_size_cm":6.0,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.740417+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_963668","record_id":"REC_0003624","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":15.4,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":33,"primary_tumor_size_cm":7.2,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.740663+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_466511","record_id":"REC_0003625","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":15,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":4.0,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":17.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.740914+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_578298","record_id":"REC_0003626","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":20,"primary_tumor_size_cm":5.7,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.741166+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_334765","record_id":"REC_0003627","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":10.0,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":4.2,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.741424+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_546543","record_id":"REC_0003628","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":4.9,"age_at_diagnosis":52,"sex":"male","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":5.9,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":19.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.741796+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_401391","record_id":"REC_0003629","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":31,"tmb_mutations_per_mb":16.5,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":7.8,"metastatic_sites_count":3,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":7.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.742045+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_909347","record_id":"REC_0003630","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":2.2,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":32,"primary_tumor_size_cm":5.8,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.742276+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_298924","record_id":"REC_0003631","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":5.3,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.742515+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_626302","record_id":"REC_0003632","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":17,"tmb_mutations_per_mb":4.8,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":34,"primary_tumor_size_cm":4.2,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.742752+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_792661","record_id":"REC_0003633","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":5.2,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":0,"smoking_pack_years":0,"primary_tumor_size_cm":6.8,"metastatic_sites_count":8,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.742987+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_386047","record_id":"REC_0003634","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":17,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":51,"sex":"female","ecog_performance_status":0,"smoking_pack_years":59,"primary_tumor_size_cm":5.7,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":5.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.743217+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_124202","record_id":"REC_0003635","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":80,"sex":"male","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":6.5,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":18.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.743450+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_356076","record_id":"REC_0003636","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":37,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":25,"primary_tumor_size_cm":4.7,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.743686+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_610582","record_id":"REC_0003637","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":6.1,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":29.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.743925+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_339940","record_id":"REC_0003638","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":19,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":87,"sex":"male","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":4.6,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.744211+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_838899","record_id":"REC_0003639","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":3.7,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.744453+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_449192","record_id":"REC_0003640","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":9.7,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":1,"smoking_pack_years":3,"primary_tumor_size_cm":6.4,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.744688+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_801927","record_id":"REC_0003641","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":7.4,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":6.5,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.744994+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_808344","record_id":"REC_0003642","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":20,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":54,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":6.4,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":17.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.745234+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_998892","record_id":"REC_0003643","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":5.6,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.745471+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_750359","record_id":"REC_0003644","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":5.1,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":20.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.745706+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_113977","record_id":"REC_0003645","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":6.1,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":19.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.745941+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_880274","record_id":"REC_0003646","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":16.8,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":5.5,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":31.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.746176+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_701081","record_id":"REC_0003647","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":19,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":1,"smoking_pack_years":51,"primary_tumor_size_cm":4.6,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.746406+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_113018","record_id":"REC_0003648","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":6.0,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.746637+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_491494","record_id":"REC_0003649","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":5,"primary_tumor_size_cm":5.8,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":17.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.746872+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_871980","record_id":"REC_0003650","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":14.7,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":4.7,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.747108+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_177742","record_id":"REC_0003651","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":1,"primary_tumor_size_cm":8.2,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.747342+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_434375","record_id":"REC_0003652","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":14.7,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":10,"primary_tumor_size_cm":5.8,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":18.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.747572+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_377111","record_id":"REC_0003653","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":4.9,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":54,"primary_tumor_size_cm":6.8,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":7.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.747800+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_993354","record_id":"REC_0003654","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":30,"tmb_mutations_per_mb":16.9,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":5.1,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.748145+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_926788","record_id":"REC_0003655","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":26,"primary_tumor_size_cm":5.0,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":16.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.748396+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_651143","record_id":"REC_0003656","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":6.0,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.748640+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_287365","record_id":"REC_0003657","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":4.4,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.748874+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_886377","record_id":"REC_0003658","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":33,"tmb_mutations_per_mb":14.8,"age_at_diagnosis":46,"sex":"male","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":5.5,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.749109+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_338073","record_id":"REC_0003659","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":6.7,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":5,"primary_tumor_size_cm":5.7,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.749341+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_973956","record_id":"REC_0003660","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":21.9,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":6.7,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.749575+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_228823","record_id":"REC_0003661","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":10.3,"age_at_diagnosis":75,"sex":"male","ecog_performance_status":3,"smoking_pack_years":14,"primary_tumor_size_cm":6.9,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":20.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.749811+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_387319","record_id":"REC_0003662","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":9.8,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":0,"smoking_pack_years":5,"primary_tumor_size_cm":4.9,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":23.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.750043+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_865236","record_id":"REC_0003663","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":15.2,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":5.6,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.750275+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_957710","record_id":"REC_0003664","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":6.4,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.750506+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_578372","record_id":"REC_0003665","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":4.4,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":1,"smoking_pack_years":46,"primary_tumor_size_cm":7.0,"metastatic_sites_count":3,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.750739+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_142432","record_id":"REC_0003666","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":9.7,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":6.0,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.750973+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_194055","record_id":"REC_0003667","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":31,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":3.6,"metastatic_sites_count":3,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.751256+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_571518","record_id":"REC_0003668","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":5.7,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":6.3,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":18.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.751492+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_718616","record_id":"REC_0003669","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":10.3,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":4.7,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.751727+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_376564","record_id":"REC_0003670","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":16.2,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":20,"primary_tumor_size_cm":5.1,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.751963+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_484943","record_id":"REC_0003671","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":9.7,"age_at_diagnosis":76,"sex":"male","ecog_performance_status":3,"smoking_pack_years":12,"primary_tumor_size_cm":5.7,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.752302+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_324801","record_id":"REC_0003672","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":8,"primary_tumor_size_cm":4.7,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":24.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.752545+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_567114","record_id":"REC_0003673","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":15.3,"age_at_diagnosis":86,"sex":"female","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":4.4,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":6.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.752793+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_448813","record_id":"REC_0003674","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":14.7,"age_at_diagnosis":83,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":5.2,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.753028+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_897553","record_id":"REC_0003675","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":2.9,"age_at_diagnosis":84,"sex":"female","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":5.7,"metastatic_sites_count":9,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.753259+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_227739","record_id":"REC_0003676","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":16.5,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":7.4,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.753497+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_265451","record_id":"REC_0003677","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":16.8,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":5.1,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":16.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.753730+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_400358","record_id":"REC_0003678","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":5.0,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":27,"primary_tumor_size_cm":6.8,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":16.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.753964+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_923120","record_id":"REC_0003679","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":19.4,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":3,"smoking_pack_years":23,"primary_tumor_size_cm":5.4,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":18.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.754195+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_456831","record_id":"REC_0003680","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":15.0,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":4.5,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":21.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.754511+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_361173","record_id":"REC_0003681","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":5.2,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.754749+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_287155","record_id":"REC_0003682","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":18,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":4.2,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.754986+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_451130","record_id":"REC_0003683","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":15.8,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":6.4,"metastatic_sites_count":8,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":21.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.755223+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_422698","record_id":"REC_0003684","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":6.7,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":61,"primary_tumor_size_cm":3.8,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":16.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.755454+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_721804","record_id":"REC_0003685","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":4.7,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.755684+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_384287","record_id":"REC_0003686","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":2.8,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":29,"primary_tumor_size_cm":5.1,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.755914+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_322870","record_id":"REC_0003687","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":15.4,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":4.8,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.756264+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_954558","record_id":"REC_0003688","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":7.9,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.756500+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_303184","record_id":"REC_0003689","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":14.7,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":2,"primary_tumor_size_cm":4.8,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.756739+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_317903","record_id":"REC_0003690","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":6.0,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":4.5,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.756967+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_768651","record_id":"REC_0003691","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":7.0,"metastatic_sites_count":3,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":5.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.757200+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_886214","record_id":"REC_0003692","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":4.4,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":0,"smoking_pack_years":35,"primary_tumor_size_cm":7.7,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.757431+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_317025","record_id":"REC_0003693","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":16.1,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":3.1,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.757748+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_753561","record_id":"REC_0003694","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":6,"primary_tumor_size_cm":8.0,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":19.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.757984+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_556758","record_id":"REC_0003695","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":5.3,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":6.6,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.758217+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_393322","record_id":"REC_0003696","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":6.4,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":5.3,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.758448+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_874007","record_id":"REC_0003697","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":8.6,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":5.6,"metastatic_sites_count":8,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.758685+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_506334","record_id":"REC_0003698","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":14.7,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.2,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":4.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.758937+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_601186","record_id":"REC_0003699","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":26,"primary_tumor_size_cm":3.8,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.759207+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_346170","record_id":"REC_0003700","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":6.1,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.759480+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_687715","record_id":"REC_0003701","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":3.6,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":21.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.759739+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_422858","record_id":"REC_0003702","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":5.2,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.759985+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_883068","record_id":"REC_0003703","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":4.4,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.760358+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_237071","record_id":"REC_0003704","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":19,"tmb_mutations_per_mb":4.3,"age_at_diagnosis":76,"sex":"male","ecog_performance_status":2,"smoking_pack_years":50,"primary_tumor_size_cm":4.5,"metastatic_sites_count":8,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.760662+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_893602","record_id":"REC_0003705","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":4.1,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":46,"primary_tumor_size_cm":6.3,"metastatic_sites_count":3,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.760929+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_832363","record_id":"REC_0003706","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":14.8,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":3.4,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.761310+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_207285","record_id":"REC_0003707","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":6.8,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":19.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.761559+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_909339","record_id":"REC_0003708","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":27,"primary_tumor_size_cm":4.6,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.761792+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_275855","record_id":"REC_0003709","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.2,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.762032+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_766883","record_id":"REC_0003710","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":16.0,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":3,"primary_tumor_size_cm":3.6,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.762270+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_334148","record_id":"REC_0003711","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":36,"tmb_mutations_per_mb":1.5,"age_at_diagnosis":88,"sex":"female","ecog_performance_status":2,"smoking_pack_years":20,"primary_tumor_size_cm":4.5,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.762505+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_670163","record_id":"REC_0003712","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":9.8,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":57,"primary_tumor_size_cm":4.8,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.762738+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_584918","record_id":"REC_0003713","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":4.3,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.762975+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_711242","record_id":"REC_0003714","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":36,"tmb_mutations_per_mb":16.2,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":4,"primary_tumor_size_cm":6.0,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.763214+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_182512","record_id":"REC_0003715","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":19,"tmb_mutations_per_mb":6.3,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":50,"primary_tumor_size_cm":8.1,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":16.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.763445+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_669453","record_id":"REC_0003716","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":56,"primary_tumor_size_cm":6.2,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.763675+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_200389","record_id":"REC_0003717","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":33,"tmb_mutations_per_mb":14.0,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":1,"smoking_pack_years":27,"primary_tumor_size_cm":6.2,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.763911+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_849968","record_id":"REC_0003718","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":5.5,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.764220+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_629487","record_id":"REC_0003719","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":7.6,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":1,"smoking_pack_years":49,"primary_tumor_size_cm":4.7,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":21.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.764532+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_103724","record_id":"REC_0003720","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":6.6,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.764782+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_189685","record_id":"REC_0003721","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":8.5,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":48,"primary_tumor_size_cm":5.6,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.765018+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_309929","record_id":"REC_0003722","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":15.7,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":25,"primary_tumor_size_cm":5.8,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":44.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.765256+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_773518","record_id":"REC_0003723","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":4.3,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":42,"primary_tumor_size_cm":3.1,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.765491+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_382207","record_id":"REC_0003724","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":7.1,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.765728+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_638154","record_id":"REC_0003725","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":10.0,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":5.6,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.765965+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_936059","record_id":"REC_0003726","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":5.4,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.766198+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_856970","record_id":"REC_0003727","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":15.6,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":5.5,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":23.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.766435+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_753309","record_id":"REC_0003728","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":5.8,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.766662+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_467410","record_id":"REC_0003729","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":14.8,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":6.0,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":16.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.766896+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_303705","record_id":"REC_0003730","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":4.2,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":20.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.767128+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_699654","record_id":"REC_0003731","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":5.7,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":22.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.767358+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_961160","record_id":"REC_0003732","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":5.9,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":6.7,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":26.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.767636+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_583091","record_id":"REC_0003733","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":16.1,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":7.2,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.767874+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_117921","record_id":"REC_0003734","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":8.4,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":19.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.768142+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_251108","record_id":"REC_0003735","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":50,"sex":"male","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":4.0,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.768387+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_711634","record_id":"REC_0003736","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":31,"tmb_mutations_per_mb":10.1,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":3.9,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.768629+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_134126","record_id":"REC_0003737","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":28,"primary_tumor_size_cm":6.1,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":32.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.768869+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_796080","record_id":"REC_0003738","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":4.6,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":4.2,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":7.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.769100+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_608466","record_id":"REC_0003739","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":5.2,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":0,"smoking_pack_years":54,"primary_tumor_size_cm":4.5,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.769339+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_544325","record_id":"REC_0003740","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":4.7,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":3,"smoking_pack_years":31,"primary_tumor_size_cm":6.4,"metastatic_sites_count":8,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.769571+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_488122","record_id":"REC_0003741","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":17.3,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":7.3,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":21.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.769804+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_166730","record_id":"REC_0003742","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":30,"tmb_mutations_per_mb":2.3,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":4.8,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.770033+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_835523","record_id":"REC_0003743","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":5.3,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.770264+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_827099","record_id":"REC_0003744","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":5.0,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.770497+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_207181","record_id":"REC_0003745","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":16,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":3.8,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.770800+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_549916","record_id":"REC_0003746","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":40,"primary_tumor_size_cm":7.0,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":20.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.771036+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_421514","record_id":"REC_0003747","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":4.2,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.771274+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_503247","record_id":"REC_0003748","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":8.7,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":4.7,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.771506+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_514531","record_id":"REC_0003749","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":8.5,"age_at_diagnosis":86,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":6.7,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.771740+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_907778","record_id":"REC_0003750","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":4.8,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.771976+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_647282","record_id":"REC_0003751","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":16,"tmb_mutations_per_mb":3.2,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":4.0,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":16.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.772257+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_171475","record_id":"REC_0003752","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":0,"smoking_pack_years":6,"primary_tumor_size_cm":7.4,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":26.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.772506+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_574419","record_id":"REC_0003753","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":6.4,"age_at_diagnosis":75,"sex":"male","ecog_performance_status":2,"smoking_pack_years":80,"primary_tumor_size_cm":4.7,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":22.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.772744+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_652207","record_id":"REC_0003754","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":14.4,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":5.1,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":20.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.772982+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_376467","record_id":"REC_0003755","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":2,"smoking_pack_years":49,"primary_tumor_size_cm":4.8,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.773211+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_743402","record_id":"REC_0003756","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":10.0,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":6.7,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":45.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.773449+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_294955","record_id":"REC_0003757","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":13.5,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":3.2,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.773684+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_802085","record_id":"REC_0003758","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":20,"tmb_mutations_per_mb":10.3,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":3.8,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":4.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.773980+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_783923","record_id":"REC_0003759","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":3.6,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":4,"primary_tumor_size_cm":5.2,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":37.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.774213+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_874660","record_id":"REC_0003760","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":75,"sex":"male","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":4.8,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.774448+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_864120","record_id":"REC_0003761","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":14.3,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":10,"primary_tumor_size_cm":4.6,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":6.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.774681+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_176576","record_id":"REC_0003762","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":5.4,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.774913+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_480692","record_id":"REC_0003763","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":4.8,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.775145+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_726400","record_id":"REC_0003764","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":16.2,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":25,"primary_tumor_size_cm":3.6,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.775376+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_999970","record_id":"REC_0003765","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":50,"sex":"male","ecog_performance_status":0,"smoking_pack_years":26,"primary_tumor_size_cm":4.2,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":21.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.775611+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_648694","record_id":"REC_0003766","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":7.9,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":4.9,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":26.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.775840+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_472708","record_id":"REC_0003767","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":7.9,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":1,"smoking_pack_years":0,"primary_tumor_size_cm":4.8,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":7.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.776167+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_788918","record_id":"REC_0003768","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":2.9,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.776435+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_622944","record_id":"REC_0003769","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":4.0,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":1,"smoking_pack_years":24,"primary_tumor_size_cm":6.5,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":19.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.776719+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_101734","record_id":"REC_0003770","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":3.2,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":54,"primary_tumor_size_cm":6.2,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.776988+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_818170","record_id":"REC_0003771","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":17.4,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":4.9,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.777426+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_188367","record_id":"REC_0003772","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":5.0,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":41,"primary_tumor_size_cm":4.7,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":22.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.777720+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_885233","record_id":"REC_0003773","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":7.2,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":31.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.777986+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_606174","record_id":"REC_0003774","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":4.7,"age_at_diagnosis":85,"sex":"female","ecog_performance_status":1,"smoking_pack_years":24,"primary_tumor_size_cm":5.5,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.778258+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_631546","record_id":"REC_0003775","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":19.1,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":2.8,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.778512+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_554092","record_id":"REC_0003776","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":13.6,"age_at_diagnosis":76,"sex":"male","ecog_performance_status":2,"smoking_pack_years":2,"primary_tumor_size_cm":5.2,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.778748+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_354734","record_id":"REC_0003777","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":18,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":84,"sex":"female","ecog_performance_status":1,"smoking_pack_years":36,"primary_tumor_size_cm":5.8,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.778986+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_488939","record_id":"REC_0003778","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":3,"smoking_pack_years":21,"primary_tumor_size_cm":3.1,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":24.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.779228+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_472603","record_id":"REC_0003779","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":4.6,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":6,"primary_tumor_size_cm":5.4,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.779473+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_417063","record_id":"REC_0003780","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":8.4,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":7.3,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.779717+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_392142","record_id":"REC_0003781","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":15.7,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":5.0,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.779960+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_150072","record_id":"REC_0003782","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":6.0,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.780268+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_855275","record_id":"REC_0003783","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":6.4,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":7.2,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":21.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.780525+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_786540","record_id":"REC_0003784","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":5.3,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.780921+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_277353","record_id":"REC_0003785","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":4.2,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":0,"smoking_pack_years":3,"primary_tumor_size_cm":5.1,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.781200+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_728962","record_id":"REC_0003786","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":7.6,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":4.9,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.781446+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_583706","record_id":"REC_0003787","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":2,"primary_tumor_size_cm":3.5,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.781686+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_444611","record_id":"REC_0003788","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":54,"primary_tumor_size_cm":4.4,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.781927+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_449533","record_id":"REC_0003789","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":17.6,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":4.3,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":5.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.782168+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_798118","record_id":"REC_0003790","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":7.4,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":4.3,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":7.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.782400+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_454453","record_id":"REC_0003791","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":34,"tmb_mutations_per_mb":1.5,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":4.9,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.782635+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_351635","record_id":"REC_0003792","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":36,"tmb_mutations_per_mb":16.0,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":6.0,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.782872+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_877516","record_id":"REC_0003793","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":5.3,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":20.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.783109+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_677008","record_id":"REC_0003794","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":6.7,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":21,"primary_tumor_size_cm":5.2,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.783336+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_370370","record_id":"REC_0003795","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":79,"sex":"male","ecog_performance_status":2,"smoking_pack_years":9,"primary_tumor_size_cm":5.7,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":20.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.783576+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_816471","record_id":"REC_0003796","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":1.8,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":5.1,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.783804+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_393053","record_id":"REC_0003797","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":17.5,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":5.9,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":20.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.784266+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_384236","record_id":"REC_0003798","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":4.3,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":32,"primary_tumor_size_cm":5.8,"metastatic_sites_count":3,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":17.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.784531+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_297159","record_id":"REC_0003799","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":0,"smoking_pack_years":59,"primary_tumor_size_cm":4.0,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.784785+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_222112","record_id":"REC_0003800","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":5.9,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":32,"primary_tumor_size_cm":6.5,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.785030+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_772617","record_id":"REC_0003801","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":7.2,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":16.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.785271+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_777083","record_id":"REC_0003802","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":5.2,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.785506+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_680469","record_id":"REC_0003803","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":14,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":4.7,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.785745+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_885188","record_id":"REC_0003804","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":6.2,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.785984+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_907180","record_id":"REC_0003805","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":9.7,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":6.4,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.786219+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_321125","record_id":"REC_0003806","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":17.6,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":3,"smoking_pack_years":8,"primary_tumor_size_cm":3.5,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":7.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.786453+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_833316","record_id":"REC_0003807","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":7.3,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.786691+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_406456","record_id":"REC_0003808","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":30,"tmb_mutations_per_mb":7.4,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":0,"smoking_pack_years":26,"primary_tumor_size_cm":3.8,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.786925+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_958654","record_id":"REC_0003809","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":10.0,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.6,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.787158+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_216749","record_id":"REC_0003810","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":0,"smoking_pack_years":51,"primary_tumor_size_cm":6.9,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":21.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.787463+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_697481","record_id":"REC_0003811","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":2.9,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":38,"primary_tumor_size_cm":7.1,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":53.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.787713+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_157411","record_id":"REC_0003812","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":5.2,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.787949+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_695750","record_id":"REC_0003813","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":8.7,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":5.8,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.788233+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_703795","record_id":"REC_0003814","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":16.8,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":5.2,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.788478+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_534021","record_id":"REC_0003815","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":17.3,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":2,"smoking_pack_years":25,"primary_tumor_size_cm":5.5,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.788723+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_326993","record_id":"REC_0003816","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":15.2,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":6.4,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":28.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.788957+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_694809","record_id":"REC_0003817","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":31,"tmb_mutations_per_mb":5.5,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":0,"smoking_pack_years":40,"primary_tumor_size_cm":4.1,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":5.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.789190+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_678258","record_id":"REC_0003818","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":21.3,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":4.7,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":5.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.789425+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_339073","record_id":"REC_0003819","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":7.4,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":5.5,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.789660+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_114342","record_id":"REC_0003820","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":4.0,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.789889+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_325914","record_id":"REC_0003821","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":2.4,"age_at_diagnosis":75,"sex":"male","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":3.5,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.790123+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_808018","record_id":"REC_0003822","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":55,"primary_tumor_size_cm":7.8,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":23.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.790350+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_227149","record_id":"REC_0003823","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":16,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":5.6,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.790645+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_589388","record_id":"REC_0003824","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":7.4,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":5.8,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.790881+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_944115","record_id":"REC_0003825","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":4.1,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.791117+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_517405","record_id":"REC_0003826","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":14.0,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":4.3,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":21.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.791352+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_997977","record_id":"REC_0003827","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":32,"tmb_mutations_per_mb":3.4,"age_at_diagnosis":54,"sex":"female","ecog_performance_status":0,"smoking_pack_years":40,"primary_tumor_size_cm":3.7,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":5.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.791581+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_305231","record_id":"REC_0003828","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":30,"tmb_mutations_per_mb":5.0,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":66,"primary_tumor_size_cm":4.9,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.791813+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_901180","record_id":"REC_0003829","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":5.9,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":7.0,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":33.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.792042+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_445969","record_id":"REC_0003830","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":31,"tmb_mutations_per_mb":14.3,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":4.9,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.792310+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_771749","record_id":"REC_0003831","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":9.7,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":4.6,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":33.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.792541+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_109643","record_id":"REC_0003832","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":17.6,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":6,"primary_tumor_size_cm":4.9,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.792775+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_146249","record_id":"REC_0003833","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":16.2,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":3.1,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.793013+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_483794","record_id":"REC_0003834","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":6.5,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.793243+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_759287","record_id":"REC_0003835","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":7.6,"age_at_diagnosis":45,"sex":"male","ecog_performance_status":0,"smoking_pack_years":27,"primary_tumor_size_cm":7.6,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.793474+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_720097","record_id":"REC_0003836","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":6.0,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.793764+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_303582","record_id":"REC_0003837","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":4.6,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.794004+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_957303","record_id":"REC_0003838","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":5.0,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":5.5,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":19.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.794236+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_826345","record_id":"REC_0003839","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":18.0,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":4.6,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.794476+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_808424","record_id":"REC_0003840","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":7.6,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":26,"primary_tumor_size_cm":7.7,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":23.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.794705+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_442696","record_id":"REC_0003841","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":32,"tmb_mutations_per_mb":4.8,"age_at_diagnosis":54,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":5.2,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.794940+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_208744","record_id":"REC_0003842","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":6.1,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.795168+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_649265","record_id":"REC_0003843","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":32,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":58,"primary_tumor_size_cm":4.0,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.795397+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_465099","record_id":"REC_0003844","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":5.1,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.795632+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_550619","record_id":"REC_0003845","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":5.1,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.795867+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_837916","record_id":"REC_0003846","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":4.3,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":16.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.796192+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_778520","record_id":"REC_0003847","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":5.1,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.796450+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_142036","record_id":"REC_0003848","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":42,"primary_tumor_size_cm":4.0,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.796686+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_904207","record_id":"REC_0003849","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":13.8,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":4.8,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.796991+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_568091","record_id":"REC_0003850","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":3,"primary_tumor_size_cm":5.8,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.797236+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_215705","record_id":"REC_0003851","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":11.1,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":4.2,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":23.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.797470+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_833390","record_id":"REC_0003852","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":15.0,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":3.6,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":29.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.797707+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_932821","record_id":"REC_0003853","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":8.5,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.797945+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_445262","record_id":"REC_0003854","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":31,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":3.6,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.798180+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_834401","record_id":"REC_0003855","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":6.3,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.798420+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_536190","record_id":"REC_0003856","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":6.9,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":4,"primary_tumor_size_cm":4.5,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":34.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.798649+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_644330","record_id":"REC_0003857","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":19.4,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":8,"primary_tumor_size_cm":5.2,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":36.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.798879+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_621710","record_id":"REC_0003858","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":4.0,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":6.1,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":17.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.799114+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_282121","record_id":"REC_0003859","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":18.0,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.0,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":34.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.799350+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_884646","record_id":"REC_0003860","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":15.4,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":3,"smoking_pack_years":30,"primary_tumor_size_cm":5.9,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":23.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.799588+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_326525","record_id":"REC_0003861","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":14.0,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":4.1,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.799832+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_437944","record_id":"REC_0003862","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":10.3,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":5.6,"metastatic_sites_count":3,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.800225+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_274217","record_id":"REC_0003863","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":14.3,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":6.4,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.800499+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_385658","record_id":"REC_0003864","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":15.6,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":5.2,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":21.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.800759+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_923929","record_id":"REC_0003865","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":18.0,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":4.7,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":5.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.801011+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_608413","record_id":"REC_0003866","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":40,"primary_tumor_size_cm":4.7,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":17.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.801264+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_536718","record_id":"REC_0003867","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":5.7,"age_at_diagnosis":52,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":5.0,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":21.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.801530+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_454595","record_id":"REC_0003868","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":11.0,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":29,"primary_tumor_size_cm":5.2,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.801779+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_899956","record_id":"REC_0003869","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":16.0,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":5.0,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.802020+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_271830","record_id":"REC_0003870","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":2.0,"age_at_diagnosis":53,"sex":"male","ecog_performance_status":0,"smoking_pack_years":2,"primary_tumor_size_cm":6.1,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.802257+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_555193","record_id":"REC_0003871","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":30,"tmb_mutations_per_mb":5.6,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":5,"primary_tumor_size_cm":7.5,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":22.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.802498+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_296407","record_id":"REC_0003872","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":6.5,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.802734+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_964255","record_id":"REC_0003873","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":6.2,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":7.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.802975+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_873975","record_id":"REC_0003874","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":9.1,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":60,"primary_tumor_size_cm":6.1,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.803207+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_747946","record_id":"REC_0003875","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":14.3,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":2.5,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.803561+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_693256","record_id":"REC_0003876","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":14.5,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":6.0,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.803808+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_730555","record_id":"REC_0003877","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":42,"primary_tumor_size_cm":2.2,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.804047+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_639841","record_id":"REC_0003878","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":17,"tmb_mutations_per_mb":6.4,"age_at_diagnosis":50,"sex":"male","ecog_performance_status":0,"smoking_pack_years":46,"primary_tumor_size_cm":5.2,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.804344+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_765297","record_id":"REC_0003879","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":25,"primary_tumor_size_cm":4.5,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.804588+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_859280","record_id":"REC_0003880","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":5.6,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.804825+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_784670","record_id":"REC_0003881","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":9.7,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":5.9,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":24.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.805059+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_778187","record_id":"REC_0003882","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":18.2,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":4.9,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.805296+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_581812","record_id":"REC_0003883","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":5.1,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":53,"primary_tumor_size_cm":4.3,"metastatic_sites_count":3,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.805527+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_716450","record_id":"REC_0003884","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":17.1,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":3,"primary_tumor_size_cm":5.2,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":7.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.805762+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_894779","record_id":"REC_0003885","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":5,"primary_tumor_size_cm":4.3,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.805996+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_139549","record_id":"REC_0003886","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":34,"tmb_mutations_per_mb":4.3,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":0,"smoking_pack_years":1,"primary_tumor_size_cm":5.0,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":7.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.806228+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_258787","record_id":"REC_0003887","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":4.6,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":5.2,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":6.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.806460+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_729788","record_id":"REC_0003888","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":17.0,"age_at_diagnosis":79,"sex":"male","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":3.7,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.806748+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_961533","record_id":"REC_0003889","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":4.9,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":45,"primary_tumor_size_cm":5.5,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.806982+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_880310","record_id":"REC_0003890","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":7.9,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":37,"primary_tumor_size_cm":6.3,"metastatic_sites_count":8,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":6.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.807211+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_471935","record_id":"REC_0003891","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":0,"smoking_pack_years":29,"primary_tumor_size_cm":5.1,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":23.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.807444+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_318437","record_id":"REC_0003892","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":15.5,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":6.5,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.807675+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_405618","record_id":"REC_0003893","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":28,"primary_tumor_size_cm":6.6,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.807902+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_720685","record_id":"REC_0003894","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":20,"tmb_mutations_per_mb":5.2,"age_at_diagnosis":47,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":5.6,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.808178+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_205295","record_id":"REC_0003895","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":19,"tmb_mutations_per_mb":8.0,"age_at_diagnosis":76,"sex":"male","ecog_performance_status":3,"smoking_pack_years":5,"primary_tumor_size_cm":7.2,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.808432+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_129796","record_id":"REC_0003896","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":5.7,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.808676+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_429813","record_id":"REC_0003897","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":5.8,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.808910+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_587395","record_id":"REC_0003898","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":16.5,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":1,"smoking_pack_years":24,"primary_tumor_size_cm":4.0,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.809144+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_975002","record_id":"REC_0003899","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None","pd_l1_tps_percent":31,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":80,"sex":"male","ecog_performance_status":1,"smoking_pack_years":45,"primary_tumor_size_cm":2.5,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":38.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.809374+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_390900","record_id":"REC_0003900","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":16,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":38,"primary_tumor_size_cm":5.1,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":17.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.809606+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_997619","record_id":"REC_0003901","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":3.4,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.809891+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_132540","record_id":"REC_0003902","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":17,"tmb_mutations_per_mb":2.5,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":47,"primary_tumor_size_cm":5.4,"metastatic_sites_count":8,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.810127+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_855064","record_id":"REC_0003903","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":7.3,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.2,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.810356+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_853952","record_id":"REC_0003904","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":18,"tmb_mutations_per_mb":5.3,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":43,"primary_tumor_size_cm":5.8,"metastatic_sites_count":8,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.810587+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_370682","record_id":"REC_0003905","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":4.7,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":5.8,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.810818+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_767102","record_id":"REC_0003906","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":83,"sex":"female","ecog_performance_status":2,"smoking_pack_years":83,"primary_tumor_size_cm":5.1,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":7.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.811045+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_882296","record_id":"REC_0003907","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":14.0,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":3,"smoking_pack_years":13,"primary_tumor_size_cm":5.0,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":16.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.811275+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_986888","record_id":"REC_0003908","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":15.4,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":6.6,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.811507+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_522834","record_id":"REC_0003909","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":16,"tmb_mutations_per_mb":14.4,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":5.1,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.811736+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_574702","record_id":"REC_0003910","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":6.4,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.811966+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_763299","record_id":"REC_0003911","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":35,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":4,"primary_tumor_size_cm":5.3,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.812240+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_737662","record_id":"REC_0003912","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":9,"primary_tumor_size_cm":7.7,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":24.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.812480+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_690438","record_id":"REC_0003913","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":30,"tmb_mutations_per_mb":6.4,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":25,"primary_tumor_size_cm":5.4,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.812719+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_819771","record_id":"REC_0003914","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":3,"smoking_pack_years":16,"primary_tumor_size_cm":4.0,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":16.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.813009+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_205246","record_id":"REC_0003915","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":4.9,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.813248+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_860202","record_id":"REC_0003916","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":7.8,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.813480+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_850712","record_id":"REC_0003917","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":77,"sex":"male","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":7.0,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":31.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.813713+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_638719","record_id":"REC_0003918","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":13.1,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":5.6,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":21.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.813948+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_468628","record_id":"REC_0003919","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":15.8,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":6.3,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.814182+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_375003","record_id":"REC_0003920","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":16.9,"age_at_diagnosis":52,"sex":"male","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":5.6,"metastatic_sites_count":9,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.814415+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_202448","record_id":"REC_0003921","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":34,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":54,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":2.9,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.814648+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_683146","record_id":"REC_0003922","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":4.4,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":0,"smoking_pack_years":42,"primary_tumor_size_cm":6.7,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":4.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.814880+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_991580","record_id":"REC_0003923","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":14.7,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":3.9,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.815117+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_287848","record_id":"REC_0003924","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":90,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":8.0,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":18.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.815346+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_901198","record_id":"REC_0003925","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":20,"tmb_mutations_per_mb":8.9,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":51,"primary_tumor_size_cm":5.9,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":6.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.815576+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_117207","record_id":"REC_0003926","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":57,"primary_tumor_size_cm":5.8,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.815804+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_720255","record_id":"REC_0003927","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":7.3,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":34,"primary_tumor_size_cm":5.2,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.816202+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_109526","record_id":"REC_0003928","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":18.2,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":28,"primary_tumor_size_cm":5.6,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.816456+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_260956","record_id":"REC_0003929","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":20,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":5.9,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.816689+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_807805","record_id":"REC_0003930","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":53,"sex":"male","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":4.4,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.816923+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_393524","record_id":"REC_0003931","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":17,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":4.0,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":38.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.817158+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_991198","record_id":"REC_0003932","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":14.1,"age_at_diagnosis":74,"sex":"male","ecog_performance_status":2,"smoking_pack_years":23,"primary_tumor_size_cm":5.9,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.817394+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_802043","record_id":"REC_0003933","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":19.4,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":4.4,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":8.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.817632+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_753896","record_id":"REC_0003934","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":8.4,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.1,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":27.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.817865+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_466699","record_id":"REC_0003935","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":16,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":79,"sex":"male","ecog_performance_status":1,"smoking_pack_years":48,"primary_tumor_size_cm":4.5,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.818104+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_114787","record_id":"REC_0003936","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":18,"tmb_mutations_per_mb":4.6,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":3.8,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":18.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.818352+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_349997","record_id":"REC_0003937","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":3.9,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.818604+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_382431","record_id":"REC_0003938","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":30,"tmb_mutations_per_mb":8.9,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":0,"smoking_pack_years":27,"primary_tumor_size_cm":6.5,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":5.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.818856+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_824061","record_id":"REC_0003939","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":7.3,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.819137+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_406193","record_id":"REC_0003940","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":7.3,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":0,"smoking_pack_years":1,"primary_tumor_size_cm":4.6,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.819514+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_929256","record_id":"REC_0003941","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":7.9,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":3.2,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":27.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.819780+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_872839","record_id":"REC_0003942","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":5.7,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":5.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.820032+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_498687","record_id":"REC_0003943","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":1,"smoking_pack_years":91,"primary_tumor_size_cm":5.2,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.820359+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_749825","record_id":"REC_0003944","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":0,"smoking_pack_years":3,"primary_tumor_size_cm":4.2,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.820623+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_608549","record_id":"REC_0003945","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":4.4,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":36,"primary_tumor_size_cm":6.2,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.820877+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_479071","record_id":"REC_0003946","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":32,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":4.7,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.821138+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_836502","record_id":"REC_0003947","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":19,"tmb_mutations_per_mb":8.1,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":4.5,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.821388+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_456713","record_id":"REC_0003948","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":16.5,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":5.0,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.821642+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_427252","record_id":"REC_0003949","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":5.2,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":40,"primary_tumor_size_cm":5.0,"metastatic_sites_count":3,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":18.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.821886+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_928891","record_id":"REC_0003950","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":8.0,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.822129+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_950562","record_id":"REC_0003951","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":16.5,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":5.8,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.822366+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_552724","record_id":"REC_0003952","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.1,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":6.0,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.822604+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_929862","record_id":"REC_0003953","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":16.1,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":4.5,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.822982+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_611741","record_id":"REC_0003954","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":19,"tmb_mutations_per_mb":13.5,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":6.7,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.823226+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_784073","record_id":"REC_0003955","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":17,"tmb_mutations_per_mb":18.8,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":6.7,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.823463+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_111645","record_id":"REC_0003956","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":14.0,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":4.8,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.823697+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_943173","record_id":"REC_0003957","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":6.0,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":49,"primary_tumor_size_cm":6.4,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.823937+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_894501","record_id":"REC_0003958","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":10.0,"age_at_diagnosis":75,"sex":"male","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":5.9,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.824259+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_629996","record_id":"REC_0003959","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":8.3,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":3,"smoking_pack_years":22,"primary_tumor_size_cm":5.8,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":18.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.824496+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_510472","record_id":"REC_0003960","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":16,"tmb_mutations_per_mb":17.6,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.7,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":19.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.824736+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_969231","record_id":"REC_0003961","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":3,"smoking_pack_years":0,"primary_tumor_size_cm":7.4,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.824971+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_103114","record_id":"REC_0003962","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":6.3,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.825202+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_420836","record_id":"REC_0003963","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":7.5,"metastatic_sites_count":9,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.825437+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_839716","record_id":"REC_0003964","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":16.2,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":6.3,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.825671+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_392108","record_id":"REC_0003965","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":7.3,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":4.5,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.825903+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_786611","record_id":"REC_0003966","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":4,"primary_tumor_size_cm":5.9,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.826209+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_909872","record_id":"REC_0003967","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":4.4,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":6.2,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":29.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.826443+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_700537","record_id":"REC_0003968","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":4.1,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":19.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.826675+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_727146","record_id":"REC_0003969","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":9.1,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":6.7,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":26.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.826908+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_758887","record_id":"REC_0003970","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":17.1,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":5,"primary_tumor_size_cm":6.2,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.827139+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_305167","record_id":"REC_0003971","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":20,"tmb_mutations_per_mb":6.7,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":6.5,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.827367+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_621608","record_id":"REC_0003972","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":8.6,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":7.3,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.827596+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_887977","record_id":"REC_0003973","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":15.6,"age_at_diagnosis":89,"sex":"female","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":6.3,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":24.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.827825+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_423985","record_id":"REC_0003974","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":14.9,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":4.2,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.828061+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_772273","record_id":"REC_0003975","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":8.7,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":6.7,"metastatic_sites_count":8,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.828328+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_974530","record_id":"REC_0003976","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":9.0,"age_at_diagnosis":85,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":3.0,"metastatic_sites_count":3,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.828556+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_957660","record_id":"REC_0003977","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":15,"tmb_mutations_per_mb":10.5,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":6.3,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":7.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.828789+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_704673","record_id":"REC_0003978","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":2.0,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":30.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.829024+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_288878","record_id":"REC_0003979","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":2,"smoking_pack_years":6,"primary_tumor_size_cm":4.2,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.829302+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_793802","record_id":"REC_0003980","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":51,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":4.5,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":22.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.829541+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_598411","record_id":"REC_0003981","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":8.7,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":4.7,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.829775+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_381154","record_id":"REC_0003982","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":4.2,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":22,"primary_tumor_size_cm":5.5,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.830003+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_840505","record_id":"REC_0003983","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":7.3,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":8.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.830237+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_316275","record_id":"REC_0003984","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":48,"sex":"female","ecog_performance_status":0,"smoking_pack_years":0,"primary_tumor_size_cm":6.2,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.830471+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_876338","record_id":"REC_0003985","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":19,"tmb_mutations_per_mb":13.6,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":4,"primary_tumor_size_cm":5.8,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.830706+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_913610","record_id":"REC_0003986","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":19,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":7.7,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.830938+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_692793","record_id":"REC_0003987","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":4.7,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":75,"primary_tumor_size_cm":3.9,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.831170+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_246766","record_id":"REC_0003988","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":4.5,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":5.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.831404+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_715579","record_id":"REC_0003989","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":7.6,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":72,"primary_tumor_size_cm":5.0,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.831635+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_684966","record_id":"REC_0003990","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":11.1,"age_at_diagnosis":85,"sex":"female","ecog_performance_status":2,"smoking_pack_years":6,"primary_tumor_size_cm":7.2,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":22.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.831863+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_732856","record_id":"REC_0003991","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":9.1,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":5,"primary_tumor_size_cm":5.2,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":23.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.832137+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_993011","record_id":"REC_0003992","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":8.1,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":5.4,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":6.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.832429+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_165217","record_id":"REC_0003993","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":2.2,"age_at_diagnosis":77,"sex":"male","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":4.3,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":27.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.832673+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_109077","record_id":"REC_0003994","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":9.8,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":5.0,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":5.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.832909+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_679089","record_id":"REC_0003995","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":2,"smoking_pack_years":24,"primary_tumor_size_cm":5.7,"metastatic_sites_count":3,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.833137+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_277201","record_id":"REC_0003996","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":19.6,"age_at_diagnosis":84,"sex":"female","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":4.5,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.833375+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_990752","record_id":"REC_0003997","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":5.1,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.833607+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_296419","record_id":"REC_0003998","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":14.4,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":25,"primary_tumor_size_cm":6.8,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.833836+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_463110","record_id":"REC_0003999","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":34,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":3,"smoking_pack_years":9,"primary_tumor_size_cm":3.5,"metastatic_sites_count":8,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.834068+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_567651","record_id":"REC_0004000","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":4.6,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":27.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.834299+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_236230","record_id":"REC_0004001","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":2.5,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":7,"primary_tumor_size_cm":7.0,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.834527+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_961193","record_id":"REC_0004002","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":4.1,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":23.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.834757+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_227729","record_id":"REC_0004003","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":6.3,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.834990+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_995174","record_id":"REC_0004004","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":7.0,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.835222+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_374610","record_id":"REC_0004005","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":36,"tmb_mutations_per_mb":16.8,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":21,"primary_tumor_size_cm":6.3,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.835503+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_758697","record_id":"REC_0004006","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":6.5,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.835733+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_896119","record_id":"REC_0004007","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":34,"primary_tumor_size_cm":5.9,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":18.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.835964+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_349434","record_id":"REC_0004008","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":4.9,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":0,"smoking_pack_years":55,"primary_tumor_size_cm":5.0,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":17.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.836298+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_404481","record_id":"REC_0004009","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":31,"tmb_mutations_per_mb":14.3,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":5.5,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.836543+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_592031","record_id":"REC_0004010","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":30,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":6.5,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.836791+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_797944","record_id":"REC_0004011","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":4.6,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":5.9,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.837023+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_289133","record_id":"REC_0004012","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":13.1,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":5.9,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.837258+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_354067","record_id":"REC_0004013","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":5.5,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.837496+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_593739","record_id":"REC_0004014","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":14.0,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":1,"smoking_pack_years":25,"primary_tumor_size_cm":5.8,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.837730+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_931958","record_id":"REC_0004015","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":19.1,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":6.7,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.837959+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_316780","record_id":"REC_0004016","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":11.1,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":5.1,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":17.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.838192+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_917928","record_id":"REC_0004017","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":8.6,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":5.6,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.838424+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_964750","record_id":"REC_0004018","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":8.5,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":35,"primary_tumor_size_cm":5.7,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.838703+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_731397","record_id":"REC_0004019","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":11,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":5.8,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.838942+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_450150","record_id":"REC_0004020","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":4.8,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":7.6,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.839169+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_890756","record_id":"REC_0004021","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":17.2,"age_at_diagnosis":85,"sex":"male","ecog_performance_status":0,"smoking_pack_years":24,"primary_tumor_size_cm":5.4,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.839408+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_527438","record_id":"REC_0004022","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":79,"sex":"male","ecog_performance_status":2,"smoking_pack_years":21,"primary_tumor_size_cm":5.9,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.839650+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_414964","record_id":"REC_0004023","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":5.5,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.839898+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_826818","record_id":"REC_0004024","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":7.9,"age_at_diagnosis":51,"sex":"female","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":3.5,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":19.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.840175+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_718608","record_id":"REC_0004025","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":32,"tmb_mutations_per_mb":17.0,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":6.8,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.840435+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_224114","record_id":"REC_0004026","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":3.8,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":4.5,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.840683+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_829509","record_id":"REC_0004027","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":16,"tmb_mutations_per_mb":9.8,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":4.6,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.840956+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_442586","record_id":"REC_0004028","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":10.5,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":5.7,"metastatic_sites_count":3,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.841238+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_576566","record_id":"REC_0004029","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":14.7,"age_at_diagnosis":53,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":3.5,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.841546+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_487462","record_id":"REC_0004030","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":13.6,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":5.3,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.841835+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_488217","record_id":"REC_0004031","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":3.9,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":76,"primary_tumor_size_cm":5.5,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":29.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.842272+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_990047","record_id":"REC_0004032","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":11.5,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":1,"smoking_pack_years":25,"primary_tumor_size_cm":6.0,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":22.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.842578+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_184792","record_id":"REC_0004033","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":18,"tmb_mutations_per_mb":2.7,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":4.5,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":5.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.842828+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_173934","record_id":"REC_0004034","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":14.5,"age_at_diagnosis":88,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":6.1,"metastatic_sites_count":3,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.843070+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_114165","record_id":"REC_0004035","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":6.0,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":6.4,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.843305+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_555187","record_id":"REC_0004036","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":57,"primary_tumor_size_cm":5.9,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.843541+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_951345","record_id":"REC_0004037","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":14.1,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":9,"primary_tumor_size_cm":7.0,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.843776+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_450739","record_id":"REC_0004038","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":4.2,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.844008+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_235654","record_id":"REC_0004039","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":8.9,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.7,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":17.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.844337+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_556283","record_id":"REC_0004040","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":14.7,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":24,"primary_tumor_size_cm":7.0,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.844582+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_445306","record_id":"REC_0004041","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":8.0,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":6.9,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":5.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.844815+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_290803","record_id":"REC_0004042","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":9.5,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":6.1,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.845048+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_570734","record_id":"REC_0004043","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":61,"primary_tumor_size_cm":3.5,"metastatic_sites_count":3,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.845284+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_161034","record_id":"REC_0004044","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":4.3,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.845644+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_657202","record_id":"REC_0004045","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":3.2,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":6.9,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":7.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.845880+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_258916","record_id":"REC_0004046","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":16,"tmb_mutations_per_mb":17.3,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":27,"primary_tumor_size_cm":5.3,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.846120+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_443821","record_id":"REC_0004047","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":16,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":1,"smoking_pack_years":3,"primary_tumor_size_cm":7.4,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.846365+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_110147","record_id":"REC_0004048","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":6,"primary_tumor_size_cm":5.3,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.846605+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_356146","record_id":"REC_0004049","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":9.5,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":5.6,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.846835+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_669246","record_id":"REC_0004050","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.6,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.847071+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_949620","record_id":"REC_0004051","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":15.8,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":3,"smoking_pack_years":16,"primary_tumor_size_cm":6.0,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.847308+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_456671","record_id":"REC_0004052","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":4.3,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":56,"primary_tumor_size_cm":7.2,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":20.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.847541+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_431643","record_id":"REC_0004053","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":84,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":3.5,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":22.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.847780+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_573548","record_id":"REC_0004054","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":16,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":3.9,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.848010+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_738048","record_id":"REC_0004055","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":33,"tmb_mutations_per_mb":8.4,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":52,"primary_tumor_size_cm":2.2,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.848348+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_413720","record_id":"REC_0004056","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":18,"tmb_mutations_per_mb":4.8,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":4,"primary_tumor_size_cm":6.5,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":19.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.848597+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_920747","record_id":"REC_0004057","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":7.2,"metastatic_sites_count":8,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.848921+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_578781","record_id":"REC_0004058","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":18.1,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":4,"primary_tumor_size_cm":6.5,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":6.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.849169+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_856499","record_id":"REC_0004059","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":14,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":7.2,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":25.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.849411+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_625674","record_id":"REC_0004060","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":24,"primary_tumor_size_cm":5.8,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":23.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.849648+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_381271","record_id":"REC_0004061","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":31,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":5.9,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.849887+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_626439","record_id":"REC_0004062","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":5.1,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":16.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.850119+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_595455","record_id":"REC_0004063","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":3.8,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":31.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.850355+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_266763","record_id":"REC_0004064","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":4.8,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":8.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.850589+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_698726","record_id":"REC_0004065","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":6.0,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.850819+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_938780","record_id":"REC_0004066","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":5.7,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":4.5,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.851054+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_219876","record_id":"REC_0004067","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":37,"tmb_mutations_per_mb":4.4,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":0,"smoking_pack_years":43,"primary_tumor_size_cm":7.2,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.851285+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_160065","record_id":"REC_0004068","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":4.4,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":5.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.851517+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_216338","record_id":"REC_0004069","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":3.5,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":5.8,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.851746+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_574342","record_id":"REC_0004070","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":26,"primary_tumor_size_cm":6.4,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":21.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.852025+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_702495","record_id":"REC_0004071","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":13.1,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":6.4,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":7.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.852309+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_896473","record_id":"REC_0004072","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":12,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":6.8,"metastatic_sites_count":3,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":6.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.852553+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_799076","record_id":"REC_0004073","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":5.4,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.852792+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_296086","record_id":"REC_0004074","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":13.6,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":4.9,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":7.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.853023+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_450190","record_id":"REC_0004075","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":9.5,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.1,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.853250+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_347357","record_id":"REC_0004076","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":13.5,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":25,"primary_tumor_size_cm":4.8,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":34.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.853489+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_257132","record_id":"REC_0004077","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":14.6,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":4.4,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":7.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.853723+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_122153","record_id":"REC_0004078","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":8.9,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":1,"primary_tumor_size_cm":5.5,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":16.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.853952+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_641988","record_id":"REC_0004079","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":11.1,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":6.1,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.854186+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_512121","record_id":"REC_0004080","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None","pd_l1_tps_percent":32,"tmb_mutations_per_mb":5.0,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":3,"smoking_pack_years":29,"primary_tumor_size_cm":6.2,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":26.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.854416+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_690187","record_id":"REC_0004081","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":17,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":0,"smoking_pack_years":26,"primary_tumor_size_cm":6.7,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.854650+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_686202","record_id":"REC_0004082","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":10.5,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":5.6,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.854880+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_740464","record_id":"REC_0004083","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":8.1,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":7.0,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.855184+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_142622","record_id":"REC_0004084","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":86,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":5.6,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":19.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.855424+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_191904","record_id":"REC_0004085","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":17.1,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.0,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":5.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.855656+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_471384","record_id":"REC_0004086","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":32,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":0,"smoking_pack_years":27,"primary_tumor_size_cm":7.1,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":33.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.855892+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_661245","record_id":"REC_0004087","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":7.5,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.856215+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_825873","record_id":"REC_0004088","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":26,"primary_tumor_size_cm":4.2,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":16.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.856466+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_910834","record_id":"REC_0004089","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":5.5,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":26,"primary_tumor_size_cm":5.3,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":16.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.856715+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_100404","record_id":"REC_0004090","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":6.6,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.856965+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_411055","record_id":"REC_0004091","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":14.1,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":4.3,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":19.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.857204+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_113265","record_id":"REC_0004092","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":20.5,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":4.9,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.857439+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_752398","record_id":"REC_0004093","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":17.3,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":3,"smoking_pack_years":11,"primary_tumor_size_cm":7.5,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":5.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.857672+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_325881","record_id":"REC_0004094","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":5.0,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":37,"primary_tumor_size_cm":5.7,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":18.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.857908+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_654143","record_id":"REC_0004095","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":31,"tmb_mutations_per_mb":5.6,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":3.4,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.858143+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_172139","record_id":"REC_0004096","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":10.5,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":7.1,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":23.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.858449+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_924205","record_id":"REC_0004097","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":54,"sex":"male","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":3.2,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.858690+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_267548","record_id":"REC_0004098","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":7.1,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.858924+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_141565","record_id":"REC_0004099","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":6.2,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.859164+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_429857","record_id":"REC_0004100","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":14.7,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":3.3,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.859408+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_708733","record_id":"REC_0004101","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":0,"smoking_pack_years":6,"primary_tumor_size_cm":5.8,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.859646+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_153329","record_id":"REC_0004102","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":4.7,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":0,"primary_tumor_size_cm":5.1,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.859879+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_323221","record_id":"REC_0004103","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":10.1,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":6.4,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.860187+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_931225","record_id":"REC_0004104","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.8,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":30.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.860446+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_507071","record_id":"REC_0004105","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":9.9,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":6.2,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.860690+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_631955","record_id":"REC_0004106","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":4.2,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":16.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.860931+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_544806","record_id":"REC_0004107","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":3,"smoking_pack_years":22,"primary_tumor_size_cm":6.2,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.861177+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_375316","record_id":"REC_0004108","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":14.8,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":6,"primary_tumor_size_cm":3.7,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.861433+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_989254","record_id":"REC_0004109","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":15.8,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":6.4,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":35.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.861828+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_714506","record_id":"REC_0004110","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":5,"primary_tumor_size_cm":3.9,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.862078+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_321324","record_id":"REC_0004111","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":25,"primary_tumor_size_cm":6.6,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":18.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.862321+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_694131","record_id":"REC_0004112","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":17,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":4.1,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.862559+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_606548","record_id":"REC_0004113","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":9.0,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":5.5,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":18.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.862791+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_477973","record_id":"REC_0004114","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":10.5,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":4,"primary_tumor_size_cm":5.6,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.863025+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_441453","record_id":"REC_0004115","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":15.2,"age_at_diagnosis":85,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":5.6,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.863263+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_799942","record_id":"REC_0004116","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":2,"smoking_pack_years":6,"primary_tumor_size_cm":7.7,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":21.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.863501+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_991319","record_id":"REC_0004117","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":6.3,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":35,"primary_tumor_size_cm":4.2,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.863732+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_433235","record_id":"REC_0004118","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":3.8,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.863974+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_302792","record_id":"REC_0004119","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":8.1,"age_at_diagnosis":84,"sex":"male","ecog_performance_status":1,"smoking_pack_years":57,"primary_tumor_size_cm":6.3,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.864263+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_395448","record_id":"REC_0004120","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":14.8,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":5,"primary_tumor_size_cm":5.8,"metastatic_sites_count":3,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.864511+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_946911","record_id":"REC_0004121","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":5.2,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":4.9,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.864746+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_132987","record_id":"REC_0004122","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":10.3,"age_at_diagnosis":54,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":4.2,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":16.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.865045+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_395051","record_id":"REC_0004123","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":15,"tmb_mutations_per_mb":4.9,"age_at_diagnosis":85,"sex":"female","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":7.5,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.865283+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_869672","record_id":"REC_0004124","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":34,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":2,"smoking_pack_years":5,"primary_tumor_size_cm":6.3,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.865526+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_313058","record_id":"REC_0004125","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":25,"primary_tumor_size_cm":5.2,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.865773+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_860947","record_id":"REC_0004126","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":7.4,"metastatic_sites_count":8,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.866011+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_691179","record_id":"REC_0004127","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":8.0,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":3,"smoking_pack_years":44,"primary_tumor_size_cm":5.3,"metastatic_sites_count":3,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":6.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.866240+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_293530","record_id":"REC_0004128","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":14,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":7.9,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.866470+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_289726","record_id":"REC_0004129","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":4.7,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.866703+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_447036","record_id":"REC_0004130","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":14.4,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":7.6,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":18.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.866941+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_864050","record_id":"REC_0004131","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":8.4,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":28,"primary_tumor_size_cm":7.4,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":18.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.867175+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_518429","record_id":"REC_0004132","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":14.8,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":7.7,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.867414+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_784659","record_id":"REC_0004133","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":4.3,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":64,"primary_tumor_size_cm":3.4,"metastatic_sites_count":3,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.867646+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_606635","record_id":"REC_0004134","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":15.2,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":3,"smoking_pack_years":13,"primary_tumor_size_cm":4.5,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.867880+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_415290","record_id":"REC_0004135","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":14.3,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":6.5,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.868245+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_726023","record_id":"REC_0004136","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":6.2,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":21.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.868494+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_608775","record_id":"REC_0004137","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":18.5,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":3.6,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.868741+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_447223","record_id":"REC_0004138","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":4.3,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":35,"primary_tumor_size_cm":6.4,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":20.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.868971+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_599834","record_id":"REC_0004139","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":25,"primary_tumor_size_cm":7.0,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":6.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.869203+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_418128","record_id":"REC_0004140","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":7.9,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":47,"primary_tumor_size_cm":4.3,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":5.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.869435+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_925817","record_id":"REC_0004141","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":16.1,"age_at_diagnosis":82,"sex":"male","ecog_performance_status":2,"smoking_pack_years":7,"primary_tumor_size_cm":3.0,"metastatic_sites_count":11,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.869670+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_724422","record_id":"REC_0004142","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":4.7,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":1,"primary_tumor_size_cm":5.2,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.869899+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_736575","record_id":"REC_0004143","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.6,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":24.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.870136+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_858438","record_id":"REC_0004144","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":40,"tmb_mutations_per_mb":7.4,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":5.4,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.870364+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_551606","record_id":"REC_0004145","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":30,"tmb_mutations_per_mb":14.3,"age_at_diagnosis":85,"sex":"male","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":5.3,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":19.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.870600+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_449691","record_id":"REC_0004146","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":20,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":4.9,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":17.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.870829+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_321560","record_id":"REC_0004147","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":30,"tmb_mutations_per_mb":13.3,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":6.6,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.871062+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_976160","record_id":"REC_0004148","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":9.1,"age_at_diagnosis":83,"sex":"female","ecog_performance_status":2,"smoking_pack_years":0,"primary_tumor_size_cm":7.2,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.871354+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_378628","record_id":"REC_0004149","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":31,"primary_tumor_size_cm":7.0,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.871588+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_268772","record_id":"REC_0004150","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":5.9,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":4.8,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.871814+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_461132","record_id":"REC_0004151","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":16,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":7,"primary_tumor_size_cm":5.1,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.872047+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_410438","record_id":"REC_0004152","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":6.2,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.872332+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_607250","record_id":"REC_0004153","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":15.9,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":4.9,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":17.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.872572+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_780367","record_id":"REC_0004154","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":55,"primary_tumor_size_cm":5.5,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":21.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.872808+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_553678","record_id":"REC_0004155","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":3.0,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":21.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.873044+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_798928","record_id":"REC_0004156","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":19.1,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":5.8,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":18.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.873278+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_705891","record_id":"REC_0004157","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":16.8,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":3,"smoking_pack_years":18,"primary_tumor_size_cm":5.7,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":5.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.873517+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_137685","record_id":"REC_0004158","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":6.4,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":56,"primary_tumor_size_cm":6.7,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":7.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.873749+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_333137","record_id":"REC_0004159","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":17.0,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":4.8,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.873986+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_748316","record_id":"REC_0004160","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":7.6,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.874215+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_611026","record_id":"REC_0004161","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":9.9,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":8.0,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.874511+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_994353","record_id":"REC_0004162","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":19,"tmb_mutations_per_mb":8.7,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":6.3,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.874748+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_464642","record_id":"REC_0004163","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":6.4,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":17.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.874987+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_918254","record_id":"REC_0004164","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":14.5,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":5.2,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":56.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.875223+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_569137","record_id":"REC_0004165","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":5.0,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.875451+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_862083","record_id":"REC_0004166","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":8.9,"age_at_diagnosis":75,"sex":"male","ecog_performance_status":2,"smoking_pack_years":36,"primary_tumor_size_cm":3.7,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":20.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.875681+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_245125","record_id":"REC_0004167","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":30,"tmb_mutations_per_mb":8.3,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":3,"smoking_pack_years":61,"primary_tumor_size_cm":6.6,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.875909+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_373280","record_id":"REC_0004168","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":37,"tmb_mutations_per_mb":4.8,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":4.3,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.876223+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_676920","record_id":"REC_0004169","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":31,"tmb_mutations_per_mb":4.8,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":56,"primary_tumor_size_cm":5.4,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":17.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.876457+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_168317","record_id":"REC_0004170","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":9.7,"age_at_diagnosis":78,"sex":"male","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":7.0,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.876692+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_391233","record_id":"REC_0004171","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":2.7,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":4.3,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":16.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.876923+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_870255","record_id":"REC_0004172","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":8.4,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":5.8,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":19.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.877158+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_340911","record_id":"REC_0004173","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":16.2,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":6.8,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.877393+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_735744","record_id":"REC_0004174","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":25,"primary_tumor_size_cm":6.0,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":5.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.877676+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_662601","record_id":"REC_0004175","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":7.1,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.877912+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_963928","record_id":"REC_0004176","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":15.5,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":4.8,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.878145+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_132395","record_id":"REC_0004177","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":32,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":25,"primary_tumor_size_cm":6.0,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.878378+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_923669","record_id":"REC_0004178","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":20.2,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":5.2,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":25.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.878606+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_867569","record_id":"REC_0004179","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":15.6,"age_at_diagnosis":54,"sex":"female","ecog_performance_status":0,"smoking_pack_years":36,"primary_tumor_size_cm":6.0,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.878840+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_356784","record_id":"REC_0004180","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":14.0,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":4.8,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.879076+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_511689","record_id":"REC_0004181","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":51,"sex":"male","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":3.4,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":21.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.879316+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_647480","record_id":"REC_0004182","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":3.7,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":3.7,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.879554+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_969316","record_id":"REC_0004183","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":3,"smoking_pack_years":14,"primary_tumor_size_cm":4.3,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.879795+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_699867","record_id":"REC_0004184","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":0,"smoking_pack_years":1,"primary_tumor_size_cm":3.3,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.880036+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_988261","record_id":"REC_0004185","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":4.2,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.880338+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_764319","record_id":"REC_0004186","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":4,"primary_tumor_size_cm":5.7,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.880600+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_278583","record_id":"REC_0004187","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":5.4,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.880965+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_330184","record_id":"REC_0004188","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":5.2,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.881259+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_235163","record_id":"REC_0004189","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":15.4,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":5.4,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":20.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.881530+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_151828","record_id":"REC_0004190","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":9.0,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":5.7,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.881775+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_770101","record_id":"REC_0004191","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":14.9,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":5.7,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":19.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.882020+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_777068","record_id":"REC_0004192","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":4.5,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":4.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.882255+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_678129","record_id":"REC_0004193","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":14,"tmb_mutations_per_mb":6.9,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":4.7,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.882490+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_408484","record_id":"REC_0004194","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":17.2,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":7.3,"metastatic_sites_count":8,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":5.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.882723+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_972998","record_id":"REC_0004195","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":16.1,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":9,"primary_tumor_size_cm":6.5,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":22.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.882959+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_344944","record_id":"REC_0004196","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":5.5,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":6.7,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":22.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.883193+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_241461","record_id":"REC_0004197","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":18,"tmb_mutations_per_mb":14.5,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":5.7,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.883431+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_854118","record_id":"REC_0004198","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":6.9,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.883667+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_597766","record_id":"REC_0004199","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":25,"primary_tumor_size_cm":7.4,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":41.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.883900+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_345759","record_id":"REC_0004200","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":3.7,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":20.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.884301+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_777580","record_id":"REC_0004201","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":5.2,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":5.1,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.884543+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_365973","record_id":"REC_0004202","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":7.9,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":24,"primary_tumor_size_cm":6.7,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.884780+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_459058","record_id":"REC_0004203","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":14.9,"age_at_diagnosis":49,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":5.0,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.885020+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_110417","record_id":"REC_0004204","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":32,"tmb_mutations_per_mb":15.1,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":2,"smoking_pack_years":10,"primary_tumor_size_cm":7.3,"metastatic_sites_count":3,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":20.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.885250+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_936242","record_id":"REC_0004205","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":16,"tmb_mutations_per_mb":9.8,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":1,"primary_tumor_size_cm":4.8,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.885479+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_686823","record_id":"REC_0004206","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":7.4,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":3.9,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.885709+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_970679","record_id":"REC_0004207","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":1,"smoking_pack_years":67,"primary_tumor_size_cm":4.0,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.885943+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_853850","record_id":"REC_0004208","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":6.2,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.886184+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_893343","record_id":"REC_0004209","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":17.1,"age_at_diagnosis":77,"sex":"male","ecog_performance_status":2,"smoking_pack_years":20,"primary_tumor_size_cm":3.6,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":24.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.886422+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_955275","record_id":"REC_0004210","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":15.0,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":5.4,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.886655+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_165588","record_id":"REC_0004211","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":19,"tmb_mutations_per_mb":8.1,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":5.5,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":23.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.886881+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_697807","record_id":"REC_0004212","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":33,"primary_tumor_size_cm":6.5,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.887111+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_883094","record_id":"REC_0004213","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":3.6,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":26.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.887421+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_376822","record_id":"REC_0004214","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":13.6,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":10,"primary_tumor_size_cm":5.4,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.887660+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_111817","record_id":"REC_0004215","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":18,"tmb_mutations_per_mb":6.9,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":45,"primary_tumor_size_cm":6.5,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.887889+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_530499","record_id":"REC_0004216","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":6.3,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":6.4,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.888154+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_603190","record_id":"REC_0004217","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":6.3,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.888397+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_253798","record_id":"REC_0004218","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":4.4,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.888629+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_252064","record_id":"REC_0004219","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":9.5,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":3.8,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.888862+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_866851","record_id":"REC_0004220","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":5.4,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.889097+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_953183","record_id":"REC_0004221","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":6.3,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.889339+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_801768","record_id":"REC_0004222","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":4.2,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.889570+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_728097","record_id":"REC_0004223","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":14.7,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":5.0,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.889802+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_463940","record_id":"REC_0004224","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":19,"tmb_mutations_per_mb":5.7,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":47,"primary_tumor_size_cm":5.7,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.890033+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_989687","record_id":"REC_0004225","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":10.0,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":6.5,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":23.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.890273+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_647206","record_id":"REC_0004226","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":11.0,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":0,"smoking_pack_years":3,"primary_tumor_size_cm":5.3,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.890631+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_576614","record_id":"REC_0004227","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":4.7,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":6.4,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.890913+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_363990","record_id":"REC_0004228","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":32,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":50,"sex":"male","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":5.5,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":17.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.891166+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_363240","record_id":"REC_0004229","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":15.2,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":5.3,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.891412+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_772796","record_id":"REC_0004230","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":34,"tmb_mutations_per_mb":11.5,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":6.7,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":35.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.891644+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_762980","record_id":"REC_0004231","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":13.1,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":5,"primary_tumor_size_cm":4.5,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.891880+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_693611","record_id":"REC_0004232","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":5.6,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.892198+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_423629","record_id":"REC_0004233","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":9.7,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":4,"primary_tumor_size_cm":3.3,"metastatic_sites_count":9,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":6.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.892451+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_204876","record_id":"REC_0004234","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":7.6,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":4.9,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.892688+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_861413","record_id":"REC_0004235","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":6.3,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":5.2,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":17.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.892921+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_164313","record_id":"REC_0004236","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":15.4,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":6.8,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":22.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.893162+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_422654","record_id":"REC_0004237","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":10.3,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":4.7,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.893396+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_936730","record_id":"REC_0004238","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":5.6,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.893628+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_924996","record_id":"REC_0004239","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":6.0,"age_at_diagnosis":86,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":4.2,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.893956+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_207994","record_id":"REC_0004240","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":5.9,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":6.3,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.894187+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_546953","record_id":"REC_0004241","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":13,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":6.2,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":21.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.894417+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_300121","record_id":"REC_0004242","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":39,"tmb_mutations_per_mb":8.1,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":22,"primary_tumor_size_cm":3.9,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":26.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.894648+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_163796","record_id":"REC_0004243","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":18.9,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":4,"primary_tumor_size_cm":4.5,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.894882+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_890214","record_id":"REC_0004244","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":18,"tmb_mutations_per_mb":15.1,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":4.8,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":17.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.895130+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_506719","record_id":"REC_0004245","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":10.5,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.5,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":4.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.895367+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_898441","record_id":"REC_0004246","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":1,"smoking_pack_years":52,"primary_tumor_size_cm":7.6,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.895599+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_539732","record_id":"REC_0004247","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":19,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":52,"sex":"female","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":8.0,"metastatic_sites_count":9,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.895837+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_990728","record_id":"REC_0004248","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":34,"tmb_mutations_per_mb":5.9,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":52,"primary_tumor_size_cm":5.1,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":25.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.896169+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_589933","record_id":"REC_0004249","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":3.7,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":4,"smoking_pack_years":22,"primary_tumor_size_cm":4.3,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":17.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.896417+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_143508","record_id":"REC_0004250","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":16.0,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":4.7,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.896660+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_379570","record_id":"REC_0004251","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":17.2,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":5.7,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.896897+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_547041","record_id":"REC_0004252","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":0,"smoking_pack_years":5,"primary_tumor_size_cm":5.6,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.897211+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_984710","record_id":"REC_0004253","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":16.1,"age_at_diagnosis":82,"sex":"male","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":5.6,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.897457+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_543897","record_id":"REC_0004254","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":19.9,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":4.6,"metastatic_sites_count":10,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.897690+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_766745","record_id":"REC_0004255","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":4.3,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":4.1,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":24.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.897924+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_782293","record_id":"REC_0004256","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":5.5,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":4.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.898162+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_417198","record_id":"REC_0004257","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":15.9,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":5.1,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.898395+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_697083","record_id":"REC_0004258","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":15.4,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":35,"primary_tumor_size_cm":6.4,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":33.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.898625+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_401706","record_id":"REC_0004259","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":10.0,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":51,"primary_tumor_size_cm":4.5,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.898857+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_201089","record_id":"REC_0004260","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":3.0,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":0,"smoking_pack_years":6,"primary_tumor_size_cm":3.2,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.899088+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_910814","record_id":"REC_0004261","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":54,"sex":"female","ecog_performance_status":0,"smoking_pack_years":58,"primary_tumor_size_cm":4.5,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.899325+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_960740","record_id":"REC_0004262","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":19,"tmb_mutations_per_mb":20.2,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":6.4,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":30.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.899563+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_830234","record_id":"REC_0004263","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":17.4,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":6.0,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.899806+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_871627","record_id":"REC_0004264","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":1,"smoking_pack_years":25,"primary_tumor_size_cm":5.4,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.900049+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_442393","record_id":"REC_0004265","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":5.0,"metastatic_sites_count":3,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.900417+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_646232","record_id":"REC_0004266","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":16.9,"age_at_diagnosis":51,"sex":"female","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":5.2,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":27.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.900674+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_859702","record_id":"REC_0004267","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":3.1,"age_at_diagnosis":89,"sex":"female","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":5.6,"metastatic_sites_count":9,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.900914+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_864191","record_id":"REC_0004268","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":18,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":48,"primary_tumor_size_cm":6.0,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.901168+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_903942","record_id":"REC_0004269","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":6.2,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.901422+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_245866","record_id":"REC_0004270","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":17.1,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":5.8,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.901667+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_818697","record_id":"REC_0004271","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":17,"tmb_mutations_per_mb":7.3,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":5.6,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":20.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.901915+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_313517","record_id":"REC_0004272","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":15.2,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":8.3,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.902161+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_737685","record_id":"REC_0004273","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":14.7,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":6.5,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.902398+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_829106","record_id":"REC_0004274","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":7.3,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":4.6,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":20.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.902640+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_301819","record_id":"REC_0004275","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":9.7,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":4.5,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.902875+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_737044","record_id":"REC_0004276","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":5.0,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":34,"primary_tumor_size_cm":4.9,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.903109+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_695965","record_id":"REC_0004277","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":5,"primary_tumor_size_cm":3.2,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.903347+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_865577","record_id":"REC_0004278","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":6.9,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":69,"primary_tumor_size_cm":4.5,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.903686+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_493995","record_id":"REC_0004279","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":8,"primary_tumor_size_cm":7.6,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.903936+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_645104","record_id":"REC_0004280","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":13.1,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":6.9,"metastatic_sites_count":9,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.904252+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_333892","record_id":"REC_0004281","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":7.4,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":4.6,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.904537+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_272726","record_id":"REC_0004282","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":31,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":6.2,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":37.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.904802+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_212682","record_id":"REC_0004283","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":6.7,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":36.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.905062+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_963506","record_id":"REC_0004284","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":15.1,"age_at_diagnosis":53,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":5.5,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":20.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.905321+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_867913","record_id":"REC_0004285","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":32,"tmb_mutations_per_mb":7.6,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":5.4,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.905587+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_690283","record_id":"REC_0004286","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":32,"tmb_mutations_per_mb":10.5,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":4.5,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.905866+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_979898","record_id":"REC_0004287","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":17.7,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":5.7,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":4.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.906122+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_979285","record_id":"REC_0004288","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":5.6,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":3,"smoking_pack_years":105,"primary_tumor_size_cm":7.6,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":7.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.906362+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_324283","record_id":"REC_0004289","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":35,"primary_tumor_size_cm":6.7,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.906605+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_875492","record_id":"REC_0004290","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":30,"tmb_mutations_per_mb":3.4,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":33,"primary_tumor_size_cm":6.5,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.906844+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_858027","record_id":"REC_0004291","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":6.3,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.907211+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_159442","record_id":"REC_0004292","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":9.9,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":5.6,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.907455+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_776125","record_id":"REC_0004293","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":51,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":4.7,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":17.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.907694+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_212855","record_id":"REC_0004294","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":3,"smoking_pack_years":23,"primary_tumor_size_cm":6.0,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.907924+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_932008","record_id":"REC_0004295","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":6.7,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.908237+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_871322","record_id":"REC_0004296","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":14,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":2.8,"metastatic_sites_count":3,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":8.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.908482+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_907393","record_id":"REC_0004297","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":14.8,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":7.7,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.908725+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_360408","record_id":"REC_0004298","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":15.3,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":3.9,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.908964+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_290987","record_id":"REC_0004299","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":20,"tmb_mutations_per_mb":8.4,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":6.6,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.909194+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_402370","record_id":"REC_0004300","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":4.5,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":23.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.909433+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_313918","record_id":"REC_0004301","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":17.6,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":1,"smoking_pack_years":4,"primary_tumor_size_cm":5.8,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.909669+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_815350","record_id":"REC_0004302","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":54,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":5.8,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.909904+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_758830","record_id":"REC_0004303","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":10.0,"age_at_diagnosis":50,"sex":"male","ecog_performance_status":0,"smoking_pack_years":24,"primary_tumor_size_cm":6.3,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":18.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.910140+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_297417","record_id":"REC_0004304","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":16.7,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":6.2,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.910442+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_459861","record_id":"REC_0004305","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":20,"tmb_mutations_per_mb":2.9,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":6.4,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":19.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.910679+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_226431","record_id":"REC_0004306","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":3.9,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":49.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.910917+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_995514","record_id":"REC_0004307","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":74,"sex":"male","ecog_performance_status":2,"smoking_pack_years":20,"primary_tumor_size_cm":6.7,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.911153+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_577555","record_id":"REC_0004308","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":15.6,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":3,"smoking_pack_years":17,"primary_tumor_size_cm":5.2,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":16.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.911386+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_790697","record_id":"REC_0004309","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":16.0,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":5.7,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.911622+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_904029","record_id":"REC_0004310","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":10.1,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":4.5,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.911851+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_476299","record_id":"REC_0004311","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":5.9,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":39,"primary_tumor_size_cm":7.5,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":7.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.912122+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_296528","record_id":"REC_0004312","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":4.7,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":4.7,"metastatic_sites_count":3,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":4.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.912356+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_462309","record_id":"REC_0004313","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":9.0,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":6.2,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.912588+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_706160","record_id":"REC_0004314","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":13.8,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":6.1,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.912818+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_825076","record_id":"REC_0004315","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":4.9,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":0,"smoking_pack_years":71,"primary_tumor_size_cm":7.9,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.913051+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_477345","record_id":"REC_0004316","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":14.3,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.1,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":19.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.913285+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_152001","record_id":"REC_0004317","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":4.7,"age_at_diagnosis":90,"sex":"female","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":7.7,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.913567+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_645923","record_id":"REC_0004318","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":9.1,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":37,"primary_tumor_size_cm":6.0,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.913799+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_305655","record_id":"REC_0004319","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":5.2,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":7.3,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.914029+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_706435","record_id":"REC_0004320","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":5.6,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.914262+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_566386","record_id":"REC_0004321","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":14.8,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.7,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":31.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.914500+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_445583","record_id":"REC_0004322","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":9.9,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":8.2,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.914730+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_932971","record_id":"REC_0004323","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":16.4,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":20,"primary_tumor_size_cm":6.9,"metastatic_sites_count":9,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.914960+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_893075","record_id":"REC_0004324","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":7.6,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":0,"smoking_pack_years":26,"primary_tumor_size_cm":6.4,"metastatic_sites_count":8,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.915192+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_978421","record_id":"REC_0004325","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":10.1,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":6.6,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.915422+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_908702","record_id":"REC_0004326","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":10,"primary_tumor_size_cm":6.3,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":7.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.915655+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_928901","record_id":"REC_0004327","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":15,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":54,"primary_tumor_size_cm":6.1,"metastatic_sites_count":8,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":7.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.915887+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_127638","record_id":"REC_0004328","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":17.5,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":6.4,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.916226+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_243604","record_id":"REC_0004329","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":8.7,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":5.4,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.916480+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_283695","record_id":"REC_0004330","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":14.3,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":3.5,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":17.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.916777+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_173577","record_id":"REC_0004331","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":17.2,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":3.9,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":39.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.917021+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_256853","record_id":"REC_0004332","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":14.5,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":5.7,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.917257+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_879338","record_id":"REC_0004333","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":2,"smoking_pack_years":24,"primary_tumor_size_cm":5.1,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.917489+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_406284","record_id":"REC_0004334","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":19,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":54,"primary_tumor_size_cm":3.7,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":17.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.917716+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_516742","record_id":"REC_0004335","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":8.9,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":20,"primary_tumor_size_cm":6.0,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.917949+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_544996","record_id":"REC_0004336","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":14.1,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":20,"primary_tumor_size_cm":6.4,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":21.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.918182+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_158618","record_id":"REC_0004337","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":101,"primary_tumor_size_cm":2.2,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":19.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.918410+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_298377","record_id":"REC_0004338","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":4.4,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.918644+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_300174","record_id":"REC_0004339","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":18,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":7.0,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.918882+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_219845","record_id":"REC_0004340","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.4,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":6.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.919115+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_421957","record_id":"REC_0004341","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":3.1,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.919348+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_924783","record_id":"REC_0004342","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":4.9,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":16.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.919590+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_661665","record_id":"REC_0004343","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":39,"primary_tumor_size_cm":6.5,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":27.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.919897+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_610434","record_id":"REC_0004344","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":77,"sex":"male","ecog_performance_status":2,"smoking_pack_years":62,"primary_tumor_size_cm":4.3,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.920228+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_525726","record_id":"REC_0004345","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":18,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":4.9,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":20.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.920488+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_215812","record_id":"REC_0004346","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":18.1,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":4.6,"metastatic_sites_count":9,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":5.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.920758+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_826881","record_id":"REC_0004347","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":1.5,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":0,"smoking_pack_years":36,"primary_tumor_size_cm":6.4,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.921005+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_472552","record_id":"REC_0004348","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":14.5,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":4.1,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":39.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.921247+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_437798","record_id":"REC_0004349","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":5.3,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":54,"primary_tumor_size_cm":8.2,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":45.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.921487+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_308263","record_id":"REC_0004350","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":8.3,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.921742+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_644822","record_id":"REC_0004351","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":4.4,"age_at_diagnosis":87,"sex":"female","ecog_performance_status":1,"smoking_pack_years":28,"primary_tumor_size_cm":3.8,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.921994+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_722405","record_id":"REC_0004352","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":3.4,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":5.3,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.922244+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_398568","record_id":"REC_0004353","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":5.8,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.922483+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_409796","record_id":"REC_0004354","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":15,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":6.2,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.922723+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_857021","record_id":"REC_0004355","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":3.8,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.922963+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_702007","record_id":"REC_0004356","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":14.3,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":5.5,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.923326+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_307955","record_id":"REC_0004357","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":32,"tmb_mutations_per_mb":16.5,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":1,"smoking_pack_years":30,"primary_tumor_size_cm":5.7,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.923573+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_350842","record_id":"REC_0004358","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":3.4,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.923813+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_624673","record_id":"REC_0004359","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":8.9,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":2,"smoking_pack_years":43,"primary_tumor_size_cm":4.6,"metastatic_sites_count":3,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.924043+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_625347","record_id":"REC_0004360","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":19,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":53,"sex":"male","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":5.4,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.924343+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_217813","record_id":"REC_0004361","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":31,"tmb_mutations_per_mb":8.7,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":4.8,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.924583+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_772363","record_id":"REC_0004362","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":34,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":5.6,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":56.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.924817+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_400268","record_id":"REC_0004363","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":6.1,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":7.3,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.925046+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_754506","record_id":"REC_0004364","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":16.9,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":5.5,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.925281+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_264122","record_id":"REC_0004365","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":7.4,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":33,"primary_tumor_size_cm":5.5,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":6.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.925516+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_256195","record_id":"REC_0004366","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":7.4,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":27,"primary_tumor_size_cm":4.4,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":5.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.925748+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_264869","record_id":"REC_0004367","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":8.0,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.925980+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_683572","record_id":"REC_0004368","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":3.7,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":21.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.926208+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_943892","record_id":"REC_0004369","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":10.3,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":82,"primary_tumor_size_cm":5.8,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.926517+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_589933","record_id":"REC_0004370","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":13.3,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":6.0,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":5.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.926757+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_788086","record_id":"REC_0004371","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":1.5,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":63,"primary_tumor_size_cm":6.8,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":17.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.926986+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_138884","record_id":"REC_0004372","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":13.6,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":7.2,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":21.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.927224+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_680350","record_id":"REC_0004373","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":85,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":7.4,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.927455+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_890293","record_id":"REC_0004374","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":24.5,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":6.5,"metastatic_sites_count":3,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.927691+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_886965","record_id":"REC_0004375","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":13.1,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":5,"primary_tumor_size_cm":5.4,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.927929+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_325758","record_id":"REC_0004376","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":1,"smoking_pack_years":29,"primary_tumor_size_cm":7.2,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.928222+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_834215","record_id":"REC_0004377","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":13,"tmb_mutations_per_mb":14.0,"age_at_diagnosis":79,"sex":"male","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":6.2,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.928475+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_304441","record_id":"REC_0004378","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":18.4,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":5,"primary_tumor_size_cm":4.6,"metastatic_sites_count":9,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.928723+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_395613","record_id":"REC_0004379","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":17,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":5.5,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.928957+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_813609","record_id":"REC_0004380","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":32,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":6.9,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":6.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.929193+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_311756","record_id":"REC_0004381","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":4.8,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":63,"primary_tumor_size_cm":6.8,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.929422+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_862240","record_id":"REC_0004382","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":14.0,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":4.3,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":18.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.929717+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_806482","record_id":"REC_0004383","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":5.6,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.929959+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_557193","record_id":"REC_0004384","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":31,"tmb_mutations_per_mb":15.9,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":3,"smoking_pack_years":9,"primary_tumor_size_cm":6.1,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":8.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.930191+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_189201","record_id":"REC_0004385","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":5.3,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":6,"primary_tumor_size_cm":6.3,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.930424+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_817455","record_id":"REC_0004386","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":5.6,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.930654+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_326160","record_id":"REC_0004387","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":19,"tmb_mutations_per_mb":5.3,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.5,"metastatic_sites_count":8,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.930886+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_725479","record_id":"REC_0004388","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":4.9,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.931125+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_257283","record_id":"REC_0004389","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":3.9,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":4.1,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.931357+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_798462","record_id":"REC_0004390","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":19.8,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":2,"smoking_pack_years":23,"primary_tumor_size_cm":6.6,"metastatic_sites_count":8,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.931591+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_343677","record_id":"REC_0004391","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":14.1,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":4.7,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.931824+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_128990","record_id":"REC_0004392","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":8.3,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":4,"primary_tumor_size_cm":7.8,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.932050+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_791076","record_id":"REC_0004393","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":50,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":5.3,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":22.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.932338+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_278087","record_id":"REC_0004394","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":6.2,"metastatic_sites_count":9,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.932576+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_499828","record_id":"REC_0004395","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":10.3,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":5.4,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":25.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.932864+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_415358","record_id":"REC_0004396","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":7.0,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.933100+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_792812","record_id":"REC_0004397","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":11.0,"age_at_diagnosis":74,"sex":"male","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":4.5,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.933337+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_669353","record_id":"REC_0004398","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":20,"tmb_mutations_per_mb":6.7,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":38,"primary_tumor_size_cm":4.2,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":29.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.933570+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_322340","record_id":"REC_0004399","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":2,"primary_tumor_size_cm":7.2,"metastatic_sites_count":3,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":23.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.933808+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_304147","record_id":"REC_0004400","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":5.0,"age_at_diagnosis":78,"sex":"male","ecog_performance_status":2,"smoking_pack_years":45,"primary_tumor_size_cm":5.7,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.934040+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_494032","record_id":"REC_0004401","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":7.0,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":22.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.934273+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_990953","record_id":"REC_0004402","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":18,"tmb_mutations_per_mb":5.1,"age_at_diagnosis":90,"sex":"female","ecog_performance_status":2,"smoking_pack_years":65,"primary_tumor_size_cm":5.9,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":22.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.934501+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_779523","record_id":"REC_0004403","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":8.5,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":6.0,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":20.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.934731+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_483481","record_id":"REC_0004404","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":5,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":5.0,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.934961+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_450067","record_id":"REC_0004405","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":1,"smoking_pack_years":54,"primary_tumor_size_cm":6.4,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":17.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.935188+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_944220","record_id":"REC_0004406","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":10,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":2,"smoking_pack_years":27,"primary_tumor_size_cm":9.6,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.935425+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_659075","record_id":"REC_0004407","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":14.5,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":4.5,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":22.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.935656+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_562456","record_id":"REC_0004408","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":8.6,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":3,"smoking_pack_years":11,"primary_tumor_size_cm":6.4,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.935924+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_739272","record_id":"REC_0004409","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":17,"tmb_mutations_per_mb":8.9,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":6.2,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.936246+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_172732","record_id":"REC_0004410","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":16.2,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":8.1,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.936488+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_644433","record_id":"REC_0004411","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":35,"tmb_mutations_per_mb":1.5,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":22,"primary_tumor_size_cm":4.1,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.936721+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_641175","record_id":"REC_0004412","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":4.5,"age_at_diagnosis":88,"sex":"female","ecog_performance_status":2,"smoking_pack_years":44,"primary_tumor_size_cm":6.1,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.936959+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_460879","record_id":"REC_0004413","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":8.0,"age_at_diagnosis":53,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":7.1,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":5.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.937192+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_612849","record_id":"REC_0004414","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":5.5,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":60,"primary_tumor_size_cm":5.4,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.937422+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_992670","record_id":"REC_0004415","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":18.6,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":5.8,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":20.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.937659+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_300551","record_id":"REC_0004416","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":14.6,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":5.7,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.937895+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_951581","record_id":"REC_0004417","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":6.0,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":40,"primary_tumor_size_cm":5.8,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.938125+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_286361","record_id":"REC_0004418","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":9.8,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":1,"smoking_pack_years":50,"primary_tumor_size_cm":4.7,"metastatic_sites_count":3,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.938351+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_743710","record_id":"REC_0004419","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":16,"tmb_mutations_per_mb":8.6,"age_at_diagnosis":54,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":4.3,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.938582+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_332666","record_id":"REC_0004420","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":79,"sex":"male","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":5.5,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.938816+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_757260","record_id":"REC_0004421","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":9.1,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":5.7,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.939102+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_241558","record_id":"REC_0004422","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":4.6,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":66,"primary_tumor_size_cm":7.4,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.939336+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_429297","record_id":"REC_0004423","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":17.6,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":5.5,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":28.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.939582+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_787364","record_id":"REC_0004424","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":6.0,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.939825+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_577141","record_id":"REC_0004425","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":32,"tmb_mutations_per_mb":17.4,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":6.2,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.940167+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_703402","record_id":"REC_0004426","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":5.1,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":0,"smoking_pack_years":67,"primary_tumor_size_cm":4.5,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":22.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.940440+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_957823","record_id":"REC_0004427","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":4.1,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.940698+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_960106","record_id":"REC_0004428","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":6.6,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.940939+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_372774","record_id":"REC_0004429","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":13.6,"age_at_diagnosis":85,"sex":"female","ecog_performance_status":3,"smoking_pack_years":8,"primary_tumor_size_cm":8.2,"metastatic_sites_count":3,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.941188+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_939321","record_id":"REC_0004430","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":18,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":51,"primary_tumor_size_cm":7.5,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":36.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.941438+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_161385","record_id":"REC_0004431","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":13.6,"age_at_diagnosis":79,"sex":"male","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":7.3,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.941697+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_896930","record_id":"REC_0004432","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":56,"primary_tumor_size_cm":6.0,"metastatic_sites_count":3,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.941947+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_508870","record_id":"REC_0004433","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":18.8,"age_at_diagnosis":79,"sex":"male","ecog_performance_status":1,"smoking_pack_years":26,"primary_tumor_size_cm":6.6,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.942190+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_262529","record_id":"REC_0004434","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":30,"primary_tumor_size_cm":5.6,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":24.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.942562+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_290247","record_id":"REC_0004435","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":15,"tmb_mutations_per_mb":13.1,"age_at_diagnosis":51,"sex":"male","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":5.6,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.942809+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_386998","record_id":"REC_0004436","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":83,"sex":"female","ecog_performance_status":2,"smoking_pack_years":22,"primary_tumor_size_cm":4.0,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":21.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.943049+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_285213","record_id":"REC_0004437","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":0,"smoking_pack_years":4,"primary_tumor_size_cm":5.3,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.943282+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_542172","record_id":"REC_0004438","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":33,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":0,"smoking_pack_years":72,"primary_tumor_size_cm":3.0,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.943515+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_635691","record_id":"REC_0004439","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":14.6,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":6.5,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.943754+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_349707","record_id":"REC_0004440","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":10,"primary_tumor_size_cm":4.5,"metastatic_sites_count":10,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.943984+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_976273","record_id":"REC_0004441","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":15,"tmb_mutations_per_mb":13.8,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":7.6,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.944372+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_931755","record_id":"REC_0004442","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":31,"tmb_mutations_per_mb":14.5,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":21,"primary_tumor_size_cm":5.5,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.944615+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_779580","record_id":"REC_0004443","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":14,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":6.6,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":28.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.944857+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_252799","record_id":"REC_0004444","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":6.3,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":4.7,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.945093+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_481977","record_id":"REC_0004445","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":17,"tmb_mutations_per_mb":3.7,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":3,"smoking_pack_years":47,"primary_tumor_size_cm":5.8,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":26.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.945336+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_397769","record_id":"REC_0004446","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":11.0,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":6.7,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.945574+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_353673","record_id":"REC_0004447","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":9.1,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":4.2,"metastatic_sites_count":8,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.945892+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_850729","record_id":"REC_0004448","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":30,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":0,"smoking_pack_years":30,"primary_tumor_size_cm":6.4,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.946133+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_601638","record_id":"REC_0004449","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":15,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":6.2,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":8.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.946368+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_727839","record_id":"REC_0004450","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":6.2,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.946599+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_598993","record_id":"REC_0004451","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":3.4,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":4.3,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.946828+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_805811","record_id":"REC_0004452","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":3.7,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.947065+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_614473","record_id":"REC_0004453","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":3.9,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.947297+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_456959","record_id":"REC_0004454","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":3.3,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.947531+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_864584","record_id":"REC_0004455","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":6.3,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":35.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.947765+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_739906","record_id":"REC_0004456","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":7.9,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":4.0,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":27.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.947996+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_743324","record_id":"REC_0004457","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":32,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":64,"primary_tumor_size_cm":5.8,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":22.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.948270+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_875104","record_id":"REC_0004458","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":1,"smoking_pack_years":0,"primary_tumor_size_cm":7.6,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.948511+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_954187","record_id":"REC_0004459","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":22.9,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":5.8,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":45.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.948753+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_827183","record_id":"REC_0004460","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":41,"primary_tumor_size_cm":4.4,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":6.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.949035+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_478246","record_id":"REC_0004461","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":19,"tmb_mutations_per_mb":7.9,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":2.0,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":25.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.949274+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_414139","record_id":"REC_0004462","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":3.5,"age_at_diagnosis":83,"sex":"female","ecog_performance_status":2,"smoking_pack_years":36,"primary_tumor_size_cm":5.7,"metastatic_sites_count":8,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.949508+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_304286","record_id":"REC_0004463","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":10.0,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":3,"smoking_pack_years":22,"primary_tumor_size_cm":5.9,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":17.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.949744+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_305907","record_id":"REC_0004464","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":86,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":6.0,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":21.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.949978+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_929849","record_id":"REC_0004465","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":10.5,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":7.0,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.950208+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_945202","record_id":"REC_0004466","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":5.2,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":3,"smoking_pack_years":8,"primary_tumor_size_cm":7.5,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.950432+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_103989","record_id":"REC_0004467","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":7.9,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":8.7,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.950659+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_666486","record_id":"REC_0004468","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":20.9,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":4.4,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":18.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.950894+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_742835","record_id":"REC_0004469","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":4.5,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":8.1,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.951122+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_533592","record_id":"REC_0004470","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":14.0,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":7.4,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.951357+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_467281","record_id":"REC_0004471","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":16,"tmb_mutations_per_mb":8.7,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":5.5,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":16.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.951588+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_711778","record_id":"REC_0004472","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":3.6,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":2,"smoking_pack_years":8,"primary_tumor_size_cm":7.0,"metastatic_sites_count":3,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.951821+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_637373","record_id":"REC_0004473","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":8,"primary_tumor_size_cm":6.5,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.952168+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_541651","record_id":"REC_0004474","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":5.3,"age_at_diagnosis":82,"sex":"male","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":5.0,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.952414+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_432084","record_id":"REC_0004475","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":31,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":5.2,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.952662+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_805342","record_id":"REC_0004476","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":4.3,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":51,"primary_tumor_size_cm":4.9,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.952892+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_115057","record_id":"REC_0004477","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":16,"tmb_mutations_per_mb":17.2,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":7.5,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.953128+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_996033","record_id":"REC_0004478","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":6.9,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":24.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.953362+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_838146","record_id":"REC_0004479","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":19,"tmb_mutations_per_mb":5.9,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":0,"smoking_pack_years":47,"primary_tumor_size_cm":5.7,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":4.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.953593+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_580629","record_id":"REC_0004480","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":10.1,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":5.5,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.953827+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_580431","record_id":"REC_0004481","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":4.2,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.0,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.954054+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_695185","record_id":"REC_0004482","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":5.5,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":23.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.954287+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_302343","record_id":"REC_0004483","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None","pd_l1_tps_percent":19,"tmb_mutations_per_mb":8.6,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":6.5,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":51.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.954514+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_366765","record_id":"REC_0004484","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":14.0,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":0,"smoking_pack_years":4,"primary_tumor_size_cm":5.8,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.954751+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_153962","record_id":"REC_0004485","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.1,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":39.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.954983+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_386863","record_id":"REC_0004486","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":4.9,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.955269+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_684991","record_id":"REC_0004487","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":31,"tmb_mutations_per_mb":3.7,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":0,"smoking_pack_years":84,"primary_tumor_size_cm":5.4,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.955509+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_494188","record_id":"REC_0004488","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":3.7,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":49,"primary_tumor_size_cm":5.9,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.955742+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_748560","record_id":"REC_0004489","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":32,"tmb_mutations_per_mb":9.5,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":5.1,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.955975+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_249048","record_id":"REC_0004490","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":29,"primary_tumor_size_cm":5.0,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":26.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.956318+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_978890","record_id":"REC_0004491","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":3,"smoking_pack_years":14,"primary_tumor_size_cm":5.8,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.956559+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_397428","record_id":"REC_0004492","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":15.9,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":1,"smoking_pack_years":0,"primary_tumor_size_cm":4.2,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.956799+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_232072","record_id":"REC_0004493","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":11.5,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":2.2,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.957036+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_522445","record_id":"REC_0004494","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":6.3,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":38,"primary_tumor_size_cm":5.0,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.957269+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_347239","record_id":"REC_0004495","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":5.2,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":22.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.957508+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_789274","record_id":"REC_0004496","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":16.2,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":6.1,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":6.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.957745+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_249833","record_id":"REC_0004497","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":8.4,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":25,"primary_tumor_size_cm":5.9,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":26.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.957977+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_584290","record_id":"REC_0004498","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":7.6,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":66,"primary_tumor_size_cm":3.9,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":18.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.958209+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_197170","record_id":"REC_0004499","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":13.3,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":4.7,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.958500+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_207829","record_id":"REC_0004500","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ALK fusion","pd_l1_tps_percent":37,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":4.3,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":19.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.958740+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_574177","record_id":"REC_0004501","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":20,"tmb_mutations_per_mb":5.5,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":0,"smoking_pack_years":34,"primary_tumor_size_cm":2.6,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.958972+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_827890","record_id":"REC_0004502","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":7,"primary_tumor_size_cm":4.9,"metastatic_sites_count":8,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.959201+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_257297","record_id":"REC_0004503","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":4.5,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.959437+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_438958","record_id":"REC_0004504","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":19.1,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":5.5,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.959679+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_902079","record_id":"REC_0004505","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":15.5,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":8.2,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":23.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.959916+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_521163","record_id":"REC_0004506","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":31,"tmb_mutations_per_mb":6.4,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":69,"primary_tumor_size_cm":4.9,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.960223+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_413027","record_id":"REC_0004507","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":15.4,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":6.5,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":22.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.960481+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_686142","record_id":"REC_0004508","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":0,"smoking_pack_years":5,"primary_tumor_size_cm":5.6,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.960748+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_801898","record_id":"REC_0004509","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":17,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":4.1,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.960992+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_152765","record_id":"REC_0004510","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":31,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":52,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":6.5,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.961232+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_387098","record_id":"REC_0004511","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":11.0,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":6.7,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.961487+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_990563","record_id":"REC_0004512","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":11.0,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":5.9,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.961881+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_436403","record_id":"REC_0004513","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":3.8,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.962150+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_962248","record_id":"REC_0004514","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":2.9,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":3,"smoking_pack_years":44,"primary_tumor_size_cm":6.2,"metastatic_sites_count":9,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.962388+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_859986","record_id":"REC_0004515","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":6.0,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.962638+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_355192","record_id":"REC_0004516","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":30,"tmb_mutations_per_mb":9.0,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":67,"primary_tumor_size_cm":4.8,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":17.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.962878+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_419402","record_id":"REC_0004517","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":17.1,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":7.7,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.963120+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_904839","record_id":"REC_0004518","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":8.3,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":6.7,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.963356+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_974928","record_id":"REC_0004519","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":15.0,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":7.6,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":31.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.963594+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_226068","record_id":"REC_0004520","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":11.5,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":5.7,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":5.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.963834+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_917186","record_id":"REC_0004521","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":8.3,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":6.3,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.964146+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_473845","record_id":"REC_0004522","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":4.8,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.964400+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_511429","record_id":"REC_0004523","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":13.1,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":6.2,"metastatic_sites_count":3,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.964640+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_853847","record_id":"REC_0004524","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":4.4,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.964874+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_358760","record_id":"REC_0004525","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":14.7,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":5.5,"metastatic_sites_count":3,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":19.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.965203+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_607441","record_id":"REC_0004526","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":88,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":4.5,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":22.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.965437+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_254620","record_id":"REC_0004527","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":8.3,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":0,"smoking_pack_years":71,"primary_tumor_size_cm":6.3,"metastatic_sites_count":3,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.965676+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_270819","record_id":"REC_0004528","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":0,"primary_tumor_size_cm":5.2,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.965908+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_737157","record_id":"REC_0004529","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":4,"primary_tumor_size_cm":6.2,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.966150+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_409418","record_id":"REC_0004530","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":8.3,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.6,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.966377+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_446430","record_id":"REC_0004531","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":9.8,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":2.6,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.966605+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_350396","record_id":"REC_0004532","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":5.9,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.966841+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_234237","record_id":"REC_0004533","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":30,"tmb_mutations_per_mb":5.1,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":67,"primary_tumor_size_cm":4.9,"metastatic_sites_count":8,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":18.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.967074+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_915039","record_id":"REC_0004534","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":3.6,"metastatic_sites_count":3,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":7.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.967311+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_648751","record_id":"REC_0004535","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":7.3,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.967545+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_473871","record_id":"REC_0004536","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":8.1,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":6.3,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":17.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.967781+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_107328","record_id":"REC_0004537","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":7.9,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":6.3,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.968012+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_212925","record_id":"REC_0004538","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":13.1,"age_at_diagnosis":74,"sex":"male","ecog_performance_status":3,"smoking_pack_years":20,"primary_tumor_size_cm":3.4,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.968355+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_580560","record_id":"REC_0004539","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":15,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":4.4,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.968601+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_884412","record_id":"REC_0004540","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":5.1,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.968843+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_977385","record_id":"REC_0004541","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":5.5,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":3,"smoking_pack_years":14,"primary_tumor_size_cm":8.8,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":28.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.969073+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_729158","record_id":"REC_0004542","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":1,"smoking_pack_years":59,"primary_tumor_size_cm":6.3,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.969309+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_488669","record_id":"REC_0004543","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":0,"smoking_pack_years":29,"primary_tumor_size_cm":6.1,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":18.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.969542+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_622797","record_id":"REC_0004544","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":4.5,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":32,"primary_tumor_size_cm":6.4,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.969772+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_776251","record_id":"REC_0004545","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":79,"sex":"male","ecog_performance_status":2,"smoking_pack_years":22,"primary_tumor_size_cm":5.6,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":27.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.970009+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_791639","record_id":"REC_0004546","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":26,"primary_tumor_size_cm":9.0,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":32.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.970245+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_224408","record_id":"REC_0004547","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":5.7,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":23.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.970475+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_239070","record_id":"REC_0004548","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":5.7,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":6.0,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":24.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.970708+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_747808","record_id":"REC_0004549","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":17,"tmb_mutations_per_mb":8.7,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":4.8,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.970936+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_771633","record_id":"REC_0004550","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":5.7,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.971167+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_824248","record_id":"REC_0004551","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":6.4,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":26.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.971457+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_603435","record_id":"REC_0004552","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":14.6,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":4.8,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.971701+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_785052","record_id":"REC_0004553","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":3.5,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":28,"primary_tumor_size_cm":4.8,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":33.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.971939+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_963921","record_id":"REC_0004554","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":2.6,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":23.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.972231+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_144835","record_id":"REC_0004555","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":20,"tmb_mutations_per_mb":4.7,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":50,"primary_tumor_size_cm":4.5,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":17.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.972471+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_749210","record_id":"REC_0004556","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":24,"primary_tumor_size_cm":6.2,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.972713+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_423049","record_id":"REC_0004557","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":7.4,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.972951+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_829013","record_id":"REC_0004558","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":4.7,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":6.3,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.973184+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_375457","record_id":"REC_0004559","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":5.3,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":6.3,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.973412+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_299508","record_id":"REC_0004560","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":6.3,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":63,"primary_tumor_size_cm":6.5,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.973644+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_267335","record_id":"REC_0004561","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":8.6,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":5.9,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.973879+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_686870","record_id":"REC_0004562","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":5.0,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":16.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.974110+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_446341","record_id":"REC_0004563","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":13.8,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":5.3,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.974338+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_985223","record_id":"REC_0004564","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":10.1,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.7,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":20.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.974627+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_644481","record_id":"REC_0004565","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":8.4,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":7.5,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":21.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.974866+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_128218","record_id":"REC_0004566","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":0,"primary_tumor_size_cm":4.8,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":5.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.975101+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_458067","record_id":"REC_0004567","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":34,"tmb_mutations_per_mb":5.6,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":7.7,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.975329+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_831805","record_id":"REC_0004568","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":4.7,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":29.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.975557+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_186634","record_id":"REC_0004569","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":8.5,"age_at_diagnosis":86,"sex":"female","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":6.6,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.975784+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_114960","record_id":"REC_0004570","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":15.1,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":6.7,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.976018+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_140960","record_id":"REC_0004571","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":49,"primary_tumor_size_cm":7.2,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":7.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.976459+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_376673","record_id":"REC_0004572","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":16.2,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":4.2,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.976724+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_462392","record_id":"REC_0004573","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":7.4,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.9,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.976962+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_838924","record_id":"REC_0004574","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":32,"primary_tumor_size_cm":5.4,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.977194+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_772804","record_id":"REC_0004575","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":1,"smoking_pack_years":4,"primary_tumor_size_cm":6.8,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":35.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.977431+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_354893","record_id":"REC_0004576","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":17.4,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":5.0,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":16.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.977664+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_320654","record_id":"REC_0004577","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":32,"primary_tumor_size_cm":5.4,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.977980+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_561233","record_id":"REC_0004578","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":16.8,"age_at_diagnosis":85,"sex":"male","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":6.0,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":18.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.978218+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_427086","record_id":"REC_0004579","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":5.2,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":36.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.978452+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_741796","record_id":"REC_0004580","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":4,"primary_tumor_size_cm":3.7,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.978689+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_736086","record_id":"REC_0004581","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":4.0,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.978923+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_823897","record_id":"REC_0004582","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":15,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":4.7,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.979157+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_178691","record_id":"REC_0004583","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":6.7,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.979389+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_189507","record_id":"REC_0004584","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":4.7,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.979628+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_513506","record_id":"REC_0004585","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":4.6,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.979874+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_244388","record_id":"REC_0004586","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":31,"tmb_mutations_per_mb":15.3,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":29,"primary_tumor_size_cm":5.2,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.980191+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_218491","record_id":"REC_0004587","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":17,"tmb_mutations_per_mb":9.0,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":5.2,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.980448+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_388580","record_id":"REC_0004588","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":14.9,"age_at_diagnosis":86,"sex":"female","ecog_performance_status":0,"smoking_pack_years":4,"primary_tumor_size_cm":5.5,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":6.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.980696+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_839704","record_id":"REC_0004589","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":16.8,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":4.7,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.980946+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_938712","record_id":"REC_0004590","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":13.3,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":7.6,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.981285+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_501298","record_id":"REC_0004591","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":11.5,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":4.3,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.981531+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_634788","record_id":"REC_0004592","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":14.4,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":7.0,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.981780+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_117532","record_id":"REC_0004593","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":16.5,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":24,"primary_tumor_size_cm":4.0,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":22.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.982033+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_922421","record_id":"REC_0004594","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":35,"tmb_mutations_per_mb":14.3,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":5.3,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.982287+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_786154","record_id":"REC_0004595","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":77,"sex":"male","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":4.4,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":21.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.982545+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_106546","record_id":"REC_0004596","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":9.8,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":6.6,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":20.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.982782+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_893913","record_id":"REC_0004597","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":4.8,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":1,"smoking_pack_years":46,"primary_tumor_size_cm":5.0,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":21.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.983021+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_136421","record_id":"REC_0004598","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":20.2,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":6.4,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.983260+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_216380","record_id":"REC_0004599","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":10.3,"age_at_diagnosis":49,"sex":"male","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":4.5,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.983497+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_165569","record_id":"REC_0004600","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":13.6,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":5.2,"metastatic_sites_count":3,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.983734+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_757651","record_id":"REC_0004601","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":10.1,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":4.6,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":39.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.983976+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_435420","record_id":"REC_0004602","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":5.5,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":4.4,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.984264+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_124689","record_id":"REC_0004603","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":0,"primary_tumor_size_cm":3.0,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.984641+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_580921","record_id":"REC_0004604","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":14.5,"age_at_diagnosis":50,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":7.7,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":28.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.984883+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_928205","record_id":"REC_0004605","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":30,"tmb_mutations_per_mb":2.7,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":7.0,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":5.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.985117+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_732835","record_id":"REC_0004606","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":9.0,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":6.5,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.985351+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_898839","record_id":"REC_0004607","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":13.3,"age_at_diagnosis":52,"sex":"male","ecog_performance_status":0,"smoking_pack_years":30,"primary_tumor_size_cm":4.6,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.985588+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_954276","record_id":"REC_0004608","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":8.4,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":5.3,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":4.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.985816+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_306238","record_id":"REC_0004609","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":30,"tmb_mutations_per_mb":3.6,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":50,"primary_tumor_size_cm":5.8,"metastatic_sites_count":8,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.986050+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_732222","record_id":"REC_0004610","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":5.6,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":4.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.986285+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_332848","record_id":"REC_0004611","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":8.9,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":6.2,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":20.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.986517+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_879138","record_id":"REC_0004612","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":5.3,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.986752+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_729322","record_id":"REC_0004613","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":3.4,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":8.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.986986+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_511561","record_id":"REC_0004614","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":10.5,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":9,"primary_tumor_size_cm":5.6,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":27.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.987216+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_489519","record_id":"REC_0004615","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":17.2,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":5,"primary_tumor_size_cm":6.9,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.987452+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_675367","record_id":"REC_0004616","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":15.7,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":3.0,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.987735+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_449150","record_id":"REC_0004617","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":13.3,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":2.0,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":17.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.987970+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_748467","record_id":"REC_0004618","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":54,"sex":"male","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":2.8,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":26.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.988260+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_818449","record_id":"REC_0004619","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":13.3,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":0,"primary_tumor_size_cm":4.7,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.988513+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_162812","record_id":"REC_0004620","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":16.4,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":24,"primary_tumor_size_cm":5.0,"metastatic_sites_count":8,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":18.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.988748+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_796410","record_id":"REC_0004621","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":23,"primary_tumor_size_cm":5.2,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.988977+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_664697","record_id":"REC_0004622","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":13.1,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":6.0,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":5.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.989212+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_832733","record_id":"REC_0004623","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":5.9,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":75,"primary_tumor_size_cm":6.3,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.989442+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_465010","record_id":"REC_0004624","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":5.8,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.989675+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_499082","record_id":"REC_0004625","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":14.5,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":4.6,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":4.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.989913+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_632421","record_id":"REC_0004626","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":20,"tmb_mutations_per_mb":4.2,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":4.2,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.990143+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_376294","record_id":"REC_0004627","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":13.5,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":5.8,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.990375+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_591117","record_id":"REC_0004628","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":6.1,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":22.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.990608+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_768939","record_id":"REC_0004629","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":7.3,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":30,"primary_tumor_size_cm":6.7,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":18.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.990891+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_229674","record_id":"REC_0004630","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":9.1,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":4.1,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":6.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.991127+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_476552","record_id":"REC_0004631","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":30,"tmb_mutations_per_mb":19.8,"age_at_diagnosis":53,"sex":"female","ecog_performance_status":0,"smoking_pack_years":2,"primary_tumor_size_cm":6.7,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.991363+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_357511","record_id":"REC_0004632","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":17.3,"age_at_diagnosis":85,"sex":"female","ecog_performance_status":2,"smoking_pack_years":9,"primary_tumor_size_cm":5.0,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":7.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.991594+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_244028","record_id":"REC_0004633","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":13.5,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":5.6,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":6.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.991828+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_389146","record_id":"REC_0004634","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":17.8,"age_at_diagnosis":54,"sex":"male","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":5.0,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.992062+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_614750","record_id":"REC_0004635","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":7.1,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.992345+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_240707","record_id":"REC_0004636","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":7.1,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.992581+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_519908","record_id":"REC_0004637","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":3.3,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":6.0,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.992815+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_219591","record_id":"REC_0004638","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":29,"primary_tumor_size_cm":6.3,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.993044+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_587067","record_id":"REC_0004639","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":4.5,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":33,"primary_tumor_size_cm":7.8,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.993278+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_525918","record_id":"REC_0004640","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":4.7,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":6.2,"metastatic_sites_count":8,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":5.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.993507+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_323110","record_id":"REC_0004641","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":15,"tmb_mutations_per_mb":10.0,"age_at_diagnosis":87,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":2.9,"metastatic_sites_count":8,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.993740+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_503523","record_id":"REC_0004642","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":77,"sex":"male","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":3.5,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.994027+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_349977","record_id":"REC_0004643","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":6.3,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":5.0,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.994259+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_422593","record_id":"REC_0004644","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":9.7,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.7,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.994489+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_573739","record_id":"REC_0004645","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":6.2,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":19.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.994722+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_942630","record_id":"REC_0004646","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":16.2,"age_at_diagnosis":83,"sex":"male","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":5.2,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":23.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.994958+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_753427","record_id":"REC_0004647","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":14.5,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":7.1,"metastatic_sites_count":3,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":5.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.995194+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_165581","record_id":"REC_0004648","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":5.4,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":50.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.995428+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_823603","record_id":"REC_0004649","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":31,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":5.9,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.995672+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_248150","record_id":"REC_0004650","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":20,"tmb_mutations_per_mb":4.2,"age_at_diagnosis":52,"sex":"female","ecog_performance_status":0,"smoking_pack_years":40,"primary_tumor_size_cm":6.0,"metastatic_sites_count":9,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":5.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.995912+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_413833","record_id":"REC_0004651","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":3.6,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":16.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.996238+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_690944","record_id":"REC_0004652","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":16.2,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":5.0,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.996480+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_558472","record_id":"REC_0004653","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":15.0,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":1,"primary_tumor_size_cm":5.6,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.996720+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_655481","record_id":"REC_0004654","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":16.2,"age_at_diagnosis":50,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":5.7,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.996953+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_685045","record_id":"REC_0004655","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":6.1,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":5.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.997248+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_765738","record_id":"REC_0004656","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.9,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.997484+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_681033","record_id":"REC_0004657","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":5.6,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":5.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.997719+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_122204","record_id":"REC_0004658","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":14,"tmb_mutations_per_mb":6.4,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":4.0,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.997948+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_503261","record_id":"REC_0004659","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":5.6,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.998180+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_369461","record_id":"REC_0004660","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":9.8,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":6.2,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.998406+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_422877","record_id":"REC_0004661","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":31,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":5.5,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.998640+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_846440","record_id":"REC_0004662","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":13.3,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":2,"primary_tumor_size_cm":4.2,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.998870+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_106414","record_id":"REC_0004663","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":15.2,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":5.4,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.999110+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_730468","record_id":"REC_0004664","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":4.8,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:57.999351+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_742590","record_id":"REC_0004665","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":28,"primary_tumor_size_cm":7.7,"metastatic_sites_count":9,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.999581+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_639987","record_id":"REC_0004666","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":19,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":5.4,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:57.999810+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_843508","record_id":"REC_0004667","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":10.5,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":7.5,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":18.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.000052+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_184560","record_id":"REC_0004668","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":21,"primary_tumor_size_cm":7.9,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.000439+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_961500","record_id":"REC_0004669","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.0,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":8.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.000703+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_673726","record_id":"REC_0004670","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":9.8,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":6.4,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":18.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.000945+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_739930","record_id":"REC_0004671","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":7.4,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":20.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.001197+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_854236","record_id":"REC_0004672","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":54,"sex":"male","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":6.0,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.001458+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_554223","record_id":"REC_0004673","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":19.3,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":3.6,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.001714+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_659359","record_id":"REC_0004674","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":16,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":5,"primary_tumor_size_cm":6.3,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.001952+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_606516","record_id":"REC_0004675","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":1,"smoking_pack_years":27,"primary_tumor_size_cm":5.4,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.002198+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_452739","record_id":"REC_0004676","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":2.9,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.002438+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_548078","record_id":"REC_0004677","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":8.1,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":5.8,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.002674+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_358780","record_id":"REC_0004678","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":42,"primary_tumor_size_cm":7.1,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":30.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.002905+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_324869","record_id":"REC_0004679","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":3.9,"metastatic_sites_count":3,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.003140+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_572116","record_id":"REC_0004680","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":10.1,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":5.9,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.003371+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_560891","record_id":"REC_0004681","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":6.9,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.003718+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_895290","record_id":"REC_0004682","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":61,"primary_tumor_size_cm":4.2,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.003966+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_865893","record_id":"REC_0004683","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":16.2,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":5.9,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.004283+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_401324","record_id":"REC_0004684","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":3.4,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":56,"primary_tumor_size_cm":4.6,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.004526+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_554919","record_id":"REC_0004685","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":30,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":6.1,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.004774+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_796742","record_id":"REC_0004686","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":17.6,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":6.5,"metastatic_sites_count":3,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":22.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.005012+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_921655","record_id":"REC_0004687","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":6.7,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":6,"primary_tumor_size_cm":4.6,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.005245+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_419923","record_id":"REC_0004688","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":16,"tmb_mutations_per_mb":15.7,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":25,"primary_tumor_size_cm":4.0,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":21.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.005479+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_915051","record_id":"REC_0004689","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":4.8,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":8.2,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.005713+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_484450","record_id":"REC_0004690","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":19,"tmb_mutations_per_mb":3.8,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":0,"smoking_pack_years":46,"primary_tumor_size_cm":6.5,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.005947+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_162326","record_id":"REC_0004691","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":14.8,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":21,"primary_tumor_size_cm":6.4,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":52.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.006183+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_593813","record_id":"REC_0004692","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":9.5,"age_at_diagnosis":75,"sex":"male","ecog_performance_status":3,"smoking_pack_years":21,"primary_tumor_size_cm":6.9,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.006430+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_986427","record_id":"REC_0004693","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":9.5,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":3.8,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.006670+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_512526","record_id":"REC_0004694","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":14.1,"age_at_diagnosis":87,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":5.9,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":26.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.007030+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_331498","record_id":"REC_0004695","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":4.3,"age_at_diagnosis":74,"sex":"male","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":5.1,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.007295+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_843302","record_id":"REC_0004696","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":4.0,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":4.7,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.007549+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_648487","record_id":"REC_0004697","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":6.7,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":6.1,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.007801+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_880815","record_id":"REC_0004698","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":30,"tmb_mutations_per_mb":4.8,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":56,"primary_tumor_size_cm":5.6,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.008050+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_787313","record_id":"REC_0004699","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":14.0,"age_at_diagnosis":79,"sex":"male","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":6.0,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":34.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.008360+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_278660","record_id":"REC_0004700","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":6.3,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":21.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.008603+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_296777","record_id":"REC_0004701","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":15.0,"age_at_diagnosis":86,"sex":"female","ecog_performance_status":2,"smoking_pack_years":20,"primary_tumor_size_cm":5.3,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.008842+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_520928","record_id":"REC_0004702","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":82,"sex":"male","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":6.4,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.009075+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_135910","record_id":"REC_0004703","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":83,"sex":"female","ecog_performance_status":2,"smoking_pack_years":44,"primary_tumor_size_cm":5.4,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.009308+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_372106","record_id":"REC_0004704","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":14.5,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":4.0,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.009542+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_407200","record_id":"REC_0004705","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":3.8,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.009777+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_622195","record_id":"REC_0004706","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":20,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":6.4,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.010008+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_174107","record_id":"REC_0004707","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":5.0,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":4.6,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.010348+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_141624","record_id":"REC_0004708","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":6.2,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.010585+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_164932","record_id":"REC_0004709","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":5.6,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":4.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.010819+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_542061","record_id":"REC_0004710","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":19.6,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":3,"smoking_pack_years":18,"primary_tumor_size_cm":6.9,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":19.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.011053+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_882467","record_id":"REC_0004711","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":4.0,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":42,"primary_tumor_size_cm":8.0,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":21.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.011288+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_871952","record_id":"REC_0004712","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":3.1,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":1,"smoking_pack_years":28,"primary_tumor_size_cm":5.4,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":23.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.011522+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_844706","record_id":"REC_0004713","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":25,"primary_tumor_size_cm":5.7,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.011753+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_787657","record_id":"REC_0004714","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":52,"sex":"male","ecog_performance_status":0,"smoking_pack_years":25,"primary_tumor_size_cm":8.1,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.011987+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_569496","record_id":"REC_0004715","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":4.6,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.012280+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_774842","record_id":"REC_0004716","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":15.5,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":2,"smoking_pack_years":10,"primary_tumor_size_cm":3.0,"metastatic_sites_count":3,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.012537+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_834881","record_id":"REC_0004717","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":5.7,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":1,"smoking_pack_years":28,"primary_tumor_size_cm":4.3,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":20.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.012792+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_717228","record_id":"REC_0004718","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":7.2,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":20.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.013033+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_183931","record_id":"REC_0004719","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":27,"primary_tumor_size_cm":5.5,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.013270+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_633370","record_id":"REC_0004720","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":19,"tmb_mutations_per_mb":9.7,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":70,"primary_tumor_size_cm":4.2,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":17.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.013615+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_138020","record_id":"REC_0004721","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":14.1,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":6.2,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.013878+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_989090","record_id":"REC_0004722","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":16.6,"age_at_diagnosis":54,"sex":"male","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":5.6,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.014128+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_785699","record_id":"REC_0004723","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":10,"primary_tumor_size_cm":5.7,"metastatic_sites_count":3,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":7.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.014366+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_683248","record_id":"REC_0004724","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":8.4,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":7.0,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":20.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.014603+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_373331","record_id":"REC_0004725","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":14.7,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":6.2,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.014836+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_725527","record_id":"REC_0004726","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":18.9,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":5.4,"metastatic_sites_count":8,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.015075+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_440492","record_id":"REC_0004727","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":5.7,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":35,"primary_tumor_size_cm":5.1,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":17.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.015308+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_597219","record_id":"REC_0004728","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":13.5,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":4,"primary_tumor_size_cm":6.1,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.015544+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_546481","record_id":"REC_0004729","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":33,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":53,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":6.7,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.015785+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_412230","record_id":"REC_0004730","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":15.6,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":3.8,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.016028+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_127984","record_id":"REC_0004731","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":6.4,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":53,"primary_tumor_size_cm":5.2,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":26.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.016383+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_849560","record_id":"REC_0004732","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":4.7,"age_at_diagnosis":84,"sex":"female","ecog_performance_status":2,"smoking_pack_years":62,"primary_tumor_size_cm":4.0,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.016655+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_229559","record_id":"REC_0004733","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":16,"tmb_mutations_per_mb":3.9,"age_at_diagnosis":76,"sex":"male","ecog_performance_status":1,"smoking_pack_years":30,"primary_tumor_size_cm":4.8,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.017089+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_896673","record_id":"REC_0004734","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":11.5,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":5.2,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":26.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.017430+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_550940","record_id":"REC_0004735","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":0,"smoking_pack_years":6,"primary_tumor_size_cm":2.6,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.017690+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_403111","record_id":"REC_0004736","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":5,"primary_tumor_size_cm":6.4,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.017934+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_172252","record_id":"REC_0004737","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":7.3,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":7.7,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.018182+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_185406","record_id":"REC_0004738","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":8.1,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":0,"smoking_pack_years":25,"primary_tumor_size_cm":3.0,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":7.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.018435+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_356483","record_id":"REC_0004739","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":83,"sex":"female","ecog_performance_status":2,"smoking_pack_years":10,"primary_tumor_size_cm":7.0,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":18.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.018683+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_607904","record_id":"REC_0004740","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":54,"sex":"male","ecog_performance_status":0,"smoking_pack_years":6,"primary_tumor_size_cm":5.1,"metastatic_sites_count":3,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.018928+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_462439","record_id":"REC_0004741","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":39,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":88,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":7.6,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.019174+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_270106","record_id":"REC_0004742","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":14.5,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":6.0,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":8.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.019418+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_945154","record_id":"REC_0004743","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":3.2,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":0,"smoking_pack_years":27,"primary_tumor_size_cm":5.1,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":21.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.019666+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_383888","record_id":"REC_0004744","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":4.3,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":6.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.019924+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_954141","record_id":"REC_0004745","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":4.2,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":1,"smoking_pack_years":49,"primary_tumor_size_cm":4.8,"metastatic_sites_count":8,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.020215+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_923948","record_id":"REC_0004746","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":13.8,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":6.8,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":33.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.020612+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_204456","record_id":"REC_0004747","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":3,"smoking_pack_years":0,"primary_tumor_size_cm":6.6,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":23.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.020867+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_907543","record_id":"REC_0004748","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":15.8,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":29,"primary_tumor_size_cm":5.9,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.021107+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_975795","record_id":"REC_0004749","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":1,"smoking_pack_years":4,"primary_tumor_size_cm":6.0,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.021346+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_472481","record_id":"REC_0004750","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":7.4,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":5,"primary_tumor_size_cm":6.4,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.021581+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_529416","record_id":"REC_0004751","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":16.0,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":23,"primary_tumor_size_cm":7.8,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":18.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.021812+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_560450","record_id":"REC_0004752","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":51,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":3.4,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.022046+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_892322","record_id":"REC_0004753","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None","pd_l1_tps_percent":20,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":40,"primary_tumor_size_cm":3.7,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":38.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.022278+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_734275","record_id":"REC_0004754","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":15.3,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":5.2,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":42.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.022515+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_729388","record_id":"REC_0004755","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":20,"tmb_mutations_per_mb":3.9,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":2,"smoking_pack_years":42,"primary_tumor_size_cm":4.7,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.022744+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_855177","record_id":"REC_0004756","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":0,"smoking_pack_years":0,"primary_tumor_size_cm":5.2,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":20.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.022980+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_332238","record_id":"REC_0004757","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":18,"tmb_mutations_per_mb":4.9,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":73,"primary_tumor_size_cm":4.6,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.023208+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_247280","record_id":"REC_0004758","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":20.3,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":7.0,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.023439+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_618470","record_id":"REC_0004759","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":0,"smoking_pack_years":58,"primary_tumor_size_cm":6.8,"metastatic_sites_count":8,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.023721+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_711747","record_id":"REC_0004760","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":3.5,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.023960+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_438597","record_id":"REC_0004761","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":15.9,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":3.0,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":28.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.024252+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_518263","record_id":"REC_0004762","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":4.1,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":30.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.024511+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_698667","record_id":"REC_0004763","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":0,"smoking_pack_years":26,"primary_tumor_size_cm":4.6,"metastatic_sites_count":3,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.024750+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_475816","record_id":"REC_0004764","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":8.1,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":5.8,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.024986+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_170101","record_id":"REC_0004765","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":9.1,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":27,"primary_tumor_size_cm":5.1,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.025217+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_895953","record_id":"REC_0004766","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":30,"tmb_mutations_per_mb":15.2,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":23,"primary_tumor_size_cm":6.4,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.025451+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_316721","record_id":"REC_0004767","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":84,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":4.9,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.025693+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_308238","record_id":"REC_0004768","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":19,"tmb_mutations_per_mb":17.0,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":4.6,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":60.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.025930+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_552863","record_id":"REC_0004769","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":15.1,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":5.7,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":24.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.026167+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_169004","record_id":"REC_0004770","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":6.8,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.026399+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_483296","record_id":"REC_0004771","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":33,"tmb_mutations_per_mb":13.3,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":6.5,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.026635+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_561986","record_id":"REC_0004772","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":32,"primary_tumor_size_cm":6.6,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":16.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.026932+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_603275","record_id":"REC_0004773","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":15.2,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":6.0,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":8.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.027180+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_679898","record_id":"REC_0004774","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":83,"sex":"male","ecog_performance_status":2,"smoking_pack_years":25,"primary_tumor_size_cm":7.3,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.027419+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_805247","record_id":"REC_0004775","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":14.8,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":6.1,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.027655+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_491621","record_id":"REC_0004776","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.5,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":0,"primary_tumor_size_cm":4.6,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":5.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.027887+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_326955","record_id":"REC_0004777","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":9,"primary_tumor_size_cm":4.9,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.028176+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_471376","record_id":"REC_0004778","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":4.4,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":59,"primary_tumor_size_cm":6.0,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.028415+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_842555","record_id":"REC_0004779","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":6.1,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.028654+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_510577","record_id":"REC_0004780","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":15.3,"age_at_diagnosis":79,"sex":"male","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":6.3,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.028902+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_135168","record_id":"REC_0004781","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":4.6,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":5.5,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":6.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.029139+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_105354","record_id":"REC_0004782","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":6.3,"age_at_diagnosis":79,"sex":"male","ecog_performance_status":2,"smoking_pack_years":49,"primary_tumor_size_cm":4.9,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":6.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.029373+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_336928","record_id":"REC_0004783","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":49,"sex":"male","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":6.6,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.029612+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_228645","record_id":"REC_0004784","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":17.8,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":6.0,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":19.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.029847+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_144608","record_id":"REC_0004785","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":17.7,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":5.0,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.030170+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_689784","record_id":"REC_0004786","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":4.2,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":21.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.030412+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_465628","record_id":"REC_0004787","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":3.0,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":5.1,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":24.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.030648+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_343988","record_id":"REC_0004788","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":30,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":5.1,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.030890+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_806908","record_id":"REC_0004789","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":5.6,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":1,"primary_tumor_size_cm":3.6,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":25.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.031125+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_794109","record_id":"REC_0004790","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":7.6,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.031360+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_169572","record_id":"REC_0004791","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":4.8,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.031596+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_187934","record_id":"REC_0004792","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":7,"primary_tumor_size_cm":3.0,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":54.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.031830+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_724407","record_id":"REC_0004793","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":52,"primary_tumor_size_cm":5.7,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.032064+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_188962","record_id":"REC_0004794","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":10.3,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":5.0,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":22.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.032342+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_520382","record_id":"REC_0004795","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":5.1,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":4.9,"metastatic_sites_count":8,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.032575+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_720692","record_id":"REC_0004796","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":5.1,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.032810+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_323222","record_id":"REC_0004797","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":3.9,"metastatic_sites_count":8,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.033041+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_277028","record_id":"REC_0004798","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":14.8,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":3.3,"metastatic_sites_count":9,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.033335+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_435373","record_id":"REC_0004799","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":6.9,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.033570+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_750846","record_id":"REC_0004800","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":17.5,"age_at_diagnosis":51,"sex":"male","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":5.5,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.033808+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_420662","record_id":"REC_0004801","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":32,"tmb_mutations_per_mb":5.3,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":1,"smoking_pack_years":44,"primary_tumor_size_cm":6.0,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":7.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.034038+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_102151","record_id":"REC_0004802","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":16.2,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":4.6,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.034272+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_219406","record_id":"REC_0004803","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":16,"tmb_mutations_per_mb":6.4,"age_at_diagnosis":52,"sex":"male","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":5.9,"metastatic_sites_count":3,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.034502+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_623592","record_id":"REC_0004804","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":11,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":6.0,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":63.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.034736+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_455112","record_id":"REC_0004805","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":18.1,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":5.2,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.034975+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_779719","record_id":"REC_0004806","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":8.9,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":5.0,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.035203+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_345549","record_id":"REC_0004807","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":8.9,"age_at_diagnosis":80,"sex":"male","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":6.7,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.035436+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_337032","record_id":"REC_0004808","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":14.4,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":4.7,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":18.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.035672+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_242048","record_id":"REC_0004809","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":7.6,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":0,"smoking_pack_years":35,"primary_tumor_size_cm":3.7,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.035904+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_721387","record_id":"REC_0004810","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":7.4,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.036234+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_865250","record_id":"REC_0004811","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":6.7,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":42,"primary_tumor_size_cm":6.3,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":18.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.036537+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_319056","record_id":"REC_0004812","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":7.4,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":6.2,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":18.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.036784+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_577508","record_id":"REC_0004813","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":3.2,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.037021+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_762789","record_id":"REC_0004814","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":54,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":7.1,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":7.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.037253+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_161615","record_id":"REC_0004815","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":5,"primary_tumor_size_cm":6.0,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":48.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.037485+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_799363","record_id":"REC_0004816","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":3.1,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":59,"primary_tumor_size_cm":8.3,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.037718+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_464227","record_id":"REC_0004817","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":5.2,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":6.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.037959+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_511838","record_id":"REC_0004818","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":4.2,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.038199+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_617023","record_id":"REC_0004819","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":14.1,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":5.4,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.038435+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_760678","record_id":"REC_0004820","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":31,"primary_tumor_size_cm":6.8,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":23.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.038663+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_469521","record_id":"REC_0004821","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":4.9,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":21,"primary_tumor_size_cm":5.9,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.038898+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_337997","record_id":"REC_0004822","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":10.3,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":4,"primary_tumor_size_cm":5.9,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.039129+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_852695","record_id":"REC_0004823","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":15.2,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":6.5,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":4.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.039364+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_419009","record_id":"REC_0004824","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":19.8,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":6.1,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.039677+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_656615","record_id":"REC_0004825","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":7.4,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.039935+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_652344","record_id":"REC_0004826","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":3.8,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":49.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.040288+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_320086","record_id":"REC_0004827","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":7.5,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":21.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.040552+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_849370","record_id":"REC_0004828","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":16,"tmb_mutations_per_mb":5.6,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":44,"primary_tumor_size_cm":4.1,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.040798+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_271224","record_id":"REC_0004829","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":5.7,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":5.5,"metastatic_sites_count":8,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.041039+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_423223","record_id":"REC_0004830","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":10.0,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":6,"primary_tumor_size_cm":5.3,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":40.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.041275+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_520930","record_id":"REC_0004831","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":18.9,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":0,"smoking_pack_years":24,"primary_tumor_size_cm":6.2,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.041523+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_211849","record_id":"REC_0004832","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":5.3,"age_at_diagnosis":78,"sex":"male","ecog_performance_status":1,"smoking_pack_years":0,"primary_tumor_size_cm":2.8,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.041775+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_828900","record_id":"REC_0004833","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":3.2,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":0,"smoking_pack_years":54,"primary_tumor_size_cm":3.1,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.042035+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_660415","record_id":"REC_0004834","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":32,"tmb_mutations_per_mb":8.0,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":7.3,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.042281+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_297945","record_id":"REC_0004835","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":6.7,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":4.4,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.042513+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_881857","record_id":"REC_0004836","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":5.7,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":72,"primary_tumor_size_cm":3.2,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.042743+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_315728","record_id":"REC_0004837","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":5.4,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":6.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.043108+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_375792","record_id":"REC_0004838","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":15,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":84,"sex":"female","ecog_performance_status":3,"smoking_pack_years":12,"primary_tumor_size_cm":4.3,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":7.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.043346+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_937771","record_id":"REC_0004839","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":5.5,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.043583+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_190384","record_id":"REC_0004840","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":7.9,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":5.9,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.043816+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_747135","record_id":"REC_0004841","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":4.2,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.044057+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_381178","record_id":"REC_0004842","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":15.1,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":3.9,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":22.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.044354+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_609873","record_id":"REC_0004843","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":30,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":1,"smoking_pack_years":24,"primary_tumor_size_cm":4.8,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.044590+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_208711","record_id":"REC_0004844","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":20.2,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":6.2,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.044826+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_612031","record_id":"REC_0004845","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":6.1,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":27.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.045058+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_316914","record_id":"REC_0004846","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":8.1,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":4.2,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":42.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.045287+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_552550","record_id":"REC_0004847","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":16.7,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":9,"primary_tumor_size_cm":5.8,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.045522+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_748161","record_id":"REC_0004848","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":6.7,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":4.9,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.045750+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_256348","record_id":"REC_0004849","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":6.9,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.045990+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_934617","record_id":"REC_0004850","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":6.0,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":8.0,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":41.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.046292+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_939324","record_id":"REC_0004851","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":5.5,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":5.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.046525+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_693241","record_id":"REC_0004852","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":20,"tmb_mutations_per_mb":6.3,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":1,"smoking_pack_years":32,"primary_tumor_size_cm":5.5,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":26.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.046757+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_765456","record_id":"REC_0004853","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":5.5,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":4.9,"metastatic_sites_count":8,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.046992+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_698194","record_id":"REC_0004854","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":31,"tmb_mutations_per_mb":9.0,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":3,"smoking_pack_years":95,"primary_tumor_size_cm":5.2,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":16.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.047223+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_782006","record_id":"REC_0004855","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":5.5,"metastatic_sites_count":10,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.047458+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_339546","record_id":"REC_0004856","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":13.3,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":2,"smoking_pack_years":7,"primary_tumor_size_cm":6.7,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.047688+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_972610","record_id":"REC_0004857","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":81,"sex":"male","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":3.7,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.047924+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_350433","record_id":"REC_0004858","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":13.1,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":5.9,"metastatic_sites_count":3,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.048216+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_442363","record_id":"REC_0004859","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":4.9,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":6.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.048469+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_690337","record_id":"REC_0004860","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":3.1,"age_at_diagnosis":78,"sex":"male","ecog_performance_status":2,"smoking_pack_years":3,"primary_tumor_size_cm":7.5,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":17.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.048707+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_392033","record_id":"REC_0004861","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":20.7,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":5.6,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.048942+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_458816","record_id":"REC_0004862","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":76,"sex":"male","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":4.9,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.049174+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_439730","record_id":"REC_0004863","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":30,"tmb_mutations_per_mb":13.3,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":3.9,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":6.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.049503+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_388639","record_id":"REC_0004864","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":16.0,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":6.0,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":42.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.049750+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_309730","record_id":"REC_0004865","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":9.7,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":8.2,"metastatic_sites_count":8,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.049983+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_309766","record_id":"REC_0004866","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":41,"primary_tumor_size_cm":6.8,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":25.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.050221+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_340592","record_id":"REC_0004867","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":19,"tmb_mutations_per_mb":8.9,"age_at_diagnosis":52,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":6.5,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.050453+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_597343","record_id":"REC_0004868","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":9.7,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.0,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":5.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.050687+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_547930","record_id":"REC_0004869","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":19,"tmb_mutations_per_mb":4.1,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":0,"smoking_pack_years":39,"primary_tumor_size_cm":5.5,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.050920+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_477969","record_id":"REC_0004870","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":7,"primary_tumor_size_cm":4.5,"metastatic_sites_count":3,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.051182+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_382747","record_id":"REC_0004871","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":5.0,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":20.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.051455+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_726669","record_id":"REC_0004872","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":4.9,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":39.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.051696+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_797805","record_id":"REC_0004873","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":15,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":1,"smoking_pack_years":25,"primary_tumor_size_cm":4.5,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":19.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.051931+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_445764","record_id":"REC_0004874","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":16.9,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":6.3,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":16.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.052249+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_930676","record_id":"REC_0004875","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":5.4,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":17.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.052502+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_223634","record_id":"REC_0004876","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":25,"primary_tumor_size_cm":5.4,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.052860+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_377907","record_id":"REC_0004877","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":5.8,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.053105+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_116231","record_id":"REC_0004878","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":31,"primary_tumor_size_cm":7.3,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.053346+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_298836","record_id":"REC_0004879","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":1,"smoking_pack_years":31,"primary_tumor_size_cm":6.0,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.053582+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_800545","record_id":"REC_0004880","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":52,"sex":"male","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":5.7,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.053816+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_772312","record_id":"REC_0004881","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":5.8,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":22.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.054050+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_936378","record_id":"REC_0004882","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":8.7,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":6.4,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.054284+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_311853","record_id":"REC_0004883","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":18.3,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":0,"primary_tumor_size_cm":5.1,"metastatic_sites_count":8,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.054512+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_358667","record_id":"REC_0004884","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":8.6,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":4.4,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.054743+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_463747","record_id":"REC_0004885","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":15.1,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":4.5,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":27.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.054975+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_128699","record_id":"REC_0004886","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":2,"smoking_pack_years":24,"primary_tumor_size_cm":4.5,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.055208+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_115967","record_id":"REC_0004887","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":15.7,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":4.9,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":5.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.055440+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_371865","record_id":"REC_0004888","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":16.1,"age_at_diagnosis":50,"sex":"male","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":4.3,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":21.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.055672+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_881434","record_id":"REC_0004889","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":9.5,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":4.4,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.055956+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_452849","record_id":"REC_0004890","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":19,"tmb_mutations_per_mb":6.9,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":51,"primary_tumor_size_cm":5.8,"metastatic_sites_count":8,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.056300+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_786538","record_id":"REC_0004891","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":6.1,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":6.0,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.056545+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_349344","record_id":"REC_0004892","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":24,"primary_tumor_size_cm":6.8,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.056783+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_819785","record_id":"REC_0004893","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":48,"sex":"male","ecog_performance_status":0,"smoking_pack_years":3,"primary_tumor_size_cm":5.8,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":6.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.057019+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_880766","record_id":"REC_0004894","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":17.1,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":5.9,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":22.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.057261+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_683689","record_id":"REC_0004895","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":10.1,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":2,"primary_tumor_size_cm":3.8,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.057496+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_410544","record_id":"REC_0004896","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":17.9,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":3.9,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.057728+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_630875","record_id":"REC_0004897","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":54,"sex":"female","ecog_performance_status":0,"smoking_pack_years":61,"primary_tumor_size_cm":4.6,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":6.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.057959+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_436857","record_id":"REC_0004898","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":52,"sex":"female","ecog_performance_status":0,"smoking_pack_years":37,"primary_tumor_size_cm":4.3,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":19.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.058190+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_440543","record_id":"REC_0004899","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":5.0,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":58,"primary_tumor_size_cm":2.5,"metastatic_sites_count":3,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.058423+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_836997","record_id":"REC_0004900","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":3.6,"age_at_diagnosis":86,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":6.7,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.058656+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_937172","record_id":"REC_0004901","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":4.7,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.058888+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_500411","record_id":"REC_0004902","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":5.2,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":6.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.059169+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_235048","record_id":"REC_0004903","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":7.6,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":1,"primary_tumor_size_cm":5.9,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":33.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.059409+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_925677","record_id":"REC_0004904","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":5.9,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":45,"primary_tumor_size_cm":6.5,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.059649+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_466229","record_id":"REC_0004905","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":5.0,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.059883+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_104867","record_id":"REC_0004906","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":7.4,"metastatic_sites_count":3,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":5.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.060180+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_952987","record_id":"REC_0004907","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":10.0,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":5.8,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":22.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.060438+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_582145","record_id":"REC_0004908","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":5.0,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":62,"primary_tumor_size_cm":4.0,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.060688+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_483883","record_id":"REC_0004909","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":35,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":51,"sex":"male","ecog_performance_status":0,"smoking_pack_years":30,"primary_tumor_size_cm":5.5,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":19.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.060927+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_842147","record_id":"REC_0004910","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":16,"tmb_mutations_per_mb":3.9,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":68,"primary_tumor_size_cm":5.7,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":16.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.061163+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_979368","record_id":"REC_0004911","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":11.1,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":6.3,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":16.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.061409+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_852997","record_id":"REC_0004912","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":8.4,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":25,"primary_tumor_size_cm":6.8,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.061657+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_684813","record_id":"REC_0004913","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":51,"sex":"male","ecog_performance_status":0,"smoking_pack_years":2,"primary_tumor_size_cm":7.0,"metastatic_sites_count":8,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.061918+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_133989","record_id":"REC_0004914","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":62,"primary_tumor_size_cm":5.7,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":28.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.062168+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_247040","record_id":"REC_0004915","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":6.9,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":75,"primary_tumor_size_cm":4.9,"metastatic_sites_count":3,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":6.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.062536+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_390508","record_id":"REC_0004916","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":85,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.5,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.062786+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_604033","record_id":"REC_0004917","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":18,"tmb_mutations_per_mb":6.7,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":53,"primary_tumor_size_cm":2.8,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.063028+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_941958","record_id":"REC_0004918","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":2.9,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.063270+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_558591","record_id":"REC_0004919","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":5.1,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.063514+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_692937","record_id":"REC_0004920","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":2,"smoking_pack_years":62,"primary_tumor_size_cm":5.1,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.063744+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_736235","record_id":"REC_0004921","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":11.0,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":21,"primary_tumor_size_cm":6.7,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.063978+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_896418","record_id":"REC_0004922","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":5.1,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.064339+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_975237","record_id":"REC_0004923","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":4.6,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":7.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.064585+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_963334","record_id":"REC_0004924","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":17.1,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":3.6,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.064827+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_462286","record_id":"REC_0004925","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":8.7,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.9,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.065061+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_618885","record_id":"REC_0004926","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":52,"sex":"male","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":4.2,"metastatic_sites_count":9,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.065293+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_818932","record_id":"REC_0004927","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":42,"primary_tumor_size_cm":5.5,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":44.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.065526+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_381483","record_id":"REC_0004928","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":7.5,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.065840+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_415224","record_id":"REC_0004929","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":14,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":4.9,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.066072+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_238015","record_id":"REC_0004930","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":19,"tmb_mutations_per_mb":6.3,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":35,"primary_tumor_size_cm":6.1,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.066303+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_282830","record_id":"REC_0004931","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":13.8,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":4.3,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":6.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.066535+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_408978","record_id":"REC_0004932","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":15.2,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":2,"primary_tumor_size_cm":6.7,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.066766+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_448846","record_id":"REC_0004933","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":19,"tmb_mutations_per_mb":15.1,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":6,"primary_tumor_size_cm":6.3,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":17.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.066996+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_666881","record_id":"REC_0004934","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":5.2,"metastatic_sites_count":3,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.067230+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_511617","record_id":"REC_0004935","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":1,"smoking_pack_years":27,"primary_tumor_size_cm":5.2,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.067466+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_453916","record_id":"REC_0004936","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":35,"tmb_mutations_per_mb":7.6,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":44,"primary_tumor_size_cm":7.0,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.067700+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_515010","record_id":"REC_0004937","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":5.0,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":43,"primary_tumor_size_cm":4.7,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":16.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.067933+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_601593","record_id":"REC_0004938","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":15.7,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":4.7,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.068202+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_642679","record_id":"REC_0004939","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":20,"tmb_mutations_per_mb":5.2,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":1,"smoking_pack_years":61,"primary_tumor_size_cm":6.2,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":18.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.068442+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_685766","record_id":"REC_0004940","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":4.7,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":4.3,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":16.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.068687+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_128215","record_id":"REC_0004941","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":33,"tmb_mutations_per_mb":8.7,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":2,"smoking_pack_years":10,"primary_tumor_size_cm":6.0,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":28.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.068996+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_542175","record_id":"REC_0004942","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":6.2,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.069238+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_915368","record_id":"REC_0004943","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":20.8,"age_at_diagnosis":75,"sex":"male","ecog_performance_status":2,"smoking_pack_years":25,"primary_tumor_size_cm":5.2,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.069478+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_719571","record_id":"REC_0004944","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":4.6,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.069714+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_235565","record_id":"REC_0004945","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":16,"tmb_mutations_per_mb":3.7,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":1,"smoking_pack_years":38,"primary_tumor_size_cm":5.4,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":16.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.069950+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_307764","record_id":"REC_0004946","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":6.7,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":17.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.070183+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_695642","record_id":"REC_0004947","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":16.3,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":27,"primary_tumor_size_cm":6.7,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":23.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.070415+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_961030","record_id":"REC_0004948","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":6.4,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":4.2,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.070647+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_457829","record_id":"REC_0004949","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":50,"sex":"male","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":8.1,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.070881+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_715076","record_id":"REC_0004950","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":8.0,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":4.5,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":27.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.071113+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_761057","record_id":"REC_0004951","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":15.7,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":4.7,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.071348+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_989026","record_id":"REC_0004952","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":82,"primary_tumor_size_cm":6.4,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":23.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.071582+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_762016","record_id":"REC_0004953","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":0,"smoking_pack_years":2,"primary_tumor_size_cm":5.5,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":7.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.071818+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_420765","record_id":"REC_0004954","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":14,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":4.5,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.072201+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_243567","record_id":"REC_0004955","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":17.0,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":4.3,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":18.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.072458+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_935244","record_id":"REC_0004956","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":10.5,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":7.1,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.072702+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_839922","record_id":"REC_0004957","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":4.7,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":27,"primary_tumor_size_cm":5.0,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.072938+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_323354","record_id":"REC_0004958","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":4.7,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.073174+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_746230","record_id":"REC_0004959","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":6.1,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":35,"primary_tumor_size_cm":4.5,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.073402+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_864746","record_id":"REC_0004960","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":35,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":83,"sex":"female","ecog_performance_status":3,"smoking_pack_years":23,"primary_tumor_size_cm":5.4,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.073634+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_270829","record_id":"REC_0004961","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":14.5,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":1,"smoking_pack_years":5,"primary_tumor_size_cm":5.3,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.073872+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_639021","record_id":"REC_0004962","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":10.5,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":5.3,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.074102+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_375163","record_id":"REC_0004963","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":18,"tmb_mutations_per_mb":16.6,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":24,"primary_tumor_size_cm":6.0,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":8.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.074337+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_771599","record_id":"REC_0004964","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":5.9,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":32,"primary_tumor_size_cm":7.3,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.074564+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_169434","record_id":"REC_0004965","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":14,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":5.0,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.074795+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_922397","record_id":"REC_0004966","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":20,"tmb_mutations_per_mb":4.4,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":6.8,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.075021+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_107822","record_id":"REC_0004967","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":11.5,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":6.0,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.075315+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_357747","record_id":"REC_0004968","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":16,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":31,"primary_tumor_size_cm":5.3,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":17.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.075544+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_457018","record_id":"REC_0004969","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":7.9,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":5.6,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.075774+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_140897","record_id":"REC_0004970","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":14.7,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":3.4,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":21.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.076010+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_738432","record_id":"REC_0004971","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":9.1,"age_at_diagnosis":52,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":5.6,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":45.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.076349+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_282786","record_id":"REC_0004972","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":16,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":10,"primary_tumor_size_cm":5.2,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.076588+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_220002","record_id":"REC_0004973","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":9.9,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":5.8,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.076823+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_563210","record_id":"REC_0004974","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":4.4,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":39,"primary_tumor_size_cm":3.9,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":23.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.077051+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_174223","record_id":"REC_0004975","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":20,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":56,"primary_tumor_size_cm":7.0,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":21.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.077284+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_517534","record_id":"REC_0004976","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":6.0,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.077515+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_500931","record_id":"REC_0004977","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":5.7,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":4.5,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":18.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.077746+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_838769","record_id":"REC_0004978","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":15.6,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":5.0,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.077977+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_511654","record_id":"REC_0004979","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":13.5,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":6,"primary_tumor_size_cm":4.3,"metastatic_sites_count":3,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.078212+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_370344","record_id":"REC_0004980","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":14.5,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":32,"primary_tumor_size_cm":4.1,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.078519+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_434468","record_id":"REC_0004981","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":34,"tmb_mutations_per_mb":11.0,"age_at_diagnosis":83,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":7.6,"metastatic_sites_count":9,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.078754+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_768777","record_id":"REC_0004982","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":6.9,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":51,"primary_tumor_size_cm":7.0,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":21.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.078981+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_764595","record_id":"REC_0004983","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":17.5,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":24,"primary_tumor_size_cm":5.8,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.079218+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_773507","record_id":"REC_0004984","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":7.8,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":21.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.079461+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_780196","record_id":"REC_0004985","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":35,"tmb_mutations_per_mb":16.9,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":2,"smoking_pack_years":7,"primary_tumor_size_cm":2.7,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.079713+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_901185","record_id":"REC_0004986","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":14,"tmb_mutations_per_mb":8.0,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":58,"primary_tumor_size_cm":6.2,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.079953+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_108368","record_id":"REC_0004987","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":6.8,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.080231+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_740066","record_id":"REC_0004988","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":7.8,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.080477+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_628940","record_id":"REC_0004989","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":9.7,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":7.3,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":19.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.080727+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_718415","record_id":"REC_0004990","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":2,"smoking_pack_years":7,"primary_tumor_size_cm":6.3,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":20.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.080987+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_776489","record_id":"REC_0004991","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":8.6,"age_at_diagnosis":84,"sex":"female","ecog_performance_status":1,"smoking_pack_years":28,"primary_tumor_size_cm":6.6,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.081235+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_106849","record_id":"REC_0004992","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":15.0,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":3,"smoking_pack_years":21,"primary_tumor_size_cm":7.0,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.081492+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_149383","record_id":"REC_0004993","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":5.3,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":6.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.081852+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_482570","record_id":"REC_0004994","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":9.9,"age_at_diagnosis":84,"sex":"female","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":6.4,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.082093+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_489383","record_id":"REC_0004995","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":20,"tmb_mutations_per_mb":4.0,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":1,"smoking_pack_years":78,"primary_tumor_size_cm":6.0,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":25.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.082333+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_136617","record_id":"REC_0004996","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":30,"tmb_mutations_per_mb":14.0,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":6.7,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.082569+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_364612","record_id":"REC_0004997","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":5.9,"age_at_diagnosis":74,"sex":"male","ecog_performance_status":3,"smoking_pack_years":19,"primary_tumor_size_cm":5.2,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.082802+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_870600","record_id":"REC_0004998","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":52,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":6.8,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.083035+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_383258","record_id":"REC_0004999","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":14.5,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":4.0,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.083272+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_379252","record_id":"REC_0005000","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":9.1,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":4.0,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.083501+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_711499","record_id":"REC_0005001","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":20,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":6.6,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":17.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.083727+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_882958","record_id":"REC_0005002","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":15.3,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":5.9,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":20.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.083961+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_748835","record_id":"REC_0005003","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":5.6,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":0,"smoking_pack_years":43,"primary_tumor_size_cm":6.1,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":23.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.084279+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_939293","record_id":"REC_0005004","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":85,"sex":"female","ecog_performance_status":3,"smoking_pack_years":18,"primary_tumor_size_cm":6.5,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.084519+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_290141","record_id":"REC_0005005","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":18,"tmb_mutations_per_mb":15.9,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":6.2,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.084757+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_402385","record_id":"REC_0005006","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":17,"tmb_mutations_per_mb":7.6,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":24,"primary_tumor_size_cm":6.4,"metastatic_sites_count":8,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":7.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.085045+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_955911","record_id":"REC_0005007","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":14.1,"age_at_diagnosis":54,"sex":"male","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":6.0,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.085289+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_260709","record_id":"REC_0005008","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":3,"primary_tumor_size_cm":8.0,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":16.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.085523+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_517375","record_id":"REC_0005009","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":7.7,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.085761+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_845709","record_id":"REC_0005010","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":3.9,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":1,"smoking_pack_years":26,"primary_tumor_size_cm":4.7,"metastatic_sites_count":9,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.085992+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_943040","record_id":"REC_0005011","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":6.7,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":1,"smoking_pack_years":26,"primary_tumor_size_cm":5.0,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.086225+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_152951","record_id":"REC_0005012","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":15.4,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":4.6,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.086458+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_448583","record_id":"REC_0005013","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":1,"smoking_pack_years":73,"primary_tumor_size_cm":3.3,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":18.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.086687+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_687926","record_id":"REC_0005014","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":17.5,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":5.2,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":23.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.086926+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_956127","record_id":"REC_0005015","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":35,"primary_tumor_size_cm":4.8,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":23.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.087159+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_914383","record_id":"REC_0005016","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ALK fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":16.3,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":6.3,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":34.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.087392+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_911016","record_id":"REC_0005017","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":3.9,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":1,"smoking_pack_years":50,"primary_tumor_size_cm":4.3,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":33.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.087625+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_744860","record_id":"REC_0005018","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":5.7,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.087856+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_997307","record_id":"REC_0005019","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":3.4,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":17.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.088186+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_953545","record_id":"REC_0005020","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":33,"tmb_mutations_per_mb":17.6,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":5.8,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.088429+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_845043","record_id":"REC_0005021","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":5.9,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":26.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.088663+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_155927","record_id":"REC_0005022","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":14.5,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":6.1,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.088904+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_519456","record_id":"REC_0005023","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":54,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":5.6,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":23.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.089138+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_291793","record_id":"REC_0005024","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":30,"tmb_mutations_per_mb":7.6,"age_at_diagnosis":83,"sex":"female","ecog_performance_status":0,"smoking_pack_years":58,"primary_tumor_size_cm":2.0,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.089367+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_441840","record_id":"REC_0005025","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":17.0,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":0,"primary_tumor_size_cm":5.7,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":19.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.089604+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_579185","record_id":"REC_0005026","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":14.4,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":6.2,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.089841+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_697157","record_id":"REC_0005027","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":15.0,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":4.7,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":21.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.090077+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_388963","record_id":"REC_0005028","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":31,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":0,"smoking_pack_years":26,"primary_tumor_size_cm":5.1,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.090312+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_108931","record_id":"REC_0005029","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":3.1,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":4.6,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.090543+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_143938","record_id":"REC_0005030","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":8.3,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":5.8,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":8.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.090769+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_155337","record_id":"REC_0005031","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":10.3,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":4.2,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.090999+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_309381","record_id":"REC_0005032","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":3.8,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":6.0,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.091281+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_267704","record_id":"REC_0005033","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":3.6,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.091523+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_130813","record_id":"REC_0005034","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":3.9,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.091757+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_277496","record_id":"REC_0005035","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":9,"primary_tumor_size_cm":4.3,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":22.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.091990+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_833749","record_id":"REC_0005036","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":11.5,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":5.8,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":24.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.092258+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_449070","record_id":"REC_0005037","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":61,"primary_tumor_size_cm":5.6,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.092490+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_496008","record_id":"REC_0005038","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":8.6,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":26,"primary_tumor_size_cm":6.2,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.092720+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_748905","record_id":"REC_0005039","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":50,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":4.4,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.092954+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_336765","record_id":"REC_0005040","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":7.6,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":5.9,"metastatic_sites_count":3,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.093183+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_763649","record_id":"REC_0005041","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":14.9,"age_at_diagnosis":54,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":3.9,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":6.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.093418+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_165891","record_id":"REC_0005042","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":15.3,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":4,"primary_tumor_size_cm":5.3,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.093649+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_173569","record_id":"REC_0005043","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":64,"primary_tumor_size_cm":5.0,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":20.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.093884+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_481976","record_id":"REC_0005044","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":4.0,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.094118+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_799821","record_id":"REC_0005045","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":4.3,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":4.1,"metastatic_sites_count":10,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.094401+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_294641","record_id":"REC_0005046","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":16.0,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":6.0,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":24.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.094639+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_366593","record_id":"REC_0005047","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":16.4,"age_at_diagnosis":50,"sex":"male","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":5.9,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.094876+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_351782","record_id":"REC_0005048","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":3.1,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":0,"smoking_pack_years":47,"primary_tumor_size_cm":5.7,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.095106+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_214775","record_id":"REC_0005049","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":30,"tmb_mutations_per_mb":5.0,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":2,"smoking_pack_years":63,"primary_tumor_size_cm":4.1,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.095334+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_421704","record_id":"REC_0005050","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":14.0,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":28,"primary_tumor_size_cm":4.2,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.095605+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_109073","record_id":"REC_0005051","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":5.7,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":4.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.095839+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_812275","record_id":"REC_0005052","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":2.7,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":3,"smoking_pack_years":6,"primary_tumor_size_cm":5.9,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.096165+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_255014","record_id":"REC_0005053","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":30,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":3,"smoking_pack_years":35,"primary_tumor_size_cm":6.2,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":18.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.096483+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_659331","record_id":"REC_0005054","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":16,"tmb_mutations_per_mb":5.6,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":48,"primary_tumor_size_cm":7.2,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":23.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.096787+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_218994","record_id":"REC_0005055","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":13.8,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":4.8,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":45.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.097054+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_732988","record_id":"REC_0005056","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":13.1,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":6.4,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.097311+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_310399","record_id":"REC_0005057","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":6.8,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.097569+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_242674","record_id":"REC_0005058","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":8.3,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":21,"primary_tumor_size_cm":4.5,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.097944+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_131333","record_id":"REC_0005059","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":11.1,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":4.5,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.098193+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_922698","record_id":"REC_0005060","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":4.6,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.098425+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_792043","record_id":"REC_0005061","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":9.9,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":5.1,"metastatic_sites_count":9,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.098662+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_518495","record_id":"REC_0005062","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":14.3,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":5.9,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":20.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.098903+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_409018","record_id":"REC_0005063","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":30,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":5.7,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.099140+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_971903","record_id":"REC_0005064","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":4.8,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":6.0,"metastatic_sites_count":8,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.099371+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_326313","record_id":"REC_0005065","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":18,"tmb_mutations_per_mb":2.9,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":44,"primary_tumor_size_cm":4.6,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":21.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.099611+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_946338","record_id":"REC_0005066","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":63,"primary_tumor_size_cm":5.2,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.099846+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_407953","record_id":"REC_0005067","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":7.0,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.100152+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_668271","record_id":"REC_0005068","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":18,"tmb_mutations_per_mb":6.3,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":29,"primary_tumor_size_cm":4.5,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.100404+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_547383","record_id":"REC_0005069","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":7.9,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":33,"primary_tumor_size_cm":6.0,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":26.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.100644+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_579338","record_id":"REC_0005070","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":9.8,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":5,"primary_tumor_size_cm":6.2,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.100873+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_915360","record_id":"REC_0005071","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":20,"tmb_mutations_per_mb":13.5,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":0,"smoking_pack_years":4,"primary_tumor_size_cm":4.2,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.101214+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_868815","record_id":"REC_0005072","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":14.1,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":5.5,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.101455+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_840917","record_id":"REC_0005073","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":7.1,"metastatic_sites_count":8,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":5.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.101690+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_791956","record_id":"REC_0005074","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":17,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":1,"smoking_pack_years":36,"primary_tumor_size_cm":5.8,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.101922+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_375905","record_id":"REC_0005075","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":14.4,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":5.5,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":33.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.102168+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_982377","record_id":"REC_0005076","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":3.6,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":26,"primary_tumor_size_cm":5.0,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":16.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.102409+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_434483","record_id":"REC_0005077","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":3.7,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":4.6,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":6.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.102639+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_706498","record_id":"REC_0005078","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":6.9,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":5,"primary_tumor_size_cm":7.8,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.102868+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_712162","record_id":"REC_0005079","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":19,"tmb_mutations_per_mb":15.9,"age_at_diagnosis":54,"sex":"male","ecog_performance_status":0,"smoking_pack_years":6,"primary_tumor_size_cm":6.5,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.103108+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_962671","record_id":"REC_0005080","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":37,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":10,"primary_tumor_size_cm":4.4,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":20.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.103344+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_954089","record_id":"REC_0005081","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":14.8,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":0,"smoking_pack_years":1,"primary_tumor_size_cm":4.2,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":30.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.103582+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_202133","record_id":"REC_0005082","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":15,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":5.9,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.103818+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_688988","record_id":"REC_0005083","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":15,"tmb_mutations_per_mb":14.7,"age_at_diagnosis":54,"sex":"female","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":5.0,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.104053+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_868748","record_id":"REC_0005084","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":32,"tmb_mutations_per_mb":7.3,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":50,"primary_tumor_size_cm":5.3,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":21.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.104523+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_469615","record_id":"REC_0005085","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":77,"sex":"male","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":6.9,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":17.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.104782+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_179539","record_id":"REC_0005086","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":5.9,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":4.7,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.105018+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_775588","record_id":"REC_0005087","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":17.0,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":1,"smoking_pack_years":24,"primary_tumor_size_cm":4.3,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":17.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.105256+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_659749","record_id":"REC_0005088","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":8.3,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":18.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.105488+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_394066","record_id":"REC_0005089","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":16.1,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":5.3,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.105724+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_325698","record_id":"REC_0005090","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":13.6,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":4.4,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":28.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.105959+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_481462","record_id":"REC_0005091","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":19,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":5.4,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.106189+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_809087","record_id":"REC_0005092","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":19.5,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":3.7,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.106426+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_854075","record_id":"REC_0005093","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":30,"tmb_mutations_per_mb":6.3,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":4.6,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":25.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.106655+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_265382","record_id":"REC_0005094","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":2,"primary_tumor_size_cm":3.8,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.106884+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_885673","record_id":"REC_0005095","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":8.9,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":5.0,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.107118+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_823728","record_id":"REC_0005096","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":5.4,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":29.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.107352+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_685153","record_id":"REC_0005097","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":5.2,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.107653+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_656856","record_id":"REC_0005098","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":6.9,"age_at_diagnosis":89,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":5.3,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.107886+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_100363","record_id":"REC_0005099","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":30,"tmb_mutations_per_mb":6.1,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":1,"smoking_pack_years":60,"primary_tumor_size_cm":6.0,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.108199+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_403759","record_id":"REC_0005100","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":35,"tmb_mutations_per_mb":4.1,"age_at_diagnosis":83,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":4.6,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.108451+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_605205","record_id":"REC_0005101","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":11.1,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":7.7,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.108695+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_197526","record_id":"REC_0005102","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":6.4,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":70,"primary_tumor_size_cm":2.6,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.108935+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_185563","record_id":"REC_0005103","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":6.5,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.109173+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_583349","record_id":"REC_0005104","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":0,"primary_tumor_size_cm":6.6,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.109403+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_780139","record_id":"REC_0005105","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":18,"tmb_mutations_per_mb":15.9,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":2,"smoking_pack_years":29,"primary_tumor_size_cm":6.3,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.109637+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_305169","record_id":"REC_0005106","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":14.5,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":6.6,"metastatic_sites_count":8,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.109877+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_151808","record_id":"REC_0005107","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":90,"sex":"male","ecog_performance_status":2,"smoking_pack_years":23,"primary_tumor_size_cm":6.7,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.110112+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_884094","record_id":"REC_0005108","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":17.8,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":6.9,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":7.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.110347+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_470888","record_id":"REC_0005109","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":4.6,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":60,"primary_tumor_size_cm":5.9,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.110581+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_103809","record_id":"REC_0005110","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":5.9,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":67,"primary_tumor_size_cm":4.5,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.110888+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_959773","record_id":"REC_0005111","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":11.5,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":29,"primary_tumor_size_cm":7.3,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":17.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.111130+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_865886","record_id":"REC_0005112","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":14.5,"age_at_diagnosis":54,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":4.1,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.111365+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_729619","record_id":"REC_0005113","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":15.3,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":6.2,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.111601+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_349379","record_id":"REC_0005114","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":4.3,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.111836+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_629805","record_id":"REC_0005115","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":0,"smoking_pack_years":26,"primary_tumor_size_cm":5.7,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.112069+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_301482","record_id":"REC_0005116","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":6.1,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":62,"primary_tumor_size_cm":5.3,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.112366+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_576308","record_id":"REC_0005117","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":14.3,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":7.9,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":27.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.112609+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_723557","record_id":"REC_0005118","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":6.1,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":0,"smoking_pack_years":40,"primary_tumor_size_cm":6.6,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":42.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.112854+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_826595","record_id":"REC_0005119","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":14.8,"age_at_diagnosis":77,"sex":"male","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":5.3,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.113094+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_391613","record_id":"REC_0005120","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":34,"tmb_mutations_per_mb":17.0,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":7.0,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.113331+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_494175","record_id":"REC_0005121","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":18,"tmb_mutations_per_mb":13.6,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":6.6,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":21.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.113562+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_859003","record_id":"REC_0005122","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":33,"tmb_mutations_per_mb":3.8,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":25,"primary_tumor_size_cm":7.7,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.113790+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_877457","record_id":"REC_0005123","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":6.0,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.114085+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_612220","record_id":"REC_0005124","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":6.1,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":7.5,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":7.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.114319+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_325822","record_id":"REC_0005125","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":4.8,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":3,"smoking_pack_years":29,"primary_tumor_size_cm":5.2,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":7.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.114554+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_380583","record_id":"REC_0005126","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":39,"tmb_mutations_per_mb":13.8,"age_at_diagnosis":45,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":6.7,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":19.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.114792+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_191327","record_id":"REC_0005127","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":16,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":25,"primary_tumor_size_cm":4.5,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.115028+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_694109","record_id":"REC_0005128","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":6.8,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.115261+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_359671","record_id":"REC_0005129","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":34,"tmb_mutations_per_mb":8.1,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":40,"primary_tumor_size_cm":3.7,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":6.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.115491+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_979008","record_id":"REC_0005130","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":21.2,"age_at_diagnosis":84,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":6.4,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.115723+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_407985","record_id":"REC_0005131","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":17,"tmb_mutations_per_mb":3.2,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":20,"primary_tumor_size_cm":4.7,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":48.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.115949+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_735967","record_id":"REC_0005132","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":6.7,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":8.2,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":6.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.116297+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_149964","record_id":"REC_0005133","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":30,"primary_tumor_size_cm":4.6,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.116540+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_877983","record_id":"REC_0005134","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":17.3,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.9,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.116779+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_708692","record_id":"REC_0005135","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":7.4,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":4.3,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":21.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.117015+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_890517","record_id":"REC_0005136","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":77,"sex":"male","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":5.8,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.117327+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_960394","record_id":"REC_0005137","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":19.8,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":6.7,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":27.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.117574+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_997090","record_id":"REC_0005138","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":1,"smoking_pack_years":72,"primary_tumor_size_cm":5.1,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":7.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.117811+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_234732","record_id":"REC_0005139","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":15.5,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":5.7,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.118049+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_912307","record_id":"REC_0005140","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":31,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":5.2,"metastatic_sites_count":8,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.118279+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_708876","record_id":"REC_0005141","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":4.9,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.118511+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_591748","record_id":"REC_0005142","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":14.1,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":4.3,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":37.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.118748+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_748094","record_id":"REC_0005143","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":7.6,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":22,"primary_tumor_size_cm":5.6,"metastatic_sites_count":8,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.118979+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_509821","record_id":"REC_0005144","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":30,"tmb_mutations_per_mb":16.5,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":3.0,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.119210+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_820494","record_id":"REC_0005145","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":18,"tmb_mutations_per_mb":9.8,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":6.7,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.119436+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_165062","record_id":"REC_0005146","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":76,"sex":"male","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":6.5,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.119670+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_769461","record_id":"REC_0005147","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":4.8,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":7.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.119905+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_837301","record_id":"REC_0005148","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":2.8,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.120192+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_721848","record_id":"REC_0005149","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":5.6,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.120532+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_116382","record_id":"REC_0005150","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":15.9,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":6.2,"metastatic_sites_count":3,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.120783+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_358063","record_id":"REC_0005151","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":3.5,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":5.0,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.121021+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_453461","record_id":"REC_0005152","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":6.1,"age_at_diagnosis":88,"sex":"male","ecog_performance_status":2,"smoking_pack_years":2,"primary_tumor_size_cm":6.9,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.121253+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_229425","record_id":"REC_0005153","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":16.8,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":5,"primary_tumor_size_cm":4.9,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.121492+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_389020","record_id":"REC_0005154","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":15.1,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":4,"primary_tumor_size_cm":4.9,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":20.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.121726+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_302103","record_id":"REC_0005155","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":22,"primary_tumor_size_cm":5.1,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.121957+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_996652","record_id":"REC_0005156","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":4.2,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":38.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.122189+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_563394","record_id":"REC_0005157","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":31,"tmb_mutations_per_mb":18.0,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":4.0,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.122426+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_967097","record_id":"REC_0005158","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":83,"sex":"male","ecog_performance_status":1,"smoking_pack_years":33,"primary_tumor_size_cm":3.8,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":23.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.122659+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_817417","record_id":"REC_0005159","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":7.3,"metastatic_sites_count":3,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":7.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.122895+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_124120","record_id":"REC_0005160","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":7.5,"metastatic_sites_count":3,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":23.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.123128+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_156343","record_id":"REC_0005161","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":3,"smoking_pack_years":19,"primary_tumor_size_cm":5.6,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.123359+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_573265","record_id":"REC_0005162","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":20.0,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":3.8,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.123658+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_305253","record_id":"REC_0005163","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":14.1,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":5.4,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.123899+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_546085","record_id":"REC_0005164","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":66,"primary_tumor_size_cm":5.2,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.124241+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_394232","record_id":"REC_0005165","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":4.0,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.124487+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_981301","record_id":"REC_0005166","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":35,"primary_tumor_size_cm":4.6,"metastatic_sites_count":8,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":6.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.124722+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_437112","record_id":"REC_0005167","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":6.1,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":5.7,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":22.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.124951+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_119244","record_id":"REC_0005168","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":9.1,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":8.6,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":7.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.125180+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_753588","record_id":"REC_0005169","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":31,"tmb_mutations_per_mb":6.0,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":3.8,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.125415+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_335049","record_id":"REC_0005170","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":5.8,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":25.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.125651+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_790815","record_id":"REC_0005171","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":2,"smoking_pack_years":20,"primary_tumor_size_cm":7.5,"metastatic_sites_count":3,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":4.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.125882+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_507343","record_id":"REC_0005172","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":6.1,"metastatic_sites_count":8,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.126113+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_774385","record_id":"REC_0005173","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":15.6,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":6.5,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.126346+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_582602","record_id":"REC_0005174","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":5.3,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.126578+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_991073","record_id":"REC_0005175","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":14.1,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":6.6,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.126875+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_594430","record_id":"REC_0005176","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":79,"sex":"male","ecog_performance_status":3,"smoking_pack_years":17,"primary_tumor_size_cm":6.4,"metastatic_sites_count":3,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.127110+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_850963","record_id":"REC_0005177","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":16.4,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":5.6,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.127352+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_225209","record_id":"REC_0005178","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":33,"tmb_mutations_per_mb":18.1,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":5.9,"metastatic_sites_count":9,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.127589+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_919331","record_id":"REC_0005179","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":10.0,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":4.5,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.127823+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_535546","record_id":"REC_0005180","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":2.8,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":1,"smoking_pack_years":68,"primary_tumor_size_cm":6.3,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":7.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.128055+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_456049","record_id":"REC_0005181","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":5,"primary_tumor_size_cm":6.1,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.128321+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_716059","record_id":"REC_0005182","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":15,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":4.0,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.128555+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_145356","record_id":"REC_0005183","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":6.3,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":17.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.128786+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_870589","record_id":"REC_0005184","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":78,"sex":"male","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":3.3,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.129023+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_535356","record_id":"REC_0005185","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":14.9,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":7.1,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":26.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.129254+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_139726","record_id":"REC_0005186","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":1,"smoking_pack_years":47,"primary_tumor_size_cm":4.5,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.129486+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_104654","record_id":"REC_0005187","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":10.0,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":24,"primary_tumor_size_cm":7.4,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.129721+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_182538","record_id":"REC_0005188","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":5.1,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":55,"primary_tumor_size_cm":6.7,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":6.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.129993+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_147946","record_id":"REC_0005189","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":6.9,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":6.1,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":34.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.130226+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_684731","record_id":"REC_0005190","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":8.4,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":8.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.130460+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_488138","record_id":"REC_0005191","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":18,"tmb_mutations_per_mb":15.2,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":24,"primary_tumor_size_cm":6.0,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.130698+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_826163","record_id":"REC_0005192","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":14.9,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":4.1,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":24.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.130929+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_765990","record_id":"REC_0005193","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":34,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":4.0,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":24.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.131163+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_545388","record_id":"REC_0005194","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":15.9,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":6.2,"metastatic_sites_count":8,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.131397+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_793944","record_id":"REC_0005195","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":0,"primary_tumor_size_cm":4.5,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":20.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.131630+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_751929","record_id":"REC_0005196","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":13.6,"age_at_diagnosis":54,"sex":"male","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":5.7,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":5.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.131862+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_772731","record_id":"REC_0005197","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":31,"tmb_mutations_per_mb":14.6,"age_at_diagnosis":74,"sex":"male","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":5.1,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":6.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.132142+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_809330","record_id":"REC_0005198","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":16.3,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":5.0,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":20.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.132384+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_156886","record_id":"REC_0005199","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":48,"sex":"male","ecog_performance_status":0,"smoking_pack_years":0,"primary_tumor_size_cm":6.9,"metastatic_sites_count":8,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.132625+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_750811","record_id":"REC_0005200","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":3.8,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":22.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.132867+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_442657","record_id":"REC_0005201","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":6.4,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":17.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.133162+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_768749","record_id":"REC_0005202","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":4.1,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":4.2,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":7.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.133398+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_997491","record_id":"REC_0005203","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":10.1,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":5.5,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.133635+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_379602","record_id":"REC_0005204","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":24,"primary_tumor_size_cm":3.9,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.133865+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_458911","record_id":"REC_0005205","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":10,"primary_tumor_size_cm":5.2,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.134097+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_240736","record_id":"REC_0005206","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":5.8,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.134328+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_184672","record_id":"REC_0005207","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":30,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.5,"metastatic_sites_count":9,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.134560+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_682465","record_id":"REC_0005208","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":13,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":7.2,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.134789+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_128340","record_id":"REC_0005209","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":4.6,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.135016+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_184292","record_id":"REC_0005210","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":53,"primary_tumor_size_cm":4.6,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.135244+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_952659","record_id":"REC_0005211","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":14.7,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":5.4,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.135479+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_535591","record_id":"REC_0005212","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":4.5,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.135710+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_343781","record_id":"REC_0005213","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":3.5,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":22.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.135942+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_281155","record_id":"REC_0005214","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":15.2,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":3.7,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.136371+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_694195","record_id":"REC_0005215","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":6.1,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":26.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.136619+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_759104","record_id":"REC_0005216","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":2,"smoking_pack_years":25,"primary_tumor_size_cm":5.7,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.136856+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_796209","record_id":"REC_0005217","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":9.1,"age_at_diagnosis":53,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":6.0,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.137087+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_560820","record_id":"REC_0005218","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":6.0,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":6.0,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.137318+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_333334","record_id":"REC_0005219","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":14.6,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":2,"primary_tumor_size_cm":4.9,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.137550+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_721061","record_id":"REC_0005220","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":17,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":5.8,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":20.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.137781+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_942829","record_id":"REC_0005221","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":4.4,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":4.5,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.138016+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_881033","record_id":"REC_0005222","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":9.5,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":5.9,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.138243+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_841794","record_id":"REC_0005223","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":9.9,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":20,"primary_tumor_size_cm":6.1,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.138472+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_439547","record_id":"REC_0005224","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":6.4,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":40,"primary_tumor_size_cm":5.1,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":30.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.138704+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_208844","record_id":"REC_0005225","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":4.2,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":7.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.138943+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_225290","record_id":"REC_0005226","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":4.6,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.139173+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_101059","record_id":"REC_0005227","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":19.2,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":4.9,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.139457+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_416357","record_id":"REC_0005228","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":5.5,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":37,"primary_tumor_size_cm":5.4,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":21.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.139695+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_566275","record_id":"REC_0005229","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":5.5,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":39,"primary_tumor_size_cm":6.2,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":16.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.139929+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_798568","record_id":"REC_0005230","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":14.6,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":6.1,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.140192+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_397079","record_id":"REC_0005231","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":1.5,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":4.0,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.140427+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_951964","record_id":"REC_0005232","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":6.0,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":24.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.140667+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_739574","record_id":"REC_0005233","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":5.4,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.140900+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_103230","record_id":"REC_0005234","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":5.9,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":6.6,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":8.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.141136+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_832201","record_id":"REC_0005235","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":5.1,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.141371+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_764514","record_id":"REC_0005236","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":7.4,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":20.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.141606+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_850763","record_id":"REC_0005237","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":9.5,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":5.3,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":22.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.141839+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_101899","record_id":"REC_0005238","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":31,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":52,"sex":"male","ecog_performance_status":0,"smoking_pack_years":24,"primary_tumor_size_cm":6.9,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.142073+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_102267","record_id":"REC_0005239","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":1,"smoking_pack_years":25,"primary_tumor_size_cm":4.5,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.142305+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_949223","record_id":"REC_0005240","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":5.4,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.142599+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_925392","record_id":"REC_0005241","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":5,"primary_tumor_size_cm":3.5,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.142836+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_676039","record_id":"REC_0005242","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":2.3,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":6.3,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.143065+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_966658","record_id":"REC_0005243","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":18,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":4.2,"metastatic_sites_count":8,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.143296+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_548021","record_id":"REC_0005244","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":6,"primary_tumor_size_cm":5.5,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.143532+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_935591","record_id":"REC_0005245","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":4.0,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.143768+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_862593","record_id":"REC_0005246","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":49,"sex":"female","ecog_performance_status":0,"smoking_pack_years":49,"primary_tumor_size_cm":5.3,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.143994+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_848205","record_id":"REC_0005247","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":6.0,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":5.8,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.144291+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_930954","record_id":"REC_0005248","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":28,"primary_tumor_size_cm":7.2,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.144531+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_832010","record_id":"REC_0005249","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":6.4,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.144769+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_973492","record_id":"REC_0005250","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.8,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":28.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.145003+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_236532","record_id":"REC_0005251","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":4.4,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.145234+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_707383","record_id":"REC_0005252","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":4.4,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":16.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.145464+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_425387","record_id":"REC_0005253","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":19,"tmb_mutations_per_mb":14.1,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":6.0,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.145776+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_250192","record_id":"REC_0005254","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":7.4,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":41,"primary_tumor_size_cm":5.8,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":16.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.146011+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_189304","record_id":"REC_0005255","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":36,"tmb_mutations_per_mb":6.9,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":26,"primary_tumor_size_cm":5.7,"metastatic_sites_count":8,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.146246+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_167833","record_id":"REC_0005256","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":6.4,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":41,"primary_tumor_size_cm":4.5,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.146474+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_277546","record_id":"REC_0005257","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":3,"smoking_pack_years":22,"primary_tumor_size_cm":5.4,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":16.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.146708+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_147315","record_id":"REC_0005258","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":15,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":8,"primary_tumor_size_cm":4.9,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.146944+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_972313","record_id":"REC_0005259","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":6.0,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":5.3,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.147185+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_653226","record_id":"REC_0005260","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":5.2,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":40,"primary_tumor_size_cm":4.9,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":5.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.147414+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_656501","record_id":"REC_0005261","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":15.0,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":6.4,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.147652+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_977297","record_id":"REC_0005262","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ALK fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":14.7,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":6.9,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":37.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.147888+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_177458","record_id":"REC_0005263","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":4.0,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.148172+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_971762","record_id":"REC_0005264","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":6.2,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.148414+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_660335","record_id":"REC_0005265","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.5,"age_at_diagnosis":90,"sex":"male","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":5.0,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.148652+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_219986","record_id":"REC_0005266","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":19,"tmb_mutations_per_mb":13.3,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":7.1,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.148945+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_728092","record_id":"REC_0005267","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":6.7,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":7.3,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":20.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.149183+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_986375","record_id":"REC_0005268","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":16.5,"age_at_diagnosis":85,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":6.5,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.149421+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_307875","record_id":"REC_0005269","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":50,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":3.8,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.149657+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_850950","record_id":"REC_0005270","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":1,"smoking_pack_years":5,"primary_tumor_size_cm":4.9,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":19.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.149888+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_862629","record_id":"REC_0005271","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":5.2,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.150118+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_885806","record_id":"REC_0005272","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":8.5,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":2,"smoking_pack_years":8,"primary_tumor_size_cm":5.0,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.150346+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_507825","record_id":"REC_0005273","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":7.2,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.150582+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_943369","record_id":"REC_0005274","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":83,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":5.9,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.150812+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_825979","record_id":"REC_0005275","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":9.1,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":6.2,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.151043+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_998751","record_id":"REC_0005276","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":8.0,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.5,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":5.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.151269+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_428545","record_id":"REC_0005277","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":4.0,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":70,"primary_tumor_size_cm":5.0,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.151501+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_978169","record_id":"REC_0005278","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":20.6,"age_at_diagnosis":52,"sex":"female","ecog_performance_status":0,"smoking_pack_years":28,"primary_tumor_size_cm":4.2,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.151737+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_324869","record_id":"REC_0005279","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":20,"tmb_mutations_per_mb":6.7,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":46,"primary_tumor_size_cm":3.7,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.152013+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_436707","record_id":"REC_0005280","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":20,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":73,"primary_tumor_size_cm":5.9,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":27.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.152280+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_497854","record_id":"REC_0005281","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":5.5,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":45.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.152518+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_708262","record_id":"REC_0005282","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":16.1,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":3.9,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":25.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.152754+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_118797","record_id":"REC_0005283","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":6,"primary_tumor_size_cm":5.2,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.152983+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_163889","record_id":"REC_0005284","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":24,"primary_tumor_size_cm":5.9,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":18.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.153216+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_548163","record_id":"REC_0005285","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":5.0,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.153449+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_836324","record_id":"REC_0005286","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":5.6,"age_at_diagnosis":53,"sex":"male","ecog_performance_status":0,"smoking_pack_years":39,"primary_tumor_size_cm":6.2,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":21.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.153676+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_436719","record_id":"REC_0005287","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":32,"tmb_mutations_per_mb":4.2,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":70,"primary_tumor_size_cm":7.5,"metastatic_sites_count":9,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.153906+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_977555","record_id":"REC_0005288","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":7.5,"metastatic_sites_count":8,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.154137+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_526006","record_id":"REC_0005289","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":16,"tmb_mutations_per_mb":15.2,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":6.9,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.154369+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_763222","record_id":"REC_0005290","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":30,"tmb_mutations_per_mb":15.2,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":26,"primary_tumor_size_cm":5.2,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":18.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.154607+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_308657","record_id":"REC_0005291","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":8.4,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":22.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.154837+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_681014","record_id":"REC_0005292","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":14.7,"age_at_diagnosis":74,"sex":"male","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":5.9,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.155115+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_643353","record_id":"REC_0005293","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":3.9,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.155359+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_601575","record_id":"REC_0005294","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":8.6,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":4.2,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.155585+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_774303","record_id":"REC_0005295","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":4.8,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":18.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.155825+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_254239","record_id":"REC_0005296","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":8.6,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":5.7,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.156055+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_621692","record_id":"REC_0005297","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":9.0,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":6.1,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":17.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.156386+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_575096","record_id":"REC_0005298","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":86,"sex":"female","ecog_performance_status":2,"smoking_pack_years":43,"primary_tumor_size_cm":6.7,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.156634+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_752608","record_id":"REC_0005299","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":16,"tmb_mutations_per_mb":6.4,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":6.5,"metastatic_sites_count":9,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.156866+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_293381","record_id":"REC_0005300","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":90,"sex":"female","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":3.1,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.157097+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_788525","record_id":"REC_0005301","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":54,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":6.0,"metastatic_sites_count":3,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":6.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.157333+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_405143","record_id":"REC_0005302","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":16,"tmb_mutations_per_mb":16.2,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":8.7,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.157562+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_219358","record_id":"REC_0005303","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":11.1,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":24,"primary_tumor_size_cm":7.5,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.157795+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_358312","record_id":"REC_0005304","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":5.3,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.158027+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_681544","record_id":"REC_0005305","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":14.6,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":4.1,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":21.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.158306+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_807310","record_id":"REC_0005306","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":32,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":6.0,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":16.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.158546+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_353423","record_id":"REC_0005307","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":16,"tmb_mutations_per_mb":20.5,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":4.2,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.158782+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_430918","record_id":"REC_0005308","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":4.6,"metastatic_sites_count":8,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.159011+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_585520","record_id":"REC_0005309","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":4.9,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.159240+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_696344","record_id":"REC_0005310","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":19,"tmb_mutations_per_mb":3.6,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":49,"primary_tumor_size_cm":4.9,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.159469+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_327510","record_id":"REC_0005311","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":8.9,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":29,"primary_tumor_size_cm":4.2,"metastatic_sites_count":3,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.159702+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_960466","record_id":"REC_0005312","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":16.4,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":6.2,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.159933+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_546511","record_id":"REC_0005313","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":5.7,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":0,"smoking_pack_years":30,"primary_tumor_size_cm":4.7,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.160209+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_947877","record_id":"REC_0005314","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":17.2,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":6.6,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":33.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.160458+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_866110","record_id":"REC_0005315","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":3.8,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":1,"smoking_pack_years":28,"primary_tumor_size_cm":6.7,"metastatic_sites_count":3,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.160694+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_227867","record_id":"REC_0005316","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":6.0,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":29.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.160926+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_297510","record_id":"REC_0005317","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":34,"tmb_mutations_per_mb":10.1,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":4.9,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.161156+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_742792","record_id":"REC_0005318","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":5.0,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":7.9,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":6.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.161450+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_296875","record_id":"REC_0005319","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":15.9,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":5.0,"metastatic_sites_count":8,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.161691+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_343644","record_id":"REC_0005320","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":18.2,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":6.4,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":18.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.161922+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_989928","record_id":"REC_0005321","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":6.8,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":26.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.162160+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_194163","record_id":"REC_0005322","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":5.6,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.162394+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_918792","record_id":"REC_0005323","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":6.9,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":37,"primary_tumor_size_cm":3.2,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":5.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.162622+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_266986","record_id":"REC_0005324","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":15.6,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":2.0,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.162853+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_855078","record_id":"REC_0005325","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":6.4,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":8.0,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.163080+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_961214","record_id":"REC_0005326","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":75,"sex":"male","ecog_performance_status":3,"smoking_pack_years":9,"primary_tumor_size_cm":7.0,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.163311+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_379980","record_id":"REC_0005327","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":51,"sex":"female","ecog_performance_status":0,"smoking_pack_years":34,"primary_tumor_size_cm":6.4,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":17.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.163544+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_121294","record_id":"REC_0005328","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":5.6,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":0,"smoking_pack_years":49,"primary_tumor_size_cm":6.9,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":7.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.163775+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_493528","record_id":"REC_0005329","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":11.5,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":3.7,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":5.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.164006+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_243922","record_id":"REC_0005330","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":3.8,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":1,"smoking_pack_years":40,"primary_tumor_size_cm":7.5,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.164281+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_346429","record_id":"REC_0005331","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":34,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":36,"primary_tumor_size_cm":5.5,"metastatic_sites_count":9,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.164567+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_405370","record_id":"REC_0005332","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":17,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.9,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.164806+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_482154","record_id":"REC_0005333","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":6.1,"age_at_diagnosis":54,"sex":"male","ecog_performance_status":0,"smoking_pack_years":64,"primary_tumor_size_cm":5.8,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.165039+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_974612","record_id":"REC_0005334","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":6.0,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":0,"smoking_pack_years":54,"primary_tumor_size_cm":5.0,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.165273+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_928666","record_id":"REC_0005335","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":31,"tmb_mutations_per_mb":11.0,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":23,"primary_tumor_size_cm":5.6,"metastatic_sites_count":3,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.165505+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_975005","record_id":"REC_0005336","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":28,"primary_tumor_size_cm":5.4,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.165738+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_992345","record_id":"REC_0005337","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":17.9,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":5.0,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.165968+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_338660","record_id":"REC_0005338","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":10.5,"age_at_diagnosis":76,"sex":"male","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":6.0,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.166202+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_976976","record_id":"REC_0005339","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":13.3,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":5.5,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.166437+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_344459","record_id":"REC_0005340","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":14,"tmb_mutations_per_mb":13.1,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":4.1,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.166671+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_947688","record_id":"REC_0005341","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":33,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":1,"smoking_pack_years":51,"primary_tumor_size_cm":5.4,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.166900+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_791815","record_id":"REC_0005342","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":3.0,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.167132+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_154197","record_id":"REC_0005343","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":30,"tmb_mutations_per_mb":8.3,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":28,"primary_tumor_size_cm":6.0,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.167361+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_813769","record_id":"REC_0005344","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":3.6,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":5.5,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":16.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.167637+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_136347","record_id":"REC_0005345","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":17.6,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":5.8,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.167879+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_432959","record_id":"REC_0005346","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":68,"primary_tumor_size_cm":6.7,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.168147+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_825333","record_id":"REC_0005347","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":30,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":6.8,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.168395+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_414446","record_id":"REC_0005348","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":14.5,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":4.3,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":19.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.168644+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_871310","record_id":"REC_0005349","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":1,"smoking_pack_years":34,"primary_tumor_size_cm":6.0,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.168879+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_336762","record_id":"REC_0005350","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":9.1,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":4.2,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.169107+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_606981","record_id":"REC_0005351","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":53,"sex":"male","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":6.0,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":16.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.169340+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_861132","record_id":"REC_0005352","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":4.5,"metastatic_sites_count":8,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.169569+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_387104","record_id":"REC_0005353","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":31,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":6.7,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.169803+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_666152","record_id":"REC_0005354","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":5.6,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":25,"primary_tumor_size_cm":7.2,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.170034+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_840697","record_id":"REC_0005355","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":20.2,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":5,"primary_tumor_size_cm":4.6,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.170266+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_839746","record_id":"REC_0005356","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":80,"sex":"male","ecog_performance_status":2,"smoking_pack_years":26,"primary_tumor_size_cm":6.5,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":17.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.170500+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_476971","record_id":"REC_0005357","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":53,"primary_tumor_size_cm":6.8,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.170777+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_537364","record_id":"REC_0005358","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":29,"primary_tumor_size_cm":4.5,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.171016+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_711561","record_id":"REC_0005359","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":4.1,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.171250+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_481042","record_id":"REC_0005360","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":11.5,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":7,"primary_tumor_size_cm":4.9,"metastatic_sites_count":3,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.171481+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_176506","record_id":"REC_0005361","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":8.7,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":6.9,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.171715+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_446919","record_id":"REC_0005362","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":14.1,"age_at_diagnosis":79,"sex":"male","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":4.7,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.171953+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_833675","record_id":"REC_0005363","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":52,"primary_tumor_size_cm":4.0,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.172219+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_312592","record_id":"REC_0005364","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":32,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":2,"smoking_pack_years":57,"primary_tumor_size_cm":7.2,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.172455+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_329220","record_id":"REC_0005365","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":4.6,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":67.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.172692+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_372864","record_id":"REC_0005366","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":4.0,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.172926+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_548661","record_id":"REC_0005367","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":19.5,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":31,"primary_tumor_size_cm":4.9,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.173160+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_210817","record_id":"REC_0005368","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":71,"primary_tumor_size_cm":6.8,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":17.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.173387+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_598776","record_id":"REC_0005369","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":32,"tmb_mutations_per_mb":13.6,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":4.9,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":5.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.173618+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_916081","record_id":"REC_0005370","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":17.2,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":5.7,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.173896+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_837336","record_id":"REC_0005371","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":5.5,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.174132+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_327368","record_id":"REC_0005372","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":18,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":6.3,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.174367+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_181066","record_id":"REC_0005373","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":6.7,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.174605+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_511030","record_id":"REC_0005374","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":13.8,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":5.5,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.174837+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_551553","record_id":"REC_0005375","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":18.9,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":3.1,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.175071+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_741187","record_id":"REC_0005376","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":26,"primary_tumor_size_cm":6.1,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.175297+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_155024","record_id":"REC_0005377","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":5.8,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.175532+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_639353","record_id":"REC_0005378","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":54,"sex":"male","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":9.3,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":22.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.175765+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_350503","record_id":"REC_0005379","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":28,"primary_tumor_size_cm":4.4,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.175996+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_751326","record_id":"REC_0005380","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":17,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":0,"smoking_pack_years":63,"primary_tumor_size_cm":3.9,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":7.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.176308+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_840710","record_id":"REC_0005381","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":21.5,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.7,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.176547+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_476956","record_id":"REC_0005382","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":10.1,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":5.0,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.176778+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_705590","record_id":"REC_0005383","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":8.0,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":4.6,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":49.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.177049+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_617128","record_id":"REC_0005384","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":54,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":3.7,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.177286+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_438369","record_id":"REC_0005385","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":11.1,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":5.3,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.177518+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_817684","record_id":"REC_0005386","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":19,"tmb_mutations_per_mb":5.6,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":7.3,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.177750+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_790997","record_id":"REC_0005387","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":5.7,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":23.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.177985+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_728578","record_id":"REC_0005388","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":7.4,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":45,"primary_tumor_size_cm":3.9,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.178215+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_594914","record_id":"REC_0005389","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":6.0,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.178448+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_443095","record_id":"REC_0005390","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":82,"sex":"male","ecog_performance_status":3,"smoking_pack_years":32,"primary_tumor_size_cm":6.5,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":29.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.178678+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_667778","record_id":"REC_0005391","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":18.2,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":25,"primary_tumor_size_cm":3.9,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.178917+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_234195","record_id":"REC_0005392","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":6.9,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":26.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.179149+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_334143","record_id":"REC_0005393","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":17.4,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":4.6,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.179386+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_181426","record_id":"REC_0005394","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":4.7,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.179623+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_364239","record_id":"REC_0005395","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":8.1,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":103,"primary_tumor_size_cm":3.8,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.179854+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_129027","record_id":"REC_0005396","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":16.8,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":3.4,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":23.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.180188+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_965254","record_id":"REC_0005397","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":5.0,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":5,"primary_tumor_size_cm":6.4,"metastatic_sites_count":3,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.180444+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_295953","record_id":"REC_0005398","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":18,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":4.7,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.180691+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_897844","record_id":"REC_0005399","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":0,"smoking_pack_years":43,"primary_tumor_size_cm":5.8,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":22.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.180926+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_300857","record_id":"REC_0005400","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":14,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":7.0,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.181162+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_667218","record_id":"REC_0005401","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":16.4,"age_at_diagnosis":78,"sex":"male","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":3.2,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.181400+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_381279","record_id":"REC_0005402","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":4.4,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":23.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.181632+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_199856","record_id":"REC_0005403","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":3.1,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":0,"smoking_pack_years":34,"primary_tumor_size_cm":6.2,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":17.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.181866+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_993815","record_id":"REC_0005404","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":4.3,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.182100+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_262268","record_id":"REC_0005405","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":9.9,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":5.3,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.182328+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_626097","record_id":"REC_0005406","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":17.6,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":6.0,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.182559+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_829271","record_id":"REC_0005407","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":0,"primary_tumor_size_cm":6.9,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":6.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.182786+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_844325","record_id":"REC_0005408","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":13.3,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.1,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.183020+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_137041","record_id":"REC_0005409","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":2.9,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":5.5,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":20.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.183335+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_285211","record_id":"REC_0005410","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":13.8,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":3.6,"metastatic_sites_count":8,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":5.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.183576+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_128838","record_id":"REC_0005411","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":6.1,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":4.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.183815+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_616541","record_id":"REC_0005412","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":4.3,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.184052+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_181230","record_id":"REC_0005413","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":4.2,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":21.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.184333+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_383044","record_id":"REC_0005414","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":48,"primary_tumor_size_cm":4.0,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.184571+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_152504","record_id":"REC_0005415","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":5.8,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":23.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.184806+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_184460","record_id":"REC_0005416","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":5.4,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":27.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.185038+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_736629","record_id":"REC_0005417","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":20,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":5.7,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":28.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.185269+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_303598","record_id":"REC_0005418","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":5.0,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":4,"primary_tumor_size_cm":5.4,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.185499+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_547540","record_id":"REC_0005419","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":16.8,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":0,"smoking_pack_years":3,"primary_tumor_size_cm":5.5,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":28.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.185732+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_494035","record_id":"REC_0005420","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":4.7,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":27.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.185968+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_643803","record_id":"REC_0005421","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":5.0,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.186199+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_497261","record_id":"REC_0005422","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":4.0,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.186477+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_426462","record_id":"REC_0005423","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":16,"tmb_mutations_per_mb":2.4,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":33,"primary_tumor_size_cm":4.5,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.186711+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_728239","record_id":"REC_0005424","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":6.0,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.186943+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_279894","record_id":"REC_0005425","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":5.5,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.187175+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_673819","record_id":"REC_0005426","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":15.2,"age_at_diagnosis":83,"sex":"male","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":6.2,"metastatic_sites_count":8,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":16.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.187410+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_660086","record_id":"REC_0005427","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":14.4,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":6.4,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.187641+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_405693","record_id":"REC_0005428","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":3.8,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":64,"primary_tumor_size_cm":8.4,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":19.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.187868+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_449328","record_id":"REC_0005429","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":7.6,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":65,"primary_tumor_size_cm":7.0,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":24.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.188179+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_127584","record_id":"REC_0005430","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":3.7,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.188422+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_924918","record_id":"REC_0005431","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":5.1,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":8.4,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":44.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.188656+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_300511","record_id":"REC_0005432","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":4.7,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":1,"smoking_pack_years":24,"primary_tumor_size_cm":5.7,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.188885+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_112355","record_id":"REC_0005433","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":0,"smoking_pack_years":5,"primary_tumor_size_cm":6.1,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.189123+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_768436","record_id":"REC_0005434","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":16.1,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":5.3,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.189352+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_569436","record_id":"REC_0005435","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":8.4,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":4.7,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.189637+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_136284","record_id":"REC_0005436","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":38,"sex":"male","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":6.8,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.189871+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_594263","record_id":"REC_0005437","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":17,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":0,"smoking_pack_years":90,"primary_tumor_size_cm":7.7,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.190105+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_855299","record_id":"REC_0005438","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":10.3,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":3,"smoking_pack_years":4,"primary_tumor_size_cm":5.0,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.190338+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_361937","record_id":"REC_0005439","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":17,"tmb_mutations_per_mb":5.6,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":0,"smoking_pack_years":25,"primary_tumor_size_cm":7.7,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.190572+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_597416","record_id":"REC_0005440","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":3.1,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":0,"smoking_pack_years":56,"primary_tumor_size_cm":4.0,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":29.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.190806+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_434284","record_id":"REC_0005441","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":54,"primary_tumor_size_cm":5.3,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.191033+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_273911","record_id":"REC_0005442","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":7.6,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":27,"primary_tumor_size_cm":6.2,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":24.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.191259+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_631934","record_id":"REC_0005443","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":9.8,"age_at_diagnosis":80,"sex":"male","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":7.4,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":18.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.191492+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_554031","record_id":"REC_0005444","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":26,"primary_tumor_size_cm":6.0,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":18.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.191725+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_320532","record_id":"REC_0005445","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":4.1,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":6.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.191952+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_680379","record_id":"REC_0005446","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":8.5,"age_at_diagnosis":48,"sex":"male","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":8.4,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":21.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.192220+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_329144","record_id":"REC_0005447","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":19,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":5.6,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.192461+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_857000","record_id":"REC_0005448","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":10.3,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":7.2,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":21.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.192748+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_567137","record_id":"REC_0005449","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":10.3,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":24,"primary_tumor_size_cm":5.8,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.192987+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_241517","record_id":"REC_0005450","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":3.6,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.193220+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_577775","record_id":"REC_0005451","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":15,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":8.4,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.193453+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_181638","record_id":"REC_0005452","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":3.0,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":53,"primary_tumor_size_cm":6.8,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.193680+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_603667","record_id":"REC_0005453","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":15.8,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":4.9,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.193916+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_932001","record_id":"REC_0005454","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":8.1,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":5.2,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.194142+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_764636","record_id":"REC_0005455","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":6.9,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":35,"primary_tumor_size_cm":6.7,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.194370+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_517299","record_id":"REC_0005456","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":17.7,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":4.3,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":29.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.194602+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_747504","record_id":"REC_0005457","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":19,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":5.1,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":61.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.194835+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_825673","record_id":"REC_0005458","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":19,"tmb_mutations_per_mb":10.1,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":6.5,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.195067+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_545614","record_id":"REC_0005459","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":3.1,"age_at_diagnosis":84,"sex":"female","ecog_performance_status":1,"smoking_pack_years":34,"primary_tumor_size_cm":4.5,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":6.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.195295+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_688644","record_id":"REC_0005460","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":14.4,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":4.7,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.195525+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_810932","record_id":"REC_0005461","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":14.5,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":3.1,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":23.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.195805+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_798977","record_id":"REC_0005462","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":17.9,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":7.5,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":16.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.196046+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_537765","record_id":"REC_0005463","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":4.2,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":6.7,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":7.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.196440+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_268145","record_id":"REC_0005464","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":90,"sex":"female","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":5.0,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":38.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.196681+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_848833","record_id":"REC_0005465","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":13.3,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":5.0,"metastatic_sites_count":9,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.196917+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_368738","record_id":"REC_0005466","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":6.1,"metastatic_sites_count":3,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":17.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.197150+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_247982","record_id":"REC_0005467","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":16.5,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":2,"smoking_pack_years":6,"primary_tumor_size_cm":3.4,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.197386+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_671762","record_id":"REC_0005468","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":15,"tmb_mutations_per_mb":7.9,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":33,"primary_tumor_size_cm":5.2,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":16.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.197634+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_155822","record_id":"REC_0005469","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":2,"smoking_pack_years":10,"primary_tumor_size_cm":4.9,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.197891+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_264339","record_id":"REC_0005470","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":18,"tmb_mutations_per_mb":13.8,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":0,"smoking_pack_years":25,"primary_tumor_size_cm":6.7,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.198155+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_393059","record_id":"REC_0005471","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":16,"tmb_mutations_per_mb":18.4,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":22,"primary_tumor_size_cm":5.7,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.198417+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_452952","record_id":"REC_0005472","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":4.6,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":34,"primary_tumor_size_cm":5.7,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":22.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.198680+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_679861","record_id":"REC_0005473","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":3,"smoking_pack_years":0,"primary_tumor_size_cm":6.9,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":5.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.198949+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_943846","record_id":"REC_0005474","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":17.7,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":7.1,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.199325+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_540237","record_id":"REC_0005475","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":4.9,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":1,"smoking_pack_years":53,"primary_tumor_size_cm":5.5,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.199581+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_875066","record_id":"REC_0005476","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":5.0,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.199820+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_700587","record_id":"REC_0005477","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":4.7,"metastatic_sites_count":3,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":16.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.200052+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_556569","record_id":"REC_0005478","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":7.5,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.200469+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_532097","record_id":"REC_0005479","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":6.2,"metastatic_sites_count":9,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.200721+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_148319","record_id":"REC_0005480","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":5.0,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":22.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.200962+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_118426","record_id":"REC_0005481","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":13.6,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":5.3,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":16.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.201198+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_378503","record_id":"REC_0005482","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":13.5,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":0,"primary_tumor_size_cm":5.3,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.201435+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_649518","record_id":"REC_0005483","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":3,"smoking_pack_years":9,"primary_tumor_size_cm":2.0,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":39.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.201675+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_695615","record_id":"REC_0005484","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":5.8,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.201912+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_535556","record_id":"REC_0005485","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":8,"primary_tumor_size_cm":6.1,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.202142+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_679289","record_id":"REC_0005486","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":30,"tmb_mutations_per_mb":4.8,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":3.1,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.202377+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_491045","record_id":"REC_0005487","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":31,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":79,"sex":"male","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":7.3,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.202694+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_155107","record_id":"REC_0005488","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":2,"primary_tumor_size_cm":6.2,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":18.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.202932+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_218977","record_id":"REC_0005489","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":16,"tmb_mutations_per_mb":1.5,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":10,"primary_tumor_size_cm":7.3,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.203167+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_354429","record_id":"REC_0005490","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":3.1,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.203399+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_597799","record_id":"REC_0005491","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":4.2,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":0,"smoking_pack_years":66,"primary_tumor_size_cm":5.2,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.203634+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_648109","record_id":"REC_0005492","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":10.3,"age_at_diagnosis":51,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":3.6,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.203873+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_286661","record_id":"REC_0005493","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":29,"primary_tumor_size_cm":5.3,"metastatic_sites_count":8,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.204280+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_926634","record_id":"REC_0005494","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":10.0,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":6.3,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.204540+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_334483","record_id":"REC_0005495","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":83,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":6.1,"metastatic_sites_count":8,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.204778+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_707529","record_id":"REC_0005496","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":17.2,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":2.2,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.205013+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_244619","record_id":"REC_0005497","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":5.3,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":4.9,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.205245+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_977530","record_id":"REC_0005498","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":3.3,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":5,"primary_tumor_size_cm":4.0,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.205481+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_556192","record_id":"REC_0005499","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":6.0,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":21.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.205720+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_146077","record_id":"REC_0005500","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":5.5,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.206020+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_785084","record_id":"REC_0005501","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":23,"primary_tumor_size_cm":4.8,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.206260+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_109902","record_id":"REC_0005502","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":13.1,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":4.9,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.206493+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_774311","record_id":"REC_0005503","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":67,"primary_tumor_size_cm":4.6,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.206723+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_118532","record_id":"REC_0005504","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":21.3,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":4.8,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":23.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.206956+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_175810","record_id":"REC_0005505","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":9.1,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":0,"smoking_pack_years":6,"primary_tumor_size_cm":6.0,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.207190+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_760306","record_id":"REC_0005506","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":15.9,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":1,"primary_tumor_size_cm":7.1,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.207420+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_409829","record_id":"REC_0005507","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":3.2,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":21.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.207653+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_381814","record_id":"REC_0005508","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":36,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":1,"smoking_pack_years":59,"primary_tumor_size_cm":4.0,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.207887+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_475484","record_id":"REC_0005509","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":86,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":5.5,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.208238+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_102391","record_id":"REC_0005510","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":19,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":6,"primary_tumor_size_cm":5.5,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.208483+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_613059","record_id":"REC_0005511","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":14.3,"age_at_diagnosis":87,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":6.0,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.208962+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_761542","record_id":"REC_0005512","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":20,"tmb_mutations_per_mb":5.5,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":3,"smoking_pack_years":51,"primary_tumor_size_cm":6.7,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.209204+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_274814","record_id":"REC_0005513","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":15.2,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":6.2,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.209536+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_609905","record_id":"REC_0005514","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":2,"smoking_pack_years":4,"primary_tumor_size_cm":4.2,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.209772+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_331401","record_id":"REC_0005515","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":9.9,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":24,"primary_tumor_size_cm":6.0,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.210003+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_551700","record_id":"REC_0005516","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":36,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":7.1,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.210240+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_122738","record_id":"REC_0005517","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":14.7,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":4.9,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":24.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.210472+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_582574","record_id":"REC_0005518","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":19,"tmb_mutations_per_mb":3.5,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":0,"smoking_pack_years":51,"primary_tumor_size_cm":6.4,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.210704+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_524690","record_id":"REC_0005519","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":32,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":0,"smoking_pack_years":24,"primary_tumor_size_cm":4.5,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.210939+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_245512","record_id":"REC_0005520","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":68,"primary_tumor_size_cm":3.4,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.211169+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_824755","record_id":"REC_0005521","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":8.0,"age_at_diagnosis":83,"sex":"female","ecog_performance_status":2,"smoking_pack_years":53,"primary_tumor_size_cm":4.8,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.211398+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_498146","record_id":"REC_0005522","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":16.4,"age_at_diagnosis":86,"sex":"female","ecog_performance_status":2,"smoking_pack_years":4,"primary_tumor_size_cm":6.5,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.211632+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_785600","record_id":"REC_0005523","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":14.7,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":7.9,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.211868+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_590758","record_id":"REC_0005524","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":5.7,"age_at_diagnosis":46,"sex":"male","ecog_performance_status":0,"smoking_pack_years":50,"primary_tumor_size_cm":4.5,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.212176+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_310631","record_id":"REC_0005525","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":8.4,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":3.6,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.212414+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_109481","record_id":"REC_0005526","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":9.1,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":3.5,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":6.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.212800+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_696773","record_id":"REC_0005527","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":9.7,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":5.1,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.213041+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_224097","record_id":"REC_0005528","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":5.7,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":21.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.213338+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_589370","record_id":"REC_0005529","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":7.3,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":1,"smoking_pack_years":33,"primary_tumor_size_cm":2.5,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":21.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.213576+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_757889","record_id":"REC_0005530","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":7.7,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.213809+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_551537","record_id":"REC_0005531","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":35,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":7.3,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":21.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.214087+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_712384","record_id":"REC_0005532","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":6.1,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":4.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.214323+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_529659","record_id":"REC_0005533","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":6.7,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":35,"primary_tumor_size_cm":4.3,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.214557+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_923883","record_id":"REC_0005534","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":16,"tmb_mutations_per_mb":6.4,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":66,"primary_tumor_size_cm":4.6,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":6.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.214785+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_883253","record_id":"REC_0005535","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":33,"tmb_mutations_per_mb":3.8,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":2,"smoking_pack_years":34,"primary_tumor_size_cm":4.5,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":29.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.215063+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_569242","record_id":"REC_0005536","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":3.4,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":19.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.215302+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_366892","record_id":"REC_0005537","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":13.1,"age_at_diagnosis":51,"sex":"female","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":4.7,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.215537+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_778681","record_id":"REC_0005538","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":3,"smoking_pack_years":17,"primary_tumor_size_cm":6.4,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.215773+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_728849","record_id":"REC_0005539","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":6.4,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.216215+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_461655","record_id":"REC_0005540","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":4.7,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":4.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.216473+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_566287","record_id":"REC_0005541","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":19,"tmb_mutations_per_mb":8.4,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":6.0,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.216711+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_591146","record_id":"REC_0005542","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":17.1,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":6.9,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.216943+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_271899","record_id":"REC_0005543","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":17.7,"age_at_diagnosis":46,"sex":"male","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":6.9,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.217182+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_616847","record_id":"REC_0005544","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":54,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":3.9,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.217418+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_749546","record_id":"REC_0005545","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":19,"tmb_mutations_per_mb":10.1,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":1,"smoking_pack_years":30,"primary_tumor_size_cm":4.5,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.217656+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_996376","record_id":"REC_0005546","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":5.6,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":42,"primary_tumor_size_cm":5.8,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":6.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.217887+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_402220","record_id":"REC_0005547","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":15.2,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":6.2,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":25.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.218125+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_141647","record_id":"REC_0005548","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":54,"sex":"male","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":5.3,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":23.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.218355+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_771895","record_id":"REC_0005549","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ALK fusion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":2,"smoking_pack_years":7,"primary_tumor_size_cm":5.6,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":17.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.218582+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_809651","record_id":"REC_0005550","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":19,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":54,"primary_tumor_size_cm":4.6,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.218818+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_697716","record_id":"REC_0005551","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":17,"tmb_mutations_per_mb":17.2,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":3,"smoking_pack_years":12,"primary_tumor_size_cm":7.9,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.219051+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_597485","record_id":"REC_0005552","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":77,"sex":"male","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":5.0,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":5.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.219337+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_669909","record_id":"REC_0005553","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":1.9,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":49,"primary_tumor_size_cm":5.8,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":30.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.219570+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_185132","record_id":"REC_0005554","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":8.6,"age_at_diagnosis":74,"sex":"male","ecog_performance_status":2,"smoking_pack_years":0,"primary_tumor_size_cm":4.7,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":53.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.219803+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_888469","record_id":"REC_0005555","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":8.6,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":6.5,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.220031+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_941914","record_id":"REC_0005556","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":3.4,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.220303+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_459978","record_id":"REC_0005557","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":15,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":6.6,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":20.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.220542+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_373114","record_id":"REC_0005558","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":15.2,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":4.9,"metastatic_sites_count":9,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.220777+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_117708","record_id":"REC_0005559","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":6.9,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":45,"primary_tumor_size_cm":4.8,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":18.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.221012+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_495488","record_id":"REC_0005560","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":19.7,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":4.8,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.221245+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_196567","record_id":"REC_0005561","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":5.6,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.221481+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_526367","record_id":"REC_0005562","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":88,"sex":"male","ecog_performance_status":2,"smoking_pack_years":61,"primary_tumor_size_cm":4.3,"metastatic_sites_count":8,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.221711+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_186908","record_id":"REC_0005563","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":19,"tmb_mutations_per_mb":6.3,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":4.9,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.221943+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_488392","record_id":"REC_0005564","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":4.9,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":25.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.222173+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_865426","record_id":"REC_0005565","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":8.4,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":3.9,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.222453+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_653259","record_id":"REC_0005566","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":16.1,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":4.9,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":4.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.222693+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_330895","record_id":"REC_0005567","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":3.5,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":6.0,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":20.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.222927+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_549558","record_id":"REC_0005568","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":5.3,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":51,"primary_tumor_size_cm":5.7,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":5.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.223155+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_677999","record_id":"REC_0005569","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":6.0,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":3,"smoking_pack_years":13,"primary_tumor_size_cm":6.0,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":34.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.223383+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_476410","record_id":"REC_0005570","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":7.4,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":7.2,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.223615+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_590314","record_id":"REC_0005571","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":16.6,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":4.8,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":7.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.223852+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_274022","record_id":"REC_0005572","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":54,"sex":"female","ecog_performance_status":0,"smoking_pack_years":34,"primary_tumor_size_cm":6.9,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":4.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.224108+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_317231","record_id":"REC_0005573","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":3.9,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":6.5,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.224345+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_787067","record_id":"REC_0005574","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":15.8,"age_at_diagnosis":75,"sex":"male","ecog_performance_status":2,"smoking_pack_years":24,"primary_tumor_size_cm":5.2,"metastatic_sites_count":9,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.224582+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_219511","record_id":"REC_0005575","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":17.9,"age_at_diagnosis":84,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":7.6,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":64.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.224816+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_653443","record_id":"REC_0005576","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":7.8,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.225051+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_839475","record_id":"REC_0005577","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":5.2,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":36,"primary_tumor_size_cm":4.9,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":18.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.225282+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_974698","record_id":"REC_0005578","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":5.1,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.225587+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_504809","record_id":"REC_0005579","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":85,"sex":"female","ecog_performance_status":3,"smoking_pack_years":57,"primary_tumor_size_cm":6.6,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.225823+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_922993","record_id":"REC_0005580","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":10.5,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":3.7,"metastatic_sites_count":3,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.226080+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_192602","record_id":"REC_0005581","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":90,"sex":"male","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":6.4,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.226353+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_464514","record_id":"REC_0005582","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":12,"tmb_mutations_per_mb":1.8,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":0,"smoking_pack_years":60,"primary_tumor_size_cm":4.7,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":4.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.226586+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_793385","record_id":"REC_0005583","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":16.8,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":7,"primary_tumor_size_cm":7.2,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.226824+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_117288","record_id":"REC_0005584","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":33,"tmb_mutations_per_mb":8.1,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":48,"primary_tumor_size_cm":6.8,"metastatic_sites_count":3,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.227056+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_734538","record_id":"REC_0005585","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":3.7,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":0,"smoking_pack_years":48,"primary_tumor_size_cm":3.3,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":30.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.227289+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_836772","record_id":"REC_0005586","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":5.7,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":2,"smoking_pack_years":53,"primary_tumor_size_cm":6.7,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":16.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.227522+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_754974","record_id":"REC_0005587","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":74,"sex":"male","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":5.6,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.227756+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_761274","record_id":"REC_0005588","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":14.0,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":3.6,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.227989+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_846425","record_id":"REC_0005589","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":15.8,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":4.8,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":21.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.228263+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_342674","record_id":"REC_0005590","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":19,"tmb_mutations_per_mb":6.7,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":1,"smoking_pack_years":46,"primary_tumor_size_cm":5.7,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":18.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.228510+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_281609","record_id":"REC_0005591","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":15.1,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":5.3,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.228792+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_283990","record_id":"REC_0005592","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":10,"primary_tumor_size_cm":5.6,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.229033+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_387758","record_id":"REC_0005593","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":15.9,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":5.3,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":4.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.229268+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_310558","record_id":"REC_0005594","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":6.7,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":7.0,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":24.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.229501+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_810531","record_id":"REC_0005595","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":10.3,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":4.9,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.229736+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_719363","record_id":"REC_0005596","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":48,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":4.0,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":18.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.229967+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_127301","record_id":"REC_0005597","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":6.5,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":23.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.230199+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_923950","record_id":"REC_0005598","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":9.5,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":5.5,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.230430+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_790751","record_id":"REC_0005599","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":39,"tmb_mutations_per_mb":9.9,"age_at_diagnosis":54,"sex":"male","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":3.7,"metastatic_sites_count":8,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.230663+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_427740","record_id":"REC_0005600","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":53,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":5.3,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.230900+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_999587","record_id":"REC_0005601","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":5.5,"age_at_diagnosis":75,"sex":"male","ecog_performance_status":2,"smoking_pack_years":7,"primary_tumor_size_cm":5.4,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.231131+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_969738","record_id":"REC_0005602","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":33,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":44,"primary_tumor_size_cm":6.6,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.231359+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_203147","record_id":"REC_0005603","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":3.1,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":27,"primary_tumor_size_cm":5.0,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.231586+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_947660","record_id":"REC_0005604","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":5.3,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":39,"primary_tumor_size_cm":5.0,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":16.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.231861+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_537667","record_id":"REC_0005605","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":15.9,"age_at_diagnosis":74,"sex":"male","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":7.0,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.232220+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_950965","record_id":"REC_0005606","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":9.8,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":6.6,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":6.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.232464+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_562412","record_id":"REC_0005607","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":4.6,"age_at_diagnosis":49,"sex":"male","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":5.8,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.232700+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_736923","record_id":"REC_0005608","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":1,"smoking_pack_years":2,"primary_tumor_size_cm":5.3,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.232936+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_720182","record_id":"REC_0005609","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":10.1,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":6.3,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":39.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.233169+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_529958","record_id":"REC_0005610","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":19,"tmb_mutations_per_mb":6.7,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":40,"primary_tumor_size_cm":5.7,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.233403+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_875057","record_id":"REC_0005611","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":3.5,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":16.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.233637+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_349093","record_id":"REC_0005612","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":8.0,"age_at_diagnosis":90,"sex":"female","ecog_performance_status":0,"smoking_pack_years":47,"primary_tumor_size_cm":4.4,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.233863+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_306343","record_id":"REC_0005613","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":4.2,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":0,"smoking_pack_years":36,"primary_tumor_size_cm":4.4,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.234095+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_305977","record_id":"REC_0005614","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":18,"tmb_mutations_per_mb":6.1,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":33,"primary_tumor_size_cm":5.4,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.234322+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_159323","record_id":"REC_0005615","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":26,"primary_tumor_size_cm":3.5,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":6.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.234556+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_363248","record_id":"REC_0005616","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":31,"tmb_mutations_per_mb":17.7,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":25,"primary_tumor_size_cm":6.2,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.234785+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_397562","record_id":"REC_0005617","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":18,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":58,"primary_tumor_size_cm":5.6,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.235070+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_402747","record_id":"REC_0005618","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":6,"primary_tumor_size_cm":4.2,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":21.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.235308+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_734542","record_id":"REC_0005619","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":8.4,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":4.5,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.235545+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_246415","record_id":"REC_0005620","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":32,"tmb_mutations_per_mb":5.9,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":5.3,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":22.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.235776+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_191748","record_id":"REC_0005621","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":14.9,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":5.8,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.236013+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_997611","record_id":"REC_0005622","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":29,"primary_tumor_size_cm":5.5,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.236327+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_639042","record_id":"REC_0005623","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":16,"tmb_mutations_per_mb":6.0,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":6.0,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.236562+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_547767","record_id":"REC_0005624","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":3.9,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":1,"smoking_pack_years":40,"primary_tumor_size_cm":6.2,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.236795+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_665034","record_id":"REC_0005625","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":50,"sex":"male","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":6.8,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.237029+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_571860","record_id":"REC_0005626","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":18,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":6.3,"metastatic_sites_count":3,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":16.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.237265+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_201970","record_id":"REC_0005627","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":8.5,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.7,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.237497+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_865827","record_id":"REC_0005628","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":5.8,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":38.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.237727+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_539476","record_id":"REC_0005629","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":9.0,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":24,"primary_tumor_size_cm":4.2,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.237960+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_873715","record_id":"REC_0005630","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":30,"tmb_mutations_per_mb":3.9,"age_at_diagnosis":90,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":6.2,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":5.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.238240+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_424437","record_id":"REC_0005631","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":7.6,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":51,"primary_tumor_size_cm":6.5,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.238475+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_225207","record_id":"REC_0005632","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":2,"smoking_pack_years":36,"primary_tumor_size_cm":6.3,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":20.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.238708+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_364571","record_id":"REC_0005633","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":31,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":5.0,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":20.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.238949+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_352329","record_id":"REC_0005634","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":5.2,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":59,"primary_tumor_size_cm":6.3,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":21.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.239180+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_596370","record_id":"REC_0005635","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.0,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":2.9,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.239411+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_519885","record_id":"REC_0005636","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":17,"tmb_mutations_per_mb":4.6,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":33,"primary_tumor_size_cm":5.1,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":18.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.239642+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_147968","record_id":"REC_0005637","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":19.4,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":4.7,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.239874+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_726157","record_id":"REC_0005638","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":2,"smoking_pack_years":21,"primary_tumor_size_cm":4.3,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.240139+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_662565","record_id":"REC_0005639","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":14.5,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":1,"smoking_pack_years":5,"primary_tumor_size_cm":5.2,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.240380+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_697151","record_id":"REC_0005640","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":17.7,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":4.7,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":27.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.240612+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_557055","record_id":"REC_0005641","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":31,"tmb_mutations_per_mb":4.5,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":34,"primary_tumor_size_cm":4.5,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.240845+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_784954","record_id":"REC_0005642","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":18,"tmb_mutations_per_mb":6.3,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":6.5,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.241073+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_176861","record_id":"REC_0005643","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":32,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":6.6,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":19.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.241349+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_295054","record_id":"REC_0005644","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":3.4,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":20,"primary_tumor_size_cm":4.7,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":27.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.241586+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_699845","record_id":"REC_0005645","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":20,"tmb_mutations_per_mb":8.6,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":37,"primary_tumor_size_cm":2.0,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.241820+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_474584","record_id":"REC_0005646","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":15.3,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":4.7,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":20.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.242053+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_184022","record_id":"REC_0005647","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":5.9,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":21.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.242283+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_891058","record_id":"REC_0005648","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":14,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":54,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":5.4,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.242516+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_940412","record_id":"REC_0005649","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":6.7,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.6,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.242743+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_759407","record_id":"REC_0005650","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":30,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.7,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.242971+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_685224","record_id":"REC_0005651","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":17,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":4.5,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.243201+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_259420","record_id":"REC_0005652","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":8.5,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":20,"primary_tumor_size_cm":4.0,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.243433+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_764524","record_id":"REC_0005653","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":19,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":50,"sex":"male","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":6.5,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.243669+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_829434","record_id":"REC_0005654","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":13.6,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":5.5,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.243906+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_272023","record_id":"REC_0005655","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":37,"tmb_mutations_per_mb":3.5,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":4.0,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.244187+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_845686","record_id":"REC_0005656","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":14,"tmb_mutations_per_mb":3.7,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":3.9,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.244465+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_156668","record_id":"REC_0005657","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":4.8,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.244708+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_620591","record_id":"REC_0005658","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":17.4,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.4,"metastatic_sites_count":9,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.244941+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_886263","record_id":"REC_0005659","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":30,"tmb_mutations_per_mb":5.5,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":5.5,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.245187+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_223420","record_id":"REC_0005660","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":18,"tmb_mutations_per_mb":6.1,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":3,"smoking_pack_years":38,"primary_tumor_size_cm":6.7,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":6.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.245416+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_179175","record_id":"REC_0005661","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":5.1,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":41,"primary_tumor_size_cm":6.9,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.245646+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_139423","record_id":"REC_0005662","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":10.5,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":5,"primary_tumor_size_cm":4.7,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":27.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.245881+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_203061","record_id":"REC_0005663","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":10.0,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":24,"primary_tumor_size_cm":3.1,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.246117+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_218388","record_id":"REC_0005664","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":3.5,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.246349+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_381886","record_id":"REC_0005665","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":15.2,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":6.1,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.246586+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_610993","record_id":"REC_0005666","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":5.4,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.246819+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_306078","record_id":"REC_0005667","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":62,"primary_tumor_size_cm":5.3,"metastatic_sites_count":3,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.247048+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_676537","record_id":"REC_0005668","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":7.1,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.247280+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_380868","record_id":"REC_0005669","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":5.1,"age_at_diagnosis":53,"sex":"male","ecog_performance_status":0,"smoking_pack_years":28,"primary_tumor_size_cm":6.7,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":20.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.247562+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_131496","record_id":"REC_0005670","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":1,"smoking_pack_years":77,"primary_tumor_size_cm":5.9,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.247797+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_615633","record_id":"REC_0005671","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":17.1,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":5.2,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.248034+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_940347","record_id":"REC_0005672","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":5.9,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":18.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.248295+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_246144","record_id":"REC_0005673","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":4.9,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":5.9,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.248531+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_408711","record_id":"REC_0005674","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":4.8,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":6.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.248763+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_494117","record_id":"REC_0005675","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":18,"tmb_mutations_per_mb":3.9,"age_at_diagnosis":51,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":5.9,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.248993+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_316338","record_id":"REC_0005676","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":17.4,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":5.5,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.249228+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_558149","record_id":"REC_0005677","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":32,"tmb_mutations_per_mb":4.6,"age_at_diagnosis":75,"sex":"male","ecog_performance_status":0,"smoking_pack_years":66,"primary_tumor_size_cm":5.4,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.249536+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_252652","record_id":"REC_0005678","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":7,"primary_tumor_size_cm":5.2,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.249776+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_405346","record_id":"REC_0005679","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":4.8,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.250009+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_923688","record_id":"REC_0005680","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":5.1,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":6.0,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.250237+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_473631","record_id":"REC_0005681","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":9.0,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":2,"smoking_pack_years":9,"primary_tumor_size_cm":5.4,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":18.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.250463+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_820442","record_id":"REC_0005682","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":13.6,"age_at_diagnosis":53,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":6.4,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":16.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.250744+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_319137","record_id":"REC_0005683","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":37,"tmb_mutations_per_mb":5.7,"age_at_diagnosis":90,"sex":"female","ecog_performance_status":3,"smoking_pack_years":62,"primary_tumor_size_cm":6.5,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.250981+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_603271","record_id":"REC_0005684","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":58,"primary_tumor_size_cm":5.2,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.251214+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_831729","record_id":"REC_0005685","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":5.4,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.251448+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_583608","record_id":"REC_0005686","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":13.3,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.6,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.251679+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_535227","record_id":"REC_0005687","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":19.0,"age_at_diagnosis":45,"sex":"male","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":3.8,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":20.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.251916+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_713866","record_id":"REC_0005688","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":19.0,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":5.1,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.252175+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_928656","record_id":"REC_0005689","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":15.6,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":8.9,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":24.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.252409+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_779658","record_id":"REC_0005690","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":4.6,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":5.9,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":40.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.252639+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_352943","record_id":"REC_0005691","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":54,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":6.5,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":22.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.252873+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_887816","record_id":"REC_0005692","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":7.9,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":7.9,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":20.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.253099+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_441896","record_id":"REC_0005693","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":15.7,"age_at_diagnosis":50,"sex":"male","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":6.3,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.253331+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_955912","record_id":"REC_0005694","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":30,"tmb_mutations_per_mb":7.3,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":58,"primary_tumor_size_cm":4.0,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.253561+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_840784","record_id":"REC_0005695","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":2.7,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":5.0,"metastatic_sites_count":9,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.253838+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_344518","record_id":"REC_0005696","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":38,"tmb_mutations_per_mb":4.3,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":71,"primary_tumor_size_cm":4.8,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.254067+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_353978","record_id":"REC_0005697","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":5.0,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.254301+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_163440","record_id":"REC_0005698","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":13.6,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":5.9,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.254533+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_894131","record_id":"REC_0005699","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":8.1,"age_at_diagnosis":52,"sex":"male","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":3.8,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":69.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.254765+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_709070","record_id":"REC_0005700","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":5.8,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":4.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.254999+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_121626","record_id":"REC_0005701","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":0,"smoking_pack_years":32,"primary_tumor_size_cm":6.0,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":7.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.255233+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_371202","record_id":"REC_0005702","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":16.6,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":22,"primary_tumor_size_cm":4.4,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.255465+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_829506","record_id":"REC_0005703","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":8.9,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":5,"primary_tumor_size_cm":3.2,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.255693+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_680098","record_id":"REC_0005704","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":4.1,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":18.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.255928+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_769590","record_id":"REC_0005705","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":2,"smoking_pack_years":21,"primary_tumor_size_cm":3.9,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.256240+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_791077","record_id":"REC_0005706","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":3,"smoking_pack_years":26,"primary_tumor_size_cm":2.9,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":8.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.256482+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_520824","record_id":"REC_0005707","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":6.0,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":0,"smoking_pack_years":45,"primary_tumor_size_cm":3.7,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.256717+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_182038","record_id":"REC_0005708","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":18.2,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":7.0,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.257009+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_676304","record_id":"REC_0005709","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":20,"primary_tumor_size_cm":5.7,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.257241+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_439118","record_id":"REC_0005710","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":14.3,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":6.5,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":24.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.257473+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_963158","record_id":"REC_0005711","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":3.3,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":28.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.257710+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_903038","record_id":"REC_0005712","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":16.8,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":5.9,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.257940+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_680472","record_id":"REC_0005713","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":9.0,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":2,"primary_tumor_size_cm":6.2,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.258174+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_480401","record_id":"REC_0005714","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":15.7,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":5.6,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.258406+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_214463","record_id":"REC_0005715","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":2,"smoking_pack_years":20,"primary_tumor_size_cm":5.7,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.258638+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_339336","record_id":"REC_0005716","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":14.8,"age_at_diagnosis":75,"sex":"male","ecog_performance_status":2,"smoking_pack_years":23,"primary_tumor_size_cm":5.0,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.258875+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_782893","record_id":"REC_0005717","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":30,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":1,"smoking_pack_years":27,"primary_tumor_size_cm":6.4,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.259106+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_602944","record_id":"REC_0005718","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":9.0,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":8,"primary_tumor_size_cm":4.4,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.259337+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_136859","record_id":"REC_0005719","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":1,"smoking_pack_years":84,"primary_tumor_size_cm":6.8,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.259569+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_800977","record_id":"REC_0005720","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":13.6,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":5.6,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.259874+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_447457","record_id":"REC_0005721","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":9.1,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":7.0,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":17.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.260182+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_430989","record_id":"REC_0005722","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":4.5,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":23.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.260423+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_631499","record_id":"REC_0005723","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":5.5,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":40,"primary_tumor_size_cm":5.9,"metastatic_sites_count":9,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":4.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.260659+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_928187","record_id":"REC_0005724","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":16,"tmb_mutations_per_mb":11.5,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":7.0,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.260896+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_538240","record_id":"REC_0005725","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":4.7,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":19.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.261125+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_525189","record_id":"REC_0005726","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":2,"smoking_pack_years":21,"primary_tumor_size_cm":6.2,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.261362+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_492304","record_id":"REC_0005727","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":6.8,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":21.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.261590+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_302928","record_id":"REC_0005728","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":5.2,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":27.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.261823+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_975234","record_id":"REC_0005729","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":17.0,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":6.7,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.262057+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_344587","record_id":"REC_0005730","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":10.3,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":24,"primary_tumor_size_cm":5.6,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.262292+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_986701","record_id":"REC_0005731","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":17.8,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":4.7,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.262526+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_889800","record_id":"REC_0005732","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":4.7,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":4.7,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":22.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.262754+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_971695","record_id":"REC_0005733","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":16.5,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":4.0,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":21.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.262985+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_667382","record_id":"REC_0005734","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":5.9,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":5.9,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":25.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.263257+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_844342","record_id":"REC_0005735","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":4.0,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":64,"primary_tumor_size_cm":5.7,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.263494+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_986161","record_id":"REC_0005736","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":15.4,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.5,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":6.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.263728+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_398213","record_id":"REC_0005737","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":13,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":4.6,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":20.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.263964+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_963153","record_id":"REC_0005738","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":90,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":4.9,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.264297+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_286785","record_id":"REC_0005739","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":18.9,"age_at_diagnosis":54,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":6.2,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":5.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.264538+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_865531","record_id":"REC_0005740","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":5.0,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":20.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.264774+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_218904","record_id":"REC_0005741","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":17.8,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":4.8,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.265008+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_764772","record_id":"REC_0005742","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":50,"sex":"male","ecog_performance_status":0,"smoking_pack_years":54,"primary_tumor_size_cm":5.0,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.265239+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_257490","record_id":"REC_0005743","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":31,"tmb_mutations_per_mb":8.6,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":6.0,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.265472+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_867962","record_id":"REC_0005744","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":4.9,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":9,"primary_tumor_size_cm":4.5,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.265697+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_178540","record_id":"REC_0005745","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":9.9,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":6.5,"metastatic_sites_count":9,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.265930+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_865099","record_id":"REC_0005746","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":52,"sex":"male","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":6.4,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":21.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.266163+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_131367","record_id":"REC_0005747","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":6.4,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":1,"smoking_pack_years":56,"primary_tumor_size_cm":7.8,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.266441+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_872948","record_id":"REC_0005748","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":15.8,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":6.2,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.266679+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_293279","record_id":"REC_0005749","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":16.0,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":23,"primary_tumor_size_cm":5.5,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.266914+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_643957","record_id":"REC_0005750","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":4.8,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":16.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.267149+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_285612","record_id":"REC_0005751","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":19,"tmb_mutations_per_mb":5.9,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":60,"primary_tumor_size_cm":6.9,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.267384+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_522022","record_id":"REC_0005752","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":10.0,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":5.9,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.267617+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_440388","record_id":"REC_0005753","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":67,"primary_tumor_size_cm":5.8,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.267843+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_144889","record_id":"REC_0005754","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":13.8,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":5.8,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.268113+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_338477","record_id":"REC_0005755","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":6.4,"age_at_diagnosis":49,"sex":"male","ecog_performance_status":0,"smoking_pack_years":64,"primary_tumor_size_cm":6.6,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.268353+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_714561","record_id":"REC_0005756","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":3.5,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.268600+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_663863","record_id":"REC_0005757","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":16,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":5.9,"metastatic_sites_count":9,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.268839+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_665329","record_id":"REC_0005758","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":19,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":0,"smoking_pack_years":52,"primary_tumor_size_cm":4.1,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.269068+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_352315","record_id":"REC_0005759","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":3.9,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":1,"smoking_pack_years":45,"primary_tumor_size_cm":7.3,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.269301+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_776102","record_id":"REC_0005760","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":18.5,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":6.5,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.269589+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_777809","record_id":"REC_0005761","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":3.0,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.269823+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_390137","record_id":"REC_0005762","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":17.9,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":4.4,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.270060+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_566177","record_id":"REC_0005763","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":14.8,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":4.9,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.270297+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_953771","record_id":"REC_0005764","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":4.1,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":5.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.270532+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_778285","record_id":"REC_0005765","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":3.9,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.270769+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_721282","record_id":"REC_0005766","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":8.3,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":5.7,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":6.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.270997+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_848808","record_id":"REC_0005767","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":3,"smoking_pack_years":7,"primary_tumor_size_cm":5.5,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.271233+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_280710","record_id":"REC_0005768","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":14.4,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":3,"smoking_pack_years":11,"primary_tumor_size_cm":5.4,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":17.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.271467+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_692758","record_id":"REC_0005769","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":19,"tmb_mutations_per_mb":16.1,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":4.6,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.271698+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_130408","record_id":"REC_0005770","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":4.7,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":25,"primary_tumor_size_cm":6.5,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":18.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.271925+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_303823","record_id":"REC_0005771","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":6.5,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":7.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.272182+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_792557","record_id":"REC_0005772","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":5.3,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":67,"primary_tumor_size_cm":4.5,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.272414+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_947504","record_id":"REC_0005773","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":81,"sex":"male","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":3.7,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":5.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.272693+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_684958","record_id":"REC_0005774","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":13,"tmb_mutations_per_mb":9.9,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":25,"primary_tumor_size_cm":3.4,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":35.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.272928+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_987996","record_id":"REC_0005775","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":53,"primary_tumor_size_cm":4.4,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":17.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.273161+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_942298","record_id":"REC_0005776","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":41,"tmb_mutations_per_mb":5.1,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":6.5,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.273390+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_208352","record_id":"REC_0005777","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":3.7,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":60,"primary_tumor_size_cm":5.8,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.273625+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_183976","record_id":"REC_0005778","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":14.7,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":4.3,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":26.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.273861+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_792315","record_id":"REC_0005779","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":36,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":5.4,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.274092+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_510553","record_id":"REC_0005780","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":19,"tmb_mutations_per_mb":5.3,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":4.0,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.274320+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_371253","record_id":"REC_0005781","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":8.4,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":21.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.274583+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_445085","record_id":"REC_0005782","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":6.7,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.274821+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_902956","record_id":"REC_0005783","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":19,"tmb_mutations_per_mb":5.7,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":20,"primary_tumor_size_cm":7.6,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.275100+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_957278","record_id":"REC_0005784","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":14.9,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":4.8,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":7.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.275398+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_543169","record_id":"REC_0005785","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":4,"smoking_pack_years":4,"primary_tumor_size_cm":4.9,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":23.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.275627+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_492550","record_id":"REC_0005786","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":50,"sex":"male","ecog_performance_status":0,"smoking_pack_years":69,"primary_tumor_size_cm":3.3,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":22.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.275904+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_189764","record_id":"REC_0005787","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":14.3,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":5.3,"metastatic_sites_count":3,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.276237+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_683204","record_id":"REC_0005788","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":5.0,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.276476+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_916212","record_id":"REC_0005789","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":4.2,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.276715+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_822418","record_id":"REC_0005790","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":15.3,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":5.3,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":41.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.276948+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_543426","record_id":"REC_0005791","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":8.1,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":4.9,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.277223+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_669079","record_id":"REC_0005792","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":21.1,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":5.3,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.277465+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_407567","record_id":"REC_0005793","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":6.4,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":38,"primary_tumor_size_cm":5.6,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":51.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.277699+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_373174","record_id":"REC_0005794","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":2.8,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":3.9,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":33.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.277927+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_506828","record_id":"REC_0005795","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":9.1,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":4.5,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":7.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.278161+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_530462","record_id":"REC_0005796","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":4.1,"age_at_diagnosis":42,"sex":"female","ecog_performance_status":0,"smoking_pack_years":44,"primary_tumor_size_cm":3.5,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":17.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.278392+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_501374","record_id":"REC_0005797","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":18,"tmb_mutations_per_mb":7.9,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":10,"primary_tumor_size_cm":7.1,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":29.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.278620+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_405965","record_id":"REC_0005798","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":17.2,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":4.8,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.278855+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_836744","record_id":"REC_0005799","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":4.6,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.279136+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_906990","record_id":"REC_0005800","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":15.5,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":5.1,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.279371+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_509145","record_id":"REC_0005801","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":13.5,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":6.3,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.279606+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_315346","record_id":"REC_0005802","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":4.0,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":21.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.279844+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_917095","record_id":"REC_0005803","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":5.4,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.280116+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_251012","record_id":"REC_0005804","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":13,"tmb_mutations_per_mb":21.8,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":5.9,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.280369+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_698968","record_id":"REC_0005805","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":1,"smoking_pack_years":39,"primary_tumor_size_cm":5.0,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":16.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.280605+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_911914","record_id":"REC_0005806","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":13,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":3.2,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.280840+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_584102","record_id":"REC_0005807","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ALK fusion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":15.3,"age_at_diagnosis":77,"sex":"male","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":4.5,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":22.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.281076+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_353420","record_id":"REC_0005808","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":18,"tmb_mutations_per_mb":10.5,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":7.2,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.281313+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_314297","record_id":"REC_0005809","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":14.3,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":6.0,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.281547+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_751797","record_id":"REC_0005810","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":78,"sex":"male","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":6.5,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.281778+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_124373","record_id":"REC_0005811","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":30,"tmb_mutations_per_mb":6.4,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":5.1,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":7.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.282008+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_498319","record_id":"REC_0005812","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":3.8,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.282280+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_317653","record_id":"REC_0005813","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":13.8,"age_at_diagnosis":85,"sex":"female","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":5.1,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.282518+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_533118","record_id":"REC_0005814","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":59,"primary_tumor_size_cm":6.6,"metastatic_sites_count":3,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.282747+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_332733","record_id":"REC_0005815","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":13.8,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":3.5,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":38.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.282985+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_859463","record_id":"REC_0005816","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":15.3,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":5.0,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":22.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.283218+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_133960","record_id":"REC_0005817","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":14.3,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":5.8,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":20.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.283450+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_611616","record_id":"REC_0005818","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":10.5,"age_at_diagnosis":74,"sex":"male","ecog_performance_status":3,"smoking_pack_years":4,"primary_tumor_size_cm":6.2,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":4.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.283682+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_441116","record_id":"REC_0005819","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":7.4,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.283913+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_690694","record_id":"REC_0005820","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":14.6,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":6.5,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.284176+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_125312","record_id":"REC_0005821","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":75,"sex":"male","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":4.4,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.284416+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_859117","record_id":"REC_0005822","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":10.1,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":6.7,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":51.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.284654+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_356279","record_id":"REC_0005823","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":19,"tmb_mutations_per_mb":11.5,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":6,"primary_tumor_size_cm":4.1,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.284886+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_992549","record_id":"REC_0005824","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":4.9,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":3.8,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":19.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.285116+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_169847","record_id":"REC_0005825","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":7.8,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.285393+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_317248","record_id":"REC_0005826","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":9.9,"age_at_diagnosis":54,"sex":"male","ecog_performance_status":0,"smoking_pack_years":25,"primary_tumor_size_cm":4.6,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.285672+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_303877","record_id":"REC_0005827","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":13.3,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":4.8,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.285911+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_940129","record_id":"REC_0005828","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":5.2,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.286147+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_186858","record_id":"REC_0005829","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":6,"primary_tumor_size_cm":6.6,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.286379+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_205088","record_id":"REC_0005830","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":4.1,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.286612+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_827407","record_id":"REC_0005831","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":3.5,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":4,"primary_tumor_size_cm":6.2,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.286842+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_363209","record_id":"REC_0005832","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":18,"tmb_mutations_per_mb":6.1,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":51,"primary_tumor_size_cm":4.3,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":4.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.287072+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_534427","record_id":"REC_0005833","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":17,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":21,"primary_tumor_size_cm":3.7,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":21.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.287309+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_376151","record_id":"REC_0005834","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":87,"primary_tumor_size_cm":7.1,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.287541+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_122283","record_id":"REC_0005835","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":6.3,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":23.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.287811+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_500755","record_id":"REC_0005836","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":6,"primary_tumor_size_cm":6.0,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":20.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.288050+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_762879","record_id":"REC_0005837","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":6.4,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":6,"primary_tumor_size_cm":4.0,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":8.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.288309+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_794559","record_id":"REC_0005838","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":4.7,"age_at_diagnosis":54,"sex":"male","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":7.7,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.288626+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_619864","record_id":"REC_0005839","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":6.9,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":27.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.288867+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_592915","record_id":"REC_0005840","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":11.0,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":5.5,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.289146+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_579826","record_id":"REC_0005841","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":8.1,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":3.9,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":25.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.289382+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_941136","record_id":"REC_0005842","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":75,"sex":"male","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":6.3,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.289638+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_723710","record_id":"REC_0005843","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":17,"tmb_mutations_per_mb":10.3,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":5.5,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":7.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.290055+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_484851","record_id":"REC_0005844","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":4.3,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":21.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.290464+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_243989","record_id":"REC_0005845","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":11.0,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":5.0,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.290777+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_455272","record_id":"REC_0005846","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":14.5,"age_at_diagnosis":52,"sex":"female","ecog_performance_status":0,"smoking_pack_years":1,"primary_tumor_size_cm":6.2,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.291016+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_445846","record_id":"REC_0005847","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":23,"primary_tumor_size_cm":6.0,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.291251+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_762488","record_id":"REC_0005848","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":6.1,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":0,"smoking_pack_years":40,"primary_tumor_size_cm":4.3,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":7.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.291481+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_194456","record_id":"REC_0005849","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":35,"tmb_mutations_per_mb":9.8,"age_at_diagnosis":83,"sex":"female","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":6.7,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.291715+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_210122","record_id":"REC_0005850","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None","pd_l1_tps_percent":32,"tmb_mutations_per_mb":3.6,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":44,"primary_tumor_size_cm":6.0,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":29.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.291946+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_222244","record_id":"REC_0005851","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":17,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":27,"primary_tumor_size_cm":5.3,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.292280+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_454887","record_id":"REC_0005852","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":19,"tmb_mutations_per_mb":5.7,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":38,"primary_tumor_size_cm":3.6,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.292512+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_437737","record_id":"REC_0005853","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":10.1,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":9,"primary_tumor_size_cm":5.6,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.292762+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_537978","record_id":"REC_0005854","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":5,"primary_tumor_size_cm":5.5,"metastatic_sites_count":3,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.292999+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_250092","record_id":"REC_0005855","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":9,"primary_tumor_size_cm":4.3,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.293231+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_234082","record_id":"REC_0005856","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":10.3,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":3.4,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.293464+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_118905","record_id":"REC_0005857","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":13.1,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":6.3,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.293697+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_309592","record_id":"REC_0005858","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":5.9,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":19.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.293931+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_602587","record_id":"REC_0005859","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":5.2,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":32,"primary_tumor_size_cm":6.2,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":5.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.294164+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_514842","record_id":"REC_0005860","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":9.7,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":6.4,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":18.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.294390+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_795406","record_id":"REC_0005861","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":16.5,"age_at_diagnosis":86,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":6.9,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.294619+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_559479","record_id":"REC_0005862","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":77,"sex":"male","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":4.5,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.294854+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_283440","record_id":"REC_0005863","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":15.7,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.5,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.295092+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_334514","record_id":"REC_0005864","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":14.3,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":3,"smoking_pack_years":15,"primary_tumor_size_cm":4.4,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":25.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.295367+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_849211","record_id":"REC_0005865","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":2,"primary_tumor_size_cm":5.8,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.295607+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_247917","record_id":"REC_0005866","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":22,"primary_tumor_size_cm":5.2,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.295837+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_996526","record_id":"REC_0005867","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":30,"tmb_mutations_per_mb":14.9,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":5.6,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.296208+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_521222","record_id":"REC_0005868","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":37,"tmb_mutations_per_mb":15.1,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":5.2,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.296457+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_647772","record_id":"REC_0005869","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":5.3,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.296698+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_304242","record_id":"REC_0005870","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":41,"primary_tumor_size_cm":3.2,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.296930+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_114143","record_id":"REC_0005871","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":5.1,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":3,"smoking_pack_years":18,"primary_tumor_size_cm":6.0,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.297166+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_356894","record_id":"REC_0005872","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":11.0,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":5.9,"metastatic_sites_count":9,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.297400+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_671763","record_id":"REC_0005873","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":19,"tmb_mutations_per_mb":9.9,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":0,"smoking_pack_years":49,"primary_tumor_size_cm":7.4,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":22.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.297633+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_663042","record_id":"REC_0005874","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":8.0,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":28,"primary_tumor_size_cm":7.7,"metastatic_sites_count":8,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.297860+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_444529","record_id":"REC_0005875","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":6.8,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.298096+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_196011","record_id":"REC_0005876","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":54,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":4.6,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":17.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.298330+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_313674","record_id":"REC_0005877","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":14.9,"age_at_diagnosis":52,"sex":"male","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":4.2,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":21.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.298611+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_722366","record_id":"REC_0005878","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":49,"sex":"male","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":4.7,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.298849+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_716147","record_id":"REC_0005879","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":16,"tmb_mutations_per_mb":16.7,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":3.6,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.299085+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_459368","record_id":"REC_0005880","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":15.2,"age_at_diagnosis":80,"sex":"male","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":6.2,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":19.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.299321+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_916968","record_id":"REC_0005881","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":4.6,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":6.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.299556+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_479645","record_id":"REC_0005882","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":15,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":5.7,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":4.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.299791+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_437308","record_id":"REC_0005883","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":30,"tmb_mutations_per_mb":13.3,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.4,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.300024+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_798138","record_id":"REC_0005884","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":14.1,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":1,"smoking_pack_years":4,"primary_tumor_size_cm":2.6,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":5.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.300289+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_395446","record_id":"REC_0005885","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":6.4,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":6.9,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.300523+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_232393","record_id":"REC_0005886","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":83,"sex":"male","ecog_performance_status":2,"smoking_pack_years":27,"primary_tumor_size_cm":5.6,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.300755+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_625373","record_id":"REC_0005887","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":8.5,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":4.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.300988+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_288632","record_id":"REC_0005888","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":5.7,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":40,"primary_tumor_size_cm":4.8,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.301218+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_239341","record_id":"REC_0005889","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":14.4,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":6.8,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.301449+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_533504","record_id":"REC_0005890","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":41,"primary_tumor_size_cm":3.6,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.301727+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_373922","record_id":"REC_0005891","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":17,"tmb_mutations_per_mb":3.7,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":6.3,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":19.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.301964+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_497005","record_id":"REC_0005892","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":4.5,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":22.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.302194+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_408898","record_id":"REC_0005893","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":8.6,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":4.9,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":22.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.302422+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_499216","record_id":"REC_0005894","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":15.0,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.1,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.302659+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_945344","record_id":"REC_0005895","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":4.3,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":1,"smoking_pack_years":45,"primary_tumor_size_cm":3.6,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.302886+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_677702","record_id":"REC_0005896","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":15.3,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":5.5,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.303121+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_908670","record_id":"REC_0005897","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":33,"tmb_mutations_per_mb":15.9,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":3,"smoking_pack_years":18,"primary_tumor_size_cm":7.3,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.303355+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_139216","record_id":"REC_0005898","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":13.5,"age_at_diagnosis":86,"sex":"female","ecog_performance_status":2,"smoking_pack_years":10,"primary_tumor_size_cm":3.5,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.303588+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_165166","record_id":"REC_0005899","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":17,"tmb_mutations_per_mb":3.6,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":77,"primary_tumor_size_cm":5.0,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":22.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.303819+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_222258","record_id":"REC_0005900","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":15.5,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.0,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.304053+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_929640","record_id":"REC_0005901","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":3.3,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":5.0,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":19.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.304345+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_390265","record_id":"REC_0005902","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":6.3,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":5.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.304582+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_773543","record_id":"REC_0005903","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":6.9,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.304864+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_106715","record_id":"REC_0005904","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":6.4,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":23.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.305103+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_408859","record_id":"REC_0005905","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":3.9,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":47.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.305348+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_725011","record_id":"REC_0005906","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":7.3,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":5.8,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.305594+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_844045","record_id":"REC_0005907","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":6.1,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":5.5,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.305843+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_178089","record_id":"REC_0005908","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":5.7,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.306091+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_538489","record_id":"REC_0005909","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":13.5,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":4.4,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":16.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.306347+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_887326","record_id":"REC_0005910","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":51,"sex":"male","ecog_performance_status":0,"smoking_pack_years":68,"primary_tumor_size_cm":5.7,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.306605+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_537700","record_id":"REC_0005911","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":6.6,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":7.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.306864+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_320242","record_id":"REC_0005912","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":3,"smoking_pack_years":18,"primary_tumor_size_cm":6.7,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":5.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.307115+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_373269","record_id":"REC_0005913","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":52,"sex":"female","ecog_performance_status":0,"smoking_pack_years":6,"primary_tumor_size_cm":3.5,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.307357+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_760982","record_id":"REC_0005914","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":82,"sex":"male","ecog_performance_status":2,"smoking_pack_years":48,"primary_tumor_size_cm":6.4,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.307592+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_445669","record_id":"REC_0005915","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":8.1,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":8.0,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.307826+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_273859","record_id":"REC_0005916","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":5.5,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":5.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.308267+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_854910","record_id":"REC_0005917","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":5.6,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":0,"smoking_pack_years":55,"primary_tumor_size_cm":5.9,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":18.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.308514+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_704965","record_id":"REC_0005918","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":6.0,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":27.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.308757+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_754175","record_id":"REC_0005919","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":9.8,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":57,"primary_tumor_size_cm":6.0,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":23.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.308996+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_826343","record_id":"REC_0005920","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":0,"primary_tumor_size_cm":6.4,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":17.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.309226+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_609710","record_id":"REC_0005921","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":16,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":3.9,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.309453+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_452280","record_id":"REC_0005922","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":4.2,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.309688+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_118440","record_id":"REC_0005923","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":15,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":50,"sex":"female","ecog_performance_status":0,"smoking_pack_years":24,"primary_tumor_size_cm":6.0,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":25.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.309922+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_528455","record_id":"REC_0005924","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":31,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":74,"sex":"male","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":4.3,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.310155+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_826171","record_id":"REC_0005925","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":8.0,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":0,"smoking_pack_years":80,"primary_tumor_size_cm":7.8,"metastatic_sites_count":3,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.310387+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_565847","record_id":"REC_0005926","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":8.0,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":64,"primary_tumor_size_cm":6.2,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":64.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.310619+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_192935","record_id":"REC_0005927","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":35,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":3.9,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.310856+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_156310","record_id":"REC_0005928","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":6.9,"age_at_diagnosis":75,"sex":"male","ecog_performance_status":1,"smoking_pack_years":78,"primary_tumor_size_cm":6.8,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":17.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.311087+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_543465","record_id":"REC_0005929","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":11.1,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":6.0,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":36.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.311383+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_471340","record_id":"REC_0005930","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":16,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":39,"primary_tumor_size_cm":4.0,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.311614+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_163028","record_id":"REC_0005931","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":13.1,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":6.9,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":18.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.311853+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_947432","record_id":"REC_0005932","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":2,"smoking_pack_years":24,"primary_tumor_size_cm":4.4,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.312176+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_404251","record_id":"REC_0005933","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":9.5,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":10,"primary_tumor_size_cm":6.0,"metastatic_sites_count":9,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.312417+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_385632","record_id":"REC_0005934","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":16.5,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":4.3,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.312650+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_704805","record_id":"REC_0005935","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":14.1,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":5.9,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":4.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.312882+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_366657","record_id":"REC_0005936","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":10.1,"age_at_diagnosis":90,"sex":"male","ecog_performance_status":2,"smoking_pack_years":64,"primary_tumor_size_cm":6.4,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":20.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.313114+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_253531","record_id":"REC_0005937","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":5.1,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.313352+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_969655","record_id":"REC_0005938","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":33,"tmb_mutations_per_mb":4.7,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":37,"primary_tumor_size_cm":7.5,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.313584+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_254279","record_id":"REC_0005939","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":5.0,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.313816+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_858621","record_id":"REC_0005940","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":11.0,"age_at_diagnosis":85,"sex":"female","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":4.4,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":5.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.314046+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_185380","record_id":"REC_0005941","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":5.0,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.314279+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_823211","record_id":"REC_0005942","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":20,"tmb_mutations_per_mb":16.0,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":5.4,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.314579+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_621466","record_id":"REC_0005943","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":88,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":4.8,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.314810+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_711961","record_id":"REC_0005944","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":61,"primary_tumor_size_cm":3.9,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.315045+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_267256","record_id":"REC_0005945","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":14.4,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":6.8,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.315284+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_862442","record_id":"REC_0005946","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":5.0,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":21,"primary_tumor_size_cm":2.0,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":35.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.315511+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_420147","record_id":"REC_0005947","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":6.5,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":17.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.315746+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_947213","record_id":"REC_0005948","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":4.6,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":4.2,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.315979+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_493625","record_id":"REC_0005949","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ALK fusion","pd_l1_tps_percent":16,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":5.3,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":42.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.316270+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_570904","record_id":"REC_0005950","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":14,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":2,"smoking_pack_years":21,"primary_tumor_size_cm":6.0,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.316517+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_876443","record_id":"REC_0005951","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":4.6,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":0,"smoking_pack_years":45,"primary_tumor_size_cm":5.8,"metastatic_sites_count":3,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.316773+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_592372","record_id":"REC_0005952","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":19,"tmb_mutations_per_mb":3.1,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":5.7,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":30.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.317011+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_968266","record_id":"REC_0005953","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":17.7,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":4.9,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.317247+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_989343","record_id":"REC_0005954","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":5.5,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":28.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.317479+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_660481","record_id":"REC_0005955","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":3,"smoking_pack_years":13,"primary_tumor_size_cm":6.3,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":6.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.317798+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_939388","record_id":"REC_0005956","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":1.5,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":2,"smoking_pack_years":51,"primary_tumor_size_cm":5.8,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":25.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.318033+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_685434","record_id":"REC_0005957","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":15.0,"age_at_diagnosis":46,"sex":"male","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":5.5,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":4.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.318272+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_744759","record_id":"REC_0005958","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":14.4,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":4.9,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":23.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.318508+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_573625","record_id":"REC_0005959","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":18,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":56,"primary_tumor_size_cm":4.2,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.318744+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_236322","record_id":"REC_0005960","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":18.5,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":6.4,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":19.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.318975+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_406678","record_id":"REC_0005961","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":6.9,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.319209+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_146772","record_id":"REC_0005962","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":6.3,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":6.2,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.319439+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_614612","record_id":"REC_0005963","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":17.1,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":7.0,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":22.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.319672+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_923809","record_id":"REC_0005964","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":5.0,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":42.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.319906+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_631307","record_id":"REC_0005965","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":1,"primary_tumor_size_cm":5.5,"metastatic_sites_count":9,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.320180+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_511268","record_id":"REC_0005966","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":7.7,"metastatic_sites_count":8,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.320426+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_866122","record_id":"REC_0005967","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":18.6,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":4.9,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":22.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.320662+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_829282","record_id":"REC_0005968","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":34,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.7,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.320989+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_784166","record_id":"REC_0005969","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":10.0,"age_at_diagnosis":53,"sex":"male","ecog_performance_status":0,"smoking_pack_years":24,"primary_tumor_size_cm":5.9,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":22.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.321233+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_116113","record_id":"REC_0005970","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":6.0,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.321466+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_180105","record_id":"REC_0005971","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":18,"tmb_mutations_per_mb":6.7,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":43,"primary_tumor_size_cm":6.3,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":21.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.321698+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_322492","record_id":"REC_0005972","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":3.2,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":4.3,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":24.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.321926+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_438821","record_id":"REC_0005973","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":6.6,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":29.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.322159+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_721362","record_id":"REC_0005974","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":4.9,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.322390+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_761737","record_id":"REC_0005975","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":15.0,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":6.0,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":33.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.322627+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_691704","record_id":"REC_0005976","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":16,"tmb_mutations_per_mb":14.7,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":4.4,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.322860+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_258862","record_id":"REC_0005977","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":19,"tmb_mutations_per_mb":5.1,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":2,"smoking_pack_years":23,"primary_tumor_size_cm":4.5,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":26.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.323092+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_567513","record_id":"REC_0005978","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":65,"primary_tumor_size_cm":6.6,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.323323+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_730283","record_id":"REC_0005979","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":15.1,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":5.8,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":17.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.323559+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_244944","record_id":"REC_0005980","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":25,"primary_tumor_size_cm":4.5,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.323792+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_213496","record_id":"REC_0005981","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":31,"tmb_mutations_per_mb":16.0,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":6.7,"metastatic_sites_count":3,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.324119+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_717959","record_id":"REC_0005982","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":15.1,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":24,"primary_tumor_size_cm":6.1,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.324359+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_191319","record_id":"REC_0005983","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":3.8,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.324593+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_627787","record_id":"REC_0005984","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":4.0,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":33,"primary_tumor_size_cm":4.2,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":5.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.324820+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_581253","record_id":"REC_0005985","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":18.0,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.2,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":20.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.325051+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_957210","record_id":"REC_0005986","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":5.6,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":35.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.325287+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_456232","record_id":"REC_0005987","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":4.6,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.325519+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_859374","record_id":"REC_0005988","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":5.8,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.325755+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_943636","record_id":"REC_0005989","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":14.7,"age_at_diagnosis":54,"sex":"male","ecog_performance_status":0,"smoking_pack_years":32,"primary_tumor_size_cm":7.2,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":17.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.325995+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_406173","record_id":"REC_0005990","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":84,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.0,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.326226+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_849737","record_id":"REC_0005991","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":5.7,"metastatic_sites_count":9,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.326457+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_227787","record_id":"REC_0005992","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":2.6,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":4.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.326692+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_228847","record_id":"REC_0005993","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":14.9,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":7.5,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":16.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.326929+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_303172","record_id":"REC_0005994","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":10.3,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":4.2,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.327214+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_332622","record_id":"REC_0005995","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":17.9,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":6.4,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.327450+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_831370","record_id":"REC_0005996","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":15,"tmb_mutations_per_mb":5.5,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":0,"smoking_pack_years":24,"primary_tumor_size_cm":4.4,"metastatic_sites_count":8,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.327682+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_812545","record_id":"REC_0005997","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":32,"primary_tumor_size_cm":4.7,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":16.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.327915+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_424429","record_id":"REC_0005998","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":17.8,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":0,"primary_tumor_size_cm":8.1,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":40.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.328328+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_681756","record_id":"REC_0005999","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":9.7,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":6.7,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":26.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.328571+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_377434","record_id":"REC_0006000","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":15.2,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":4.8,"metastatic_sites_count":3,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":23.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.328822+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_309204","record_id":"REC_0006001","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":17.3,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":8.2,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":27.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.329060+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_585256","record_id":"REC_0006002","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":31,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":75,"sex":"male","ecog_performance_status":2,"smoking_pack_years":23,"primary_tumor_size_cm":3.9,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.329294+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_135323","record_id":"REC_0006003","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":52,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":5.5,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":26.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.329528+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_566367","record_id":"REC_0006004","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":4.6,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":5.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.329760+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_932825","record_id":"REC_0006005","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":6.8,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.329994+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_253121","record_id":"REC_0006006","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":6,"primary_tumor_size_cm":6.3,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.330225+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_302168","record_id":"REC_0006007","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":8.9,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":48,"primary_tumor_size_cm":3.7,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.330507+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_407256","record_id":"REC_0006008","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":17.0,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":4.0,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":18.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.330747+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_282327","record_id":"REC_0006009","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":6.0,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":4,"smoking_pack_years":20,"primary_tumor_size_cm":5.7,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":7.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.330973+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_412760","record_id":"REC_0006010","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":13.8,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":4.9,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":5.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.331209+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_829009","record_id":"REC_0006011","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":11.1,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":7.7,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.331441+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_613484","record_id":"REC_0006012","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":16.9,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":6.3,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":23.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.331676+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_239233","record_id":"REC_0006013","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":5.8,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.331910+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_333233","record_id":"REC_0006014","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":4.4,"metastatic_sites_count":9,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.332194+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_469782","record_id":"REC_0006015","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":18,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":0,"smoking_pack_years":6,"primary_tumor_size_cm":4.8,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.332436+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_570876","record_id":"REC_0006016","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":15.0,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":3.7,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":17.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.332672+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_899940","record_id":"REC_0006017","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":14,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":4.3,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":18.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.332906+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_862384","record_id":"REC_0006018","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":9.8,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":4.6,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":20.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.333132+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_439346","record_id":"REC_0006019","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":17.4,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":4,"primary_tumor_size_cm":7.8,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.333366+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_726908","record_id":"REC_0006020","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":5.1,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.333647+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_532618","record_id":"REC_0006021","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":4.8,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":66,"primary_tumor_size_cm":5.2,"metastatic_sites_count":9,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":22.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.333883+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_648378","record_id":"REC_0006022","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":9.1,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":6.9,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.334121+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_305313","record_id":"REC_0006023","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":0,"smoking_pack_years":5,"primary_tumor_size_cm":3.5,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":17.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.334360+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_635022","record_id":"REC_0006024","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":14.1,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":4.6,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.334600+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_160055","record_id":"REC_0006025","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":7.4,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.334832+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_768448","record_id":"REC_0006026","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":5.0,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":8,"primary_tumor_size_cm":5.7,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":4.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.335062+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_874924","record_id":"REC_0006027","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":0,"primary_tumor_size_cm":4.9,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.335300+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_207944","record_id":"REC_0006028","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":18.4,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":4.8,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.335536+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_672296","record_id":"REC_0006029","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":6.7,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":5.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.335768+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_420340","record_id":"REC_0006030","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":6.4,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.336003+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_492993","record_id":"REC_0006031","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":10.0,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":7.4,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.336287+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_404054","record_id":"REC_0006032","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":14.5,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":20,"primary_tumor_size_cm":7.5,"metastatic_sites_count":8,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.336524+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_302664","record_id":"REC_0006033","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":13.3,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":2,"smoking_pack_years":4,"primary_tumor_size_cm":3.3,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.336847+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_602824","record_id":"REC_0006034","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":4.5,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.337090+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_363101","record_id":"REC_0006035","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":16.6,"age_at_diagnosis":53,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":4.4,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.337328+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_880035","record_id":"REC_0006036","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":6.0,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":7.0,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":20.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.337561+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_311467","record_id":"REC_0006037","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":3,"smoking_pack_years":2,"primary_tumor_size_cm":3.6,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.337790+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_197936","record_id":"REC_0006038","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.1,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":3.6,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.338026+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_116825","record_id":"REC_0006039","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":4.5,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.338261+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_989479","record_id":"REC_0006040","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":33,"tmb_mutations_per_mb":11.1,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":5.6,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":16.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.338495+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_938419","record_id":"REC_0006041","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":13.5,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":6.9,"metastatic_sites_count":3,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.338727+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_582260","record_id":"REC_0006042","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":5.5,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":25.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.338963+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_611750","record_id":"REC_0006043","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":5.1,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":37,"primary_tumor_size_cm":6.0,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":17.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.339191+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_687689","record_id":"REC_0006044","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":3.5,"age_at_diagnosis":82,"sex":"male","ecog_performance_status":1,"smoking_pack_years":1,"primary_tumor_size_cm":5.4,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.339424+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_413505","record_id":"REC_0006045","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":8.3,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":4.4,"metastatic_sites_count":9,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.339652+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_806109","record_id":"REC_0006046","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":5.6,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":2,"smoking_pack_years":43,"primary_tumor_size_cm":5.5,"metastatic_sites_count":9,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.339949+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_606632","record_id":"REC_0006047","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":7.7,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.340262+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_703892","record_id":"REC_0006048","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":8.3,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":3.9,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":23.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.340496+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_220811","record_id":"REC_0006049","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":5.2,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.340746+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_696900","record_id":"REC_0006050","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":14.3,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":6.1,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.340982+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_929057","record_id":"REC_0006051","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":8.7,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":4.8,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.341215+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_215753","record_id":"REC_0006052","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.2,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.341445+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_752512","record_id":"REC_0006053","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":4.5,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.341681+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_705338","record_id":"REC_0006054","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":18,"tmb_mutations_per_mb":13.8,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":2,"primary_tumor_size_cm":5.6,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.341915+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_613715","record_id":"REC_0006055","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":14,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":1,"smoking_pack_years":5,"primary_tumor_size_cm":5.7,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":31.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.342151+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_238137","record_id":"REC_0006056","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":15.5,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":7.1,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.342381+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_583182","record_id":"REC_0006057","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":10.0,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":4.6,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":16.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.342612+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_822649","record_id":"REC_0006058","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":11.5,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":2,"primary_tumor_size_cm":3.7,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.342845+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_577744","record_id":"REC_0006059","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":9.0,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":5.6,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.343134+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_401295","record_id":"REC_0006060","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":5.5,"age_at_diagnosis":75,"sex":"male","ecog_performance_status":1,"smoking_pack_years":86,"primary_tumor_size_cm":2.9,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":21.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.343369+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_103657","record_id":"REC_0006061","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":0,"primary_tumor_size_cm":5.8,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.343600+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_602372","record_id":"REC_0006062","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.4,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.343832+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_716070","record_id":"REC_0006063","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":7.6,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.344065+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_691129","record_id":"REC_0006064","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":14.4,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":4.8,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.344335+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_803650","record_id":"REC_0006065","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":1.5,"age_at_diagnosis":84,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":5.2,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.344566+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_815073","record_id":"REC_0006066","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":16.7,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":6.1,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":17.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.344803+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_684105","record_id":"REC_0006067","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":7.3,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.345038+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_433776","record_id":"REC_0006068","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":14.9,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":4.6,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.345269+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_109576","record_id":"REC_0006069","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":6.8,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.345506+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_726528","record_id":"REC_0006070","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":56,"primary_tumor_size_cm":7.7,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.345740+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_606854","record_id":"REC_0006071","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":4.7,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.1,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.345968+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_217648","record_id":"REC_0006072","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":33,"tmb_mutations_per_mb":21.6,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":6.2,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.346247+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_794869","record_id":"REC_0006073","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":16.5,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":3,"smoking_pack_years":22,"primary_tumor_size_cm":4.0,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.346485+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_234744","record_id":"REC_0006074","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":19,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":7.2,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":5.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.346719+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_116116","record_id":"REC_0006075","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":4.6,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":1,"smoking_pack_years":43,"primary_tumor_size_cm":6.5,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.346950+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_895167","record_id":"REC_0006076","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":14.7,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":25,"primary_tumor_size_cm":6.8,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":5.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.347184+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_398265","record_id":"REC_0006077","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":24,"primary_tumor_size_cm":3.9,"metastatic_sites_count":8,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":8.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.347416+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_936858","record_id":"REC_0006078","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":18.7,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":3.3,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":17.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.347650+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_287406","record_id":"REC_0006079","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":5.4,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.347883+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_101584","record_id":"REC_0006080","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":5.9,"age_at_diagnosis":86,"sex":"female","ecog_performance_status":3,"smoking_pack_years":39,"primary_tumor_size_cm":4.3,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":24.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.348140+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_934262","record_id":"REC_0006081","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":18.6,"age_at_diagnosis":80,"sex":"male","ecog_performance_status":3,"smoking_pack_years":11,"primary_tumor_size_cm":3.7,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.348383+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_126921","record_id":"REC_0006082","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":14.9,"age_at_diagnosis":80,"sex":"male","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":2.8,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":22.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.348620+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_786531","record_id":"REC_0006083","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":6.4,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.348857+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_480499","record_id":"REC_0006084","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":6.3,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":5.8,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.349084+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_399855","record_id":"REC_0006085","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":17.2,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":9,"primary_tumor_size_cm":6.6,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.349364+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_964333","record_id":"REC_0006086","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":17,"tmb_mutations_per_mb":7.6,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":73,"primary_tumor_size_cm":5.2,"metastatic_sites_count":8,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.349598+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_200617","record_id":"REC_0006087","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":16,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":41,"primary_tumor_size_cm":6.5,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":17.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.349832+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_380276","record_id":"REC_0006088","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":19,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":51,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":6.8,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.350064+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_399448","record_id":"REC_0006089","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":3,"smoking_pack_years":16,"primary_tumor_size_cm":6.0,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":7.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.350301+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_749640","record_id":"REC_0006090","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":11,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":3.5,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.350530+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_295755","record_id":"REC_0006091","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":19,"tmb_mutations_per_mb":3.3,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":5.6,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.350758+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_731049","record_id":"REC_0006092","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":17.1,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":6.1,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":16.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.350994+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_512150","record_id":"REC_0006093","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":17,"tmb_mutations_per_mb":2.2,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":38,"primary_tumor_size_cm":5.7,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":18.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.351220+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_888322","record_id":"REC_0006094","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":15.2,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":3,"smoking_pack_years":18,"primary_tumor_size_cm":5.5,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":16.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.351456+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_401356","record_id":"REC_0006095","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":5.3,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.351685+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_562247","record_id":"REC_0006096","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":11,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":8.5,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.351916+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_372088","record_id":"REC_0006097","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":3.5,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.352201+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_636448","record_id":"REC_0006098","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":8.0,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":20.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.352486+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_780438","record_id":"REC_0006099","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":2.5,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":74,"primary_tumor_size_cm":5.6,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":25.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.352735+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_471644","record_id":"REC_0006100","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":33,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":48,"primary_tumor_size_cm":5.4,"metastatic_sites_count":9,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.352964+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_723984","record_id":"REC_0006101","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":4.2,"age_at_diagnosis":41,"sex":"male","ecog_performance_status":0,"smoking_pack_years":49,"primary_tumor_size_cm":6.3,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.353201+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_390549","record_id":"REC_0006102","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":1.5,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":4.9,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":16.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.353429+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_765507","record_id":"REC_0006103","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":84,"sex":"female","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":4.4,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.353662+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_596350","record_id":"REC_0006104","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":1,"smoking_pack_years":5,"primary_tumor_size_cm":5.8,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.353897+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_934372","record_id":"REC_0006105","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":32,"tmb_mutations_per_mb":3.7,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":26,"primary_tumor_size_cm":2.8,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.354124+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_692843","record_id":"REC_0006106","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":15.7,"age_at_diagnosis":77,"sex":"male","ecog_performance_status":0,"smoking_pack_years":26,"primary_tumor_size_cm":4.5,"metastatic_sites_count":8,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.354359+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_320575","record_id":"REC_0006107","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":11.5,"age_at_diagnosis":52,"sex":"male","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":5.8,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":25.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.354594+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_336373","record_id":"REC_0006108","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":30,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":88,"primary_tumor_size_cm":3.8,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":25.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.354826+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_591663","record_id":"REC_0006109","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":32,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":0,"smoking_pack_years":73,"primary_tumor_size_cm":4.8,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":6.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.355061+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_791119","record_id":"REC_0006110","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":31,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":4.6,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":20.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.355297+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_421840","record_id":"REC_0006111","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":19,"tmb_mutations_per_mb":8.6,"age_at_diagnosis":77,"sex":"male","ecog_performance_status":1,"smoking_pack_years":5,"primary_tumor_size_cm":5.1,"metastatic_sites_count":8,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.355578+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_608834","record_id":"REC_0006112","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":6.1,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.355811+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_814644","record_id":"REC_0006113","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":10.5,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.2,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":20.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.356046+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_930718","record_id":"REC_0006114","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":16,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":3,"smoking_pack_years":6,"primary_tumor_size_cm":3.2,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.356485+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_303957","record_id":"REC_0006115","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":30,"tmb_mutations_per_mb":8.1,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":3.6,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.356716+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_285101","record_id":"REC_0006116","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":5.9,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":6.2,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.356948+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_756584","record_id":"REC_0006117","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":20.1,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":4.0,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.357186+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_599701","record_id":"REC_0006118","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":2,"smoking_pack_years":24,"primary_tumor_size_cm":5.2,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.357418+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_344505","record_id":"REC_0006119","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":9.5,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":6.9,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.357650+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_119215","record_id":"REC_0006120","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":5.2,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":3.8,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.357882+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_651127","record_id":"REC_0006121","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":32,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":3.5,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.358116+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_777846","record_id":"REC_0006122","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":14.5,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":5.3,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.358352+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_576617","record_id":"REC_0006123","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":14.0,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":4.5,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.358589+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_850248","record_id":"REC_0006124","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":20,"tmb_mutations_per_mb":4.4,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":48,"primary_tumor_size_cm":5.9,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":40.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.358872+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_463687","record_id":"REC_0006125","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":8.1,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":7.0,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.359111+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_570740","record_id":"REC_0006126","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":5.2,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.359347+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_593237","record_id":"REC_0006127","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":8.4,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":33,"primary_tumor_size_cm":7.5,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":5.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.359584+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_658915","record_id":"REC_0006128","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":4.8,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":71,"primary_tumor_size_cm":6.8,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.359814+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_814368","record_id":"REC_0006129","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":4.6,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.360050+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_928914","record_id":"REC_0006130","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":9.9,"age_at_diagnosis":83,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.6,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.360327+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_395083","record_id":"REC_0006131","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":19,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":74,"sex":"male","ecog_performance_status":2,"smoking_pack_years":9,"primary_tumor_size_cm":3.6,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":23.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.360565+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_729366","record_id":"REC_0006132","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":15.9,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":1,"smoking_pack_years":1,"primary_tumor_size_cm":4.3,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.360801+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_144182","record_id":"REC_0006133","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":30,"tmb_mutations_per_mb":5.7,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":0,"smoking_pack_years":45,"primary_tumor_size_cm":5.9,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":16.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.361035+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_995774","record_id":"REC_0006134","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":30,"tmb_mutations_per_mb":5.5,"age_at_diagnosis":75,"sex":"male","ecog_performance_status":3,"smoking_pack_years":16,"primary_tumor_size_cm":6.7,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.361269+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_341043","record_id":"REC_0006135","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":9.0,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":4.4,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.361507+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_553414","record_id":"REC_0006136","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":6.5,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.361737+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_211462","record_id":"REC_0006137","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":10.0,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":3.1,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.362055+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_892227","record_id":"REC_0006138","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":1.5,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":53,"primary_tumor_size_cm":6.2,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":21.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.362292+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_623397","record_id":"REC_0006139","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":6.7,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":5.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.362527+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_125511","record_id":"REC_0006140","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":13.6,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":6.9,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.362765+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_769404","record_id":"REC_0006141","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":1,"smoking_pack_years":59,"primary_tumor_size_cm":6.8,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":21.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.363001+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_748455","record_id":"REC_0006142","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":7.8,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":44.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.363239+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_413176","record_id":"REC_0006143","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":32,"tmb_mutations_per_mb":8.3,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":5.3,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.363470+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_119837","record_id":"REC_0006144","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":37,"tmb_mutations_per_mb":10.1,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":5.6,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.363708+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_128707","record_id":"REC_0006145","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":10.1,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":27,"primary_tumor_size_cm":5.6,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.363945+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_292163","record_id":"REC_0006146","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":31,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":22,"primary_tumor_size_cm":5.6,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.364247+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_381970","record_id":"REC_0006147","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":1.5,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":36,"primary_tumor_size_cm":5.8,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":20.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.364488+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_549907","record_id":"REC_0006148","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":16.0,"age_at_diagnosis":52,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":5.6,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":25.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.364726+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_662094","record_id":"REC_0006149","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":3.5,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.364974+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_466407","record_id":"REC_0006150","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":11.5,"age_at_diagnosis":50,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":4.1,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.365283+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_129354","record_id":"REC_0006151","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":28,"primary_tumor_size_cm":6.0,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":7.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.365523+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_603317","record_id":"REC_0006152","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":16,"tmb_mutations_per_mb":13.1,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":7.7,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":18.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.365756+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_787662","record_id":"REC_0006153","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":7.2,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.365992+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_320865","record_id":"REC_0006154","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":8.4,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":5.4,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":16.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.366219+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_323038","record_id":"REC_0006155","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":5.1,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.366458+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_333500","record_id":"REC_0006156","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":2,"primary_tumor_size_cm":5.0,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.366692+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_792251","record_id":"REC_0006157","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":20.8,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":6.8,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.366927+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_105678","record_id":"REC_0006158","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":4.3,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.367163+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_931517","record_id":"REC_0006159","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":17.3,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":3.8,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.367399+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_799981","record_id":"REC_0006160","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":5.3,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.367632+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_204900","record_id":"REC_0006161","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":4.7,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":19.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.367863+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_331112","record_id":"REC_0006162","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":5.3,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.368124+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_937867","record_id":"REC_0006163","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":18.1,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":5.7,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.368418+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_430568","record_id":"REC_0006164","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":0,"smoking_pack_years":69,"primary_tumor_size_cm":5.2,"metastatic_sites_count":8,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.368654+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_987292","record_id":"REC_0006165","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":10.5,"age_at_diagnosis":54,"sex":"male","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":3.3,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":18.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.368889+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_949402","record_id":"REC_0006166","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":1,"smoking_pack_years":24,"primary_tumor_size_cm":4.5,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":21.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.369123+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_263716","record_id":"REC_0006167","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":6.5,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.369355+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_441465","record_id":"REC_0006168","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":17.4,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":6.2,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.369588+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_608804","record_id":"REC_0006169","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":14.6,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":3.0,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.369821+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_853617","record_id":"REC_0006170","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":3.5,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":39,"primary_tumor_size_cm":5.0,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":18.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.370049+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_270816","record_id":"REC_0006171","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":6.0,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":43,"primary_tumor_size_cm":7.7,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":16.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.370278+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_584149","record_id":"REC_0006172","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.5,"age_at_diagnosis":83,"sex":"male","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":5.2,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.370515+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_136000","record_id":"REC_0006173","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":14.7,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":7.9,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.370748+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_160640","record_id":"REC_0006174","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":3,"primary_tumor_size_cm":6.0,"metastatic_sites_count":3,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.370980+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_637993","record_id":"REC_0006175","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.6,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.371211+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_497502","record_id":"REC_0006176","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":4.8,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":22.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.371497+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_885304","record_id":"REC_0006177","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":14.3,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":6.1,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.371736+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_806743","record_id":"REC_0006178","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":32,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":5.1,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.371969+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_328489","record_id":"REC_0006179","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":18,"tmb_mutations_per_mb":14.4,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":2,"smoking_pack_years":26,"primary_tumor_size_cm":3.3,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":8.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.372237+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_471265","record_id":"REC_0006180","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":5.0,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":2,"smoking_pack_years":28,"primary_tumor_size_cm":6.7,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.372470+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_388653","record_id":"REC_0006181","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":81,"sex":"male","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":6.2,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.372704+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_910844","record_id":"REC_0006182","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":5.0,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.372939+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_738720","record_id":"REC_0006183","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":15,"tmb_mutations_per_mb":8.6,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":1,"smoking_pack_years":57,"primary_tumor_size_cm":5.6,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.373171+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_316820","record_id":"REC_0006184","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":5.7,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":34,"primary_tumor_size_cm":5.1,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.373402+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_522400","record_id":"REC_0006185","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":15.7,"age_at_diagnosis":84,"sex":"male","ecog_performance_status":2,"smoking_pack_years":4,"primary_tumor_size_cm":8.0,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":64.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.373637+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_339464","record_id":"REC_0006186","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.0,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.373869+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_255376","record_id":"REC_0006187","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":6.9,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":4.3,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":22.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.374100+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_689650","record_id":"REC_0006188","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":7.6,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":6.8,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.374330+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_498964","record_id":"REC_0006189","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":8.5,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":5.9,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":5.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.374602+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_811001","record_id":"REC_0006190","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":4.5,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.374836+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_696933","record_id":"REC_0006191","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":19,"tmb_mutations_per_mb":6.3,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":1,"smoking_pack_years":49,"primary_tumor_size_cm":4.7,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.375072+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_305833","record_id":"REC_0006192","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":9.7,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":8.1,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.375303+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_358194","record_id":"REC_0006193","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":14.1,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":5.8,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.375539+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_416456","record_id":"REC_0006194","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":6.9,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":16.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.375773+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_899805","record_id":"REC_0006195","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":4.0,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":56,"primary_tumor_size_cm":7.0,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":17.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.376003+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_959968","record_id":"REC_0006196","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":3.3,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":7.1,"metastatic_sites_count":3,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":6.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.376374+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_743278","record_id":"REC_0006197","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.8,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.376614+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_726074","record_id":"REC_0006198","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":19,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":5,"primary_tumor_size_cm":5.5,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":47.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.376852+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_748061","record_id":"REC_0006199","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":14.9,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":5.0,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.377085+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_653190","record_id":"REC_0006200","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":4.5,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.377318+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_706274","record_id":"REC_0006201","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":32,"tmb_mutations_per_mb":8.5,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":5.5,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.377550+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_898810","record_id":"REC_0006202","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":14.0,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":3.6,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":24.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.377834+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_966347","record_id":"REC_0006203","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":5.5,"age_at_diagnosis":53,"sex":"female","ecog_performance_status":0,"smoking_pack_years":73,"primary_tumor_size_cm":4.8,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.378070+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_145453","record_id":"REC_0006204","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":6.3,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":3,"primary_tumor_size_cm":5.3,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.378305+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_280944","record_id":"REC_0006205","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":15.7,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":4,"primary_tumor_size_cm":6.5,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.378537+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_371240","record_id":"REC_0006206","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":34,"tmb_mutations_per_mb":1.5,"age_at_diagnosis":50,"sex":"female","ecog_performance_status":0,"smoking_pack_years":37,"primary_tumor_size_cm":6.4,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":17.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.378771+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_431582","record_id":"REC_0006207","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":15.8,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":3.8,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.379004+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_913684","record_id":"REC_0006208","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":6.7,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":40,"primary_tumor_size_cm":5.1,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.379233+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_747682","record_id":"REC_0006209","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":31,"tmb_mutations_per_mb":6.9,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":44,"primary_tumor_size_cm":5.3,"metastatic_sites_count":8,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.379460+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_348874","record_id":"REC_0006210","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":10.1,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":6.2,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.379690+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_429524","record_id":"REC_0006211","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":15.6,"age_at_diagnosis":50,"sex":"male","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":4.5,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.379925+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_896195","record_id":"REC_0006212","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":4.1,"metastatic_sites_count":3,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":18.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.380183+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_780430","record_id":"REC_0006213","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":35,"tmb_mutations_per_mb":5.6,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":4.2,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.380416+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_340070","record_id":"REC_0006214","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":18.3,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.5,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.380656+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_558015","record_id":"REC_0006215","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":5.5,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":3.9,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.380933+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_627147","record_id":"REC_0006216","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":7.9,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":5.2,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.381164+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_156386","record_id":"REC_0006217","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":3,"smoking_pack_years":22,"primary_tumor_size_cm":4.8,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.381399+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_742166","record_id":"REC_0006218","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":30,"primary_tumor_size_cm":6.9,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.381631+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_895727","record_id":"REC_0006219","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":15.5,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":6.1,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":4.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.381866+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_872294","record_id":"REC_0006220","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":3.8,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":68,"primary_tumor_size_cm":4.9,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.382094+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_538739","record_id":"REC_0006221","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":16.1,"age_at_diagnosis":54,"sex":"male","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":5.4,"metastatic_sites_count":3,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.382328+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_835469","record_id":"REC_0006222","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":7.3,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":4.7,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.382558+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_573836","record_id":"REC_0006223","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":4.2,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":27.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.382792+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_209930","record_id":"REC_0006224","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":7.9,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":54,"primary_tumor_size_cm":5.3,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":16.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.383019+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_125309","record_id":"REC_0006225","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":5.0,"age_at_diagnosis":90,"sex":"female","ecog_performance_status":1,"smoking_pack_years":74,"primary_tumor_size_cm":5.5,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.383247+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_183308","record_id":"REC_0006226","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":30,"tmb_mutations_per_mb":17.2,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":4.8,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":17.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.383482+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_997088","record_id":"REC_0006227","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":31,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":3,"smoking_pack_years":17,"primary_tumor_size_cm":4.6,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":7.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.383713+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_560683","record_id":"REC_0006228","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":15.0,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":4.4,"metastatic_sites_count":9,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.383994+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_224220","record_id":"REC_0006229","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":7.6,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.384262+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_537326","record_id":"REC_0006230","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":13.8,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":5.2,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":44.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.384503+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_271244","record_id":"REC_0006231","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":8.1,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":2,"primary_tumor_size_cm":6.8,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":7.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.384738+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_718774","record_id":"REC_0006232","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":36,"tmb_mutations_per_mb":15.3,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":20,"primary_tumor_size_cm":7.4,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.384968+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_655541","record_id":"REC_0006233","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":15.2,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":5.1,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.385200+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_406230","record_id":"REC_0006234","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":87,"sex":"male","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":4.0,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.385435+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_471517","record_id":"REC_0006235","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":18,"tmb_mutations_per_mb":13.8,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":5.2,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":18.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.385669+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_666949","record_id":"REC_0006236","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":15,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":6.7,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":5.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.385903+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_972282","record_id":"REC_0006237","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":75,"sex":"male","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":6.3,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.386139+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_159141","record_id":"REC_0006238","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":10.3,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":0,"smoking_pack_years":1,"primary_tumor_size_cm":4.5,"metastatic_sites_count":8,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":7.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.386370+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_821740","record_id":"REC_0006239","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":15.3,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":4.3,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.386605+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_777620","record_id":"REC_0006240","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":18.0,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":5.7,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.386837+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_491551","record_id":"REC_0006241","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":32,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":5.5,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":7.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.387111+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_605983","record_id":"REC_0006242","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":4.9,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":27,"primary_tumor_size_cm":5.5,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":25.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.387343+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_709163","record_id":"REC_0006243","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":7.8,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.387573+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_169691","record_id":"REC_0006244","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":8.5,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":3.9,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.387806+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_307442","record_id":"REC_0006245","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":16,"tmb_mutations_per_mb":8.9,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":6.6,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.388034+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_705640","record_id":"REC_0006246","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":11.5,"age_at_diagnosis":54,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":6.8,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":6.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.388317+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_710225","record_id":"REC_0006247","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":14.0,"age_at_diagnosis":53,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":3.9,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.388557+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_387520","record_id":"REC_0006248","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":75,"sex":"male","ecog_performance_status":1,"smoking_pack_years":41,"primary_tumor_size_cm":4.9,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":7.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.388803+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_870413","record_id":"REC_0006249","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":4.8,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":5.7,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":26.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.389032+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_405644","record_id":"REC_0006250","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":14.5,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":6.0,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.389266+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_832100","record_id":"REC_0006251","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":6.2,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.389500+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_289474","record_id":"REC_0006252","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":9.8,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.0,"metastatic_sites_count":8,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.389727+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_812155","record_id":"REC_0006253","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":21,"primary_tumor_size_cm":6.9,"metastatic_sites_count":8,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.389962+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_499569","record_id":"REC_0006254","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":15.8,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.1,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.390245+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_885156","record_id":"REC_0006255","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":53,"primary_tumor_size_cm":6.5,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":31.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.390482+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_616201","record_id":"REC_0006256","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":4.8,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":6.0,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":21.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.390713+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_691454","record_id":"REC_0006257","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":30,"tmb_mutations_per_mb":7.4,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":6.6,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":5.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.390946+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_245079","record_id":"REC_0006258","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":2.3,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":0,"smoking_pack_years":41,"primary_tumor_size_cm":6.1,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":37.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.391175+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_598988","record_id":"REC_0006259","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":13,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":0,"smoking_pack_years":25,"primary_tumor_size_cm":4.2,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":20.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.391409+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_269787","record_id":"REC_0006260","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":5,"primary_tumor_size_cm":3.9,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.391643+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_631700","record_id":"REC_0006261","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":8.5,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":6.2,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.391876+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_871804","record_id":"REC_0006262","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":4.5,"age_at_diagnosis":54,"sex":"female","ecog_performance_status":0,"smoking_pack_years":65,"primary_tumor_size_cm":6.1,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":23.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.392209+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_868440","record_id":"REC_0006263","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":6,"primary_tumor_size_cm":6.0,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.392455+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_193809","record_id":"REC_0006264","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":4.6,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":5.7,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":43.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.392683+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_226259","record_id":"REC_0006265","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":38,"tmb_mutations_per_mb":10.5,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":3,"primary_tumor_size_cm":5.6,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.392916+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_572444","record_id":"REC_0006266","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":13.6,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":6.2,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.393147+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_362395","record_id":"REC_0006267","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":8.0,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":5.8,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.393424+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_212679","record_id":"REC_0006268","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.9,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":16.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.393657+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_997360","record_id":"REC_0006269","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":51,"sex":"male","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":5.8,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.393892+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_235590","record_id":"REC_0006270","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":15.6,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":4.5,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":36.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.394123+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_975666","record_id":"REC_0006271","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":6.2,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.394355+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_712178","record_id":"REC_0006272","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":17,"tmb_mutations_per_mb":4.6,"age_at_diagnosis":52,"sex":"female","ecog_performance_status":0,"smoking_pack_years":56,"primary_tumor_size_cm":5.2,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.394585+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_617015","record_id":"REC_0006273","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":7.9,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":29.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.394821+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_250364","record_id":"REC_0006274","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":16,"tmb_mutations_per_mb":14.0,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":5.4,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.395059+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_148877","record_id":"REC_0006275","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":18.0,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":2,"smoking_pack_years":6,"primary_tumor_size_cm":4.8,"metastatic_sites_count":9,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":6.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.395287+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_969478","record_id":"REC_0006276","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":5.2,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":3,"smoking_pack_years":37,"primary_tumor_size_cm":5.5,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":16.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.395515+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_573932","record_id":"REC_0006277","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":7.4,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.395747+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_364910","record_id":"REC_0006278","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":5.7,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":1,"smoking_pack_years":41,"primary_tumor_size_cm":5.5,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":17.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.395981+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_300310","record_id":"REC_0006279","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":6.3,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":35,"primary_tumor_size_cm":5.2,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.396301+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_266825","record_id":"REC_0006280","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":9.5,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":3,"smoking_pack_years":18,"primary_tumor_size_cm":5.7,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.396581+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_175475","record_id":"REC_0006281","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":14.3,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":6.1,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":43.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.396821+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_247903","record_id":"REC_0006282","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":10.0,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":4.9,"metastatic_sites_count":8,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":4.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.397052+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_928049","record_id":"REC_0006283","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":3.5,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.397287+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_997201","record_id":"REC_0006284","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":52,"primary_tumor_size_cm":4.4,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":4.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.397515+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_910191","record_id":"REC_0006285","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":13.8,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":4.1,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.397747+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_958238","record_id":"REC_0006286","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":12,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":4.8,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":23.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.397982+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_207731","record_id":"REC_0006287","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":14.3,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":31,"primary_tumor_size_cm":5.6,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.398214+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_184561","record_id":"REC_0006288","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":10,"tmb_mutations_per_mb":2.6,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":5.8,"metastatic_sites_count":8,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.398445+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_961246","record_id":"REC_0006289","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":10.0,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":3,"smoking_pack_years":10,"primary_tumor_size_cm":5.6,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":33.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.398678+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_939127","record_id":"REC_0006290","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":30,"tmb_mutations_per_mb":8.1,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":5.8,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":36.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.398909+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_760538","record_id":"REC_0006291","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":1,"smoking_pack_years":25,"primary_tumor_size_cm":8.7,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.399143+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_777139","record_id":"REC_0006292","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":8.9,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":21,"primary_tumor_size_cm":4.5,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":17.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.399371+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_707659","record_id":"REC_0006293","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":7.9,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":6.3,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.399643+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_424900","record_id":"REC_0006294","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":14.0,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":4.2,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":18.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.399880+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_189675","record_id":"REC_0006295","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":19,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":77,"sex":"male","ecog_performance_status":2,"smoking_pack_years":62,"primary_tumor_size_cm":5.1,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.400173+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_191554","record_id":"REC_0006296","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":20,"tmb_mutations_per_mb":6.4,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":79,"primary_tumor_size_cm":7.8,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":7.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.400413+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_540539","record_id":"REC_0006297","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":18.3,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":7.4,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.400660+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_393281","record_id":"REC_0006298","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":16.6,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":6.5,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":16.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.400894+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_900030","record_id":"REC_0006299","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":4.2,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.401129+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_331142","record_id":"REC_0006300","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":13.3,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":5.0,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.401361+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_406891","record_id":"REC_0006301","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":5.7,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":1,"smoking_pack_years":61,"primary_tumor_size_cm":6.8,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":29.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.401587+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_396656","record_id":"REC_0006302","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":4.5,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":10,"primary_tumor_size_cm":5.8,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.401817+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_481461","record_id":"REC_0006303","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":6.2,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.402057+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_619623","record_id":"REC_0006304","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":8.1,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":39,"primary_tumor_size_cm":5.1,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.402286+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_440227","record_id":"REC_0006305","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":3,"smoking_pack_years":13,"primary_tumor_size_cm":5.0,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.402521+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_968123","record_id":"REC_0006306","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":14.5,"age_at_diagnosis":86,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":4.1,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.402797+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_448328","record_id":"REC_0006307","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":16.2,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":7.0,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":5.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.403032+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_482107","record_id":"REC_0006308","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":0,"primary_tumor_size_cm":7.0,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":22.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.403263+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_732731","record_id":"REC_0006309","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ALK fusion","pd_l1_tps_percent":15,"tmb_mutations_per_mb":8.4,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":4.7,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":54.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.403495+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_914080","record_id":"REC_0006310","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":13.3,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":6.4,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":21.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.403726+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_247668","record_id":"REC_0006311","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":8.7,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":3,"smoking_pack_years":65,"primary_tumor_size_cm":4.1,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.403954+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_205304","record_id":"REC_0006312","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":33,"tmb_mutations_per_mb":4.1,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":70,"primary_tumor_size_cm":4.6,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":24.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.404210+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_813714","record_id":"REC_0006313","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":4.3,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":2,"smoking_pack_years":64,"primary_tumor_size_cm":5.0,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":45.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.404443+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_115714","record_id":"REC_0006314","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":15.0,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":4.8,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.404675+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_504242","record_id":"REC_0006315","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":5.2,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.404903+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_610520","record_id":"REC_0006316","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":5.1,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":5,"primary_tumor_size_cm":6.0,"metastatic_sites_count":8,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.405128+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_164536","record_id":"REC_0006317","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":17,"tmb_mutations_per_mb":5.6,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":6.0,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.405359+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_953476","record_id":"REC_0006318","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":31,"tmb_mutations_per_mb":14.5,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":4,"primary_tumor_size_cm":4.4,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.405588+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_739473","record_id":"REC_0006319","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":31,"tmb_mutations_per_mb":8.7,"age_at_diagnosis":52,"sex":"male","ecog_performance_status":0,"smoking_pack_years":86,"primary_tumor_size_cm":5.2,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":18.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.405869+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_324826","record_id":"REC_0006320","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":17,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":3.5,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.406102+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_335373","record_id":"REC_0006321","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":33,"primary_tumor_size_cm":4.8,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.406331+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_907468","record_id":"REC_0006322","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":3.0,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":3.3,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.406563+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_360978","record_id":"REC_0006323","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":5.7,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":26.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.406798+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_157586","record_id":"REC_0006324","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":30,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":4.0,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.407031+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_560915","record_id":"REC_0006325","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":1.5,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":3.7,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.407261+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_571650","record_id":"REC_0006326","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":50,"primary_tumor_size_cm":5.0,"metastatic_sites_count":3,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.407492+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_494217","record_id":"REC_0006327","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":14.8,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":5.0,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.407728+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_767421","record_id":"REC_0006328","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":20,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":5.6,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.407958+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_438042","record_id":"REC_0006329","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":15.5,"age_at_diagnosis":50,"sex":"male","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":6.3,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":19.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.408215+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_386080","record_id":"REC_0006330","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":9.1,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":8.6,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.408450+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_722498","record_id":"REC_0006331","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":4.6,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":16.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.408684+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_215683","record_id":"REC_0006332","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":34,"tmb_mutations_per_mb":11.5,"age_at_diagnosis":52,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":7.1,"metastatic_sites_count":3,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.408961+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_638667","record_id":"REC_0006333","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":5.8,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.409200+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_904578","record_id":"REC_0006334","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":6.4,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":27,"primary_tumor_size_cm":6.5,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.409427+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_183552","record_id":"REC_0006335","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":4.4,"metastatic_sites_count":9,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.409662+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_860804","record_id":"REC_0006336","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":18,"tmb_mutations_per_mb":9.9,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":1,"smoking_pack_years":26,"primary_tumor_size_cm":3.1,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.409893+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_531435","record_id":"REC_0006337","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":31,"tmb_mutations_per_mb":9.9,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":53,"primary_tumor_size_cm":5.4,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":28.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.410125+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_188921","record_id":"REC_0006338","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":16,"tmb_mutations_per_mb":6.7,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":2.5,"metastatic_sites_count":9,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.410357+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_425007","record_id":"REC_0006339","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":14.7,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":3.1,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.410589+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_638697","record_id":"REC_0006340","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":18,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":54,"sex":"male","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":5.8,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":7.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.410823+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_677386","record_id":"REC_0006341","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":16.1,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":3.9,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.411055+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_773995","record_id":"REC_0006342","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":17.5,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":6.5,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":24.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.411286+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_986345","record_id":"REC_0006343","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":5.0,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.411519+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_556475","record_id":"REC_0006344","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":17,"tmb_mutations_per_mb":14.9,"age_at_diagnosis":54,"sex":"male","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":5.3,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.411752+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_812580","record_id":"REC_0006345","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":7.1,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":27.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.412031+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_685879","record_id":"REC_0006346","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":20,"tmb_mutations_per_mb":5.3,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":3.2,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.412304+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_410388","record_id":"REC_0006347","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":31,"tmb_mutations_per_mb":13.3,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.9,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.412546+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_378208","record_id":"REC_0006348","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":32,"tmb_mutations_per_mb":16.4,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":0,"smoking_pack_years":28,"primary_tumor_size_cm":6.4,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.412797+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_129224","record_id":"REC_0006349","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":14.8,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":5.0,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":4.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.413039+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_745090","record_id":"REC_0006350","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":14.3,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":5.9,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.413278+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_709697","record_id":"REC_0006351","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":6.3,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":26.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.413521+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_110327","record_id":"REC_0006352","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":5.3,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":7.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.413756+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_546042","record_id":"REC_0006353","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":15.1,"age_at_diagnosis":84,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":5.9,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":22.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.413988+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_625700","record_id":"REC_0006354","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":6.1,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.414221+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_615824","record_id":"REC_0006355","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":53,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":3.6,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":24.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.414451+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_903442","record_id":"REC_0006356","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":30,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":8.3,"metastatic_sites_count":3,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.414687+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_640069","record_id":"REC_0006357","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":7.9,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":4.8,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.414918+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_259241","record_id":"REC_0006358","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":15.6,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":5,"primary_tumor_size_cm":6.5,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.415247+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_312712","record_id":"REC_0006359","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":5.0,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.415480+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_521785","record_id":"REC_0006360","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":15.4,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":6,"primary_tumor_size_cm":5.3,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.415716+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_110666","record_id":"REC_0006361","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":13.6,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":5.7,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":25.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.415948+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_957532","record_id":"REC_0006362","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":0,"smoking_pack_years":40,"primary_tumor_size_cm":4.9,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":16.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.416294+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_995953","record_id":"REC_0006363","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":5.2,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":26.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.416536+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_437550","record_id":"REC_0006364","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":3.8,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.416767+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_441519","record_id":"REC_0006365","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":9.8,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":8,"primary_tumor_size_cm":6.2,"metastatic_sites_count":3,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.417001+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_136110","record_id":"REC_0006366","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":7.0,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":34.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.417234+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_296701","record_id":"REC_0006367","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":9.8,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":4.3,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.417464+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_864667","record_id":"REC_0006368","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":16.9,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":8.5,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.417697+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_879278","record_id":"REC_0006369","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":7.3,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":67,"primary_tumor_size_cm":4.8,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.417928+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_625160","record_id":"REC_0006370","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":6.4,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.418160+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_884758","record_id":"REC_0006371","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":9.1,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":5.0,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.418445+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_893577","record_id":"REC_0006372","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":5.2,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":29,"primary_tumor_size_cm":7.0,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.418682+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_615458","record_id":"REC_0006373","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":18,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":1,"smoking_pack_years":52,"primary_tumor_size_cm":5.1,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":20.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.418914+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_651539","record_id":"REC_0006374","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":18.3,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":7.1,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.419149+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_763566","record_id":"REC_0006375","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":5.7,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.419388+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_719578","record_id":"REC_0006376","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":8.7,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":4.6,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.419619+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_428119","record_id":"REC_0006377","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":16.3,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":25,"primary_tumor_size_cm":4.5,"metastatic_sites_count":3,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.419852+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_868322","record_id":"REC_0006378","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":16.1,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":30,"primary_tumor_size_cm":5.6,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.420111+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_378159","record_id":"REC_0006379","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":7.0,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.420351+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_703238","record_id":"REC_0006380","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":18.0,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":3.8,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":20.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.420588+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_166860","record_id":"REC_0006381","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":51,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":6.8,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.420815+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_249578","record_id":"REC_0006382","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":6.1,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":7.1,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":34.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.421040+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_997800","record_id":"REC_0006383","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":16.4,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":5.0,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.421277+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_915902","record_id":"REC_0006384","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":14.8,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":4.7,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.421558+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_708037","record_id":"REC_0006385","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":3.2,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":5.6,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":20.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.421788+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_917857","record_id":"REC_0006386","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":77,"sex":"male","ecog_performance_status":1,"smoking_pack_years":5,"primary_tumor_size_cm":6.6,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":32.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.422021+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_775598","record_id":"REC_0006387","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":3.7,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":50,"primary_tumor_size_cm":3.4,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":28.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.422249+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_606275","record_id":"REC_0006388","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":10.3,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":5.1,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":24.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.422485+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_534537","record_id":"REC_0006389","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":6.4,"age_at_diagnosis":75,"sex":"male","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":4.3,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":16.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.422716+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_422548","record_id":"REC_0006390","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":15.2,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":4.4,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.422950+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_605414","record_id":"REC_0006391","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":19.4,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":4.2,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.423188+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_377407","record_id":"REC_0006392","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":28,"primary_tumor_size_cm":5.8,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":24.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.423420+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_914939","record_id":"REC_0006393","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":6.3,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":21.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.423652+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_573162","record_id":"REC_0006394","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":8.0,"age_at_diagnosis":53,"sex":"male","ecog_performance_status":0,"smoking_pack_years":47,"primary_tumor_size_cm":4.0,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":19.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.423879+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_425066","record_id":"REC_0006395","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":14.3,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":4.1,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":24.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.424167+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_745615","record_id":"REC_0006396","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":8.5,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":3.4,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":20.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.424400+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_142251","record_id":"REC_0006397","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":10.1,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":5.7,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.424693+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_135593","record_id":"REC_0006398","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":14.8,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":7.5,"metastatic_sites_count":3,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.424927+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_903127","record_id":"REC_0006399","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":6.7,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.425168+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_404479","record_id":"REC_0006400","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":17,"tmb_mutations_per_mb":5.0,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":37,"primary_tumor_size_cm":4.8,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":18.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.425402+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_780622","record_id":"REC_0006401","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":15.1,"age_at_diagnosis":76,"sex":"male","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":5.4,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.425636+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_139584","record_id":"REC_0006402","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":8.6,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":6,"primary_tumor_size_cm":4.8,"metastatic_sites_count":3,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":6.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.425862+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_547026","record_id":"REC_0006403","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":8.6,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":4.8,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.426090+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_781237","record_id":"REC_0006404","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":16.5,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":4.2,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.426325+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_136052","record_id":"REC_0006405","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":89,"sex":"female","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":4.4,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":22.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.426556+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_992888","record_id":"REC_0006406","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":19,"tmb_mutations_per_mb":8.0,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":5.2,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.426782+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_403082","record_id":"REC_0006407","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":14,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":71,"primary_tumor_size_cm":3.8,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":19.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.427013+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_750484","record_id":"REC_0006408","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":19,"tmb_mutations_per_mb":8.3,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":5.8,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.427241+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_965378","record_id":"REC_0006409","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":6.8,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":28.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.427476+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_128129","record_id":"REC_0006410","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":5.2,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":18.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.427749+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_478348","record_id":"REC_0006411","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":34,"tmb_mutations_per_mb":13.3,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":7.8,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":7.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.427985+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_487330","record_id":"REC_0006412","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":3.9,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":5.3,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":22.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.428244+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_322713","record_id":"REC_0006413","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":3.3,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":19.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.428485+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_248057","record_id":"REC_0006414","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":11.0,"age_at_diagnosis":84,"sex":"female","ecog_performance_status":1,"smoking_pack_years":25,"primary_tumor_size_cm":6.5,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":37.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.428716+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_678068","record_id":"REC_0006415","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":8.7,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":62,"primary_tumor_size_cm":4.8,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.428946+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_103552","record_id":"REC_0006416","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":35,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.5,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.429178+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_945906","record_id":"REC_0006417","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":16.9,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":5.6,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":39.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.429411+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_230434","record_id":"REC_0006418","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":5.8,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":4.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.429647+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_273894","record_id":"REC_0006419","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":30,"tmb_mutations_per_mb":16.7,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":7.4,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.429877+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_458420","record_id":"REC_0006420","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":5.5,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.430102+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_903505","record_id":"REC_0006421","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":11.1,"age_at_diagnosis":90,"sex":"female","ecog_performance_status":1,"smoking_pack_years":1,"primary_tumor_size_cm":4.6,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.430332+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_548580","record_id":"REC_0006422","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":4.1,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":24,"primary_tumor_size_cm":5.3,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":28.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.430560+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_881418","record_id":"REC_0006423","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":4.4,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.430844+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_521993","record_id":"REC_0006424","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":4.6,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.431075+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_106990","record_id":"REC_0006425","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":14.7,"age_at_diagnosis":87,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":4.9,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.431306+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_827865","record_id":"REC_0006426","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":17.2,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":7.3,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":6.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.431541+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_106174","record_id":"REC_0006427","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":7.2,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.431774+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_782602","record_id":"REC_0006428","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":6.4,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":7.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.432005+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_795623","record_id":"REC_0006429","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":14.6,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":5.7,"metastatic_sites_count":10,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":17.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.432265+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_390123","record_id":"REC_0006430","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":3.7,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":40,"primary_tumor_size_cm":5.4,"metastatic_sites_count":3,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":6.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.432494+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_158652","record_id":"REC_0006431","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":18,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":54,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":6.2,"metastatic_sites_count":8,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.432727+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_506809","record_id":"REC_0006432","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":6.6,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":17.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.432955+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_792476","record_id":"REC_0006433","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":6.7,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":91,"primary_tumor_size_cm":6.4,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.433186+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_305519","record_id":"REC_0006434","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":13.5,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":2,"smoking_pack_years":20,"primary_tumor_size_cm":5.2,"metastatic_sites_count":9,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":8.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.433421+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_151125","record_id":"REC_0006435","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":10.3,"age_at_diagnosis":54,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":2.3,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":56.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.433654+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_626436","record_id":"REC_0006436","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":13.1,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":5.8,"metastatic_sites_count":9,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.433928+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_420451","record_id":"REC_0006437","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":8.6,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":6.8,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.434159+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_289573","record_id":"REC_0006438","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":51,"sex":"male","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":6.9,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":17.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.434389+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_895711","record_id":"REC_0006439","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":0,"smoking_pack_years":25,"primary_tumor_size_cm":6.5,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.434626+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_101488","record_id":"REC_0006440","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":14.7,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":6.2,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":36.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.434856+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_257882","record_id":"REC_0006441","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":18,"tmb_mutations_per_mb":5.0,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":37,"primary_tumor_size_cm":5.8,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":17.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.435085+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_656163","record_id":"REC_0006442","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":6.0,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.435322+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_864207","record_id":"REC_0006443","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":3.9,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":54,"primary_tumor_size_cm":6.5,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.435549+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_359150","record_id":"REC_0006444","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":41,"tmb_mutations_per_mb":20.4,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":5.8,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":23.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.435787+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_736193","record_id":"REC_0006445","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":2,"smoking_pack_years":46,"primary_tumor_size_cm":7.2,"metastatic_sites_count":3,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":18.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.436018+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_224472","record_id":"REC_0006446","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":18,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":5.6,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.436443+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_677188","record_id":"REC_0006447","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":5,"primary_tumor_size_cm":5.9,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":22.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.436692+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_141444","record_id":"REC_0006448","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":4.2,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":35,"primary_tumor_size_cm":6.0,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.436925+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_886023","record_id":"REC_0006449","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":16.3,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":3,"smoking_pack_years":13,"primary_tumor_size_cm":7.6,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.437202+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_385799","record_id":"REC_0006450","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":5.9,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":31,"primary_tumor_size_cm":4.6,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":27.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.437438+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_671714","record_id":"REC_0006451","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":20,"tmb_mutations_per_mb":14.8,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":3,"smoking_pack_years":33,"primary_tumor_size_cm":5.1,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":17.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.437671+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_492273","record_id":"REC_0006452","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":35,"tmb_mutations_per_mb":9.9,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":5.7,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.437900+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_276037","record_id":"REC_0006453","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":0,"smoking_pack_years":24,"primary_tumor_size_cm":3.7,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":44.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.438132+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_807335","record_id":"REC_0006454","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":2.6,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.438366+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_514118","record_id":"REC_0006455","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":9.9,"age_at_diagnosis":54,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":5.3,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.438597+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_619241","record_id":"REC_0006456","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":78,"sex":"male","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":5.0,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":17.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.438835+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_772151","record_id":"REC_0006457","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":2,"smoking_pack_years":20,"primary_tumor_size_cm":4.2,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.439068+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_552912","record_id":"REC_0006458","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":6.5,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.439307+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_524860","record_id":"REC_0006459","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":3.5,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.439542+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_863192","record_id":"REC_0006460","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":4.9,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.439780+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_533806","record_id":"REC_0006461","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":16.0,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":4.8,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.440019+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_180111","record_id":"REC_0006462","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":10.0,"age_at_diagnosis":90,"sex":"female","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":4.8,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.440364+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_970718","record_id":"REC_0006463","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":5.7,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.440609+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_419347","record_id":"REC_0006464","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":0,"smoking_pack_years":1,"primary_tumor_size_cm":4.7,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.440844+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_421633","record_id":"REC_0006465","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":30,"tmb_mutations_per_mb":4.8,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":0,"smoking_pack_years":29,"primary_tumor_size_cm":6.0,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":22.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.441077+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_893575","record_id":"REC_0006466","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":4.0,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":5.7,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.441306+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_136664","record_id":"REC_0006467","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":15.6,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":5.5,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.441541+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_567522","record_id":"REC_0006468","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":32,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":5.8,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.441772+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_434116","record_id":"REC_0006469","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":32,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":6.4,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":22.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.442007+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_360868","record_id":"REC_0006470","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":9.5,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":4.7,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.442241+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_189385","record_id":"REC_0006471","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":15,"tmb_mutations_per_mb":5.7,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":64,"primary_tumor_size_cm":5.0,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":7.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.442475+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_510533","record_id":"REC_0006472","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":31,"tmb_mutations_per_mb":5.1,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":6.0,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.442703+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_692749","record_id":"REC_0006473","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":1.5,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":6.6,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":25.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.442935+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_475113","record_id":"REC_0006474","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":14.7,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":24,"primary_tumor_size_cm":4.6,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":23.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.443166+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_993566","record_id":"REC_0006475","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":4.1,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":50,"primary_tumor_size_cm":6.6,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":21.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.443467+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_197219","record_id":"REC_0006476","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":20,"tmb_mutations_per_mb":6.0,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":8.7,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.443705+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_692494","record_id":"REC_0006477","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":20,"tmb_mutations_per_mb":6.7,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":37,"primary_tumor_size_cm":6.6,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.444023+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_461640","record_id":"REC_0006478","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":8.1,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.1,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.444301+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_107562","record_id":"REC_0006479","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":15.8,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":3.5,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.444542+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_319432","record_id":"REC_0006480","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":10.3,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":4.2,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":5.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.444778+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_346746","record_id":"REC_0006481","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":25,"primary_tumor_size_cm":5.6,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.445010+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_350780","record_id":"REC_0006482","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":57,"primary_tumor_size_cm":5.4,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":22.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.445239+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_184583","record_id":"REC_0006483","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.3,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.445476+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_453842","record_id":"REC_0006484","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":35,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":5.5,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.445712+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_569196","record_id":"REC_0006485","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":39,"primary_tumor_size_cm":5.3,"metastatic_sites_count":3,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.445939+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_602255","record_id":"REC_0006486","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":43,"primary_tumor_size_cm":6.1,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.446171+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_436943","record_id":"REC_0006487","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":79,"sex":"male","ecog_performance_status":3,"smoking_pack_years":5,"primary_tumor_size_cm":4.9,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.446407+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_175791","record_id":"REC_0006488","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":3.9,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":4.0,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.446699+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_216227","record_id":"REC_0006489","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":5.5,"age_at_diagnosis":47,"sex":"male","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":4.9,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.446934+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_737664","record_id":"REC_0006490","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":4.5,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":55,"primary_tumor_size_cm":5.6,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":17.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.447167+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_886399","record_id":"REC_0006491","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":15,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":7.0,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.447401+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_139551","record_id":"REC_0006492","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":5.7,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.447633+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_314830","record_id":"REC_0006493","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":15,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":6.9,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.447868+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_546147","record_id":"REC_0006494","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":30,"tmb_mutations_per_mb":3.7,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":60,"primary_tumor_size_cm":7.3,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.448149+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_401568","record_id":"REC_0006495","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":15.7,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":6.2,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":5.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.448395+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_403516","record_id":"REC_0006496","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":5.0,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":66,"primary_tumor_size_cm":4.6,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":7.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.448628+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_104202","record_id":"REC_0006497","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":20,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":0,"smoking_pack_years":58,"primary_tumor_size_cm":7.0,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.448862+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_322971","record_id":"REC_0006498","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":3.5,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":37,"primary_tumor_size_cm":6.6,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.449089+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_387880","record_id":"REC_0006499","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":8.4,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":4.7,"metastatic_sites_count":9,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.449318+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_720962","record_id":"REC_0006500","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":32,"tmb_mutations_per_mb":17.5,"age_at_diagnosis":74,"sex":"male","ecog_performance_status":3,"smoking_pack_years":22,"primary_tumor_size_cm":5.8,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.449562+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_908368","record_id":"REC_0006501","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":8.4,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":5.8,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.449853+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_121831","record_id":"REC_0006502","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":20,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":29,"primary_tumor_size_cm":5.5,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":18.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.450087+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_700311","record_id":"REC_0006503","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":9.7,"age_at_diagnosis":80,"sex":"male","ecog_performance_status":1,"smoking_pack_years":24,"primary_tumor_size_cm":5.0,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.450323+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_834063","record_id":"REC_0006504","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":4.8,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":23.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.450552+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_511458","record_id":"REC_0006505","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":5.6,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.450785+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_244338","record_id":"REC_0006506","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":3.0,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":4.4,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":22.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.451013+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_257492","record_id":"REC_0006507","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":5.9,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":2,"smoking_pack_years":8,"primary_tumor_size_cm":5.5,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":26.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.451246+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_393281","record_id":"REC_0006508","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":15.0,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.6,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.451477+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_641072","record_id":"REC_0006509","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":33,"tmb_mutations_per_mb":8.6,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":5.6,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":26.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.451709+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_450599","record_id":"REC_0006510","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":34,"tmb_mutations_per_mb":7.6,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":3,"smoking_pack_years":3,"primary_tumor_size_cm":5.5,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.451940+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_523460","record_id":"REC_0006511","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":3,"smoking_pack_years":22,"primary_tumor_size_cm":5.8,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.452204+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_614832","record_id":"REC_0006512","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":5.2,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.452438+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_676143","record_id":"REC_0006513","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":3.9,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":3,"smoking_pack_years":64,"primary_tumor_size_cm":7.0,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.452668+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_610004","record_id":"REC_0006514","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":8.2,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.452948+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_843862","record_id":"REC_0006515","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.0,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":19.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.453191+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_416353","record_id":"REC_0006516","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":13.8,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":4.3,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":23.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.453426+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_516972","record_id":"REC_0006517","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":30,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":6.2,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":7.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.453662+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_884332","record_id":"REC_0006518","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":7.2,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.453894+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_875996","record_id":"REC_0006519","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":4.3,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":40,"primary_tumor_size_cm":7.8,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.454128+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_658080","record_id":"REC_0006520","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":15.5,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":4.9,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.454363+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_317670","record_id":"REC_0006521","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":33,"tmb_mutations_per_mb":15.5,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":4.6,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":24.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.454597+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_691636","record_id":"REC_0006522","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":6.1,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.454833+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_133341","record_id":"REC_0006523","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":7.2,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.455070+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_562877","record_id":"REC_0006524","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":5.3,"age_at_diagnosis":83,"sex":"female","ecog_performance_status":3,"smoking_pack_years":50,"primary_tumor_size_cm":6.6,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.455296+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_282460","record_id":"REC_0006525","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":14.8,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":4.2,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.455533+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_637970","record_id":"REC_0006526","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":35,"tmb_mutations_per_mb":8.6,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":4.0,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":16.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.455763+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_226110","record_id":"REC_0006527","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":15.4,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":4.5,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":17.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.456041+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_277464","record_id":"REC_0006528","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":5.6,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.456395+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_455270","record_id":"REC_0006529","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":10.0,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":6.0,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.456634+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_807131","record_id":"REC_0006530","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":13,"tmb_mutations_per_mb":5.3,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":5.7,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.456867+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_756140","record_id":"REC_0006531","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":30,"tmb_mutations_per_mb":5.0,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":1,"smoking_pack_years":44,"primary_tumor_size_cm":8.0,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":34.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.457097+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_144425","record_id":"REC_0006532","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":5.6,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.457330+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_814909","record_id":"REC_0006533","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":13.1,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":6.0,"metastatic_sites_count":3,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":19.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.457567+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_831699","record_id":"REC_0006534","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":14.5,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":7.6,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.457801+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_743333","record_id":"REC_0006535","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":15.2,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":7.3,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.458036+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_759623","record_id":"REC_0006536","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":11.0,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":3.8,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.458273+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_294649","record_id":"REC_0006537","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":6.6,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":17.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.458502+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_670001","record_id":"REC_0006538","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":26,"primary_tumor_size_cm":3.1,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.458733+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_267826","record_id":"REC_0006539","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":5.2,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.458964+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_404769","record_id":"REC_0006540","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.0,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.459242+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_672088","record_id":"REC_0006541","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":46,"sex":"male","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":7.0,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.459479+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_117105","record_id":"REC_0006542","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":3.5,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":4.8,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.459707+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_854456","record_id":"REC_0006543","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":31,"tmb_mutations_per_mb":3.8,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":0,"smoking_pack_years":66,"primary_tumor_size_cm":6.7,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.459944+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_207621","record_id":"REC_0006544","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":78,"sex":"male","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":3.9,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.460229+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_764200","record_id":"REC_0006545","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":2.8,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.460481+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_544187","record_id":"REC_0006546","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":3.9,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.460715+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_282912","record_id":"REC_0006547","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":8.4,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":63,"primary_tumor_size_cm":5.0,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.460948+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_338230","record_id":"REC_0006548","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":35,"tmb_mutations_per_mb":17.6,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":7.0,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.461182+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_469918","record_id":"REC_0006549","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":10.5,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":5.9,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.461418+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_878626","record_id":"REC_0006550","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":54,"primary_tumor_size_cm":4.7,"metastatic_sites_count":3,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.461648+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_246194","record_id":"REC_0006551","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":9.9,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":3.7,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.461876+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_834145","record_id":"REC_0006552","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":2.9,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":3,"smoking_pack_years":11,"primary_tumor_size_cm":5.4,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.462101+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_623261","record_id":"REC_0006553","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":3.5,"metastatic_sites_count":8,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.462377+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_571729","record_id":"REC_0006554","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":9.7,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":2,"smoking_pack_years":6,"primary_tumor_size_cm":4.4,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.462609+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_113500","record_id":"REC_0006555","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":7.0,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.462842+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_515786","record_id":"REC_0006556","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":4.4,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":5.8,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.463073+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_980705","record_id":"REC_0006557","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":16.9,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":4.3,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":16.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.463309+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_726734","record_id":"REC_0006558","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":2,"smoking_pack_years":49,"primary_tumor_size_cm":6.1,"metastatic_sites_count":9,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.463539+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_435604","record_id":"REC_0006559","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":33,"primary_tumor_size_cm":5.2,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":6.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.463776+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_348607","record_id":"REC_0006560","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":7.4,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":5.1,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":17.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.464010+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_843785","record_id":"REC_0006561","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":15,"tmb_mutations_per_mb":14.9,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":4,"primary_tumor_size_cm":5.9,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.464271+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_549521","record_id":"REC_0006562","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":36,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":5.8,"metastatic_sites_count":8,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":17.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.464511+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_881505","record_id":"REC_0006563","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":4.4,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.464743+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_821097","record_id":"REC_0006564","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":15,"tmb_mutations_per_mb":6.1,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":6.0,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.464977+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_263931","record_id":"REC_0006565","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":7.3,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":4.9,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.465205+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_239878","record_id":"REC_0006566","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":5.2,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.465483+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_363666","record_id":"REC_0006567","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":4.2,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":19.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.465724+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_988483","record_id":"REC_0006568","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":6.4,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.465957+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_459034","record_id":"REC_0006569","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":11.5,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":24,"primary_tumor_size_cm":2.5,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":6.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.466188+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_222620","record_id":"REC_0006570","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":9.5,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":4.7,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":21.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.466420+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_513568","record_id":"REC_0006571","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":5.9,"age_at_diagnosis":83,"sex":"female","ecog_performance_status":2,"smoking_pack_years":23,"primary_tumor_size_cm":5.7,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.466647+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_900233","record_id":"REC_0006572","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":13.5,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":0,"smoking_pack_years":3,"primary_tumor_size_cm":5.1,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.466881+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_871452","record_id":"REC_0006573","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":16,"tmb_mutations_per_mb":14.6,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":3.1,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.467115+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_208239","record_id":"REC_0006574","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":18.0,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":4.3,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.467349+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_529855","record_id":"REC_0006575","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":26,"primary_tumor_size_cm":4.3,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.467583+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_943042","record_id":"REC_0006576","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":83,"sex":"male","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":6.2,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.467812+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_497182","record_id":"REC_0006577","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":8.5,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":3,"smoking_pack_years":17,"primary_tumor_size_cm":5.6,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.468037+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_611146","record_id":"REC_0006578","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":14.9,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":6.0,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.468293+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_618298","record_id":"REC_0006579","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":7.7,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.468566+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_899499","record_id":"REC_0006580","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":9.0,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":5.7,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.468796+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_261104","record_id":"REC_0006581","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":5.2,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":3.8,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.469028+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_192841","record_id":"REC_0006582","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":83,"sex":"female","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":8.0,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":20.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.469265+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_113346","record_id":"REC_0006583","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":4.0,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":32,"primary_tumor_size_cm":6.0,"metastatic_sites_count":3,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.469496+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_201849","record_id":"REC_0006584","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":11,"tmb_mutations_per_mb":14.6,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":4.5,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":24.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.469726+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_384145","record_id":"REC_0006585","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":22,"primary_tumor_size_cm":4.0,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":20.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.469958+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_587795","record_id":"REC_0006586","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":32,"tmb_mutations_per_mb":4.9,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":1,"smoking_pack_years":39,"primary_tumor_size_cm":4.3,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":6.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.470187+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_230181","record_id":"REC_0006587","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":4.0,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":1,"smoking_pack_years":40,"primary_tumor_size_cm":3.6,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.470422+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_184685","record_id":"REC_0006588","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":5.5,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":5.1,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.470650+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_957394","record_id":"REC_0006589","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":5.9,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":5.0,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":30.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.470882+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_505501","record_id":"REC_0006590","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":3.7,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":27.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.471111+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_734868","record_id":"REC_0006591","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":11.5,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":7.0,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.471347+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_377995","record_id":"REC_0006592","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":30,"tmb_mutations_per_mb":6.1,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":54,"primary_tumor_size_cm":7.3,"metastatic_sites_count":8,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.471624+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_843665","record_id":"REC_0006593","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":17.7,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":6.9,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":18.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.471860+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_962987","record_id":"REC_0006594","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":8.1,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":6.6,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":21.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.472132+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_144337","record_id":"REC_0006595","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":31,"tmb_mutations_per_mb":16.8,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":6.9,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.472377+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_865679","record_id":"REC_0006596","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":14.9,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":5.8,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":19.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.472622+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_510834","record_id":"REC_0006597","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":6.7,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":21.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.472860+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_981149","record_id":"REC_0006598","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":30,"tmb_mutations_per_mb":14.5,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":6.8,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.473088+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_728603","record_id":"REC_0006599","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":78,"sex":"male","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":6.4,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.473325+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_540071","record_id":"REC_0006600","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":1,"smoking_pack_years":51,"primary_tumor_size_cm":4.9,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":19.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.473558+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_968810","record_id":"REC_0006601","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":8.4,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":6.5,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.473788+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_991831","record_id":"REC_0006602","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":6.2,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":7.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.474019+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_405444","record_id":"REC_0006603","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":7.0,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.474254+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_910849","record_id":"REC_0006604","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":15.3,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":6.6,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":20.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.474482+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_809437","record_id":"REC_0006605","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":4.3,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.474757+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_984452","record_id":"REC_0006606","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":8.6,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":7.4,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":4.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.474991+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_149738","record_id":"REC_0006607","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":15.2,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":2,"smoking_pack_years":2,"primary_tumor_size_cm":5.6,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":30.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.475225+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_645464","record_id":"REC_0006608","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":9.1,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":6.6,"metastatic_sites_count":9,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.475458+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_131279","record_id":"REC_0006609","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":5.5,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.475694+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_671979","record_id":"REC_0006610","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":14.3,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":5.7,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":16.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.475924+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_129727","record_id":"REC_0006611","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":19,"tmb_mutations_per_mb":5.5,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":67,"primary_tumor_size_cm":4.5,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.476232+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_400695","record_id":"REC_0006612","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":16,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":4,"primary_tumor_size_cm":4.1,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.476472+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_904968","record_id":"REC_0006613","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":18,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":5.9,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.476718+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_417796","record_id":"REC_0006614","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":15.2,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":6.1,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":22.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.476956+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_503056","record_id":"REC_0006615","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":19,"tmb_mutations_per_mb":5.3,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":5.2,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.477195+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_369474","record_id":"REC_0006616","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":5.0,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":6.2,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":24.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.477425+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_930036","record_id":"REC_0006617","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":3,"smoking_pack_years":20,"primary_tumor_size_cm":5.3,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.477659+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_829630","record_id":"REC_0006618","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":22.8,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":7.4,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.477954+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_829926","record_id":"REC_0006619","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":5.0,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":25.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.478194+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_748490","record_id":"REC_0006620","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":11.0,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":10,"primary_tumor_size_cm":4.6,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.478426+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_667020","record_id":"REC_0006621","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":2,"primary_tumor_size_cm":4.2,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":8.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.478660+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_679028","record_id":"REC_0006622","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":12,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":6.4,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":18.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.478896+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_758198","record_id":"REC_0006623","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":5.0,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":40,"primary_tumor_size_cm":5.6,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.479131+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_146517","record_id":"REC_0006624","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":3.8,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":43,"primary_tumor_size_cm":2.2,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.479358+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_374672","record_id":"REC_0006625","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":18,"tmb_mutations_per_mb":7.6,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":1,"smoking_pack_years":26,"primary_tumor_size_cm":3.4,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":22.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.479591+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_234884","record_id":"REC_0006626","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":5.6,"metastatic_sites_count":3,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.479823+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_639858","record_id":"REC_0006627","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":10.3,"age_at_diagnosis":75,"sex":"male","ecog_performance_status":2,"smoking_pack_years":7,"primary_tumor_size_cm":5.0,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":23.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.480059+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_287451","record_id":"REC_0006628","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":3.8,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.480327+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_451039","record_id":"REC_0006629","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":6.9,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":21,"primary_tumor_size_cm":4.4,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":7.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.480556+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_437259","record_id":"REC_0006630","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":13.3,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":3.3,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.480792+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_932957","record_id":"REC_0006631","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":3,"primary_tumor_size_cm":5.9,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":20.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.481075+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_899714","record_id":"REC_0006632","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":15.3,"age_at_diagnosis":54,"sex":"male","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":4.7,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":20.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.481313+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_911819","record_id":"REC_0006633","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":13.8,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":6.5,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":17.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.481546+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_380759","record_id":"REC_0006634","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":3.6,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":30,"primary_tumor_size_cm":5.7,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.481780+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_994466","record_id":"REC_0006635","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":18,"tmb_mutations_per_mb":4.6,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":4.5,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.482013+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_959869","record_id":"REC_0006636","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":5.9,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.482244+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_716770","record_id":"REC_0006637","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":5.3,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":20.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.482480+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_736385","record_id":"REC_0006638","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":19,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":5,"primary_tumor_size_cm":5.3,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.482708+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_209027","record_id":"REC_0006639","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":37,"primary_tumor_size_cm":2.9,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.482935+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_709742","record_id":"REC_0006640","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":18.6,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":4.4,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.483168+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_121964","record_id":"REC_0006641","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":6.5,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.483401+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_705931","record_id":"REC_0006642","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":30,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":4.5,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.483632+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_217991","record_id":"REC_0006643","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":5.2,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":2,"smoking_pack_years":6,"primary_tumor_size_cm":6.4,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":24.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.483865+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_655120","record_id":"REC_0006644","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":10.5,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":2,"smoking_pack_years":21,"primary_tumor_size_cm":3.8,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":16.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.484210+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_109202","record_id":"REC_0006645","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":10.0,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":2,"smoking_pack_years":0,"primary_tumor_size_cm":7.2,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.484461+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_459996","record_id":"REC_0006646","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":51,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":5.1,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.484698+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_569916","record_id":"REC_0006647","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":7.4,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":5.0,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.484934+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_715650","record_id":"REC_0006648","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":19,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":5.0,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":21.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.485184+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_649984","record_id":"REC_0006649","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":19,"tmb_mutations_per_mb":3.2,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":7.6,"metastatic_sites_count":3,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.485418+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_499163","record_id":"REC_0006650","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":6.4,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.0,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":16.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.485652+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_463971","record_id":"REC_0006651","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":16.1,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":4.8,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.485888+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_922494","record_id":"REC_0006652","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":20,"tmb_mutations_per_mb":7.9,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":6.6,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":17.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.486118+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_756134","record_id":"REC_0006653","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":13,"tmb_mutations_per_mb":5.9,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":66,"primary_tumor_size_cm":5.5,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.486354+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_946008","record_id":"REC_0006654","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":3.2,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":64,"primary_tumor_size_cm":6.7,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.486588+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_899511","record_id":"REC_0006655","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":32,"tmb_mutations_per_mb":7.6,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":7.0,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.486815+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_688098","record_id":"REC_0006656","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":15.4,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":26,"primary_tumor_size_cm":6.3,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.487050+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_789287","record_id":"REC_0006657","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":17,"tmb_mutations_per_mb":8.4,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":6.3,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.487335+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_660598","record_id":"REC_0006658","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":15.5,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":1,"smoking_pack_years":26,"primary_tumor_size_cm":5.7,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.487575+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_408499","record_id":"REC_0006659","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":10.0,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":4.0,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":28.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.487808+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_832763","record_id":"REC_0006660","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":5.8,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":23.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.488043+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_831963","record_id":"REC_0006661","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":6.2,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":16.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.488417+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_709240","record_id":"REC_0006662","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":9.8,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":4.4,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.488654+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_514953","record_id":"REC_0006663","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":7.4,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":1,"smoking_pack_years":41,"primary_tumor_size_cm":4.7,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":4.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.488894+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_763683","record_id":"REC_0006664","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":6.0,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":20.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.489131+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_322799","record_id":"REC_0006665","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":2.0,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":6.8,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.489359+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_881115","record_id":"REC_0006666","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":4.7,"age_at_diagnosis":43,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":5.1,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":20.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.489588+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_529005","record_id":"REC_0006667","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":20,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":4.5,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.489819+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_396341","record_id":"REC_0006668","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":14.8,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":8.4,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":31.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.490058+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_953278","record_id":"REC_0006669","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":4.3,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.490289+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_809108","record_id":"REC_0006670","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":13.1,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":5.1,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.490583+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_298631","record_id":"REC_0006671","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":1,"smoking_pack_years":61,"primary_tumor_size_cm":7.4,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":21.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.490818+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_416467","record_id":"REC_0006672","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":5.4,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":36.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.491056+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_751119","record_id":"REC_0006673","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":35,"tmb_mutations_per_mb":7.3,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":88,"primary_tumor_size_cm":5.7,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":18.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.491290+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_359873","record_id":"REC_0006674","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":18,"tmb_mutations_per_mb":2.8,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":6.2,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.491518+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_323149","record_id":"REC_0006675","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":15.7,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":5.5,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.491750+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_747804","record_id":"REC_0006676","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":14.8,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":5.8,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.491981+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_871868","record_id":"REC_0006677","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":3.1,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":21.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.492240+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_357033","record_id":"REC_0006678","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":18,"tmb_mutations_per_mb":3.5,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":2.6,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.492471+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_951543","record_id":"REC_0006679","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":4.9,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":31,"primary_tumor_size_cm":2.8,"metastatic_sites_count":8,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.492706+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_204612","record_id":"REC_0006680","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":6.3,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":0,"smoking_pack_years":44,"primary_tumor_size_cm":5.8,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.492937+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_884006","record_id":"REC_0006681","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":4.2,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":5.8,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":24.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.493172+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_907244","record_id":"REC_0006682","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":6.3,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.493406+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_603473","record_id":"REC_0006683","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":3.7,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":20.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.493701+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_141087","record_id":"REC_0006684","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":16,"tmb_mutations_per_mb":18.9,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":9,"primary_tumor_size_cm":4.6,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":16.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.493936+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_531308","record_id":"REC_0006685","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":11,"tmb_mutations_per_mb":5.0,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":4.6,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.494169+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_701746","record_id":"REC_0006686","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":4,"primary_tumor_size_cm":3.4,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.494400+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_650248","record_id":"REC_0006687","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":7.9,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":3,"smoking_pack_years":38,"primary_tumor_size_cm":4.4,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.494636+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_395916","record_id":"REC_0006688","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":6.4,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.494868+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_430103","record_id":"REC_0006689","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":15.3,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":4.3,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":5.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.495105+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_840017","record_id":"REC_0006690","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":18,"tmb_mutations_per_mb":9.1,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":4.5,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.495337+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_688026","record_id":"REC_0006691","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":9.7,"age_at_diagnosis":52,"sex":"male","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":2.0,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":8.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.495569+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_222560","record_id":"REC_0006692","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":17.0,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":4.7,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.495802+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_910393","record_id":"REC_0006693","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":14,"tmb_mutations_per_mb":15.5,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":5.5,"metastatic_sites_count":8,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.496030+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_529443","record_id":"REC_0006694","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":8.9,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":6.5,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":26.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.496369+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_941289","record_id":"REC_0006695","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":13,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":9,"primary_tumor_size_cm":5.7,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.496607+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_226934","record_id":"REC_0006696","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":18,"tmb_mutations_per_mb":16.1,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":1,"smoking_pack_years":5,"primary_tumor_size_cm":6.3,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":20.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.496904+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_348378","record_id":"REC_0006697","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":31,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":5.2,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.497155+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_504693","record_id":"REC_0006698","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":4.9,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":30,"primary_tumor_size_cm":3.6,"metastatic_sites_count":3,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.497386+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_826045","record_id":"REC_0006699","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":6.7,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.497623+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_906600","record_id":"REC_0006700","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":31,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":4.9,"metastatic_sites_count":8,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.497850+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_965617","record_id":"REC_0006701","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":2.0,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":25,"primary_tumor_size_cm":4.1,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":21.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.498080+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_670801","record_id":"REC_0006702","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":33,"tmb_mutations_per_mb":14.9,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":2,"smoking_pack_years":7,"primary_tumor_size_cm":3.7,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":8.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.498312+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_947011","record_id":"REC_0006703","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":6.4,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.498548+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_229529","record_id":"REC_0006704","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":13.5,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":3.9,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.498785+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_387506","record_id":"REC_0006705","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":6.9,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":5.0,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.499013+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_420502","record_id":"REC_0006706","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":7.9,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":5.0,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":17.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.499243+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_571828","record_id":"REC_0006707","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":35,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":0,"smoking_pack_years":24,"primary_tumor_size_cm":5.5,"metastatic_sites_count":3,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":24.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.499473+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_115929","record_id":"REC_0006708","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":15.9,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":5.3,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.499709+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_408063","record_id":"REC_0006709","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":5.2,"age_at_diagnosis":83,"sex":"female","ecog_performance_status":1,"smoking_pack_years":33,"primary_tumor_size_cm":6.3,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":18.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.499990+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_775508","record_id":"REC_0006710","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":6.3,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":7.0,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.500254+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_970235","record_id":"REC_0006711","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":3,"smoking_pack_years":12,"primary_tumor_size_cm":4.9,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.500488+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_341300","record_id":"REC_0006712","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":0,"smoking_pack_years":25,"primary_tumor_size_cm":4.5,"metastatic_sites_count":10,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":5.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.500727+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_978220","record_id":"REC_0006713","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":11.1,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":4.6,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.500962+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_756104","record_id":"REC_0006714","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":32,"tmb_mutations_per_mb":10.1,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":0,"smoking_pack_years":50,"primary_tumor_size_cm":6.9,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":18.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.501198+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_593789","record_id":"REC_0006715","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":18,"tmb_mutations_per_mb":18.4,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":6.3,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.501436+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_485000","record_id":"REC_0006716","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":6.5,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":51.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.501666+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_841899","record_id":"REC_0006717","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":8.4,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":4.6,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":21.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.501899+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_779475","record_id":"REC_0006718","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":19,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":3,"primary_tumor_size_cm":5.3,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":25.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.502127+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_227031","record_id":"REC_0006719","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":4.8,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":4.0,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.502357+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_589784","record_id":"REC_0006720","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":32,"tmb_mutations_per_mb":16.6,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":6.6,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.502590+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_397862","record_id":"REC_0006721","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":10.1,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.7,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.502823+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_176243","record_id":"REC_0006722","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":8.5,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":5.9,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.503107+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_456490","record_id":"REC_0006723","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":14.8,"age_at_diagnosis":52,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":6.4,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.503346+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_173988","record_id":"REC_0006724","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":85,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":7.0,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":17.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.503585+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_148202","record_id":"REC_0006725","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":8.1,"age_at_diagnosis":81,"sex":"male","ecog_performance_status":0,"smoking_pack_years":24,"primary_tumor_size_cm":6.0,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.503818+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_137026","record_id":"REC_0006726","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":5.5,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":1,"smoking_pack_years":24,"primary_tumor_size_cm":6.0,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":43.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.504048+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_941898","record_id":"REC_0006727","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":15.8,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":6.0,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.504311+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_532731","record_id":"REC_0006728","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":34,"tmb_mutations_per_mb":7.3,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":47,"primary_tumor_size_cm":6.5,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":29.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.504545+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_500722","record_id":"REC_0006729","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":7.0,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.504783+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_574215","record_id":"REC_0006730","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":75,"sex":"male","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":6.6,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.505020+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_870851","record_id":"REC_0006731","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":3.7,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.505258+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_576525","record_id":"REC_0006732","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":14.0,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":5.3,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.505494+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_810784","record_id":"REC_0006733","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":14.5,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":6.1,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":19.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.505730+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_185541","record_id":"REC_0006734","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":5.7,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":0,"smoking_pack_years":65,"primary_tumor_size_cm":4.1,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.505966+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_431262","record_id":"REC_0006735","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":5.6,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.506262+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_131246","record_id":"REC_0006736","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":18,"tmb_mutations_per_mb":10.0,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":0,"primary_tumor_size_cm":5.4,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.506500+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_997797","record_id":"REC_0006737","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":28,"primary_tumor_size_cm":5.0,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.506735+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_388206","record_id":"REC_0006738","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":14.4,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":5.4,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.506972+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_470496","record_id":"REC_0006739","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":7.4,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":6.4,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.507204+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_760462","record_id":"REC_0006740","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":5,"primary_tumor_size_cm":5.6,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":22.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.507439+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_102295","record_id":"REC_0006741","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":19,"tmb_mutations_per_mb":14.0,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":6.5,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.507675+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_606825","record_id":"REC_0006742","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":32,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":48,"primary_tumor_size_cm":5.4,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":17.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.507906+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_667986","record_id":"REC_0006743","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":9.1,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":4.6,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":6.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.508194+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_237506","record_id":"REC_0006744","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":13.3,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":4.0,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":28.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.508437+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_300018","record_id":"REC_0006745","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":16.3,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":6.0,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.508671+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_713328","record_id":"REC_0006746","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":17,"tmb_mutations_per_mb":4.0,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":37,"primary_tumor_size_cm":6.2,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.508914+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_595034","record_id":"REC_0006747","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":15.8,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":3.6,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.509148+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_162359","record_id":"REC_0006748","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":14.4,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":6.6,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":16.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.509460+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_937797","record_id":"REC_0006749","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":11.5,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":2,"smoking_pack_years":21,"primary_tumor_size_cm":3.2,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":16.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.509698+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_852837","record_id":"REC_0006750","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":17.1,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":7.1,"metastatic_sites_count":8,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.509936+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_204112","record_id":"REC_0006751","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":3.8,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":4.7,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.510165+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_708128","record_id":"REC_0006752","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":33,"tmb_mutations_per_mb":5.5,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":88,"primary_tumor_size_cm":5.6,"metastatic_sites_count":3,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.510398+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_267677","record_id":"REC_0006753","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":7.4,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":5.7,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":18.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.510627+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_176397","record_id":"REC_0006754","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":14.9,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":7.4,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":17.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.510862+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_688623","record_id":"REC_0006755","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":14.5,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":3.8,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":8.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.511095+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_719297","record_id":"REC_0006756","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":14.4,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":4.6,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.511330+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_218225","record_id":"REC_0006757","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":2.2,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":5.6,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.511562+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_304100","record_id":"REC_0006758","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":4.8,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":21.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.511793+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_461587","record_id":"REC_0006759","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":4.8,"metastatic_sites_count":9,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.512028+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_731533","record_id":"REC_0006760","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":6.1,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.512291+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_854304","record_id":"REC_0006761","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":16,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":6.7,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":27.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.512580+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_831716","record_id":"REC_0006762","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":6.0,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":56,"primary_tumor_size_cm":4.1,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":6.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.512813+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_767658","record_id":"REC_0006763","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":4,"smoking_pack_years":12,"primary_tumor_size_cm":5.5,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.513048+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_857658","record_id":"REC_0006764","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":17,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":43,"sex":"female","ecog_performance_status":0,"smoking_pack_years":25,"primary_tumor_size_cm":5.6,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.513280+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_470885","record_id":"REC_0006765","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":13.3,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":7.0,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.513518+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_276485","record_id":"REC_0006766","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":7.4,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":71,"primary_tumor_size_cm":5.9,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.513750+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_323098","record_id":"REC_0006767","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":10.1,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":5.7,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.513984+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_766242","record_id":"REC_0006768","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":0,"primary_tumor_size_cm":5.9,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":5.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.514217+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_559717","record_id":"REC_0006769","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":8.7,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":5.2,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.514445+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_410023","record_id":"REC_0006770","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":4.4,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":16.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.514671+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_506550","record_id":"REC_0006771","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":18,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":6.3,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.514907+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_426831","record_id":"REC_0006772","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":10.1,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":4.7,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":18.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.515138+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_375257","record_id":"REC_0006773","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":17,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":6.0,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":24.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.515374+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_977627","record_id":"REC_0006774","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":0,"smoking_pack_years":31,"primary_tumor_size_cm":3.8,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.515667+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_694060","record_id":"REC_0006775","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":15.6,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":6.8,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.515909+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_200254","record_id":"REC_0006776","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":6.3,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":2.7,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.516172+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_482061","record_id":"REC_0006777","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":13.6,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":10.0,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.516412+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_424061","record_id":"REC_0006778","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":16.2,"age_at_diagnosis":75,"sex":"male","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":4.0,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":66.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.516650+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_487429","record_id":"REC_0006779","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":5.9,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.516882+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_900605","record_id":"REC_0006780","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":6.6,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.517112+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_709952","record_id":"REC_0006781","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":5.2,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.517345+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_632491","record_id":"REC_0006782","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":8.5,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":2.8,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.517573+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_202923","record_id":"REC_0006783","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":18.4,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":4.8,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.517812+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_639939","record_id":"REC_0006784","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":8.0,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":5.9,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.518042+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_360476","record_id":"REC_0006785","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":5.4,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.518276+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_361363","record_id":"REC_0006786","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":15.9,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":2,"smoking_pack_years":21,"primary_tumor_size_cm":6.8,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.518510+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_183978","record_id":"REC_0006787","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":34,"tmb_mutations_per_mb":17.8,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":5.0,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.518802+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_261177","record_id":"REC_0006788","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":4.1,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":83,"primary_tumor_size_cm":7.7,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.519036+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_246658","record_id":"REC_0006789","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":17,"tmb_mutations_per_mb":15.6,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":4.7,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.519274+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_735567","record_id":"REC_0006790","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":14.5,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":3.6,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.519508+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_655191","record_id":"REC_0006791","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":15.0,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":6,"primary_tumor_size_cm":5.4,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.519744+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_489254","record_id":"REC_0006792","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":9.7,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":9.5,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.519973+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_166221","record_id":"REC_0006793","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":16,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":6.5,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.520339+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_318771","record_id":"REC_0006794","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":34,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":82,"sex":"male","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":6.4,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.520603+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_461924","record_id":"REC_0006795","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":19,"tmb_mutations_per_mb":16.4,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":5.0,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":17.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.520840+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_326065","record_id":"REC_0006796","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":9.7,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":7.8,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.521071+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_334365","record_id":"REC_0006797","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":19,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":4.9,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":17.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.521299+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_434470","record_id":"REC_0006798","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":15.7,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":4.8,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.521529+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_233847","record_id":"REC_0006799","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":8.0,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":61,"primary_tumor_size_cm":4.4,"metastatic_sites_count":3,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.521759+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_708796","record_id":"REC_0006800","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":41,"primary_tumor_size_cm":6.2,"metastatic_sites_count":3,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.522047+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_296734","record_id":"REC_0006801","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":16.3,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":5.8,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.522288+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_274814","record_id":"REC_0006802","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":8.4,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":5.3,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.522520+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_933727","record_id":"REC_0006803","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":10.5,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":5.0,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":17.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.522755+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_862114","record_id":"REC_0006804","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":5.3,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":22.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.522988+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_263824","record_id":"REC_0006805","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":34,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":5.1,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.523224+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_409523","record_id":"REC_0006806","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":8.4,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":5.2,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":31.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.523450+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_839140","record_id":"REC_0006807","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":6.9,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":6.3,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.523686+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_319083","record_id":"REC_0006808","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":16.8,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":0,"primary_tumor_size_cm":3.9,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":24.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.523921+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_978258","record_id":"REC_0006809","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":16.0,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":5.4,"metastatic_sites_count":3,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.524187+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_952935","record_id":"REC_0006810","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":31,"tmb_mutations_per_mb":14.8,"age_at_diagnosis":78,"sex":"male","ecog_performance_status":2,"smoking_pack_years":7,"primary_tumor_size_cm":5.1,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.524427+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_662260","record_id":"REC_0006811","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":11.0,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":6.8,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":19.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.524665+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_140948","record_id":"REC_0006812","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":2.0,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.524896+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_468378","record_id":"REC_0006813","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":17.2,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":5.4,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.525187+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_832074","record_id":"REC_0006814","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":2,"smoking_pack_years":8,"primary_tumor_size_cm":5.9,"metastatic_sites_count":8,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":6.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.525427+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_576125","record_id":"REC_0006815","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":13.8,"age_at_diagnosis":48,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":5.0,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.525667+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_335588","record_id":"REC_0006816","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":6.0,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":6.7,"metastatic_sites_count":3,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":6.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.525897+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_142564","record_id":"REC_0006817","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":9.7,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":4.7,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.526127+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_644208","record_id":"REC_0006818","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":3.6,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":17.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.526357+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_149978","record_id":"REC_0006819","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":19,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":5.5,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.526594+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_480559","record_id":"REC_0006820","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":3,"smoking_pack_years":8,"primary_tumor_size_cm":5.9,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":23.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.526825+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_399698","record_id":"REC_0006821","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":5.1,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.527061+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_587472","record_id":"REC_0006822","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":23,"primary_tumor_size_cm":4.0,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.527298+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_727958","record_id":"REC_0006823","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":3.3,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.6,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.527526+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_935078","record_id":"REC_0006824","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":5.0,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.527762+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_469561","record_id":"REC_0006825","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":9.7,"age_at_diagnosis":83,"sex":"male","ecog_performance_status":2,"smoking_pack_years":21,"primary_tumor_size_cm":6.4,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":17.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.527993+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_340685","record_id":"REC_0006826","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":34,"primary_tumor_size_cm":4.3,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":6.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.528301+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_760064","record_id":"REC_0006827","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":9.0,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":4.1,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":23.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.528535+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_541159","record_id":"REC_0006828","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":4.0,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":59,"primary_tumor_size_cm":5.9,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":20.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.528763+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_267566","record_id":"REC_0006829","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":18,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":5.2,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.529000+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_939319","record_id":"REC_0006830","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":14.5,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":5.1,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.529231+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_865364","record_id":"REC_0006831","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":14.5,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":4,"primary_tumor_size_cm":4.9,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.529466+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_880155","record_id":"REC_0006832","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":10.3,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":5,"primary_tumor_size_cm":5.7,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.529696+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_941747","record_id":"REC_0006833","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":6.0,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":5.9,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.529925+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_395747","record_id":"REC_0006834","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":6.4,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":21.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.530160+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_813986","record_id":"REC_0006835","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":16.2,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":4.1,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.530395+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_710295","record_id":"REC_0006836","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":17,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":54,"sex":"male","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":6.0,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":25.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.530623+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_628603","record_id":"REC_0006837","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":14.6,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":4.3,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.530859+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_173797","record_id":"REC_0006838","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":14.6,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":6.3,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":4.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.531090+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_970926","record_id":"REC_0006839","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":4.9,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.531371+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_663565","record_id":"REC_0006840","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":18.2,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":5.4,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.531608+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_197236","record_id":"REC_0006841","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":76,"sex":"male","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":5.4,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.531842+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_819496","record_id":"REC_0006842","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":13.1,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":6.1,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.532128+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_480640","record_id":"REC_0006843","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":77,"sex":"male","ecog_performance_status":1,"smoking_pack_years":25,"primary_tumor_size_cm":6.1,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.532374+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_183808","record_id":"REC_0006844","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":8.9,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":6.7,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.532608+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_667446","record_id":"REC_0006845","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":5.2,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.532854+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_511629","record_id":"REC_0006846","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":6.5,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.533089+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_764013","record_id":"REC_0006847","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":47,"sex":"male","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":6.3,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.533325+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_455162","record_id":"REC_0006848","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":13.3,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":5.5,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.533561+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_244362","record_id":"REC_0006849","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":44,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":5.6,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.533796+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_704614","record_id":"REC_0006850","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":14.3,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":2,"smoking_pack_years":24,"primary_tumor_size_cm":2.6,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.534033+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_194835","record_id":"REC_0006851","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":6.4,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":6.0,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":6.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.534267+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_994679","record_id":"REC_0006852","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":14.5,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":6.1,"metastatic_sites_count":9,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.534552+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_730269","record_id":"REC_0006853","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":18.2,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":5.5,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":22.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.534789+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_101318","record_id":"REC_0006854","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":4.5,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":24,"primary_tumor_size_cm":5.5,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":25.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.535022+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_600942","record_id":"REC_0006855","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":15.4,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":4.5,"metastatic_sites_count":8,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.535262+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_741925","record_id":"REC_0006856","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":18.0,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":2,"smoking_pack_years":7,"primary_tumor_size_cm":5.5,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.535499+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_726260","record_id":"REC_0006857","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":77,"sex":"male","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":5.0,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.535729+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_571533","record_id":"REC_0006858","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":46,"primary_tumor_size_cm":2.4,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":22.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.535957+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_646684","record_id":"REC_0006859","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":33,"tmb_mutations_per_mb":8.6,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":5.2,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.536225+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_246915","record_id":"REC_0006860","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":5.0,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":0,"smoking_pack_years":48,"primary_tumor_size_cm":7.6,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.536462+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_746823","record_id":"REC_0006861","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":15,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":7.0,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.536692+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_593885","record_id":"REC_0006862","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":88,"sex":"female","ecog_performance_status":1,"smoking_pack_years":24,"primary_tumor_size_cm":4.5,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":8.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.536928+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_138733","record_id":"REC_0006863","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":5.0,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":3,"smoking_pack_years":7,"primary_tumor_size_cm":5.8,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.537160+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_668998","record_id":"REC_0006864","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":8.5,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":4.8,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.537393+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_712543","record_id":"REC_0006865","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":4.3,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":1,"smoking_pack_years":33,"primary_tumor_size_cm":4.7,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.537695+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_813181","record_id":"REC_0006866","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":14.0,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":5,"primary_tumor_size_cm":6.7,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.537932+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_755475","record_id":"REC_0006867","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":4.9,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.538171+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_565621","record_id":"REC_0006868","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":3.6,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":32,"primary_tumor_size_cm":5.5,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":7.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.538404+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_544694","record_id":"REC_0006869","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":7.4,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":20,"primary_tumor_size_cm":5.3,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.538639+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_345433","record_id":"REC_0006870","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":6.5,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.538874+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_255493","record_id":"REC_0006871","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":7.9,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":5.7,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.539106+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_849066","record_id":"REC_0006872","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":6.1,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":55,"primary_tumor_size_cm":6.2,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":25.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.539338+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_124840","record_id":"REC_0006873","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":4.8,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":1,"smoking_pack_years":68,"primary_tumor_size_cm":7.5,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.539570+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_211254","record_id":"REC_0006874","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":6.3,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":5.3,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.539798+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_865949","record_id":"REC_0006875","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":11.5,"age_at_diagnosis":53,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":8.2,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":30.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.540032+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_475913","record_id":"REC_0006876","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":54,"primary_tumor_size_cm":7.8,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":28.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.540290+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_510212","record_id":"REC_0006877","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":30,"tmb_mutations_per_mb":16.1,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":9,"primary_tumor_size_cm":5.2,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":5.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.540526+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_546479","record_id":"REC_0006878","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":14.4,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":6.1,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.540810+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_949093","record_id":"REC_0006879","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":14.3,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":4.6,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":23.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.541054+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_527174","record_id":"REC_0006880","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":19,"tmb_mutations_per_mb":8.6,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":6.4,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.541282+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_402504","record_id":"REC_0006881","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":6.0,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":77,"primary_tumor_size_cm":7.8,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":7.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.541512+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_344320","record_id":"REC_0006882","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":17.0,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":3.8,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.541747+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_887270","record_id":"REC_0006883","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":35,"primary_tumor_size_cm":5.6,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":24.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.541980+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_241139","record_id":"REC_0006884","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":19,"tmb_mutations_per_mb":5.6,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":1,"smoking_pack_years":29,"primary_tumor_size_cm":6.6,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":19.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.542210+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_145257","record_id":"REC_0006885","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":9.8,"age_at_diagnosis":53,"sex":"female","ecog_performance_status":0,"smoking_pack_years":42,"primary_tumor_size_cm":4.7,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":16.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.542444+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_737723","record_id":"REC_0006886","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":34,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":6.6,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":22.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.542674+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_149363","record_id":"REC_0006887","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":8.3,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":7.3,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.542904+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_445440","record_id":"REC_0006888","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":11.0,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":4.0,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.543136+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_309489","record_id":"REC_0006889","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":15.8,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":4.2,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.543368+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_510930","record_id":"REC_0006890","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":4.5,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":21.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.543601+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_876759","record_id":"REC_0006891","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":16,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":7.1,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":22.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.543889+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_560579","record_id":"REC_0006892","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":11.5,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":1,"smoking_pack_years":1,"primary_tumor_size_cm":6.7,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.544189+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_419067","record_id":"REC_0006893","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":4.8,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.544431+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_688320","record_id":"REC_0006894","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":3,"smoking_pack_years":16,"primary_tumor_size_cm":5.5,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":21.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.544679+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_195805","record_id":"REC_0006895","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":16.2,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":6.8,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.544918+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_737708","record_id":"REC_0006896","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.1,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":5,"primary_tumor_size_cm":5.5,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":17.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.545155+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_766701","record_id":"REC_0006897","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":2,"smoking_pack_years":52,"primary_tumor_size_cm":6.9,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":16.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.545382+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_262030","record_id":"REC_0006898","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":7.4,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":67,"primary_tumor_size_cm":4.3,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.545613+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_441590","record_id":"REC_0006899","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":15,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":5.6,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":21.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.545845+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_144466","record_id":"REC_0006900","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":19,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":6.7,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.546083+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_313680","record_id":"REC_0006901","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":8.4,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":4.2,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":18.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.546316+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_252581","record_id":"REC_0006902","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":39,"sex":"male","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":6.2,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.546551+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_342520","record_id":"REC_0006903","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":5.2,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":1,"smoking_pack_years":31,"primary_tumor_size_cm":5.7,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":6.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.546784+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_274008","record_id":"REC_0006904","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":0,"primary_tumor_size_cm":5.3,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":16.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.547079+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_265364","record_id":"REC_0006905","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":33,"tmb_mutations_per_mb":9.8,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":5.9,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":22.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.547318+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_355252","record_id":"REC_0006906","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":15.8,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":7.0,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.547549+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_263445","record_id":"REC_0006907","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":13.8,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":6.2,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.547781+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_633836","record_id":"REC_0006908","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":16.2,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.9,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.548016+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_153939","record_id":"REC_0006909","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":9.0,"age_at_diagnosis":85,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":5.7,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.548280+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_109777","record_id":"REC_0006910","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":13.8,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":2,"smoking_pack_years":25,"primary_tumor_size_cm":5.5,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":34.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.548516+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_333162","record_id":"REC_0006911","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":17.2,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":24,"primary_tumor_size_cm":6.4,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.548753+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_605531","record_id":"REC_0006912","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":18.5,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":3.9,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.548993+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_388738","record_id":"REC_0006913","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":15,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":6.2,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.549232+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_700101","record_id":"REC_0006914","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":1,"smoking_pack_years":66,"primary_tumor_size_cm":3.5,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.549463+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_485214","record_id":"REC_0006915","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":9.7,"age_at_diagnosis":84,"sex":"female","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":3.9,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.549693+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_528700","record_id":"REC_0006916","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":2,"smoking_pack_years":26,"primary_tumor_size_cm":4.8,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.549922+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_444351","record_id":"REC_0006917","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":8.5,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":25,"primary_tumor_size_cm":5.3,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":6.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.550201+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_251061","record_id":"REC_0006918","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":8.6,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":4.5,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":8.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.550436+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_161632","record_id":"REC_0006919","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":35,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":52,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":5.7,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.550671+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_577989","record_id":"REC_0006920","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":75,"sex":"male","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":6.9,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.550909+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_252672","record_id":"REC_0006921","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":9.1,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":5.9,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.551141+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_183014","record_id":"REC_0006922","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":9.9,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":4.8,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.551372+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_421196","record_id":"REC_0006923","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":15.0,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":3,"smoking_pack_years":11,"primary_tumor_size_cm":5.5,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":6.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.551603+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_778972","record_id":"REC_0006924","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":15.1,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":6.2,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.551837+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_753906","record_id":"REC_0006925","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":5,"primary_tumor_size_cm":4.6,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":23.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.552067+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_733938","record_id":"REC_0006926","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":6.4,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":27.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.552402+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_406217","record_id":"REC_0006927","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":5.3,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":28,"primary_tumor_size_cm":3.8,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.552639+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_626916","record_id":"REC_0006928","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":5.7,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.552875+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_258171","record_id":"REC_0006929","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":15.6,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":6.4,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":23.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.553113+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_395593","record_id":"REC_0006930","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":19.7,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":5.4,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.553409+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_501811","record_id":"REC_0006931","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":16,"tmb_mutations_per_mb":15.5,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":6.6,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.553650+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_670369","record_id":"REC_0006932","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":4.8,"metastatic_sites_count":3,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.553884+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_501618","record_id":"REC_0006933","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":18,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":4.4,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.554121+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_516114","record_id":"REC_0006934","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":6.0,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.554351+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_128186","record_id":"REC_0006935","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":0,"primary_tumor_size_cm":4.8,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.554580+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_400602","record_id":"REC_0006936","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":14.0,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":5.8,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":29.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.554812+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_312689","record_id":"REC_0006937","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":7,"primary_tumor_size_cm":5.5,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":22.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.555042+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_500830","record_id":"REC_0006938","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":19.9,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":5.3,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":23.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.555278+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_568070","record_id":"REC_0006939","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":16,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":3.8,"metastatic_sites_count":9,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":6.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.555512+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_838473","record_id":"REC_0006940","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":8.4,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":5.7,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":7.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.555744+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_171208","record_id":"REC_0006941","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":16.9,"age_at_diagnosis":78,"sex":"male","ecog_performance_status":2,"smoking_pack_years":10,"primary_tumor_size_cm":6.6,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":16.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.555978+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_132007","record_id":"REC_0006942","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":32,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":4.5,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.556311+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_772972","record_id":"REC_0006943","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":31,"tmb_mutations_per_mb":15.0,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.2,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.556625+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_687888","record_id":"REC_0006944","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":7.7,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.556869+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_970776","record_id":"REC_0006945","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":4.3,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.557108+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_933556","record_id":"REC_0006946","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":5.5,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":34,"primary_tumor_size_cm":5.7,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":7.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.557338+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_380377","record_id":"REC_0006947","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":13.5,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":4.5,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":5.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.557570+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_429666","record_id":"REC_0006948","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":14.7,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":6.3,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.557805+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_364425","record_id":"REC_0006949","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":32,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":85,"sex":"female","ecog_performance_status":1,"smoking_pack_years":69,"primary_tumor_size_cm":3.5,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.558033+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_170556","record_id":"REC_0006950","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":9.7,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":4.8,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":4.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.558267+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_456768","record_id":"REC_0006951","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":34,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":47,"primary_tumor_size_cm":4.8,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":7.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.558495+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_671656","record_id":"REC_0006952","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.0,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":33.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.558733+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_216482","record_id":"REC_0006953","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.6,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.558966+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_649242","record_id":"REC_0006954","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":16.6,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":7.9,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.559202+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_825288","record_id":"REC_0006955","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":78,"sex":"male","ecog_performance_status":2,"smoking_pack_years":0,"primary_tumor_size_cm":6.5,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.559438+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_275914","record_id":"REC_0006956","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":4.5,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":4.4,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.559715+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_684447","record_id":"REC_0006957","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":14.3,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":0,"smoking_pack_years":26,"primary_tumor_size_cm":8.5,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":24.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.559955+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_289396","record_id":"REC_0006958","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":80,"sex":"male","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":5.2,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.560288+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_402772","record_id":"REC_0006959","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":78,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":3.0,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":21.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.560537+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_464030","record_id":"REC_0006960","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":8.3,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":6.5,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.560767+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_184671","record_id":"REC_0006961","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":8.0,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":22,"primary_tumor_size_cm":8.1,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":37.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.560996+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_942229","record_id":"REC_0006962","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":4.7,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":24.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.561229+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_788277","record_id":"REC_0006963","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":6.6,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":18.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.561461+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_829124","record_id":"REC_0006964","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":13.5,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":0,"smoking_pack_years":2,"primary_tumor_size_cm":6.6,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":18.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.561698+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_858927","record_id":"REC_0006965","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":4.3,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":3,"smoking_pack_years":10,"primary_tumor_size_cm":4.8,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.561928+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_897649","record_id":"REC_0006966","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":31,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":5.6,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.562159+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_706991","record_id":"REC_0006967","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":13.8,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":4.8,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.562396+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_940500","record_id":"REC_0006968","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":13.6,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":5.4,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.562631+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_321303","record_id":"REC_0006969","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":16,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":81,"sex":"male","ecog_performance_status":3,"smoking_pack_years":17,"primary_tumor_size_cm":6.2,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.562933+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_694212","record_id":"REC_0006970","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":30,"tmb_mutations_per_mb":2.2,"age_at_diagnosis":79,"sex":"male","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":6.8,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.563170+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_908348","record_id":"REC_0006971","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":4.5,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.563404+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_904887","record_id":"REC_0006972","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":5.1,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.563635+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_262082","record_id":"REC_0006973","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.1,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":42.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.563870+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_427812","record_id":"REC_0006974","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":19.5,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":5.7,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.564136+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_165702","record_id":"REC_0006975","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":7.1,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.564378+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_942456","record_id":"REC_0006976","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":15.4,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":4.4,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":7.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.564612+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_310274","record_id":"REC_0006977","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":6.1,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":4.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.564847+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_640870","record_id":"REC_0006978","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":13.5,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":2.6,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":29.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.565084+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_157551","record_id":"REC_0006979","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":14.1,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":5.5,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":19.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.565318+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_946575","record_id":"REC_0006980","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":8.1,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":7.4,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.565552+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_384200","record_id":"REC_0006981","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":9.7,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.1,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.565783+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_409792","record_id":"REC_0006982","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":20,"tmb_mutations_per_mb":5.3,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":4.6,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.566068+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_405382","record_id":"REC_0006983","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":7.9,"age_at_diagnosis":78,"sex":"male","ecog_performance_status":2,"smoking_pack_years":23,"primary_tumor_size_cm":8.2,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.566307+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_758971","record_id":"REC_0006984","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":3.9,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":18.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.566537+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_246458","record_id":"REC_0006985","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":11.1,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":7.4,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.566774+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_814404","record_id":"REC_0006986","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":5.6,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.567011+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_779965","record_id":"REC_0006987","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":15.2,"age_at_diagnosis":77,"sex":"male","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":6.0,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.567248+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_771945","record_id":"REC_0006988","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":32,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":6.4,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.567479+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_113440","record_id":"REC_0006989","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":32,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":7.9,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":24.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.567712+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_731322","record_id":"REC_0006990","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":4.9,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":4.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.567950+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_460387","record_id":"REC_0006991","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":8.9,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":31,"primary_tumor_size_cm":6.8,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.568262+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_173040","record_id":"REC_0006992","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":2.8,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":3.5,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":7.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.568526+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_822793","record_id":"REC_0006993","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":14.3,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":6.1,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.568766+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_257112","record_id":"REC_0006994","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":4.2,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":17.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.569005+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_297524","record_id":"REC_0006995","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":18.2,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":6.1,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.569325+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_266908","record_id":"REC_0006996","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":18,"tmb_mutations_per_mb":14.6,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":4.0,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.569567+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_488384","record_id":"REC_0006997","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":5.6,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.569803+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_589130","record_id":"REC_0006998","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":14.4,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":4.0,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.570041+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_476003","record_id":"REC_0006999","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":33,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":54,"sex":"male","ecog_performance_status":0,"smoking_pack_years":2,"primary_tumor_size_cm":3.0,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.570281+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_211756","record_id":"REC_0007000","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":15.2,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":6.6,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.570516+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_282680","record_id":"REC_0007001","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":5.0,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":27.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.570751+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_832631","record_id":"REC_0007002","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":7.6,"age_at_diagnosis":47,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":3.9,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.570979+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_262496","record_id":"REC_0007003","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":32,"primary_tumor_size_cm":5.8,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.571210+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_652666","record_id":"REC_0007004","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":4.4,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":0,"primary_tumor_size_cm":5.7,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.571438+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_238531","record_id":"REC_0007005","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":7.9,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":4.9,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":26.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.571665+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_608552","record_id":"REC_0007006","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":2,"primary_tumor_size_cm":5.1,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.571901+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_237234","record_id":"REC_0007007","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":17,"tmb_mutations_per_mb":11.1,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":5.4,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.572176+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_342963","record_id":"REC_0007008","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":17,"tmb_mutations_per_mb":5.6,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":4.6,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.572461+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_182096","record_id":"REC_0007009","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":4.3,"age_at_diagnosis":74,"sex":"male","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":3.8,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.572700+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_845144","record_id":"REC_0007010","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":7.2,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.572934+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_520305","record_id":"REC_0007011","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":5.0,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.573170+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_355571","record_id":"REC_0007012","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":6.3,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.573405+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_959474","record_id":"REC_0007013","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":9.1,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":2,"smoking_pack_years":6,"primary_tumor_size_cm":3.5,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.573641+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_819759","record_id":"REC_0007014","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":6.6,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.573875+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_500513","record_id":"REC_0007015","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":13.6,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":6.5,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":28.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.574109+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_406829","record_id":"REC_0007016","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":16,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":51,"sex":"female","ecog_performance_status":0,"smoking_pack_years":2,"primary_tumor_size_cm":4.9,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.574345+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_306710","record_id":"REC_0007017","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":16,"tmb_mutations_per_mb":6.7,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":4.2,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.574576+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_852128","record_id":"REC_0007018","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":5.7,"metastatic_sites_count":8,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.574806+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_206451","record_id":"REC_0007019","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":6.1,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":31,"primary_tumor_size_cm":5.5,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":28.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.575040+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_443408","record_id":"REC_0007020","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":25,"primary_tumor_size_cm":4.4,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.575275+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_957370","record_id":"REC_0007021","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":8.5,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":32,"primary_tumor_size_cm":6.3,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.575550+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_981008","record_id":"REC_0007022","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":9.8,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":6.8,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.575784+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_955121","record_id":"REC_0007023","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":18,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":30,"primary_tumor_size_cm":3.2,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":7.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.576023+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_737454","record_id":"REC_0007024","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":4.8,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":16.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.576352+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_242677","record_id":"REC_0007025","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":3.7,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":5.7,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.576583+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_163221","record_id":"REC_0007026","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":5.6,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":37,"primary_tumor_size_cm":4.6,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":21.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.576816+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_613479","record_id":"REC_0007027","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":16,"tmb_mutations_per_mb":9.9,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":44,"primary_tumor_size_cm":5.6,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.577044+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_976792","record_id":"REC_0007028","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":35,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":3.4,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":8.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.577281+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_687895","record_id":"REC_0007029","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":16,"tmb_mutations_per_mb":17.9,"age_at_diagnosis":81,"sex":"male","ecog_performance_status":2,"smoking_pack_years":8,"primary_tumor_size_cm":5.3,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.577518+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_557453","record_id":"REC_0007030","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":53,"sex":"male","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":6.1,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":5.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.577752+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_620797","record_id":"REC_0007031","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":15.7,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":6.3,"metastatic_sites_count":3,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.577986+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_917950","record_id":"REC_0007032","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":30,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":3.7,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":7.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.578218+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_140729","record_id":"REC_0007033","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":8.0,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":4,"primary_tumor_size_cm":6.2,"metastatic_sites_count":8,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.578447+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_766815","record_id":"REC_0007034","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":13.3,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":4.5,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":17.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.578727+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_462651","record_id":"REC_0007035","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":53,"sex":"female","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":6.8,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":25.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.578965+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_111439","record_id":"REC_0007036","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":5.9,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.579198+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_237920","record_id":"REC_0007037","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None","pd_l1_tps_percent":20,"tmb_mutations_per_mb":3.7,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":32,"primary_tumor_size_cm":2.3,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.579427+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_758221","record_id":"REC_0007038","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":17.3,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":4.7,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.579661+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_721917","record_id":"REC_0007039","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":9.8,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":50,"primary_tumor_size_cm":4.5,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.579891+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_664086","record_id":"REC_0007040","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":16.0,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":5.8,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.580176+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_812167","record_id":"REC_0007041","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":31,"primary_tumor_size_cm":5.6,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.580416+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_149882","record_id":"REC_0007042","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":18,"tmb_mutations_per_mb":4.5,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":1,"smoking_pack_years":66,"primary_tumor_size_cm":5.0,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":19.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.580662+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_344722","record_id":"REC_0007043","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":4.9,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.580900+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_272068","record_id":"REC_0007044","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":10.1,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":3,"smoking_pack_years":5,"primary_tumor_size_cm":5.0,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.581131+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_981912","record_id":"REC_0007045","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":15.0,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":5.5,"metastatic_sites_count":9,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.581365+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_143354","record_id":"REC_0007046","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":13.3,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":4.1,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":36.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.581599+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_734091","record_id":"REC_0007047","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":15,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":74,"sex":"male","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":5.5,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":20.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.581884+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_830848","record_id":"REC_0007048","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":17.2,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":7.0,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.582120+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_421536","record_id":"REC_0007049","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":2.9,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":33,"primary_tumor_size_cm":3.9,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.582353+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_602141","record_id":"REC_0007050","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":30,"tmb_mutations_per_mb":5.2,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":47,"primary_tumor_size_cm":5.8,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":7.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.582586+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_319665","record_id":"REC_0007051","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":14.0,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":4.8,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.582817+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_574337","record_id":"REC_0007052","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":13.1,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":5.0,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.583050+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_516439","record_id":"REC_0007053","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":24,"primary_tumor_size_cm":7.1,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.583280+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_915214","record_id":"REC_0007054","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":64,"primary_tumor_size_cm":4.1,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.583508+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_193802","record_id":"REC_0007055","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":2,"smoking_pack_years":10,"primary_tumor_size_cm":5.7,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.583738+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_804455","record_id":"REC_0007056","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":36,"tmb_mutations_per_mb":14.9,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":7.4,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":21.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.583974+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_779601","record_id":"REC_0007057","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":8.6,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":4.5,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.584308+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_254154","record_id":"REC_0007058","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":20.4,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":5.6,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.584555+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_238130","record_id":"REC_0007059","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":18,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":4.7,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.584787+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_715364","record_id":"REC_0007060","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":16.2,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":5.5,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.585078+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_900091","record_id":"REC_0007061","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":30,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":8.2,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.585310+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_264035","record_id":"REC_0007062","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":6.1,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":24.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.585542+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_168813","record_id":"REC_0007063","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":1,"smoking_pack_years":40,"primary_tumor_size_cm":6.1,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":4.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.585776+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_985049","record_id":"REC_0007064","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":46,"sex":"female","ecog_performance_status":0,"smoking_pack_years":5,"primary_tumor_size_cm":4.0,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.586011+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_450956","record_id":"REC_0007065","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":5.6,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":19.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.586245+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_166317","record_id":"REC_0007066","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":4.8,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":79,"primary_tumor_size_cm":6.8,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.586475+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_527655","record_id":"REC_0007067","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":32,"tmb_mutations_per_mb":7.6,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":6.8,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":21.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.586703+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_834926","record_id":"REC_0007068","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":77,"sex":"male","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.7,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":21.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.586935+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_406811","record_id":"REC_0007069","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":4.6,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.587169+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_620610","record_id":"REC_0007070","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":9.0,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":4,"primary_tumor_size_cm":5.4,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.587398+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_771044","record_id":"REC_0007071","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":32,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":3.9,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":18.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.587634+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_502924","record_id":"REC_0007072","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":31,"tmb_mutations_per_mb":6.0,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":1,"smoking_pack_years":70,"primary_tumor_size_cm":5.6,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":7.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.587865+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_757164","record_id":"REC_0007073","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":6.1,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":5.7,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":47.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.588159+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_573482","record_id":"REC_0007074","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":20,"tmb_mutations_per_mb":6.0,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":47,"primary_tumor_size_cm":5.6,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.588398+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_527481","record_id":"REC_0007075","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":6.7,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":4,"primary_tumor_size_cm":3.9,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.588636+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_205341","record_id":"REC_0007076","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":33,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":55,"primary_tumor_size_cm":5.9,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.588877+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_161822","record_id":"REC_0007077","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":18,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":4.4,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":22.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.589114+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_901637","record_id":"REC_0007078","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":14.1,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":8,"primary_tumor_size_cm":6.5,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.589347+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_694361","record_id":"REC_0007079","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":78,"sex":"male","ecog_performance_status":1,"smoking_pack_years":35,"primary_tumor_size_cm":4.3,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.589583+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_701103","record_id":"REC_0007080","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":5.7,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":1,"smoking_pack_years":33,"primary_tumor_size_cm":3.1,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":27.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.589817+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_413760","record_id":"REC_0007081","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":17.3,"age_at_diagnosis":85,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":4.8,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.590051+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_106758","record_id":"REC_0007082","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":6.7,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":4.0,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.590283+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_360716","record_id":"REC_0007083","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":32,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":56,"primary_tumor_size_cm":4.3,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.590509+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_405636","record_id":"REC_0007084","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":8.5,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":24,"primary_tumor_size_cm":6.5,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":8.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.590738+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_909741","record_id":"REC_0007085","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":6.7,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":4.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.590973+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_380316","record_id":"REC_0007086","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":14,"tmb_mutations_per_mb":7.4,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":4,"smoking_pack_years":14,"primary_tumor_size_cm":6.2,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":26.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.591258+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_902586","record_id":"REC_0007087","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":6.0,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.591499+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_398770","record_id":"REC_0007088","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":8.9,"age_at_diagnosis":74,"sex":"male","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":5.0,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":17.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.591731+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_844974","record_id":"REC_0007089","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":3.9,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":85,"primary_tumor_size_cm":5.3,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":37.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.591964+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_830214","record_id":"REC_0007090","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":15,"tmb_mutations_per_mb":8.3,"age_at_diagnosis":75,"sex":"male","ecog_performance_status":1,"smoking_pack_years":48,"primary_tumor_size_cm":6.1,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":20.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.592255+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_535930","record_id":"REC_0007091","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":15.2,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":5.6,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":7.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.592510+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_114905","record_id":"REC_0007092","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":16.5,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":7.3,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.592746+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_330711","record_id":"REC_0007093","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":1,"smoking_pack_years":24,"primary_tumor_size_cm":4.3,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":7.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.592974+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_457291","record_id":"REC_0007094","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":3.9,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.593205+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_992052","record_id":"REC_0007095","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":39,"primary_tumor_size_cm":2.8,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":21.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.593437+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_350101","record_id":"REC_0007096","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":5.2,"age_at_diagnosis":87,"sex":"female","ecog_performance_status":2,"smoking_pack_years":48,"primary_tumor_size_cm":5.9,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":16.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.593669+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_700736","record_id":"REC_0007097","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":7.9,"age_at_diagnosis":54,"sex":"male","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":5.1,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":18.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.593900+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_677369","record_id":"REC_0007098","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":36,"tmb_mutations_per_mb":17.6,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":6.7,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.594133+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_802390","record_id":"REC_0007099","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":4.5,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":19.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.594414+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_421595","record_id":"REC_0007100","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":32,"tmb_mutations_per_mb":5.9,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":83,"primary_tumor_size_cm":6.8,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.594644+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_648931","record_id":"REC_0007101","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":32,"tmb_mutations_per_mb":13.8,"age_at_diagnosis":54,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":7.7,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.594882+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_652421","record_id":"REC_0007102","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":7.9,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":2,"smoking_pack_years":21,"primary_tumor_size_cm":6.2,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":28.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.595111+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_950240","record_id":"REC_0007103","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":6.9,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":25,"primary_tumor_size_cm":5.2,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":24.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.595341+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_577473","record_id":"REC_0007104","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":15.0,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":4,"primary_tumor_size_cm":4.6,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.595576+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_317077","record_id":"REC_0007105","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":21,"primary_tumor_size_cm":6.0,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.595808+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_475566","record_id":"REC_0007106","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":15.7,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":1,"primary_tumor_size_cm":3.8,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.596036+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_830984","record_id":"REC_0007107","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":4.0,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":19.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.596370+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_876850","record_id":"REC_0007108","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":4.7,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.596605+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_895346","record_id":"REC_0007109","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":6.1,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":48,"primary_tumor_size_cm":5.6,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":4.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.596839+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_750223","record_id":"REC_0007110","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":88,"sex":"female","ecog_performance_status":2,"smoking_pack_years":9,"primary_tumor_size_cm":5.8,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":21.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.597072+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_574078","record_id":"REC_0007111","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":14.7,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":6.4,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.597308+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_256996","record_id":"REC_0007112","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":30,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":4.1,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.597585+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_817249","record_id":"REC_0007113","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":6.4,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.597826+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_526518","record_id":"REC_0007114","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":16.5,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":0,"smoking_pack_years":25,"primary_tumor_size_cm":4.0,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.598061+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_946909","record_id":"REC_0007115","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":6.1,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.598293+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_322936","record_id":"REC_0007116","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":4.0,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.598527+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_182786","record_id":"REC_0007117","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":31,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":5.3,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":21.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.598759+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_573819","record_id":"REC_0007118","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":6.9,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":7.5,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.598990+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_251726","record_id":"REC_0007119","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":4.2,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":5.1,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.599224+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_609037","record_id":"REC_0007120","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":3.5,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":36,"primary_tumor_size_cm":3.6,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.599451+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_587217","record_id":"REC_0007121","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":8.4,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":17.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.599687+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_762649","record_id":"REC_0007122","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":14.5,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":4.9,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":28.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.599916+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_379170","record_id":"REC_0007123","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":9.9,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":6.3,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.600174+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_276320","record_id":"REC_0007124","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":6.7,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":43.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.600412+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_858876","record_id":"REC_0007125","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":4,"primary_tumor_size_cm":4.1,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":7.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.600695+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_594079","record_id":"REC_0007126","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":9.5,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":3,"smoking_pack_years":13,"primary_tumor_size_cm":5.2,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":20.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.600928+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_202537","record_id":"REC_0007127","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":16.2,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":5.9,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":25.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.601162+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_535226","record_id":"REC_0007128","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":74,"sex":"male","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":6.5,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.601400+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_397800","record_id":"REC_0007129","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":6.4,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.601635+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_450199","record_id":"REC_0007130","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":8.9,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":3,"smoking_pack_years":0,"primary_tumor_size_cm":8.0,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.601862+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_685059","record_id":"REC_0007131","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":5.7,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.602095+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_350663","record_id":"REC_0007132","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":10.0,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":26,"primary_tumor_size_cm":6.0,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.602331+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_115406","record_id":"REC_0007133","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":9.9,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":4.7,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.602560+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_895893","record_id":"REC_0007134","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":34,"tmb_mutations_per_mb":17.0,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":6.8,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":17.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.602790+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_300597","record_id":"REC_0007135","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":52,"sex":"female","ecog_performance_status":0,"smoking_pack_years":6,"primary_tumor_size_cm":5.5,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.603022+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_756827","record_id":"REC_0007136","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":8.1,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":6.8,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.603253+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_111186","record_id":"REC_0007137","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":15.6,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":6,"primary_tumor_size_cm":4.7,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.603491+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_984751","record_id":"REC_0007138","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":48,"primary_tumor_size_cm":5.4,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.603786+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_900112","record_id":"REC_0007139","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":6.6,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.604026+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_406322","record_id":"REC_0007140","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":13.6,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":3,"smoking_pack_years":19,"primary_tumor_size_cm":8.3,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.604317+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_344717","record_id":"REC_0007141","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":4.1,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":4.4,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.604553+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_713388","record_id":"REC_0007142","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":2.9,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":1,"smoking_pack_years":26,"primary_tumor_size_cm":6.7,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.604785+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_926971","record_id":"REC_0007143","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":4.7,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.605025+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_279060","record_id":"REC_0007144","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":14,"tmb_mutations_per_mb":16.5,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":5.6,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.605262+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_755964","record_id":"REC_0007145","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":16.0,"age_at_diagnosis":76,"sex":"male","ecog_performance_status":2,"smoking_pack_years":7,"primary_tumor_size_cm":5.0,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.605499+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_294883","record_id":"REC_0007146","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":16.7,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":9.4,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.605729+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_962998","record_id":"REC_0007147","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":6.3,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.605964+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_169177","record_id":"REC_0007148","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":4.1,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":48,"primary_tumor_size_cm":7.6,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.606195+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_322891","record_id":"REC_0007149","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":8.3,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":6.5,"metastatic_sites_count":9,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":4.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.606422+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_672703","record_id":"REC_0007150","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":4.5,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.606657+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_610910","record_id":"REC_0007151","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":8.4,"age_at_diagnosis":76,"sex":"male","ecog_performance_status":2,"smoking_pack_years":10,"primary_tumor_size_cm":6.0,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.606939+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_147502","record_id":"REC_0007152","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":7.0,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":26.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.607171+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_588485","record_id":"REC_0007153","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":18,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":2.3,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":18.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.607404+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_922703","record_id":"REC_0007154","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":14,"tmb_mutations_per_mb":4.3,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":1,"smoking_pack_years":42,"primary_tumor_size_cm":4.6,"metastatic_sites_count":3,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.607636+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_965189","record_id":"REC_0007155","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":4.5,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.607867+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_507105","record_id":"REC_0007156","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":30,"tmb_mutations_per_mb":16.1,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":10,"primary_tumor_size_cm":5.0,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.608129+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_994621","record_id":"REC_0007157","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":15.1,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":4.0,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.608366+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_423181","record_id":"REC_0007158","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":4.2,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.608602+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_500514","record_id":"REC_0007159","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":19.0,"age_at_diagnosis":53,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":6.9,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":19.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.608838+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_692353","record_id":"REC_0007160","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":31,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":4,"smoking_pack_years":0,"primary_tumor_size_cm":4.2,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":6.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.609067+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_262665","record_id":"REC_0007161","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":7,"primary_tumor_size_cm":6.1,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.609298+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_874738","record_id":"REC_0007162","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":71,"primary_tumor_size_cm":5.3,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":20.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.609529+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_204134","record_id":"REC_0007163","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":5.6,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":76,"primary_tumor_size_cm":6.6,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":19.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.609757+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_385110","record_id":"REC_0007164","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":77,"sex":"male","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":5.5,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":5.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.610035+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_783575","record_id":"REC_0007165","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":16,"tmb_mutations_per_mb":14.4,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":5.4,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.610275+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_646134","record_id":"REC_0007166","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":2.2,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":5.7,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.610510+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_159660","record_id":"REC_0007167","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":32,"tmb_mutations_per_mb":16.7,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":6.0,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.610750+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_740651","record_id":"REC_0007168","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":2,"smoking_pack_years":23,"primary_tumor_size_cm":5.9,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.610979+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_951645","record_id":"REC_0007169","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":16.1,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":4.3,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.611216+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_483050","record_id":"REC_0007170","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":5.6,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":27,"primary_tumor_size_cm":3.5,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.611447+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_960120","record_id":"REC_0007171","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":21.8,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":6.6,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.611683+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_583421","record_id":"REC_0007172","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":31,"tmb_mutations_per_mb":14.0,"age_at_diagnosis":84,"sex":"female","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":4.6,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.611920+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_717145","record_id":"REC_0007173","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":15.2,"age_at_diagnosis":51,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":5.4,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":18.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.612207+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_996648","record_id":"REC_0007174","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":8.1,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":0,"smoking_pack_years":24,"primary_tumor_size_cm":6.6,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.612448+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_460686","record_id":"REC_0007175","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":25,"primary_tumor_size_cm":4.2,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.612677+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_263639","record_id":"REC_0007176","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":76,"sex":"male","ecog_performance_status":2,"smoking_pack_years":4,"primary_tumor_size_cm":4.6,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.612913+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_127899","record_id":"REC_0007177","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":13.6,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":20,"primary_tumor_size_cm":6.3,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.613188+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_543224","record_id":"REC_0007178","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":14,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":2.2,"metastatic_sites_count":10,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.613423+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_321317","record_id":"REC_0007179","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":6.0,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.613659+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_319635","record_id":"REC_0007180","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":6.8,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":36.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.613885+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_254404","record_id":"REC_0007181","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":84,"sex":"male","ecog_performance_status":3,"smoking_pack_years":14,"primary_tumor_size_cm":5.0,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.614120+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_956327","record_id":"REC_0007182","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":6.0,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":7.2,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.614345+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_198454","record_id":"REC_0007183","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":14.5,"age_at_diagnosis":45,"sex":"female","ecog_performance_status":0,"smoking_pack_years":25,"primary_tumor_size_cm":5.0,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.614579+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_133185","record_id":"REC_0007184","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":4.3,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.614811+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_819111","record_id":"REC_0007185","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":18.0,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":6.1,"metastatic_sites_count":3,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.615045+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_638068","record_id":"REC_0007186","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":3,"smoking_pack_years":0,"primary_tumor_size_cm":7.4,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.615278+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_169909","record_id":"REC_0007187","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":6.9,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":6.8,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":31.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.615506+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_788014","record_id":"REC_0007188","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":66,"primary_tumor_size_cm":7.3,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":34.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.615732+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_739376","record_id":"REC_0007189","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":4.8,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":5.0,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.615960+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_845880","record_id":"REC_0007190","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":14.3,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":7.5,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.616466+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_975347","record_id":"REC_0007191","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":16.8,"age_at_diagnosis":44,"sex":"male","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":3.7,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.616718+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_212655","record_id":"REC_0007192","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":19,"tmb_mutations_per_mb":3.5,"age_at_diagnosis":86,"sex":"female","ecog_performance_status":1,"smoking_pack_years":54,"primary_tumor_size_cm":6.0,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.616960+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_801680","record_id":"REC_0007193","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":10.1,"age_at_diagnosis":83,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":5.7,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":19.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.617196+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_909693","record_id":"REC_0007194","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":6.3,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":5.6,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.617428+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_915624","record_id":"REC_0007195","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":7.7,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":20.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.617660+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_794696","record_id":"REC_0007196","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":7.6,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":5,"primary_tumor_size_cm":6.4,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.617890+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_229950","record_id":"REC_0007197","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":3.3,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":4.4,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.618120+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_309339","record_id":"REC_0007198","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":34,"tmb_mutations_per_mb":3.9,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":6,"primary_tumor_size_cm":3.6,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":21.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.618353+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_935426","record_id":"REC_0007199","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":20,"primary_tumor_size_cm":6.9,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.618589+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_416133","record_id":"REC_0007200","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":2.9,"age_at_diagnosis":84,"sex":"female","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":5.6,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.618818+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_877262","record_id":"REC_0007201","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":6.9,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":4.4,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.619050+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_288625","record_id":"REC_0007202","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":19.0,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":5.9,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":26.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.619280+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_276593","record_id":"REC_0007203","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":4.9,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.619574+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_937421","record_id":"REC_0007204","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":5.8,"metastatic_sites_count":8,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":16.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.619806+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_326250","record_id":"REC_0007205","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":3.8,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":4.0,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.620037+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_482321","record_id":"REC_0007206","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":14.8,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.3,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.620310+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_363677","record_id":"REC_0007207","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":37,"tmb_mutations_per_mb":17.6,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":6.7,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.620543+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_938408","record_id":"REC_0007208","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":11.5,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":4.2,"metastatic_sites_count":9,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.620775+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_192165","record_id":"REC_0007209","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":14.5,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":6.7,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":20.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.621011+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_834721","record_id":"REC_0007210","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":14.8,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":5.6,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.621244+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_894374","record_id":"REC_0007211","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":2.7,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.621476+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_544720","record_id":"REC_0007212","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":19,"tmb_mutations_per_mb":6.3,"age_at_diagnosis":54,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":5.4,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":5.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.621705+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_919929","record_id":"REC_0007213","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":5.0,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.621933+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_636099","record_id":"REC_0007214","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":6.3,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":21.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.622166+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_408400","record_id":"REC_0007215","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":6.3,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":0,"smoking_pack_years":5,"primary_tumor_size_cm":5.6,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":28.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.622402+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_787618","record_id":"REC_0007216","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":31,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":5.8,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":18.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.622680+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_117576","record_id":"REC_0007217","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":10.0,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":5.2,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.622916+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_519893","record_id":"REC_0007218","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":4.9,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.623146+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_754897","record_id":"REC_0007219","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":31,"tmb_mutations_per_mb":9.9,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":6.7,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.623381+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_329223","record_id":"REC_0007220","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":7.4,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":3.8,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.623610+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_460645","record_id":"REC_0007221","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":17.8,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":6.8,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.623846+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_635108","record_id":"REC_0007222","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":14.1,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":6.6,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":6.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.624108+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_519270","record_id":"REC_0007223","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":2,"smoking_pack_years":9,"primary_tumor_size_cm":4.7,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":21.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.624344+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_112012","record_id":"REC_0007224","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":2,"smoking_pack_years":20,"primary_tumor_size_cm":4.0,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.624582+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_184752","record_id":"REC_0007225","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":4.7,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.624817+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_947153","record_id":"REC_0007226","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":16.2,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":7.2,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.625048+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_525540","record_id":"REC_0007227","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":30,"tmb_mutations_per_mb":16.1,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":7.0,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.625286+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_476383","record_id":"REC_0007228","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":54,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":4.1,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":5.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.625515+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_858695","record_id":"REC_0007229","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":5.0,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":6.7,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.625791+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_500214","record_id":"REC_0007230","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":5.7,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.626030+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_395642","record_id":"REC_0007231","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":18.1,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":4.1,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":22.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.626264+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_435279","record_id":"REC_0007232","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":4.0,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":53,"primary_tumor_size_cm":5.3,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":4.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.626493+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_944568","record_id":"REC_0007233","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":9.8,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":4.8,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":17.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.626722+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_277413","record_id":"REC_0007234","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":18,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":5.5,"metastatic_sites_count":8,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":7.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.626957+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_253207","record_id":"REC_0007235","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":8.5,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":66,"primary_tumor_size_cm":6.0,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":27.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.627191+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_937346","record_id":"REC_0007236","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":50,"sex":"male","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":4.7,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":39.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.627425+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_874104","record_id":"REC_0007237","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":4.4,"metastatic_sites_count":3,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.627658+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_411439","record_id":"REC_0007238","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":6.5,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.627893+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_839931","record_id":"REC_0007239","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":20,"tmb_mutations_per_mb":6.0,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":35,"primary_tumor_size_cm":5.1,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.628175+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_258844","record_id":"REC_0007240","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":31,"tmb_mutations_per_mb":4.6,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":4.3,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.628410+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_647199","record_id":"REC_0007241","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":5.6,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":7.3,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.628652+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_922935","record_id":"REC_0007242","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":5.1,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.628933+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_270569","record_id":"REC_0007243","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":18.0,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":6.7,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":5.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.629172+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_733039","record_id":"REC_0007244","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":30,"tmb_mutations_per_mb":3.4,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":2,"smoking_pack_years":42,"primary_tumor_size_cm":6.0,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.629405+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_812229","record_id":"REC_0007245","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":14.7,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":7.6,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.629640+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_135454","record_id":"REC_0007246","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":4.2,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":3.6,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":34.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.629867+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_593715","record_id":"REC_0007247","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":14.5,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":4.1,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":29.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.630105+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_741533","record_id":"REC_0007248","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":5.7,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":57,"primary_tumor_size_cm":5.3,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":5.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.630331+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_979554","record_id":"REC_0007249","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":3,"smoking_pack_years":16,"primary_tumor_size_cm":6.8,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.630562+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_652492","record_id":"REC_0007250","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":3.6,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":22.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.630791+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_493482","record_id":"REC_0007251","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":16.5,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":4.7,"metastatic_sites_count":8,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":6.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.631023+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_887689","record_id":"REC_0007252","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":4.4,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.631255+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_140330","record_id":"REC_0007253","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":11.5,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":7.5,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.631487+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_945573","record_id":"REC_0007254","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":4,"primary_tumor_size_cm":7.3,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.631721+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_479443","record_id":"REC_0007255","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":10.5,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":0,"smoking_pack_years":24,"primary_tumor_size_cm":5.6,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.631999+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_275688","record_id":"REC_0007256","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":6.6,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.632300+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_282046","record_id":"REC_0007257","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":76,"primary_tumor_size_cm":4.0,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":20.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.632532+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_857563","record_id":"REC_0007258","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":9.9,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":5.0,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":20.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.632765+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_707767","record_id":"REC_0007259","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":16.3,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":3.3,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":29.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.633000+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_679234","record_id":"REC_0007260","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":50,"primary_tumor_size_cm":7.5,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":19.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.633228+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_427277","record_id":"REC_0007261","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":8.3,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":3,"smoking_pack_years":8,"primary_tumor_size_cm":2.9,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":23.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.633456+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_767033","record_id":"REC_0007262","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":4.6,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":0,"smoking_pack_years":30,"primary_tumor_size_cm":4.0,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.633687+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_833349","record_id":"REC_0007263","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":5.7,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":2,"smoking_pack_years":21,"primary_tumor_size_cm":6.4,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":4.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.633920+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_271513","record_id":"REC_0007264","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":14.9,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":8.2,"metastatic_sites_count":8,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":17.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.634155+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_381431","record_id":"REC_0007265","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":32,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":1,"smoking_pack_years":54,"primary_tumor_size_cm":3.6,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":17.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.634387+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_993141","record_id":"REC_0007266","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":31,"tmb_mutations_per_mb":10.3,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":4.3,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":7.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.634619+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_248453","record_id":"REC_0007267","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":17,"tmb_mutations_per_mb":14.3,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":7.8,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.634850+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_637995","record_id":"REC_0007268","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":17,"tmb_mutations_per_mb":14.6,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":5.8,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.635125+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_209636","record_id":"REC_0007269","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":15.8,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":6.5,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.635359+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_306266","record_id":"REC_0007270","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":6.6,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.635592+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_703554","record_id":"REC_0007271","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":3,"primary_tumor_size_cm":5.7,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.635825+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_457627","record_id":"REC_0007272","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":18,"tmb_mutations_per_mb":9.0,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":5.3,"metastatic_sites_count":8,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.636055+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_587400","record_id":"REC_0007273","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":6.1,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":16.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.636389+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_388134","record_id":"REC_0007274","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":30,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":58,"primary_tumor_size_cm":2.7,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.636619+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_372261","record_id":"REC_0007275","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":6.7,"age_at_diagnosis":83,"sex":"female","ecog_performance_status":2,"smoking_pack_years":37,"primary_tumor_size_cm":5.9,"metastatic_sites_count":8,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.636849+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_686584","record_id":"REC_0007276","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":6.5,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":17.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.637079+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_858938","record_id":"REC_0007277","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":8.9,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":5.4,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.637308+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_681875","record_id":"REC_0007278","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":20,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":77,"sex":"male","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.2,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":17.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.637542+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_446905","record_id":"REC_0007279","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":9.0,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":21,"primary_tumor_size_cm":6.2,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.637771+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_160986","record_id":"REC_0007280","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":8.7,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":6.6,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":43.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.638002+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_606837","record_id":"REC_0007281","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":3,"smoking_pack_years":9,"primary_tumor_size_cm":5.3,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.638279+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_593464","record_id":"REC_0007282","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":78,"sex":"male","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":4.2,"metastatic_sites_count":8,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.638517+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_914492","record_id":"REC_0007283","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":5.2,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.2,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":6.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.638746+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_278719","record_id":"REC_0007284","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":6.7,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.638977+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_197117","record_id":"REC_0007285","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":13.6,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.7,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":21.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.639209+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_605945","record_id":"REC_0007286","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":34,"tmb_mutations_per_mb":15.5,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":3,"primary_tumor_size_cm":5.4,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":21.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.639443+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_971104","record_id":"REC_0007287","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":15.9,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":6.0,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":25.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.639678+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_465481","record_id":"REC_0007288","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":1,"smoking_pack_years":4,"primary_tumor_size_cm":5.1,"metastatic_sites_count":3,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.639912+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_352643","record_id":"REC_0007289","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":18.4,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":5.8,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":27.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.640214+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_685684","record_id":"REC_0007290","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":5.3,"age_at_diagnosis":53,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":6.2,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.640451+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_216771","record_id":"REC_0007291","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":3.6,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.640684+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_947615","record_id":"REC_0007292","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":6.1,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":45.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.640917+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_840113","record_id":"REC_0007293","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":8.3,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":60,"primary_tumor_size_cm":6.6,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.641148+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_147095","record_id":"REC_0007294","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":17,"tmb_mutations_per_mb":15.3,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":5.6,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.641430+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_342873","record_id":"REC_0007295","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":5.7,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.641670+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_640178","record_id":"REC_0007296","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":6.3,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":31,"primary_tumor_size_cm":6.1,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.641902+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_464600","record_id":"REC_0007297","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":11,"tmb_mutations_per_mb":13.5,"age_at_diagnosis":48,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":7.6,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":50.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.642136+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_931569","record_id":"REC_0007298","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":17,"tmb_mutations_per_mb":8.7,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.6,"metastatic_sites_count":3,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.642363+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_797272","record_id":"REC_0007299","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":17.6,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":6,"primary_tumor_size_cm":3.5,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.642593+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_648867","record_id":"REC_0007300","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":8.3,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.642822+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_750622","record_id":"REC_0007301","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":15.2,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":2.0,"metastatic_sites_count":9,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.643056+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_313395","record_id":"REC_0007302","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":6.3,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.643286+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_600242","record_id":"REC_0007303","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":24,"primary_tumor_size_cm":6.4,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.643519+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_440435","record_id":"REC_0007304","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":13.8,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":4.7,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":34.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.643755+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_442557","record_id":"REC_0007305","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":4.0,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.643986+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_227074","record_id":"REC_0007306","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":16.3,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":3,"smoking_pack_years":25,"primary_tumor_size_cm":5.2,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":17.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.644246+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_826642","record_id":"REC_0007307","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":2.8,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":2,"smoking_pack_years":10,"primary_tumor_size_cm":6.2,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.644526+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_738456","record_id":"REC_0007308","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":13,"tmb_mutations_per_mb":3.5,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":6.4,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":5.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.644757+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_767780","record_id":"REC_0007309","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":11.1,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":0,"smoking_pack_years":5,"primary_tumor_size_cm":4.1,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":18.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.644994+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_361206","record_id":"REC_0007310","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":25,"primary_tumor_size_cm":7.4,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.645229+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_506071","record_id":"REC_0007311","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":32,"tmb_mutations_per_mb":3.2,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":4.6,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.645466+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_647943","record_id":"REC_0007312","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":4.9,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.645700+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_102000","record_id":"REC_0007313","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":32,"tmb_mutations_per_mb":7.4,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":5.3,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":25.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.645931+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_343506","record_id":"REC_0007314","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":5.0,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":3,"smoking_pack_years":64,"primary_tumor_size_cm":7.7,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":20.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.646162+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_442338","record_id":"REC_0007315","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":32,"tmb_mutations_per_mb":14.7,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":4.1,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.646400+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_122345","record_id":"REC_0007316","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":4.8,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.646626+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_191130","record_id":"REC_0007317","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":6.2,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.646859+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_965102","record_id":"REC_0007318","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":7.3,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":0,"smoking_pack_years":5,"primary_tumor_size_cm":8.1,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":27.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.647089+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_492125","record_id":"REC_0007319","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":6.3,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":6.8,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.647320+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_975001","record_id":"REC_0007320","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":4.4,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.647596+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_127374","record_id":"REC_0007321","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":2.2,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":10,"primary_tumor_size_cm":8.1,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":24.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.647827+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_232023","record_id":"REC_0007322","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":5.2,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":7.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.648061+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_629262","record_id":"REC_0007323","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":34,"tmb_mutations_per_mb":15.0,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":5.9,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.648430+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_275965","record_id":"REC_0007324","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":33,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":6.3,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.648663+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_426389","record_id":"REC_0007325","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":9.5,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":4.2,"metastatic_sites_count":3,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":17.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.648897+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_298806","record_id":"REC_0007326","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":2,"primary_tumor_size_cm":7.2,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.649127+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_735774","record_id":"REC_0007327","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":10.3,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":4.0,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":18.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.649362+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_947784","record_id":"REC_0007328","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":5.1,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":16.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.649592+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_108143","record_id":"REC_0007329","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":8.2,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":22.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.649827+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_470945","record_id":"REC_0007330","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":5.4,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.650058+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_873907","record_id":"REC_0007331","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":32,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":4.2,"metastatic_sites_count":8,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.650293+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_546526","record_id":"REC_0007332","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":7.3,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.650529+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_760611","record_id":"REC_0007333","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":52,"sex":"female","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":5.5,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.650810+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_418426","record_id":"REC_0007334","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":15.1,"age_at_diagnosis":53,"sex":"male","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":6.5,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.651048+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_998856","record_id":"REC_0007335","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":6.2,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":18.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.651290+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_696976","record_id":"REC_0007336","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":39,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":25,"primary_tumor_size_cm":6.4,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":27.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.651527+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_785484","record_id":"REC_0007337","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":11.1,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":4.5,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.651763+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_312771","record_id":"REC_0007338","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":18,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.0,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":5.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.651995+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_542100","record_id":"REC_0007339","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":17.6,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":3.8,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.652262+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_686648","record_id":"REC_0007340","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":6.4,"age_at_diagnosis":75,"sex":"male","ecog_performance_status":2,"smoking_pack_years":69,"primary_tumor_size_cm":5.2,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.652510+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_604940","record_id":"REC_0007341","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":6.1,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":4.6,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":21.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.652744+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_571576","record_id":"REC_0007342","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":6.5,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.652980+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_781936","record_id":"REC_0007343","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":15,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":5.6,"metastatic_sites_count":3,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.653212+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_345544","record_id":"REC_0007344","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":13.5,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":7.2,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.653450+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_996640","record_id":"REC_0007345","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":35,"tmb_mutations_per_mb":8.1,"age_at_diagnosis":46,"sex":"male","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":6.4,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.653684+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_654714","record_id":"REC_0007346","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":5.0,"age_at_diagnosis":77,"sex":"male","ecog_performance_status":1,"smoking_pack_years":43,"primary_tumor_size_cm":5.3,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.653959+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_481327","record_id":"REC_0007347","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":4.4,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":1,"smoking_pack_years":36,"primary_tumor_size_cm":6.2,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":16.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.654193+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_181373","record_id":"REC_0007348","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":13.8,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":0,"smoking_pack_years":0,"primary_tumor_size_cm":6.3,"metastatic_sites_count":3,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":5.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.654428+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_507619","record_id":"REC_0007349","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":31,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":5.6,"metastatic_sites_count":8,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":6.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.654665+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_959024","record_id":"REC_0007350","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":5.8,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":21.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.654898+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_763228","record_id":"REC_0007351","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":32,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":6,"primary_tumor_size_cm":5.7,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":17.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.655130+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_341040","record_id":"REC_0007352","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.9,"metastatic_sites_count":3,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.655362+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_564117","record_id":"REC_0007353","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":4.1,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":36,"primary_tumor_size_cm":7.4,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.655591+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_529148","record_id":"REC_0007354","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":16.1,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":4.9,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.655826+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_531179","record_id":"REC_0007355","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":31,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":37,"primary_tumor_size_cm":8.6,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":7.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.656057+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_194565","record_id":"REC_0007356","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":16,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":5.8,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.656395+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_971262","record_id":"REC_0007357","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":15.0,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":0,"smoking_pack_years":3,"primary_tumor_size_cm":6.1,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.656627+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_136374","record_id":"REC_0007358","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":76,"sex":"male","ecog_performance_status":2,"smoking_pack_years":44,"primary_tumor_size_cm":5.1,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":24.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.656860+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_939431","record_id":"REC_0007359","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":13.5,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":3.8,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.657143+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_389236","record_id":"REC_0007360","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":18,"tmb_mutations_per_mb":3.7,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":4,"primary_tumor_size_cm":7.7,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":28.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.657375+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_688374","record_id":"REC_0007361","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":0,"smoking_pack_years":6,"primary_tumor_size_cm":6.1,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":28.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.657607+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_353666","record_id":"REC_0007362","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":13.3,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.1,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":18.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.657839+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_751483","record_id":"REC_0007363","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":34,"tmb_mutations_per_mb":4.0,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":7.9,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.658067+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_501531","record_id":"REC_0007364","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":0,"smoking_pack_years":6,"primary_tumor_size_cm":7.4,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.658297+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_825565","record_id":"REC_0007365","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":15.6,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":7.3,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.658529+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_920137","record_id":"REC_0007366","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":88,"sex":"female","ecog_performance_status":0,"smoking_pack_years":66,"primary_tumor_size_cm":6.5,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":16.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.658758+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_430980","record_id":"REC_0007367","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":14.8,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":6,"primary_tumor_size_cm":5.2,"metastatic_sites_count":9,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.658994+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_182919","record_id":"REC_0007368","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":30,"tmb_mutations_per_mb":8.1,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":1,"smoking_pack_years":39,"primary_tumor_size_cm":5.0,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.659227+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_404659","record_id":"REC_0007369","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":6.7,"metastatic_sites_count":8,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.659458+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_615584","record_id":"REC_0007370","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":4.3,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.659695+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_989534","record_id":"REC_0007371","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":6.0,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":20.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.659932+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_639777","record_id":"REC_0007372","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":10.5,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":3,"smoking_pack_years":15,"primary_tumor_size_cm":3.5,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":18.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.660232+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_288848","record_id":"REC_0007373","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":35,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":4.5,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.660472+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_611871","record_id":"REC_0007374","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":5.0,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.660706+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_773925","record_id":"REC_0007375","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":20.0,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":5.7,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.660945+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_801343","record_id":"REC_0007376","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":3,"smoking_pack_years":23,"primary_tumor_size_cm":6.2,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.661176+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_470717","record_id":"REC_0007377","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":4.3,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":41,"primary_tumor_size_cm":6.8,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.661404+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_998259","record_id":"REC_0007378","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":5.0,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.661640+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_144025","record_id":"REC_0007379","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":4.1,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.661877+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_914333","record_id":"REC_0007380","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":54,"primary_tumor_size_cm":5.5,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":20.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.662107+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_351116","record_id":"REC_0007381","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":6.0,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":43,"primary_tumor_size_cm":3.7,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":7.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.662340+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_823276","record_id":"REC_0007382","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":31,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":5.5,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.662570+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_956284","record_id":"REC_0007383","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":10.0,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":3,"smoking_pack_years":12,"primary_tumor_size_cm":6.2,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.662805+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_485391","record_id":"REC_0007384","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":19,"tmb_mutations_per_mb":5.6,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":3,"smoking_pack_years":48,"primary_tumor_size_cm":8.2,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.663032+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_984600","record_id":"REC_0007385","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":30,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":53,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":5.1,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.663313+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_399545","record_id":"REC_0007386","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":15.0,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":6.0,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.663551+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_318068","record_id":"REC_0007387","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":18,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":0,"smoking_pack_years":42,"primary_tumor_size_cm":4.4,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.663782+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_313452","record_id":"REC_0007388","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":46,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":5.7,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.664016+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_463115","record_id":"REC_0007389","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":6.2,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":26.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.664314+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_849264","record_id":"REC_0007390","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":78,"sex":"male","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":4.0,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":23.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.664555+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_194926","record_id":"REC_0007391","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":10.3,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.3,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":5.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.664791+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_991833","record_id":"REC_0007392","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":7.1,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":23.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.665019+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_221027","record_id":"REC_0007393","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":25,"primary_tumor_size_cm":7.5,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.665247+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_539120","record_id":"REC_0007394","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":84,"sex":"female","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":3.1,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.665478+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_980502","record_id":"REC_0007395","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":5,"primary_tumor_size_cm":5.9,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.665710+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_203402","record_id":"REC_0007396","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":14.0,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":6.1,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.665940+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_710260","record_id":"REC_0007397","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":7.9,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":20,"primary_tumor_size_cm":5.3,"metastatic_sites_count":8,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":7.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.666165+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_515890","record_id":"REC_0007398","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":17,"tmb_mutations_per_mb":7.4,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":58,"primary_tumor_size_cm":4.5,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":6.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.666442+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_189248","record_id":"REC_0007399","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":8.1,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":4.2,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":4.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.666677+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_263689","record_id":"REC_0007400","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":13.3,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":9,"primary_tumor_size_cm":7.1,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.666907+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_447915","record_id":"REC_0007401","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":6.1,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":21.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.667139+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_737762","record_id":"REC_0007402","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":14.0,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":5.3,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":16.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.667369+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_822803","record_id":"REC_0007403","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":34,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":54,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":5.2,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.667606+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_528128","record_id":"REC_0007404","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":14.7,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":5.1,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.667839+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_557152","record_id":"REC_0007405","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":5,"primary_tumor_size_cm":7.3,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.668096+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_490897","record_id":"REC_0007406","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":33,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":30,"primary_tumor_size_cm":5.6,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.668329+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_773525","record_id":"REC_0007407","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":20,"tmb_mutations_per_mb":5.1,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":3,"smoking_pack_years":36,"primary_tumor_size_cm":6.2,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":5.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.668562+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_535436","record_id":"REC_0007408","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":15.3,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":6.5,"metastatic_sites_count":8,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.668792+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_613185","record_id":"REC_0007409","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":5.7,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":22.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.669025+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_215773","record_id":"REC_0007410","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":18.4,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":5.3,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.669259+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_434111","record_id":"REC_0007411","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":16.8,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":3,"smoking_pack_years":11,"primary_tumor_size_cm":5.3,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.669532+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_450919","record_id":"REC_0007412","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":31,"tmb_mutations_per_mb":16.2,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":5.9,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.669771+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_285576","record_id":"REC_0007413","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":31,"tmb_mutations_per_mb":10.5,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":4.3,"metastatic_sites_count":3,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":6.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.670006+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_595389","record_id":"REC_0007414","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":6.0,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":19.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.670235+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_608127","record_id":"REC_0007415","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":20,"tmb_mutations_per_mb":8.4,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":3,"smoking_pack_years":13,"primary_tumor_size_cm":5.4,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.670468+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_566861","record_id":"REC_0007416","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":10.3,"age_at_diagnosis":83,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":4.0,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.670698+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_220362","record_id":"REC_0007417","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":5.6,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":4.9,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":17.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.670931+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_342005","record_id":"REC_0007418","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":13.8,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":10,"primary_tumor_size_cm":5.1,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.671163+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_637028","record_id":"REC_0007419","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":8.5,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.671396+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_521819","record_id":"REC_0007420","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":14.1,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":7.7,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.671629+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_360254","record_id":"REC_0007421","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":7.6,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.671863+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_764876","record_id":"REC_0007422","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":3.8,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.672121+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_558409","record_id":"REC_0007423","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":48,"sex":"female","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":3.9,"metastatic_sites_count":9,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.672356+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_717659","record_id":"REC_0007424","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":20,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":1,"smoking_pack_years":61,"primary_tumor_size_cm":4.3,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":28.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.672637+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_563303","record_id":"REC_0007425","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":4.9,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.672877+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_566864","record_id":"REC_0007426","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":15.8,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":24,"primary_tumor_size_cm":4.5,"metastatic_sites_count":9,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.673110+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_971033","record_id":"REC_0007427","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":5.7,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.673343+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_406788","record_id":"REC_0007428","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":77,"sex":"male","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":6.9,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":20.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.673579+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_951220","record_id":"REC_0007429","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":19.8,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":4.5,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":4.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.673817+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_248445","record_id":"REC_0007430","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":5.2,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.674054+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_281479","record_id":"REC_0007431","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":0,"smoking_pack_years":45,"primary_tumor_size_cm":4.7,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":29.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.674288+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_266071","record_id":"REC_0007432","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":52,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":5.3,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":17.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.674521+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_562455","record_id":"REC_0007433","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":6.4,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.674757+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_798339","record_id":"REC_0007434","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":5.1,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":2,"smoking_pack_years":20,"primary_tumor_size_cm":5.2,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":35.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.674986+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_303158","record_id":"REC_0007435","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":9.8,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.0,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.675220+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_485936","record_id":"REC_0007436","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":5.5,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":25,"primary_tumor_size_cm":7.0,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.675444+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_271688","record_id":"REC_0007437","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":5.7,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":6.2,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.675717+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_908390","record_id":"REC_0007438","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":84,"sex":"male","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":7.5,"metastatic_sites_count":3,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.675957+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_594652","record_id":"REC_0007439","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":2,"smoking_pack_years":7,"primary_tumor_size_cm":6.4,"metastatic_sites_count":3,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":29.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.676316+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_255215","record_id":"REC_0007440","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":14.5,"age_at_diagnosis":53,"sex":"male","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":5.6,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.676560+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_995588","record_id":"REC_0007441","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":51,"sex":"male","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":5.2,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.676796+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_740654","record_id":"REC_0007442","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":30,"tmb_mutations_per_mb":17.2,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":5.4,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.677030+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_402630","record_id":"REC_0007443","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":19,"tmb_mutations_per_mb":4.9,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":3,"primary_tumor_size_cm":5.2,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.677263+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_770506","record_id":"REC_0007444","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":17,"tmb_mutations_per_mb":15.2,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":6.5,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.677497+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_964525","record_id":"REC_0007445","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":18,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":6.6,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":27.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.677733+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_620928","record_id":"REC_0007446","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":13.8,"age_at_diagnosis":54,"sex":"male","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":5.3,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.677965+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_529517","record_id":"REC_0007447","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":32,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":36,"primary_tumor_size_cm":4.2,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.678199+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_878584","record_id":"REC_0007448","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":33,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":4.9,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.678434+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_936229","record_id":"REC_0007449","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":5.9,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":6.7,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.678665+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_233256","record_id":"REC_0007450","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":49,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":4.8,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.678945+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_264541","record_id":"REC_0007451","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":31,"tmb_mutations_per_mb":5.7,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":0,"smoking_pack_years":68,"primary_tumor_size_cm":2.5,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.679188+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_907824","record_id":"REC_0007452","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":18,"tmb_mutations_per_mb":15.2,"age_at_diagnosis":49,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":5.0,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.679434+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_998043","record_id":"REC_0007453","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":8.3,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":4.6,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.679684+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_183213","record_id":"REC_0007454","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":14.6,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":6,"primary_tumor_size_cm":5.6,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":7.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.679918+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_148552","record_id":"REC_0007455","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":16.7,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":5.5,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":26.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.680340+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_462837","record_id":"REC_0007456","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":34,"tmb_mutations_per_mb":14.9,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":4.5,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.680619+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_984669","record_id":"REC_0007457","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":19,"tmb_mutations_per_mb":9.0,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":25,"primary_tumor_size_cm":7.0,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.680868+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_536483","record_id":"REC_0007458","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ALK fusion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":48,"sex":"female","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":7.1,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":54.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.681106+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_202126","record_id":"REC_0007459","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":8.1,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":6.0,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.681344+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_584089","record_id":"REC_0007460","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":4.1,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":5.2,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.681576+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_697521","record_id":"REC_0007461","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":18.4,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":4.4,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.681817+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_511083","record_id":"REC_0007462","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":70,"primary_tumor_size_cm":5.2,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.682048+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_613826","record_id":"REC_0007463","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":32,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":6.0,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":17.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.682390+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_456983","record_id":"REC_0007464","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":7.4,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":1,"smoking_pack_years":27,"primary_tumor_size_cm":3.1,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.682632+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_458939","record_id":"REC_0007465","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":2.5,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":2,"smoking_pack_years":2,"primary_tumor_size_cm":4.2,"metastatic_sites_count":8,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.682863+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_564614","record_id":"REC_0007466","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":19.3,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":4.2,"metastatic_sites_count":8,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":4.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.683098+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_698251","record_id":"REC_0007467","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":9.5,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":6.9,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.683332+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_285290","record_id":"REC_0007468","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":5.1,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":1,"smoking_pack_years":33,"primary_tumor_size_cm":5.2,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":17.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.683566+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_520099","record_id":"REC_0007469","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":6.1,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.683798+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_392652","record_id":"REC_0007470","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":35,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":1,"smoking_pack_years":27,"primary_tumor_size_cm":6.5,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":23.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.684032+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_364731","record_id":"REC_0007471","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":4.9,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.684552+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_224895","record_id":"REC_0007472","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":16.1,"age_at_diagnosis":53,"sex":"female","ecog_performance_status":0,"smoking_pack_years":5,"primary_tumor_size_cm":4.6,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.684799+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_227085","record_id":"REC_0007473","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":4.7,"age_at_diagnosis":53,"sex":"male","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":4.8,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.685036+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_423852","record_id":"REC_0007474","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":6.1,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.685271+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_299192","record_id":"REC_0007475","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":5.6,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":7.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.685504+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_113767","record_id":"REC_0007476","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":6.7,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":23,"primary_tumor_size_cm":4.3,"metastatic_sites_count":8,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":7.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.685821+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_911331","record_id":"REC_0007477","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":18.7,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":6.9,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.686061+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_215243","record_id":"REC_0007478","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":13.6,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":5.3,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":22.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.686298+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_574142","record_id":"REC_0007479","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":16,"tmb_mutations_per_mb":7.6,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":68,"primary_tumor_size_cm":4.7,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.686534+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_782771","record_id":"REC_0007480","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":6.0,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":25.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.686772+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_229817","record_id":"REC_0007481","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":4.6,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.687008+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_916488","record_id":"REC_0007482","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":4.1,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":2,"smoking_pack_years":24,"primary_tumor_size_cm":5.5,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.687240+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_575621","record_id":"REC_0007483","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":3.3,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.687477+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_887300","record_id":"REC_0007484","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":6.5,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.687710+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_977348","record_id":"REC_0007485","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":4.5,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":5.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.687944+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_924342","record_id":"REC_0007486","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":6.7,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":99,"primary_tumor_size_cm":5.6,"metastatic_sites_count":3,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.688263+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_222584","record_id":"REC_0007487","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":18.5,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":5.9,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.688508+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_870982","record_id":"REC_0007488","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":4.9,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":1,"smoking_pack_years":53,"primary_tumor_size_cm":5.9,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":23.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.688739+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_902070","record_id":"REC_0007489","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":30,"tmb_mutations_per_mb":3.8,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":83,"primary_tumor_size_cm":6.0,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":5.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.689028+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_493026","record_id":"REC_0007490","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":7.0,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.689267+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_655229","record_id":"REC_0007491","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":14.8,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":21,"primary_tumor_size_cm":5.8,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.689499+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_982570","record_id":"REC_0007492","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":9.7,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":5,"primary_tumor_size_cm":5.2,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":39.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.689733+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_457433","record_id":"REC_0007493","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":10.3,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":5.1,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.689971+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_972097","record_id":"REC_0007494","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":8.0,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":5.8,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":27.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.690205+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_772465","record_id":"REC_0007495","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":3.1,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.690440+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_918783","record_id":"REC_0007496","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":4.7,"metastatic_sites_count":8,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.690676+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_525043","record_id":"REC_0007497","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":13,"tmb_mutations_per_mb":15.2,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":5.2,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":22.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.690913+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_455221","record_id":"REC_0007498","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":7.6,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":71,"primary_tumor_size_cm":7.5,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.691141+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_852974","record_id":"REC_0007499","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":6.1,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":54,"primary_tumor_size_cm":4.8,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.691373+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_131239","record_id":"REC_0007500","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":11,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":75,"sex":"male","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":5.2,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.691611+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_191655","record_id":"REC_0007501","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":6.7,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":34,"primary_tumor_size_cm":5.0,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.691851+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_871241","record_id":"REC_0007502","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":34,"tmb_mutations_per_mb":14.5,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":0,"smoking_pack_years":5,"primary_tumor_size_cm":4.4,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":28.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.692203+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_139239","record_id":"REC_0007503","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":4.3,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.692455+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_833262","record_id":"REC_0007504","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":0,"smoking_pack_years":30,"primary_tumor_size_cm":4.0,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.692693+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_524028","record_id":"REC_0007505","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":8.4,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":2,"smoking_pack_years":30,"primary_tumor_size_cm":3.5,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.692925+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_738485","record_id":"REC_0007506","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":14.7,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":5.6,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.693164+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_785769","record_id":"REC_0007507","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":3.5,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":49,"primary_tumor_size_cm":6.8,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":18.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.693399+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_764695","record_id":"REC_0007508","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":16,"tmb_mutations_per_mb":10.5,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":1,"smoking_pack_years":24,"primary_tumor_size_cm":5.4,"metastatic_sites_count":3,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.693635+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_137747","record_id":"REC_0007509","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":6.7,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":45,"primary_tumor_size_cm":4.5,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.693869+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_459546","record_id":"REC_0007510","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":30,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":75,"primary_tumor_size_cm":3.5,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.694098+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_123701","record_id":"REC_0007511","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":38,"tmb_mutations_per_mb":8.0,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":51,"primary_tumor_size_cm":5.7,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":21.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.694334+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_827209","record_id":"REC_0007512","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":9.7,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":4,"primary_tumor_size_cm":3.8,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.694567+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_129451","record_id":"REC_0007513","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":30,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":4.7,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.694797+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_552462","record_id":"REC_0007514","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":6.0,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":1,"smoking_pack_years":28,"primary_tumor_size_cm":6.4,"metastatic_sites_count":8,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.695030+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_318458","record_id":"REC_0007515","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":4.1,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.695345+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_429167","record_id":"REC_0007516","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":0,"primary_tumor_size_cm":5.3,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.695582+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_131856","record_id":"REC_0007517","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":15.5,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":6.3,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.695819+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_890878","record_id":"REC_0007518","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":18,"tmb_mutations_per_mb":14.4,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":6.6,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.696054+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_480767","record_id":"REC_0007519","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":7,"primary_tumor_size_cm":4.1,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.696413+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_955546","record_id":"REC_0007520","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":10.0,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":3.7,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.696656+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_796049","record_id":"REC_0007521","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":32,"tmb_mutations_per_mb":14.1,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.6,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.696892+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_417631","record_id":"REC_0007522","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":8.4,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.697127+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_114022","record_id":"REC_0007523","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":11.0,"age_at_diagnosis":75,"sex":"male","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":5.0,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":16.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.697364+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_153107","record_id":"REC_0007524","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":4.6,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":1,"smoking_pack_years":30,"primary_tumor_size_cm":3.8,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":20.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.697595+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_848595","record_id":"REC_0007525","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":2.7,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":49,"primary_tumor_size_cm":4.5,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":7.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.697828+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_288071","record_id":"REC_0007526","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":16.0,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":4,"primary_tumor_size_cm":5.5,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":37.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.698066+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_502609","record_id":"REC_0007527","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":6.2,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.698296+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_584491","record_id":"REC_0007528","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":6.1,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":1,"smoking_pack_years":2,"primary_tumor_size_cm":5.1,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.698583+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_937133","record_id":"REC_0007529","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":30,"tmb_mutations_per_mb":4.6,"age_at_diagnosis":49,"sex":"female","ecog_performance_status":0,"smoking_pack_years":6,"primary_tumor_size_cm":5.2,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.698819+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_800198","record_id":"REC_0007530","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":14.1,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":5.3,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":6.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.699050+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_540752","record_id":"REC_0007531","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":15.0,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":4.8,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.699288+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_549535","record_id":"REC_0007532","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":4.2,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":5.4,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.699514+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_376572","record_id":"REC_0007533","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":83,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":5.8,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.699746+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_203024","record_id":"REC_0007534","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":8.7,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":5.5,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.699976+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_495143","record_id":"REC_0007535","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":31,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":81,"sex":"male","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":5.3,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.700287+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_170832","record_id":"REC_0007536","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":4.8,"metastatic_sites_count":8,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":7.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.700526+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_987480","record_id":"REC_0007537","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":7.4,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":34,"primary_tumor_size_cm":5.1,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.700766+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_553161","record_id":"REC_0007538","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":5.0,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.701010+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_209853","record_id":"REC_0007539","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":17.1,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":6.6,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":26.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.701250+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_832459","record_id":"REC_0007540","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":10.3,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":7.6,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":17.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.701484+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_790951","record_id":"REC_0007541","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":18.2,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":6.0,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.701766+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_701039","record_id":"REC_0007542","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":8.3,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":7.6,"metastatic_sites_count":3,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.702002+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_178744","record_id":"REC_0007543","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":90,"sex":"male","ecog_performance_status":2,"smoking_pack_years":36,"primary_tumor_size_cm":5.6,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.702236+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_660698","record_id":"REC_0007544","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":16.8,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":5.4,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.702468+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_600601","record_id":"REC_0007545","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":8.1,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":36,"primary_tumor_size_cm":5.2,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.702697+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_849610","record_id":"REC_0007546","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":36,"tmb_mutations_per_mb":16.8,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":28,"primary_tumor_size_cm":5.5,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.702927+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_731158","record_id":"REC_0007547","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":7.6,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":54,"primary_tumor_size_cm":5.5,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.703155+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_641900","record_id":"REC_0007548","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":5.8,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.703390+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_716721","record_id":"REC_0007549","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":54,"sex":"male","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":7.2,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":18.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.703621+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_395880","record_id":"REC_0007550","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":6.3,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":55,"primary_tumor_size_cm":5.2,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":23.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.703856+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_600082","record_id":"REC_0007551","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":77,"sex":"male","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":5.1,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":5.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.704121+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_117510","record_id":"REC_0007552","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":32,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":8,"primary_tumor_size_cm":4.7,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":28.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.704366+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_588784","record_id":"REC_0007553","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":4.6,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":6.0,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":21.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.704596+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_649666","record_id":"REC_0007554","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":30,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.3,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.704884+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_652486","record_id":"REC_0007555","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":4.3,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.705121+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_120466","record_id":"REC_0007556","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":18,"tmb_mutations_per_mb":6.0,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":35,"primary_tumor_size_cm":4.2,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.705352+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_124154","record_id":"REC_0007557","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":36,"tmb_mutations_per_mb":15.9,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":5.3,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.705589+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_913372","record_id":"REC_0007558","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":8.7,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.5,"metastatic_sites_count":8,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.705820+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_357553","record_id":"REC_0007559","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":18,"tmb_mutations_per_mb":4.4,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":42,"primary_tumor_size_cm":7.2,"metastatic_sites_count":9,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.706051+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_254097","record_id":"REC_0007560","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":6.7,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":5.0,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.706280+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_420829","record_id":"REC_0007561","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":19,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":68,"primary_tumor_size_cm":4.4,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.706513+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_321822","record_id":"REC_0007562","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":15.9,"age_at_diagnosis":53,"sex":"male","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":4.8,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.706756+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_885247","record_id":"REC_0007563","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":5.3,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":1,"smoking_pack_years":74,"primary_tumor_size_cm":4.0,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":67.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.706996+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_409500","record_id":"REC_0007564","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":14,"tmb_mutations_per_mb":2.5,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":6.5,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.707237+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_309962","record_id":"REC_0007565","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":78,"sex":"male","ecog_performance_status":1,"smoking_pack_years":39,"primary_tumor_size_cm":5.5,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":17.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.707483+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_179979","record_id":"REC_0007566","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":6.5,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.707733+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_659719","record_id":"REC_0007567","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":17.8,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":3.4,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":16.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.708202+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_104607","record_id":"REC_0007568","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":5.0,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":17.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.708495+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_130044","record_id":"REC_0007569","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":5.2,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":6.6,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":21.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.708750+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_758081","record_id":"REC_0007570","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":5.9,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.709005+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_930160","record_id":"REC_0007571","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":14.3,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":7,"primary_tumor_size_cm":6.2,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.709262+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_745276","record_id":"REC_0007572","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":87,"sex":"female","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":8.2,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":8.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.709523+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_302473","record_id":"REC_0007573","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":17.0,"age_at_diagnosis":85,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":5.6,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.709771+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_499643","record_id":"REC_0007574","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":20.5,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":6.1,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.710014+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_117997","record_id":"REC_0007575","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":18.0,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":5.7,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.710260+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_657499","record_id":"REC_0007576","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":18,"tmb_mutations_per_mb":6.0,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":1,"smoking_pack_years":44,"primary_tumor_size_cm":4.3,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.710510+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_535868","record_id":"REC_0007577","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":53,"primary_tumor_size_cm":6.3,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.710757+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_421091","record_id":"REC_0007578","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":7.5,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.711007+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_141644","record_id":"REC_0007579","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":3,"primary_tumor_size_cm":5.2,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.711255+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_310333","record_id":"REC_0007580","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":8.6,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":1,"primary_tumor_size_cm":4.5,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":18.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.711657+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_459871","record_id":"REC_0007581","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":7.1,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.711922+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_683455","record_id":"REC_0007582","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":5.1,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.712364+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_274707","record_id":"REC_0007583","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":34,"tmb_mutations_per_mb":5.2,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":3.6,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":23.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.712644+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_415565","record_id":"REC_0007584","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":17.6,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":2,"smoking_pack_years":10,"primary_tumor_size_cm":8.3,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":7.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.712905+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_180947","record_id":"REC_0007585","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":17,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":25,"primary_tumor_size_cm":5.4,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.713155+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_949443","record_id":"REC_0007586","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":4.4,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":16.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.713398+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_894912","record_id":"REC_0007587","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":6,"primary_tumor_size_cm":6.7,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.713644+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_345271","record_id":"REC_0007588","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":20.5,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":6.3,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.713889+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_497841","record_id":"REC_0007589","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":76,"sex":"male","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":5.5,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":39.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.714137+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_518905","record_id":"REC_0007590","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":3.2,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":0,"smoking_pack_years":45,"primary_tumor_size_cm":5.4,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.714382+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_952097","record_id":"REC_0007591","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":12,"tmb_mutations_per_mb":11.5,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":3.0,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.714630+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_602426","record_id":"REC_0007592","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":5.2,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":6.2,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.714876+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_433449","record_id":"REC_0007593","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":90,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.7,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.715254+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_354202","record_id":"REC_0007594","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":53,"primary_tumor_size_cm":5.3,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.715506+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_876793","record_id":"REC_0007595","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ALK fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":4.3,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":37.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.715757+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_533881","record_id":"REC_0007596","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":6.3,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":4.4,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":23.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.716007+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_238117","record_id":"REC_0007597","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":18,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":8,"primary_tumor_size_cm":6.0,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.716314+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_473701","record_id":"REC_0007598","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":3,"smoking_pack_years":16,"primary_tumor_size_cm":7.8,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":18.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.716564+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_248997","record_id":"REC_0007599","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":8,"primary_tumor_size_cm":5.9,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":33.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.716820+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_470110","record_id":"REC_0007600","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":14.4,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":6.6,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.717072+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_932531","record_id":"REC_0007601","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":14,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":39,"primary_tumor_size_cm":5.1,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":45.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.717321+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_910005","record_id":"REC_0007602","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":9,"primary_tumor_size_cm":4.5,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.717571+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_534863","record_id":"REC_0007603","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":6.4,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.717825+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_983363","record_id":"REC_0007604","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":5.2,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.718069+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_836126","record_id":"REC_0007605","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":9.7,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":5.6,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":22.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.718322+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_190063","record_id":"REC_0007606","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":14.6,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":2,"primary_tumor_size_cm":3.9,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.718718+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_621200","record_id":"REC_0007607","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":16.3,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":6.1,"metastatic_sites_count":8,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.718968+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_835927","record_id":"REC_0007608","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":9.7,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.6,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":22.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.719204+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_927900","record_id":"REC_0007609","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":53,"sex":"male","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":5.1,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":30.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.719440+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_558092","record_id":"REC_0007610","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":15.5,"age_at_diagnosis":54,"sex":"male","ecog_performance_status":0,"smoking_pack_years":29,"primary_tumor_size_cm":3.6,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.719675+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_797911","record_id":"REC_0007611","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":6.5,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.719909+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_629412","record_id":"REC_0007612","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":35,"tmb_mutations_per_mb":15.4,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":4.6,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":24.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.720199+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_731611","record_id":"REC_0007613","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":83,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":6.9,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":43.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.720440+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_896516","record_id":"REC_0007614","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":5.0,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":7.3,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.720675+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_109244","record_id":"REC_0007615","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":33,"tmb_mutations_per_mb":14.4,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":4.6,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.720914+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_622603","record_id":"REC_0007616","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":3.3,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":6.5,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.721148+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_276012","record_id":"REC_0007617","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":6.9,"metastatic_sites_count":8,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":18.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.721388+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_654541","record_id":"REC_0007618","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":16.7,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":4.4,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":30.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.721622+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_673719","record_id":"REC_0007619","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":86,"sex":"male","ecog_performance_status":2,"smoking_pack_years":0,"primary_tumor_size_cm":4.3,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.721914+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_562021","record_id":"REC_0007620","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":7.6,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":24.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.722158+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_946002","record_id":"REC_0007621","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":5.5,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.722410+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_198826","record_id":"REC_0007622","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":85,"sex":"female","ecog_performance_status":0,"smoking_pack_years":55,"primary_tumor_size_cm":5.4,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":25.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.722640+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_521380","record_id":"REC_0007623","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":7.9,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":37,"primary_tumor_size_cm":4.0,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":18.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.722915+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_414574","record_id":"REC_0007624","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":6.4,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.723164+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_837229","record_id":"REC_0007625","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":85,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":4.8,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.723399+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_644998","record_id":"REC_0007626","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":6.2,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.723630+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_936668","record_id":"REC_0007627","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":5.4,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":25.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.723861+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_621933","record_id":"REC_0007628","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":19,"tmb_mutations_per_mb":4.2,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":5.1,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":29.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.724152+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_714423","record_id":"REC_0007629","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":4.0,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.724406+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_457534","record_id":"REC_0007630","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":26,"primary_tumor_size_cm":4.0,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.724643+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_203770","record_id":"REC_0007631","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":6.1,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.724880+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_992147","record_id":"REC_0007632","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":16,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":4.3,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.725156+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_955937","record_id":"REC_0007633","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":10.0,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":5.5,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":32.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.725397+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_486359","record_id":"REC_0007634","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":58,"primary_tumor_size_cm":6.2,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":26.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.725624+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_795089","record_id":"REC_0007635","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":17,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":79,"sex":"male","ecog_performance_status":3,"smoking_pack_years":45,"primary_tumor_size_cm":4.4,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.725860+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_119245","record_id":"REC_0007636","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":16,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":5.5,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.726095+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_460581","record_id":"REC_0007637","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":13.3,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":6.8,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.726333+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_568043","record_id":"REC_0007638","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":15.6,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":6.9,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":19.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.726563+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_871352","record_id":"REC_0007639","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":19,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":1,"smoking_pack_years":5,"primary_tumor_size_cm":4.2,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":19.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.726797+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_658490","record_id":"REC_0007640","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":8.7,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":4.6,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":6.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.727027+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_799568","record_id":"REC_0007641","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":6.0,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.727262+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_799097","record_id":"REC_0007642","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":30,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":3.5,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.727492+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_348997","record_id":"REC_0007643","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":7.0,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":20.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.727728+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_889259","record_id":"REC_0007644","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":11.1,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":69,"primary_tumor_size_cm":5.7,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.727962+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_115888","record_id":"REC_0007645","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":19.1,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":7.2,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":50.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.728268+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_905150","record_id":"REC_0007646","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":6.8,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":43.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.728508+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_392288","record_id":"REC_0007647","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":8.3,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":5.1,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":7.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.728737+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_895104","record_id":"REC_0007648","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":6.1,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.728969+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_737720","record_id":"REC_0007649","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":30,"tmb_mutations_per_mb":9.8,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":6.5,"metastatic_sites_count":3,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":6.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.729199+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_322785","record_id":"REC_0007650","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":31,"tmb_mutations_per_mb":15.4,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":1,"smoking_pack_years":32,"primary_tumor_size_cm":5.7,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.729436+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_268955","record_id":"REC_0007651","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":27,"primary_tumor_size_cm":3.7,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.729671+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_881936","record_id":"REC_0007652","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":9.1,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":5.7,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":23.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.729907+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_420804","record_id":"REC_0007653","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":4.0,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":22.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.730145+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_491454","record_id":"REC_0007654","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":17,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":4.4,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.730376+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_163184","record_id":"REC_0007655","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":4.7,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.730611+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_996103","record_id":"REC_0007656","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":18,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":5.7,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.730847+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_378800","record_id":"REC_0007657","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":16.8,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":3,"smoking_pack_years":2,"primary_tumor_size_cm":6.8,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":22.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.731080+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_545068","record_id":"REC_0007658","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":14.8,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":5.1,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.731365+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_445500","record_id":"REC_0007659","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":30,"tmb_mutations_per_mb":4.7,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":4.7,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.731601+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_823457","record_id":"REC_0007660","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":3.9,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":23.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.731833+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_713142","record_id":"REC_0007661","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":2,"smoking_pack_years":7,"primary_tumor_size_cm":2.0,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.732066+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_316091","record_id":"REC_0007662","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":35,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":30,"primary_tumor_size_cm":7.0,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":20.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.732337+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_573887","record_id":"REC_0007663","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":18,"tmb_mutations_per_mb":5.7,"age_at_diagnosis":54,"sex":"male","ecog_performance_status":0,"smoking_pack_years":49,"primary_tumor_size_cm":4.6,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":21.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.732574+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_582847","record_id":"REC_0007664","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":4.8,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":23.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.732802+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_306255","record_id":"REC_0007665","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":30,"primary_tumor_size_cm":4.3,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.733032+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_586682","record_id":"REC_0007666","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":14.9,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":4.6,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":4.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.733265+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_648885","record_id":"REC_0007667","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":3,"smoking_pack_years":22,"primary_tumor_size_cm":4.2,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.733496+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_623955","record_id":"REC_0007668","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":7.3,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":28.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.733726+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_174989","record_id":"REC_0007669","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":9.9,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":6.6,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.733954+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_439820","record_id":"REC_0007670","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":18,"tmb_mutations_per_mb":2.8,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":4.6,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":7.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.734182+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_144902","record_id":"REC_0007671","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":18,"tmb_mutations_per_mb":10.1,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":1,"smoking_pack_years":41,"primary_tumor_size_cm":4.4,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":29.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.734457+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_947458","record_id":"REC_0007672","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":49,"primary_tumor_size_cm":3.6,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.734689+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_879571","record_id":"REC_0007673","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":3,"smoking_pack_years":15,"primary_tumor_size_cm":7.5,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.734924+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_430862","record_id":"REC_0007674","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":16.8,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":7.8,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.735154+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_381921","record_id":"REC_0007675","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":1.5,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":5.2,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":24.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.735382+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_869516","record_id":"REC_0007676","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":2,"smoking_pack_years":57,"primary_tumor_size_cm":4.4,"metastatic_sites_count":3,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.735609+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_260030","record_id":"REC_0007677","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":8.1,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":55,"primary_tumor_size_cm":5.5,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.735842+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_688646","record_id":"REC_0007678","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":3.8,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":6.5,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.736183+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_895442","record_id":"REC_0007679","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":20,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":3,"smoking_pack_years":7,"primary_tumor_size_cm":4.2,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.736440+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_499987","record_id":"REC_0007680","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":34,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":24,"primary_tumor_size_cm":3.0,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":20.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.736686+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_885738","record_id":"REC_0007681","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":4.9,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":50,"primary_tumor_size_cm":5.7,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.736924+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_217972","record_id":"REC_0007682","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":14.4,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":25,"primary_tumor_size_cm":3.6,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":7.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.737164+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_299043","record_id":"REC_0007683","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":7.9,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":4.2,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":21.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.737404+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_236557","record_id":"REC_0007684","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":64,"primary_tumor_size_cm":6.1,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":19.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.737716+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_532167","record_id":"REC_0007685","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":8.9,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":25,"primary_tumor_size_cm":3.5,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":17.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.737958+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_384173","record_id":"REC_0007686","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":16,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":4.9,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.738198+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_383303","record_id":"REC_0007687","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":13.1,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":2,"primary_tumor_size_cm":5.0,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.738445+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_644247","record_id":"REC_0007688","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":33,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":3.6,"metastatic_sites_count":3,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":18.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.738700+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_343186","record_id":"REC_0007689","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":15,"tmb_mutations_per_mb":8.0,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":7,"primary_tumor_size_cm":5.6,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":7.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.738943+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_736893","record_id":"REC_0007690","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":15.7,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":29,"primary_tumor_size_cm":3.4,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":27.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.739191+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_307933","record_id":"REC_0007691","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":6.0,"age_at_diagnosis":86,"sex":"female","ecog_performance_status":3,"smoking_pack_years":72,"primary_tumor_size_cm":5.2,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.739446+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_178438","record_id":"REC_0007692","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":15.9,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":5.1,"metastatic_sites_count":10,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.739701+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_265188","record_id":"REC_0007693","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":15.8,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":6.3,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":42.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.739956+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_286978","record_id":"REC_0007694","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":5.7,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":17.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.740263+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_133681","record_id":"REC_0007695","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":5.6,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":28,"primary_tumor_size_cm":3.9,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":7.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.740516+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_459047","record_id":"REC_0007696","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":52,"sex":"male","ecog_performance_status":0,"smoking_pack_years":6,"primary_tumor_size_cm":6.6,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.740766+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_971167","record_id":"REC_0007697","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":15.6,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":5,"primary_tumor_size_cm":5.4,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.741170+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_754723","record_id":"REC_0007698","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":8.4,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":5.3,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.741446+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_305016","record_id":"REC_0007699","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":60,"primary_tumor_size_cm":4.0,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.741698+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_297021","record_id":"REC_0007700","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":8.5,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":32.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.741944+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_457108","record_id":"REC_0007701","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":6.1,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":4.8,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.742177+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_996834","record_id":"REC_0007702","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":31,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":22,"primary_tumor_size_cm":5.5,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.742407+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_306801","record_id":"REC_0007703","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":32,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":6.5,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.742647+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_958349","record_id":"REC_0007704","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":10.3,"age_at_diagnosis":74,"sex":"male","ecog_performance_status":3,"smoking_pack_years":22,"primary_tumor_size_cm":5.4,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.742887+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_946725","record_id":"REC_0007705","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":27,"primary_tumor_size_cm":5.6,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.743127+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_590854","record_id":"REC_0007706","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":14.5,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":4.7,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.743366+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_753707","record_id":"REC_0007707","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":5.5,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.743598+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_707455","record_id":"REC_0007708","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":23,"primary_tumor_size_cm":3.8,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.743830+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_975753","record_id":"REC_0007709","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":5.5,"age_at_diagnosis":74,"sex":"male","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":6.1,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.744064+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_773478","record_id":"REC_0007710","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":2,"smoking_pack_years":24,"primary_tumor_size_cm":5.3,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":6.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.744451+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_105215","record_id":"REC_0007711","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":4.6,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.744692+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_444199","record_id":"REC_0007712","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":8.4,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":9,"primary_tumor_size_cm":7.3,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.744923+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_784127","record_id":"REC_0007713","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":14.4,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":5.4,"metastatic_sites_count":8,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":5.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.745159+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_523187","record_id":"REC_0007714","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":3,"smoking_pack_years":16,"primary_tumor_size_cm":3.3,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.745391+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_417373","record_id":"REC_0007715","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":4.2,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":8.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.745630+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_221829","record_id":"REC_0007716","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":8.9,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":5.7,"metastatic_sites_count":8,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.745857+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_916266","record_id":"REC_0007717","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":5.3,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.746091+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_296670","record_id":"REC_0007718","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":3.5,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":5.0,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":16.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.746321+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_278297","record_id":"REC_0007719","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":9.0,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":1,"smoking_pack_years":31,"primary_tumor_size_cm":5.5,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.746553+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_232960","record_id":"REC_0007720","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":6.2,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.746786+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_858820","record_id":"REC_0007721","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":5.3,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":16.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.747014+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_626778","record_id":"REC_0007722","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":30,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":0,"smoking_pack_years":5,"primary_tumor_size_cm":6.8,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.747249+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_214869","record_id":"REC_0007723","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":4.7,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":4.3,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":17.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.747527+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_513830","record_id":"REC_0007724","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":5.2,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.747764+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_639046","record_id":"REC_0007725","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":14.6,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":6.1,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":19.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.747998+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_158486","record_id":"REC_0007726","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":30,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":4.8,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":7.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.748298+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_597216","record_id":"REC_0007727","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":7.9,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":4.8,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.748543+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_138289","record_id":"REC_0007728","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":4.8,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":24.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.748779+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_424662","record_id":"REC_0007729","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":3.2,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.749013+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_330022","record_id":"REC_0007730","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":3.9,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.749248+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_314837","record_id":"REC_0007731","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":36,"tmb_mutations_per_mb":6.0,"age_at_diagnosis":46,"sex":"female","ecog_performance_status":0,"smoking_pack_years":43,"primary_tumor_size_cm":5.4,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":17.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.749480+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_678348","record_id":"REC_0007732","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":15.7,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":5.2,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.749711+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_659743","record_id":"REC_0007733","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":30,"tmb_mutations_per_mb":19.3,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":5.0,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":22.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.749945+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_939571","record_id":"REC_0007734","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":13.3,"age_at_diagnosis":48,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":4.5,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":23.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.750178+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_935645","record_id":"REC_0007735","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":33,"tmb_mutations_per_mb":8.6,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":6.6,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":21.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.750411+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_989987","record_id":"REC_0007736","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":14.0,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":5.1,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":39.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.750686+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_927170","record_id":"REC_0007737","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":18.5,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":28,"primary_tumor_size_cm":7.1,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.750943+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_165638","record_id":"REC_0007738","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":5.0,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.751251+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_606408","record_id":"REC_0007739","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":33,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":4.7,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":7.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.751532+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_373661","record_id":"REC_0007740","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":32,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":6.2,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.751791+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_307592","record_id":"REC_0007741","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":14.5,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":6.1,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":6.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.752041+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_697941","record_id":"REC_0007742","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.1,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":2,"smoking_pack_years":9,"primary_tumor_size_cm":5.3,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":19.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.752328+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_820726","record_id":"REC_0007743","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":14,"tmb_mutations_per_mb":8.6,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":1,"smoking_pack_years":26,"primary_tumor_size_cm":7.5,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":6.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.752574+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_389560","record_id":"REC_0007744","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":6.7,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":24.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.752820+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_661167","record_id":"REC_0007745","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":18.2,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":6.1,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.753067+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_880963","record_id":"REC_0007746","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":15.8,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":3.9,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":4.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.753312+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_272057","record_id":"REC_0007747","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":54,"sex":"male","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":6.1,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.753559+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_719466","record_id":"REC_0007748","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":4.6,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":21.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.753809+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_367627","record_id":"REC_0007749","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":6.1,"age_at_diagnosis":49,"sex":"female","ecog_performance_status":0,"smoking_pack_years":50,"primary_tumor_size_cm":6.7,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.754147+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_138160","record_id":"REC_0007750","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":3.6,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.754397+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_651083","record_id":"REC_0007751","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":8.4,"age_at_diagnosis":46,"sex":"male","ecog_performance_status":0,"smoking_pack_years":0,"primary_tumor_size_cm":7.0,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.754632+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_865961","record_id":"REC_0007752","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":5.1,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.754871+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_987007","record_id":"REC_0007753","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":25,"primary_tumor_size_cm":5.3,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":30.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.755118+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_848534","record_id":"REC_0007754","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":74,"sex":"male","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":3.6,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.755371+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_482447","record_id":"REC_0007755","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":5.7,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":6.3,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.755620+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_378504","record_id":"REC_0007756","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":33,"tmb_mutations_per_mb":16.5,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":6.8,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":20.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.755872+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_821906","record_id":"REC_0007757","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":17.7,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":6.2,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.756175+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_760088","record_id":"REC_0007758","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":27,"primary_tumor_size_cm":4.6,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.756427+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_102117","record_id":"REC_0007759","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":31,"primary_tumor_size_cm":3.7,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.756681+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_159753","record_id":"REC_0007760","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":5.7,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":0,"smoking_pack_years":30,"primary_tumor_size_cm":5.5,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.756921+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_373136","record_id":"REC_0007761","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":15.2,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":5.7,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.757166+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_834662","record_id":"REC_0007762","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":4.4,"metastatic_sites_count":3,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.757505+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_693324","record_id":"REC_0007763","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":22,"primary_tumor_size_cm":5.5,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.757764+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_396488","record_id":"REC_0007764","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":13.3,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":6.9,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.758009+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_772047","record_id":"REC_0007765","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":20.6,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":2,"smoking_pack_years":22,"primary_tumor_size_cm":5.2,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":22.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.758262+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_123922","record_id":"REC_0007766","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":6.0,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.758508+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_557345","record_id":"REC_0007767","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":4.4,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.758766+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_930822","record_id":"REC_0007768","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":14.7,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":4.2,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.759023+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_438473","record_id":"REC_0007769","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":10.1,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":2.9,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.759267+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_207006","record_id":"REC_0007770","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":5.3,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.759518+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_771304","record_id":"REC_0007771","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":13.8,"age_at_diagnosis":78,"sex":"male","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":4.0,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.759765+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_906156","record_id":"REC_0007772","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":4.4,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":61,"primary_tumor_size_cm":7.8,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":7.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.760011+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_662144","record_id":"REC_0007773","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":14.5,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":5.2,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":6.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.760372+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_167617","record_id":"REC_0007774","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":16.5,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":5.1,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.760626+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_559049","record_id":"REC_0007775","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":4.7,"metastatic_sites_count":8,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.760987+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_109875","record_id":"REC_0007776","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":54,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":6.2,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":6.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.761241+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_794659","record_id":"REC_0007777","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":85,"sex":"female","ecog_performance_status":3,"smoking_pack_years":23,"primary_tumor_size_cm":3.2,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.761490+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_121387","record_id":"REC_0007778","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":4.2,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.761738+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_646973","record_id":"REC_0007779","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":9.5,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":3.8,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.761996+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_177340","record_id":"REC_0007780","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":8.4,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":7.6,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":21.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.762243+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_247133","record_id":"REC_0007781","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":16.8,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":6.2,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.762494+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_484230","record_id":"REC_0007782","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":20,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":50,"primary_tumor_size_cm":3.8,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.762732+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_220764","record_id":"REC_0007783","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":15,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":1,"smoking_pack_years":62,"primary_tumor_size_cm":5.5,"metastatic_sites_count":3,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.762983+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_462548","record_id":"REC_0007784","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":19,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":51,"primary_tumor_size_cm":7.0,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.763230+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_567829","record_id":"REC_0007785","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":6.3,"age_at_diagnosis":52,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":6.7,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.763481+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_806568","record_id":"REC_0007786","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":15.0,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":3.4,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.763737+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_807641","record_id":"REC_0007787","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":14,"tmb_mutations_per_mb":5.0,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":0,"smoking_pack_years":28,"primary_tumor_size_cm":7.0,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.763981+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_225781","record_id":"REC_0007788","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":30,"tmb_mutations_per_mb":6.3,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":4.7,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.764391+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_715938","record_id":"REC_0007789","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":44,"primary_tumor_size_cm":4.9,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":25.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.764657+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_877165","record_id":"REC_0007790","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":18,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":74,"sex":"male","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":3.7,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.764913+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_524847","record_id":"REC_0007791","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":14.6,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":5.3,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":17.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.765168+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_892542","record_id":"REC_0007792","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":20.2,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":4.7,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.765423+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_522149","record_id":"REC_0007793","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":6.3,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":64,"primary_tumor_size_cm":4.6,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":28.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.765674+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_785447","record_id":"REC_0007794","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":7.6,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":4.5,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.765927+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_232805","record_id":"REC_0007795","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":8.1,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":6.2,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":17.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.766173+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_147271","record_id":"REC_0007796","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":74,"sex":"male","ecog_performance_status":1,"smoking_pack_years":1,"primary_tumor_size_cm":5.6,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.766424+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_814744","record_id":"REC_0007797","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":5.0,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.766670+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_793924","record_id":"REC_0007798","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":33,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":0,"smoking_pack_years":44,"primary_tumor_size_cm":8.1,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.766922+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_576709","record_id":"REC_0007799","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":15,"tmb_mutations_per_mb":15.3,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.4,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.767177+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_358209","record_id":"REC_0007800","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":14.0,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":8.4,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":26.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.767423+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_507245","record_id":"REC_0007801","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":6.4,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":7.3,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.767772+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_361240","record_id":"REC_0007802","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":26,"primary_tumor_size_cm":7.1,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.768033+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_714582","record_id":"REC_0007803","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":6.8,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.768334+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_495107","record_id":"REC_0007804","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":31,"tmb_mutations_per_mb":8.6,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":7.8,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":6.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.768575+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_564026","record_id":"REC_0007805","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":2.7,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":55,"primary_tumor_size_cm":6.3,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.768819+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_693101","record_id":"REC_0007806","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":16.2,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":5.8,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.769066+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_319949","record_id":"REC_0007807","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":9.9,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":4.1,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.769315+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_134973","record_id":"REC_0007808","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":18,"tmb_mutations_per_mb":4.9,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":44,"primary_tumor_size_cm":7.8,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":6.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.769564+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_121638","record_id":"REC_0007809","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":5.0,"age_at_diagnosis":49,"sex":"male","ecog_performance_status":0,"smoking_pack_years":56,"primary_tumor_size_cm":3.5,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.769815+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_810202","record_id":"REC_0007810","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":4.4,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":6.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.770055+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_609414","record_id":"REC_0007811","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":16.6,"age_at_diagnosis":84,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":6.0,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.770301+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_914815","record_id":"REC_0007812","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":13.8,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":0,"smoking_pack_years":4,"primary_tumor_size_cm":2.7,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.770553+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_267548","record_id":"REC_0007813","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":30,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":30,"primary_tumor_size_cm":4.3,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.770795+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_685835","record_id":"REC_0007814","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":30,"tmb_mutations_per_mb":9.0,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":2,"smoking_pack_years":20,"primary_tumor_size_cm":4.3,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":5.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.771145+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_223948","record_id":"REC_0007815","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":8.6,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":6.2,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":21.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.771390+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_332962","record_id":"REC_0007816","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":8.1,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.771640+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_790010","record_id":"REC_0007817","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":2.6,"age_at_diagnosis":53,"sex":"male","ecog_performance_status":0,"smoking_pack_years":47,"primary_tumor_size_cm":6.8,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.771904+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_748164","record_id":"REC_0007818","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":13.8,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":2,"smoking_pack_years":22,"primary_tumor_size_cm":5.0,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.772314+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_366670","record_id":"REC_0007819","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":25,"primary_tumor_size_cm":7.8,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.772606+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_219795","record_id":"REC_0007820","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":8.7,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":0,"smoking_pack_years":55,"primary_tumor_size_cm":4.9,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.772843+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_987218","record_id":"REC_0007821","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":10.5,"age_at_diagnosis":80,"sex":"male","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":5.0,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":72.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.773082+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_812071","record_id":"REC_0007822","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":31,"tmb_mutations_per_mb":4.6,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":3.8,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.773315+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_991992","record_id":"REC_0007823","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":11,"tmb_mutations_per_mb":4.4,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":30,"primary_tumor_size_cm":3.0,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.773546+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_120461","record_id":"REC_0007824","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":17.5,"age_at_diagnosis":52,"sex":"male","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":5.5,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":20.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.773783+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_651586","record_id":"REC_0007825","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":34,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":6.1,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.774022+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_186649","record_id":"REC_0007826","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":10.3,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":3.8,"metastatic_sites_count":9,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.774257+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_829177","record_id":"REC_0007827","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":6.4,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":1,"smoking_pack_years":54,"primary_tumor_size_cm":3.8,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.774586+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_387102","record_id":"REC_0007828","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":30,"tmb_mutations_per_mb":17.6,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":6.6,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":5.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.774821+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_241719","record_id":"REC_0007829","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":15.6,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":5.2,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.775059+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_146891","record_id":"REC_0007830","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":24,"primary_tumor_size_cm":5.9,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.775295+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_829727","record_id":"REC_0007831","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":14.3,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":1,"smoking_pack_years":1,"primary_tumor_size_cm":3.5,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.775528+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_287363","record_id":"REC_0007832","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":19,"tmb_mutations_per_mb":3.6,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":70,"primary_tumor_size_cm":5.9,"metastatic_sites_count":3,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":6.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.775761+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_399635","record_id":"REC_0007833","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":20,"tmb_mutations_per_mb":3.7,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":36,"primary_tumor_size_cm":5.4,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.775988+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_261831","record_id":"REC_0007834","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":6.7,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":6.0,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.776337+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_721094","record_id":"REC_0007835","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":16.4,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":28,"primary_tumor_size_cm":4.9,"metastatic_sites_count":8,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.776574+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_216180","record_id":"REC_0007836","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":16.1,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":7.2,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.776811+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_195686","record_id":"REC_0007837","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":7.6,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.777044+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_994761","record_id":"REC_0007838","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":4.0,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":1,"smoking_pack_years":32,"primary_tumor_size_cm":3.4,"metastatic_sites_count":8,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.777276+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_829940","record_id":"REC_0007839","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":5.9,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":2,"smoking_pack_years":30,"primary_tumor_size_cm":6.0,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.777508+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_106187","record_id":"REC_0007840","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":6.1,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":41,"primary_tumor_size_cm":4.3,"metastatic_sites_count":3,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.777790+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_255035","record_id":"REC_0007841","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":83,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":6.5,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.778026+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_777906","record_id":"REC_0007842","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":76,"sex":"male","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":7.4,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":33.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.778261+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_293992","record_id":"REC_0007843","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":17.1,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":4.6,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.778499+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_384805","record_id":"REC_0007844","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":83,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.1,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.778737+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_872663","record_id":"REC_0007845","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":5.1,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.778986+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_978083","record_id":"REC_0007846","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":14.5,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":4.0,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.779233+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_141391","record_id":"REC_0007847","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":9.5,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":4.1,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":39.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.779480+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_623112","record_id":"REC_0007848","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":18.1,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":4.5,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.779727+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_930978","record_id":"REC_0007849","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":20,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":42,"primary_tumor_size_cm":7.6,"metastatic_sites_count":8,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.779972+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_377515","record_id":"REC_0007850","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":31,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":44,"primary_tumor_size_cm":6.4,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.780265+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_244525","record_id":"REC_0007851","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":90,"sex":"female","ecog_performance_status":1,"smoking_pack_years":50,"primary_tumor_size_cm":7.1,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":16.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.780522+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_218659","record_id":"REC_0007852","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":15,"tmb_mutations_per_mb":3.8,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":59,"primary_tumor_size_cm":5.4,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.780768+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_972987","record_id":"REC_0007853","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.7,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.781122+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_980464","record_id":"REC_0007854","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":7.4,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":2,"smoking_pack_years":25,"primary_tumor_size_cm":5.3,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":25.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.781372+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_299028","record_id":"REC_0007855","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":10.3,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":3.5,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":23.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.781612+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_336272","record_id":"REC_0007856","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":7.3,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":87,"primary_tumor_size_cm":5.0,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":5.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.781844+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_203668","record_id":"REC_0007857","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":17,"tmb_mutations_per_mb":1.7,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":7.5,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.782077+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_503530","record_id":"REC_0007858","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":16.7,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":8,"primary_tumor_size_cm":4.7,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.782309+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_956114","record_id":"REC_0007859","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":30,"tmb_mutations_per_mb":16.6,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":0,"smoking_pack_years":27,"primary_tumor_size_cm":5.6,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.782544+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_324363","record_id":"REC_0007860","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":19,"tmb_mutations_per_mb":14.8,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":22,"primary_tumor_size_cm":4.2,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.782784+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_614058","record_id":"REC_0007861","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":31,"tmb_mutations_per_mb":10.5,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":2.8,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":6.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.783021+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_419871","record_id":"REC_0007862","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":40,"primary_tumor_size_cm":6.5,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.783252+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_915856","record_id":"REC_0007863","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":16.6,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":6.1,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":35.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.783490+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_443121","record_id":"REC_0007864","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":14.8,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":6.2,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.783721+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_418637","record_id":"REC_0007865","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":19,"tmb_mutations_per_mb":8.3,"age_at_diagnosis":90,"sex":"female","ecog_performance_status":3,"smoking_pack_years":21,"primary_tumor_size_cm":6.8,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.783953+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_290619","record_id":"REC_0007866","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":18.9,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":5.1,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":24.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.784312+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_558352","record_id":"REC_0007867","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":14.1,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":3.7,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.784571+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_984133","record_id":"REC_0007868","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":15,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":5.2,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.784809+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_366217","record_id":"REC_0007869","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":18,"tmb_mutations_per_mb":8.7,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":6,"primary_tumor_size_cm":3.3,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":27.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.785043+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_137793","record_id":"REC_0007870","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.2,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":16.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.785276+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_210217","record_id":"REC_0007871","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":0,"smoking_pack_years":27,"primary_tumor_size_cm":6.4,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.785512+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_564729","record_id":"REC_0007872","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":8.0,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":0,"smoking_pack_years":57,"primary_tumor_size_cm":5.5,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.785746+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_841180","record_id":"REC_0007873","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":30,"tmb_mutations_per_mb":6.0,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":4.3,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.785978+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_598130","record_id":"REC_0007874","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":2.9,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":9,"primary_tumor_size_cm":6.0,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":17.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.786207+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_843814","record_id":"REC_0007875","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":9.7,"age_at_diagnosis":78,"sex":"male","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":5.8,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.786439+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_234128","record_id":"REC_0007876","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":8.7,"age_at_diagnosis":74,"sex":"male","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":4.0,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.786668+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_680875","record_id":"REC_0007877","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":6.1,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":69,"primary_tumor_size_cm":8.7,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":6.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.786899+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_234126","record_id":"REC_0007878","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":13.8,"age_at_diagnosis":51,"sex":"male","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":3.8,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":26.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.787131+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_560283","record_id":"REC_0007879","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":18.2,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":10,"primary_tumor_size_cm":4.3,"metastatic_sites_count":9,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.787409+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_683822","record_id":"REC_0007880","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":8.7,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":4.2,"metastatic_sites_count":8,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.787642+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_416568","record_id":"REC_0007881","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":4.8,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.787874+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_882104","record_id":"REC_0007882","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":18.5,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":5.5,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":7.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.788141+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_861425","record_id":"REC_0007883","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":18,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":6.5,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":30.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.788379+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_334799","record_id":"REC_0007884","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":17,"tmb_mutations_per_mb":15.1,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":4.2,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.788620+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_872613","record_id":"REC_0007885","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":51,"sex":"male","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":7.7,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":24.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.788855+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_515513","record_id":"REC_0007886","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":0,"smoking_pack_years":65,"primary_tumor_size_cm":4.7,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.789088+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_152023","record_id":"REC_0007887","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":2.5,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":5.9,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":21.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.789318+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_727026","record_id":"REC_0007888","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":30,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":5.4,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":31.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.789550+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_433665","record_id":"REC_0007889","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":18,"tmb_mutations_per_mb":10.3,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":6.6,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.789782+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_616439","record_id":"REC_0007890","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":18.0,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":4.5,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":5.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.790017+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_416458","record_id":"REC_0007891","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":10.1,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":6.0,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.790253+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_600225","record_id":"REC_0007892","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":16.1,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":20,"primary_tumor_size_cm":5.8,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.790536+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_712793","record_id":"REC_0007893","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":17,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":2,"smoking_pack_years":9,"primary_tumor_size_cm":4.2,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.790773+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_729666","record_id":"REC_0007894","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":6.0,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":5.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.791000+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_430810","record_id":"REC_0007895","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.6,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":19.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.791238+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_788970","record_id":"REC_0007896","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":6.4,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":2,"smoking_pack_years":73,"primary_tumor_size_cm":6.1,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.791469+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_275699","record_id":"REC_0007897","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":76,"sex":"male","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":4.5,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.791701+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_366943","record_id":"REC_0007898","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":4.7,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":43.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.791933+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_217272","record_id":"REC_0007899","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":31,"tmb_mutations_per_mb":15.7,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":27,"primary_tumor_size_cm":4.9,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.792190+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_941933","record_id":"REC_0007900","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":15.2,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":6.1,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.792426+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_660636","record_id":"REC_0007901","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":4.1,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.792664+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_495128","record_id":"REC_0007902","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":10.3,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":5.9,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.792895+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_250778","record_id":"REC_0007903","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":17.1,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":7.0,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.793132+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_350214","record_id":"REC_0007904","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":52,"sex":"male","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":5.5,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":16.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.793365+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_498756","record_id":"REC_0007905","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":2,"smoking_pack_years":23,"primary_tumor_size_cm":5.0,"metastatic_sites_count":9,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.793645+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_945580","record_id":"REC_0007906","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":16.2,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":8.2,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":18.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.793883+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_827016","record_id":"REC_0007907","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":6.5,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.794115+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_568135","record_id":"REC_0007908","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":8.9,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":2,"smoking_pack_years":3,"primary_tumor_size_cm":3.9,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":18.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.794345+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_753460","record_id":"REC_0007909","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":6.0,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.794582+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_190697","record_id":"REC_0007910","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":11.5,"age_at_diagnosis":80,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":6.7,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":17.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.794815+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_474822","record_id":"REC_0007911","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":3,"smoking_pack_years":16,"primary_tumor_size_cm":5.9,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.795051+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_540928","record_id":"REC_0007912","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":14.1,"age_at_diagnosis":51,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":6.4,"metastatic_sites_count":8,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.795283+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_997469","record_id":"REC_0007913","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":10.0,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":4.3,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.795515+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_160837","record_id":"REC_0007914","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":20,"tmb_mutations_per_mb":5.1,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":39,"primary_tumor_size_cm":5.8,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":7.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.795743+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_282155","record_id":"REC_0007915","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":5.0,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":25.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.795981+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_562702","record_id":"REC_0007916","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":16.6,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":5.0,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.796370+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_548354","record_id":"REC_0007917","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":53,"sex":"male","ecog_performance_status":0,"smoking_pack_years":24,"primary_tumor_size_cm":3.8,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":21.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.796612+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_914852","record_id":"REC_0007918","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":17,"tmb_mutations_per_mb":3.8,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":5.2,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":40.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.796895+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_214991","record_id":"REC_0007919","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":18,"tmb_mutations_per_mb":4.6,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":33,"primary_tumor_size_cm":4.4,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.797131+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_692176","record_id":"REC_0007920","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":32,"tmb_mutations_per_mb":13.5,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":5.7,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":19.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.797380+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_365459","record_id":"REC_0007921","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":16,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":5.1,"metastatic_sites_count":8,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.797613+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_465134","record_id":"REC_0007922","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":31,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":6.5,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.797841+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_360182","record_id":"REC_0007923","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":6.4,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":3,"smoking_pack_years":8,"primary_tumor_size_cm":7.4,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.798068+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_664601","record_id":"REC_0007924","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":14.5,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":7.2,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.798302+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_210501","record_id":"REC_0007925","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":25,"primary_tumor_size_cm":8.4,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":22.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.798535+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_827001","record_id":"REC_0007926","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":3,"smoking_pack_years":14,"primary_tumor_size_cm":3.1,"metastatic_sites_count":3,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.798766+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_340404","record_id":"REC_0007927","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":10.1,"age_at_diagnosis":87,"sex":"female","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":3.7,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.798999+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_895795","record_id":"REC_0007928","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":18.6,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":7.4,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.799231+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_484469","record_id":"REC_0007929","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":10.5,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":3,"smoking_pack_years":14,"primary_tumor_size_cm":2.0,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.799466+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_296077","record_id":"REC_0007930","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":13.8,"age_at_diagnosis":52,"sex":"male","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":6.3,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":18.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.799699+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_553830","record_id":"REC_0007931","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":8.0,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.799986+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_527951","record_id":"REC_0007932","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":19.6,"age_at_diagnosis":78,"sex":"male","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":6.2,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.800253+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_880067","record_id":"REC_0007933","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":6.9,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.800494+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_189485","record_id":"REC_0007934","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":30,"tmb_mutations_per_mb":5.1,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":5.0,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":22.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.800723+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_741799","record_id":"REC_0007935","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":2.7,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":54.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.800960+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_480452","record_id":"REC_0007936","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":4.8,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.801196+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_432918","record_id":"REC_0007937","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":32,"tmb_mutations_per_mb":8.1,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":7.7,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":21.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.801425+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_355537","record_id":"REC_0007938","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":6.3,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.801661+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_876879","record_id":"REC_0007939","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":6.8,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.801895+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_315361","record_id":"REC_0007940","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":30,"tmb_mutations_per_mb":9.1,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":4.8,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.802123+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_316056","record_id":"REC_0007941","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":9,"primary_tumor_size_cm":6.6,"metastatic_sites_count":8,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.802350+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_802873","record_id":"REC_0007942","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":0,"smoking_pack_years":25,"primary_tumor_size_cm":5.2,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.802587+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_459624","record_id":"REC_0007943","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":9.9,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":2,"smoking_pack_years":3,"primary_tumor_size_cm":7.0,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.802820+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_507774","record_id":"REC_0007944","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":5.8,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.803097+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_179720","record_id":"REC_0007945","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":5.9,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":50,"primary_tumor_size_cm":6.5,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.803332+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_150045","record_id":"REC_0007946","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":17.0,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":5.1,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":19.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.803564+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_141252","record_id":"REC_0007947","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":2.9,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.803793+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_867449","record_id":"REC_0007948","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":4.6,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":6.2,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.804022+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_323144","record_id":"REC_0007949","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":53,"sex":"male","ecog_performance_status":0,"smoking_pack_years":31,"primary_tumor_size_cm":7.3,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.804282+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_333233","record_id":"REC_0007950","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":6.9,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.804516+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_301273","record_id":"REC_0007951","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":13.3,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.0,"metastatic_sites_count":3,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":5.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.804754+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_225781","record_id":"REC_0007952","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":2,"smoking_pack_years":49,"primary_tumor_size_cm":6.5,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.804983+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_657866","record_id":"REC_0007953","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":6.0,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":23.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.805219+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_257620","record_id":"REC_0007954","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":7.6,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":55,"primary_tumor_size_cm":4.1,"metastatic_sites_count":8,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":17.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.805445+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_332541","record_id":"REC_0007955","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":3.3,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":1,"primary_tumor_size_cm":7.3,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":19.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.805675+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_583594","record_id":"REC_0007956","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":19,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":3,"smoking_pack_years":74,"primary_tumor_size_cm":7.3,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.805908+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_990039","record_id":"REC_0007957","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":16.2,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":4,"primary_tumor_size_cm":5.8,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.806185+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_962105","record_id":"REC_0007958","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":11.1,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":6.2,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.806423+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_112831","record_id":"REC_0007959","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":7.8,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":20.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.806662+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_267234","record_id":"REC_0007960","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":10.1,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":6.2,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.806897+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_855037","record_id":"REC_0007961","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":5.7,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.807126+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_228726","record_id":"REC_0007962","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":32,"tmb_mutations_per_mb":7.3,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":5.5,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.807359+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_361366","record_id":"REC_0007963","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":4.1,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":0,"smoking_pack_years":43,"primary_tumor_size_cm":2.3,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":22.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.807593+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_235248","record_id":"REC_0007964","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":17.6,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":6.3,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":6.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.807830+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_590366","record_id":"REC_0007965","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":15.6,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":3,"smoking_pack_years":15,"primary_tumor_size_cm":6.8,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":5.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.808068+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_312366","record_id":"REC_0007966","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":5.7,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":41,"primary_tumor_size_cm":4.4,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.808496+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_677304","record_id":"REC_0007967","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":8,"primary_tumor_size_cm":2.4,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.808751+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_352385","record_id":"REC_0007968","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":8.9,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":4.7,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.808989+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_892218","record_id":"REC_0007969","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":9.7,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":24,"primary_tumor_size_cm":4.7,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.809231+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_494256","record_id":"REC_0007970","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":52,"sex":"female","ecog_performance_status":0,"smoking_pack_years":0,"primary_tumor_size_cm":5.5,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":23.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.809592+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_147265","record_id":"REC_0007971","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":51,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":4.6,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.809838+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_534217","record_id":"REC_0007972","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":3.7,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.810085+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_871567","record_id":"REC_0007973","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":76,"sex":"male","ecog_performance_status":1,"smoking_pack_years":24,"primary_tumor_size_cm":3.7,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.810334+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_502493","record_id":"REC_0007974","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":4.0,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.810573+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_641910","record_id":"REC_0007975","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":19,"tmb_mutations_per_mb":5.7,"age_at_diagnosis":50,"sex":"male","ecog_performance_status":0,"smoking_pack_years":27,"primary_tumor_size_cm":3.4,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.810813+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_452759","record_id":"REC_0007976","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":4.8,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":5.2,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.811045+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_849525","record_id":"REC_0007977","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":54,"sex":"male","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":5.6,"metastatic_sites_count":8,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.811281+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_511643","record_id":"REC_0007978","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.5,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.811534+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_965652","record_id":"REC_0007979","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":11.0,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":7.0,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.811784+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_931350","record_id":"REC_0007980","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":18,"tmb_mutations_per_mb":4.0,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":0,"smoking_pack_years":79,"primary_tumor_size_cm":6.4,"metastatic_sites_count":3,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":6.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.812034+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_450011","record_id":"REC_0007981","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":6.6,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.812362+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_956101","record_id":"REC_0007982","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":5.5,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":59,"primary_tumor_size_cm":4.0,"metastatic_sites_count":8,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.812624+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_673947","record_id":"REC_0007983","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":30,"tmb_mutations_per_mb":14.9,"age_at_diagnosis":54,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":6.3,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":18.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.813030+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_378259","record_id":"REC_0007984","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":15,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":6.1,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":16.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.813295+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_435477","record_id":"REC_0007985","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":9.5,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":5.1,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":19.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.813544+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_339800","record_id":"REC_0007986","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":9.5,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":5.0,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":18.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.813785+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_673079","record_id":"REC_0007987","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":7.9,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":6.0,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":17.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.814027+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_402531","record_id":"REC_0007988","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":3.4,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":39,"primary_tumor_size_cm":7.1,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.814274+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_883226","record_id":"REC_0007989","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":30,"tmb_mutations_per_mb":15.7,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":6.1,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.814529+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_313861","record_id":"REC_0007990","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":7.6,"age_at_diagnosis":84,"sex":"female","ecog_performance_status":1,"smoking_pack_years":56,"primary_tumor_size_cm":3.7,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.814779+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_677244","record_id":"REC_0007991","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":32,"tmb_mutations_per_mb":5.7,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":43,"primary_tumor_size_cm":7.2,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.815024+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_858929","record_id":"REC_0007992","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":16.4,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":4.1,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.815273+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_779664","record_id":"REC_0007993","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":4.0,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":41,"primary_tumor_size_cm":3.4,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.815522+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_343056","record_id":"REC_0007994","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":6.3,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":6.1,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":32.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.815768+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_845051","record_id":"REC_0007995","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":3.4,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.816021+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_213917","record_id":"REC_0007996","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":7.6,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":6.3,"metastatic_sites_count":10,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.816500+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_323214","record_id":"REC_0007997","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":5.5,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":5,"primary_tumor_size_cm":5.6,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.816777+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_202653","record_id":"REC_0007998","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":10,"primary_tumor_size_cm":7.9,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.817038+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_706590","record_id":"REC_0007999","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":33,"tmb_mutations_per_mb":9.0,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":0,"smoking_pack_years":6,"primary_tumor_size_cm":7.4,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.817288+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_860061","record_id":"REC_0008000","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":11.0,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":7.0,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.817536+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_630904","record_id":"REC_0008001","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":9.9,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":5.1,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.817776+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_699474","record_id":"REC_0008002","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":9.5,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":4.3,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.818017+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_220648","record_id":"REC_0008003","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":10.5,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":4.7,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":22.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.818264+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_846743","record_id":"REC_0008004","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":19,"tmb_mutations_per_mb":11.1,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":27,"primary_tumor_size_cm":6.9,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":30.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.818510+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_769251","record_id":"REC_0008005","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":6.8,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.818764+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_295625","record_id":"REC_0008006","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":3,"smoking_pack_years":14,"primary_tumor_size_cm":6.3,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":35.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.819021+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_498251","record_id":"REC_0008007","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":30,"tmb_mutations_per_mb":4.3,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":73,"primary_tumor_size_cm":4.8,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.819272+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_586724","record_id":"REC_0008008","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":9.0,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":5.1,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.819533+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_788531","record_id":"REC_0008009","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":34,"tmb_mutations_per_mb":14.7,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":5.7,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":23.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.819929+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_744015","record_id":"REC_0008010","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":3,"smoking_pack_years":16,"primary_tumor_size_cm":5.3,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":4.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.820258+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_148639","record_id":"REC_0008011","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":3.7,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.820539+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_679034","record_id":"REC_0008012","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":6.9,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":45,"primary_tumor_size_cm":6.0,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.820795+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_557461","record_id":"REC_0008013","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":16.1,"age_at_diagnosis":52,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":5.3,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.821063+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_711715","record_id":"REC_0008014","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":19,"tmb_mutations_per_mb":18.0,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":7.9,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":19.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.821323+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_221284","record_id":"REC_0008015","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":9.8,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":5.3,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.821575+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_810857","record_id":"REC_0008016","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":16,"tmb_mutations_per_mb":17.3,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":5.5,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.821823+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_387120","record_id":"REC_0008017","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":7.1,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":28.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.822074+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_258320","record_id":"REC_0008018","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":5.6,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":54,"primary_tumor_size_cm":5.3,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":21.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.822320+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_119419","record_id":"REC_0008019","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":13.8,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":5.0,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":22.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.822571+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_645042","record_id":"REC_0008020","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":19,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":60,"primary_tumor_size_cm":3.9,"metastatic_sites_count":3,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.822819+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_377524","record_id":"REC_0008021","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":19,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":7.1,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.823066+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_802943","record_id":"REC_0008022","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":14.3,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":5.8,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.823430+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_410082","record_id":"REC_0008023","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":7.4,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":4.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.823689+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_350488","record_id":"REC_0008024","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":5.5,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.823941+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_685996","record_id":"REC_0008025","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":85,"sex":"male","ecog_performance_status":2,"smoking_pack_years":56,"primary_tumor_size_cm":4.4,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":43.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.824240+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_343945","record_id":"REC_0008026","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":29,"primary_tumor_size_cm":5.0,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":7.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.824496+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_339516","record_id":"REC_0008027","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":6.1,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":18.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.824746+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_467249","record_id":"REC_0008028","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":6.0,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":21.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.824988+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_985616","record_id":"REC_0008029","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":67,"primary_tumor_size_cm":7.6,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.825226+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_345329","record_id":"REC_0008030","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":6.0,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":4.7,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.825464+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_265977","record_id":"REC_0008031","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":18,"tmb_mutations_per_mb":9.9,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":3.2,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":20.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.825699+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_481192","record_id":"REC_0008032","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":13.1,"age_at_diagnosis":78,"sex":"male","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":5.2,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.825935+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_768648","record_id":"REC_0008033","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":6.4,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":2,"smoking_pack_years":24,"primary_tumor_size_cm":6.2,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":26.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.826168+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_105977","record_id":"REC_0008034","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":14.4,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":3,"smoking_pack_years":3,"primary_tumor_size_cm":6.5,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":48.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.826402+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_897114","record_id":"REC_0008035","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":8.6,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":5.0,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":7.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.826733+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_657617","record_id":"REC_0008036","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":19,"tmb_mutations_per_mb":6.4,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":4.2,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.826969+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_257389","record_id":"REC_0008037","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":15.1,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":4.7,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":39.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.827202+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_827165","record_id":"REC_0008038","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":53,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":6.7,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":6.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.827438+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_722658","record_id":"REC_0008039","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":15.4,"age_at_diagnosis":90,"sex":"female","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":7.1,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.827672+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_159158","record_id":"REC_0008040","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":5.4,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.827904+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_735558","record_id":"REC_0008041","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":14.7,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":6.3,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.828176+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_663684","record_id":"REC_0008042","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":18,"tmb_mutations_per_mb":8.7,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":7.2,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.828412+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_265591","record_id":"REC_0008043","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":3.6,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.828644+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_717805","record_id":"REC_0008044","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":5.6,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":1,"smoking_pack_years":78,"primary_tumor_size_cm":5.0,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":23.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.828879+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_702826","record_id":"REC_0008045","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":4.4,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":75,"primary_tumor_size_cm":4.3,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.829105+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_675652","record_id":"REC_0008046","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":4.3,"age_at_diagnosis":54,"sex":"female","ecog_performance_status":0,"smoking_pack_years":70,"primary_tumor_size_cm":6.5,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":27.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.829336+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_132758","record_id":"REC_0008047","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":14.8,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":3.8,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.829569+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_919188","record_id":"REC_0008048","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":18.6,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":3.5,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.829849+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_548854","record_id":"REC_0008049","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":13.6,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":7.3,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.830089+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_406280","record_id":"REC_0008050","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":6.0,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.830325+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_723120","record_id":"REC_0008051","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":4.0,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":5.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.830557+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_275830","record_id":"REC_0008052","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":2,"primary_tumor_size_cm":3.9,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.830793+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_546036","record_id":"REC_0008053","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":87,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":7.1,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":21.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.831025+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_961020","record_id":"REC_0008054","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":4.3,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.831261+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_360922","record_id":"REC_0008055","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":4.2,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":1,"smoking_pack_years":40,"primary_tumor_size_cm":6.5,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.831493+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_229139","record_id":"REC_0008056","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":4.3,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":4.6,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.831727+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_419534","record_id":"REC_0008057","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":3.2,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":6.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.831959+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_994453","record_id":"REC_0008058","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":15.1,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":3,"smoking_pack_years":8,"primary_tumor_size_cm":5.2,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":24.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.832247+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_400517","record_id":"REC_0008059","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":3,"smoking_pack_years":13,"primary_tumor_size_cm":4.5,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.832485+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_890728","record_id":"REC_0008060","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":3.8,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":4.0,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":27.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.832731+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_752342","record_id":"REC_0008061","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":9.9,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":5.2,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.833006+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_371382","record_id":"REC_0008062","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":19,"tmb_mutations_per_mb":15.8,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":5.9,"metastatic_sites_count":8,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":8.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.833246+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_927855","record_id":"REC_0008063","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":5.1,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.833485+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_361979","record_id":"REC_0008064","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":5.9,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.833720+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_117951","record_id":"REC_0008065","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":7.8,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":22.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.833955+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_209680","record_id":"REC_0008066","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":4.5,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":57,"primary_tumor_size_cm":6.7,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.834185+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_816770","record_id":"REC_0008067","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":16.2,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":0,"smoking_pack_years":25,"primary_tumor_size_cm":4.4,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":59.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.834423+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_457053","record_id":"REC_0008068","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":6.7,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":46,"primary_tumor_size_cm":4.9,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.834653+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_134336","record_id":"REC_0008069","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":3.6,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.834881+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_327072","record_id":"REC_0008070","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":8.0,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.835111+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_644738","record_id":"REC_0008071","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":4.8,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":22.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.835345+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_593757","record_id":"REC_0008072","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":30,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":5.0,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":22.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.835573+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_785827","record_id":"REC_0008073","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":3.3,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.835804+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_457132","record_id":"REC_0008074","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":16.1,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":3.5,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.836188+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_918823","record_id":"REC_0008075","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":16.6,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":6.9,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":4.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.836440+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_757735","record_id":"REC_0008076","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":24,"primary_tumor_size_cm":6.9,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.836698+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_344385","record_id":"REC_0008077","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":13.8,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":4.1,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.836946+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_427675","record_id":"REC_0008078","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":8.9,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":5.5,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.837176+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_532710","record_id":"REC_0008079","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.3,"metastatic_sites_count":8,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":8.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.837413+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_699424","record_id":"REC_0008080","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":4.6,"age_at_diagnosis":83,"sex":"male","ecog_performance_status":3,"smoking_pack_years":81,"primary_tumor_size_cm":5.3,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":4.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.837650+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_819534","record_id":"REC_0008081","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":14.9,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":1,"smoking_pack_years":5,"primary_tumor_size_cm":4.7,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":18.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.837897+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_440901","record_id":"REC_0008082","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":15.4,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":2.5,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.838143+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_614161","record_id":"REC_0008083","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":2,"smoking_pack_years":9,"primary_tumor_size_cm":5.9,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.838392+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_250387","record_id":"REC_0008084","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":35,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":6,"primary_tumor_size_cm":5.0,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.838643+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_457282","record_id":"REC_0008085","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":42,"sex":"female","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":5.4,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.838897+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_909641","record_id":"REC_0008086","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":17,"tmb_mutations_per_mb":9.8,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":5.7,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":33.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.839137+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_168402","record_id":"REC_0008087","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":14.3,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":6.3,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":25.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.839505+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_916110","record_id":"REC_0008088","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":4.7,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":80,"primary_tumor_size_cm":5.1,"metastatic_sites_count":3,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.839754+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_429146","record_id":"REC_0008089","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":9.7,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":4.5,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.839987+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_772800","record_id":"REC_0008090","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":4.9,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":3,"smoking_pack_years":15,"primary_tumor_size_cm":6.2,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":4.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.840322+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_450541","record_id":"REC_0008091","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":5.2,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":3,"smoking_pack_years":6,"primary_tumor_size_cm":5.2,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.840564+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_406603","record_id":"REC_0008092","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":18.3,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":6.2,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.840801+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_128672","record_id":"REC_0008093","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":16.4,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":5.2,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.841037+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_132601","record_id":"REC_0008094","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":4,"primary_tumor_size_cm":4.6,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":16.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.841269+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_912580","record_id":"REC_0008095","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":18,"tmb_mutations_per_mb":6.3,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":32,"primary_tumor_size_cm":2.6,"metastatic_sites_count":3,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":22.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.841503+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_533103","record_id":"REC_0008096","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":18,"tmb_mutations_per_mb":14.4,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":3.7,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":17.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.841739+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_855570","record_id":"REC_0008097","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":6.0,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.841974+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_305994","record_id":"REC_0008098","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":18,"tmb_mutations_per_mb":5.2,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":1,"smoking_pack_years":34,"primary_tumor_size_cm":7.0,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.842205+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_729380","record_id":"REC_0008099","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":8.6,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":6.6,"metastatic_sites_count":3,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.842432+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_171727","record_id":"REC_0008100","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":1,"smoking_pack_years":0,"primary_tumor_size_cm":2.6,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.842728+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_577592","record_id":"REC_0008101","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":6.9,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.842971+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_552921","record_id":"REC_0008102","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":13.5,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":6.0,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.843208+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_153855","record_id":"REC_0008103","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":9.9,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":5.2,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.843440+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_452966","record_id":"REC_0008104","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":54,"sex":"female","ecog_performance_status":0,"smoking_pack_years":46,"primary_tumor_size_cm":5.9,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":24.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.843672+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_414002","record_id":"REC_0008105","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":34,"tmb_mutations_per_mb":14.4,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":4.5,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.843909+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_760809","record_id":"REC_0008106","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":6.8,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.844190+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_312856","record_id":"REC_0008107","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":18.8,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":3.9,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.844435+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_732436","record_id":"REC_0008108","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":15,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":6.6,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.844678+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_906410","record_id":"REC_0008109","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":6.0,"metastatic_sites_count":8,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.844915+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_505903","record_id":"REC_0008110","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":5.8,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.845145+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_719980","record_id":"REC_0008111","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":4.1,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":29.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.845382+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_120511","record_id":"REC_0008112","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":16.8,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":2,"smoking_pack_years":20,"primary_tumor_size_cm":4.3,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":25.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.845617+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_433670","record_id":"REC_0008113","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":34,"tmb_mutations_per_mb":5.5,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":6.6,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.845894+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_962072","record_id":"REC_0008114","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":14.0,"age_at_diagnosis":78,"sex":"male","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":4.3,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.846134+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_205333","record_id":"REC_0008115","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":9.1,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":5.6,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.846369+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_841558","record_id":"REC_0008116","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":4.3,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":18.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.846612+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_752374","record_id":"REC_0008117","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":7.6,"age_at_diagnosis":52,"sex":"male","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":5.3,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.846858+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_989182","record_id":"REC_0008118","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":16.9,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":5.1,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":5.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.847098+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_873188","record_id":"REC_0008119","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":53,"sex":"female","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":6.7,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":22.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.847337+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_744390","record_id":"REC_0008120","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":6.4,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":18.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.847575+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_225809","record_id":"REC_0008121","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":6.4,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":0,"smoking_pack_years":39,"primary_tumor_size_cm":6.8,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":18.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.847808+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_787677","record_id":"REC_0008122","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":5.4,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.848043+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_979190","record_id":"REC_0008123","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":15.2,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":5.8,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":27.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.848319+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_365456","record_id":"REC_0008124","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":20.1,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":6.5,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.848561+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_792768","record_id":"REC_0008125","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":4.2,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.848886+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_519266","record_id":"REC_0008126","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":4.4,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":34,"primary_tumor_size_cm":7.4,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.849244+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_290037","record_id":"REC_0008127","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":34,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":1,"smoking_pack_years":34,"primary_tumor_size_cm":6.6,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.849502+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_622885","record_id":"REC_0008128","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":3.1,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":18.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.849742+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_190107","record_id":"REC_0008129","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":31,"tmb_mutations_per_mb":16.8,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":3.5,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.849985+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_349594","record_id":"REC_0008130","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":0,"smoking_pack_years":61,"primary_tumor_size_cm":5.7,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":17.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.850221+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_570437","record_id":"REC_0008131","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":14.8,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":4.1,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.850457+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_255770","record_id":"REC_0008132","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":13.3,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":2,"smoking_pack_years":24,"primary_tumor_size_cm":5.4,"metastatic_sites_count":9,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":6.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.850734+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_471145","record_id":"REC_0008133","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":4.8,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":3.7,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.851017+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_957765","record_id":"REC_0008134","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":32,"tmb_mutations_per_mb":14.0,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":5.8,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.851266+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_306968","record_id":"REC_0008135","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":18,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":77,"sex":"male","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":6.3,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.851516+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_404506","record_id":"REC_0008136","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":15.0,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":6.8,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.851752+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_716487","record_id":"REC_0008137","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":14.7,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":4.0,"metastatic_sites_count":3,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":17.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.851984+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_508051","record_id":"REC_0008138","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":4.1,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.852291+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_580713","record_id":"REC_0008139","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":8.5,"age_at_diagnosis":52,"sex":"female","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":6.0,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":16.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.852618+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_364559","record_id":"REC_0008140","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":13.1,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":7.6,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.852860+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_658611","record_id":"REC_0008141","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":10,"primary_tumor_size_cm":5.1,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.853091+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_520305","record_id":"REC_0008142","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":10.1,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":6.4,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":35.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.853324+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_260485","record_id":"REC_0008143","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.1,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":3.6,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":25.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.853563+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_684012","record_id":"REC_0008144","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":19.1,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":2,"smoking_pack_years":9,"primary_tumor_size_cm":4.0,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.853800+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_450186","record_id":"REC_0008145","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":19,"tmb_mutations_per_mb":13.5,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.4,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.854033+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_838594","record_id":"REC_0008146","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":9.5,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":7.0,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.854265+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_705304","record_id":"REC_0008147","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":8.5,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":4.9,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.854497+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_200609","record_id":"REC_0008148","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":19.9,"age_at_diagnosis":75,"sex":"male","ecog_performance_status":0,"smoking_pack_years":0,"primary_tumor_size_cm":7.1,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.854730+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_635574","record_id":"REC_0008149","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":4.2,"age_at_diagnosis":76,"sex":"male","ecog_performance_status":1,"smoking_pack_years":37,"primary_tumor_size_cm":7.4,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":16.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.854962+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_852034","record_id":"REC_0008150","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":13.6,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":6.4,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":47.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.855198+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_726339","record_id":"REC_0008151","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":6.0,"age_at_diagnosis":85,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":2.0,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":20.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.855428+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_370340","record_id":"REC_0008152","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":6.7,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.855711+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_788933","record_id":"REC_0008153","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":2.4,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":3.1,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":5.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.855981+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_503551","record_id":"REC_0008154","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":9.7,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":39,"primary_tumor_size_cm":8.4,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.856359+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_456123","record_id":"REC_0008155","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":3,"smoking_pack_years":21,"primary_tumor_size_cm":4.4,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.856625+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_811317","record_id":"REC_0008156","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":19,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":5.8,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.856882+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_584437","record_id":"REC_0008157","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":15.7,"age_at_diagnosis":84,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":7.5,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.857192+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_773770","record_id":"REC_0008158","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":6.1,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.857443+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_149202","record_id":"REC_0008159","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":14.0,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":6.1,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.857734+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_418605","record_id":"REC_0008160","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":8.3,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":5.2,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.858017+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_781224","record_id":"REC_0008161","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":19,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":7.5,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":23.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.858300+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_209506","record_id":"REC_0008162","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":3.8,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.858580+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_248860","record_id":"REC_0008163","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":5.1,"metastatic_sites_count":8,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.858938+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_901274","record_id":"REC_0008164","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":6,"primary_tumor_size_cm":6.5,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.859302+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_306082","record_id":"REC_0008165","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":3,"smoking_pack_years":10,"primary_tumor_size_cm":7.9,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":6.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.859796+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_455329","record_id":"REC_0008166","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":84,"sex":"female","ecog_performance_status":1,"smoking_pack_years":0,"primary_tumor_size_cm":6.4,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":4.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.860245+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_577492","record_id":"REC_0008167","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":15.4,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":0,"primary_tumor_size_cm":7.3,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.860521+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_274983","record_id":"REC_0008168","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":4.3,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.860791+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_600224","record_id":"REC_0008169","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":20.9,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":3,"smoking_pack_years":23,"primary_tumor_size_cm":6.1,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":24.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.861156+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_719472","record_id":"REC_0008170","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":5.0,"metastatic_sites_count":3,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.861407+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_107376","record_id":"REC_0008171","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":17.6,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":5.0,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.861665+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_438139","record_id":"REC_0008172","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":8.9,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":5.4,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":18.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.861907+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_810441","record_id":"REC_0008173","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":8.7,"age_at_diagnosis":53,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":4.2,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.862159+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_116431","record_id":"REC_0008174","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.4,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.862425+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_143638","record_id":"REC_0008175","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":17,"tmb_mutations_per_mb":10.5,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":5.5,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.862677+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_775003","record_id":"REC_0008176","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":4.8,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":17.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.862933+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_965837","record_id":"REC_0008177","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":15.3,"age_at_diagnosis":53,"sex":"male","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":8.4,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.863192+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_988841","record_id":"REC_0008178","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":15.4,"age_at_diagnosis":54,"sex":"male","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":5.0,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.863566+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_622614","record_id":"REC_0008179","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":6.9,"age_at_diagnosis":83,"sex":"female","ecog_performance_status":2,"smoking_pack_years":33,"primary_tumor_size_cm":4.0,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":7.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.864217+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_598980","record_id":"REC_0008180","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":4.7,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.864484+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_863321","record_id":"REC_0008181","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":8.0,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":20,"primary_tumor_size_cm":4.8,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":19.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.864920+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_157747","record_id":"REC_0008182","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":19,"tmb_mutations_per_mb":14.1,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":5.2,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":18.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.865210+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_767455","record_id":"REC_0008183","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":14.3,"age_at_diagnosis":87,"sex":"female","ecog_performance_status":2,"smoking_pack_years":5,"primary_tumor_size_cm":6.3,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":18.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.865512+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_532230","record_id":"REC_0008184","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":9.8,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":5.0,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.865823+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_926572","record_id":"REC_0008185","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":17.6,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":5.4,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":22.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.866075+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_159645","record_id":"REC_0008186","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.2,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":17.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.866422+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_179951","record_id":"REC_0008187","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":6.7,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.3,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":27.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.866667+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_438186","record_id":"REC_0008188","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":15.6,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":4.2,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.867168+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_178780","record_id":"REC_0008189","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":4.9,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.867789+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_137205","record_id":"REC_0008190","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":15,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":78,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":3.9,"metastatic_sites_count":8,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.868039+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_894063","record_id":"REC_0008191","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":22,"primary_tumor_size_cm":3.5,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":7.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.868513+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_276900","record_id":"REC_0008192","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":4.8,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":40,"primary_tumor_size_cm":5.7,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":4.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.868799+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_771733","record_id":"REC_0008193","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":14.0,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":6.9,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":23.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.869062+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_488952","record_id":"REC_0008194","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":4.4,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":27,"primary_tumor_size_cm":5.9,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.869325+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_956810","record_id":"REC_0008195","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":8.4,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":47,"primary_tumor_size_cm":4.8,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":25.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.869582+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_208378","record_id":"REC_0008196","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":6.6,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.869835+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_355813","record_id":"REC_0008197","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":6.0,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":16.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.870088+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_839655","record_id":"REC_0008198","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":20,"tmb_mutations_per_mb":5.9,"age_at_diagnosis":83,"sex":"male","ecog_performance_status":3,"smoking_pack_years":48,"primary_tumor_size_cm":7.4,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":20.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.870337+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_407823","record_id":"REC_0008199","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":15,"tmb_mutations_per_mb":13.5,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":8.1,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.870608+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_877409","record_id":"REC_0008200","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":19,"tmb_mutations_per_mb":3.7,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":30,"primary_tumor_size_cm":5.2,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.870864+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_600449","record_id":"REC_0008201","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":80,"sex":"male","ecog_performance_status":2,"smoking_pack_years":3,"primary_tumor_size_cm":4.2,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.871123+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_925012","record_id":"REC_0008202","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":6.2,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":26.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.871433+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_120190","record_id":"REC_0008203","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":5.1,"age_at_diagnosis":54,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":5.5,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.871803+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_630159","record_id":"REC_0008204","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":7.2,"metastatic_sites_count":9,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.872349+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_857962","record_id":"REC_0008205","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":15.4,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":3.9,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.872667+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_602115","record_id":"REC_0008206","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":7.0,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.872989+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_617909","record_id":"REC_0008207","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":5.3,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":4.5,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":37.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.873306+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_958240","record_id":"REC_0008208","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":10.1,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":8.1,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.873567+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_203528","record_id":"REC_0008209","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":9.0,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":5.5,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.873825+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_370561","record_id":"REC_0008210","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":14.8,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":6.6,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":18.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.874090+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_609341","record_id":"REC_0008211","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":4.3,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":47,"primary_tumor_size_cm":5.4,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":5.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.874392+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_968744","record_id":"REC_0008212","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":6.3,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":45.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.874842+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_403170","record_id":"REC_0008213","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":4.2,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":36,"primary_tumor_size_cm":6.9,"metastatic_sites_count":3,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":7.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.875194+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_275430","record_id":"REC_0008214","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":48,"sex":"female","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":6.2,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.875446+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_252746","record_id":"REC_0008215","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":9.9,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":4.3,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":24.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.875693+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_202610","record_id":"REC_0008216","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":40,"primary_tumor_size_cm":4.9,"metastatic_sites_count":3,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.875930+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_910445","record_id":"REC_0008217","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":14.4,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":6.1,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.876365+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_927004","record_id":"REC_0008218","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":11.0,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":7.7,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.876757+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_550968","record_id":"REC_0008219","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":15.0,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":8.0,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.877010+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_168455","record_id":"REC_0008220","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":14.4,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":6.6,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.877249+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_940415","record_id":"REC_0008221","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":15.2,"age_at_diagnosis":90,"sex":"male","ecog_performance_status":2,"smoking_pack_years":6,"primary_tumor_size_cm":6.3,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.877741+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_971014","record_id":"REC_0008222","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":31,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":4.1,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.878146+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_226113","record_id":"REC_0008223","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":2.2,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":6.6,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.878615+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_362874","record_id":"REC_0008224","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":6.1,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":33.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.879040+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_988986","record_id":"REC_0008225","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":5.9,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":46,"primary_tumor_size_cm":3.9,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.879498+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_735621","record_id":"REC_0008226","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":61,"primary_tumor_size_cm":5.0,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":20.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.879743+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_846137","record_id":"REC_0008227","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":53,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":6.0,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":34.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.880039+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_770326","record_id":"REC_0008228","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":5.2,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":2,"smoking_pack_years":78,"primary_tumor_size_cm":3.8,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.880398+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_923815","record_id":"REC_0008229","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":15.8,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":5.8,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.880650+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_986508","record_id":"REC_0008230","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":5.6,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.880984+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_527528","record_id":"REC_0008231","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":17.0,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":4,"primary_tumor_size_cm":5.4,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":4.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.881228+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_641293","record_id":"REC_0008232","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":13.5,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.0,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.881464+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_803767","record_id":"REC_0008233","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":9.1,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":4.7,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.881696+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_666006","record_id":"REC_0008234","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":33,"tmb_mutations_per_mb":10.0,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":5.3,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":60.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.881931+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_878521","record_id":"REC_0008235","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":6.1,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":25.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.882161+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_161459","record_id":"REC_0008236","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":7.6,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":3.1,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.882390+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_118827","record_id":"REC_0008237","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.8,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.882626+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_296868","record_id":"REC_0008238","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":16,"tmb_mutations_per_mb":13.8,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":5.8,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.882858+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_730781","record_id":"REC_0008239","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":9.1,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":4.2,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.883088+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_609485","record_id":"REC_0008240","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":6.2,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.883321+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_376433","record_id":"REC_0008241","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":32,"tmb_mutations_per_mb":10.5,"age_at_diagnosis":52,"sex":"female","ecog_performance_status":0,"smoking_pack_years":0,"primary_tumor_size_cm":5.0,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":4.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.883555+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_321771","record_id":"REC_0008242","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":18,"tmb_mutations_per_mb":15.8,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":29,"primary_tumor_size_cm":5.2,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.883791+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_984218","record_id":"REC_0008243","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":4.1,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.884123+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_739739","record_id":"REC_0008244","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":20,"tmb_mutations_per_mb":5.1,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":92,"primary_tumor_size_cm":5.9,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.884370+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_273717","record_id":"REC_0008245","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":5.2,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.884606+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_588536","record_id":"REC_0008246","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":4.9,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":37.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.884836+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_710070","record_id":"REC_0008247","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":30,"tmb_mutations_per_mb":4.5,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":42,"primary_tumor_size_cm":5.5,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.885070+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_993930","record_id":"REC_0008248","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":30,"tmb_mutations_per_mb":18.3,"age_at_diagnosis":54,"sex":"male","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":2.9,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":20.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.885306+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_663281","record_id":"REC_0008249","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":6.6,"metastatic_sites_count":8,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.885542+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_923894","record_id":"REC_0008250","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":20,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":6.0,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":32.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.885776+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_198426","record_id":"REC_0008251","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":14.6,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":1,"smoking_pack_years":29,"primary_tumor_size_cm":6.5,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":31.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.886010+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_294488","record_id":"REC_0008252","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":2,"smoking_pack_years":24,"primary_tumor_size_cm":5.5,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.886242+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_986846","record_id":"REC_0008253","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":9.1,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":5.6,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.886473+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_636182","record_id":"REC_0008254","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":7.9,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":5.6,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.886704+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_691744","record_id":"REC_0008255","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":2.9,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":57,"primary_tumor_size_cm":5.1,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":7.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.886932+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_468126","record_id":"REC_0008256","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":17.7,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":5.6,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.887209+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_295052","record_id":"REC_0008257","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":1,"smoking_pack_years":0,"primary_tumor_size_cm":5.2,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":17.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.887445+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_500300","record_id":"REC_0008258","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":8,"tmb_mutations_per_mb":13.6,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":3,"smoking_pack_years":22,"primary_tumor_size_cm":4.2,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.887679+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_492022","record_id":"REC_0008259","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":31,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":6.3,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.887911+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_386932","record_id":"REC_0008260","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":19,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":87,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":6.8,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":21.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.888224+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_665340","record_id":"REC_0008261","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":3.7,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":21.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.888472+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_973376","record_id":"REC_0008262","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":15.8,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":6.4,"metastatic_sites_count":9,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.888706+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_823362","record_id":"REC_0008263","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":54,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":4.4,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.888942+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_161451","record_id":"REC_0008264","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":11.5,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":27,"primary_tumor_size_cm":6.0,"metastatic_sites_count":3,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.889175+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_953258","record_id":"REC_0008265","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":3.7,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":6.0,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":17.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.889409+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_655134","record_id":"REC_0008266","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":32,"tmb_mutations_per_mb":8.7,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":5.4,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":21.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.889636+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_528820","record_id":"REC_0008267","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":16.2,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":8,"primary_tumor_size_cm":3.8,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.889875+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_993505","record_id":"REC_0008268","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":14,"tmb_mutations_per_mb":5.5,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":0,"smoking_pack_years":63,"primary_tumor_size_cm":6.7,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.890115+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_424129","record_id":"REC_0008269","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":10.3,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":7.6,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":19.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.890564+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_246580","record_id":"REC_0008270","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":14.9,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":7.0,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":17.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.890815+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_619766","record_id":"REC_0008271","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":6.3,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":54.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.891062+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_600747","record_id":"REC_0008272","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":20,"tmb_mutations_per_mb":7.6,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":1,"smoking_pack_years":36,"primary_tumor_size_cm":5.6,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.891297+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_202191","record_id":"REC_0008273","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":3.0,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":22.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.891533+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_664150","record_id":"REC_0008274","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":85,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":4.8,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.891763+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_428057","record_id":"REC_0008275","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":2.1,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":83,"primary_tumor_size_cm":4.2,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":6.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.891991+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_323250","record_id":"REC_0008276","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":9.1,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":8.4,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.892276+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_321692","record_id":"REC_0008277","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":6.3,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.892520+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_650239","record_id":"REC_0008278","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":18,"tmb_mutations_per_mb":3.9,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":35,"primary_tumor_size_cm":6.1,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.892764+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_273024","record_id":"REC_0008279","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":45,"sex":"male","ecog_performance_status":0,"smoking_pack_years":3,"primary_tumor_size_cm":5.2,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":25.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.893019+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_554849","record_id":"REC_0008280","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":5.4,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":18.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.893272+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_986706","record_id":"REC_0008281","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":59,"primary_tumor_size_cm":6.5,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":19.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.893525+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_541151","record_id":"REC_0008282","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":16.2,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":6.5,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.893868+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_308103","record_id":"REC_0008283","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":6,"primary_tumor_size_cm":5.1,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":36.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.894115+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_525494","record_id":"REC_0008284","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":5.6,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":25.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.894349+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_461747","record_id":"REC_0008285","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":51,"sex":"male","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":5.3,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.894583+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_869695","record_id":"REC_0008286","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":36,"tmb_mutations_per_mb":13.3,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":5.5,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.894818+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_199847","record_id":"REC_0008287","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":19.7,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":4.2,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":26.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.895049+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_826003","record_id":"REC_0008288","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":4.6,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.895283+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_422785","record_id":"REC_0008289","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":13.6,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":5.5,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.895515+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_960861","record_id":"REC_0008290","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":2.2,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":2.1,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.895746+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_171325","record_id":"REC_0008291","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":15.0,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":6.4,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":18.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.895984+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_897406","record_id":"REC_0008292","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":5.0,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.896266+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_117415","record_id":"REC_0008293","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":25,"primary_tumor_size_cm":6.3,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.896501+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_634685","record_id":"REC_0008294","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":14.8,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":3,"smoking_pack_years":19,"primary_tumor_size_cm":6.9,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.896732+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_817211","record_id":"REC_0008295","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":15.0,"age_at_diagnosis":46,"sex":"male","ecog_performance_status":0,"smoking_pack_years":2,"primary_tumor_size_cm":5.2,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":26.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.897021+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_990923","record_id":"REC_0008296","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":20,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":84,"sex":"female","ecog_performance_status":2,"smoking_pack_years":28,"primary_tumor_size_cm":6.0,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.897254+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_983133","record_id":"REC_0008297","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":3.7,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.897489+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_444407","record_id":"REC_0008298","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":5.2,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":19.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.897724+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_976908","record_id":"REC_0008299","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":4.8,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":43,"primary_tumor_size_cm":4.8,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.897951+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_274006","record_id":"REC_0008300","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":24,"primary_tumor_size_cm":5.4,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":22.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.898180+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_746540","record_id":"REC_0008301","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":5.9,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":83.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.898416+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_333759","record_id":"REC_0008302","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":4.8,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.898646+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_831974","record_id":"REC_0008303","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":30,"tmb_mutations_per_mb":9.1,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":2,"smoking_pack_years":9,"primary_tumor_size_cm":6.2,"metastatic_sites_count":3,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":5.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.898876+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_747244","record_id":"REC_0008304","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":9.7,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":4,"primary_tumor_size_cm":6.0,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.899106+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_582848","record_id":"REC_0008305","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":16.5,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":10,"primary_tumor_size_cm":5.6,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.899341+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_685055","record_id":"REC_0008306","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":17.7,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":5.7,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.899577+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_271272","record_id":"REC_0008307","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":15.7,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":28,"primary_tumor_size_cm":5.2,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.899811+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_346880","record_id":"REC_0008308","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":6.5,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.900162+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_500950","record_id":"REC_0008309","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":4.2,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":2,"smoking_pack_years":22,"primary_tumor_size_cm":5.2,"metastatic_sites_count":9,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.900414+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_356295","record_id":"REC_0008310","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":1,"smoking_pack_years":48,"primary_tumor_size_cm":4.9,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":23.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.900649+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_304182","record_id":"REC_0008311","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":5.3,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.5,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.900893+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_554020","record_id":"REC_0008312","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":23.0,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":4.3,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.901132+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_250107","record_id":"REC_0008313","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":30,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":51,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":6.8,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.901372+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_360741","record_id":"REC_0008314","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None","pd_l1_tps_percent":31,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":5.3,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":44.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.901605+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_545918","record_id":"REC_0008315","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":7.9,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":8,"primary_tumor_size_cm":6.7,"metastatic_sites_count":3,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":16.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.901847+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_813935","record_id":"REC_0008316","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":5.9,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":0,"smoking_pack_years":54,"primary_tumor_size_cm":4.5,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":6.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.902084+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_437565","record_id":"REC_0008317","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":3.6,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.902323+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_397439","record_id":"REC_0008318","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":16,"tmb_mutations_per_mb":16.1,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":0,"smoking_pack_years":25,"primary_tumor_size_cm":5.4,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.902559+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_150304","record_id":"REC_0008319","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":30,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":4.4,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.902802+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_750222","record_id":"REC_0008320","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":8.2,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.903037+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_374084","record_id":"REC_0008321","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":5.7,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.903373+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_457582","record_id":"REC_0008322","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":25,"primary_tumor_size_cm":5.1,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":19.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.903610+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_403094","record_id":"REC_0008323","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":9.9,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":6.4,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.903847+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_579384","record_id":"REC_0008324","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":31,"tmb_mutations_per_mb":13.8,"age_at_diagnosis":83,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":8.4,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.904207+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_692579","record_id":"REC_0008325","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":6.5,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":28.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.904468+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_788315","record_id":"REC_0008326","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":3.5,"age_at_diagnosis":80,"sex":"male","ecog_performance_status":0,"smoking_pack_years":64,"primary_tumor_size_cm":6.0,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":21.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.904708+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_682119","record_id":"REC_0008327","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":7.3,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":8.3,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.904942+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_764535","record_id":"REC_0008328","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":5.0,"metastatic_sites_count":8,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.905180+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_722936","record_id":"REC_0008329","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":32,"tmb_mutations_per_mb":4.6,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":53,"primary_tumor_size_cm":5.2,"metastatic_sites_count":8,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":17.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.905422+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_208726","record_id":"REC_0008330","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":6.0,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":4.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.905663+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_318381","record_id":"REC_0008331","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":8.6,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":44,"primary_tumor_size_cm":6.3,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.905895+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_299130","record_id":"REC_0008332","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":15.2,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.0,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.906147+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_188853","record_id":"REC_0008333","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":6.7,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":58,"primary_tumor_size_cm":5.4,"metastatic_sites_count":3,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":16.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.906380+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_106253","record_id":"REC_0008334","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":16.6,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":7.2,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.906711+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_712012","record_id":"REC_0008335","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":6.9,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":25,"primary_tumor_size_cm":4.7,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":21.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.906959+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_456450","record_id":"REC_0008336","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":2,"smoking_pack_years":4,"primary_tumor_size_cm":3.5,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":17.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.907205+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_919046","record_id":"REC_0008337","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":8.9,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":4.5,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.907455+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_233472","record_id":"REC_0008338","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":24,"primary_tumor_size_cm":3.3,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":22.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.907703+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_395907","record_id":"REC_0008339","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":1.5,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":1,"smoking_pack_years":85,"primary_tumor_size_cm":5.3,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":23.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.907956+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_266797","record_id":"REC_0008340","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":6.0,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.908268+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_228093","record_id":"REC_0008341","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":35,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":7.1,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":5.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.908533+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_281682","record_id":"REC_0008342","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":4.6,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.908784+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_943076","record_id":"REC_0008343","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":4.1,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":28.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.909032+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_629200","record_id":"REC_0008344","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":34,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":5.2,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.909268+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_328824","record_id":"REC_0008345","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":32,"primary_tumor_size_cm":7.2,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":7.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.909501+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_581234","record_id":"REC_0008346","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":6.3,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":2,"smoking_pack_years":63,"primary_tumor_size_cm":5.5,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.909738+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_348578","record_id":"REC_0008347","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":15,"tmb_mutations_per_mb":5.3,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":4.5,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.910103+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_824750","record_id":"REC_0008348","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":20,"tmb_mutations_per_mb":7.6,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":33,"primary_tumor_size_cm":3.9,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.910362+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_590329","record_id":"REC_0008349","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":32,"tmb_mutations_per_mb":5.9,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":9,"primary_tumor_size_cm":7.7,"metastatic_sites_count":8,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":6.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.910598+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_173134","record_id":"REC_0008350","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":3.9,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.910839+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_389585","record_id":"REC_0008351","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":5.4,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":6.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.911079+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_427695","record_id":"REC_0008352","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":30,"tmb_mutations_per_mb":5.6,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":0,"smoking_pack_years":57,"primary_tumor_size_cm":4.0,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":5.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.911315+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_386257","record_id":"REC_0008353","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":4.8,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.911560+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_753006","record_id":"REC_0008354","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":10.5,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":6.1,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.911806+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_921146","record_id":"REC_0008355","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":6.5,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.912057+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_634815","record_id":"REC_0008356","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":7.6,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":3,"smoking_pack_years":14,"primary_tumor_size_cm":4.2,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":22.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.912433+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_566232","record_id":"REC_0008357","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":15.3,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":26,"primary_tumor_size_cm":4.0,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":22.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.912700+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_522669","record_id":"REC_0008358","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":8.9,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":49,"primary_tumor_size_cm":5.8,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":17.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.912964+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_423990","record_id":"REC_0008359","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":5.2,"metastatic_sites_count":10,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.913223+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_558124","record_id":"REC_0008360","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":15.3,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":4.8,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.913630+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_590430","record_id":"REC_0008361","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":2.7,"age_at_diagnosis":54,"sex":"male","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":5.2,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":20.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.913914+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_342223","record_id":"REC_0008362","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":8.9,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":25,"primary_tumor_size_cm":4.1,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.914167+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_100843","record_id":"REC_0008363","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":20,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":89,"sex":"female","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":4.6,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":6.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.914428+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_758727","record_id":"REC_0008364","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":5.1,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.914697+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_381536","record_id":"REC_0008365","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.2,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.914985+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_522817","record_id":"REC_0008366","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":15.9,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":6.8,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.915251+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_643176","record_id":"REC_0008367","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":15,"tmb_mutations_per_mb":10.3,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":26,"primary_tumor_size_cm":5.6,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.915532+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_808687","record_id":"REC_0008368","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":49,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":7.7,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.915790+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_378192","record_id":"REC_0008369","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":5.3,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.916043+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_242036","record_id":"REC_0008370","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":5.6,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.916426+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_108418","record_id":"REC_0008371","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":17.9,"age_at_diagnosis":54,"sex":"male","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":5.7,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.916700+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_516585","record_id":"REC_0008372","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":13,"tmb_mutations_per_mb":14.0,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":5.4,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.916986+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_854987","record_id":"REC_0008373","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":10.5,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":5.3,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.917327+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_358474","record_id":"REC_0008374","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":6.1,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.917573+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_893608","record_id":"REC_0008375","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":5.5,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.917827+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_206544","record_id":"REC_0008376","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":8.7,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":4.5,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.918073+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_305554","record_id":"REC_0008377","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":5.2,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":0,"smoking_pack_years":28,"primary_tumor_size_cm":6.5,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.918304+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_933311","record_id":"REC_0008378","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":5.9,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":17.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.918537+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_782383","record_id":"REC_0008379","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":2.2,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":22.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.918805+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_679736","record_id":"REC_0008380","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":2,"smoking_pack_years":10,"primary_tumor_size_cm":6.2,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":20.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.919057+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_108928","record_id":"REC_0008381","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":5.7,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.919295+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_484635","record_id":"REC_0008382","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":13.6,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":6.3,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.919529+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_851727","record_id":"REC_0008383","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":15.0,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":2,"smoking_pack_years":21,"primary_tumor_size_cm":6.5,"metastatic_sites_count":3,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.919828+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_390469","record_id":"REC_0008384","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":17,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":5.0,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.920116+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_835615","record_id":"REC_0008385","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":14.7,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":4.1,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.920365+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_744405","record_id":"REC_0008386","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":14.4,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":6.0,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.920713+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_592638","record_id":"REC_0008387","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":8.9,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":5.4,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.920955+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_760286","record_id":"REC_0008388","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":15.1,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":3.9,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.921191+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_468728","record_id":"REC_0008389","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":7.4,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":5.3,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.921434+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_824764","record_id":"REC_0008390","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":16.6,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":4.6,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.921699+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_859556","record_id":"REC_0008391","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":5.0,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":53,"primary_tumor_size_cm":4.0,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.921938+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_746307","record_id":"REC_0008392","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.1,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":5.6,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.922171+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_355326","record_id":"REC_0008393","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":4.5,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":28,"primary_tumor_size_cm":3.7,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":6.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.922404+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_976141","record_id":"REC_0008394","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":4.3,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":0,"smoking_pack_years":25,"primary_tumor_size_cm":4.9,"metastatic_sites_count":3,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.922637+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_136499","record_id":"REC_0008395","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":25,"primary_tumor_size_cm":4.3,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.922867+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_466114","record_id":"REC_0008396","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":5,"primary_tumor_size_cm":4.2,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":25.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.923097+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_597514","record_id":"REC_0008397","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":11,"tmb_mutations_per_mb":19.0,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":3.8,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":30.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.923330+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_159043","record_id":"REC_0008398","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":9.9,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":4.8,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.923554+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_222556","record_id":"REC_0008399","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":5.5,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":5.5,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.923847+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_473844","record_id":"REC_0008400","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":51,"primary_tumor_size_cm":6.7,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.924144+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_238845","record_id":"REC_0008401","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":4.9,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.2,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":20.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.924384+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_288369","record_id":"REC_0008402","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":15.7,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":3,"smoking_pack_years":8,"primary_tumor_size_cm":4.4,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":6.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.924633+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_355584","record_id":"REC_0008403","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":17,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":1,"smoking_pack_years":42,"primary_tumor_size_cm":8.6,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.924869+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_303747","record_id":"REC_0008404","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":90,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":4.2,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.925107+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_108614","record_id":"REC_0008405","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":15.6,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":4.0,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":5.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.925347+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_647675","record_id":"REC_0008406","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":9.8,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":7,"primary_tumor_size_cm":6.4,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.925575+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_380098","record_id":"REC_0008407","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":8.7,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":5.2,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.925804+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_183681","record_id":"REC_0008408","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":8.4,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":70,"primary_tumor_size_cm":4.0,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.926041+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_370653","record_id":"REC_0008409","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":5.2,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":63,"primary_tumor_size_cm":4.4,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.926274+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_791444","record_id":"REC_0008410","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":4.4,"age_at_diagnosis":89,"sex":"male","ecog_performance_status":2,"smoking_pack_years":8,"primary_tumor_size_cm":3.0,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.926511+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_233059","record_id":"REC_0008411","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":14.7,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":5.7,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":23.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.926747+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_998650","record_id":"REC_0008412","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":6.4,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":5.8,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":26.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.927041+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_324301","record_id":"REC_0008413","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":5.1,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":25,"primary_tumor_size_cm":7.3,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":16.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.927278+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_909266","record_id":"REC_0008414","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":16,"tmb_mutations_per_mb":4.5,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":0,"smoking_pack_years":61,"primary_tumor_size_cm":5.7,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":26.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.927506+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_673749","record_id":"REC_0008415","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":6.1,"age_at_diagnosis":46,"sex":"male","ecog_performance_status":0,"smoking_pack_years":58,"primary_tumor_size_cm":5.4,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.927741+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_965803","record_id":"REC_0008416","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.0,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":0,"smoking_pack_years":0,"primary_tumor_size_cm":6.6,"metastatic_sites_count":3,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.927977+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_248885","record_id":"REC_0008417","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":6.8,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.928245+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_537923","record_id":"REC_0008418","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":17.8,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":6.1,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.928485+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_227648","record_id":"REC_0008419","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":3.3,"metastatic_sites_count":8,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.928721+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_231312","record_id":"REC_0008420","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":19,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":0,"smoking_pack_years":38,"primary_tumor_size_cm":4.6,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":21.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.928957+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_177161","record_id":"REC_0008421","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":3.5,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.929194+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_802045","record_id":"REC_0008422","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":16,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":5.5,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.929427+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_883150","record_id":"REC_0008423","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":13.3,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":25,"primary_tumor_size_cm":4.3,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.929660+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_134308","record_id":"REC_0008424","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":16.6,"age_at_diagnosis":52,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":5.2,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.929895+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_412577","record_id":"REC_0008425","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":5.5,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":46,"primary_tumor_size_cm":4.8,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.930174+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_637062","record_id":"REC_0008426","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":31,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":51,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":5.3,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":20.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.930412+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_262086","record_id":"REC_0008427","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":10.1,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":4.7,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.930650+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_571198","record_id":"REC_0008428","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":26,"primary_tumor_size_cm":4.8,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.930882+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_951881","record_id":"REC_0008429","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":9.9,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":6.2,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.931112+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_887312","record_id":"REC_0008430","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":19,"tmb_mutations_per_mb":3.8,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":3,"smoking_pack_years":15,"primary_tumor_size_cm":6.1,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":17.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.931339+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_155644","record_id":"REC_0008431","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":13.5,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":5.3,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":19.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.931571+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_809349","record_id":"REC_0008432","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":8.5,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":5.3,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.931802+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_366357","record_id":"REC_0008433","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":18.5,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":1,"smoking_pack_years":25,"primary_tumor_size_cm":5.1,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":17.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.932032+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_965200","record_id":"REC_0008434","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":85,"sex":"female","ecog_performance_status":2,"smoking_pack_years":45,"primary_tumor_size_cm":4.1,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.932363+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_381112","record_id":"REC_0008435","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":33,"tmb_mutations_per_mb":11.5,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":4.4,"metastatic_sites_count":3,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":7.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.932609+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_110603","record_id":"REC_0008436","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":20,"tmb_mutations_per_mb":4.3,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":0,"smoking_pack_years":44,"primary_tumor_size_cm":4.5,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":5.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.932846+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_553546","record_id":"REC_0008437","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":9.9,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":4.8,"metastatic_sites_count":8,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.933078+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_352185","record_id":"REC_0008438","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":18.3,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":25,"primary_tumor_size_cm":6.3,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.933367+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_976791","record_id":"REC_0008439","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":4.5,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":5.7,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":18.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.933605+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_859404","record_id":"REC_0008440","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":7.9,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":20.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.933840+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_454747","record_id":"REC_0008441","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":86,"sex":"female","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":4.7,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":24.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.934070+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_683451","record_id":"REC_0008442","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":5.3,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":25,"primary_tumor_size_cm":4.3,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.934300+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_904333","record_id":"REC_0008443","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":4.8,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.934538+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_728699","record_id":"REC_0008444","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":3,"smoking_pack_years":14,"primary_tumor_size_cm":6.3,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.934772+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_509285","record_id":"REC_0008445","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":7.2,"metastatic_sites_count":9,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.935004+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_771151","record_id":"REC_0008446","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":6.7,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":17.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.935238+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_291421","record_id":"REC_0008447","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":83,"sex":"female","ecog_performance_status":2,"smoking_pack_years":23,"primary_tumor_size_cm":4.7,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.935472+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_596242","record_id":"REC_0008448","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":13.8,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":5.8,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.935708+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_182209","record_id":"REC_0008449","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":2,"smoking_pack_years":21,"primary_tumor_size_cm":6.4,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":22.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.935941+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_830025","record_id":"REC_0008450","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":14.9,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":5.4,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.936415+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_806892","record_id":"REC_0008451","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":15.6,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":3.4,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.936721+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_172256","record_id":"REC_0008452","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":1,"smoking_pack_years":26,"primary_tumor_size_cm":5.0,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":23.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.936970+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_842632","record_id":"REC_0008453","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":9.5,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":6.2,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":18.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.937209+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_578222","record_id":"REC_0008454","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":78,"sex":"male","ecog_performance_status":3,"smoking_pack_years":8,"primary_tumor_size_cm":6.7,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":17.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.937453+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_790193","record_id":"REC_0008455","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":16,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":50,"primary_tumor_size_cm":3.7,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.937688+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_734796","record_id":"REC_0008456","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":13.1,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":6,"primary_tumor_size_cm":6.8,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":17.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.937923+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_548022","record_id":"REC_0008457","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":5.2,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":7.6,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.938150+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_766920","record_id":"REC_0008458","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":13.3,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":5.2,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.938387+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_135538","record_id":"REC_0008459","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":8.6,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":6.8,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.938620+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_878326","record_id":"REC_0008460","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":6.0,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":2,"smoking_pack_years":59,"primary_tumor_size_cm":4.0,"metastatic_sites_count":8,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":4.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.938851+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_527161","record_id":"REC_0008461","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":9.7,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":2,"smoking_pack_years":22,"primary_tumor_size_cm":4.8,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.939082+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_232477","record_id":"REC_0008462","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":33,"tmb_mutations_per_mb":10.3,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":59,"primary_tumor_size_cm":4.1,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.939314+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_566566","record_id":"REC_0008463","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":19,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":32,"primary_tumor_size_cm":5.7,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":22.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.939550+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_909344","record_id":"REC_0008464","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":5.3,"age_at_diagnosis":85,"sex":"female","ecog_performance_status":1,"smoking_pack_years":93,"primary_tumor_size_cm":6.2,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.939821+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_327565","record_id":"REC_0008465","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":14.9,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":5.0,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.940061+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_625379","record_id":"REC_0008466","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":10.0,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":6.8,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.940329+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_713809","record_id":"REC_0008467","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":19,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":35,"primary_tumor_size_cm":4.3,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":18.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.940559+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_712625","record_id":"REC_0008468","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":14,"tmb_mutations_per_mb":13.6,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":4.6,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.940794+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_551519","record_id":"REC_0008469","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":4.6,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.941029+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_321924","record_id":"REC_0008470","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":15.2,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":6.6,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.941262+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_709508","record_id":"REC_0008471","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":8.1,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":5.7,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.941496+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_511064","record_id":"REC_0008472","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":34,"primary_tumor_size_cm":5.1,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.941727+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_557599","record_id":"REC_0008473","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":4,"smoking_pack_years":10,"primary_tumor_size_cm":5.5,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.941958+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_222669","record_id":"REC_0008474","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":31,"tmb_mutations_per_mb":15.0,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":6.9,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.942192+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_744805","record_id":"REC_0008475","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":16,"tmb_mutations_per_mb":15.1,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":4.6,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":6.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.942426+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_206263","record_id":"REC_0008476","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":3.9,"age_at_diagnosis":79,"sex":"male","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":3.5,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":22.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.942658+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_435166","record_id":"REC_0008477","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":32,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":25,"primary_tumor_size_cm":5.2,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":6.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.942938+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_165420","record_id":"REC_0008478","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":11.1,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":4.6,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":34.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.943174+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_783278","record_id":"REC_0008479","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":51,"sex":"male","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":5.3,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.943406+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_394827","record_id":"REC_0008480","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":35,"tmb_mutations_per_mb":17.8,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":4.1,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.943641+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_862206","record_id":"REC_0008481","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":33,"tmb_mutations_per_mb":10.1,"age_at_diagnosis":76,"sex":"male","ecog_performance_status":3,"smoking_pack_years":28,"primary_tumor_size_cm":7.8,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":48.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.943877+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_108165","record_id":"REC_0008482","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":2,"primary_tumor_size_cm":6.3,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.944140+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_544121","record_id":"REC_0008483","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":16.9,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":5.8,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":62.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.944385+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_698347","record_id":"REC_0008484","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":19,"tmb_mutations_per_mb":3.8,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":1,"smoking_pack_years":43,"primary_tumor_size_cm":5.9,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":30.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.944618+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_777739","record_id":"REC_0008485","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":8.0,"age_at_diagnosis":74,"sex":"male","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":5.9,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":18.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.944851+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_879273","record_id":"REC_0008486","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":10.3,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":5.4,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.945084+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_460118","record_id":"REC_0008487","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":32,"tmb_mutations_per_mb":15.0,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":7.0,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.945318+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_698134","record_id":"REC_0008488","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":1.5,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":25,"primary_tumor_size_cm":6.3,"metastatic_sites_count":3,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.945547+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_461595","record_id":"REC_0008489","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":75,"sex":"male","ecog_performance_status":2,"smoking_pack_years":27,"primary_tumor_size_cm":6.7,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":17.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.945777+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_235933","record_id":"REC_0008490","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":15.6,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":6.6,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.946061+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_693608","record_id":"REC_0008491","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":34,"tmb_mutations_per_mb":16.4,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":0,"smoking_pack_years":33,"primary_tumor_size_cm":6.5,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.946303+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_329743","record_id":"REC_0008492","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":6.6,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.946535+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_489533","record_id":"REC_0008493","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":16.5,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":4.8,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.946766+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_788125","record_id":"REC_0008494","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":8.3,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":3.5,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.946997+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_712205","record_id":"REC_0008495","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":20,"primary_tumor_size_cm":4.2,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":5.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.947232+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_386582","record_id":"REC_0008496","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":10.3,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":46,"primary_tumor_size_cm":6.2,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":4.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.947466+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_863974","record_id":"REC_0008497","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":15.6,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":4.4,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.947698+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_356185","record_id":"REC_0008498","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":7.4,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":1,"primary_tumor_size_cm":4.8,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":19.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.947929+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_818197","record_id":"REC_0008499","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":86,"sex":"female","ecog_performance_status":1,"smoking_pack_years":27,"primary_tumor_size_cm":5.6,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.948210+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_723893","record_id":"REC_0008500","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":4.2,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.948459+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_806489","record_id":"REC_0008501","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":34,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":49,"sex":"male","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":5.1,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":17.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.948699+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_227014","record_id":"REC_0008502","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":7.2,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":17.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.948931+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_535135","record_id":"REC_0008503","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":4.8,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":41,"primary_tumor_size_cm":7.2,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":16.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.949206+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_922344","record_id":"REC_0008504","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":4.7,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.949445+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_916843","record_id":"REC_0008505","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":3.6,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":43,"primary_tumor_size_cm":5.9,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":6.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.949677+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_336814","record_id":"REC_0008506","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":17.1,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":6.0,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.949912+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_982620","record_id":"REC_0008507","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":54,"sex":"female","ecog_performance_status":0,"smoking_pack_years":60,"primary_tumor_size_cm":6.1,"metastatic_sites_count":8,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.950146+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_176568","record_id":"REC_0008508","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":7.7,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":31.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.950377+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_590550","record_id":"REC_0008509","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":5.0,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":40,"primary_tumor_size_cm":6.4,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":23.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.950606+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_793101","record_id":"REC_0008510","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":39,"tmb_mutations_per_mb":13.5,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":7.4,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.950840+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_766477","record_id":"REC_0008511","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":9.0,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":6.7,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.951067+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_473473","record_id":"REC_0008512","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":6.1,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":7.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.951298+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_946198","record_id":"REC_0008513","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":54,"sex":"male","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":4.5,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":52.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.951530+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_994010","record_id":"REC_0008514","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":4.5,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.951767+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_883703","record_id":"REC_0008515","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":3.7,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":3.6,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.952001+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_837827","record_id":"REC_0008516","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":18.9,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":3.9,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.952303+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_357099","record_id":"REC_0008517","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":15.6,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":5.1,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":22.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.952543+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_827043","record_id":"REC_0008518","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":7.9,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":7.5,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":26.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.952772+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_645204","record_id":"REC_0008519","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":19,"tmb_mutations_per_mb":9.8,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":7.1,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":4.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.953007+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_279734","record_id":"REC_0008520","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":22,"primary_tumor_size_cm":4.4,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.953238+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_751175","record_id":"REC_0008521","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":4.5,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.953478+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_955501","record_id":"REC_0008522","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":9.0,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":6.8,"metastatic_sites_count":3,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.953710+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_826635","record_id":"REC_0008523","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":31,"tmb_mutations_per_mb":14.6,"age_at_diagnosis":53,"sex":"male","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":8.8,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.953942+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_556214","record_id":"REC_0008524","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":83,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":5.2,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.954173+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_380150","record_id":"REC_0008525","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":8.6,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":4.7,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.954405+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_172669","record_id":"REC_0008526","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":18.6,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":4,"smoking_pack_years":16,"primary_tumor_size_cm":5.6,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.954636+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_311558","record_id":"REC_0008527","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":13.5,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":4.7,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.954867+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_991672","record_id":"REC_0008528","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":4.4,"metastatic_sites_count":3,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.955094+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_225894","record_id":"REC_0008529","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":8.3,"age_at_diagnosis":88,"sex":"male","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":2.4,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.955369+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_526552","record_id":"REC_0008530","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":7.4,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.955609+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_207042","record_id":"REC_0008531","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":15,"tmb_mutations_per_mb":13.1,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":0,"smoking_pack_years":26,"primary_tumor_size_cm":5.9,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.955847+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_550709","record_id":"REC_0008532","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":5.6,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":5.3,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":22.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.956190+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_641662","record_id":"REC_0008533","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":32,"tmb_mutations_per_mb":5.5,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":31,"primary_tumor_size_cm":4.4,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":17.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.956435+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_216406","record_id":"REC_0008534","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":15.0,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":5.0,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.956675+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_966067","record_id":"REC_0008535","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":18,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":4.5,"metastatic_sites_count":3,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":20.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.956909+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_623000","record_id":"REC_0008536","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":3,"smoking_pack_years":23,"primary_tumor_size_cm":6.5,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.957139+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_532029","record_id":"REC_0008537","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":7.6,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":26,"primary_tumor_size_cm":5.6,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.957373+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_404779","record_id":"REC_0008538","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":11.0,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":6.9,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.957607+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_839139","record_id":"REC_0008539","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":16.5,"age_at_diagnosis":75,"sex":"male","ecog_performance_status":2,"smoking_pack_years":6,"primary_tumor_size_cm":7.4,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.957839+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_932060","record_id":"REC_0008540","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":51,"sex":"female","ecog_performance_status":0,"smoking_pack_years":5,"primary_tumor_size_cm":4.9,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.958074+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_500234","record_id":"REC_0008541","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":21,"primary_tumor_size_cm":3.5,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.958308+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_886468","record_id":"REC_0008542","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":14.8,"age_at_diagnosis":52,"sex":"male","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":3.5,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":6.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.958587+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_466160","record_id":"REC_0008543","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":30,"tmb_mutations_per_mb":13.1,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":5.2,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":20.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.958825+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_347348","record_id":"REC_0008544","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":9.0,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.1,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":5.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.959054+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_685833","record_id":"REC_0008545","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":16.5,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":8.1,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.959289+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_867753","record_id":"REC_0008546","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":2,"smoking_pack_years":10,"primary_tumor_size_cm":6.8,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.959515+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_263952","record_id":"REC_0008547","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":5.0,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":26.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.959751+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_624958","record_id":"REC_0008548","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":16,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":4,"primary_tumor_size_cm":6.6,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":4.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.959980+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_702187","record_id":"REC_0008549","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":16,"tmb_mutations_per_mb":13.5,"age_at_diagnosis":75,"sex":"male","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.9,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.960276+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_641427","record_id":"REC_0008550","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":5.6,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.960520+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_956158","record_id":"REC_0008551","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":19,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":7.3,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.960758+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_873145","record_id":"REC_0008552","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":13.8,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":2,"smoking_pack_years":20,"primary_tumor_size_cm":6.9,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":7.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.960988+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_706210","record_id":"REC_0008553","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":5.1,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.961220+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_850938","record_id":"REC_0008554","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":2.5,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.961453+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_149059","record_id":"REC_0008555","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":9.8,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":4.3,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.961738+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_380225","record_id":"REC_0008556","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":3,"smoking_pack_years":10,"primary_tumor_size_cm":3.5,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.961975+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_478097","record_id":"REC_0008557","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":49,"primary_tumor_size_cm":5.0,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.962206+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_825110","record_id":"REC_0008558","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":7.3,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":52,"primary_tumor_size_cm":7.7,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":5.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.962433+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_129203","record_id":"REC_0008559","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":20,"tmb_mutations_per_mb":3.6,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":0,"smoking_pack_years":26,"primary_tumor_size_cm":6.8,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":6.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.962665+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_275284","record_id":"REC_0008560","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":15,"tmb_mutations_per_mb":18.6,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":4.8,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":18.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.962898+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_985825","record_id":"REC_0008561","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":33,"tmb_mutations_per_mb":18.9,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":5.1,"metastatic_sites_count":3,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":4.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.963134+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_986414","record_id":"REC_0008562","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":20,"tmb_mutations_per_mb":4.6,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":1,"smoking_pack_years":36,"primary_tumor_size_cm":6.0,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":19.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.963360+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_146918","record_id":"REC_0008563","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":30,"tmb_mutations_per_mb":4.0,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":1,"smoking_pack_years":45,"primary_tumor_size_cm":4.9,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":16.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.963595+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_588579","record_id":"REC_0008564","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":6.7,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":6.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.963826+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_720516","record_id":"REC_0008565","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":9.5,"age_at_diagnosis":85,"sex":"female","ecog_performance_status":1,"smoking_pack_years":28,"primary_tumor_size_cm":5.2,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.964052+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_190946","record_id":"REC_0008566","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":20,"tmb_mutations_per_mb":8.5,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":32,"primary_tumor_size_cm":7.8,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.964335+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_187154","record_id":"REC_0008567","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":5.9,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.964572+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_451460","record_id":"REC_0008568","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":15.7,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":4.4,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":17.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.964872+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_850936","record_id":"REC_0008569","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":5.6,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.965109+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_245299","record_id":"REC_0008570","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":5.5,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.965342+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_253290","record_id":"REC_0008571","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":5.9,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.965572+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_948259","record_id":"REC_0008572","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":2,"smoking_pack_years":7,"primary_tumor_size_cm":3.0,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.965806+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_756024","record_id":"REC_0008573","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":1.9,"age_at_diagnosis":54,"sex":"female","ecog_performance_status":0,"smoking_pack_years":42,"primary_tumor_size_cm":6.0,"metastatic_sites_count":3,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.966036+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_116268","record_id":"REC_0008574","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":5.2,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.966266+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_486685","record_id":"REC_0008575","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":7.4,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":5.4,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.966499+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_544477","record_id":"REC_0008576","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":8.6,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":3,"primary_tumor_size_cm":5.9,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.966727+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_519389","record_id":"REC_0008577","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":13.3,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":6.3,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.966963+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_923969","record_id":"REC_0008578","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":18.6,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.5,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":21.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.967196+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_835851","record_id":"REC_0008579","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":4.4,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":40,"primary_tumor_size_cm":8.2,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.967428+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_660998","record_id":"REC_0008580","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":2.8,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":7.8,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.967661+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_110311","record_id":"REC_0008581","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":4.2,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":33,"primary_tumor_size_cm":4.3,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":18.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.967945+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_944014","record_id":"REC_0008582","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":8.3,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":5,"primary_tumor_size_cm":5.2,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":18.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.968271+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_822312","record_id":"REC_0008583","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":8.3,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":5.0,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":19.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.968508+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_766264","record_id":"REC_0008584","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":7.9,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":4.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.968744+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_515172","record_id":"REC_0008585","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":0,"primary_tumor_size_cm":6.0,"metastatic_sites_count":3,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.968980+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_239706","record_id":"REC_0008586","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":18.6,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":3,"smoking_pack_years":13,"primary_tumor_size_cm":6.0,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":25.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.969214+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_711604","record_id":"REC_0008587","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":7.2,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.969444+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_664463","record_id":"REC_0008588","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":40,"primary_tumor_size_cm":3.3,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.969675+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_274274","record_id":"REC_0008589","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":19.5,"age_at_diagnosis":54,"sex":"male","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":6.7,"metastatic_sites_count":8,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.969911+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_190176","record_id":"REC_0008590","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":5.3,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.970146+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_939938","record_id":"REC_0008591","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":11.0,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":26,"primary_tumor_size_cm":5.4,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":21.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.970383+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_490836","record_id":"REC_0008592","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":2.8,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":3,"smoking_pack_years":0,"primary_tumor_size_cm":7.1,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":23.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.970610+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_251763","record_id":"REC_0008593","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":31,"tmb_mutations_per_mb":6.4,"age_at_diagnosis":54,"sex":"male","ecog_performance_status":0,"smoking_pack_years":31,"primary_tumor_size_cm":5.5,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.970841+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_317888","record_id":"REC_0008594","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":11.0,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":5.3,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":4.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.971120+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_533461","record_id":"REC_0008595","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":6.8,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.971357+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_791869","record_id":"REC_0008596","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":84,"sex":"female","ecog_performance_status":1,"smoking_pack_years":47,"primary_tumor_size_cm":8.2,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.971585+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_634624","record_id":"REC_0008597","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":32,"tmb_mutations_per_mb":4.5,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":35,"primary_tumor_size_cm":5.1,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.971820+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_455927","record_id":"REC_0008598","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":13.8,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":27,"primary_tumor_size_cm":5.2,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":6.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.972051+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_188309","record_id":"REC_0008599","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":6.7,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":7.2,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.972325+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_712416","record_id":"REC_0008600","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":6.1,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":45,"primary_tumor_size_cm":5.7,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.972572+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_400565","record_id":"REC_0008601","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":18,"tmb_mutations_per_mb":17.1,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.0,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.972806+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_337641","record_id":"REC_0008602","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":15.1,"age_at_diagnosis":85,"sex":"female","ecog_performance_status":2,"smoking_pack_years":7,"primary_tumor_size_cm":4.8,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":37.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.973036+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_410656","record_id":"REC_0008603","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":25,"primary_tumor_size_cm":5.1,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.973275+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_478789","record_id":"REC_0008604","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":21.2,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":7.0,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.973510+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_868682","record_id":"REC_0008605","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":30,"tmb_mutations_per_mb":8.7,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":3.4,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.973738+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_390492","record_id":"REC_0008606","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":19.5,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":6.0,"metastatic_sites_count":3,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.973971+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_796827","record_id":"REC_0008607","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":6.0,"age_at_diagnosis":54,"sex":"male","ecog_performance_status":0,"smoking_pack_years":28,"primary_tumor_size_cm":3.4,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":16.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.974246+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_368872","record_id":"REC_0008608","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":3.2,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":27.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.974479+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_943569","record_id":"REC_0008609","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":7,"primary_tumor_size_cm":7.4,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.974710+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_679796","record_id":"REC_0008610","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":18,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":5.2,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":5.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.974945+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_605375","record_id":"REC_0008611","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":79,"sex":"male","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":6.8,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.975179+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_806634","record_id":"REC_0008612","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":84,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":6.3,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.975411+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_801681","record_id":"REC_0008613","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":15.4,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":7.5,"metastatic_sites_count":3,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.975643+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_820430","record_id":"REC_0008614","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":3.6,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":3,"smoking_pack_years":12,"primary_tumor_size_cm":4.9,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.975874+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_286620","record_id":"REC_0008615","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":14.6,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":4.5,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.976195+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_604805","record_id":"REC_0008616","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":0,"smoking_pack_years":24,"primary_tumor_size_cm":4.0,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.976433+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_304015","record_id":"REC_0008617","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":19,"tmb_mutations_per_mb":8.3,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":5.7,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.976664+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_557833","record_id":"REC_0008618","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":13.6,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":3.8,"metastatic_sites_count":9,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.976899+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_795695","record_id":"REC_0008619","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":20,"tmb_mutations_per_mb":3.9,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":24,"primary_tumor_size_cm":6.5,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.977129+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_941525","record_id":"REC_0008620","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":8.0,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":5.5,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.977404+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_148670","record_id":"REC_0008621","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":11.0,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":6.9,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":8.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.977643+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_276009","record_id":"REC_0008622","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":5.3,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.977874+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_623220","record_id":"REC_0008623","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":33,"tmb_mutations_per_mb":3.5,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":50,"primary_tumor_size_cm":4.2,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.978106+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_502006","record_id":"REC_0008624","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":4.3,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.978339+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_574633","record_id":"REC_0008625","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":16.7,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":6.0,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.978575+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_345816","record_id":"REC_0008626","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":4.9,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":37,"primary_tumor_size_cm":4.9,"metastatic_sites_count":8,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":7.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.978803+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_510699","record_id":"REC_0008627","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":6.1,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":0,"smoking_pack_years":46,"primary_tumor_size_cm":6.6,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":16.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.979035+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_919147","record_id":"REC_0008628","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":3.9,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":24,"primary_tumor_size_cm":6.4,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":5.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.979268+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_408162","record_id":"REC_0008629","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":30,"tmb_mutations_per_mb":4.2,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":1,"smoking_pack_years":67,"primary_tumor_size_cm":6.3,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.979500+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_383912","record_id":"REC_0008630","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":11,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.6,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.979735+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_694129","record_id":"REC_0008631","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":38,"tmb_mutations_per_mb":11.0,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":5.1,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":18.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.979966+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_882768","record_id":"REC_0008632","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":30,"tmb_mutations_per_mb":4.4,"age_at_diagnosis":83,"sex":"female","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":5.9,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.980217+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_776169","record_id":"REC_0008633","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":13.8,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":6.4,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.980499+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_907637","record_id":"REC_0008634","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":8.3,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":63,"primary_tumor_size_cm":7.3,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":21.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.980730+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_110401","record_id":"REC_0008635","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":4.3,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":92,"primary_tumor_size_cm":5.7,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.980959+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_638426","record_id":"REC_0008636","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":35,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":6.6,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.981196+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_942131","record_id":"REC_0008637","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":14.0,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":7.8,"metastatic_sites_count":8,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.981430+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_160039","record_id":"REC_0008638","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":14.0,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":6.5,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":30.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.981664+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_542979","record_id":"REC_0008639","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":2.2,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":1,"smoking_pack_years":76,"primary_tumor_size_cm":6.3,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":18.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.981895+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_274735","record_id":"REC_0008640","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":10.0,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":20,"primary_tumor_size_cm":7.3,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.982126+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_490081","record_id":"REC_0008641","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":16.6,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":4.7,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":19.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.982361+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_451274","record_id":"REC_0008642","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":15.4,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":5.8,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.982593+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_988909","record_id":"REC_0008643","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":24,"primary_tumor_size_cm":5.9,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.982821+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_124187","record_id":"REC_0008644","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":24,"primary_tumor_size_cm":6.1,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":7.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.983051+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_324318","record_id":"REC_0008645","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":18,"tmb_mutations_per_mb":15.6,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":3.0,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.983283+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_901992","record_id":"REC_0008646","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":9.0,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":2,"smoking_pack_years":27,"primary_tumor_size_cm":4.7,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.983555+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_144104","record_id":"REC_0008647","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":3.1,"age_at_diagnosis":84,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":3.3,"metastatic_sites_count":8,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.983785+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_507398","record_id":"REC_0008648","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":51,"sex":"male","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":5.9,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":36.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.984018+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_804008","record_id":"REC_0008649","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":13.6,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":6.8,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.984302+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_770543","record_id":"REC_0008650","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":6.3,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":34.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.984552+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_802467","record_id":"REC_0008651","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":5.1,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":34,"primary_tumor_size_cm":3.4,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.984782+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_189198","record_id":"REC_0008652","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":3.9,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":1,"smoking_pack_years":50,"primary_tumor_size_cm":6.9,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.985013+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_346501","record_id":"REC_0008653","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":6.4,"metastatic_sites_count":8,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.985252+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_448714","record_id":"REC_0008654","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":30,"tmb_mutations_per_mb":6.1,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":5.5,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.985483+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_555331","record_id":"REC_0008655","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":10.0,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":24,"primary_tumor_size_cm":7.2,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.985720+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_352553","record_id":"REC_0008656","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":14.6,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":1,"smoking_pack_years":3,"primary_tumor_size_cm":5.9,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.985955+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_944528","record_id":"REC_0008657","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":14.3,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":4.9,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.986194+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_151811","record_id":"REC_0008658","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":22,"primary_tumor_size_cm":4.1,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":6.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.986425+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_448001","record_id":"REC_0008659","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":13.5,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":7.1,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":46.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.986702+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_986387","record_id":"REC_0008660","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":49,"sex":"male","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":5.4,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.986939+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_903718","record_id":"REC_0008661","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":16,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":4.2,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.987176+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_234802","record_id":"REC_0008662","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":6.3,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.987412+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_381654","record_id":"REC_0008663","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":19.2,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":7.4,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.987647+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_855532","record_id":"REC_0008664","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":84,"sex":"female","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":3.2,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.987883+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_202391","record_id":"REC_0008665","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":5.6,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":64,"primary_tumor_size_cm":8.1,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.988140+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_916293","record_id":"REC_0008666","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":7.0,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.988377+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_570871","record_id":"REC_0008667","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":21,"primary_tumor_size_cm":4.4,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":6.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.988609+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_707540","record_id":"REC_0008668","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":10.1,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":5.3,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.988845+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_956265","record_id":"REC_0008669","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":31,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":1,"smoking_pack_years":66,"primary_tumor_size_cm":4.9,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.989074+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_259357","record_id":"REC_0008670","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":6.1,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.989311+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_702169","record_id":"REC_0008671","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":6.6,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.989543+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_257079","record_id":"REC_0008672","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":17.9,"age_at_diagnosis":75,"sex":"male","ecog_performance_status":0,"smoking_pack_years":26,"primary_tumor_size_cm":4.9,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.989826+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_822290","record_id":"REC_0008673","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":20,"tmb_mutations_per_mb":4.6,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":5.4,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.990057+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_132766","record_id":"REC_0008674","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":68,"primary_tumor_size_cm":6.8,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":23.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.990290+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_355738","record_id":"REC_0008675","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":17.0,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":7.1,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.990522+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_907091","record_id":"REC_0008676","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":4.7,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":17.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.990757+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_320229","record_id":"REC_0008677","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":8.6,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":10,"primary_tumor_size_cm":4.2,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":60.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.990987+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_438528","record_id":"REC_0008678","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":18,"tmb_mutations_per_mb":15.1,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":23,"primary_tumor_size_cm":8.3,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":7.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.991220+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_321983","record_id":"REC_0008679","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":13.5,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":4.5,"metastatic_sites_count":8,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.991454+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_394163","record_id":"REC_0008680","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":9.9,"age_at_diagnosis":51,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":7.2,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":20.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.991688+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_987083","record_id":"REC_0008681","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":8.0,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":7.4,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.991917+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_845535","record_id":"REC_0008682","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":15.5,"age_at_diagnosis":86,"sex":"female","ecog_performance_status":1,"smoking_pack_years":25,"primary_tumor_size_cm":6.3,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.992180+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_703135","record_id":"REC_0008683","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":19,"tmb_mutations_per_mb":7.4,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":9,"primary_tumor_size_cm":4.8,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.992412+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_989188","record_id":"REC_0008684","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":7.6,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":5.8,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.992644+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_177204","record_id":"REC_0008685","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":81,"sex":"male","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":7.2,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":20.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.992928+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_892616","record_id":"REC_0008686","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":16,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":85,"sex":"female","ecog_performance_status":2,"smoking_pack_years":24,"primary_tumor_size_cm":5.8,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.993171+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_312596","record_id":"REC_0008687","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":16,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":4.8,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.993410+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_396453","record_id":"REC_0008688","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":5.1,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":23.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.993642+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_535683","record_id":"REC_0008689","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":52,"sex":"male","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":6.6,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.993874+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_861650","record_id":"REC_0008690","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":33,"tmb_mutations_per_mb":15.0,"age_at_diagnosis":87,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":6.1,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":22.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.994105+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_211012","record_id":"REC_0008691","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":54,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":6.1,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":21.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.994339+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_557283","record_id":"REC_0008692","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":51,"primary_tumor_size_cm":6.5,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":30.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.994571+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_765345","record_id":"REC_0008693","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":18.4,"age_at_diagnosis":78,"sex":"male","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":6.8,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.994808+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_462317","record_id":"REC_0008694","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":8.0,"age_at_diagnosis":54,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":5.2,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.995041+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_873934","record_id":"REC_0008695","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":23.7,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":1,"smoking_pack_years":32,"primary_tumor_size_cm":4.5,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.995277+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_176546","record_id":"REC_0008696","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.3,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":16.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.995508+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_702551","record_id":"REC_0008697","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None","pd_l1_tps_percent":20,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":67,"primary_tumor_size_cm":4.6,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":22.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.995735+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_533220","record_id":"REC_0008698","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":1,"smoking_pack_years":61,"primary_tumor_size_cm":5.1,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":19.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.996009+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_174182","record_id":"REC_0008699","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":7.6,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":51,"primary_tumor_size_cm":6.8,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.996350+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_540758","record_id":"REC_0008700","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":4.1,"metastatic_sites_count":9,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.996609+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_877256","record_id":"REC_0008701","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":83,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":7.5,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.996852+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_175653","record_id":"REC_0008702","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":14.7,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":4.5,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.997090+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_256379","record_id":"REC_0008703","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":18,"tmb_mutations_per_mb":16.5,"age_at_diagnosis":83,"sex":"female","ecog_performance_status":2,"smoking_pack_years":10,"primary_tumor_size_cm":4.7,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.997328+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_378661","record_id":"REC_0008704","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":6.7,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.997564+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_365622","record_id":"REC_0008705","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":29,"primary_tumor_size_cm":4.8,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.997795+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_890404","record_id":"REC_0008706","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":2.9,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.998033+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_892099","record_id":"REC_0008707","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":16.0,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":7.5,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.998268+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_493458","record_id":"REC_0008708","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":19.0,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":5.4,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.998498+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_155481","record_id":"REC_0008709","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":13,"tmb_mutations_per_mb":14.3,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":5.2,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":18.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.998734+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_202620","record_id":"REC_0008710","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":31,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":4.7,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.998959+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_350993","record_id":"REC_0008711","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":5.2,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":69,"primary_tumor_size_cm":5.4,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":20.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.999238+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_532889","record_id":"REC_0008712","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":74,"sex":"male","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":5.8,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.999474+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_854395","record_id":"REC_0008713","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":6.4,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:58.999703+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_567637","record_id":"REC_0008714","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":3,"smoking_pack_years":9,"primary_tumor_size_cm":6.6,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:58.999939+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_948405","record_id":"REC_0008715","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":15,"tmb_mutations_per_mb":14.9,"age_at_diagnosis":46,"sex":"male","ecog_performance_status":0,"smoking_pack_years":24,"primary_tumor_size_cm":4.0,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.000202+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_113551","record_id":"REC_0008716","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":36,"tmb_mutations_per_mb":13.6,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":5.3,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.000437+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_852622","record_id":"REC_0008717","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":4.5,"age_at_diagnosis":53,"sex":"female","ecog_performance_status":0,"smoking_pack_years":57,"primary_tumor_size_cm":7.7,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.000669+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_156164","record_id":"REC_0008718","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":5.7,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.000904+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_769800","record_id":"REC_0008719","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":5.1,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":1,"smoking_pack_years":24,"primary_tumor_size_cm":8.6,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":23.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.001140+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_924114","record_id":"REC_0008720","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":32,"tmb_mutations_per_mb":14.4,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":6.2,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":4.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.001377+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_873583","record_id":"REC_0008721","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":4.4,"age_at_diagnosis":52,"sex":"male","ecog_performance_status":0,"smoking_pack_years":49,"primary_tumor_size_cm":4.6,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.001610+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_662979","record_id":"REC_0008722","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":16.8,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":2.0,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":17.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.001849+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_173376","record_id":"REC_0008723","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":5.7,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":5.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.002085+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_805402","record_id":"REC_0008724","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":5,"primary_tumor_size_cm":6.6,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":19.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.002367+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_844259","record_id":"REC_0008725","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":4.2,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":5.7,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.002604+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_657830","record_id":"REC_0008726","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":3.9,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.003086+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_222918","record_id":"REC_0008727","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":3,"smoking_pack_years":17,"primary_tumor_size_cm":5.0,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.003336+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_370181","record_id":"REC_0008728","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":19,"tmb_mutations_per_mb":14.6,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":4.7,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":8.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.003586+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_449021","record_id":"REC_0008729","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":35,"tmb_mutations_per_mb":4.6,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":39,"primary_tumor_size_cm":7.6,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.003821+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_690264","record_id":"REC_0008730","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":9.0,"age_at_diagnosis":86,"sex":"female","ecog_performance_status":2,"smoking_pack_years":20,"primary_tumor_size_cm":5.3,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":19.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.004053+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_237223","record_id":"REC_0008731","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":5.6,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":5.5,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.004321+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_951836","record_id":"REC_0008732","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":15.0,"age_at_diagnosis":49,"sex":"male","ecog_performance_status":0,"smoking_pack_years":3,"primary_tumor_size_cm":6.3,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.004557+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_946633","record_id":"REC_0008733","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":16.4,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":6.6,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.004791+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_878744","record_id":"REC_0008734","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":8.6,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":5.8,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":40.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.005030+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_360124","record_id":"REC_0008735","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":2,"smoking_pack_years":9,"primary_tumor_size_cm":6.8,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.005269+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_938065","record_id":"REC_0008736","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":3.7,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":6.0,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":16.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.005506+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_705597","record_id":"REC_0008737","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":13.1,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":6.6,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.005815+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_686248","record_id":"REC_0008738","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":3.6,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":19.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.006056+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_411620","record_id":"REC_0008739","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":55,"primary_tumor_size_cm":6.5,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.006287+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_508536","record_id":"REC_0008740","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":31,"tmb_mutations_per_mb":17.0,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":6.2,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.006521+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_255314","record_id":"REC_0008741","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":6.3,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":7.5,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":4.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.006757+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_114856","record_id":"REC_0008742","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":6.1,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":53,"primary_tumor_size_cm":6.0,"metastatic_sites_count":3,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.006986+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_748918","record_id":"REC_0008743","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":34,"tmb_mutations_per_mb":10.5,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":5.6,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.007219+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_731028","record_id":"REC_0008744","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":4.5,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.007454+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_262246","record_id":"REC_0008745","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":32,"tmb_mutations_per_mb":4.5,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":58,"primary_tumor_size_cm":5.0,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":7.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.007682+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_176115","record_id":"REC_0008746","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":33,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":5.5,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":5.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.007920+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_259590","record_id":"REC_0008747","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":17.0,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":1,"smoking_pack_years":25,"primary_tumor_size_cm":4.1,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.008230+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_195435","record_id":"REC_0008748","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":45,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":4.2,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":20.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.008475+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_381878","record_id":"REC_0008749","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":6.0,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.008711+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_856247","record_id":"REC_0008750","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":4.0,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":22.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.008994+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_413786","record_id":"REC_0008751","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":4.9,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":7.5,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":16.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.009232+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_677990","record_id":"REC_0008752","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":17,"tmb_mutations_per_mb":19.9,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":4.4,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":4.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.009467+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_834594","record_id":"REC_0008753","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":32,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":6.0,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.009703+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_650806","record_id":"REC_0008754","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":15.9,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":24,"primary_tumor_size_cm":5.0,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.009936+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_734393","record_id":"REC_0008755","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":19,"tmb_mutations_per_mb":11.1,"age_at_diagnosis":86,"sex":"female","ecog_performance_status":2,"smoking_pack_years":21,"primary_tumor_size_cm":6.8,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.010171+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_692047","record_id":"REC_0008756","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":10.5,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":6.0,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.010404+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_417558","record_id":"REC_0008757","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":8.7,"age_at_diagnosis":53,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":5.5,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":6.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.010640+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_716858","record_id":"REC_0008758","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":19,"tmb_mutations_per_mb":6.4,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":0,"smoking_pack_years":47,"primary_tumor_size_cm":3.8,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":16.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.010876+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_945603","record_id":"REC_0008759","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":16.4,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":5.6,"metastatic_sites_count":9,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.011112+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_282753","record_id":"REC_0008760","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":0,"primary_tumor_size_cm":4.2,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":21.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.011393+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_671763","record_id":"REC_0008761","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":5.0,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":63,"primary_tumor_size_cm":5.9,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":6.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.011630+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_394576","record_id":"REC_0008762","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":7.9,"age_at_diagnosis":85,"sex":"female","ecog_performance_status":2,"smoking_pack_years":51,"primary_tumor_size_cm":3.0,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.011857+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_860322","record_id":"REC_0008763","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":16.4,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":6.2,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.012178+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_746552","record_id":"REC_0008764","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":6.2,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":4.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.012418+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_323477","record_id":"REC_0008765","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":15.8,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":4.5,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.012651+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_634569","record_id":"REC_0008766","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":9.8,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":5.5,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.012881+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_479443","record_id":"REC_0008767","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":4.7,"age_at_diagnosis":82,"sex":"male","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":4.1,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":16.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.013114+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_458990","record_id":"REC_0008768","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":4.4,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.013347+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_300290","record_id":"REC_0008769","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":8.5,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":5.7,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":17.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.013663+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_413807","record_id":"REC_0008770","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":4,"primary_tumor_size_cm":6.3,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.013901+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_345707","record_id":"REC_0008771","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":19,"tmb_mutations_per_mb":6.9,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":7.5,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.014135+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_753891","record_id":"REC_0008772","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":16.7,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":5.3,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.014366+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_613942","record_id":"REC_0008773","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":6.0,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":40,"primary_tumor_size_cm":3.9,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.014596+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_566740","record_id":"REC_0008774","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":6.4,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":4.2,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.014822+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_514613","record_id":"REC_0008775","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":13.1,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":5.7,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.015058+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_493513","record_id":"REC_0008776","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":5.6,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":41,"primary_tumor_size_cm":4.9,"metastatic_sites_count":3,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.015340+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_555157","record_id":"REC_0008777","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":13.3,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":6.1,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.015577+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_952516","record_id":"REC_0008778","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":14,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":6.2,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.015814+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_124792","record_id":"REC_0008779","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":9.9,"age_at_diagnosis":54,"sex":"female","ecog_performance_status":0,"smoking_pack_years":3,"primary_tumor_size_cm":7.4,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.016044+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_961773","record_id":"REC_0008780","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":30,"tmb_mutations_per_mb":8.5,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":67,"primary_tumor_size_cm":4.4,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.016384+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_617662","record_id":"REC_0008781","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":17,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":5.4,"metastatic_sites_count":9,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.016620+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_915884","record_id":"REC_0008782","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":14.4,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":4.9,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.016856+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_148985","record_id":"REC_0008783","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":3.9,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.017095+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_312409","record_id":"REC_0008784","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":14.0,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":6.4,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.017329+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_418542","record_id":"REC_0008785","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":31,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":5.7,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.017563+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_963651","record_id":"REC_0008786","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":3,"smoking_pack_years":16,"primary_tumor_size_cm":5.7,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":35.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.017788+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_206886","record_id":"REC_0008787","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":2.5,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":6.3,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.018025+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_750224","record_id":"REC_0008788","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":15.4,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":6.4,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.018258+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_367003","record_id":"REC_0008789","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":16.0,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":5,"primary_tumor_size_cm":4.0,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.018543+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_860978","record_id":"REC_0008790","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":4.3,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":19.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.018781+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_356296","record_id":"REC_0008791","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":19.1,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":4.1,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.019013+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_254071","record_id":"REC_0008792","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":8.7,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.8,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.019244+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_366307","record_id":"REC_0008793","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":8.3,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":3.8,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.019472+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_200735","record_id":"REC_0008794","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":16.3,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":5.1,"metastatic_sites_count":8,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":5.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.019701+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_354042","record_id":"REC_0008795","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":6.1,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":0,"smoking_pack_years":36,"primary_tumor_size_cm":8.7,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.019932+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_822603","record_id":"REC_0008796","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":16,"tmb_mutations_per_mb":16.3,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":4.8,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.020231+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_837737","record_id":"REC_0008797","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":5.3,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":17.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.020484+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_195756","record_id":"REC_0008798","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":16.0,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":26,"primary_tumor_size_cm":5.3,"metastatic_sites_count":3,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.020726+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_865634","record_id":"REC_0008799","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":18.1,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":4.2,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.020960+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_275966","record_id":"REC_0008800","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":17.9,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":10,"primary_tumor_size_cm":5.4,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":28.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.021195+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_841134","record_id":"REC_0008801","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":16.8,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":6.2,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.021428+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_114952","record_id":"REC_0008802","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":20.6,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":6.4,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.021720+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_697941","record_id":"REC_0008803","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":7.4,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.021960+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_224242","record_id":"REC_0008804","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":6.7,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.022192+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_236015","record_id":"REC_0008805","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":30,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":24,"primary_tumor_size_cm":4.2,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":48.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.022425+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_832114","record_id":"REC_0008806","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":14.1,"age_at_diagnosis":77,"sex":"male","ecog_performance_status":2,"smoking_pack_years":23,"primary_tumor_size_cm":6.0,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.022664+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_172436","record_id":"REC_0008807","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":37,"primary_tumor_size_cm":5.5,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.022893+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_872148","record_id":"REC_0008808","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":16.3,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":2.6,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.023132+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_857866","record_id":"REC_0008809","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.5,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":6.7,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.023370+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_910208","record_id":"REC_0008810","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":4.5,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":7.5,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.023604+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_518342","record_id":"REC_0008811","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":7.0,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":24.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.023836+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_538232","record_id":"REC_0008812","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":4.3,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":8.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.024067+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_990135","record_id":"REC_0008813","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":31,"tmb_mutations_per_mb":13.6,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":5.2,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.024340+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_246053","record_id":"REC_0008814","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":3.5,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":2,"smoking_pack_years":25,"primary_tumor_size_cm":6.7,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.024575+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_837565","record_id":"REC_0008815","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":24.9,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.1,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":24.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.024854+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_715472","record_id":"REC_0008816","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":19.5,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":4.2,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.025093+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_352007","record_id":"REC_0008817","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.9,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.025329+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_394929","record_id":"REC_0008818","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":4.6,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":28,"primary_tumor_size_cm":6.6,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.025556+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_561584","record_id":"REC_0008819","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":14.4,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":5.9,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":6.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.025792+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_539648","record_id":"REC_0008820","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":3.4,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.026026+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_562915","record_id":"REC_0008821","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":19.6,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":5.3,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.026260+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_888749","record_id":"REC_0008822","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":31,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":1,"smoking_pack_years":49,"primary_tumor_size_cm":7.2,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.026491+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_673736","record_id":"REC_0008823","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":32,"tmb_mutations_per_mb":10.5,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":6.5,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":18.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.026724+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_812242","record_id":"REC_0008824","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":19,"tmb_mutations_per_mb":13.5,"age_at_diagnosis":80,"sex":"male","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":5.4,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.026964+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_281621","record_id":"REC_0008825","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":15,"tmb_mutations_per_mb":8.5,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":4.2,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.027196+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_857750","record_id":"REC_0008826","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":32,"tmb_mutations_per_mb":5.3,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":45,"primary_tumor_size_cm":6.7,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.027427+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_680824","record_id":"REC_0008827","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":5.6,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":5.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.027658+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_644926","record_id":"REC_0008828","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":15,"tmb_mutations_per_mb":8.0,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":4.8,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.027926+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_745559","record_id":"REC_0008829","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":31,"primary_tumor_size_cm":7.8,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":16.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.028191+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_197778","record_id":"REC_0008830","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":20.2,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":6.6,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":17.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.028432+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_466029","record_id":"REC_0008831","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":8.0,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":22.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.028669+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_406083","record_id":"REC_0008832","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":15.2,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":28,"primary_tumor_size_cm":7.0,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":60.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.028903+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_514275","record_id":"REC_0008833","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":30,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":5.5,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.029138+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_514543","record_id":"REC_0008834","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":27,"primary_tumor_size_cm":6.3,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":6.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.029370+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_778528","record_id":"REC_0008835","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":13.5,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":5.0,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":6.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.029605+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_125381","record_id":"REC_0008836","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":3.4,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.029838+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_459632","record_id":"REC_0008837","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":15.7,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":6.2,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.030075+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_842992","record_id":"REC_0008838","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":15.6,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":23,"primary_tumor_size_cm":5.9,"metastatic_sites_count":8,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":16.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.030308+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_537917","record_id":"REC_0008839","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":11.5,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.4,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.030539+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_571891","record_id":"REC_0008840","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":0,"primary_tumor_size_cm":6.3,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.030767+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_349793","record_id":"REC_0008841","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":33,"tmb_mutations_per_mb":9.1,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":2,"smoking_pack_years":5,"primary_tumor_size_cm":4.9,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":18.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.031039+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_736173","record_id":"REC_0008842","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":67,"primary_tumor_size_cm":5.0,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.031273+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_919889","record_id":"REC_0008843","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":15,"tmb_mutations_per_mb":6.9,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":5.6,"metastatic_sites_count":3,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.031505+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_394015","record_id":"REC_0008844","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":3,"smoking_pack_years":8,"primary_tumor_size_cm":4.4,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.031733+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_334186","record_id":"REC_0008845","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":16,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.1,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.031965+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_124396","record_id":"REC_0008846","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":5.5,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":65,"primary_tumor_size_cm":5.0,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.032239+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_207852","record_id":"REC_0008847","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":3.3,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":36,"primary_tumor_size_cm":3.5,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":29.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.032489+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_182330","record_id":"REC_0008848","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":6.7,"metastatic_sites_count":8,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":6.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.032723+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_161321","record_id":"REC_0008849","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":15.1,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":4.8,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":21.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.032957+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_730396","record_id":"REC_0008850","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":6.2,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.033189+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_592780","record_id":"REC_0008851","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":4.3,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.033421+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_936156","record_id":"REC_0008852","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":13.5,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":2,"smoking_pack_years":9,"primary_tumor_size_cm":6.5,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.033651+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_671283","record_id":"REC_0008853","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":5.2,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":6.2,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":22.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.033886+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_336887","record_id":"REC_0008854","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":10.0,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":4.7,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":23.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.034161+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_929067","record_id":"REC_0008855","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":18.1,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":34,"primary_tumor_size_cm":5.5,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.034400+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_301732","record_id":"REC_0008856","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":7.8,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":23.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.034635+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_267435","record_id":"REC_0008857","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":20,"tmb_mutations_per_mb":3.6,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":54,"primary_tumor_size_cm":5.5,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.034865+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_482559","record_id":"REC_0008858","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":17.0,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":4.5,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.035099+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_244494","record_id":"REC_0008859","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":2.5,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":49,"primary_tumor_size_cm":2.8,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.035326+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_495002","record_id":"REC_0008860","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":13.5,"age_at_diagnosis":52,"sex":"male","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":8.7,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":23.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.035560+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_306163","record_id":"REC_0008861","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":30,"tmb_mutations_per_mb":7.4,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":6.5,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":42.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.035793+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_788070","record_id":"REC_0008862","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":13.3,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":6.5,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.036027+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_381404","record_id":"REC_0008863","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":4.2,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":38,"primary_tumor_size_cm":4.9,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":4.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.036359+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_800195","record_id":"REC_0008864","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":5.3,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.036604+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_817656","record_id":"REC_0008865","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":16,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":5.1,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":5.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.036851+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_881261","record_id":"REC_0008866","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":4.9,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.037094+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_275191","record_id":"REC_0008867","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":4.7,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":16.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.037692+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_739900","record_id":"REC_0008868","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":5.3,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.038122+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_149863","record_id":"REC_0008869","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":1,"smoking_pack_years":27,"primary_tumor_size_cm":4.5,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.038430+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_252918","record_id":"REC_0008870","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":17.1,"age_at_diagnosis":79,"sex":"male","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":5.6,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.038732+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_496703","record_id":"REC_0008871","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":5.7,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":1,"smoking_pack_years":64,"primary_tumor_size_cm":5.1,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":30.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.039011+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_827122","record_id":"REC_0008872","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":5.3,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":70,"primary_tumor_size_cm":7.1,"metastatic_sites_count":3,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":4.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.039277+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_480510","record_id":"REC_0008873","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":83,"sex":"female","ecog_performance_status":0,"smoking_pack_years":27,"primary_tumor_size_cm":3.5,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.039539+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_436605","record_id":"REC_0008874","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":15.9,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":6.3,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.039793+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_474361","record_id":"REC_0008875","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":6.7,"metastatic_sites_count":8,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.040049+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_495371","record_id":"REC_0008876","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":3.6,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.040402+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_763353","record_id":"REC_0008877","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":3.2,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":4.5,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.040696+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_352403","record_id":"REC_0008878","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":30,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":5.9,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.040984+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_994274","record_id":"REC_0008879","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":8.7,"age_at_diagnosis":50,"sex":"male","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":7.2,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.041266+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_887326","record_id":"REC_0008880","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":20,"tmb_mutations_per_mb":9.5,"age_at_diagnosis":87,"sex":"male","ecog_performance_status":1,"smoking_pack_years":40,"primary_tumor_size_cm":7.7,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":17.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.041694+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_673467","record_id":"REC_0008881","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":7.3,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":0,"smoking_pack_years":41,"primary_tumor_size_cm":4.7,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.042022+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_983546","record_id":"REC_0008882","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":9.9,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":4.4,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.042321+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_579243","record_id":"REC_0008883","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":6.4,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.042630+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_124748","record_id":"REC_0008884","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":17.5,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":4.3,"metastatic_sites_count":10,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.042920+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_149493","record_id":"REC_0008885","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":34,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":5.1,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.043181+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_839235","record_id":"REC_0008886","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":7.3,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.8,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.043434+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_526656","record_id":"REC_0008887","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":16,"tmb_mutations_per_mb":2.4,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":45,"primary_tumor_size_cm":4.0,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.043673+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_795706","record_id":"REC_0008888","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":15.5,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":4.5,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.043916+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_853614","record_id":"REC_0008889","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":11.0,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":4.8,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.044244+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_113923","record_id":"REC_0008890","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":32,"tmb_mutations_per_mb":3.9,"age_at_diagnosis":51,"sex":"male","ecog_performance_status":0,"smoking_pack_years":40,"primary_tumor_size_cm":5.8,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":24.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.044522+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_738280","record_id":"REC_0008891","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":9.5,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":6.8,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.044777+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_546509","record_id":"REC_0008892","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":10.5,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":6.2,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.045022+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_545441","record_id":"REC_0008893","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":6.7,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.045386+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_501067","record_id":"REC_0008894","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":23,"primary_tumor_size_cm":5.8,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":25.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.045651+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_330789","record_id":"REC_0008895","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":4.7,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":29,"primary_tumor_size_cm":8.3,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.045912+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_918603","record_id":"REC_0008896","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":9.0,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":3.9,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":18.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.046178+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_859450","record_id":"REC_0008897","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":8.5,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":2,"smoking_pack_years":22,"primary_tumor_size_cm":6.2,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":23.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.046444+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_205508","record_id":"REC_0008898","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":19,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":5.8,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.046708+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_915605","record_id":"REC_0008899","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":20,"tmb_mutations_per_mb":6.3,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":56,"primary_tumor_size_cm":6.9,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":18.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.046975+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_236644","record_id":"REC_0008900","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":4.3,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.047231+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_444564","record_id":"REC_0008901","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":10.5,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":24,"primary_tumor_size_cm":6.3,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.047497+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_400649","record_id":"REC_0008902","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":5.3,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.047756+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_711159","record_id":"REC_0008903","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":11.0,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":6.8,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.048013+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_802877","record_id":"REC_0008904","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":20,"tmb_mutations_per_mb":5.7,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":68,"primary_tumor_size_cm":5.3,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.048324+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_387363","record_id":"REC_0008905","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":17.3,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":5.2,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.048581+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_286098","record_id":"REC_0008906","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":5.9,"metastatic_sites_count":8,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.048940+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_414772","record_id":"REC_0008907","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":8.3,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":6.8,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.049264+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_912994","record_id":"REC_0008908","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":4.5,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":3,"smoking_pack_years":78,"primary_tumor_size_cm":5.1,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.049516+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_534071","record_id":"REC_0008909","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":3,"smoking_pack_years":19,"primary_tumor_size_cm":4.3,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.049758+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_851430","record_id":"REC_0008910","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":8.7,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":4.5,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.049994+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_961050","record_id":"REC_0008911","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":6.4,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.050229+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_136407","record_id":"REC_0008912","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":4.3,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":20.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.050462+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_700919","record_id":"REC_0008913","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":5.2,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":6.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.050701+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_804040","record_id":"REC_0008914","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":30,"tmb_mutations_per_mb":10.1,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":5.1,"metastatic_sites_count":3,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":8.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.051006+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_948823","record_id":"REC_0008915","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":4.0,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":61,"primary_tumor_size_cm":4.7,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.051250+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_784105","record_id":"REC_0008916","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":14.9,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":8.0,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.051489+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_137638","record_id":"REC_0008917","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":50,"sex":"male","ecog_performance_status":0,"smoking_pack_years":24,"primary_tumor_size_cm":4.2,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.051733+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_763713","record_id":"REC_0008918","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":7.6,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":3.4,"metastatic_sites_count":10,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.051978+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_594703","record_id":"REC_0008919","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":85,"primary_tumor_size_cm":7.4,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":17.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.052423+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_550086","record_id":"REC_0008920","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":47,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":7.0,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":5.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.052688+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_382666","record_id":"REC_0008921","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":16.6,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":3.7,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":7.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.052941+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_799711","record_id":"REC_0008922","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":9.9,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":25,"primary_tumor_size_cm":5.4,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":43.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.053181+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_315941","record_id":"REC_0008923","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":10.0,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":7.3,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":45.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.053426+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_522624","record_id":"REC_0008924","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":51,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":5.5,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":29.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.053676+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_983545","record_id":"REC_0008925","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":18.1,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":5.7,"metastatic_sites_count":9,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":5.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.053924+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_741276","record_id":"REC_0008926","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":7.9,"age_at_diagnosis":79,"sex":"male","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":3.0,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.054166+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_841112","record_id":"REC_0008927","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":5.4,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.054409+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_785763","record_id":"REC_0008928","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":15.6,"age_at_diagnosis":52,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":5.9,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":53.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.054657+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_642388","record_id":"REC_0008929","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":3.2,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.054902+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_164929","record_id":"REC_0008930","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":5.8,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":17.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.055138+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_373840","record_id":"REC_0008931","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":24,"primary_tumor_size_cm":3.4,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.055375+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_383187","record_id":"REC_0008932","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":31,"primary_tumor_size_cm":5.6,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":20.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.055713+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_845214","record_id":"REC_0008933","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":13,"tmb_mutations_per_mb":18.6,"age_at_diagnosis":77,"sex":"male","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":5.7,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.055960+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_101877","record_id":"REC_0008934","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ALK fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":4.0,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":60.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.056505+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_508807","record_id":"REC_0008935","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":2.5,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.057060+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_997791","record_id":"REC_0008936","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":5.9,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":29.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.057498+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_978284","record_id":"REC_0008937","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":6.0,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.057921+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_721615","record_id":"REC_0008938","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":0,"smoking_pack_years":1,"primary_tumor_size_cm":5.6,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.058304+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_587364","record_id":"REC_0008939","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":19,"tmb_mutations_per_mb":14.8,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":5.0,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.058549+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_687933","record_id":"REC_0008940","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":13.3,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":6.3,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.058787+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_336168","record_id":"REC_0008941","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":7.3,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":1,"smoking_pack_years":40,"primary_tumor_size_cm":6.4,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.059026+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_707214","record_id":"REC_0008942","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":3,"primary_tumor_size_cm":5.5,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.059267+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_943436","record_id":"REC_0008943","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":17.8,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":4.5,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.059506+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_478544","record_id":"REC_0008944","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":46,"primary_tumor_size_cm":5.8,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.059734+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_682507","record_id":"REC_0008945","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":12,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":24,"primary_tumor_size_cm":5.6,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.060106+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_116787","record_id":"REC_0008946","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":13.5,"age_at_diagnosis":78,"sex":"male","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":6.0,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.060372+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_873317","record_id":"REC_0008947","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":13.8,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":33,"primary_tumor_size_cm":4.3,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":4.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.060616+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_735436","record_id":"REC_0008948","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":5.1,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":44.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.060861+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_791444","record_id":"REC_0008949","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":4.7,"metastatic_sites_count":8,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":6.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.061115+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_553390","record_id":"REC_0008950","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":4.8,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":21.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.061367+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_506466","record_id":"REC_0008951","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":17.4,"age_at_diagnosis":54,"sex":"male","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":7.2,"metastatic_sites_count":9,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.061610+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_480544","record_id":"REC_0008952","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":5.9,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":3,"smoking_pack_years":20,"primary_tumor_size_cm":4.2,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":22.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.061842+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_737626","record_id":"REC_0008953","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":5.9,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.062091+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_911918","record_id":"REC_0008954","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":49,"primary_tumor_size_cm":4.2,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":19.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.062334+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_780326","record_id":"REC_0008955","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":6.8,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":20.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.062589+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_176013","record_id":"REC_0008956","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":5.4,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.062844+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_367137","record_id":"REC_0008957","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":4.5,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.063098+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_149607","record_id":"REC_0008958","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":6.2,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":21.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.063504+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_537872","record_id":"REC_0008959","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":5.0,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":5.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.063780+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_103210","record_id":"REC_0008960","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":18.5,"age_at_diagnosis":74,"sex":"male","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":6.8,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":16.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.064040+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_152665","record_id":"REC_0008961","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":16.2,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":5.5,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.064436+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_173412","record_id":"REC_0008962","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":8.1,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":21,"primary_tumor_size_cm":7.8,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.064710+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_577629","record_id":"REC_0008963","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":16.2,"age_at_diagnosis":51,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":7.1,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.064973+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_864208","record_id":"REC_0008964","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":54,"primary_tumor_size_cm":5.7,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":24.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.065221+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_994533","record_id":"REC_0008965","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":7.4,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":35,"primary_tumor_size_cm":4.6,"metastatic_sites_count":3,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.065470+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_536870","record_id":"REC_0008966","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":9.1,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":4.9,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":6.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.065717+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_837184","record_id":"REC_0008967","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":10.0,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":26,"primary_tumor_size_cm":3.7,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.065965+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_676365","record_id":"REC_0008968","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":7.4,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":3.9,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.066201+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_750617","record_id":"REC_0008969","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":18,"tmb_mutations_per_mb":6.9,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":48,"primary_tumor_size_cm":7.6,"metastatic_sites_count":9,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.066439+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_427226","record_id":"REC_0008970","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":9.9,"age_at_diagnosis":52,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":5.2,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":21.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.066675+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_223896","record_id":"REC_0008971","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":30,"tmb_mutations_per_mb":4.3,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":5.0,"metastatic_sites_count":3,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.067025+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_969197","record_id":"REC_0008972","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":7.6,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":6.8,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.067268+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_253727","record_id":"REC_0008973","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":32,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":5.7,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.067508+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_456595","record_id":"REC_0008974","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":6.4,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":4.6,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.067750+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_223419","record_id":"REC_0008975","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":80,"sex":"male","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":4.0,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.067988+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_465419","record_id":"REC_0008976","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":32,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":2,"smoking_pack_years":21,"primary_tumor_size_cm":4.7,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":22.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.068300+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_353459","record_id":"REC_0008977","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":6.5,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.068558+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_759492","record_id":"REC_0008978","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":20.4,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":8.1,"metastatic_sites_count":8,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":19.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.068801+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_516464","record_id":"REC_0008979","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":6.7,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":21.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.069042+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_566195","record_id":"REC_0008980","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":36,"tmb_mutations_per_mb":5.0,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":30,"primary_tumor_size_cm":7.2,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":16.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.069279+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_944336","record_id":"REC_0008981","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":8.3,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":4.9,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.069513+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_811603","record_id":"REC_0008982","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":30,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":6.8,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":29.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.069751+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_518209","record_id":"REC_0008983","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":8.6,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":40,"primary_tumor_size_cm":4.7,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":20.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.069991+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_995192","record_id":"REC_0008984","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":34,"tmb_mutations_per_mb":9.1,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":0,"smoking_pack_years":3,"primary_tumor_size_cm":5.5,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.070342+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_719169","record_id":"REC_0008985","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":26,"primary_tumor_size_cm":3.9,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.070608+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_953993","record_id":"REC_0008986","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":19,"tmb_mutations_per_mb":13.1,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":6.4,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":30.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.070860+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_107247","record_id":"REC_0008987","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":17.5,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.9,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.071122+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_301597","record_id":"REC_0008988","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":7.3,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":1,"smoking_pack_years":40,"primary_tumor_size_cm":6.1,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":17.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.071372+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_111691","record_id":"REC_0008989","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":3,"primary_tumor_size_cm":2.2,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":6.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.071622+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_177830","record_id":"REC_0008990","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":18.0,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":7.0,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.071878+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_577680","record_id":"REC_0008991","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":33,"primary_tumor_size_cm":4.7,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.072177+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_296566","record_id":"REC_0008992","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":30,"tmb_mutations_per_mb":5.5,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":63,"primary_tumor_size_cm":5.6,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":19.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.072444+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_736691","record_id":"REC_0008993","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":3.6,"age_at_diagnosis":84,"sex":"female","ecog_performance_status":2,"smoking_pack_years":59,"primary_tumor_size_cm":4.3,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":16.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.072698+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_391211","record_id":"REC_0008994","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":2.9,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":5.3,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":21.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.072952+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_655179","record_id":"REC_0008995","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":1.7,"age_at_diagnosis":83,"sex":"female","ecog_performance_status":2,"smoking_pack_years":32,"primary_tumor_size_cm":2.8,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":7.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.073205+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_747186","record_id":"REC_0008996","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":1,"smoking_pack_years":44,"primary_tumor_size_cm":6.0,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.073449+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_515320","record_id":"REC_0008997","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":17,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":65,"primary_tumor_size_cm":5.6,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":7.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.073784+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_921521","record_id":"REC_0008998","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":15.9,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":6.6,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.074037+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_848190","record_id":"REC_0008999","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":20,"tmb_mutations_per_mb":5.5,"age_at_diagnosis":53,"sex":"female","ecog_performance_status":0,"smoking_pack_years":67,"primary_tumor_size_cm":7.9,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":21.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.074285+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_475774","record_id":"REC_0009000","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":11.0,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":4.5,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.074532+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_579849","record_id":"REC_0009001","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":5.2,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":25,"primary_tumor_size_cm":5.2,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":42.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.074783+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_733907","record_id":"REC_0009002","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":31,"tmb_mutations_per_mb":8.7,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.7,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":24.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.075026+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_228812","record_id":"REC_0009003","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":15.9,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":6.6,"metastatic_sites_count":9,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.075278+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_873753","record_id":"REC_0009004","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":15.0,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":7.1,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.075525+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_792091","record_id":"REC_0009005","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":4.4,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.075772+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_864863","record_id":"REC_0009006","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":17.2,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":32,"primary_tumor_size_cm":6.5,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.076020+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_327721","record_id":"REC_0009007","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":6.0,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.076336+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_338933","record_id":"REC_0009008","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":13.5,"age_at_diagnosis":51,"sex":"male","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":5.2,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.076600+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_748970","record_id":"REC_0009009","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":5.6,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":31.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.076858+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_626443","record_id":"REC_0009010","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":8.6,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":5.4,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.077233+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_406185","record_id":"REC_0009011","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":2,"smoking_pack_years":25,"primary_tumor_size_cm":4.7,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":6.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.077500+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_547990","record_id":"REC_0009012","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":9.8,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":6.2,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.077743+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_277103","record_id":"REC_0009013","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":16.8,"age_at_diagnosis":83,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":7.4,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":4.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.077977+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_416895","record_id":"REC_0009014","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":9.7,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":9.8,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":17.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.078204+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_539810","record_id":"REC_0009015","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":19,"tmb_mutations_per_mb":8.3,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":0,"smoking_pack_years":35,"primary_tumor_size_cm":5.3,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":19.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.078448+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_526869","record_id":"REC_0009016","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":2.8,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.078690+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_838171","record_id":"REC_0009017","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":86,"sex":"female","ecog_performance_status":0,"smoking_pack_years":74,"primary_tumor_size_cm":7.2,"metastatic_sites_count":8,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.078931+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_848628","record_id":"REC_0009018","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":13.1,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":5.4,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":29.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.079180+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_791099","record_id":"REC_0009019","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":19,"tmb_mutations_per_mb":7.4,"age_at_diagnosis":54,"sex":"female","ecog_performance_status":0,"smoking_pack_years":37,"primary_tumor_size_cm":5.4,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.079429+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_250749","record_id":"REC_0009020","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":90,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":4.3,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.079673+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_112629","record_id":"REC_0009021","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":3.8,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.079918+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_824410","record_id":"REC_0009022","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":17,"tmb_mutations_per_mb":8.9,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":4.9,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":18.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.080306+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_791931","record_id":"REC_0009023","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":6.1,"age_at_diagnosis":90,"sex":"male","ecog_performance_status":2,"smoking_pack_years":51,"primary_tumor_size_cm":8.4,"metastatic_sites_count":8,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.080681+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_995217","record_id":"REC_0009024","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":10.0,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":6.1,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.080947+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_468279","record_id":"REC_0009025","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":10.5,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":3.5,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":16.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.081204+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_260009","record_id":"REC_0009026","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":15.7,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":6.4,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.081465+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_519846","record_id":"REC_0009027","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":6.1,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":20.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.081717+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_751194","record_id":"REC_0009028","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":3.9,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":38,"primary_tumor_size_cm":6.5,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":16.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.081961+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_585356","record_id":"REC_0009029","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":15.2,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":21,"primary_tumor_size_cm":5.1,"metastatic_sites_count":9,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.082211+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_197150","record_id":"REC_0009030","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":5.2,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.082455+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_982894","record_id":"REC_0009031","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":4.7,"age_at_diagnosis":76,"sex":"male","ecog_performance_status":3,"smoking_pack_years":56,"primary_tumor_size_cm":6.2,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.082698+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_127830","record_id":"REC_0009032","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":5.5,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":35,"primary_tumor_size_cm":5.6,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":19.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.082941+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_347705","record_id":"REC_0009033","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":47,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":4.6,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":5.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.083184+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_763212","record_id":"REC_0009034","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":4.3,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":8.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.083422+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_265529","record_id":"REC_0009035","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":8.0,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":6.2,"metastatic_sites_count":9,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.083660+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_318869","record_id":"REC_0009036","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":4.8,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.083995+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_500493","record_id":"REC_0009037","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":30,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":3.9,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.084291+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_366615","record_id":"REC_0009038","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":20,"tmb_mutations_per_mb":5.7,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":51,"primary_tumor_size_cm":4.7,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.084540+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_245650","record_id":"REC_0009039","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":16.6,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":6.2,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.084797+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_128677","record_id":"REC_0009040","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":3,"primary_tumor_size_cm":4.2,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.085033+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_774393","record_id":"REC_0009041","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":14.1,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":25,"primary_tumor_size_cm":6.0,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":17.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.085286+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_791184","record_id":"REC_0009042","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":9.9,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":6.2,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":21.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.085527+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_466095","record_id":"REC_0009043","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":8.1,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.2,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.085768+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_254083","record_id":"REC_0009044","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":26,"primary_tumor_size_cm":4.9,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":31.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.086015+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_161636","record_id":"REC_0009045","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":20,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.8,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.086267+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_883160","record_id":"REC_0009046","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":6.1,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.086515+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_347178","record_id":"REC_0009047","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":33,"tmb_mutations_per_mb":1.6,"age_at_diagnosis":79,"sex":"male","ecog_performance_status":1,"smoking_pack_years":54,"primary_tumor_size_cm":7.2,"metastatic_sites_count":8,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.086755+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_600642","record_id":"REC_0009048","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":52,"primary_tumor_size_cm":5.0,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.086993+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_334261","record_id":"REC_0009049","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":8.0,"age_at_diagnosis":54,"sex":"male","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":7.3,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.087334+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_801002","record_id":"REC_0009050","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":9,"primary_tumor_size_cm":6.2,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.087573+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_622652","record_id":"REC_0009051","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":4.5,"metastatic_sites_count":3,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.087813+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_941161","record_id":"REC_0009052","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":4.8,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":22.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.088051+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_826887","record_id":"REC_0009053","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":4.0,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":19.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.088337+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_711025","record_id":"REC_0009054","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":18,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":25,"primary_tumor_size_cm":4.0,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.088573+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_463964","record_id":"REC_0009055","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":16.0,"age_at_diagnosis":44,"sex":"male","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":5.0,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":25.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.088813+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_830504","record_id":"REC_0009056","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":32,"tmb_mutations_per_mb":4.7,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":25,"primary_tumor_size_cm":5.8,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":16.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.089046+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_363222","record_id":"REC_0009057","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":8.4,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":2,"primary_tumor_size_cm":4.9,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.089282+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_702863","record_id":"REC_0009058","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":5.2,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":20.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.089521+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_152193","record_id":"REC_0009059","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":4.0,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":3.7,"metastatic_sites_count":8,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.089761+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_474093","record_id":"REC_0009060","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":13.1,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":4.4,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.090007+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_324010","record_id":"REC_0009061","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":16.0,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":5.5,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":59.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.090241+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_955416","record_id":"REC_0009062","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":4.6,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":8.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.090554+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_528468","record_id":"REC_0009063","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":8.0,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":26,"primary_tumor_size_cm":5.0,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":5.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.090803+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_790601","record_id":"REC_0009064","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":6.4,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.091041+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_765747","record_id":"REC_0009065","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":4.7,"age_at_diagnosis":85,"sex":"male","ecog_performance_status":0,"smoking_pack_years":42,"primary_tumor_size_cm":6.9,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":22.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.091276+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_487228","record_id":"REC_0009066","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":20,"tmb_mutations_per_mb":5.9,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":63,"primary_tumor_size_cm":4.2,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.091512+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_539570","record_id":"REC_0009067","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":6.7,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":1,"smoking_pack_years":5,"primary_tumor_size_cm":4.9,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.091749+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_335631","record_id":"REC_0009068","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":6.1,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":46,"primary_tumor_size_cm":5.8,"metastatic_sites_count":10,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.091983+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_545428","record_id":"REC_0009069","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":20,"tmb_mutations_per_mb":15.1,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":2.0,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.092290+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_990491","record_id":"REC_0009070","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":6.0,"age_at_diagnosis":80,"sex":"male","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":6.0,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.092528+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_215257","record_id":"REC_0009071","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":6.2,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":5.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.092767+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_357635","record_id":"REC_0009072","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":6.4,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":43,"primary_tumor_size_cm":5.5,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":5.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.093000+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_311056","record_id":"REC_0009073","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":9.0,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":4.2,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.093230+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_431461","record_id":"REC_0009074","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":21.2,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":5.4,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":37.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.093467+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_259368","record_id":"REC_0009075","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":6.6,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":5.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.093772+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_456627","record_id":"REC_0009076","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":15.6,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":3,"primary_tumor_size_cm":6.1,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":23.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.094008+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_593193","record_id":"REC_0009077","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":74,"sex":"male","ecog_performance_status":1,"smoking_pack_years":40,"primary_tumor_size_cm":5.7,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":29.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.094244+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_145268","record_id":"REC_0009078","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":0,"smoking_pack_years":4,"primary_tumor_size_cm":4.2,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":7.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.094481+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_148588","record_id":"REC_0009079","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":8.4,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":6.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.094720+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_772481","record_id":"REC_0009080","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":4.5,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":19.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.094956+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_135248","record_id":"REC_0009081","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":18,"tmb_mutations_per_mb":17.5,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":6.3,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.095197+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_143392","record_id":"REC_0009082","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":7.0,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.095436+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_816502","record_id":"REC_0009083","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":6.3,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.095677+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_357069","record_id":"REC_0009084","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":6.7,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":9,"primary_tumor_size_cm":6.4,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":5.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.095905+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_820937","record_id":"REC_0009085","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":6.8,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.096259+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_589568","record_id":"REC_0009086","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":2,"primary_tumor_size_cm":7.1,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":7.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.096514+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_368378","record_id":"REC_0009087","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":4.8,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.096754+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_260995","record_id":"REC_0009088","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":5.1,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":5.6,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.097098+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_349563","record_id":"REC_0009089","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":34,"tmb_mutations_per_mb":10.3,"age_at_diagnosis":74,"sex":"male","ecog_performance_status":2,"smoking_pack_years":9,"primary_tumor_size_cm":4.6,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.097360+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_185374","record_id":"REC_0009090","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":6.9,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":29.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.097616+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_113270","record_id":"REC_0009091","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":32,"tmb_mutations_per_mb":15.2,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":4.3,"metastatic_sites_count":8,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.097860+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_533342","record_id":"REC_0009092","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":6.0,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":24.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.098095+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_117402","record_id":"REC_0009093","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":31,"tmb_mutations_per_mb":6.1,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":3.9,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.098326+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_936617","record_id":"REC_0009094","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":29,"primary_tumor_size_cm":5.3,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.098558+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_356759","record_id":"REC_0009095","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":6.1,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.098795+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_210099","record_id":"REC_0009096","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":5.2,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":49,"primary_tumor_size_cm":6.4,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.099029+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_744779","record_id":"REC_0009097","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":0,"smoking_pack_years":37,"primary_tumor_size_cm":5.4,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":17.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.099263+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_846493","record_id":"REC_0009098","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":8.0,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":3,"smoking_pack_years":22,"primary_tumor_size_cm":4.0,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.099495+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_575084","record_id":"REC_0009099","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":4.5,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":19.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.099724+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_406928","record_id":"REC_0009100","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":5.6,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":30,"primary_tumor_size_cm":4.0,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.099956+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_760095","record_id":"REC_0009101","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":33,"tmb_mutations_per_mb":8.3,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":4.6,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":17.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.100313+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_787826","record_id":"REC_0009102","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":14.7,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":6.0,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":23.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.100557+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_170951","record_id":"REC_0009103","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":2,"primary_tumor_size_cm":6.2,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.100795+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_586419","record_id":"REC_0009104","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":3.2,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":1,"smoking_pack_years":46,"primary_tumor_size_cm":5.8,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":50.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.101030+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_160446","record_id":"REC_0009105","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":4.8,"age_at_diagnosis":51,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":4.9,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.101263+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_528033","record_id":"REC_0009106","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":10.3,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":6.2,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.101497+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_339607","record_id":"REC_0009107","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":6.0,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":47,"primary_tumor_size_cm":6.2,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":21.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.101731+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_447559","record_id":"REC_0009108","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":15.0,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":6.1,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.101966+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_701765","record_id":"REC_0009109","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":4.1,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":0,"smoking_pack_years":62,"primary_tumor_size_cm":4.0,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":7.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.102196+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_519013","record_id":"REC_0009110","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":15.3,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":4.9,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.102433+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_999944","record_id":"REC_0009111","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":7.9,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":6.4,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.102663+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_540185","record_id":"REC_0009112","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":2,"smoking_pack_years":10,"primary_tumor_size_cm":3.6,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":6.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.102899+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_840176","record_id":"REC_0009113","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":30,"tmb_mutations_per_mb":6.1,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":41,"primary_tumor_size_cm":5.2,"metastatic_sites_count":3,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":17.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.103131+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_789917","record_id":"REC_0009114","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":9.9,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":5.3,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.103406+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_362570","record_id":"REC_0009115","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":4.9,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.103642+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_318341","record_id":"REC_0009116","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":5.2,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":6.6,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":7.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.103872+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_586445","record_id":"REC_0009117","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":4.1,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.104160+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_265141","record_id":"REC_0009118","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":17.9,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":5.1,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.104413+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_793776","record_id":"REC_0009119","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":6.7,"metastatic_sites_count":9,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.104649+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_519573","record_id":"REC_0009120","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":3.9,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.104885+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_981187","record_id":"REC_0009121","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":17.1,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":8.0,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":7.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.105131+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_273597","record_id":"REC_0009122","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":35,"tmb_mutations_per_mb":14.9,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":4.8,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":28.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.105380+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_505661","record_id":"REC_0009123","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":7.6,"age_at_diagnosis":79,"sex":"male","ecog_performance_status":1,"smoking_pack_years":26,"primary_tumor_size_cm":5.4,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":50.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.105619+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_916723","record_id":"REC_0009124","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":79,"sex":"male","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":6.2,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.105855+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_323297","record_id":"REC_0009125","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":15.9,"age_at_diagnosis":53,"sex":"male","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":5.7,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.106096+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_610724","record_id":"REC_0009126","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":3.6,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.106336+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_597134","record_id":"REC_0009127","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":16,"tmb_mutations_per_mb":8.3,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.6,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.106643+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_132400","record_id":"REC_0009128","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":9.0,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":2.2,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.106894+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_377047","record_id":"REC_0009129","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":41,"primary_tumor_size_cm":6.5,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.107135+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_262777","record_id":"REC_0009130","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None","pd_l1_tps_percent":30,"tmb_mutations_per_mb":5.3,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":42,"primary_tumor_size_cm":5.6,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.107378+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_213177","record_id":"REC_0009131","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":8.9,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":5.3,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.107631+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_556028","record_id":"REC_0009132","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":14.7,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":4.7,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.107879+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_113290","record_id":"REC_0009133","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":16,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":48,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":4.3,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.108206+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_161148","record_id":"REC_0009134","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":5.2,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.108478+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_498792","record_id":"REC_0009135","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":36,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":2,"primary_tumor_size_cm":5.1,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.108730+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_502184","record_id":"REC_0009136","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":35,"tmb_mutations_per_mb":5.7,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":52,"primary_tumor_size_cm":3.1,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":16.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.108971+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_195620","record_id":"REC_0009137","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":5.2,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":5.1,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.109215+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_673456","record_id":"REC_0009138","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":2.9,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":42,"primary_tumor_size_cm":5.6,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":7.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.109459+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_837746","record_id":"REC_0009139","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":4.8,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":19.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.109702+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_614089","record_id":"REC_0009140","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":4.1,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.110061+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_509763","record_id":"REC_0009141","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":10.5,"age_at_diagnosis":82,"sex":"male","ecog_performance_status":2,"smoking_pack_years":9,"primary_tumor_size_cm":8.1,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.110314+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_161975","record_id":"REC_0009142","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":14.4,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":28,"primary_tumor_size_cm":5.3,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.110552+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_532402","record_id":"REC_0009143","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":5.0,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":3,"smoking_pack_years":36,"primary_tumor_size_cm":4.7,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":19.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.110796+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_244723","record_id":"REC_0009144","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":9.9,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":5,"primary_tumor_size_cm":5.5,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":24.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.111034+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_279316","record_id":"REC_0009145","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":9.8,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":3,"smoking_pack_years":23,"primary_tumor_size_cm":4.3,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":16.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.111265+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_356552","record_id":"REC_0009146","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":14.6,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":4,"primary_tumor_size_cm":7.5,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":22.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.111510+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_986064","record_id":"REC_0009147","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":16.9,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":4.6,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.111749+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_280848","record_id":"REC_0009148","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":17.2,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":5.4,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.111986+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_948734","record_id":"REC_0009149","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":16.7,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":6.5,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.112269+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_674017","record_id":"REC_0009150","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":4.7,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":6.3,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":17.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.112509+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_282664","record_id":"REC_0009151","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":19,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":5.7,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.112758+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_970529","record_id":"REC_0009152","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":18,"tmb_mutations_per_mb":9.1,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":4.6,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.112994+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_545277","record_id":"REC_0009153","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":31,"tmb_mutations_per_mb":5.3,"age_at_diagnosis":42,"sex":"male","ecog_performance_status":0,"smoking_pack_years":57,"primary_tumor_size_cm":5.0,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.113372+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_684735","record_id":"REC_0009154","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":4.8,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":4.8,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.113629+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_594716","record_id":"REC_0009155","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":4.7,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":67,"primary_tumor_size_cm":5.0,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.113862+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_535230","record_id":"REC_0009156","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":31,"tmb_mutations_per_mb":4.5,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":5.4,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.114108+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_287509","record_id":"REC_0009157","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":3,"primary_tumor_size_cm":5.9,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.114347+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_973602","record_id":"REC_0009158","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":19.4,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":2,"smoking_pack_years":20,"primary_tumor_size_cm":5.8,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.114597+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_952640","record_id":"REC_0009159","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":19,"tmb_mutations_per_mb":15.7,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":4.9,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":34.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.114852+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_379377","record_id":"REC_0009160","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":13.8,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":6.0,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.115097+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_386745","record_id":"REC_0009161","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":5.5,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":3.9,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.115346+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_703109","record_id":"REC_0009162","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":3,"smoking_pack_years":14,"primary_tumor_size_cm":5.0,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.115591+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_242857","record_id":"REC_0009163","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":14.0,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":28,"primary_tumor_size_cm":5.7,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.115833+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_529230","record_id":"REC_0009164","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":6.7,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":20.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.116125+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_775751","record_id":"REC_0009165","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":10.3,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":5.9,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":5.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.116381+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_359261","record_id":"REC_0009166","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":18,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":5.4,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.116745+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_187311","record_id":"REC_0009167","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":16.7,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":4,"primary_tumor_size_cm":6.4,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.116995+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_824359","record_id":"REC_0009168","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":20,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":6.2,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":18.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.117234+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_926704","record_id":"REC_0009169","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":15.0,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":4.8,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.117487+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_292031","record_id":"REC_0009170","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":16.2,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":21,"primary_tumor_size_cm":5.6,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":4.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.117730+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_392599","record_id":"REC_0009171","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":18.7,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":4,"primary_tumor_size_cm":4.5,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":6.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.117973+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_625225","record_id":"REC_0009172","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":31,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":86,"sex":"male","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":5.7,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.118213+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_927470","record_id":"REC_0009173","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":4.4,"metastatic_sites_count":8,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.118448+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_967024","record_id":"REC_0009174","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":32,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":5.6,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.118676+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_337319","record_id":"REC_0009175","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":15.1,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":6.1,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.118919+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_902198","record_id":"REC_0009176","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":4.0,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":24,"primary_tumor_size_cm":6.5,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.119157+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_591818","record_id":"REC_0009177","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":5.5,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.119396+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_399930","record_id":"REC_0009178","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":6.0,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":25.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.119635+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_352839","record_id":"REC_0009179","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":19,"tmb_mutations_per_mb":3.8,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":6.8,"metastatic_sites_count":3,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":16.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.119963+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_677324","record_id":"REC_0009180","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":7.3,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":5.4,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":25.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.120248+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_229694","record_id":"REC_0009181","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":47,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":4.0,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":16.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.120487+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_207632","record_id":"REC_0009182","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":18,"tmb_mutations_per_mb":19.0,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":1,"smoking_pack_years":5,"primary_tumor_size_cm":7.9,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":35.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.120722+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_823729","record_id":"REC_0009183","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":14.1,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":20,"primary_tumor_size_cm":5.2,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.120956+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_514307","record_id":"REC_0009184","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":5.8,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.121196+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_897417","record_id":"REC_0009185","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":3,"smoking_pack_years":21,"primary_tumor_size_cm":4.6,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.121436+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_101132","record_id":"REC_0009186","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":5.4,"metastatic_sites_count":9,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.121669+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_280195","record_id":"REC_0009187","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":31,"tmb_mutations_per_mb":5.9,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":25,"primary_tumor_size_cm":5.1,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":6.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.121897+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_342946","record_id":"REC_0009188","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":5.3,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":5,"primary_tumor_size_cm":4.7,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":16.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.122131+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_661196","record_id":"REC_0009189","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":5.2,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":6.8,"metastatic_sites_count":8,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.122367+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_149255","record_id":"REC_0009190","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":31,"tmb_mutations_per_mb":7.9,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.4,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":22.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.122601+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_328334","record_id":"REC_0009191","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":5.7,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":8.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.122844+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_113033","record_id":"REC_0009192","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":34,"tmb_mutations_per_mb":4.9,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":5.4,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":28.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.123159+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_604001","record_id":"REC_0009193","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":4.2,"metastatic_sites_count":8,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.123405+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_634434","record_id":"REC_0009194","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":4.5,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":4.2,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":19.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.123646+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_994807","record_id":"REC_0009195","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":15.3,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":7.4,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":40.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.123897+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_636650","record_id":"REC_0009196","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":6.1,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.124192+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_986416","record_id":"REC_0009197","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":4.9,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":4,"primary_tumor_size_cm":6.1,"metastatic_sites_count":8,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.124458+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_475068","record_id":"REC_0009198","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":20,"tmb_mutations_per_mb":15.8,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":0,"smoking_pack_years":27,"primary_tumor_size_cm":6.1,"metastatic_sites_count":8,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":16.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.124711+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_609313","record_id":"REC_0009199","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":16.5,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":5.9,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":22.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.124953+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_452052","record_id":"REC_0009200","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":14.7,"age_at_diagnosis":77,"sex":"male","ecog_performance_status":2,"smoking_pack_years":21,"primary_tumor_size_cm":6.7,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.125193+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_951942","record_id":"REC_0009201","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":15.0,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":7.1,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":17.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.125432+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_416484","record_id":"REC_0009202","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":15.3,"age_at_diagnosis":84,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":7.3,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.125677+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_314795","record_id":"REC_0009203","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":13.8,"age_at_diagnosis":74,"sex":"male","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":8.1,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":19.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.125927+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_503791","record_id":"REC_0009204","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":14.4,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":0,"smoking_pack_years":6,"primary_tumor_size_cm":5.2,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.126194+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_690368","record_id":"REC_0009205","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":17.4,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":4.8,"metastatic_sites_count":8,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.126537+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_294946","record_id":"REC_0009206","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":3.7,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":4.7,"metastatic_sites_count":3,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":19.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.126801+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_577804","record_id":"REC_0009207","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":4.8,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":3,"smoking_pack_years":36,"primary_tumor_size_cm":6.0,"metastatic_sites_count":3,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.127043+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_751404","record_id":"REC_0009208","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":14,"tmb_mutations_per_mb":14.3,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":1,"smoking_pack_years":4,"primary_tumor_size_cm":4.1,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.127280+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_593611","record_id":"REC_0009209","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":15.4,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":7.8,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":20.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.127517+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_638418","record_id":"REC_0009210","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":5.6,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.127761+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_376196","record_id":"REC_0009211","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":30,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":6.8,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":20.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.128007+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_403242","record_id":"REC_0009212","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":13,"tmb_mutations_per_mb":16.3,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":5.0,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.128383+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_911147","record_id":"REC_0009213","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":14.7,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":6.4,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.128638+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_534851","record_id":"REC_0009214","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":4.3,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.128879+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_241130","record_id":"REC_0009215","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":19,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":1,"smoking_pack_years":66,"primary_tumor_size_cm":5.2,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.129123+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_604819","record_id":"REC_0009216","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":19,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":5.5,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.129363+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_225387","record_id":"REC_0009217","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":17,"tmb_mutations_per_mb":8.0,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":4.4,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.129600+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_811954","record_id":"REC_0009218","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":5.0,"age_at_diagnosis":84,"sex":"female","ecog_performance_status":1,"smoking_pack_years":26,"primary_tumor_size_cm":5.5,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":22.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.129909+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_970936","record_id":"REC_0009219","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":33,"tmb_mutations_per_mb":14.5,"age_at_diagnosis":75,"sex":"male","ecog_performance_status":2,"smoking_pack_years":22,"primary_tumor_size_cm":7.4,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":20.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.130153+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_278840","record_id":"REC_0009220","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":4.3,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.130384+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_483596","record_id":"REC_0009221","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":4.6,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.130623+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_490664","record_id":"REC_0009222","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":34,"tmb_mutations_per_mb":9.7,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":3,"smoking_pack_years":11,"primary_tumor_size_cm":5.2,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":6.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.130857+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_295817","record_id":"REC_0009223","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":4.8,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.131090+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_783759","record_id":"REC_0009224","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":34,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":28,"primary_tumor_size_cm":3.8,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":4.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.131328+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_695382","record_id":"REC_0009225","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":75,"sex":"male","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":4.2,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":7.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.131569+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_948382","record_id":"REC_0009226","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":5.6,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":8.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.131814+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_117330","record_id":"REC_0009227","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":33,"tmb_mutations_per_mb":6.7,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":5.3,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":6.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.132055+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_649932","record_id":"REC_0009228","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.4,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.132338+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_630576","record_id":"REC_0009229","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":14.3,"age_at_diagnosis":74,"sex":"male","ecog_performance_status":3,"smoking_pack_years":13,"primary_tumor_size_cm":7.7,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.132588+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_747995","record_id":"REC_0009230","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":17,"tmb_mutations_per_mb":9.5,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":5.6,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.132831+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_574435","record_id":"REC_0009231","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":5,"primary_tumor_size_cm":7.3,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.133183+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_588289","record_id":"REC_0009232","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":3,"smoking_pack_years":18,"primary_tumor_size_cm":4.7,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.133442+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_469863","record_id":"REC_0009233","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":6.3,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.133705+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_915747","record_id":"REC_0009234","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":7.3,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.133968+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_290419","record_id":"REC_0009235","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":51,"primary_tumor_size_cm":4.3,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.134226+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_828248","record_id":"REC_0009236","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":31,"primary_tumor_size_cm":6.6,"metastatic_sites_count":3,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":5.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.134484+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_124761","record_id":"REC_0009237","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":3.7,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":23,"primary_tumor_size_cm":6.2,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.134734+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_180798","record_id":"REC_0009238","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":32,"tmb_mutations_per_mb":15.4,"age_at_diagnosis":85,"sex":"female","ecog_performance_status":2,"smoking_pack_years":22,"primary_tumor_size_cm":4.3,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":8.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.134978+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_433677","record_id":"REC_0009239","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":49,"sex":"male","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":6.0,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.135240+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_731444","record_id":"REC_0009240","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":16.1,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":2,"smoking_pack_years":9,"primary_tumor_size_cm":3.0,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":24.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.135484+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_672994","record_id":"REC_0009241","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":18.0,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":3,"primary_tumor_size_cm":3.5,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.135728+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_252849","record_id":"REC_0009242","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":15.2,"age_at_diagnosis":52,"sex":"female","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":7.9,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":16.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.135972+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_276850","record_id":"REC_0009243","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":3.5,"age_at_diagnosis":86,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":7.6,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.136258+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_655852","record_id":"REC_0009244","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":6.4,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":7.3,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":21.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.136616+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_495088","record_id":"REC_0009245","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.0,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":5.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.136881+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_328358","record_id":"REC_0009246","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":33,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":54,"primary_tumor_size_cm":6.1,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.137127+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_679793","record_id":"REC_0009247","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":3,"smoking_pack_years":12,"primary_tumor_size_cm":4.1,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.137374+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_988459","record_id":"REC_0009248","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":9.0,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":6.7,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.137627+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_584333","record_id":"REC_0009249","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":15.2,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":4.3,"metastatic_sites_count":3,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":22.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.137873+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_500039","record_id":"REC_0009250","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":13.3,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":4.2,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.138116+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_759427","record_id":"REC_0009251","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":3.3,"age_at_diagnosis":84,"sex":"female","ecog_performance_status":2,"smoking_pack_years":52,"primary_tumor_size_cm":4.5,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.138358+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_139124","record_id":"REC_0009252","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":17,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":3.3,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":21.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.138596+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_875343","record_id":"REC_0009253","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":4.9,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.138830+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_315887","record_id":"REC_0009254","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":5.0,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":6.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.139061+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_164588","record_id":"REC_0009255","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":16.6,"age_at_diagnosis":47,"sex":"male","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":6.5,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":27.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.139295+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_699344","record_id":"REC_0009256","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":20,"tmb_mutations_per_mb":2.7,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":33,"primary_tumor_size_cm":6.6,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.139523+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_633401","record_id":"REC_0009257","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":13.6,"age_at_diagnosis":52,"sex":"male","ecog_performance_status":0,"smoking_pack_years":5,"primary_tumor_size_cm":5.0,"metastatic_sites_count":3,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":16.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.139845+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_392719","record_id":"REC_0009258","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":54,"sex":"female","ecog_performance_status":0,"smoking_pack_years":27,"primary_tumor_size_cm":4.8,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.140158+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_705256","record_id":"REC_0009259","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":14.8,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":30,"primary_tumor_size_cm":5.2,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.140415+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_816079","record_id":"REC_0009260","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":19,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":4.0,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.140660+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_490002","record_id":"REC_0009261","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":16,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":54,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":2.6,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.140901+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_665776","record_id":"REC_0009262","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":14.1,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":4,"primary_tumor_size_cm":7.9,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":16.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.141140+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_851780","record_id":"REC_0009263","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":5.9,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":0,"smoking_pack_years":59,"primary_tumor_size_cm":6.2,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":18.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.141383+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_953397","record_id":"REC_0009264","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":76,"sex":"male","ecog_performance_status":3,"smoking_pack_years":25,"primary_tumor_size_cm":5.6,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.141622+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_738599","record_id":"REC_0009265","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":30,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":5.1,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.141856+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_937686","record_id":"REC_0009266","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":6.1,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":0,"smoking_pack_years":49,"primary_tumor_size_cm":3.6,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":17.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.142089+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_634661","record_id":"REC_0009267","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":31,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":4.5,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":24.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.142324+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_972991","record_id":"REC_0009268","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":4.2,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":21.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.142565+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_590385","record_id":"REC_0009269","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":16.5,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":7.5,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.142801+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_242176","record_id":"REC_0009270","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":33,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":6.0,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":5.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.143086+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_308688","record_id":"REC_0009271","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.5,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":7.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.143324+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_607864","record_id":"REC_0009272","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":14.0,"age_at_diagnosis":51,"sex":"male","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":6.0,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.143560+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_319516","record_id":"REC_0009273","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":13.3,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":4.5,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":4.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.143797+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_344920","record_id":"REC_0009274","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":15.4,"age_at_diagnosis":78,"sex":"male","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":4.5,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":23.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.144031+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_634929","record_id":"REC_0009275","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":3.7,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":6.2,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.144291+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_337188","record_id":"REC_0009276","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":4.3,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":4.5,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.144520+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_392970","record_id":"REC_0009277","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":6.1,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":34.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.144754+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_873431","record_id":"REC_0009278","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.1,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":5.7,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.144985+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_207968","record_id":"REC_0009279","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":10.1,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":5.0,"metastatic_sites_count":9,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.145217+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_812418","record_id":"REC_0009280","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":19,"tmb_mutations_per_mb":1.5,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":64,"primary_tumor_size_cm":4.8,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":18.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.145445+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_872686","record_id":"REC_0009281","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":5.9,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.145682+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_238243","record_id":"REC_0009282","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":16,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":5.7,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.145921+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_165938","record_id":"REC_0009283","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":14,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":6.3,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.146212+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_613414","record_id":"REC_0009284","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":20,"tmb_mutations_per_mb":4.6,"age_at_diagnosis":74,"sex":"male","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":7.5,"metastatic_sites_count":3,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.146454+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_422113","record_id":"REC_0009285","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":29,"primary_tumor_size_cm":5.2,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.146702+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_969259","record_id":"REC_0009286","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":17.1,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":5.5,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.146942+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_341408","record_id":"REC_0009287","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":8.3,"age_at_diagnosis":79,"sex":"male","ecog_performance_status":3,"smoking_pack_years":16,"primary_tumor_size_cm":6.4,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":4.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.147184+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_823096","record_id":"REC_0009288","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.1,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.147428+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_903703","record_id":"REC_0009289","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":4.9,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.147680+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_855994","record_id":"REC_0009290","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":20,"tmb_mutations_per_mb":2.4,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":6.3,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":22.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.147928+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_261501","record_id":"REC_0009291","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":10.0,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":22,"primary_tumor_size_cm":6.5,"metastatic_sites_count":8,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.148239+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_310320","record_id":"REC_0009292","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":16,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":76,"sex":"male","ecog_performance_status":2,"smoking_pack_years":20,"primary_tumor_size_cm":6.3,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.148508+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_468306","record_id":"REC_0009293","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":5.7,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":54,"primary_tumor_size_cm":5.5,"metastatic_sites_count":9,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.148752+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_996710","record_id":"REC_0009294","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":39,"tmb_mutations_per_mb":11.1,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":24,"primary_tumor_size_cm":5.0,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.149005+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_558134","record_id":"REC_0009295","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":5.2,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.149254+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_981381","record_id":"REC_0009296","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":81,"sex":"male","ecog_performance_status":2,"smoking_pack_years":28,"primary_tumor_size_cm":5.0,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.149603+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_465936","record_id":"REC_0009297","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":30,"tmb_mutations_per_mb":4.9,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":2,"smoking_pack_years":21,"primary_tumor_size_cm":6.1,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":17.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.149851+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_720505","record_id":"REC_0009298","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":2.6,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":2,"primary_tumor_size_cm":5.6,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.150094+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_870045","record_id":"REC_0009299","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":13.6,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":6.2,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":6.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.150339+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_501223","record_id":"REC_0009300","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":10.1,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":5.1,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.150581+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_457873","record_id":"REC_0009301","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":18,"tmb_mutations_per_mb":3.2,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":0,"smoking_pack_years":3,"primary_tumor_size_cm":5.3,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.150822+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_359147","record_id":"REC_0009302","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":18,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":4.9,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":5.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.151065+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_117251","record_id":"REC_0009303","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":2,"smoking_pack_years":27,"primary_tumor_size_cm":4.4,"metastatic_sites_count":10,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":6.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.151294+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_432040","record_id":"REC_0009304","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":17,"tmb_mutations_per_mb":8.4,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":3,"smoking_pack_years":18,"primary_tumor_size_cm":4.8,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.151524+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_173852","record_id":"REC_0009305","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":11.1,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":6.1,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.151761+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_994740","record_id":"REC_0009306","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":32,"tmb_mutations_per_mb":14.9,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":4.9,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.151997+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_284167","record_id":"REC_0009307","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":8.7,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.0,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":28.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.152313+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_576100","record_id":"REC_0009308","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":31,"tmb_mutations_per_mb":4.7,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":5,"primary_tumor_size_cm":3.6,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.152551+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_481900","record_id":"REC_0009309","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":18.2,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":7.1,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.152875+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_192551","record_id":"REC_0009310","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":14.4,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":26,"primary_tumor_size_cm":5.4,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.153114+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_941173","record_id":"REC_0009311","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":6.4,"age_at_diagnosis":85,"sex":"male","ecog_performance_status":3,"smoking_pack_years":30,"primary_tumor_size_cm":7.9,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":20.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.153355+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_714279","record_id":"REC_0009312","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":10.5,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":6.0,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":18.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.153593+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_757414","record_id":"REC_0009313","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":5.0,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.1,"metastatic_sites_count":9,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.153826+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_938086","record_id":"REC_0009314","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":30,"tmb_mutations_per_mb":20.8,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":7.2,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":17.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.154070+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_150244","record_id":"REC_0009315","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":9.8,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":5.3,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":4.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.154311+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_256745","record_id":"REC_0009316","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":8.6,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":7.7,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.154549+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_451593","record_id":"REC_0009317","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":4.1,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":6.0,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":16.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.154780+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_149452","record_id":"REC_0009318","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":11.1,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":4.0,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.155019+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_435681","record_id":"REC_0009319","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":15.1,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":4.2,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":16.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.155262+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_402384","record_id":"REC_0009320","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":6.4,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":31.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.155501+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_799383","record_id":"REC_0009321","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":2,"primary_tumor_size_cm":3.4,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.155737+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_905832","record_id":"REC_0009322","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":15.3,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":4,"primary_tumor_size_cm":5.4,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":18.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.156067+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_987516","record_id":"REC_0009323","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":14.3,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":6.0,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":23.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.156414+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_405088","record_id":"REC_0009324","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":10.3,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":5.9,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":20.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.156658+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_993439","record_id":"REC_0009325","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":9.7,"age_at_diagnosis":54,"sex":"male","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":5.2,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":6.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.156896+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_714009","record_id":"REC_0009326","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":8.1,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":6.6,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":17.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.157131+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_442773","record_id":"REC_0009327","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":6.0,"age_at_diagnosis":78,"sex":"male","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":5.3,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":33.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.157374+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_485613","record_id":"REC_0009328","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":13.8,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":4.6,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.157618+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_543864","record_id":"REC_0009329","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None","pd_l1_tps_percent":19,"tmb_mutations_per_mb":6.0,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":65,"primary_tumor_size_cm":4.1,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":29.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.157851+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_329650","record_id":"REC_0009330","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":6.1,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":51.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.158092+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_110244","record_id":"REC_0009331","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":13.8,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":5.6,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":21.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.158340+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_333943","record_id":"REC_0009332","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":10.3,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":5.0,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.158583+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_118253","record_id":"REC_0009333","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":8.5,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":24,"primary_tumor_size_cm":5.0,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.158816+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_768696","record_id":"REC_0009334","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":18.9,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":2,"smoking_pack_years":8,"primary_tumor_size_cm":4.1,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":6.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.159053+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_228273","record_id":"REC_0009335","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":18.0,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":5.2,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.159443+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_576070","record_id":"REC_0009336","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":9.5,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":5.7,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.159679+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_820647","record_id":"REC_0009337","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":8.6,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":26,"primary_tumor_size_cm":4.3,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.159926+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_448560","record_id":"REC_0009338","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":32,"tmb_mutations_per_mb":15.5,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":4.6,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":8.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.160321+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_304557","record_id":"REC_0009339","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":34,"tmb_mutations_per_mb":8.9,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":5,"primary_tumor_size_cm":4.7,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.160571+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_483827","record_id":"REC_0009340","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":18.3,"age_at_diagnosis":87,"sex":"male","ecog_performance_status":2,"smoking_pack_years":25,"primary_tumor_size_cm":6.4,"metastatic_sites_count":9,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.160822+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_350345","record_id":"REC_0009341","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":18.8,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":6.0,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":16.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.161071+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_803331","record_id":"REC_0009342","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":20,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":1,"smoking_pack_years":25,"primary_tumor_size_cm":6.7,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":6.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.161313+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_475870","record_id":"REC_0009343","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":14.8,"age_at_diagnosis":48,"sex":"female","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":5.2,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.161563+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_575903","record_id":"REC_0009344","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":32,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":0,"smoking_pack_years":28,"primary_tumor_size_cm":5.7,"metastatic_sites_count":8,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.161822+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_345715","record_id":"REC_0009345","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":15,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":62,"primary_tumor_size_cm":4.3,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.162131+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_470518","record_id":"REC_0009346","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":32,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":3,"smoking_pack_years":13,"primary_tumor_size_cm":4.4,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.162446+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_705716","record_id":"REC_0009347","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":35,"tmb_mutations_per_mb":13.6,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":5.4,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.162703+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_250093","record_id":"REC_0009348","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":30,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":67,"primary_tumor_size_cm":4.3,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":18.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.163077+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_980258","record_id":"REC_0009349","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":8.4,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":4.8,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":22.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.163337+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_328604","record_id":"REC_0009350","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":5.2,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":0,"smoking_pack_years":67,"primary_tumor_size_cm":6.3,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":18.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.163585+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_527130","record_id":"REC_0009351","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":5.9,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":28.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.163825+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_496603","record_id":"REC_0009352","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":85,"sex":"female","ecog_performance_status":2,"smoking_pack_years":7,"primary_tumor_size_cm":5.7,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.164058+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_981434","record_id":"REC_0009353","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":18.5,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":7.3,"metastatic_sites_count":3,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.164388+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_816923","record_id":"REC_0009354","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":15.4,"age_at_diagnosis":44,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":7.2,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":20.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.164649+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_639185","record_id":"REC_0009355","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":17.5,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":6.2,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.164888+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_224246","record_id":"REC_0009356","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":20,"tmb_mutations_per_mb":13.6,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":3.8,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.165139+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_944871","record_id":"REC_0009357","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":5.2,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":5.0,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":31.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.165393+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_379970","record_id":"REC_0009358","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":7.4,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":4.8,"metastatic_sites_count":9,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.165633+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_497429","record_id":"REC_0009359","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":51,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":5.3,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.165875+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_521902","record_id":"REC_0009360","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":4.7,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":24.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.166120+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_237568","record_id":"REC_0009361","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":30,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":40,"primary_tumor_size_cm":6.0,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.166441+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_967852","record_id":"REC_0009362","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":15.8,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":3.8,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.166685+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_970786","record_id":"REC_0009363","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":3.8,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":3,"smoking_pack_years":38,"primary_tumor_size_cm":6.4,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.166918+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_169603","record_id":"REC_0009364","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":5.7,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":55,"primary_tumor_size_cm":5.2,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.167162+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_107111","record_id":"REC_0009365","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":4.0,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":23.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.167405+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_935941","record_id":"REC_0009366","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":9.5,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":6.5,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.167633+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_298737","record_id":"REC_0009367","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":50,"sex":"male","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":4.6,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":8.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.167880+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_447654","record_id":"REC_0009368","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":16,"tmb_mutations_per_mb":16.3,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":3,"smoking_pack_years":6,"primary_tumor_size_cm":6.1,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":24.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.168205+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_650290","record_id":"REC_0009369","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":17.0,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":6.5,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.168457+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_508690","record_id":"REC_0009370","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":8.9,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":3,"smoking_pack_years":20,"primary_tumor_size_cm":4.5,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":5.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.168689+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_365537","record_id":"REC_0009371","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":16.7,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":5.3,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":16.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.168934+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_932140","record_id":"REC_0009372","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":18,"tmb_mutations_per_mb":9.1,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":61,"primary_tumor_size_cm":6.4,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":17.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.169177+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_588066","record_id":"REC_0009373","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":18,"tmb_mutations_per_mb":5.6,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":1,"smoking_pack_years":49,"primary_tumor_size_cm":5.0,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.169418+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_802884","record_id":"REC_0009374","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":18.1,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":5.6,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":16.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.169750+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_942650","record_id":"REC_0009375","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":25,"primary_tumor_size_cm":4.6,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":18.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.170002+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_460514","record_id":"REC_0009376","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":3,"smoking_pack_years":52,"primary_tumor_size_cm":4.7,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.170249+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_903094","record_id":"REC_0009377","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":4.8,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":32.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.170493+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_835232","record_id":"REC_0009378","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":8.1,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":5.8,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":22.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.170741+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_249012","record_id":"REC_0009379","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":6.3,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":0,"smoking_pack_years":41,"primary_tumor_size_cm":5.5,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.170996+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_354847","record_id":"REC_0009380","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":31,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":47,"sex":"male","ecog_performance_status":0,"smoking_pack_years":0,"primary_tumor_size_cm":2.5,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.171232+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_878155","record_id":"REC_0009381","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":33,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":4.6,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.171464+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_812015","record_id":"REC_0009382","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":53,"sex":"male","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":6.2,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":49.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.171699+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_991777","record_id":"REC_0009383","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":15.0,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":6.1,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.171939+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_371696","record_id":"REC_0009384","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":3,"smoking_pack_years":3,"primary_tumor_size_cm":3.4,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.172219+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_472259","record_id":"REC_0009385","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":19,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":4.5,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.172479+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_457025","record_id":"REC_0009386","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":0,"smoking_pack_years":6,"primary_tumor_size_cm":6.7,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.172732+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_279263","record_id":"REC_0009387","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":16.3,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":6.2,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":18.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.173067+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_332034","record_id":"REC_0009388","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":4.1,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":3.5,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.173313+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_756384","record_id":"REC_0009389","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":6.9,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":26,"primary_tumor_size_cm":3.3,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.173555+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_678726","record_id":"REC_0009390","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":5,"primary_tumor_size_cm":5.8,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.173804+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_587860","record_id":"REC_0009391","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":7.0,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":23.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.174057+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_681333","record_id":"REC_0009392","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":17.1,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":7.4,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":30.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.174307+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_702270","record_id":"REC_0009393","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":8.6,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":6.1,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":17.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.174550+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_169566","record_id":"REC_0009394","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":4.0,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":55,"primary_tumor_size_cm":6.2,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":6.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.174783+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_233050","record_id":"REC_0009395","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":4.8,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":33,"primary_tumor_size_cm":7.1,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.175026+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_237215","record_id":"REC_0009396","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":9.5,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":6.4,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.175269+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_643037","record_id":"REC_0009397","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":4.3,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.3,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":22.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.175507+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_519557","record_id":"REC_0009398","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":14.7,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":3.7,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":17.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.175751+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_733295","record_id":"REC_0009399","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":76,"sex":"male","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":3.4,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.176000+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_149301","record_id":"REC_0009400","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":16.7,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":2.9,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.176493+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_443277","record_id":"REC_0009401","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":6.9,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":20.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.176754+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_816321","record_id":"REC_0009402","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":8.1,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":3.7,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":21.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.177005+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_650932","record_id":"REC_0009403","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":3.8,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":36.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.177258+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_460273","record_id":"REC_0009404","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":8.1,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":6.3,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.177503+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_711955","record_id":"REC_0009405","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.3,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.177747+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_159964","record_id":"REC_0009406","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":5.9,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":16.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.177989+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_645852","record_id":"REC_0009407","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":5.0,"age_at_diagnosis":74,"sex":"male","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":6.9,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.178231+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_405430","record_id":"REC_0009408","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":8.8,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.178474+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_616310","record_id":"REC_0009409","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":5.5,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":0,"smoking_pack_years":60,"primary_tumor_size_cm":3.8,"metastatic_sites_count":8,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.178714+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_108868","record_id":"REC_0009410","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":7.4,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":46,"primary_tumor_size_cm":5.8,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":17.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.178956+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_537314","record_id":"REC_0009411","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":11.1,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":5.2,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.179202+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_809569","record_id":"REC_0009412","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":8.6,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":4.6,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.179450+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_822489","record_id":"REC_0009413","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":78,"sex":"male","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":4.5,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.179825+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_386962","record_id":"REC_0009414","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":7.6,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":1,"smoking_pack_years":57,"primary_tumor_size_cm":7.7,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.180254+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_710788","record_id":"REC_0009415","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":34,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":5.8,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.180548+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_135671","record_id":"REC_0009416","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":2.9,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":5.0,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":27.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.180804+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_696219","record_id":"REC_0009417","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":8.6,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":24,"primary_tumor_size_cm":5.8,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":17.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.181053+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_980487","record_id":"REC_0009418","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":5.5,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":27.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.181292+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_123143","record_id":"REC_0009419","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":1,"primary_tumor_size_cm":6.2,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":27.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.181529+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_430678","record_id":"REC_0009420","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":6.4,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":7.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.181761+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_744998","record_id":"REC_0009421","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":32,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":4.5,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":18.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.181999+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_328207","record_id":"REC_0009422","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":9.7,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":4.7,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":24.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.182240+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_944279","record_id":"REC_0009423","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":15,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":48,"sex":"male","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":5.5,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.182483+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_313862","record_id":"REC_0009424","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":8.9,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":6.2,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":6.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.182722+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_269680","record_id":"REC_0009425","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":9.1,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":6.3,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":17.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.182966+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_883362","record_id":"REC_0009426","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":31,"tmb_mutations_per_mb":17.7,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":0,"primary_tumor_size_cm":6.8,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.183340+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_347878","record_id":"REC_0009427","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":32,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":1,"smoking_pack_years":39,"primary_tumor_size_cm":5.8,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.183599+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_835469","record_id":"REC_0009428","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":7.6,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":5,"primary_tumor_size_cm":6.4,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.183841+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_301833","record_id":"REC_0009429","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":7.9,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":20,"primary_tumor_size_cm":7.2,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":18.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.184124+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_942294","record_id":"REC_0009430","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":27,"primary_tumor_size_cm":5.1,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.184390+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_324046","record_id":"REC_0009431","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":5.7,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":25,"primary_tumor_size_cm":7.4,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.184642+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_744338","record_id":"REC_0009432","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":19,"tmb_mutations_per_mb":8.6,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":5.9,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.184888+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_949858","record_id":"REC_0009433","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":4.7,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":49,"primary_tumor_size_cm":6.4,"metastatic_sites_count":9,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.185133+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_628096","record_id":"REC_0009434","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":6.5,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.185392+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_774360","record_id":"REC_0009435","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":7.1,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.185632+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_614541","record_id":"REC_0009436","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":4.0,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":6.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.185867+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_212728","record_id":"REC_0009437","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":19,"tmb_mutations_per_mb":5.5,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":23,"primary_tumor_size_cm":2.1,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":36.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.186099+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_284646","record_id":"REC_0009438","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":6.4,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":4.9,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.186342+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_320152","record_id":"REC_0009439","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":2.7,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":25.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.186698+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_866064","record_id":"REC_0009440","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":1,"smoking_pack_years":25,"primary_tumor_size_cm":5.7,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":26.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.186955+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_374222","record_id":"REC_0009441","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":9.1,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":5.9,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":17.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.187208+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_605897","record_id":"REC_0009442","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":9.0,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":24,"primary_tumor_size_cm":4.4,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.187447+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_874604","record_id":"REC_0009443","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":17.2,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":6.0,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":31.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.187686+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_130472","record_id":"REC_0009444","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.6,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.187923+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_449348","record_id":"REC_0009445","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":6.0,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":26.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.188231+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_417947","record_id":"REC_0009446","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":3.8,"metastatic_sites_count":8,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":16.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.188500+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_367286","record_id":"REC_0009447","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":35,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":5.4,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.188752+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_600956","record_id":"REC_0009448","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":7.3,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":4.5,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.189008+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_127507","record_id":"REC_0009449","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":9.1,"age_at_diagnosis":51,"sex":"female","ecog_performance_status":0,"smoking_pack_years":0,"primary_tumor_size_cm":4.4,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":27.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.189267+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_121899","record_id":"REC_0009450","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":4.3,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":26,"primary_tumor_size_cm":4.4,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.189511+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_715732","record_id":"REC_0009451","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":5.5,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.189771+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_458804","record_id":"REC_0009452","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":15.4,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":6.7,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":26.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.190140+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_785764","record_id":"REC_0009453","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":4.0,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.190413+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_173088","record_id":"REC_0009454","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":15.3,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":5.0,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.190719+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_778422","record_id":"REC_0009455","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":13.8,"age_at_diagnosis":84,"sex":"female","ecog_performance_status":1,"smoking_pack_years":5,"primary_tumor_size_cm":5.0,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.191046+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_141967","record_id":"REC_0009456","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":4.8,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":7.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.191542+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_241429","record_id":"REC_0009457","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":16.2,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":5.2,"metastatic_sites_count":9,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.192005+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_233422","record_id":"REC_0009458","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":17.3,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":6.0,"metastatic_sites_count":9,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":18.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.192999+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_643823","record_id":"REC_0009459","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":6.8,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.193252+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_510777","record_id":"REC_0009460","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":5.3,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.193505+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_623645","record_id":"REC_0009461","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":10.1,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":4.6,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.193745+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_813989","record_id":"REC_0009462","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":18.9,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.2,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.193987+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_742341","record_id":"REC_0009463","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":14,"tmb_mutations_per_mb":5.1,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":3.5,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":21.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.194227+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_699428","record_id":"REC_0009464","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":0,"smoking_pack_years":6,"primary_tumor_size_cm":7.0,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.194467+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_891934","record_id":"REC_0009465","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":19,"tmb_mutations_per_mb":3.5,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":1,"smoking_pack_years":29,"primary_tumor_size_cm":5.9,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":17.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.194816+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_578403","record_id":"REC_0009466","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":5.3,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":0,"smoking_pack_years":6,"primary_tumor_size_cm":5.8,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":6.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.195071+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_618856","record_id":"REC_0009467","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":34,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":3,"smoking_pack_years":11,"primary_tumor_size_cm":4.8,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.195321+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_871531","record_id":"REC_0009468","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":10.3,"age_at_diagnosis":54,"sex":"male","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":6.4,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.195573+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_947697","record_id":"REC_0009469","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":1,"smoking_pack_years":5,"primary_tumor_size_cm":3.6,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.195817+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_771711","record_id":"REC_0009470","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":16.5,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":3,"primary_tumor_size_cm":6.1,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":18.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.196068+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_389879","record_id":"REC_0009471","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":4.8,"metastatic_sites_count":9,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.196522+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_472159","record_id":"REC_0009472","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":13,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":5.3,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.196783+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_457778","record_id":"REC_0009473","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":9.9,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":26,"primary_tumor_size_cm":6.1,"metastatic_sites_count":8,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.197032+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_464628","record_id":"REC_0009474","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":19,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":54,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":5.0,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.197271+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_389311","record_id":"REC_0009475","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":5.0,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.197510+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_846410","record_id":"REC_0009476","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":0,"smoking_pack_years":67,"primary_tumor_size_cm":3.4,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":18.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.197741+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_666599","record_id":"REC_0009477","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":5.0,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.197978+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_584923","record_id":"REC_0009478","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":14.1,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":5.5,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":23.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.198341+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_864943","record_id":"REC_0009479","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":14,"tmb_mutations_per_mb":5.0,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":62,"primary_tumor_size_cm":5.2,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":7.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.198602+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_256574","record_id":"REC_0009480","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":16.0,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":7.0,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.198848+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_257105","record_id":"REC_0009481","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":16.6,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":6.7,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.199091+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_682494","record_id":"REC_0009482","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":15.5,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":9,"primary_tumor_size_cm":5.4,"metastatic_sites_count":9,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":5.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.199343+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_130128","record_id":"REC_0009483","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":4.5,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.199587+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_431652","record_id":"REC_0009484","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":8.9,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":30,"primary_tumor_size_cm":6.8,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.199827+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_232574","record_id":"REC_0009485","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":8.4,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":4.4,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.200065+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_233812","record_id":"REC_0009486","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":16.6,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":6.2,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.200388+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_281779","record_id":"REC_0009487","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":1,"smoking_pack_years":48,"primary_tumor_size_cm":6.4,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":30.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.200640+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_856439","record_id":"REC_0009488","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":6.4,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":20.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.200886+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_129302","record_id":"REC_0009489","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.4,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.201135+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_387272","record_id":"REC_0009490","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":8.7,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":6.0,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.201376+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_884139","record_id":"REC_0009491","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":5.1,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":22,"primary_tumor_size_cm":7.2,"metastatic_sites_count":3,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":16.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.201707+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_549715","record_id":"REC_0009492","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":14.9,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":7.9,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.201957+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_318007","record_id":"REC_0009493","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":10.5,"age_at_diagnosis":78,"sex":"male","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":4.8,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.202209+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_956281","record_id":"REC_0009494","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":85,"sex":"female","ecog_performance_status":3,"smoking_pack_years":8,"primary_tumor_size_cm":5.7,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":6.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.202446+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_331424","record_id":"REC_0009495","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":30,"tmb_mutations_per_mb":4.8,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":5.1,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.202684+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_613549","record_id":"REC_0009496","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":34,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":5.1,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.202922+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_712426","record_id":"REC_0009497","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":15.1,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":5.5,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":16.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.203164+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_224594","record_id":"REC_0009498","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":9.5,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":6.8,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":30.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.203395+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_502576","record_id":"REC_0009499","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":4.6,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":20.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.203633+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_584377","record_id":"REC_0009500","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":6.6,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.203870+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_727943","record_id":"REC_0009501","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":30,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":5.7,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":21.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.204151+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_905760","record_id":"REC_0009502","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":7.7,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.204400+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_358533","record_id":"REC_0009503","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":2,"smoking_pack_years":21,"primary_tumor_size_cm":4.3,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":7.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.204639+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_546293","record_id":"REC_0009504","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":17,"tmb_mutations_per_mb":13.8,"age_at_diagnosis":40,"sex":"female","ecog_performance_status":0,"smoking_pack_years":25,"primary_tumor_size_cm":5.8,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":17.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.204956+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_262334","record_id":"REC_0009505","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":19,"tmb_mutations_per_mb":8.4,"age_at_diagnosis":50,"sex":"female","ecog_performance_status":0,"smoking_pack_years":71,"primary_tumor_size_cm":5.5,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":27.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.205203+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_870051","record_id":"REC_0009506","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":24,"primary_tumor_size_cm":7.5,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.205447+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_815552","record_id":"REC_0009507","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":24,"primary_tumor_size_cm":5.6,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":16.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.205698+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_384863","record_id":"REC_0009508","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":3,"primary_tumor_size_cm":5.1,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.205948+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_662393","record_id":"REC_0009509","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":4.0,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":52,"primary_tumor_size_cm":5.9,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":23.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.206194+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_660190","record_id":"REC_0009510","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":8.3,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":9.4,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.206443+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_143979","record_id":"REC_0009511","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":5.1,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":25.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.206690+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_120633","record_id":"REC_0009512","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":4.2,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":0,"smoking_pack_years":28,"primary_tumor_size_cm":4.7,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.206931+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_715323","record_id":"REC_0009513","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":4.8,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":75,"primary_tumor_size_cm":6.0,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.207182+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_598886","record_id":"REC_0009514","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":6.3,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":6,"primary_tumor_size_cm":6.3,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.207423+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_397552","record_id":"REC_0009515","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":6.9,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.207661+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_905605","record_id":"REC_0009516","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":59,"primary_tumor_size_cm":4.1,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.207891+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_473065","record_id":"REC_0009517","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":6.0,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":0,"smoking_pack_years":63,"primary_tumor_size_cm":7.0,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":18.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.208308+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_918420","record_id":"REC_0009518","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":3,"smoking_pack_years":10,"primary_tumor_size_cm":3.9,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":41.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.208567+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_351588","record_id":"REC_0009519","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":11.5,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":7.3,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.208806+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_467742","record_id":"REC_0009520","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":30,"tmb_mutations_per_mb":6.0,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":3.3,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":18.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.209040+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_534221","record_id":"REC_0009521","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":9,"primary_tumor_size_cm":5.8,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.209276+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_566368","record_id":"REC_0009522","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":8.5,"age_at_diagnosis":52,"sex":"female","ecog_performance_status":0,"smoking_pack_years":33,"primary_tumor_size_cm":6.2,"metastatic_sites_count":3,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.209514+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_535987","record_id":"REC_0009523","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":6.1,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":70,"primary_tumor_size_cm":5.1,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.209748+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_649756","record_id":"REC_0009524","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":2,"smoking_pack_years":7,"primary_tumor_size_cm":5.7,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":71.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.209988+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_643347","record_id":"REC_0009525","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":6.7,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":28,"primary_tumor_size_cm":4.9,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.210220+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_963205","record_id":"REC_0009526","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":7.4,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":3,"smoking_pack_years":19,"primary_tumor_size_cm":5.8,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":23.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.210452+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_544228","record_id":"REC_0009527","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":16.6,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":7.6,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.210687+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_250270","record_id":"REC_0009528","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":9.1,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":4.9,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.210918+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_320240","record_id":"REC_0009529","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":9.8,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":4.7,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.211150+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_829761","record_id":"REC_0009530","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":13.8,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":4.7,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":4.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.211500+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_904662","record_id":"REC_0009531","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":15.1,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":4.8,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.211751+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_178822","record_id":"REC_0009532","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":16.9,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":28,"primary_tumor_size_cm":4.1,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":23.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.211995+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_703684","record_id":"REC_0009533","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":4.1,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.212336+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_713199","record_id":"REC_0009534","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":18.0,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":6.0,"metastatic_sites_count":9,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.212601+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_143289","record_id":"REC_0009535","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":5.8,"metastatic_sites_count":8,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.212845+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_719582","record_id":"REC_0009536","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":13.1,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":4.0,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":46.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.213082+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_898788","record_id":"REC_0009537","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":23.8,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":6.6,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.213322+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_829826","record_id":"REC_0009538","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":30,"tmb_mutations_per_mb":4.6,"age_at_diagnosis":77,"sex":"male","ecog_performance_status":1,"smoking_pack_years":4,"primary_tumor_size_cm":6.6,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.213559+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_429840","record_id":"REC_0009539","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":32,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":5.5,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":36.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.213798+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_778980","record_id":"REC_0009540","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":3.5,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":64,"primary_tumor_size_cm":6.1,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":27.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.214037+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_170393","record_id":"REC_0009541","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":13.8,"age_at_diagnosis":85,"sex":"female","ecog_performance_status":3,"smoking_pack_years":13,"primary_tumor_size_cm":4.9,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.214277+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_826027","record_id":"REC_0009542","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":17,"tmb_mutations_per_mb":17.5,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":4.0,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.214520+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_310703","record_id":"REC_0009543","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":7.6,"age_at_diagnosis":51,"sex":"male","ecog_performance_status":0,"smoking_pack_years":52,"primary_tumor_size_cm":7.7,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":5.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.214886+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_553938","record_id":"REC_0009544","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":3.9,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.215135+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_824273","record_id":"REC_0009545","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":2.3,"age_at_diagnosis":85,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":2.1,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.215373+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_919128","record_id":"REC_0009546","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":5.7,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":5.5,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.215611+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_500866","record_id":"REC_0009547","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":19.5,"age_at_diagnosis":52,"sex":"male","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":6.2,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":23.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.215850+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_896007","record_id":"REC_0009548","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":6.4,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":6.3,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.216140+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_812840","record_id":"REC_0009549","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":5.5,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":7.1,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.216396+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_764990","record_id":"REC_0009550","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":14.3,"age_at_diagnosis":82,"sex":"male","ecog_performance_status":3,"smoking_pack_years":18,"primary_tumor_size_cm":7.1,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.216639+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_748020","record_id":"REC_0009551","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":6.0,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":1,"smoking_pack_years":68,"primary_tumor_size_cm":4.0,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.216876+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_832023","record_id":"REC_0009552","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":17,"tmb_mutations_per_mb":4.9,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":77,"primary_tumor_size_cm":4.5,"metastatic_sites_count":8,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.217112+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_854610","record_id":"REC_0009553","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":4.5,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":0,"smoking_pack_years":50,"primary_tumor_size_cm":6.3,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":17.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.217346+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_616297","record_id":"REC_0009554","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":31,"tmb_mutations_per_mb":6.3,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":40,"primary_tumor_size_cm":6.8,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.217577+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_238230","record_id":"REC_0009555","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":15.4,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":5.5,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.217814+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_485938","record_id":"REC_0009556","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":8.9,"age_at_diagnosis":79,"sex":"male","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":5.3,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":24.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.218154+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_624130","record_id":"REC_0009557","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":11.5,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.9,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.218393+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_467552","record_id":"REC_0009558","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":10.1,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":4,"primary_tumor_size_cm":4.2,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.218624+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_534423","record_id":"REC_0009559","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":13,"tmb_mutations_per_mb":17.6,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":3,"smoking_pack_years":19,"primary_tumor_size_cm":6.5,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.218860+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_597801","record_id":"REC_0009560","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":11.1,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":4.1,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.219095+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_531571","record_id":"REC_0009561","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":4.9,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":5.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.219322+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_996539","record_id":"REC_0009562","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":9.9,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":6.2,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.219552+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_574341","record_id":"REC_0009563","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":17.4,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":5.8,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.219787+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_865547","record_id":"REC_0009564","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":18,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":5.9,"metastatic_sites_count":8,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":7.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.220014+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_898308","record_id":"REC_0009565","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":5.1,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.220285+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_777616","record_id":"REC_0009566","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":19,"tmb_mutations_per_mb":9.7,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":55,"primary_tumor_size_cm":4.5,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.220517+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_540873","record_id":"REC_0009567","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":4.8,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":72,"primary_tumor_size_cm":5.2,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":6.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.220757+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_944951","record_id":"REC_0009568","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":11.0,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":2,"smoking_pack_years":8,"primary_tumor_size_cm":7.3,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.220988+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_105505","record_id":"REC_0009569","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.0,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":0,"smoking_pack_years":28,"primary_tumor_size_cm":6.1,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":21.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.221270+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_673515","record_id":"REC_0009570","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":15.4,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":5.9,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":20.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.221508+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_887943","record_id":"REC_0009571","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":7.6,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":25.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.221743+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_254606","record_id":"REC_0009572","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":34,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":6.5,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.221981+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_580803","record_id":"REC_0009573","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":5.0,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.222216+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_222641","record_id":"REC_0009574","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":4,"primary_tumor_size_cm":5.5,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.222448+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_421138","record_id":"REC_0009575","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":8,"primary_tumor_size_cm":6.6,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.222680+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_798674","record_id":"REC_0009576","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":19.3,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":0,"smoking_pack_years":3,"primary_tumor_size_cm":6.0,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":17.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.222913+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_329134","record_id":"REC_0009577","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":4.0,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.223146+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_119945","record_id":"REC_0009578","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":16,"tmb_mutations_per_mb":10.3,"age_at_diagnosis":52,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":5.0,"metastatic_sites_count":3,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.223378+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_242372","record_id":"REC_0009579","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":5.1,"metastatic_sites_count":3,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":21.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.223613+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_789876","record_id":"REC_0009580","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":9.7,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":8.7,"metastatic_sites_count":8,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":7.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.223841+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_996647","record_id":"REC_0009581","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":50,"sex":"male","ecog_performance_status":0,"smoking_pack_years":43,"primary_tumor_size_cm":6.4,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.224182+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_866430","record_id":"REC_0009582","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":5.1,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":19.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.224480+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_571788","record_id":"REC_0009583","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":14,"tmb_mutations_per_mb":14.1,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":6.6,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.224722+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_453626","record_id":"REC_0009584","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":32,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":42,"primary_tumor_size_cm":5.1,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.224952+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_966862","record_id":"REC_0009585","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":5.1,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":19.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.225191+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_985068","record_id":"REC_0009586","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":30,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":5.5,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.225426+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_150915","record_id":"REC_0009587","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":41,"primary_tumor_size_cm":4.2,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.225658+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_540849","record_id":"REC_0009588","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":15,"tmb_mutations_per_mb":13.6,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":5.3,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":5.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.225893+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_590329","record_id":"REC_0009589","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":4.7,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.226129+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_643444","record_id":"REC_0009590","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":21.1,"age_at_diagnosis":52,"sex":"male","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":4.0,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":47.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.226366+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_277814","record_id":"REC_0009591","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":26,"primary_tumor_size_cm":3.9,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":24.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.226602+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_397285","record_id":"REC_0009592","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":6.0,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.226833+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_178112","record_id":"REC_0009593","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":17,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":4.3,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.227069+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_199874","record_id":"REC_0009594","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":15.3,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":5.1,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":22.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.227303+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_995900","record_id":"REC_0009595","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":20,"tmb_mutations_per_mb":5.2,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":2,"smoking_pack_years":26,"primary_tumor_size_cm":6.8,"metastatic_sites_count":3,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":19.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.227572+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_194910","record_id":"REC_0009596","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":30,"tmb_mutations_per_mb":7.6,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":2,"smoking_pack_years":41,"primary_tumor_size_cm":6.2,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":32.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.227809+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_839600","record_id":"REC_0009597","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":17.4,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":4,"primary_tumor_size_cm":6.1,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":7.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.228049+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_731932","record_id":"REC_0009598","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":8.7,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.4,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":24.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.228349+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_449135","record_id":"REC_0009599","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":30,"tmb_mutations_per_mb":6.0,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":59,"primary_tumor_size_cm":3.7,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.228584+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_623751","record_id":"REC_0009600","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":24,"primary_tumor_size_cm":4.3,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.228820+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_209380","record_id":"REC_0009601","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":6.2,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":22.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.229052+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_194375","record_id":"REC_0009602","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":17,"tmb_mutations_per_mb":2.0,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":26,"primary_tumor_size_cm":5.3,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":19.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.229289+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_500447","record_id":"REC_0009603","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":15.0,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":0,"smoking_pack_years":31,"primary_tumor_size_cm":6.3,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.229523+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_456041","record_id":"REC_0009604","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":9.9,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":29,"primary_tumor_size_cm":4.0,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":35.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.229751+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_927581","record_id":"REC_0009605","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":15.0,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":4.0,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.229998+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_533236","record_id":"REC_0009606","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":15,"tmb_mutations_per_mb":16.3,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":7.1,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.230261+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_134092","record_id":"REC_0009607","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":18,"tmb_mutations_per_mb":14.6,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":4.1,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":25.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.230499+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_655600","record_id":"REC_0009608","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":6.6,"metastatic_sites_count":8,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.230781+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_103429","record_id":"REC_0009609","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":3.7,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":31.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.231017+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_366388","record_id":"REC_0009610","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":14.3,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":7.6,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":6.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.231252+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_892354","record_id":"REC_0009611","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":8.5,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":6.1,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.231492+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_554988","record_id":"REC_0009612","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":6.7,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":5.3,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":18.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.231725+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_633188","record_id":"REC_0009613","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":6.7,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":5.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.231969+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_908235","record_id":"REC_0009614","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":9.0,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":8.7,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.232227+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_996921","record_id":"REC_0009615","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":14.7,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":4.9,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":5.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.232477+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_132608","record_id":"REC_0009616","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":5.8,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":27.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.232771+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_497523","record_id":"REC_0009617","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":7,"primary_tumor_size_cm":6.4,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":20.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.233012+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_420174","record_id":"REC_0009618","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":4.8,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":30.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.233253+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_429191","record_id":"REC_0009619","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.0,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":6.4,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":26.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.233493+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_686358","record_id":"REC_0009620","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":32,"tmb_mutations_per_mb":6.0,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":6.0,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.233734+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_606409","record_id":"REC_0009621","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":18,"tmb_mutations_per_mb":8.4,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":56,"primary_tumor_size_cm":6.3,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.234059+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_974168","record_id":"REC_0009622","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":0,"smoking_pack_years":33,"primary_tumor_size_cm":5.8,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":17.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.234329+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_994695","record_id":"REC_0009623","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":6.7,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":1,"smoking_pack_years":4,"primary_tumor_size_cm":5.9,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":24.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.234584+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_422734","record_id":"REC_0009624","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":4.7,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":46,"primary_tumor_size_cm":3.4,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.234833+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_982244","record_id":"REC_0009625","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":4.7,"metastatic_sites_count":8,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.235077+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_393407","record_id":"REC_0009626","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":14.1,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":6.1,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.235318+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_667424","record_id":"REC_0009627","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":33,"tmb_mutations_per_mb":16.3,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":6.5,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":17.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.235579+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_875009","record_id":"REC_0009628","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":14.4,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":22,"primary_tumor_size_cm":6.7,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":5.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.235818+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_624487","record_id":"REC_0009629","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":4.3,"metastatic_sites_count":8,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.236068+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_451036","record_id":"REC_0009630","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":13,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":6.7,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":23.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.236459+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_445752","record_id":"REC_0009631","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":16.5,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":7.0,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.236706+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_443680","record_id":"REC_0009632","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":19,"tmb_mutations_per_mb":6.1,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":1,"smoking_pack_years":50,"primary_tumor_size_cm":4.8,"metastatic_sites_count":3,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.236944+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_108516","record_id":"REC_0009633","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":13,"tmb_mutations_per_mb":10.3,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":5.6,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.237181+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_178661","record_id":"REC_0009634","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":11.0,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":5.9,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":17.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.237534+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_109615","record_id":"REC_0009635","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":19,"tmb_mutations_per_mb":16.3,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":0,"smoking_pack_years":25,"primary_tumor_size_cm":5.4,"metastatic_sites_count":8,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.237779+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_428665","record_id":"REC_0009636","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":6.5,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.238011+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_561485","record_id":"REC_0009637","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":8.1,"age_at_diagnosis":83,"sex":"female","ecog_performance_status":1,"smoking_pack_years":30,"primary_tumor_size_cm":6.5,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.238241+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_198316","record_id":"REC_0009638","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":2.8,"age_at_diagnosis":79,"sex":"male","ecog_performance_status":2,"smoking_pack_years":63,"primary_tumor_size_cm":5.4,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":5.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.238479+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_586492","record_id":"REC_0009639","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":7.7,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.238717+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_506749","record_id":"REC_0009640","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":10,"primary_tumor_size_cm":4.5,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.238953+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_561694","record_id":"REC_0009641","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":10.3,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":6.2,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.239182+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_368546","record_id":"REC_0009642","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":9.5,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":28,"primary_tumor_size_cm":5.1,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.239408+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_309022","record_id":"REC_0009643","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":32,"tmb_mutations_per_mb":6.0,"age_at_diagnosis":75,"sex":"male","ecog_performance_status":2,"smoking_pack_years":10,"primary_tumor_size_cm":4.6,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.239643+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_400983","record_id":"REC_0009644","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":44,"primary_tumor_size_cm":5.7,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":7.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.239867+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_884742","record_id":"REC_0009645","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":7.6,"age_at_diagnosis":83,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":6.1,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.240144+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_548749","record_id":"REC_0009646","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":4.1,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":46,"primary_tumor_size_cm":3.2,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":19.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.240393+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_728038","record_id":"REC_0009647","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":34,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":6.4,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.240768+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_258804","record_id":"REC_0009648","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":33,"tmb_mutations_per_mb":3.9,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":0,"smoking_pack_years":46,"primary_tumor_size_cm":7.0,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":4.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.241014+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_240866","record_id":"REC_0009649","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":5.5,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.241281+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_568791","record_id":"REC_0009650","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":19,"tmb_mutations_per_mb":8.3,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":5.0,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":5.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.241559+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_692961","record_id":"REC_0009651","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":17,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":48,"primary_tumor_size_cm":5.4,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.241885+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_270999","record_id":"REC_0009652","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ALK fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":4.5,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.242132+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_590767","record_id":"REC_0009653","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":31,"tmb_mutations_per_mb":13.3,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":0,"smoking_pack_years":6,"primary_tumor_size_cm":4.6,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.242377+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_332873","record_id":"REC_0009654","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":30,"tmb_mutations_per_mb":15.3,"age_at_diagnosis":85,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":3.8,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.242616+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_763147","record_id":"REC_0009655","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":5.6,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":4.5,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":7.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.242861+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_287548","record_id":"REC_0009656","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":15.2,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":9,"primary_tumor_size_cm":7.6,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.243117+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_298613","record_id":"REC_0009657","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":15.4,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":7.7,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.243357+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_173470","record_id":"REC_0009658","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":13.5,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":5.1,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.243597+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_472879","record_id":"REC_0009659","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":6.4,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":20.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.243838+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_222554","record_id":"REC_0009660","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":16.7,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":6.4,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":18.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.244203+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_707380","record_id":"REC_0009661","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":2.1,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":61,"primary_tumor_size_cm":5.9,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":17.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.244449+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_562050","record_id":"REC_0009662","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":16.1,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":3.5,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":21.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.244696+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_368388","record_id":"REC_0009663","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":10.1,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":6.5,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.244936+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_867211","record_id":"REC_0009664","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":31,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":77,"sex":"male","ecog_performance_status":2,"smoking_pack_years":44,"primary_tumor_size_cm":4.1,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":23.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.245169+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_700120","record_id":"REC_0009665","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.4,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.245408+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_892151","record_id":"REC_0009666","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":2.0,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":0,"smoking_pack_years":54,"primary_tumor_size_cm":5.9,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":23.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.245636+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_428881","record_id":"REC_0009667","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.0,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.245872+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_373343","record_id":"REC_0009668","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.8,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.246107+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_851712","record_id":"REC_0009669","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":16,"tmb_mutations_per_mb":3.0,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":6.6,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.246335+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_581087","record_id":"REC_0009670","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":3.4,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":5.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.246568+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_364433","record_id":"REC_0009671","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":6.2,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":4.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.246802+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_378588","record_id":"REC_0009672","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":2.4,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":3.0,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.247032+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_730493","record_id":"REC_0009673","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":14.5,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":4.5,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.247324+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_777749","record_id":"REC_0009674","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":18.1,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":24,"primary_tumor_size_cm":7.0,"metastatic_sites_count":3,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.247563+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_811804","record_id":"REC_0009675","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":7.0,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.247797+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_214639","record_id":"REC_0009676","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":7.9,"age_at_diagnosis":83,"sex":"female","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":4.7,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.248023+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_553496","record_id":"REC_0009677","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":16.4,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":7.6,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.248322+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_257794","record_id":"REC_0009678","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":8.4,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":4.3,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":17.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.248561+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_220920","record_id":"REC_0009679","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":7.0,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.248799+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_332414","record_id":"REC_0009680","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":5.1,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":8,"primary_tumor_size_cm":7.7,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":17.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.249026+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_835964","record_id":"REC_0009681","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":10.3,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":6.9,"metastatic_sites_count":3,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":19.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.249261+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_150949","record_id":"REC_0009682","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":14.8,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":4.8,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.249498+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_997718","record_id":"REC_0009683","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":30,"primary_tumor_size_cm":6.0,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":7.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.249737+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_436243","record_id":"REC_0009684","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":33,"tmb_mutations_per_mb":19.6,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":25,"primary_tumor_size_cm":6.0,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.249974+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_421933","record_id":"REC_0009685","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":11,"tmb_mutations_per_mb":9.0,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":68,"primary_tumor_size_cm":7.1,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.250200+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_905031","record_id":"REC_0009686","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":31,"tmb_mutations_per_mb":3.5,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":5.3,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":16.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.250488+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_306620","record_id":"REC_0009687","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":82,"sex":"male","ecog_performance_status":1,"smoking_pack_years":4,"primary_tumor_size_cm":5.9,"metastatic_sites_count":3,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.250731+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_609511","record_id":"REC_0009688","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":6.2,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":39.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.250973+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_912962","record_id":"REC_0009689","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":17.3,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":5.2,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":18.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.251217+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_321829","record_id":"REC_0009690","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":5.4,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":24.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.251453+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_736010","record_id":"REC_0009691","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":49,"primary_tumor_size_cm":5.5,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":19.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.251687+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_421841","record_id":"REC_0009692","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":5.2,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":35.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.251923+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_758817","record_id":"REC_0009693","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":3.8,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":62,"primary_tumor_size_cm":5.7,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.252183+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_716443","record_id":"REC_0009694","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":30,"tmb_mutations_per_mb":6.7,"age_at_diagnosis":54,"sex":"female","ecog_performance_status":0,"smoking_pack_years":51,"primary_tumor_size_cm":3.9,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.252423+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_857648","record_id":"REC_0009695","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":16.5,"age_at_diagnosis":74,"sex":"male","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":6.8,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":23.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.252672+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_303455","record_id":"REC_0009696","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":16.1,"age_at_diagnosis":85,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":6.5,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.252918+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_103374","record_id":"REC_0009697","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":5.0,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":26.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.253193+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_477372","record_id":"REC_0009698","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":2.8,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.253432+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_680221","record_id":"REC_0009699","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":45,"sex":"female","ecog_performance_status":0,"smoking_pack_years":24,"primary_tumor_size_cm":3.5,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.253727+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_985406","record_id":"REC_0009700","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":5.6,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.253970+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_317378","record_id":"REC_0009701","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":4.5,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":1,"smoking_pack_years":48,"primary_tumor_size_cm":6.2,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":20.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.254221+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_571941","record_id":"REC_0009702","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":6.2,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":28.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.254469+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_824252","record_id":"REC_0009703","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":4.4,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":31,"primary_tumor_size_cm":5.9,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.254700+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_277025","record_id":"REC_0009704","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.5,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":7,"primary_tumor_size_cm":6.5,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.254945+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_633181","record_id":"REC_0009705","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":16,"tmb_mutations_per_mb":14.8,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":0,"primary_tumor_size_cm":6.8,"metastatic_sites_count":9,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.255189+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_908045","record_id":"REC_0009706","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":5.3,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":3.3,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.255431+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_758555","record_id":"REC_0009707","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":16.9,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":5.2,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":24.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.255673+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_840252","record_id":"REC_0009708","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":25,"primary_tumor_size_cm":4.8,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.255915+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_462235","record_id":"REC_0009709","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":5.7,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.256198+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_332212","record_id":"REC_0009710","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":32,"tmb_mutations_per_mb":1.5,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":44,"primary_tumor_size_cm":5.6,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.256456+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_258423","record_id":"REC_0009711","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":31,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":3.6,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":36.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.256711+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_149974","record_id":"REC_0009712","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.7,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.257050+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_970503","record_id":"REC_0009713","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":16.6,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":3.8,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":21.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.257312+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_976658","record_id":"REC_0009714","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":7.6,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":2,"primary_tumor_size_cm":6.3,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.257556+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_560338","record_id":"REC_0009715","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":20,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":7.4,"metastatic_sites_count":3,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.257810+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_770197","record_id":"REC_0009716","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":19,"tmb_mutations_per_mb":16.2,"age_at_diagnosis":76,"sex":"male","ecog_performance_status":2,"smoking_pack_years":8,"primary_tumor_size_cm":6.9,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":7.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.258071+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_579834","record_id":"REC_0009717","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":15.8,"age_at_diagnosis":84,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":4.1,"metastatic_sites_count":9,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.258319+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_505648","record_id":"REC_0009718","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":36,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":3.8,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.258576+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_889745","record_id":"REC_0009719","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":5.2,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.258851+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_244975","record_id":"REC_0009720","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":8.5,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":5.4,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":4.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.259103+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_104338","record_id":"REC_0009721","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":6.7,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":6.5,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.259341+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_587386","record_id":"REC_0009722","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":17.3,"age_at_diagnosis":78,"sex":"male","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":5.7,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.259586+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_187206","record_id":"REC_0009723","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":13.6,"age_at_diagnosis":84,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":3.0,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":31.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.259824+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_844682","record_id":"REC_0009724","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":33,"tmb_mutations_per_mb":5.5,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":7.3,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":19.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.260061+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_685890","record_id":"REC_0009725","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":16.9,"age_at_diagnosis":84,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":3.8,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":24.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.260556+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_114122","record_id":"REC_0009726","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":57,"primary_tumor_size_cm":6.8,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.260801+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_653361","record_id":"REC_0009727","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":84,"sex":"female","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":4.8,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.261054+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_314547","record_id":"REC_0009728","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":5.1,"metastatic_sites_count":8,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.261292+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_123051","record_id":"REC_0009729","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":18.9,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":6.0,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":16.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.261537+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_595898","record_id":"REC_0009730","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":21.7,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":6.5,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.261777+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_483640","record_id":"REC_0009731","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":2.8,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.262011+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_213938","record_id":"REC_0009732","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":26,"primary_tumor_size_cm":4.1,"metastatic_sites_count":3,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":7.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.262246+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_861088","record_id":"REC_0009733","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":5.9,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":46,"primary_tumor_size_cm":6.0,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.262480+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_955761","record_id":"REC_0009734","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":32,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":6.0,"metastatic_sites_count":3,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.262727+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_925117","record_id":"REC_0009735","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":14.9,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":7.6,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.262988+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_275119","record_id":"REC_0009736","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":9.1,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":3.9,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.263234+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_164799","record_id":"REC_0009737","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":0,"smoking_pack_years":79,"primary_tumor_size_cm":4.4,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":16.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.263480+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_345288","record_id":"REC_0009738","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":6.3,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":26.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.263894+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_718417","record_id":"REC_0009739","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":15.8,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":2.9,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.264247+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_642213","record_id":"REC_0009740","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":4.8,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.264504+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_967796","record_id":"REC_0009741","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":4.7,"metastatic_sites_count":8,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.264752+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_424286","record_id":"REC_0009742","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":5.7,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":4.8,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.264984+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_401448","record_id":"REC_0009743","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":2,"smoking_pack_years":47,"primary_tumor_size_cm":5.5,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":28.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.265218+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_928165","record_id":"REC_0009744","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":0,"smoking_pack_years":2,"primary_tumor_size_cm":6.5,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.265457+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_409811","record_id":"REC_0009745","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":14.7,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":3,"smoking_pack_years":15,"primary_tumor_size_cm":6.7,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":17.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.265699+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_802120","record_id":"REC_0009746","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":14.9,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":21,"primary_tumor_size_cm":5.6,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":20.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.265937+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_344880","record_id":"REC_0009747","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":8.9,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":5.0,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":16.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.266171+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_735986","record_id":"REC_0009748","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":3.1,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.266399+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_524512","record_id":"REC_0009749","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":5.9,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":34,"primary_tumor_size_cm":4.6,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.266627+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_463322","record_id":"REC_0009750","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":7.4,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":31,"primary_tumor_size_cm":4.5,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.266862+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_866987","record_id":"REC_0009751","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":5.7,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.267216+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_313489","record_id":"REC_0009752","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":33,"primary_tumor_size_cm":6.5,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.267469+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_503757","record_id":"REC_0009753","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":33,"tmb_mutations_per_mb":15.6,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":6.2,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.267726+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_844145","record_id":"REC_0009754","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":13.5,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":3.8,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.267974+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_418328","record_id":"REC_0009755","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":12,"tmb_mutations_per_mb":15.2,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":4.4,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.268274+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_856277","record_id":"REC_0009756","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":3.0,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":58,"primary_tumor_size_cm":4.7,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.268524+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_104502","record_id":"REC_0009757","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":15.2,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":6.3,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":6.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.268775+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_701648","record_id":"REC_0009758","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":7.6,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":2,"smoking_pack_years":57,"primary_tumor_size_cm":6.0,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.269014+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_774232","record_id":"REC_0009759","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":6.3,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":8.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.269269+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_809802","record_id":"REC_0009760","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":6.1,"metastatic_sites_count":3,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":5.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.269524+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_733464","record_id":"REC_0009761","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":43,"primary_tumor_size_cm":6.2,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.269769+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_561133","record_id":"REC_0009762","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":31,"tmb_mutations_per_mb":6.1,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":3.6,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.270021+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_951060","record_id":"REC_0009763","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":13.3,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":5.2,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.270271+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_587494","record_id":"REC_0009764","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":4.0,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":3,"smoking_pack_years":27,"primary_tumor_size_cm":5.3,"metastatic_sites_count":8,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.270645+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_115909","record_id":"REC_0009765","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":6,"primary_tumor_size_cm":7.0,"metastatic_sites_count":9,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.270915+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_267123","record_id":"REC_0009766","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":50,"sex":"male","ecog_performance_status":0,"smoking_pack_years":58,"primary_tumor_size_cm":4.1,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":23.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.271215+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_473302","record_id":"REC_0009767","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":18.5,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":5.7,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.271469+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_819855","record_id":"REC_0009768","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":89,"sex":"male","ecog_performance_status":2,"smoking_pack_years":21,"primary_tumor_size_cm":7.3,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":7.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.271720+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_109752","record_id":"REC_0009769","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":17.9,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":6.2,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.271964+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_915375","record_id":"REC_0009770","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":15.6,"age_at_diagnosis":74,"sex":"male","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":3.6,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.272277+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_859196","record_id":"REC_0009771","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":17.1,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":5.9,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":23.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.272522+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_463181","record_id":"REC_0009772","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":4.2,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":1,"smoking_pack_years":61,"primary_tumor_size_cm":5.6,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":5.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.272765+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_485860","record_id":"REC_0009773","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":3.8,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.273007+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_872906","record_id":"REC_0009774","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":6.9,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":7.3,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":16.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.273242+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_782505","record_id":"REC_0009775","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":8.1,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":3.8,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":31.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.273481+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_846418","record_id":"REC_0009776","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":5.9,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.273726+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_187599","record_id":"REC_0009777","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":8.0,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.274093+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_332341","record_id":"REC_0009778","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":14.9,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":5,"primary_tumor_size_cm":2.7,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.274373+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_250999","record_id":"REC_0009779","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":32,"tmb_mutations_per_mb":6.1,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":1,"smoking_pack_years":41,"primary_tumor_size_cm":6.2,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.274622+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_937532","record_id":"REC_0009780","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":5.2,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":6.2,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.274931+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_498660","record_id":"REC_0009781","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":3,"smoking_pack_years":16,"primary_tumor_size_cm":3.4,"metastatic_sites_count":3,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":7.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.275181+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_696831","record_id":"REC_0009782","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None","pd_l1_tps_percent":16,"tmb_mutations_per_mb":5.0,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":44,"primary_tumor_size_cm":6.5,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":33.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.275430+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_855578","record_id":"REC_0009783","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":4.9,"age_at_diagnosis":81,"sex":"male","ecog_performance_status":1,"smoking_pack_years":51,"primary_tumor_size_cm":5.8,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.275682+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_574933","record_id":"REC_0009784","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":18,"tmb_mutations_per_mb":8.3,"age_at_diagnosis":74,"sex":"male","ecog_performance_status":2,"smoking_pack_years":29,"primary_tumor_size_cm":4.5,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.275933+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_848603","record_id":"REC_0009785","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":7.6,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":1,"primary_tumor_size_cm":4.8,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.276223+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_150498","record_id":"REC_0009786","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":7.5,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.276477+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_737991","record_id":"REC_0009787","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":14.3,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":5.6,"metastatic_sites_count":8,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.276725+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_697939","record_id":"REC_0009788","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":15,"tmb_mutations_per_mb":6.1,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":6.1,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":29.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.276958+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_345173","record_id":"REC_0009789","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":17.7,"age_at_diagnosis":81,"sex":"male","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":6.4,"metastatic_sites_count":9,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.277206+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_173275","record_id":"REC_0009790","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":59,"primary_tumor_size_cm":6.5,"metastatic_sites_count":3,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.277568+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_165737","record_id":"REC_0009791","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":38,"primary_tumor_size_cm":5.5,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.277863+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_610722","record_id":"REC_0009792","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":6.9,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":19.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.278115+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_551520","record_id":"REC_0009793","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":30,"tmb_mutations_per_mb":9.5,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":4,"primary_tumor_size_cm":6.3,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.278358+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_878861","record_id":"REC_0009794","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":31,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":83,"sex":"female","ecog_performance_status":3,"smoking_pack_years":55,"primary_tumor_size_cm":7.3,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.278603+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_392512","record_id":"REC_0009795","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":28,"primary_tumor_size_cm":4.1,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.278851+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_408549","record_id":"REC_0009796","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":21,"primary_tumor_size_cm":4.9,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.279102+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_532824","record_id":"REC_0009797","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":5.0,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.279357+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_341393","record_id":"REC_0009798","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":16.0,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":4.7,"metastatic_sites_count":3,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":20.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.279615+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_999760","record_id":"REC_0009799","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":26,"primary_tumor_size_cm":6.6,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":23.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.279887+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_446920","record_id":"REC_0009800","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":17.1,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":6.3,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":6.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.280252+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_166441","record_id":"REC_0009801","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.5,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.280535+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_940332","record_id":"REC_0009802","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":5.6,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":5.0,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.280821+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_402610","record_id":"REC_0009803","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":5.3,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.281237+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_139782","record_id":"REC_0009804","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":18,"tmb_mutations_per_mb":4.6,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":55,"primary_tumor_size_cm":5.9,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":25.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.281500+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_931171","record_id":"REC_0009805","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":1,"smoking_pack_years":0,"primary_tumor_size_cm":4.5,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.281760+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_102474","record_id":"REC_0009806","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":8,"primary_tumor_size_cm":6.8,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.282022+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_371722","record_id":"REC_0009807","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":35,"tmb_mutations_per_mb":9.1,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":8.0,"metastatic_sites_count":8,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.282273+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_943704","record_id":"REC_0009808","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":54,"sex":"male","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":5.5,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.282525+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_542681","record_id":"REC_0009809","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.6,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.282780+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_990350","record_id":"REC_0009810","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":30,"tmb_mutations_per_mb":5.1,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":3,"smoking_pack_years":26,"primary_tumor_size_cm":7.9,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":18.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.283029+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_415609","record_id":"REC_0009811","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None","pd_l1_tps_percent":30,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":1,"smoking_pack_years":51,"primary_tumor_size_cm":5.5,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":38.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.283285+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_319044","record_id":"REC_0009812","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":31,"tmb_mutations_per_mb":4.6,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":4.1,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.283539+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_988197","record_id":"REC_0009813","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":2.7,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":42,"primary_tumor_size_cm":3.0,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.283795+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_566323","record_id":"REC_0009814","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":9.8,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":4.7,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":17.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.284048+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_491559","record_id":"REC_0009815","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":28,"primary_tumor_size_cm":5.0,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.284397+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_173636","record_id":"REC_0009816","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":4.5,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":18.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.284775+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_129104","record_id":"REC_0009817","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":5.7,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":5.3,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":16.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.285039+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_262339","record_id":"REC_0009818","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":19,"tmb_mutations_per_mb":5.0,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":63,"primary_tumor_size_cm":5.7,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":4.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.285278+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_808781","record_id":"REC_0009819","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":30,"tmb_mutations_per_mb":4.3,"age_at_diagnosis":53,"sex":"male","ecog_performance_status":0,"smoking_pack_years":59,"primary_tumor_size_cm":5.9,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":6.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.285528+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_729211","record_id":"REC_0009820","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":31,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":3.1,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":29.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.285776+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_968521","record_id":"REC_0009821","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":55,"primary_tumor_size_cm":4.2,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.286019+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_727098","record_id":"REC_0009822","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":8.1,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":0,"primary_tumor_size_cm":6.2,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":7.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.286254+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_638068","record_id":"REC_0009823","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":13.3,"age_at_diagnosis":53,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":6.8,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.286491+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_998223","record_id":"REC_0009824","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":7.4,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":1,"smoking_pack_years":39,"primary_tumor_size_cm":5.3,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.286728+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_194848","record_id":"REC_0009825","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":83,"sex":"female","ecog_performance_status":2,"smoking_pack_years":7,"primary_tumor_size_cm":7.1,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":5.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.286963+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_521648","record_id":"REC_0009826","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":15.8,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":6.5,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.287202+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_814923","record_id":"REC_0009827","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":7.6,"age_at_diagnosis":75,"sex":"male","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":5.4,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":20.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.287452+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_904043","record_id":"REC_0009828","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":4.8,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.287702+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_731933","record_id":"REC_0009829","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":4,"primary_tumor_size_cm":6.3,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":21.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.288064+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_830959","record_id":"REC_0009830","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":13.3,"age_at_diagnosis":52,"sex":"female","ecog_performance_status":0,"smoking_pack_years":26,"primary_tumor_size_cm":4.7,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":21.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.288421+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_794316","record_id":"REC_0009831","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":19,"tmb_mutations_per_mb":8.1,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":5.5,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.288683+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_278174","record_id":"REC_0009832","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":30,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":5.6,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.288929+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_422478","record_id":"REC_0009833","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":14.9,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":24,"primary_tumor_size_cm":8.8,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":25.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.289167+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_255955","record_id":"REC_0009834","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":5.9,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":6.2,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":18.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.289397+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_575820","record_id":"REC_0009835","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":5.3,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":62,"primary_tumor_size_cm":5.9,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.289628+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_893911","record_id":"REC_0009836","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":54,"sex":"male","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":5.1,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.289871+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_327395","record_id":"REC_0009837","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":7.3,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":5.8,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.290118+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_741744","record_id":"REC_0009838","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":5.1,"age_at_diagnosis":86,"sex":"female","ecog_performance_status":3,"smoking_pack_years":46,"primary_tumor_size_cm":6.9,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.290362+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_855409","record_id":"REC_0009839","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":6.8,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.290613+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_173089","record_id":"REC_0009840","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":14.3,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":6.2,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.290863+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_955965","record_id":"REC_0009841","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":15.4,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":4.9,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.291103+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_577912","record_id":"REC_0009842","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":8.9,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":10,"primary_tumor_size_cm":5.0,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.291436+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_682666","record_id":"REC_0009843","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":14.9,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":4.7,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.291684+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_437251","record_id":"REC_0009844","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":3.5,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":25,"primary_tumor_size_cm":6.4,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":21.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.291929+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_267950","record_id":"REC_0009845","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":5.7,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":28.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.292232+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_951312","record_id":"REC_0009846","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":24,"primary_tumor_size_cm":5.5,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.292490+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_154002","record_id":"REC_0009847","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":15,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":84,"sex":"female","ecog_performance_status":1,"smoking_pack_years":24,"primary_tumor_size_cm":6.4,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.292742+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_640800","record_id":"REC_0009848","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":5.3,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.292993+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_549431","record_id":"REC_0009849","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":16,"tmb_mutations_per_mb":6.7,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":32,"primary_tumor_size_cm":6.3,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":5.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.293245+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_464797","record_id":"REC_0009850","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":10.1,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":7,"primary_tumor_size_cm":6.8,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.293509+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_831205","record_id":"REC_0009851","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":1,"smoking_pack_years":5,"primary_tumor_size_cm":5.0,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":25.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.293758+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_202724","record_id":"REC_0009852","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":5.5,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.294013+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_468464","record_id":"REC_0009853","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":6.0,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":19.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.294273+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_817114","record_id":"REC_0009854","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":16,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":45,"primary_tumor_size_cm":4.0,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.294528+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_761445","record_id":"REC_0009855","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":18.3,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":7.0,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":5.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.294912+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_248941","record_id":"REC_0009856","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":8.7,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":6.3,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.295183+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_265184","record_id":"REC_0009857","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":14.0,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":7.9,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":20.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.295441+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_670566","record_id":"REC_0009858","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":9.3,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.295692+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_676202","record_id":"REC_0009859","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":5.0,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":67,"primary_tumor_size_cm":4.5,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.295937+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_270459","record_id":"REC_0009860","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":18,"tmb_mutations_per_mb":4.5,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":32,"primary_tumor_size_cm":3.6,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":16.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.296327+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_319369","record_id":"REC_0009861","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":6.9,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.296603+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_162469","record_id":"REC_0009862","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":36,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":3,"primary_tumor_size_cm":5.8,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":17.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.296873+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_879013","record_id":"REC_0009863","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":6.7,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":5.4,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.297120+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_713613","record_id":"REC_0009864","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":18,"tmb_mutations_per_mb":5.0,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":6.2,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.297362+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_852992","record_id":"REC_0009865","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":14.0,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":6.8,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":5.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.297607+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_186095","record_id":"REC_0009866","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":28,"primary_tumor_size_cm":6.4,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":24.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.297856+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_603470","record_id":"REC_0009867","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":0,"primary_tumor_size_cm":5.2,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.298103+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_603509","record_id":"REC_0009868","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":50,"primary_tumor_size_cm":8.5,"metastatic_sites_count":9,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":5.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.298452+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_255399","record_id":"REC_0009869","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":16,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":5.3,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.298701+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_793302","record_id":"REC_0009870","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":17.2,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":5,"primary_tumor_size_cm":4.2,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.298941+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_783726","record_id":"REC_0009871","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":3.3,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":58,"primary_tumor_size_cm":6.0,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.299183+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_843214","record_id":"REC_0009872","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":7.6,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":17.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.299424+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_169735","record_id":"REC_0009873","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":8.7,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":2.5,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.299672+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_379021","record_id":"REC_0009874","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":18,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":3,"smoking_pack_years":21,"primary_tumor_size_cm":5.1,"metastatic_sites_count":3,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.299905+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_876102","record_id":"REC_0009875","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":17.7,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":5.7,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":4.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.300195+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_656866","record_id":"REC_0009876","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":5.5,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":4.8,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.300448+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_866754","record_id":"REC_0009877","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":5.5,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":23.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.300700+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_291007","record_id":"REC_0009878","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":31,"tmb_mutations_per_mb":5.9,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":0,"smoking_pack_years":37,"primary_tumor_size_cm":4.9,"metastatic_sites_count":3,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.300952+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_405184","record_id":"REC_0009879","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":14,"tmb_mutations_per_mb":5.3,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":6.5,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.301206+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_975879","record_id":"REC_0009880","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":74,"sex":"male","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":6.0,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.301451+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_257330","record_id":"REC_0009881","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":20,"tmb_mutations_per_mb":7.9,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":47,"primary_tumor_size_cm":4.4,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.301812+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_327015","record_id":"REC_0009882","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":11.5,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":5.0,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":4.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.302078+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_753350","record_id":"REC_0009883","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":33,"tmb_mutations_per_mb":9.0,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":7.3,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":53.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.302326+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_554318","record_id":"REC_0009884","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":3.5,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":4.6,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.302575+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_984923","record_id":"REC_0009885","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":19,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":2,"smoking_pack_years":41,"primary_tumor_size_cm":3.8,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.302817+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_330532","record_id":"REC_0009886","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":7.9,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":2.8,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.303057+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_474643","record_id":"REC_0009887","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":31,"primary_tumor_size_cm":5.7,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.303305+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_440906","record_id":"REC_0009888","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":13.6,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":5.7,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.303548+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_779813","record_id":"REC_0009889","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":35,"tmb_mutations_per_mb":5.9,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":49,"primary_tumor_size_cm":5.4,"metastatic_sites_count":8,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":5.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.303791+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_435435","record_id":"REC_0009890","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":14.5,"age_at_diagnosis":53,"sex":"male","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":8.3,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.304039+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_688444","record_id":"REC_0009891","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":54,"sex":"female","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":5.7,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.304414+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_932181","record_id":"REC_0009892","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":4.7,"age_at_diagnosis":83,"sex":"male","ecog_performance_status":1,"smoking_pack_years":34,"primary_tumor_size_cm":4.7,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.304701+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_943790","record_id":"REC_0009893","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":3.1,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":18.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.304958+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_778511","record_id":"REC_0009894","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":15.6,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":5.8,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":26.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.305327+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_461227","record_id":"REC_0009895","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":3.6,"age_at_diagnosis":75,"sex":"male","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":6.8,"metastatic_sites_count":3,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":6.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.305583+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_210174","record_id":"REC_0009896","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":7.4,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":4.2,"metastatic_sites_count":8,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":6.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.305833+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_966419","record_id":"REC_0009897","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":3.7,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":0,"smoking_pack_years":53,"primary_tumor_size_cm":4.1,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":23.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.306078+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_530391","record_id":"REC_0009898","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":18.6,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":8.5,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":6.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.306323+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_564121","record_id":"REC_0009899","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":9.7,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":6.6,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.306570+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_242468","record_id":"REC_0009900","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":18.4,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":3.8,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.306814+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_552225","record_id":"REC_0009901","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":3.7,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.307070+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_276130","record_id":"REC_0009902","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":5.3,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":44,"primary_tumor_size_cm":7.7,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.307323+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_969875","record_id":"REC_0009903","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":13.6,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":4.2,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":22.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.307569+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_438021","record_id":"REC_0009904","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":14,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":7.0,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.307833+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_735998","record_id":"REC_0009905","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":6.0,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.308208+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_717318","record_id":"REC_0009906","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":4.2,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.308548+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_582672","record_id":"REC_0009907","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":74,"sex":"male","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":6.5,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":5.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.309005+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_150204","record_id":"REC_0009908","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":4.9,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":5.8,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.309332+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_787364","record_id":"REC_0009909","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":13.3,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.7,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.309645+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_971525","record_id":"REC_0009910","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":8.5,"age_at_diagnosis":85,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":4.0,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.309935+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_202728","record_id":"REC_0009911","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":6,"primary_tumor_size_cm":6.2,"metastatic_sites_count":8,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.310179+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_761205","record_id":"REC_0009912","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":5.9,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.310422+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_488393","record_id":"REC_0009913","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":53,"sex":"male","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":5.0,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.310656+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_304936","record_id":"REC_0009914","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":5.4,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":30.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.310893+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_103418","record_id":"REC_0009915","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":17.6,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":5.2,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.311140+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_460206","record_id":"REC_0009916","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":5.1,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":7.4,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.311387+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_358453","record_id":"REC_0009917","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":4.1,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":0,"smoking_pack_years":41,"primary_tumor_size_cm":3.9,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.311652+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_587482","record_id":"REC_0009918","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":15,"tmb_mutations_per_mb":9.9,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":4.5,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.311926+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_666676","record_id":"REC_0009919","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":5.1,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.312270+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_400341","record_id":"REC_0009920","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":33,"tmb_mutations_per_mb":6.4,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":0,"smoking_pack_years":44,"primary_tumor_size_cm":5.1,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":16.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.312664+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_110948","record_id":"REC_0009921","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":4.7,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.312908+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_249427","record_id":"REC_0009922","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":59,"primary_tumor_size_cm":5.0,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":18.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.313144+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_804770","record_id":"REC_0009923","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":8.7,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":4.0,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":16.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.313380+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_114414","record_id":"REC_0009924","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":7.0,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.313610+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_717073","record_id":"REC_0009925","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":7.7,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.313843+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_159837","record_id":"REC_0009926","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":5.8,"metastatic_sites_count":8,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.314073+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_824390","record_id":"REC_0009927","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":15.5,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":4.5,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.314321+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_521643","record_id":"REC_0009928","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":19,"tmb_mutations_per_mb":5.2,"age_at_diagnosis":83,"sex":"female","ecog_performance_status":1,"smoking_pack_years":34,"primary_tumor_size_cm":5.3,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.314558+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_390476","record_id":"REC_0009929","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":28,"primary_tumor_size_cm":5.7,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":33.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.314818+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_724142","record_id":"REC_0009930","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":31,"tmb_mutations_per_mb":5.6,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":1,"smoking_pack_years":60,"primary_tumor_size_cm":4.9,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.315068+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_702139","record_id":"REC_0009931","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":26,"primary_tumor_size_cm":6.0,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.315312+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_848583","record_id":"REC_0009932","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":31,"tmb_mutations_per_mb":4.2,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":40,"primary_tumor_size_cm":7.1,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":4.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.315554+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_395360","record_id":"REC_0009933","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":1,"smoking_pack_years":4,"primary_tumor_size_cm":4.9,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.315942+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_951408","record_id":"REC_0009934","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":6.2,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.316271+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_853592","record_id":"REC_0009935","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":9.7,"age_at_diagnosis":54,"sex":"female","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":5.2,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.316532+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_139017","record_id":"REC_0009936","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":4.8,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":22.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.316779+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_195826","record_id":"REC_0009937","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":3.7,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.317016+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_517782","record_id":"REC_0009938","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":14.8,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":7.7,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.317256+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_214580","record_id":"REC_0009939","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":19,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":6.6,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.317511+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_161754","record_id":"REC_0009940","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":6.7,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":38,"primary_tumor_size_cm":7.0,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.317758+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_320851","record_id":"REC_0009941","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":9.7,"age_at_diagnosis":82,"sex":"male","ecog_performance_status":3,"smoking_pack_years":7,"primary_tumor_size_cm":5.8,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.318023+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_180308","record_id":"REC_0009942","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":3.8,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":25.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.318279+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_732952","record_id":"REC_0009943","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":9.9,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":4.5,"metastatic_sites_count":3,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":22.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.318536+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_310639","record_id":"REC_0009944","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":18,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":0,"primary_tumor_size_cm":5.2,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.318791+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_458079","record_id":"REC_0009945","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":17.2,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":5.0,"metastatic_sites_count":3,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":6.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.319043+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_369684","record_id":"REC_0009946","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":17,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":5.3,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.319404+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_195078","record_id":"REC_0009947","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":16.1,"age_at_diagnosis":79,"sex":"male","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":7.5,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.319656+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_981421","record_id":"REC_0009948","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":18,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":4.0,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":8.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.319894+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_286003","record_id":"REC_0009949","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":11.1,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.7,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":24.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.320296+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_721350","record_id":"REC_0009950","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":8.0,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":6.5,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":20.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.320563+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_448079","record_id":"REC_0009951","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":10.0,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":3,"smoking_pack_years":18,"primary_tumor_size_cm":4.2,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.320815+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_788766","record_id":"REC_0009952","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":17.2,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":4,"primary_tumor_size_cm":6.3,"metastatic_sites_count":3,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":17.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.321059+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_885553","record_id":"REC_0009953","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":15.0,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":5.5,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.321300+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_574263","record_id":"REC_0009954","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":6.7,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":32.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.321538+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_602092","record_id":"REC_0009955","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":5.5,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":3,"smoking_pack_years":57,"primary_tumor_size_cm":4.3,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":16.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.321779+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_838721","record_id":"REC_0009956","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":19,"tmb_mutations_per_mb":15.5,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":23,"primary_tumor_size_cm":4.8,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":7.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.322027+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_137932","record_id":"REC_0009957","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":52,"sex":"male","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":4.2,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":23.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.322279+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_119009","record_id":"REC_0009958","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":4.4,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.322532+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_468876","record_id":"REC_0009959","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":15,"tmb_mutations_per_mb":3.9,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":1,"smoking_pack_years":53,"primary_tumor_size_cm":6.2,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":6.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.322902+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_174426","record_id":"REC_0009960","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":6.4,"age_at_diagnosis":90,"sex":"female","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":4.9,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.323164+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_599876","record_id":"REC_0009961","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":3.9,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.323423+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_659821","record_id":"REC_0009962","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":11.1,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.7,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.323673+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_492820","record_id":"REC_0009963","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":6.5,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.323923+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_862095","record_id":"REC_0009964","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":3.9,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":38,"primary_tumor_size_cm":5.7,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.324222+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_356318","record_id":"REC_0009965","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":34,"tmb_mutations_per_mb":15.1,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":1,"smoking_pack_years":24,"primary_tumor_size_cm":5.3,"metastatic_sites_count":8,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.324508+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_304992","record_id":"REC_0009966","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":4.7,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":36,"primary_tumor_size_cm":5.3,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.324767+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_754670","record_id":"REC_0009967","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":17.9,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":6.3,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.325027+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_266596","record_id":"REC_0009968","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":4.8,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.325278+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_166227","record_id":"REC_0009969","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":19.4,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":26,"primary_tumor_size_cm":5.5,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.325525+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_814648","record_id":"REC_0009970","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":18.8,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":4.4,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.325775+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_200708","record_id":"REC_0009971","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":8.9,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":4.5,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":20.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.326018+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_699388","record_id":"REC_0009972","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":6.3,"metastatic_sites_count":8,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.326389+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_841173","record_id":"REC_0009973","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":13.8,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":6.1,"metastatic_sites_count":3,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.326660+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_149388","record_id":"REC_0009974","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":3.9,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.326921+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_482463","record_id":"REC_0009975","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":1,"smoking_pack_years":38,"primary_tumor_size_cm":6.8,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":25.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.327181+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_462605","record_id":"REC_0009976","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":7.3,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":27,"primary_tumor_size_cm":4.5,"metastatic_sites_count":3,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.327428+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_861175","record_id":"REC_0009977","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":13.8,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":4.2,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.327683+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_271829","record_id":"REC_0009978","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":5.7,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":58,"primary_tumor_size_cm":7.1,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":7.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.327931+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_281966","record_id":"REC_0009979","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":5.1,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.328235+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_450118","record_id":"REC_0009980","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":18,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":2.0,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.328513+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_616592","record_id":"REC_0009981","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":5.7,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":7.0,"metastatic_sites_count":3,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.328764+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_224650","record_id":"REC_0009982","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":8.4,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":6.3,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.329007+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_348806","record_id":"REC_0009983","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":5.7,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":19.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.329265+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_104970","record_id":"REC_0009984","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":10.3,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":5.1,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":40.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.329519+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_616556","record_id":"REC_0009985","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":5.8,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":24.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.329897+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_322912","record_id":"REC_0009986","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":6.3,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.330160+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_189030","record_id":"REC_0009987","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":0,"smoking_pack_years":24,"primary_tumor_size_cm":4.9,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":63.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.330418+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_877715","record_id":"REC_0009988","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":16,"tmb_mutations_per_mb":11.5,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":6.3,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.330661+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_993056","record_id":"REC_0009989","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":7.6,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.330897+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_622853","record_id":"REC_0009990","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":13.5,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":5.0,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.331134+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_157697","record_id":"REC_0009991","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":7.3,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":7.0,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.331371+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_969869","record_id":"REC_0009992","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":7.3,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":24,"primary_tumor_size_cm":5.0,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":21.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.331603+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_215791","record_id":"REC_0009993","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":14.9,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":4.8,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.331839+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_664926","record_id":"REC_0009994","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":74,"sex":"male","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":4.9,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.332145+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_881347","record_id":"REC_0009995","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":4.0,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":8.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.332430+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_249632","record_id":"REC_0009996","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":15.4,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":3,"smoking_pack_years":16,"primary_tumor_size_cm":5.0,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.332699+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_233337","record_id":"REC_0009997","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":4.8,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":26.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.332962+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_515506","record_id":"REC_0009998","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":6.7,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":6.2,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.333348+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_651017","record_id":"REC_0009999","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":4.6,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":18.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.333644+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_860977","record_id":"REC_0010000","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":17.2,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":4.3,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.333921+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_103324","record_id":"REC_0010001","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":30,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":4.9,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.334337+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_775183","record_id":"REC_0010002","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":6.3,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":6.9,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.334624+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_215366","record_id":"REC_0010003","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":17.6,"age_at_diagnosis":86,"sex":"male","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":8.1,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.334900+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_104326","record_id":"REC_0010004","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":8.9,"age_at_diagnosis":79,"sex":"male","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":5.3,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":21.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.335171+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_208747","record_id":"REC_0010005","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":5.5,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":6.8,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.335450+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_860680","record_id":"REC_0010006","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":4.8,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":36,"primary_tumor_size_cm":5.9,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":18.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.335738+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_781049","record_id":"REC_0010007","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":16.1,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":4.5,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.336036+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_901993","record_id":"REC_0010008","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":19,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":6.6,"metastatic_sites_count":8,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":8.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.336406+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_324645","record_id":"REC_0010009","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":6.4,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":17.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.336721+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_881357","record_id":"REC_0010010","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":34,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":5.4,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.337015+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_256756","record_id":"REC_0010011","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":18.2,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":9,"primary_tumor_size_cm":6.5,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":19.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.337479+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_180372","record_id":"REC_0010012","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":13.8,"age_at_diagnosis":53,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":6.0,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":6.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.337803+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_933267","record_id":"REC_0010013","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":10.0,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.2,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":17.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.338106+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_395824","record_id":"REC_0010014","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":4.4,"age_at_diagnosis":51,"sex":"female","ecog_performance_status":0,"smoking_pack_years":72,"primary_tumor_size_cm":3.5,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.338412+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_980335","record_id":"REC_0010015","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":4.9,"age_at_diagnosis":49,"sex":"female","ecog_performance_status":0,"smoking_pack_years":42,"primary_tumor_size_cm":5.4,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":5.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.338715+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_629581","record_id":"REC_0010016","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":36,"tmb_mutations_per_mb":20.0,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":6.0,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.339005+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_596156","record_id":"REC_0010017","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":4.6,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":35,"primary_tumor_size_cm":5.8,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":23.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.339277+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_105996","record_id":"REC_0010018","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":5.0,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":1,"smoking_pack_years":24,"primary_tumor_size_cm":7.0,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.339565+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_523308","record_id":"REC_0010019","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":6.0,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.339851+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_367092","record_id":"REC_0010020","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":6.1,"age_at_diagnosis":47,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":5.5,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":42.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.340185+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_354357","record_id":"REC_0010021","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":25,"primary_tumor_size_cm":5.9,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.340488+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_329370","record_id":"REC_0010022","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":18,"tmb_mutations_per_mb":15.8,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":6.2,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.340780+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_696890","record_id":"REC_0010023","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":7.4,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":53,"primary_tumor_size_cm":5.5,"metastatic_sites_count":3,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.341082+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_871187","record_id":"REC_0010024","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":5.5,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":49,"primary_tumor_size_cm":3.4,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":19.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.341509+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_460304","record_id":"REC_0010025","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":9,"tmb_mutations_per_mb":3.7,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":39,"primary_tumor_size_cm":4.5,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.341847+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_939291","record_id":"REC_0010026","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":5.3,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.342157+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_215744","record_id":"REC_0010027","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":8.3,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":5.8,"metastatic_sites_count":3,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":5.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.342462+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_425749","record_id":"REC_0010028","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":5.7,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":39,"primary_tumor_size_cm":6.7,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":30.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.342746+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_410194","record_id":"REC_0010029","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":24,"primary_tumor_size_cm":4.6,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.343062+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_581049","record_id":"REC_0010030","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":4.0,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":6.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.343395+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_994810","record_id":"REC_0010031","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":6.0,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.343691+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_844606","record_id":"REC_0010032","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":25.0,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":5.5,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":5.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.343968+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_801721","record_id":"REC_0010033","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":1,"smoking_pack_years":25,"primary_tumor_size_cm":2.5,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.344357+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_756222","record_id":"REC_0010034","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":33,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":0,"smoking_pack_years":62,"primary_tumor_size_cm":5.0,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":16.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.344714+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_179688","record_id":"REC_0010035","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":18,"tmb_mutations_per_mb":16.9,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":6.2,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.344986+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_877781","record_id":"REC_0010036","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":9.5,"age_at_diagnosis":51,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":7.8,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.345415+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_386196","record_id":"REC_0010037","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":36,"tmb_mutations_per_mb":9.7,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":6.9,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":38.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.346158+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_227957","record_id":"REC_0010038","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":5.3,"age_at_diagnosis":51,"sex":"male","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":5.0,"metastatic_sites_count":8,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.346580+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_478132","record_id":"REC_0010039","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":8.6,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":5.1,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.346918+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_801524","record_id":"REC_0010040","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":6.3,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.347206+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_830648","record_id":"REC_0010041","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":87,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":5.3,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.347479+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_133804","record_id":"REC_0010042","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":4.5,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":5.4,"metastatic_sites_count":8,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.347754+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_652251","record_id":"REC_0010043","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":3.6,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":31,"primary_tumor_size_cm":5.6,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":28.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.348020+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_888133","record_id":"REC_0010044","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":9.9,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":5.8,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.348357+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_838024","record_id":"REC_0010045","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":6.2,"metastatic_sites_count":3,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":8.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.348639+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_881271","record_id":"REC_0010046","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":84,"sex":"male","ecog_performance_status":3,"smoking_pack_years":8,"primary_tumor_size_cm":5.8,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.348921+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_647244","record_id":"REC_0010047","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":9.1,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":6.0,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.349210+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_295680","record_id":"REC_0010048","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":8.2,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":23.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.349533+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_974581","record_id":"REC_0010049","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":15.8,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":4.6,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.349829+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_733315","record_id":"REC_0010050","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":4.7,"metastatic_sites_count":8,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":7.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.350237+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_922095","record_id":"REC_0010051","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":6.1,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.350554+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_615846","record_id":"REC_0010052","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":26,"primary_tumor_size_cm":4.2,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":8.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.350863+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_405069","record_id":"REC_0010053","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":0,"smoking_pack_years":6,"primary_tumor_size_cm":3.6,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.351207+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_975384","record_id":"REC_0010054","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":6.3,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":32,"primary_tumor_size_cm":6.6,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.351485+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_369428","record_id":"REC_0010055","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":31,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":4.2,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":7.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.351763+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_294183","record_id":"REC_0010056","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":16.6,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":7.8,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":5.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.352029+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_645113","record_id":"REC_0010057","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":6.4,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":21,"primary_tumor_size_cm":4.9,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":18.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.352444+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_638106","record_id":"REC_0010058","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":46,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":7.3,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.352746+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_504969","record_id":"REC_0010059","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":9.9,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":7.0,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":19.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.353023+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_572635","record_id":"REC_0010060","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":13.1,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":6.1,"metastatic_sites_count":8,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":20.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.353288+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_651855","record_id":"REC_0010061","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":16.4,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":6.0,"metastatic_sites_count":3,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.353551+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_575546","record_id":"REC_0010062","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":3.3,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":42,"primary_tumor_size_cm":3.8,"metastatic_sites_count":3,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":19.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.353804+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_150111","record_id":"REC_0010063","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":3.4,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":7.8,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.354203+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_791332","record_id":"REC_0010064","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":3.3,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":6.1,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":5.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.354475+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_187354","record_id":"REC_0010065","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":14.9,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":3,"primary_tumor_size_cm":4.7,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.354742+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_414951","record_id":"REC_0010066","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":4.3,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":34.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.355001+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_117014","record_id":"REC_0010067","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":7.5,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.355255+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_771999","record_id":"REC_0010068","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":5.9,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.355519+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_995496","record_id":"REC_0010069","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":83,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":4.7,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.355790+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_811502","record_id":"REC_0010070","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":13.6,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":5.6,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.356058+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_738299","record_id":"REC_0010071","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":18.6,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":4.6,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.356575+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_625514","record_id":"REC_0010072","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":11.1,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":6.8,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.356911+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_431821","record_id":"REC_0010073","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":2,"smoking_pack_years":2,"primary_tumor_size_cm":5.2,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.357233+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_297346","record_id":"REC_0010074","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":32,"primary_tumor_size_cm":6.9,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.357535+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_985457","record_id":"REC_0010075","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":5.9,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.357837+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_150938","record_id":"REC_0010076","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":10.1,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":6.1,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.358343+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_652832","record_id":"REC_0010077","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":16.9,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":4.8,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.358738+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_221949","record_id":"REC_0010078","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":33,"tmb_mutations_per_mb":8.7,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":43,"primary_tumor_size_cm":6.1,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":30.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.359070+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_273118","record_id":"REC_0010079","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":8.4,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":3.6,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.359410+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_377813","record_id":"REC_0010080","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":15.5,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":1,"smoking_pack_years":2,"primary_tumor_size_cm":5.1,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.359747+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_377386","record_id":"REC_0010081","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":6.0,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":1,"smoking_pack_years":52,"primary_tumor_size_cm":6.1,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.360136+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_977320","record_id":"REC_0010082","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":21.3,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":6.2,"metastatic_sites_count":8,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.360541+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_901560","record_id":"REC_0010083","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":14.0,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":5.8,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.360909+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_132393","record_id":"REC_0010084","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":5.1,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":22.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.361266+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_391309","record_id":"REC_0010085","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":8.1,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":6.8,"metastatic_sites_count":3,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":22.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.361599+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_758518","record_id":"REC_0010086","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":13.6,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":3.2,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":23.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.361963+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_535285","record_id":"REC_0010087","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":2,"smoking_pack_years":2,"primary_tumor_size_cm":7.6,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.362347+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_687620","record_id":"REC_0010088","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":5.1,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.362689+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_845497","record_id":"REC_0010089","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":37,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.9,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":5.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.363203+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_697683","record_id":"REC_0010090","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":7.1,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.363549+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_264345","record_id":"REC_0010091","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":6.4,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":48,"primary_tumor_size_cm":7.5,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":16.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.363874+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_696964","record_id":"REC_0010092","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":14.6,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":6.4,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.364208+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_612692","record_id":"REC_0010093","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":5.0,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":19.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.364487+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_605524","record_id":"REC_0010094","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":15.6,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":7.1,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.364777+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_898404","record_id":"REC_0010095","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":5.3,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":6.0,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":39.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.365029+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_571433","record_id":"REC_0010096","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":18.2,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":5.3,"metastatic_sites_count":8,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":6.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.365302+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_767000","record_id":"REC_0010097","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":7.0,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.365552+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_398961","record_id":"REC_0010098","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":16.6,"age_at_diagnosis":85,"sex":"male","ecog_performance_status":0,"smoking_pack_years":5,"primary_tumor_size_cm":6.4,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.365818+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_678903","record_id":"REC_0010099","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":20.0,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":5.0,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.366079+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_185091","record_id":"REC_0010100","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":16.3,"age_at_diagnosis":75,"sex":"male","ecog_performance_status":2,"smoking_pack_years":23,"primary_tumor_size_cm":4.0,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.366342+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_852642","record_id":"REC_0010101","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":11.0,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":5.5,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.366590+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_179504","record_id":"REC_0010102","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":6.4,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.366941+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_730816","record_id":"REC_0010103","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":2,"smoking_pack_years":5,"primary_tumor_size_cm":4.9,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.367200+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_615989","record_id":"REC_0010104","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":14,"tmb_mutations_per_mb":10.0,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":21,"primary_tumor_size_cm":4.9,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.367440+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_586769","record_id":"REC_0010105","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":17.0,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":3,"smoking_pack_years":22,"primary_tumor_size_cm":5.9,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":22.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.367695+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_287508","record_id":"REC_0010106","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":1.9,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":25,"primary_tumor_size_cm":6.6,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":16.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.367955+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_855589","record_id":"REC_0010107","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":14.8,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":6,"primary_tumor_size_cm":4.8,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":17.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.368278+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_742147","record_id":"REC_0010108","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":16.7,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":9,"primary_tumor_size_cm":4.4,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.368583+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_571072","record_id":"REC_0010109","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":18,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":4,"primary_tumor_size_cm":3.7,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":22.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.368910+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_521329","record_id":"REC_0010110","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":15.2,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":4.3,"metastatic_sites_count":8,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.369279+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_337811","record_id":"REC_0010111","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":20,"tmb_mutations_per_mb":5.7,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":30,"primary_tumor_size_cm":3.1,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.369636+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_115498","record_id":"REC_0010112","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":3.8,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":3,"smoking_pack_years":43,"primary_tumor_size_cm":5.9,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":18.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.369955+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_713140","record_id":"REC_0010113","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":10.0,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":4.2,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":5.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.370279+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_959795","record_id":"REC_0010114","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":6.2,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.370637+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_750804","record_id":"REC_0010115","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":9.1,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":21,"primary_tumor_size_cm":6.8,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.371164+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_420919","record_id":"REC_0010116","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":14.9,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":3,"smoking_pack_years":22,"primary_tumor_size_cm":6.7,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":57.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.371527+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_780467","record_id":"REC_0010117","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":4.5,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":19.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.371878+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_739824","record_id":"REC_0010118","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":2.2,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":2,"smoking_pack_years":52,"primary_tumor_size_cm":5.9,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.372260+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_136637","record_id":"REC_0010119","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":17.5,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":5.2,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":19.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.372609+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_197021","record_id":"REC_0010120","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":5.1,"age_at_diagnosis":45,"sex":"female","ecog_performance_status":0,"smoking_pack_years":55,"primary_tumor_size_cm":6.0,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":18.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.372922+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_547979","record_id":"REC_0010121","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":5.5,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":19.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.373239+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_201652","record_id":"REC_0010122","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":5.5,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":56.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.373561+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_732781","record_id":"REC_0010123","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":33,"tmb_mutations_per_mb":7.6,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":4.9,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":17.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.373856+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_619004","record_id":"REC_0010124","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":18,"tmb_mutations_per_mb":13.8,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":6,"primary_tumor_size_cm":5.3,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.374125+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_290092","record_id":"REC_0010125","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":54,"sex":"male","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":3.6,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.374392+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_879624","record_id":"REC_0010126","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":3.5,"metastatic_sites_count":8,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.374660+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_406616","record_id":"REC_0010127","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":7.6,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":47,"primary_tumor_size_cm":4.4,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.374927+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_347352","record_id":"REC_0010128","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":3.5,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":7.5,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":5.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.375318+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_785433","record_id":"REC_0010129","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":5.8,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.375610+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_239985","record_id":"REC_0010130","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":19,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":59,"primary_tumor_size_cm":5.2,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.375901+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_103097","record_id":"REC_0010131","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":5.7,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.8,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":17.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.376228+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_453977","record_id":"REC_0010132","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":30,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":6.5,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.376492+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_529495","record_id":"REC_0010133","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":3.4,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.376739+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_386557","record_id":"REC_0010134","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":19.3,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":6.2,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":55.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.376990+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_145703","record_id":"REC_0010135","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":14.6,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":7.5,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.377249+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_838087","record_id":"REC_0010136","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":20,"tmb_mutations_per_mb":8.7,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":3,"smoking_pack_years":11,"primary_tumor_size_cm":4.3,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":5.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.377499+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_425419","record_id":"REC_0010137","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":9.9,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":6.6,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":28.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.377749+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_119979","record_id":"REC_0010138","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":15.8,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":4.3,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":23.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.378003+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_657146","record_id":"REC_0010139","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":17.2,"age_at_diagnosis":52,"sex":"male","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":4.2,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.378256+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_453102","record_id":"REC_0010140","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":4.2,"metastatic_sites_count":8,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":4.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.378511+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_831521","record_id":"REC_0010141","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":5.6,"age_at_diagnosis":74,"sex":"male","ecog_performance_status":0,"smoking_pack_years":50,"primary_tumor_size_cm":6.5,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":6.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.378889+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_605585","record_id":"REC_0010142","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":16.8,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":3.4,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":24.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.379170+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_905703","record_id":"REC_0010143","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":5.6,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":60,"primary_tumor_size_cm":7.1,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":31.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.379467+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_684244","record_id":"REC_0010144","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":13.1,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":1,"smoking_pack_years":25,"primary_tumor_size_cm":5.7,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.379759+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_868459","record_id":"REC_0010145","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":7.4,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.380136+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_430169","record_id":"REC_0010146","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":14.4,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":8.3,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.380472+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_219417","record_id":"REC_0010147","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":8.9,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":25,"primary_tumor_size_cm":5.0,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.380842+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_593203","record_id":"REC_0010148","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":6.3,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":8.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.381171+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_654476","record_id":"REC_0010149","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":17,"tmb_mutations_per_mb":13.1,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":10,"primary_tumor_size_cm":5.8,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":46.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.381454+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_372334","record_id":"REC_0010150","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":4.9,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":6.1,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":7.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.381726+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_531826","record_id":"REC_0010151","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":8.2,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.381987+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_901182","record_id":"REC_0010152","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":14.4,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":6.0,"metastatic_sites_count":3,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.382238+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_664996","record_id":"REC_0010153","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":3.8,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":2,"smoking_pack_years":42,"primary_tumor_size_cm":5.8,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.382484+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_361391","record_id":"REC_0010154","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":74,"sex":"male","ecog_performance_status":1,"smoking_pack_years":3,"primary_tumor_size_cm":5.4,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":32.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.382856+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_509076","record_id":"REC_0010155","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":19,"tmb_mutations_per_mb":15.8,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":4.8,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.383121+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_476797","record_id":"REC_0010156","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":5.3,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":33,"primary_tumor_size_cm":2.4,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.383374+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_370674","record_id":"REC_0010157","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":5.9,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.383633+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_776422","record_id":"REC_0010158","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":30,"tmb_mutations_per_mb":7.3,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":0,"smoking_pack_years":5,"primary_tumor_size_cm":3.8,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":7.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.383893+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_103705","record_id":"REC_0010159","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":14.0,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":4.9,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":4.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.384208+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_940271","record_id":"REC_0010160","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":8.0,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":3.6,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.384483+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_869541","record_id":"REC_0010161","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":83,"sex":"female","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":5.7,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":23.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.384757+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_643731","record_id":"REC_0010162","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":5.4,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.385038+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_735675","record_id":"REC_0010163","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":5.0,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":30.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.385330+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_173934","record_id":"REC_0010164","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":8.5,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":6.4,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":7.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.385601+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_743986","record_id":"REC_0010165","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":4.7,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":46,"primary_tumor_size_cm":6.5,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":7.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.385859+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_738213","record_id":"REC_0010166","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":6.9,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":5.9,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.386114+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_879195","record_id":"REC_0010167","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":15.3,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":24,"primary_tumor_size_cm":4.5,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.386504+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_417508","record_id":"REC_0010168","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":3.5,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":5.4,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.386805+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_848187","record_id":"REC_0010169","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":14.8,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.7,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.387114+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_120132","record_id":"REC_0010170","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":6.1,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":91,"primary_tumor_size_cm":4.6,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.387395+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_670718","record_id":"REC_0010171","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":9.7,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":3,"smoking_pack_years":8,"primary_tumor_size_cm":5.4,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.387663+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_121483","record_id":"REC_0010172","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.1,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":5.8,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.387913+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_841090","record_id":"REC_0010173","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":1,"smoking_pack_years":4,"primary_tumor_size_cm":3.4,"metastatic_sites_count":3,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":6.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.388220+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_489455","record_id":"REC_0010174","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":13.3,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":2.7,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":21.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.388479+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_711900","record_id":"REC_0010175","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":18.4,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":4.9,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.388730+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_368667","record_id":"REC_0010176","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":19,"tmb_mutations_per_mb":11.1,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":6.4,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":5.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.388978+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_759909","record_id":"REC_0010177","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":8.6,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":4.0,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.389233+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_156999","record_id":"REC_0010178","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":13.5,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":5.4,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.389494+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_339271","record_id":"REC_0010179","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":13.3,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":5.0,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.389770+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_645936","record_id":"REC_0010180","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":8.4,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":6.1,"metastatic_sites_count":9,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.390166+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_121655","record_id":"REC_0010181","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":16,"tmb_mutations_per_mb":13.3,"age_at_diagnosis":50,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":5.3,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":24.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.390448+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_488913","record_id":"REC_0010182","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":5.0,"metastatic_sites_count":9,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.390706+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_214972","record_id":"REC_0010183","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":2,"smoking_pack_years":22,"primary_tumor_size_cm":4.3,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.390959+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_175510","record_id":"REC_0010184","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":9.8,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":4.0,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.391213+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_491270","record_id":"REC_0010185","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":4.7,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.391468+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_378357","record_id":"REC_0010186","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":5.9,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.391723+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_474040","record_id":"REC_0010187","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":6.8,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":22.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.391977+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_552496","record_id":"REC_0010188","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":9.7,"age_at_diagnosis":83,"sex":"female","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":3.8,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.392351+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_157489","record_id":"REC_0010189","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":4.0,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.392626+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_137689","record_id":"REC_0010190","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":6.0,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":6.2,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":6.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.392884+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_667000","record_id":"REC_0010191","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":19,"tmb_mutations_per_mb":7.9,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":88,"primary_tumor_size_cm":6.0,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":16.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.393137+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_761491","record_id":"REC_0010192","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":17.9,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":4.6,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.393396+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_436456","record_id":"REC_0010193","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":5.6,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.393767+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_428884","record_id":"REC_0010194","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":16.8,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":8.0,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.394038+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_905278","record_id":"REC_0010195","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":4.7,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.394300+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_412335","record_id":"REC_0010196","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":7.6,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":5.8,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":7.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.394550+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_292261","record_id":"REC_0010197","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":15.8,"age_at_diagnosis":78,"sex":"male","ecog_performance_status":2,"smoking_pack_years":31,"primary_tumor_size_cm":4.6,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":25.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.394802+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_285759","record_id":"REC_0010198","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":8.0,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":73,"primary_tumor_size_cm":6.8,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.395051+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_958502","record_id":"REC_0010199","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":5.2,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":6.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.395297+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_148471","record_id":"REC_0010200","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":15.6,"age_at_diagnosis":86,"sex":"female","ecog_performance_status":2,"smoking_pack_years":25,"primary_tumor_size_cm":5.3,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.395544+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_568413","record_id":"REC_0010201","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":5.0,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":4.1,"metastatic_sites_count":8,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.395783+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_548580","record_id":"REC_0010202","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":51,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":5.2,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.396032+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_879452","record_id":"REC_0010203","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":7.4,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":3.8,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.396349+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_546761","record_id":"REC_0010204","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":6.7,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":49,"primary_tumor_size_cm":5.1,"metastatic_sites_count":9,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.396601+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_533827","record_id":"REC_0010205","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":14.9,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":6.2,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.396867+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_802354","record_id":"REC_0010206","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":9.7,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":2.1,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.397236+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_856053","record_id":"REC_0010207","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":5.7,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":22,"primary_tumor_size_cm":8.2,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.397497+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_439016","record_id":"REC_0010208","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":4.9,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":26.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.397753+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_141951","record_id":"REC_0010209","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":34,"tmb_mutations_per_mb":13.6,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":4.6,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.398015+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_122614","record_id":"REC_0010210","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":9.7,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":4.3,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.398264+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_234064","record_id":"REC_0010211","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":14.8,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":5.4,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.398497+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_524744","record_id":"REC_0010212","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":5.6,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.398746+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_207918","record_id":"REC_0010213","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":56,"primary_tumor_size_cm":4.3,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.399013+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_440299","record_id":"REC_0010214","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":9.0,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":0,"smoking_pack_years":46,"primary_tumor_size_cm":6.1,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.399314+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_535079","record_id":"REC_0010215","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":6.3,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":6.3,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.399610+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_838612","record_id":"REC_0010216","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":16.3,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":5.7,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.399896+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_910631","record_id":"REC_0010217","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":3.9,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":28.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.400226+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_344229","record_id":"REC_0010218","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":14.7,"age_at_diagnosis":40,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":4.0,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.400540+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_355067","record_id":"REC_0010219","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":17,"tmb_mutations_per_mb":11.5,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":6.0,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":17.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.400982+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_827709","record_id":"REC_0010220","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":9.8,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":4.5,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.401316+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_599576","record_id":"REC_0010221","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":3.6,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":52,"primary_tumor_size_cm":4.8,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":23.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.401607+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_815814","record_id":"REC_0010222","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":6.9,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":6.0,"metastatic_sites_count":9,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.401864+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_241769","record_id":"REC_0010223","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":5.3,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.402133+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_144438","record_id":"REC_0010224","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":9.5,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":5.2,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.402404+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_594120","record_id":"REC_0010225","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":6.3,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.402693+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_199451","record_id":"REC_0010226","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":19,"tmb_mutations_per_mb":3.1,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":3.8,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.402972+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_146969","record_id":"REC_0010227","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":16.8,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":2.6,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":17.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.403236+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_197159","record_id":"REC_0010228","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":15.8,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":2,"primary_tumor_size_cm":4.8,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.403509+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_755824","record_id":"REC_0010229","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":62,"primary_tumor_size_cm":3.1,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.403781+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_733159","record_id":"REC_0010230","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":6.4,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":4.9,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":30.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.404173+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_203695","record_id":"REC_0010231","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":32,"tmb_mutations_per_mb":5.1,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":6.3,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":5.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.404542+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_356648","record_id":"REC_0010232","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":4.0,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.404985+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_292020","record_id":"REC_0010233","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":41,"primary_tumor_size_cm":4.6,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":20.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.405321+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_826205","record_id":"REC_0010234","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":17.9,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":4.8,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.405630+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_691260","record_id":"REC_0010235","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":18,"tmb_mutations_per_mb":14.7,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":4,"primary_tumor_size_cm":6.1,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.405923+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_495619","record_id":"REC_0010236","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":6.3,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":24,"primary_tumor_size_cm":5.0,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.406238+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_626665","record_id":"REC_0010237","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":2,"primary_tumor_size_cm":6.3,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.406592+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_575887","record_id":"REC_0010238","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":4.3,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":5.3,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.407327+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_709030","record_id":"REC_0010239","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":5.5,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.407689+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_256031","record_id":"REC_0010240","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":8.6,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":34,"primary_tumor_size_cm":5.9,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.408035+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_984353","record_id":"REC_0010241","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":32,"tmb_mutations_per_mb":15.2,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":6.7,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.408471+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_700543","record_id":"REC_0010242","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":13.8,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":3.5,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":18.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.408834+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_888313","record_id":"REC_0010243","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":15.8,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":5.7,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.409142+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_997558","record_id":"REC_0010244","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":34,"tmb_mutations_per_mb":9.5,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":5.7,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.409418+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_390698","record_id":"REC_0010245","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":10.5,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":4.8,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.409920+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_528337","record_id":"REC_0010246","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":3,"smoking_pack_years":11,"primary_tumor_size_cm":4.7,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.410331+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_476917","record_id":"REC_0010247","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":74,"sex":"male","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":6.0,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.410694+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_720169","record_id":"REC_0010248","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":4.1,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":6.6,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.411058+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_342977","record_id":"REC_0010249","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":15,"tmb_mutations_per_mb":9.5,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.7,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.411412+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_578527","record_id":"REC_0010250","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":3.5,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":51,"primary_tumor_size_cm":5.4,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.411741+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_847418","record_id":"REC_0010251","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":5.9,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":62,"primary_tumor_size_cm":6.5,"metastatic_sites_count":9,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.412022+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_495376","record_id":"REC_0010252","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":15,"tmb_mutations_per_mb":19.4,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":5.0,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":4.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.412577+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_733291","record_id":"REC_0010253","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":14.8,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":5.3,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":22.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.412889+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_350507","record_id":"REC_0010254","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":30,"tmb_mutations_per_mb":5.5,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":5.9,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.413153+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_356174","record_id":"REC_0010255","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":8.5,"age_at_diagnosis":77,"sex":"male","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":5.2,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.413420+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_808983","record_id":"REC_0010256","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":4.2,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":51,"primary_tumor_size_cm":8.2,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":34.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.413669+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_513187","record_id":"REC_0010257","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":42,"primary_tumor_size_cm":6.3,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.413910+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_213246","record_id":"REC_0010258","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":4.1,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.414320+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_432650","record_id":"REC_0010259","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":16,"tmb_mutations_per_mb":14.8,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":25,"primary_tumor_size_cm":6.3,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.414593+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_291953","record_id":"REC_0010260","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":20,"tmb_mutations_per_mb":14.1,"age_at_diagnosis":83,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":4.0,"metastatic_sites_count":3,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.414855+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_712007","record_id":"REC_0010261","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":30,"tmb_mutations_per_mb":5.3,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":26,"primary_tumor_size_cm":6.0,"metastatic_sites_count":8,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":7.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.415109+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_390190","record_id":"REC_0010262","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":19.0,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":8.4,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.415383+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_154920","record_id":"REC_0010263","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":31,"tmb_mutations_per_mb":7.6,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":48,"primary_tumor_size_cm":4.8,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.415637+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_304506","record_id":"REC_0010264","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":39,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":5.0,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.415891+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_126103","record_id":"REC_0010265","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":8.4,"age_at_diagnosis":52,"sex":"male","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":3.1,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":5.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.416226+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_448196","record_id":"REC_0010266","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":7.2,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.416522+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_181088","record_id":"REC_0010267","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":5.1,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":2,"smoking_pack_years":35,"primary_tumor_size_cm":5.2,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":22.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.416803+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_535137","record_id":"REC_0010268","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":15.7,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":6.7,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.417121+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_954278","record_id":"REC_0010269","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":8.7,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":7.6,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.417431+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_490301","record_id":"REC_0010270","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":15.4,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.0,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.417778+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_433225","record_id":"REC_0010271","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":6.9,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":5.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.418296+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_782334","record_id":"REC_0010272","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":4.8,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":6.7,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":24.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.418639+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_571176","record_id":"REC_0010273","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":5.8,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.418938+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_371448","record_id":"REC_0010274","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":30,"tmb_mutations_per_mb":4.1,"age_at_diagnosis":51,"sex":"male","ecog_performance_status":0,"smoking_pack_years":39,"primary_tumor_size_cm":5.7,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":6.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.419235+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_417860","record_id":"REC_0010275","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":5.9,"age_at_diagnosis":49,"sex":"female","ecog_performance_status":0,"smoking_pack_years":32,"primary_tumor_size_cm":6.4,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":7.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.419494+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_556706","record_id":"REC_0010276","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":5.7,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":37,"primary_tumor_size_cm":8.0,"metastatic_sites_count":9,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.419738+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_269862","record_id":"REC_0010277","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":18.1,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":24,"primary_tumor_size_cm":6.2,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":17.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.419990+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_949458","record_id":"REC_0010278","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":6.4,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.420289+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_862544","record_id":"REC_0010279","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":10.0,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":6.2,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.420535+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_125854","record_id":"REC_0010280","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":14.5,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":5.6,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.420771+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_342318","record_id":"REC_0010281","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":8.9,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":0,"primary_tumor_size_cm":5.6,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.421008+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_578590","record_id":"REC_0010282","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":5.6,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":47,"primary_tumor_size_cm":5.9,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.421240+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_828064","record_id":"REC_0010283","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":38,"sex":"female","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":6.2,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.421476+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_529117","record_id":"REC_0010284","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":6.0,"age_at_diagnosis":80,"sex":"male","ecog_performance_status":2,"smoking_pack_years":29,"primary_tumor_size_cm":5.7,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.421808+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_346992","record_id":"REC_0010285","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":3,"primary_tumor_size_cm":6.2,"metastatic_sites_count":8,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.422047+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_629277","record_id":"REC_0010286","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":6.9,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":0,"smoking_pack_years":3,"primary_tumor_size_cm":5.3,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.422284+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_669936","record_id":"REC_0010287","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":9.8,"age_at_diagnosis":76,"sex":"male","ecog_performance_status":0,"smoking_pack_years":26,"primary_tumor_size_cm":4.5,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.422519+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_331387","record_id":"REC_0010288","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":15.5,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":3.8,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.422754+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_624670","record_id":"REC_0010289","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":5.0,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":7.2,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.422985+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_258564","record_id":"REC_0010290","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":13.8,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":6.3,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.423217+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_419675","record_id":"REC_0010291","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":15.3,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":7.7,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":19.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.423448+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_668210","record_id":"REC_0010292","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":18.9,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":6.3,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.423679+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_351570","record_id":"REC_0010293","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":7.9,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":6.6,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":5.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.423905+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_706004","record_id":"REC_0010294","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":5.8,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":17.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.424173+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_183786","record_id":"REC_0010295","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":9.5,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":26,"primary_tumor_size_cm":6.0,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":20.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.424410+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_460708","record_id":"REC_0010296","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":6.7,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.424642+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_290129","record_id":"REC_0010297","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":18,"tmb_mutations_per_mb":3.1,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":6.1,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.424932+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_800210","record_id":"REC_0010298","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":18.6,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":4.3,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":26.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.425174+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_720995","record_id":"REC_0010299","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":16,"tmb_mutations_per_mb":8.0,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":37,"primary_tumor_size_cm":5.9,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":17.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.425413+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_504630","record_id":"REC_0010300","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":3.4,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":50,"primary_tumor_size_cm":4.1,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.425646+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_767218","record_id":"REC_0010301","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":83,"sex":"male","ecog_performance_status":2,"smoking_pack_years":10,"primary_tumor_size_cm":6.0,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.425882+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_324690","record_id":"REC_0010302","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":7.9,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":5.0,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.426114+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_641204","record_id":"REC_0010303","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":0,"smoking_pack_years":28,"primary_tumor_size_cm":5.6,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":16.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.426346+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_686573","record_id":"REC_0010304","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":9.0,"age_at_diagnosis":54,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":5.3,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":7.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.426579+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_192395","record_id":"REC_0010305","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":18,"tmb_mutations_per_mb":8.1,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":1,"smoking_pack_years":53,"primary_tumor_size_cm":7.0,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":29.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.426810+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_916774","record_id":"REC_0010306","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":14.9,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":1,"smoking_pack_years":27,"primary_tumor_size_cm":5.9,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.427042+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_815038","record_id":"REC_0010307","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":6.1,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.427273+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_937016","record_id":"REC_0010308","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":81,"sex":"male","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":4.9,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.427511+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_795965","record_id":"REC_0010309","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":10.1,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":5.7,"metastatic_sites_count":3,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.427742+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_432663","record_id":"REC_0010310","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":11.1,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":6.4,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.428026+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_480997","record_id":"REC_0010311","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":13.8,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.1,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.428404+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_424696","record_id":"REC_0010312","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":14.9,"age_at_diagnosis":77,"sex":"male","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":6.7,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":17.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.428650+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_946895","record_id":"REC_0010313","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":74,"sex":"male","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":6.5,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":6.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.428887+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_534134","record_id":"REC_0010314","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":10.5,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":3,"primary_tumor_size_cm":4.6,"metastatic_sites_count":9,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":16.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.429123+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_812357","record_id":"REC_0010315","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":5.7,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.429363+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_615900","record_id":"REC_0010316","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":64,"primary_tumor_size_cm":5.7,"metastatic_sites_count":10,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.429591+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_128905","record_id":"REC_0010317","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":9.9,"age_at_diagnosis":54,"sex":"male","ecog_performance_status":0,"smoking_pack_years":2,"primary_tumor_size_cm":4.8,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.429823+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_618601","record_id":"REC_0010318","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":4.2,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":16.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.430057+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_929835","record_id":"REC_0010319","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":3.2,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":0,"smoking_pack_years":64,"primary_tumor_size_cm":4.8,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.430293+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_957867","record_id":"REC_0010320","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":11.5,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":5.7,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.430524+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_998807","record_id":"REC_0010321","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":8.4,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":3.4,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.430757+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_351690","record_id":"REC_0010322","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":2.2,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":0,"primary_tumor_size_cm":6.2,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.430981+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_333967","record_id":"REC_0010323","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":20,"tmb_mutations_per_mb":5.7,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":0,"smoking_pack_years":64,"primary_tumor_size_cm":6.9,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":19.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.431262+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_571350","record_id":"REC_0010324","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":19,"tmb_mutations_per_mb":14.1,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":6.1,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.431502+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_392847","record_id":"REC_0010325","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":5.8,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.431738+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_724968","record_id":"REC_0010326","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":4.3,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":70,"primary_tumor_size_cm":7.0,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":26.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.431968+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_427303","record_id":"REC_0010327","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":5.1,"metastatic_sites_count":9,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.432233+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_842170","record_id":"REC_0010328","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":4.9,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":7.7,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":41.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.432473+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_919959","record_id":"REC_0010329","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":1,"smoking_pack_years":57,"primary_tumor_size_cm":6.4,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.432708+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_562620","record_id":"REC_0010330","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":3.8,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":5.1,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.432935+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_326506","record_id":"REC_0010331","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":5.7,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":68,"primary_tumor_size_cm":4.7,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.433163+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_464215","record_id":"REC_0010332","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":6.2,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.433396+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_133985","record_id":"REC_0010333","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":7.4,"age_at_diagnosis":53,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":6.4,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":21.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.433626+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_264740","record_id":"REC_0010334","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":8.0,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":5.0,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":17.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.433854+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_512271","record_id":"REC_0010335","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":5.1,"metastatic_sites_count":3,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.434084+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_838011","record_id":"REC_0010336","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":34,"tmb_mutations_per_mb":14.6,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":0,"smoking_pack_years":4,"primary_tumor_size_cm":5.7,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.434380+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_252677","record_id":"REC_0010337","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":5.2,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":7.2,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":24.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.434611+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_109385","record_id":"REC_0010338","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":50,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":7.4,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.434843+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_417196","record_id":"REC_0010339","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":6.9,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.435074+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_349215","record_id":"REC_0010340","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":4.8,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":1,"smoking_pack_years":56,"primary_tumor_size_cm":5.5,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":19.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.435305+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_915103","record_id":"REC_0010341","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":16.3,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":5.2,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.435538+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_378480","record_id":"REC_0010342","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":7.1,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.435772+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_118088","record_id":"REC_0010343","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":14.0,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":6,"primary_tumor_size_cm":4.5,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":17.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.436005+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_413418","record_id":"REC_0010344","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":31,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":5.7,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.436273+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_628123","record_id":"REC_0010345","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":10.3,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":4.4,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.436510+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_777144","record_id":"REC_0010346","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":47,"sex":"male","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":7.7,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.436746+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_733917","record_id":"REC_0010347","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":5.0,"metastatic_sites_count":8,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.436979+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_542290","record_id":"REC_0010348","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":4.9,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":23.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.437209+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_833650","record_id":"REC_0010349","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":5.8,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":7.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.437500+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_623254","record_id":"REC_0010350","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":9.8,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":4.3,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":21.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.437737+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_773188","record_id":"REC_0010351","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":0,"smoking_pack_years":36,"primary_tumor_size_cm":6.9,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.437971+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_659489","record_id":"REC_0010352","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":19,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":7.4,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.438202+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_322550","record_id":"REC_0010353","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":14.9,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":2,"primary_tumor_size_cm":5.4,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":23.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.438433+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_465479","record_id":"REC_0010354","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":4.8,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":5.8,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":22.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.438662+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_429000","record_id":"REC_0010355","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":7.9,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":5.7,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.438905+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_786560","record_id":"REC_0010356","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":33,"tmb_mutations_per_mb":9.1,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":2,"smoking_pack_years":6,"primary_tumor_size_cm":5.6,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.439148+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_284490","record_id":"REC_0010357","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.5,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":5.3,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":7.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.439387+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_485082","record_id":"REC_0010358","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":33,"tmb_mutations_per_mb":20.4,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":7.0,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":34.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.439625+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_784337","record_id":"REC_0010359","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":10.5,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":7.1,"metastatic_sites_count":8,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.439862+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_393188","record_id":"REC_0010360","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":4.1,"age_at_diagnosis":48,"sex":"female","ecog_performance_status":0,"smoking_pack_years":27,"primary_tumor_size_cm":6.8,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":22.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.440155+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_208602","record_id":"REC_0010361","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":7.3,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":0,"smoking_pack_years":31,"primary_tumor_size_cm":5.3,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":4.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.440406+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_753774","record_id":"REC_0010362","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":30,"tmb_mutations_per_mb":8.6,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":23,"primary_tumor_size_cm":4.9,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.440732+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_858702","record_id":"REC_0010363","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":20.2,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":5.6,"metastatic_sites_count":3,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.440993+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_969375","record_id":"REC_0010364","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":13.5,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":3.1,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.441250+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_921149","record_id":"REC_0010365","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":16.1,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":4.1,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":28.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.441497+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_557830","record_id":"REC_0010366","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":13.6,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":25,"primary_tumor_size_cm":6.8,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.441732+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_781727","record_id":"REC_0010367","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":13.6,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":6.5,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.441969+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_897651","record_id":"REC_0010368","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":9.8,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":4.9,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.442198+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_810416","record_id":"REC_0010369","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":19,"tmb_mutations_per_mb":17.5,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":5.0,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":34.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.442436+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_963965","record_id":"REC_0010370","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":18.3,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":24,"primary_tumor_size_cm":6.3,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.442669+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_961953","record_id":"REC_0010371","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":19.9,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":21,"primary_tumor_size_cm":4.7,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.442909+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_108013","record_id":"REC_0010372","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":14.7,"age_at_diagnosis":83,"sex":"male","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":5.5,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.443148+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_740975","record_id":"REC_0010373","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":21.9,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":7.7,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.443381+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_322641","record_id":"REC_0010374","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":14.4,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":6,"primary_tumor_size_cm":6.5,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.443617+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_395712","record_id":"REC_0010375","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":18.6,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":5.2,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.443947+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_525203","record_id":"REC_0010376","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":8.5,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":6.2,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.444226+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_141160","record_id":"REC_0010377","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":5.7,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.444482+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_858058","record_id":"REC_0010378","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":5.0,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.444721+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_939944","record_id":"REC_0010379","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":8.9,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":1,"smoking_pack_years":40,"primary_tumor_size_cm":5.8,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.444955+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_929959","record_id":"REC_0010380","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":12,"tmb_mutations_per_mb":13.6,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":4.6,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.445196+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_881332","record_id":"REC_0010381","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":15.5,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":3.9,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":4.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.445432+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_234442","record_id":"REC_0010382","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":5.2,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.445673+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_598693","record_id":"REC_0010383","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":4.1,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.445941+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_965007","record_id":"REC_0010384","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":5.0,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":20.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.446199+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_477198","record_id":"REC_0010385","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":5.2,"metastatic_sites_count":8,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":4.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.446447+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_246476","record_id":"REC_0010386","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":32,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":5.5,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.446687+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_735695","record_id":"REC_0010387","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":16.1,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":3,"smoking_pack_years":9,"primary_tumor_size_cm":6.0,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.446935+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_353975","record_id":"REC_0010388","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":31,"tmb_mutations_per_mb":15.3,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":5.2,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.447282+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_862838","record_id":"REC_0010389","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":9.0,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":5.9,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.447526+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_812458","record_id":"REC_0010390","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":17.4,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":4.7,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":21.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.447766+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_227779","record_id":"REC_0010391","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":16.8,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":3.5,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.448005+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_610834","record_id":"REC_0010392","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":6.3,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":17.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.448405+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_768489","record_id":"REC_0010393","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":5.3,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":67,"primary_tumor_size_cm":7.8,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.448665+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_401598","record_id":"REC_0010394","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":6.9,"age_at_diagnosis":54,"sex":"female","ecog_performance_status":0,"smoking_pack_years":38,"primary_tumor_size_cm":7.6,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":27.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.448907+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_884058","record_id":"REC_0010395","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":8.0,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":3.8,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.449143+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_855386","record_id":"REC_0010396","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":54,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":6.3,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":5.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.449381+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_556123","record_id":"REC_0010397","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":19,"tmb_mutations_per_mb":13.8,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":1,"smoking_pack_years":4,"primary_tumor_size_cm":2.9,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.449622+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_845325","record_id":"REC_0010398","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":4.4,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.449860+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_530210","record_id":"REC_0010399","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":17.4,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":5.9,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.450101+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_885848","record_id":"REC_0010400","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.2,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.450333+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_343811","record_id":"REC_0010401","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":16.7,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":6.1,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.450655+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_767805","record_id":"REC_0010402","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":30,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":3.9,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.450897+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_491285","record_id":"REC_0010403","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":6,"primary_tumor_size_cm":4.3,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.451133+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_838396","record_id":"REC_0010404","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":3.0,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":1,"smoking_pack_years":68,"primary_tumor_size_cm":4.2,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.451368+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_194853","record_id":"REC_0010405","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":15.7,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":4.9,"metastatic_sites_count":8,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":16.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.451605+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_605400","record_id":"REC_0010406","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":6.4,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.451847+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_988682","record_id":"REC_0010407","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":4.6,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":3.5,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.452135+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_341280","record_id":"REC_0010408","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":37,"tmb_mutations_per_mb":14.8,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":5.8,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.452394+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_426608","record_id":"REC_0010409","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":6.7,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":7.3,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.452644+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_938595","record_id":"REC_0010410","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":31,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":6.3,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":32.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.452915+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_675029","record_id":"REC_0010411","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":14.3,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":7.4,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.453209+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_653483","record_id":"REC_0010412","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":80,"sex":"male","ecog_performance_status":1,"smoking_pack_years":29,"primary_tumor_size_cm":5.3,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.453725+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_417158","record_id":"REC_0010413","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":13.6,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":6.7,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.454015+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_307349","record_id":"REC_0010414","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":5.4,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.454428+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_784830","record_id":"REC_0010415","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":8.5,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":3,"smoking_pack_years":4,"primary_tumor_size_cm":7.0,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.454721+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_673969","record_id":"REC_0010416","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":15.5,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":4.5,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":25.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.454972+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_655796","record_id":"REC_0010417","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":6.1,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":3.5,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.455219+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_982012","record_id":"REC_0010418","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":14.9,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":6.2,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.455473+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_745732","record_id":"REC_0010419","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":5.6,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.455716+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_400309","record_id":"REC_0010420","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":18,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":4.0,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.455967+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_319503","record_id":"REC_0010421","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":15.5,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":4.6,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":16.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.456312+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_257232","record_id":"REC_0010422","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":3.1,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.456579+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_770042","record_id":"REC_0010423","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":16.4,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":5.0,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":17.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.456830+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_475501","record_id":"REC_0010424","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":16.3,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":5.3,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.457078+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_872035","record_id":"REC_0010425","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":6.9,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.457330+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_894264","record_id":"REC_0010426","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":4.6,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.457601+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_321319","record_id":"REC_0010427","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":9.1,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":4.3,"metastatic_sites_count":3,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.457960+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_150551","record_id":"REC_0010428","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":10,"tmb_mutations_per_mb":4.6,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":1,"smoking_pack_years":61,"primary_tumor_size_cm":6.6,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.458218+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_825115","record_id":"REC_0010429","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":20,"primary_tumor_size_cm":3.6,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.458455+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_359026","record_id":"REC_0010430","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":17,"tmb_mutations_per_mb":2.6,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":0,"smoking_pack_years":46,"primary_tumor_size_cm":7.0,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":4.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.458700+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_540573","record_id":"REC_0010431","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":19.1,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":4.2,"metastatic_sites_count":3,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.458963+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_234927","record_id":"REC_0010432","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":14.4,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":2.9,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":27.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.459212+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_888368","record_id":"REC_0010433","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":5.9,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":64,"primary_tumor_size_cm":6.3,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.459458+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_830827","record_id":"REC_0010434","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":2,"smoking_pack_years":3,"primary_tumor_size_cm":5.0,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":25.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.459704+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_242741","record_id":"REC_0010435","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":4.5,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.459946+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_518786","record_id":"REC_0010436","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":4.0,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.460247+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_772326","record_id":"REC_0010437","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":3.0,"age_at_diagnosis":44,"sex":"male","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":6.1,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.460521+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_997639","record_id":"REC_0010438","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":6.7,"metastatic_sites_count":8,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.460799+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_301014","record_id":"REC_0010439","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":14.8,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":7.0,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.461051+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_331210","record_id":"REC_0010440","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":3,"smoking_pack_years":20,"primary_tumor_size_cm":3.5,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.461425+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_305785","record_id":"REC_0010441","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":5.2,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":6.1,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.461680+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_673440","record_id":"REC_0010442","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":19.6,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":3.9,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":32.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.461928+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_254507","record_id":"REC_0010443","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":9.7,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":5.3,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.462200+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_800444","record_id":"REC_0010444","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":9.9,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":10,"primary_tumor_size_cm":7.7,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.462450+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_602120","record_id":"REC_0010445","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":5.5,"age_at_diagnosis":84,"sex":"female","ecog_performance_status":2,"smoking_pack_years":8,"primary_tumor_size_cm":6.6,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":32.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.462680+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_905876","record_id":"REC_0010446","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":11.1,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":5,"primary_tumor_size_cm":6.9,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.462915+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_927580","record_id":"REC_0010447","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":23,"primary_tumor_size_cm":5.3,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.463149+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_218206","record_id":"REC_0010448","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":9.0,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":3.1,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":7.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.463398+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_857757","record_id":"REC_0010449","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":7.6,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":6.3,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":26.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.463630+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_110169","record_id":"REC_0010450","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":18,"tmb_mutations_per_mb":16.0,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":6.3,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.463863+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_229697","record_id":"REC_0010451","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":6.8,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":16.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.464143+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_422031","record_id":"REC_0010452","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":5.7,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":5.4,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.464414+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_619495","record_id":"REC_0010453","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":19,"tmb_mutations_per_mb":4.9,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":57,"primary_tumor_size_cm":4.3,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.464811+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_180982","record_id":"REC_0010454","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":5.6,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":52,"primary_tumor_size_cm":7.6,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":19.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.465107+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_800726","record_id":"REC_0010455","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":8.5,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":6.2,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":19.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.465400+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_455646","record_id":"REC_0010456","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":15,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":34,"primary_tumor_size_cm":3.8,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.465665+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_243720","record_id":"REC_0010457","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":16,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":1,"smoking_pack_years":50,"primary_tumor_size_cm":5.6,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":19.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.465915+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_829742","record_id":"REC_0010458","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":19.7,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":1,"smoking_pack_years":28,"primary_tumor_size_cm":6.4,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.466150+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_193444","record_id":"REC_0010459","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":34,"tmb_mutations_per_mb":11.5,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":6.0,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.466390+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_244704","record_id":"REC_0010460","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":18.8,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":10,"primary_tumor_size_cm":6.2,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.466623+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_393127","record_id":"REC_0010461","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":0,"smoking_pack_years":45,"primary_tumor_size_cm":5.0,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":17.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.466861+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_681739","record_id":"REC_0010462","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":16,"tmb_mutations_per_mb":3.7,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":29,"primary_tumor_size_cm":3.6,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":23.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.467119+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_185158","record_id":"REC_0010463","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":2,"smoking_pack_years":29,"primary_tumor_size_cm":7.5,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.467410+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_856118","record_id":"REC_0010464","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":6.1,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":6.5,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.467699+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_448890","record_id":"REC_0010465","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":11,"tmb_mutations_per_mb":5.2,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":7.1,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":19.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.468003+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_172159","record_id":"REC_0010466","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":4.9,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":6.1,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.468507+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_346620","record_id":"REC_0010467","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":8.0,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":1,"smoking_pack_years":75,"primary_tumor_size_cm":5.8,"metastatic_sites_count":8,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":16.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.468826+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_684567","record_id":"REC_0010468","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":9.1,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":26,"primary_tumor_size_cm":5.8,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.469092+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_429054","record_id":"REC_0010469","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":14,"tmb_mutations_per_mb":13.5,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":5.2,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.469360+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_362043","record_id":"REC_0010470","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":3.7,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":21.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.469612+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_141548","record_id":"REC_0010471","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":48,"primary_tumor_size_cm":5.1,"metastatic_sites_count":3,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":7.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.469854+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_350290","record_id":"REC_0010472","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":16.5,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":7.2,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.470105+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_857343","record_id":"REC_0010473","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":7.3,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":4.3,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.470342+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_207892","record_id":"REC_0010474","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":7.2,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.470579+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_553473","record_id":"REC_0010475","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":6.0,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.470832+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_544027","record_id":"REC_0010476","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":20,"tmb_mutations_per_mb":5.9,"age_at_diagnosis":47,"sex":"male","ecog_performance_status":0,"smoking_pack_years":50,"primary_tumor_size_cm":5.5,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":19.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.471079+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_262452","record_id":"REC_0010477","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":8.4,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":6.7,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.471316+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_252851","record_id":"REC_0010478","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":4.8,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":40.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.471560+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_433105","record_id":"REC_0010479","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":7.2,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.471908+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_513710","record_id":"REC_0010480","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":14.7,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":2.0,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.472211+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_602734","record_id":"REC_0010481","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":4.3,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":34.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.472457+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_201612","record_id":"REC_0010482","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":3.6,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":0,"smoking_pack_years":31,"primary_tumor_size_cm":5.0,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.472691+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_238742","record_id":"REC_0010483","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":15.1,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":0,"smoking_pack_years":5,"primary_tumor_size_cm":6.2,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.472927+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_791956","record_id":"REC_0010484","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":16.3,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":7.2,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.473166+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_370767","record_id":"REC_0010485","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":6.0,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":22.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.473405+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_648088","record_id":"REC_0010486","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":0,"smoking_pack_years":50,"primary_tumor_size_cm":4.7,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":43.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.473633+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_549532","record_id":"REC_0010487","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":20.6,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":0,"smoking_pack_years":24,"primary_tumor_size_cm":5.7,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.473873+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_175109","record_id":"REC_0010488","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":6.4,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":6.3,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":24.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.474108+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_735497","record_id":"REC_0010489","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":14.3,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":7.0,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.474341+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_295188","record_id":"REC_0010490","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":26,"primary_tumor_size_cm":4.4,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.474578+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_439485","record_id":"REC_0010491","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":16,"tmb_mutations_per_mb":8.9,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.4,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.474807+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_726430","record_id":"REC_0010492","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":18,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":3,"smoking_pack_years":7,"primary_tumor_size_cm":5.7,"metastatic_sites_count":8,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.475117+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_435932","record_id":"REC_0010493","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":2.4,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":6.0,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.475354+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_777277","record_id":"REC_0010494","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":30,"tmb_mutations_per_mb":4.6,"age_at_diagnosis":77,"sex":"male","ecog_performance_status":1,"smoking_pack_years":48,"primary_tumor_size_cm":6.0,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.475588+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_647261","record_id":"REC_0010495","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":2.6,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.475817+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_649870","record_id":"REC_0010496","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":4.4,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.476148+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_449819","record_id":"REC_0010497","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":14.3,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":6.7,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.476411+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_670215","record_id":"REC_0010498","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.0,"age_at_diagnosis":74,"sex":"male","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":6.9,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.476671+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_800716","record_id":"REC_0010499","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":85,"sex":"female","ecog_performance_status":2,"smoking_pack_years":63,"primary_tumor_size_cm":5.5,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.476957+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_508068","record_id":"REC_0010500","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":19,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":53,"sex":"female","ecog_performance_status":0,"smoking_pack_years":31,"primary_tumor_size_cm":6.6,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.477197+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_797504","record_id":"REC_0010501","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":14.5,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":5,"primary_tumor_size_cm":5.0,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":16.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.477438+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_750623","record_id":"REC_0010502","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":8.3,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":2,"primary_tumor_size_cm":4.1,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":17.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.477669+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_931016","record_id":"REC_0010503","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":4.8,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.477921+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_187848","record_id":"REC_0010504","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":16.6,"age_at_diagnosis":52,"sex":"male","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":5.5,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.478155+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_642777","record_id":"REC_0010505","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":34,"tmb_mutations_per_mb":7.9,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":31,"primary_tumor_size_cm":4.5,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":7.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.478472+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_893026","record_id":"REC_0010506","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":14.1,"age_at_diagnosis":52,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":6.5,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.478719+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_772049","record_id":"REC_0010507","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":6.1,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":22.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.478969+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_262673","record_id":"REC_0010508","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":3,"primary_tumor_size_cm":4.0,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.479205+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_394678","record_id":"REC_0010509","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":25,"primary_tumor_size_cm":4.2,"metastatic_sites_count":8,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.479438+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_648084","record_id":"REC_0010510","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":16,"tmb_mutations_per_mb":4.2,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":7.2,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.479673+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_332577","record_id":"REC_0010511","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":36,"tmb_mutations_per_mb":4.4,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":6.2,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.480004+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_698464","record_id":"REC_0010512","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":3.9,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":50,"primary_tumor_size_cm":2.8,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":16.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.480282+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_252411","record_id":"REC_0010513","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":16.1,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":3.7,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.480548+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_882822","record_id":"REC_0010514","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":20,"tmb_mutations_per_mb":8.3,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":57,"primary_tumor_size_cm":4.9,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.480802+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_622156","record_id":"REC_0010515","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":15.1,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":5.0,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.481056+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_986056","record_id":"REC_0010516","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":17.2,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":6.8,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.481304+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_454309","record_id":"REC_0010517","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":15,"tmb_mutations_per_mb":9.0,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":3,"primary_tumor_size_cm":5.0,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":21.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.481536+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_202289","record_id":"REC_0010518","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":9.1,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":4.3,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":23.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.481876+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_927653","record_id":"REC_0010519","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":20,"tmb_mutations_per_mb":17.5,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":4.7,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":5.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.482136+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_690423","record_id":"REC_0010520","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":16.1,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":4.4,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.482374+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_930489","record_id":"REC_0010521","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":16.0,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":2.9,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":18.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.482628+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_626526","record_id":"REC_0010522","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":4.6,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.482862+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_290265","record_id":"REC_0010523","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":33,"tmb_mutations_per_mb":2.6,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":2,"primary_tumor_size_cm":4.5,"metastatic_sites_count":3,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.483092+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_643498","record_id":"REC_0010524","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":30,"tmb_mutations_per_mb":9.0,"age_at_diagnosis":52,"sex":"female","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":6.3,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":8.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.483324+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_871606","record_id":"REC_0010525","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":9.8,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":4.4,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.483563+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_416391","record_id":"REC_0010526","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":5.6,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":4.0,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":18.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.483809+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_442974","record_id":"REC_0010527","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":16.6,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":4.7,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.484052+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_990925","record_id":"REC_0010528","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":6.6,"metastatic_sites_count":10,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.484332+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_685753","record_id":"REC_0010529","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":14.0,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":6.0,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.484569+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_730789","record_id":"REC_0010530","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":14.9,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":6.0,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.484853+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_850068","record_id":"REC_0010531","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":5.7,"age_at_diagnosis":87,"sex":"female","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":6.6,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":16.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.485146+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_640849","record_id":"REC_0010532","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":1.5,"age_at_diagnosis":75,"sex":"male","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":5.7,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.485427+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_686562","record_id":"REC_0010533","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":15.5,"age_at_diagnosis":53,"sex":"female","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":5.0,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.485663+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_121744","record_id":"REC_0010534","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":7.8,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":18.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.485897+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_981325","record_id":"REC_0010535","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":15.2,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":4.7,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.486180+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_977087","record_id":"REC_0010536","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":20,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":48,"primary_tumor_size_cm":5.2,"metastatic_sites_count":8,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.486406+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_877179","record_id":"REC_0010537","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":1,"smoking_pack_years":26,"primary_tumor_size_cm":6.5,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.486679+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_310349","record_id":"REC_0010538","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":31,"tmb_mutations_per_mb":5.3,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":53,"primary_tumor_size_cm":6.4,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":17.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.486909+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_501471","record_id":"REC_0010539","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":4.5,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":37,"primary_tumor_size_cm":6.1,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.487140+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_783352","record_id":"REC_0010540","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":13.8,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":6.3,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.487373+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_217287","record_id":"REC_0010541","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":5.2,"age_at_diagnosis":75,"sex":"male","ecog_performance_status":1,"smoking_pack_years":47,"primary_tumor_size_cm":4.5,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.487604+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_273691","record_id":"REC_0010542","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":5.0,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":45,"primary_tumor_size_cm":4.9,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.487832+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_639291","record_id":"REC_0010543","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":10.3,"age_at_diagnosis":82,"sex":"male","ecog_performance_status":3,"smoking_pack_years":26,"primary_tumor_size_cm":6.0,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":19.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.488067+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_931411","record_id":"REC_0010544","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":16,"tmb_mutations_per_mb":14.3,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":3.9,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.488412+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_698982","record_id":"REC_0010545","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":15.4,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":26,"primary_tumor_size_cm":5.9,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.488659+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_186797","record_id":"REC_0010546","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":18.2,"age_at_diagnosis":83,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":6.3,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":24.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.488897+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_590325","record_id":"REC_0010547","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":36,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":4.3,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.489134+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_956852","record_id":"REC_0010548","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":5.5,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.489379+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_353537","record_id":"REC_0010549","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":19.1,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":8.5,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":24.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.489645+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_701930","record_id":"REC_0010550","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":0,"smoking_pack_years":27,"primary_tumor_size_cm":4.3,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.489914+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_538811","record_id":"REC_0010551","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":9.5,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":8.6,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":21.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.490158+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_528621","record_id":"REC_0010552","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":5.7,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":1,"smoking_pack_years":40,"primary_tumor_size_cm":5.2,"metastatic_sites_count":8,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.490395+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_825156","record_id":"REC_0010553","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":0,"primary_tumor_size_cm":5.3,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":17.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.490634+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_182954","record_id":"REC_0010554","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":16.4,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":6.3,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.490865+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_334371","record_id":"REC_0010555","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":83,"sex":"male","ecog_performance_status":2,"smoking_pack_years":9,"primary_tumor_size_cm":3.7,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":31.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.491101+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_819900","record_id":"REC_0010556","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":19,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":35,"primary_tumor_size_cm":5.8,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.491328+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_615458","record_id":"REC_0010557","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":5.4,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.491662+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_896589","record_id":"REC_0010558","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":37,"tmb_mutations_per_mb":15.3,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":5.4,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":23.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.491903+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_347507","record_id":"REC_0010559","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":13.3,"age_at_diagnosis":51,"sex":"male","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":8.2,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":7.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.492185+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_270355","record_id":"REC_0010560","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":5.2,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.492421+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_517619","record_id":"REC_0010561","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":15.5,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":3,"smoking_pack_years":17,"primary_tumor_size_cm":4.6,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":18.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.492654+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_157850","record_id":"REC_0010562","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":34,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":70,"primary_tumor_size_cm":6.1,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.492882+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_649308","record_id":"REC_0010563","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":35,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":4.6,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":6.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.493121+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_639639","record_id":"REC_0010564","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":18,"tmb_mutations_per_mb":5.9,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":45,"primary_tumor_size_cm":4.9,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":31.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.493350+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_339457","record_id":"REC_0010565","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":18,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":6.4,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":7.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.493587+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_732766","record_id":"REC_0010566","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":4.7,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.493818+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_547391","record_id":"REC_0010567","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":34,"tmb_mutations_per_mb":9.0,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":5.4,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":21.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.494045+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_567407","record_id":"REC_0010568","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":6.4,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":3.8,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":4.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.494275+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_724521","record_id":"REC_0010569","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":16.1,"age_at_diagnosis":52,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":2.6,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.494508+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_653981","record_id":"REC_0010570","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":15.6,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":24,"primary_tumor_size_cm":5.6,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.494802+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_167486","record_id":"REC_0010571","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.0,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.495042+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_632629","record_id":"REC_0010572","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":2.9,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":25,"primary_tumor_size_cm":5.7,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":5.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.495273+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_615165","record_id":"REC_0010573","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":15.5,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":4.1,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.495503+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_350743","record_id":"REC_0010574","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":14,"tmb_mutations_per_mb":10.5,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":5.7,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.495734+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_293736","record_id":"REC_0010575","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":77,"sex":"male","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":6.1,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":4.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.495970+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_969997","record_id":"REC_0010576","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":7.3,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.496255+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_673381","record_id":"REC_0010577","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":9.8,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":5.2,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.496508+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_277250","record_id":"REC_0010578","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":20,"tmb_mutations_per_mb":8.3,"age_at_diagnosis":53,"sex":"female","ecog_performance_status":0,"smoking_pack_years":65,"primary_tumor_size_cm":5.6,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.496757+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_948621","record_id":"REC_0010579","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":20,"primary_tumor_size_cm":6.3,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.496990+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_927919","record_id":"REC_0010580","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":8.0,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":6.7,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.497218+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_690515","record_id":"REC_0010581","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":6.2,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.497454+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_648574","record_id":"REC_0010582","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":30,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":5.4,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.497682+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_339972","record_id":"REC_0010583","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":9.5,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":2.5,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.498047+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_626682","record_id":"REC_0010584","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":4.7,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":56,"primary_tumor_size_cm":5.0,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":17.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.498281+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_801266","record_id":"REC_0010585","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":3.5,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":2,"smoking_pack_years":93,"primary_tumor_size_cm":8.3,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.498511+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_265785","record_id":"REC_0010586","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ALK fusion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":2,"smoking_pack_years":7,"primary_tumor_size_cm":4.1,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":56.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.498762+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_750156","record_id":"REC_0010587","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":17.0,"age_at_diagnosis":88,"sex":"female","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":4.7,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":6.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.499003+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_524048","record_id":"REC_0010588","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":20.4,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":4.7,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.499239+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_183940","record_id":"REC_0010589","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":3.6,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":24,"primary_tumor_size_cm":4.5,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":27.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.499473+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_612851","record_id":"REC_0010590","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":14.9,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":5,"primary_tumor_size_cm":8.5,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.499713+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_687998","record_id":"REC_0010591","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":6.1,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":21.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.499962+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_583179","record_id":"REC_0010592","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":8,"primary_tumor_size_cm":3.8,"metastatic_sites_count":8,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.500268+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_307394","record_id":"REC_0010593","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":14,"tmb_mutations_per_mb":5.6,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":2,"smoking_pack_years":58,"primary_tumor_size_cm":4.7,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.500575+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_767727","record_id":"REC_0010594","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":17.6,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":5.1,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":49.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.500834+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_846232","record_id":"REC_0010595","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":54,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":5.3,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.501091+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_235033","record_id":"REC_0010596","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":15.6,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":7.0,"metastatic_sites_count":9,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.501898+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_327756","record_id":"REC_0010597","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":2,"primary_tumor_size_cm":5.2,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.502171+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_771180","record_id":"REC_0010598","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":17.3,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":6.3,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.502415+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_160250","record_id":"REC_0010599","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.7,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.502648+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_899043","record_id":"REC_0010600","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":5.3,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":37,"primary_tumor_size_cm":3.7,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":7.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.502888+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_843269","record_id":"REC_0010601","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":30,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":3.8,"metastatic_sites_count":9,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.503138+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_396741","record_id":"REC_0010602","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":17,"tmb_mutations_per_mb":7.6,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":56,"primary_tumor_size_cm":6.7,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.503368+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_266026","record_id":"REC_0010603","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":14.0,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":6.6,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":31.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.503604+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_697448","record_id":"REC_0010604","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":10.3,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.2,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.503837+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_769368","record_id":"REC_0010605","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":4.7,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":56,"primary_tumor_size_cm":5.3,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.504109+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_969638","record_id":"REC_0010606","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":16.9,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":2,"smoking_pack_years":23,"primary_tumor_size_cm":5.2,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.504359+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_904395","record_id":"REC_0010607","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":2.2,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":1,"smoking_pack_years":49,"primary_tumor_size_cm":7.0,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.504598+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_428188","record_id":"REC_0010608","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":0,"primary_tumor_size_cm":6.9,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":4.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.504828+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_902621","record_id":"REC_0010609","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":5.5,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":3.5,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.505142+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_522168","record_id":"REC_0010610","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":17.6,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":6.2,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":19.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.505383+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_761163","record_id":"REC_0010611","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":14.8,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":3.8,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.505617+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_786217","record_id":"REC_0010612","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":3.1,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":23.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.505849+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_334661","record_id":"REC_0010613","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":16.6,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":4.5,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.506087+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_752777","record_id":"REC_0010614","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":31,"tmb_mutations_per_mb":7.9,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":6.0,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.506316+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_506795","record_id":"REC_0010615","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":16.1,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":7.0,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.506550+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_618129","record_id":"REC_0010616","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":13,"tmb_mutations_per_mb":8.6,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":4.6,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":22.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.506780+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_666622","record_id":"REC_0010617","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":18,"tmb_mutations_per_mb":11.0,"age_at_diagnosis":75,"sex":"male","ecog_performance_status":2,"smoking_pack_years":4,"primary_tumor_size_cm":7.0,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":17.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.507019+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_217721","record_id":"REC_0010618","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":17,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":47,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":5.0,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.507251+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_859997","record_id":"REC_0010619","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":32,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":0,"smoking_pack_years":34,"primary_tumor_size_cm":6.9,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":17.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.507483+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_400945","record_id":"REC_0010620","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":14.7,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":28,"primary_tumor_size_cm":4.2,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":18.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.507716+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_967130","record_id":"REC_0010621","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":19,"tmb_mutations_per_mb":15.8,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":5.7,"metastatic_sites_count":3,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.507950+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_966498","record_id":"REC_0010622","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":14.9,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":5.0,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.508317+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_578510","record_id":"REC_0010623","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":8.3,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":3.6,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":47.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.508579+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_569344","record_id":"REC_0010624","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":7.2,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":20.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.508840+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_958816","record_id":"REC_0010625","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":19,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":5.8,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":23.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.509089+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_494807","record_id":"REC_0010626","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":8.4,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.509337+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_121824","record_id":"REC_0010627","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":16.4,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.9,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":44.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.509599+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_867538","record_id":"REC_0010628","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":6.5,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.509862+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_168398","record_id":"REC_0010629","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":16.1,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.2,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":31.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.510106+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_550913","record_id":"REC_0010630","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":50,"primary_tumor_size_cm":5.7,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.510345+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_835935","record_id":"REC_0010631","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":19.6,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":5.4,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.510581+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_432516","record_id":"REC_0010632","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":5.2,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":2,"smoking_pack_years":27,"primary_tumor_size_cm":5.4,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.510812+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_777209","record_id":"REC_0010633","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":17.2,"age_at_diagnosis":75,"sex":"male","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":6.7,"metastatic_sites_count":3,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.511054+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_292756","record_id":"REC_0010634","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":2,"smoking_pack_years":5,"primary_tumor_size_cm":7.0,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":22.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.511294+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_287056","record_id":"REC_0010635","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":13.1,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":3.3,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.511623+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_781559","record_id":"REC_0010636","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":5.6,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":0,"smoking_pack_years":33,"primary_tumor_size_cm":7.3,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.511862+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_342206","record_id":"REC_0010637","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":5.3,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":6.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.512146+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_352400","record_id":"REC_0010638","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":10.5,"age_at_diagnosis":53,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":4.1,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":24.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.512412+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_709756","record_id":"REC_0010639","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":5.3,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":35,"primary_tumor_size_cm":6.0,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":21.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.512653+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_323020","record_id":"REC_0010640","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":18,"tmb_mutations_per_mb":18.0,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":6.3,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.512892+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_848834","record_id":"REC_0010641","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":16.8,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":4.1,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":31.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.513129+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_271342","record_id":"REC_0010642","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":15,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":4.6,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":20.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.513363+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_996329","record_id":"REC_0010643","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":3.3,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":16.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.513599+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_826173","record_id":"REC_0010644","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":5.0,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.513844+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_829256","record_id":"REC_0010645","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":17.5,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":3.6,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":20.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.514075+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_121826","record_id":"REC_0010646","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":19,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":5.6,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.514309+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_209017","record_id":"REC_0010647","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":5.8,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":17.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.514544+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_694731","record_id":"REC_0010648","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":78,"sex":"male","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":4.7,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":23.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.514893+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_280359","record_id":"REC_0010649","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":13.5,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":4.5,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.515139+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_152860","record_id":"REC_0010650","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":6.5,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.515374+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_286135","record_id":"REC_0010651","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":15.3,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":6.7,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":22.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.515606+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_960758","record_id":"REC_0010652","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":30,"tmb_mutations_per_mb":11.5,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":5.3,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.515842+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_130219","record_id":"REC_0010653","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":4.7,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.516122+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_808640","record_id":"REC_0010654","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":8.3,"age_at_diagnosis":41,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":6.1,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.516366+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_791628","record_id":"REC_0010655","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":18,"tmb_mutations_per_mb":7.4,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":49,"primary_tumor_size_cm":5.7,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":23.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.516604+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_594537","record_id":"REC_0010656","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":8.6,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":2,"smoking_pack_years":23,"primary_tumor_size_cm":5.8,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":27.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.516845+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_357065","record_id":"REC_0010657","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":2.6,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":3,"smoking_pack_years":6,"primary_tumor_size_cm":5.1,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.517076+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_974019","record_id":"REC_0010658","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":15.2,"age_at_diagnosis":53,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":5.1,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":22.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.517314+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_755387","record_id":"REC_0010659","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":8.4,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":4.9,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.517548+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_264539","record_id":"REC_0010660","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":3,"primary_tumor_size_cm":4.8,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.517784+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_637077","record_id":"REC_0010661","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":16.7,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":6.3,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.518099+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_888150","record_id":"REC_0010662","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":51,"sex":"male","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":7.3,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.518345+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_734139","record_id":"REC_0010663","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":15,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":4.7,"metastatic_sites_count":9,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.518580+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_749478","record_id":"REC_0010664","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":18,"tmb_mutations_per_mb":6.3,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":79,"primary_tumor_size_cm":4.6,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.518819+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_359061","record_id":"REC_0010665","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":5.9,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":5.8,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.519059+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_658244","record_id":"REC_0010666","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":30,"tmb_mutations_per_mb":13.6,"age_at_diagnosis":50,"sex":"male","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":5.8,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":26.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.519296+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_358423","record_id":"REC_0010667","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":10.1,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":4.5,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":5.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.519530+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_531849","record_id":"REC_0010668","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":54,"sex":"male","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":4.3,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":5.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.519761+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_258566","record_id":"REC_0010669","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":78,"primary_tumor_size_cm":6.0,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":21.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.519993+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_733559","record_id":"REC_0010670","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":9.1,"age_at_diagnosis":53,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":6.5,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.520267+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_391584","record_id":"REC_0010671","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":5.2,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":102,"primary_tumor_size_cm":6.4,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.520503+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_382967","record_id":"REC_0010672","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":9.9,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":4.5,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.520736+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_164185","record_id":"REC_0010673","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":3.8,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":4.7,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.520969+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_970149","record_id":"REC_0010674","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":16,"tmb_mutations_per_mb":4.6,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":0,"smoking_pack_years":52,"primary_tumor_size_cm":5.0,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.521275+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_920007","record_id":"REC_0010675","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":4.2,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":72,"primary_tumor_size_cm":4.8,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":21.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.521511+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_995130","record_id":"REC_0010676","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":54,"sex":"male","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":7.8,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.521752+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_160679","record_id":"REC_0010677","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":33,"tmb_mutations_per_mb":16.9,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":6.0,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.521994+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_935018","record_id":"REC_0010678","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":18,"tmb_mutations_per_mb":8.1,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":1,"smoking_pack_years":30,"primary_tumor_size_cm":5.7,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":17.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.522221+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_342259","record_id":"REC_0010679","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":17.4,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":7.5,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.522460+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_606909","record_id":"REC_0010680","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":14.5,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":3,"smoking_pack_years":22,"primary_tumor_size_cm":7.3,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":32.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.522703+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_431199","record_id":"REC_0010681","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":18.0,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":5.3,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":4.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.522939+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_451579","record_id":"REC_0010682","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":10.3,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":4.9,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.523173+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_342815","record_id":"REC_0010683","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":9.0,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":52,"primary_tumor_size_cm":6.4,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":25.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.523407+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_677593","record_id":"REC_0010684","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":1,"smoking_pack_years":54,"primary_tumor_size_cm":5.6,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.523646+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_356458","record_id":"REC_0010685","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":15,"tmb_mutations_per_mb":15.2,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":6.3,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.523876+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_270963","record_id":"REC_0010686","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":16.6,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":4.7,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.524137+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_735589","record_id":"REC_0010687","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":27,"primary_tumor_size_cm":3.9,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.524455+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_513621","record_id":"REC_0010688","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":79,"sex":"male","ecog_performance_status":1,"smoking_pack_years":33,"primary_tumor_size_cm":6.1,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.524742+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_799603","record_id":"REC_0010689","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":7.2,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":22.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.525028+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_887144","record_id":"REC_0010690","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":30,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":24,"primary_tumor_size_cm":5.0,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.525420+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_947279","record_id":"REC_0010691","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ALK fusion","pd_l1_tps_percent":16,"tmb_mutations_per_mb":5.9,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":4.6,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":58.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.525669+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_818508","record_id":"REC_0010692","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":11,"tmb_mutations_per_mb":9.1,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":4.6,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":25.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.525906+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_608083","record_id":"REC_0010693","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":13,"tmb_mutations_per_mb":8.7,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":5.2,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":16.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.526149+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_928673","record_id":"REC_0010694","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":6.3,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":22.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.526488+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_193994","record_id":"REC_0010695","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":24,"primary_tumor_size_cm":7.0,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.526719+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_190806","record_id":"REC_0010696","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":13.6,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":5.6,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":17.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.526961+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_636386","record_id":"REC_0010697","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":18,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":32,"primary_tumor_size_cm":3.7,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.527193+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_205789","record_id":"REC_0010698","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":13.8,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":5.3,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.527429+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_313754","record_id":"REC_0010699","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":31,"primary_tumor_size_cm":5.7,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":16.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.527657+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_830101","record_id":"REC_0010700","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":16.4,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":5.9,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.527995+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_580754","record_id":"REC_0010701","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":16.5,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":5.5,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":5.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.528311+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_451258","record_id":"REC_0010702","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":16.9,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":7.1,"metastatic_sites_count":3,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.528550+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_122958","record_id":"REC_0010703","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":4.8,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.528818+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_877650","record_id":"REC_0010704","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":16,"tmb_mutations_per_mb":9.8,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":3,"primary_tumor_size_cm":5.3,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.529050+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_403290","record_id":"REC_0010705","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":16.5,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":6.3,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":7.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.529288+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_684373","record_id":"REC_0010706","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":16.2,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":5.2,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":28.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.529532+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_210584","record_id":"REC_0010707","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":32,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":4.7,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.529797+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_353890","record_id":"REC_0010708","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":16,"tmb_mutations_per_mb":17.4,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":5.6,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.530043+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_151337","record_id":"REC_0010709","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":5.8,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":4.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.530318+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_673086","record_id":"REC_0010710","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":32,"tmb_mutations_per_mb":14.6,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":7,"primary_tumor_size_cm":5.1,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":34.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.530568+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_707115","record_id":"REC_0010711","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":19,"tmb_mutations_per_mb":13.3,"age_at_diagnosis":45,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":4.2,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.530818+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_152249","record_id":"REC_0010712","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":16.9,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":4.1,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.531062+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_260950","record_id":"REC_0010713","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":14.6,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":3,"smoking_pack_years":1,"primary_tumor_size_cm":5.5,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.531505+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_907309","record_id":"REC_0010714","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":8.1,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":7.5,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.531921+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_554076","record_id":"REC_0010715","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":5.1,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.532221+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_191016","record_id":"REC_0010716","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":19.6,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":6.0,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.532493+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_575870","record_id":"REC_0010717","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":6.0,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":5.9,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":53.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.532742+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_754635","record_id":"REC_0010718","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":6.9,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":6.2,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":19.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.532984+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_514146","record_id":"REC_0010719","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":6.7,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":26,"primary_tumor_size_cm":3.2,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":38.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.533226+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_333464","record_id":"REC_0010720","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":5.2,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":6.7,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.533481+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_334682","record_id":"REC_0010721","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":11.5,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.8,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.533744+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_984681","record_id":"REC_0010722","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":5.0,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":7.1,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":30.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.534000+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_416657","record_id":"REC_0010723","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":75,"sex":"male","ecog_performance_status":1,"smoking_pack_years":24,"primary_tumor_size_cm":6.6,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.534261+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_987152","record_id":"REC_0010724","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":3.9,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":41,"primary_tumor_size_cm":5.3,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":4.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.534525+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_213630","record_id":"REC_0010725","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":2.9,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":3,"smoking_pack_years":22,"primary_tumor_size_cm":3.6,"metastatic_sites_count":3,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.534782+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_740676","record_id":"REC_0010726","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":4.4,"age_at_diagnosis":83,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":8.7,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.535198+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_175544","record_id":"REC_0010727","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":6.7,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.535495+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_434374","record_id":"REC_0010728","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":31,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":6.1,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":8.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.535740+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_585013","record_id":"REC_0010729","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":19,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":6.7,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.535982+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_859459","record_id":"REC_0010730","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":14.1,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":4.5,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":18.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.536283+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_927186","record_id":"REC_0010731","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":5.6,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":6.1,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.536535+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_885779","record_id":"REC_0010732","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":7.2,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.536768+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_864569","record_id":"REC_0010733","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":17.1,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":4.8,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.537000+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_994292","record_id":"REC_0010734","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":5.0,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":6.2,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":21.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.537234+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_381970","record_id":"REC_0010735","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":17,"tmb_mutations_per_mb":11.5,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":4.4,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":17.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.537467+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_899865","record_id":"REC_0010736","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":7.4,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.537706+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_954306","record_id":"REC_0010737","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":16,"tmb_mutations_per_mb":5.2,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":62,"primary_tumor_size_cm":4.8,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.537939+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_203573","record_id":"REC_0010738","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":7.5,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":17.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.538173+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_915667","record_id":"REC_0010739","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":3.3,"age_at_diagnosis":54,"sex":"male","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":5.0,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":24.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.538507+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_643221","record_id":"REC_0010740","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":15.1,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":5.5,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.538752+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_749299","record_id":"REC_0010741","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None","pd_l1_tps_percent":35,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":1,"smoking_pack_years":63,"primary_tumor_size_cm":6.6,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":28.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.539000+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_210805","record_id":"REC_0010742","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":34,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":59,"primary_tumor_size_cm":3.0,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.539251+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_586274","record_id":"REC_0010743","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":31,"tmb_mutations_per_mb":4.2,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":47,"primary_tumor_size_cm":5.0,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":6.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.539490+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_638374","record_id":"REC_0010744","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":7.3,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":23.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.539728+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_435389","record_id":"REC_0010745","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":9.8,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":24,"primary_tumor_size_cm":6.3,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":53.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.539968+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_354366","record_id":"REC_0010746","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":53,"sex":"male","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":5.0,"metastatic_sites_count":8,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.540250+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_730568","record_id":"REC_0010747","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":14.3,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":0,"smoking_pack_years":24,"primary_tumor_size_cm":4.2,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.540488+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_706806","record_id":"REC_0010748","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":17.1,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":3.3,"metastatic_sites_count":8,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.540726+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_279230","record_id":"REC_0010749","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":6.3,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":59,"primary_tumor_size_cm":4.5,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.540959+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_941375","record_id":"REC_0010750","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":14.8,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":7.1,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":18.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.541193+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_606486","record_id":"REC_0010751","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":6.2,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":6.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.541431+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_347320","record_id":"REC_0010752","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":1.5,"age_at_diagnosis":79,"sex":"male","ecog_performance_status":1,"smoking_pack_years":4,"primary_tumor_size_cm":7.1,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.541788+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_803415","record_id":"REC_0010753","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":19,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":5.3,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":6.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.542054+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_305333","record_id":"REC_0010754","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":4.4,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":4.3,"metastatic_sites_count":8,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":7.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.542297+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_488691","record_id":"REC_0010755","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":3.1,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.542535+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_554691","record_id":"REC_0010756","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":16.6,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":7.7,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.542778+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_295120","record_id":"REC_0010757","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":7.6,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":6.8,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.543030+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_762885","record_id":"REC_0010758","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":30,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":0,"smoking_pack_years":43,"primary_tumor_size_cm":5.0,"metastatic_sites_count":8,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.543317+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_562479","record_id":"REC_0010759","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":10.1,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":6.0,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":22.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.543621+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_553891","record_id":"REC_0010760","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":5.9,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.543907+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_319225","record_id":"REC_0010761","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":20,"tmb_mutations_per_mb":14.4,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":2.6,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":25.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.544216+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_310833","record_id":"REC_0010762","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":8.7,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":5.7,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.544490+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_235037","record_id":"REC_0010763","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":54,"sex":"male","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":7.0,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":34.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.544750+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_788625","record_id":"REC_0010764","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":31,"tmb_mutations_per_mb":6.3,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":3.5,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.545001+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_107627","record_id":"REC_0010765","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":8.6,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":5.9,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.545361+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_714880","record_id":"REC_0010766","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":9.7,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":7.2,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.545604+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_443133","record_id":"REC_0010767","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":5.6,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":63,"primary_tumor_size_cm":5.5,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":16.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.545840+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_286032","record_id":"REC_0010768","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":20,"primary_tumor_size_cm":4.4,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.546082+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_139654","record_id":"REC_0010769","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":10.0,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":5.3,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":47.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.546320+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_834754","record_id":"REC_0010770","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":6.0,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":58,"primary_tumor_size_cm":5.7,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.546551+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_221657","record_id":"REC_0010771","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":35,"tmb_mutations_per_mb":14.0,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":4.1,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":27.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.546783+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_532663","record_id":"REC_0010772","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":18.3,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":4.9,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.547015+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_214782","record_id":"REC_0010773","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":15.6,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":2,"smoking_pack_years":6,"primary_tumor_size_cm":6.1,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":28.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.547250+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_849547","record_id":"REC_0010774","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":3.3,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":7.2,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":27.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.547481+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_302536","record_id":"REC_0010775","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":24,"primary_tumor_size_cm":6.7,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.547712+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_213401","record_id":"REC_0010776","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":16.4,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":4,"primary_tumor_size_cm":6.7,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.547949+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_586032","record_id":"REC_0010777","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":11.0,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":5.7,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.548266+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_708029","record_id":"REC_0010778","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":11.1,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":6.5,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.548568+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_668297","record_id":"REC_0010779","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":7.3,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":1,"smoking_pack_years":51,"primary_tumor_size_cm":5.6,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":29.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.548805+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_101037","record_id":"REC_0010780","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":3,"smoking_pack_years":18,"primary_tumor_size_cm":6.4,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.549037+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_953922","record_id":"REC_0010781","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":17.1,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":6.3,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.549273+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_843159","record_id":"REC_0010782","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":6.3,"age_at_diagnosis":74,"sex":"male","ecog_performance_status":3,"smoking_pack_years":41,"primary_tumor_size_cm":4.7,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.549505+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_790322","record_id":"REC_0010783","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":36,"tmb_mutations_per_mb":17.1,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":4.7,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":27.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.549741+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_267134","record_id":"REC_0010784","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":83,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":7.7,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":16.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.549972+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_113989","record_id":"REC_0010785","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":15,"tmb_mutations_per_mb":4.8,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":4.3,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":21.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.550204+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_960295","record_id":"REC_0010786","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":3.3,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.550438+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_620004","record_id":"REC_0010787","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":11.0,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":5.5,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":21.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.550677+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_657217","record_id":"REC_0010788","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":8.4,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":2.8,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":23.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.550907+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_391892","record_id":"REC_0010789","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":36,"tmb_mutations_per_mb":16.3,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":5.7,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":18.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.551138+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_768284","record_id":"REC_0010790","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":14.5,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":1,"primary_tumor_size_cm":4.7,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":21.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.551373+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_166883","record_id":"REC_0010791","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":7.9,"age_at_diagnosis":52,"sex":"male","ecog_performance_status":0,"smoking_pack_years":70,"primary_tumor_size_cm":5.2,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":16.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.551652+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_702107","record_id":"REC_0010792","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":10.5,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":3.4,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.551908+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_127558","record_id":"REC_0010793","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":5.3,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":6.2,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.552199+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_130835","record_id":"REC_0010794","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":3.9,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":17.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.552455+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_389517","record_id":"REC_0010795","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":5,"primary_tumor_size_cm":5.0,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.552705+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_586627","record_id":"REC_0010796","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":4.8,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":19.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.552986+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_546717","record_id":"REC_0010797","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":17,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":0,"smoking_pack_years":47,"primary_tumor_size_cm":6.5,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":7.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.553238+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_740574","record_id":"REC_0010798","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":9.5,"age_at_diagnosis":85,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":7.4,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.553512+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_703640","record_id":"REC_0010799","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":5.6,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.553775+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_900595","record_id":"REC_0010800","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":8.4,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":4.3,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":18.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.554038+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_505743","record_id":"REC_0010801","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":24,"primary_tumor_size_cm":5.5,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":25.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.554312+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_647338","record_id":"REC_0010802","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":4,"primary_tumor_size_cm":5.1,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":18.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.554589+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_311210","record_id":"REC_0010803","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":7.8,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":17.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.554854+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_357647","record_id":"REC_0010804","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":14.1,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":3.2,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.555291+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_369758","record_id":"REC_0010805","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":30,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":2.6,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.555607+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_255987","record_id":"REC_0010806","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":8.0,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":6.0,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":4.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.555880+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_782483","record_id":"REC_0010807","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":3.4,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":0,"smoking_pack_years":44,"primary_tumor_size_cm":5.0,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.556244+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_888470","record_id":"REC_0010808","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":9.9,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":24,"primary_tumor_size_cm":3.6,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.556554+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_906906","record_id":"REC_0010809","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":2.8,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":26.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.556908+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_519720","record_id":"REC_0010810","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":11.5,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":7.4,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":20.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.557236+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_652405","record_id":"REC_0010811","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":16.9,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":7.0,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":28.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.557484+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_616067","record_id":"REC_0010812","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":82,"sex":"male","ecog_performance_status":3,"smoking_pack_years":15,"primary_tumor_size_cm":5.6,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.557745+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_412962","record_id":"REC_0010813","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":6.4,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":0,"smoking_pack_years":50,"primary_tumor_size_cm":4.4,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":17.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.557999+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_322147","record_id":"REC_0010814","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":30,"tmb_mutations_per_mb":15.2,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":6.5,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.558256+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_505333","record_id":"REC_0010815","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":16.7,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":6.1,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":19.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.558504+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_316330","record_id":"REC_0010816","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":30,"tmb_mutations_per_mb":18.9,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":5.0,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.558749+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_231231","record_id":"REC_0010817","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":14.0,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":4.8,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.559115+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_215553","record_id":"REC_0010818","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":3.8,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.559362+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_773953","record_id":"REC_0010819","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":0,"smoking_pack_years":40,"primary_tumor_size_cm":6.8,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.559596+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_356046","record_id":"REC_0010820","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":14.0,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":4.4,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":22.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.559834+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_696063","record_id":"REC_0010821","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":14.8,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":2,"smoking_pack_years":6,"primary_tumor_size_cm":5.2,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":21.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.560123+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_389306","record_id":"REC_0010822","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":6.9,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":44,"primary_tumor_size_cm":6.5,"metastatic_sites_count":3,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":19.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.560386+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_611004","record_id":"REC_0010823","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":9.0,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":5.7,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":22.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.560644+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_416005","record_id":"REC_0010824","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":14,"tmb_mutations_per_mb":4.6,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":8.5,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.560905+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_109708","record_id":"REC_0010825","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":31,"tmb_mutations_per_mb":7.6,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":1,"smoking_pack_years":65,"primary_tumor_size_cm":6.2,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.561174+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_795990","record_id":"REC_0010826","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":19.9,"age_at_diagnosis":85,"sex":"male","ecog_performance_status":2,"smoking_pack_years":9,"primary_tumor_size_cm":5.0,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.561505+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_388812","record_id":"REC_0010827","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":4.9,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.561756+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_960728","record_id":"REC_0010828","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":6.0,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":39,"primary_tumor_size_cm":8.0,"metastatic_sites_count":3,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.561994+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_916720","record_id":"REC_0010829","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":16.5,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":3.6,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.562231+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_215858","record_id":"REC_0010830","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":6.3,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.562573+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_846567","record_id":"REC_0010831","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":8.7,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":25,"primary_tumor_size_cm":6.9,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.562816+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_839747","record_id":"REC_0010832","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":9.0,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":6.7,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":5.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.563047+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_864031","record_id":"REC_0010833","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":8.3,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":4.0,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.563279+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_399657","record_id":"REC_0010834","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.6,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":21.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.563515+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_690053","record_id":"REC_0010835","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":0,"smoking_pack_years":4,"primary_tumor_size_cm":6.3,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.563861+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_868327","record_id":"REC_0010836","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":1,"smoking_pack_years":49,"primary_tumor_size_cm":4.3,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":18.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.564366+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_627388","record_id":"REC_0010837","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":31,"tmb_mutations_per_mb":5.7,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":68,"primary_tumor_size_cm":5.2,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":21.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.564858+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_167667","record_id":"REC_0010838","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":15.9,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":5.5,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.565100+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_158025","record_id":"REC_0010839","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":31,"tmb_mutations_per_mb":4.6,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":71,"primary_tumor_size_cm":4.9,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":16.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.565335+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_144637","record_id":"REC_0010840","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":53,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":5.7,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.565572+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_814571","record_id":"REC_0010841","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":14.0,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":5.8,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.565850+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_643584","record_id":"REC_0010842","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":4.3,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.566092+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_400602","record_id":"REC_0010843","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":3.8,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":6.5,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":24.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.566392+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_389024","record_id":"REC_0010844","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":32,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":4.2,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.566628+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_757121","record_id":"REC_0010845","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":11.5,"age_at_diagnosis":54,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":4.8,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.566862+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_830023","record_id":"REC_0010846","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":20,"tmb_mutations_per_mb":10.3,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":43,"primary_tumor_size_cm":5.9,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.567095+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_218776","record_id":"REC_0010847","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":18.0,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":27,"primary_tumor_size_cm":4.3,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.567333+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_749536","record_id":"REC_0010848","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":16,"tmb_mutations_per_mb":9.7,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":1,"smoking_pack_years":4,"primary_tumor_size_cm":5.5,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":20.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.567574+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_253649","record_id":"REC_0010849","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":5.7,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":72,"primary_tumor_size_cm":6.6,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":16.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.567813+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_751119","record_id":"REC_0010850","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":6.9,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.568044+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_219297","record_id":"REC_0010851","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":20,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":4.8,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":20.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.568312+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_271558","record_id":"REC_0010852","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":4.7,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":70,"primary_tumor_size_cm":5.5,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":24.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.568558+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_255011","record_id":"REC_0010853","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":6.6,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.568803+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_512409","record_id":"REC_0010854","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":6.0,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.569049+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_241206","record_id":"REC_0010855","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":5.6,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":42,"primary_tumor_size_cm":6.9,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.569311+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_280398","record_id":"REC_0010856","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":80,"sex":"male","ecog_performance_status":3,"smoking_pack_years":13,"primary_tumor_size_cm":5.0,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.569735+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_153931","record_id":"REC_0010857","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":19,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":80,"sex":"male","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":6.1,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":21.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.570068+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_362758","record_id":"REC_0010858","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":4.1,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.570415+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_553915","record_id":"REC_0010859","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":5.5,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":7.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.570676+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_223072","record_id":"REC_0010860","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":5.2,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":5.2,"metastatic_sites_count":8,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":4.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.570931+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_370717","record_id":"REC_0010861","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":33,"tmb_mutations_per_mb":9.8,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":7.4,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.571190+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_358731","record_id":"REC_0010862","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":5.7,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":5.9,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.571460+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_328707","record_id":"REC_0010863","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":18,"tmb_mutations_per_mb":15.1,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":8.0,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.571725+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_133554","record_id":"REC_0010864","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":14.1,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":6.0,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.571966+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_450284","record_id":"REC_0010865","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":5.2,"metastatic_sites_count":8,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":17.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.572250+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_565586","record_id":"REC_0010866","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":5.3,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.572513+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_189599","record_id":"REC_0010867","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":4.3,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":16.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.572770+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_250737","record_id":"REC_0010868","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":16.2,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":5.1,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.573008+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_381763","record_id":"REC_0010869","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":3.2,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":7.5,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.573359+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_952309","record_id":"REC_0010870","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":16.0,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":6.9,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.573626+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_366494","record_id":"REC_0010871","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":5.9,"age_at_diagnosis":54,"sex":"male","ecog_performance_status":0,"smoking_pack_years":31,"primary_tumor_size_cm":6.1,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.573920+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_942494","record_id":"REC_0010872","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":4.4,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":5,"primary_tumor_size_cm":5.6,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.574323+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_392487","record_id":"REC_0010873","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":13.8,"age_at_diagnosis":85,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":5.5,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.574584+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_680373","record_id":"REC_0010874","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":8.5,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.0,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.574846+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_783429","record_id":"REC_0010875","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":4.7,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":39,"primary_tumor_size_cm":5.5,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.575135+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_198151","record_id":"REC_0010876","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":65,"primary_tumor_size_cm":4.4,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":24.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.575406+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_804072","record_id":"REC_0010877","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":2.3,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":6.2,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.575673+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_188968","record_id":"REC_0010878","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":31,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":5.2,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.575949+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_376868","record_id":"REC_0010879","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":9.9,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":4.7,"metastatic_sites_count":8,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.576293+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_411591","record_id":"REC_0010880","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":3.4,"metastatic_sites_count":8,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":7.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.576622+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_237104","record_id":"REC_0010881","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":8.4,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":5.4,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.576909+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_352919","record_id":"REC_0010882","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":4.8,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":3,"smoking_pack_years":43,"primary_tumor_size_cm":4.8,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.577332+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_754629","record_id":"REC_0010883","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":16.9,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":4.9,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.577594+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_225154","record_id":"REC_0010884","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":4.5,"age_at_diagnosis":85,"sex":"female","ecog_performance_status":2,"smoking_pack_years":27,"primary_tumor_size_cm":5.6,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":24.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.577838+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_253265","record_id":"REC_0010885","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":19.8,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":6.8,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":24.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.578082+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_775268","record_id":"REC_0010886","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":18,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":4.5,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":19.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.578319+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_767701","record_id":"REC_0010887","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":17,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":4.9,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.578556+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_267315","record_id":"REC_0010888","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":15.0,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":3.7,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.578812+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_210665","record_id":"REC_0010889","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":3.1,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":29.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.579215+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_949428","record_id":"REC_0010890","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":32,"tmb_mutations_per_mb":4.5,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":42,"primary_tumor_size_cm":5.7,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":6.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.579492+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_604374","record_id":"REC_0010891","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":11.1,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":6.7,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":21.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.579769+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_648517","record_id":"REC_0010892","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":3.3,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":4.1,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.580056+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_487747","record_id":"REC_0010893","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":2,"smoking_pack_years":54,"primary_tumor_size_cm":5.4,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.580435+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_162337","record_id":"REC_0010894","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":11.5,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":5.4,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":50.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.580750+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_803262","record_id":"REC_0010895","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":5.3,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.581163+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_662772","record_id":"REC_0010896","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":18,"tmb_mutations_per_mb":4.6,"age_at_diagnosis":47,"sex":"male","ecog_performance_status":0,"smoking_pack_years":57,"primary_tumor_size_cm":6.3,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.581435+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_643062","record_id":"REC_0010897","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":6.8,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.581687+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_481467","record_id":"REC_0010898","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":16.3,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":3.6,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.581933+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_460987","record_id":"REC_0010899","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":31,"primary_tumor_size_cm":5.0,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.582180+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_967099","record_id":"REC_0010900","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":3.9,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":17.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.582426+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_336947","record_id":"REC_0010901","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":18,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":6.0,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.582671+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_565126","record_id":"REC_0010902","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":33,"primary_tumor_size_cm":5.6,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.582908+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_674704","record_id":"REC_0010903","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":10.3,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":7.0,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":18.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.583153+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_154285","record_id":"REC_0010904","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":4.0,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":3.7,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":29.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.583392+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_806469","record_id":"REC_0010905","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":15.2,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":5.2,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.583650+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_812456","record_id":"REC_0010906","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":13.5,"age_at_diagnosis":53,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":6.7,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":16.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.583897+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_559369","record_id":"REC_0010907","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":5.2,"age_at_diagnosis":78,"sex":"male","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":7.5,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.584198+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_248903","record_id":"REC_0010908","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":51,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":5.9,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":43.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.584584+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_281248","record_id":"REC_0010909","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":10.3,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":3.8,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.584851+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_330548","record_id":"REC_0010910","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":5.4,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.585101+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_939479","record_id":"REC_0010911","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":8.3,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":6,"primary_tumor_size_cm":5.8,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.585350+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_415782","record_id":"REC_0010912","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":13.5,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":6.0,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":5.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.585590+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_323308","record_id":"REC_0010913","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":18.2,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":5.0,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.585846+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_789505","record_id":"REC_0010914","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":4.4,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.586092+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_819507","record_id":"REC_0010915","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":14.6,"age_at_diagnosis":75,"sex":"male","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":7.5,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.586337+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_416796","record_id":"REC_0010916","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":8.3,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":5.5,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.586580+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_686132","record_id":"REC_0010917","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":15.1,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":4.0,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.586853+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_193024","record_id":"REC_0010918","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":13.6,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":6.2,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.587122+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_918630","record_id":"REC_0010919","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":16.3,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":4.7,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":19.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.587365+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_573903","record_id":"REC_0010920","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":17,"tmb_mutations_per_mb":5.7,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":4.6,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.587602+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_171423","record_id":"REC_0010921","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":3,"smoking_pack_years":2,"primary_tumor_size_cm":2.4,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.587956+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_991917","record_id":"REC_0010922","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":3.3,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":5.8,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":19.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.588243+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_899249","record_id":"REC_0010923","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":15.8,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":2.9,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.588489+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_369726","record_id":"REC_0010924","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":19,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":7.2,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":25.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.588727+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_533413","record_id":"REC_0010925","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":3.5,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":7.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.588968+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_643648","record_id":"REC_0010926","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":7.9,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":5.4,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":20.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.589200+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_745226","record_id":"REC_0010927","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":5.1,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":32,"primary_tumor_size_cm":5.5,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":7.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.589428+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_550635","record_id":"REC_0010928","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":15,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":5.1,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":35.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.589666+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_131617","record_id":"REC_0010929","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":16.3,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":4.7,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":21.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.589901+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_967822","record_id":"REC_0010930","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":14,"tmb_mutations_per_mb":8.5,"age_at_diagnosis":48,"sex":"male","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":5.3,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":16.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.590135+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_867889","record_id":"REC_0010931","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":4.5,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.590367+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_143142","record_id":"REC_0010932","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":21.4,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":4.6,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":22.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.590604+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_851927","record_id":"REC_0010933","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":4.3,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.590832+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_825662","record_id":"REC_0010934","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":6.0,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":2,"smoking_pack_years":72,"primary_tumor_size_cm":3.4,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.591119+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_296011","record_id":"REC_0010935","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":14.1,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":5.8,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":4.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.591368+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_190860","record_id":"REC_0010936","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":5.5,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":50.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.591599+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_770529","record_id":"REC_0010937","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":3.5,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":1,"smoking_pack_years":38,"primary_tumor_size_cm":6.3,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.591833+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_221743","record_id":"REC_0010938","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":8.3,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":26,"primary_tumor_size_cm":3.9,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":40.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.592066+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_100127","record_id":"REC_0010939","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":32,"tmb_mutations_per_mb":17.8,"age_at_diagnosis":42,"sex":"male","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":6.9,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":21.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.592385+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_751640","record_id":"REC_0010940","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None","pd_l1_tps_percent":14,"tmb_mutations_per_mb":7.9,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":68,"primary_tumor_size_cm":3.8,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":50.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.592624+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_967550","record_id":"REC_0010941","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":6.7,"age_at_diagnosis":78,"sex":"male","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":5.7,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":28.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.592860+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_500217","record_id":"REC_0010942","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":16.6,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":3,"primary_tumor_size_cm":4.8,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":4.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.593095+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_886234","record_id":"REC_0010943","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":6.4,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.593332+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_467315","record_id":"REC_0010944","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":6.4,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.593562+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_627125","record_id":"REC_0010945","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":16.4,"age_at_diagnosis":84,"sex":"female","ecog_performance_status":2,"smoking_pack_years":8,"primary_tumor_size_cm":4.4,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.593794+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_311601","record_id":"REC_0010946","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":6.2,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":39.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.594025+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_510260","record_id":"REC_0010947","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":9.5,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":6.9,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":30.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.594316+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_201817","record_id":"REC_0010948","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":14.5,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":3.2,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.594554+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_305110","record_id":"REC_0010949","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":4.2,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":5.6,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":6.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.594786+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_861874","record_id":"REC_0010950","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":4.3,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.595017+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_334348","record_id":"REC_0010951","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":15.3,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":6.4,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":41.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.595251+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_430237","record_id":"REC_0010952","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":5.6,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":8.1,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.595481+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_384379","record_id":"REC_0010953","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":3.5,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":49,"primary_tumor_size_cm":6.3,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":6.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.595713+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_976631","record_id":"REC_0010954","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":4.8,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":7.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.595949+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_947506","record_id":"REC_0010955","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":5.2,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":59,"primary_tumor_size_cm":5.3,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":20.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.596266+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_995734","record_id":"REC_0010956","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":7.9,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":5.1,"metastatic_sites_count":3,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.596513+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_488912","record_id":"REC_0010957","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":4.9,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.596746+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_659458","record_id":"REC_0010958","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":80,"sex":"male","ecog_performance_status":1,"smoking_pack_years":48,"primary_tumor_size_cm":5.8,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":19.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.596979+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_540820","record_id":"REC_0010959","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":11.0,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":5.3,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.597219+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_137620","record_id":"REC_0010960","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":4.2,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.597501+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_124433","record_id":"REC_0010961","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":18.5,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":8,"primary_tumor_size_cm":3.7,"metastatic_sites_count":3,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":18.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.597737+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_947731","record_id":"REC_0010962","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":14.6,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":6.7,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.597971+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_360764","record_id":"REC_0010963","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":16,"tmb_mutations_per_mb":7.3,"age_at_diagnosis":80,"sex":"male","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":3.3,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":27.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.598202+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_934834","record_id":"REC_0010964","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":9.8,"age_at_diagnosis":85,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":4.3,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":16.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.598429+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_927294","record_id":"REC_0010965","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":6.2,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.598663+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_199154","record_id":"REC_0010966","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":3.4,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":6.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.598905+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_600662","record_id":"REC_0010967","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":8.6,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":35,"primary_tumor_size_cm":2.8,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":23.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.599142+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_791286","record_id":"REC_0010968","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":8.7,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":6.5,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.599374+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_254455","record_id":"REC_0010969","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.1,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":28.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.599606+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_654176","record_id":"REC_0010970","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":53,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":5.7,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.599839+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_795517","record_id":"REC_0010971","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":6.0,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":0,"smoking_pack_years":52,"primary_tumor_size_cm":5.5,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":5.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.600067+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_347257","record_id":"REC_0010972","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":13.5,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":6.0,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.600344+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_200715","record_id":"REC_0010973","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":8.0,"age_at_diagnosis":50,"sex":"female","ecog_performance_status":0,"smoking_pack_years":1,"primary_tumor_size_cm":4.2,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.600655+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_147600","record_id":"REC_0010974","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":16.8,"age_at_diagnosis":85,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":3.3,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.600909+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_744038","record_id":"REC_0010975","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":85,"sex":"male","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":6.4,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.601160+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_530154","record_id":"REC_0010976","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":5.2,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":5.6,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.601401+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_761616","record_id":"REC_0010977","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":4.8,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.601643+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_673026","record_id":"REC_0010978","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":16.9,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":26,"primary_tumor_size_cm":4.9,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.601878+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_888281","record_id":"REC_0010979","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":25,"primary_tumor_size_cm":6.2,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.602117+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_883057","record_id":"REC_0010980","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":31,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":3.0,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":8.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.602348+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_291532","record_id":"REC_0010981","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.0,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":5.9,"metastatic_sites_count":8,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.602580+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_271085","record_id":"REC_0010982","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":4.5,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.602814+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_380778","record_id":"REC_0010983","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":20.9,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":4.9,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.603047+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_599848","record_id":"REC_0010984","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":7.3,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.603286+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_820540","record_id":"REC_0010985","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":9.7,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":4.8,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":7.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.603516+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_553337","record_id":"REC_0010986","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":32,"tmb_mutations_per_mb":4.8,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":5.7,"metastatic_sites_count":8,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.603827+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_869742","record_id":"REC_0010987","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":4.3,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":6.1,"metastatic_sites_count":3,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.604066+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_519751","record_id":"REC_0010988","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":4.9,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.604349+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_709863","record_id":"REC_0010989","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":9.7,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":8.3,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":16.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.604585+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_363848","record_id":"REC_0010990","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":39,"primary_tumor_size_cm":6.3,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":5.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.604819+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_521506","record_id":"REC_0010991","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":15.0,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":6.4,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.605057+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_113396","record_id":"REC_0010992","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":15.1,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":0,"smoking_pack_years":25,"primary_tumor_size_cm":4.6,"metastatic_sites_count":8,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.605292+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_228830","record_id":"REC_0010993","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":83,"sex":"female","ecog_performance_status":3,"smoking_pack_years":15,"primary_tumor_size_cm":6.8,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.605527+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_998570","record_id":"REC_0010994","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":19.1,"age_at_diagnosis":54,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":5.6,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":22.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.605765+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_802521","record_id":"REC_0010995","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":14,"tmb_mutations_per_mb":14.4,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":0,"smoking_pack_years":25,"primary_tumor_size_cm":3.1,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.606006+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_803212","record_id":"REC_0010996","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":13.6,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":5.0,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.606257+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_772666","record_id":"REC_0010997","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":4.8,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":21.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.606510+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_177583","record_id":"REC_0010998","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":35,"tmb_mutations_per_mb":14.6,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":0,"smoking_pack_years":2,"primary_tumor_size_cm":5.0,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.606781+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_414232","record_id":"REC_0010999","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":6.1,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":8.6,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.607137+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_313180","record_id":"REC_0011000","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":9.9,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":26,"primary_tumor_size_cm":5.2,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":5.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.607399+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_434993","record_id":"REC_0011001","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":19,"tmb_mutations_per_mb":3.6,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":60,"primary_tumor_size_cm":4.6,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.607658+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_217936","record_id":"REC_0011002","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":4.3,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.607899+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_418472","record_id":"REC_0011003","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":5.0,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.608330+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_464181","record_id":"REC_0011004","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":7.3,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":3,"smoking_pack_years":69,"primary_tumor_size_cm":4.8,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":6.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.608619+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_567640","record_id":"REC_0011005","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":2.9,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.608894+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_829725","record_id":"REC_0011006","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":13.8,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":2,"smoking_pack_years":9,"primary_tumor_size_cm":4.9,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.609162+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_541489","record_id":"REC_0011007","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":7.6,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":0,"primary_tumor_size_cm":5.0,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":18.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.609432+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_970292","record_id":"REC_0011008","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":14,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":4.8,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.609708+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_180470","record_id":"REC_0011009","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":16,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":5.7,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":17.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.609962+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_646009","record_id":"REC_0011010","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":4.3,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.610200+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_558812","record_id":"REC_0011011","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":19,"tmb_mutations_per_mb":2.3,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":6.9,"metastatic_sites_count":3,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.610440+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_500436","record_id":"REC_0011012","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":6.9,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":36,"primary_tumor_size_cm":5.6,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":17.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.610798+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_105004","record_id":"REC_0011013","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":33,"tmb_mutations_per_mb":5.7,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":65,"primary_tumor_size_cm":8.3,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.611052+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_144990","record_id":"REC_0011014","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":2,"smoking_pack_years":4,"primary_tumor_size_cm":4.4,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.611303+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_865373","record_id":"REC_0011015","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":4.1,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":1,"smoking_pack_years":74,"primary_tumor_size_cm":4.7,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.611559+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_365744","record_id":"REC_0011016","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":6.0,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":68,"primary_tumor_size_cm":4.2,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":24.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.611800+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_942302","record_id":"REC_0011017","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":5.5,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":19.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.612037+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_814412","record_id":"REC_0011018","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":83,"sex":"male","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":4.9,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.612340+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_814435","record_id":"REC_0011019","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":5.2,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.612607+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_939233","record_id":"REC_0011020","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":16.0,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":4.9,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.612895+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_987810","record_id":"REC_0011021","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":13.8,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":4.0,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.613199+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_245700","record_id":"REC_0011022","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":3.3,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":28,"primary_tumor_size_cm":4.4,"metastatic_sites_count":8,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":7.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.613495+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_720849","record_id":"REC_0011023","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":8.9,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":5.6,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":21.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.613773+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_327094","record_id":"REC_0011024","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":14.4,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":5.1,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.614060+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_739928","record_id":"REC_0011025","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":16.5,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":5.6,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":24.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.614546+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_488807","record_id":"REC_0011026","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":6.4,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.614878+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_940971","record_id":"REC_0011027","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":14.8,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":4.8,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.615322+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_551831","record_id":"REC_0011028","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":14.3,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":5.9,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.615627+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_150887","record_id":"REC_0011029","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":8.3,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":24,"primary_tumor_size_cm":5.7,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":18.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.615912+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_576385","record_id":"REC_0011030","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":10.0,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":5.1,"metastatic_sites_count":3,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.616295+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_797616","record_id":"REC_0011031","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":8.3,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":3,"smoking_pack_years":17,"primary_tumor_size_cm":4.6,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.616602+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_649056","record_id":"REC_0011032","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":8,"tmb_mutations_per_mb":3.9,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":47,"primary_tumor_size_cm":5.6,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":16.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.616894+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_319040","record_id":"REC_0011033","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":17.2,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":4.0,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.617189+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_356250","record_id":"REC_0011034","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":18,"tmb_mutations_per_mb":5.6,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":0,"smoking_pack_years":71,"primary_tumor_size_cm":6.3,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":7.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.617474+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_681489","record_id":"REC_0011035","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":5.0,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.617763+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_394665","record_id":"REC_0011036","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":17.0,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":5.7,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.618057+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_197305","record_id":"REC_0011037","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":6.1,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":20.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.618365+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_884711","record_id":"REC_0011038","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":5.6,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.618836+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_873679","record_id":"REC_0011039","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":9.0,"metastatic_sites_count":3,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.619208+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_455848","record_id":"REC_0011040","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":8.1,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.619532+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_456219","record_id":"REC_0011041","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":6.2,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":27.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.619831+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_455150","record_id":"REC_0011042","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":14.9,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.2,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.620217+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_610429","record_id":"REC_0011043","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":2,"smoking_pack_years":20,"primary_tumor_size_cm":6.2,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.620522+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_656416","record_id":"REC_0011044","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":3.8,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":51,"primary_tumor_size_cm":4.0,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.620815+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_345355","record_id":"REC_0011045","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":16.0,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":3.9,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.621109+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_257725","record_id":"REC_0011046","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":3.5,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":24.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.621370+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_523588","record_id":"REC_0011047","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":4.0,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":47,"primary_tumor_size_cm":3.2,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.621616+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_160355","record_id":"REC_0011048","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":16.3,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":6.4,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.621852+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_303475","record_id":"REC_0011049","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":15.0,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":5.8,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":20.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.622090+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_441132","record_id":"REC_0011050","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":48,"primary_tumor_size_cm":6.9,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":27.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.622320+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_687287","record_id":"REC_0011051","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":84,"sex":"male","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":3.0,"metastatic_sites_count":3,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":20.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.622671+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_583339","record_id":"REC_0011052","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":30,"tmb_mutations_per_mb":13.6,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":5.9,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.622913+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_322480","record_id":"REC_0011053","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":6.4,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.623153+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_708488","record_id":"REC_0011054","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":9.9,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":4.7,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.623389+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_985802","record_id":"REC_0011055","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.9,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":18.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.623624+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_187538","record_id":"REC_0011056","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":13.3,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":6.2,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.623855+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_248943","record_id":"REC_0011057","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":9.1,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":5.0,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.624131+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_284349","record_id":"REC_0011058","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":18,"tmb_mutations_per_mb":6.0,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":4.6,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":7.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.624383+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_341212","record_id":"REC_0011059","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":20,"tmb_mutations_per_mb":4.0,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":4.1,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":72.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.624627+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_495906","record_id":"REC_0011060","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":5.1,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":0,"smoking_pack_years":66,"primary_tumor_size_cm":3.7,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":20.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.624859+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_642083","record_id":"REC_0011061","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":1,"smoking_pack_years":24,"primary_tumor_size_cm":7.3,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.625089+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_192697","record_id":"REC_0011062","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":17.4,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":4.4,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":18.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.625323+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_994659","record_id":"REC_0011063","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":14.1,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":6.6,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.625556+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_534168","record_id":"REC_0011064","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":7.6,"age_at_diagnosis":54,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":5.6,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.625844+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_128887","record_id":"REC_0011065","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":61,"primary_tumor_size_cm":3.5,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.626083+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_486192","record_id":"REC_0011066","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":3.9,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.626317+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_140627","record_id":"REC_0011067","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":8.6,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":4.9,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":23.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.626546+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_844779","record_id":"REC_0011068","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None","pd_l1_tps_percent":19,"tmb_mutations_per_mb":6.3,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":29,"primary_tumor_size_cm":5.3,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":39.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.626781+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_309934","record_id":"REC_0011069","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":4.4,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.627032+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_623098","record_id":"REC_0011070","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":4.6,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":1,"smoking_pack_years":46,"primary_tumor_size_cm":2.2,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":6.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.627272+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_527568","record_id":"REC_0011071","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":6.6,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":25.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.627515+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_303422","record_id":"REC_0011072","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":2,"smoking_pack_years":5,"primary_tumor_size_cm":5.5,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.628014+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_144001","record_id":"REC_0011073","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":15.2,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":25,"primary_tumor_size_cm":6.6,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":5.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.628456+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_482013","record_id":"REC_0011074","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":7.3,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":7.5,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":21.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.628729+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_748158","record_id":"REC_0011075","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":20,"tmb_mutations_per_mb":3.7,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":62,"primary_tumor_size_cm":3.8,"metastatic_sites_count":9,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.629010+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_862712","record_id":"REC_0011076","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":18,"tmb_mutations_per_mb":5.6,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":62,"primary_tumor_size_cm":4.0,"metastatic_sites_count":3,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":6.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.629268+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_746433","record_id":"REC_0011077","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":5.3,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":32,"primary_tumor_size_cm":4.5,"metastatic_sites_count":8,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":7.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.629639+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_744052","record_id":"REC_0011078","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":14.1,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":5.4,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.629886+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_935771","record_id":"REC_0011079","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":6.0,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":21.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.630147+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_577892","record_id":"REC_0011080","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":14.7,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":5.5,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":7.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.630387+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_621868","record_id":"REC_0011081","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":32,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":4.8,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.630627+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_535948","record_id":"REC_0011082","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":7.8,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.630857+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_345372","record_id":"REC_0011083","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":6.4,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":5.4,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.631091+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_414175","record_id":"REC_0011084","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":18,"tmb_mutations_per_mb":16.3,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":4.5,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.631324+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_387912","record_id":"REC_0011085","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":11,"tmb_mutations_per_mb":6.4,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":35,"primary_tumor_size_cm":6.7,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.631554+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_811922","record_id":"REC_0011086","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":6.2,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":17.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.631785+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_720560","record_id":"REC_0011087","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":18.5,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":5.5,"metastatic_sites_count":8,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.632028+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_145154","record_id":"REC_0011088","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":33,"primary_tumor_size_cm":5.1,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.632321+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_795682","record_id":"REC_0011089","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":6.2,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.632569+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_206537","record_id":"REC_0011090","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":11.5,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":4.6,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.632889+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_812089","record_id":"REC_0011091","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.5,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":3.7,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.633133+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_743726","record_id":"REC_0011092","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":5.3,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":6.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.633372+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_781652","record_id":"REC_0011093","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":13.1,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":3.4,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.633609+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_182403","record_id":"REC_0011094","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":6.1,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.633844+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_656120","record_id":"REC_0011095","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":4.7,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.634079+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_121150","record_id":"REC_0011096","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":10.1,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.3,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.634310+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_939758","record_id":"REC_0011097","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":14.5,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":7.2,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.634545+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_609343","record_id":"REC_0011098","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":8.5,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":4.6,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.634771+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_454500","record_id":"REC_0011099","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":4.8,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.635002+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_107886","record_id":"REC_0011100","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":32,"tmb_mutations_per_mb":13.5,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":5.5,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":8.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.635245+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_508456","record_id":"REC_0011101","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":14.0,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":25,"primary_tumor_size_cm":4.9,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":28.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.635480+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_186210","record_id":"REC_0011102","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":30,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":0,"smoking_pack_years":49,"primary_tumor_size_cm":6.2,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.635711+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_274863","record_id":"REC_0011103","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":10,"tmb_mutations_per_mb":11.5,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":6.5,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.635998+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_967267","record_id":"REC_0011104","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":11.0,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":5.6,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":7.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.636363+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_847865","record_id":"REC_0011105","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":16.6,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":0,"smoking_pack_years":6,"primary_tumor_size_cm":6.0,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.636620+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_980052","record_id":"REC_0011106","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":15.1,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":4.9,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":6.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.637004+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_823932","record_id":"REC_0011107","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":4.4,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.637291+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_900237","record_id":"REC_0011108","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":8.5,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":1,"smoking_pack_years":35,"primary_tumor_size_cm":4.6,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":6.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.637556+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_208013","record_id":"REC_0011109","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":15.9,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":4.3,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.637818+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_460407","record_id":"REC_0011110","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":15.0,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":3.3,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":16.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.638067+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_542358","record_id":"REC_0011111","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":23.0,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":3,"smoking_pack_years":19,"primary_tumor_size_cm":3.8,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.638318+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_847110","record_id":"REC_0011112","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":27,"primary_tumor_size_cm":7.0,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":17.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.638564+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_201151","record_id":"REC_0011113","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":5.0,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":45,"primary_tumor_size_cm":8.0,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.638819+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_852386","record_id":"REC_0011114","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":9.1,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":4.1,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":8.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.639069+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_615271","record_id":"REC_0011115","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":15.9,"age_at_diagnosis":81,"sex":"male","ecog_performance_status":2,"smoking_pack_years":5,"primary_tumor_size_cm":6.2,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.639327+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_991044","record_id":"REC_0011116","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":8.9,"age_at_diagnosis":52,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":5.8,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.639712+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_811595","record_id":"REC_0011117","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":19,"tmb_mutations_per_mb":14.8,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":5.4,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":5.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.639984+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_444165","record_id":"REC_0011118","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":4.2,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":26,"primary_tumor_size_cm":5.0,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.640477+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_637812","record_id":"REC_0011119","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":5.0,"metastatic_sites_count":8,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":7.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.640800+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_785891","record_id":"REC_0011120","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":9.0,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":5.8,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":18.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.641050+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_670456","record_id":"REC_0011121","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":10.5,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.5,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":18.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.641285+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_467876","record_id":"REC_0011122","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":30,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":6.4,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.641523+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_184534","record_id":"REC_0011123","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":11.5,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.8,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.641760+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_691091","record_id":"REC_0011124","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":16,"tmb_mutations_per_mb":15.2,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":4.8,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.641998+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_259951","record_id":"REC_0011125","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":10.3,"age_at_diagnosis":78,"sex":"male","ecog_performance_status":3,"smoking_pack_years":12,"primary_tumor_size_cm":3.9,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.642245+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_130873","record_id":"REC_0011126","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":11.0,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":26,"primary_tumor_size_cm":4.6,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":22.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.642498+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_681442","record_id":"REC_0011127","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":13.5,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":5.5,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":5.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.642738+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_153434","record_id":"REC_0011128","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":7.6,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":7.7,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.642973+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_561061","record_id":"REC_0011129","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":31,"tmb_mutations_per_mb":14.4,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":6,"primary_tumor_size_cm":6.8,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.643316+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_573529","record_id":"REC_0011130","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":1,"smoking_pack_years":68,"primary_tumor_size_cm":3.8,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.643549+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_452663","record_id":"REC_0011131","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":6.2,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.643789+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_401598","record_id":"REC_0011132","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":30,"tmb_mutations_per_mb":8.0,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":3,"smoking_pack_years":53,"primary_tumor_size_cm":6.0,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":16.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.644021+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_203534","record_id":"REC_0011133","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":6.3,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":20.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.644372+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_817858","record_id":"REC_0011134","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":15.1,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":24,"primary_tumor_size_cm":5.9,"metastatic_sites_count":10,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.644624+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_125319","record_id":"REC_0011135","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":31,"tmb_mutations_per_mb":5.6,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":4.3,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.644876+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_831692","record_id":"REC_0011136","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":4.4,"metastatic_sites_count":8,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":4.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.645144+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_777925","record_id":"REC_0011137","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":4.9,"metastatic_sites_count":9,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.645474+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_478892","record_id":"REC_0011138","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":2.8,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":28,"primary_tumor_size_cm":6.9,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":18.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.645720+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_487538","record_id":"REC_0011139","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":5.7,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":5,"primary_tumor_size_cm":5.6,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":7.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.645966+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_489447","record_id":"REC_0011140","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":2.9,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.646214+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_647066","record_id":"REC_0011141","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":14.7,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":4.4,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.646475+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_694173","record_id":"REC_0011142","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":18,"tmb_mutations_per_mb":7.4,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":65,"primary_tumor_size_cm":7.0,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.646851+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_546452","record_id":"REC_0011143","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":8.9,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":6.2,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.647102+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_451409","record_id":"REC_0011144","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":8.6,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":63,"primary_tumor_size_cm":6.1,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.647344+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_623461","record_id":"REC_0011145","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":10.0,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":4.9,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.647590+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_190832","record_id":"REC_0011146","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":4.6,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.647829+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_963836","record_id":"REC_0011147","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":4.4,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.648122+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_818683","record_id":"REC_0011148","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":13.1,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":4.6,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":5.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.648396+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_613392","record_id":"REC_0011149","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":14.8,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":8,"primary_tumor_size_cm":4.7,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":31.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.648651+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_331227","record_id":"REC_0011150","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":5.5,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":7.6,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.648903+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_368198","record_id":"REC_0011151","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":14.0,"age_at_diagnosis":84,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":6.3,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":18.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.649146+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_198760","record_id":"REC_0011152","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":16.7,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":5.0,"metastatic_sites_count":3,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.649387+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_574291","record_id":"REC_0011153","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":30,"tmb_mutations_per_mb":5.7,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":1,"smoking_pack_years":61,"primary_tumor_size_cm":4.0,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.649636+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_725822","record_id":"REC_0011154","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":85,"sex":"female","ecog_performance_status":2,"smoking_pack_years":20,"primary_tumor_size_cm":4.1,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.649887+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_380578","record_id":"REC_0011155","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":4.2,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":8.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.650261+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_679563","record_id":"REC_0011156","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":78,"sex":"male","ecog_performance_status":2,"smoking_pack_years":83,"primary_tumor_size_cm":4.9,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.650521+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_238601","record_id":"REC_0011157","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":18,"tmb_mutations_per_mb":14.6,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":24,"primary_tumor_size_cm":5.8,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.650787+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_135282","record_id":"REC_0011158","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":4.2,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":67,"primary_tumor_size_cm":7.6,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":33.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.651058+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_428443","record_id":"REC_0011159","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":34,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":2,"primary_tumor_size_cm":5.7,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.651337+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_243900","record_id":"REC_0011160","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":6.3,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.651598+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_700385","record_id":"REC_0011161","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":6.1,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":2,"smoking_pack_years":37,"primary_tumor_size_cm":3.4,"metastatic_sites_count":8,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.651850+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_793398","record_id":"REC_0011162","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":6.1,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":24,"primary_tumor_size_cm":3.8,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":18.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.652150+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_808115","record_id":"REC_0011163","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":6.3,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":47,"primary_tumor_size_cm":4.8,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":22.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.652422+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_275776","record_id":"REC_0011164","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":14.3,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":6.8,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.652686+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_693118","record_id":"REC_0011165","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":25,"primary_tumor_size_cm":3.6,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":19.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.652942+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_650264","record_id":"REC_0011166","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":3,"primary_tumor_size_cm":4.9,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":4.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.653183+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_207819","record_id":"REC_0011167","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":7.6,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":36,"primary_tumor_size_cm":5.3,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.653430+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_845598","record_id":"REC_0011168","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":5.3,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":1,"smoking_pack_years":28,"primary_tumor_size_cm":6.7,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":6.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.653823+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_165486","record_id":"REC_0011169","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":3.5,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":6.3,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":17.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.654117+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_755788","record_id":"REC_0011170","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":53,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":7.6,"metastatic_sites_count":10,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.654392+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_224241","record_id":"REC_0011171","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":0,"smoking_pack_years":33,"primary_tumor_size_cm":6.7,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":16.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.654641+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_661143","record_id":"REC_0011172","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":16.7,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":7.5,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.654889+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_104364","record_id":"REC_0011173","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":8.9,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.5,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.655135+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_932845","record_id":"REC_0011174","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":14.9,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":3,"smoking_pack_years":10,"primary_tumor_size_cm":5.1,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.655392+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_600941","record_id":"REC_0011175","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":24,"primary_tumor_size_cm":8.0,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":16.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.655643+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_543417","record_id":"REC_0011176","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":4.5,"metastatic_sites_count":8,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":5.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.655895+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_916128","record_id":"REC_0011177","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":20,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":6.0,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":16.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.656279+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_544090","record_id":"REC_0011178","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":51,"sex":"female","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":7.0,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.656554+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_321111","record_id":"REC_0011179","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":16.1,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":5.5,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.656823+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_123889","record_id":"REC_0011180","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":15,"tmb_mutations_per_mb":5.2,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":4.5,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":6.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.657071+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_764481","record_id":"REC_0011181","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":4.0,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":7.0,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.657444+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_105028","record_id":"REC_0011182","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":4.2,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.657702+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_794317","record_id":"REC_0011183","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":5.0,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.657952+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_672786","record_id":"REC_0011184","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":5.0,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":38.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.658204+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_223582","record_id":"REC_0011185","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":31,"tmb_mutations_per_mb":8.1,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":6.7,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.658470+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_739418","record_id":"REC_0011186","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":13.3,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":4,"primary_tumor_size_cm":3.9,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":22.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.658740+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_712005","record_id":"REC_0011187","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":16,"tmb_mutations_per_mb":17.8,"age_at_diagnosis":74,"sex":"male","ecog_performance_status":1,"smoking_pack_years":5,"primary_tumor_size_cm":5.8,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.658987+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_477893","record_id":"REC_0011188","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":30,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":4.0,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":18.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.659216+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_293142","record_id":"REC_0011189","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":5.2,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":21.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.659464+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_824807","record_id":"REC_0011190","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":17.1,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":7.1,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.659714+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_465146","record_id":"REC_0011191","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":6.3,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":5.7,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.659952+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_220599","record_id":"REC_0011192","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":5.8,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.660229+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_419141","record_id":"REC_0011193","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":15.5,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":5.8,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":6.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.660471+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_764201","record_id":"REC_0011194","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":16,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":1,"smoking_pack_years":29,"primary_tumor_size_cm":4.8,"metastatic_sites_count":3,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.660814+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_498141","record_id":"REC_0011195","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":33,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":4.2,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":8.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.661060+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_342108","record_id":"REC_0011196","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":5.9,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":5.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.661297+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_846241","record_id":"REC_0011197","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":15.4,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":27,"primary_tumor_size_cm":5.9,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.661531+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_124100","record_id":"REC_0011198","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":6.9,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":6.3,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.661764+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_855356","record_id":"REC_0011199","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":14.0,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":4.1,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.662002+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_560059","record_id":"REC_0011200","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":5.9,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":4.8,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.662228+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_133670","record_id":"REC_0011201","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":6.0,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":62,"primary_tumor_size_cm":7.1,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":28.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.662460+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_604647","record_id":"REC_0011202","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":15.6,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":3.1,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.662695+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_769406","record_id":"REC_0011203","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":5.0,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":52.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.662923+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_287501","record_id":"REC_0011204","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":7.7,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":57.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.663159+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_107612","record_id":"REC_0011205","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":16.3,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":5.9,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.663395+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_513529","record_id":"REC_0011206","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":30,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":48,"primary_tumor_size_cm":7.4,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.663627+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_187843","record_id":"REC_0011207","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":19,"tmb_mutations_per_mb":9.5,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":4.5,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.663908+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_305059","record_id":"REC_0011208","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":33,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":6.1,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.664181+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_790821","record_id":"REC_0011209","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":16.9,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":6.0,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":17.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.664425+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_602959","record_id":"REC_0011210","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":32,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":83,"sex":"male","ecog_performance_status":2,"smoking_pack_years":3,"primary_tumor_size_cm":5.0,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.664667+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_938724","record_id":"REC_0011211","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":13.1,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":5.0,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.664899+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_757412","record_id":"REC_0011212","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":2.3,"age_at_diagnosis":47,"sex":"male","ecog_performance_status":0,"smoking_pack_years":61,"primary_tumor_size_cm":5.5,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":7.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.665131+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_231367","record_id":"REC_0011213","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":75,"sex":"male","ecog_performance_status":2,"smoking_pack_years":8,"primary_tumor_size_cm":7.2,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":7.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.665369+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_687062","record_id":"REC_0011214","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":5.6,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":5.2,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":16.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.665596+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_880809","record_id":"REC_0011215","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":11.1,"age_at_diagnosis":53,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":4.9,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.665830+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_429297","record_id":"REC_0011216","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":4.0,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":5.9,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":27.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.666066+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_565199","record_id":"REC_0011217","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":4,"primary_tumor_size_cm":4.9,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":16.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.666302+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_446505","record_id":"REC_0011218","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":6.0,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":5.5,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":32.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.666534+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_519167","record_id":"REC_0011219","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":18.8,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":1,"smoking_pack_years":5,"primary_tumor_size_cm":5.5,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.666769+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_963200","record_id":"REC_0011220","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":19.6,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":2,"smoking_pack_years":6,"primary_tumor_size_cm":5.6,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.667048+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_715828","record_id":"REC_0011221","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":80,"sex":"male","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":6.1,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.667291+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_366017","record_id":"REC_0011222","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":17,"tmb_mutations_per_mb":15.4,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":3.9,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.667531+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_871774","record_id":"REC_0011223","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":4.9,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.667768+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_887427","record_id":"REC_0011224","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":5.0,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":18.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.668001+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_470748","record_id":"REC_0011225","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":10.0,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":6,"primary_tumor_size_cm":5.5,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.668305+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_679795","record_id":"REC_0011226","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":34,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":75,"sex":"male","ecog_performance_status":3,"smoking_pack_years":22,"primary_tumor_size_cm":2.6,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":22.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.668557+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_954048","record_id":"REC_0011227","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":3.4,"metastatic_sites_count":8,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.668797+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_572258","record_id":"REC_0011228","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":4.3,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":4.5,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.669057+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_842166","record_id":"REC_0011229","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":35,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":8.5,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.669297+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_236384","record_id":"REC_0011230","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":3.4,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":5.3,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.669523+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_390684","record_id":"REC_0011231","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":6.2,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":17.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.669756+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_157499","record_id":"REC_0011232","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":6.3,"age_at_diagnosis":50,"sex":"female","ecog_performance_status":0,"smoking_pack_years":64,"primary_tumor_size_cm":6.8,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.669985+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_530895","record_id":"REC_0011233","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":5.3,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":6.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.670276+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_390057","record_id":"REC_0011234","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":9.9,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":3.7,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":6.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.670506+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_199808","record_id":"REC_0011235","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":5.9,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":6.1,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.670734+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_671200","record_id":"REC_0011236","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":7.4,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":4.9,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":19.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.670961+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_204927","record_id":"REC_0011237","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":13.3,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":1,"primary_tumor_size_cm":6.0,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.671192+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_824847","record_id":"REC_0011238","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":0,"smoking_pack_years":6,"primary_tumor_size_cm":7.5,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.671421+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_932553","record_id":"REC_0011239","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":3.6,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":0,"smoking_pack_years":43,"primary_tumor_size_cm":6.3,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.671658+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_420906","record_id":"REC_0011240","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":13.5,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":6.8,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.671902+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_384555","record_id":"REC_0011241","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":84,"sex":"female","ecog_performance_status":1,"smoking_pack_years":76,"primary_tumor_size_cm":5.0,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.672286+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_777553","record_id":"REC_0011242","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":3.6,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.672554+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_584311","record_id":"REC_0011243","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":3.8,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.672823+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_745030","record_id":"REC_0011244","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":9.7,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":7.3,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.673074+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_761474","record_id":"REC_0011245","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":13.1,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":6.9,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.673324+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_282618","record_id":"REC_0011246","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":4.3,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":44,"primary_tumor_size_cm":5.4,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":5.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.673742+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_245332","record_id":"REC_0011247","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":5.1,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.674014+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_167524","record_id":"REC_0011248","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":5.5,"age_at_diagnosis":75,"sex":"male","ecog_performance_status":2,"smoking_pack_years":36,"primary_tumor_size_cm":4.2,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.674257+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_584784","record_id":"REC_0011249","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":17.0,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":6.3,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.674502+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_644232","record_id":"REC_0011250","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":4.6,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.674744+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_417970","record_id":"REC_0011251","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":31,"primary_tumor_size_cm":4.8,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":27.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.674991+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_747782","record_id":"REC_0011252","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":14.1,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":5.5,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":26.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.675237+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_876547","record_id":"REC_0011253","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":5.8,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.675479+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_316346","record_id":"REC_0011254","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":4.0,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":33,"primary_tumor_size_cm":4.8,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":41.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.675715+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_984642","record_id":"REC_0011255","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":9.9,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":7.4,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":21.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.675963+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_483141","record_id":"REC_0011256","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":36,"tmb_mutations_per_mb":15.5,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":2,"smoking_pack_years":10,"primary_tumor_size_cm":6.0,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":6.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.676534+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_978190","record_id":"REC_0011257","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":6.4,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.676841+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_622815","record_id":"REC_0011258","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":13.1,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":1,"smoking_pack_years":26,"primary_tumor_size_cm":4.9,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.677110+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_656226","record_id":"REC_0011259","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":14.6,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":1,"primary_tumor_size_cm":4.2,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.677553+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_104738","record_id":"REC_0011260","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":5.8,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.677822+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_111265","record_id":"REC_0011261","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":21.0,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":4.4,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.678064+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_462204","record_id":"REC_0011262","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":9.1,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":4.6,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.678305+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_585324","record_id":"REC_0011263","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":14.8,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":6,"primary_tumor_size_cm":5.1,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.678556+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_223848","record_id":"REC_0011264","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":5.6,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":29.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.678822+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_569351","record_id":"REC_0011265","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":14,"tmb_mutations_per_mb":14.6,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":1,"smoking_pack_years":27,"primary_tumor_size_cm":5.5,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.679112+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_902512","record_id":"REC_0011266","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":3.6,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.679392+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_583108","record_id":"REC_0011267","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":9.5,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":3.2,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":27.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.679648+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_434418","record_id":"REC_0011268","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":3.8,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":5.3,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":24.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.680031+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_175839","record_id":"REC_0011269","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":8.1,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":4.9,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":24.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.680529+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_679469","record_id":"REC_0011270","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":14.6,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":6.0,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.680825+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_600956","record_id":"REC_0011271","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":53,"primary_tumor_size_cm":4.8,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":6.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.681085+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_186373","record_id":"REC_0011272","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":18,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":5.4,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":8.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.681456+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_925307","record_id":"REC_0011273","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":16.9,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":4.8,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":31.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.681716+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_721509","record_id":"REC_0011274","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":20,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":3,"smoking_pack_years":17,"primary_tumor_size_cm":6.4,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":5.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.681963+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_194784","record_id":"REC_0011275","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":7.3,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":7.4,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.682221+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_697408","record_id":"REC_0011276","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":3.8,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":55,"primary_tumor_size_cm":6.1,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":24.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.682466+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_480810","record_id":"REC_0011277","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":20.6,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":3,"primary_tumor_size_cm":6.1,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.682719+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_397402","record_id":"REC_0011278","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":16.4,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":7.2,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.682972+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_109678","record_id":"REC_0011279","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":14.1,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":3,"smoking_pack_years":3,"primary_tumor_size_cm":5.8,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.683214+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_986129","record_id":"REC_0011280","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":31,"tmb_mutations_per_mb":18.4,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":6.0,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":7.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.683462+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_266387","record_id":"REC_0011281","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":17,"tmb_mutations_per_mb":7.4,"age_at_diagnosis":74,"sex":"male","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":6.4,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.683717+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_198531","record_id":"REC_0011282","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":6.4,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":4.2,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":18.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.683974+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_657856","record_id":"REC_0011283","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":4.8,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.684297+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_801373","record_id":"REC_0011284","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":14.0,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":5.3,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":8.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.684557+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_571630","record_id":"REC_0011285","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":17.3,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":5.7,"metastatic_sites_count":8,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.684927+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_662617","record_id":"REC_0011286","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":6.3,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":5.0,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.685179+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_982507","record_id":"REC_0011287","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.5,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":3,"smoking_pack_years":20,"primary_tumor_size_cm":6.0,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.685415+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_551435","record_id":"REC_0011288","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":13.5,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":2.5,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.685657+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_327537","record_id":"REC_0011289","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":71,"primary_tumor_size_cm":4.9,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":6.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.685889+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_302998","record_id":"REC_0011290","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":20,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":6.7,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.686126+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_902674","record_id":"REC_0011291","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":18.2,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":10,"primary_tumor_size_cm":6.7,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.686359+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_313774","record_id":"REC_0011292","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":5.4,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":23.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.686587+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_111980","record_id":"REC_0011293","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":4.3,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":41,"primary_tumor_size_cm":4.7,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.686825+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_289079","record_id":"REC_0011294","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":24,"primary_tumor_size_cm":3.8,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.687059+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_582000","record_id":"REC_0011295","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":5.7,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.687293+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_755203","record_id":"REC_0011296","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":5.0,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.687525+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_816359","record_id":"REC_0011297","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":14.5,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":0,"smoking_pack_years":26,"primary_tumor_size_cm":5.2,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":24.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.687760+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_918797","record_id":"REC_0011298","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":8,"primary_tumor_size_cm":5.3,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.688038+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_169807","record_id":"REC_0011299","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":19,"tmb_mutations_per_mb":6.4,"age_at_diagnosis":75,"sex":"male","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":7.3,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.688326+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_217714","record_id":"REC_0011300","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":4,"primary_tumor_size_cm":6.8,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.688564+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_154109","record_id":"REC_0011301","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":14.6,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":3,"smoking_pack_years":8,"primary_tumor_size_cm":5.7,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.688799+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_331024","record_id":"REC_0011302","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":9.1,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":4.0,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.689028+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_467787","record_id":"REC_0011303","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":5.4,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":19.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.689263+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_387923","record_id":"REC_0011304","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":31,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":1,"primary_tumor_size_cm":4.6,"metastatic_sites_count":3,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.689493+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_486556","record_id":"REC_0011305","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":7.4,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.689726+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_478940","record_id":"REC_0011306","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":17.2,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":4.1,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.689960+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_297569","record_id":"REC_0011307","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":30,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":1,"smoking_pack_years":26,"primary_tumor_size_cm":4.6,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.690196+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_278801","record_id":"REC_0011308","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":7.0,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":49.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.690430+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_671124","record_id":"REC_0011309","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":14.8,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":1,"smoking_pack_years":2,"primary_tumor_size_cm":4.8,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":21.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.690663+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_286252","record_id":"REC_0011310","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":9.8,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":5.8,"metastatic_sites_count":8,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.690895+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_829679","record_id":"REC_0011311","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":18.0,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":3,"smoking_pack_years":15,"primary_tumor_size_cm":5.4,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.691174+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_655204","record_id":"REC_0011312","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":4.6,"age_at_diagnosis":53,"sex":"female","ecog_performance_status":0,"smoking_pack_years":87,"primary_tumor_size_cm":6.2,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.691409+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_657496","record_id":"REC_0011313","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ALK fusion","pd_l1_tps_percent":11,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":6.1,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":22.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.691642+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_146473","record_id":"REC_0011314","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":25,"primary_tumor_size_cm":5.5,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.691875+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_799910","record_id":"REC_0011315","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":32,"tmb_mutations_per_mb":14.1,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":4.1,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.692146+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_470393","record_id":"REC_0011316","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":22,"primary_tumor_size_cm":8.8,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.692398+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_269404","record_id":"REC_0011317","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":8.6,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":5.9,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.692634+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_572308","record_id":"REC_0011318","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":6.7,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":16.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.692870+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_355512","record_id":"REC_0011319","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":4.8,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.693105+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_595159","record_id":"REC_0011320","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":3.3,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":7.2,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":20.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.693338+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_320765","record_id":"REC_0011321","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":30,"primary_tumor_size_cm":5.8,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.693573+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_362989","record_id":"REC_0011322","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":28,"primary_tumor_size_cm":8.2,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.693809+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_545383","record_id":"REC_0011323","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":22,"primary_tumor_size_cm":7.3,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":19.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.694060+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_882394","record_id":"REC_0011324","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":3.0,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":4.3,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":29.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.694420+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_802649","record_id":"REC_0011325","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":6.1,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.694692+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_839101","record_id":"REC_0011326","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":16.6,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":5.0,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.694948+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_810300","record_id":"REC_0011327","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":13.6,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":22,"primary_tumor_size_cm":5.4,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.695226+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_511591","record_id":"REC_0011328","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":13.8,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":5.7,"metastatic_sites_count":3,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":6.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.695493+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_742994","record_id":"REC_0011329","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":5.0,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":5.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.695746+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_120780","record_id":"REC_0011330","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":2.4,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":39,"primary_tumor_size_cm":5.9,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.696003+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_426870","record_id":"REC_0011331","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":9.8,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.0,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":23.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.696396+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_634581","record_id":"REC_0011332","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":19,"tmb_mutations_per_mb":10.3,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":6.4,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.696660+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_259544","record_id":"REC_0011333","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":15.1,"age_at_diagnosis":83,"sex":"female","ecog_performance_status":2,"smoking_pack_years":23,"primary_tumor_size_cm":4.5,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.696910+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_943751","record_id":"REC_0011334","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":6.1,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":1,"smoking_pack_years":60,"primary_tumor_size_cm":7.2,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.697153+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_781362","record_id":"REC_0011335","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":14.1,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":10,"primary_tumor_size_cm":5.6,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":21.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.697412+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_570642","record_id":"REC_0011336","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":2,"smoking_pack_years":8,"primary_tumor_size_cm":5.5,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":26.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.697657+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_507741","record_id":"REC_0011337","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":14.0,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":5.0,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.698068+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_892342","record_id":"REC_0011338","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":3.0,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":4.7,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.698338+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_579294","record_id":"REC_0011339","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":3,"primary_tumor_size_cm":6.1,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":17.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.698599+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_461992","record_id":"REC_0011340","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":14.1,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":6.3,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.698867+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_471557","record_id":"REC_0011341","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":3,"smoking_pack_years":15,"primary_tumor_size_cm":4.5,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.699143+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_457560","record_id":"REC_0011342","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":3.0,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":20.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.699403+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_631168","record_id":"REC_0011343","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":4.0,"metastatic_sites_count":3,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":23.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.699654+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_627266","record_id":"REC_0011344","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":58,"primary_tumor_size_cm":6.9,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.699911+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_584133","record_id":"REC_0011345","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":30,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":4.2,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.700210+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_102429","record_id":"REC_0011346","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":14.5,"age_at_diagnosis":80,"sex":"male","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":4.5,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.700471+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_666221","record_id":"REC_0011347","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":34,"tmb_mutations_per_mb":13.3,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":6.3,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.700719+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_703815","record_id":"REC_0011348","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":54,"sex":"male","ecog_performance_status":0,"smoking_pack_years":24,"primary_tumor_size_cm":5.4,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.700959+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_218798","record_id":"REC_0011349","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":4.5,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.701203+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_512132","record_id":"REC_0011350","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":7.4,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":52,"primary_tumor_size_cm":3.4,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.701548+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_532826","record_id":"REC_0011351","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":13.1,"age_at_diagnosis":54,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":7.4,"metastatic_sites_count":8,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":16.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.701802+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_924368","record_id":"REC_0011352","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":8.7,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":1,"smoking_pack_years":4,"primary_tumor_size_cm":5.5,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":16.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.702044+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_804112","record_id":"REC_0011353","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":14.4,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":3.2,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":38.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.702296+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_684415","record_id":"REC_0011354","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":5.0,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.702543+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_197125","record_id":"REC_0011355","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":4.4,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.702795+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_299639","record_id":"REC_0011356","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":14,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":28,"primary_tumor_size_cm":5.2,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.703057+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_492329","record_id":"REC_0011357","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":77,"sex":"male","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":6.6,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":24.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.703309+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_322959","record_id":"REC_0011358","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":4.9,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":23.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.703548+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_428391","record_id":"REC_0011359","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":16.2,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":5.4,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.703789+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_270522","record_id":"REC_0011360","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":17,"tmb_mutations_per_mb":16.1,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":2,"smoking_pack_years":8,"primary_tumor_size_cm":8.7,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.704031+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_727112","record_id":"REC_0011361","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":19,"tmb_mutations_per_mb":3.1,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":26,"primary_tumor_size_cm":4.7,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.704502+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_855686","record_id":"REC_0011362","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":3.7,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.704775+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_572118","record_id":"REC_0011363","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":39,"tmb_mutations_per_mb":15.1,"age_at_diagnosis":83,"sex":"male","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":6.2,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.705146+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_136595","record_id":"REC_0011364","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":14.9,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":4.3,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":27.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.705402+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_962385","record_id":"REC_0011365","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None","pd_l1_tps_percent":31,"tmb_mutations_per_mb":3.1,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":0,"smoking_pack_years":79,"primary_tumor_size_cm":7.4,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":36.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.705642+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_551429","record_id":"REC_0011366","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":9.9,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":7.3,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.705890+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_908087","record_id":"REC_0011367","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":6.0,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":2,"smoking_pack_years":28,"primary_tumor_size_cm":6.3,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.706137+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_211973","record_id":"REC_0011368","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":4.8,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":26.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.706373+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_945831","record_id":"REC_0011369","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":10.1,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":4.6,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.706614+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_458980","record_id":"REC_0011370","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":7.7,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":4.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.706859+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_166270","record_id":"REC_0011371","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":4.0,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":25,"primary_tumor_size_cm":4.5,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":20.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.707113+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_763546","record_id":"REC_0011372","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":14.4,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":4.7,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.707371+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_831728","record_id":"REC_0011373","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":3.9,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":5,"primary_tumor_size_cm":6.4,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.707626+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_200853","record_id":"REC_0011374","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":0,"smoking_pack_years":0,"primary_tumor_size_cm":5.8,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.707889+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_740965","record_id":"REC_0011375","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":13.6,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":5.4,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.708234+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_178747","record_id":"REC_0011376","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":8.7,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":1,"smoking_pack_years":30,"primary_tumor_size_cm":5.5,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":21.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.708618+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_728761","record_id":"REC_0011377","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":7.4,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":6.4,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":6.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.708878+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_454330","record_id":"REC_0011378","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":6.7,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.709154+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_322792","record_id":"REC_0011379","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":7.6,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.4,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.709426+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_774583","record_id":"REC_0011380","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":30,"tmb_mutations_per_mb":7.4,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":3.6,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.709715+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_153974","record_id":"REC_0011381","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":11.5,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":2,"primary_tumor_size_cm":5.5,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.710017+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_568069","record_id":"REC_0011382","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":5.6,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.710298+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_467097","record_id":"REC_0011383","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":7.5,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.710586+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_737881","record_id":"REC_0011384","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":9.5,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":2,"smoking_pack_years":10,"primary_tumor_size_cm":4.4,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.710869+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_568081","record_id":"REC_0011385","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":18,"tmb_mutations_per_mb":8.4,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":23,"primary_tumor_size_cm":6.2,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":22.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.711155+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_424971","record_id":"REC_0011386","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":0,"smoking_pack_years":32,"primary_tumor_size_cm":4.2,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.711441+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_257759","record_id":"REC_0011387","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":6.2,"metastatic_sites_count":3,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.711699+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_204067","record_id":"REC_0011388","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":15,"tmb_mutations_per_mb":16.1,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":4.8,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.711952+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_639564","record_id":"REC_0011389","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":30,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":84,"sex":"female","ecog_performance_status":1,"smoking_pack_years":40,"primary_tumor_size_cm":4.1,"metastatic_sites_count":3,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":18.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.712405+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_745050","record_id":"REC_0011390","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":14.1,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":3,"smoking_pack_years":15,"primary_tumor_size_cm":6.8,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.712687+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_826852","record_id":"REC_0011391","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":4.4,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":7.9,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":19.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.712929+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_271377","record_id":"REC_0011392","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":15.9,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":1,"smoking_pack_years":26,"primary_tumor_size_cm":5.9,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.713177+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_293246","record_id":"REC_0011393","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":6.9,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":24,"primary_tumor_size_cm":4.6,"metastatic_sites_count":3,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.713412+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_276610","record_id":"REC_0011394","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":6.8,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":24.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.713649+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_550305","record_id":"REC_0011395","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":18,"tmb_mutations_per_mb":5.1,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":5.3,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.713888+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_467284","record_id":"REC_0011396","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":14,"tmb_mutations_per_mb":16.4,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":5.6,"metastatic_sites_count":9,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":7.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.714127+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_619180","record_id":"REC_0011397","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":5.6,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":0,"smoking_pack_years":24,"primary_tumor_size_cm":4.7,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":17.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.714362+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_134169","record_id":"REC_0011398","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":2.2,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.8,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.714598+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_304908","record_id":"REC_0011399","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":15.5,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":3,"primary_tumor_size_cm":6.9,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":19.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.714838+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_512260","record_id":"REC_0011400","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":15,"tmb_mutations_per_mb":16.0,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":3.8,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.715081+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_270177","record_id":"REC_0011401","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":14.4,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.4,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":19.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.715467+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_644288","record_id":"REC_0011402","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":13.1,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":2,"smoking_pack_years":21,"primary_tumor_size_cm":6.8,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.716062+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_840349","record_id":"REC_0011403","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":15.0,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":5.6,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.716502+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_329430","record_id":"REC_0011404","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":15.7,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":6.0,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.716764+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_863410","record_id":"REC_0011405","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":18,"tmb_mutations_per_mb":9.9,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":6.5,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.717004+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_263203","record_id":"REC_0011406","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":15.1,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":5.5,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":25.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.717253+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_186357","record_id":"REC_0011407","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":62,"primary_tumor_size_cm":6.3,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":21.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.717497+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_638008","record_id":"REC_0011408","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":19,"tmb_mutations_per_mb":1.6,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":4.1,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":23.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.717742+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_804446","record_id":"REC_0011409","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":4.5,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":2,"smoking_pack_years":77,"primary_tumor_size_cm":5.5,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":7.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.717988+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_861282","record_id":"REC_0011410","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":15.5,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":7.9,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.718231+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_164697","record_id":"REC_0011411","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":4.7,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":28,"primary_tumor_size_cm":5.5,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.718469+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_577120","record_id":"REC_0011412","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":74,"sex":"male","ecog_performance_status":2,"smoking_pack_years":20,"primary_tumor_size_cm":5.9,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":32.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.718722+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_393989","record_id":"REC_0011413","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":77,"sex":"male","ecog_performance_status":1,"smoking_pack_years":27,"primary_tumor_size_cm":4.8,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.718977+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_214248","record_id":"REC_0011414","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":14.4,"age_at_diagnosis":45,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":6.7,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.719242+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_537512","record_id":"REC_0011415","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":87,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.7,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":24.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.719636+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_557810","record_id":"REC_0011416","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":3.9,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.719905+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_968090","record_id":"REC_0011417","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":18.4,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":6.5,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":25.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.720206+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_213396","record_id":"REC_0011418","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":25.0,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":7.1,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.720474+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_105001","record_id":"REC_0011419","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":16.1,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":5.2,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.720734+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_250119","record_id":"REC_0011420","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":30,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":5,"primary_tumor_size_cm":7.0,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":18.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.721095+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_650966","record_id":"REC_0011421","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":9.5,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":5.1,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.721374+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_790262","record_id":"REC_0011422","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":10,"primary_tumor_size_cm":6.0,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.721631+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_556138","record_id":"REC_0011423","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":8.0,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":4,"primary_tumor_size_cm":5.8,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.721880+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_180794","record_id":"REC_0011424","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":5.5,"age_at_diagnosis":76,"sex":"male","ecog_performance_status":1,"smoking_pack_years":66,"primary_tumor_size_cm":6.9,"metastatic_sites_count":8,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.722136+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_949457","record_id":"REC_0011425","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.1,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":26.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.722391+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_948715","record_id":"REC_0011426","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":16,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.6,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.722634+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_120454","record_id":"REC_0011427","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":32,"tmb_mutations_per_mb":5.0,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":6.1,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":5.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.722873+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_785351","record_id":"REC_0011428","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":15,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":9,"primary_tumor_size_cm":5.7,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.723266+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_223467","record_id":"REC_0011429","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":4.9,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.723518+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_837867","record_id":"REC_0011430","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":15.1,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":4.8,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":6.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.723764+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_537828","record_id":"REC_0011431","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":17.4,"age_at_diagnosis":54,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":5.9,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.724008+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_149165","record_id":"REC_0011432","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":34,"tmb_mutations_per_mb":8.6,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":6.2,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.724389+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_675602","record_id":"REC_0011433","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":9.9,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":7.9,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.724647+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_575329","record_id":"REC_0011434","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":31,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":23,"primary_tumor_size_cm":6.7,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":7.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.724892+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_730849","record_id":"REC_0011435","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":30,"tmb_mutations_per_mb":9.9,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":5.0,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.725140+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_341209","record_id":"REC_0011436","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":5.2,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.725415+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_192289","record_id":"REC_0011437","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":32,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":5.5,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.725677+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_757040","record_id":"REC_0011438","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":38,"primary_tumor_size_cm":3.9,"metastatic_sites_count":3,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.726113+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_212566","record_id":"REC_0011439","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":9.7,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":3.6,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.726370+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_193231","record_id":"REC_0011440","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":32,"primary_tumor_size_cm":6.9,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":27.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.726605+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_632695","record_id":"REC_0011441","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":17.2,"age_at_diagnosis":86,"sex":"female","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":8.1,"metastatic_sites_count":8,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.726991+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_836405","record_id":"REC_0011442","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":35,"tmb_mutations_per_mb":8.7,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":4.5,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":22.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.727235+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_517085","record_id":"REC_0011443","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":3.6,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":1,"smoking_pack_years":56,"primary_tumor_size_cm":5.9,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":6.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.727477+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_457605","record_id":"REC_0011444","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":6.9,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":18.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.727722+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_911020","record_id":"REC_0011445","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":6.0,"age_at_diagnosis":48,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":5.9,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.727975+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_680611","record_id":"REC_0011446","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":15.2,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":4.5,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.728292+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_361531","record_id":"REC_0011447","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":4.3,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.728568+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_821672","record_id":"REC_0011448","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":13.1,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":0,"smoking_pack_years":25,"primary_tumor_size_cm":4.4,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.728867+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_466749","record_id":"REC_0011449","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":6.3,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.729172+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_837982","record_id":"REC_0011450","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":31,"tmb_mutations_per_mb":4.2,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":46,"primary_tumor_size_cm":5.7,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":18.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.729424+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_375132","record_id":"REC_0011451","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":6.9,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":3,"primary_tumor_size_cm":6.2,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.729659+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_719669","record_id":"REC_0011452","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":8.1,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":7.5,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.729895+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_157828","record_id":"REC_0011453","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":16.3,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":1,"smoking_pack_years":5,"primary_tumor_size_cm":5.4,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":23.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.730132+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_572336","record_id":"REC_0011454","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":5.5,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":51,"primary_tumor_size_cm":4.3,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.730480+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_978915","record_id":"REC_0011455","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":14.9,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.4,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.730727+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_449647","record_id":"REC_0011456","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":5.7,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":16.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.730958+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_157724","record_id":"REC_0011457","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":4.1,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":10,"primary_tumor_size_cm":5.9,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.731187+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_506367","record_id":"REC_0011458","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.5,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.731421+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_472277","record_id":"REC_0011459","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":6.2,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.731658+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_627659","record_id":"REC_0011460","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":5.6,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":4.8,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.731891+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_771622","record_id":"REC_0011461","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":18,"tmb_mutations_per_mb":4.4,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":5.6,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":7.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.732170+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_142910","record_id":"REC_0011462","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":87,"sex":"female","ecog_performance_status":2,"smoking_pack_years":5,"primary_tumor_size_cm":7.2,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.732411+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_149096","record_id":"REC_0011463","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":11.0,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":6.0,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.732648+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_526370","record_id":"REC_0011464","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":15.4,"age_at_diagnosis":54,"sex":"female","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":4.9,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.732880+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_307311","record_id":"REC_0011465","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":7.7,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":16.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.733118+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_388220","record_id":"REC_0011466","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":8.7,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.5,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":17.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.733353+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_527145","record_id":"REC_0011467","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":30,"tmb_mutations_per_mb":6.0,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":6.3,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":7.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.733707+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_817004","record_id":"REC_0011468","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":7.1,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.733995+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_767472","record_id":"REC_0011469","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":11.1,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":3.7,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.734239+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_738210","record_id":"REC_0011470","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":5.6,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.734475+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_383180","record_id":"REC_0011471","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":4.7,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":4.4,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.734708+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_174131","record_id":"REC_0011472","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":6.7,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":24.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.734945+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_885156","record_id":"REC_0011473","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":6.3,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":1,"smoking_pack_years":54,"primary_tumor_size_cm":4.0,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.735178+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_277813","record_id":"REC_0011474","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":10.0,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":3.6,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":18.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.735412+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_143705","record_id":"REC_0011475","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":7.9,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":3,"smoking_pack_years":14,"primary_tumor_size_cm":4.0,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.735642+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_822252","record_id":"REC_0011476","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":19.1,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":4.9,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":5.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.735876+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_757547","record_id":"REC_0011477","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":4.7,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":22.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.736154+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_201085","record_id":"REC_0011478","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":8.3,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":7.1,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":7.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.736399+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_643078","record_id":"REC_0011479","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":10.0,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":6.3,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":24.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.736636+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_792322","record_id":"REC_0011480","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":6.1,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":1,"smoking_pack_years":47,"primary_tumor_size_cm":4.7,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.736937+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_535642","record_id":"REC_0011481","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":11.1,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":5.9,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":5.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.737178+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_202410","record_id":"REC_0011482","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":25,"primary_tumor_size_cm":6.7,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.737415+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_136044","record_id":"REC_0011483","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":4.9,"age_at_diagnosis":87,"sex":"female","ecog_performance_status":1,"smoking_pack_years":63,"primary_tumor_size_cm":6.5,"metastatic_sites_count":3,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.737652+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_140162","record_id":"REC_0011484","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":4.2,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":8.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.737884+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_619135","record_id":"REC_0011485","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":8.6,"metastatic_sites_count":8,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":20.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.738122+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_801430","record_id":"REC_0011486","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":20,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":75,"sex":"male","ecog_performance_status":1,"smoking_pack_years":43,"primary_tumor_size_cm":7.8,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.738357+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_703538","record_id":"REC_0011487","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":6.9,"age_at_diagnosis":76,"sex":"male","ecog_performance_status":2,"smoking_pack_years":54,"primary_tumor_size_cm":4.4,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":5.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.738588+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_290525","record_id":"REC_0011488","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":4.8,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.738828+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_371818","record_id":"REC_0011489","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":5.7,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":5.0,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.739055+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_789216","record_id":"REC_0011490","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":4.1,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":5.7,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.739286+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_755591","record_id":"REC_0011491","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":15.6,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":5.5,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.739521+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_703919","record_id":"REC_0011492","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":19,"tmb_mutations_per_mb":11.5,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":5.5,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":19.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.739755+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_266639","record_id":"REC_0011493","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":4.6,"metastatic_sites_count":9,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":8.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.740036+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_117200","record_id":"REC_0011494","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":14.4,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":4.5,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.740363+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_681238","record_id":"REC_0011495","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":49,"sex":"female","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":5.2,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.740609+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_853759","record_id":"REC_0011496","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":15.5,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":4.0,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.740850+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_362499","record_id":"REC_0011497","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":0,"smoking_pack_years":51,"primary_tumor_size_cm":5.3,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.741082+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_112993","record_id":"REC_0011498","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":26,"primary_tumor_size_cm":6.1,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.741316+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_395577","record_id":"REC_0011499","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":14.8,"age_at_diagnosis":54,"sex":"male","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":6.5,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.741552+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_439217","record_id":"REC_0011500","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":8.6,"age_at_diagnosis":84,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":6.6,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":23.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.741778+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_546425","record_id":"REC_0011501","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":6.6,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.742014+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_819347","record_id":"REC_0011502","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":20,"tmb_mutations_per_mb":7.3,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":0,"smoking_pack_years":0,"primary_tumor_size_cm":5.7,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.742245+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_318410","record_id":"REC_0011503","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":24,"primary_tumor_size_cm":4.8,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.742477+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_945703","record_id":"REC_0011504","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":3,"primary_tumor_size_cm":4.9,"metastatic_sites_count":8,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":8.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.742709+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_447754","record_id":"REC_0011505","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":26,"primary_tumor_size_cm":6.1,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":23.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.742939+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_292975","record_id":"REC_0011506","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":5.1,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":73,"primary_tumor_size_cm":7.0,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.743228+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_419450","record_id":"REC_0011507","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":75,"sex":"male","ecog_performance_status":3,"smoking_pack_years":18,"primary_tumor_size_cm":5.3,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.743470+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_203720","record_id":"REC_0011508","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":19,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":4,"primary_tumor_size_cm":4.8,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.743703+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_368769","record_id":"REC_0011509","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":7.3,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.743936+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_298740","record_id":"REC_0011510","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":14.4,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":1,"smoking_pack_years":4,"primary_tumor_size_cm":6.1,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.744206+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_688217","record_id":"REC_0011511","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":6,"primary_tumor_size_cm":6.5,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.744453+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_172012","record_id":"REC_0011512","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":2.8,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.744702+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_655295","record_id":"REC_0011513","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":16,"tmb_mutations_per_mb":15.7,"age_at_diagnosis":46,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":6.0,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":19.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.744979+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_608624","record_id":"REC_0011514","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":16.2,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":5.8,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.745243+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_598375","record_id":"REC_0011515","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ALK fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":8.6,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":21,"primary_tumor_size_cm":5.3,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":47.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.745487+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_571260","record_id":"REC_0011516","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":4.9,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.745732+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_833208","record_id":"REC_0011517","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":17.5,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":3.8,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":8.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.745975+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_974633","record_id":"REC_0011518","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.8,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":25.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.746234+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_206885","record_id":"REC_0011519","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":10.3,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":4.5,"metastatic_sites_count":9,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":4.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.746602+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_510078","record_id":"REC_0011520","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":14.4,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":1,"primary_tumor_size_cm":3.7,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.746857+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_167443","record_id":"REC_0011521","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":15.5,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":4.4,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":17.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.747102+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_233413","record_id":"REC_0011522","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":5.0,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":5.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.747343+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_891797","record_id":"REC_0011523","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":5.9,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.747583+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_656657","record_id":"REC_0011524","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":17.1,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":28,"primary_tumor_size_cm":5.1,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.747816+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_794716","record_id":"REC_0011525","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":11.1,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":3.3,"metastatic_sites_count":8,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.748057+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_628456","record_id":"REC_0011526","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":21,"primary_tumor_size_cm":4.8,"metastatic_sites_count":8,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.748365+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_813652","record_id":"REC_0011527","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":11.5,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":6.0,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":26.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.748635+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_986108","record_id":"REC_0011528","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":17,"tmb_mutations_per_mb":5.6,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":5.1,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":6.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.748890+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_933863","record_id":"REC_0011529","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":2.5,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":1,"smoking_pack_years":53,"primary_tumor_size_cm":4.6,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":5.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.749133+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_916214","record_id":"REC_0011530","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":3.6,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.749374+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_988820","record_id":"REC_0011531","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":7.9,"age_at_diagnosis":50,"sex":"female","ecog_performance_status":0,"smoking_pack_years":51,"primary_tumor_size_cm":5.1,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":21.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.749612+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_737085","record_id":"REC_0011532","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":13.3,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":4.2,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.749974+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_973413","record_id":"REC_0011533","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":11.5,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":5.2,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.750229+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_328255","record_id":"REC_0011534","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":8.6,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":3,"smoking_pack_years":19,"primary_tumor_size_cm":4.7,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.750465+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_177430","record_id":"REC_0011535","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":35,"tmb_mutations_per_mb":13.1,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":6.2,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.750708+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_579545","record_id":"REC_0011536","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":35,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":5,"primary_tumor_size_cm":5.9,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":22.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.750948+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_954104","record_id":"REC_0011537","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":2,"smoking_pack_years":22,"primary_tumor_size_cm":2.6,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.751190+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_768271","record_id":"REC_0011538","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":52,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":5.2,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":17.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.751428+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_421050","record_id":"REC_0011539","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":16.4,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":7.1,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.751670+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_800686","record_id":"REC_0011540","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":4.3,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.751904+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_952052","record_id":"REC_0011541","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":19,"tmb_mutations_per_mb":6.7,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":63,"primary_tumor_size_cm":7.8,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.752227+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_440605","record_id":"REC_0011542","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":8.7,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":6.2,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.752519+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_599448","record_id":"REC_0011543","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":9.9,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":4.5,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.752791+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_982100","record_id":"REC_0011544","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":53,"sex":"female","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":5.4,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.753028+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_264986","record_id":"REC_0011545","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":34,"tmb_mutations_per_mb":14.9,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":6.1,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":5.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.753374+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_774787","record_id":"REC_0011546","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":15.1,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":5.9,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.753616+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_981081","record_id":"REC_0011547","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":16.5,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":3.5,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.753854+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_812072","record_id":"REC_0011548","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":5.6,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":20.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.754088+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_649538","record_id":"REC_0011549","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":5.2,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":48,"primary_tumor_size_cm":7.2,"metastatic_sites_count":8,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.754321+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_407699","record_id":"REC_0011550","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":4.0,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":2,"smoking_pack_years":43,"primary_tumor_size_cm":6.1,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.754549+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_558687","record_id":"REC_0011551","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":17.5,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":5.8,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.754785+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_401352","record_id":"REC_0011552","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":6.2,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.755021+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_860764","record_id":"REC_0011553","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":9.0,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":4.0,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.755249+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_545097","record_id":"REC_0011554","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":25,"primary_tumor_size_cm":7.0,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.755480+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_593645","record_id":"REC_0011555","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":3.9,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.755712+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_467061","record_id":"REC_0011556","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":8.1,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":6.8,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.755943+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_272769","record_id":"REC_0011557","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":33,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":4.2,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":22.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.756285+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_446322","record_id":"REC_0011558","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":11.1,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":6,"primary_tumor_size_cm":3.8,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.756571+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_828074","record_id":"REC_0011559","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":14.3,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":6.0,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.756812+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_831007","record_id":"REC_0011560","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":17,"tmb_mutations_per_mb":5.7,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":5.2,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":23.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.757042+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_745367","record_id":"REC_0011561","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":4.0,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.757278+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_826629","record_id":"REC_0011562","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":4.2,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":7.7,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":34.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.757508+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_389217","record_id":"REC_0011563","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":4.6,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.757739+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_734957","record_id":"REC_0011564","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":18,"tmb_mutations_per_mb":8.5,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":5.6,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":22.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.757969+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_597831","record_id":"REC_0011565","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":13,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":46,"primary_tumor_size_cm":5.4,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.758196+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_302063","record_id":"REC_0011566","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":5.6,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.758428+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_958594","record_id":"REC_0011567","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":15.9,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":3.9,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.758666+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_127387","record_id":"REC_0011568","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":24,"primary_tumor_size_cm":6.9,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":5.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.758899+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_251772","record_id":"REC_0011569","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":6.4,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.759130+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_741013","record_id":"REC_0011570","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":19,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":8.1,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.759364+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_549186","record_id":"REC_0011571","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":0,"smoking_pack_years":42,"primary_tumor_size_cm":5.2,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.759640+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_996121","record_id":"REC_0011572","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":19,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":7,"primary_tumor_size_cm":3.4,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":17.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.759871+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_355432","record_id":"REC_0011573","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":2.6,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":1,"smoking_pack_years":59,"primary_tumor_size_cm":4.2,"metastatic_sites_count":8,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.760131+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_614785","record_id":"REC_0011574","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":50,"sex":"male","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":4.7,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.760372+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_878126","record_id":"REC_0011575","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":6.3,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":6.3,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.760607+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_517271","record_id":"REC_0011576","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":14.6,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":5.3,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.760844+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_646004","record_id":"REC_0011577","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":15.7,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":3.4,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.761079+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_254391","record_id":"REC_0011578","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":14,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":47,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":5.2,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.761314+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_962649","record_id":"REC_0011579","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":5.9,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":4.6,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":17.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.761545+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_379511","record_id":"REC_0011580","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":14.0,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":4.9,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.761779+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_572383","record_id":"REC_0011581","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":16.9,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":6.3,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":7.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.762016+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_680698","record_id":"REC_0011582","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":6.4,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":32.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.762249+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_584124","record_id":"REC_0011583","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":15.2,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":5.3,"metastatic_sites_count":8,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.762485+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_697395","record_id":"REC_0011584","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":6.9,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.762779+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_307587","record_id":"REC_0011585","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":20,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":2,"smoking_pack_years":10,"primary_tumor_size_cm":2.8,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.763022+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_320256","record_id":"REC_0011586","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":10.5,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":0,"smoking_pack_years":2,"primary_tumor_size_cm":6.8,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.763257+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_518103","record_id":"REC_0011587","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":35,"primary_tumor_size_cm":5.8,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.763487+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_306256","record_id":"REC_0011588","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":13.6,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":0,"smoking_pack_years":5,"primary_tumor_size_cm":6.4,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":34.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.763722+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_135901","record_id":"REC_0011589","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":4.6,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.763957+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_797636","record_id":"REC_0011590","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":7.9,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.764242+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_982975","record_id":"REC_0011591","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":15.0,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":6.9,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":19.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.764502+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_566890","record_id":"REC_0011592","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":14.8,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":3.9,"metastatic_sites_count":9,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.764737+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_193914","record_id":"REC_0011593","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":14.6,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":3.9,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.764972+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_853578","record_id":"REC_0011594","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":15.3,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":0,"smoking_pack_years":5,"primary_tumor_size_cm":2.5,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":17.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.765215+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_247528","record_id":"REC_0011595","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":0,"smoking_pack_years":48,"primary_tumor_size_cm":5.4,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.765447+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_524986","record_id":"REC_0011596","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":19,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":53,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":7.0,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.765679+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_265310","record_id":"REC_0011597","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":5.9,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":21.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.765973+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_450438","record_id":"REC_0011598","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":8.7,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.5,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":23.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.766211+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_215714","record_id":"REC_0011599","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":19,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":6.7,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":21.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.766445+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_357608","record_id":"REC_0011600","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":33,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":6.8,"metastatic_sites_count":9,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.766677+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_796060","record_id":"REC_0011601","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":6.0,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.766912+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_572377","record_id":"REC_0011602","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":4.9,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":41.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.767144+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_753526","record_id":"REC_0011603","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":3.3,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":5.2,"metastatic_sites_count":9,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.767375+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_443883","record_id":"REC_0011604","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":4.5,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":17.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.767602+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_180844","record_id":"REC_0011605","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":54,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":7.0,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":16.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.767841+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_393006","record_id":"REC_0011606","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":7.9,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":5.8,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.768102+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_270828","record_id":"REC_0011607","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":5.5,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":1,"smoking_pack_years":41,"primary_tumor_size_cm":6.0,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.768340+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_701953","record_id":"REC_0011608","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":5.7,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.768577+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_590810","record_id":"REC_0011609","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":9.8,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":26,"primary_tumor_size_cm":5.4,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":7.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.768805+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_548415","record_id":"REC_0011610","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":6.2,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.769097+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_662680","record_id":"REC_0011611","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":10.1,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":5.0,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.769332+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_876063","record_id":"REC_0011612","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":13.5,"age_at_diagnosis":87,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":4.5,"metastatic_sites_count":3,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":19.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.769566+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_158355","record_id":"REC_0011613","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":18,"tmb_mutations_per_mb":6.9,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":24,"primary_tumor_size_cm":3.9,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":20.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.769802+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_975511","record_id":"REC_0011614","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":35,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":54,"sex":"female","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":5.8,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.770033+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_879530","record_id":"REC_0011615","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":19,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":44,"primary_tumor_size_cm":5.8,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.770266+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_538884","record_id":"REC_0011616","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":19.0,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":0,"smoking_pack_years":31,"primary_tumor_size_cm":4.2,"metastatic_sites_count":9,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.770499+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_564922","record_id":"REC_0011617","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":8.7,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":6.0,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.770728+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_541363","record_id":"REC_0011618","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":4.3,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.770958+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_427825","record_id":"REC_0011619","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":10.0,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":3.9,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.771194+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_508961","record_id":"REC_0011620","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":16.8,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":4.5,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.771426+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_401903","record_id":"REC_0011621","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":14.6,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":7.0,"metastatic_sites_count":3,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.771657+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_171310","record_id":"REC_0011622","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":14.3,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":1,"smoking_pack_years":4,"primary_tumor_size_cm":6.1,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.771891+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_190024","record_id":"REC_0011623","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":15,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":6.1,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.772204+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_881243","record_id":"REC_0011624","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":4.8,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":19.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.772439+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_632685","record_id":"REC_0011625","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":10.3,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.5,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.772675+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_958906","record_id":"REC_0011626","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":16.1,"age_at_diagnosis":52,"sex":"male","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":4.7,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":16.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.772910+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_423761","record_id":"REC_0011627","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":7.0,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":7.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.773141+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_390620","record_id":"REC_0011628","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":5.9,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":2,"smoking_pack_years":21,"primary_tumor_size_cm":6.0,"metastatic_sites_count":3,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.773372+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_514181","record_id":"REC_0011629","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":6.7,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.773602+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_361680","record_id":"REC_0011630","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":8.6,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":3.3,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.773835+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_760450","record_id":"REC_0011631","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":5.6,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":27,"primary_tumor_size_cm":6.0,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.774064+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_464561","record_id":"REC_0011632","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":16,"tmb_mutations_per_mb":19.7,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":5.3,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.774297+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_546924","record_id":"REC_0011633","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":6.6,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.774531+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_664545","record_id":"REC_0011634","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":5.1,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":44,"primary_tumor_size_cm":5.5,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":6.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.774762+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_710925","record_id":"REC_0011635","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":2.9,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":7.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.774995+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_947719","record_id":"REC_0011636","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":20,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":68,"primary_tumor_size_cm":8.6,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.775266+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_941982","record_id":"REC_0011637","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":13.6,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":5.4,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":8.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.775503+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_674269","record_id":"REC_0011638","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":54,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":6.7,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.775740+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_545583","record_id":"REC_0011639","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":30,"tmb_mutations_per_mb":2.5,"age_at_diagnosis":84,"sex":"male","ecog_performance_status":1,"smoking_pack_years":25,"primary_tumor_size_cm":6.8,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":21.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.775971+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_558491","record_id":"REC_0011640","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":14.8,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":7.9,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":16.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.776366+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_407139","record_id":"REC_0011641","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":85,"sex":"male","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":5.9,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.776613+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_319904","record_id":"REC_0011642","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":9.9,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":6.2,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.776849+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_968737","record_id":"REC_0011643","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":16.1,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":2,"smoking_pack_years":3,"primary_tumor_size_cm":6.8,"metastatic_sites_count":8,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":6.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.777085+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_262111","record_id":"REC_0011644","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":20,"tmb_mutations_per_mb":5.6,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":39,"primary_tumor_size_cm":4.8,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.777312+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_142858","record_id":"REC_0011645","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":7.2,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":27.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.777548+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_355615","record_id":"REC_0011646","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":8.9,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":4.5,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.777779+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_249800","record_id":"REC_0011647","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":0,"smoking_pack_years":25,"primary_tumor_size_cm":6.5,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.778012+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_532638","record_id":"REC_0011648","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":10.3,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":5.3,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":21.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.778245+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_571928","record_id":"REC_0011649","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":15.8,"age_at_diagnosis":54,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":5.6,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":7.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.778526+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_126866","record_id":"REC_0011650","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":15,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":5.7,"metastatic_sites_count":8,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.778763+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_606921","record_id":"REC_0011651","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":8.7,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":5.3,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.778991+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_489392","record_id":"REC_0011652","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":6.8,"metastatic_sites_count":8,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.779225+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_159248","record_id":"REC_0011653","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":5.0,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":6.3,"metastatic_sites_count":3,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.779456+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_369753","record_id":"REC_0011654","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":1,"smoking_pack_years":24,"primary_tumor_size_cm":4.2,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.779692+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_403974","record_id":"REC_0011655","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":4.2,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.779928+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_605026","record_id":"REC_0011656","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":16.0,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":3.4,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.780190+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_466975","record_id":"REC_0011657","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":5.3,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":0,"smoking_pack_years":28,"primary_tumor_size_cm":6.4,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":7.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.780421+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_623395","record_id":"REC_0011658","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None","pd_l1_tps_percent":20,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":0,"smoking_pack_years":62,"primary_tumor_size_cm":3.2,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":21.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.780735+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_381002","record_id":"REC_0011659","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":15.1,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":2.6,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":5.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.780977+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_308096","record_id":"REC_0011660","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":15.2,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":5.5,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.781216+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_506624","record_id":"REC_0011661","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":32,"tmb_mutations_per_mb":8.5,"age_at_diagnosis":48,"sex":"male","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":6.0,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":24.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.781447+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_895190","record_id":"REC_0011662","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":54,"sex":"male","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":3.6,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.781723+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_501631","record_id":"REC_0011663","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":8.9,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":1,"smoking_pack_years":5,"primary_tumor_size_cm":8.7,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.781958+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_739111","record_id":"REC_0011664","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":8.5,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":5.1,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":8.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.782188+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_221313","record_id":"REC_0011665","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":6,"primary_tumor_size_cm":5.0,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.782420+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_254143","record_id":"REC_0011666","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":16.2,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":23,"primary_tumor_size_cm":4.5,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.782649+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_315844","record_id":"REC_0011667","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":9.7,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":4.2,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.782876+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_508758","record_id":"REC_0011668","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":18.1,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":5.1,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.783106+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_376058","record_id":"REC_0011669","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":6.5,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.783343+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_736050","record_id":"REC_0011670","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":14.4,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":4.2,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":17.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.783578+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_691339","record_id":"REC_0011671","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":15.0,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":7.3,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.783814+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_899121","record_id":"REC_0011672","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":9.7,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":0,"smoking_pack_years":26,"primary_tumor_size_cm":4.3,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.784044+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_667941","record_id":"REC_0011673","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":5.2,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":3.3,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":17.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.784302+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_565600","record_id":"REC_0011674","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":2.0,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":19.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.784541+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_150093","record_id":"REC_0011675","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":5.6,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.784817+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_788559","record_id":"REC_0011676","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":16.1,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":7.0,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":45.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.785054+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_927532","record_id":"REC_0011677","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":30,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":6.3,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":8.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.785292+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_571539","record_id":"REC_0011678","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":30,"tmb_mutations_per_mb":4.1,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":43,"primary_tumor_size_cm":6.7,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":32.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.785538+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_633607","record_id":"REC_0011679","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":2,"smoking_pack_years":9,"primary_tumor_size_cm":4.4,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.785800+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_473110","record_id":"REC_0011680","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":17,"tmb_mutations_per_mb":5.9,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":42,"primary_tumor_size_cm":5.6,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":7.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.786041+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_586599","record_id":"REC_0011681","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":9.0,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":37,"primary_tumor_size_cm":3.9,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.786281+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_520424","record_id":"REC_0011682","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":5.1,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":17.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.786539+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_899882","record_id":"REC_0011683","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":7.5,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.786783+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_672719","record_id":"REC_0011684","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":37,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":5.8,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.787026+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_264202","record_id":"REC_0011685","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":84,"sex":"male","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":6.2,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":5.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.787277+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_132942","record_id":"REC_0011686","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":6.9,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":4.8,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.787543+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_230069","record_id":"REC_0011687","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":6.8,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.787793+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_379430","record_id":"REC_0011688","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":4.5,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":21.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.788236+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_141543","record_id":"REC_0011689","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":4.6,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":29,"primary_tumor_size_cm":5.2,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.788503+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_127006","record_id":"REC_0011690","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":8.3,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":6.1,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":22.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.788739+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_208203","record_id":"REC_0011691","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":16,"tmb_mutations_per_mb":7.4,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":1,"smoking_pack_years":47,"primary_tumor_size_cm":3.2,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":5.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.788977+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_244320","record_id":"REC_0011692","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":7.6,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":5.9,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":19.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.789216+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_126198","record_id":"REC_0011693","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":6.4,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.789468+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_223758","record_id":"REC_0011694","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":6.3,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.789704+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_612787","record_id":"REC_0011695","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":9.5,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":3.1,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.789940+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_676792","record_id":"REC_0011696","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":6.5,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.790175+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_116571","record_id":"REC_0011697","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":14.1,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":5.4,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":4.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.790408+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_316969","record_id":"REC_0011698","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":47,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":7.0,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.790644+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_213896","record_id":"REC_0011699","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":43,"primary_tumor_size_cm":7.0,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":18.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.790875+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_854306","record_id":"REC_0011700","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":3,"smoking_pack_years":9,"primary_tumor_size_cm":5.7,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":27.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.791104+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_375469","record_id":"REC_0011701","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":10.1,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":5.1,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.791443+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_581408","record_id":"REC_0011702","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":34,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":85,"sex":"female","ecog_performance_status":2,"smoking_pack_years":8,"primary_tumor_size_cm":7.3,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.791683+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_210363","record_id":"REC_0011703","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":7.7,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":21.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.791920+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_261059","record_id":"REC_0011704","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":6.1,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":6.5,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.792208+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_464068","record_id":"REC_0011705","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":6.7,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.792449+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_497150","record_id":"REC_0011706","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":3.2,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":38,"primary_tumor_size_cm":5.7,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.792679+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_708610","record_id":"REC_0011707","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":4.8,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":66,"primary_tumor_size_cm":6.7,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.792913+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_647724","record_id":"REC_0011708","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":14.8,"age_at_diagnosis":50,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":5.4,"metastatic_sites_count":9,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.793150+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_216397","record_id":"REC_0011709","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":6.7,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.793382+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_770311","record_id":"REC_0011710","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":7.8,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.793617+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_312960","record_id":"REC_0011711","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":8.6,"age_at_diagnosis":83,"sex":"male","ecog_performance_status":2,"smoking_pack_years":4,"primary_tumor_size_cm":5.5,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.793849+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_725419","record_id":"REC_0011712","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":15.1,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":7.4,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.794084+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_233594","record_id":"REC_0011713","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None","pd_l1_tps_percent":19,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":74,"primary_tumor_size_cm":5.0,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":18.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.794311+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_617485","record_id":"REC_0011714","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":8.6,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":2,"smoking_pack_years":42,"primary_tumor_size_cm":5.1,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.794606+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_634610","record_id":"REC_0011715","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":4.9,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":2,"primary_tumor_size_cm":5.2,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.794844+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_614897","record_id":"REC_0011716","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":20,"primary_tumor_size_cm":7.3,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.795082+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_639267","record_id":"REC_0011717","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":3.1,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":7.5,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":16.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.795314+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_282303","record_id":"REC_0011718","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":6.6,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.795548+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_744984","record_id":"REC_0011719","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":5.3,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.795778+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_972058","record_id":"REC_0011720","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":19,"tmb_mutations_per_mb":4.0,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":4.7,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":28.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.796009+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_700430","record_id":"REC_0011721","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":6.1,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":31.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.796271+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_212648","record_id":"REC_0011722","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":4.0,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.796504+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_694525","record_id":"REC_0011723","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":54,"sex":"female","ecog_performance_status":0,"smoking_pack_years":47,"primary_tumor_size_cm":6.8,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.796735+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_502879","record_id":"REC_0011724","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":13.8,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":2,"smoking_pack_years":10,"primary_tumor_size_cm":5.7,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.796969+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_191199","record_id":"REC_0011725","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":49,"sex":"male","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":6.1,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":16.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.797204+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_281221","record_id":"REC_0011726","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":18,"tmb_mutations_per_mb":7.9,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.6,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.797437+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_766133","record_id":"REC_0011727","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":19.6,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":0,"smoking_pack_years":28,"primary_tumor_size_cm":4.8,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":19.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.797720+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_692592","record_id":"REC_0011728","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":13.3,"age_at_diagnosis":54,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":3.5,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.797957+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_400464","record_id":"REC_0011729","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":15.1,"age_at_diagnosis":54,"sex":"male","ecog_performance_status":0,"smoking_pack_years":25,"primary_tumor_size_cm":5.2,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":6.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.798193+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_569946","record_id":"REC_0011730","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":15.9,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":2,"smoking_pack_years":21,"primary_tumor_size_cm":5.5,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":7.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.798430+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_542625","record_id":"REC_0011731","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":13.5,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":5.6,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.798664+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_672581","record_id":"REC_0011732","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":49,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":5.5,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.798899+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_747236","record_id":"REC_0011733","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":7.0,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":17.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.799137+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_480816","record_id":"REC_0011734","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":4.3,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":33,"primary_tumor_size_cm":7.1,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.799367+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_521101","record_id":"REC_0011735","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":31,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":1,"smoking_pack_years":72,"primary_tumor_size_cm":5.7,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.799599+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_951586","record_id":"REC_0011736","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":5.3,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":16.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.799829+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_804560","record_id":"REC_0011737","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":14.0,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":5.6,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.800059+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_838442","record_id":"REC_0011738","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":5.7,"metastatic_sites_count":8,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.800428+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_147993","record_id":"REC_0011739","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":20,"tmb_mutations_per_mb":5.3,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":5.6,"metastatic_sites_count":3,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":26.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.800659+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_786573","record_id":"REC_0011740","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":31,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":26,"primary_tumor_size_cm":8.2,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":17.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.800941+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_749920","record_id":"REC_0011741","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.0,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":5.0,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.801180+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_442521","record_id":"REC_0011742","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":75,"sex":"male","ecog_performance_status":3,"smoking_pack_years":6,"primary_tumor_size_cm":5.7,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":17.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.801412+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_543614","record_id":"REC_0011743","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":10.3,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":26,"primary_tumor_size_cm":5.9,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.801646+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_172755","record_id":"REC_0011744","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":28,"primary_tumor_size_cm":6.6,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.801872+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_207108","record_id":"REC_0011745","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":8.5,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":3.8,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":7.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.802104+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_560965","record_id":"REC_0011746","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":19,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":2,"smoking_pack_years":10,"primary_tumor_size_cm":6.8,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":20.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.802335+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_457859","record_id":"REC_0011747","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":7.7,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":22.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.802568+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_258120","record_id":"REC_0011748","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":20,"tmb_mutations_per_mb":4.9,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":80,"primary_tumor_size_cm":4.7,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.802794+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_363230","record_id":"REC_0011749","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":4.5,"age_at_diagnosis":47,"sex":"male","ecog_performance_status":0,"smoking_pack_years":34,"primary_tumor_size_cm":5.0,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.803026+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_409324","record_id":"REC_0011750","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":4.4,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":33,"primary_tumor_size_cm":7.6,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.803257+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_801537","record_id":"REC_0011751","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":19,"tmb_mutations_per_mb":3.8,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":6.0,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":5.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.803488+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_931409","record_id":"REC_0011752","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":4.7,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":17.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.803720+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_889384","record_id":"REC_0011753","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":1,"smoking_pack_years":63,"primary_tumor_size_cm":6.8,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":20.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.803992+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_365525","record_id":"REC_0011754","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":16.4,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":5.0,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":29.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.804258+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_856365","record_id":"REC_0011755","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":15.3,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":4.6,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.804492+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_901628","record_id":"REC_0011756","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":18,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":75,"sex":"male","ecog_performance_status":2,"smoking_pack_years":86,"primary_tumor_size_cm":6.5,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.804726+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_536323","record_id":"REC_0011757","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":4.8,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":55,"primary_tumor_size_cm":5.4,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":19.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.804958+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_130567","record_id":"REC_0011758","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":2,"smoking_pack_years":9,"primary_tumor_size_cm":6.6,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":4.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.805193+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_210360","record_id":"REC_0011759","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":8.1,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.805426+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_141555","record_id":"REC_0011760","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":7.8,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.805662+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_378403","record_id":"REC_0011761","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":3.5,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":27.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.805896+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_340632","record_id":"REC_0011762","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":6.8,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.806132+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_205315","record_id":"REC_0011763","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":4.9,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.806364+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_319072","record_id":"REC_0011764","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":13.1,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":4.3,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.806601+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_334834","record_id":"REC_0011765","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":24.9,"age_at_diagnosis":79,"sex":"male","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":5.7,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.806837+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_944164","record_id":"REC_0011766","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":11.1,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":5.4,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":7.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.807127+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_684489","record_id":"REC_0011767","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":7.0,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.807502+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_602581","record_id":"REC_0011768","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":1,"smoking_pack_years":62,"primary_tumor_size_cm":5.7,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":17.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.807766+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_535471","record_id":"REC_0011769","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":5.1,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":17.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.808033+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_834823","record_id":"REC_0011770","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":15,"tmb_mutations_per_mb":3.6,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":7.3,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.808322+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_714318","record_id":"REC_0011771","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":4.2,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":2,"smoking_pack_years":54,"primary_tumor_size_cm":5.8,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.808560+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_249483","record_id":"REC_0011772","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":15.3,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":6.7,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.808802+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_644011","record_id":"REC_0011773","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":4.4,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":27.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.809035+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_706854","record_id":"REC_0011774","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":33,"tmb_mutations_per_mb":4.7,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":4.5,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.809280+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_482290","record_id":"REC_0011775","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":9.5,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":8.0,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":22.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.809527+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_805662","record_id":"REC_0011776","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":17,"tmb_mutations_per_mb":8.5,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":3,"smoking_pack_years":10,"primary_tumor_size_cm":3.9,"metastatic_sites_count":3,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":19.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.809762+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_729897","record_id":"REC_0011777","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":3,"smoking_pack_years":12,"primary_tumor_size_cm":2.6,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.810000+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_345797","record_id":"REC_0011778","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":10.5,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":5,"primary_tumor_size_cm":4.0,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.810237+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_656209","record_id":"REC_0011779","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":15.4,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":5.3,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.810581+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_831231","record_id":"REC_0011780","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":11.1,"age_at_diagnosis":51,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":4.7,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.810826+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_587567","record_id":"REC_0011781","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":7.4,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.811062+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_977661","record_id":"REC_0011782","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":5.6,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.811298+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_276823","record_id":"REC_0011783","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":19,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":5.4,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":45.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.811536+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_192324","record_id":"REC_0011784","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":8.3,"age_at_diagnosis":83,"sex":"male","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":4.4,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.811767+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_398198","record_id":"REC_0011785","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.5,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.812003+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_684628","record_id":"REC_0011786","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":8.7,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":4.5,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":17.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.812300+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_245933","record_id":"REC_0011787","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":3.3,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":6.4,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.812548+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_345942","record_id":"REC_0011788","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":19,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":1,"smoking_pack_years":47,"primary_tumor_size_cm":7.4,"metastatic_sites_count":3,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.812783+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_344262","record_id":"REC_0011789","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":13.3,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":5.7,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":5.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.813020+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_436878","record_id":"REC_0011790","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":8.4,"age_at_diagnosis":47,"sex":"male","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":7.8,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.813250+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_415829","record_id":"REC_0011791","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":6.7,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":26,"primary_tumor_size_cm":5.8,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.813481+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_157084","record_id":"REC_0011792","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":8.3,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":4.6,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.813775+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_711824","record_id":"REC_0011793","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":86,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":5.2,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":44.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.814011+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_214275","record_id":"REC_0011794","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":18.0,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":5.2,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.814248+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_602943","record_id":"REC_0011795","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":5.7,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.814480+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_310108","record_id":"REC_0011796","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":16,"tmb_mutations_per_mb":14.6,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":5,"primary_tumor_size_cm":6.8,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":22.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.814711+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_283960","record_id":"REC_0011797","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":15,"tmb_mutations_per_mb":8.0,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":6.2,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":37.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.814943+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_714912","record_id":"REC_0011798","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":6.1,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":0,"smoking_pack_years":64,"primary_tumor_size_cm":6.1,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.815178+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_743594","record_id":"REC_0011799","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":33,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":45,"primary_tumor_size_cm":5.6,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":24.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.815414+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_753080","record_id":"REC_0011800","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":15.9,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":3,"smoking_pack_years":4,"primary_tumor_size_cm":3.8,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.815649+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_695762","record_id":"REC_0011801","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":16.2,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":1,"smoking_pack_years":5,"primary_tumor_size_cm":4.8,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.815883+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_579839","record_id":"REC_0011802","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":8.6,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":3,"smoking_pack_years":32,"primary_tumor_size_cm":5.2,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":26.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.816151+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_900423","record_id":"REC_0011803","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":16.9,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":5.8,"metastatic_sites_count":3,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.816391+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_146515","record_id":"REC_0011804","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":14.3,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":4.2,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.816625+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_944235","record_id":"REC_0011805","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":6.7,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":3.0,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":17.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.816914+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_205146","record_id":"REC_0011806","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":8.4,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":5.5,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.817146+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_599923","record_id":"REC_0011807","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":4.7,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.817382+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_400203","record_id":"REC_0011808","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":20,"tmb_mutations_per_mb":4.2,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":4.4,"metastatic_sites_count":9,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.817615+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_538037","record_id":"REC_0011809","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":6.7,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":0,"smoking_pack_years":31,"primary_tumor_size_cm":5.4,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":21.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.817846+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_539061","record_id":"REC_0011810","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":6.0,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":4.3,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":28.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.818075+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_336126","record_id":"REC_0011811","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":4.3,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.818309+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_768022","record_id":"REC_0011812","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":5.0,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":6.5,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.818538+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_295146","record_id":"REC_0011813","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":16.0,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":5.4,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":7.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.818771+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_365810","record_id":"REC_0011814","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":4.6,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.819001+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_621848","record_id":"REC_0011815","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":8.3,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":5.7,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.819233+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_626188","record_id":"REC_0011816","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":2.8,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":74,"primary_tumor_size_cm":3.8,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":21.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.819464+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_416249","record_id":"REC_0011817","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":0,"smoking_pack_years":34,"primary_tumor_size_cm":3.5,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.819694+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_461148","record_id":"REC_0011818","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":8.6,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":3,"smoking_pack_years":9,"primary_tumor_size_cm":5.2,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.819964+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_646316","record_id":"REC_0011819","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":15.8,"age_at_diagnosis":90,"sex":"male","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":6.8,"metastatic_sites_count":8,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.820232+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_543471","record_id":"REC_0011820","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":5,"primary_tumor_size_cm":5.4,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.820471+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_332679","record_id":"REC_0011821","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":24,"primary_tumor_size_cm":7.0,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.820699+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_287137","record_id":"REC_0011822","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":6.3,"age_at_diagnosis":48,"sex":"female","ecog_performance_status":0,"smoking_pack_years":49,"primary_tumor_size_cm":7.3,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":16.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.820931+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_388565","record_id":"REC_0011823","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":5.7,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.821166+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_482713","record_id":"REC_0011824","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":9.1,"age_at_diagnosis":87,"sex":"female","ecog_performance_status":1,"smoking_pack_years":3,"primary_tumor_size_cm":3.6,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.821392+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_379052","record_id":"REC_0011825","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":4.2,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":17.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.821627+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_767073","record_id":"REC_0011826","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":15,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":5.2,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":6.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.821858+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_895549","record_id":"REC_0011827","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.5,"metastatic_sites_count":9,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.822095+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_831021","record_id":"REC_0011828","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":18,"tmb_mutations_per_mb":5.5,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":6.3,"metastatic_sites_count":3,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.822325+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_331422","record_id":"REC_0011829","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":1,"smoking_pack_years":32,"primary_tumor_size_cm":6.9,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.822557+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_109407","record_id":"REC_0011830","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":5.1,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":19.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.822789+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_470305","record_id":"REC_0011831","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":79,"sex":"male","ecog_performance_status":1,"smoking_pack_years":51,"primary_tumor_size_cm":4.2,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":20.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.823063+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_855021","record_id":"REC_0011832","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":15.8,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":8,"primary_tumor_size_cm":3.8,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":6.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.823296+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_620835","record_id":"REC_0011833","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":16,"tmb_mutations_per_mb":17.5,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":6.6,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.823528+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_121007","record_id":"REC_0011834","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":17.4,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":5.5,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.823763+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_617406","record_id":"REC_0011835","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":8.9,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":5.8,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.824002+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_248872","record_id":"REC_0011836","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":10.0,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":3.7,"metastatic_sites_count":8,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.824314+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_809828","record_id":"REC_0011837","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":4.3,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":6.7,"metastatic_sites_count":3,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":24.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.824568+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_212995","record_id":"REC_0011838","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":7.3,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":43.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.824820+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_520704","record_id":"REC_0011839","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":16.4,"age_at_diagnosis":76,"sex":"male","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":6.0,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":22.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.825070+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_374191","record_id":"REC_0011840","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":20.3,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":6.3,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.825316+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_892547","record_id":"REC_0011841","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":10.5,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":8.5,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.825561+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_853416","record_id":"REC_0011842","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":21.6,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":27,"primary_tumor_size_cm":4.0,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.825810+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_133565","record_id":"REC_0011843","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":6,"primary_tumor_size_cm":4.5,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.826055+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_580100","record_id":"REC_0011844","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":4.4,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":5,"primary_tumor_size_cm":6.9,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.826424+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_134850","record_id":"REC_0011845","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":6.1,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.826692+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_233637","record_id":"REC_0011846","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":7.7,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.826962+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_789611","record_id":"REC_0011847","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":4.5,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.827211+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_267656","record_id":"REC_0011848","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":4.6,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":20.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.827447+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_178395","record_id":"REC_0011849","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":15.0,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":6.3,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":16.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.827698+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_386508","record_id":"REC_0011850","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":15.2,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":5.6,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.827974+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_661143","record_id":"REC_0011851","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":11,"tmb_mutations_per_mb":8.5,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":7,"primary_tumor_size_cm":6.5,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.828258+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_696495","record_id":"REC_0011852","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":10.5,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":3,"smoking_pack_years":9,"primary_tumor_size_cm":6.3,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.828499+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_217301","record_id":"REC_0011853","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":7.4,"age_at_diagnosis":53,"sex":"male","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":6.6,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":24.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.828737+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_132492","record_id":"REC_0011854","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":4.5,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.828970+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_764203","record_id":"REC_0011855","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":17.0,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":5.6,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":6.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.829207+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_328000","record_id":"REC_0011856","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":85,"sex":"female","ecog_performance_status":2,"smoking_pack_years":40,"primary_tumor_size_cm":5.0,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.829433+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_336259","record_id":"REC_0011857","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":15,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":27,"primary_tumor_size_cm":5.7,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":5.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.829752+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_812667","record_id":"REC_0011858","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":17,"tmb_mutations_per_mb":6.3,"age_at_diagnosis":54,"sex":"male","ecog_performance_status":0,"smoking_pack_years":53,"primary_tumor_size_cm":6.6,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":4.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.829996+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_195227","record_id":"REC_0011859","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":14.7,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":5,"primary_tumor_size_cm":3.9,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.830249+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_669068","record_id":"REC_0011860","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":11.1,"age_at_diagnosis":77,"sex":"male","ecog_performance_status":2,"smoking_pack_years":20,"primary_tumor_size_cm":6.5,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":18.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.830537+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_874262","record_id":"REC_0011861","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":98,"primary_tumor_size_cm":4.8,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":5.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.830767+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_275448","record_id":"REC_0011862","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":9.8,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":4.2,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.831060+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_377934","record_id":"REC_0011863","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":8.3,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.831299+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_756136","record_id":"REC_0011864","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":19.9,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":6.3,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":36.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.831585+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_557193","record_id":"REC_0011865","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":8.0,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":5.2,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":25.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.831821+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_197304","record_id":"REC_0011866","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":6.3,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":18.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.832163+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_269988","record_id":"REC_0011867","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":10.3,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":6.9,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.832407+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_709349","record_id":"REC_0011868","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":16.2,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":5.5,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":23.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.832643+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_705701","record_id":"REC_0011869","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":16,"tmb_mutations_per_mb":17.4,"age_at_diagnosis":51,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":6.3,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":22.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.832902+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_442390","record_id":"REC_0011870","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.8,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.833200+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_432912","record_id":"REC_0011871","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":17.5,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":0,"primary_tumor_size_cm":4.9,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.833437+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_783595","record_id":"REC_0011872","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":20,"tmb_mutations_per_mb":3.6,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":36,"primary_tumor_size_cm":5.5,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.833670+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_993239","record_id":"REC_0011873","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":19.6,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":8.3,"metastatic_sites_count":3,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.833907+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_646896","record_id":"REC_0011874","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":5.7,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":45,"primary_tumor_size_cm":6.1,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.834138+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_800717","record_id":"REC_0011875","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":90,"sex":"male","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":3.7,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.834382+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_416298","record_id":"REC_0011876","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":10.0,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":6.0,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.834618+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_345024","record_id":"REC_0011877","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":18.5,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":5.9,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":6.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.834879+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_279445","record_id":"REC_0011878","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":30,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":3,"primary_tumor_size_cm":9.5,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.835126+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_797824","record_id":"REC_0011879","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":4.2,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.835386+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_354327","record_id":"REC_0011880","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":48,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":6.8,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":17.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.835626+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_137624","record_id":"REC_0011881","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":7.3,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":2,"smoking_pack_years":38,"primary_tumor_size_cm":5.4,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.835869+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_252961","record_id":"REC_0011882","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":15.7,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":5.8,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.836249+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_264977","record_id":"REC_0011883","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":16.2,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":6.6,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.836589+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_449529","record_id":"REC_0011884","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":5.8,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.836839+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_803524","record_id":"REC_0011885","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":16,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":4.3,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.837079+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_225695","record_id":"REC_0011886","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":31,"primary_tumor_size_cm":7.3,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":21.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.837309+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_683585","record_id":"REC_0011887","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":16.1,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":6.1,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.837545+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_931562","record_id":"REC_0011888","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":3.5,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.837781+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_723484","record_id":"REC_0011889","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":34,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":4,"primary_tumor_size_cm":6.7,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":22.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.838018+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_454189","record_id":"REC_0011890","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":13.6,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":4.9,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.838253+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_801046","record_id":"REC_0011891","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":31,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":23,"primary_tumor_size_cm":4.7,"metastatic_sites_count":3,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.838496+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_240041","record_id":"REC_0011892","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":4.7,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.838727+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_659466","record_id":"REC_0011893","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":9.8,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":7.2,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.838960+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_937044","record_id":"REC_0011894","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":1,"smoking_pack_years":49,"primary_tumor_size_cm":5.4,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.839193+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_475061","record_id":"REC_0011895","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":8.1,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":5.8,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.839435+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_393174","record_id":"REC_0011896","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":32,"tmb_mutations_per_mb":15.0,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":5.2,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":21.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.839728+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_150081","record_id":"REC_0011897","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":5.0,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":22.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.839976+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_432716","record_id":"REC_0011898","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":5.5,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":30,"primary_tumor_size_cm":4.9,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.840244+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_816921","record_id":"REC_0011899","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":52,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":4.7,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.840480+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_915192","record_id":"REC_0011900","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":19.2,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.4,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.840721+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_748956","record_id":"REC_0011901","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":5.9,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":4.0,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.840949+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_824699","record_id":"REC_0011902","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":17,"tmb_mutations_per_mb":5.7,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":5.8,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.841176+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_382617","record_id":"REC_0011903","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":14.6,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":6.7,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.841414+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_561618","record_id":"REC_0011904","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":17.6,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":4.9,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":29.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.841654+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_121046","record_id":"REC_0011905","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":15.0,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":6.2,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.841895+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_714845","record_id":"REC_0011906","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":15.2,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":6.0,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.842129+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_632280","record_id":"REC_0011907","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":19,"tmb_mutations_per_mb":16.8,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":4.5,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.842366+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_892128","record_id":"REC_0011908","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":5.2,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":1,"smoking_pack_years":51,"primary_tumor_size_cm":6.3,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":29.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.842598+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_692902","record_id":"REC_0011909","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":8.9,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":6.5,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.842881+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_950003","record_id":"REC_0011910","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":24,"primary_tumor_size_cm":5.5,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.843119+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_426174","record_id":"REC_0011911","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":14,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":4.8,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.843355+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_914924","record_id":"REC_0011912","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":31,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":7.1,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.843599+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_742999","record_id":"REC_0011913","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":3.8,"age_at_diagnosis":81,"sex":"male","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":5.4,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.843833+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_697061","record_id":"REC_0011914","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":9.0,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":6,"primary_tumor_size_cm":4.3,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.844108+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_731505","record_id":"REC_0011915","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":11.0,"age_at_diagnosis":83,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":5.7,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":17.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.844348+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_872367","record_id":"REC_0011916","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":5,"primary_tumor_size_cm":3.0,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":26.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.844585+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_253462","record_id":"REC_0011917","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":6.7,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":19.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.844818+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_706036","record_id":"REC_0011918","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":9.9,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":4.3,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.845060+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_559303","record_id":"REC_0011919","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":2.8,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":7.0,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.845305+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_906495","record_id":"REC_0011920","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":8.6,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":5.2,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.845537+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_317438","record_id":"REC_0011921","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":4.7,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.845770+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_386678","record_id":"REC_0011922","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":17.4,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":5.7,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.846060+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_803629","record_id":"REC_0011923","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":13.3,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":3,"smoking_pack_years":6,"primary_tumor_size_cm":7.3,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.846300+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_780967","record_id":"REC_0011924","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":76,"sex":"male","ecog_performance_status":3,"smoking_pack_years":61,"primary_tumor_size_cm":4.9,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.846533+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_716585","record_id":"REC_0011925","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":10.3,"age_at_diagnosis":53,"sex":"male","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":6.5,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.846770+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_217424","record_id":"REC_0011926","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":9,"primary_tumor_size_cm":6.7,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.846998+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_837944","record_id":"REC_0011927","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":3.7,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.847234+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_235168","record_id":"REC_0011928","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":24,"primary_tumor_size_cm":6.3,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.847464+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_662892","record_id":"REC_0011929","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":16.8,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":3.7,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.847700+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_499940","record_id":"REC_0011930","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":15.9,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":5.8,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":18.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.847934+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_373554","record_id":"REC_0011931","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":9.1,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":4.5,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":6.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.848231+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_715672","record_id":"REC_0011932","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":4.4,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":5.5,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":24.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.848471+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_926811","record_id":"REC_0011933","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":9.1,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.2,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.848712+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_322914","record_id":"REC_0011934","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":6.9,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":5.8,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.848943+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_521514","record_id":"REC_0011935","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":6.5,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":25.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.849226+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_132160","record_id":"REC_0011936","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":16.2,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":5.6,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.849465+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_651029","record_id":"REC_0011937","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":14.5,"age_at_diagnosis":52,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":6.8,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.849703+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_638503","record_id":"REC_0011938","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":5.6,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":5.1,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":17.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.849935+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_341889","record_id":"REC_0011939","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":5.6,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":2,"smoking_pack_years":4,"primary_tumor_size_cm":6.0,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.850165+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_778742","record_id":"REC_0011940","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":6.9,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":41.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.850399+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_445268","record_id":"REC_0011941","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":5.7,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":56,"primary_tumor_size_cm":5.5,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":27.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.850627+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_780214","record_id":"REC_0011942","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":4.8,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":3.6,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.850867+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_401570","record_id":"REC_0011943","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":5.9,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":23.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.851105+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_662889","record_id":"REC_0011944","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":14.9,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":5.0,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.851340+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_770012","record_id":"REC_0011945","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":7.3,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":5.5,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":20.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.851570+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_849506","record_id":"REC_0011946","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.5,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.851802+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_336284","record_id":"REC_0011947","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":6.3,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":22.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.852037+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_250864","record_id":"REC_0011948","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":31,"tmb_mutations_per_mb":13.5,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":7.3,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":25.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.852383+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_789413","record_id":"REC_0011949","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":8.3,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":7.2,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.852624+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_715092","record_id":"REC_0011950","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":3,"smoking_pack_years":17,"primary_tumor_size_cm":8.2,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.852864+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_984722","record_id":"REC_0011951","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":3.0,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":6.1,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":21.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.853098+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_498963","record_id":"REC_0011952","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":31,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":8.0,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":6.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.853330+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_962755","record_id":"REC_0011953","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":20,"primary_tumor_size_cm":5.5,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.853561+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_375354","record_id":"REC_0011954","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":16,"tmb_mutations_per_mb":7.9,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":71,"primary_tumor_size_cm":5.5,"metastatic_sites_count":3,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.853790+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_581116","record_id":"REC_0011955","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":18.9,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":7,"primary_tumor_size_cm":7.0,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.854023+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_189069","record_id":"REC_0011956","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":7.4,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":7.0,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.854247+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_229700","record_id":"REC_0011957","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":4.9,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.854473+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_704104","record_id":"REC_0011958","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":15.7,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":0,"smoking_pack_years":3,"primary_tumor_size_cm":5.6,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.854754+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_414200","record_id":"REC_0011959","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":10.5,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":5.6,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.854987+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_915458","record_id":"REC_0011960","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":14.3,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":6.3,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.855217+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_708217","record_id":"REC_0011961","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":15,"tmb_mutations_per_mb":8.6,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":2,"smoking_pack_years":10,"primary_tumor_size_cm":4.8,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":7.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.855494+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_309283","record_id":"REC_0011962","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":13.1,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":26,"primary_tumor_size_cm":6.4,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.855730+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_974095","record_id":"REC_0011963","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":17,"tmb_mutations_per_mb":14.3,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":4.0,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.855963+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_116647","record_id":"REC_0011964","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":30,"tmb_mutations_per_mb":2.9,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":0,"smoking_pack_years":38,"primary_tumor_size_cm":6.2,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.856229+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_990894","record_id":"REC_0011965","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":8.0,"age_at_diagnosis":53,"sex":"male","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":3.9,"metastatic_sites_count":8,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.856523+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_924900","record_id":"REC_0011966","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":5.0,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":6.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.857118+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_626541","record_id":"REC_0011967","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":18,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":6.6,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":17.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.857445+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_672845","record_id":"REC_0011968","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":19,"tmb_mutations_per_mb":4.0,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":1,"smoking_pack_years":51,"primary_tumor_size_cm":5.1,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":5.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.857680+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_226102","record_id":"REC_0011969","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":7.0,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":7.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.857910+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_386618","record_id":"REC_0011970","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":5.5,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":17.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.858141+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_604533","record_id":"REC_0011971","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":17.0,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":6.1,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.858376+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_865233","record_id":"REC_0011972","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":7.9,"age_at_diagnosis":74,"sex":"male","ecog_performance_status":2,"smoking_pack_years":3,"primary_tumor_size_cm":5.3,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.858608+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_245855","record_id":"REC_0011973","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":6.2,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":20.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.858839+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_237432","record_id":"REC_0011974","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":8.7,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":5.9,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":18.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.859127+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_507728","record_id":"REC_0011975","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":5.3,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.859367+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_522851","record_id":"REC_0011976","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":34,"tmb_mutations_per_mb":5.2,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":4.9,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.859598+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_535170","record_id":"REC_0011977","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":14.7,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":24,"primary_tumor_size_cm":3.9,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.859830+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_190514","record_id":"REC_0011978","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":6.3,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":0,"smoking_pack_years":40,"primary_tumor_size_cm":5.7,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.860057+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_477236","record_id":"REC_0011979","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":8.1,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":3,"smoking_pack_years":14,"primary_tumor_size_cm":6.3,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":27.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.860327+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_678006","record_id":"REC_0011980","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":20,"tmb_mutations_per_mb":4.2,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":58,"primary_tumor_size_cm":5.4,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":25.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.860558+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_367250","record_id":"REC_0011981","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":1.9,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":0,"smoking_pack_years":34,"primary_tumor_size_cm":7.2,"metastatic_sites_count":9,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":16.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.860794+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_554829","record_id":"REC_0011982","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":14.8,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":4.0,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.861026+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_737594","record_id":"REC_0011983","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":18,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":32,"primary_tumor_size_cm":7.3,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":18.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.861257+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_439835","record_id":"REC_0011984","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":15.3,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":6.4,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.861488+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_561084","record_id":"REC_0011985","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":0,"smoking_pack_years":31,"primary_tumor_size_cm":5.3,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.861715+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_593064","record_id":"REC_0011986","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":7.8,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":22.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.861942+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_236365","record_id":"REC_0011987","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":32,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":6.6,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.862226+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_622902","record_id":"REC_0011988","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":5.9,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":1,"smoking_pack_years":43,"primary_tumor_size_cm":6.0,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.862460+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_698468","record_id":"REC_0011989","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":51,"primary_tumor_size_cm":6.1,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":17.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.862692+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_122351","record_id":"REC_0011990","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":6.0,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":53,"primary_tumor_size_cm":6.2,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.862924+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_697757","record_id":"REC_0011991","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":5.6,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.863162+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_279641","record_id":"REC_0011992","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":8.1,"age_at_diagnosis":53,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":7.8,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":29.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.863395+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_203565","record_id":"REC_0011993","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":9.9,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":4.8,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":6.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.863622+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_532794","record_id":"REC_0011994","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":8.6,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":28,"primary_tumor_size_cm":4.2,"metastatic_sites_count":8,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.863852+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_457477","record_id":"REC_0011995","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":5.2,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.864179+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_357010","record_id":"REC_0011996","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":15.8,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":6.2,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.864437+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_673286","record_id":"REC_0011997","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":5.6,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":21.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.864674+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_818642","record_id":"REC_0011998","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":8.3,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":5,"primary_tumor_size_cm":6.1,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.864906+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_629562","record_id":"REC_0011999","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":15.6,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":5.8,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":4.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.865143+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_660044","record_id":"REC_0012000","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":30,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":3.5,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":25.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.865427+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_515809","record_id":"REC_0012001","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":8.6,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":1,"smoking_pack_years":50,"primary_tumor_size_cm":4.0,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.865666+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_832849","record_id":"REC_0012002","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":39,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":6.3,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.865900+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_303587","record_id":"REC_0012003","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":10.1,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":0,"smoking_pack_years":6,"primary_tumor_size_cm":4.5,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":18.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.866140+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_988423","record_id":"REC_0012004","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":7.0,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":35.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.866373+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_399578","record_id":"REC_0012005","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":13.5,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":6.8,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.866603+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_268346","record_id":"REC_0012006","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":13.5,"age_at_diagnosis":53,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":5.9,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":23.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.866836+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_673910","record_id":"REC_0012007","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":20,"primary_tumor_size_cm":6.1,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.867067+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_385610","record_id":"REC_0012008","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":14.3,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":7.0,"metastatic_sites_count":8,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.867302+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_764596","record_id":"REC_0012009","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":18,"tmb_mutations_per_mb":16.6,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":8,"primary_tumor_size_cm":6.0,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.867536+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_382526","record_id":"REC_0012010","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":5.5,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":36.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.867765+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_554581","record_id":"REC_0012011","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":30,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":5.9,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.868001+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_233565","record_id":"REC_0012012","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":17,"tmb_mutations_per_mb":3.8,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":0,"smoking_pack_years":25,"primary_tumor_size_cm":5.0,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.868259+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_109527","record_id":"REC_0012013","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":7.8,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":23.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.868535+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_112387","record_id":"REC_0012014","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":8.3,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":24,"primary_tumor_size_cm":4.2,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":16.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.868771+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_825306","record_id":"REC_0012015","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":46,"sex":"male","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":7.3,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":44.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.869010+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_951677","record_id":"REC_0012016","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ALK fusion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":4.1,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":21.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.869246+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_790988","record_id":"REC_0012017","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":15.7,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":4.5,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.869481+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_192104","record_id":"REC_0012018","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":52,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":6.3,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":6.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.869710+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_616939","record_id":"REC_0012019","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":13.3,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":2,"smoking_pack_years":10,"primary_tumor_size_cm":6.4,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.869943+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_493178","record_id":"REC_0012020","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":13.6,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":3.0,"metastatic_sites_count":8,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":17.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.870175+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_499857","record_id":"REC_0012021","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":20,"tmb_mutations_per_mb":7.6,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":43,"primary_tumor_size_cm":5.6,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":18.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.870402+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_753731","record_id":"REC_0012022","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":17.9,"age_at_diagnosis":75,"sex":"male","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":6.1,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.870638+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_200692","record_id":"REC_0012023","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":18,"tmb_mutations_per_mb":16.9,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":6.9,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.870870+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_597099","record_id":"REC_0012024","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":13.5,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":7.0,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.871104+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_508544","record_id":"REC_0012025","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":17.3,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":6.0,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":19.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.871338+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_952524","record_id":"REC_0012026","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":5.9,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.871610+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_436185","record_id":"REC_0012027","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":15.5,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":1,"smoking_pack_years":4,"primary_tumor_size_cm":4.6,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.871844+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_486671","record_id":"REC_0012028","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":7.6,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":7.0,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.872094+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_818978","record_id":"REC_0012029","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":14,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":6.3,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.872336+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_233919","record_id":"REC_0012030","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":34,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":3.3,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.872564+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_796838","record_id":"REC_0012031","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":15.2,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":6.0,"metastatic_sites_count":8,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":6.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.872803+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_905277","record_id":"REC_0012032","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":5.1,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":66,"primary_tumor_size_cm":5.8,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.873035+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_196224","record_id":"REC_0012033","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":4,"primary_tumor_size_cm":6.9,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":7.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.873272+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_359467","record_id":"REC_0012034","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":4.6,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.873507+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_828722","record_id":"REC_0012035","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":52,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":5.2,"metastatic_sites_count":8,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.873740+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_610541","record_id":"REC_0012036","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":7.4,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":2,"smoking_pack_years":38,"primary_tumor_size_cm":6.9,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.873965+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_344003","record_id":"REC_0012037","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":6.7,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":4.1,"metastatic_sites_count":10,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.874198+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_736928","record_id":"REC_0012038","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":4.4,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.874427+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_204077","record_id":"REC_0012039","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":20.9,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":24,"primary_tumor_size_cm":3.4,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.874702+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_680193","record_id":"REC_0012040","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":8.1,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":0,"smoking_pack_years":58,"primary_tumor_size_cm":5.0,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":7.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.874941+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_993593","record_id":"REC_0012041","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":9.8,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":4.6,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.875172+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_371336","record_id":"REC_0012042","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":37,"tmb_mutations_per_mb":13.8,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":6.1,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.875409+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_209801","record_id":"REC_0012043","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":26,"primary_tumor_size_cm":2.4,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.875644+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_216126","record_id":"REC_0012044","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":9.5,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":6.3,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":7.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.875873+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_884873","record_id":"REC_0012045","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":54,"primary_tumor_size_cm":6.2,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.876218+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_433166","record_id":"REC_0012046","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":2.9,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":6.0,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":20.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.876470+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_444455","record_id":"REC_0012047","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":35,"tmb_mutations_per_mb":16.8,"age_at_diagnosis":83,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":4.7,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":5.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.876707+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_374287","record_id":"REC_0012048","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":14.3,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":1,"smoking_pack_years":4,"primary_tumor_size_cm":6.4,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":38.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.876938+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_165997","record_id":"REC_0012049","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":16.3,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":6.0,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.877169+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_445273","record_id":"REC_0012050","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":5.0,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":6.1,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.877396+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_287346","record_id":"REC_0012051","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":16.4,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":5.6,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.877625+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_692786","record_id":"REC_0012052","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":6.1,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":1,"smoking_pack_years":89,"primary_tumor_size_cm":4.4,"metastatic_sites_count":3,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.877902+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_321336","record_id":"REC_0012053","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":5.2,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":46,"primary_tumor_size_cm":5.4,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.878138+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_747938","record_id":"REC_0012054","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":10.1,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":3.0,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.878369+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_233762","record_id":"REC_0012055","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":14.8,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":5.7,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":5.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.878605+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_991603","record_id":"REC_0012056","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":13.8,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":4.2,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.878835+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_438999","record_id":"REC_0012057","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":3.2,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.879075+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_844460","record_id":"REC_0012058","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":14.1,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":4.8,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.879309+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_138590","record_id":"REC_0012059","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":15.2,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.2,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":5.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.879547+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_452355","record_id":"REC_0012060","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":0,"smoking_pack_years":6,"primary_tumor_size_cm":6.4,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":34.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.879781+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_272368","record_id":"REC_0012061","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":15.4,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":7,"primary_tumor_size_cm":5.9,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.880011+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_543586","record_id":"REC_0012062","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":8.9,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":6.1,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.880267+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_668849","record_id":"REC_0012063","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":3.5,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.880507+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_376361","record_id":"REC_0012064","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":30,"tmb_mutations_per_mb":9.1,"age_at_diagnosis":83,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":5.5,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.880737+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_986525","record_id":"REC_0012065","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":0,"smoking_pack_years":27,"primary_tumor_size_cm":5.0,"metastatic_sites_count":3,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.881020+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_565426","record_id":"REC_0012066","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":8.7,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":7.4,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.881255+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_389473","record_id":"REC_0012067","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":10.1,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.2,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.881491+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_961686","record_id":"REC_0012068","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":3,"smoking_pack_years":7,"primary_tumor_size_cm":4.2,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":19.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.881723+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_556666","record_id":"REC_0012069","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":16.4,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":2,"smoking_pack_years":20,"primary_tumor_size_cm":7.0,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.881960+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_204226","record_id":"REC_0012070","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":19,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":4.3,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.882189+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_279552","record_id":"REC_0012071","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":3.8,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.882423+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_315879","record_id":"REC_0012072","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":34,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":3,"smoking_pack_years":16,"primary_tumor_size_cm":6.6,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.882657+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_104138","record_id":"REC_0012073","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":3.7,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.882892+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_396051","record_id":"REC_0012074","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":15,"tmb_mutations_per_mb":7.6,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":32,"primary_tumor_size_cm":2.7,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.883118+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_112686","record_id":"REC_0012075","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":14.5,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":5.5,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":4.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.883356+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_173353","record_id":"REC_0012076","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":7.6,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":2,"smoking_pack_years":20,"primary_tumor_size_cm":5.7,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":21.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.883583+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_997660","record_id":"REC_0012077","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":16,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":7,"primary_tumor_size_cm":4.0,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.883812+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_788818","record_id":"REC_0012078","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.3,"metastatic_sites_count":8,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.884116+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_259390","record_id":"REC_0012079","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":16.0,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":6.0,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.884362+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_902882","record_id":"REC_0012080","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":15.2,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":3,"primary_tumor_size_cm":5.7,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":20.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.884596+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_622090","record_id":"REC_0012081","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":9.1,"age_at_diagnosis":48,"sex":"male","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":4.6,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.884827+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_957945","record_id":"REC_0012082","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":14.3,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":5.9,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":19.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.885055+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_879862","record_id":"REC_0012083","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":12,"tmb_mutations_per_mb":4.2,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":6.4,"metastatic_sites_count":3,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.885284+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_178294","record_id":"REC_0012084","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":13.3,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":5.3,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":6.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.885515+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_559666","record_id":"REC_0012085","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":54,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":5.5,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.885754+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_887053","record_id":"REC_0012086","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":5.0,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.885989+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_505529","record_id":"REC_0012087","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":6.7,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":5.7,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":26.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.886220+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_406828","record_id":"REC_0012088","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":17,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":6.4,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.886450+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_936445","record_id":"REC_0012089","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":6.9,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":52,"primary_tumor_size_cm":5.9,"metastatic_sites_count":3,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.886679+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_205394","record_id":"REC_0012090","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":3.8,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":31,"primary_tumor_size_cm":6.0,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.886907+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_249565","record_id":"REC_0012091","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":2.7,"age_at_diagnosis":46,"sex":"male","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":6.5,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":5.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.887186+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_778505","record_id":"REC_0012092","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":15,"tmb_mutations_per_mb":19.8,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":3,"smoking_pack_years":19,"primary_tumor_size_cm":4.4,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.887419+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_615828","record_id":"REC_0012093","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":30,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":4.8,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":21.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.887655+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_207507","record_id":"REC_0012094","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":9.0,"age_at_diagnosis":49,"sex":"male","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":6.3,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":4.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.887884+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_237156","record_id":"REC_0012095","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":5.4,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.888162+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_763840","record_id":"REC_0012096","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":16.5,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":3,"smoking_pack_years":18,"primary_tumor_size_cm":5.2,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.888411+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_824579","record_id":"REC_0012097","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":16.6,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":5.9,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.888648+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_508278","record_id":"REC_0012098","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":5.5,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":4.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.888880+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_718184","record_id":"REC_0012099","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":18.9,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":7.2,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.889117+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_702139","record_id":"REC_0012100","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":76,"sex":"male","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":4.0,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.889350+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_367113","record_id":"REC_0012101","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":4.9,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":0,"smoking_pack_years":56,"primary_tumor_size_cm":5.3,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":49.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.889579+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_765860","record_id":"REC_0012102","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":18.4,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":7.0,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.889813+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_536544","record_id":"REC_0012103","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":14,"tmb_mutations_per_mb":13.1,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":4,"primary_tumor_size_cm":5.3,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.890047+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_482581","record_id":"REC_0012104","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":47,"primary_tumor_size_cm":5.7,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":21.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.890328+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_280380","record_id":"REC_0012105","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":7.9,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":4.7,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.890566+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_860703","record_id":"REC_0012106","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":5.3,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":6.3,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.890797+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_136193","record_id":"REC_0012107","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":15.7,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":24,"primary_tumor_size_cm":6.0,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.891028+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_508427","record_id":"REC_0012108","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":17.1,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":4.5,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":6.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.891262+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_483392","record_id":"REC_0012109","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":50,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":6.7,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.891497+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_224914","record_id":"REC_0012110","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":8.3,"age_at_diagnosis":83,"sex":"male","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":3.0,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.891731+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_426869","record_id":"REC_0012111","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None","pd_l1_tps_percent":37,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":73,"primary_tumor_size_cm":9.1,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":39.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.891958+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_525704","record_id":"REC_0012112","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":17.7,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":4.8,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":6.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.892228+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_743925","record_id":"REC_0012113","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":15.8,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":5.4,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":7.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.892483+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_149258","record_id":"REC_0012114","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":8.1,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":6.0,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":40.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.892733+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_710845","record_id":"REC_0012115","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":9,"primary_tumor_size_cm":2.2,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.892979+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_239250","record_id":"REC_0012116","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":15.4,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":5.2,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.893234+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_577550","record_id":"REC_0012117","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":18.1,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":4.3,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.893601+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_527840","record_id":"REC_0012118","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":81,"sex":"male","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":5.8,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.893862+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_714546","record_id":"REC_0012119","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":17,"tmb_mutations_per_mb":6.1,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":5.7,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":16.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.894110+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_158680","record_id":"REC_0012120","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":35,"tmb_mutations_per_mb":2.4,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":49,"primary_tumor_size_cm":3.5,"metastatic_sites_count":3,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":19.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.894361+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_402449","record_id":"REC_0012121","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":16.9,"age_at_diagnosis":83,"sex":"female","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":5.3,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.894610+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_525307","record_id":"REC_0012122","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":24,"primary_tumor_size_cm":5.3,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.894861+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_934498","record_id":"REC_0012123","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":7.6,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":42,"primary_tumor_size_cm":4.5,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":17.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.895185+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_872474","record_id":"REC_0012124","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":17.7,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":3.4,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":21.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.895433+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_594320","record_id":"REC_0012125","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":11.0,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":5.8,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.895679+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_889969","record_id":"REC_0012126","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":30,"tmb_mutations_per_mb":15.6,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":29,"primary_tumor_size_cm":6.6,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.895923+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_241264","record_id":"REC_0012127","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":16.1,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":7.2,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.896227+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_390256","record_id":"REC_0012128","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":9,"primary_tumor_size_cm":6.5,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":19.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.896488+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_115768","record_id":"REC_0012129","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":4.0,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":23.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.896738+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_871990","record_id":"REC_0012130","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":30,"tmb_mutations_per_mb":3.7,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":4.4,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":16.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.897088+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_660445","record_id":"REC_0012131","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":31,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":7.0,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.897334+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_685314","record_id":"REC_0012132","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":35,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":24,"primary_tumor_size_cm":5.0,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":19.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.897569+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_894395","record_id":"REC_0012133","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":5.2,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":6.8,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":34.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.897800+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_802216","record_id":"REC_0012134","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":16.6,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":6.2,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.898032+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_686699","record_id":"REC_0012135","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":19,"tmb_mutations_per_mb":9.5,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":5.0,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.898265+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_669028","record_id":"REC_0012136","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":11.1,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":5.2,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":17.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.898502+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_846516","record_id":"REC_0012137","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":5.8,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":17.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.898743+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_950328","record_id":"REC_0012138","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":7.3,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.898989+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_260415","record_id":"REC_0012139","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.3,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":44.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.899218+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_327395","record_id":"REC_0012140","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":3.7,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.899448+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_516266","record_id":"REC_0012141","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":8.6,"age_at_diagnosis":84,"sex":"female","ecog_performance_status":3,"smoking_pack_years":10,"primary_tumor_size_cm":5.9,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.899676+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_529139","record_id":"REC_0012142","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":3.9,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.899908+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_822101","record_id":"REC_0012143","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":19,"tmb_mutations_per_mb":3.4,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":44,"primary_tumor_size_cm":4.9,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":19.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.900289+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_740604","record_id":"REC_0012144","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":0,"smoking_pack_years":28,"primary_tumor_size_cm":5.7,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":18.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.900535+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_489526","record_id":"REC_0012145","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":9.8,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":3,"smoking_pack_years":14,"primary_tumor_size_cm":5.3,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.900779+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_523594","record_id":"REC_0012146","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":5.6,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.901015+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_291038","record_id":"REC_0012147","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":18.3,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":5.7,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":20.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.901247+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_592298","record_id":"REC_0012148","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":7.4,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":4.5,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":19.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.901476+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_332598","record_id":"REC_0012149","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":13,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":0,"smoking_pack_years":4,"primary_tumor_size_cm":6.8,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":43.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.901708+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_634724","record_id":"REC_0012150","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":14,"tmb_mutations_per_mb":3.4,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":3.5,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.901938+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_458796","record_id":"REC_0012151","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":4.7,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.902169+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_131281","record_id":"REC_0012152","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":2.6,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":16.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.902400+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_246783","record_id":"REC_0012153","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":4.5,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":5.2,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":27.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.902630+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_626222","record_id":"REC_0012154","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":15,"tmb_mutations_per_mb":13.5,"age_at_diagnosis":75,"sex":"male","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":6.1,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":18.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.902865+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_462244","record_id":"REC_0012155","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":14.0,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":7.5,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.903098+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_379110","record_id":"REC_0012156","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":2,"smoking_pack_years":10,"primary_tumor_size_cm":4.8,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.903378+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_909625","record_id":"REC_0012157","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":16.4,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":6,"primary_tumor_size_cm":5.0,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.903622+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_221872","record_id":"REC_0012158","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":9,"primary_tumor_size_cm":5.3,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":7.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.903857+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_915280","record_id":"REC_0012159","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":19,"tmb_mutations_per_mb":8.7,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":4.4,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.904133+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_279569","record_id":"REC_0012160","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":3,"smoking_pack_years":22,"primary_tumor_size_cm":5.8,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.904372+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_114126","record_id":"REC_0012161","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":6.1,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.904608+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_747770","record_id":"REC_0012162","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":5.9,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":6.7,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":28.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.904839+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_221222","record_id":"REC_0012163","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":31,"tmb_mutations_per_mb":3.6,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":4.2,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.905075+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_216784","record_id":"REC_0012164","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":4.2,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":8.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.905311+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_689284","record_id":"REC_0012165","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":10.1,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":0,"smoking_pack_years":30,"primary_tumor_size_cm":4.9,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.905542+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_170472","record_id":"REC_0012166","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":19,"tmb_mutations_per_mb":7.4,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":0,"smoking_pack_years":49,"primary_tumor_size_cm":5.6,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.905771+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_934416","record_id":"REC_0012167","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":6.0,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.906007+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_122108","record_id":"REC_0012168","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":17.9,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":6.8,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":17.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.906240+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_419149","record_id":"REC_0012169","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":16,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":4.3,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.906542+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_595831","record_id":"REC_0012170","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":13.3,"age_at_diagnosis":53,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":8.0,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.906785+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_241567","record_id":"REC_0012171","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":13.5,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":6.4,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.907018+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_752016","record_id":"REC_0012172","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":7,"primary_tumor_size_cm":5.5,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.907253+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_267732","record_id":"REC_0012173","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":30,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":6.0,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.907481+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_113126","record_id":"REC_0012174","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":8.7,"age_at_diagnosis":53,"sex":"female","ecog_performance_status":0,"smoking_pack_years":64,"primary_tumor_size_cm":3.5,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.907713+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_207227","record_id":"REC_0012175","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":12,"tmb_mutations_per_mb":3.0,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":0,"smoking_pack_years":33,"primary_tumor_size_cm":5.8,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.907948+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_847305","record_id":"REC_0012176","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":13.1,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.8,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.908210+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_356718","record_id":"REC_0012177","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":6,"primary_tumor_size_cm":5.3,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":26.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.908446+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_907526","record_id":"REC_0012178","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":5.2,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":4.7,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.908677+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_339700","record_id":"REC_0012179","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":7.9,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":5.4,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":21.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.908910+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_652323","record_id":"REC_0012180","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":76,"sex":"male","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.1,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":16.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.909154+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_742650","record_id":"REC_0012181","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":18.1,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":6.4,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.909397+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_794450","record_id":"REC_0012182","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":6.1,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":33.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.909718+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_992053","record_id":"REC_0012183","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":14.1,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":2,"primary_tumor_size_cm":5.7,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.909983+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_551509","record_id":"REC_0012184","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":14,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":3,"smoking_pack_years":19,"primary_tumor_size_cm":4.7,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.910241+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_710158","record_id":"REC_0012185","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":78,"sex":"male","ecog_performance_status":1,"smoking_pack_years":4,"primary_tumor_size_cm":6.0,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":29.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.910503+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_256469","record_id":"REC_0012186","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":2.8,"metastatic_sites_count":3,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.910748+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_462444","record_id":"REC_0012187","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":14.3,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":7.6,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.910989+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_614577","record_id":"REC_0012188","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":3.2,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":38,"primary_tumor_size_cm":5.1,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.911216+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_423272","record_id":"REC_0012189","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":13,"tmb_mutations_per_mb":8.5,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":8,"primary_tumor_size_cm":5.0,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.911446+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_166305","record_id":"REC_0012190","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":15,"tmb_mutations_per_mb":10.1,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":3,"smoking_pack_years":52,"primary_tumor_size_cm":3.1,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.911682+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_532110","record_id":"REC_0012191","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":28,"primary_tumor_size_cm":5.9,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.911915+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_279594","record_id":"REC_0012192","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":10,"primary_tumor_size_cm":5.6,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":23.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.912202+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_365145","record_id":"REC_0012193","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":34,"tmb_mutations_per_mb":16.9,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":5.8,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.912462+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_250222","record_id":"REC_0012194","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":31,"tmb_mutations_per_mb":6.9,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":4.5,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":23.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.912692+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_130389","record_id":"REC_0012195","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":5.7,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":16.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.913014+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_140277","record_id":"REC_0012196","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":4.8,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.913253+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_940507","record_id":"REC_0012197","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":16,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":7.0,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":18.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.913493+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_539518","record_id":"REC_0012198","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":5.6,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":6.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.913721+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_920811","record_id":"REC_0012199","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":0,"smoking_pack_years":72,"primary_tumor_size_cm":7.2,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.913952+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_399410","record_id":"REC_0012200","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":8.0,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":0,"smoking_pack_years":47,"primary_tumor_size_cm":8.2,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.914187+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_238550","record_id":"REC_0012201","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":7.4,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":49,"primary_tumor_size_cm":3.8,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.914417+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_970978","record_id":"REC_0012202","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":25,"primary_tumor_size_cm":6.0,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":42.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.914652+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_637582","record_id":"REC_0012203","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":31,"tmb_mutations_per_mb":19.6,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":6.7,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":18.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.914888+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_381060","record_id":"REC_0012204","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":63,"primary_tumor_size_cm":5.0,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":20.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.915116+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_953955","record_id":"REC_0012205","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":31,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":1,"smoking_pack_years":47,"primary_tumor_size_cm":6.9,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.915349+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_741256","record_id":"REC_0012206","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":6.3,"age_at_diagnosis":83,"sex":"male","ecog_performance_status":1,"smoking_pack_years":61,"primary_tumor_size_cm":5.6,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":7.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.915579+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_551931","record_id":"REC_0012207","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":1,"smoking_pack_years":2,"primary_tumor_size_cm":6.4,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.915816+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_589179","record_id":"REC_0012208","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":4.5,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":6.3,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":16.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.916191+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_855578","record_id":"REC_0012209","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":5.9,"metastatic_sites_count":8,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.916439+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_173399","record_id":"REC_0012210","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":36,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":4.0,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.916674+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_518160","record_id":"REC_0012211","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":8.7,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":5.5,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.916908+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_149366","record_id":"REC_0012212","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":2.7,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":0,"smoking_pack_years":6,"primary_tumor_size_cm":4.3,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":28.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.917140+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_799520","record_id":"REC_0012213","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":5.4,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":7.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.917373+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_545191","record_id":"REC_0012214","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":8.1,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":7.3,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.917600+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_529977","record_id":"REC_0012215","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":9.9,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":6.5,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":18.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.917831+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_755718","record_id":"REC_0012216","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":20,"tmb_mutations_per_mb":5.5,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":31,"primary_tumor_size_cm":5.3,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":7.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.918061+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_903536","record_id":"REC_0012217","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":1,"smoking_pack_years":2,"primary_tumor_size_cm":8.7,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.918301+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_881977","record_id":"REC_0012218","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":0,"smoking_pack_years":33,"primary_tumor_size_cm":7.4,"metastatic_sites_count":8,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":5.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.918538+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_537000","record_id":"REC_0012219","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":10,"primary_tumor_size_cm":4.5,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.918770+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_994924","record_id":"REC_0012220","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":5.2,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":40,"primary_tumor_size_cm":8.8,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.919001+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_751191","record_id":"REC_0012221","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":13.5,"age_at_diagnosis":81,"sex":"male","ecog_performance_status":2,"smoking_pack_years":9,"primary_tumor_size_cm":6.9,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.919283+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_569197","record_id":"REC_0012222","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":20.9,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":4.9,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":28.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.919522+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_184667","record_id":"REC_0012223","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":5.0,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.919762+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_669386","record_id":"REC_0012224","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":34,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":5.9,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":5.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.919997+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_413264","record_id":"REC_0012225","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":19.6,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":6.3,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.920258+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_121732","record_id":"REC_0012226","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":18.0,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":6.9,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.920493+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_152567","record_id":"REC_0012227","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":19,"tmb_mutations_per_mb":15.0,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.7,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.920722+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_426376","record_id":"REC_0012228","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":36,"tmb_mutations_per_mb":7.6,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":6.6,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.920947+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_727826","record_id":"REC_0012229","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":13.3,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":6.5,"metastatic_sites_count":8,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.921183+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_887603","record_id":"REC_0012230","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":6.2,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":34.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.921417+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_868564","record_id":"REC_0012231","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":17,"tmb_mutations_per_mb":7.9,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":4.7,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.921648+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_898424","record_id":"REC_0012232","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":61,"primary_tumor_size_cm":4.0,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.921879+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_593969","record_id":"REC_0012233","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":4.7,"age_at_diagnosis":74,"sex":"male","ecog_performance_status":1,"smoking_pack_years":50,"primary_tumor_size_cm":4.0,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":6.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.922117+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_721289","record_id":"REC_0012234","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":2.5,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":36,"primary_tumor_size_cm":4.4,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.922390+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_371643","record_id":"REC_0012235","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":38,"primary_tumor_size_cm":4.3,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.922626+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_685976","record_id":"REC_0012236","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":5.3,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.922861+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_210728","record_id":"REC_0012237","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":13.8,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":3,"smoking_pack_years":20,"primary_tumor_size_cm":4.7,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.923094+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_343178","record_id":"REC_0012238","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":3.9,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":16.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.923327+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_196563","record_id":"REC_0012239","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":83,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":5.5,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":25.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.923561+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_191590","record_id":"REC_0012240","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":17.4,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":3,"primary_tumor_size_cm":7.2,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":7.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.923797+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_908983","record_id":"REC_0012241","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":68,"primary_tumor_size_cm":5.0,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.924027+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_351551","record_id":"REC_0012242","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":30,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.9,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.924362+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_517048","record_id":"REC_0012243","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":13.3,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":3,"smoking_pack_years":9,"primary_tumor_size_cm":3.8,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.924605+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_413222","record_id":"REC_0012244","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":6.7,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":3.2,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.924832+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_248907","record_id":"REC_0012245","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":8.4,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":1,"smoking_pack_years":5,"primary_tumor_size_cm":6.0,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.925073+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_224848","record_id":"REC_0012246","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":9.1,"age_at_diagnosis":76,"sex":"male","ecog_performance_status":3,"smoking_pack_years":13,"primary_tumor_size_cm":4.9,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.925304+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_701720","record_id":"REC_0012247","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":4.5,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":38,"primary_tumor_size_cm":3.4,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.925577+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_326277","record_id":"REC_0012248","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":5.5,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.925817+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_678921","record_id":"REC_0012249","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":16,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":4.9,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.926052+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_795597","record_id":"REC_0012250","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":13.8,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":4.4,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.926286+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_978090","record_id":"REC_0012251","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":5.6,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":4.2,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.926517+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_454446","record_id":"REC_0012252","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":14.8,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":5.3,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.926751+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_685254","record_id":"REC_0012253","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":5.8,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":6.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.926986+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_243093","record_id":"REC_0012254","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":5.4,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.927214+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_989615","record_id":"REC_0012255","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":4.6,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":0,"smoking_pack_years":59,"primary_tumor_size_cm":7.0,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":18.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.927447+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_303141","record_id":"REC_0012256","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":8.5,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":4.2,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":17.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.927673+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_617525","record_id":"REC_0012257","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":8.4,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":5.7,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":25.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.927909+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_716900","record_id":"REC_0012258","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":4.5,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":21.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.928207+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_280775","record_id":"REC_0012259","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":30,"tmb_mutations_per_mb":6.0,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":3,"smoking_pack_years":42,"primary_tumor_size_cm":4.8,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":6.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.928445+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_165524","record_id":"REC_0012260","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":4.3,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":18.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.928731+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_621699","record_id":"REC_0012261","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":5.8,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":29.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.928968+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_406441","record_id":"REC_0012262","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":13.6,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":6.6,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":16.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.929204+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_391926","record_id":"REC_0012263","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":3.3,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":4.8,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.929437+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_137956","record_id":"REC_0012264","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":9.1,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":6.0,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":50.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.929663+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_244262","record_id":"REC_0012265","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":53,"sex":"male","ecog_performance_status":0,"smoking_pack_years":6,"primary_tumor_size_cm":6.0,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":20.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.929894+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_488032","record_id":"REC_0012266","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":56,"primary_tumor_size_cm":5.6,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":19.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.930124+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_323842","record_id":"REC_0012267","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":6.7,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":1,"smoking_pack_years":24,"primary_tumor_size_cm":4.2,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":18.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.930355+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_576160","record_id":"REC_0012268","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":4.0,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.930583+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_928642","record_id":"REC_0012269","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":8.7,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":4.9,"metastatic_sites_count":3,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.930811+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_168952","record_id":"REC_0012270","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":6.9,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":2.0,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":6.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.931042+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_755312","record_id":"REC_0012271","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":6.9,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.931273+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_899357","record_id":"REC_0012272","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.0,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":7.7,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":23.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.931508+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_620822","record_id":"REC_0012273","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.6,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.931786+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_664401","record_id":"REC_0012274","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":19,"tmb_mutations_per_mb":8.9,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":5.1,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.932023+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_244660","record_id":"REC_0012275","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":9.8,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":2,"smoking_pack_years":23,"primary_tumor_size_cm":3.1,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.932284+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_169340","record_id":"REC_0012276","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":9.5,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":4.5,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.932520+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_833341","record_id":"REC_0012277","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":17.3,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":5.9,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":7.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.932755+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_396987","record_id":"REC_0012278","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ALK fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":5.9,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":30.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.932984+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_853915","record_id":"REC_0012279","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":15.0,"age_at_diagnosis":81,"sex":"male","ecog_performance_status":1,"smoking_pack_years":28,"primary_tumor_size_cm":6.0,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":22.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.933220+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_824497","record_id":"REC_0012280","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":16.6,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":3.9,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":23.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.933449+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_494835","record_id":"REC_0012281","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":14.8,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":6.4,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.933686+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_809243","record_id":"REC_0012282","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":6.2,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.933915+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_492563","record_id":"REC_0012283","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":20,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":32,"primary_tumor_size_cm":3.6,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.934144+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_361279","record_id":"REC_0012284","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":24,"primary_tumor_size_cm":6.5,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.934381+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_124494","record_id":"REC_0012285","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":7.3,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":50,"primary_tumor_size_cm":6.1,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.934614+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_647935","record_id":"REC_0012286","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":30,"tmb_mutations_per_mb":14.1,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":6.5,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.934893+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_305122","record_id":"REC_0012287","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":18.5,"age_at_diagnosis":51,"sex":"male","ecog_performance_status":0,"smoking_pack_years":5,"primary_tumor_size_cm":6.4,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.935131+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_506365","record_id":"REC_0012288","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":44,"primary_tumor_size_cm":4.7,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":6.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.935361+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_878414","record_id":"REC_0012289","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":7.5,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":17.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.935591+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_981635","record_id":"REC_0012290","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":34,"tmb_mutations_per_mb":13.3,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":6.1,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.935829+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_637015","record_id":"REC_0012291","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":8.9,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":5.6,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.936059+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_167918","record_id":"REC_0012292","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":8.9,"age_at_diagnosis":52,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":5.6,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":17.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.936416+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_933931","record_id":"REC_0012293","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":15.1,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":7.9,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.936657+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_442745","record_id":"REC_0012294","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":41,"tmb_mutations_per_mb":11.1,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":20,"primary_tumor_size_cm":3.8,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.936888+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_998420","record_id":"REC_0012295","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":17.4,"age_at_diagnosis":86,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":6.6,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.937124+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_886633","record_id":"REC_0012296","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":6.0,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.937352+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_906684","record_id":"REC_0012297","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":4.8,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.937584+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_870349","record_id":"REC_0012298","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":7.4,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":3,"smoking_pack_years":36,"primary_tumor_size_cm":6.5,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.937810+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_168533","record_id":"REC_0012299","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":5.2,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":5.0,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.938087+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_483252","record_id":"REC_0012300","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":9.7,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":3.0,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.938316+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_267662","record_id":"REC_0012301","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":16.5,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":2,"smoking_pack_years":8,"primary_tumor_size_cm":5.1,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.938547+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_174001","record_id":"REC_0012302","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":16.6,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":6.0,"metastatic_sites_count":8,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.938779+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_528925","record_id":"REC_0012303","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":5.5,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":5.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.939012+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_616212","record_id":"REC_0012304","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":17.9,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":5.0,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.939248+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_450668","record_id":"REC_0012305","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":32,"tmb_mutations_per_mb":4.3,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":0,"smoking_pack_years":28,"primary_tumor_size_cm":4.0,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.939482+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_926264","record_id":"REC_0012306","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":36,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":5.6,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":24.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.939712+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_112389","record_id":"REC_0012307","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":10.1,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":6.1,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.939951+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_982058","record_id":"REC_0012308","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":14.8,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":5.7,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.940235+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_457915","record_id":"REC_0012309","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":6.0,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":23,"primary_tumor_size_cm":4.4,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.940491+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_747191","record_id":"REC_0012310","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":7.6,"age_at_diagnosis":79,"sex":"male","ecog_performance_status":1,"smoking_pack_years":24,"primary_tumor_size_cm":6.2,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.940747+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_955531","record_id":"REC_0012311","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":2,"smoking_pack_years":50,"primary_tumor_size_cm":4.3,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":27.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.941010+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_590925","record_id":"REC_0012312","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":15.6,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":2,"primary_tumor_size_cm":6.1,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.941386+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_971395","record_id":"REC_0012313","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":8.5,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":4.6,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.941650+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_141781","record_id":"REC_0012314","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":16.6,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":4.9,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.941900+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_566823","record_id":"REC_0012315","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":15,"tmb_mutations_per_mb":10.0,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":6.0,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.942150+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_506049","record_id":"REC_0012316","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":5.2,"age_at_diagnosis":50,"sex":"female","ecog_performance_status":0,"smoking_pack_years":39,"primary_tumor_size_cm":3.9,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.942381+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_536063","record_id":"REC_0012317","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":10,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":5.6,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.942620+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_971437","record_id":"REC_0012318","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":31,"tmb_mutations_per_mb":4.8,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":2,"smoking_pack_years":41,"primary_tumor_size_cm":4.8,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":21.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.942854+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_227024","record_id":"REC_0012319","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":19,"tmb_mutations_per_mb":17.6,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":5.0,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":22.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.943090+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_778109","record_id":"REC_0012320","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":2.1,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":27,"primary_tumor_size_cm":5.5,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":16.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.943321+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_763621","record_id":"REC_0012321","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":17.2,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":5.5,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.943557+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_138995","record_id":"REC_0012322","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":16.0,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":0,"primary_tumor_size_cm":6.1,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":24.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.943793+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_757297","record_id":"REC_0012323","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":3.8,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":6.2,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.944023+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_501651","record_id":"REC_0012324","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":14.8,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":6.1,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.944305+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_406471","record_id":"REC_0012325","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":19,"tmb_mutations_per_mb":6.3,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":84,"primary_tumor_size_cm":3.6,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":23.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.944615+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_785490","record_id":"REC_0012326","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":5.5,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":6.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.944852+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_559912","record_id":"REC_0012327","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":7.1,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":6.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.945082+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_466060","record_id":"REC_0012328","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":17.8,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":5.4,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":30.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.945316+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_513448","record_id":"REC_0012329","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":52,"primary_tumor_size_cm":6.5,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.945554+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_752490","record_id":"REC_0012330","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":76,"sex":"male","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":4.8,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.945791+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_212512","record_id":"REC_0012331","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":8.4,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":6.3,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.946024+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_268827","record_id":"REC_0012332","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":13,"tmb_mutations_per_mb":14.5,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":4.0,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.946255+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_112527","record_id":"REC_0012333","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":24,"primary_tumor_size_cm":5.2,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":52.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.946490+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_276777","record_id":"REC_0012334","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":25,"primary_tumor_size_cm":4.6,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.946723+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_268995","record_id":"REC_0012335","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":19,"tmb_mutations_per_mb":4.2,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":1,"smoking_pack_years":36,"primary_tumor_size_cm":5.1,"metastatic_sites_count":8,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":17.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.946954+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_935567","record_id":"REC_0012336","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":8.9,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":6.2,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.947183+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_670744","record_id":"REC_0012337","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":5.7,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.947415+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_445914","record_id":"REC_0012338","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":53,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":5.3,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":22.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.947692+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_815533","record_id":"REC_0012339","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":7.0,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.947927+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_208935","record_id":"REC_0012340","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":11.1,"age_at_diagnosis":75,"sex":"male","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":4.2,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.948213+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_911433","record_id":"REC_0012341","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":16.2,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":4.7,"metastatic_sites_count":3,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.948468+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_787886","record_id":"REC_0012342","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":15.3,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":4.5,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.948713+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_170565","record_id":"REC_0012343","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":16.3,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":5.6,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.948960+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_598171","record_id":"REC_0012344","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":17.0,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":4.0,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":20.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.949216+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_524661","record_id":"REC_0012345","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":77,"sex":"male","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":5.6,"metastatic_sites_count":8,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":6.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.949463+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_310379","record_id":"REC_0012346","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":20.1,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":6.2,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":48.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.949707+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_677990","record_id":"REC_0012347","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":6.7,"age_at_diagnosis":47,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":5.2,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.949946+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_750316","record_id":"REC_0012348","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":10.0,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":3,"smoking_pack_years":19,"primary_tumor_size_cm":5.6,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":4.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.950184+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_535726","record_id":"REC_0012349","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":5.9,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.950423+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_756779","record_id":"REC_0012350","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":15,"tmb_mutations_per_mb":5.7,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":51,"primary_tumor_size_cm":5.0,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":22.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.950662+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_795136","record_id":"REC_0012351","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":6.4,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":6.8,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.951056+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_976704","record_id":"REC_0012352","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":30,"tmb_mutations_per_mb":7.9,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":53,"primary_tumor_size_cm":6.2,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.951355+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_181360","record_id":"REC_0012353","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":8.4,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":9.1,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":22.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.951650+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_387569","record_id":"REC_0012354","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":9.0,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":4.1,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.951943+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_405524","record_id":"REC_0012355","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":4.4,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":1,"smoking_pack_years":54,"primary_tumor_size_cm":6.4,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.952320+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_876459","record_id":"REC_0012356","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":15.8,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":6.4,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":4.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.952662+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_444076","record_id":"REC_0012357","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":80,"sex":"male","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":5.8,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.952981+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_139904","record_id":"REC_0012358","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":3,"smoking_pack_years":9,"primary_tumor_size_cm":4.7,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.953288+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_253456","record_id":"REC_0012359","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":3.1,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.953590+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_115161","record_id":"REC_0012360","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":6.4,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":19.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.953862+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_689803","record_id":"REC_0012361","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":20,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":2,"smoking_pack_years":20,"primary_tumor_size_cm":4.3,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":21.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.954119+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_746542","record_id":"REC_0012362","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":6.0,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.954404+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_739834","record_id":"REC_0012363","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":20,"primary_tumor_size_cm":6.8,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":19.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.954655+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_821924","record_id":"REC_0012364","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":18.9,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":6.1,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":20.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.955034+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_494899","record_id":"REC_0012365","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":20,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":86,"sex":"female","ecog_performance_status":1,"smoking_pack_years":41,"primary_tumor_size_cm":4.3,"metastatic_sites_count":3,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.955315+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_888021","record_id":"REC_0012366","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":22.5,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":4.6,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.955573+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_593946","record_id":"REC_0012367","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":31,"tmb_mutations_per_mb":16.6,"age_at_diagnosis":49,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":5.2,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":6.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.955832+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_656215","record_id":"REC_0012368","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":6.3,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":1,"smoking_pack_years":1,"primary_tumor_size_cm":4.6,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.956151+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_751236","record_id":"REC_0012369","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":32,"tmb_mutations_per_mb":3.4,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":6.4,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.956429+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_389625","record_id":"REC_0012370","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":15.6,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":4.8,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.956698+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_324191","record_id":"REC_0012371","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":16.1,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":5.8,"metastatic_sites_count":8,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.956963+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_854111","record_id":"REC_0012372","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":20,"tmb_mutations_per_mb":2.5,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":49,"primary_tumor_size_cm":5.4,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":7.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.957231+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_674159","record_id":"REC_0012373","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":14.4,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":6.2,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":7.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.957495+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_487025","record_id":"REC_0012374","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":2,"smoking_pack_years":1,"primary_tumor_size_cm":5.2,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.957748+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_896357","record_id":"REC_0012375","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":15.9,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":29,"primary_tumor_size_cm":4.8,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":8.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.958006+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_693307","record_id":"REC_0012376","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":5.5,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":8,"primary_tumor_size_cm":6.1,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.958252+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_376692","record_id":"REC_0012377","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":19,"tmb_mutations_per_mb":14.9,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":4.4,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.958644+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_713561","record_id":"REC_0012378","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.3,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":17.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.958901+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_434735","record_id":"REC_0012379","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":67,"primary_tumor_size_cm":4.5,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":28.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.959152+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_660078","record_id":"REC_0012380","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":52,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":4.3,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.959409+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_987211","record_id":"REC_0012381","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":14.4,"age_at_diagnosis":53,"sex":"female","ecog_performance_status":0,"smoking_pack_years":4,"primary_tumor_size_cm":5.8,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.959652+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_539412","record_id":"REC_0012382","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":20,"tmb_mutations_per_mb":5.6,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":37,"primary_tumor_size_cm":5.0,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.959887+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_807715","record_id":"REC_0012383","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":11.5,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":6.5,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":17.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.960253+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_176044","record_id":"REC_0012384","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":17,"tmb_mutations_per_mb":6.4,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":4.3,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":19.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.960511+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_849240","record_id":"REC_0012385","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":13.8,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":6,"primary_tumor_size_cm":4.8,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.960752+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_876726","record_id":"REC_0012386","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":5.4,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":45.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.960994+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_559512","record_id":"REC_0012387","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":5.3,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.961228+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_470001","record_id":"REC_0012388","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":7.5,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.961457+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_664555","record_id":"REC_0012389","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":6.3,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":4,"primary_tumor_size_cm":6.1,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":18.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.961692+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_179247","record_id":"REC_0012390","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":4.6,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.962043+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_123659","record_id":"REC_0012391","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":11.0,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":5.1,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.962314+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_335632","record_id":"REC_0012392","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":14.7,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":3.6,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.962556+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_651629","record_id":"REC_0012393","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":8.7,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":7.0,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.962793+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_645514","record_id":"REC_0012394","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":7.6,"age_at_diagnosis":47,"sex":"female","ecog_performance_status":0,"smoking_pack_years":62,"primary_tumor_size_cm":5.1,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.963025+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_355500","record_id":"REC_0012395","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":4.3,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":17.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.963264+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_304260","record_id":"REC_0012396","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":9.5,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":5.3,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.963497+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_371073","record_id":"REC_0012397","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":11.0,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":5.1,"metastatic_sites_count":8,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.963733+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_840959","record_id":"REC_0012398","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":4.5,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.963965+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_381830","record_id":"REC_0012399","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":1,"smoking_pack_years":41,"primary_tumor_size_cm":5.1,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":34.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.964249+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_563896","record_id":"REC_0012400","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":3.5,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":17.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.964489+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_983699","record_id":"REC_0012401","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":8.3,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":5.8,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":35.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.964728+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_590483","record_id":"REC_0012402","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":5.9,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":4.5,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":7.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.964967+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_992458","record_id":"REC_0012403","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":14.0,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":6.0,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":5.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.965311+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_660553","record_id":"REC_0012404","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":5.8,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.965596+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_889962","record_id":"REC_0012405","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":9.0,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":25,"primary_tumor_size_cm":5.0,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.965841+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_503411","record_id":"REC_0012406","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":9.1,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":5,"primary_tumor_size_cm":6.3,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.966089+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_466682","record_id":"REC_0012407","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":13.1,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":6.2,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":18.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.966354+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_422771","record_id":"REC_0012408","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":13.6,"age_at_diagnosis":53,"sex":"female","ecog_performance_status":0,"smoking_pack_years":0,"primary_tumor_size_cm":6.1,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":28.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.966609+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_716443","record_id":"REC_0012409","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":7.2,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":17.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.966878+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_358458","record_id":"REC_0012410","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":5.8,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":21.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.967151+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_878312","record_id":"REC_0012411","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":16.2,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":5.1,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":21.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.967429+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_554841","record_id":"REC_0012412","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":15.3,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":6.4,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.967720+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_508266","record_id":"REC_0012413","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":11.1,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":4.3,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.968042+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_271960","record_id":"REC_0012414","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":14.3,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":4,"smoking_pack_years":15,"primary_tumor_size_cm":4.3,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.968413+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_695521","record_id":"REC_0012415","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":8.9,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":2,"primary_tumor_size_cm":7.1,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.968739+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_548167","record_id":"REC_0012416","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":4.2,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":2,"smoking_pack_years":33,"primary_tumor_size_cm":5.8,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.969222+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_725950","record_id":"REC_0012417","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":5.7,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.969590+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_133830","record_id":"REC_0012418","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":2,"smoking_pack_years":70,"primary_tumor_size_cm":7.2,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":20.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.969878+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_672045","record_id":"REC_0012419","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":16.2,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":4.1,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.970183+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_865169","record_id":"REC_0012420","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":6.0,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":26,"primary_tumor_size_cm":7.7,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":27.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.970480+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_434268","record_id":"REC_0012421","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":2.1,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":21.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.970780+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_915630","record_id":"REC_0012422","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":5.7,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":46.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.971078+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_646405","record_id":"REC_0012423","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":6.8,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.971376+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_884715","record_id":"REC_0012424","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":15.3,"age_at_diagnosis":53,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":7.4,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.971654+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_949610","record_id":"REC_0012425","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":4.6,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":59,"primary_tumor_size_cm":8.1,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":17.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.971938+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_995069","record_id":"REC_0012426","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":15.7,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.3,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":6.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.972374+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_352615","record_id":"REC_0012427","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":1.5,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":5.2,"metastatic_sites_count":3,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.972705+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_839007","record_id":"REC_0012428","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":4.9,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":22.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.973029+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_367868","record_id":"REC_0012429","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":14.8,"age_at_diagnosis":51,"sex":"male","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":4.9,"metastatic_sites_count":3,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.973475+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_677435","record_id":"REC_0012430","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":4.2,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":47,"primary_tumor_size_cm":6.4,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.973810+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_661587","record_id":"REC_0012431","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":4.4,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":18.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.974119+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_325010","record_id":"REC_0012432","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":3.9,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.974422+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_252812","record_id":"REC_0012433","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":13.8,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":5.2,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.974718+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_626240","record_id":"REC_0012434","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":15.3,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":5.0,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":47.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.975009+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_517518","record_id":"REC_0012435","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":7.0,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.975305+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_367321","record_id":"REC_0012436","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":27,"primary_tumor_size_cm":5.8,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":22.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.975608+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_572588","record_id":"REC_0012437","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":6.4,"metastatic_sites_count":3,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":17.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.975900+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_440277","record_id":"REC_0012438","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":40,"primary_tumor_size_cm":5.7,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":6.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.976261+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_730761","record_id":"REC_0012439","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":3.6,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":1,"smoking_pack_years":64,"primary_tumor_size_cm":6.2,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.976572+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_768329","record_id":"REC_0012440","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":35,"tmb_mutations_per_mb":15.2,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":4.9,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.976882+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_415464","record_id":"REC_0012441","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":1.5,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":5.8,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.977183+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_545279","record_id":"REC_0012442","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":13.1,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":5.4,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.977661+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_190812","record_id":"REC_0012443","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":53,"sex":"male","ecog_performance_status":0,"smoking_pack_years":55,"primary_tumor_size_cm":7.6,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":19.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.978017+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_763049","record_id":"REC_0012444","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":5.1,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":1,"smoking_pack_years":47,"primary_tumor_size_cm":4.2,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.978385+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_456490","record_id":"REC_0012445","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":15.9,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":7.0,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.978836+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_579076","record_id":"REC_0012446","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":19.0,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":5.4,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.979197+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_849575","record_id":"REC_0012447","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":13.8,"age_at_diagnosis":53,"sex":"male","ecog_performance_status":0,"smoking_pack_years":4,"primary_tumor_size_cm":7.2,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":8.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.979535+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_898512","record_id":"REC_0012448","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":6.4,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":5.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.979886+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_692312","record_id":"REC_0012449","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":17,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":3,"smoking_pack_years":20,"primary_tumor_size_cm":6.8,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.980338+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_679241","record_id":"REC_0012450","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":19.3,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":4.0,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.980756+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_948914","record_id":"REC_0012451","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":20,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":3,"smoking_pack_years":54,"primary_tumor_size_cm":5.1,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":6.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.981146+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_594385","record_id":"REC_0012452","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":8.0,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":7.5,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.981523+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_107069","record_id":"REC_0012453","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":6.0,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.981891+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_186191","record_id":"REC_0012454","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":19,"tmb_mutations_per_mb":6.4,"age_at_diagnosis":87,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":4.6,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.982297+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_322550","record_id":"REC_0012455","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":8.0,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":1,"smoking_pack_years":4,"primary_tumor_size_cm":6.0,"metastatic_sites_count":8,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":16.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.982821+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_116979","record_id":"REC_0012456","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":14.3,"age_at_diagnosis":90,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":4.3,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":29.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.983249+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_621476","record_id":"REC_0012457","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":2.6,"age_at_diagnosis":85,"sex":"male","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":5.0,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.983630+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_933335","record_id":"REC_0012458","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":8.1,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":1,"smoking_pack_years":40,"primary_tumor_size_cm":2.0,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.983999+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_819129","record_id":"REC_0012459","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":0,"smoking_pack_years":3,"primary_tumor_size_cm":4.9,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.984429+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_317386","record_id":"REC_0012460","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":4.1,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.984783+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_464115","record_id":"REC_0012461","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":4.6,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":22.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.985120+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_223204","record_id":"REC_0012462","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":18,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":4.1,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.985478+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_979970","record_id":"REC_0012463","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":30,"tmb_mutations_per_mb":15.2,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":3,"smoking_pack_years":16,"primary_tumor_size_cm":3.4,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.985821+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_366915","record_id":"REC_0012464","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":16.4,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":3.6,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":17.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.986165+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_682660","record_id":"REC_0012465","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":4,"primary_tumor_size_cm":5.0,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.986475+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_697061","record_id":"REC_0012466","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":16.4,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":7.0,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.986798+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_429631","record_id":"REC_0012467","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":5.3,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":4.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.987111+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_396815","record_id":"REC_0012468","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":13.5,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":6.3,"metastatic_sites_count":10,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.987565+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_925254","record_id":"REC_0012469","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":11.1,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":5.0,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":22.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.987936+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_104084","record_id":"REC_0012470","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":7.3,"age_at_diagnosis":77,"sex":"male","ecog_performance_status":2,"smoking_pack_years":37,"primary_tumor_size_cm":5.9,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":45.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.988410+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_299835","record_id":"REC_0012471","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":7.0,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.988803+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_450750","record_id":"REC_0012472","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":5.8,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.989172+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_670876","record_id":"REC_0012473","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":6.0,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":39,"primary_tumor_size_cm":4.3,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.989554+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_198696","record_id":"REC_0012474","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":2,"smoking_pack_years":10,"primary_tumor_size_cm":3.8,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.989923+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_151506","record_id":"REC_0012475","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":30,"tmb_mutations_per_mb":5.3,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":6.8,"metastatic_sites_count":3,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.990294+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_886919","record_id":"REC_0012476","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":22,"primary_tumor_size_cm":4.4,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.990616+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_277211","record_id":"REC_0012477","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":16.1,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":22,"primary_tumor_size_cm":5.8,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.990942+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_419318","record_id":"REC_0012478","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":15.7,"age_at_diagnosis":54,"sex":"female","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":6.9,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.991249+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_407798","record_id":"REC_0012479","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":15.5,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":3,"smoking_pack_years":17,"primary_tumor_size_cm":4.8,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.991559+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_497845","record_id":"REC_0012480","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":2.3,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":45,"primary_tumor_size_cm":2.7,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":26.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.991863+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_893115","record_id":"REC_0012481","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":6.6,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:35:59.992529+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_673145","record_id":"REC_0012482","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":9.0,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":2.9,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.992926+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_482003","record_id":"REC_0012483","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":5.2,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":20.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.993247+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_145462","record_id":"REC_0012484","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":8.4,"age_at_diagnosis":53,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":6.3,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.993552+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_122845","record_id":"REC_0012485","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":4.7,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":55,"primary_tumor_size_cm":5.3,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":19.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.993855+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_280577","record_id":"REC_0012486","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":16,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":6.3,"metastatic_sites_count":3,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.994178+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_428496","record_id":"REC_0012487","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":4.7,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":5.6,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.994497+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_271472","record_id":"REC_0012488","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":19.2,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.4,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.994820+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_602556","record_id":"REC_0012489","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":75,"sex":"male","ecog_performance_status":1,"smoking_pack_years":0,"primary_tumor_size_cm":5.9,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":20.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.995141+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_404058","record_id":"REC_0012490","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":5.6,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":5.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.995453+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_382109","record_id":"REC_0012491","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":5.9,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":51,"primary_tumor_size_cm":7.2,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":22.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.995753+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_852637","record_id":"REC_0012492","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":16.9,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":10,"primary_tumor_size_cm":6.8,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":16.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.996057+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_623494","record_id":"REC_0012493","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":20,"tmb_mutations_per_mb":5.7,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":7.1,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":26.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.996584+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_447894","record_id":"REC_0012494","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":37,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":5.3,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.997180+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_143939","record_id":"REC_0012495","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":0,"smoking_pack_years":45,"primary_tumor_size_cm":5.9,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.997607+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_300674","record_id":"REC_0012496","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":5.4,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.997992+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_910591","record_id":"REC_0012497","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":6.4,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":2,"smoking_pack_years":24,"primary_tumor_size_cm":4.1,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":19.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.998368+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_444742","record_id":"REC_0012498","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":7.6,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":2,"smoking_pack_years":7,"primary_tumor_size_cm":4.6,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.998720+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_376691","record_id":"REC_0012499","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":5.5,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.999053+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_365877","record_id":"REC_0012500","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":6.1,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":3,"primary_tumor_size_cm":4.0,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":19.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.999377+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_186397","record_id":"REC_0012501","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":30,"tmb_mutations_per_mb":9.9,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":5.7,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":19.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:35:59.999707+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_958706","record_id":"REC_0012502","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":19.9,"age_at_diagnosis":83,"sex":"female","ecog_performance_status":2,"smoking_pack_years":10,"primary_tumor_size_cm":6.9,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":34.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.000028+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_855091","record_id":"REC_0012503","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":4.6,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":16.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.000469+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_141973","record_id":"REC_0012504","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":9.8,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":6.5,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.000868+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_959337","record_id":"REC_0012505","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":8.0,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":4.9,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.001231+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_506088","record_id":"REC_0012506","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":5.0,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":26.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.001554+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_954612","record_id":"REC_0012507","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":15.6,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":3,"smoking_pack_years":21,"primary_tumor_size_cm":5.5,"metastatic_sites_count":3,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":7.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.002048+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_709278","record_id":"REC_0012508","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":35,"primary_tumor_size_cm":4.8,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":7.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.002412+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_223435","record_id":"REC_0012509","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":7.2,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.002733+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_915827","record_id":"REC_0012510","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":5.4,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.003063+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_752725","record_id":"REC_0012511","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":16,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":24,"primary_tumor_size_cm":5.1,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.003401+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_360206","record_id":"REC_0012512","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":5.6,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.003715+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_132778","record_id":"REC_0012513","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":3.7,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":19.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.004047+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_417019","record_id":"REC_0012514","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":15.5,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":6.2,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.004546+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_174087","record_id":"REC_0012515","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.1,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":5.3,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":40.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.004913+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_796463","record_id":"REC_0012516","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":15.2,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":25,"primary_tumor_size_cm":7.8,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.005248+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_970857","record_id":"REC_0012517","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":20,"primary_tumor_size_cm":4.0,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.005585+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_922892","record_id":"REC_0012518","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":16.7,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":7.6,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.005919+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_466581","record_id":"REC_0012519","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":6.4,"age_at_diagnosis":78,"sex":"male","ecog_performance_status":3,"smoking_pack_years":60,"primary_tumor_size_cm":6.6,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":20.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.006239+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_939188","record_id":"REC_0012520","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":8.1,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":1,"smoking_pack_years":70,"primary_tumor_size_cm":6.6,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":16.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.006732+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_951362","record_id":"REC_0012521","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":6.9,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":40,"primary_tumor_size_cm":3.3,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.007102+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_750347","record_id":"REC_0012522","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":8.9,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":6.4,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.007447+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_691119","record_id":"REC_0012523","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":6.7,"age_at_diagnosis":48,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":3.5,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.007772+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_435974","record_id":"REC_0012524","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":14.9,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":5.2,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.008153+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_735114","record_id":"REC_0012525","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":28,"primary_tumor_size_cm":7.4,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.008522+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_245929","record_id":"REC_0012526","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":0,"smoking_pack_years":5,"primary_tumor_size_cm":8.2,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.008862+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_826004","record_id":"REC_0012527","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":16.8,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":4.4,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.009199+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_517822","record_id":"REC_0012528","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":6.0,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.009530+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_610292","record_id":"REC_0012529","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":77,"sex":"male","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":5.2,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.009852+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_526375","record_id":"REC_0012530","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":20,"tmb_mutations_per_mb":5.1,"age_at_diagnosis":52,"sex":"female","ecog_performance_status":0,"smoking_pack_years":41,"primary_tumor_size_cm":3.7,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.010194+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_986952","record_id":"REC_0012531","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":3.8,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.010536+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_846381","record_id":"REC_0012532","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":0,"smoking_pack_years":5,"primary_tumor_size_cm":6.1,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.010869+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_622629","record_id":"REC_0012533","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":18.4,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":4,"smoking_pack_years":14,"primary_tumor_size_cm":7.1,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":20.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.011430+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_809128","record_id":"REC_0012534","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":5.6,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":4.1,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.011795+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_712575","record_id":"REC_0012535","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":31,"tmb_mutations_per_mb":4.4,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":6.4,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":7.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.012199+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_653716","record_id":"REC_0012536","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":5.5,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":5.0,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.012613+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_546325","record_id":"REC_0012537","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":5.6,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.012959+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_794847","record_id":"REC_0012538","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":6,"primary_tumor_size_cm":6.5,"metastatic_sites_count":8,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.013308+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_463357","record_id":"REC_0012539","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":4.3,"age_at_diagnosis":84,"sex":"female","ecog_performance_status":2,"smoking_pack_years":63,"primary_tumor_size_cm":5.6,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":6.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.013682+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_392519","record_id":"REC_0012540","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":6.9,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.014052+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_862177","record_id":"REC_0012541","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":20,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":38,"primary_tumor_size_cm":3.7,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.014414+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_878379","record_id":"REC_0012542","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":9.0,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":2,"smoking_pack_years":27,"primary_tumor_size_cm":8.7,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":22.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.014785+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_534232","record_id":"REC_0012543","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":5.0,"metastatic_sites_count":3,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.015186+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_407938","record_id":"REC_0012544","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":15.7,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":6.2,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.015592+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_890179","record_id":"REC_0012545","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":6.3,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":4.4,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":26.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.015946+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_302859","record_id":"REC_0012546","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":8.5,"age_at_diagnosis":81,"sex":"male","ecog_performance_status":1,"smoking_pack_years":0,"primary_tumor_size_cm":6.8,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.016584+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_221027","record_id":"REC_0012547","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":18,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":5.1,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":16.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.017018+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_190496","record_id":"REC_0012548","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":5.5,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":31.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.017415+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_167079","record_id":"REC_0012549","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":34,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":1,"primary_tumor_size_cm":3.0,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.017799+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_183009","record_id":"REC_0012550","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":14.1,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":5,"primary_tumor_size_cm":4.6,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.018174+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_882667","record_id":"REC_0012551","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":17.4,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":4.5,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.018543+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_640847","record_id":"REC_0012552","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":3.7,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.018914+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_543454","record_id":"REC_0012553","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":20,"tmb_mutations_per_mb":4.8,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":0,"smoking_pack_years":48,"primary_tumor_size_cm":3.9,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.019286+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_256383","record_id":"REC_0012554","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":7.8,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.019660+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_403630","record_id":"REC_0012555","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":1,"smoking_pack_years":1,"primary_tumor_size_cm":4.4,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.020034+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_324406","record_id":"REC_0012556","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":4.6,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":0,"smoking_pack_years":35,"primary_tumor_size_cm":7.8,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":16.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.020884+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_377576","record_id":"REC_0012557","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":6.4,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.021317+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_543424","record_id":"REC_0012558","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":8.0,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":5.6,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.021675+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_664670","record_id":"REC_0012559","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":1,"smoking_pack_years":38,"primary_tumor_size_cm":5.5,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.022256+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_987361","record_id":"REC_0012560","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":1,"smoking_pack_years":40,"primary_tumor_size_cm":7.3,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.022682+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_379425","record_id":"REC_0012561","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":2.6,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.023070+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_951193","record_id":"REC_0012562","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":33,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":6.2,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.023472+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_122452","record_id":"REC_0012563","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":15,"tmb_mutations_per_mb":4.7,"age_at_diagnosis":53,"sex":"male","ecog_performance_status":0,"smoking_pack_years":30,"primary_tumor_size_cm":5.2,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":18.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.025679+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_655606","record_id":"REC_0012564","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":17.9,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":25,"primary_tumor_size_cm":5.2,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":4.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.026147+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_239944","record_id":"REC_0012565","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":6.6,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":22.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.026512+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_299201","record_id":"REC_0012566","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":2.5,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":58,"primary_tumor_size_cm":6.1,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.026822+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_314995","record_id":"REC_0012567","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":10.0,"age_at_diagnosis":74,"sex":"male","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":4.6,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.027143+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_319815","record_id":"REC_0012568","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":14.1,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":3,"smoking_pack_years":19,"primary_tumor_size_cm":5.4,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.027472+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_415993","record_id":"REC_0012569","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":7.5,"metastatic_sites_count":9,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.027804+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_620212","record_id":"REC_0012570","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":6.3,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":6.2,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.028214+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_550333","record_id":"REC_0012571","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":14.5,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":2,"smoking_pack_years":4,"primary_tumor_size_cm":6.0,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":22.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.028633+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_650506","record_id":"REC_0012572","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":5.9,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":43,"primary_tumor_size_cm":7.7,"metastatic_sites_count":9,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.029193+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_399834","record_id":"REC_0012573","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":5.6,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.029568+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_399295","record_id":"REC_0012574","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":31,"tmb_mutations_per_mb":4.7,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":57,"primary_tumor_size_cm":8.1,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":17.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.029879+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_971994","record_id":"REC_0012575","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":33,"tmb_mutations_per_mb":5.5,"age_at_diagnosis":89,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":3.8,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":7.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.030235+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_314487","record_id":"REC_0012576","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":6.2,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":22.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.030614+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_947828","record_id":"REC_0012577","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":5.1,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":29.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.030965+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_118606","record_id":"REC_0012578","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":5.9,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.031344+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_559348","record_id":"REC_0012579","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":35,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":1,"smoking_pack_years":2,"primary_tumor_size_cm":6.6,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.031721+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_516302","record_id":"REC_0012580","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":10.1,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":2,"smoking_pack_years":24,"primary_tumor_size_cm":7.9,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.032576+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_558940","record_id":"REC_0012581","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":20,"tmb_mutations_per_mb":9.8,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":6.2,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":38.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.033080+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_791084","record_id":"REC_0012582","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":15.8,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":4.8,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.033436+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_457183","record_id":"REC_0012583","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":14,"tmb_mutations_per_mb":5.2,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":45,"primary_tumor_size_cm":5.3,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.033775+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_382347","record_id":"REC_0012584","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":21,"primary_tumor_size_cm":4.9,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.034115+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_122855","record_id":"REC_0012585","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":1,"smoking_pack_years":30,"primary_tumor_size_cm":7.7,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.034643+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_312928","record_id":"REC_0012586","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":9.5,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":5,"primary_tumor_size_cm":4.2,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":27.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.035032+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_774939","record_id":"REC_0012587","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":30,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":2.4,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":27.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.035371+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_988489","record_id":"REC_0012588","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":4.7,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.035692+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_980030","record_id":"REC_0012589","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":17.6,"age_at_diagnosis":90,"sex":"male","ecog_performance_status":2,"smoking_pack_years":22,"primary_tumor_size_cm":6.4,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.036003+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_155709","record_id":"REC_0012590","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":5.5,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":19.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.036513+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_153742","record_id":"REC_0012591","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":8.9,"age_at_diagnosis":84,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":6.8,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.036882+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_408244","record_id":"REC_0012592","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":4.2,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.037249+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_359829","record_id":"REC_0012593","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":15,"tmb_mutations_per_mb":13.3,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":1,"smoking_pack_years":5,"primary_tumor_size_cm":6.8,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.037651+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_366127","record_id":"REC_0012594","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":87,"sex":"male","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":6.2,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":22.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.038042+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_880364","record_id":"REC_0012595","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":17.9,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":4.5,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":16.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.038416+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_554480","record_id":"REC_0012596","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":4.8,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":6.1,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":20.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.038769+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_719826","record_id":"REC_0012597","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":27,"primary_tumor_size_cm":7.0,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":24.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.039143+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_790597","record_id":"REC_0012598","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":13.1,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":9,"primary_tumor_size_cm":7.4,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":22.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.039704+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_758762","record_id":"REC_0012599","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":6.2,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":20.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.040208+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_623014","record_id":"REC_0012600","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":6.7,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":66,"primary_tumor_size_cm":4.1,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":16.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.040643+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_181810","record_id":"REC_0012601","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":8.0,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":4.1,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.041040+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_144313","record_id":"REC_0012602","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":19,"tmb_mutations_per_mb":6.3,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":71,"primary_tumor_size_cm":6.4,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":24.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.041429+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_881385","record_id":"REC_0012603","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":15.3,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":4.7,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":21.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.041817+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_499279","record_id":"REC_0012604","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":6.9,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.044371+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_979276","record_id":"REC_0012605","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":11,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":4.9,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.044889+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_121238","record_id":"REC_0012606","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":10.5,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":6.5,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.045270+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_847025","record_id":"REC_0012607","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":8.5,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":5.6,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.045618+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_360365","record_id":"REC_0012608","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":16,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":2,"primary_tumor_size_cm":6.1,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":6.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.045970+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_227836","record_id":"REC_0012609","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":11.5,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":5.6,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":21.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.046317+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_629932","record_id":"REC_0012610","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":5.3,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.046664+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_791330","record_id":"REC_0012611","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":6.2,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":25.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.047191+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_265138","record_id":"REC_0012612","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":5.1,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.047531+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_218358","record_id":"REC_0012613","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":16,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":5,"primary_tumor_size_cm":6.3,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.047853+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_678678","record_id":"REC_0012614","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":17,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":4.9,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":55.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.049500+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_984433","record_id":"REC_0012615","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":25,"primary_tumor_size_cm":5.7,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.050051+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_544549","record_id":"REC_0012616","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":13.6,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":3,"smoking_pack_years":10,"primary_tumor_size_cm":6.3,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.050465+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_450101","record_id":"REC_0012617","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":15.6,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":4.9,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":19.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.050836+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_736661","record_id":"REC_0012618","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":17.2,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":5.9,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.051220+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_322573","record_id":"REC_0012619","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":18.2,"age_at_diagnosis":54,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":7.6,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.051557+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_376949","record_id":"REC_0012620","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":15.8,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":5,"primary_tumor_size_cm":5.3,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.051896+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_464726","record_id":"REC_0012621","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":19,"tmb_mutations_per_mb":4.9,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":42,"primary_tumor_size_cm":6.2,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":20.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.052905+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_949683","record_id":"REC_0012622","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":15.2,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":2.6,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.053399+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_706223","record_id":"REC_0012623","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":6.9,"age_at_diagnosis":80,"sex":"male","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":4.8,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":23.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.053822+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_373718","record_id":"REC_0012624","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":18,"tmb_mutations_per_mb":15.1,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":2.4,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":5.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.054461+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_366158","record_id":"REC_0012625","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":15,"tmb_mutations_per_mb":10.3,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":7.3,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.054901+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_439325","record_id":"REC_0012626","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":16.1,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":5.3,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.055246+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_367139","record_id":"REC_0012627","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":31,"tmb_mutations_per_mb":18.4,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":6.9,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.055611+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_352369","record_id":"REC_0012628","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":37,"tmb_mutations_per_mb":4.4,"age_at_diagnosis":90,"sex":"female","ecog_performance_status":1,"smoking_pack_years":53,"primary_tumor_size_cm":6.0,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.055957+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_928673","record_id":"REC_0012629","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":8.9,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":6.0,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":18.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.056497+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_639173","record_id":"REC_0012630","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":7.6,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":23.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.056913+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_467301","record_id":"REC_0012631","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":15.5,"age_at_diagnosis":54,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":6.9,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":7.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.057304+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_740086","record_id":"REC_0012632","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":30,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":27,"primary_tumor_size_cm":5.9,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":18.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.057800+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_361959","record_id":"REC_0012633","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":4.3,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":0,"smoking_pack_years":30,"primary_tumor_size_cm":6.9,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":17.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.058168+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_320416","record_id":"REC_0012634","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":15.0,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":5.0,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":22.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.058499+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_338626","record_id":"REC_0012635","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":5.2,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.058847+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_806072","record_id":"REC_0012636","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":15.7,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":6,"primary_tumor_size_cm":6.2,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.059229+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_649823","record_id":"REC_0012637","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":5.5,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":5.1,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":16.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.059761+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_526179","record_id":"REC_0012638","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":16,"tmb_mutations_per_mb":15.8,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":24,"primary_tumor_size_cm":5.3,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.060203+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_247581","record_id":"REC_0012639","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":4.0,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.3,"metastatic_sites_count":3,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.060589+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_930070","record_id":"REC_0012640","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":85,"sex":"female","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":5.4,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.061001+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_168859","record_id":"REC_0012641","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":6.4,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":51,"primary_tumor_size_cm":7.6,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.061369+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_795165","record_id":"REC_0012642","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":8.1,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":5.1,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":21.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.061718+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_534381","record_id":"REC_0012643","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":30,"tmb_mutations_per_mb":7.4,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":6.5,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":7.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.062029+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_564438","record_id":"REC_0012644","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":8.9,"age_at_diagnosis":83,"sex":"male","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":5.1,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.062328+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_282314","record_id":"REC_0012645","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":9.9,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":5.1,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.062647+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_139987","record_id":"REC_0012646","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":40,"primary_tumor_size_cm":4.5,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":6.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.063012+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_456821","record_id":"REC_0012647","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":13.8,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":26,"primary_tumor_size_cm":5.5,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.063374+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_181559","record_id":"REC_0012648","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":17.5,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.2,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.063705+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_335907","record_id":"REC_0012649","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":2,"primary_tumor_size_cm":6.7,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.063997+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_658999","record_id":"REC_0012650","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":9.0,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":0,"primary_tumor_size_cm":6.5,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":18.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.064554+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_204128","record_id":"REC_0012651","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":6.3,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":16.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.064932+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_557118","record_id":"REC_0012652","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":9.8,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":6.7,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.065266+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_860677","record_id":"REC_0012653","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":17.9,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":2.3,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":27.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.065595+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_883226","record_id":"REC_0012654","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":31,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":3,"smoking_pack_years":16,"primary_tumor_size_cm":4.6,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.065962+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_749821","record_id":"REC_0012655","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":4.8,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.066331+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_831649","record_id":"REC_0012656","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":9.5,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":6.0,"metastatic_sites_count":3,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.066630+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_239735","record_id":"REC_0012657","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":13.6,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":4.5,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":17.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.066925+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_530352","record_id":"REC_0012658","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":2,"smoking_pack_years":7,"primary_tumor_size_cm":6.2,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.067251+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_835402","record_id":"REC_0012659","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":8.1,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":4.4,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":51.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.067580+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_925559","record_id":"REC_0012660","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":48,"sex":"male","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":4.8,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.067922+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_686908","record_id":"REC_0012661","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":7.3,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":6.1,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.068339+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_741369","record_id":"REC_0012662","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":19,"tmb_mutations_per_mb":15.4,"age_at_diagnosis":51,"sex":"male","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":5.5,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.068728+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_412783","record_id":"REC_0012663","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":31,"primary_tumor_size_cm":4.5,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.069349+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_581605","record_id":"REC_0012664","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":11.0,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":7,"primary_tumor_size_cm":5.8,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":16.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.069749+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_240229","record_id":"REC_0012665","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":50,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":5.0,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.070120+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_214825","record_id":"REC_0012666","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":3.0,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":87,"primary_tumor_size_cm":6.2,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.070534+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_479650","record_id":"REC_0012667","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":13.5,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":4.8,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.070922+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_961597","record_id":"REC_0012668","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":30,"tmb_mutations_per_mb":18.6,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":4.6,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.071436+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_219719","record_id":"REC_0012669","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":16,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":4.8,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":30.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.071842+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_575565","record_id":"REC_0012670","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":39,"primary_tumor_size_cm":4.4,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.072264+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_575562","record_id":"REC_0012671","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":15.9,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":7.3,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.072615+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_716902","record_id":"REC_0012672","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":7.6,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":4.7,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.072926+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_414242","record_id":"REC_0012673","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":4.6,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":22.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.073242+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_921149","record_id":"REC_0012674","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":4.1,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":40,"primary_tumor_size_cm":8.7,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.073535+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_541767","record_id":"REC_0012675","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":5.1,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.073821+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_327847","record_id":"REC_0012676","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":4.0,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.074225+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_305760","record_id":"REC_0012677","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":5.4,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.074507+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_170807","record_id":"REC_0012678","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":8.4,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":0,"smoking_pack_years":52,"primary_tumor_size_cm":7.2,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":47.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.074752+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_405763","record_id":"REC_0012679","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":16.8,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":7,"primary_tumor_size_cm":5.8,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.075005+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_208647","record_id":"REC_0012680","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":6.0,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":1,"smoking_pack_years":69,"primary_tumor_size_cm":5.6,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.075249+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_671949","record_id":"REC_0012681","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":31,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":53,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":6.5,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.075521+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_407836","record_id":"REC_0012682","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":36,"tmb_mutations_per_mb":4.7,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":31,"primary_tumor_size_cm":6.7,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.075787+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_385071","record_id":"REC_0012683","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":15.5,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":6,"primary_tumor_size_cm":4.3,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.076128+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_328181","record_id":"REC_0012684","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":19.4,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":7.6,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":4.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.076503+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_228821","record_id":"REC_0012685","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":2.8,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.076848+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_852968","record_id":"REC_0012686","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":10.5,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":6.3,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":16.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.077180+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_173504","record_id":"REC_0012687","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":21.4,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":4.8,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.077493+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_602684","record_id":"REC_0012688","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":19.5,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":5.2,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.077807+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_687606","record_id":"REC_0012689","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":30,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":3.5,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":24.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.078299+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_689404","record_id":"REC_0012690","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":16.9,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":6.1,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.078696+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_878832","record_id":"REC_0012691","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":17.7,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":5.5,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.079085+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_766014","record_id":"REC_0012692","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":3.1,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":17.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.079465+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_141858","record_id":"REC_0012693","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":91,"primary_tumor_size_cm":7.0,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.079811+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_561281","record_id":"REC_0012694","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":75,"sex":"male","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":4.9,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":21.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.080259+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_664709","record_id":"REC_0012695","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":13.5,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":5.8,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.080693+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_573876","record_id":"REC_0012696","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":8.4,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":9,"primary_tumor_size_cm":6.2,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.081050+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_218706","record_id":"REC_0012697","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":3,"smoking_pack_years":27,"primary_tumor_size_cm":6.0,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.081391+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_674532","record_id":"REC_0012698","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":7.1,"metastatic_sites_count":3,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":18.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.081722+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_603512","record_id":"REC_0012699","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":8.6,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":5.9,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":5.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.082086+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_339802","record_id":"REC_0012700","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":4.2,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":26,"primary_tumor_size_cm":4.5,"metastatic_sites_count":8,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":5.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.082477+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_119817","record_id":"REC_0012701","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":6.4,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":47,"primary_tumor_size_cm":7.1,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.082851+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_329984","record_id":"REC_0012702","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":2.9,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":5.7,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.083346+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_150248","record_id":"REC_0012703","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":1,"smoking_pack_years":70,"primary_tumor_size_cm":6.7,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":23.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.083707+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_618496","record_id":"REC_0012704","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":30,"tmb_mutations_per_mb":17.3,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":5.9,"metastatic_sites_count":8,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.084063+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_554801","record_id":"REC_0012705","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":8.4,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":5.7,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":22.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.084517+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_939847","record_id":"REC_0012706","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":5.4,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.084896+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_466229","record_id":"REC_0012707","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":85,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":7.4,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":16.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.085278+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_385117","record_id":"REC_0012708","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":13.5,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":6.5,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.085655+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_565599","record_id":"REC_0012709","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":13,"tmb_mutations_per_mb":14.7,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":4.2,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.086036+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_580966","record_id":"REC_0012710","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":8.1,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":5.2,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.086432+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_335028","record_id":"REC_0012711","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":14.1,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":6,"primary_tumor_size_cm":8.2,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":6.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.086819+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_116766","record_id":"REC_0012712","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":26,"primary_tumor_size_cm":6.0,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":41.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.087199+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_983063","record_id":"REC_0012713","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":16.2,"age_at_diagnosis":51,"sex":"male","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":5.4,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":30.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.087591+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_613486","record_id":"REC_0012714","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":15,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":0,"smoking_pack_years":0,"primary_tumor_size_cm":5.4,"metastatic_sites_count":3,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":16.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.087941+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_748387","record_id":"REC_0012715","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":15.3,"age_at_diagnosis":54,"sex":"male","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":3.0,"metastatic_sites_count":9,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.088603+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_397029","record_id":"REC_0012716","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":14.6,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":6.4,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.089001+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_335804","record_id":"REC_0012717","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":3.3,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":7.0,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":16.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.089344+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_488475","record_id":"REC_0012718","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":13.5,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.6,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.089664+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_557045","record_id":"REC_0012719","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":5.6,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":6.0,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.089963+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_488597","record_id":"REC_0012720","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":19,"tmb_mutations_per_mb":6.7,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":93,"primary_tumor_size_cm":3.7,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":20.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.090269+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_304664","record_id":"REC_0012721","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":6.5,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.090584+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_825536","record_id":"REC_0012722","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":13.5,"age_at_diagnosis":74,"sex":"male","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":5.7,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":16.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.090883+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_508847","record_id":"REC_0012723","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":4.2,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.091182+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_366810","record_id":"REC_0012724","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":5.4,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.091465+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_358819","record_id":"REC_0012725","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":5.8,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.091733+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_592212","record_id":"REC_0012726","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":32,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":5.3,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.091995+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_753667","record_id":"REC_0012727","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":6.2,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.092393+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_866561","record_id":"REC_0012728","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":18.0,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":7.4,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.092806+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_440489","record_id":"REC_0012729","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":19.2,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":4.3,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":6.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.093109+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_936330","record_id":"REC_0012730","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":8.6,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":69,"primary_tumor_size_cm":5.3,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.093379+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_797114","record_id":"REC_0012731","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":8.7,"age_at_diagnosis":84,"sex":"female","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":5.0,"metastatic_sites_count":3,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.093640+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_385131","record_id":"REC_0012732","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.2,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.093912+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_775623","record_id":"REC_0012733","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":8.0,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":6.6,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":16.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.094189+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_651465","record_id":"REC_0012734","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":5.1,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.094460+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_885004","record_id":"REC_0012735","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":30,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":6.1,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":43.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.094748+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_144902","record_id":"REC_0012736","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":11.0,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":5,"primary_tumor_size_cm":5.7,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.095057+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_281999","record_id":"REC_0012737","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":3.5,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":4.0,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.095373+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_534344","record_id":"REC_0012738","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":15.4,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":5.7,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.095689+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_152384","record_id":"REC_0012739","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":15.9,"age_at_diagnosis":75,"sex":"male","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":7.2,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.095985+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_445885","record_id":"REC_0012740","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":13,"tmb_mutations_per_mb":7.3,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":1,"smoking_pack_years":81,"primary_tumor_size_cm":5.4,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":7.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.096365+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_316869","record_id":"REC_0012741","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":4.6,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":53,"primary_tumor_size_cm":4.8,"metastatic_sites_count":8,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.096901+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_109482","record_id":"REC_0012742","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":17.8,"age_at_diagnosis":54,"sex":"male","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":6.1,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":17.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.097273+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_502776","record_id":"REC_0012743","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":19,"tmb_mutations_per_mb":7.4,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":4.7,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.097569+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_443153","record_id":"REC_0012744","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":18.5,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":6.0,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":35.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.097894+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_575370","record_id":"REC_0012745","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None","pd_l1_tps_percent":18,"tmb_mutations_per_mb":3.8,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":34,"primary_tumor_size_cm":5.5,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":46.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.098228+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_930024","record_id":"REC_0012746","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":9.9,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":5.3,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.098598+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_168743","record_id":"REC_0012747","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":6.1,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":6.7,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.098978+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_662323","record_id":"REC_0012748","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":5.6,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":1,"smoking_pack_years":74,"primary_tumor_size_cm":3.1,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":7.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.099354+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_230720","record_id":"REC_0012749","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":4.6,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.099694+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_804966","record_id":"REC_0012750","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ALK fusion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":11.0,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":5.5,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":26.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.099996+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_338050","record_id":"REC_0012751","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":16.9,"age_at_diagnosis":74,"sex":"male","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":4.9,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":22.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.101609+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_857932","record_id":"REC_0012752","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":5.3,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":5.9,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":19.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.102008+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_906894","record_id":"REC_0012753","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":3,"smoking_pack_years":22,"primary_tumor_size_cm":5.9,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.102343+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_943113","record_id":"REC_0012754","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":4.1,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.102826+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_397366","record_id":"REC_0012755","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":7.6,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":1,"smoking_pack_years":70,"primary_tumor_size_cm":6.7,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.103181+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_586418","record_id":"REC_0012756","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":8.5,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":4.7,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.103524+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_220485","record_id":"REC_0012757","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":2,"smoking_pack_years":30,"primary_tumor_size_cm":5.2,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.103848+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_636462","record_id":"REC_0012758","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":2.7,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":37.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.104251+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_323368","record_id":"REC_0012759","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":0,"smoking_pack_years":56,"primary_tumor_size_cm":5.0,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":32.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.104610+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_811582","record_id":"REC_0012760","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":6.6,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.104925+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_614072","record_id":"REC_0012761","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":17,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":7.0,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":18.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.105242+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_744216","record_id":"REC_0012762","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":3.3,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":5.3,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":5.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.105546+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_149489","record_id":"REC_0012763","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":39,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":5.8,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":22.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.105855+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_850835","record_id":"REC_0012764","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":16.7,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":4.0,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":21.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.106159+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_245496","record_id":"REC_0012765","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":14.1,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":6.8,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.106454+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_143287","record_id":"REC_0012766","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":83,"sex":"female","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":8.1,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":18.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.106745+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_867281","record_id":"REC_0012767","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":15.2,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":23,"primary_tumor_size_cm":4.8,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.107197+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_947604","record_id":"REC_0012768","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":18.6,"age_at_diagnosis":52,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":7.5,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.107526+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_643063","record_id":"REC_0012769","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":6.2,"metastatic_sites_count":3,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":16.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.107812+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_958670","record_id":"REC_0012770","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":10.0,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":8,"primary_tumor_size_cm":7.9,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.108557+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_244727","record_id":"REC_0012771","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":5.8,"metastatic_sites_count":9,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.109022+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_383327","record_id":"REC_0012772","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":53,"sex":"male","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":5.5,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.109361+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_835108","record_id":"REC_0012773","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":50,"primary_tumor_size_cm":3.9,"metastatic_sites_count":3,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.109671+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_589054","record_id":"REC_0012774","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":14.9,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":5.8,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":16.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.109973+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_152375","record_id":"REC_0012775","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":32,"tmb_mutations_per_mb":14.9,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":6.2,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":30.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.110264+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_598579","record_id":"REC_0012776","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":32,"tmb_mutations_per_mb":4.0,"age_at_diagnosis":83,"sex":"female","ecog_performance_status":2,"smoking_pack_years":4,"primary_tumor_size_cm":4.6,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":6.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.110560+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_842410","record_id":"REC_0012777","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":13.6,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":4.6,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":22.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.111021+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_468243","record_id":"REC_0012778","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":35,"primary_tumor_size_cm":5.5,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":20.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.111378+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_130072","record_id":"REC_0012779","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":9.8,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":5.3,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":27.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.111692+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_627096","record_id":"REC_0012780","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":31,"tmb_mutations_per_mb":9.0,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":4.6,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.112230+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_434267","record_id":"REC_0012781","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":17.0,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":6.3,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.112592+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_483911","record_id":"REC_0012782","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":15.8,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":8,"primary_tumor_size_cm":5.2,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.112911+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_861479","record_id":"REC_0012783","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":76,"sex":"male","ecog_performance_status":2,"smoking_pack_years":8,"primary_tumor_size_cm":7.9,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.113231+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_887774","record_id":"REC_0012784","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":8.4,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":4.6,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.113546+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_314442","record_id":"REC_0012785","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":13.3,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":4.5,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":19.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.113852+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_214450","record_id":"REC_0012786","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":54,"sex":"male","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":3.8,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.114142+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_254097","record_id":"REC_0012787","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":6.0,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.114436+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_498635","record_id":"REC_0012788","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":3.1,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":5.2,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":7.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.114727+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_308253","record_id":"REC_0012789","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":31,"tmb_mutations_per_mb":7.3,"age_at_diagnosis":88,"sex":"male","ecog_performance_status":1,"smoking_pack_years":34,"primary_tumor_size_cm":7.0,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.115036+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_192944","record_id":"REC_0012790","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":48,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":6.6,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":41.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.115371+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_134451","record_id":"REC_0012791","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":8.6,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":7.7,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.115679+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_182191","record_id":"REC_0012792","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":3.1,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":20.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.115994+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_472652","record_id":"REC_0012793","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":6.0,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":7.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.116659+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_734230","record_id":"REC_0012794","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":14.4,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":6.8,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.117013+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_230718","record_id":"REC_0012795","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":10.1,"age_at_diagnosis":52,"sex":"male","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":5.8,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.117314+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_398368","record_id":"REC_0012796","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":5.9,"age_at_diagnosis":79,"sex":"male","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":5.0,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":22.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.117620+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_461844","record_id":"REC_0012797","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":7.0,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.117923+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_336304","record_id":"REC_0012798","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":3.5,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":0,"smoking_pack_years":57,"primary_tumor_size_cm":5.0,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.118199+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_735075","record_id":"REC_0012799","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":7.3,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.118487+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_104861","record_id":"REC_0012800","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":13.8,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":22,"primary_tumor_size_cm":5.6,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":24.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.118810+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_924999","record_id":"REC_0012801","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":14.9,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":5.4,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":43.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.119135+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_848012","record_id":"REC_0012802","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":7.9,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.119453+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_747406","record_id":"REC_0012803","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":3.4,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":18.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.119772+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_725887","record_id":"REC_0012804","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":34,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":25,"primary_tumor_size_cm":3.5,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.120118+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_335965","record_id":"REC_0012805","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":15.2,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":5.7,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.120469+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_299033","record_id":"REC_0012806","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":14.0,"age_at_diagnosis":74,"sex":"male","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":6.2,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.120966+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_405529","record_id":"REC_0012807","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":5.0,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":23.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.121313+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_626725","record_id":"REC_0012808","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":7.6,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.121615+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_481053","record_id":"REC_0012809","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":17.2,"age_at_diagnosis":80,"sex":"male","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":5.4,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":4.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.121909+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_670913","record_id":"REC_0012810","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":9.1,"age_at_diagnosis":79,"sex":"male","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":9.1,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.122202+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_578747","record_id":"REC_0012811","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":30,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":2,"primary_tumor_size_cm":4.3,"metastatic_sites_count":3,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":7.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.122490+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_729091","record_id":"REC_0012812","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":37,"tmb_mutations_per_mb":13.5,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":6.0,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":27.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.122788+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_590659","record_id":"REC_0012813","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":6.2,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":4.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.123095+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_570227","record_id":"REC_0012814","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":30,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.2,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.123398+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_477727","record_id":"REC_0012815","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":3.6,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":4.5,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.123707+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_324477","record_id":"REC_0012816","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":9.1,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":5.4,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":20.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.124005+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_860712","record_id":"REC_0012817","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":15,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":4.6,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":5.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.124432+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_195532","record_id":"REC_0012818","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":16.0,"age_at_diagnosis":83,"sex":"male","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":7.9,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.124769+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_984671","record_id":"REC_0012819","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":5.3,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.125237+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_595403","record_id":"REC_0012820","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":4.0,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.125562+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_772758","record_id":"REC_0012821","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":66,"primary_tumor_size_cm":4.9,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":6.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.125870+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_752320","record_id":"REC_0012822","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":14.3,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":5.2,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":5.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.126166+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_357023","record_id":"REC_0012823","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":15.9,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":0,"smoking_pack_years":27,"primary_tumor_size_cm":5.3,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.126462+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_702839","record_id":"REC_0012824","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":30,"tmb_mutations_per_mb":5.0,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":1,"smoking_pack_years":53,"primary_tumor_size_cm":6.1,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":17.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.126742+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_187574","record_id":"REC_0012825","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":4.5,"metastatic_sites_count":8,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":20.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.127032+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_979175","record_id":"REC_0012826","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":4.9,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.127315+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_957939","record_id":"REC_0012827","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":1,"smoking_pack_years":5,"primary_tumor_size_cm":5.3,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.127599+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_346245","record_id":"REC_0012828","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":15,"tmb_mutations_per_mb":6.7,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":0,"smoking_pack_years":30,"primary_tumor_size_cm":5.4,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":22.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.127864+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_742561","record_id":"REC_0012829","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":32,"tmb_mutations_per_mb":3.8,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":1,"smoking_pack_years":50,"primary_tumor_size_cm":7.0,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.128216+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_907341","record_id":"REC_0012830","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":5.5,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.128532+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_487329","record_id":"REC_0012831","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":15.2,"age_at_diagnosis":84,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":4.8,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.128826+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_342009","record_id":"REC_0012832","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":7.9,"age_at_diagnosis":51,"sex":"female","ecog_performance_status":0,"smoking_pack_years":34,"primary_tumor_size_cm":6.3,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.129283+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_735374","record_id":"REC_0012833","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":2.0,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":3,"smoking_pack_years":13,"primary_tumor_size_cm":7.2,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":6.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.129599+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_955070","record_id":"REC_0012834","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.5,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":5,"primary_tumor_size_cm":2.7,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":37.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.129895+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_948586","record_id":"REC_0012835","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":7.9,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":5.8,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.130210+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_964180","record_id":"REC_0012836","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":16.5,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":5.6,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":4.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.130497+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_169378","record_id":"REC_0012837","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":17.0,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.7,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":20.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.130783+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_416287","record_id":"REC_0012838","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":21,"primary_tumor_size_cm":4.2,"metastatic_sites_count":3,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.131091+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_517308","record_id":"REC_0012839","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":20,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":6.1,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.131371+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_407305","record_id":"REC_0012840","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":2.9,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.131671+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_293475","record_id":"REC_0012841","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":17,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":6.6,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.132010+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_349745","record_id":"REC_0012842","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":15,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":63,"primary_tumor_size_cm":5.6,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.132434+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_246672","record_id":"REC_0012843","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":17,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":82,"sex":"male","ecog_performance_status":1,"smoking_pack_years":37,"primary_tumor_size_cm":3.4,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":21.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.132803+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_700766","record_id":"REC_0012844","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":17.8,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":5.2,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":40.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.133144+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_842173","record_id":"REC_0012845","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":6.0,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.133633+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_419390","record_id":"REC_0012846","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":6.2,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":22.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.133963+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_110671","record_id":"REC_0012847","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":5.3,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":54,"primary_tumor_size_cm":3.6,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":18.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.134263+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_181870","record_id":"REC_0012848","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":0,"smoking_pack_years":48,"primary_tumor_size_cm":4.7,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.134568+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_451494","record_id":"REC_0012849","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":30,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":60,"primary_tumor_size_cm":6.0,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":17.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.134886+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_185432","record_id":"REC_0012850","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":4.0,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":2,"smoking_pack_years":42,"primary_tumor_size_cm":3.1,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.135228+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_912456","record_id":"REC_0012851","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":14.4,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":3,"primary_tumor_size_cm":6.0,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.135546+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_153266","record_id":"REC_0012852","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":17.6,"age_at_diagnosis":46,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":6.1,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.135852+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_306007","record_id":"REC_0012853","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":31,"tmb_mutations_per_mb":9.8,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":8,"primary_tumor_size_cm":6.4,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":24.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.136212+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_283211","record_id":"REC_0012854","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":21,"primary_tumor_size_cm":5.7,"metastatic_sites_count":9,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.136527+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_320073","record_id":"REC_0012855","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":6.7,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":28,"primary_tumor_size_cm":5.4,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":60.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.136822+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_774477","record_id":"REC_0012856","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":6.2,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":6.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.137146+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_197314","record_id":"REC_0012857","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":26,"primary_tumor_size_cm":6.3,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.137439+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_796454","record_id":"REC_0012858","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":18,"tmb_mutations_per_mb":15.5,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":5.9,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":22.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.137866+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_375115","record_id":"REC_0012859","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":3.0,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":28.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.138232+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_198410","record_id":"REC_0012860","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":6.0,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.138543+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_102134","record_id":"REC_0012861","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":6.5,"metastatic_sites_count":3,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.138842+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_275647","record_id":"REC_0012862","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":0,"primary_tumor_size_cm":5.3,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":17.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.139146+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_931281","record_id":"REC_0012863","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":6.0,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":1,"smoking_pack_years":46,"primary_tumor_size_cm":3.5,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.139488+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_839328","record_id":"REC_0012864","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":6.5,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.139845+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_139655","record_id":"REC_0012865","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":17.6,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":5.1,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.140263+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_128002","record_id":"REC_0012866","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":19,"tmb_mutations_per_mb":10.0,"age_at_diagnosis":52,"sex":"female","ecog_performance_status":0,"smoking_pack_years":4,"primary_tumor_size_cm":5.4,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.140612+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_255886","record_id":"REC_0012867","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":5.9,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":6.1,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":7.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.140917+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_454871","record_id":"REC_0012868","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":16.9,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":5.7,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.141202+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_415970","record_id":"REC_0012869","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":6.4,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":5.7,"metastatic_sites_count":8,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":6.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.141489+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_700501","record_id":"REC_0012870","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":35,"tmb_mutations_per_mb":5.3,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":26,"primary_tumor_size_cm":5.8,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.141775+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_264254","record_id":"REC_0012871","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":16,"tmb_mutations_per_mb":18.3,"age_at_diagnosis":83,"sex":"female","ecog_performance_status":2,"smoking_pack_years":9,"primary_tumor_size_cm":6.9,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.142219+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_272827","record_id":"REC_0012872","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":4.8,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":35,"primary_tumor_size_cm":5.0,"metastatic_sites_count":8,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.142530+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_769243","record_id":"REC_0012873","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":6.0,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":21.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.142833+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_693496","record_id":"REC_0012874","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":3.8,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":0,"smoking_pack_years":24,"primary_tumor_size_cm":5.9,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":28.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.143122+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_557565","record_id":"REC_0012875","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":3.4,"age_at_diagnosis":54,"sex":"male","ecog_performance_status":0,"smoking_pack_years":39,"primary_tumor_size_cm":4.2,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":16.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.143406+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_253336","record_id":"REC_0012876","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":34,"tmb_mutations_per_mb":17.8,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":4.9,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":4.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.143698+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_210671","record_id":"REC_0012877","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":23,"primary_tumor_size_cm":4.9,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.143984+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_874032","record_id":"REC_0012878","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":14.6,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":2,"smoking_pack_years":10,"primary_tumor_size_cm":6.6,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.144346+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_345217","record_id":"REC_0012879","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":3.2,"age_at_diagnosis":76,"sex":"male","ecog_performance_status":2,"smoking_pack_years":31,"primary_tumor_size_cm":4.4,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":47.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.144648+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_891721","record_id":"REC_0012880","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":6.7,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":6.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.144943+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_313252","record_id":"REC_0012881","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":18.5,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":5.8,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.145230+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_917055","record_id":"REC_0012882","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":27,"primary_tumor_size_cm":4.8,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.145505+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_175990","record_id":"REC_0012883","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":36,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":4.8,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.145788+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_221988","record_id":"REC_0012884","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":5.7,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":6.5,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":21.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.146208+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_246745","record_id":"REC_0012885","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":14.9,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":5.9,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":22.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.146508+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_887890","record_id":"REC_0012886","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":30,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":3.1,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.146798+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_389821","record_id":"REC_0012887","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":19,"tmb_mutations_per_mb":11.0,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":4.1,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":5.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.147076+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_407744","record_id":"REC_0012888","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":5.0,"metastatic_sites_count":9,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.147357+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_174242","record_id":"REC_0012889","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.5,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.147654+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_970060","record_id":"REC_0012890","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":16.1,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":4.9,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.147942+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_780311","record_id":"REC_0012891","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":19.6,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":5.5,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.148278+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_930095","record_id":"REC_0012892","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":16.5,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":6.1,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.148623+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_498946","record_id":"REC_0012893","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":15.2,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":6.1,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":20.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.148974+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_228249","record_id":"REC_0012894","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":5.9,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":5.8,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.149332+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_765240","record_id":"REC_0012895","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":5.2,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.149687+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_534819","record_id":"REC_0012896","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":4.6,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":34,"primary_tumor_size_cm":5.6,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":25.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.149999+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_812325","record_id":"REC_0012897","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":5.3,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":58,"primary_tumor_size_cm":6.7,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.150481+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_631955","record_id":"REC_0012898","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":10.5,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":5.6,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":25.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.150847+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_193494","record_id":"REC_0012899","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":34,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":80,"sex":"male","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":6.2,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":8.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.151170+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_456002","record_id":"REC_0012900","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":35,"tmb_mutations_per_mb":10.3,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":6.2,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.151498+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_599253","record_id":"REC_0012901","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":3.2,"age_at_diagnosis":86,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":3.4,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.151821+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_806640","record_id":"REC_0012902","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":9,"primary_tumor_size_cm":4.3,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":24.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.152305+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_412958","record_id":"REC_0012903","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":4.3,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":49,"primary_tumor_size_cm":5.1,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":31.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.152686+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_148026","record_id":"REC_0012904","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":4.8,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.153010+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_513054","record_id":"REC_0012905","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":6.2,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.153307+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_487658","record_id":"REC_0012906","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":43,"primary_tumor_size_cm":5.8,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.153587+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_953995","record_id":"REC_0012907","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":13,"tmb_mutations_per_mb":18.3,"age_at_diagnosis":46,"sex":"female","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":6.6,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.153864+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_638734","record_id":"REC_0012908","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":15.3,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":4.7,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.154222+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_454913","record_id":"REC_0012909","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":4.1,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":19.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.154535+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_555652","record_id":"REC_0012910","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":54,"sex":"male","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":5.8,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.155006+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_786545","record_id":"REC_0012911","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":17.0,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":25,"primary_tumor_size_cm":4.1,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.155342+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_346808","record_id":"REC_0012912","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":4.5,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.155634+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_378984","record_id":"REC_0012913","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":16.4,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":1,"smoking_pack_years":3,"primary_tumor_size_cm":4.2,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.155911+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_931148","record_id":"REC_0012914","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":5.4,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.156248+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_513725","record_id":"REC_0012915","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":21.4,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":22,"primary_tumor_size_cm":6.6,"metastatic_sites_count":3,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.156584+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_213400","record_id":"REC_0012916","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":6.9,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.156906+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_261633","record_id":"REC_0012917","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":17.2,"age_at_diagnosis":74,"sex":"male","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":5.5,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.157224+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_370133","record_id":"REC_0012918","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":7.1,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.157512+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_119925","record_id":"REC_0012919","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":8.3,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":6.8,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.157791+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_232464","record_id":"REC_0012920","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":12,"tmb_mutations_per_mb":3.1,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":3,"primary_tumor_size_cm":7.2,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.158071+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_734457","record_id":"REC_0012921","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":5.3,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":71,"primary_tumor_size_cm":5.5,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":27.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.158369+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_670385","record_id":"REC_0012922","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":2,"smoking_pack_years":20,"primary_tumor_size_cm":6.5,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.158675+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_430665","record_id":"REC_0012923","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":11.5,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":6.4,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.159120+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_282399","record_id":"REC_0012924","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":4.8,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":3,"smoking_pack_years":36,"primary_tumor_size_cm":6.0,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.159437+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_874332","record_id":"REC_0012925","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":24,"primary_tumor_size_cm":4.8,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.159730+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_531903","record_id":"REC_0012926","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":5.1,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.160023+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_596882","record_id":"REC_0012927","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":31,"tmb_mutations_per_mb":6.1,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":5.2,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.160376+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_830455","record_id":"REC_0012928","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":15.2,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":6.8,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.160672+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_478688","record_id":"REC_0012929","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":14.6,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":6.2,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":16.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.160946+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_431054","record_id":"REC_0012930","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":18.0,"age_at_diagnosis":83,"sex":"male","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":4.6,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.161218+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_684416","record_id":"REC_0012931","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":13.1,"age_at_diagnosis":78,"sex":"male","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":3.8,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":37.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.161491+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_329514","record_id":"REC_0012932","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":6.4,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.161768+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_154230","record_id":"REC_0012933","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":9.7,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":6.0,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":24.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.162050+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_289783","record_id":"REC_0012934","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":89,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":4.3,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":49.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.162327+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_215255","record_id":"REC_0012935","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":34,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":1,"smoking_pack_years":71,"primary_tumor_size_cm":7.7,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":16.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.162603+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_236351","record_id":"REC_0012936","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":7.2,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.163042+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_690809","record_id":"REC_0012937","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":6.1,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.163370+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_145280","record_id":"REC_0012938","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":3.4,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":5.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.163685+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_596936","record_id":"REC_0012939","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":7.3,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":7.2,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.163987+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_743755","record_id":"REC_0012940","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":83,"sex":"female","ecog_performance_status":2,"smoking_pack_years":22,"primary_tumor_size_cm":5.8,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.164398+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_432231","record_id":"REC_0012941","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":9.1,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":6.2,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.164709+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_142568","record_id":"REC_0012942","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":15.4,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":3.9,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.165041+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_675536","record_id":"REC_0012943","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":6.4,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":2,"smoking_pack_years":35,"primary_tumor_size_cm":5.3,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":18.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.165391+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_853650","record_id":"REC_0012944","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":11.1,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":4.5,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":24.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.165752+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_353352","record_id":"REC_0012945","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":52,"sex":"female","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":5.7,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":36.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.166106+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_439794","record_id":"REC_0012946","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":5.3,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.6,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":35.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.166438+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_375521","record_id":"REC_0012947","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":9.1,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":7.0,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.166769+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_235475","record_id":"REC_0012948","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":15,"tmb_mutations_per_mb":6.7,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":5.6,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.167082+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_955004","record_id":"REC_0012949","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":14.5,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":7.0,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":33.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.167528+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_212577","record_id":"REC_0012950","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":4.9,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":17.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.167853+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_546541","record_id":"REC_0012951","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":13.6,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":6.6,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.168269+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_253063","record_id":"REC_0012952","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":15,"tmb_mutations_per_mb":5.9,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":6.7,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.168627+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_127087","record_id":"REC_0012953","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":9.9,"age_at_diagnosis":53,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":5.8,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.168961+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_805332","record_id":"REC_0012954","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":17,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":6.3,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.169279+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_417731","record_id":"REC_0012955","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":4.0,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":6.8,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.169590+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_462232","record_id":"REC_0012956","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":6.4,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":31.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.169911+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_632419","record_id":"REC_0012957","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.2,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.170234+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_880103","record_id":"REC_0012958","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":15,"tmb_mutations_per_mb":13.3,"age_at_diagnosis":54,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":4.2,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.170565+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_837670","record_id":"REC_0012959","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":13.3,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":4.4,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.170874+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_420935","record_id":"REC_0012960","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":5.9,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":6.2,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":38.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.171184+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_717573","record_id":"REC_0012961","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":5.3,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":23.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.171512+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_593024","record_id":"REC_0012962","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":34,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":4.2,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":5.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.172022+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_510507","record_id":"REC_0012963","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":15.7,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":4.9,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":21.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.172552+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_393840","record_id":"REC_0012964","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":7.9,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":21,"primary_tumor_size_cm":5.8,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.172882+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_805910","record_id":"REC_0012965","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":7.9,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":3.6,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.173386+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_760362","record_id":"REC_0012966","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":16.1,"age_at_diagnosis":90,"sex":"male","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":7.2,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.173722+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_839983","record_id":"REC_0012967","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":2.6,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.174020+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_987497","record_id":"REC_0012968","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":19,"tmb_mutations_per_mb":5.1,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":25,"primary_tumor_size_cm":6.0,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.174290+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_100121","record_id":"REC_0012969","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":19.8,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":7.5,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":24.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.174568+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_119655","record_id":"REC_0012970","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":10.5,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":6.7,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.174863+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_450397","record_id":"REC_0012971","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":6.7,"age_at_diagnosis":83,"sex":"female","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":3.6,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":23.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.175167+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_650806","record_id":"REC_0012972","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":16,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":0,"primary_tumor_size_cm":4.0,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":23.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.175477+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_724786","record_id":"REC_0012973","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":15,"tmb_mutations_per_mb":6.1,"age_at_diagnosis":53,"sex":"male","ecog_performance_status":0,"smoking_pack_years":55,"primary_tumor_size_cm":5.1,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.175776+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_270321","record_id":"REC_0012974","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":13.3,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":1,"smoking_pack_years":5,"primary_tumor_size_cm":6.3,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.176069+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_136305","record_id":"REC_0012975","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":17.1,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":6.9,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.185184+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_333253","record_id":"REC_0012976","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":54,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":7.1,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.186590+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_671371","record_id":"REC_0012977","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":6.0,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":4.5,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":4.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.186971+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_237370","record_id":"REC_0012978","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":5.9,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":21.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.187265+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_459162","record_id":"REC_0012979","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":15.5,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":4.9,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.187668+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_744415","record_id":"REC_0012980","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":6.0,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.187994+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_750845","record_id":"REC_0012981","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":6.4,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.188401+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_622078","record_id":"REC_0012982","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":13.5,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":5.6,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":25.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.188705+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_849887","record_id":"REC_0012983","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":53,"sex":"female","ecog_performance_status":0,"smoking_pack_years":4,"primary_tumor_size_cm":5.7,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.189008+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_311954","record_id":"REC_0012984","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":5.9,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":44,"primary_tumor_size_cm":7.8,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":17.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.189288+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_307674","record_id":"REC_0012985","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":4.1,"age_at_diagnosis":52,"sex":"male","ecog_performance_status":0,"smoking_pack_years":67,"primary_tumor_size_cm":5.6,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":43.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.189583+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_181807","record_id":"REC_0012986","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":3.9,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.189864+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_386083","record_id":"REC_0012987","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":5.8,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.190130+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_631911","record_id":"REC_0012988","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":9.1,"age_at_diagnosis":52,"sex":"male","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":4.0,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.190530+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_437032","record_id":"REC_0012989","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":4.6,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":17.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.199769+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_560920","record_id":"REC_0012990","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":6.3,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.201729+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_279691","record_id":"REC_0012991","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":13.3,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":4.0,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.206809+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_450111","record_id":"REC_0012992","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":9.8,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":5.0,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.207218+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_148185","record_id":"REC_0012993","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":19,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":4,"primary_tumor_size_cm":6.0,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":22.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.207554+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_648686","record_id":"REC_0012994","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":2.4,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":36,"primary_tumor_size_cm":5.8,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":7.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.207885+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_749327","record_id":"REC_0012995","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":4.5,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.208315+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_286830","record_id":"REC_0012996","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":16.7,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":24,"primary_tumor_size_cm":5.8,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.208692+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_947913","record_id":"REC_0012997","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":15.5,"age_at_diagnosis":52,"sex":"male","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":5.0,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":16.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.209021+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_339650","record_id":"REC_0012998","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":14.1,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":1,"smoking_pack_years":28,"primary_tumor_size_cm":5.3,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.209350+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_485968","record_id":"REC_0012999","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":17.8,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":5.4,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.209659+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_855142","record_id":"REC_0013000","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":16,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":51,"sex":"male","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":5.5,"metastatic_sites_count":8,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.209966+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_312303","record_id":"REC_0013001","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":7.4,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":59,"primary_tumor_size_cm":7.8,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.210442+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_280534","record_id":"REC_0013002","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.0,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":5.9,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":24.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.210757+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_655207","record_id":"REC_0013003","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":18,"tmb_mutations_per_mb":2.5,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":72,"primary_tumor_size_cm":7.1,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":6.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.211039+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_884365","record_id":"REC_0013004","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":48,"sex":"female","ecog_performance_status":0,"smoking_pack_years":61,"primary_tumor_size_cm":4.7,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.211346+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_934595","record_id":"REC_0013005","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":33,"tmb_mutations_per_mb":8.0,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":7.0,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.211693+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_573114","record_id":"REC_0013006","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":80,"sex":"male","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":6.2,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.212005+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_523569","record_id":"REC_0013007","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":16.3,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":4.5,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.213348+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_475585","record_id":"REC_0013008","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":18.1,"age_at_diagnosis":80,"sex":"male","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":5.2,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.213758+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_452341","record_id":"REC_0013009","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":17,"tmb_mutations_per_mb":3.6,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":6.3,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":7.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.214168+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_316928","record_id":"REC_0013010","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":7.6,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":49,"primary_tumor_size_cm":7.0,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":18.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.214474+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_684697","record_id":"REC_0013011","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":5.6,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":3,"smoking_pack_years":64,"primary_tumor_size_cm":5.0,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":16.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.214766+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_101401","record_id":"REC_0013012","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":18.2,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":6.0,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.215080+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_825538","record_id":"REC_0013013","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":15.2,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":4.3,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":6.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.215413+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_284303","record_id":"REC_0013014","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":15,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":85,"sex":"female","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":3.4,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":19.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.215906+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_880044","record_id":"REC_0013015","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":7.3,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":21,"primary_tumor_size_cm":6.5,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.216723+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_461066","record_id":"REC_0013016","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":15.5,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":5.7,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":25.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.217136+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_269872","record_id":"REC_0013017","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":3.9,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":5.5,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":16.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.217480+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_184881","record_id":"REC_0013018","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":2.5,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.217780+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_607412","record_id":"REC_0013019","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":4.9,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":0,"smoking_pack_years":41,"primary_tumor_size_cm":5.7,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.218084+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_738714","record_id":"REC_0013020","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":29,"primary_tumor_size_cm":5.2,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.218424+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_947237","record_id":"REC_0013021","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":4.6,"age_at_diagnosis":80,"sex":"male","ecog_performance_status":2,"smoking_pack_years":38,"primary_tumor_size_cm":6.6,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":24.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.218735+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_110055","record_id":"REC_0013022","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":7.8,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.219062+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_161274","record_id":"REC_0013023","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":19,"tmb_mutations_per_mb":17.6,"age_at_diagnosis":53,"sex":"male","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":6.6,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.219383+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_416741","record_id":"REC_0013024","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":22.3,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":5.1,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.219700+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_193350","record_id":"REC_0013025","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":5.5,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":5.2,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":23.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.219988+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_539708","record_id":"REC_0013026","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":17,"tmb_mutations_per_mb":13.1,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":3.3,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.220366+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_873798","record_id":"REC_0013027","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":31,"tmb_mutations_per_mb":7.4,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":1,"smoking_pack_years":60,"primary_tumor_size_cm":5.2,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.221015+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_665564","record_id":"REC_0013028","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":5.6,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":55,"primary_tumor_size_cm":6.0,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.221399+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_430537","record_id":"REC_0013029","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":18,"tmb_mutations_per_mb":7.3,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":4.1,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.221719+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_519089","record_id":"REC_0013030","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":12,"tmb_mutations_per_mb":8.7,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":1,"smoking_pack_years":72,"primary_tumor_size_cm":6.5,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":17.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.222034+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_597803","record_id":"REC_0013031","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":5.1,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":47,"primary_tumor_size_cm":5.6,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":16.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.222322+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_927842","record_id":"REC_0013032","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":16.2,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":5.5,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.222633+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_532362","record_id":"REC_0013033","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":34,"tmb_mutations_per_mb":5.3,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":0,"primary_tumor_size_cm":5.4,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.222941+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_103278","record_id":"REC_0013034","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":15.5,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":4.5,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.223265+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_960355","record_id":"REC_0013035","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.4,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":7.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.223598+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_313341","record_id":"REC_0013036","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":6.7,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.223947+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_934317","record_id":"REC_0013037","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":2.1,"age_at_diagnosis":74,"sex":"male","ecog_performance_status":1,"smoking_pack_years":44,"primary_tumor_size_cm":8.4,"metastatic_sites_count":8,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.224767+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_438804","record_id":"REC_0013038","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":11.5,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":5.5,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.225172+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_851084","record_id":"REC_0013039","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":14.9,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":5.1,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.225556+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_321475","record_id":"REC_0013040","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":7.9,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.226106+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_350823","record_id":"REC_0013041","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":19,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":5.6,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":23.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.226504+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_139420","record_id":"REC_0013042","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":5.1,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":4.6,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.226835+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_149499","record_id":"REC_0013043","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":10.5,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":6.3,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.227153+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_460719","record_id":"REC_0013044","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":6.5,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":32.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.227459+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_663193","record_id":"REC_0013045","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":36,"tmb_mutations_per_mb":13.5,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":5.2,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.227758+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_635687","record_id":"REC_0013046","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":16.0,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":5.1,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.228051+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_910638","record_id":"REC_0013047","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":4.2,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":7.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.228465+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_143471","record_id":"REC_0013048","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":13.8,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":4.8,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.228828+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_430146","record_id":"REC_0013049","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":17.2,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":5.8,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":34.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.229159+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_959381","record_id":"REC_0013050","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":4.6,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":1,"smoking_pack_years":44,"primary_tumor_size_cm":6.5,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.229463+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_990170","record_id":"REC_0013051","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":50,"sex":"female","ecog_performance_status":0,"smoking_pack_years":63,"primary_tumor_size_cm":5.0,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":16.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.229779+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_888234","record_id":"REC_0013052","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":3.7,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":57.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.230119+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_507710","record_id":"REC_0013053","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":4.4,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.230611+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_156512","record_id":"REC_0013054","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":5.0,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.230950+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_896977","record_id":"REC_0013055","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":5.9,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":42.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.231279+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_744497","record_id":"REC_0013056","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":1,"smoking_pack_years":59,"primary_tumor_size_cm":6.2,"metastatic_sites_count":10,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.231632+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_588045","record_id":"REC_0013057","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":14.0,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":7,"primary_tumor_size_cm":6.7,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.232010+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_104255","record_id":"REC_0013058","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":2.2,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.232474+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_762716","record_id":"REC_0013059","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":14.8,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":5.6,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":16.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.232896+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_310344","record_id":"REC_0013060","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":10.3,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":5.9,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":28.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.233293+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_622246","record_id":"REC_0013061","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":5.9,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.233670+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_669895","record_id":"REC_0013062","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":8.5,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":4.5,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":27.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.234033+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_688889","record_id":"REC_0013063","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":34,"primary_tumor_size_cm":6.5,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":19.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.234414+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_546603","record_id":"REC_0013064","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":16,"tmb_mutations_per_mb":5.7,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":6.8,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.234765+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_100256","record_id":"REC_0013065","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":7.1,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.235093+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_196600","record_id":"REC_0013066","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":16.2,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":8.2,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":16.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.235544+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_763905","record_id":"REC_0013067","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":9.1,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":8.7,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.235917+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_420590","record_id":"REC_0013068","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":13.1,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":0,"smoking_pack_years":6,"primary_tumor_size_cm":7.1,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":20.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.236381+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_883648","record_id":"REC_0013069","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":2,"smoking_pack_years":52,"primary_tumor_size_cm":5.8,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.236886+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_803747","record_id":"REC_0013070","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":4.5,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":52,"primary_tumor_size_cm":4.0,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":20.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.237303+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_639443","record_id":"REC_0013071","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":20,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":4.2,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":4.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.237701+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_754959","record_id":"REC_0013072","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":13.1,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":4.8,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.238057+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_368803","record_id":"REC_0013073","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":30,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":5.7,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.238436+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_767888","record_id":"REC_0013074","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":5.9,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.238877+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_363083","record_id":"REC_0013075","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":4.8,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.239269+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_717098","record_id":"REC_0013076","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":16,"tmb_mutations_per_mb":6.9,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":4.8,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":18.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.240531+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_350829","record_id":"REC_0013077","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":9.7,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":2.5,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.241376+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_981185","record_id":"REC_0013078","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":4.8,"age_at_diagnosis":53,"sex":"female","ecog_performance_status":0,"smoking_pack_years":27,"primary_tumor_size_cm":4.2,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.241796+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_963642","record_id":"REC_0013079","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":14.1,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":7.2,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.242336+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_194975","record_id":"REC_0013080","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":28,"primary_tumor_size_cm":5.3,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.242712+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_944679","record_id":"REC_0013081","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":31,"tmb_mutations_per_mb":4.1,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":4.5,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":5.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.243065+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_234447","record_id":"REC_0013082","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":9.9,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":4.1,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.243415+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_844396","record_id":"REC_0013083","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":7,"primary_tumor_size_cm":5.1,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.243769+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_764522","record_id":"REC_0013084","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":9.8,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":3,"smoking_pack_years":18,"primary_tumor_size_cm":3.5,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.244500+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_945022","record_id":"REC_0013085","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":5.1,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.245164+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_195924","record_id":"REC_0013086","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":7.2,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.245577+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_794009","record_id":"REC_0013087","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":5.6,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":0,"smoking_pack_years":63,"primary_tumor_size_cm":3.8,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.245944+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_486872","record_id":"REC_0013088","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":13.1,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":6.4,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.246923+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_570018","record_id":"REC_0013089","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":4.6,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":57,"primary_tumor_size_cm":5.6,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.251664+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_778735","record_id":"REC_0013090","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":6.2,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.252010+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_158316","record_id":"REC_0013091","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":77,"primary_tumor_size_cm":6.1,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.252502+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_792642","record_id":"REC_0013092","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":3.7,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":1,"smoking_pack_years":66,"primary_tumor_size_cm":6.7,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.253076+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_993754","record_id":"REC_0013093","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":19,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":4.8,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":33.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.253497+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_782212","record_id":"REC_0013094","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":16.4,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":5.7,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":16.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.253876+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_588893","record_id":"REC_0013095","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":14.7,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":4.4,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.254330+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_383755","record_id":"REC_0013096","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":15.6,"age_at_diagnosis":50,"sex":"male","ecog_performance_status":0,"smoking_pack_years":26,"primary_tumor_size_cm":4.6,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":29.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.254762+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_474987","record_id":"REC_0013097","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":19,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":6.7,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.255247+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_332909","record_id":"REC_0013098","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":16,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":0,"smoking_pack_years":48,"primary_tumor_size_cm":5.7,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.255673+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_704509","record_id":"REC_0013099","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":5.2,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.256048+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_187153","record_id":"REC_0013100","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":8.7,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":6.6,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.256485+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_536172","record_id":"REC_0013101","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":13.1,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":26,"primary_tumor_size_cm":5.2,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":25.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.256872+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_824581","record_id":"REC_0013102","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":80,"primary_tumor_size_cm":6.3,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.257235+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_131380","record_id":"REC_0013103","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":19,"tmb_mutations_per_mb":7.4,"age_at_diagnosis":47,"sex":"male","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":6.8,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.257594+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_725152","record_id":"REC_0013104","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":32,"tmb_mutations_per_mb":4.8,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":0,"smoking_pack_years":39,"primary_tumor_size_cm":6.0,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.257959+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_320304","record_id":"REC_0013105","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":4.3,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.258499+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_160396","record_id":"REC_0013106","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":7.4,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":8.3,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":29.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.258866+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_474668","record_id":"REC_0013107","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":36,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":7.5,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.259208+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_472226","record_id":"REC_0013108","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.1,"age_at_diagnosis":84,"sex":"female","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":4.6,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":21.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.259551+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_583662","record_id":"REC_0013109","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":6.2,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.259872+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_988122","record_id":"REC_0013110","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":8.4,"age_at_diagnosis":76,"sex":"male","ecog_performance_status":3,"smoking_pack_years":20,"primary_tumor_size_cm":5.8,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":24.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.260327+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_177394","record_id":"REC_0013111","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.5,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":4.5,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.260672+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_103205","record_id":"REC_0013112","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":18,"tmb_mutations_per_mb":8.4,"age_at_diagnosis":52,"sex":"male","ecog_performance_status":0,"smoking_pack_years":6,"primary_tumor_size_cm":3.8,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.260964+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_556468","record_id":"REC_0013113","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":19,"tmb_mutations_per_mb":5.6,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":47,"primary_tumor_size_cm":4.4,"metastatic_sites_count":8,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":7.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.261243+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_786176","record_id":"REC_0013114","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":5.9,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.261517+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_364731","record_id":"REC_0013115","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":6.9,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":19.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.261809+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_536589","record_id":"REC_0013116","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":30,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":6.8,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":17.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.262103+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_405148","record_id":"REC_0013117","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":78,"sex":"male","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":6.5,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":7.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.262380+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_272483","record_id":"REC_0013118","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":5.4,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":43.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.262773+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_710107","record_id":"REC_0013119","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":5.5,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.263092+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_456598","record_id":"REC_0013120","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":8.6,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":35,"primary_tumor_size_cm":7.3,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.263371+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_769117","record_id":"REC_0013121","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":5.7,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.263699+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_138871","record_id":"REC_0013122","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":5.3,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":5.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.263996+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_422335","record_id":"REC_0013123","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":40,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":36,"primary_tumor_size_cm":6.3,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.264373+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_456567","record_id":"REC_0013124","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":4.5,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.264712+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_260019","record_id":"REC_0013125","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":5.0,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.265043+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_465445","record_id":"REC_0013126","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":88,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":4.7,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.265388+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_811021","record_id":"REC_0013127","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":1,"smoking_pack_years":3,"primary_tumor_size_cm":5.5,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":18.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.265732+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_614937","record_id":"REC_0013128","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":5.6,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":0,"smoking_pack_years":33,"primary_tumor_size_cm":5.1,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":16.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.266062+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_847070","record_id":"REC_0013129","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":5.1,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":47.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.266372+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_591830","record_id":"REC_0013130","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":19,"tmb_mutations_per_mb":3.8,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":38,"primary_tumor_size_cm":5.5,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.266674+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_525518","record_id":"REC_0013131","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":9.0,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":5.5,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.267184+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_985273","record_id":"REC_0013132","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":17.5,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":26,"primary_tumor_size_cm":5.8,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.267526+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_217714","record_id":"REC_0013133","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":13.6,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":4.1,"metastatic_sites_count":3,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.267833+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_219887","record_id":"REC_0013134","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":36,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":6.1,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":17.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.268187+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_129028","record_id":"REC_0013135","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":14.5,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":5.3,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.268577+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_950640","record_id":"REC_0013136","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":12,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":7.0,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.268951+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_988816","record_id":"REC_0013137","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":83,"sex":"female","ecog_performance_status":2,"smoking_pack_years":3,"primary_tumor_size_cm":5.3,"metastatic_sites_count":9,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":18.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.269328+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_247238","record_id":"REC_0013138","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":6.3,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":4.2,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":26.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.269704+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_198943","record_id":"REC_0013139","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":15.8,"age_at_diagnosis":52,"sex":"male","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":3.3,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":17.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.270072+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_447250","record_id":"REC_0013140","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":17,"tmb_mutations_per_mb":8.3,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":5.1,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.270413+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_554971","record_id":"REC_0013141","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":4.9,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.270732+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_863809","record_id":"REC_0013142","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":3.6,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":27.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.271044+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_679618","record_id":"REC_0013143","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":19,"tmb_mutations_per_mb":16.0,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":4.3,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.271388+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_879023","record_id":"REC_0013144","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":19,"tmb_mutations_per_mb":15.2,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.7,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":47.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.271847+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_498792","record_id":"REC_0013145","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":16,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":51,"sex":"male","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":5.3,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.272252+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_594848","record_id":"REC_0013146","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":11.5,"age_at_diagnosis":52,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":5.5,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.272619+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_252155","record_id":"REC_0013147","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":2.1,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":1,"smoking_pack_years":32,"primary_tumor_size_cm":5.2,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.272982+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_294417","record_id":"REC_0013148","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":7.9,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":0,"smoking_pack_years":46,"primary_tumor_size_cm":6.7,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":18.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.273321+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_648726","record_id":"REC_0013149","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":14,"tmb_mutations_per_mb":18.1,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":5.9,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.273633+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_917256","record_id":"REC_0013150","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":7.6,"age_at_diagnosis":83,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":6.0,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":24.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.273917+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_780073","record_id":"REC_0013151","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":5.0,"metastatic_sites_count":8,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":6.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.274207+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_995276","record_id":"REC_0013152","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":17.8,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":5.5,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.274488+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_729496","record_id":"REC_0013153","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":18,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":6.8,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.274766+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_616380","record_id":"REC_0013154","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":14.5,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":6.2,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.275046+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_193158","record_id":"REC_0013155","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":20,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":5.6,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":16.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.275329+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_625068","record_id":"REC_0013156","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":17,"tmb_mutations_per_mb":5.7,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":50,"primary_tumor_size_cm":3.7,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":24.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.275616+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_291358","record_id":"REC_0013157","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":11,"tmb_mutations_per_mb":13.1,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":4.7,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.276233+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_589045","record_id":"REC_0013158","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":13.6,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":1,"smoking_pack_years":30,"primary_tumor_size_cm":7.2,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":28.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.276641+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_794213","record_id":"REC_0013159","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":9.9,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":5.4,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.276960+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_410374","record_id":"REC_0013160","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":5.1,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":6.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.277256+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_337335","record_id":"REC_0013161","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":3.8,"metastatic_sites_count":9,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":5.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.277576+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_844192","record_id":"REC_0013162","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":5.2,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":27,"primary_tumor_size_cm":5.9,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":24.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.277899+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_708028","record_id":"REC_0013163","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":4.8,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.278257+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_508592","record_id":"REC_0013164","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":3.0,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":5.5,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.278606+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_512409","record_id":"REC_0013165","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":4.9,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":3.9,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.278945+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_170110","record_id":"REC_0013166","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":6.1,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":2,"smoking_pack_years":21,"primary_tumor_size_cm":5.4,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.279252+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_164828","record_id":"REC_0013167","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":16,"tmb_mutations_per_mb":1.6,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":1,"smoking_pack_years":46,"primary_tumor_size_cm":5.0,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":21.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.279566+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_341534","record_id":"REC_0013168","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":3,"primary_tumor_size_cm":4.9,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.279863+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_501695","record_id":"REC_0013169","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":4.5,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":5.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.280273+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_587256","record_id":"REC_0013170","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":0,"smoking_pack_years":6,"primary_tumor_size_cm":4.2,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":21.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.280771+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_168773","record_id":"REC_0013171","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":1.5,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":37,"primary_tumor_size_cm":5.6,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":29.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.281137+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_839815","record_id":"REC_0013172","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":17,"tmb_mutations_per_mb":15.5,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":4.1,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.281483+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_849400","record_id":"REC_0013173","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":35,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":4.9,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":19.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.281835+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_714178","record_id":"REC_0013174","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":18.2,"age_at_diagnosis":48,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":7.0,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.282321+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_364802","record_id":"REC_0013175","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":13.3,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":5.2,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":4.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.282710+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_710968","record_id":"REC_0013176","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":9.8,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":4.4,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.283012+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_956805","record_id":"REC_0013177","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":4.4,"age_at_diagnosis":81,"sex":"male","ecog_performance_status":3,"smoking_pack_years":56,"primary_tumor_size_cm":3.8,"metastatic_sites_count":3,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":17.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.283324+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_395569","record_id":"REC_0013178","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":15,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":3,"smoking_pack_years":28,"primary_tumor_size_cm":5.8,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.283641+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_672693","record_id":"REC_0013179","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":9.8,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":5.8,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.283935+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_223396","record_id":"REC_0013180","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":7.6,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":3,"primary_tumor_size_cm":4.3,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.284280+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_575217","record_id":"REC_0013181","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":31,"tmb_mutations_per_mb":4.2,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":59,"primary_tumor_size_cm":6.4,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.284575+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_885934","record_id":"REC_0013182","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":17,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":2.0,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.284860+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_696278","record_id":"REC_0013183","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":18,"tmb_mutations_per_mb":6.3,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":5,"primary_tumor_size_cm":2.7,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.285316+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_705198","record_id":"REC_0013184","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":5.3,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.285674+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_458680","record_id":"REC_0013185","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.4,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.286024+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_244289","record_id":"REC_0013186","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":3.0,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":61,"primary_tumor_size_cm":6.0,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":24.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.286361+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_364987","record_id":"REC_0013187","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":30,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":6.2,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.286696+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_252742","record_id":"REC_0013188","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":19.4,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":4.1,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.288282+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_924157","record_id":"REC_0013189","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":4.5,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":23.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.288681+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_231732","record_id":"REC_0013190","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":16.8,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":6.6,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.288990+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_851436","record_id":"REC_0013191","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":18.5,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":5.0,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.289279+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_616661","record_id":"REC_0013192","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":10.3,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":5.4,"metastatic_sites_count":8,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.289577+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_315951","record_id":"REC_0013193","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":19,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":6,"primary_tumor_size_cm":5.9,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.289888+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_235040","record_id":"REC_0013194","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":6.6,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.290190+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_955792","record_id":"REC_0013195","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":59,"primary_tumor_size_cm":5.8,"metastatic_sites_count":8,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":7.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.290493+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_854256","record_id":"REC_0013196","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":5.6,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.290922+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_703983","record_id":"REC_0013197","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":35,"tmb_mutations_per_mb":14.5,"age_at_diagnosis":51,"sex":"female","ecog_performance_status":0,"smoking_pack_years":6,"primary_tumor_size_cm":6.9,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.291261+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_560947","record_id":"REC_0013198","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":14,"tmb_mutations_per_mb":4.5,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":65,"primary_tumor_size_cm":8.3,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.291559+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_260778","record_id":"REC_0013199","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":16.8,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":3.8,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.291845+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_532218","record_id":"REC_0013200","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":11.0,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":5.0,"metastatic_sites_count":8,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":16.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.292228+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_567712","record_id":"REC_0013201","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":5.6,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.292547+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_147881","record_id":"REC_0013202","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":4.5,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":4.7,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.292825+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_634733","record_id":"REC_0013203","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":5.6,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":9.6,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":18.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.293101+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_338190","record_id":"REC_0013204","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":7.9,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.0,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.293409+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_325887","record_id":"REC_0013205","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":15,"tmb_mutations_per_mb":17.0,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":6.0,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.293680+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_920881","record_id":"REC_0013206","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":8,"primary_tumor_size_cm":4.8,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.293937+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_300240","record_id":"REC_0013207","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":4.7,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.294202+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_111704","record_id":"REC_0013208","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":5.9,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":26,"primary_tumor_size_cm":4.7,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.294450+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_478756","record_id":"REC_0013209","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":5.1,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":5.3,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.294839+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_144219","record_id":"REC_0013210","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":6.2,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":8.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.295150+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_635959","record_id":"REC_0013211","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":5.5,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.295452+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_495338","record_id":"REC_0013212","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":6.0,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":26.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.295721+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_423250","record_id":"REC_0013213","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":18.5,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":5.4,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.295994+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_441062","record_id":"REC_0013214","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":22.1,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":1,"smoking_pack_years":3,"primary_tumor_size_cm":5.1,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":23.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.296346+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_707925","record_id":"REC_0013215","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":2.8,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":22.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.296656+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_459007","record_id":"REC_0013216","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":0,"primary_tumor_size_cm":6.9,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.296977+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_608332","record_id":"REC_0013217","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":10.0,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":3,"smoking_pack_years":0,"primary_tumor_size_cm":4.2,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.297266+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_246288","record_id":"REC_0013218","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":19,"tmb_mutations_per_mb":8.0,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":43,"primary_tumor_size_cm":5.6,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.297557+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_782302","record_id":"REC_0013219","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":6.5,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.297817+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_933258","record_id":"REC_0013220","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":10.3,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":4,"primary_tumor_size_cm":5.9,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":18.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.298090+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_137628","record_id":"REC_0013221","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":21.1,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":5.3,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.298395+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_431975","record_id":"REC_0013222","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":16.7,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":7.2,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":20.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.298940+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_721236","record_id":"REC_0013223","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":1,"smoking_pack_years":47,"primary_tumor_size_cm":5.1,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":21.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.301475+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_202502","record_id":"REC_0013224","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":14.8,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":6.8,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.301954+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_826426","record_id":"REC_0013225","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":19,"tmb_mutations_per_mb":3.5,"age_at_diagnosis":52,"sex":"female","ecog_performance_status":0,"smoking_pack_years":34,"primary_tumor_size_cm":4.0,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.302327+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_902491","record_id":"REC_0013226","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":25.0,"age_at_diagnosis":82,"sex":"male","ecog_performance_status":3,"smoking_pack_years":6,"primary_tumor_size_cm":7.3,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":5.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.302632+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_893802","record_id":"REC_0013227","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":6.7,"age_at_diagnosis":52,"sex":"male","ecog_performance_status":0,"smoking_pack_years":54,"primary_tumor_size_cm":6.5,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.302942+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_391523","record_id":"REC_0013228","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":6.1,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.303255+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_667478","record_id":"REC_0013229","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":3,"smoking_pack_years":14,"primary_tumor_size_cm":6.6,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":5.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.303539+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_238178","record_id":"REC_0013230","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":35,"tmb_mutations_per_mb":15.4,"age_at_diagnosis":52,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":7.3,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":18.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.303833+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_690453","record_id":"REC_0013231","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":6.3,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":4.2,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.304197+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_609549","record_id":"REC_0013232","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":30,"tmb_mutations_per_mb":5.2,"age_at_diagnosis":49,"sex":"male","ecog_performance_status":0,"smoking_pack_years":31,"primary_tumor_size_cm":3.2,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.304562+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_408161","record_id":"REC_0013233","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":7.9,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":7.1,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.304932+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_351571","record_id":"REC_0013234","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":9.8,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":6.1,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.305266+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_319783","record_id":"REC_0013235","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":4.9,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":18.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.305786+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_684184","record_id":"REC_0013236","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":36,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":23,"primary_tumor_size_cm":6.4,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.306134+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_723452","record_id":"REC_0013237","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":15.6,"age_at_diagnosis":52,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":5.2,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.306433+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_277280","record_id":"REC_0013238","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":7.3,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.306748+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_705167","record_id":"REC_0013239","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":4.5,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":1,"smoking_pack_years":88,"primary_tumor_size_cm":6.8,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.307064+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_223367","record_id":"REC_0013240","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":13.8,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":3,"smoking_pack_years":14,"primary_tumor_size_cm":6.4,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.307384+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_448284","record_id":"REC_0013241","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":5.7,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":4.9,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.307692+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_199245","record_id":"REC_0013242","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":5.7,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":4.2,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.307970+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_379030","record_id":"REC_0013243","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":9.1,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":27,"primary_tumor_size_cm":6.0,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.308343+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_765450","record_id":"REC_0013244","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":16.6,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":5.0,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":47.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.308683+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_318799","record_id":"REC_0013245","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":5.7,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":6.4,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.308992+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_585846","record_id":"REC_0013246","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":7.1,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":21.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.309294+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_613380","record_id":"REC_0013247","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":14.1,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":3.6,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.309592+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_966634","record_id":"REC_0013248","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":18,"tmb_mutations_per_mb":14.4,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":8.2,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.310077+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_272179","record_id":"REC_0013249","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":34,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":3.8,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.310439+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_106229","record_id":"REC_0013250","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":20,"tmb_mutations_per_mb":5.6,"age_at_diagnosis":52,"sex":"female","ecog_performance_status":0,"smoking_pack_years":44,"primary_tumor_size_cm":5.0,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.310722+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_176543","record_id":"REC_0013251","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":4.9,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":47,"primary_tumor_size_cm":6.3,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":18.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.311018+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_164071","record_id":"REC_0013252","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":5.0,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.311307+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_125303","record_id":"REC_0013253","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":14.1,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":5.5,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.311656+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_105677","record_id":"REC_0013254","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":5.9,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":24.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.312047+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_478412","record_id":"REC_0013255","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":14.5,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":6.2,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.312461+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_626592","record_id":"REC_0013256","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":17.6,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":1,"primary_tumor_size_cm":5.8,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.312796+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_721625","record_id":"REC_0013257","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":19,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":0,"smoking_pack_years":39,"primary_tumor_size_cm":6.2,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.313092+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_603216","record_id":"REC_0013258","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":4.8,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":29.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.313434+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_684055","record_id":"REC_0013259","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":4.8,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":2,"smoking_pack_years":45,"primary_tumor_size_cm":5.6,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.313711+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_109174","record_id":"REC_0013260","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":4.2,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":35,"primary_tumor_size_cm":4.1,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":6.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.314005+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_114001","record_id":"REC_0013261","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":6.7,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":5.0,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.314441+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_941164","record_id":"REC_0013262","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":5.7,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":28.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.314769+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_872333","record_id":"REC_0013263","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":4.2,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":4.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.315113+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_930008","record_id":"REC_0013264","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":9.1,"age_at_diagnosis":76,"sex":"male","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":6.8,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.315468+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_353685","record_id":"REC_0013265","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":16.8,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":6.7,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.315840+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_208971","record_id":"REC_0013266","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":7.4,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":6.1,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.316356+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_916823","record_id":"REC_0013267","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":10.5,"age_at_diagnosis":75,"sex":"male","ecog_performance_status":1,"smoking_pack_years":26,"primary_tumor_size_cm":6.0,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.316751+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_598925","record_id":"REC_0013268","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":14.4,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":6.0,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":5.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.317081+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_742109","record_id":"REC_0013269","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":6.4,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":4.9,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":5.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.317403+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_869506","record_id":"REC_0013270","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":34,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":25,"primary_tumor_size_cm":4.4,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":7.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.317734+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_847343","record_id":"REC_0013271","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":4.6,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":0,"primary_tumor_size_cm":7.2,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.318095+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_867617","record_id":"REC_0013272","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":17.6,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":6.8,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.318431+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_662843","record_id":"REC_0013273","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":5.3,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":4.8,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.318753+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_916421","record_id":"REC_0013274","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":77,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":6.7,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.319270+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_787556","record_id":"REC_0013275","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":67,"primary_tumor_size_cm":7.7,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.319700+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_121720","record_id":"REC_0013276","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":18,"tmb_mutations_per_mb":16.2,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":6.8,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":6.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.324272+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_511370","record_id":"REC_0013277","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":3.8,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":52,"primary_tumor_size_cm":6.3,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.324820+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_149881","record_id":"REC_0013278","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":5.9,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":3.4,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":6.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.325168+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_539913","record_id":"REC_0013279","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":20,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":4.2,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.325485+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_456663","record_id":"REC_0013280","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":17,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":4.9,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":5.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.325771+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_827246","record_id":"REC_0013281","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":6.2,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.326075+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_353729","record_id":"REC_0013282","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":3.8,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.326406+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_511642","record_id":"REC_0013283","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":37,"tmb_mutations_per_mb":8.3,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":0,"primary_tumor_size_cm":5.0,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.326708+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_339478","record_id":"REC_0013284","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.0,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":2,"smoking_pack_years":2,"primary_tumor_size_cm":7.2,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.327008+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_396520","record_id":"REC_0013285","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":19.0,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":4.7,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.327305+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_610795","record_id":"REC_0013286","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":4.3,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":6.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.327591+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_626176","record_id":"REC_0013287","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":6.4,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":4,"primary_tumor_size_cm":5.8,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":67.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.330260+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_270099","record_id":"REC_0013288","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":7.3,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.9,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.330782+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_590304","record_id":"REC_0013289","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":77,"sex":"male","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":6.3,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":16.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.331170+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_683902","record_id":"REC_0013290","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":5.2,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":56,"primary_tumor_size_cm":4.3,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":23.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.331534+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_447248","record_id":"REC_0013291","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":4.6,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":44,"primary_tumor_size_cm":2.3,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.331868+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_441851","record_id":"REC_0013292","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":3.6,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":3,"smoking_pack_years":44,"primary_tumor_size_cm":5.0,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":23.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.332913+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_454809","record_id":"REC_0013293","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":8.7,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":54,"primary_tumor_size_cm":7.1,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.333385+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_966789","record_id":"REC_0013294","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":16.1,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.5,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":19.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.333739+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_868136","record_id":"REC_0013295","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":5.8,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.334065+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_498382","record_id":"REC_0013296","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":4.7,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.334377+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_247851","record_id":"REC_0013297","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":16.4,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":7.6,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.334796+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_103201","record_id":"REC_0013298","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":3,"smoking_pack_years":14,"primary_tumor_size_cm":7.1,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.335152+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_706274","record_id":"REC_0013299","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":16.0,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":22,"primary_tumor_size_cm":5.4,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.335500+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_814417","record_id":"REC_0013300","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":6.2,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":17.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.336041+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_960218","record_id":"REC_0013301","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":2,"smoking_pack_years":20,"primary_tumor_size_cm":5.8,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.336699+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_828803","record_id":"REC_0013302","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":6.9,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":6.0,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":4.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.337074+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_622061","record_id":"REC_0013303","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":21,"primary_tumor_size_cm":3.7,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":16.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.337407+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_636836","record_id":"REC_0013304","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":7.0,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":23.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.337760+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_796108","record_id":"REC_0013305","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":4.8,"metastatic_sites_count":3,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.338108+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_857353","record_id":"REC_0013306","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":17,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":20,"primary_tumor_size_cm":7.3,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":18.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.338460+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_105277","record_id":"REC_0013307","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":12,"tmb_mutations_per_mb":7.9,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":2,"smoking_pack_years":20,"primary_tumor_size_cm":5.3,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":18.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.338792+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_226140","record_id":"REC_0013308","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":5.5,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.339113+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_581001","record_id":"REC_0013309","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":2,"smoking_pack_years":21,"primary_tumor_size_cm":4.0,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.339426+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_941185","record_id":"REC_0013310","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":9.1,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":0,"smoking_pack_years":27,"primary_tumor_size_cm":4.3,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":22.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.339735+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_890789","record_id":"REC_0013311","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.3,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":7.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.340052+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_394813","record_id":"REC_0013312","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":4,"primary_tumor_size_cm":3.5,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.340769+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_126163","record_id":"REC_0013313","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":6.9,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":67,"primary_tumor_size_cm":4.2,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":16.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.341345+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_807237","record_id":"REC_0013314","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":2,"primary_tumor_size_cm":6.0,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.341733+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_927993","record_id":"REC_0013315","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":18,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":3,"smoking_pack_years":16,"primary_tumor_size_cm":4.6,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.342107+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_776727","record_id":"REC_0013316","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":31,"tmb_mutations_per_mb":13.1,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":20,"primary_tumor_size_cm":9.1,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.342401+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_980469","record_id":"REC_0013317","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":35,"tmb_mutations_per_mb":13.1,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":2,"smoking_pack_years":20,"primary_tumor_size_cm":6.0,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.342694+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_998835","record_id":"REC_0013318","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":16.9,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":27,"primary_tumor_size_cm":5.6,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.342993+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_254096","record_id":"REC_0013319","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":31,"tmb_mutations_per_mb":8.3,"age_at_diagnosis":53,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":5.8,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.343280+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_549419","record_id":"REC_0013320","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":4.7,"metastatic_sites_count":3,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":7.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.343575+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_228328","record_id":"REC_0013321","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":30,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":4,"primary_tumor_size_cm":7.8,"metastatic_sites_count":8,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":5.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.343861+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_376101","record_id":"REC_0013322","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":15.6,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":5.9,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":25.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.344193+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_368791","record_id":"REC_0013323","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":19.7,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":5.8,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":30.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.344511+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_381679","record_id":"REC_0013324","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":2.2,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":91,"primary_tumor_size_cm":3.3,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":22.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.344791+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_805181","record_id":"REC_0013325","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":14.3,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":6.9,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.345078+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_221917","record_id":"REC_0013326","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":17,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":0,"smoking_pack_years":64,"primary_tumor_size_cm":4.2,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":6.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.345463+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_597023","record_id":"REC_0013327","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":15.5,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":6.8,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.345773+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_158535","record_id":"REC_0013328","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":31,"tmb_mutations_per_mb":7.4,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":5.0,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.346067+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_624587","record_id":"REC_0013329","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":8.5,"age_at_diagnosis":86,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":6.4,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":17.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.346363+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_861403","record_id":"REC_0013330","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":19,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":1,"smoking_pack_years":54,"primary_tumor_size_cm":7.0,"metastatic_sites_count":3,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":17.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.346656+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_364059","record_id":"REC_0013331","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":3,"smoking_pack_years":26,"primary_tumor_size_cm":5.7,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.347037+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_929515","record_id":"REC_0013332","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":18.0,"age_at_diagnosis":90,"sex":"male","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":2.9,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.347390+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_965675","record_id":"REC_0013333","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":10.3,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":3.8,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.347762+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_628814","record_id":"REC_0013334","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":31,"tmb_mutations_per_mb":2.2,"age_at_diagnosis":88,"sex":"male","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":3.7,"metastatic_sites_count":9,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":5.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.348138+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_855854","record_id":"REC_0013335","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":16.6,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":24,"primary_tumor_size_cm":5.5,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":7.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.348524+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_424539","record_id":"REC_0013336","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":18,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":6.1,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.348880+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_255754","record_id":"REC_0013337","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":15,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":4.5,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":26.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.349222+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_340273","record_id":"REC_0013338","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":34,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":3.7,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.349528+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_525300","record_id":"REC_0013339","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":9.8,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":5.4,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.349978+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_878515","record_id":"REC_0013340","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":32,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":3.9,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":23.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.350318+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_796478","record_id":"REC_0013341","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":14.3,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":23,"primary_tumor_size_cm":3.8,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":21.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.350621+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_106465","record_id":"REC_0013342","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":53,"primary_tumor_size_cm":5.3,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.350928+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_235410","record_id":"REC_0013343","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":13,"tmb_mutations_per_mb":7.6,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":6.4,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.351236+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_808105","record_id":"REC_0013344","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":6.8,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":6.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.351538+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_698461","record_id":"REC_0013345","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":9.1,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":4.9,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.351828+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_520822","record_id":"REC_0013346","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":6.4,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.352173+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_751395","record_id":"REC_0013347","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":3.0,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.352532+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_442570","record_id":"REC_0013348","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":46,"sex":"male","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":6.7,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.352843+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_345664","record_id":"REC_0013349","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":6.2,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.353147+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_965841","record_id":"REC_0013350","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":14.1,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":5.6,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.353444+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_550851","record_id":"REC_0013351","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":6.2,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.353739+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_538127","record_id":"REC_0013352","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":4.0,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.354180+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_733155","record_id":"REC_0013353","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":6.4,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":41,"primary_tumor_size_cm":4.9,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":18.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.354510+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_592682","record_id":"REC_0013354","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":15,"tmb_mutations_per_mb":15.8,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":25,"primary_tumor_size_cm":6.3,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":35.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.354810+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_381547","record_id":"REC_0013355","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":13.1,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":5.4,"metastatic_sites_count":8,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":16.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.355106+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_224240","record_id":"REC_0013356","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":4.7,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":34,"primary_tumor_size_cm":6.3,"metastatic_sites_count":3,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":7.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.355415+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_879449","record_id":"REC_0013357","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":25,"primary_tumor_size_cm":7.5,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":29.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.355728+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_961896","record_id":"REC_0013358","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":60,"primary_tumor_size_cm":5.0,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.356018+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_277728","record_id":"REC_0013359","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":3.5,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":24.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.356849+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_924939","record_id":"REC_0013360","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":35,"primary_tumor_size_cm":4.7,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":4.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.357198+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_355677","record_id":"REC_0013361","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":5.3,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":0,"smoking_pack_years":1,"primary_tumor_size_cm":5.5,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":16.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.357521+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_616790","record_id":"REC_0013362","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":14.8,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":3,"smoking_pack_years":15,"primary_tumor_size_cm":5.9,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.357813+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_888096","record_id":"REC_0013363","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":31,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":5.9,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":57.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.358107+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_797793","record_id":"REC_0013364","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":14.4,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":4.2,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":22.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.358407+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_644024","record_id":"REC_0013365","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":14.8,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":25,"primary_tumor_size_cm":5.5,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":5.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.358884+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_148312","record_id":"REC_0013366","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":16,"tmb_mutations_per_mb":17.2,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":6.2,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":22.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.359263+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_333026","record_id":"REC_0013367","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":16.0,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":5.2,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":4.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.359602+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_648956","record_id":"REC_0013368","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":85,"sex":"male","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":5.6,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.359937+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_148438","record_id":"REC_0013369","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":31,"tmb_mutations_per_mb":15.0,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":4.0,"metastatic_sites_count":3,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.360967+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_461557","record_id":"REC_0013370","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":5.4,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.361335+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_603601","record_id":"REC_0013371","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":31,"tmb_mutations_per_mb":5.7,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":38,"primary_tumor_size_cm":5.6,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.361649+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_380977","record_id":"REC_0013372","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":54,"sex":"female","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":4.9,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.361967+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_252700","record_id":"REC_0013373","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":4.6,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":4.1,"metastatic_sites_count":8,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.362268+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_681939","record_id":"REC_0013374","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":6.3,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":9.0,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.362560+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_742590","record_id":"REC_0013375","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":5.3,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.362866+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_950770","record_id":"REC_0013376","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":7.6,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":5.7,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":27.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.363168+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_736908","record_id":"REC_0013377","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":6.3,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":21.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.363493+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_515275","record_id":"REC_0013378","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":9.7,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":3,"smoking_pack_years":11,"primary_tumor_size_cm":6.5,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":22.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.363984+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_560309","record_id":"REC_0013379","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":14.4,"age_at_diagnosis":54,"sex":"male","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":6.0,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.364723+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_631573","record_id":"REC_0013380","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":19,"tmb_mutations_per_mb":20.6,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":3.0,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.365136+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_243929","record_id":"REC_0013381","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":13.3,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.2,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":8.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.365497+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_587033","record_id":"REC_0013382","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":4.2,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":20,"primary_tumor_size_cm":7.7,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.365837+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_358484","record_id":"REC_0013383","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":6.1,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":7.6,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":19.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.366700+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_415883","record_id":"REC_0013384","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":30,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":43,"primary_tumor_size_cm":5.5,"metastatic_sites_count":8,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.367107+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_301417","record_id":"REC_0013385","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":4.6,"metastatic_sites_count":9,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.367525+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_359768","record_id":"REC_0013386","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":7.1,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.367858+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_289612","record_id":"REC_0013387","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":9.7,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":22,"primary_tumor_size_cm":3.5,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.368283+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_558597","record_id":"REC_0013388","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":16,"tmb_mutations_per_mb":4.9,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.3,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.368652+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_477341","record_id":"REC_0013389","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":3.8,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":76,"primary_tumor_size_cm":7.7,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":31.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.368976+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_881568","record_id":"REC_0013390","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":4.7,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":21.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.369271+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_712388","record_id":"REC_0013391","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":3.3,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.369762+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_510929","record_id":"REC_0013392","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":19,"tmb_mutations_per_mb":7.3,"age_at_diagnosis":50,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":6.5,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":20.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.370143+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_725211","record_id":"REC_0013393","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":3.8,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":6.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.370509+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_536569","record_id":"REC_0013394","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":16,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":3,"smoking_pack_years":20,"primary_tumor_size_cm":5.8,"metastatic_sites_count":8,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":17.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.370849+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_812333","record_id":"REC_0013395","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":53,"sex":"male","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":4.8,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.371221+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_593400","record_id":"REC_0013396","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":30,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":6.6,"metastatic_sites_count":8,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":8.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.371567+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_871419","record_id":"REC_0013397","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":5.5,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":25,"primary_tumor_size_cm":6.4,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.371892+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_853223","record_id":"REC_0013398","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.4,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.375602+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_604680","record_id":"REC_0013399","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":15.1,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":10,"primary_tumor_size_cm":6.4,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.376158+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_430842","record_id":"REC_0013400","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":2.0,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":6.2,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":24.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.376762+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_555527","record_id":"REC_0013401","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":46,"primary_tumor_size_cm":6.5,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.377161+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_833778","record_id":"REC_0013402","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":30,"tmb_mutations_per_mb":6.0,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":0,"smoking_pack_years":36,"primary_tumor_size_cm":6.1,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.377483+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_354952","record_id":"REC_0013403","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":8.1,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":0,"smoking_pack_years":44,"primary_tumor_size_cm":5.5,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":5.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.377786+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_218570","record_id":"REC_0013404","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":10,"primary_tumor_size_cm":4.2,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":21.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.378262+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_119975","record_id":"REC_0013405","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":3.1,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":4.5,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.378620+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_764749","record_id":"REC_0013406","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":16.5,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":2,"smoking_pack_years":6,"primary_tumor_size_cm":5.3,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.378956+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_792436","record_id":"REC_0013407","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":14.9,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":4.8,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.379292+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_410564","record_id":"REC_0013408","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":6.3,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":6.3,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.379624+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_250339","record_id":"REC_0013409","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":13,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":4.0,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.379933+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_210678","record_id":"REC_0013410","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":7.6,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":7.3,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.380390+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_823752","record_id":"REC_0013411","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":5.5,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":5.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.380754+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_546296","record_id":"REC_0013412","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":14.1,"age_at_diagnosis":52,"sex":"male","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":4.7,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.381097+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_547405","record_id":"REC_0013413","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":14.9,"age_at_diagnosis":51,"sex":"male","ecog_performance_status":0,"smoking_pack_years":29,"primary_tumor_size_cm":4.0,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":34.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.381414+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_244068","record_id":"REC_0013414","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":20.0,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":3.2,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":7.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.381737+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_774776","record_id":"REC_0013415","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":10,"primary_tumor_size_cm":5.4,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":26.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.382114+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_872439","record_id":"REC_0013416","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":34,"primary_tumor_size_cm":4.0,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":22.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.382477+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_459208","record_id":"REC_0013417","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":4.2,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.382977+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_548754","record_id":"REC_0013418","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":8.0,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":4.5,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.383382+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_502110","record_id":"REC_0013419","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":16.6,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":6.1,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.383775+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_765907","record_id":"REC_0013420","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":17.0,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":6.2,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":18.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.384566+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_112952","record_id":"REC_0013421","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":20.9,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":5.2,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":20.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.385037+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_954406","record_id":"REC_0013422","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":7.4,"age_at_diagnosis":52,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":6.7,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.385408+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_677958","record_id":"REC_0013423","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":16,"tmb_mutations_per_mb":13.8,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":26,"primary_tumor_size_cm":5.5,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":26.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.385805+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_459012","record_id":"REC_0013424","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":11.0,"age_at_diagnosis":85,"sex":"male","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":4.0,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.386202+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_484351","record_id":"REC_0013425","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":16.5,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":4.0,"metastatic_sites_count":8,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.386648+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_704935","record_id":"REC_0013426","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":16.3,"age_at_diagnosis":89,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":6.8,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.387074+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_367644","record_id":"REC_0013427","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":4.5,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":19.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.387470+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_924329","record_id":"REC_0013428","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":31,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":82,"primary_tumor_size_cm":4.5,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.387814+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_818718","record_id":"REC_0013429","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":30,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":6.2,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":21.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.389179+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_954958","record_id":"REC_0013430","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":6.2,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.389822+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_372979","record_id":"REC_0013431","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":6.9,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.390230+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_822681","record_id":"REC_0013432","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":2,"smoking_pack_years":1,"primary_tumor_size_cm":4.0,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":29.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.390570+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_201781","record_id":"REC_0013433","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":2.6,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":43,"primary_tumor_size_cm":6.3,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":38.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.390883+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_752352","record_id":"REC_0013434","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":5.2,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":48,"primary_tumor_size_cm":5.5,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":24.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.391199+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_477278","record_id":"REC_0013435","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":6.4,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":5.8,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":30.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.391515+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_546213","record_id":"REC_0013436","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":7.5,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":23.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.391831+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_558838","record_id":"REC_0013437","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":19,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":29,"primary_tumor_size_cm":5.9,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.392972+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_885463","record_id":"REC_0013438","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":5.0,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.393440+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_788053","record_id":"REC_0013439","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":4.2,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":20.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.393793+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_654532","record_id":"REC_0013440","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":8.5,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":1,"smoking_pack_years":0,"primary_tumor_size_cm":6.1,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.394107+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_645395","record_id":"REC_0013441","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":54,"sex":"male","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":5.0,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.394416+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_733466","record_id":"REC_0013442","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":6.3,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":68,"primary_tumor_size_cm":7.5,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.394707+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_670556","record_id":"REC_0013443","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":32,"tmb_mutations_per_mb":6.7,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":6.2,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.395146+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_542944","record_id":"REC_0013444","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":5.8,"metastatic_sites_count":8,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":4.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.395464+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_843388","record_id":"REC_0013445","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":14,"tmb_mutations_per_mb":7.4,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":5.7,"metastatic_sites_count":8,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.395756+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_824578","record_id":"REC_0013446","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":16.4,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":5.7,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.396041+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_786702","record_id":"REC_0013447","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":31,"tmb_mutations_per_mb":14.3,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":7.7,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":23.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.396824+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_855793","record_id":"REC_0013448","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":9.9,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":8.0,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.397176+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_229577","record_id":"REC_0013449","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":3,"primary_tumor_size_cm":5.5,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":16.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.397479+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_863093","record_id":"REC_0013450","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":74,"sex":"male","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":4.5,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.397782+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_577716","record_id":"REC_0013451","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":14.0,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":6,"primary_tumor_size_cm":5.6,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.398126+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_498954","record_id":"REC_0013452","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":16.2,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":3.9,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":27.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.398480+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_264178","record_id":"REC_0013453","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":17.0,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":6.9,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.398837+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_173247","record_id":"REC_0013454","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":4.8,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":2,"primary_tumor_size_cm":5.7,"metastatic_sites_count":3,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.399157+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_488318","record_id":"REC_0013455","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":30,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":1,"smoking_pack_years":28,"primary_tumor_size_cm":2.7,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":18.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.399482+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_239879","record_id":"REC_0013456","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":8.5,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":4.4,"metastatic_sites_count":8,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.400061+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_136659","record_id":"REC_0013457","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":6.7,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":20.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.400556+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_683975","record_id":"REC_0013458","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":6.3,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":3.4,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.400924+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_530590","record_id":"REC_0013459","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":15.7,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":7.6,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.401248+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_870645","record_id":"REC_0013460","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":8.1,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":4.8,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.401548+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_501794","record_id":"REC_0013461","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":7.6,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":30,"primary_tumor_size_cm":5.3,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.401844+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_151562","record_id":"REC_0013462","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":14.0,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":6.3,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.402161+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_641299","record_id":"REC_0013463","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":68,"primary_tumor_size_cm":4.5,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":31.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.402490+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_306831","record_id":"REC_0013464","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":15.2,"age_at_diagnosis":74,"sex":"male","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":6.1,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.402860+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_507038","record_id":"REC_0013465","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":6.3,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.403206+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_859546","record_id":"REC_0013466","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":14.4,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":5.9,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.403549+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_268885","record_id":"REC_0013467","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":3.7,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.403899+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_691377","record_id":"REC_0013468","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":11.1,"age_at_diagnosis":76,"sex":"male","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":2.4,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":26.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.404736+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_375091","record_id":"REC_0013469","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":5.5,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":8,"primary_tumor_size_cm":5.3,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.405303+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_950742","record_id":"REC_0013470","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":34,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":4.6,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.405658+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_443881","record_id":"REC_0013471","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":33,"tmb_mutations_per_mb":4.6,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":71,"primary_tumor_size_cm":5.7,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":20.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.405977+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_634701","record_id":"REC_0013472","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":18,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":31,"primary_tumor_size_cm":6.1,"metastatic_sites_count":3,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.406289+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_727793","record_id":"REC_0013473","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":76,"sex":"male","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.5,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.406597+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_876312","record_id":"REC_0013474","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":25,"primary_tumor_size_cm":4.3,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.406891+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_593620","record_id":"REC_0013475","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":4.1,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":4.4,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.407188+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_156798","record_id":"REC_0013476","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":6.5,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":19.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.407475+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_762753","record_id":"REC_0013477","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":8.4,"age_at_diagnosis":78,"sex":"male","ecog_performance_status":1,"smoking_pack_years":46,"primary_tumor_size_cm":5.7,"metastatic_sites_count":9,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.407758+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_295729","record_id":"REC_0013478","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":8.6,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":5.6,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.408064+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_623158","record_id":"REC_0013479","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":21.8,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":6.8,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":26.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.408845+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_208895","record_id":"REC_0013480","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":14.1,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":7.2,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.409249+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_939775","record_id":"REC_0013481","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":9.5,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":4.9,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.409568+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_879647","record_id":"REC_0013482","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":5.2,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":6.0,"metastatic_sites_count":9,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.410038+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_664625","record_id":"REC_0013483","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":3,"smoking_pack_years":20,"primary_tumor_size_cm":4.1,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.410386+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_387414","record_id":"REC_0013484","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":6.0,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.410701+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_526385","record_id":"REC_0013485","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":30,"tmb_mutations_per_mb":14.3,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":6.5,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.411015+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_112945","record_id":"REC_0013486","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":32,"tmb_mutations_per_mb":15.0,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":7,"primary_tumor_size_cm":6.0,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":23.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.411310+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_248788","record_id":"REC_0013487","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":16,"tmb_mutations_per_mb":16.9,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":6.3,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":16.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.411611+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_121129","record_id":"REC_0013488","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":3.4,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":46,"primary_tumor_size_cm":3.9,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":22.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.411915+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_338758","record_id":"REC_0013489","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":30,"tmb_mutations_per_mb":20.4,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":6.0,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":24.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.412307+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_402311","record_id":"REC_0013490","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":10.3,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":6.3,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.412635+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_487630","record_id":"REC_0013491","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":5.9,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":5.9,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":18.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.412939+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_621277","record_id":"REC_0013492","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":6.0,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.413240+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_377283","record_id":"REC_0013493","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.9,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.413562+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_572825","record_id":"REC_0013494","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":18.7,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":3.5,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.413872+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_857491","record_id":"REC_0013495","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":8.9,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":3.2,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":26.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.414351+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_869101","record_id":"REC_0013496","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":7.4,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.414696+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_904250","record_id":"REC_0013497","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":20,"primary_tumor_size_cm":7.5,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.415029+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_447538","record_id":"REC_0013498","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":5.1,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":23.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.415371+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_294883","record_id":"REC_0013499","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":49,"sex":"male","ecog_performance_status":0,"smoking_pack_years":0,"primary_tumor_size_cm":7.5,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.415699+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_601219","record_id":"REC_0013500","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":17,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":4.9,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":28.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.416025+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_350597","record_id":"REC_0013501","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":20,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":82,"sex":"male","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":6.7,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":24.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.416457+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_909247","record_id":"REC_0013502","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":3.9,"age_at_diagnosis":54,"sex":"male","ecog_performance_status":0,"smoking_pack_years":27,"primary_tumor_size_cm":7.6,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.416810+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_262804","record_id":"REC_0013503","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":5.2,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":19.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.417148+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_843066","record_id":"REC_0013504","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":15,"tmb_mutations_per_mb":8.9,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":8,"primary_tumor_size_cm":3.5,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.417448+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_238859","record_id":"REC_0013505","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":14.9,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":6.6,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.417745+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_719759","record_id":"REC_0013506","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":19,"tmb_mutations_per_mb":6.0,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":0,"smoking_pack_years":2,"primary_tumor_size_cm":6.6,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.418047+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_860536","record_id":"REC_0013507","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":14.4,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":5.5,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.418365+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_286282","record_id":"REC_0013508","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":18,"tmb_mutations_per_mb":13.6,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":7.0,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":36.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.418855+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_824267","record_id":"REC_0013509","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":5.3,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.419241+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_948987","record_id":"REC_0013510","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":15.2,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":6.6,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.419584+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_167198","record_id":"REC_0013511","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":7.4,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":4.8,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.419945+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_221578","record_id":"REC_0013512","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":36,"tmb_mutations_per_mb":15.0,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":6.0,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.420411+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_677221","record_id":"REC_0013513","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":18.6,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":5.8,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":18.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.420828+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_346021","record_id":"REC_0013514","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":7.4,"age_at_diagnosis":51,"sex":"female","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":6.7,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.421234+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_517624","record_id":"REC_0013515","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":5.0,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.421610+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_988684","record_id":"REC_0013516","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":53,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":4.3,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":5.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.422004+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_738351","record_id":"REC_0013517","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":13.8,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":6.9,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":6.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.422402+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_928167","record_id":"REC_0013518","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":9.8,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":4.8,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":6.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.422780+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_317065","record_id":"REC_0013519","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":32,"tmb_mutations_per_mb":4.3,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":33,"primary_tumor_size_cm":3.7,"metastatic_sites_count":8,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.423178+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_394224","record_id":"REC_0013520","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":4.0,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":38.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.423577+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_351236","record_id":"REC_0013521","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":15.7,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":3.5,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":7.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.424223+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_578374","record_id":"REC_0013522","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":0,"smoking_pack_years":6,"primary_tumor_size_cm":6.0,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.424661+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_834283","record_id":"REC_0013523","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":9.7,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":6,"primary_tumor_size_cm":5.8,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":18.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.425020+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_502516","record_id":"REC_0013524","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":4.0,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":1,"smoking_pack_years":26,"primary_tumor_size_cm":6.2,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.425378+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_689161","record_id":"REC_0013525","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":4,"primary_tumor_size_cm":6.3,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.425731+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_363745","record_id":"REC_0013526","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":61,"primary_tumor_size_cm":3.7,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.426078+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_716702","record_id":"REC_0013527","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":35,"tmb_mutations_per_mb":18.5,"age_at_diagnosis":77,"sex":"male","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":3.7,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.426442+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_522266","record_id":"REC_0013528","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":14.8,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":1,"smoking_pack_years":5,"primary_tumor_size_cm":8.2,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":7.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.426804+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_538954","record_id":"REC_0013529","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":11,"tmb_mutations_per_mb":16.5,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":3.9,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":17.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.427154+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_461702","record_id":"REC_0013530","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":0,"smoking_pack_years":5,"primary_tumor_size_cm":4.3,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.427545+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_297112","record_id":"REC_0013531","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":84,"sex":"female","ecog_performance_status":2,"smoking_pack_years":20,"primary_tumor_size_cm":4.9,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":18.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.427952+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_285103","record_id":"REC_0013532","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":50,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":3.9,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":29.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.428452+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_941935","record_id":"REC_0013533","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":10.1,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":6.1,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":55.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.428897+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_285000","record_id":"REC_0013534","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":10.0,"age_at_diagnosis":83,"sex":"female","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":4.0,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.429462+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_864717","record_id":"REC_0013535","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":0,"smoking_pack_years":53,"primary_tumor_size_cm":5.7,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":24.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.429875+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_796955","record_id":"REC_0013536","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":25,"primary_tumor_size_cm":4.3,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.430241+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_860062","record_id":"REC_0013537","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":14.5,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":4.7,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.430588+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_300566","record_id":"REC_0013538","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":17.6,"age_at_diagnosis":54,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":6.1,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.430902+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_355078","record_id":"REC_0013539","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":18.3,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":4.5,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.431226+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_336004","record_id":"REC_0013540","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":6.1,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.431548+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_357730","record_id":"REC_0013541","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":9.1,"age_at_diagnosis":87,"sex":"female","ecog_performance_status":2,"smoking_pack_years":20,"primary_tumor_size_cm":5.7,"metastatic_sites_count":3,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.431853+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_496998","record_id":"REC_0013542","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":52,"sex":"male","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":7.4,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.432221+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_765464","record_id":"REC_0013543","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":16,"tmb_mutations_per_mb":9.0,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":4.6,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":6.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.432562+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_687655","record_id":"REC_0013544","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":5.1,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.432861+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_352386","record_id":"REC_0013545","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":8.7,"age_at_diagnosis":79,"sex":"male","ecog_performance_status":1,"smoking_pack_years":24,"primary_tumor_size_cm":4.0,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":30.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.433159+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_941004","record_id":"REC_0013546","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":31,"tmb_mutations_per_mb":4.2,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":0,"smoking_pack_years":26,"primary_tumor_size_cm":4.5,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":16.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.433464+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_553869","record_id":"REC_0013547","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":5.0,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":4.8,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":19.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.433913+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_627847","record_id":"REC_0013548","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":88,"primary_tumor_size_cm":5.0,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.434257+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_679716","record_id":"REC_0013549","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":14.4,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":6.5,"metastatic_sites_count":3,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":16.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.434569+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_548999","record_id":"REC_0013550","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":18,"tmb_mutations_per_mb":17.7,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":5.7,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.434892+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_764466","record_id":"REC_0013551","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":16.0,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":4.5,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":18.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.435221+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_486777","record_id":"REC_0013552","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":19,"tmb_mutations_per_mb":4.8,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":5.8,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.435537+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_361806","record_id":"REC_0013553","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":16.9,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":20,"primary_tumor_size_cm":4.3,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.435856+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_462433","record_id":"REC_0013554","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":8.4,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":5.6,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.436221+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_855718","record_id":"REC_0013555","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":5.7,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.436553+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_416500","record_id":"REC_0013556","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":9.8,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":4.9,"metastatic_sites_count":10,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.436860+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_840744","record_id":"REC_0013557","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":9.1,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":2.9,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.437148+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_162843","record_id":"REC_0013558","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":37,"tmb_mutations_per_mb":4.8,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":3,"smoking_pack_years":23,"primary_tumor_size_cm":7.2,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":23.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.437918+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_412876","record_id":"REC_0013559","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":18,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":3,"smoking_pack_years":9,"primary_tumor_size_cm":3.8,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.438301+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_255713","record_id":"REC_0013560","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":6.2,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.438792+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_266185","record_id":"REC_0013561","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":31,"tmb_mutations_per_mb":7.4,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":40,"primary_tumor_size_cm":4.9,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.439145+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_237995","record_id":"REC_0013562","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":16.3,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":3,"smoking_pack_years":10,"primary_tumor_size_cm":5.7,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.439471+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_106842","record_id":"REC_0013563","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":14.7,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":33,"primary_tumor_size_cm":5.2,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.439797+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_347685","record_id":"REC_0013564","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":6.7,"age_at_diagnosis":46,"sex":"female","ecog_performance_status":0,"smoking_pack_years":1,"primary_tumor_size_cm":5.2,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":6.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.440154+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_230696","record_id":"REC_0013565","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":9.8,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":6.4,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.440547+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_329636","record_id":"REC_0013566","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":32,"tmb_mutations_per_mb":15.7,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":0,"smoking_pack_years":26,"primary_tumor_size_cm":6.1,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.440872+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_938503","record_id":"REC_0013567","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":20.3,"age_at_diagnosis":77,"sex":"male","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":6.2,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.441176+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_747768","record_id":"REC_0013568","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":19,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":5.2,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":29.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.441473+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_218879","record_id":"REC_0013569","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":15,"tmb_mutations_per_mb":5.2,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":7.2,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":7.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.441770+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_429702","record_id":"REC_0013570","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":33,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":56,"primary_tumor_size_cm":6.5,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":20.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.442066+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_828812","record_id":"REC_0013571","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":11.5,"age_at_diagnosis":78,"sex":"male","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":4.5,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.442375+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_105808","record_id":"REC_0013572","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":7.6,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":5.5,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":20.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.442676+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_880698","record_id":"REC_0013573","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":34,"tmb_mutations_per_mb":18.8,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":5.8,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":32.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.443150+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_329511","record_id":"REC_0013574","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":4.2,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":16.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.443491+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_242367","record_id":"REC_0013575","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":5.3,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.443799+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_285696","record_id":"REC_0013576","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":5.3,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":56,"primary_tumor_size_cm":4.5,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":17.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.444144+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_748425","record_id":"REC_0013577","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":15.0,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.8,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":20.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.444519+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_141252","record_id":"REC_0013578","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":53,"sex":"male","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":6.9,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.444846+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_972083","record_id":"REC_0013579","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":0,"smoking_pack_years":29,"primary_tumor_size_cm":6.0,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":18.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.445162+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_227097","record_id":"REC_0013580","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":5.9,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":2.7,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":19.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.445491+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_547395","record_id":"REC_0013581","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":20,"tmb_mutations_per_mb":7.3,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":28,"primary_tumor_size_cm":6.3,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":25.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.445820+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_165386","record_id":"REC_0013582","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":32,"tmb_mutations_per_mb":10.5,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.4,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.446120+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_280359","record_id":"REC_0013583","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":13.8,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":26,"primary_tumor_size_cm":5.1,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.446423+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_583296","record_id":"REC_0013584","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":15.4,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":5.2,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.446707+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_149378","record_id":"REC_0013585","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":4.9,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":1,"smoking_pack_years":1,"primary_tumor_size_cm":6.7,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":23.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.447043+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_244221","record_id":"REC_0013586","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":3,"primary_tumor_size_cm":7.6,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.447494+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_315782","record_id":"REC_0013587","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":11.0,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":5.7,"metastatic_sites_count":8,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.447836+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_121163","record_id":"REC_0013588","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":13.6,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":5.3,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.448204+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_546957","record_id":"REC_0013589","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":7.8,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":33.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.448537+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_748992","record_id":"REC_0013590","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":10.5,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":4,"smoking_pack_years":7,"primary_tumor_size_cm":6.2,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.448891+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_404984","record_id":"REC_0013591","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":50,"primary_tumor_size_cm":5.7,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":16.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.449252+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_533439","record_id":"REC_0013592","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":6.8,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":36.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.449604+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_381536","record_id":"REC_0013593","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":11.0,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":4.3,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.449943+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_791168","record_id":"REC_0013594","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":53,"primary_tumor_size_cm":4.7,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":5.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.450278+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_802410","record_id":"REC_0013595","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":3,"smoking_pack_years":22,"primary_tumor_size_cm":5.5,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":19.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.450613+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_920194","record_id":"REC_0013596","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":0,"smoking_pack_years":81,"primary_tumor_size_cm":2.7,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.450932+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_931902","record_id":"REC_0013597","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":6.5,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.451222+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_768499","record_id":"REC_0013598","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":6.7,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.451529+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_201932","record_id":"REC_0013599","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":2,"smoking_pack_years":7,"primary_tumor_size_cm":6.8,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.451994+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_219366","record_id":"REC_0013600","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":8.0,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":6,"primary_tumor_size_cm":9.5,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.452462+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_190192","record_id":"REC_0013601","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":3,"smoking_pack_years":17,"primary_tumor_size_cm":6.3,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.452850+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_316221","record_id":"REC_0013602","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":17.3,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":3,"smoking_pack_years":5,"primary_tumor_size_cm":6.9,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.453222+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_994463","record_id":"REC_0013603","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":14,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":4.8,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":27.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.453579+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_373334","record_id":"REC_0013604","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":24,"primary_tumor_size_cm":6.3,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.453906+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_423784","record_id":"REC_0013605","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":14,"tmb_mutations_per_mb":9.9,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":4.4,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.454198+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_641339","record_id":"REC_0013606","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":36,"tmb_mutations_per_mb":10.5,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":7.1,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":19.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.454491+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_425581","record_id":"REC_0013607","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":9.5,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":6.1,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.454806+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_693906","record_id":"REC_0013608","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":0,"primary_tumor_size_cm":4.9,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":7.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.455126+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_355798","record_id":"REC_0013609","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":17.0,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":6.8,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.455444+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_280021","record_id":"REC_0013610","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":61,"primary_tumor_size_cm":6.5,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.455732+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_482784","record_id":"REC_0013611","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":10.0,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":6.2,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.456017+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_516813","record_id":"REC_0013612","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":37,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":29,"primary_tumor_size_cm":9.2,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.456513+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_203077","record_id":"REC_0013613","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":0,"smoking_pack_years":30,"primary_tumor_size_cm":6.2,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":23.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.456826+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_475825","record_id":"REC_0013614","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":17.6,"age_at_diagnosis":82,"sex":"male","ecog_performance_status":2,"smoking_pack_years":26,"primary_tumor_size_cm":2.6,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":7.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.457126+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_640362","record_id":"REC_0013615","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":8.6,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":4.1,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.457420+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_654478","record_id":"REC_0013616","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":8.4,"age_at_diagnosis":52,"sex":"male","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":7.0,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":26.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.457697+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_366170","record_id":"REC_0013617","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":5.0,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.458003+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_652616","record_id":"REC_0013618","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":4.4,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":3.2,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.458300+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_170509","record_id":"REC_0013619","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":20,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":65,"primary_tumor_size_cm":3.1,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.458619+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_609350","record_id":"REC_0013620","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":22.3,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":7.3,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.458950+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_237084","record_id":"REC_0013621","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":15.5,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":8.1,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":16.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.459269+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_144807","record_id":"REC_0013622","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":4.0,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":4.9,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.459560+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_127505","record_id":"REC_0013623","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":6.3,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":30.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.459875+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_572808","record_id":"REC_0013624","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":4.4,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.460377+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_284701","record_id":"REC_0013625","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":10.5,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":6.2,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.460914+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_517124","record_id":"REC_0013626","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":15.4,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":6.0,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.461315+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_164821","record_id":"REC_0013627","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":5,"primary_tumor_size_cm":3.9,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":16.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.461655+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_525651","record_id":"REC_0013628","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":3.8,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.461992+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_310394","record_id":"REC_0013629","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":30,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":62,"primary_tumor_size_cm":5.9,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.462309+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_276741","record_id":"REC_0013630","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":17,"tmb_mutations_per_mb":4.0,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":6.5,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.462640+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_322861","record_id":"REC_0013631","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":77,"sex":"male","ecog_performance_status":2,"smoking_pack_years":7,"primary_tumor_size_cm":4.8,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.462974+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_362086","record_id":"REC_0013632","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":8.7,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":24,"primary_tumor_size_cm":3.9,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":16.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.463293+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_912172","record_id":"REC_0013633","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":13.5,"age_at_diagnosis":81,"sex":"male","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":6.7,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":5.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.463657+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_197488","record_id":"REC_0013634","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":53,"primary_tumor_size_cm":5.2,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":18.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.463984+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_801487","record_id":"REC_0013635","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":17.0,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":3,"smoking_pack_years":16,"primary_tumor_size_cm":7.3,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":19.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.464727+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_566028","record_id":"REC_0013636","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":1,"smoking_pack_years":71,"primary_tumor_size_cm":5.2,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":17.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.465115+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_102299","record_id":"REC_0013637","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":8.0,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":30.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.465481+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_200059","record_id":"REC_0013638","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":1,"smoking_pack_years":25,"primary_tumor_size_cm":5.2,"metastatic_sites_count":3,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.466061+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_245150","record_id":"REC_0013639","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":3,"smoking_pack_years":40,"primary_tumor_size_cm":4.7,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.466492+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_519930","record_id":"REC_0013640","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":15.5,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":6.2,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.466845+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_111567","record_id":"REC_0013641","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":10.3,"age_at_diagnosis":90,"sex":"male","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":6.6,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":23.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.467178+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_447092","record_id":"REC_0013642","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":16.1,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":28,"primary_tumor_size_cm":4.8,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":24.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.467497+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_265211","record_id":"REC_0013643","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":7.8,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.467830+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_573361","record_id":"REC_0013644","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":9.1,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":5.8,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":7.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.468223+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_409961","record_id":"REC_0013645","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":13.1,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":5.1,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.468607+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_776084","record_id":"REC_0013646","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":15.6,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":5.7,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.468952+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_376920","record_id":"REC_0013647","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":11.0,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":5.2,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.470354+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_688179","record_id":"REC_0013648","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":18,"tmb_mutations_per_mb":14.9,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":4.3,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":38.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.470769+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_846852","record_id":"REC_0013649","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":11.1,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":6.0,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.472390+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_696832","record_id":"REC_0013650","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":15,"tmb_mutations_per_mb":11.1,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":5.7,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.472876+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_675790","record_id":"REC_0013651","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":4.3,"age_at_diagnosis":84,"sex":"female","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":6.0,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.473351+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_181593","record_id":"REC_0013652","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.1,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":6.9,"metastatic_sites_count":8,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.473684+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_500146","record_id":"REC_0013653","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":18.0,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":5.8,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":5.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.474003+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_461262","record_id":"REC_0013654","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":34,"tmb_mutations_per_mb":21.3,"age_at_diagnosis":86,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":3.6,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.474301+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_202509","record_id":"REC_0013655","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":32,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":5.7,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.474598+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_956558","record_id":"REC_0013656","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":11.5,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":4.9,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.474894+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_746530","record_id":"REC_0013657","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":19,"tmb_mutations_per_mb":5.0,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":6.1,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.475173+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_789023","record_id":"REC_0013658","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":16.2,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.7,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":28.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.475461+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_757656","record_id":"REC_0013659","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":34,"tmb_mutations_per_mb":15.8,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":6.1,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.475747+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_359727","record_id":"REC_0013660","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":7.9,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":2,"primary_tumor_size_cm":6.9,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":4.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.476024+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_412950","record_id":"REC_0013661","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":15.0,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":23,"primary_tumor_size_cm":4.1,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":5.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.476421+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_941101","record_id":"REC_0013662","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":8.4,"age_at_diagnosis":76,"sex":"male","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":6.0,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":24.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.476775+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_682925","record_id":"REC_0013663","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":13.3,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":4.7,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":22.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.477094+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_165147","record_id":"REC_0013664","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":30,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.8,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.477561+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_616318","record_id":"REC_0013665","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":10.5,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":4.2,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.477926+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_474697","record_id":"REC_0013666","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":17.9,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":5.4,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.478242+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_958681","record_id":"REC_0013667","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":16.0,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":4.9,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":51.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.478545+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_651724","record_id":"REC_0013668","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":31,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":5.4,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.478852+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_394958","record_id":"REC_0013669","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":16.9,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":7.4,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":6.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.479177+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_502157","record_id":"REC_0013670","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":1,"smoking_pack_years":3,"primary_tumor_size_cm":7.1,"metastatic_sites_count":8,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":6.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.479459+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_623624","record_id":"REC_0013671","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":7.6,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.479784+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_801467","record_id":"REC_0013672","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":16,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":23,"primary_tumor_size_cm":6.1,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.480146+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_556755","record_id":"REC_0013673","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":16,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":4.5,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.480545+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_273378","record_id":"REC_0013674","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":30,"tmb_mutations_per_mb":4.1,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":58,"primary_tumor_size_cm":5.9,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":19.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.480926+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_341701","record_id":"REC_0013675","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":3.5,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":22.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.481281+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_673264","record_id":"REC_0013676","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":17,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":6.1,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.481833+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_747904","record_id":"REC_0013677","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":36,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":5.2,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.482629+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_677103","record_id":"REC_0013678","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":36,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":5.1,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.483616+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_925174","record_id":"REC_0013679","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":31,"primary_tumor_size_cm":5.5,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.484432+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_971604","record_id":"REC_0013680","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":3.4,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":4.8,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.485061+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_366807","record_id":"REC_0013681","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":3.4,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.485447+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_291445","record_id":"REC_0013682","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":55,"primary_tumor_size_cm":6.4,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.485780+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_969404","record_id":"REC_0013683","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":4.8,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":1,"smoking_pack_years":5,"primary_tumor_size_cm":5.6,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":37.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.486095+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_707697","record_id":"REC_0013684","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":30,"tmb_mutations_per_mb":4.6,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":3,"smoking_pack_years":25,"primary_tumor_size_cm":9.5,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.486391+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_143681","record_id":"REC_0013685","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":32,"tmb_mutations_per_mb":15.8,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":24,"primary_tumor_size_cm":3.7,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.486711+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_297012","record_id":"REC_0013686","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":87,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":6.8,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.487023+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_613819","record_id":"REC_0013687","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":19,"tmb_mutations_per_mb":17.1,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":4.0,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.487333+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_104033","record_id":"REC_0013688","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":17,"tmb_mutations_per_mb":8.0,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":1,"smoking_pack_years":35,"primary_tumor_size_cm":7.1,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":6.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.487641+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_816527","record_id":"REC_0013689","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":17.5,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":4.1,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":5.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.487975+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_842958","record_id":"REC_0013690","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":6.0,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":20.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.488879+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_721240","record_id":"REC_0013691","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":5.9,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":19.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.489337+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_206726","record_id":"REC_0013692","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":14.8,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":6.9,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":27.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.489719+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_469356","record_id":"REC_0013693","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":9.7,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":2.8,"metastatic_sites_count":3,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":22.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.490086+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_819189","record_id":"REC_0013694","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":19.4,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":5.6,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.490460+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_898062","record_id":"REC_0013695","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":6.7,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":25,"primary_tumor_size_cm":5.5,"metastatic_sites_count":3,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.490805+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_572145","record_id":"REC_0013696","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":3.9,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":6.1,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":25.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.491138+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_252687","record_id":"REC_0013697","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":22.2,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":24,"primary_tumor_size_cm":5.8,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.491478+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_697618","record_id":"REC_0013698","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":15.4,"age_at_diagnosis":77,"sex":"male","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":7.0,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.491833+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_512952","record_id":"REC_0013699","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":8.9,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":2,"primary_tumor_size_cm":5.3,"metastatic_sites_count":3,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.492217+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_952599","record_id":"REC_0013700","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":7,"primary_tumor_size_cm":7.2,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.492563+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_853157","record_id":"REC_0013701","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":34,"tmb_mutations_per_mb":7.6,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":3,"smoking_pack_years":10,"primary_tumor_size_cm":4.4,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.492890+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_715076","record_id":"REC_0013702","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":32,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.5,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.493209+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_421353","record_id":"REC_0013703","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":52,"sex":"male","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":3.2,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.493674+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_730237","record_id":"REC_0013704","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":7.6,"metastatic_sites_count":3,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.494005+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_347503","record_id":"REC_0013705","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":35,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":4.6,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.494330+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_723226","record_id":"REC_0013706","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":17.0,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":3,"primary_tumor_size_cm":4.6,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.494681+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_332079","record_id":"REC_0013707","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":3.9,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.495051+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_324241","record_id":"REC_0013708","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":15.8,"age_at_diagnosis":54,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":4.1,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":40.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.495410+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_219942","record_id":"REC_0013709","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":4.4,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":3,"smoking_pack_years":44,"primary_tumor_size_cm":4.5,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":26.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.495757+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_369480","record_id":"REC_0013710","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":5.3,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":21.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.496171+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_373713","record_id":"REC_0013711","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":8.0,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":22.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.496590+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_658350","record_id":"REC_0013712","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":16,"tmb_mutations_per_mb":15.7,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":2,"smoking_pack_years":25,"primary_tumor_size_cm":5.1,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.497009+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_130285","record_id":"REC_0013713","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":4.3,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":2,"smoking_pack_years":4,"primary_tumor_size_cm":4.1,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.497353+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_231148","record_id":"REC_0013714","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":3.3,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.497705+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_438878","record_id":"REC_0013715","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":4.3,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":24.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.498112+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_508303","record_id":"REC_0013716","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":11.0,"age_at_diagnosis":53,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":5.4,"metastatic_sites_count":9,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.498649+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_425843","record_id":"REC_0013717","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":4.6,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":49.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.499036+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_261487","record_id":"REC_0013718","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":10.5,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":0,"smoking_pack_years":40,"primary_tumor_size_cm":6.2,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.499390+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_561695","record_id":"REC_0013719","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":0,"smoking_pack_years":6,"primary_tumor_size_cm":4.2,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.499756+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_268931","record_id":"REC_0013720","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":16.6,"age_at_diagnosis":84,"sex":"male","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":4.9,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":47.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.502158+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_938836","record_id":"REC_0013721","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":7.0,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.502675+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_344111","record_id":"REC_0013722","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":9.7,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":1,"smoking_pack_years":2,"primary_tumor_size_cm":6.3,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.503041+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_570088","record_id":"REC_0013723","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":2.0,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.503373+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_787462","record_id":"REC_0013724","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":5.0,"age_at_diagnosis":85,"sex":"female","ecog_performance_status":1,"smoking_pack_years":62,"primary_tumor_size_cm":5.8,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.503694+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_969905","record_id":"REC_0013725","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":15.0,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":28,"primary_tumor_size_cm":5.8,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.504041+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_935544","record_id":"REC_0013726","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":16.7,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":7.3,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":16.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.504508+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_696258","record_id":"REC_0013727","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":6.2,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":17.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.504901+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_622256","record_id":"REC_0013728","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":6.2,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":21.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.505301+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_780328","record_id":"REC_0013729","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":6.2,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.505809+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_287937","record_id":"REC_0013730","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":15,"tmb_mutations_per_mb":6.7,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":4.6,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.506199+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_563761","record_id":"REC_0013731","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":4.4,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":1,"smoking_pack_years":33,"primary_tumor_size_cm":6.7,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":5.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.506547+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_468770","record_id":"REC_0013732","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":19,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":6.3,"metastatic_sites_count":3,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.506865+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_806824","record_id":"REC_0013733","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":41,"sex":"male","ecog_performance_status":0,"smoking_pack_years":4,"primary_tumor_size_cm":3.8,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.507150+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_941493","record_id":"REC_0013734","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":16.4,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":4.7,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":16.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.507457+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_955207","record_id":"REC_0013735","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":17.4,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":6.1,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.507757+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_205197","record_id":"REC_0013736","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":6.3,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.508131+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_300145","record_id":"REC_0013737","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":49,"primary_tumor_size_cm":6.2,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":6.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.508510+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_924790","record_id":"REC_0013738","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":9.5,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":4.0,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":5.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.508838+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_931293","record_id":"REC_0013739","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":4.0,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":17.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.509150+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_763632","record_id":"REC_0013740","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":5.8,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":44.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.509460+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_892199","record_id":"REC_0013741","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":30,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":55,"primary_tumor_size_cm":4.2,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.509796+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_371685","record_id":"REC_0013742","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":6.6,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.510326+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_545770","record_id":"REC_0013743","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":16,"tmb_mutations_per_mb":13.1,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.7,"metastatic_sites_count":3,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.510698+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_442972","record_id":"REC_0013744","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":7.9,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":0,"smoking_pack_years":26,"primary_tumor_size_cm":2.7,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.511013+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_635314","record_id":"REC_0013745","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":10.1,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":6.1,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":22.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.511734+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_168618","record_id":"REC_0013746","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":5.2,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":20.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.512160+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_630084","record_id":"REC_0013747","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":3.0,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":19.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.512501+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_463489","record_id":"REC_0013748","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":10.1,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":6.8,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.512830+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_790153","record_id":"REC_0013749","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":8.6,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":57,"primary_tumor_size_cm":6.1,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":17.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.513154+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_619368","record_id":"REC_0013750","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":19.3,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":7,"primary_tumor_size_cm":7.2,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.513499+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_656001","record_id":"REC_0013751","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":64,"primary_tumor_size_cm":3.8,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.513814+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_743914","record_id":"REC_0013752","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":5.6,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":6.0,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":7.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.514122+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_983968","record_id":"REC_0013753","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":18.6,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":4.0,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.514445+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_724135","record_id":"REC_0013754","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":84,"sex":"female","ecog_performance_status":2,"smoking_pack_years":8,"primary_tumor_size_cm":6.6,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.514766+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_900200","record_id":"REC_0013755","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":3,"smoking_pack_years":44,"primary_tumor_size_cm":4.8,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":5.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.515272+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_986060","record_id":"REC_0013756","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":7,"primary_tumor_size_cm":4.8,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":21.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.515637+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_862005","record_id":"REC_0013757","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":4.7,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":20.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.515963+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_778959","record_id":"REC_0013758","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":4.8,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":46,"primary_tumor_size_cm":4.9,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":5.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.516356+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_497968","record_id":"REC_0013759","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":17.4,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":6.4,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.516661+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_632056","record_id":"REC_0013760","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":30,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":65,"primary_tumor_size_cm":5.5,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.516958+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_249790","record_id":"REC_0013761","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":6.4,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":31,"primary_tumor_size_cm":4.1,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.517260+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_184071","record_id":"REC_0013762","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":17.1,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":6.0,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":64.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.517562+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_621808","record_id":"REC_0013763","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":8.1,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":67,"primary_tumor_size_cm":3.7,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":20.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.517864+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_491445","record_id":"REC_0013764","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":8.7,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":6.3,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.518192+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_509270","record_id":"REC_0013765","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":32,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":4.6,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.518517+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_879759","record_id":"REC_0013766","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":15.0,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":4.3,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.518839+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_699791","record_id":"REC_0013767","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":32,"tmb_mutations_per_mb":4.6,"age_at_diagnosis":78,"sex":"male","ecog_performance_status":0,"smoking_pack_years":53,"primary_tumor_size_cm":5.7,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":25.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.519164+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_690228","record_id":"REC_0013768","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":5.3,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":4.9,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":18.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.519663+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_285426","record_id":"REC_0013769","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":14.9,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":6.0,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.520068+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_876943","record_id":"REC_0013770","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":15.8,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":1,"smoking_pack_years":3,"primary_tumor_size_cm":5.7,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":7.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.520468+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_124819","record_id":"REC_0013771","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":10.1,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":3.4,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.520823+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_343329","record_id":"REC_0013772","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":30,"tmb_mutations_per_mb":6.3,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":6,"primary_tumor_size_cm":3.9,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.521165+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_304082","record_id":"REC_0013773","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":14,"tmb_mutations_per_mb":3.9,"age_at_diagnosis":84,"sex":"female","ecog_performance_status":3,"smoking_pack_years":17,"primary_tumor_size_cm":6.2,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":45.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.521470+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_531321","record_id":"REC_0013774","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":9.7,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":7.1,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.521790+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_882253","record_id":"REC_0013775","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":33,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":34,"primary_tumor_size_cm":4.8,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":19.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.522138+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_989318","record_id":"REC_0013776","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":5.9,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":31,"primary_tumor_size_cm":4.3,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":17.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.522477+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_963642","record_id":"REC_0013777","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":4.7,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":0,"smoking_pack_years":0,"primary_tumor_size_cm":6.3,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.522822+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_695199","record_id":"REC_0013778","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":5.9,"age_at_diagnosis":83,"sex":"female","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":6.3,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":20.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.523139+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_530544","record_id":"REC_0013779","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":18.7,"age_at_diagnosis":90,"sex":"male","ecog_performance_status":3,"smoking_pack_years":16,"primary_tumor_size_cm":9.4,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":6.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.523451+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_795727","record_id":"REC_0013780","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":31,"tmb_mutations_per_mb":19.7,"age_at_diagnosis":77,"sex":"male","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":4.8,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.523781+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_589190","record_id":"REC_0013781","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":18.8,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":6.5,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":32.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.524404+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_753654","record_id":"REC_0013782","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":13.8,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":5.0,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":24.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.524765+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_648707","record_id":"REC_0013783","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":16,"tmb_mutations_per_mb":10.5,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":4.7,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.525082+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_105145","record_id":"REC_0013784","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":2.2,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":17.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.525379+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_833474","record_id":"REC_0013785","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":17.7,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":4.5,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.525663+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_584196","record_id":"REC_0013786","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":6.3,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.525957+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_482234","record_id":"REC_0013787","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":2.1,"age_at_diagnosis":76,"sex":"male","ecog_performance_status":3,"smoking_pack_years":10,"primary_tumor_size_cm":4.1,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.526268+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_610741","record_id":"REC_0013788","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":11.1,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":6.2,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":27.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.526575+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_868500","record_id":"REC_0013789","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":14.5,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":6.2,"metastatic_sites_count":9,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.526890+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_349711","record_id":"REC_0013790","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":37,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.1,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.527185+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_189917","record_id":"REC_0013791","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":8.6,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":2.3,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.527474+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_148410","record_id":"REC_0013792","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":19,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":1,"smoking_pack_years":44,"primary_tumor_size_cm":4.0,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.527776+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_674000","record_id":"REC_0013793","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ALK fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":85,"sex":"female","ecog_performance_status":2,"smoking_pack_years":10,"primary_tumor_size_cm":4.9,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":16.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.528067+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_315566","record_id":"REC_0013794","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":19,"tmb_mutations_per_mb":5.6,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":6.0,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.528605+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_703309","record_id":"REC_0013795","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":14.0,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":2,"primary_tumor_size_cm":4.6,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.528951+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_181937","record_id":"REC_0013796","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":10.5,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":22,"primary_tumor_size_cm":6.7,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.529264+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_403772","record_id":"REC_0013797","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":16.1,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":5.5,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.529573+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_762182","record_id":"REC_0013798","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":3.3,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":48,"primary_tumor_size_cm":4.8,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":22.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.529873+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_696268","record_id":"REC_0013799","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":31,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":78,"sex":"male","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":6.5,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":24.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.530193+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_612620","record_id":"REC_0013800","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":21.6,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":4.3,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.530493+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_995866","record_id":"REC_0013801","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":19.1,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":5.2,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.530777+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_545951","record_id":"REC_0013802","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":9.8,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":2,"smoking_pack_years":8,"primary_tumor_size_cm":4.9,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.531070+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_811464","record_id":"REC_0013803","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":2.7,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.531360+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_185612","record_id":"REC_0013804","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":14.1,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":5,"primary_tumor_size_cm":7.0,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.531695+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_250407","record_id":"REC_0013805","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":6.4,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":62,"primary_tumor_size_cm":6.1,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":31.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.532069+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_266262","record_id":"REC_0013806","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":3,"smoking_pack_years":36,"primary_tumor_size_cm":6.2,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.532521+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_976428","record_id":"REC_0013807","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ALK fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.6,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":39.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.533039+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_316033","record_id":"REC_0013808","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":18,"tmb_mutations_per_mb":9.7,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":6.5,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":21.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.533418+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_819494","record_id":"REC_0013809","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":5.7,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.533775+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_373167","record_id":"REC_0013810","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":8.0,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":17.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.534122+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_563949","record_id":"REC_0013811","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":4.2,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":4.8,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.534451+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_937228","record_id":"REC_0013812","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":15,"tmb_mutations_per_mb":4.8,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":1,"smoking_pack_years":42,"primary_tumor_size_cm":4.0,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.534759+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_696070","record_id":"REC_0013813","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":11.0,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":4.6,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.535068+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_296723","record_id":"REC_0013814","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":11.5,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":5.1,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.535369+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_275682","record_id":"REC_0013815","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":7.0,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.535689+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_896737","record_id":"REC_0013816","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":14.5,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":4.6,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.535991+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_421182","record_id":"REC_0013817","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":7.3,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":7.0,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.536356+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_797547","record_id":"REC_0013818","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":16.2,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":8.1,"metastatic_sites_count":8,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.536670+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_224227","record_id":"REC_0013819","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":6.0,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":21.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.536982+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_485697","record_id":"REC_0013820","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":5.2,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":4.7,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.537458+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_798202","record_id":"REC_0013821","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":9.5,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":21,"primary_tumor_size_cm":5.3,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.537782+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_117785","record_id":"REC_0013822","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":19,"tmb_mutations_per_mb":16.6,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":6.6,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.538664+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_221183","record_id":"REC_0013823","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":30,"tmb_mutations_per_mb":9.8,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":4.1,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.539102+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_622231","record_id":"REC_0013824","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":14.1,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":6.4,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.539465+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_844751","record_id":"REC_0013825","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":9.5,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.3,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.539775+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_904533","record_id":"REC_0013826","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":0,"primary_tumor_size_cm":7.8,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.540128+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_145080","record_id":"REC_0013827","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":5.5,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":5.3,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":16.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.540604+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_344337","record_id":"REC_0013828","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":5.8,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.540978+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_990985","record_id":"REC_0013829","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":7.3,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":5.5,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.541282+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_580057","record_id":"REC_0013830","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":4.9,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":4.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.542653+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_541078","record_id":"REC_0013831","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":15.4,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":1,"smoking_pack_years":1,"primary_tumor_size_cm":5.5,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.543067+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_424680","record_id":"REC_0013832","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":7.4,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":4.2,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":24.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.543381+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_882749","record_id":"REC_0013833","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":18,"tmb_mutations_per_mb":10.3,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":1,"smoking_pack_years":5,"primary_tumor_size_cm":6.5,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.543854+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_859889","record_id":"REC_0013834","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":5.9,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.544263+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_839717","record_id":"REC_0013835","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":15.8,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":4.8,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":40.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.544612+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_277435","record_id":"REC_0013836","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":81,"sex":"male","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":6.3,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":7.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.545046+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_998516","record_id":"REC_0013837","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":15,"tmb_mutations_per_mb":8.7,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":5.1,"metastatic_sites_count":3,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.545706+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_239039","record_id":"REC_0013838","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":5.8,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":18.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.546060+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_175049","record_id":"REC_0013839","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":3.7,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":7,"primary_tumor_size_cm":3.6,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.546372+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_486812","record_id":"REC_0013840","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":14.9,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":6.4,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.546678+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_690870","record_id":"REC_0013841","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":15.7,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":0,"smoking_pack_years":6,"primary_tumor_size_cm":4.7,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":7.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.547083+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_390440","record_id":"REC_0013842","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":0,"smoking_pack_years":39,"primary_tumor_size_cm":5.5,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.547444+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_360103","record_id":"REC_0013843","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":7.3,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":5.6,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.547766+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_797447","record_id":"REC_0013844","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":8.1,"age_at_diagnosis":54,"sex":"male","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":4.8,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.548128+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_643636","record_id":"REC_0013845","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":75,"sex":"male","ecog_performance_status":1,"smoking_pack_years":24,"primary_tumor_size_cm":6.7,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":39.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.550992+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_322724","record_id":"REC_0013846","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":13.8,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":3.1,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.551645+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_846523","record_id":"REC_0013847","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":34,"primary_tumor_size_cm":7.2,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.552034+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_261905","record_id":"REC_0013848","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":9.9,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":6.0,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.552443+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_597049","record_id":"REC_0013849","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":14.9,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":4.7,"metastatic_sites_count":10,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":5.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.552757+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_203097","record_id":"REC_0013850","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":4.1,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.553065+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_701473","record_id":"REC_0013851","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":9.7,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":5.2,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.553358+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_268526","record_id":"REC_0013852","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":4.8,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":16.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.553663+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_333893","record_id":"REC_0013853","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":10.5,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":7.7,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.553961+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_729623","record_id":"REC_0013854","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":36,"tmb_mutations_per_mb":14.7,"age_at_diagnosis":54,"sex":"male","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":6.5,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":20.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.554269+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_408093","record_id":"REC_0013855","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":17.4,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":4.4,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.554602+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_111348","record_id":"REC_0013856","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":35,"tmb_mutations_per_mb":3.9,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":33,"primary_tumor_size_cm":3.2,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":30.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.554959+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_760167","record_id":"REC_0013857","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":11.5,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":5.6,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.555327+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_255574","record_id":"REC_0013858","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":34,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":75,"sex":"male","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":2.7,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":51.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.555685+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_351128","record_id":"REC_0013859","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":15.1,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":6.1,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.556281+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_255207","record_id":"REC_0013860","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":1.5,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":55,"primary_tumor_size_cm":4.7,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":16.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.556704+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_290566","record_id":"REC_0013861","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":6.1,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":6.5,"metastatic_sites_count":8,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":17.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.557095+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_880266","record_id":"REC_0013862","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":17.0,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":4.7,"metastatic_sites_count":3,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":8.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.557465+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_852228","record_id":"REC_0013863","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":19,"tmb_mutations_per_mb":5.2,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":8.7,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":25.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.557842+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_415097","record_id":"REC_0013864","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":3.9,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":87,"primary_tumor_size_cm":3.7,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.558321+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_578128","record_id":"REC_0013865","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":25,"primary_tumor_size_cm":4.7,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":7.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.558735+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_824660","record_id":"REC_0013866","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":16.3,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":6.8,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":16.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.559112+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_153270","record_id":"REC_0013867","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":6.2,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":6.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.559492+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_128082","record_id":"REC_0013868","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":15.1,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":3.8,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.559841+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_826164","record_id":"REC_0013869","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":5.3,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":5.2,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.560287+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_813801","record_id":"REC_0013870","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":13.3,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":5.8,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.560765+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_323006","record_id":"REC_0013871","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":3.6,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.561187+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_608685","record_id":"REC_0013872","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":4.4,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.561811+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_947309","record_id":"REC_0013873","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":21.8,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":5.2,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.562244+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_791674","record_id":"REC_0013874","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":8.0,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":53,"primary_tumor_size_cm":5.5,"metastatic_sites_count":3,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":18.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.562633+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_467113","record_id":"REC_0013875","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":16.5,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":6.1,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.563016+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_530056","record_id":"REC_0013876","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None","pd_l1_tps_percent":20,"tmb_mutations_per_mb":6.4,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":42,"primary_tumor_size_cm":4.6,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":38.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.563395+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_793325","record_id":"REC_0013877","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":1,"smoking_pack_years":44,"primary_tumor_size_cm":6.3,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":6.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.563872+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_543272","record_id":"REC_0013878","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":19,"tmb_mutations_per_mb":4.8,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":55,"primary_tumor_size_cm":5.9,"metastatic_sites_count":9,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.564492+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_501996","record_id":"REC_0013879","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":4.6,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.564971+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_215801","record_id":"REC_0013880","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":21,"primary_tumor_size_cm":6.0,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.565397+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_268248","record_id":"REC_0013881","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":2.7,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":19.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.565803+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_414506","record_id":"REC_0013882","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":17.9,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":4.4,"metastatic_sites_count":8,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":5.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.566197+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_454280","record_id":"REC_0013883","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":8.0,"age_at_diagnosis":75,"sex":"male","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":7.3,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.566596+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_903510","record_id":"REC_0013884","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":13,"tmb_mutations_per_mb":6.7,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.3,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":7.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.566983+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_915154","record_id":"REC_0013885","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":76,"sex":"male","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":5.1,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":16.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.567537+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_653162","record_id":"REC_0013886","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":6.6,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":32.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.567934+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_863854","record_id":"REC_0013887","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":6.9,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.568353+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_172952","record_id":"REC_0013888","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":8.9,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":6.7,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":21.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.568675+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_936872","record_id":"REC_0013889","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":7.8,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":20.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.568967+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_956508","record_id":"REC_0013890","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":16.3,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":5.9,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":17.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.569259+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_347601","record_id":"REC_0013891","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":1.5,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":5.5,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.569548+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_129674","record_id":"REC_0013892","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":14.1,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":10,"primary_tumor_size_cm":4.7,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.569833+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_748190","record_id":"REC_0013893","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":15.9,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":5.9,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":16.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.570145+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_315370","record_id":"REC_0013894","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":1.5,"age_at_diagnosis":74,"sex":"male","ecog_performance_status":2,"smoking_pack_years":8,"primary_tumor_size_cm":2.1,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.570448+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_983356","record_id":"REC_0013895","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":5.8,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.570754+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_921330","record_id":"REC_0013896","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":14.9,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":5.7,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":4.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.571055+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_443108","record_id":"REC_0013897","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":10.0,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":24,"primary_tumor_size_cm":6.2,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.571347+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_634836","record_id":"REC_0013898","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":3,"smoking_pack_years":4,"primary_tumor_size_cm":7.2,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":16.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.571766+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_860214","record_id":"REC_0013899","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":17.5,"age_at_diagnosis":54,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":6.3,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.572163+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_501025","record_id":"REC_0013900","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":6.1,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":7.1,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.572497+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_151610","record_id":"REC_0013901","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":13.8,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":25,"primary_tumor_size_cm":4.8,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.572891+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_939826","record_id":"REC_0013902","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":5.2,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":27.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.573196+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_700913","record_id":"REC_0013903","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":4.4,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.573479+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_799755","record_id":"REC_0013904","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":9.1,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":3.9,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.573773+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_884311","record_id":"REC_0013905","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":25,"primary_tumor_size_cm":7.5,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.574075+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_820722","record_id":"REC_0013906","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":4.6,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":29,"primary_tumor_size_cm":4.5,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.574356+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_561926","record_id":"REC_0013907","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":4.7,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.574754+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_580764","record_id":"REC_0013908","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":30,"tmb_mutations_per_mb":7.6,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":4.8,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.575122+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_843222","record_id":"REC_0013909","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":13.6,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":4.7,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.575448+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_581816","record_id":"REC_0013910","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":10.1,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":2,"smoking_pack_years":6,"primary_tumor_size_cm":3.8,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.575748+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_292266","record_id":"REC_0013911","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":4,"primary_tumor_size_cm":8.6,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.576299+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_241533","record_id":"REC_0013912","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":11.0,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":0,"primary_tumor_size_cm":6.2,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":21.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.576672+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_936370","record_id":"REC_0013913","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":32,"tmb_mutations_per_mb":5.2,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":2,"smoking_pack_years":68,"primary_tumor_size_cm":5.9,"metastatic_sites_count":3,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":21.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.576970+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_134796","record_id":"REC_0013914","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":17.5,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":4.8,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.577288+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_153262","record_id":"REC_0013915","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":20.7,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":4.4,"metastatic_sites_count":8,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.577620+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_305166","record_id":"REC_0013916","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":18,"tmb_mutations_per_mb":3.8,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":4.7,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.577953+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_617648","record_id":"REC_0013917","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":4.2,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.578285+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_730125","record_id":"REC_0013918","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":5.9,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":24.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.578634+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_895046","record_id":"REC_0013919","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":14.8,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":5.5,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":6.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.578996+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_769858","record_id":"REC_0013920","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":6.0,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":18.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.579358+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_586252","record_id":"REC_0013921","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":8.7,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":37.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.579710+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_324661","record_id":"REC_0013922","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":7.2,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.580159+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_898250","record_id":"REC_0013923","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":4.9,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":1,"smoking_pack_years":62,"primary_tumor_size_cm":4.6,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":18.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.580689+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_312622","record_id":"REC_0013924","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":18,"tmb_mutations_per_mb":8.9,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":27,"primary_tumor_size_cm":8.3,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":6.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.581411+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_477667","record_id":"REC_0013925","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":4.0,"age_at_diagnosis":84,"sex":"male","ecog_performance_status":1,"smoking_pack_years":44,"primary_tumor_size_cm":5.1,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.581900+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_552616","record_id":"REC_0013926","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":10.3,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.1,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.582366+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_442301","record_id":"REC_0013927","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":6.5,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":16.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.582765+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_971121","record_id":"REC_0013928","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":11.5,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":3.8,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.583112+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_903571","record_id":"REC_0013929","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":17.3,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":31,"primary_tumor_size_cm":5.7,"metastatic_sites_count":8,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.583441+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_720722","record_id":"REC_0013930","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":8.0,"age_at_diagnosis":54,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":3.7,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.583791+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_604808","record_id":"REC_0013931","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":5.6,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.584212+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_764173","record_id":"REC_0013932","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":17.0,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":6.4,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":6.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.584558+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_462395","record_id":"REC_0013933","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":18.9,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":5.0,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.584884+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_293755","record_id":"REC_0013934","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":5.2,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":16.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.585221+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_713164","record_id":"REC_0013935","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":21,"primary_tumor_size_cm":5.2,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":41.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.585596+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_422161","record_id":"REC_0013936","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":7.9,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":56,"primary_tumor_size_cm":6.8,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":41.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.585986+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_216268","record_id":"REC_0013937","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":5.2,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":5.8,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":24.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.586517+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_728668","record_id":"REC_0013938","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":20,"tmb_mutations_per_mb":16.6,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":9,"primary_tumor_size_cm":6.3,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":22.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.586917+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_913682","record_id":"REC_0013939","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":6.2,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.587294+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_542913","record_id":"REC_0013940","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":39,"primary_tumor_size_cm":4.9,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":16.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.587792+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_165644","record_id":"REC_0013941","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":8.4,"age_at_diagnosis":51,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":4.8,"metastatic_sites_count":3,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":7.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.588296+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_929026","record_id":"REC_0013942","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":18.2,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":6.0,"metastatic_sites_count":3,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.588705+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_173796","record_id":"REC_0013943","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":13,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":7.9,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":27.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.589054+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_704820","record_id":"REC_0013944","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":4.0,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":21.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.589383+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_458714","record_id":"REC_0013945","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":4.9,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.589695+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_891030","record_id":"REC_0013946","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":6.3,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.589994+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_862221","record_id":"REC_0013947","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":13.5,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":4.7,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.590294+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_718501","record_id":"REC_0013948","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.0,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.590584+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_171671","record_id":"REC_0013949","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":6.1,"age_at_diagnosis":84,"sex":"female","ecog_performance_status":2,"smoking_pack_years":33,"primary_tumor_size_cm":5.4,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.590875+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_689878","record_id":"REC_0013950","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":19.6,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":4.5,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.591361+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_388106","record_id":"REC_0013951","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":6.7,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.591852+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_655710","record_id":"REC_0013952","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":4.2,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.592399+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_428520","record_id":"REC_0013953","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":8.3,"age_at_diagnosis":83,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":6.6,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.592793+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_468773","record_id":"REC_0013954","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":14.7,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":5.3,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.593155+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_366914","record_id":"REC_0013955","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":51,"sex":"male","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":5.1,"metastatic_sites_count":8,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.593589+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_607135","record_id":"REC_0013956","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":5.5,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":4.0,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.593983+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_168584","record_id":"REC_0013957","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":19,"tmb_mutations_per_mb":6.0,"age_at_diagnosis":50,"sex":"male","ecog_performance_status":0,"smoking_pack_years":83,"primary_tumor_size_cm":5.1,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":5.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.594360+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_520828","record_id":"REC_0013958","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":14,"tmb_mutations_per_mb":8.3,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":100,"primary_tumor_size_cm":7.2,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":7.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.594717+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_666327","record_id":"REC_0013959","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":7.3,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":50,"primary_tumor_size_cm":4.6,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":22.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.595061+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_484141","record_id":"REC_0013960","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":2,"smoking_pack_years":20,"primary_tumor_size_cm":4.6,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.595414+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_191341","record_id":"REC_0013961","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":2.8,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":2,"smoking_pack_years":46,"primary_tumor_size_cm":6.0,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":6.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.595768+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_612806","record_id":"REC_0013962","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":5.5,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.596186+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_482414","record_id":"REC_0013963","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":2,"smoking_pack_years":20,"primary_tumor_size_cm":6.2,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":27.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.596699+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_925239","record_id":"REC_0013964","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":3,"primary_tumor_size_cm":4.6,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":29.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.597231+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_168724","record_id":"REC_0013965","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":11.0,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":5.8,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.597684+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_105021","record_id":"REC_0013966","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":44,"sex":"female","ecog_performance_status":0,"smoking_pack_years":26,"primary_tumor_size_cm":7.8,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.598075+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_878634","record_id":"REC_0013967","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":6.5,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":23.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.598483+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_225801","record_id":"REC_0013968","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":7.4,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":18.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.598865+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_420819","record_id":"REC_0013969","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":16,"tmb_mutations_per_mb":16.1,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":5.2,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":20.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.599229+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_376911","record_id":"REC_0013970","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":8.0,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":6.2,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.599615+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_114199","record_id":"REC_0013971","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":9.0,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":2,"smoking_pack_years":6,"primary_tumor_size_cm":5.2,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":6.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.600008+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_963825","record_id":"REC_0013972","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":4.8,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":21.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.600612+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_511311","record_id":"REC_0013973","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":15.0,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":6.8,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.601064+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_153562","record_id":"REC_0013974","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":17.0,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":1,"smoking_pack_years":2,"primary_tumor_size_cm":7.1,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.601507+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_899333","record_id":"REC_0013975","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":4.9,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.601933+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_161325","record_id":"REC_0013976","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":6.1,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.602494+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_988089","record_id":"REC_0013977","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":31,"primary_tumor_size_cm":6.2,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":23.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.602890+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_450893","record_id":"REC_0013978","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":34,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":5.0,"metastatic_sites_count":3,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.603344+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_907034","record_id":"REC_0013979","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":30,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":4.6,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.603761+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_290244","record_id":"REC_0013980","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":4.1,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.604214+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_205139","record_id":"REC_0013981","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":2,"smoking_pack_years":25,"primary_tumor_size_cm":5.6,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.604643+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_853853","record_id":"REC_0013982","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":18.5,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":4.6,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.605031+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_535440","record_id":"REC_0013983","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":22.2,"age_at_diagnosis":77,"sex":"male","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":4.1,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.605389+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_350477","record_id":"REC_0013984","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":15.4,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":6,"primary_tumor_size_cm":4.8,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.605727+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_742839","record_id":"REC_0013985","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":5.0,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":19.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.606067+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_356699","record_id":"REC_0013986","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":6.2,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":18.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.606419+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_392495","record_id":"REC_0013987","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.5,"age_at_diagnosis":46,"sex":"male","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":3.1,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.606752+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_723562","record_id":"REC_0013988","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":5.4,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.607059+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_774867","record_id":"REC_0013989","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":17,"tmb_mutations_per_mb":13.3,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":4.6,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":21.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.607553+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_505587","record_id":"REC_0013990","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":6.0,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":1,"smoking_pack_years":27,"primary_tumor_size_cm":9.0,"metastatic_sites_count":3,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.607918+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_520244","record_id":"REC_0013991","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":51,"sex":"male","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":3.7,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.608325+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_669255","record_id":"REC_0013992","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":16,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":47,"sex":"male","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":5.1,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.608671+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_781349","record_id":"REC_0013993","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":33,"tmb_mutations_per_mb":10.0,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":5.1,"metastatic_sites_count":3,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.609022+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_829796","record_id":"REC_0013994","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":3,"smoking_pack_years":12,"primary_tumor_size_cm":5.2,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.609361+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_165154","record_id":"REC_0013995","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":4.8,"age_at_diagnosis":51,"sex":"male","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":5.3,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.609691+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_458582","record_id":"REC_0013996","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":6.4,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.610046+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_393187","record_id":"REC_0013997","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":4.4,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.610393+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_988278","record_id":"REC_0013998","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":13.1,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":6.8,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":4.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.610745+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_496872","record_id":"REC_0013999","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":1.6,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":81,"primary_tumor_size_cm":5.0,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.611092+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_167449","record_id":"REC_0014000","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":5.1,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.611417+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_654712","record_id":"REC_0014001","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":16.6,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":6.9,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.611750+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_225253","record_id":"REC_0014002","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":16.5,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":6.0,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":5.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.612276+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_214127","record_id":"REC_0014003","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":9.9,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":6.2,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.612700+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_660624","record_id":"REC_0014004","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":4.8,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.613061+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_967134","record_id":"REC_0014005","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":15.6,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":5.2,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":7.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.613415+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_304562","record_id":"REC_0014006","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":4.7,"metastatic_sites_count":3,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":24.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.613965+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_652455","record_id":"REC_0014007","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":15.3,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":1,"smoking_pack_years":26,"primary_tumor_size_cm":6.2,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.614388+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_186499","record_id":"REC_0014008","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":13.5,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":4.2,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.614710+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_507134","record_id":"REC_0014009","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":11.0,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":4,"primary_tumor_size_cm":4.0,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.615058+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_777441","record_id":"REC_0014010","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":8.1,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":4.9,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":22.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.615468+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_480410","record_id":"REC_0014011","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":17.3,"age_at_diagnosis":76,"sex":"male","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":3.0,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.615826+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_804068","record_id":"REC_0014012","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":19.2,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":9,"primary_tumor_size_cm":6.0,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":4.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.616227+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_593970","record_id":"REC_0014013","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":5.6,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":7.2,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.616578+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_308112","record_id":"REC_0014014","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":9.9,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":7.3,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.616907+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_231138","record_id":"REC_0014015","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":7.4,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":17.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.617419+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_798558","record_id":"REC_0014016","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":4.5,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.617826+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_106693","record_id":"REC_0014017","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":16,"tmb_mutations_per_mb":4.4,"age_at_diagnosis":45,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":4.2,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":22.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.618208+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_936399","record_id":"REC_0014018","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None","pd_l1_tps_percent":30,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":0,"smoking_pack_years":42,"primary_tumor_size_cm":4.6,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":38.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.618562+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_967913","record_id":"REC_0014019","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":5.2,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":5.2,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":17.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.618885+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_115200","record_id":"REC_0014020","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":19,"tmb_mutations_per_mb":3.6,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":31,"primary_tumor_size_cm":3.3,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":20.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.619301+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_423255","record_id":"REC_0014021","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":19,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":61,"primary_tumor_size_cm":6.7,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":18.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.619697+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_185241","record_id":"REC_0014022","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":30,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":5.4,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":25.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.620071+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_720115","record_id":"REC_0014023","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":4.3,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.620505+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_290073","record_id":"REC_0014024","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":5.1,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.620877+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_398537","record_id":"REC_0014025","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":6.2,"metastatic_sites_count":3,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.621211+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_832938","record_id":"REC_0014026","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":14.8,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":6.3,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.621545+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_424840","record_id":"REC_0014027","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":10.0,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":37,"primary_tumor_size_cm":5.6,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":17.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.621867+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_614745","record_id":"REC_0014028","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":6.3,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.622343+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_404191","record_id":"REC_0014029","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":14.5,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":5.5,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.622700+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_806133","record_id":"REC_0014030","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":30,"tmb_mutations_per_mb":3.6,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":3,"primary_tumor_size_cm":6.5,"metastatic_sites_count":3,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.623019+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_339159","record_id":"REC_0014031","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":32,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":3,"smoking_pack_years":14,"primary_tumor_size_cm":5.3,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.623320+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_374851","record_id":"REC_0014032","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":6,"primary_tumor_size_cm":8.0,"metastatic_sites_count":8,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":5.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.623601+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_873545","record_id":"REC_0014033","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":16.3,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":7.8,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":18.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.623866+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_974449","record_id":"REC_0014034","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":8.6,"age_at_diagnosis":79,"sex":"male","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":6.4,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.624197+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_226513","record_id":"REC_0014035","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":9.7,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":3,"primary_tumor_size_cm":6.3,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":6.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.624491+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_538998","record_id":"REC_0014036","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":7.4,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":6.7,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.624778+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_293395","record_id":"REC_0014037","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":6.8,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":60.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.625076+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_579753","record_id":"REC_0014038","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":20,"tmb_mutations_per_mb":6.4,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":1,"smoking_pack_years":40,"primary_tumor_size_cm":5.5,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":17.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.625380+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_159977","record_id":"REC_0014039","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":5.8,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.625668+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_298966","record_id":"REC_0014040","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":16.9,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":5.9,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.625961+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_264781","record_id":"REC_0014041","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":2,"smoking_pack_years":23,"primary_tumor_size_cm":5.0,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.626431+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_536394","record_id":"REC_0014042","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":4.3,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.626757+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_460788","record_id":"REC_0014043","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":4.5,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":0,"smoking_pack_years":63,"primary_tumor_size_cm":6.2,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.627068+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_743820","record_id":"REC_0014044","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":3.6,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":23.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.627365+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_166840","record_id":"REC_0014045","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":2,"primary_tumor_size_cm":6.2,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.627657+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_772575","record_id":"REC_0014046","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":5.1,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.627960+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_118182","record_id":"REC_0014047","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":99,"primary_tumor_size_cm":4.1,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.628363+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_540831","record_id":"REC_0014048","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":86,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":4.7,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.628704+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_498656","record_id":"REC_0014049","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":13.6,"age_at_diagnosis":53,"sex":"female","ecog_performance_status":0,"smoking_pack_years":28,"primary_tumor_size_cm":3.8,"metastatic_sites_count":10,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":7.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.629042+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_914117","record_id":"REC_0014050","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":2,"smoking_pack_years":8,"primary_tumor_size_cm":3.7,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.629383+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_372416","record_id":"REC_0014051","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":5.7,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":62,"primary_tumor_size_cm":6.7,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":6.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.629720+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_259198","record_id":"REC_0014052","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":5.7,"metastatic_sites_count":9,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.630066+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_121037","record_id":"REC_0014053","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":4.9,"age_at_diagnosis":89,"sex":"male","ecog_performance_status":2,"smoking_pack_years":7,"primary_tumor_size_cm":3.8,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":25.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.630382+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_264794","record_id":"REC_0014054","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":49,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":6.7,"metastatic_sites_count":8,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.630915+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_356910","record_id":"REC_0014055","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":10.0,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.7,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.631302+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_459602","record_id":"REC_0014056","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":16.3,"age_at_diagnosis":85,"sex":"female","ecog_performance_status":2,"smoking_pack_years":9,"primary_tumor_size_cm":6.5,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.631664+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_329332","record_id":"REC_0014057","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":6.3,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":2,"smoking_pack_years":10,"primary_tumor_size_cm":5.2,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.632057+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_236744","record_id":"REC_0014058","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":19,"tmb_mutations_per_mb":3.0,"age_at_diagnosis":75,"sex":"male","ecog_performance_status":2,"smoking_pack_years":51,"primary_tumor_size_cm":7.1,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":21.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.633328+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_322910","record_id":"REC_0014059","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":3.7,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.633668+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_161689","record_id":"REC_0014060","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":15.2,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":6.6,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.633967+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_434658","record_id":"REC_0014061","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":5.9,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":36,"primary_tumor_size_cm":5.2,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.634283+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_605954","record_id":"REC_0014062","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":5.4,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.634658+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_266968","record_id":"REC_0014063","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":17.3,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":3,"primary_tumor_size_cm":3.8,"metastatic_sites_count":8,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":16.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.634992+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_656832","record_id":"REC_0014064","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":13.6,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":5.2,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":28.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.635288+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_454507","record_id":"REC_0014065","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":8.7,"age_at_diagnosis":52,"sex":"male","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":5.1,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":20.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.635581+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_143519","record_id":"REC_0014066","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":49,"sex":"male","ecog_performance_status":0,"smoking_pack_years":44,"primary_tumor_size_cm":4.9,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.635874+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_487453","record_id":"REC_0014067","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":3.3,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":74,"primary_tumor_size_cm":5.2,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":6.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.636383+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_258449","record_id":"REC_0014068","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":4.0,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":5.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.636706+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_345887","record_id":"REC_0014069","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":33,"tmb_mutations_per_mb":8.5,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":6.1,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.636994+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_420820","record_id":"REC_0014070","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":57,"primary_tumor_size_cm":5.6,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.637272+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_228981","record_id":"REC_0014071","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":5.9,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.637545+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_960272","record_id":"REC_0014072","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":31,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":4.7,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.637823+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_510372","record_id":"REC_0014073","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":5.2,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.638104+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_165185","record_id":"REC_0014074","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":16.4,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":27,"primary_tumor_size_cm":5.8,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.638388+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_481114","record_id":"REC_0014075","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":16,"tmb_mutations_per_mb":14.0,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":3.6,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.638674+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_370510","record_id":"REC_0014076","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":13,"tmb_mutations_per_mb":14.4,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.6,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.638958+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_509684","record_id":"REC_0014077","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":8.1,"age_at_diagnosis":50,"sex":"male","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":5.5,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":25.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.639250+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_122701","record_id":"REC_0014078","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":3.8,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":25.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.639541+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_376564","record_id":"REC_0014079","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":15.2,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.7,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":24.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.639841+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_771436","record_id":"REC_0014080","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":6.9,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":4.7,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.640326+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_395036","record_id":"REC_0014081","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":11.0,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":7.2,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":18.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.640673+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_497099","record_id":"REC_0014082","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":8.9,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":4.8,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.640986+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_291133","record_id":"REC_0014083","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":19.7,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":5.5,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":26.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.641290+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_281950","record_id":"REC_0014084","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":4.9,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":45,"primary_tumor_size_cm":4.2,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":7.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.641586+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_654586","record_id":"REC_0014085","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":5.0,"age_at_diagnosis":53,"sex":"male","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":7.0,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.641892+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_627715","record_id":"REC_0014086","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":4.8,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":54,"primary_tumor_size_cm":6.0,"metastatic_sites_count":3,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.642209+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_368547","record_id":"REC_0014087","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":0,"primary_tumor_size_cm":5.1,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.642552+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_208433","record_id":"REC_0014088","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":49,"primary_tumor_size_cm":6.9,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.642891+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_735301","record_id":"REC_0014089","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":3.9,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.643243+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_543700","record_id":"REC_0014090","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":19,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":54,"sex":"male","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":6.9,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.643582+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_126989","record_id":"REC_0014091","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":6.7,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":0,"smoking_pack_years":27,"primary_tumor_size_cm":6.9,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.643900+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_761961","record_id":"REC_0014092","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":4.2,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.644307+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_189462","record_id":"REC_0014093","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":9.7,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":3,"primary_tumor_size_cm":6.4,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.644823+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_820527","record_id":"REC_0014094","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":16.6,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":6.7,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.645230+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_697847","record_id":"REC_0014095","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":14.5,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":5.3,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.645571+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_180334","record_id":"REC_0014096","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":13.8,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":3.6,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.645921+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_345169","record_id":"REC_0014097","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":8.0,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":5.6,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.646231+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_152850","record_id":"REC_0014098","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":16.1,"age_at_diagnosis":89,"sex":"male","ecog_performance_status":2,"smoking_pack_years":20,"primary_tumor_size_cm":5.3,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":22.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.646567+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_192760","record_id":"REC_0014099","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":5.5,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.646910+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_842902","record_id":"REC_0014100","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":10.5,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":6.7,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.647241+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_875518","record_id":"REC_0014101","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":2.5,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":7.9,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":18.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.647595+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_816487","record_id":"REC_0014102","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":13.8,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":21,"primary_tumor_size_cm":5.7,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.647986+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_572032","record_id":"REC_0014103","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":15.3,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.7,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.648399+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_916452","record_id":"REC_0014104","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":6.9,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":4.2,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":5.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.648772+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_934739","record_id":"REC_0014105","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":7.0,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.649119+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_138990","record_id":"REC_0014106","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":10.0,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":7.6,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.649609+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_826501","record_id":"REC_0014107","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":32,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":4.7,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.649979+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_184046","record_id":"REC_0014108","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":16.2,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":4.8,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":22.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.650314+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_499028","record_id":"REC_0014109","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":4.3,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":17.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.650661+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_252404","record_id":"REC_0014110","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":30,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":4,"primary_tumor_size_cm":8.2,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":55.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.650999+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_730403","record_id":"REC_0014111","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":9.7,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":4.2,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":29.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.651310+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_663342","record_id":"REC_0014112","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":26,"primary_tumor_size_cm":4.0,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.651621+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_801192","record_id":"REC_0014113","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":9.0,"age_at_diagnosis":50,"sex":"male","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":6.5,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.651936+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_708423","record_id":"REC_0014114","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":10.3,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":4.6,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":18.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.652374+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_229699","record_id":"REC_0014115","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":5.3,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":74,"primary_tumor_size_cm":5.7,"metastatic_sites_count":8,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.652730+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_269711","record_id":"REC_0014116","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":3.8,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":6.3,"metastatic_sites_count":3,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":19.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.653028+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_159894","record_id":"REC_0014117","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":8.0,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":5.4,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.653316+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_411249","record_id":"REC_0014118","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":7.5,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":20.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.653620+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_862591","record_id":"REC_0014119","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":5.0,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.654139+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_984563","record_id":"REC_0014120","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":13.1,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":23,"primary_tumor_size_cm":6.9,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.654503+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_608148","record_id":"REC_0014121","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":6.0,"age_at_diagnosis":81,"sex":"male","ecog_performance_status":2,"smoking_pack_years":7,"primary_tumor_size_cm":7.0,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.654816+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_775069","record_id":"REC_0014122","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":7.4,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":21.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.655118+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_792623","record_id":"REC_0014123","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":18,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":48,"sex":"male","ecog_performance_status":0,"smoking_pack_years":3,"primary_tumor_size_cm":4.8,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.655415+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_595585","record_id":"REC_0014124","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":19,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":24,"primary_tumor_size_cm":4.0,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.655706+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_907809","record_id":"REC_0014125","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":5.4,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.656005+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_948148","record_id":"REC_0014126","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":31,"tmb_mutations_per_mb":13.8,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":26,"primary_tumor_size_cm":2.8,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":21.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.656391+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_576824","record_id":"REC_0014127","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":77,"sex":"male","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":7.6,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.656734+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_840498","record_id":"REC_0014128","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":16,"tmb_mutations_per_mb":5.7,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":1,"smoking_pack_years":25,"primary_tumor_size_cm":5.0,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":20.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.657044+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_258506","record_id":"REC_0014129","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":5,"primary_tumor_size_cm":7.2,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.657360+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_476199","record_id":"REC_0014130","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":9.5,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":4.5,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.657683+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_812630","record_id":"REC_0014131","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":3.6,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":34,"primary_tumor_size_cm":5.1,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":38.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.658001+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_173022","record_id":"REC_0014132","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":19,"tmb_mutations_per_mb":3.8,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":52,"primary_tumor_size_cm":5.2,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.658520+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_237594","record_id":"REC_0014133","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":15,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":1,"smoking_pack_years":62,"primary_tumor_size_cm":2.6,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.658865+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_526959","record_id":"REC_0014134","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":9.9,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":4.2,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.659207+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_698452","record_id":"REC_0014135","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":54,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":6.8,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":22.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.659575+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_140790","record_id":"REC_0014136","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":9.0,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":6,"primary_tumor_size_cm":5.1,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":20.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.659899+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_175511","record_id":"REC_0014137","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":5.5,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.660305+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_261372","record_id":"REC_0014138","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":31,"tmb_mutations_per_mb":18.2,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":6.2,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":29.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.660685+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_582164","record_id":"REC_0014139","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":3.9,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":20.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.661009+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_542932","record_id":"REC_0014140","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":14.9,"age_at_diagnosis":49,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":2.6,"metastatic_sites_count":3,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.661339+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_722869","record_id":"REC_0014141","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":30,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":4.6,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.661651+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_382934","record_id":"REC_0014142","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":2.9,"age_at_diagnosis":82,"sex":"male","ecog_performance_status":1,"smoking_pack_years":2,"primary_tumor_size_cm":5.9,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":21.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.661987+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_383283","record_id":"REC_0014143","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":15,"tmb_mutations_per_mb":8.4,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":6.4,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.662333+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_149631","record_id":"REC_0014144","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":15,"tmb_mutations_per_mb":9.1,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":6.6,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.662654+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_105143","record_id":"REC_0014145","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":14.7,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":2,"smoking_pack_years":20,"primary_tumor_size_cm":3.0,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.663131+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_273674","record_id":"REC_0014146","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":4.7,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":16.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.663516+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_493906","record_id":"REC_0014147","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":19.8,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":5.6,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":20.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.663975+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_848544","record_id":"REC_0014148","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":18,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":4.5,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.664421+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_508573","record_id":"REC_0014149","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":50,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":6.5,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.664820+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_902114","record_id":"REC_0014150","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":17.6,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":5.6,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.665199+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_800320","record_id":"REC_0014151","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":8.6,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":22.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.665562+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_371945","record_id":"REC_0014152","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":31,"tmb_mutations_per_mb":8.6,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":5.3,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":4.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.665922+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_535290","record_id":"REC_0014153","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":7.4,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":4.3,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.666281+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_459959","record_id":"REC_0014154","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":20,"primary_tumor_size_cm":5.6,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":27.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.666602+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_210792","record_id":"REC_0014155","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":11.1,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":0,"primary_tumor_size_cm":6.9,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.666925+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_847851","record_id":"REC_0014156","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":25,"primary_tumor_size_cm":4.7,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.667280+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_839884","record_id":"REC_0014157","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":16.6,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":5.6,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.667623+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_265947","record_id":"REC_0014158","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":32,"tmb_mutations_per_mb":4.8,"age_at_diagnosis":49,"sex":"male","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":4.5,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":5.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.668210+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_633171","record_id":"REC_0014159","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":7.9,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":2,"smoking_pack_years":44,"primary_tumor_size_cm":5.9,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.668616+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_309099","record_id":"REC_0014160","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":14.8,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":0,"primary_tumor_size_cm":3.4,"metastatic_sites_count":8,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.668929+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_158746","record_id":"REC_0014161","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":16.1,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":5.5,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.669248+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_550979","record_id":"REC_0014162","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":16.2,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":2.0,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.669570+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_308734","record_id":"REC_0014163","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":8.0,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":4.9,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.669895+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_742698","record_id":"REC_0014164","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":15,"tmb_mutations_per_mb":15.0,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":4.9,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":21.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.670387+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_940019","record_id":"REC_0014165","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":9.1,"age_at_diagnosis":51,"sex":"female","ecog_performance_status":0,"smoking_pack_years":0,"primary_tumor_size_cm":6.7,"metastatic_sites_count":3,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.670753+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_455399","record_id":"REC_0014166","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":24,"primary_tumor_size_cm":6.0,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.671092+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_490420","record_id":"REC_0014167","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":54,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":5.8,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":26.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.671425+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_362698","record_id":"REC_0014168","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":4.1,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":42,"primary_tumor_size_cm":2.9,"metastatic_sites_count":3,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.671747+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_196448","record_id":"REC_0014169","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":4.7,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.672134+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_479254","record_id":"REC_0014170","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":30,"tmb_mutations_per_mb":6.4,"age_at_diagnosis":49,"sex":"female","ecog_performance_status":0,"smoking_pack_years":30,"primary_tumor_size_cm":5.8,"metastatic_sites_count":8,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":19.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.672494+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_388455","record_id":"REC_0014171","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":16.2,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":5.2,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.673000+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_420390","record_id":"REC_0014172","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":5.6,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.673379+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_429360","record_id":"REC_0014173","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":34,"tmb_mutations_per_mb":2.7,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":5.9,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.673723+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_288625","record_id":"REC_0014174","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":4.2,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":6.4,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.674057+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_317449","record_id":"REC_0014175","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":15,"tmb_mutations_per_mb":16.5,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":4.7,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":17.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.674417+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_481631","record_id":"REC_0014176","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.4,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":18.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.674755+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_530871","record_id":"REC_0014177","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":3.7,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":3,"smoking_pack_years":49,"primary_tumor_size_cm":3.4,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.675099+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_418426","record_id":"REC_0014178","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":18,"tmb_mutations_per_mb":7.4,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":4.8,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.675427+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_687079","record_id":"REC_0014179","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":17,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":84,"sex":"male","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":4.0,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.675785+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_641585","record_id":"REC_0014180","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":5.0,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":59,"primary_tumor_size_cm":4.2,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.676257+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_464192","record_id":"REC_0014181","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":6.5,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.676625+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_879332","record_id":"REC_0014182","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":9.0,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":2,"smoking_pack_years":46,"primary_tumor_size_cm":6.4,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.676964+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_864928","record_id":"REC_0014183","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":13.1,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":0,"smoking_pack_years":6,"primary_tumor_size_cm":5.6,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.677312+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_934568","record_id":"REC_0014184","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":11,"tmb_mutations_per_mb":11.1,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":7.3,"metastatic_sites_count":8,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.677843+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_285924","record_id":"REC_0014185","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":6.1,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":6.7,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":16.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.678238+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_188052","record_id":"REC_0014186","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":10.1,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":6.3,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.678580+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_243143","record_id":"REC_0014187","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":10.0,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":3,"smoking_pack_years":12,"primary_tumor_size_cm":6.0,"metastatic_sites_count":8,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.678906+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_835245","record_id":"REC_0014188","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":13.1,"age_at_diagnosis":77,"sex":"male","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":6.1,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.679262+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_825249","record_id":"REC_0014189","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":34,"tmb_mutations_per_mb":5.2,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":4,"primary_tumor_size_cm":5.5,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.679605+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_538828","record_id":"REC_0014190","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":33,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":4,"primary_tumor_size_cm":6.9,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.679957+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_218083","record_id":"REC_0014191","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":14.8,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":7.1,"metastatic_sites_count":3,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":18.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.680393+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_596630","record_id":"REC_0014192","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":17.3,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":4.1,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.680809+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_603541","record_id":"REC_0014193","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":5.6,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":3.6,"metastatic_sites_count":3,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.681153+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_773204","record_id":"REC_0014194","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":87,"sex":"female","ecog_performance_status":2,"smoking_pack_years":4,"primary_tumor_size_cm":5.4,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":20.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.681508+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_928377","record_id":"REC_0014195","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":4.6,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":70,"primary_tumor_size_cm":6.6,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":16.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.681871+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_628911","record_id":"REC_0014196","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":5.0,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.682390+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_123478","record_id":"REC_0014197","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":8.6,"age_at_diagnosis":74,"sex":"male","ecog_performance_status":2,"smoking_pack_years":9,"primary_tumor_size_cm":5.4,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.682911+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_375523","record_id":"REC_0014198","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":7.3,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":5.3,"metastatic_sites_count":8,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.683275+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_485942","record_id":"REC_0014199","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":4.6,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":43,"primary_tumor_size_cm":6.1,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.683617+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_674459","record_id":"REC_0014200","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":5.9,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":6,"primary_tumor_size_cm":5.2,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.683967+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_480084","record_id":"REC_0014201","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":19,"tmb_mutations_per_mb":6.0,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":5.4,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.684381+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_766546","record_id":"REC_0014202","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":9.8,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":5.5,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.684736+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_673668","record_id":"REC_0014203","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":14.8,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":4.5,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":26.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.685088+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_503215","record_id":"REC_0014204","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":76,"sex":"male","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":5.2,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":5.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.685437+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_183446","record_id":"REC_0014205","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":16.0,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":4.7,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.685774+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_831680","record_id":"REC_0014206","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":17.3,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":8.8,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":20.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.686111+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_407081","record_id":"REC_0014207","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":13.3,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":4.2,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.686439+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_445641","record_id":"REC_0014208","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":54,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":6.6,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.686764+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_362212","record_id":"REC_0014209","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":14.1,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":5.3,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.687066+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_249467","record_id":"REC_0014210","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":9.0,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":26,"primary_tumor_size_cm":4.5,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":21.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.687558+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_745646","record_id":"REC_0014211","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":33,"tmb_mutations_per_mb":10.5,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.3,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.687929+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_761988","record_id":"REC_0014212","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":1,"smoking_pack_years":36,"primary_tumor_size_cm":6.0,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.688359+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_994490","record_id":"REC_0014213","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":8.5,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":0,"smoking_pack_years":36,"primary_tumor_size_cm":6.8,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.688748+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_408591","record_id":"REC_0014214","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":13.6,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":3.7,"metastatic_sites_count":8,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.689109+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_756645","record_id":"REC_0014215","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":14,"tmb_mutations_per_mb":14.1,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":3.3,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.689481+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_446120","record_id":"REC_0014216","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":19.2,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":6.7,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.689825+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_986295","record_id":"REC_0014217","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":14.5,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":4.0,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.690175+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_198366","record_id":"REC_0014218","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":7.3,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":22.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.690494+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_354777","record_id":"REC_0014219","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":18.9,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":2,"smoking_pack_years":10,"primary_tumor_size_cm":3.4,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":29.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.690818+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_527570","record_id":"REC_0014220","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":4.5,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":45.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.691154+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_981601","record_id":"REC_0014221","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":7.5,"metastatic_sites_count":3,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":4.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.691507+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_621484","record_id":"REC_0014222","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":32,"tmb_mutations_per_mb":11.0,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":7.3,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.691851+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_756180","record_id":"REC_0014223","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":5.0,"age_at_diagnosis":54,"sex":"male","ecog_performance_status":0,"smoking_pack_years":38,"primary_tumor_size_cm":5.7,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.692464+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_330792","record_id":"REC_0014224","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":14.6,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":5.2,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.692882+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_924325","record_id":"REC_0014225","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":52,"sex":"male","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":6.9,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.693251+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_146594","record_id":"REC_0014226","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":1.5,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":4.7,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":63.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.693576+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_937262","record_id":"REC_0014227","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":17,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":51,"primary_tumor_size_cm":5.5,"metastatic_sites_count":8,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.693922+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_461755","record_id":"REC_0014228","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":14.6,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":5.6,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.694277+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_235933","record_id":"REC_0014229","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":22.3,"age_at_diagnosis":51,"sex":"male","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":6.2,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.694617+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_941738","record_id":"REC_0014230","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":90,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":4.5,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":16.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.694973+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_698266","record_id":"REC_0014231","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":3.7,"metastatic_sites_count":8,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.695310+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_535903","record_id":"REC_0014232","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":20,"tmb_mutations_per_mb":6.3,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":0,"smoking_pack_years":35,"primary_tumor_size_cm":3.6,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":16.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.695646+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_444448","record_id":"REC_0014233","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":8.6,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":0,"smoking_pack_years":52,"primary_tumor_size_cm":5.3,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.695997+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_969123","record_id":"REC_0014234","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":3,"smoking_pack_years":54,"primary_tumor_size_cm":6.5,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.696477+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_821612","record_id":"REC_0014235","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":5.4,"metastatic_sites_count":9,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":4.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.696882+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_717530","record_id":"REC_0014236","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":5.3,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":54,"primary_tumor_size_cm":5.2,"metastatic_sites_count":3,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":18.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.697406+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_866504","record_id":"REC_0014237","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":9,"primary_tumor_size_cm":6.4,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.697796+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_463284","record_id":"REC_0014238","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":8.4,"age_at_diagnosis":79,"sex":"male","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":5.0,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.698141+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_136800","record_id":"REC_0014239","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":8.7,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":4.0,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":29.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.698481+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_603479","record_id":"REC_0014240","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":13.6,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":7.3,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.698835+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_992542","record_id":"REC_0014241","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":16,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":53,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":6.6,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.699180+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_333636","record_id":"REC_0014242","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":14,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":25,"primary_tumor_size_cm":7.1,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":17.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.699518+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_302857","record_id":"REC_0014243","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":37,"tmb_mutations_per_mb":14.8,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":9.3,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.699853+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_711205","record_id":"REC_0014244","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":2,"smoking_pack_years":0,"primary_tumor_size_cm":4.1,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":31.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.700257+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_306409","record_id":"REC_0014245","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":13.6,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":25,"primary_tumor_size_cm":6.9,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.700621+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_723466","record_id":"REC_0014246","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":20,"tmb_mutations_per_mb":7.4,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":5.6,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":18.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.700974+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_150393","record_id":"REC_0014247","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":14.7,"age_at_diagnosis":54,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":3.7,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.701333+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_344885","record_id":"REC_0014248","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":14.4,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":6.5,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.701694+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_885037","record_id":"REC_0014249","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":19.3,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":6.1,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.702179+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_359582","record_id":"REC_0014250","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":18.5,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":7.3,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.702541+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_908017","record_id":"REC_0014251","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":8.6,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":68,"primary_tumor_size_cm":5.5,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.702872+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_414103","record_id":"REC_0014252","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":6.6,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.703221+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_332050","record_id":"REC_0014253","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":7,"primary_tumor_size_cm":7.5,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":26.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.703560+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_901909","record_id":"REC_0014254","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":5.3,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":35,"primary_tumor_size_cm":5.8,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":17.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.703890+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_315176","record_id":"REC_0014255","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":8.6,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":4.3,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.704301+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_962071","record_id":"REC_0014256","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":17.8,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":5.6,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":28.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.704679+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_563330","record_id":"REC_0014257","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":8.7,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":6.0,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":32.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.705011+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_339437","record_id":"REC_0014258","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":13.6,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":23,"primary_tumor_size_cm":6.6,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":29.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.705341+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_409067","record_id":"REC_0014259","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":8.6,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.9,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":5.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.705680+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_234350","record_id":"REC_0014260","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":20,"tmb_mutations_per_mb":7.3,"age_at_diagnosis":54,"sex":"male","ecog_performance_status":0,"smoking_pack_years":31,"primary_tumor_size_cm":7.0,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.706011+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_127397","record_id":"REC_0014261","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":17.6,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":7.1,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.706366+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_174423","record_id":"REC_0014262","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":14.9,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":6.4,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.706928+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_732337","record_id":"REC_0014263","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":30,"tmb_mutations_per_mb":15.1,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":6.3,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":6.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.707368+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_220436","record_id":"REC_0014264","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":15.9,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":5.2,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":5.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.707775+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_338478","record_id":"REC_0014265","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":15,"tmb_mutations_per_mb":8.5,"age_at_diagnosis":52,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":7.8,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":21.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.708241+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_809585","record_id":"REC_0014266","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":81,"sex":"male","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.6,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.708681+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_823547","record_id":"REC_0014267","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":9.1,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":4.4,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.709088+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_808185","record_id":"REC_0014268","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":17,"tmb_mutations_per_mb":1.7,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":5.8,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.709449+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_273190","record_id":"REC_0014269","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":16,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":6.2,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.709828+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_709847","record_id":"REC_0014270","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":14.5,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":5.5,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":31.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.710162+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_317014","record_id":"REC_0014271","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":19,"tmb_mutations_per_mb":6.0,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":3.3,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":5.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.710517+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_725191","record_id":"REC_0014272","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":13.5,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":6.5,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.710891+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_509563","record_id":"REC_0014273","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":17.3,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":3.7,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":21.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.711254+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_730646","record_id":"REC_0014274","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":9.8,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":4.0,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.711593+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_811285","record_id":"REC_0014275","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":34,"tmb_mutations_per_mb":9.1,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":8.3,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.712057+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_217231","record_id":"REC_0014276","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":5.7,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":22.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.712484+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_721372","record_id":"REC_0014277","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":13.6,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":6.3,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":18.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.712831+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_554777","record_id":"REC_0014278","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":9.1,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":6.4,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":41.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.713174+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_773466","record_id":"REC_0014279","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":6.1,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.713553+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_974404","record_id":"REC_0014280","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":5.3,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.713908+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_533945","record_id":"REC_0014281","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":19.1,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":7.6,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.714283+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_542013","record_id":"REC_0014282","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":6.5,"metastatic_sites_count":9,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.714647+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_497822","record_id":"REC_0014283","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":15.8,"age_at_diagnosis":49,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":5.8,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.717771+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_712161","record_id":"REC_0014284","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":8.2,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.718328+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_968361","record_id":"REC_0014285","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.6,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":6.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.718672+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_317951","record_id":"REC_0014286","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":8.7,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":0,"smoking_pack_years":50,"primary_tumor_size_cm":5.5,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.719022+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_264429","record_id":"REC_0014287","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":32,"tmb_mutations_per_mb":15.3,"age_at_diagnosis":76,"sex":"male","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":6.4,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":17.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.719341+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_231366","record_id":"REC_0014288","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":17.3,"age_at_diagnosis":52,"sex":"male","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":3.1,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":6.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.719838+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_412745","record_id":"REC_0014289","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":30,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":7.7,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.720303+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_701571","record_id":"REC_0014290","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":10.3,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":6.5,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":30.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.720654+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_832520","record_id":"REC_0014291","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":6.1,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":7.0,"metastatic_sites_count":8,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.721028+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_945462","record_id":"REC_0014292","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":6.3,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":57,"primary_tumor_size_cm":8.0,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.721363+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_566314","record_id":"REC_0014293","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":4.8,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":72,"primary_tumor_size_cm":4.2,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.721701+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_757546","record_id":"REC_0014294","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":15.4,"age_at_diagnosis":74,"sex":"male","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":6.0,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":5.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.722077+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_862427","record_id":"REC_0014295","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":83,"sex":"female","ecog_performance_status":1,"smoking_pack_years":66,"primary_tumor_size_cm":3.5,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.722469+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_290373","record_id":"REC_0014296","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":9.1,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":24,"primary_tumor_size_cm":5.5,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.722883+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_593235","record_id":"REC_0014297","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":78,"sex":"male","ecog_performance_status":1,"smoking_pack_years":58,"primary_tumor_size_cm":6.1,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":24.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.723282+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_256524","record_id":"REC_0014298","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":3.4,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":1,"smoking_pack_years":63,"primary_tumor_size_cm":7.1,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":28.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.723674+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_445297","record_id":"REC_0014299","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":1.5,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":5.3,"metastatic_sites_count":8,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.724054+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_716036","record_id":"REC_0014300","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":3.0,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":6.6,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.724496+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_266878","record_id":"REC_0014301","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":4.4,"metastatic_sites_count":3,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.725005+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_350253","record_id":"REC_0014302","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":14,"tmb_mutations_per_mb":13.8,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":4.5,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.725379+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_847611","record_id":"REC_0014303","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":15.5,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":5.6,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.725718+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_120581","record_id":"REC_0014304","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":5.1,"metastatic_sites_count":8,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.726060+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_354851","record_id":"REC_0014305","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":8.3,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":6.1,"metastatic_sites_count":9,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.726398+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_183673","record_id":"REC_0014306","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":13,"tmb_mutations_per_mb":5.5,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":5.9,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.726737+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_618579","record_id":"REC_0014307","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":30,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":56,"primary_tumor_size_cm":2.7,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.727080+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_856247","record_id":"REC_0014308","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":9.1,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":1,"primary_tumor_size_cm":4.7,"metastatic_sites_count":8,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":7.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.727453+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_688232","record_id":"REC_0014309","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":79,"sex":"male","ecog_performance_status":2,"smoking_pack_years":27,"primary_tumor_size_cm":4.8,"metastatic_sites_count":9,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":4.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.727821+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_218287","record_id":"REC_0014310","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":19,"tmb_mutations_per_mb":4.8,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":47,"primary_tumor_size_cm":8.2,"metastatic_sites_count":8,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.728675+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_192844","record_id":"REC_0014311","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":14.3,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":5.7,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.729139+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_863880","record_id":"REC_0014312","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":15.1,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":6.4,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.729612+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_136583","record_id":"REC_0014313","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":15.7,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":5.1,"metastatic_sites_count":8,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.730037+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_678026","record_id":"REC_0014314","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":20.2,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":7.1,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.730671+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_864051","record_id":"REC_0014315","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":10.1,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":5.7,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":16.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.731137+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_378499","record_id":"REC_0014316","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":7.8,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.734098+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_908794","record_id":"REC_0014317","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":8.1,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":7.4,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":18.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.734646+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_235676","record_id":"REC_0014318","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":6.3,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":25.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.736059+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_941346","record_id":"REC_0014319","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":5.0,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":4.2,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":24.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.736563+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_964322","record_id":"REC_0014320","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":7.1,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.736961+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_232082","record_id":"REC_0014321","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":8.2,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":20.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.737312+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_826879","record_id":"REC_0014322","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":8.3,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":6,"primary_tumor_size_cm":6.4,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":6.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.737651+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_422671","record_id":"REC_0014323","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":9.8,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":5.1,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":5.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.738001+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_347081","record_id":"REC_0014324","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":14.5,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":4.7,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":21.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.738352+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_720078","record_id":"REC_0014325","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":4.6,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":4.2,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":18.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.738747+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_248488","record_id":"REC_0014326","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":4.8,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":6.1,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.739158+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_128823","record_id":"REC_0014327","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":5.6,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.739810+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_409084","record_id":"REC_0014328","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":18.1,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":6.3,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":33.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.740377+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_797366","record_id":"REC_0014329","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":18.9,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":25,"primary_tumor_size_cm":5.7,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":20.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.740929+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_569787","record_id":"REC_0014330","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":6.5,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.741399+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_817906","record_id":"REC_0014331","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":20,"primary_tumor_size_cm":5.2,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.741884+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_850222","record_id":"REC_0014332","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":30,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":3,"smoking_pack_years":35,"primary_tumor_size_cm":5.2,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.742381+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_817477","record_id":"REC_0014333","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":10.5,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":5.5,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.742866+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_654238","record_id":"REC_0014334","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":20.5,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":5.6,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.743312+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_582223","record_id":"REC_0014335","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":36,"tmb_mutations_per_mb":4.1,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":33,"primary_tumor_size_cm":5.5,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":17.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.743753+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_147477","record_id":"REC_0014336","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":5.5,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.744237+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_535659","record_id":"REC_0014337","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":5.8,"metastatic_sites_count":9,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":5.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.744690+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_670122","record_id":"REC_0014338","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":4.3,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":28,"primary_tumor_size_cm":4.8,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.745090+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_756173","record_id":"REC_0014339","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":1.5,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":6.2,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":4.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.745464+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_372608","record_id":"REC_0014340","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":5.7,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":1,"smoking_pack_years":45,"primary_tumor_size_cm":4.7,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":21.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.746102+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_957524","record_id":"REC_0014341","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":10.1,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":30,"primary_tumor_size_cm":4.1,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.746588+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_457596","record_id":"REC_0014342","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":83,"sex":"female","ecog_performance_status":2,"smoking_pack_years":24,"primary_tumor_size_cm":5.5,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.747047+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_736620","record_id":"REC_0014343","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":17.0,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":5.7,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.747516+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_773097","record_id":"REC_0014344","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":5.1,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.747957+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_714249","record_id":"REC_0014345","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":50,"sex":"female","ecog_performance_status":0,"smoking_pack_years":39,"primary_tumor_size_cm":5.6,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.751282+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_951186","record_id":"REC_0014346","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":7.0,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.751851+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_710886","record_id":"REC_0014347","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":13.3,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":3,"smoking_pack_years":15,"primary_tumor_size_cm":3.9,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.753228+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_202270","record_id":"REC_0014348","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":7.3,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.753677+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_109701","record_id":"REC_0014349","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":2,"smoking_pack_years":36,"primary_tumor_size_cm":5.1,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.754052+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_110741","record_id":"REC_0014350","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":19.6,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":3,"smoking_pack_years":23,"primary_tumor_size_cm":6.6,"metastatic_sites_count":10,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.754427+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_784363","record_id":"REC_0014351","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":6.7,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.754776+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_957688","record_id":"REC_0014352","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":4.9,"age_at_diagnosis":44,"sex":"male","ecog_performance_status":0,"smoking_pack_years":27,"primary_tumor_size_cm":4.1,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":28.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.755123+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_154370","record_id":"REC_0014353","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":16,"tmb_mutations_per_mb":14.5,"age_at_diagnosis":78,"sex":"male","ecog_performance_status":2,"smoking_pack_years":26,"primary_tumor_size_cm":5.5,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.755643+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_370369","record_id":"REC_0014354","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":32,"tmb_mutations_per_mb":7.3,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":2,"smoking_pack_years":51,"primary_tumor_size_cm":5.7,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":16.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.755972+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_286591","record_id":"REC_0014355","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":2,"smoking_pack_years":5,"primary_tumor_size_cm":8.9,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":53.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.756744+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_609809","record_id":"REC_0014356","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":9.9,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":4.4,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.757231+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_306040","record_id":"REC_0014357","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":8.4,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":4.9,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.757620+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_898990","record_id":"REC_0014358","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":3.5,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.757976+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_194386","record_id":"REC_0014359","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":6.7,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.758314+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_923709","record_id":"REC_0014360","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":16.3,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":5.1,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.758986+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_829733","record_id":"REC_0014361","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":16,"tmb_mutations_per_mb":14.6,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":4.8,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.759402+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_434466","record_id":"REC_0014362","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":5.2,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":19.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.759736+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_621785","record_id":"REC_0014363","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":6.3,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":51,"primary_tumor_size_cm":5.9,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.760123+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_760616","record_id":"REC_0014364","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":8.1,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":0,"smoking_pack_years":86,"primary_tumor_size_cm":6.3,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":22.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.760505+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_796192","record_id":"REC_0014365","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":34,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":5.9,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.760883+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_166424","record_id":"REC_0014366","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":7.2,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.761426+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_786886","record_id":"REC_0014367","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":16.9,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":7.5,"metastatic_sites_count":3,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":19.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.761841+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_712160","record_id":"REC_0014368","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":9.1,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":51,"primary_tumor_size_cm":5.2,"metastatic_sites_count":8,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.762495+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_737931","record_id":"REC_0014369","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":9.1,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":20,"primary_tumor_size_cm":5.7,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.762966+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_610894","record_id":"REC_0014370","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":14.0,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":5.0,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":22.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.763317+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_777253","record_id":"REC_0014371","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":1,"smoking_pack_years":45,"primary_tumor_size_cm":7.4,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.763660+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_609912","record_id":"REC_0014372","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":3.4,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.763999+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_646040","record_id":"REC_0014373","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":5.3,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.764436+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_170869","record_id":"REC_0014374","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":31,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":5.9,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.764761+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_817749","record_id":"REC_0014375","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":4.0,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":6.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.765086+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_528453","record_id":"REC_0014376","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":76,"sex":"male","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":4.5,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":16.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.765456+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_453489","record_id":"REC_0014377","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":15.3,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":6.4,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.765816+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_645437","record_id":"REC_0014378","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":7.3,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":6.7,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":21.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.766180+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_989090","record_id":"REC_0014379","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":3.0,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":5.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.766694+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_284411","record_id":"REC_0014380","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":15.7,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":4.5,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.767053+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_826246","record_id":"REC_0014381","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":15.1,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":7.5,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.767402+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_822830","record_id":"REC_0014382","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":15.9,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":6.4,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.767748+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_254966","record_id":"REC_0014383","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":8.0,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":4,"primary_tumor_size_cm":4.5,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.768162+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_188898","record_id":"REC_0014384","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":30,"tmb_mutations_per_mb":4.7,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":4.8,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":42.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.768548+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_713192","record_id":"REC_0014385","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":31,"tmb_mutations_per_mb":8.9,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":1,"smoking_pack_years":47,"primary_tumor_size_cm":6.1,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.768903+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_142918","record_id":"REC_0014386","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":17,"tmb_mutations_per_mb":13.5,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":5.3,"metastatic_sites_count":9,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":5.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.769239+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_150388","record_id":"REC_0014387","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":19,"tmb_mutations_per_mb":10.3,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":5.5,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.769601+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_579446","record_id":"REC_0014388","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":3.3,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":0,"smoking_pack_years":57,"primary_tumor_size_cm":6.3,"metastatic_sites_count":8,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.769943+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_222795","record_id":"REC_0014389","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":3.9,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.770280+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_604434","record_id":"REC_0014390","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":4.9,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":0,"smoking_pack_years":47,"primary_tumor_size_cm":6.3,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.770599+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_781000","record_id":"REC_0014391","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":14.9,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":6.7,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.770945+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_394492","record_id":"REC_0014392","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":19,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":0,"smoking_pack_years":65,"primary_tumor_size_cm":7.0,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":20.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.771458+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_236540","record_id":"REC_0014393","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":12,"tmb_mutations_per_mb":6.7,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":3.9,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.771854+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_769321","record_id":"REC_0014394","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":19,"tmb_mutations_per_mb":15.0,"age_at_diagnosis":83,"sex":"female","ecog_performance_status":2,"smoking_pack_years":21,"primary_tumor_size_cm":4.8,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.772320+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_196426","record_id":"REC_0014395","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":24,"primary_tumor_size_cm":4.3,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":28.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.772722+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_535233","record_id":"REC_0014396","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":15.8,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":4.4,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.773132+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_309540","record_id":"REC_0014397","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":15.5,"age_at_diagnosis":74,"sex":"male","ecog_performance_status":2,"smoking_pack_years":2,"primary_tumor_size_cm":3.7,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.773540+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_699264","record_id":"REC_0014398","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":9.1,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":6.1,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.773927+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_590420","record_id":"REC_0014399","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":5.5,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.774325+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_747431","record_id":"REC_0014400","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":20.1,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":6.0,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.774714+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_153939","record_id":"REC_0014401","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":4.8,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":33,"primary_tumor_size_cm":5.9,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":21.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.775100+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_644927","record_id":"REC_0014402","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ALK fusion","pd_l1_tps_percent":15,"tmb_mutations_per_mb":16.4,"age_at_diagnosis":52,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":5.1,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":55.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.775480+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_918984","record_id":"REC_0014403","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":5.5,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.775812+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_215344","record_id":"REC_0014404","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":19,"tmb_mutations_per_mb":8.5,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":4.3,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.777078+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_237918","record_id":"REC_0014405","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":34,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":0,"smoking_pack_years":24,"primary_tumor_size_cm":4.0,"metastatic_sites_count":9,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.777816+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_329023","record_id":"REC_0014406","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":5.5,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.5,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.778213+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_702487","record_id":"REC_0014407","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":6,"primary_tumor_size_cm":7.0,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.778573+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_441324","record_id":"REC_0014408","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":31,"tmb_mutations_per_mb":7.3,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":6.6,"metastatic_sites_count":3,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.778901+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_548050","record_id":"REC_0014409","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":19,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":7.0,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.779238+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_913785","record_id":"REC_0014410","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":13.5,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":4.5,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.779573+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_123172","record_id":"REC_0014411","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":5.9,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":26.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.779902+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_452113","record_id":"REC_0014412","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":32,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":54,"sex":"male","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":6.7,"metastatic_sites_count":3,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.780336+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_643902","record_id":"REC_0014413","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":3.7,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":17.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.780700+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_495653","record_id":"REC_0014414","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":24,"primary_tumor_size_cm":5.2,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.781014+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_247682","record_id":"REC_0014415","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":9.0,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":5.3,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.781327+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_831467","record_id":"REC_0014416","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":14.8,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":6.1,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":17.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.781647+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_394511","record_id":"REC_0014417","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":4.5,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.782001+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_991702","record_id":"REC_0014418","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":6.4,"metastatic_sites_count":3,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":6.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.782506+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_725902","record_id":"REC_0014419","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":16,"tmb_mutations_per_mb":15.9,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":8.6,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":5.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.782864+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_486099","record_id":"REC_0014420","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":5.5,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":4.8,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.783206+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_105384","record_id":"REC_0014421","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":32,"tmb_mutations_per_mb":16.8,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":3.9,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.783532+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_708349","record_id":"REC_0014422","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":32,"tmb_mutations_per_mb":13.8,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":21,"primary_tumor_size_cm":3.8,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":26.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.783866+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_175544","record_id":"REC_0014423","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":4.3,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":2.5,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":5.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.784321+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_126682","record_id":"REC_0014424","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":4.3,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.784701+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_790734","record_id":"REC_0014425","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":6.3,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":29.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.785050+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_759250","record_id":"REC_0014426","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":31,"tmb_mutations_per_mb":17.0,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":6.0,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.785400+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_717296","record_id":"REC_0014427","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":2,"smoking_pack_years":21,"primary_tumor_size_cm":3.8,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.785742+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_736332","record_id":"REC_0014428","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":53,"sex":"male","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":5.5,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.786093+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_114733","record_id":"REC_0014429","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":17,"tmb_mutations_per_mb":6.1,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":4.6,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.786413+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_529960","record_id":"REC_0014430","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":30,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":44,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":5.7,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":5.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.786786+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_351185","record_id":"REC_0014431","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":4.7,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":47.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.787254+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_146434","record_id":"REC_0014432","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":3.0,"age_at_diagnosis":83,"sex":"female","ecog_performance_status":2,"smoking_pack_years":69,"primary_tumor_size_cm":5.6,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":43.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.787624+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_738463","record_id":"REC_0014433","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":6.9,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":2,"smoking_pack_years":49,"primary_tumor_size_cm":4.7,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":7.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.787963+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_243262","record_id":"REC_0014434","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":6.4,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":3,"smoking_pack_years":72,"primary_tumor_size_cm":4.8,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":17.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.788528+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_395033","record_id":"REC_0014435","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":52,"sex":"male","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":6.5,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":20.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.788947+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_196232","record_id":"REC_0014436","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":7.4,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":31,"primary_tumor_size_cm":3.3,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.789307+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_210232","record_id":"REC_0014437","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":14.6,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":1,"smoking_pack_years":1,"primary_tumor_size_cm":6.0,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.789671+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_932109","record_id":"REC_0014438","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":20,"tmb_mutations_per_mb":4.2,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":28,"primary_tumor_size_cm":5.0,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.790017+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_801723","record_id":"REC_0014439","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":7.8,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":20.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.790367+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_568470","record_id":"REC_0014440","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":5.3,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.790747+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_235767","record_id":"REC_0014441","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":7.2,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.791050+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_562211","record_id":"REC_0014442","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":4.3,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.791357+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_998659","record_id":"REC_0014443","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":15.3,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":4.5,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.791654+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_489286","record_id":"REC_0014444","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":3,"smoking_pack_years":17,"primary_tumor_size_cm":3.9,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.792212+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_926874","record_id":"REC_0014445","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":5.2,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":1,"smoking_pack_years":25,"primary_tumor_size_cm":5.2,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.792603+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_913202","record_id":"REC_0014446","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":16,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":5.7,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.792931+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_936328","record_id":"REC_0014447","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":2.8,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":21.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.793266+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_514780","record_id":"REC_0014448","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":10.0,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":7.4,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":20.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.793620+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_829455","record_id":"REC_0014449","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":16,"tmb_mutations_per_mb":14.0,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":4.0,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":23.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.793954+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_254572","record_id":"REC_0014450","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":16.3,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":5.1,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.794269+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_967185","record_id":"REC_0014451","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":15.8,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.9,"metastatic_sites_count":8,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.794599+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_428700","record_id":"REC_0014452","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":16.6,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":3.7,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.794916+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_976440","record_id":"REC_0014453","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":31,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":53,"sex":"male","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":5.8,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.795226+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_634337","record_id":"REC_0014454","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":5.9,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":6.3,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":4.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.795541+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_931626","record_id":"REC_0014455","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":8.4,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":5.1,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":5.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.795854+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_108749","record_id":"REC_0014456","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":3.6,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":25,"primary_tumor_size_cm":4.9,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":50.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.796254+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_831547","record_id":"REC_0014457","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":18.5,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":2,"primary_tumor_size_cm":5.3,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.796933+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_297922","record_id":"REC_0014458","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":6.0,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":37,"primary_tumor_size_cm":5.4,"metastatic_sites_count":3,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.797365+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_159125","record_id":"REC_0014459","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":82,"sex":"male","ecog_performance_status":2,"smoking_pack_years":8,"primary_tumor_size_cm":4.9,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":27.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.797761+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_596427","record_id":"REC_0014460","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":14.9,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":5.4,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":5.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.798356+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_573307","record_id":"REC_0014461","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":18,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":20,"primary_tumor_size_cm":4.8,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":21.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.798762+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_865317","record_id":"REC_0014462","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":4.4,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":2,"smoking_pack_years":6,"primary_tumor_size_cm":4.2,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.804481+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_553983","record_id":"REC_0014463","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":31,"tmb_mutations_per_mb":16.8,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":6.5,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.804985+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_161835","record_id":"REC_0014464","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":85,"sex":"female","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":6.1,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":33.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.805382+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_278573","record_id":"REC_0014465","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":8.7,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":0,"primary_tumor_size_cm":5.9,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.805766+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_338503","record_id":"REC_0014466","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":4.4,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":23,"primary_tumor_size_cm":5.5,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.806128+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_129153","record_id":"REC_0014467","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":16.8,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":7.0,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":17.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.806491+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_583943","record_id":"REC_0014468","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ALK fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":10.0,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":6.5,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":54.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.806858+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_895717","record_id":"REC_0014469","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":54,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":5.6,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":27.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.807273+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_695157","record_id":"REC_0014470","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":8.4,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":5,"primary_tumor_size_cm":3.1,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":17.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.807799+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_779992","record_id":"REC_0014471","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":30,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":83,"sex":"female","ecog_performance_status":2,"smoking_pack_years":61,"primary_tumor_size_cm":3.9,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.808938+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_637286","record_id":"REC_0014472","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":31,"tmb_mutations_per_mb":6.4,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":45,"primary_tumor_size_cm":6.0,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":19.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.809441+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_454693","record_id":"REC_0014473","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":14.8,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":7.6,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":19.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.809826+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_496107","record_id":"REC_0014474","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":8.5,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":6.5,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.810198+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_785428","record_id":"REC_0014475","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":16.1,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":5.1,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.810555+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_201928","record_id":"REC_0014476","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":13,"tmb_mutations_per_mb":14.9,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":7,"primary_tumor_size_cm":5.6,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":17.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.810942+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_988538","record_id":"REC_0014477","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":4.3,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":44,"primary_tumor_size_cm":4.2,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.811287+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_916005","record_id":"REC_0014478","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":18.2,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":25,"primary_tumor_size_cm":4.1,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.811645+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_455504","record_id":"REC_0014479","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":5.9,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.812015+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_800718","record_id":"REC_0014480","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":3.4,"metastatic_sites_count":8,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.812502+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_295400","record_id":"REC_0014481","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.1,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":26,"primary_tumor_size_cm":5.2,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.812854+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_162801","record_id":"REC_0014482","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":9.9,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":2,"primary_tumor_size_cm":3.9,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.813192+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_741868","record_id":"REC_0014483","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":10.5,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":7.3,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.813780+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_784471","record_id":"REC_0014484","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":6.3,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.814207+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_660230","record_id":"REC_0014485","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":0,"smoking_pack_years":6,"primary_tumor_size_cm":4.4,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.814580+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_348043","record_id":"REC_0014486","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":4.1,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.814931+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_346402","record_id":"REC_0014487","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":16.2,"age_at_diagnosis":53,"sex":"female","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":7.3,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":5.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.815323+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_375211","record_id":"REC_0014488","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":18.4,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":3,"primary_tumor_size_cm":5.4,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.815728+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_408074","record_id":"REC_0014489","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":13.1,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":5.8,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.816186+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_810025","record_id":"REC_0014490","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":75,"sex":"male","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":3.6,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.816606+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_330053","record_id":"REC_0014491","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":6.3,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":39,"primary_tumor_size_cm":6.0,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":48.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.817023+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_417192","record_id":"REC_0014492","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":39,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":4.2,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.817452+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_527150","record_id":"REC_0014493","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":4.0,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":24.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.817835+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_501107","record_id":"REC_0014494","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":4.2,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.818229+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_612963","record_id":"REC_0014495","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":8.4,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":55,"primary_tumor_size_cm":4.4,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.818698+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_107145","record_id":"REC_0014496","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":18.6,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":6.0,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":5.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.819292+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_138961","record_id":"REC_0014497","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":2.1,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":24,"primary_tumor_size_cm":7.5,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.819745+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_423350","record_id":"REC_0014498","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":7.6,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":7,"primary_tumor_size_cm":4.0,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.820204+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_364596","record_id":"REC_0014499","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":3.1,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":6.1,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.820603+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_233609","record_id":"REC_0014500","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":6.0,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.821022+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_816644","record_id":"REC_0014501","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":30,"tmb_mutations_per_mb":5.7,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":6.6,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":23.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.821382+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_397628","record_id":"REC_0014502","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":31,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":7.6,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.821750+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_669159","record_id":"REC_0014503","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":56,"primary_tumor_size_cm":3.8,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.822100+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_488105","record_id":"REC_0014504","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":20,"tmb_mutations_per_mb":16.6,"age_at_diagnosis":90,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":5.9,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":5.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.822500+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_937575","record_id":"REC_0014505","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.5,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":4.6,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.822856+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_855744","record_id":"REC_0014506","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":45,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":5.9,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":23.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.823217+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_403810","record_id":"REC_0014507","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":3.4,"age_at_diagnosis":75,"sex":"male","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.0,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.823565+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_872778","record_id":"REC_0014508","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":4.7,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.823900+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_161908","record_id":"REC_0014509","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":5.0,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.824459+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_894412","record_id":"REC_0014510","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":30,"tmb_mutations_per_mb":17.0,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":4.9,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.824857+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_232858","record_id":"REC_0014511","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":30,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":0,"smoking_pack_years":81,"primary_tumor_size_cm":5.9,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.825189+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_852610","record_id":"REC_0014512","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":3.6,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.825631+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_640369","record_id":"REC_0014513","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":24,"primary_tumor_size_cm":6.6,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.825992+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_941258","record_id":"REC_0014514","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":8.0,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":0,"smoking_pack_years":38,"primary_tumor_size_cm":5.1,"metastatic_sites_count":3,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.826357+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_169067","record_id":"REC_0014515","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":13.3,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":4.5,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":21.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.826742+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_970062","record_id":"REC_0014516","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":6.1,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":6.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.827090+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_500288","record_id":"REC_0014517","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":5.2,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":50,"primary_tumor_size_cm":5.2,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":17.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.827439+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_607357","record_id":"REC_0014518","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":6.2,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":33.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.827763+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_166863","record_id":"REC_0014519","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":30,"tmb_mutations_per_mb":3.9,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":5.7,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.828148+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_303855","record_id":"REC_0014520","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":3.9,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.828530+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_397289","record_id":"REC_0014521","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":8.1,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":24,"primary_tumor_size_cm":5.0,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.828879+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_637543","record_id":"REC_0014522","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":9.9,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":4.5,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.829378+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_771417","record_id":"REC_0014523","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":17,"tmb_mutations_per_mb":5.6,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":46,"primary_tumor_size_cm":5.2,"metastatic_sites_count":3,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":7.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.829806+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_645689","record_id":"REC_0014524","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":35,"tmb_mutations_per_mb":9.7,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":5.7,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.830205+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_757591","record_id":"REC_0014525","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":5,"primary_tumor_size_cm":5.3,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.830571+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_496739","record_id":"REC_0014526","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":38,"tmb_mutations_per_mb":11.0,"age_at_diagnosis":77,"sex":"male","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":5.7,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.830915+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_697939","record_id":"REC_0014527","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":70,"primary_tumor_size_cm":6.8,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":40.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.831256+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_957698","record_id":"REC_0014528","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":14.8,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":1,"smoking_pack_years":24,"primary_tumor_size_cm":4.5,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":18.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.833010+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_874254","record_id":"REC_0014529","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":34,"tmb_mutations_per_mb":4.3,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":6.0,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.833906+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_100992","record_id":"REC_0014530","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.1,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":4.5,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":24.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.834569+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_752354","record_id":"REC_0014531","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":14.7,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":24,"primary_tumor_size_cm":3.0,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.836272+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_535662","record_id":"REC_0014532","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":14.3,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":5.6,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":17.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.836820+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_583151","record_id":"REC_0014533","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":8.0,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":5.5,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.837202+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_905156","record_id":"REC_0014534","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":26,"primary_tumor_size_cm":5.7,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.837645+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_919606","record_id":"REC_0014535","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":11.0,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":7.1,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":18.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.838180+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_653081","record_id":"REC_0014536","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":17.8,"age_at_diagnosis":50,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":4.9,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.838578+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_543454","record_id":"REC_0014537","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":34,"tmb_mutations_per_mb":4.7,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":6.3,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":7.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.838934+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_684770","record_id":"REC_0014538","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":8.9,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":5.1,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.839292+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_300252","record_id":"REC_0014539","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":20,"tmb_mutations_per_mb":8.4,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":9.4,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":41.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.839676+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_764460","record_id":"REC_0014540","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":5.0,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.840002+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_573540","record_id":"REC_0014541","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":3,"primary_tumor_size_cm":3.1,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":16.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.840438+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_805013","record_id":"REC_0014542","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":6.0,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":29.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.840781+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_928789","record_id":"REC_0014543","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":14.9,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":6.4,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.841113+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_655383","record_id":"REC_0014544","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":78,"sex":"male","ecog_performance_status":2,"smoking_pack_years":6,"primary_tumor_size_cm":4.8,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.841439+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_202752","record_id":"REC_0014545","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":5.2,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":22.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.841752+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_812356","record_id":"REC_0014546","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":19,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":4,"primary_tumor_size_cm":6.9,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":31.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.842065+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_363154","record_id":"REC_0014547","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":14.0,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":5.4,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":5.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.842420+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_850641","record_id":"REC_0014548","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":4.5,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":3.2,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":6.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.842863+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_230612","record_id":"REC_0014549","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":5.9,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.843226+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_148331","record_id":"REC_0014550","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":5.4,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":17.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.843578+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_662536","record_id":"REC_0014551","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":16.8,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":5.2,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.843947+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_445190","record_id":"REC_0014552","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":6.5,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.844418+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_977479","record_id":"REC_0014553","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":8.9,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":4.2,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.844748+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_425492","record_id":"REC_0014554","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":4.4,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":34,"primary_tumor_size_cm":6.1,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.845075+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_286967","record_id":"REC_0014555","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":30,"tmb_mutations_per_mb":8.3,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":4.9,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.845427+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_639483","record_id":"REC_0014556","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":52,"sex":"female","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":4.5,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.845768+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_122766","record_id":"REC_0014557","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":13.6,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":4.5,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.846085+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_517804","record_id":"REC_0014558","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":14.4,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":6.4,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.846390+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_243850","record_id":"REC_0014559","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":4.7,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":25.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.846695+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_819904","record_id":"REC_0014560","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":30,"tmb_mutations_per_mb":14.9,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":5,"primary_tumor_size_cm":6.9,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.847039+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_425626","record_id":"REC_0014561","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":31,"tmb_mutations_per_mb":2.4,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":27,"primary_tumor_size_cm":5.2,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":19.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.847496+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_278687","record_id":"REC_0014562","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":6.9,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.847829+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_679354","record_id":"REC_0014563","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":6.7,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":19.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.848188+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_705027","record_id":"REC_0014564","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":13.6,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":4.5,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":19.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.848567+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_800543","record_id":"REC_0014565","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":31,"tmb_mutations_per_mb":7.4,"age_at_diagnosis":81,"sex":"male","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":6.6,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.848922+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_336995","record_id":"REC_0014566","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":15.2,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":3.1,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":23.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.849230+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_676956","record_id":"REC_0014567","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":7.3,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":5,"primary_tumor_size_cm":4.7,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.849512+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_633224","record_id":"REC_0014568","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":75,"sex":"male","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":6.0,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.849818+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_195788","record_id":"REC_0014569","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":6.4,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":27.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.850178+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_465463","record_id":"REC_0014570","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":31,"tmb_mutations_per_mb":9.1,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":3,"smoking_pack_years":39,"primary_tumor_size_cm":5.8,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.850487+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_336833","record_id":"REC_0014571","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":30,"tmb_mutations_per_mb":5.9,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":5.2,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":20.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.850807+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_780658","record_id":"REC_0014572","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":4.8,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.851103+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_815774","record_id":"REC_0014573","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":3.6,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":34,"primary_tumor_size_cm":5.0,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":30.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.851394+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_180959","record_id":"REC_0014574","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":10,"primary_tumor_size_cm":3.5,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":25.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.851849+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_187398","record_id":"REC_0014575","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":7.4,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":1,"smoking_pack_years":52,"primary_tumor_size_cm":5.5,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.852263+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_700485","record_id":"REC_0014576","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":30,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.8,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":8.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.852565+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_461342","record_id":"REC_0014577","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":5.2,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.852848+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_652296","record_id":"REC_0014578","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":4.8,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.853129+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_974594","record_id":"REC_0014579","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":4.5,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.853415+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_383813","record_id":"REC_0014580","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":15.8,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":8.4,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.853730+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_845771","record_id":"REC_0014581","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":24,"primary_tumor_size_cm":4.4,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.854048+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_121572","record_id":"REC_0014582","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":3.6,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.854362+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_935614","record_id":"REC_0014583","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":2,"primary_tumor_size_cm":5.2,"metastatic_sites_count":3,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.854663+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_298910","record_id":"REC_0014584","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":3.0,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.855046+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_700556","record_id":"REC_0014585","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":10.5,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":5.3,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.855419+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_137340","record_id":"REC_0014586","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":9.1,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":1,"smoking_pack_years":44,"primary_tumor_size_cm":7.4,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":7.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.855727+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_311755","record_id":"REC_0014587","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":5.7,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.856295+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_368879","record_id":"REC_0014588","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":19.4,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":4.4,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.856678+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_126075","record_id":"REC_0014589","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":20.3,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":6.4,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":16.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.857058+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_903461","record_id":"REC_0014590","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":19,"tmb_mutations_per_mb":4.8,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":5.1,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":26.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.857412+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_357904","record_id":"REC_0014591","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":5.4,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":20.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.857742+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_207746","record_id":"REC_0014592","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":17.6,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":8.1,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.858058+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_758092","record_id":"REC_0014593","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":6.4,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.858384+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_158480","record_id":"REC_0014594","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":33,"tmb_mutations_per_mb":9.7,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":2.7,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.858702+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_856719","record_id":"REC_0014595","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":2,"primary_tumor_size_cm":5.3,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.859069+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_792993","record_id":"REC_0014596","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":11.5,"age_at_diagnosis":45,"sex":"male","ecog_performance_status":0,"smoking_pack_years":24,"primary_tumor_size_cm":6.5,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.859388+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_466765","record_id":"REC_0014597","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":13.1,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":3.5,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.859711+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_277232","record_id":"REC_0014598","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":16.6,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":4.4,"metastatic_sites_count":8,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.860061+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_688585","record_id":"REC_0014599","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":3.9,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":26,"primary_tumor_size_cm":6.1,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.860503+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_633761","record_id":"REC_0014600","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":19.5,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":6.2,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.861015+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_219235","record_id":"REC_0014601","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":6.9,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":5.2,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.861377+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_495947","record_id":"REC_0014602","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":22,"primary_tumor_size_cm":6.0,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":16.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.861690+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_991420","record_id":"REC_0014603","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":5.0,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":3.5,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":32.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.862010+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_150317","record_id":"REC_0014604","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":6.1,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":36.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.862346+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_304947","record_id":"REC_0014605","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":18.2,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":5.7,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.862696+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_934960","record_id":"REC_0014606","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":17.1,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":28,"primary_tumor_size_cm":4.4,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.863068+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_944821","record_id":"REC_0014607","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":32,"tmb_mutations_per_mb":7.4,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":28,"primary_tumor_size_cm":5.2,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":7.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.863365+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_542309","record_id":"REC_0014608","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":24,"primary_tumor_size_cm":4.6,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.863717+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_223852","record_id":"REC_0014609","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":16.6,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":5.5,"metastatic_sites_count":3,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":4.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.864001+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_689313","record_id":"REC_0014610","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":5.0,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":70,"primary_tumor_size_cm":4.6,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":16.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.864347+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_161733","record_id":"REC_0014611","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":14.8,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":4.1,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.864650+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_992721","record_id":"REC_0014612","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":5.1,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.864943+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_633533","record_id":"REC_0014613","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":8.0,"age_at_diagnosis":52,"sex":"male","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":5.1,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.865371+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_370987","record_id":"REC_0014614","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":81,"sex":"male","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":5.2,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.865700+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_635060","record_id":"REC_0014615","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":3,"smoking_pack_years":19,"primary_tumor_size_cm":6.3,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":31.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.865991+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_173795","record_id":"REC_0014616","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":15.4,"age_at_diagnosis":87,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":4.3,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.866274+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_300289","record_id":"REC_0014617","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":10.5,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":6.3,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.866562+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_440233","record_id":"REC_0014618","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":5.8,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":6.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.866893+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_255810","record_id":"REC_0014619","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.5,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":1,"smoking_pack_years":30,"primary_tumor_size_cm":4.1,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.867219+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_483217","record_id":"REC_0014620","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.6,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":24.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.867540+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_440798","record_id":"REC_0014621","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":6.7,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":2.9,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.867852+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_152740","record_id":"REC_0014622","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.8,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.868241+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_400933","record_id":"REC_0014623","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":18,"tmb_mutations_per_mb":6.0,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.5,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":25.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.868605+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_494143","record_id":"REC_0014624","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":35,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":4.3,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.868905+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_476100","record_id":"REC_0014625","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":10.0,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":6,"primary_tumor_size_cm":5.5,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.869212+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_591989","record_id":"REC_0014626","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.8,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.869741+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_277301","record_id":"REC_0014627","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":85,"sex":"male","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":6.4,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.870088+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_172184","record_id":"REC_0014628","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":19,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":2,"smoking_pack_years":24,"primary_tumor_size_cm":4.9,"metastatic_sites_count":10,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.870405+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_855877","record_id":"REC_0014629","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":16.5,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":4,"primary_tumor_size_cm":7.0,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.870741+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_479504","record_id":"REC_0014630","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":20,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":54,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":6.4,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":7.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.871065+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_349262","record_id":"REC_0014631","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":13.1,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":3,"smoking_pack_years":0,"primary_tumor_size_cm":5.3,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":39.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.871377+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_606916","record_id":"REC_0014632","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":20,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":55,"primary_tumor_size_cm":5.6,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.871679+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_930020","record_id":"REC_0014633","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":14.4,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":7.3,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.871957+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_527974","record_id":"REC_0014634","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":16.7,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":7.3,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":21.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.872338+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_905975","record_id":"REC_0014635","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":16.3,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.8,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.872680+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_622715","record_id":"REC_0014636","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":11.1,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":5.8,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.873001+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_954733","record_id":"REC_0014637","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":4.9,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":6.2,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":25.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.873334+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_443182","record_id":"REC_0014638","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":53,"sex":"female","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":6.4,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.873675+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_919978","record_id":"REC_0014639","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":2,"primary_tumor_size_cm":7.0,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.874161+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_545413","record_id":"REC_0014640","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":13.5,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":0,"smoking_pack_years":25,"primary_tumor_size_cm":6.0,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":19.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.874535+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_730523","record_id":"REC_0014641","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":51,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":5.9,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.874864+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_897319","record_id":"REC_0014642","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":10.1,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":6.9,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.875178+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_320281","record_id":"REC_0014643","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":11.1,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":5.6,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.875513+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_401804","record_id":"REC_0014644","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":5.3,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":21,"primary_tumor_size_cm":4.7,"metastatic_sites_count":3,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.875851+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_165820","record_id":"REC_0014645","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":3,"smoking_pack_years":13,"primary_tumor_size_cm":4.8,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.876257+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_229681","record_id":"REC_0014646","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":6.9,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.876613+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_881670","record_id":"REC_0014647","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":17.2,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":5.1,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":6.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.876968+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_896515","record_id":"REC_0014648","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":19,"tmb_mutations_per_mb":2.9,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":49,"primary_tumor_size_cm":6.2,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.877319+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_893902","record_id":"REC_0014649","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":78,"sex":"male","ecog_performance_status":2,"smoking_pack_years":22,"primary_tumor_size_cm":4.2,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.877660+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_833462","record_id":"REC_0014650","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":35,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":6.5,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":21.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.877990+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_577494","record_id":"REC_0014651","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":15,"tmb_mutations_per_mb":16.1,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":7.2,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.878321+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_413366","record_id":"REC_0014652","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":3.2,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":5.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.878805+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_490446","record_id":"REC_0014653","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":8.4,"age_at_diagnosis":47,"sex":"female","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":7.1,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.879172+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_594805","record_id":"REC_0014654","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":88,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":4.8,"metastatic_sites_count":8,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.879549+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_238255","record_id":"REC_0014655","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":6.4,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":7,"primary_tumor_size_cm":6.0,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":6.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.879895+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_268100","record_id":"REC_0014656","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":16,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":4.8,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":41.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.880315+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_544717","record_id":"REC_0014657","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":10.5,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":5.7,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":4.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.880669+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_610989","record_id":"REC_0014658","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":54,"primary_tumor_size_cm":4.5,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.880996+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_373878","record_id":"REC_0014659","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":4.9,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":27.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.881345+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_184572","record_id":"REC_0014660","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":4,"primary_tumor_size_cm":7.0,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":43.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.881683+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_711344","record_id":"REC_0014661","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":5.5,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":6.4,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.882003+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_610698","record_id":"REC_0014662","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":19,"tmb_mutations_per_mb":13.8,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":6.3,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.882317+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_216519","record_id":"REC_0014663","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":3.0,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.882624+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_631367","record_id":"REC_0014664","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":13.5,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":4.9,"metastatic_sites_count":9,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.882906+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_214903","record_id":"REC_0014665","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":16,"tmb_mutations_per_mb":14.1,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":3,"smoking_pack_years":22,"primary_tumor_size_cm":5.5,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.883281+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_364647","record_id":"REC_0014666","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":5.1,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":3.8,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":5.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.883536+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_880458","record_id":"REC_0014667","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":11.1,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":3,"smoking_pack_years":9,"primary_tumor_size_cm":6.3,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.883818+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_748313","record_id":"REC_0014668","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":4.5,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.884157+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_871474","record_id":"REC_0014669","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":10.0,"age_at_diagnosis":76,"sex":"male","ecog_performance_status":2,"smoking_pack_years":5,"primary_tumor_size_cm":5.3,"metastatic_sites_count":9,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.884467+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_527943","record_id":"REC_0014670","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":11.1,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":24,"primary_tumor_size_cm":5.7,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":7.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.884775+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_773725","record_id":"REC_0014671","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":4.1,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":6.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.885063+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_132750","record_id":"REC_0014672","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":19.1,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":3.4,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":19.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.885314+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_847360","record_id":"REC_0014673","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":4.2,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":1,"smoking_pack_years":26,"primary_tumor_size_cm":5.3,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.885559+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_972674","record_id":"REC_0014674","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":6.9,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":66,"primary_tumor_size_cm":6.2,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.885798+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_757132","record_id":"REC_0014675","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":53,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":5.4,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":7.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.886036+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_289780","record_id":"REC_0014676","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":6.1,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":1,"smoking_pack_years":89,"primary_tumor_size_cm":3.4,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":24.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.886291+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_312858","record_id":"REC_0014677","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":9.8,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":6.1,"metastatic_sites_count":8,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.886588+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_786564","record_id":"REC_0014678","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":4.3,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":51,"primary_tumor_size_cm":6.5,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":6.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.886980+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_547194","record_id":"REC_0014679","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":3.8,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.887257+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_510309","record_id":"REC_0014680","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":32,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":3.8,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.887533+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_451806","record_id":"REC_0014681","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":15.3,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":4.7,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.887789+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_757496","record_id":"REC_0014682","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":8.4,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":61,"primary_tumor_size_cm":6.3,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.888046+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_650255","record_id":"REC_0014683","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":45,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":4.0,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.888387+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_194860","record_id":"REC_0014684","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":30,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":1,"smoking_pack_years":65,"primary_tumor_size_cm":4.8,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.888665+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_686933","record_id":"REC_0014685","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":8.0,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":48,"primary_tumor_size_cm":4.9,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.888916+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_924941","record_id":"REC_0014686","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":5.8,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.889170+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_601059","record_id":"REC_0014687","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":85,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":5.5,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":18.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.889429+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_139803","record_id":"REC_0014688","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":5.0,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":29,"primary_tumor_size_cm":5.8,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":19.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.889682+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_204594","record_id":"REC_0014689","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":7.4,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":7.0,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":31.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.889927+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_137913","record_id":"REC_0014690","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":13.1,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":4.6,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":18.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.890182+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_532927","record_id":"REC_0014691","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":34,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.8,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":5.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.890578+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_841001","record_id":"REC_0014692","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":31,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":25,"primary_tumor_size_cm":3.8,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":25.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.890861+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_116759","record_id":"REC_0014693","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":4.8,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.891140+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_171566","record_id":"REC_0014694","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":5.8,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.891412+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_566197","record_id":"REC_0014695","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":9.0,"age_at_diagnosis":52,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":4.1,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":28.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.891690+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_748480","record_id":"REC_0014696","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":11.0,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":7.3,"metastatic_sites_count":8,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":16.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.891959+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_695403","record_id":"REC_0014697","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":4,"smoking_pack_years":72,"primary_tumor_size_cm":5.2,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.892288+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_300924","record_id":"REC_0014698","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":13.5,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":6.0,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":25.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.892563+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_215395","record_id":"REC_0014699","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":27,"primary_tumor_size_cm":5.3,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.892833+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_750422","record_id":"REC_0014700","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":6.7,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":2,"smoking_pack_years":46,"primary_tumor_size_cm":6.1,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.893085+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_547729","record_id":"REC_0014701","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":8.3,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":43,"primary_tumor_size_cm":6.3,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.893361+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_467482","record_id":"REC_0014702","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":6.8,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":17.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.893643+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_431861","record_id":"REC_0014703","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":3.9,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":21.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.893922+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_863917","record_id":"REC_0014704","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":10.0,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":3,"smoking_pack_years":15,"primary_tumor_size_cm":4.6,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.894367+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_233060","record_id":"REC_0014705","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":5.3,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.894690+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_404439","record_id":"REC_0014706","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":4.9,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":6.2,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.894970+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_599935","record_id":"REC_0014707","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":4.1,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":40.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.895259+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_293508","record_id":"REC_0014708","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":22.0,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":7.4,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":23.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.895545+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_515174","record_id":"REC_0014709","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":52,"primary_tumor_size_cm":4.8,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":16.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.895821+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_233524","record_id":"REC_0014710","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":16.6,"age_at_diagnosis":74,"sex":"male","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":5.8,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.896136+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_237238","record_id":"REC_0014711","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":5.7,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":51,"primary_tumor_size_cm":4.0,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.896436+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_406273","record_id":"REC_0014712","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":14.6,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":6.1,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.896744+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_211070","record_id":"REC_0014713","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":9.7,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":4.5,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":21.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.897039+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_905553","record_id":"REC_0014714","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":4.6,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":3.6,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.897311+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_958926","record_id":"REC_0014715","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":3.7,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":6.0,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.897595+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_850852","record_id":"REC_0014716","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":14.4,"age_at_diagnosis":83,"sex":"female","ecog_performance_status":0,"smoking_pack_years":4,"primary_tumor_size_cm":4.9,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":5.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.897860+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_812339","record_id":"REC_0014717","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":17.5,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":4.6,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.898293+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_638071","record_id":"REC_0014718","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":78,"sex":"male","ecog_performance_status":1,"smoking_pack_years":37,"primary_tumor_size_cm":6.7,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.898589+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_446365","record_id":"REC_0014719","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":31,"tmb_mutations_per_mb":15.1,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":4.2,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":48.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.898871+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_540426","record_id":"REC_0014720","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":34,"tmb_mutations_per_mb":11.1,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":4.8,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.899189+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_507286","record_id":"REC_0014721","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":14.3,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":3,"smoking_pack_years":13,"primary_tumor_size_cm":4.8,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.899516+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_968740","record_id":"REC_0014722","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":5.6,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":36.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.899845+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_678624","record_id":"REC_0014723","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":3.9,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":5.8,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.900225+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_117826","record_id":"REC_0014724","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":31,"tmb_mutations_per_mb":8.3,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":50,"primary_tumor_size_cm":4.5,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.900570+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_374981","record_id":"REC_0014725","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":30,"tmb_mutations_per_mb":5.1,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":1,"smoking_pack_years":47,"primary_tumor_size_cm":6.5,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":21.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.900886+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_627470","record_id":"REC_0014726","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":9.7,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":4.3,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":31.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.901222+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_874335","record_id":"REC_0014727","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":9.7,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":1,"smoking_pack_years":27,"primary_tumor_size_cm":3.8,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.901527+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_924474","record_id":"REC_0014728","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":16.1,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":5.5,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":20.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.901834+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_994401","record_id":"REC_0014729","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":5,"primary_tumor_size_cm":5.4,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.902140+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_147519","record_id":"REC_0014730","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":32,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":6.1,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":24.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.902619+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_828284","record_id":"REC_0014731","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":1,"smoking_pack_years":54,"primary_tumor_size_cm":5.8,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":30.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.902951+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_988040","record_id":"REC_0014732","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":6.9,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.903260+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_974601","record_id":"REC_0014733","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":0,"smoking_pack_years":24,"primary_tumor_size_cm":6.5,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.903555+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_506862","record_id":"REC_0014734","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":20,"tmb_mutations_per_mb":3.8,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":1,"smoking_pack_years":46,"primary_tumor_size_cm":7.5,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.903851+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_494199","record_id":"REC_0014735","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":18,"tmb_mutations_per_mb":5.0,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":3,"smoking_pack_years":26,"primary_tumor_size_cm":5.0,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.904206+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_182198","record_id":"REC_0014736","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":18.8,"age_at_diagnosis":53,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":6.3,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.904534+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_269061","record_id":"REC_0014737","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":5.0,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.904841+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_586720","record_id":"REC_0014738","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":8.4,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":4,"primary_tumor_size_cm":5.8,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.905136+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_468581","record_id":"REC_0014739","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":3.0,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":18.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.905422+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_683968","record_id":"REC_0014740","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":15.0,"age_at_diagnosis":85,"sex":"female","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":5.7,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.905734+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_951846","record_id":"REC_0014741","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":17.1,"age_at_diagnosis":83,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":4.4,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":4.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.906043+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_410502","record_id":"REC_0014742","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":3.7,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":16.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.906366+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_994196","record_id":"REC_0014743","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":54,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":5.7,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":7.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.906856+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_736777","record_id":"REC_0014744","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":44,"primary_tumor_size_cm":5.9,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.907185+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_332255","record_id":"REC_0014745","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":14.5,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":4.7,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.907511+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_235564","record_id":"REC_0014746","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":3.9,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":29,"primary_tumor_size_cm":4.9,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":31.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.907828+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_827506","record_id":"REC_0014747","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":14.1,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":4.2,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":32.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.908240+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_654018","record_id":"REC_0014748","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":2.4,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":4.5,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":5.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.908562+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_627983","record_id":"REC_0014749","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":32,"tmb_mutations_per_mb":16.3,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":6.5,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":7.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.908896+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_243774","record_id":"REC_0014750","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":5.8,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":8.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.909215+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_273377","record_id":"REC_0014751","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":13.8,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":5.3,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.909537+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_556458","record_id":"REC_0014752","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":4.3,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":1,"smoking_pack_years":58,"primary_tumor_size_cm":6.9,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":7.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.909831+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_839602","record_id":"REC_0014753","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":15,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":5.4,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.910177+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_944701","record_id":"REC_0014754","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":5.2,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":1,"smoking_pack_years":40,"primary_tumor_size_cm":7.3,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.910488+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_907241","record_id":"REC_0014755","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":16,"tmb_mutations_per_mb":4.4,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":35,"primary_tumor_size_cm":6.4,"metastatic_sites_count":3,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":6.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.910875+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_749262","record_id":"REC_0014756","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":3.2,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.911350+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_425542","record_id":"REC_0014757","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":9.0,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":1,"smoking_pack_years":24,"primary_tumor_size_cm":4.4,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":7.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.911696+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_696324","record_id":"REC_0014758","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":2,"smoking_pack_years":2,"primary_tumor_size_cm":5.3,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.912004+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_351383","record_id":"REC_0014759","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":51,"primary_tumor_size_cm":7.0,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.912396+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_239120","record_id":"REC_0014760","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":5.5,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.912713+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_405547","record_id":"REC_0014761","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":7.8,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":19.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.912986+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_615676","record_id":"REC_0014762","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":4.6,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":48,"primary_tumor_size_cm":5.8,"metastatic_sites_count":9,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.913247+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_281912","record_id":"REC_0014763","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":8.9,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":31,"primary_tumor_size_cm":5.3,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.913529+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_465085","record_id":"REC_0014764","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":14.4,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":2,"smoking_pack_years":9,"primary_tumor_size_cm":5.2,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.913806+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_655181","record_id":"REC_0014765","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":34,"tmb_mutations_per_mb":7.4,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.5,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.914100+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_659079","record_id":"REC_0014766","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":5.8,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":30.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.914401+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_290387","record_id":"REC_0014767","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":20,"tmb_mutations_per_mb":5.1,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":63,"primary_tumor_size_cm":8.2,"metastatic_sites_count":8,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":5.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.914720+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_766658","record_id":"REC_0014768","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":1.5,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":6.4,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":32.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.915015+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_275841","record_id":"REC_0014769","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.5,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.915429+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_305285","record_id":"REC_0014770","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":34,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":5.1,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":23.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.915718+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_831306","record_id":"REC_0014771","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":19,"tmb_mutations_per_mb":19.5,"age_at_diagnosis":53,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":7.0,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":21.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.915983+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_746528","record_id":"REC_0014772","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":31,"tmb_mutations_per_mb":15.9,"age_at_diagnosis":75,"sex":"male","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":7.1,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.916312+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_835345","record_id":"REC_0014773","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":9.1,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":8.2,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":39.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.916593+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_644050","record_id":"REC_0014774","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":17.7,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":5.4,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":17.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.916882+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_650804","record_id":"REC_0014775","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":16.4,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":5.4,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.917171+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_306805","record_id":"REC_0014776","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":8.4,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":4.7,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":33.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.917441+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_225814","record_id":"REC_0014777","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":15.9,"age_at_diagnosis":43,"sex":"female","ecog_performance_status":0,"smoking_pack_years":5,"primary_tumor_size_cm":5.9,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.917723+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_790865","record_id":"REC_0014778","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":9.9,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":4.6,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":21.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.918018+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_800658","record_id":"REC_0014779","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":16,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":7,"primary_tumor_size_cm":5.3,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.918314+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_599729","record_id":"REC_0014780","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":2.9,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.918627+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_345310","record_id":"REC_0014781","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":18,"tmb_mutations_per_mb":6.4,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":43,"primary_tumor_size_cm":6.5,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.918915+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_738988","record_id":"REC_0014782","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":14.1,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":23,"primary_tumor_size_cm":6.1,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":22.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.919372+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_890738","record_id":"REC_0014783","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":15.7,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":3.9,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":29.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.919734+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_519277","record_id":"REC_0014784","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":6.8,"metastatic_sites_count":3,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.920132+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_679855","record_id":"REC_0014785","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":14,"tmb_mutations_per_mb":16.7,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":4.2,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.920533+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_254411","record_id":"REC_0014786","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":6.0,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.920892+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_678653","record_id":"REC_0014787","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":8.6,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.2,"metastatic_sites_count":10,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.921266+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_225156","record_id":"REC_0014788","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":8.7,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":3,"smoking_pack_years":20,"primary_tumor_size_cm":6.0,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.921619+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_541374","record_id":"REC_0014789","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":17.1,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":4.5,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.921969+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_580257","record_id":"REC_0014790","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":17,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":7.4,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.922298+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_897320","record_id":"REC_0014791","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":20,"tmb_mutations_per_mb":4.8,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":0,"smoking_pack_years":2,"primary_tumor_size_cm":6.6,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.922650+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_994756","record_id":"REC_0014792","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":9.9,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":3,"smoking_pack_years":10,"primary_tumor_size_cm":7.5,"metastatic_sites_count":9,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.922988+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_983620","record_id":"REC_0014793","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":32,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":22,"primary_tumor_size_cm":5.9,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.923315+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_346653","record_id":"REC_0014794","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":19.1,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":6.7,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.923684+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_519691","record_id":"REC_0014795","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":3.6,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":6.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.924280+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_815533","record_id":"REC_0014796","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":16.2,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":5.2,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":23.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.924681+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_638807","record_id":"REC_0014797","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":17,"tmb_mutations_per_mb":6.1,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":1,"smoking_pack_years":39,"primary_tumor_size_cm":6.4,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.925050+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_803675","record_id":"REC_0014798","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":4.6,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":5.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.925403+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_284430","record_id":"REC_0014799","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":5.4,"metastatic_sites_count":9,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.925758+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_862737","record_id":"REC_0014800","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":4.1,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":7.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.926115+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_321530","record_id":"REC_0014801","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":15.9,"age_at_diagnosis":87,"sex":"female","ecog_performance_status":2,"smoking_pack_years":7,"primary_tumor_size_cm":6.3,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":30.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.926482+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_629471","record_id":"REC_0014802","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":4.5,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":6.5,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":21.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.926839+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_316195","record_id":"REC_0014803","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":2,"smoking_pack_years":45,"primary_tumor_size_cm":5.6,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.927207+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_963444","record_id":"REC_0014804","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":8.6,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":5.4,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.927558+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_291555","record_id":"REC_0014805","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":13.5,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":5.5,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":24.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.927900+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_915400","record_id":"REC_0014806","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":5.0,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":6.0,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":59.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.928268+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_898023","record_id":"REC_0014807","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":5.7,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":6.6,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.928593+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_892158","record_id":"REC_0014808","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":7.0,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.929096+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_125843","record_id":"REC_0014809","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":8.5,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":6.1,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.929476+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_855695","record_id":"REC_0014810","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":14.8,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":5.4,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.929831+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_101235","record_id":"REC_0014811","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.4,"metastatic_sites_count":8,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.930204+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_192707","record_id":"REC_0014812","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":88,"sex":"female","ecog_performance_status":2,"smoking_pack_years":8,"primary_tumor_size_cm":5.7,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":16.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.930554+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_597060","record_id":"REC_0014813","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":8.3,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":0,"smoking_pack_years":60,"primary_tumor_size_cm":5.2,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.930900+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_772715","record_id":"REC_0014814","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":5.9,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":6.8,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.931219+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_571901","record_id":"REC_0014815","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":28,"primary_tumor_size_cm":6.0,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.931554+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_841042","record_id":"REC_0014816","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":5.6,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.931909+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_644017","record_id":"REC_0014817","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":18.0,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":4.8,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.932393+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_911229","record_id":"REC_0014818","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":6.0,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":17.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.932802+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_536336","record_id":"REC_0014819","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":75,"primary_tumor_size_cm":6.2,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.933148+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_887761","record_id":"REC_0014820","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":9.9,"age_at_diagnosis":87,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":6.1,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":22.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.933490+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_860628","record_id":"REC_0014821","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":34,"tmb_mutations_per_mb":16.9,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":5.8,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.933993+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_356343","record_id":"REC_0014822","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":14.1,"age_at_diagnosis":77,"sex":"male","ecog_performance_status":3,"smoking_pack_years":23,"primary_tumor_size_cm":6.1,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.934419+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_279081","record_id":"REC_0014823","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":14.1,"age_at_diagnosis":50,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":4.6,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.934824+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_375731","record_id":"REC_0014824","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":12,"tmb_mutations_per_mb":3.1,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":5.9,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":7.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.935244+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_731395","record_id":"REC_0014825","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":17.1,"age_at_diagnosis":50,"sex":"male","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":5.8,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.935645+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_209151","record_id":"REC_0014826","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":5.4,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":5.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.936156+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_282192","record_id":"REC_0014827","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":10.5,"age_at_diagnosis":84,"sex":"female","ecog_performance_status":3,"smoking_pack_years":18,"primary_tumor_size_cm":7.1,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.936782+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_685759","record_id":"REC_0014828","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":6.1,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":3.0,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":16.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.937220+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_404221","record_id":"REC_0014829","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":12,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":24,"primary_tumor_size_cm":3.4,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.937561+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_248629","record_id":"REC_0014830","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":9.5,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":33,"primary_tumor_size_cm":5.8,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.937898+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_806493","record_id":"REC_0014831","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":19.4,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":4.2,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.938238+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_176408","record_id":"REC_0014832","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":19,"tmb_mutations_per_mb":3.9,"age_at_diagnosis":76,"sex":"male","ecog_performance_status":2,"smoking_pack_years":53,"primary_tumor_size_cm":6.3,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":6.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.938567+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_149611","record_id":"REC_0014833","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":4,"primary_tumor_size_cm":4.3,"metastatic_sites_count":9,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.938897+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_414186","record_id":"REC_0014834","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":3.5,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":58.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.939413+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_259295","record_id":"REC_0014835","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":15,"tmb_mutations_per_mb":3.6,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":24,"primary_tumor_size_cm":4.7,"metastatic_sites_count":9,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.939805+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_476833","record_id":"REC_0014836","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":5,"primary_tumor_size_cm":7.0,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.940218+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_280972","record_id":"REC_0014837","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":19,"tmb_mutations_per_mb":6.4,"age_at_diagnosis":48,"sex":"female","ecog_performance_status":0,"smoking_pack_years":37,"primary_tumor_size_cm":6.3,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.940576+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_702529","record_id":"REC_0014838","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":4.5,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":5.0,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":23.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.940904+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_440553","record_id":"REC_0014839","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":8.6,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":6.0,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.941239+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_421337","record_id":"REC_0014840","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":50,"sex":"male","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":7.3,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.941570+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_393634","record_id":"REC_0014841","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":10.1,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":5.3,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.941881+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_327112","record_id":"REC_0014842","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":15,"tmb_mutations_per_mb":5.9,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":31,"primary_tumor_size_cm":3.8,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.942192+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_344513","record_id":"REC_0014843","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":4.7,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":25.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.942532+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_285695","record_id":"REC_0014844","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":3.9,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":3.8,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.942871+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_893042","record_id":"REC_0014845","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":5.1,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":19.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.943221+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_300599","record_id":"REC_0014846","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":14.8,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":5.0,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.943576+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_860232","record_id":"REC_0014847","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":5.1,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":4.9,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.944122+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_324313","record_id":"REC_0014848","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":86,"sex":"female","ecog_performance_status":1,"smoking_pack_years":4,"primary_tumor_size_cm":6.2,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":6.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.944493+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_221323","record_id":"REC_0014849","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":9,"primary_tumor_size_cm":4.7,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":7.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.944816+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_244359","record_id":"REC_0014850","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":61,"primary_tumor_size_cm":6.5,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.945134+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_605333","record_id":"REC_0014851","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":7.5,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.945452+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_992387","record_id":"REC_0014852","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.1,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":6.1,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.945777+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_256769","record_id":"REC_0014853","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":31,"tmb_mutations_per_mb":5.7,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":1,"smoking_pack_years":47,"primary_tumor_size_cm":5.5,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":6.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.946079+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_937083","record_id":"REC_0014854","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":14.6,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":4.0,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":29.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.946365+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_926162","record_id":"REC_0014855","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":20,"tmb_mutations_per_mb":6.0,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":33,"primary_tumor_size_cm":5.9,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":20.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.946652+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_646367","record_id":"REC_0014856","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":33,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":25,"primary_tumor_size_cm":5.8,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.946947+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_547626","record_id":"REC_0014857","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":20,"primary_tumor_size_cm":6.2,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.947249+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_627341","record_id":"REC_0014858","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":11.0,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":48,"primary_tumor_size_cm":6.0,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.947553+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_758407","record_id":"REC_0014859","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":34,"primary_tumor_size_cm":5.2,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":19.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.947827+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_367246","record_id":"REC_0014860","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":15.7,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":27,"primary_tumor_size_cm":10.0,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.948338+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_955629","record_id":"REC_0014861","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":18.8,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":7.0,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":4.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.948684+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_153981","record_id":"REC_0014862","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":18.1,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":0,"smoking_pack_years":1,"primary_tumor_size_cm":5.6,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.948999+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_978227","record_id":"REC_0014863","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":16.5,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":4.1,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":7.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.949330+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_262263","record_id":"REC_0014864","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":6.1,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.949649+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_310393","record_id":"REC_0014865","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":32,"primary_tumor_size_cm":3.6,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.949959+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_843029","record_id":"REC_0014866","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":13.8,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":5.8,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.950290+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_304443","record_id":"REC_0014867","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":14.8,"age_at_diagnosis":52,"sex":"male","ecog_performance_status":0,"smoking_pack_years":25,"primary_tumor_size_cm":5.3,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.950632+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_636108","record_id":"REC_0014868","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":6.1,"age_at_diagnosis":51,"sex":"male","ecog_performance_status":0,"smoking_pack_years":31,"primary_tumor_size_cm":2.7,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":17.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.950976+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_650173","record_id":"REC_0014869","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":2,"primary_tumor_size_cm":4.1,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.951323+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_613900","record_id":"REC_0014870","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":8.9,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":0,"primary_tumor_size_cm":5.0,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.951645+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_786752","record_id":"REC_0014871","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.0,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":7.1,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.952001+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_796443","record_id":"REC_0014872","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":5.5,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.952395+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_967286","record_id":"REC_0014873","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":5.3,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":67,"primary_tumor_size_cm":6.7,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":29.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.952883+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_203737","record_id":"REC_0014874","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":19.2,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":6.3,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.953266+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_603322","record_id":"REC_0014875","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":15.9,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":3,"primary_tumor_size_cm":5.9,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.953608+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_248832","record_id":"REC_0014876","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":28,"primary_tumor_size_cm":5.6,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":18.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.953911+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_311117","record_id":"REC_0014877","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":16,"tmb_mutations_per_mb":15.3,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":6.3,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.954227+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_998010","record_id":"REC_0014878","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":16.1,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":21,"primary_tumor_size_cm":3.9,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.954532+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_684556","record_id":"REC_0014879","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":33,"tmb_mutations_per_mb":5.9,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":4.6,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":22.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.954850+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_172843","record_id":"REC_0014880","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":15.8,"age_at_diagnosis":76,"sex":"male","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":4.6,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.955171+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_584983","record_id":"REC_0014881","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":14.8,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":6.2,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":16.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.955491+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_529420","record_id":"REC_0014882","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":16.4,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":5.3,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":30.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.955804+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_506786","record_id":"REC_0014883","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":17.9,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":6.8,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.956258+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_332412","record_id":"REC_0014884","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":3.7,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":1,"smoking_pack_years":44,"primary_tumor_size_cm":6.9,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":7.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.956625+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_383973","record_id":"REC_0014885","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":14.8,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":6.5,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.956933+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_311561","record_id":"REC_0014886","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":30,"tmb_mutations_per_mb":8.5,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":36,"primary_tumor_size_cm":5.7,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":7.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.957408+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_316946","record_id":"REC_0014887","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":4.2,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":7.6,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":20.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.957777+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_785981","record_id":"REC_0014888","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":31,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":3.0,"metastatic_sites_count":3,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":29.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.958112+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_150631","record_id":"REC_0014889","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":30,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":53,"sex":"female","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":5.1,"metastatic_sites_count":3,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.958465+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_356723","record_id":"REC_0014890","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":19.4,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":4.3,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.958809+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_978568","record_id":"REC_0014891","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":53,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":5.3,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.959150+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_462188","record_id":"REC_0014892","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":12,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":40,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":3.7,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.959511+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_391675","record_id":"REC_0014893","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":21.1,"age_at_diagnosis":87,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":6.6,"metastatic_sites_count":8,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.959862+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_586278","record_id":"REC_0014894","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":16,"tmb_mutations_per_mb":6.7,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":1,"smoking_pack_years":28,"primary_tumor_size_cm":4.6,"metastatic_sites_count":3,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":4.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.960269+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_805140","record_id":"REC_0014895","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":49,"primary_tumor_size_cm":5.1,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":16.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.960647+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_877200","record_id":"REC_0014896","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":5.1,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.960987+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_585305","record_id":"REC_0014897","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":7.0,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":18.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.961361+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_865708","record_id":"REC_0014898","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":5.3,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.961736+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_555136","record_id":"REC_0014899","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":5.2,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":3,"smoking_pack_years":23,"primary_tumor_size_cm":7.1,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.962266+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_476425","record_id":"REC_0014900","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":7.7,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.962706+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_750467","record_id":"REC_0014901","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":15.5,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":5.4,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":22.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.963108+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_333587","record_id":"REC_0014902","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":4,"primary_tumor_size_cm":5.9,"metastatic_sites_count":8,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.963510+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_664308","record_id":"REC_0014903","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":35,"tmb_mutations_per_mb":7.3,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":0,"smoking_pack_years":32,"primary_tumor_size_cm":6.7,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.963905+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_754356","record_id":"REC_0014904","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":7.6,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":5.3,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":29.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.964470+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_340082","record_id":"REC_0014905","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":6.3,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.964903+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_181674","record_id":"REC_0014906","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":19,"tmb_mutations_per_mb":17.4,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":5.7,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.965302+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_529443","record_id":"REC_0014907","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":13.6,"age_at_diagnosis":51,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":5.2,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.965761+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_487189","record_id":"REC_0014908","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":9,"primary_tumor_size_cm":4.2,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.966166+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_484871","record_id":"REC_0014909","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":9.5,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":4.3,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":21.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.966527+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_778273","record_id":"REC_0014910","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":5.1,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":20.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.966865+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_801736","record_id":"REC_0014911","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":4.8,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.967227+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_132696","record_id":"REC_0014912","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.2,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.967793+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_263415","record_id":"REC_0014913","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":17.2,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":3,"smoking_pack_years":14,"primary_tumor_size_cm":5.0,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":24.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.968407+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_624867","record_id":"REC_0014914","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":11.5,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":0,"smoking_pack_years":24,"primary_tumor_size_cm":5.8,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.968941+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_485949","record_id":"REC_0014915","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":9.7,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":5.2,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":7.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.969393+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_639837","record_id":"REC_0014916","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":3.5,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":23.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.969799+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_760648","record_id":"REC_0014917","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":5.2,"metastatic_sites_count":3,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.970207+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_122933","record_id":"REC_0014918","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":8.3,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":25.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.970602+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_365709","record_id":"REC_0014919","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":9.9,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":8,"primary_tumor_size_cm":7.3,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.970953+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_648927","record_id":"REC_0014920","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":14.9,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":8.1,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.971372+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_975312","record_id":"REC_0014921","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":35,"tmb_mutations_per_mb":9.1,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":4.8,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.971766+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_380154","record_id":"REC_0014922","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":6.7,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":22,"primary_tumor_size_cm":6.7,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.972265+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_703367","record_id":"REC_0014923","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":7.5,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":26.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.972658+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_858724","record_id":"REC_0014924","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":16.1,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":6.5,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":19.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.973029+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_966678","record_id":"REC_0014925","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":0,"smoking_pack_years":3,"primary_tumor_size_cm":5.5,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":35.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.973594+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_601277","record_id":"REC_0014926","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":15.9,"age_at_diagnosis":83,"sex":"male","ecog_performance_status":2,"smoking_pack_years":9,"primary_tumor_size_cm":4.2,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.974038+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_239915","record_id":"REC_0014927","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":5.0,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":4.9,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.974412+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_875685","record_id":"REC_0014928","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":8.0,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":6.6,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.974799+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_496972","record_id":"REC_0014929","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":6.5,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.975199+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_599571","record_id":"REC_0014930","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":9.1,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":5.9,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":23.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.975601+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_397690","record_id":"REC_0014931","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":7.3,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.975974+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_837975","record_id":"REC_0014932","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":6.9,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.976415+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_500405","record_id":"REC_0014933","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":19,"tmb_mutations_per_mb":5.5,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":6.5,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.976800+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_851614","record_id":"REC_0014934","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":6,"primary_tumor_size_cm":4.8,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":24.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.977163+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_838831","record_id":"REC_0014935","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":13.1,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":5.1,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.977518+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_808130","record_id":"REC_0014936","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":5.3,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":19.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.977878+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_646703","record_id":"REC_0014937","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":4.2,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.978217+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_729714","record_id":"REC_0014938","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":24,"primary_tumor_size_cm":6.0,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.978735+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_546884","record_id":"REC_0014939","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":6.1,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":53,"primary_tumor_size_cm":5.0,"metastatic_sites_count":3,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.979161+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_711382","record_id":"REC_0014940","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":3,"smoking_pack_years":56,"primary_tumor_size_cm":6.0,"metastatic_sites_count":3,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":17.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.979552+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_199402","record_id":"REC_0014941","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":15.7,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":4.5,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":5.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.979933+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_406437","record_id":"REC_0014942","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":5.9,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.980446+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_671947","record_id":"REC_0014943","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":10.3,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.8,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":17.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.980834+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_405381","record_id":"REC_0014944","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":54,"sex":"male","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":4.8,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":6.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.981237+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_396243","record_id":"REC_0014945","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":6.2,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.981605+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_435831","record_id":"REC_0014946","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":14.8,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":6.2,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.982314+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_411384","record_id":"REC_0014947","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":75,"sex":"male","ecog_performance_status":1,"smoking_pack_years":31,"primary_tumor_size_cm":6.8,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.982783+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_129547","record_id":"REC_0014948","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":16.8,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":6.4,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.983200+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_817441","record_id":"REC_0014949","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":3.7,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":4.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.983596+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_239019","record_id":"REC_0014950","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":90,"sex":"female","ecog_performance_status":2,"smoking_pack_years":3,"primary_tumor_size_cm":7.0,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":16.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.983975+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_189258","record_id":"REC_0014951","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":16.7,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":5.5,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.984647+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_557917","record_id":"REC_0014952","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":3.4,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":35.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.985090+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_409205","record_id":"REC_0014953","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":2,"smoking_pack_years":26,"primary_tumor_size_cm":2.5,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.985535+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_926343","record_id":"REC_0014954","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":5.0,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":94,"primary_tumor_size_cm":5.1,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.985956+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_112952","record_id":"REC_0014955","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":4.5,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.986366+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_475191","record_id":"REC_0014956","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":3,"primary_tumor_size_cm":6.4,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":20.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.986761+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_100852","record_id":"REC_0014957","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":2.2,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":4,"primary_tumor_size_cm":6.1,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":17.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.987119+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_248359","record_id":"REC_0014958","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":7.6,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.987474+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_652347","record_id":"REC_0014959","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ALK fusion","pd_l1_tps_percent":37,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":6.6,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":60.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.987845+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_271701","record_id":"REC_0014960","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":5.5,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":4.9,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":21.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.988364+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_245525","record_id":"REC_0014961","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":3.7,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":23.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.988777+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_960912","record_id":"REC_0014962","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":4.6,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":73,"primary_tumor_size_cm":6.1,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.989548+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_574959","record_id":"REC_0014963","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":5.5,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.6,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":16.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.990016+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_589861","record_id":"REC_0014964","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":16.5,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":7.1,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":26.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.990597+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_768628","record_id":"REC_0014965","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":13.8,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":1,"smoking_pack_years":26,"primary_tumor_size_cm":2.4,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.991044+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_570693","record_id":"REC_0014966","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":14.0,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":6.0,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":6.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.991471+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_660565","record_id":"REC_0014967","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":5.4,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.991875+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_358121","record_id":"REC_0014968","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":34,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":5.4,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":21.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.992328+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_834821","record_id":"REC_0014969","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":5.7,"metastatic_sites_count":8,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.992735+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_621940","record_id":"REC_0014970","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":8.5,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":4.1,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.993110+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_820050","record_id":"REC_0014971","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":11.0,"age_at_diagnosis":51,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":7.0,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.993491+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_960353","record_id":"REC_0014972","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":17.8,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":5.4,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":24.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.993866+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_665783","record_id":"REC_0014973","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":2.2,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":5.6,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.994230+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_408325","record_id":"REC_0014974","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":9.9,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":5.5,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":18.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.994609+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_808175","record_id":"REC_0014975","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":76,"sex":"male","ecog_performance_status":2,"smoking_pack_years":52,"primary_tumor_size_cm":7.3,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.994999+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_581492","record_id":"REC_0014976","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":4.6,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":3,"primary_tumor_size_cm":6.6,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":40.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.995399+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_609619","record_id":"REC_0014977","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":5.0,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":5.0,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.995938+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_453500","record_id":"REC_0014978","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":8.9,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":3.5,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.996498+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_711074","record_id":"REC_0014979","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":37,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":6.3,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":24.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.996896+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_943869","record_id":"REC_0014980","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":17,"tmb_mutations_per_mb":2.7,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":0,"smoking_pack_years":58,"primary_tumor_size_cm":3.6,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.997240+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_203098","record_id":"REC_0014981","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":24,"primary_tumor_size_cm":8.2,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.997560+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_466325","record_id":"REC_0014982","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":5.1,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":18.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.997859+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_938157","record_id":"REC_0014983","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":4.5,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":2,"smoking_pack_years":54,"primary_tumor_size_cm":5.6,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.998446+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_230552","record_id":"REC_0014984","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":14.6,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":6.5,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.998932+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_847234","record_id":"REC_0014985","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":15.1,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":6.4,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:00.999352+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_104622","record_id":"REC_0014986","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":7,"primary_tumor_size_cm":5.0,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:00.999777+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_379536","record_id":"REC_0014987","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":18.9,"age_at_diagnosis":54,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":5.1,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.000253+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_676985","record_id":"REC_0014988","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":5.3,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":5,"primary_tumor_size_cm":3.2,"metastatic_sites_count":8,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.000687+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_524049","record_id":"REC_0014989","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":5.2,"age_at_diagnosis":90,"sex":"female","ecog_performance_status":1,"smoking_pack_years":40,"primary_tumor_size_cm":6.9,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.003031+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_463007","record_id":"REC_0014990","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":16,"tmb_mutations_per_mb":20.5,"age_at_diagnosis":54,"sex":"male","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":4.1,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":19.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.003848+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_797543","record_id":"REC_0014991","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":5.3,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":1,"smoking_pack_years":51,"primary_tumor_size_cm":5.1,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.004422+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_124340","record_id":"REC_0014992","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":18.7,"age_at_diagnosis":53,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":5.6,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.004860+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_840629","record_id":"REC_0014993","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":3.0,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.005259+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_815629","record_id":"REC_0014994","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":19,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":4,"primary_tumor_size_cm":5.1,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":21.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.005616+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_164334","record_id":"REC_0014995","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":3,"smoking_pack_years":58,"primary_tumor_size_cm":6.4,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.005986+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_692089","record_id":"REC_0014996","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":8.1,"age_at_diagnosis":50,"sex":"female","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":6.8,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.006365+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_616442","record_id":"REC_0014997","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":19,"tmb_mutations_per_mb":17.4,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":6.9,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":8.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.006736+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_887610","record_id":"REC_0014998","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":6.8,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.007110+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_503447","record_id":"REC_0014999","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":18,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":0,"smoking_pack_years":38,"primary_tumor_size_cm":4.3,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.007485+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_605109","record_id":"REC_0015000","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":31,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":3.5,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":4.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.007844+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_591314","record_id":"REC_0015001","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":3,"smoking_pack_years":30,"primary_tumor_size_cm":5.6,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.008307+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_177821","record_id":"REC_0015002","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":33,"primary_tumor_size_cm":6.8,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.008709+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_861494","record_id":"REC_0015003","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":9.7,"age_at_diagnosis":52,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":3.5,"metastatic_sites_count":8,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.009390+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_449945","record_id":"REC_0015004","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":14.4,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":4.3,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.009863+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_452418","record_id":"REC_0015005","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":4.1,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.010263+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_140036","record_id":"REC_0015006","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":3,"smoking_pack_years":41,"primary_tumor_size_cm":5.6,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":5.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.010616+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_658666","record_id":"REC_0015007","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":7.9,"metastatic_sites_count":3,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":6.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.010991+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_141484","record_id":"REC_0015008","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":9.1,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":3.9,"metastatic_sites_count":8,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.011319+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_864164","record_id":"REC_0015009","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":5.8,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.011682+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_786978","record_id":"REC_0015010","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":18.8,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":6.4,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":17.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.012069+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_328770","record_id":"REC_0015011","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":14.4,"age_at_diagnosis":75,"sex":"male","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":4.5,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.012550+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_467465","record_id":"REC_0015012","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":8.0,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":3.6,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":18.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.012951+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_948524","record_id":"REC_0015013","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":4.9,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.013371+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_350083","record_id":"REC_0015014","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":9.8,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":7.8,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.013807+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_796118","record_id":"REC_0015015","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":16.0,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":6.5,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.014205+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_605654","record_id":"REC_0015016","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":85,"sex":"female","ecog_performance_status":1,"smoking_pack_years":27,"primary_tumor_size_cm":4.4,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.014756+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_381211","record_id":"REC_0015017","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":51,"sex":"male","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":5.1,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.015493+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_232490","record_id":"REC_0015018","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":32,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":7.6,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":27.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.015924+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_359454","record_id":"REC_0015019","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":14.7,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":4.5,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":20.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.016412+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_606343","record_id":"REC_0015020","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":6.6,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.016810+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_607891","record_id":"REC_0015021","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":10.0,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":6.2,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":30.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.017165+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_454641","record_id":"REC_0015022","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":30,"tmb_mutations_per_mb":1.5,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":3.2,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.017527+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_302523","record_id":"REC_0015023","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":5.3,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":4.0,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.018106+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_255063","record_id":"REC_0015024","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":15.0,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":4.8,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.018529+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_147026","record_id":"REC_0015025","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":16.0,"age_at_diagnosis":52,"sex":"male","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":4.7,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":4.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.018941+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_116783","record_id":"REC_0015026","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":1.5,"age_at_diagnosis":77,"sex":"male","ecog_performance_status":2,"smoking_pack_years":48,"primary_tumor_size_cm":7.0,"metastatic_sites_count":8,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":4.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.021620+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_144568","record_id":"REC_0015027","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":53,"sex":"female","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":5.0,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.022211+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_138514","record_id":"REC_0015028","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":17.0,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":6.8,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.022693+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_605270","record_id":"REC_0015029","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":8.5,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":6.2,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.023342+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_813204","record_id":"REC_0015030","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":5.0,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":4,"primary_tumor_size_cm":6.6,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.023776+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_890221","record_id":"REC_0015031","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":17,"tmb_mutations_per_mb":14.8,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":5.2,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":4.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.024252+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_755380","record_id":"REC_0015032","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":9.0,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":5.0,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.024670+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_925500","record_id":"REC_0015033","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":7.2,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.025057+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_106455","record_id":"REC_0015034","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":0,"smoking_pack_years":6,"primary_tumor_size_cm":5.4,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.025431+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_563231","record_id":"REC_0015035","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":20.6,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":6.5,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.025797+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_883285","record_id":"REC_0015036","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":3,"smoking_pack_years":15,"primary_tumor_size_cm":5.4,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.026200+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_493438","record_id":"REC_0015037","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":2.2,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":3.5,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":18.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.026590+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_147132","record_id":"REC_0015038","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":7.9,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":7.8,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":21.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.026966+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_528727","record_id":"REC_0015039","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":11.5,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":20,"primary_tumor_size_cm":8.1,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":22.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.027312+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_558872","record_id":"REC_0015040","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":4.4,"age_at_diagnosis":85,"sex":"female","ecog_performance_status":2,"smoking_pack_years":30,"primary_tumor_size_cm":5.6,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.027653+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_723533","record_id":"REC_0015041","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":30,"tmb_mutations_per_mb":2.6,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":5.8,"metastatic_sites_count":3,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.027998+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_750055","record_id":"REC_0015042","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":15,"tmb_mutations_per_mb":14.0,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":6.8,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":25.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.028603+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_320499","record_id":"REC_0015043","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":68,"primary_tumor_size_cm":6.1,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.029029+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_314552","record_id":"REC_0015044","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":14.4,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":5.0,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.029409+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_739937","record_id":"REC_0015045","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":5.7,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":7.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.029771+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_488956","record_id":"REC_0015046","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":3.9,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":27,"primary_tumor_size_cm":6.0,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.030147+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_698910","record_id":"REC_0015047","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":10.1,"age_at_diagnosis":84,"sex":"female","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":5.5,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":8.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.030564+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_149712","record_id":"REC_0015048","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":20,"primary_tumor_size_cm":5.7,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.030940+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_701848","record_id":"REC_0015049","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":5.7,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":0,"smoking_pack_years":44,"primary_tumor_size_cm":4.0,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":17.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.031287+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_623063","record_id":"REC_0015050","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":17,"tmb_mutations_per_mb":4.8,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":44,"primary_tumor_size_cm":3.8,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.031893+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_356335","record_id":"REC_0015051","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":14.9,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":10,"primary_tumor_size_cm":4.3,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.032407+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_459010","record_id":"REC_0015052","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":7.9,"age_at_diagnosis":51,"sex":"male","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":6.2,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":28.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.032841+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_866040","record_id":"REC_0015053","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":5.3,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":6.7,"metastatic_sites_count":3,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.033269+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_460749","record_id":"REC_0015054","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":4,"primary_tumor_size_cm":4.4,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.033681+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_262290","record_id":"REC_0015055","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":19.0,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":7.1,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.034301+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_747396","record_id":"REC_0015056","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":5.6,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":1,"smoking_pack_years":50,"primary_tumor_size_cm":5.8,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":17.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.034699+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_618543","record_id":"REC_0015057","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":18,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":29,"primary_tumor_size_cm":3.9,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":21.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.035087+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_996405","record_id":"REC_0015058","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":8.6,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":25,"primary_tumor_size_cm":5.5,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.035479+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_969045","record_id":"REC_0015059","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.9,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.035845+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_807999","record_id":"REC_0015060","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":89,"sex":"male","ecog_performance_status":2,"smoking_pack_years":50,"primary_tumor_size_cm":4.7,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":5.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.036260+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_975897","record_id":"REC_0015061","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":1,"smoking_pack_years":5,"primary_tumor_size_cm":8.1,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":7.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.036611+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_848701","record_id":"REC_0015062","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":0,"smoking_pack_years":35,"primary_tumor_size_cm":6.0,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":18.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.037001+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_885662","record_id":"REC_0015063","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":51,"sex":"female","ecog_performance_status":0,"smoking_pack_years":39,"primary_tumor_size_cm":4.0,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":21.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.037406+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_900065","record_id":"REC_0015064","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":19,"tmb_mutations_per_mb":6.0,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":2.9,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":6.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.037820+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_276902","record_id":"REC_0015065","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":8.6,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":5.5,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.038187+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_156242","record_id":"REC_0015066","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":5.2,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.038552+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_107472","record_id":"REC_0015067","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":9.7,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":3,"smoking_pack_years":12,"primary_tumor_size_cm":5.4,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.038902+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_826319","record_id":"REC_0015068","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":10.1,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":4.1,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.039445+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_976415","record_id":"REC_0015069","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":30,"tmb_mutations_per_mb":20.1,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":5.8,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.039861+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_771578","record_id":"REC_0015070","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":15.8,"age_at_diagnosis":79,"sex":"male","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":4.9,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.040602+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_534328","record_id":"REC_0015071","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":10.1,"age_at_diagnosis":53,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":6.3,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.041087+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_647759","record_id":"REC_0015072","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":9.7,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":5.4,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":22.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.041494+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_567419","record_id":"REC_0015073","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":5.7,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.041894+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_243917","record_id":"REC_0015074","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":2.2,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":4.6,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":19.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.042294+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_220551","record_id":"REC_0015075","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":10.5,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":3.1,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.042694+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_918851","record_id":"REC_0015076","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":9.1,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":5.6,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":46.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.043125+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_390850","record_id":"REC_0015077","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":7.3,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":7,"primary_tumor_size_cm":5.5,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":4.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.043584+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_892456","record_id":"REC_0015078","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":18.2,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":26,"primary_tumor_size_cm":3.9,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.043986+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_948119","record_id":"REC_0015079","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":4.5,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":5.5,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.044558+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_196642","record_id":"REC_0015080","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":54,"sex":"male","ecog_performance_status":0,"smoking_pack_years":5,"primary_tumor_size_cm":6.5,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":5.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.044970+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_300942","record_id":"REC_0015081","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":20,"tmb_mutations_per_mb":3.7,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":5.3,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.045586+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_618292","record_id":"REC_0015082","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":4.2,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":50,"primary_tumor_size_cm":7.7,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":24.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.046045+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_780289","record_id":"REC_0015083","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":14.0,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":7.2,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":28.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.046462+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_332299","record_id":"REC_0015084","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":7.2,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.046841+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_341248","record_id":"REC_0015085","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":14.7,"age_at_diagnosis":53,"sex":"female","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":7.0,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.047237+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_456950","record_id":"REC_0015086","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":9.8,"age_at_diagnosis":77,"sex":"male","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":6.7,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.047634+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_721945","record_id":"REC_0015087","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":5.9,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":54,"primary_tumor_size_cm":4.9,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.048026+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_596517","record_id":"REC_0015088","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":18.6,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":7.1,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.048762+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_697846","record_id":"REC_0015089","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":14.1,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":4.3,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.049168+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_889467","record_id":"REC_0015090","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":19,"tmb_mutations_per_mb":11.0,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":5.1,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.049575+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_970317","record_id":"REC_0015091","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":2.8,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.049953+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_474982","record_id":"REC_0015092","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":7.5,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.050297+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_179837","record_id":"REC_0015093","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":5.6,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.050657+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_309949","record_id":"REC_0015094","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":5.2,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":4.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.051184+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_849895","record_id":"REC_0015095","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":6.7,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":34,"primary_tumor_size_cm":4.7,"metastatic_sites_count":9,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.051608+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_234162","record_id":"REC_0015096","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":8.0,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":0,"smoking_pack_years":59,"primary_tumor_size_cm":5.2,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.051988+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_117303","record_id":"REC_0015097","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":32,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":52,"sex":"male","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":6.8,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":19.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.052489+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_708777","record_id":"REC_0015098","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":53,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":7.9,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":43.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.052876+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_607199","record_id":"REC_0015099","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":6.7,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":2.7,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.053253+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_193897","record_id":"REC_0015100","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":16.8,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":4.9,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.053629+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_980617","record_id":"REC_0015101","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":11.0,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":6.9,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":8.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.054177+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_984788","record_id":"REC_0015102","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":3.1,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.054627+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_509469","record_id":"REC_0015103","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":14,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":3,"smoking_pack_years":14,"primary_tumor_size_cm":3.8,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":8.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.054994+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_370682","record_id":"REC_0015104","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":17.0,"age_at_diagnosis":76,"sex":"male","ecog_performance_status":3,"smoking_pack_years":24,"primary_tumor_size_cm":3.2,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.055341+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_583815","record_id":"REC_0015105","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":21.8,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":5.2,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.055715+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_747545","record_id":"REC_0015106","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":85,"primary_tumor_size_cm":7.3,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.056169+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_608988","record_id":"REC_0015107","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":5.5,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.056807+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_327744","record_id":"REC_0015108","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None","pd_l1_tps_percent":31,"tmb_mutations_per_mb":5.9,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":44,"primary_tumor_size_cm":5.4,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":43.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.057231+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_803399","record_id":"REC_0015109","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":5.0,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":29,"primary_tumor_size_cm":4.5,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":18.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.057603+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_740124","record_id":"REC_0015110","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":4.7,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.057979+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_276740","record_id":"REC_0015111","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":5.3,"metastatic_sites_count":8,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.058382+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_652925","record_id":"REC_0015112","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":5.8,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.058768+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_871212","record_id":"REC_0015113","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":18.3,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":5.2,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.059189+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_914025","record_id":"REC_0015114","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":9.9,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":6,"primary_tumor_size_cm":5.1,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.059570+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_962987","record_id":"REC_0015115","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":4,"primary_tumor_size_cm":5.8,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.059994+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_476270","record_id":"REC_0015116","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":16.8,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":6.1,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.060462+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_572605","record_id":"REC_0015117","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":5.2,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":3.6,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.060846+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_244376","record_id":"REC_0015118","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":5.3,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.061235+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_280881","record_id":"REC_0015119","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":5.6,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.061605+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_574955","record_id":"REC_0015120","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":6.2,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.062142+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_141616","record_id":"REC_0015121","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":7.4,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":0,"smoking_pack_years":51,"primary_tumor_size_cm":6.6,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.062549+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_374206","record_id":"REC_0015122","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":6.0,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":36,"primary_tumor_size_cm":5.5,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":26.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.062909+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_443909","record_id":"REC_0015123","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":15.5,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":4.8,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.063284+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_607336","record_id":"REC_0015124","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":30,"tmb_mutations_per_mb":5.7,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":38,"primary_tumor_size_cm":5.2,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":6.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.063658+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_988436","record_id":"REC_0015125","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":0,"smoking_pack_years":55,"primary_tumor_size_cm":6.0,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.064006+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_789344","record_id":"REC_0015126","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":3.4,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":78,"primary_tumor_size_cm":6.5,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":16.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.064511+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_813652","record_id":"REC_0015127","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":13.3,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":4.5,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":17.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.064917+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_219027","record_id":"REC_0015128","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":15.4,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":4.7,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.065331+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_474766","record_id":"REC_0015129","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":26,"primary_tumor_size_cm":5.9,"metastatic_sites_count":3,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.065722+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_926453","record_id":"REC_0015130","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":10.0,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":88,"primary_tumor_size_cm":3.7,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":6.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.066073+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_770051","record_id":"REC_0015131","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":74,"sex":"male","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":4.4,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.066490+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_968833","record_id":"REC_0015132","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":33,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":42,"primary_tumor_size_cm":6.1,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.066904+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_725847","record_id":"REC_0015133","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":51,"primary_tumor_size_cm":7.7,"metastatic_sites_count":8,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.067466+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_645627","record_id":"REC_0015134","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":16.8,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":6.9,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":45.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.067893+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_978805","record_id":"REC_0015135","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":19,"tmb_mutations_per_mb":14.1,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":7.7,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.069094+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_291189","record_id":"REC_0015136","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":30,"tmb_mutations_per_mb":4.5,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":6.5,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.069563+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_929362","record_id":"REC_0015137","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":17.1,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":5.6,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":4.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.069938+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_377414","record_id":"REC_0015138","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":6.8,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.070293+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_173110","record_id":"REC_0015139","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":14.9,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":9,"primary_tumor_size_cm":5.3,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.070692+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_912889","record_id":"REC_0015140","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":10.1,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.7,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.071075+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_359278","record_id":"REC_0015141","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":67,"primary_tumor_size_cm":5.6,"metastatic_sites_count":8,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.071479+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_573292","record_id":"REC_0015142","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":4.3,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":0,"smoking_pack_years":40,"primary_tumor_size_cm":5.2,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.071887+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_680692","record_id":"REC_0015143","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":5.9,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.072385+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_841682","record_id":"REC_0015144","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":16,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":26,"primary_tumor_size_cm":5.2,"metastatic_sites_count":10,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.072810+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_823326","record_id":"REC_0015145","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":8.4,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":4.6,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":20.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.073213+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_664765","record_id":"REC_0015146","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":3.9,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.073842+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_140789","record_id":"REC_0015147","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":35,"tmb_mutations_per_mb":1.5,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":29,"primary_tumor_size_cm":5.6,"metastatic_sites_count":8,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":16.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.074260+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_408641","record_id":"REC_0015148","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":18.0,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":3.7,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.074660+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_823403","record_id":"REC_0015149","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":4.2,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":25.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.075057+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_778064","record_id":"REC_0015150","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":16.3,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":27,"primary_tumor_size_cm":3.8,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":7.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.075463+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_918967","record_id":"REC_0015151","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":6.2,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.075880+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_864135","record_id":"REC_0015152","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":4.9,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":29.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.076398+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_503924","record_id":"REC_0015153","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":17.2,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":3.5,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":6.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.076827+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_395409","record_id":"REC_0015154","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":16.2,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":6.0,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.077221+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_807120","record_id":"REC_0015155","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":2.8,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":5.7,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":28.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.077592+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_861258","record_id":"REC_0015156","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":4.7,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":48,"primary_tumor_size_cm":6.3,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":16.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.077956+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_816114","record_id":"REC_0015157","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":9.7,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":6.2,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.078369+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_133901","record_id":"REC_0015158","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":10.5,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":5.8,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.078753+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_684869","record_id":"REC_0015159","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":19,"tmb_mutations_per_mb":16.4,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":5,"primary_tumor_size_cm":6.2,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.079378+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_368493","record_id":"REC_0015160","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":4.4,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.079838+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_602032","record_id":"REC_0015161","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":6.4,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":5.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.080486+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_870216","record_id":"REC_0015162","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":3.2,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":26.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.080954+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_133180","record_id":"REC_0015163","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":18.1,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":0,"smoking_pack_years":24,"primary_tumor_size_cm":6.4,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":36.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.081682+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_577147","record_id":"REC_0015164","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":9.8,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":6.9,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":6.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.082365+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_116941","record_id":"REC_0015165","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":6.1,"age_at_diagnosis":54,"sex":"male","ecog_performance_status":0,"smoking_pack_years":49,"primary_tumor_size_cm":5.9,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":7.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.082829+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_599154","record_id":"REC_0015166","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":3.8,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.083195+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_363486","record_id":"REC_0015167","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":31,"tmb_mutations_per_mb":5.5,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":6.0,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.083556+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_966848","record_id":"REC_0015168","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":6.9,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":1,"smoking_pack_years":65,"primary_tumor_size_cm":5.9,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.083942+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_322646","record_id":"REC_0015169","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":5.6,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.084461+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_594448","record_id":"REC_0015170","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":3.1,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":26,"primary_tumor_size_cm":4.7,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.084882+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_104493","record_id":"REC_0015171","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":3.0,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.085345+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_817202","record_id":"REC_0015172","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":5.0,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":42.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.085939+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_978364","record_id":"REC_0015173","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":82,"sex":"male","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":4.3,"metastatic_sites_count":3,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.086422+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_900751","record_id":"REC_0015174","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":19.6,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":4.7,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.086857+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_243740","record_id":"REC_0015175","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":5.7,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":19.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.087291+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_939246","record_id":"REC_0015176","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":19,"tmb_mutations_per_mb":5.3,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":6.8,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.087693+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_291418","record_id":"REC_0015177","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":6.3,"age_at_diagnosis":86,"sex":"female","ecog_performance_status":1,"smoking_pack_years":59,"primary_tumor_size_cm":5.9,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.088179+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_657354","record_id":"REC_0015178","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":15.0,"age_at_diagnosis":51,"sex":"female","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":7.5,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.088656+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_347858","record_id":"REC_0015179","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":0,"smoking_pack_years":6,"primary_tumor_size_cm":7.1,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.089062+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_858583","record_id":"REC_0015180","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":5.5,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":6.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.089474+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_917175","record_id":"REC_0015181","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":24,"primary_tumor_size_cm":7.2,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.089866+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_819235","record_id":"REC_0015182","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":13.5,"age_at_diagnosis":52,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":3.9,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":26.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.090271+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_294334","record_id":"REC_0015183","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":5.2,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":4.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.090656+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_734665","record_id":"REC_0015184","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":8.3,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":5.4,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.091043+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_633268","record_id":"REC_0015185","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":3.4,"age_at_diagnosis":80,"sex":"male","ecog_performance_status":1,"smoking_pack_years":63,"primary_tumor_size_cm":6.4,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.091607+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_651852","record_id":"REC_0015186","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":14.9,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":2,"smoking_pack_years":0,"primary_tumor_size_cm":5.0,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":16.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.092021+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_646497","record_id":"REC_0015187","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":14.4,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":3,"primary_tumor_size_cm":6.9,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":17.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.094052+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_772614","record_id":"REC_0015188","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":4.2,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":0,"smoking_pack_years":28,"primary_tumor_size_cm":6.5,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.094482+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_153208","record_id":"REC_0015189","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":5.4,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":17.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.094877+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_464630","record_id":"REC_0015190","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":14.0,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":5.9,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.095258+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_647746","record_id":"REC_0015191","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":17.6,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":7.3,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.095637+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_934153","record_id":"REC_0015192","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":4.5,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":23.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.096023+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_429481","record_id":"REC_0015193","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":4.2,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":1,"smoking_pack_years":40,"primary_tumor_size_cm":5.4,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.096491+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_827939","record_id":"REC_0015194","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":85,"sex":"female","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":5.0,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.096915+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_618387","record_id":"REC_0015195","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":13.8,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":5.7,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.097352+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_770386","record_id":"REC_0015196","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":19.0,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":3.6,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.097734+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_938920","record_id":"REC_0015197","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":6.1,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":1,"smoking_pack_years":30,"primary_tumor_size_cm":4.7,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.098308+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_856940","record_id":"REC_0015198","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":6.7,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":66,"primary_tumor_size_cm":6.5,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":16.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.098991+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_960312","record_id":"REC_0015199","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":14,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":42,"primary_tumor_size_cm":7.9,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.099454+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_445884","record_id":"REC_0015200","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":5.6,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.099852+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_643214","record_id":"REC_0015201","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":6.4,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.100424+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_279142","record_id":"REC_0015202","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":14.0,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":5.9,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.100892+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_631168","record_id":"REC_0015203","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":14,"tmb_mutations_per_mb":7.6,"age_at_diagnosis":54,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":5.2,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.101334+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_363935","record_id":"REC_0015204","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":6.0,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":2,"smoking_pack_years":49,"primary_tumor_size_cm":6.8,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.101766+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_488522","record_id":"REC_0015205","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":14.1,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":3.9,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":4.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.102208+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_487923","record_id":"REC_0015206","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":16,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":79,"sex":"male","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":6.8,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":44.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.102601+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_677428","record_id":"REC_0015207","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":36,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":6.4,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.107386+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_997175","record_id":"REC_0015208","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":4.8,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":18.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.107958+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_287767","record_id":"REC_0015209","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.5,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":4.3,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.108533+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_116609","record_id":"REC_0015210","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":16.2,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.4,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.108985+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_455191","record_id":"REC_0015211","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":16.2,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":6.2,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":6.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.109580+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_397492","record_id":"REC_0015212","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":31,"tmb_mutations_per_mb":14.6,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":2,"smoking_pack_years":21,"primary_tumor_size_cm":6.8,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.109982+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_999034","record_id":"REC_0015213","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":9.5,"age_at_diagnosis":90,"sex":"male","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":6.2,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.110341+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_385143","record_id":"REC_0015214","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":74,"sex":"male","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":5.2,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.110699+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_646271","record_id":"REC_0015215","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":34,"tmb_mutations_per_mb":3.4,"age_at_diagnosis":78,"sex":"male","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":5.3,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.111101+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_541283","record_id":"REC_0015216","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":5.9,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.111521+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_409037","record_id":"REC_0015217","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":6.8,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":19.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.111911+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_254030","record_id":"REC_0015218","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":5.0,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":56.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.112479+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_329539","record_id":"REC_0015219","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":19,"tmb_mutations_per_mb":5.5,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":37,"primary_tumor_size_cm":5.0,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":17.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.112875+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_172765","record_id":"REC_0015220","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":8.5,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":5.1,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.113263+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_992773","record_id":"REC_0015221","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":9.8,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":5,"primary_tumor_size_cm":7.3,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.113662+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_612141","record_id":"REC_0015222","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":6.0,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":4.0,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.114058+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_483207","record_id":"REC_0015223","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":9.5,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":5.2,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":22.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.114455+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_390246","record_id":"REC_0015224","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":19,"tmb_mutations_per_mb":3.4,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":56,"primary_tumor_size_cm":8.2,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.114978+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_186630","record_id":"REC_0015225","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":30,"tmb_mutations_per_mb":9.1,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":6,"primary_tumor_size_cm":5.1,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.115414+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_256690","record_id":"REC_0015226","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":18.4,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":4.0,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":21.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.115831+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_105894","record_id":"REC_0015227","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":13.1,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":4.3,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":21.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.116291+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_328561","record_id":"REC_0015228","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":5.9,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.116679+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_836318","record_id":"REC_0015229","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":6.9,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.117048+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_338773","record_id":"REC_0015230","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":8.1,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":26,"primary_tumor_size_cm":6.4,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":8.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.117445+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_550987","record_id":"REC_0015231","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":9.1,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":0,"smoking_pack_years":24,"primary_tumor_size_cm":7.2,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.117842+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_171320","record_id":"REC_0015232","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":24.6,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":4.2,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":21.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.118246+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_825057","record_id":"REC_0015233","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":6.1,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":1,"smoking_pack_years":29,"primary_tumor_size_cm":6.1,"metastatic_sites_count":9,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.118636+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_564889","record_id":"REC_0015234","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":5.5,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":5.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.119019+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_924495","record_id":"REC_0015235","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":6.4,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":24.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.122120+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_468830","record_id":"REC_0015236","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.6,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":18.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.122607+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_772679","record_id":"REC_0015237","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":7.6,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":4.6,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.123285+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_633985","record_id":"REC_0015238","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":16.6,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":5.2,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.123809+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_647161","record_id":"REC_0015239","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":4.3,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":42,"primary_tumor_size_cm":8.4,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":17.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.124323+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_911171","record_id":"REC_0015240","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":4.5,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":54,"primary_tumor_size_cm":7.2,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":6.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.124766+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_534377","record_id":"REC_0015241","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":31,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.9,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":6.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.125205+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_460902","record_id":"REC_0015242","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":51,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":5.2,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":30.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.125615+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_218544","record_id":"REC_0015243","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":6.2,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":8.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.126045+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_630332","record_id":"REC_0015244","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":16,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":6.1,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.126437+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_186409","record_id":"REC_0015245","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":3.1,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.126833+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_676050","record_id":"REC_0015246","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":6.4,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":4.5,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.127254+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_722732","record_id":"REC_0015247","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":20,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":2,"smoking_pack_years":44,"primary_tumor_size_cm":5.1,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.127632+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_501367","record_id":"REC_0015248","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":15.8,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":6,"primary_tumor_size_cm":6.4,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":21.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.128021+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_882455","record_id":"REC_0015249","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":37,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":0,"primary_tumor_size_cm":4.7,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":17.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.128462+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_834820","record_id":"REC_0015250","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":20.5,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":5.0,"metastatic_sites_count":8,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.129078+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_915155","record_id":"REC_0015251","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":8.9,"age_at_diagnosis":53,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":4.6,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":5.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.129501+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_863629","record_id":"REC_0015252","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":16.5,"age_at_diagnosis":77,"sex":"male","ecog_performance_status":3,"smoking_pack_years":19,"primary_tumor_size_cm":5.1,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.129909+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_915201","record_id":"REC_0015253","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.6,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":21.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.130292+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_528783","record_id":"REC_0015254","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":20,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":54,"sex":"female","ecog_performance_status":0,"smoking_pack_years":81,"primary_tumor_size_cm":5.7,"metastatic_sites_count":8,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":4.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.130650+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_609607","record_id":"REC_0015255","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":6.8,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":5.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.130999+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_994654","record_id":"REC_0015256","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.1,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":6.9,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.131333+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_449718","record_id":"REC_0015257","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":33,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":3,"smoking_pack_years":20,"primary_tumor_size_cm":6.6,"metastatic_sites_count":3,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.131684+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_732502","record_id":"REC_0015258","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":6.4,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.132150+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_990821","record_id":"REC_0015259","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":6.3,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":1,"smoking_pack_years":57,"primary_tumor_size_cm":4.3,"metastatic_sites_count":3,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.132586+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_197821","record_id":"REC_0015260","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":16.2,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":4.8,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.132973+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_670195","record_id":"REC_0015261","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":8,"primary_tumor_size_cm":8.0,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":19.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.133337+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_677609","record_id":"REC_0015262","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":17,"tmb_mutations_per_mb":8.3,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":51,"primary_tumor_size_cm":3.7,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.133695+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_747968","record_id":"REC_0015263","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":14.1,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":4.7,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":41.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.134316+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_518616","record_id":"REC_0015264","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":8.5,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":1,"smoking_pack_years":56,"primary_tumor_size_cm":5.9,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.134742+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_285025","record_id":"REC_0015265","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":19,"tmb_mutations_per_mb":7.6,"age_at_diagnosis":77,"sex":"male","ecog_performance_status":1,"smoking_pack_years":48,"primary_tumor_size_cm":3.6,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":5.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.135091+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_402668","record_id":"REC_0015266","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":0,"primary_tumor_size_cm":5.7,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.135408+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_242341","record_id":"REC_0015267","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":15.9,"age_at_diagnosis":87,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":6.1,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":33.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.138366+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_539023","record_id":"REC_0015268","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":6.4,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":27.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.138861+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_548775","record_id":"REC_0015269","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":53,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":4.8,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.139314+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_568159","record_id":"REC_0015270","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":6.4,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":59,"primary_tumor_size_cm":6.4,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":7.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.139701+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_243171","record_id":"REC_0015271","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":19.3,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":7.1,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.140169+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_297186","record_id":"REC_0015272","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":15.1,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":4.5,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.140657+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_671364","record_id":"REC_0015273","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":6.1,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.141061+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_241959","record_id":"REC_0015274","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":10.0,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":4.0,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":18.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.141416+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_298954","record_id":"REC_0015275","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":14.8,"age_at_diagnosis":50,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":5.7,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.141788+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_167267","record_id":"REC_0015276","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":4.1,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":24.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.142413+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_849817","record_id":"REC_0015277","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":0,"smoking_pack_years":4,"primary_tumor_size_cm":5.4,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.142903+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_181688","record_id":"REC_0015278","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":17,"tmb_mutations_per_mb":4.0,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":3,"smoking_pack_years":13,"primary_tumor_size_cm":7.3,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":39.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.143300+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_889889","record_id":"REC_0015279","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":17.9,"age_at_diagnosis":83,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":5.7,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":25.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.143692+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_287332","record_id":"REC_0015280","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":31,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":25,"primary_tumor_size_cm":5.0,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.144237+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_761662","record_id":"REC_0015281","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":6.4,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.144781+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_579403","record_id":"REC_0015282","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":15.6,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":4.4,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":47.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.145207+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_284901","record_id":"REC_0015283","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":19.5,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":2.7,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.145566+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_744943","record_id":"REC_0015284","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":15.0,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":5.2,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":5.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.145926+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_246142","record_id":"REC_0015285","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":4.1,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.146318+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_247123","record_id":"REC_0015286","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":8.1,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":7.8,"metastatic_sites_count":3,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":17.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.146718+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_721433","record_id":"REC_0015287","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":5.8,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.147099+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_210807","record_id":"REC_0015288","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":6.7,"age_at_diagnosis":75,"sex":"male","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":4.7,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":17.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.147488+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_125660","record_id":"REC_0015289","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":30,"tmb_mutations_per_mb":13.3,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":25,"primary_tumor_size_cm":4.6,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":8.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.148016+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_880146","record_id":"REC_0015290","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":14.5,"age_at_diagnosis":90,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":6.5,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.148547+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_999960","record_id":"REC_0015291","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":44,"primary_tumor_size_cm":4.1,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.148928+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_801166","record_id":"REC_0015292","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":6.0,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":3,"smoking_pack_years":21,"primary_tumor_size_cm":5.2,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.149334+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_407919","record_id":"REC_0015293","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":31,"tmb_mutations_per_mb":14.8,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":3.4,"metastatic_sites_count":3,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":4.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.149771+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_136897","record_id":"REC_0015294","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":8.5,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":6.0,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":4.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.150157+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_336111","record_id":"REC_0015295","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":14.1,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":7.3,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.150544+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_436157","record_id":"REC_0015296","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":4.8,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":1,"smoking_pack_years":71,"primary_tumor_size_cm":5.0,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.150904+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_517328","record_id":"REC_0015297","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":16.9,"age_at_diagnosis":85,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":4.0,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.151296+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_124222","record_id":"REC_0015298","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":5.7,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.151690+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_148209","record_id":"REC_0015299","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":10.3,"age_at_diagnosis":78,"sex":"male","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":5.5,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":5.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.152121+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_556566","record_id":"REC_0015300","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":32,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":0,"smoking_pack_years":43,"primary_tumor_size_cm":5.3,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":21.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.152557+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_441211","record_id":"REC_0015301","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":5.0,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.155496+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_172323","record_id":"REC_0015302","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":54,"primary_tumor_size_cm":8.3,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":16.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.156364+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_391351","record_id":"REC_0015303","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":16.0,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":3,"smoking_pack_years":6,"primary_tumor_size_cm":3.2,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.156868+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_955442","record_id":"REC_0015304","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":16,"tmb_mutations_per_mb":4.3,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":25,"primary_tumor_size_cm":7.4,"metastatic_sites_count":10,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.157280+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_923594","record_id":"REC_0015305","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":14,"tmb_mutations_per_mb":3.3,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":4.4,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":16.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.157903+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_222448","record_id":"REC_0015306","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":26,"primary_tumor_size_cm":7.5,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.158379+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_177973","record_id":"REC_0015307","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":7.3,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":0,"smoking_pack_years":72,"primary_tumor_size_cm":6.0,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.158773+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_339763","record_id":"REC_0015308","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":8.1,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":4.3,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.159176+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_426471","record_id":"REC_0015309","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":13.5,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":6.3,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.159593+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_232317","record_id":"REC_0015310","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":5.3,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":6.0,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.159981+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_679365","record_id":"REC_0015311","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":6.9,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":0,"smoking_pack_years":31,"primary_tumor_size_cm":5.3,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":6.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.160426+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_744924","record_id":"REC_0015312","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":8.5,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":81,"primary_tumor_size_cm":5.2,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.160834+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_479000","record_id":"REC_0015313","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":6.3,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":82,"primary_tumor_size_cm":5.7,"metastatic_sites_count":3,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.161227+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_171371","record_id":"REC_0015314","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":0,"primary_tumor_size_cm":5.7,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":18.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.161587+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_242685","record_id":"REC_0015315","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":8.7,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":5.6,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.162191+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_131171","record_id":"REC_0015316","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":5.0,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":7.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.162653+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_505815","record_id":"REC_0015317","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":77,"sex":"male","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":4.2,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":22.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.163134+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_223614","record_id":"REC_0015318","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":14.9,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":4.8,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.163562+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_980006","record_id":"REC_0015319","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":14,"tmb_mutations_per_mb":19.2,"age_at_diagnosis":75,"sex":"male","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":5.5,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":4.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.163986+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_985716","record_id":"REC_0015320","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":10.3,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":6.6,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.172334+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_415165","record_id":"REC_0015321","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":4.3,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.172818+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_985341","record_id":"REC_0015322","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":15.5,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":5.9,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":40.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.173224+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_232215","record_id":"REC_0015323","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":20,"tmb_mutations_per_mb":8.6,"age_at_diagnosis":54,"sex":"female","ecog_performance_status":0,"smoking_pack_years":27,"primary_tumor_size_cm":4.3,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":20.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.173606+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_990598","record_id":"REC_0015324","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":5.1,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":18.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.174020+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_268429","record_id":"REC_0015325","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":33,"tmb_mutations_per_mb":2.3,"age_at_diagnosis":76,"sex":"male","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":4.9,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":18.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.174413+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_968136","record_id":"REC_0015326","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":20,"tmb_mutations_per_mb":4.6,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":2,"smoking_pack_years":54,"primary_tumor_size_cm":4.9,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.174784+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_219548","record_id":"REC_0015327","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":14,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":39,"primary_tumor_size_cm":5.2,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.175153+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_260953","record_id":"REC_0015328","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":30,"tmb_mutations_per_mb":7.6,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":6.7,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.175920+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_991847","record_id":"REC_0015329","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":5.0,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":5.8,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.176508+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_941527","record_id":"REC_0015330","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":5.5,"age_at_diagnosis":76,"sex":"male","ecog_performance_status":2,"smoking_pack_years":41,"primary_tumor_size_cm":5.6,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.176932+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_561715","record_id":"REC_0015331","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":4.2,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":6.3,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.177308+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_289191","record_id":"REC_0015332","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":8.6,"metastatic_sites_count":3,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.177690+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_213568","record_id":"REC_0015333","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":15.2,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":3,"smoking_pack_years":15,"primary_tumor_size_cm":6.4,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.178097+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_493848","record_id":"REC_0015334","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":2.1,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":5.7,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.178486+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_335641","record_id":"REC_0015335","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":6.0,"age_at_diagnosis":53,"sex":"female","ecog_performance_status":0,"smoking_pack_years":62,"primary_tumor_size_cm":3.6,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.178863+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_501877","record_id":"REC_0015336","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":8.6,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":42,"primary_tumor_size_cm":5.6,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.179270+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_287948","record_id":"REC_0015337","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":19,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":5.6,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.179672+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_395640","record_id":"REC_0015338","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":16,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":6.5,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.184191+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_314918","record_id":"REC_0015339","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":16.4,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":28,"primary_tumor_size_cm":6.0,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.184898+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_722628","record_id":"REC_0015340","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":17,"tmb_mutations_per_mb":14.5,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":5.3,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.187943+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_139930","record_id":"REC_0015341","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":19,"tmb_mutations_per_mb":6.1,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":4.8,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.188813+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_724261","record_id":"REC_0015342","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":5.9,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.189342+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_778441","record_id":"REC_0015343","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":16.3,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":2,"smoking_pack_years":7,"primary_tumor_size_cm":5.6,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":21.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.189765+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_504022","record_id":"REC_0015344","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":14.7,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":4.9,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":23.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.190181+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_132430","record_id":"REC_0015345","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":17.7,"age_at_diagnosis":54,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":4.5,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":24.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.190596+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_722301","record_id":"REC_0015346","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":8.7,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":5.3,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.190985+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_926387","record_id":"REC_0015347","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":13,"tmb_mutations_per_mb":14.0,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":7.8,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.191372+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_833318","record_id":"REC_0015348","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":5.8,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.191772+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_377526","record_id":"REC_0015349","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":14.0,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":5.5,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":19.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.192848+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_880122","record_id":"REC_0015350","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":11.0,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":2,"primary_tumor_size_cm":7.0,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.193387+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_141595","record_id":"REC_0015351","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":87,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":5.4,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":49.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.193795+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_337078","record_id":"REC_0015352","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":4.5,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":31.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.194195+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_652161","record_id":"REC_0015353","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":9.8,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":6.0,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.194588+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_535347","record_id":"REC_0015354","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":6.2,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.195186+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_640437","record_id":"REC_0015355","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":1,"primary_tumor_size_cm":7.0,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.195614+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_134873","record_id":"REC_0015356","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":4.9,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":16.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.196013+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_190811","record_id":"REC_0015357","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":80,"sex":"male","ecog_performance_status":1,"smoking_pack_years":44,"primary_tumor_size_cm":6.5,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.196581+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_946891","record_id":"REC_0015358","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":11.0,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":6.2,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.197013+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_773587","record_id":"REC_0015359","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":14.1,"age_at_diagnosis":49,"sex":"male","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":6.8,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.197414+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_171105","record_id":"REC_0015360","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":16.7,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":27,"primary_tumor_size_cm":5.7,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":36.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.197793+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_888889","record_id":"REC_0015361","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":15.4,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":6.5,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":5.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.198149+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_254345","record_id":"REC_0015362","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":6.7,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":6.8,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.198552+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_413780","record_id":"REC_0015363","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":3.5,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.198961+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_573662","record_id":"REC_0015364","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":13.1,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":6.7,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.199352+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_100038","record_id":"REC_0015365","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":5.3,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":29,"primary_tumor_size_cm":5.4,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":20.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.199737+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_515896","record_id":"REC_0015366","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":15,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":25,"primary_tumor_size_cm":5.3,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":18.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.200137+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_545448","record_id":"REC_0015367","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":6.2,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.200762+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_806605","record_id":"REC_0015368","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":9.9,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":6.1,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":20.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.201199+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_552450","record_id":"REC_0015369","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":7.3,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":24,"primary_tumor_size_cm":6.2,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":16.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.201613+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_591009","record_id":"REC_0015370","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":32,"tmb_mutations_per_mb":9.8,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":8,"primary_tumor_size_cm":7.8,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.204630+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_300111","record_id":"REC_0015371","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":7.6,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":18.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.205260+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_851224","record_id":"REC_0015372","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":5.7,"age_at_diagnosis":54,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":5.0,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.205739+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_909273","record_id":"REC_0015373","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":11.1,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":3.7,"metastatic_sites_count":9,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.206201+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_753352","record_id":"REC_0015374","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":2.5,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":8.2,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.206626+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_996544","record_id":"REC_0015375","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":6.9,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.207053+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_871073","record_id":"REC_0015376","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":3.8,"age_at_diagnosis":51,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":6.1,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":17.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.207464+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_974956","record_id":"REC_0015377","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":75,"sex":"male","ecog_performance_status":2,"smoking_pack_years":22,"primary_tumor_size_cm":8.1,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.207852+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_210784","record_id":"REC_0015378","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":17.6,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":4.9,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":30.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.208513+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_607693","record_id":"REC_0015379","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":14.4,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":5.5,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.208959+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_254977","record_id":"REC_0015380","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":20,"tmb_mutations_per_mb":4.0,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":89,"primary_tumor_size_cm":6.0,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":7.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.209605+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_811792","record_id":"REC_0015381","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":20,"tmb_mutations_per_mb":16.7,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":4.9,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.210067+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_324977","record_id":"REC_0015382","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":56,"primary_tumor_size_cm":5.2,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":57.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.210493+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_336003","record_id":"REC_0015383","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":11.0,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":4.1,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":5.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.210886+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_614187","record_id":"REC_0015384","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":32,"tmb_mutations_per_mb":4.6,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":1,"smoking_pack_years":44,"primary_tumor_size_cm":6.0,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":4.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.211316+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_910968","record_id":"REC_0015385","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":17,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":4.5,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.211714+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_232930","record_id":"REC_0015386","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":11.1,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":4.5,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":19.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.212208+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_870849","record_id":"REC_0015387","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":14.1,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":5.4,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":38.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.212660+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_845320","record_id":"REC_0015388","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":14.3,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":25,"primary_tumor_size_cm":3.3,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":18.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.213068+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_885491","record_id":"REC_0015389","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":7.8,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.213440+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_549377","record_id":"REC_0015390","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":10.5,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":6.2,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.213793+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_688137","record_id":"REC_0015391","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":76,"sex":"male","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":4.5,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":18.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.214154+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_132801","record_id":"REC_0015392","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":8.7,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":6.8,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.214533+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_585830","record_id":"REC_0015393","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":16.2,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":5.7,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":28.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.217241+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_922734","record_id":"REC_0015394","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":9.7,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":2,"smoking_pack_years":23,"primary_tumor_size_cm":6.1,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":17.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.218323+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_402973","record_id":"REC_0015395","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":6.1,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":3,"smoking_pack_years":44,"primary_tumor_size_cm":6.3,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":5.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.218883+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_717181","record_id":"REC_0015396","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":8.9,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":2.8,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.219339+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_321606","record_id":"REC_0015397","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":4.5,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.219766+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_624409","record_id":"REC_0015398","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":19,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":5.4,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":46.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.220298+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_981823","record_id":"REC_0015399","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":2.5,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.5,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":24.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.221380+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_640060","record_id":"REC_0015400","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":11.5,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":3.4,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.222610+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_801576","record_id":"REC_0015401","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":5.9,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.223196+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_553780","record_id":"REC_0015402","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":6.9,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.223644+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_837055","record_id":"REC_0015403","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":32,"tmb_mutations_per_mb":6.7,"age_at_diagnosis":49,"sex":"male","ecog_performance_status":0,"smoking_pack_years":62,"primary_tumor_size_cm":7.3,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.224128+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_963687","record_id":"REC_0015404","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":75,"sex":"male","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":7.2,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":31.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.224588+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_853567","record_id":"REC_0015405","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":1.5,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":0,"smoking_pack_years":52,"primary_tumor_size_cm":5.5,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.224971+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_317796","record_id":"REC_0015406","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":19,"tmb_mutations_per_mb":9.1,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":1,"smoking_pack_years":64,"primary_tumor_size_cm":5.6,"metastatic_sites_count":8,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.225494+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_756179","record_id":"REC_0015407","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":15.0,"age_at_diagnosis":54,"sex":"male","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":5.3,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":28.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.225874+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_385380","record_id":"REC_0015408","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":10.0,"age_at_diagnosis":83,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":5.7,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.226249+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_739464","record_id":"REC_0015409","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":9.7,"age_at_diagnosis":75,"sex":"male","ecog_performance_status":2,"smoking_pack_years":20,"primary_tumor_size_cm":8.5,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.226632+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_805113","record_id":"REC_0015410","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":18.3,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":5.2,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.226999+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_488434","record_id":"REC_0015411","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":42,"primary_tumor_size_cm":6.3,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":23.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.227376+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_980159","record_id":"REC_0015412","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":18.5,"age_at_diagnosis":44,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":3.8,"metastatic_sites_count":8,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.227818+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_734955","record_id":"REC_0015413","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":15.9,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":7,"primary_tumor_size_cm":7.1,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":18.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.234420+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_790799","record_id":"REC_0015414","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":20,"tmb_mutations_per_mb":7.3,"age_at_diagnosis":52,"sex":"male","ecog_performance_status":0,"smoking_pack_years":49,"primary_tumor_size_cm":5.3,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.234959+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_957877","record_id":"REC_0015415","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":30,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":5.1,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":18.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.235356+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_409975","record_id":"REC_0015416","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":5.0,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":0,"smoking_pack_years":52,"primary_tumor_size_cm":4.5,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":21.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.235751+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_711394","record_id":"REC_0015417","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":7.0,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.238757+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_270400","record_id":"REC_0015418","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":17,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":76,"sex":"male","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":4.0,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.239241+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_151530","record_id":"REC_0015419","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":32,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":1,"primary_tumor_size_cm":7.3,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.239825+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_216825","record_id":"REC_0015420","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":17,"tmb_mutations_per_mb":9.1,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":4,"primary_tumor_size_cm":3.8,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.240435+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_632778","record_id":"REC_0015421","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":7.5,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.240903+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_757544","record_id":"REC_0015422","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":7.9,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.241326+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_896053","record_id":"REC_0015423","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":53,"sex":"female","ecog_performance_status":0,"smoking_pack_years":42,"primary_tumor_size_cm":6.1,"metastatic_sites_count":3,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.241889+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_893296","record_id":"REC_0015424","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":9.8,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":3.4,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.242350+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_691965","record_id":"REC_0015425","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.5,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":25.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.242748+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_208811","record_id":"REC_0015426","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":75,"sex":"male","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":7.2,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.243152+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_938081","record_id":"REC_0015427","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.5,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":5.9,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.243519+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_681708","record_id":"REC_0015428","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":87,"sex":"female","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":5.9,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":23.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.243887+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_889521","record_id":"REC_0015429","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":5.6,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":53,"primary_tumor_size_cm":8.3,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.244357+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_963687","record_id":"REC_0015430","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":5.2,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.244761+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_368790","record_id":"REC_0015431","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":33,"tmb_mutations_per_mb":8.4,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":26,"primary_tumor_size_cm":5.3,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":16.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.245135+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_482639","record_id":"REC_0015432","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":7.4,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.245721+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_186500","record_id":"REC_0015433","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":17,"tmb_mutations_per_mb":16.9,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":6.3,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.246197+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_277920","record_id":"REC_0015434","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":18.4,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":4.7,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.246567+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_976911","record_id":"REC_0015435","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":3,"smoking_pack_years":10,"primary_tumor_size_cm":3.9,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":22.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.246938+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_841369","record_id":"REC_0015436","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":4.5,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.247322+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_529295","record_id":"REC_0015437","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":9.7,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":4.9,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.247677+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_939999","record_id":"REC_0015438","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":19,"tmb_mutations_per_mb":7.6,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":3,"smoking_pack_years":55,"primary_tumor_size_cm":6.3,"metastatic_sites_count":3,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.248021+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_456282","record_id":"REC_0015439","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":14.4,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":6.4,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":21.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.248630+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_918600","record_id":"REC_0015440","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":5.9,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":0,"smoking_pack_years":84,"primary_tumor_size_cm":5.5,"metastatic_sites_count":3,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.249058+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_690957","record_id":"REC_0015441","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":5.7,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.249460+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_570696","record_id":"REC_0015442","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":2,"smoking_pack_years":60,"primary_tumor_size_cm":4.3,"metastatic_sites_count":3,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":20.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.249806+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_539618","record_id":"REC_0015443","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":5.5,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":83,"primary_tumor_size_cm":4.1,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":26.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.250154+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_474077","record_id":"REC_0015444","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":15.6,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":20,"primary_tumor_size_cm":6.5,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":19.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.250526+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_765060","record_id":"REC_0015445","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":17,"tmb_mutations_per_mb":7.4,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":76,"primary_tumor_size_cm":5.4,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":5.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.251995+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_686918","record_id":"REC_0015446","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":8.9,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":2,"smoking_pack_years":23,"primary_tumor_size_cm":4.4,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.252585+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_653496","record_id":"REC_0015447","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":4.8,"metastatic_sites_count":8,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":5.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.253013+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_675971","record_id":"REC_0015448","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":17.3,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":5.3,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":50.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.253428+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_114879","record_id":"REC_0015449","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":13.8,"age_at_diagnosis":52,"sex":"male","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":4.8,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.253845+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_110895","record_id":"REC_0015450","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":7.9,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.254818+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_702634","record_id":"REC_0015451","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":2.5,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":29,"primary_tumor_size_cm":2.0,"metastatic_sites_count":8,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":6.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.255286+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_370300","record_id":"REC_0015452","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":6.1,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":17.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.257044+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_361532","record_id":"REC_0015453","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":87,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":3.5,"metastatic_sites_count":9,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.257533+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_873379","record_id":"REC_0015454","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":4.8,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.257951+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_795326","record_id":"REC_0015455","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":2,"smoking_pack_years":10,"primary_tumor_size_cm":5.3,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.258363+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_691568","record_id":"REC_0015456","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":13.3,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.3,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":38.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.258783+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_385469","record_id":"REC_0015457","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":4.3,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.259214+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_729266","record_id":"REC_0015458","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":7.5,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.260067+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_794822","record_id":"REC_0015459","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":8.9,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":5.5,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.260596+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_655908","record_id":"REC_0015460","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":16.7,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":5.9,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":20.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.261013+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_604039","record_id":"REC_0015461","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":4.6,"age_at_diagnosis":47,"sex":"male","ecog_performance_status":0,"smoking_pack_years":48,"primary_tumor_size_cm":7.2,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.261423+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_442012","record_id":"REC_0015462","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":34,"tmb_mutations_per_mb":14.8,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":5.4,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.261760+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_800008","record_id":"REC_0015463","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":14.4,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":6.8,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.262091+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_843237","record_id":"REC_0015464","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":9.9,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":27,"primary_tumor_size_cm":5.5,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":5.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.262418+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_581488","record_id":"REC_0015465","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":21,"primary_tumor_size_cm":4.9,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":36.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.262724+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_142830","record_id":"REC_0015466","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":19,"tmb_mutations_per_mb":15.5,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":6.2,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.263071+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_644419","record_id":"REC_0015467","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":2.9,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":21,"primary_tumor_size_cm":3.6,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":33.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.263441+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_789657","record_id":"REC_0015468","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":5.5,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.263822+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_651834","record_id":"REC_0015469","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":18.3,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":0,"smoking_pack_years":25,"primary_tumor_size_cm":4.0,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":23.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.264285+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_187100","record_id":"REC_0015470","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":13.1,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":4.7,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.267045+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_835376","record_id":"REC_0015471","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":18.7,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":3.0,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":19.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.267845+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_901668","record_id":"REC_0015472","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":9.1,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":0,"primary_tumor_size_cm":7.0,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":21.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.269142+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_695255","record_id":"REC_0015473","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":14.3,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":6.7,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.269617+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_585568","record_id":"REC_0015474","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":2.3,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":4.4,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":39.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.270034+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_251836","record_id":"REC_0015475","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":5.6,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.270455+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_968068","record_id":"REC_0015476","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":10.5,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":3.7,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":20.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.270872+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_464656","record_id":"REC_0015477","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":2,"smoking_pack_years":58,"primary_tumor_size_cm":6.3,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":24.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.271975+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_938241","record_id":"REC_0015478","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":31,"tmb_mutations_per_mb":5.7,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":34,"primary_tumor_size_cm":5.5,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":4.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.273570+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_344676","record_id":"REC_0015479","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":21.3,"age_at_diagnosis":86,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":4.7,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":19.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.274172+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_720480","record_id":"REC_0015480","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":17,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":5.2,"metastatic_sites_count":9,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.274607+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_430202","record_id":"REC_0015481","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":4.9,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.275013+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_446909","record_id":"REC_0015482","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.7,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.275439+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_580824","record_id":"REC_0015483","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":33,"tmb_mutations_per_mb":18.1,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":7.0,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":31.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.275814+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_971591","record_id":"REC_0015484","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":79,"sex":"male","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":6.5,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.276460+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_958621","record_id":"REC_0015485","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":7.1,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":7.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.276997+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_929336","record_id":"REC_0015486","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":15.9,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":6.3,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.277756+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_235429","record_id":"REC_0015487","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":2,"smoking_pack_years":20,"primary_tumor_size_cm":3.2,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.278231+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_731245","record_id":"REC_0015488","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":3.5,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":5.7,"metastatic_sites_count":8,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.278626+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_764730","record_id":"REC_0015489","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":6.7,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":0,"smoking_pack_years":45,"primary_tumor_size_cm":2.5,"metastatic_sites_count":8,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.279023+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_960839","record_id":"REC_0015490","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":32,"primary_tumor_size_cm":6.9,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":29.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.279391+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_702355","record_id":"REC_0015491","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":7.3,"age_at_diagnosis":86,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":6.4,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.279788+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_660348","record_id":"REC_0015492","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":18,"tmb_mutations_per_mb":14.5,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":26,"primary_tumor_size_cm":5.9,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":6.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.280280+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_885354","record_id":"REC_0015493","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":35,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":25,"primary_tumor_size_cm":4.1,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.280703+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_242184","record_id":"REC_0015494","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":31,"tmb_mutations_per_mb":14.5,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.1,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.281137+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_862987","record_id":"REC_0015495","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":18.7,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":4.6,"metastatic_sites_count":9,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.284317+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_449202","record_id":"REC_0015496","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":20.5,"age_at_diagnosis":80,"sex":"male","ecog_performance_status":1,"smoking_pack_years":3,"primary_tumor_size_cm":4.9,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":27.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.284815+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_281982","record_id":"REC_0015497","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":15.3,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":4,"primary_tumor_size_cm":5.8,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.286039+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_619096","record_id":"REC_0015498","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":16.2,"age_at_diagnosis":50,"sex":"female","ecog_performance_status":0,"smoking_pack_years":5,"primary_tumor_size_cm":5.8,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.286520+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_478616","record_id":"REC_0015499","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":5.7,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":3.8,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.286952+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_559470","record_id":"REC_0015500","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":15.9,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":7.8,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":21.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.287368+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_665498","record_id":"REC_0015501","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":19,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":10,"primary_tumor_size_cm":6.5,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.288394+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_367661","record_id":"REC_0015502","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":4.7,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.290630+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_317818","record_id":"REC_0015503","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":1,"smoking_pack_years":24,"primary_tumor_size_cm":5.9,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.291132+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_618467","record_id":"REC_0015504","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":9.1,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":7.2,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":8.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.291581+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_168580","record_id":"REC_0015505","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":18.4,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":5.8,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.292024+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_623888","record_id":"REC_0015506","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":6.0,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.292548+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_344310","record_id":"REC_0015507","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":19,"tmb_mutations_per_mb":16.0,"age_at_diagnosis":54,"sex":"male","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":6.5,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":18.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.292931+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_239338","record_id":"REC_0015508","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":16,"tmb_mutations_per_mb":13.8,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":4.5,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.293279+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_558565","record_id":"REC_0015509","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":8.0,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":0,"smoking_pack_years":28,"primary_tumor_size_cm":6.2,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.293613+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_675724","record_id":"REC_0015510","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":10.1,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":3,"primary_tumor_size_cm":2.8,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.294154+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_328243","record_id":"REC_0015511","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":10.0,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":5.1,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":17.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.294543+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_151390","record_id":"REC_0015512","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":8.7,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":4,"primary_tumor_size_cm":5.3,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":6.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.294857+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_236973","record_id":"REC_0015513","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":32,"tmb_mutations_per_mb":13.3,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":5.6,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.295180+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_421215","record_id":"REC_0015514","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":15.4,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":4.9,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":22.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.295490+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_158692","record_id":"REC_0015515","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":13,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":8.2,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.295796+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_782013","record_id":"REC_0015516","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":4.5,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.2,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.296167+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_144901","record_id":"REC_0015517","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":8.3,"age_at_diagnosis":53,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":6.6,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.296512+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_611711","record_id":"REC_0015518","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":35,"tmb_mutations_per_mb":4.0,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":43,"primary_tumor_size_cm":7.9,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":6.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.296867+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_480769","record_id":"REC_0015519","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":17.0,"age_at_diagnosis":50,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":7.3,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.297253+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_679647","record_id":"REC_0015520","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":15.1,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":5.6,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.297639+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_925658","record_id":"REC_0015521","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":4.8,"age_at_diagnosis":74,"sex":"male","ecog_performance_status":2,"smoking_pack_years":22,"primary_tumor_size_cm":5.6,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":24.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.300337+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_679648","record_id":"REC_0015522","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":31,"tmb_mutations_per_mb":10.1,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":6.2,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":7.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.300945+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_715157","record_id":"REC_0015523","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":14.3,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":3.6,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.302231+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_732872","record_id":"REC_0015524","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":5,"primary_tumor_size_cm":5.1,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.302724+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_409337","record_id":"REC_0015525","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":5.3,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":28.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.303171+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_589463","record_id":"REC_0015526","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":8.4,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":4.5,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":22.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.303590+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_359544","record_id":"REC_0015527","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":5.1,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":32,"primary_tumor_size_cm":5.9,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.304646+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_491704","record_id":"REC_0015528","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":16.0,"age_at_diagnosis":51,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":6.5,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.305282+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_277780","record_id":"REC_0015529","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":30,"tmb_mutations_per_mb":6.0,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":7.0,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":16.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.306734+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_358119","record_id":"REC_0015530","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":9.8,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":6.1,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.307260+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_991674","record_id":"REC_0015531","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":5.5,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":18.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.307658+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_532158","record_id":"REC_0015532","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":8.5,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":4.9,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":6.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.308050+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_105420","record_id":"REC_0015533","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":4.9,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":4.7,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.308537+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_730590","record_id":"REC_0015534","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":84,"sex":"female","ecog_performance_status":2,"smoking_pack_years":111,"primary_tumor_size_cm":5.4,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.308932+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_315388","record_id":"REC_0015535","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":53,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":5.4,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.309329+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_944678","record_id":"REC_0015536","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":6.6,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":29.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.309902+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_433908","record_id":"REC_0015537","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":8.7,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":25,"primary_tumor_size_cm":5.6,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.310362+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_350201","record_id":"REC_0015538","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":50,"sex":"female","ecog_performance_status":0,"smoking_pack_years":2,"primary_tumor_size_cm":7.1,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.310802+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_798839","record_id":"REC_0015539","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":8.4,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":35.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.311204+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_190030","record_id":"REC_0015540","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":20.2,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":6.7,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.311595+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_738255","record_id":"REC_0015541","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":16.6,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":5.4,"metastatic_sites_count":3,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":21.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.311997+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_857056","record_id":"REC_0015542","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":16,"tmb_mutations_per_mb":17.2,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":6.9,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":49.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.312487+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_532443","record_id":"REC_0015543","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":3.2,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":21,"primary_tumor_size_cm":3.6,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.312883+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_396386","record_id":"REC_0015544","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":9.7,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":32,"primary_tumor_size_cm":5.3,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.313280+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_423262","record_id":"REC_0015545","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":10.0,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":5.4,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":39.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.313652+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_421064","record_id":"REC_0015546","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":15,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":5.6,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.314026+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_209340","record_id":"REC_0015547","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":16.8,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":6.1,"metastatic_sites_count":3,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.314406+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_702278","record_id":"REC_0015548","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":11.1,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":5.8,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.317902+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_952572","record_id":"REC_0015549","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":6.9,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":35,"primary_tumor_size_cm":5.8,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":21.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.318568+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_717853","record_id":"REC_0015550","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":15.9,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":6.1,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":17.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.318999+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_618069","record_id":"REC_0015551","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.6,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.319373+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_663333","record_id":"REC_0015552","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":1.5,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":0,"smoking_pack_years":71,"primary_tumor_size_cm":4.5,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":16.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.319727+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_790561","record_id":"REC_0015553","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":7.3,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":4.5,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.320192+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_272123","record_id":"REC_0015554","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.2,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":4.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.320672+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_277070","record_id":"REC_0015555","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":19,"tmb_mutations_per_mb":13.3,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":5.7,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.321092+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_245219","record_id":"REC_0015556","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":73,"primary_tumor_size_cm":5.8,"metastatic_sites_count":8,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.321510+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_200884","record_id":"REC_0015557","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":8,"primary_tumor_size_cm":4.3,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.321930+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_536437","record_id":"REC_0015558","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":30,"tmb_mutations_per_mb":3.3,"age_at_diagnosis":54,"sex":"female","ecog_performance_status":0,"smoking_pack_years":57,"primary_tumor_size_cm":5.1,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.322335+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_862611","record_id":"REC_0015559","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":16.4,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":6.3,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":16.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.322709+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_598405","record_id":"REC_0015560","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":7.6,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":6.8,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.323095+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_637319","record_id":"REC_0015561","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":4.3,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.323481+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_957843","record_id":"REC_0015562","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":4.9,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":5.0,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.323972+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_162113","record_id":"REC_0015563","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":15.8,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":6.4,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.324437+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_768178","record_id":"REC_0015564","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":5.9,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.324790+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_410896","record_id":"REC_0015565","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":1,"smoking_pack_years":37,"primary_tumor_size_cm":6.1,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.325108+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_339534","record_id":"REC_0015566","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":5.6,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":47.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.325408+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_140768","record_id":"REC_0015567","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":20,"tmb_mutations_per_mb":5.7,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.2,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.325728+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_595422","record_id":"REC_0015568","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":1,"smoking_pack_years":62,"primary_tumor_size_cm":4.9,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":20.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.326053+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_779075","record_id":"REC_0015569","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":6.4,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":4.1,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.326365+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_797803","record_id":"REC_0015570","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":5.1,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":30,"primary_tumor_size_cm":8.3,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":16.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.326677+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_901056","record_id":"REC_0015571","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":4.0,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":0,"primary_tumor_size_cm":5.5,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":29.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.326998+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_824777","record_id":"REC_0015572","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":16.9,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":4.8,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.327352+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_740453","record_id":"REC_0015573","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":2,"smoking_pack_years":8,"primary_tumor_size_cm":6.3,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.327740+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_540846","record_id":"REC_0015574","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":9.8,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":4.1,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":21.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.328207+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_192071","record_id":"REC_0015575","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":4.2,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.328840+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_375191","record_id":"REC_0015576","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":5.5,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":5.9,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.329296+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_127868","record_id":"REC_0015577","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":8.9,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":6.8,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.329711+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_108905","record_id":"REC_0015578","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":5.9,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.330133+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_172307","record_id":"REC_0015579","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.5,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":17.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.330540+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_683722","record_id":"REC_0015580","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":4.0,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":51,"primary_tumor_size_cm":5.8,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.330941+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_850305","record_id":"REC_0015581","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":19,"tmb_mutations_per_mb":8.4,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":4.0,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":29.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.331379+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_535403","record_id":"REC_0015582","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":13.3,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":5.1,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.332046+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_996133","record_id":"REC_0015583","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":7.6,"age_at_diagnosis":80,"sex":"male","ecog_performance_status":2,"smoking_pack_years":20,"primary_tumor_size_cm":6.5,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.332562+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_192530","record_id":"REC_0015584","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":11.0,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":6.6,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.332967+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_895199","record_id":"REC_0015585","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":13.8,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":5.5,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":42.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.333347+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_388905","record_id":"REC_0015586","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":10,"primary_tumor_size_cm":4.6,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":24.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.333693+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_335118","record_id":"REC_0015587","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":33,"tmb_mutations_per_mb":17.8,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":4.3,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":19.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.334078+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_705326","record_id":"REC_0015588","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":9.5,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":4.6,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":24.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.334708+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_922006","record_id":"REC_0015589","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":4.3,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":29.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.335158+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_151949","record_id":"REC_0015590","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":20.2,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":5.4,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.335549+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_888196","record_id":"REC_0015591","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":3,"smoking_pack_years":51,"primary_tumor_size_cm":5.6,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.338583+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_500204","record_id":"REC_0015592","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":24,"primary_tumor_size_cm":5.8,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.339071+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_837535","record_id":"REC_0015593","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":73,"primary_tumor_size_cm":5.6,"metastatic_sites_count":3,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.339479+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_737176","record_id":"REC_0015594","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":6.3,"age_at_diagnosis":78,"sex":"male","ecog_performance_status":1,"smoking_pack_years":61,"primary_tumor_size_cm":4.8,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":39.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.339877+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_925247","record_id":"REC_0015595","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":5.7,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.340574+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_434943","record_id":"REC_0015596","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":38,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":30,"primary_tumor_size_cm":6.0,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":7.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.341035+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_435524","record_id":"REC_0015597","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":90,"sex":"female","ecog_performance_status":2,"smoking_pack_years":8,"primary_tumor_size_cm":3.5,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.341422+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_770225","record_id":"REC_0015598","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":34,"tmb_mutations_per_mb":6.9,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":5.7,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.341796+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_820747","record_id":"REC_0015599","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":78,"sex":"male","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":5.1,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.342190+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_514141","record_id":"REC_0015600","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":20,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":1,"smoking_pack_years":26,"primary_tumor_size_cm":5.8,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.342627+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_923788","record_id":"REC_0015601","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":14,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":5.5,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":43.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.343436+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_532959","record_id":"REC_0015602","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":5.7,"age_at_diagnosis":51,"sex":"female","ecog_performance_status":0,"smoking_pack_years":30,"primary_tumor_size_cm":8.2,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.343869+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_693889","record_id":"REC_0015603","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":6.5,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.344322+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_401410","record_id":"REC_0015604","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":4.3,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":6.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.344728+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_520141","record_id":"REC_0015605","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":6.3,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":7.4,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":16.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.345110+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_914864","record_id":"REC_0015606","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":33,"tmb_mutations_per_mb":10.0,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":4.8,"metastatic_sites_count":3,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.345480+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_675185","record_id":"REC_0015607","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":5.5,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.345868+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_767511","record_id":"REC_0015608","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":4.7,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":4.9,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":19.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.346257+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_612628","record_id":"REC_0015609","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":33,"tmb_mutations_per_mb":15.6,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":4.8,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":18.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.346652+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_822503","record_id":"REC_0015610","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":6.4,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.347042+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_274042","record_id":"REC_0015611","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":6.1,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.347430+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_527447","record_id":"REC_0015612","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":4.7,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.347834+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_836577","record_id":"REC_0015613","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":54,"sex":"male","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":6.2,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":17.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.348487+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_700266","record_id":"REC_0015614","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":6.8,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.349137+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_370690","record_id":"REC_0015615","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":5.5,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":5.1,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":23.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.349578+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_546505","record_id":"REC_0015616","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":2.4,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":29,"primary_tumor_size_cm":6.3,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.349943+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_201199","record_id":"REC_0015617","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":17.2,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":2,"smoking_pack_years":8,"primary_tumor_size_cm":6.4,"metastatic_sites_count":8,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":7.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.350314+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_106664","record_id":"REC_0015618","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":6.0,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":2,"smoking_pack_years":22,"primary_tumor_size_cm":5.3,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.350666+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_139265","record_id":"REC_0015619","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":6.6,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":7.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.351061+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_958483","record_id":"REC_0015620","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":4.6,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.351436+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_455798","record_id":"REC_0015621","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":16.2,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":4.8,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.351795+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_750330","record_id":"REC_0015622","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":1.9,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":4.8,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.352281+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_944982","record_id":"REC_0015623","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":4.2,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":50,"primary_tumor_size_cm":4.8,"metastatic_sites_count":8,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.352706+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_805157","record_id":"REC_0015624","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":83,"primary_tumor_size_cm":5.5,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.353088+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_808926","record_id":"REC_0015625","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":8.1,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":6.6,"metastatic_sites_count":3,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":6.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.353492+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_838944","record_id":"REC_0015626","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":5.6,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":7.5,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.356369+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_755831","record_id":"REC_0015627","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":15.4,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":1,"smoking_pack_years":3,"primary_tumor_size_cm":5.5,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.359334+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_712273","record_id":"REC_0015628","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":4.0,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.359831+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_853506","record_id":"REC_0015629","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":30,"tmb_mutations_per_mb":11.5,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":5.5,"metastatic_sites_count":8,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":5.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.360362+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_719124","record_id":"REC_0015630","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":2,"smoking_pack_years":60,"primary_tumor_size_cm":4.7,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.361071+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_123865","record_id":"REC_0015631","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":19,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":0,"smoking_pack_years":47,"primary_tumor_size_cm":5.7,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":22.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.361525+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_549745","record_id":"REC_0015632","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":16.0,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":4.1,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.361944+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_978772","record_id":"REC_0015633","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":20,"primary_tumor_size_cm":4.6,"metastatic_sites_count":8,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.362363+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_328768","record_id":"REC_0015634","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":5.3,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.362787+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_755400","record_id":"REC_0015635","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":30,"tmb_mutations_per_mb":9.8,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":20,"primary_tumor_size_cm":5.7,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":34.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.363196+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_350695","record_id":"REC_0015636","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":4.2,"metastatic_sites_count":3,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.363895+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_988035","record_id":"REC_0015637","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":7.3,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":9,"primary_tumor_size_cm":4.5,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":31.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.364543+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_671348","record_id":"REC_0015638","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":34,"tmb_mutations_per_mb":5.1,"age_at_diagnosis":90,"sex":"male","ecog_performance_status":1,"smoking_pack_years":3,"primary_tumor_size_cm":5.6,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":18.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.365288+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_561419","record_id":"REC_0015639","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":35,"tmb_mutations_per_mb":15.7,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":6.5,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":17.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.365734+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_878852","record_id":"REC_0015640","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":13.6,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":7.1,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.366366+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_931099","record_id":"REC_0015641","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":4.8,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":17.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.366794+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_175067","record_id":"REC_0015642","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":19,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":4,"primary_tumor_size_cm":7.1,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.367214+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_188599","record_id":"REC_0015643","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":4.7,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":23.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.367569+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_559641","record_id":"REC_0015644","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":20,"tmb_mutations_per_mb":16.0,"age_at_diagnosis":54,"sex":"male","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":5.2,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.367934+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_242255","record_id":"REC_0015645","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":9.7,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":5.0,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.368439+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_189650","record_id":"REC_0015646","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":18,"tmb_mutations_per_mb":8.5,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.3,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.368831+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_166442","record_id":"REC_0015647","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":5.5,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":39,"primary_tumor_size_cm":5.1,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.371396+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_346466","record_id":"REC_0015648","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":0,"smoking_pack_years":36,"primary_tumor_size_cm":5.5,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.372537+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_111398","record_id":"REC_0015649","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":4.1,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":3,"smoking_pack_years":40,"primary_tumor_size_cm":6.5,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.373010+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_593180","record_id":"REC_0015650","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":4.7,"age_at_diagnosis":43,"sex":"female","ecog_performance_status":0,"smoking_pack_years":35,"primary_tumor_size_cm":5.9,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.373370+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_168201","record_id":"REC_0015651","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":5.0,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.373721+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_127659","record_id":"REC_0015652","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":22.8,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":7,"primary_tumor_size_cm":3.4,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.374232+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_772925","record_id":"REC_0015653","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":20,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":3.7,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.374841+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_842221","record_id":"REC_0015654","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":24,"primary_tumor_size_cm":5.9,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":16.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.375279+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_681631","record_id":"REC_0015655","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":4,"primary_tumor_size_cm":6.2,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.375706+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_232205","record_id":"REC_0015656","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":8.5,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":57,"primary_tumor_size_cm":8.3,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":16.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.376249+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_634989","record_id":"REC_0015657","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":7.2,"metastatic_sites_count":8,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":6.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.376686+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_583789","record_id":"REC_0015658","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":6.8,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":17.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.377047+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_413876","record_id":"REC_0015659","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":16.1,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":6.0,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.377398+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_807558","record_id":"REC_0015660","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":15.8,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.9,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":20.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.377732+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_438135","record_id":"REC_0015661","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":4.1,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":32,"primary_tumor_size_cm":5.2,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":7.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.378081+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_648212","record_id":"REC_0015662","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":41,"primary_tumor_size_cm":4.2,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":19.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.378466+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_227809","record_id":"REC_0015663","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":1,"smoking_pack_years":29,"primary_tumor_size_cm":5.5,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":7.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.378848+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_381883","record_id":"REC_0015664","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":18.9,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":6.5,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.379256+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_165019","record_id":"REC_0015665","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":16.4,"age_at_diagnosis":85,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":4.2,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.379657+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_668813","record_id":"REC_0015666","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":18,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":4.9,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.380404+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_519488","record_id":"REC_0015667","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":15.9,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":0,"smoking_pack_years":28,"primary_tumor_size_cm":6.2,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":19.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.381134+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_509954","record_id":"REC_0015668","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":4.6,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":67,"primary_tumor_size_cm":6.8,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":27.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.381810+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_528775","record_id":"REC_0015669","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":31,"tmb_mutations_per_mb":5.6,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":1,"smoking_pack_years":66,"primary_tumor_size_cm":6.7,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":17.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.382270+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_263230","record_id":"REC_0015670","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":19,"tmb_mutations_per_mb":22.5,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":2.0,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.382692+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_604788","record_id":"REC_0015671","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":17.4,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":6.4,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.383087+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_745200","record_id":"REC_0015672","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":8.1,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":29,"primary_tumor_size_cm":6.4,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.383464+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_121333","record_id":"REC_0015673","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":18,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":2,"smoking_pack_years":10,"primary_tumor_size_cm":4.5,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.383836+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_193187","record_id":"REC_0015674","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":15.7,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":6.2,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.384302+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_769576","record_id":"REC_0015675","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":5.6,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.384703+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_590877","record_id":"REC_0015676","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":4,"primary_tumor_size_cm":7.1,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":17.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.385081+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_583802","record_id":"REC_0015677","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":4.0,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.387670+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_534326","record_id":"REC_0015678","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":8.3,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":6.7,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.388666+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_626991","record_id":"REC_0015679","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":4.0,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.389320+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_116495","record_id":"REC_0015680","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":9.1,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":4.8,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":30.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.389740+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_491208","record_id":"REC_0015681","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":9.0,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":4.4,"metastatic_sites_count":9,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":6.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.390130+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_350655","record_id":"REC_0015682","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":5.9,"age_at_diagnosis":54,"sex":"female","ecog_performance_status":0,"smoking_pack_years":61,"primary_tumor_size_cm":6.6,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":16.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.390466+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_282924","record_id":"REC_0015683","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":5.8,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.390817+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_298121","record_id":"REC_0015684","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":18,"tmb_mutations_per_mb":14.6,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":6.2,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.391160+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_996674","record_id":"REC_0015685","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":77,"sex":"male","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":5.9,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.391488+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_164397","record_id":"REC_0015686","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":19,"tmb_mutations_per_mb":4.5,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":5.5,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.391822+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_845625","record_id":"REC_0015687","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":5.8,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.392237+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_938112","record_id":"REC_0015688","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":20,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":3,"smoking_pack_years":21,"primary_tumor_size_cm":4.4,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":17.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.392640+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_743961","record_id":"REC_0015689","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":14.1,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":0,"smoking_pack_years":3,"primary_tumor_size_cm":6.2,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.393020+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_703879","record_id":"REC_0015690","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":9.0,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":25,"primary_tumor_size_cm":5.7,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.393391+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_347664","record_id":"REC_0015691","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":5.6,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":44,"primary_tumor_size_cm":5.7,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":33.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.393750+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_267653","record_id":"REC_0015692","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":4.8,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.7,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.394306+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_903629","record_id":"REC_0015693","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":15,"tmb_mutations_per_mb":7.3,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":5.0,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":48.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.394694+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_549790","record_id":"REC_0015694","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":5.1,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.395086+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_956608","record_id":"REC_0015695","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":5.5,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":23.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.395457+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_428737","record_id":"REC_0015696","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":8.4,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":7.1,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.395806+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_596905","record_id":"REC_0015697","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":17,"tmb_mutations_per_mb":17.4,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":1,"smoking_pack_years":4,"primary_tumor_size_cm":6.7,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.396323+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_569673","record_id":"REC_0015698","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":45,"sex":"male","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":3.9,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.396696+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_550706","record_id":"REC_0015699","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":5.7,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":30.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.397058+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_653436","record_id":"REC_0015700","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":6.0,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.397435+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_386549","record_id":"REC_0015701","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":9.1,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":6.2,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":8.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.397794+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_699397","record_id":"REC_0015702","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":6.3,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.398140+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_176055","record_id":"REC_0015703","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":18,"tmb_mutations_per_mb":3.8,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":36,"primary_tumor_size_cm":3.8,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.398526+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_896085","record_id":"REC_0015704","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":16,"tmb_mutations_per_mb":14.6,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":6.3,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":20.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.398939+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_798669","record_id":"REC_0015705","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":16.5,"age_at_diagnosis":84,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":2.7,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":22.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.399583+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_787459","record_id":"REC_0015706","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":5.0,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":6.2,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":7.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.400023+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_780093","record_id":"REC_0015707","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":1,"smoking_pack_years":24,"primary_tumor_size_cm":6.5,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":6.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.400713+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_974131","record_id":"REC_0015708","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":48,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":5.1,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.401157+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_596674","record_id":"REC_0015709","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":8.5,"age_at_diagnosis":83,"sex":"male","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":7.2,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":23.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.402229+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_450005","record_id":"REC_0015710","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":0,"primary_tumor_size_cm":5.6,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":17.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.402698+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_614549","record_id":"REC_0015711","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":14.8,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":5.6,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":7.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.403158+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_528423","record_id":"REC_0015712","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":4.7,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":6.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.403601+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_933096","record_id":"REC_0015713","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":20,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":0,"smoking_pack_years":38,"primary_tumor_size_cm":4.8,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":5.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.404046+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_101384","record_id":"REC_0015714","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":4.8,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":2,"primary_tumor_size_cm":6.8,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":20.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.404587+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_713565","record_id":"REC_0015715","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":6.3,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":2,"smoking_pack_years":10,"primary_tumor_size_cm":5.6,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.405134+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_154323","record_id":"REC_0015716","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":5.4,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":6.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.405524+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_217214","record_id":"REC_0015717","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":30,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":3,"smoking_pack_years":22,"primary_tumor_size_cm":6.9,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":5.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.405912+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_265390","record_id":"REC_0015718","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":16.8,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":6.2,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.406522+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_665010","record_id":"REC_0015719","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":7.2,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":26.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.406917+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_445042","record_id":"REC_0015720","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":3.6,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.407281+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_352395","record_id":"REC_0015721","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":3.9,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":37,"primary_tumor_size_cm":6.5,"metastatic_sites_count":3,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":16.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.407644+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_444795","record_id":"REC_0015722","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":13.6,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":0,"smoking_pack_years":5,"primary_tumor_size_cm":7.4,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.408002+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_129808","record_id":"REC_0015723","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":15,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":0,"primary_tumor_size_cm":6.7,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":24.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.408443+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_967230","record_id":"REC_0015724","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":15.4,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":0,"smoking_pack_years":29,"primary_tumor_size_cm":5.3,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.408903+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_841984","record_id":"REC_0015725","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":3,"smoking_pack_years":13,"primary_tumor_size_cm":5.2,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.409342+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_147588","record_id":"REC_0015726","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":4.6,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":26,"primary_tumor_size_cm":4.4,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":6.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.409749+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_866954","record_id":"REC_0015727","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":6.8,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.410145+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_224924","record_id":"REC_0015728","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":6.5,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.410522+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_566550","record_id":"REC_0015729","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":18,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":34,"primary_tumor_size_cm":5.3,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.410941+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_696399","record_id":"REC_0015730","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":15.9,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":4.1,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":22.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.411382+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_290605","record_id":"REC_0015731","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":7.1,"metastatic_sites_count":3,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.411996+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_474337","record_id":"REC_0015732","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":6.0,"age_at_diagnosis":75,"sex":"male","ecog_performance_status":2,"smoking_pack_years":29,"primary_tumor_size_cm":4.1,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.412601+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_121609","record_id":"REC_0015733","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":34,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":84,"sex":"female","ecog_performance_status":2,"smoking_pack_years":27,"primary_tumor_size_cm":7.2,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.412995+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_940026","record_id":"REC_0015734","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":6.7,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":5.8,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.413402+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_734421","record_id":"REC_0015735","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":30,"tmb_mutations_per_mb":5.3,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":58,"primary_tumor_size_cm":4.0,"metastatic_sites_count":8,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.413774+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_350142","record_id":"REC_0015736","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":18.5,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":3,"smoking_pack_years":0,"primary_tumor_size_cm":6.0,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":20.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.414126+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_158103","record_id":"REC_0015737","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":4.7,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":3,"smoking_pack_years":43,"primary_tumor_size_cm":6.5,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.414452+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_844487","record_id":"REC_0015738","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":79,"primary_tumor_size_cm":6.7,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.414787+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_686541","record_id":"REC_0015739","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":4.0,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":24.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.415171+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_124489","record_id":"REC_0015740","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":6.4,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.415560+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_281226","record_id":"REC_0015741","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":7.6,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":4.4,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":20.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.415935+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_963266","record_id":"REC_0015742","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":32,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":30,"primary_tumor_size_cm":3.9,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.416740+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_405762","record_id":"REC_0015743","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":2,"smoking_pack_years":22,"primary_tumor_size_cm":4.9,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.417324+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_351834","record_id":"REC_0015744","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":9.7,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":7.1,"metastatic_sites_count":8,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":8.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.417985+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_930090","record_id":"REC_0015745","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":30,"tmb_mutations_per_mb":8.1,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":21,"primary_tumor_size_cm":7.7,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":23.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.418461+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_239715","record_id":"REC_0015746","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":10,"primary_tumor_size_cm":5.7,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.418884+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_515459","record_id":"REC_0015747","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":14.3,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":4.5,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":36.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.419317+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_226072","record_id":"REC_0015748","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":12,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":5,"primary_tumor_size_cm":4.1,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":7.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.419712+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_421541","record_id":"REC_0015749","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":14.9,"age_at_diagnosis":50,"sex":"male","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":5.9,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.420190+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_794822","record_id":"REC_0015750","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":5.6,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.420612+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_669278","record_id":"REC_0015751","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":15,"tmb_mutations_per_mb":8.7,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":7.0,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":52.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.421017+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_895493","record_id":"REC_0015752","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":34,"primary_tumor_size_cm":5.2,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.421407+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_791825","record_id":"REC_0015753","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":31,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":50,"sex":"female","ecog_performance_status":0,"smoking_pack_years":35,"primary_tumor_size_cm":4.8,"metastatic_sites_count":8,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":6.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.421793+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_322782","record_id":"REC_0015754","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":17,"tmb_mutations_per_mb":5.9,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":50,"primary_tumor_size_cm":7.1,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":16.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.423245+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_864507","record_id":"REC_0015755","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":4.3,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.423710+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_552153","record_id":"REC_0015756","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":31,"primary_tumor_size_cm":5.6,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.424234+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_543404","record_id":"REC_0015757","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":6.1,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":38.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.424913+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_545543","record_id":"REC_0015758","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":18,"tmb_mutations_per_mb":5.7,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":2,"smoking_pack_years":70,"primary_tumor_size_cm":4.1,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":30.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.425363+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_641642","record_id":"REC_0015759","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":3.8,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.425822+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_226192","record_id":"REC_0015760","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":9.5,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":24,"primary_tumor_size_cm":5.9,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.426268+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_677751","record_id":"REC_0015761","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":4.9,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":6.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.426673+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_627037","record_id":"REC_0015762","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":3,"smoking_pack_years":4,"primary_tumor_size_cm":5.3,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.427096+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_430683","record_id":"REC_0015763","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":15.2,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":6.7,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.427485+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_685803","record_id":"REC_0015764","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":31,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":6.3,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.427878+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_256701","record_id":"REC_0015765","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":16.7,"age_at_diagnosis":83,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":6.1,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":19.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.428347+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_731066","record_id":"REC_0015766","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":15.7,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":4.7,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":4.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.428717+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_335477","record_id":"REC_0015767","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":14.8,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":4.8,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.429197+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_738554","record_id":"REC_0015768","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":1.5,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":3,"smoking_pack_years":9,"primary_tumor_size_cm":5.3,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":26.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.429650+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_997549","record_id":"REC_0015769","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":4.2,"metastatic_sites_count":8,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.430009+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_620076","record_id":"REC_0015770","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":15.4,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":6.7,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.430579+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_892831","record_id":"REC_0015771","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":10.0,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":5.6,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.431019+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_562945","record_id":"REC_0015772","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":20.7,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":6.5,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.431437+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_846206","record_id":"REC_0015773","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":16,"tmb_mutations_per_mb":9.0,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":6.7,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.431829+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_247361","record_id":"REC_0015774","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":15.6,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":6.8,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":27.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.432343+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_105311","record_id":"REC_0015775","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":4.8,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":5.2,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":7.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.432798+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_185143","record_id":"REC_0015776","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":4.3,"metastatic_sites_count":9,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":7.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.433244+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_285060","record_id":"REC_0015777","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":5.5,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.433689+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_228320","record_id":"REC_0015778","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":30,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":5.0,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.434106+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_833558","record_id":"REC_0015779","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":5.8,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.434523+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_242477","record_id":"REC_0015780","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":31,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":4.8,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.434921+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_547099","record_id":"REC_0015781","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":4.1,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":0,"smoking_pack_years":87,"primary_tumor_size_cm":6.5,"metastatic_sites_count":3,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.435292+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_326701","record_id":"REC_0015782","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":14.4,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":4.7,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.435669+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_609076","record_id":"REC_0015783","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":11.1,"age_at_diagnosis":80,"sex":"male","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":7.2,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.436387+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_743298","record_id":"REC_0015784","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":6.3,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":50.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.436835+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_458408","record_id":"REC_0015785","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":0,"smoking_pack_years":4,"primary_tumor_size_cm":5.2,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.437245+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_209497","record_id":"REC_0015786","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":14,"tmb_mutations_per_mb":17.7,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":5.2,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":20.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.437632+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_576769","record_id":"REC_0015787","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":16,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":50,"sex":"male","ecog_performance_status":0,"smoking_pack_years":28,"primary_tumor_size_cm":5.0,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.438015+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_446495","record_id":"REC_0015788","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":6.3,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":30,"primary_tumor_size_cm":3.1,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":39.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.438398+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_818108","record_id":"REC_0015789","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":26,"primary_tumor_size_cm":3.4,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":16.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.438754+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_667070","record_id":"REC_0015790","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":33,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":5.0,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":16.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.439134+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_806712","record_id":"REC_0015791","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":20,"tmb_mutations_per_mb":10.0,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":48,"primary_tumor_size_cm":5.3,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.439525+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_859353","record_id":"REC_0015792","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":53,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":5.8,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.439885+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_385490","record_id":"REC_0015793","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":7.0,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.440324+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_730626","record_id":"REC_0015794","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":9.0,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":5.3,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.440713+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_679220","record_id":"REC_0015795","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":16,"tmb_mutations_per_mb":16.9,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":6.8,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.441100+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_778668","record_id":"REC_0015796","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":20,"tmb_mutations_per_mb":4.6,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":3.7,"metastatic_sites_count":8,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":4.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.441640+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_918359","record_id":"REC_0015797","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":14.0,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":5.4,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":7.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.442080+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_915360","record_id":"REC_0015798","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":14.3,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":3,"smoking_pack_years":22,"primary_tumor_size_cm":6.8,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.442482+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_242162","record_id":"REC_0015799","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":8.4,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":38,"primary_tumor_size_cm":5.4,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.442877+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_849935","record_id":"REC_0015800","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":27,"primary_tumor_size_cm":5.2,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.443270+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_632591","record_id":"REC_0015801","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":3.9,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":1,"smoking_pack_years":34,"primary_tumor_size_cm":5.9,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":18.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.443698+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_502655","record_id":"REC_0015802","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":15.8,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":7.4,"metastatic_sites_count":8,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.444186+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_163985","record_id":"REC_0015803","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ALK fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":54,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":4.1,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":50.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.444618+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_951723","record_id":"REC_0015804","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":14.3,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":1,"smoking_pack_years":25,"primary_tumor_size_cm":2.7,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.445050+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_887242","record_id":"REC_0015805","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":4.7,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.445451+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_169044","record_id":"REC_0015806","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":14.6,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":4.6,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.445876+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_528831","record_id":"REC_0015807","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":18,"tmb_mutations_per_mb":5.0,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":65,"primary_tumor_size_cm":5.7,"metastatic_sites_count":8,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":7.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.446285+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_448557","record_id":"REC_0015808","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":27,"primary_tumor_size_cm":6.0,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":20.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.446679+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_389154","record_id":"REC_0015809","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":31,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":1,"primary_tumor_size_cm":4.4,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":18.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.447296+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_688601","record_id":"REC_0015810","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":19,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":6.7,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":17.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.447714+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_719130","record_id":"REC_0015811","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":3.8,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":2,"smoking_pack_years":66,"primary_tumor_size_cm":5.1,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.448243+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_765527","record_id":"REC_0015812","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":5.6,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.448680+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_433947","record_id":"REC_0015813","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":11.0,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":6.1,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":6.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.449129+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_806392","record_id":"REC_0015814","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":5.6,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.449528+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_115166","record_id":"REC_0015815","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":2.9,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":6.2,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":17.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.449906+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_161864","record_id":"REC_0015816","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":30,"tmb_mutations_per_mb":3.7,"age_at_diagnosis":74,"sex":"male","ecog_performance_status":2,"smoking_pack_years":77,"primary_tumor_size_cm":8.3,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.450254+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_222057","record_id":"REC_0015817","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":5.8,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.450639+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_162602","record_id":"REC_0015818","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":50,"primary_tumor_size_cm":3.9,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.450994+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_123359","record_id":"REC_0015819","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ALK fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":13.5,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":7.1,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":44.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.451615+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_889382","record_id":"REC_0015820","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":10.3,"age_at_diagnosis":84,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":7.4,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.452119+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_565865","record_id":"REC_0015821","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":4.1,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.452563+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_132200","record_id":"REC_0015822","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":4.9,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":68,"primary_tumor_size_cm":6.1,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":4.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.453160+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_934871","record_id":"REC_0015823","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":9.7,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":5.1,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":21.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.453624+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_702156","record_id":"REC_0015824","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":43,"primary_tumor_size_cm":6.8,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.454027+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_987697","record_id":"REC_0015825","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":19.6,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":5.2,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.454418+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_296060","record_id":"REC_0015826","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":34,"tmb_mutations_per_mb":14.8,"age_at_diagnosis":51,"sex":"female","ecog_performance_status":0,"smoking_pack_years":5,"primary_tumor_size_cm":4.8,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.454788+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_222249","record_id":"REC_0015827","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":6.0,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.455179+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_755198","record_id":"REC_0015828","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":17.9,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":5.4,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":34.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.455565+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_397152","record_id":"REC_0015829","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":4.5,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.455949+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_800417","record_id":"REC_0015830","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":30,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":3,"smoking_pack_years":14,"primary_tumor_size_cm":4.2,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.456391+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_578314","record_id":"REC_0015831","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.9,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":16.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.456815+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_903747","record_id":"REC_0015832","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":15.3,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":5.4,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":23.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.457221+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_845616","record_id":"REC_0015833","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":18,"tmb_mutations_per_mb":15.0,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":5.6,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.457612+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_125261","record_id":"REC_0015834","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":14,"tmb_mutations_per_mb":20.0,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":6.8,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":21.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.458001+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_722695","record_id":"REC_0015835","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":10.5,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":3.9,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.458608+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_951844","record_id":"REC_0015836","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":31,"tmb_mutations_per_mb":8.7,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":4.1,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.459061+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_575944","record_id":"REC_0015837","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":4.7,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.459475+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_517373","record_id":"REC_0015838","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":31,"tmb_mutations_per_mb":8.0,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":6.0,"metastatic_sites_count":8,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.459929+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_426834","record_id":"REC_0015839","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":4.9,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.461150+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_275736","record_id":"REC_0015840","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":14.5,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.5,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.461628+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_340233","record_id":"REC_0015841","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":10.3,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":5.2,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.462029+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_271067","record_id":"REC_0015842","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":4.9,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.462459+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_967357","record_id":"REC_0015843","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":4.0,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":5.0,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.462851+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_804659","record_id":"REC_0015844","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":20,"primary_tumor_size_cm":5.6,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.463433+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_223718","record_id":"REC_0015845","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":5.9,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.463919+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_896112","record_id":"REC_0015846","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":3,"primary_tumor_size_cm":4.9,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":7.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.464641+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_631949","record_id":"REC_0015847","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":5.3,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.465305+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_108020","record_id":"REC_0015848","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":13.3,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":6.1,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.466076+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_647957","record_id":"REC_0015849","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":18,"tmb_mutations_per_mb":9.8,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":1,"smoking_pack_years":28,"primary_tumor_size_cm":5.9,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.466557+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_278340","record_id":"REC_0015850","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":16,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":5.6,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":17.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.466999+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_430152","record_id":"REC_0015851","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":17,"tmb_mutations_per_mb":5.9,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.5,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":6.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.467446+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_488052","record_id":"REC_0015852","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":8.6,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.467883+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_986626","record_id":"REC_0015853","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":31,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":4.1,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":22.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.468485+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_116938","record_id":"REC_0015854","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":9.1,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":6.7,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.468955+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_539205","record_id":"REC_0015855","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":7.5,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":8.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.469389+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_603108","record_id":"REC_0015856","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":4.2,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.469845+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_761198","record_id":"REC_0015857","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":5,"primary_tumor_size_cm":5.9,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":20.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.470246+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_438236","record_id":"REC_0015858","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":14.0,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.4,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":5.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.470590+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_326044","record_id":"REC_0015859","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":19,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":0,"smoking_pack_years":5,"primary_tumor_size_cm":5.7,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.471060+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_648399","record_id":"REC_0015860","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":4,"primary_tumor_size_cm":4.5,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.471727+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_686642","record_id":"REC_0015861","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":5.5,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.472919+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_123049","record_id":"REC_0015862","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":10.0,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":5,"primary_tumor_size_cm":5.5,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.473457+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_723141","record_id":"REC_0015863","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":7.6,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.473959+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_518324","record_id":"REC_0015864","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":51,"sex":"male","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":5.1,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":16.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.474397+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_142911","record_id":"REC_0015865","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":19,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":7.2,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":27.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.474832+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_402439","record_id":"REC_0015866","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":17.3,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":5.5,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":24.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.475243+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_359695","record_id":"REC_0015867","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":80,"sex":"male","ecog_performance_status":2,"smoking_pack_years":8,"primary_tumor_size_cm":2.6,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.475658+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_573681","record_id":"REC_0015868","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":2.7,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":6.0,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.476047+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_964005","record_id":"REC_0015869","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":1,"smoking_pack_years":0,"primary_tumor_size_cm":5.4,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.476492+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_326563","record_id":"REC_0015870","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":17.2,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":3,"smoking_pack_years":13,"primary_tumor_size_cm":6.0,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.476917+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_764875","record_id":"REC_0015871","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":53,"sex":"male","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":7.2,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.477331+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_443336","record_id":"REC_0015872","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":19.9,"age_at_diagnosis":54,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":7.6,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.477746+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_910576","record_id":"REC_0015873","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":7.3,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":67,"primary_tumor_size_cm":4.4,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.478136+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_330806","record_id":"REC_0015874","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":19.8,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":3.7,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.478756+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_970934","record_id":"REC_0015875","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":15.6,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":3.9,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":6.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.479184+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_967734","record_id":"REC_0015876","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":14,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":3.8,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.479764+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_626182","record_id":"REC_0015877","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":5,"primary_tumor_size_cm":4.4,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.480320+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_210452","record_id":"REC_0015878","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":15,"tmb_mutations_per_mb":4.7,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":5.7,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.480740+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_494440","record_id":"REC_0015879","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":56,"primary_tumor_size_cm":3.6,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.481157+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_220139","record_id":"REC_0015880","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":8.1,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":4.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.481593+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_313469","record_id":"REC_0015881","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":6.4,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":1,"smoking_pack_years":67,"primary_tumor_size_cm":5.8,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.482007+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_251558","record_id":"REC_0015882","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":7.4,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":3,"smoking_pack_years":19,"primary_tumor_size_cm":7.5,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":22.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.482415+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_179950","record_id":"REC_0015883","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":2.8,"age_at_diagnosis":53,"sex":"male","ecog_performance_status":0,"smoking_pack_years":53,"primary_tumor_size_cm":6.4,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":4.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.482810+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_589808","record_id":"REC_0015884","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":17.4,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":5.9,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.483168+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_116951","record_id":"REC_0015885","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":16.5,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":6.7,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.483565+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_488092","record_id":"REC_0015886","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":5.9,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.483976+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_783060","record_id":"REC_0015887","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":4.6,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":60,"primary_tumor_size_cm":7.1,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.484609+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_331859","record_id":"REC_0015888","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":33,"tmb_mutations_per_mb":6.4,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":36,"primary_tumor_size_cm":6.0,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":22.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.485059+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_968942","record_id":"REC_0015889","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":7.5,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":23.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.485445+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_493675","record_id":"REC_0015890","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":5.0,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":5.8,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.485836+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_977266","record_id":"REC_0015891","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":16.1,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":5.2,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.486265+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_230057","record_id":"REC_0015892","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":8.1,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":5.3,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.486658+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_436990","record_id":"REC_0015893","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":8.4,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":5.4,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.487047+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_144988","record_id":"REC_0015894","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":15.0,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":5.4,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.487418+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_648630","record_id":"REC_0015895","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":31,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":5.2,"metastatic_sites_count":8,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.487783+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_657440","record_id":"REC_0015896","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":5.0,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":58,"primary_tumor_size_cm":6.4,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":25.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.488214+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_711938","record_id":"REC_0015897","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":5.8,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.488615+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_559537","record_id":"REC_0015898","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":4.6,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":20.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.489000+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_883252","record_id":"REC_0015899","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":6.1,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.489383+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_961653","record_id":"REC_0015900","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":6.9,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":21.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.489948+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_392950","record_id":"REC_0015901","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.9,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.490347+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_450160","record_id":"REC_0015902","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":7.0,"metastatic_sites_count":3,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":19.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.490724+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_422485","record_id":"REC_0015903","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":6.5,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.491096+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_513695","record_id":"REC_0015904","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":83,"sex":"male","ecog_performance_status":2,"smoking_pack_years":57,"primary_tumor_size_cm":3.8,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.491497+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_583420","record_id":"REC_0015905","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":20.5,"age_at_diagnosis":85,"sex":"female","ecog_performance_status":2,"smoking_pack_years":0,"primary_tumor_size_cm":6.7,"metastatic_sites_count":8,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.491909+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_200958","record_id":"REC_0015906","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":18.9,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":6.8,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":31.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.492389+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_724647","record_id":"REC_0015907","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":8.3,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":6.0,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":26.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.492787+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_756155","record_id":"REC_0015908","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":32,"tmb_mutations_per_mb":8.4,"age_at_diagnosis":76,"sex":"male","ecog_performance_status":1,"smoking_pack_years":28,"primary_tumor_size_cm":5.8,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.493153+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_703324","record_id":"REC_0015909","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":16.0,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":4.8,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":18.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.493535+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_651432","record_id":"REC_0015910","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":16,"tmb_mutations_per_mb":4.6,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":0,"smoking_pack_years":74,"primary_tumor_size_cm":4.5,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":21.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.493917+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_245375","record_id":"REC_0015911","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":19.8,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":7.2,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.494283+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_815252","record_id":"REC_0015912","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":15.9,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":3,"smoking_pack_years":13,"primary_tumor_size_cm":5.0,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":8.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.494691+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_764715","record_id":"REC_0015913","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":31,"tmb_mutations_per_mb":15.8,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":4.8,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.495284+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_804584","record_id":"REC_0015914","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":30,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":5.4,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.495673+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_310025","record_id":"REC_0015915","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":6.8,"metastatic_sites_count":8,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.496291+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_658917","record_id":"REC_0015916","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":3.5,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":0,"smoking_pack_years":47,"primary_tumor_size_cm":5.8,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.496837+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_293271","record_id":"REC_0015917","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":6.4,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":5.5,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.497214+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_546283","record_id":"REC_0015918","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":10.0,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":4.4,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.497628+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_480381","record_id":"REC_0015919","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":4.2,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.497973+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_182765","record_id":"REC_0015920","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":13.1,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":3,"smoking_pack_years":27,"primary_tumor_size_cm":6.1,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.498381+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_220088","record_id":"REC_0015921","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":18.5,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":6.4,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":5.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.498765+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_412608","record_id":"REC_0015922","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":6.3,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":5.9,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":5.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.499139+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_700531","record_id":"REC_0015923","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":4,"primary_tumor_size_cm":5.6,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":26.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.499532+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_127297","record_id":"REC_0015924","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":4.5,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.499920+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_381172","record_id":"REC_0015925","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":13.8,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":5.5,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.500372+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_624007","record_id":"REC_0015926","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":19,"tmb_mutations_per_mb":7.3,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":2,"smoking_pack_years":68,"primary_tumor_size_cm":3.8,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.500994+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_208416","record_id":"REC_0015927","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":7.4,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":6.3,"metastatic_sites_count":8,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.501462+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_892251","record_id":"REC_0015928","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":4.8,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":1,"smoking_pack_years":31,"primary_tumor_size_cm":4.2,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":4.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.501899+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_919534","record_id":"REC_0015929","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":6.6,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":19.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.502311+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_613870","record_id":"REC_0015930","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":1,"smoking_pack_years":5,"primary_tumor_size_cm":7.3,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.502706+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_437634","record_id":"REC_0015931","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":42,"primary_tumor_size_cm":4.4,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":19.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.503089+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_540159","record_id":"REC_0015932","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":6.1,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":2,"smoking_pack_years":1,"primary_tumor_size_cm":5.0,"metastatic_sites_count":3,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":7.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.503480+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_286449","record_id":"REC_0015933","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":49,"sex":"male","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":6.4,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.503860+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_808844","record_id":"REC_0015934","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":4.6,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":50,"primary_tumor_size_cm":4.9,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.504304+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_152712","record_id":"REC_0015935","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":4.9,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":2,"primary_tumor_size_cm":4.4,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.504690+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_976979","record_id":"REC_0015936","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":8.5,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":5.5,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":21.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.505078+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_108406","record_id":"REC_0015937","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":5.5,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":51,"primary_tumor_size_cm":3.3,"metastatic_sites_count":3,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":19.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.505477+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_888819","record_id":"REC_0015938","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":32,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":6.1,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":22.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.505842+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_680984","record_id":"REC_0015939","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":8.4,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":5,"primary_tumor_size_cm":5.4,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.509355+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_366134","record_id":"REC_0015940","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":19,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":5.9,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.509874+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_346382","record_id":"REC_0015941","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":14.3,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":6.1,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.510298+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_569046","record_id":"REC_0015942","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":30,"tmb_mutations_per_mb":15.8,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":5.7,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":17.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.510743+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_778729","record_id":"REC_0015943","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":31,"tmb_mutations_per_mb":5.1,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":34,"primary_tumor_size_cm":3.5,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":23.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.511136+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_291079","record_id":"REC_0015944","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":4.7,"age_at_diagnosis":78,"sex":"male","ecog_performance_status":1,"smoking_pack_years":58,"primary_tumor_size_cm":4.1,"metastatic_sites_count":3,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":16.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.511523+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_843830","record_id":"REC_0015945","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":17,"tmb_mutations_per_mb":5.7,"age_at_diagnosis":83,"sex":"male","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":6.3,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":22.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.511886+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_899131","record_id":"REC_0015946","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":20.0,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":3.3,"metastatic_sites_count":8,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.512369+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_499426","record_id":"REC_0015947","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":7.0,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.512751+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_743679","record_id":"REC_0015948","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":3.9,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":1,"smoking_pack_years":73,"primary_tumor_size_cm":2.7,"metastatic_sites_count":8,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":6.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.513161+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_476534","record_id":"REC_0015949","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":5.5,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.513643+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_451779","record_id":"REC_0015950","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":4.8,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":23.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.515714+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_322021","record_id":"REC_0015951","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":11.5,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":6.3,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.518138+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_709094","record_id":"REC_0015952","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":4.2,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":24.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.518842+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_135528","record_id":"REC_0015953","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":31,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":52,"sex":"male","ecog_performance_status":0,"smoking_pack_years":27,"primary_tumor_size_cm":3.1,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.521331+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_795717","record_id":"REC_0015954","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":14.0,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":3.5,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":24.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.521862+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_200314","record_id":"REC_0015955","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":10.5,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.0,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.522308+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_878121","record_id":"REC_0015956","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":5.0,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":5,"primary_tumor_size_cm":6.0,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":5.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.522705+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_207268","record_id":"REC_0015957","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":8.4,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":7.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.523091+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_729196","record_id":"REC_0015958","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":7.4,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":35,"primary_tumor_size_cm":4.8,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.523495+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_584947","record_id":"REC_0015959","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":4.0,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":6.6,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.523872+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_382403","record_id":"REC_0015960","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":22,"primary_tumor_size_cm":4.9,"metastatic_sites_count":8,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":6.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.524305+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_126606","record_id":"REC_0015961","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":4.3,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.524692+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_129622","record_id":"REC_0015962","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.5,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":3.5,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.525078+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_319186","record_id":"REC_0015963","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":30,"primary_tumor_size_cm":9.3,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":5.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.525472+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_501897","record_id":"REC_0015964","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":5.1,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.525875+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_202458","record_id":"REC_0015965","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":20.2,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":4.4,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":20.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.527998+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_739516","record_id":"REC_0015966","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":4.0,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":16.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.528916+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_578888","record_id":"REC_0015967","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":7.6,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.529423+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_419680","record_id":"REC_0015968","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":13.1,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":4.8,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":35.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.529912+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_254518","record_id":"REC_0015969","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":17.8,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":6.1,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.530348+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_635976","record_id":"REC_0015970","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":7.0,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.530770+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_705032","record_id":"REC_0015971","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":3.2,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":27,"primary_tumor_size_cm":4.3,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":21.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.531140+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_195317","record_id":"REC_0015972","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":31,"tmb_mutations_per_mb":5.6,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":7.3,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.531487+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_460478","record_id":"REC_0015973","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":17.1,"age_at_diagnosis":48,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":6.5,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":22.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.531981+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_874096","record_id":"REC_0015974","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":8.0,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.532550+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_988603","record_id":"REC_0015975","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":30,"tmb_mutations_per_mb":3.2,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":26,"primary_tumor_size_cm":6.4,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":16.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.532930+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_735250","record_id":"REC_0015976","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":14.9,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":24,"primary_tumor_size_cm":5.3,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.533291+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_264558","record_id":"REC_0015977","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":9.5,"age_at_diagnosis":85,"sex":"female","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":6.4,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.533605+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_280953","record_id":"REC_0015978","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":4.3,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.534103+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_223572","record_id":"REC_0015979","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":11.1,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":21,"primary_tumor_size_cm":5.5,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.534513+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_463241","record_id":"REC_0015980","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":41,"primary_tumor_size_cm":6.4,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.534865+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_961506","record_id":"REC_0015981","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":15.2,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":3.9,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.535220+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_664826","record_id":"REC_0015982","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":3.8,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.535585+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_487900","record_id":"REC_0015983","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":4.3,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":25,"primary_tumor_size_cm":6.1,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":29.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.540999+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_956803","record_id":"REC_0015984","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":15.1,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":6.5,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.542132+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_437998","record_id":"REC_0015985","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":9.0,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":2,"smoking_pack_years":10,"primary_tumor_size_cm":6.1,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.542992+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_103807","record_id":"REC_0015986","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":6.0,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":73,"primary_tumor_size_cm":5.9,"metastatic_sites_count":3,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":17.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.543475+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_755734","record_id":"REC_0015987","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":14.1,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":4.5,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":43.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.543843+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_839105","record_id":"REC_0015988","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":4.6,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":25,"primary_tumor_size_cm":6.0,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.544223+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_168773","record_id":"REC_0015989","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":13.6,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":4.6,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.544588+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_935053","record_id":"REC_0015990","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":16.1,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":20,"primary_tumor_size_cm":5.5,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.546336+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_561121","record_id":"REC_0015991","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":15.3,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":6.5,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":8.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.547029+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_218270","record_id":"REC_0015992","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":15.1,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":5.3,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.547453+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_962147","record_id":"REC_0015993","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":4.0,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":6,"primary_tumor_size_cm":5.6,"metastatic_sites_count":9,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.548383+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_861993","record_id":"REC_0015994","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":28,"primary_tumor_size_cm":5.5,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.549004+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_502225","record_id":"REC_0015995","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":8.1,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":3.9,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":6.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.549913+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_498264","record_id":"REC_0015996","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":7.4,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":0,"smoking_pack_years":5,"primary_tumor_size_cm":5.7,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.550403+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_967920","record_id":"REC_0015997","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":10.0,"age_at_diagnosis":90,"sex":"female","ecog_performance_status":2,"smoking_pack_years":21,"primary_tumor_size_cm":4.2,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":25.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.550820+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_769834","record_id":"REC_0015998","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":26,"primary_tumor_size_cm":5.0,"metastatic_sites_count":8,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.551281+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_240407","record_id":"REC_0015999","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":4.2,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.551634+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_183062","record_id":"REC_0016000","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":74,"sex":"male","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":6.7,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.551960+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_426652","record_id":"REC_0016001","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":7.4,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":3.7,"metastatic_sites_count":3,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.554513+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_386994","record_id":"REC_0016002","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":6.7,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":74,"primary_tumor_size_cm":6.9,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.555179+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_442608","record_id":"REC_0016003","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":35,"primary_tumor_size_cm":4.8,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.555831+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_620071","record_id":"REC_0016004","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":7.4,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":9,"primary_tumor_size_cm":6.7,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":18.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.556578+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_267402","record_id":"REC_0016005","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":22,"primary_tumor_size_cm":4.2,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.556988+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_948539","record_id":"REC_0016006","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":6.7,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":7,"primary_tumor_size_cm":4.5,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.558331+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_145084","record_id":"REC_0016007","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":19,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":4.9,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.558780+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_247109","record_id":"REC_0016008","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":11.0,"age_at_diagnosis":78,"sex":"male","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":5.0,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":21.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.559173+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_826736","record_id":"REC_0016009","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":76,"sex":"male","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":6.4,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":6.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.559527+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_641322","record_id":"REC_0016010","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":9.8,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":0,"smoking_pack_years":2,"primary_tumor_size_cm":4.3,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.559863+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_844254","record_id":"REC_0016011","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":20.6,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":4.5,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":16.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.560280+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_584608","record_id":"REC_0016012","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":17,"tmb_mutations_per_mb":3.3,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":7.1,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.560695+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_535936","record_id":"REC_0016013","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":4.1,"age_at_diagnosis":79,"sex":"male","ecog_performance_status":1,"smoking_pack_years":48,"primary_tumor_size_cm":7.0,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.561088+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_489438","record_id":"REC_0016014","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":20,"tmb_mutations_per_mb":6.3,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":47,"primary_tumor_size_cm":5.7,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.561491+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_923451","record_id":"REC_0016015","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":10.0,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":7.0,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.561900+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_560829","record_id":"REC_0016016","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":6.1,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.562272+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_794401","record_id":"REC_0016017","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":8.0,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.3,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":32.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.562858+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_555552","record_id":"REC_0016018","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":3.9,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":5.7,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.563320+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_989201","record_id":"REC_0016019","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":74,"sex":"male","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":6.0,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":4.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.563752+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_604129","record_id":"REC_0016020","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":3.8,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":58,"primary_tumor_size_cm":7.2,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":51.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.564187+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_426632","record_id":"REC_0016021","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":11.0,"age_at_diagnosis":54,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":6.1,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":21.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.564637+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_874641","record_id":"REC_0016022","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":8.7,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":5.2,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":24.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.565275+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_736720","record_id":"REC_0016023","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":7.3,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.565760+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_144849","record_id":"REC_0016024","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":6.7,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":6.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.566161+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_141707","record_id":"REC_0016025","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":31,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":5.2,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.566517+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_850856","record_id":"REC_0016026","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":4.1,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.566910+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_921154","record_id":"REC_0016027","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":31,"tmb_mutations_per_mb":16.4,"age_at_diagnosis":54,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":4.2,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.567286+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_702165","record_id":"REC_0016028","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":15.3,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":5.9,"metastatic_sites_count":9,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.567658+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_241993","record_id":"REC_0016029","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":32,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":4.3,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":22.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.568454+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_156608","record_id":"REC_0016030","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":31,"tmb_mutations_per_mb":5.6,"age_at_diagnosis":74,"sex":"male","ecog_performance_status":2,"smoking_pack_years":47,"primary_tumor_size_cm":7.7,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.569105+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_661890","record_id":"REC_0016031","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":0,"primary_tumor_size_cm":5.1,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.569580+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_126124","record_id":"REC_0016032","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":15.3,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":4.9,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.570019+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_757798","record_id":"REC_0016033","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":7.0,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.570446+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_163013","record_id":"REC_0016034","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":6.1,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":4,"primary_tumor_size_cm":5.0,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":6.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.570839+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_813310","record_id":"REC_0016035","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":36,"tmb_mutations_per_mb":4.4,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":1,"smoking_pack_years":62,"primary_tumor_size_cm":5.6,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":7.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.571230+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_877062","record_id":"REC_0016036","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":6.3,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.571618+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_864750","record_id":"REC_0016037","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":7.9,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":4.2,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":23.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.572026+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_521496","record_id":"REC_0016038","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":14.7,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":5.0,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.574262+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_213077","record_id":"REC_0016039","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":4.2,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.574759+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_206309","record_id":"REC_0016040","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":3,"smoking_pack_years":12,"primary_tumor_size_cm":4.6,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":42.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.575130+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_939346","record_id":"REC_0016041","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":7.7,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.575524+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_400632","record_id":"REC_0016042","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":6.0,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.575918+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_158732","record_id":"REC_0016043","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":6.4,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":5.7,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":16.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.576571+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_356971","record_id":"REC_0016044","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":32,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":5.0,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":21.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.577040+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_970731","record_id":"REC_0016045","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":7.8,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.577461+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_586673","record_id":"REC_0016046","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":18,"tmb_mutations_per_mb":15.6,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":7.3,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.577844+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_366844","record_id":"REC_0016047","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":19,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":46,"primary_tumor_size_cm":4.5,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.578229+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_577938","record_id":"REC_0016048","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":15.2,"age_at_diagnosis":83,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":6.2,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.578618+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_786476","record_id":"REC_0016049","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":13,"tmb_mutations_per_mb":11.0,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":6.2,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.578993+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_632275","record_id":"REC_0016050","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":17.5,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":7.4,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":24.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.579340+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_451472","record_id":"REC_0016051","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":8.0,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":8.6,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.579684+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_432068","record_id":"REC_0016052","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":51,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":7.0,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.580127+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_504350","record_id":"REC_0016053","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":2,"smoking_pack_years":10,"primary_tumor_size_cm":5.1,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":26.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.580536+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_233738","record_id":"REC_0016054","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":34,"tmb_mutations_per_mb":15.3,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":6.4,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":23.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.580907+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_867144","record_id":"REC_0016055","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":31,"tmb_mutations_per_mb":4.6,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":6.1,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.581275+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_774310","record_id":"REC_0016056","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":10.1,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":4.2,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":7.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.582024+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_213951","record_id":"REC_0016057","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":9.8,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":58,"primary_tumor_size_cm":5.6,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":7.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.582550+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_482708","record_id":"REC_0016058","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":17,"tmb_mutations_per_mb":4.5,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":54,"primary_tumor_size_cm":6.4,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":24.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.583000+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_623366","record_id":"REC_0016059","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":5.0,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":9,"primary_tumor_size_cm":6.5,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":18.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.583566+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_281719","record_id":"REC_0016060","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":11.5,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":7.0,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.584144+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_660349","record_id":"REC_0016061","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":5.8,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.584644+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_335627","record_id":"REC_0016062","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":30,"tmb_mutations_per_mb":15.6,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":5.7,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.585074+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_927093","record_id":"REC_0016063","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":8.9,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":6.1,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.585471+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_707301","record_id":"REC_0016064","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":6.4,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.585866+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_181321","record_id":"REC_0016065","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":13.5,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":3.4,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":20.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.586286+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_596440","record_id":"REC_0016066","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":6.0,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":1,"smoking_pack_years":73,"primary_tumor_size_cm":2.5,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.586682+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_868372","record_id":"REC_0016067","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":33,"tmb_mutations_per_mb":5.0,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":4.3,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.587111+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_871863","record_id":"REC_0016068","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":4.9,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.587518+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_928819","record_id":"REC_0016069","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":13.8,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":8.4,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":27.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.588184+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_811379","record_id":"REC_0016070","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":3.9,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.588637+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_862023","record_id":"REC_0016071","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":8.4,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":59,"primary_tumor_size_cm":5.8,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.589016+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_473509","record_id":"REC_0016072","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":16.7,"age_at_diagnosis":80,"sex":"male","ecog_performance_status":3,"smoking_pack_years":21,"primary_tumor_size_cm":3.6,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.589418+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_868096","record_id":"REC_0016073","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":15.1,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":5.0,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":4.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.589802+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_187874","record_id":"REC_0016074","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ALK fusion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":6.9,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":5.5,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":48.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.590179+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_695115","record_id":"REC_0016075","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":18,"tmb_mutations_per_mb":14.4,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":6,"primary_tumor_size_cm":5.9,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":23.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.590575+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_543301","record_id":"REC_0016076","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":9.9,"age_at_diagnosis":53,"sex":"male","ecog_performance_status":0,"smoking_pack_years":2,"primary_tumor_size_cm":6.5,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":25.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.590977+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_681767","record_id":"REC_0016077","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":16.8,"age_at_diagnosis":75,"sex":"male","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":6.2,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.591368+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_617447","record_id":"REC_0016078","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":4.8,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.591757+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_268231","record_id":"REC_0016079","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":5.8,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.592233+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_680056","record_id":"REC_0016080","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":5.5,"age_at_diagnosis":46,"sex":"male","ecog_performance_status":0,"smoking_pack_years":102,"primary_tumor_size_cm":6.3,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":26.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.592796+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_492892","record_id":"REC_0016081","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":5.0,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":6.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.593243+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_289254","record_id":"REC_0016082","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":9.9,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":7.3,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":16.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.593845+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_633916","record_id":"REC_0016083","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":30,"tmb_mutations_per_mb":8.1,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":4.4,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.594300+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_962581","record_id":"REC_0016084","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":13.3,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":26,"primary_tumor_size_cm":3.5,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.594726+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_217877","record_id":"REC_0016085","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None","pd_l1_tps_percent":30,"tmb_mutations_per_mb":5.3,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":34,"primary_tumor_size_cm":5.7,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":39.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.595129+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_488991","record_id":"REC_0016086","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":18,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":6.9,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.595542+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_630158","record_id":"REC_0016087","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":6.0,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.595946+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_446211","record_id":"REC_0016088","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":18,"tmb_mutations_per_mb":1.5,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":4.8,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.596422+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_652200","record_id":"REC_0016089","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":7.8,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":18.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.596864+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_797917","record_id":"REC_0016090","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":20,"primary_tumor_size_cm":2.6,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.597244+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_729403","record_id":"REC_0016091","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":6.0,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.597623+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_914918","record_id":"REC_0016092","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":4.1,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":24,"primary_tumor_size_cm":6.2,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.598059+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_412091","record_id":"REC_0016093","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":19,"tmb_mutations_per_mb":4.1,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":78,"primary_tumor_size_cm":6.8,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.598742+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_558419","record_id":"REC_0016094","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":4.1,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":34,"primary_tumor_size_cm":6.6,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.599151+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_667473","record_id":"REC_0016095","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":7.7,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.599747+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_674266","record_id":"REC_0016096","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":10.0,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":5.9,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.600275+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_817397","record_id":"REC_0016097","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":5.9,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":22.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.600683+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_704063","record_id":"REC_0016098","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":5.3,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":5.8,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":20.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.601091+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_119264","record_id":"REC_0016099","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":11.0,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":1,"smoking_pack_years":3,"primary_tumor_size_cm":5.9,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":23.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.601514+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_944464","record_id":"REC_0016100","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":18.4,"age_at_diagnosis":76,"sex":"male","ecog_performance_status":1,"smoking_pack_years":25,"primary_tumor_size_cm":5.8,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.601913+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_730336","record_id":"REC_0016101","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":14.6,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":4.0,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":5.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.602309+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_770011","record_id":"REC_0016102","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":8.9,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":4.9,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.602701+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_514452","record_id":"REC_0016103","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":8.3,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":0,"primary_tumor_size_cm":5.7,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.603105+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_522079","record_id":"REC_0016104","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":34,"tmb_mutations_per_mb":18.3,"age_at_diagnosis":53,"sex":"female","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":4.2,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.603486+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_248333","record_id":"REC_0016105","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":34,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":4.3,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.603857+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_598220","record_id":"REC_0016106","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":7.6,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":4.3,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.605119+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_234106","record_id":"REC_0016107","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":5.5,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":24,"primary_tumor_size_cm":5.5,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.605637+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_490881","record_id":"REC_0016108","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":13.5,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":6.7,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.606284+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_368523","record_id":"REC_0016109","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":10.3,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":7.3,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.606744+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_503930","record_id":"REC_0016110","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":18.5,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":25,"primary_tumor_size_cm":4.8,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.607131+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_756612","record_id":"REC_0016111","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":15.3,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":5.1,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.607513+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_123401","record_id":"REC_0016112","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":30,"tmb_mutations_per_mb":6.3,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":31,"primary_tumor_size_cm":5.1,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.607889+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_696009","record_id":"REC_0016113","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":6.4,"age_at_diagnosis":78,"sex":"male","ecog_performance_status":2,"smoking_pack_years":44,"primary_tumor_size_cm":6.9,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":7.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.608354+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_455882","record_id":"REC_0016114","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":8.3,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":4.8,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":22.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.608781+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_782331","record_id":"REC_0016115","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":74,"sex":"male","ecog_performance_status":3,"smoking_pack_years":38,"primary_tumor_size_cm":5.8,"metastatic_sites_count":3,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.609201+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_776946","record_id":"REC_0016116","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":20.1,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":2,"primary_tumor_size_cm":5.4,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":7.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.609624+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_433948","record_id":"REC_0016117","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":16.1,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":7.4,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.610048+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_458338","record_id":"REC_0016118","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":3.9,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.610450+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_213117","record_id":"REC_0016119","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":5.3,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.610863+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_649530","record_id":"REC_0016120","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":49,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":6.7,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.611230+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_486761","record_id":"REC_0016121","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":6.1,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":1,"smoking_pack_years":42,"primary_tumor_size_cm":6.6,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":16.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.611792+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_723721","record_id":"REC_0016122","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":9.0,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":5.9,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.612308+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_602440","record_id":"REC_0016123","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":5.0,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":3,"smoking_pack_years":51,"primary_tumor_size_cm":5.5,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.612725+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_573038","record_id":"REC_0016124","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":8.0,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.1,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.613122+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_267969","record_id":"REC_0016125","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":16,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":5.5,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":7.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.613531+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_976617","record_id":"REC_0016126","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":6.1,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.613905+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_617252","record_id":"REC_0016127","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":30,"tmb_mutations_per_mb":16.1,"age_at_diagnosis":81,"sex":"male","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":5.7,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":46.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.614302+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_862323","record_id":"REC_0016128","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":19,"tmb_mutations_per_mb":5.3,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":31,"primary_tumor_size_cm":3.7,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":18.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.614659+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_438609","record_id":"REC_0016129","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":2,"smoking_pack_years":31,"primary_tumor_size_cm":4.2,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":40.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.615213+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_665627","record_id":"REC_0016130","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":6.8,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.615655+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_370186","record_id":"REC_0016131","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":15.0,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":7.4,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.616066+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_525227","record_id":"REC_0016132","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":9.8,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":6.5,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":22.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.616520+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_805781","record_id":"REC_0016133","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":32,"tmb_mutations_per_mb":4.3,"age_at_diagnosis":54,"sex":"male","ecog_performance_status":0,"smoking_pack_years":54,"primary_tumor_size_cm":5.1,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":16.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.616917+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_140984","record_id":"REC_0016134","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":14.4,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":10,"primary_tumor_size_cm":5.0,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.617529+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_334269","record_id":"REC_0016135","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":16,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":53,"sex":"male","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":5.7,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.617954+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_538580","record_id":"REC_0016136","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":6.8,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":22.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.618316+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_169600","record_id":"REC_0016137","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":3.7,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":5.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.618681+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_445394","record_id":"REC_0016138","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":13.5,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":20,"primary_tumor_size_cm":5.2,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.619042+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_541691","record_id":"REC_0016139","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":4.0,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":2,"smoking_pack_years":26,"primary_tumor_size_cm":5.9,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.619435+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_294263","record_id":"REC_0016140","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":11.1,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":4.9,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":23.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.619787+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_873396","record_id":"REC_0016141","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":31,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":76,"sex":"male","ecog_performance_status":0,"smoking_pack_years":51,"primary_tumor_size_cm":6.2,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.620203+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_521051","record_id":"REC_0016142","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":5.0,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.620579+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_820466","record_id":"REC_0016143","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":15,"tmb_mutations_per_mb":7.3,"age_at_diagnosis":54,"sex":"male","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":5.8,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.620958+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_975861","record_id":"REC_0016144","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":16.6,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":4.9,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":25.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.621489+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_859238","record_id":"REC_0016145","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":4.3,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":28.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.621901+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_587832","record_id":"REC_0016146","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":18,"tmb_mutations_per_mb":9.5,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":0,"smoking_pack_years":44,"primary_tumor_size_cm":5.1,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.622294+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_434586","record_id":"REC_0016147","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":8.3,"age_at_diagnosis":88,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":3.7,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":34.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.622903+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_838125","record_id":"REC_0016148","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":3.6,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":66,"primary_tumor_size_cm":5.7,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.623348+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_926085","record_id":"REC_0016149","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":18.2,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":4.5,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.623751+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_198294","record_id":"REC_0016150","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":9.7,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":5.7,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.624219+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_217596","record_id":"REC_0016151","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":11.0,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":4.5,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.624727+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_946091","record_id":"REC_0016152","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":2,"smoking_pack_years":10,"primary_tumor_size_cm":5.1,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":5.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.625164+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_131758","record_id":"REC_0016153","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":14.9,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.8,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.625524+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_198356","record_id":"REC_0016154","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":5.9,"age_at_diagnosis":53,"sex":"male","ecog_performance_status":0,"smoking_pack_years":61,"primary_tumor_size_cm":3.6,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.625885+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_753918","record_id":"REC_0016155","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":4.3,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":4.3,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.626270+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_591347","record_id":"REC_0016156","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":1,"smoking_pack_years":5,"primary_tumor_size_cm":5.5,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":21.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.626651+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_459616","record_id":"REC_0016157","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":3.7,"age_at_diagnosis":50,"sex":"male","ecog_performance_status":0,"smoking_pack_years":24,"primary_tumor_size_cm":6.5,"metastatic_sites_count":8,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.627010+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_122761","record_id":"REC_0016158","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":9.1,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":5.8,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.627383+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_376799","record_id":"REC_0016159","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":30,"tmb_mutations_per_mb":3.6,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.9,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":24.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.627706+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_664047","record_id":"REC_0016160","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":5.5,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":31,"primary_tumor_size_cm":5.3,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.628234+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_254216","record_id":"REC_0016161","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":13.3,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":5.9,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.628648+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_475903","record_id":"REC_0016162","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":11.1,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":4.5,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":26.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.629022+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_781830","record_id":"REC_0016163","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":9.5,"age_at_diagnosis":74,"sex":"male","ecog_performance_status":2,"smoking_pack_years":8,"primary_tumor_size_cm":7.0,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.629342+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_835151","record_id":"REC_0016164","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":3.1,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":0,"smoking_pack_years":27,"primary_tumor_size_cm":5.4,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":29.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.629646+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_494852","record_id":"REC_0016165","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":16.3,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":4.7,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":39.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.630044+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_919011","record_id":"REC_0016166","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":35,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":82,"sex":"male","ecog_performance_status":2,"smoking_pack_years":56,"primary_tumor_size_cm":4.3,"metastatic_sites_count":8,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.630560+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_246720","record_id":"REC_0016167","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":5.9,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":5.6,"metastatic_sites_count":8,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.630929+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_189258","record_id":"REC_0016168","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":5.3,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.631227+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_179645","record_id":"REC_0016169","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":4.8,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":33,"primary_tumor_size_cm":4.9,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.631530+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_912297","record_id":"REC_0016170","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":6.7,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.632040+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_819427","record_id":"REC_0016171","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":8.1,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":6.2,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":18.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.632519+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_979738","record_id":"REC_0016172","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":15.9,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":6.6,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":24.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.632886+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_641329","record_id":"REC_0016173","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":0,"smoking_pack_years":24,"primary_tumor_size_cm":4.5,"metastatic_sites_count":3,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.633386+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_140080","record_id":"REC_0016174","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":3.7,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":36,"primary_tumor_size_cm":4.3,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":7.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.633750+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_646447","record_id":"REC_0016175","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":9.0,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":4.9,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.634097+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_522407","record_id":"REC_0016176","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":16.9,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":4.8,"metastatic_sites_count":3,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":5.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.634470+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_519495","record_id":"REC_0016177","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":24,"primary_tumor_size_cm":7.3,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.634817+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_612626","record_id":"REC_0016178","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":15.9,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":4.0,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":22.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.635211+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_637351","record_id":"REC_0016179","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":19,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":45,"primary_tumor_size_cm":5.9,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":5.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.635625+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_983972","record_id":"REC_0016180","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":6.7,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":4.8,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.635987+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_266662","record_id":"REC_0016181","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":15.5,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":6.5,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":21.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.636465+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_894560","record_id":"REC_0016182","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":31,"tmb_mutations_per_mb":5.7,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":6.0,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.636876+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_693077","record_id":"REC_0016183","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":16.2,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":6.0,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.637308+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_571458","record_id":"REC_0016184","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":14.6,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.6,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.637719+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_983174","record_id":"REC_0016185","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":6.7,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":8.1,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.638063+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_334167","record_id":"REC_0016186","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":83,"sex":"female","ecog_performance_status":2,"smoking_pack_years":22,"primary_tumor_size_cm":6.4,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.638607+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_504938","record_id":"REC_0016187","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":15.1,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":6.4,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":23.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.639031+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_810950","record_id":"REC_0016188","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":5.1,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":3,"smoking_pack_years":62,"primary_tumor_size_cm":5.0,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":6.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.639437+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_738698","record_id":"REC_0016189","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":67,"primary_tumor_size_cm":6.9,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":30.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.639828+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_150113","record_id":"REC_0016190","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":4.0,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":20.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.640274+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_797912","record_id":"REC_0016191","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":11.0,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":4.1,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":19.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.640726+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_515222","record_id":"REC_0016192","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":3.8,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":50,"primary_tumor_size_cm":5.6,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.641163+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_727454","record_id":"REC_0016193","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":4.4,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":5.7,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":19.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.641543+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_342882","record_id":"REC_0016194","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":9.0,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":51,"primary_tumor_size_cm":4.7,"metastatic_sites_count":8,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.641906+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_858902","record_id":"REC_0016195","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":4.6,"age_at_diagnosis":84,"sex":"female","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":5.6,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":16.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.642261+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_431710","record_id":"REC_0016196","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":5.2,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":34,"primary_tumor_size_cm":5.8,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":25.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.642615+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_438910","record_id":"REC_0016197","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":5.3,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":0,"smoking_pack_years":25,"primary_tumor_size_cm":3.2,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.642959+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_516069","record_id":"REC_0016198","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":5.5,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.643307+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_471747","record_id":"REC_0016199","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":4.4,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.643819+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_505340","record_id":"REC_0016200","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":3.0,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.644240+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_849378","record_id":"REC_0016201","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":33,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":28,"primary_tumor_size_cm":5.6,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":25.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.644630+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_269286","record_id":"REC_0016202","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":14.4,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":4.0,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":21.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.645006+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_961994","record_id":"REC_0016203","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":10.1,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":6.8,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.645358+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_626630","record_id":"REC_0016204","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":15.4,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.4,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.645745+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_233902","record_id":"REC_0016205","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":5.3,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.646083+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_822900","record_id":"REC_0016206","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":33,"tmb_mutations_per_mb":5.1,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":5.8,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.646411+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_913307","record_id":"REC_0016207","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":5.8,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.646728+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_812460","record_id":"REC_0016208","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":16.5,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":6.7,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":17.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.647048+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_999731","record_id":"REC_0016209","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":14.3,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":7.1,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.647349+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_956649","record_id":"REC_0016210","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":85,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":3.6,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.647652+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_530348","record_id":"REC_0016211","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":15,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":7.3,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":7.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.647982+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_718635","record_id":"REC_0016212","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":53,"sex":"male","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":3.5,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.648591+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_998989","record_id":"REC_0016213","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":15.8,"age_at_diagnosis":76,"sex":"male","ecog_performance_status":2,"smoking_pack_years":22,"primary_tumor_size_cm":5.7,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.649042+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_328947","record_id":"REC_0016214","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":85,"sex":"female","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":7.2,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.649415+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_810264","record_id":"REC_0016215","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.4,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":16.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.649748+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_890308","record_id":"REC_0016216","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":10.1,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":5.1,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.650086+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_572864","record_id":"REC_0016217","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":8.4,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.9,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.650443+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_354819","record_id":"REC_0016218","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":11.5,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":0,"primary_tumor_size_cm":3.7,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.650789+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_432503","record_id":"REC_0016219","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":0,"smoking_pack_years":36,"primary_tumor_size_cm":4.2,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.651141+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_755790","record_id":"REC_0016220","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":20,"tmb_mutations_per_mb":10.0,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":4.8,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.651494+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_717683","record_id":"REC_0016221","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":33,"tmb_mutations_per_mb":9.0,"age_at_diagnosis":50,"sex":"female","ecog_performance_status":0,"smoking_pack_years":28,"primary_tumor_size_cm":5.8,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.651852+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_326026","record_id":"REC_0016222","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":5.3,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":1,"smoking_pack_years":82,"primary_tumor_size_cm":7.8,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":25.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.652268+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_128266","record_id":"REC_0016223","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":52,"sex":"male","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":5.8,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.652654+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_333303","record_id":"REC_0016224","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":20,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":53,"sex":"female","ecog_performance_status":0,"smoking_pack_years":27,"primary_tumor_size_cm":5.9,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":21.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.653051+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_966675","record_id":"REC_0016225","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":6.9,"metastatic_sites_count":3,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.653603+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_757600","record_id":"REC_0016226","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":16.4,"age_at_diagnosis":77,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":4.2,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.654048+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_275122","record_id":"REC_0016227","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":39,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":4.9,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":24.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.654363+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_434051","record_id":"REC_0016228","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":4.3,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":4.3,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":5.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.654682+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_604988","record_id":"REC_0016229","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":4.8,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.655012+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_926391","record_id":"REC_0016230","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":19,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":0,"smoking_pack_years":64,"primary_tumor_size_cm":5.2,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.655329+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_650774","record_id":"REC_0016231","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":13.8,"age_at_diagnosis":79,"sex":"male","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":5.4,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":25.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.655659+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_620256","record_id":"REC_0016232","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":26,"primary_tumor_size_cm":5.0,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.655999+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_466830","record_id":"REC_0016233","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":14.3,"age_at_diagnosis":90,"sex":"female","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":4.5,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":16.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.656393+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_967718","record_id":"REC_0016234","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":17.7,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":35,"primary_tumor_size_cm":5.5,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.656717+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_344195","record_id":"REC_0016235","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":18,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":51,"sex":"male","ecog_performance_status":0,"smoking_pack_years":4,"primary_tumor_size_cm":5.6,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.656992+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_113503","record_id":"REC_0016236","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":18.0,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":3.8,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":7.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.657246+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_289292","record_id":"REC_0016237","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":32,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":5.9,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":28.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.657491+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_865444","record_id":"REC_0016238","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":16.7,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":6.3,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":17.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.657890+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_293651","record_id":"REC_0016239","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":16.1,"age_at_diagnosis":87,"sex":"female","ecog_performance_status":2,"smoking_pack_years":20,"primary_tumor_size_cm":5.3,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":23.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.658211+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_307395","record_id":"REC_0016240","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":6.8,"metastatic_sites_count":8,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.658522+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_958509","record_id":"REC_0016241","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":20.7,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":5.8,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.658808+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_848990","record_id":"REC_0016242","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":13.1,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":6.1,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.659080+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_703875","record_id":"REC_0016243","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":10.1,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":32,"primary_tumor_size_cm":4.5,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.659359+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_764460","record_id":"REC_0016244","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":0,"smoking_pack_years":6,"primary_tumor_size_cm":4.3,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":24.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.659649+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_168915","record_id":"REC_0016245","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":33,"tmb_mutations_per_mb":5.7,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":25,"primary_tumor_size_cm":4.2,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":7.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.659952+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_803873","record_id":"REC_0016246","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":49,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":3.6,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":16.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.660334+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_707434","record_id":"REC_0016247","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":10.5,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":4.6,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":16.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.660674+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_291540","record_id":"REC_0016248","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":6.9,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":27,"primary_tumor_size_cm":5.2,"metastatic_sites_count":3,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":16.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.661033+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_904695","record_id":"REC_0016249","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":17,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":7.6,"metastatic_sites_count":3,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":27.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.661389+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_676862","record_id":"REC_0016250","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":31,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":5.5,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.661716+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_659368","record_id":"REC_0016251","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":6.8,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":6.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.662208+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_954324","record_id":"REC_0016252","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":17.8,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":28,"primary_tumor_size_cm":4.6,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.662574+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_734467","record_id":"REC_0016253","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":4.9,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":45,"primary_tumor_size_cm":5.5,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":21.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.662937+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_702004","record_id":"REC_0016254","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":0,"smoking_pack_years":0,"primary_tumor_size_cm":8.2,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.663650+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_138775","record_id":"REC_0016255","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":8.5,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":6.6,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.663983+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_743886","record_id":"REC_0016256","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":5.1,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.664407+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_472725","record_id":"REC_0016257","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":13,"tmb_mutations_per_mb":14.8,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":5.4,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.664814+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_371087","record_id":"REC_0016258","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":8.1,"age_at_diagnosis":84,"sex":"female","ecog_performance_status":2,"smoking_pack_years":21,"primary_tumor_size_cm":3.6,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":16.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.665322+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_485393","record_id":"REC_0016259","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":20,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":0,"smoking_pack_years":0,"primary_tumor_size_cm":5.9,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.665767+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_395154","record_id":"REC_0016260","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":35,"tmb_mutations_per_mb":6.4,"age_at_diagnosis":87,"sex":"female","ecog_performance_status":2,"smoking_pack_years":29,"primary_tumor_size_cm":6.6,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.666195+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_187159","record_id":"REC_0016261","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":7.4,"age_at_diagnosis":77,"sex":"male","ecog_performance_status":1,"smoking_pack_years":27,"primary_tumor_size_cm":6.0,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.666572+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_366665","record_id":"REC_0016262","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":5.0,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":5.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.666953+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_347619","record_id":"REC_0016263","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":11.0,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":8.6,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.667329+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_467238","record_id":"REC_0016264","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":18.0,"age_at_diagnosis":76,"sex":"male","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":3.3,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.667929+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_821945","record_id":"REC_0016265","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":13.3,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":7.9,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.668473+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_298107","record_id":"REC_0016266","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":0,"primary_tumor_size_cm":6.6,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":22.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.668869+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_317432","record_id":"REC_0016267","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":30,"tmb_mutations_per_mb":9.7,"age_at_diagnosis":50,"sex":"male","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":3.0,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.669257+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_765110","record_id":"REC_0016268","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":3.4,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.669624+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_361153","record_id":"REC_0016269","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":15.2,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":4.7,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.669988+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_963661","record_id":"REC_0016270","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":9.7,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":0,"smoking_pack_years":0,"primary_tumor_size_cm":4.8,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":24.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.670344+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_472414","record_id":"REC_0016271","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":18,"tmb_mutations_per_mb":10.1,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":3,"smoking_pack_years":20,"primary_tumor_size_cm":3.7,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":25.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.670716+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_690542","record_id":"REC_0016272","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":15,"tmb_mutations_per_mb":16.3,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":5.3,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":5.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.671175+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_563420","record_id":"REC_0016273","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":30,"tmb_mutations_per_mb":13.5,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":4.4,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.671627+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_502402","record_id":"REC_0016274","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":8.4,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":17.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.672139+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_827941","record_id":"REC_0016275","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":6.2,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":19.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.672613+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_112904","record_id":"REC_0016276","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":8.0,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":5.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.672986+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_602602","record_id":"REC_0016277","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":6.0,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.673587+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_386270","record_id":"REC_0016278","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":3.9,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":4.1,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":18.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.674031+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_989854","record_id":"REC_0016279","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":13.1,"age_at_diagnosis":52,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":7.5,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.674425+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_645235","record_id":"REC_0016280","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":50,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":5.2,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.674756+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_937709","record_id":"REC_0016281","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":8.5,"age_at_diagnosis":54,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":5.4,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":6.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.675100+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_868388","record_id":"REC_0016282","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":10.3,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":24,"primary_tumor_size_cm":6.0,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.675443+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_816137","record_id":"REC_0016283","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":14.0,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":6.3,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.675789+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_513005","record_id":"REC_0016284","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":4.9,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.676215+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_189836","record_id":"REC_0016285","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":14.4,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":5.0,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.676604+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_209669","record_id":"REC_0016286","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":7.4,"age_at_diagnosis":49,"sex":"female","ecog_performance_status":0,"smoking_pack_years":6,"primary_tumor_size_cm":6.1,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":5.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.676984+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_326211","record_id":"REC_0016287","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":6.8,"metastatic_sites_count":3,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":5.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.677362+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_448827","record_id":"REC_0016288","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":30,"tmb_mutations_per_mb":7.6,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":38,"primary_tumor_size_cm":5.8,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.677733+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_873603","record_id":"REC_0016289","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":3.9,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":8.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.678121+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_731367","record_id":"REC_0016290","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":1,"smoking_pack_years":28,"primary_tumor_size_cm":4.2,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.678609+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_736071","record_id":"REC_0016291","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.5,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":19.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.678985+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_939680","record_id":"REC_0016292","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":19,"tmb_mutations_per_mb":6.7,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":30,"primary_tumor_size_cm":5.3,"metastatic_sites_count":8,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.679346+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_900562","record_id":"REC_0016293","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":32,"tmb_mutations_per_mb":13.5,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":24,"primary_tumor_size_cm":6.9,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.679691+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_528237","record_id":"REC_0016294","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":16.6,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":4.7,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":5.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.680036+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_508273","record_id":"REC_0016295","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":14,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":7.2,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":4.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.680855+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_903728","record_id":"REC_0016296","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":31,"tmb_mutations_per_mb":5.5,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":36,"primary_tumor_size_cm":6.5,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.681385+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_791958","record_id":"REC_0016297","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":7.2,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":23.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.682070+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_136020","record_id":"REC_0016298","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":7.1,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.682580+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_465672","record_id":"REC_0016299","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":7.7,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":29.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.682973+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_574894","record_id":"REC_0016300","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":2.0,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.683356+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_128616","record_id":"REC_0016301","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":50,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":4.8,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.683707+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_128901","record_id":"REC_0016302","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":6.4,"metastatic_sites_count":9,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":4.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.684070+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_905465","record_id":"REC_0016303","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":18.1,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":6.5,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":33.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.685028+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_570097","record_id":"REC_0016304","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":30,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":4.5,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.685548+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_221401","record_id":"REC_0016305","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":6.0,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":7.0,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.685958+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_325340","record_id":"REC_0016306","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":15.1,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.7,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.686357+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_453876","record_id":"REC_0016307","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":16.2,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":5.3,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.686764+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_635205","record_id":"REC_0016308","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":32,"tmb_mutations_per_mb":3.6,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":6.6,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":25.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.687171+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_246110","record_id":"REC_0016309","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":6.4,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.687589+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_334131","record_id":"REC_0016310","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":5.5,"age_at_diagnosis":54,"sex":"female","ecog_performance_status":0,"smoking_pack_years":34,"primary_tumor_size_cm":3.9,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.688004+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_845828","record_id":"REC_0016311","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":4.7,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":4.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.688531+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_831194","record_id":"REC_0016312","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":4.7,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":60,"primary_tumor_size_cm":3.5,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":6.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.688948+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_105511","record_id":"REC_0016313","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":5.2,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.689368+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_225806","record_id":"REC_0016314","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":15,"tmb_mutations_per_mb":2.8,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":50,"primary_tumor_size_cm":6.3,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.689762+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_640625","record_id":"REC_0016315","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":17.8,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":3.4,"metastatic_sites_count":9,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.690384+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_332766","record_id":"REC_0016316","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":17.4,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":3.8,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.691069+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_152461","record_id":"REC_0016317","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":22.5,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":6.1,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.691588+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_771812","record_id":"REC_0016318","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":5.7,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":6.7,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.692011+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_930500","record_id":"REC_0016319","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":18.8,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":9.7,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.692482+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_177263","record_id":"REC_0016320","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":13.1,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":7.0,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.692862+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_317071","record_id":"REC_0016321","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":20,"tmb_mutations_per_mb":7.9,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":4.3,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.693217+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_944991","record_id":"REC_0016322","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":20,"tmb_mutations_per_mb":5.7,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":34,"primary_tumor_size_cm":5.6,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.693550+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_451221","record_id":"REC_0016323","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":6.7,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":0,"smoking_pack_years":67,"primary_tumor_size_cm":7.9,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":7.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.693911+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_825387","record_id":"REC_0016324","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":4.9,"age_at_diagnosis":85,"sex":"female","ecog_performance_status":3,"smoking_pack_years":14,"primary_tumor_size_cm":7.5,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":7.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.694276+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_284803","record_id":"REC_0016325","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":9.8,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":7.1,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":17.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.694616+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_874854","record_id":"REC_0016326","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":32,"tmb_mutations_per_mb":7.3,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":5.0,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":16.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.694957+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_755980","record_id":"REC_0016327","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":34,"tmb_mutations_per_mb":9.7,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":3,"primary_tumor_size_cm":4.3,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.695269+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_703193","record_id":"REC_0016328","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":19,"tmb_mutations_per_mb":8.0,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":5.0,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.695583+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_113546","record_id":"REC_0016329","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":34,"tmb_mutations_per_mb":16.6,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":6.5,"metastatic_sites_count":8,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.696312+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_841799","record_id":"REC_0016330","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":4.9,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":6.0,"metastatic_sites_count":3,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.696855+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_848895","record_id":"REC_0016331","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":8.5,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":3.5,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.697745+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_853992","record_id":"REC_0016332","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":31,"tmb_mutations_per_mb":15.4,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":7.0,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.698371+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_115886","record_id":"REC_0016333","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":4.5,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.698863+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_785332","record_id":"REC_0016334","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":18.4,"age_at_diagnosis":76,"sex":"male","ecog_performance_status":2,"smoking_pack_years":22,"primary_tumor_size_cm":4.8,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":7.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.699278+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_610521","record_id":"REC_0016335","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":5.3,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":6.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.699694+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_994028","record_id":"REC_0016336","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":8.6,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":5,"primary_tumor_size_cm":7.4,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":34.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.700146+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_433126","record_id":"REC_0016337","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":6.6,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.700529+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_811927","record_id":"REC_0016338","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":8.7,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":5.8,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":5.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.700902+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_440409","record_id":"REC_0016339","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":8.6,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":5.1,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":17.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.701248+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_283395","record_id":"REC_0016340","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":3,"smoking_pack_years":24,"primary_tumor_size_cm":7.8,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":49.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.701614+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_556593","record_id":"REC_0016341","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":5.2,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.701937+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_563729","record_id":"REC_0016342","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":5.6,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":18.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.702435+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_675236","record_id":"REC_0016343","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":8.7,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":5.3,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.702864+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_887225","record_id":"REC_0016344","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":15,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":4.0,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.703252+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_710431","record_id":"REC_0016345","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":18,"tmb_mutations_per_mb":3.9,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":3.6,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":19.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.703610+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_473077","record_id":"REC_0016346","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":6.1,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":63,"primary_tumor_size_cm":5.4,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.703958+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_788495","record_id":"REC_0016347","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":1,"smoking_pack_years":1,"primary_tumor_size_cm":6.2,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":20.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.704576+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_558822","record_id":"REC_0016348","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":4,"primary_tumor_size_cm":7.3,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.704977+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_816108","record_id":"REC_0016349","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":16.6,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.2,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.705327+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_869679","record_id":"REC_0016350","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":3,"smoking_pack_years":40,"primary_tumor_size_cm":4.1,"metastatic_sites_count":3,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":6.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.706202+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_201926","record_id":"REC_0016351","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":4.4,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":30.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.706703+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_494615","record_id":"REC_0016352","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":6.3,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.707036+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_905071","record_id":"REC_0016353","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":2.5,"age_at_diagnosis":52,"sex":"male","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":6.3,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.707389+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_562072","record_id":"REC_0016354","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":3.5,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":36,"primary_tumor_size_cm":5.5,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.707758+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_940845","record_id":"REC_0016355","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":14.9,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":7.5,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":20.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.708611+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_989232","record_id":"REC_0016356","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":14.1,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":8.5,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":23.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.709067+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_157719","record_id":"REC_0016357","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":15.3,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":5.8,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.709456+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_187708","record_id":"REC_0016358","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":7.4,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":72,"primary_tumor_size_cm":5.6,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.709801+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_574909","record_id":"REC_0016359","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":8.9,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":7.8,"metastatic_sites_count":10,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.710215+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_985514","record_id":"REC_0016360","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":9.8,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":6.0,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":20.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.710563+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_654882","record_id":"REC_0016361","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":14.9,"age_at_diagnosis":50,"sex":"male","ecog_performance_status":0,"smoking_pack_years":25,"primary_tumor_size_cm":4.7,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.710918+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_124993","record_id":"REC_0016362","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":8.1,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":0,"smoking_pack_years":24,"primary_tumor_size_cm":6.0,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.711272+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_463755","record_id":"REC_0016363","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":30,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":84,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":4.8,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.711606+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_299737","record_id":"REC_0016364","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":14.3,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":8.1,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.711962+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_488730","record_id":"REC_0016365","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":11.1,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":6.2,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.712417+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_453623","record_id":"REC_0016366","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":14,"tmb_mutations_per_mb":3.7,"age_at_diagnosis":78,"sex":"male","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":4.2,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.712762+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_703290","record_id":"REC_0016367","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":6.0,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":4.7,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.713036+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_352790","record_id":"REC_0016368","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":14.6,"age_at_diagnosis":48,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":5.5,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.713424+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_200234","record_id":"REC_0016369","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":6.0,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":5,"primary_tumor_size_cm":5.0,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":4.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.713709+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_281621","record_id":"REC_0016370","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":10.3,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":5.7,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.714012+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_527440","record_id":"REC_0016371","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":5.3,"age_at_diagnosis":54,"sex":"male","ecog_performance_status":0,"smoking_pack_years":31,"primary_tumor_size_cm":5.1,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.714334+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_482083","record_id":"REC_0016372","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":17.3,"age_at_diagnosis":50,"sex":"female","ecog_performance_status":0,"smoking_pack_years":31,"primary_tumor_size_cm":5.7,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":7.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.714777+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_300246","record_id":"REC_0016373","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":19,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":34,"primary_tumor_size_cm":5.2,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.715200+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_507273","record_id":"REC_0016374","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":17.6,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":3.9,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":19.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.715591+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_368613","record_id":"REC_0016375","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":10.3,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":25,"primary_tumor_size_cm":5.4,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.716004+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_808424","record_id":"REC_0016376","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":17.6,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":6.8,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":20.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.716483+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_145621","record_id":"REC_0016377","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":6.7,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":35.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.716889+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_813375","record_id":"REC_0016378","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":32,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":6.1,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.717296+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_661054","record_id":"REC_0016379","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":15.0,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":4.5,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.717720+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_654110","record_id":"REC_0016380","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":18,"tmb_mutations_per_mb":9.9,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":0,"smoking_pack_years":58,"primary_tumor_size_cm":6.0,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":17.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.718075+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_342407","record_id":"REC_0016381","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":85,"sex":"male","ecog_performance_status":3,"smoking_pack_years":27,"primary_tumor_size_cm":6.9,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.718597+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_123858","record_id":"REC_0016382","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":9.5,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":25,"primary_tumor_size_cm":7.3,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.719001+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_925432","record_id":"REC_0016383","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":4.4,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.719401+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_465790","record_id":"REC_0016384","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":10.0,"age_at_diagnosis":52,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":4.9,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.719803+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_800878","record_id":"REC_0016385","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":4.8,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":23.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.720285+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_486357","record_id":"REC_0016386","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":5.0,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.720677+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_466517","record_id":"REC_0016387","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":5.1,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.721054+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_249911","record_id":"REC_0016388","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":16.3,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":4.7,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.721503+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_397243","record_id":"REC_0016389","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":17.0,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":6.8,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":21.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.721935+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_697508","record_id":"REC_0016390","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":35,"tmb_mutations_per_mb":6.9,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":44,"primary_tumor_size_cm":5.2,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":19.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.722335+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_635746","record_id":"REC_0016391","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":34,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":6.8,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.722741+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_530109","record_id":"REC_0016392","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":11.1,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":25,"primary_tumor_size_cm":5.0,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.723106+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_932540","record_id":"REC_0016393","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":19.3,"age_at_diagnosis":75,"sex":"male","ecog_performance_status":2,"smoking_pack_years":3,"primary_tumor_size_cm":8.4,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.723442+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_260955","record_id":"REC_0016394","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":14.5,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":4.5,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":20.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.723960+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_803389","record_id":"REC_0016395","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":15.2,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":6.8,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":33.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.724431+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_173008","record_id":"REC_0016396","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":14.3,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":3.6,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.724881+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_880123","record_id":"REC_0016397","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":17.8,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":24,"primary_tumor_size_cm":5.0,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.725261+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_442214","record_id":"REC_0016398","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":7.8,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.725640+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_304140","record_id":"REC_0016399","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":6.2,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":26.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.726022+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_503397","record_id":"REC_0016400","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":4.8,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":20.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.726440+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_572238","record_id":"REC_0016401","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":16.7,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.9,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":22.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.726827+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_369252","record_id":"REC_0016402","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":7.0,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.727207+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_776353","record_id":"REC_0016403","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":17.1,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":5.7,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":20.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.727566+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_454728","record_id":"REC_0016404","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":6.0,"age_at_diagnosis":52,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":4.7,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.727935+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_363662","record_id":"REC_0016405","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":3.3,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":7.4,"metastatic_sites_count":8,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.728405+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_413879","record_id":"REC_0016406","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":6.7,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":21.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.728823+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_564856","record_id":"REC_0016407","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":18,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":31,"primary_tumor_size_cm":4.3,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.729280+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_914604","record_id":"REC_0016408","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":18,"tmb_mutations_per_mb":7.4,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":6.1,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":7.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.729586+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_230849","record_id":"REC_0016409","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":16,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":5.2,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":16.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.729885+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_670808","record_id":"REC_0016410","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":3,"smoking_pack_years":10,"primary_tumor_size_cm":4.6,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.730200+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_972786","record_id":"REC_0016411","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":6.1,"metastatic_sites_count":3,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.730525+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_985693","record_id":"REC_0016412","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":8.5,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.730845+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_754206","record_id":"REC_0016413","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":4.8,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.731170+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_752859","record_id":"REC_0016414","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":2,"smoking_pack_years":8,"primary_tumor_size_cm":4.8,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.731482+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_740015","record_id":"REC_0016415","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":4.7,"metastatic_sites_count":8,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.731848+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_557045","record_id":"REC_0016416","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":7.5,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.732337+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_627548","record_id":"REC_0016417","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":6.9,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.732771+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_444892","record_id":"REC_0016418","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":16.0,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":5.1,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":27.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.733163+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_927427","record_id":"REC_0016419","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":4.8,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.733505+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_831407","record_id":"REC_0016420","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":11.5,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":27,"primary_tumor_size_cm":6.2,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.734054+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_661339","record_id":"REC_0016421","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":4.7,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":5.4,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.734462+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_908203","record_id":"REC_0016422","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":0,"smoking_pack_years":4,"primary_tumor_size_cm":5.9,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.734816+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_140650","record_id":"REC_0016423","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":13.3,"age_at_diagnosis":52,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":5.0,"metastatic_sites_count":8,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.735186+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_369667","record_id":"REC_0016424","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":90,"sex":"female","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":4.4,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":8.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.735546+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_769035","record_id":"REC_0016425","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":11.1,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":5.7,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":5.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.735897+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_740051","record_id":"REC_0016426","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":5.9,"age_at_diagnosis":49,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":5.5,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.736336+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_858767","record_id":"REC_0016427","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":4.1,"age_at_diagnosis":84,"sex":"female","ecog_performance_status":2,"smoking_pack_years":7,"primary_tumor_size_cm":5.4,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.736723+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_653010","record_id":"REC_0016428","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":5.0,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":24.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.737084+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_165398","record_id":"REC_0016429","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":14,"tmb_mutations_per_mb":9.7,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.9,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.737473+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_229518","record_id":"REC_0016430","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":85,"sex":"female","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":4.8,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.737874+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_957718","record_id":"REC_0016431","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":30,"tmb_mutations_per_mb":8.3,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":4,"primary_tumor_size_cm":5.5,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.738268+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_707255","record_id":"REC_0016432","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":2.5,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.738667+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_520898","record_id":"REC_0016433","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":7.9,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":6.2,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.739267+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_291335","record_id":"REC_0016434","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":24,"primary_tumor_size_cm":5.2,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.739690+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_578990","record_id":"REC_0016435","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":80,"sex":"male","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":6.9,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":21.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.740060+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_736408","record_id":"REC_0016436","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":11.1,"age_at_diagnosis":49,"sex":"male","ecog_performance_status":0,"smoking_pack_years":6,"primary_tumor_size_cm":6.8,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.740596+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_858405","record_id":"REC_0016437","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":42,"sex":"female","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":5.2,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.741024+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_217975","record_id":"REC_0016438","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":19,"tmb_mutations_per_mb":15.2,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":7.2,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.741450+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_372281","record_id":"REC_0016439","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":6.0,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":28.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.741858+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_819410","record_id":"REC_0016440","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":4.7,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":3,"smoking_pack_years":47,"primary_tumor_size_cm":6.1,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":18.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.742243+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_913460","record_id":"REC_0016441","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":32,"tmb_mutations_per_mb":6.7,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":33,"primary_tumor_size_cm":4.3,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":19.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.742619+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_259196","record_id":"REC_0016442","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":3,"smoking_pack_years":11,"primary_tumor_size_cm":6.3,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.743014+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_545025","record_id":"REC_0016443","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":33,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":10,"primary_tumor_size_cm":5.1,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.743402+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_708088","record_id":"REC_0016444","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":25,"primary_tumor_size_cm":4.7,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":32.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.743805+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_146238","record_id":"REC_0016445","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":14.4,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":3.8,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.744207+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_964639","record_id":"REC_0016446","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":8.6,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":7.8,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":33.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.744738+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_858452","record_id":"REC_0016447","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":34,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":4.0,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.745184+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_635748","record_id":"REC_0016448","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":18.3,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":0,"smoking_pack_years":25,"primary_tumor_size_cm":5.0,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.745580+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_528347","record_id":"REC_0016449","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":6.0,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.745947+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_970267","record_id":"REC_0016450","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":6.2,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.746321+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_498423","record_id":"REC_0016451","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":4.6,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":76,"primary_tumor_size_cm":3.0,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":7.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.746683+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_806512","record_id":"REC_0016452","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":17.3,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":3.3,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.747017+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_403459","record_id":"REC_0016453","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":5.2,"metastatic_sites_count":8,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.747373+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_397283","record_id":"REC_0016454","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":1.5,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":4.6,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.747696+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_973258","record_id":"REC_0016455","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":17,"tmb_mutations_per_mb":14.9,"age_at_diagnosis":76,"sex":"male","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":6.8,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.748038+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_923320","record_id":"REC_0016456","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":15.8,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":5.3,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":17.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.748461+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_423567","record_id":"REC_0016457","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":0,"smoking_pack_years":51,"primary_tumor_size_cm":6.3,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":20.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.748841+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_322181","record_id":"REC_0016458","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":8.9,"age_at_diagnosis":46,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":5.6,"metastatic_sites_count":3,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.749237+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_563195","record_id":"REC_0016459","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":9.1,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":6.1,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.749767+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_220926","record_id":"REC_0016460","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":18,"tmb_mutations_per_mb":10.1,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":4.0,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":6.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.750166+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_195707","record_id":"REC_0016461","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":14.7,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":4.2,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.750517+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_745328","record_id":"REC_0016462","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":10.5,"age_at_diagnosis":43,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":3.3,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.750832+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_138653","record_id":"REC_0016463","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":10.3,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":10,"primary_tumor_size_cm":7.2,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.751156+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_118038","record_id":"REC_0016464","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":8.1,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":8.9,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.751498+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_802582","record_id":"REC_0016465","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":1,"primary_tumor_size_cm":3.4,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.751845+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_125304","record_id":"REC_0016466","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":3,"smoking_pack_years":15,"primary_tumor_size_cm":5.1,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":29.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.752275+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_158694","record_id":"REC_0016467","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":14,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":1,"smoking_pack_years":5,"primary_tumor_size_cm":7.5,"metastatic_sites_count":8,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":16.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.752685+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_306756","record_id":"REC_0016468","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":3.0,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":0,"smoking_pack_years":40,"primary_tumor_size_cm":4.6,"metastatic_sites_count":8,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":7.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.753065+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_842692","record_id":"REC_0016469","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":6.3,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":5.3,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":35.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.753386+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_748368","record_id":"REC_0016470","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":16.2,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":6.1,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.753658+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_131976","record_id":"REC_0016471","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":5.9,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":4.7,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":24.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.753921+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_795536","record_id":"REC_0016472","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":17.9,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":7.0,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.754425+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_972647","record_id":"REC_0016473","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":14.3,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":5.0,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":25.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.754835+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_616530","record_id":"REC_0016474","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":19,"tmb_mutations_per_mb":15.0,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":4.5,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.755189+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_759280","record_id":"REC_0016475","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":18.7,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":8,"primary_tumor_size_cm":4.8,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.755530+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_723866","record_id":"REC_0016476","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":5.0,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.755871+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_922316","record_id":"REC_0016477","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":14.7,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":3,"smoking_pack_years":18,"primary_tumor_size_cm":6.5,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.756304+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_293139","record_id":"REC_0016478","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":30,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":3,"smoking_pack_years":14,"primary_tumor_size_cm":6.9,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":21.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.756672+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_502882","record_id":"REC_0016479","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":4.4,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":19.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.757003+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_654613","record_id":"REC_0016480","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":19,"tmb_mutations_per_mb":6.0,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":1,"smoking_pack_years":36,"primary_tumor_size_cm":5.9,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":5.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.757336+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_471001","record_id":"REC_0016481","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":5.3,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.757685+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_917876","record_id":"REC_0016482","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":3,"primary_tumor_size_cm":4.2,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.758091+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_149378","record_id":"REC_0016483","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":9.7,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":4.5,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.758483+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_894769","record_id":"REC_0016484","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":43,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":3.6,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.758872+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_756850","record_id":"REC_0016485","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":7.2,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.759483+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_162561","record_id":"REC_0016486","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":17.3,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":5.7,"metastatic_sites_count":9,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":7.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.759900+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_449387","record_id":"REC_0016487","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":31,"tmb_mutations_per_mb":18.6,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":4.9,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.760365+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_792761","record_id":"REC_0016488","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":78,"sex":"male","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":6.5,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.760724+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_252058","record_id":"REC_0016489","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":9.1,"age_at_diagnosis":53,"sex":"male","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":6.0,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.761084+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_566846","record_id":"REC_0016490","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":10.0,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":6,"primary_tumor_size_cm":6.9,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":4.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.761422+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_326098","record_id":"REC_0016491","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":12,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":3.6,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.761754+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_171931","record_id":"REC_0016492","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":6.3,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":5.0,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":5.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.762105+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_697023","record_id":"REC_0016493","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":7.6,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":4.5,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.762451+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_810141","record_id":"REC_0016494","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":8.3,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":4.0,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":28.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.762807+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_616549","record_id":"REC_0016495","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":6.5,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":20.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.763216+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_813360","record_id":"REC_0016496","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":4.8,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.763598+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_957779","record_id":"REC_0016497","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":6.7,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.763980+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_472654","record_id":"REC_0016498","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":8.1,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":6.5,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":16.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.764629+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_951495","record_id":"REC_0016499","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":20,"tmb_mutations_per_mb":7.6,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":59,"primary_tumor_size_cm":5.0,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.765090+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_651314","record_id":"REC_0016500","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":13.8,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":6.4,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.765518+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_780382","record_id":"REC_0016501","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":0,"smoking_pack_years":6,"primary_tumor_size_cm":5.9,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.765937+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_618755","record_id":"REC_0016502","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":4.9,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.766354+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_429260","record_id":"REC_0016503","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":7.3,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":18.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.766758+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_553216","record_id":"REC_0016504","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":18.9,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":3.6,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.767164+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_618995","record_id":"REC_0016505","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":16,"tmb_mutations_per_mb":10.1,"age_at_diagnosis":51,"sex":"male","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":6.2,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":34.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.767541+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_183925","record_id":"REC_0016506","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":7.3,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.767966+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_144654","record_id":"REC_0016507","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":6.7,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":22.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.768442+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_505325","record_id":"REC_0016508","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":52,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":4.9,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":7.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.768829+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_566070","record_id":"REC_0016509","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":5.9,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":5.4,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.769221+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_356460","record_id":"REC_0016510","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":15.6,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":4.1,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":23.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.769620+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_843890","record_id":"REC_0016511","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":10.5,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":24,"primary_tumor_size_cm":5.2,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.770164+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_636625","record_id":"REC_0016512","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":18,"tmb_mutations_per_mb":14.8,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":6.3,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.770576+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_345156","record_id":"REC_0016513","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":6.4,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":4.4,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":23.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.770983+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_985090","record_id":"REC_0016514","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":17.5,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":6.8,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.771393+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_975947","record_id":"REC_0016515","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":4.6,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":26,"primary_tumor_size_cm":5.2,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.771824+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_347911","record_id":"REC_0016516","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":3.8,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":4.5,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":23.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.772284+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_860431","record_id":"REC_0016517","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":47,"sex":"male","ecog_performance_status":0,"smoking_pack_years":0,"primary_tumor_size_cm":5.9,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":4.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.772712+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_936478","record_id":"REC_0016518","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.1,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":7.6,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.773084+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_401707","record_id":"REC_0016519","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":1,"smoking_pack_years":56,"primary_tumor_size_cm":5.6,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.773448+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_631925","record_id":"REC_0016520","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":7.3,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":0,"smoking_pack_years":42,"primary_tumor_size_cm":6.0,"metastatic_sites_count":3,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":21.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.773818+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_764026","record_id":"REC_0016521","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":30,"tmb_mutations_per_mb":9.9,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":6.0,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.774216+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_846504","record_id":"REC_0016522","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":5.8,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":27.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.774604+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_242529","record_id":"REC_0016523","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":8.3,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":2.9,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":18.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.774977+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_165424","record_id":"REC_0016524","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":0,"smoking_pack_years":24,"primary_tumor_size_cm":5.4,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.775561+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_916597","record_id":"REC_0016525","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":3.2,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":58,"primary_tumor_size_cm":6.2,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.776001+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_847822","record_id":"REC_0016526","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":13.1,"age_at_diagnosis":54,"sex":"female","ecog_performance_status":0,"smoking_pack_years":26,"primary_tumor_size_cm":4.1,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.776465+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_731962","record_id":"REC_0016527","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":17,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":28,"primary_tumor_size_cm":6.6,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.776880+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_510316","record_id":"REC_0016528","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":17.7,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":6.4,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.777265+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_166393","record_id":"REC_0016529","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":5.0,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.777633+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_832961","record_id":"REC_0016530","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":1,"smoking_pack_years":54,"primary_tumor_size_cm":5.6,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":24.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.777982+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_559002","record_id":"REC_0016531","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":4,"primary_tumor_size_cm":6.7,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":7.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.778364+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_476109","record_id":"REC_0016532","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":6.0,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.779347+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_788714","record_id":"REC_0016533","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":31,"tmb_mutations_per_mb":1.8,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":45,"primary_tumor_size_cm":4.9,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.779856+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_937025","record_id":"REC_0016534","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":23,"primary_tumor_size_cm":3.8,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":6.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.780343+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_892521","record_id":"REC_0016535","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":5.7,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":5.5,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":6.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.780773+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_760285","record_id":"REC_0016536","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":16.3,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":5,"primary_tumor_size_cm":5.8,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":28.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.781210+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_548045","record_id":"REC_0016537","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":4.4,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.781789+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_635175","record_id":"REC_0016538","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":6.5,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.782226+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_244023","record_id":"REC_0016539","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":2,"smoking_pack_years":20,"primary_tumor_size_cm":7.7,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.782648+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_536158","record_id":"REC_0016540","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":30,"tmb_mutations_per_mb":16.0,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":5.2,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.783100+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_369860","record_id":"REC_0016541","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":13.6,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":4.8,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":22.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.783612+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_423400","record_id":"REC_0016542","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":5.5,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.784044+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_720468","record_id":"REC_0016543","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":9.8,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":7.7,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":30.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.784491+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_347426","record_id":"REC_0016544","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":18,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":5.0,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.784861+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_863814","record_id":"REC_0016545","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":11.1,"age_at_diagnosis":84,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":5.2,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.785222+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_371827","record_id":"REC_0016546","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":10.5,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":7.0,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":25.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.785752+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_628474","record_id":"REC_0016547","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":7.6,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":0,"smoking_pack_years":33,"primary_tumor_size_cm":5.0,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.786342+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_609254","record_id":"REC_0016548","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":4.6,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.786915+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_262740","record_id":"REC_0016549","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":5,"primary_tumor_size_cm":4.4,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.787330+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_539372","record_id":"REC_0016550","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":14,"tmb_mutations_per_mb":14.8,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":6.2,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.787932+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_315856","record_id":"REC_0016551","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":16,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":5.3,"metastatic_sites_count":8,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.788474+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_900711","record_id":"REC_0016552","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":16.6,"age_at_diagnosis":53,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":4.9,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":8.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.788926+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_789512","record_id":"REC_0016553","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":9.7,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":4.4,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":21.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.789328+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_817795","record_id":"REC_0016554","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":8.1,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":6.0,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.789716+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_721752","record_id":"REC_0016555","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":14,"tmb_mutations_per_mb":8.6,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":5.5,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.790124+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_916922","record_id":"REC_0016556","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":9.0,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":5.1,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.790569+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_877193","record_id":"REC_0016557","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":9.7,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":5.3,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.790983+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_144216","record_id":"REC_0016558","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":17,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":6.0,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.791434+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_698048","record_id":"REC_0016559","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":33,"tmb_mutations_per_mb":8.0,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":1,"smoking_pack_years":5,"primary_tumor_size_cm":5.4,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.791848+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_215749","record_id":"REC_0016560","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":32,"tmb_mutations_per_mb":13.1,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":4.8,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":26.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.792487+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_681436","record_id":"REC_0016561","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":15.8,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":1,"smoking_pack_years":4,"primary_tumor_size_cm":3.8,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.793013+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_160974","record_id":"REC_0016562","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":10.3,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":3.9,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":22.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.793497+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_286801","record_id":"REC_0016563","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":17.3,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":6.9,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.794199+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_782470","record_id":"REC_0016564","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":16,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":8.1,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":17.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.794715+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_635231","record_id":"REC_0016565","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":11.5,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":6.3,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.795187+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_532983","record_id":"REC_0016566","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":8.3,"age_at_diagnosis":88,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":6.1,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":24.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.795613+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_290791","record_id":"REC_0016567","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":15.6,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":8.0,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":49.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.795994+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_628127","record_id":"REC_0016568","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":5.9,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.796435+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_474247","record_id":"REC_0016569","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":5.5,"metastatic_sites_count":8,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.796863+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_302490","record_id":"REC_0016570","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":22.0,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":4.3,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.797229+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_528465","record_id":"REC_0016571","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":41,"primary_tumor_size_cm":5.6,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.797567+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_423973","record_id":"REC_0016572","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":4.2,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":31.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.797917+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_472122","record_id":"REC_0016573","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":14,"tmb_mutations_per_mb":4.0,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":6.0,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.798294+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_788011","record_id":"REC_0016574","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":17,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":44,"primary_tumor_size_cm":5.8,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":17.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.798684+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_106709","record_id":"REC_0016575","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":4.2,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.799093+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_119255","record_id":"REC_0016576","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":17.6,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":0,"smoking_pack_years":25,"primary_tumor_size_cm":6.9,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":5.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.799680+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_599170","record_id":"REC_0016577","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":5.1,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":35.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.800176+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_657807","record_id":"REC_0016578","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":16.3,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":6.0,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.800639+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_881774","record_id":"REC_0016579","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":4.4,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":28,"primary_tumor_size_cm":6.6,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.801287+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_613189","record_id":"REC_0016580","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":16.4,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":5.2,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":19.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.801707+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_428495","record_id":"REC_0016581","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":16.8,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":5.2,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.802113+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_154903","record_id":"REC_0016582","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":8.0,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.802487+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_630241","record_id":"REC_0016583","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":5.6,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.802841+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_433699","record_id":"REC_0016584","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":3.5,"age_at_diagnosis":50,"sex":"male","ecog_performance_status":0,"smoking_pack_years":52,"primary_tumor_size_cm":5.7,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":25.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.803221+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_561251","record_id":"REC_0016585","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":7.4,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":58,"primary_tumor_size_cm":6.2,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.803604+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_246568","record_id":"REC_0016586","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":5.5,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":64,"primary_tumor_size_cm":3.9,"metastatic_sites_count":3,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":16.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.803957+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_738734","record_id":"REC_0016587","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":13.6,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":0,"smoking_pack_years":6,"primary_tumor_size_cm":6.7,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":26.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.804444+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_131134","record_id":"REC_0016588","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":31,"tmb_mutations_per_mb":16.4,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.5,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.804858+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_850943","record_id":"REC_0016589","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":34,"tmb_mutations_per_mb":16.3,"age_at_diagnosis":52,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":5.7,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.805435+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_941410","record_id":"REC_0016590","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":5.9,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":27.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.805880+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_171132","record_id":"REC_0016591","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":8.1,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":3.4,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":25.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.806260+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_248094","record_id":"REC_0016592","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":3.5,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":44,"primary_tumor_size_cm":6.8,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":21.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.806624+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_688180","record_id":"REC_0016593","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":6.1,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":18.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.807024+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_598134","record_id":"REC_0016594","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":4.3,"age_at_diagnosis":53,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":5.2,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":18.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.807438+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_565204","record_id":"REC_0016595","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":31,"tmb_mutations_per_mb":14.5,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":4.6,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":5.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.807871+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_441256","record_id":"REC_0016596","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":20,"tmb_mutations_per_mb":3.8,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":40,"primary_tumor_size_cm":6.2,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.808350+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_818518","record_id":"REC_0016597","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":6.0,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":3,"smoking_pack_years":34,"primary_tumor_size_cm":3.5,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.808792+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_305654","record_id":"REC_0016598","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":3,"smoking_pack_years":7,"primary_tumor_size_cm":5.1,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.809220+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_826858","record_id":"REC_0016599","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":16.3,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":4.2,"metastatic_sites_count":8,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.809635+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_444311","record_id":"REC_0016600","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":5.8,"metastatic_sites_count":9,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.810030+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_894988","record_id":"REC_0016601","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":4.3,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.810419+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_407882","record_id":"REC_0016602","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":14.5,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.3,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":21.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.811058+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_877012","record_id":"REC_0016603","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":15.4,"age_at_diagnosis":84,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":5.3,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.811577+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_110487","record_id":"REC_0016604","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":13.1,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":5.5,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.812048+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_833728","record_id":"REC_0016605","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":3.7,"age_at_diagnosis":84,"sex":"male","ecog_performance_status":3,"smoking_pack_years":57,"primary_tumor_size_cm":5.0,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.812620+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_995536","record_id":"REC_0016606","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":21.3,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":5.2,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.813022+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_824169","record_id":"REC_0016607","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":5.4,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.813409+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_288110","record_id":"REC_0016608","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":14.4,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":8,"primary_tumor_size_cm":6.0,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.814093+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_553106","record_id":"REC_0016609","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":31,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":6.0,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.814533+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_458688","record_id":"REC_0016610","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":30,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":1,"smoking_pack_years":4,"primary_tumor_size_cm":4.8,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.814882+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_673247","record_id":"REC_0016611","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":4.5,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.815242+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_999290","record_id":"REC_0016612","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":20,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":4.6,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.815646+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_467178","record_id":"REC_0016613","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":5.5,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.816529+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_473706","record_id":"REC_0016614","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":3.8,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.816953+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_313254","record_id":"REC_0016615","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":20.1,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":4.6,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":29.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.817590+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_352737","record_id":"REC_0016616","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":43,"primary_tumor_size_cm":7.8,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.818048+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_406035","record_id":"REC_0016617","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":7.9,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":5.8,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.818443+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_546336","record_id":"REC_0016618","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":30,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":43,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":4.5,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.818813+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_399979","record_id":"REC_0016619","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":4.3,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.819192+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_331536","record_id":"REC_0016620","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":6.1,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":24,"primary_tumor_size_cm":6.3,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":20.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.819574+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_999974","record_id":"REC_0016621","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":11.5,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":4,"primary_tumor_size_cm":5.8,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.819966+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_340512","record_id":"REC_0016622","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":7.1,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.820471+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_166182","record_id":"REC_0016623","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":14,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":44,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":4.6,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.820894+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_617110","record_id":"REC_0016624","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":74,"sex":"male","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":6.0,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.821358+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_677291","record_id":"REC_0016625","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":4.4,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.821742+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_987055","record_id":"REC_0016626","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":35,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":4.2,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":36.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.822126+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_760713","record_id":"REC_0016627","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":13.6,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":4.4,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.822511+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_351970","record_id":"REC_0016628","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":3,"smoking_pack_years":9,"primary_tumor_size_cm":5.7,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.823086+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_126152","record_id":"REC_0016629","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":4.8,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":4.6,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":19.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.823554+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_658205","record_id":"REC_0016630","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":1,"primary_tumor_size_cm":5.0,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.823950+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_176232","record_id":"REC_0016631","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":5.6,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.824452+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_545068","record_id":"REC_0016632","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":19,"tmb_mutations_per_mb":6.9,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":4.7,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.824844+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_599999","record_id":"REC_0016633","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":6.7,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.825237+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_249769","record_id":"REC_0016634","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":14.5,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":1,"smoking_pack_years":28,"primary_tumor_size_cm":4.5,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":25.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.825568+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_153947","record_id":"REC_0016635","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.7,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.825908+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_837972","record_id":"REC_0016636","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":8.9,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":4.7,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":24.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.826284+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_473315","record_id":"REC_0016637","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":9.8,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":7.7,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.826647+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_444512","record_id":"REC_0016638","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":5.2,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":7.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.827006+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_853583","record_id":"REC_0016639","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":14.9,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":8.3,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.827373+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_240017","record_id":"REC_0016640","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":3.6,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":3.6,"metastatic_sites_count":8,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.827748+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_567793","record_id":"REC_0016641","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":6.2,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":21.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.828331+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_716921","record_id":"REC_0016642","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":4.1,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":6.6,"metastatic_sites_count":3,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.828763+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_967279","record_id":"REC_0016643","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":5.5,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":26,"primary_tumor_size_cm":7.4,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.829140+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_720771","record_id":"REC_0016644","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":32,"tmb_mutations_per_mb":5.9,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":57,"primary_tumor_size_cm":2.8,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.829483+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_814527","record_id":"REC_0016645","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":9.7,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":4.5,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.829808+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_608135","record_id":"REC_0016646","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":30,"tmb_mutations_per_mb":3.9,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":27,"primary_tumor_size_cm":6.3,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.830147+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_746021","record_id":"REC_0016647","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":15.2,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":7.6,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.830514+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_955156","record_id":"REC_0016648","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":6.9,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":6.7,"metastatic_sites_count":3,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.830853+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_126871","record_id":"REC_0016649","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":7.8,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":17.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.831194+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_738920","record_id":"REC_0016650","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":3.3,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":4.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.831573+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_144117","record_id":"REC_0016651","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":3,"smoking_pack_years":6,"primary_tumor_size_cm":6.7,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.831961+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_334012","record_id":"REC_0016652","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":17.5,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":7.2,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":17.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.832430+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_887101","record_id":"REC_0016653","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":4.7,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.832842+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_850094","record_id":"REC_0016654","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":16,"tmb_mutations_per_mb":2.5,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":3,"smoking_pack_years":9,"primary_tumor_size_cm":7.1,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":18.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.833458+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_862116","record_id":"REC_0016655","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":8.4,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":4.8,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":17.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.833963+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_662251","record_id":"REC_0016656","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":8.3,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":4.8,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.834387+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_107667","record_id":"REC_0016657","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":9,"primary_tumor_size_cm":6.5,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.834741+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_462849","record_id":"REC_0016658","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":3.9,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":7.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.835153+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_185290","record_id":"REC_0016659","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":9.8,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":5.6,"metastatic_sites_count":9,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.835555+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_112356","record_id":"REC_0016660","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":20,"tmb_mutations_per_mb":3.8,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":49,"primary_tumor_size_cm":7.3,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.835927+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_355568","record_id":"REC_0016661","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":8.7,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":5.5,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":19.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.836362+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_103391","record_id":"REC_0016662","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":16,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":5.5,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.836773+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_254877","record_id":"REC_0016663","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":4.9,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.837207+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_672506","record_id":"REC_0016664","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":19,"tmb_mutations_per_mb":14.0,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":6.5,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":17.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.837630+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_564856","record_id":"REC_0016665","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.6,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.838063+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_921147","record_id":"REC_0016666","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":1.5,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":2,"primary_tumor_size_cm":5.1,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":40.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.838447+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_979296","record_id":"REC_0016667","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":5.7,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":7.0,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":17.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.838986+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_789379","record_id":"REC_0016668","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":32,"tmb_mutations_per_mb":14.7,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":6.6,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":31.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.839463+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_452604","record_id":"REC_0016669","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":10.5,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":26,"primary_tumor_size_cm":6.8,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.839850+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_939141","record_id":"REC_0016670","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":11.1,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":5.5,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.840301+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_810367","record_id":"REC_0016671","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":8.6,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":5.9,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":24.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.840714+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_929102","record_id":"REC_0016672","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":15.3,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":4.8,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.841128+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_669753","record_id":"REC_0016673","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":8.3,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":5.1,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.841587+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_656272","record_id":"REC_0016674","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":9.8,"age_at_diagnosis":47,"sex":"male","ecog_performance_status":0,"smoking_pack_years":24,"primary_tumor_size_cm":7.1,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":17.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.842009+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_534251","record_id":"REC_0016675","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.5,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":24.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.842414+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_475586","record_id":"REC_0016676","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":30,"tmb_mutations_per_mb":10.1,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":4.8,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":27.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.842811+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_580276","record_id":"REC_0016677","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":33,"tmb_mutations_per_mb":7.3,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":4,"primary_tumor_size_cm":5.8,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.843226+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_260165","record_id":"REC_0016678","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":43,"primary_tumor_size_cm":4.3,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.843631+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_762510","record_id":"REC_0016679","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":30,"tmb_mutations_per_mb":16.7,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":0,"primary_tumor_size_cm":4.0,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.844061+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_899532","record_id":"REC_0016680","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":10.3,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":5.3,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.844822+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_167232","record_id":"REC_0016681","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":5.4,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.845234+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_245251","record_id":"REC_0016682","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":3,"smoking_pack_years":14,"primary_tumor_size_cm":3.7,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":20.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.845633+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_792125","record_id":"REC_0016683","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":13.5,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":3.5,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.846004+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_629527","record_id":"REC_0016684","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":33,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":7.1,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":7.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.846381+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_957736","record_id":"REC_0016685","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":30,"tmb_mutations_per_mb":7.3,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":1,"smoking_pack_years":57,"primary_tumor_size_cm":3.0,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":17.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.846765+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_692022","record_id":"REC_0016686","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":63,"primary_tumor_size_cm":8.0,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.847132+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_603623","record_id":"REC_0016687","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":6.3,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.847507+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_445755","record_id":"REC_0016688","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":16.5,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":0,"smoking_pack_years":0,"primary_tumor_size_cm":4.7,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":29.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.847884+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_175544","record_id":"REC_0016689","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":5.5,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":5,"primary_tumor_size_cm":4.2,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.848503+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_229046","record_id":"REC_0016690","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":5.9,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.848940+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_209101","record_id":"REC_0016691","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":5.5,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":4.6,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.849340+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_957111","record_id":"REC_0016692","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":51,"sex":"male","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":4.5,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.849727+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_697710","record_id":"REC_0016693","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":16,"tmb_mutations_per_mb":2.5,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":1,"smoking_pack_years":55,"primary_tumor_size_cm":4.6,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.850314+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_386835","record_id":"REC_0016694","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":6.2,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.850689+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_409158","record_id":"REC_0016695","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":14.8,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":5.7,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":52.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.851023+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_984116","record_id":"REC_0016696","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":4.9,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":25.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.851366+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_448183","record_id":"REC_0016697","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":20,"tmb_mutations_per_mb":5.9,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":0,"smoking_pack_years":61,"primary_tumor_size_cm":5.3,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":18.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.851725+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_998722","record_id":"REC_0016698","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":0,"smoking_pack_years":26,"primary_tumor_size_cm":6.0,"metastatic_sites_count":3,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.852146+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_130963","record_id":"REC_0016699","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":5.2,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":37,"primary_tumor_size_cm":4.2,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.852507+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_557054","record_id":"REC_0016700","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":18.7,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.8,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.852864+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_102180","record_id":"REC_0016701","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":17.6,"age_at_diagnosis":52,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":5.5,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":8.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.853231+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_726163","record_id":"REC_0016702","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":5.5,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":77,"primary_tumor_size_cm":7.0,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.853598+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_396026","record_id":"REC_0016703","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":32,"tmb_mutations_per_mb":15.4,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":7.0,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.853977+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_908024","record_id":"REC_0016704","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":3.1,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.854362+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_372534","record_id":"REC_0016705","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":10,"primary_tumor_size_cm":6.2,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.854753+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_423396","record_id":"REC_0016706","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":6.1,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":39,"primary_tumor_size_cm":5.5,"metastatic_sites_count":9,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":7.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.855319+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_520972","record_id":"REC_0016707","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":9.1,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":7.2,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.855754+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_709152","record_id":"REC_0016708","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":36,"tmb_mutations_per_mb":13.3,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":5.2,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.856210+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_763219","record_id":"REC_0016709","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":8.9,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":4.0,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.856629+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_701384","record_id":"REC_0016710","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":3.0,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":4.2,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":16.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.857028+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_631608","record_id":"REC_0016711","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":18,"tmb_mutations_per_mb":11.1,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":24,"primary_tumor_size_cm":7.4,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.857399+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_139216","record_id":"REC_0016712","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":5.8,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.857724+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_219678","record_id":"REC_0016713","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":6.1,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":5.9,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.858059+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_369494","record_id":"REC_0016714","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":4.6,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":6.7,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.858405+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_626122","record_id":"REC_0016715","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":5.1,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":72,"primary_tumor_size_cm":6.9,"metastatic_sites_count":3,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":25.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.858768+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_388022","record_id":"REC_0016716","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":4.9,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":40,"primary_tumor_size_cm":5.7,"metastatic_sites_count":3,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":7.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.859130+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_843580","record_id":"REC_0016717","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":0,"smoking_pack_years":6,"primary_tumor_size_cm":4.6,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.859497+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_264300","record_id":"REC_0016718","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":32,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":3.8,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.859929+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_237329","record_id":"REC_0016719","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":13.1,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":4.5,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.860606+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_790351","record_id":"REC_0016720","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":4.9,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":22.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.861034+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_862321","record_id":"REC_0016721","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":7.0,"metastatic_sites_count":8,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.861472+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_961229","record_id":"REC_0016722","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":30,"tmb_mutations_per_mb":8.7,"age_at_diagnosis":52,"sex":"male","ecog_performance_status":0,"smoking_pack_years":55,"primary_tumor_size_cm":3.5,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.861872+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_271126","record_id":"REC_0016723","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":6.6,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.862237+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_549084","record_id":"REC_0016724","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":16,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":3.4,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.862593+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_844690","record_id":"REC_0016725","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":10.5,"age_at_diagnosis":84,"sex":"female","ecog_performance_status":2,"smoking_pack_years":9,"primary_tumor_size_cm":5.3,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.862954+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_658911","record_id":"REC_0016726","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":4.2,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.863297+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_194800","record_id":"REC_0016727","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":6.3,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.863626+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_875918","record_id":"REC_0016728","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":6.3,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":8.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.863956+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_651040","record_id":"REC_0016729","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":5.0,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":0,"smoking_pack_years":29,"primary_tumor_size_cm":4.4,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.864408+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_160068","record_id":"REC_0016730","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":13.8,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.4,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":22.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.864786+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_860046","record_id":"REC_0016731","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ALK fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":16.4,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":4.5,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":39.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.865168+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_798510","record_id":"REC_0016732","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":11.0,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":7.3,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.865727+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_605503","record_id":"REC_0016733","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":11.0,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":2.6,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.866154+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_463369","record_id":"REC_0016734","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":17,"tmb_mutations_per_mb":5.1,"age_at_diagnosis":90,"sex":"female","ecog_performance_status":2,"smoking_pack_years":40,"primary_tumor_size_cm":5.7,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.866567+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_601585","record_id":"REC_0016735","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":4.7,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.866952+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_730197","record_id":"REC_0016736","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":19,"tmb_mutations_per_mb":6.0,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":4.5,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.867337+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_488671","record_id":"REC_0016737","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":6.0,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":6,"primary_tumor_size_cm":6.5,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":16.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.867680+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_913326","record_id":"REC_0016738","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":2,"smoking_pack_years":25,"primary_tumor_size_cm":5.4,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.868010+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_652303","record_id":"REC_0016739","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":8.3,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":4.4,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":5.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.868464+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_198711","record_id":"REC_0016740","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":3,"primary_tumor_size_cm":7.2,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":17.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.868841+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_612502","record_id":"REC_0016741","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":9.1,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.4,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":17.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.869220+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_487758","record_id":"REC_0016742","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":6.4,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":34,"primary_tumor_size_cm":4.2,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.869551+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_600679","record_id":"REC_0016743","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":17.0,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":7.4,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.869916+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_923160","record_id":"REC_0016744","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":15.7,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":4.8,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":16.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.870288+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_577926","record_id":"REC_0016745","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":5.1,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":38,"primary_tumor_size_cm":3.7,"metastatic_sites_count":8,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.870842+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_490649","record_id":"REC_0016746","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":7.7,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.871273+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_787877","record_id":"REC_0016747","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":6.1,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":36.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.871702+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_224030","record_id":"REC_0016748","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":3.9,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":0,"smoking_pack_years":43,"primary_tumor_size_cm":5.7,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.872161+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_438773","record_id":"REC_0016749","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":17.6,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":5.8,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.873176+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_121928","record_id":"REC_0016750","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":20,"tmb_mutations_per_mb":4.8,"age_at_diagnosis":50,"sex":"male","ecog_performance_status":0,"smoking_pack_years":51,"primary_tumor_size_cm":5.9,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":25.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.873648+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_572231","record_id":"REC_0016751","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":30,"tmb_mutations_per_mb":6.7,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":28,"primary_tumor_size_cm":6.4,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.874061+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_274542","record_id":"REC_0016752","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":2,"primary_tumor_size_cm":4.6,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":23.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.874455+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_281799","record_id":"REC_0016753","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":19.0,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":8.5,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":23.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.874882+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_174248","record_id":"REC_0016754","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":10.3,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":6.4,"metastatic_sites_count":3,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":8.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.875280+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_124694","record_id":"REC_0016755","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":0,"primary_tumor_size_cm":6.3,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":21.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.875667+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_470847","record_id":"REC_0016756","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":17.1,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":4.0,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.876044+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_611105","record_id":"REC_0016757","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":4.6,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":5,"primary_tumor_size_cm":6.8,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":23.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.876468+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_848574","record_id":"REC_0016758","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":6.4,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":6.7,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.877109+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_723951","record_id":"REC_0016759","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":10,"primary_tumor_size_cm":6.1,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":18.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.877540+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_238150","record_id":"REC_0016760","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":31,"tmb_mutations_per_mb":13.8,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":5.0,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.877875+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_774031","record_id":"REC_0016761","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":32,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":4.5,"metastatic_sites_count":8,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":7.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.878209+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_673779","record_id":"REC_0016762","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":2.1,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":2.1,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":17.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.878528+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_798575","record_id":"REC_0016763","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":7.3,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":6.5,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.878858+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_807651","record_id":"REC_0016764","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":5.2,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":6.1,"metastatic_sites_count":9,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.879200+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_174094","record_id":"REC_0016765","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":3.7,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":6.7,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.879544+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_197138","record_id":"REC_0016766","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":16,"tmb_mutations_per_mb":7.3,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":2,"smoking_pack_years":56,"primary_tumor_size_cm":5.4,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":7.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.879895+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_945988","record_id":"REC_0016767","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":17.4,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":5.9,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":21.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.880309+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_816036","record_id":"REC_0016768","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":19.4,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":9,"primary_tumor_size_cm":7.2,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.880733+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_988046","record_id":"REC_0016769","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":19.3,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":0,"primary_tumor_size_cm":6.0,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.881154+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_641424","record_id":"REC_0016770","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":5.2,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.881550+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_569159","record_id":"REC_0016771","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":2.3,"age_at_diagnosis":76,"sex":"male","ecog_performance_status":2,"smoking_pack_years":47,"primary_tumor_size_cm":3.6,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.882153+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_850668","record_id":"REC_0016772","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":14.8,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":8.5,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":28.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.882629+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_607735","record_id":"REC_0016773","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":16.8,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":20,"primary_tumor_size_cm":6.3,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.883046+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_650464","record_id":"REC_0016774","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":9.7,"age_at_diagnosis":74,"sex":"male","ecog_performance_status":2,"smoking_pack_years":20,"primary_tumor_size_cm":4.7,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.883429+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_775356","record_id":"REC_0016775","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":18.7,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":6.0,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.883830+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_889060","record_id":"REC_0016776","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":47,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":7.4,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.884346+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_239597","record_id":"REC_0016777","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":8.3,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":23,"primary_tumor_size_cm":5.9,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.884746+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_895630","record_id":"REC_0016778","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":5.2,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":67,"primary_tumor_size_cm":5.7,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.885163+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_507408","record_id":"REC_0016779","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":9.0,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":5.0,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.885576+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_555403","record_id":"REC_0016780","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":15.7,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":4.9,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.885963+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_377553","record_id":"REC_0016781","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":10.5,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":9,"primary_tumor_size_cm":7.6,"metastatic_sites_count":10,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.886382+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_344425","record_id":"REC_0016782","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":17,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.3,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":61.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.886779+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_843550","record_id":"REC_0016783","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":5.3,"metastatic_sites_count":8,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":6.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.887193+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_535066","record_id":"REC_0016784","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":14.9,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":7.1,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.887874+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_302509","record_id":"REC_0016785","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":18.8,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":1,"smoking_pack_years":4,"primary_tumor_size_cm":4.2,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.888425+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_534123","record_id":"REC_0016786","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":6.9,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":3.8,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.888890+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_529746","record_id":"REC_0016787","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":5,"primary_tumor_size_cm":7.0,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.889353+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_618679","record_id":"REC_0016788","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":14.9,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.9,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.889781+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_977248","record_id":"REC_0016789","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":20,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":56,"primary_tumor_size_cm":5.5,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":17.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.890194+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_532567","record_id":"REC_0016790","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":39,"primary_tumor_size_cm":4.6,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.890602+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_885318","record_id":"REC_0016791","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":0,"smoking_pack_years":24,"primary_tumor_size_cm":5.2,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":18.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.891059+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_707962","record_id":"REC_0016792","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":6.8,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.891480+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_445362","record_id":"REC_0016793","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":8.4,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":7.9,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.891891+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_392298","record_id":"REC_0016794","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":34,"primary_tumor_size_cm":6.8,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":4.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.892373+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_668492","record_id":"REC_0016795","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":18,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":3,"primary_tumor_size_cm":5.3,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.892791+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_321158","record_id":"REC_0016796","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":11.1,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":6.2,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":21.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.893202+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_336103","record_id":"REC_0016797","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":74,"sex":"male","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":3.9,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":25.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.893753+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_765581","record_id":"REC_0016798","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":4.2,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":6.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.894160+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_713825","record_id":"REC_0016799","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":0,"smoking_pack_years":6,"primary_tumor_size_cm":4.5,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":16.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.894555+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_254047","record_id":"REC_0016800","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":15.3,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":5.5,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.894960+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_149900","record_id":"REC_0016801","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":16.3,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":6.2,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":16.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.895349+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_695057","record_id":"REC_0016802","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":15,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.3,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.895721+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_133971","record_id":"REC_0016803","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":5.3,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":5.8,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":31.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.896043+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_491952","record_id":"REC_0016804","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":15.4,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":4.0,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.896514+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_472492","record_id":"REC_0016805","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":14.5,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":3.8,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.896872+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_158064","record_id":"REC_0016806","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":5.8,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.897220+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_505853","record_id":"REC_0016807","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":7.9,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":6.7,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.897515+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_575656","record_id":"REC_0016808","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":4.2,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":7.2,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":5.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.897808+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_154280","record_id":"REC_0016809","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":14.1,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":21,"primary_tumor_size_cm":4.5,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.898129+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_948121","record_id":"REC_0016810","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":2,"smoking_pack_years":0,"primary_tumor_size_cm":7.6,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":7.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.898641+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_585897","record_id":"REC_0016811","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":8.5,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.2,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":53.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.899056+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_206050","record_id":"REC_0016812","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":3,"smoking_pack_years":9,"primary_tumor_size_cm":6.4,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.899453+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_999118","record_id":"REC_0016813","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":6.9,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":24,"primary_tumor_size_cm":5.3,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.899840+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_262937","record_id":"REC_0016814","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":66,"primary_tumor_size_cm":5.9,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.900333+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_299701","record_id":"REC_0016815","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":8.3,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":7.2,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":20.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.900751+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_929189","record_id":"REC_0016816","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":16.9,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":8.2,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.901132+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_500498","record_id":"REC_0016817","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":4.8,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":57,"primary_tumor_size_cm":3.3,"metastatic_sites_count":3,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.901500+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_153408","record_id":"REC_0016818","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":2.1,"age_at_diagnosis":74,"sex":"male","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":5.8,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":20.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.901900+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_948812","record_id":"REC_0016819","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":31,"tmb_mutations_per_mb":5.2,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":5.2,"metastatic_sites_count":8,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.902293+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_203690","record_id":"REC_0016820","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":22.6,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":4.1,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":24.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.902712+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_422702","record_id":"REC_0016821","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":8.6,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.2,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.903123+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_843995","record_id":"REC_0016822","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":53,"sex":"male","ecog_performance_status":0,"smoking_pack_years":48,"primary_tumor_size_cm":6.0,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":18.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.903529+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_767303","record_id":"REC_0016823","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":19.2,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":3.2,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.904157+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_421198","record_id":"REC_0016824","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":9.8,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":6.1,"metastatic_sites_count":9,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.904606+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_192304","record_id":"REC_0016825","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":3.5,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.905011+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_961502","record_id":"REC_0016826","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":5.7,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":70,"primary_tumor_size_cm":5.8,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.905392+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_231798","record_id":"REC_0016827","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":5.4,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.905790+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_704674","record_id":"REC_0016828","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":9.5,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":5.2,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.906235+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_420788","record_id":"REC_0016829","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":4.0,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.906681+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_623094","record_id":"REC_0016830","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":0,"smoking_pack_years":29,"primary_tumor_size_cm":5.9,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.907095+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_750675","record_id":"REC_0016831","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":8.6,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":5.5,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.907493+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_769952","record_id":"REC_0016832","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":14.5,"age_at_diagnosis":81,"sex":"male","ecog_performance_status":2,"smoking_pack_years":20,"primary_tumor_size_cm":5.0,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":27.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.907905+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_615561","record_id":"REC_0016833","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":5.8,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":30.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.908541+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_932985","record_id":"REC_0016834","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":16.3,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":4.6,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":19.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.909034+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_345139","record_id":"REC_0016835","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":32,"tmb_mutations_per_mb":6.4,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":2,"smoking_pack_years":3,"primary_tumor_size_cm":5.1,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.909518+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_409051","record_id":"REC_0016836","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":17,"tmb_mutations_per_mb":6.3,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":61,"primary_tumor_size_cm":5.0,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":7.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.910176+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_833996","record_id":"REC_0016837","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":2.7,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":2,"smoking_pack_years":48,"primary_tumor_size_cm":5.8,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":25.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.910871+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_824591","record_id":"REC_0016838","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":35,"tmb_mutations_per_mb":14.0,"age_at_diagnosis":86,"sex":"female","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":5.8,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.911188+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_130086","record_id":"REC_0016839","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":4.2,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.911499+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_232142","record_id":"REC_0016840","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":16.7,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":2,"smoking_pack_years":24,"primary_tumor_size_cm":4.7,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":17.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.911882+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_419157","record_id":"REC_0016841","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":4.0,"age_at_diagnosis":76,"sex":"male","ecog_performance_status":1,"smoking_pack_years":43,"primary_tumor_size_cm":8.4,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":22.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.912476+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_999282","record_id":"REC_0016842","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":30,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":3.0,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.912992+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_742442","record_id":"REC_0016843","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":37,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":4.2,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.913475+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_595069","record_id":"REC_0016844","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":4.0,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":26.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.913915+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_961745","record_id":"REC_0016845","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":3.5,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":6.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.914316+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_617750","record_id":"REC_0016846","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":5.2,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":5.8,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":24.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.914726+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_862907","record_id":"REC_0016847","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":13.1,"age_at_diagnosis":84,"sex":"female","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":6.8,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.915072+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_307900","record_id":"REC_0016848","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":8.5,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":37,"primary_tumor_size_cm":4.9,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.915431+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_146239","record_id":"REC_0016849","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":86,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":6.5,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.916139+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_674017","record_id":"REC_0016850","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":15,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":4.3,"metastatic_sites_count":9,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.916846+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_206023","record_id":"REC_0016851","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":7.2,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":27.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.917541+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_440445","record_id":"REC_0016852","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":6.0,"metastatic_sites_count":8,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":4.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.918195+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_306688","record_id":"REC_0016853","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":22.4,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":5.1,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":21.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.918650+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_922627","record_id":"REC_0016854","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":16,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":7.5,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.919076+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_269041","record_id":"REC_0016855","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":14.4,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":6.1,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.919486+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_214421","record_id":"REC_0016856","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":76,"sex":"male","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":4.4,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":25.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.919963+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_602776","record_id":"REC_0016857","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":5.6,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.920644+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_490598","record_id":"REC_0016858","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":15.2,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":4.3,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":27.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.921128+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_829399","record_id":"REC_0016859","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":9.7,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":6.4,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.921588+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_307972","record_id":"REC_0016860","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":4.2,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":4.7,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":25.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.922001+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_955776","record_id":"REC_0016861","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":11.5,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":20,"primary_tumor_size_cm":3.6,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.922396+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_769505","record_id":"REC_0016862","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":19,"tmb_mutations_per_mb":7.9,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":6.0,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":6.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.922998+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_857962","record_id":"REC_0016863","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":5.7,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":3.5,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":17.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.923486+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_107636","record_id":"REC_0016864","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":23,"primary_tumor_size_cm":6.2,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":6.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.923912+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_188235","record_id":"REC_0016865","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":5.0,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":28.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.924417+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_454176","record_id":"REC_0016866","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":8.0,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":5.4,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.925049+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_318496","record_id":"REC_0016867","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":7.9,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":4.7,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.925453+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_480491","record_id":"REC_0016868","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":8.5,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":7.6,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":8.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.925825+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_505482","record_id":"REC_0016869","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":13.5,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":6.3,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":4.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.926181+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_337608","record_id":"REC_0016870","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":0,"smoking_pack_years":50,"primary_tumor_size_cm":4.7,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.926527+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_393853","record_id":"REC_0016871","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":32,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":1,"smoking_pack_years":36,"primary_tumor_size_cm":5.5,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":21.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.926895+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_557058","record_id":"REC_0016872","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":32,"tmb_mutations_per_mb":5.5,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":1,"smoking_pack_years":60,"primary_tumor_size_cm":6.2,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.927251+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_174660","record_id":"REC_0016873","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":5.7,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":3.7,"metastatic_sites_count":8,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.927595+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_560519","record_id":"REC_0016874","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":7.4,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":1,"smoking_pack_years":45,"primary_tumor_size_cm":6.1,"metastatic_sites_count":3,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.927922+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_775344","record_id":"REC_0016875","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":3.8,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.928545+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_672802","record_id":"REC_0016876","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":11.0,"age_at_diagnosis":80,"sex":"male","ecog_performance_status":2,"smoking_pack_years":10,"primary_tumor_size_cm":7.2,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.928980+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_956396","record_id":"REC_0016877","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":15,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":6.2,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":7.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.929380+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_744214","record_id":"REC_0016878","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":5,"primary_tumor_size_cm":6.7,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.929788+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_620447","record_id":"REC_0016879","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":16.0,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":5.8,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.930195+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_583994","record_id":"REC_0016880","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":10.3,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":31,"primary_tumor_size_cm":4.2,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":22.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.930543+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_812284","record_id":"REC_0016881","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":32,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":5.8,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":20.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.930855+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_524425","record_id":"REC_0016882","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":8.0,"age_at_diagnosis":78,"sex":"male","ecog_performance_status":1,"smoking_pack_years":24,"primary_tumor_size_cm":6.0,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.931224+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_350036","record_id":"REC_0016883","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":5.9,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":7.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.931615+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_795779","record_id":"REC_0016884","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":6.1,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":19.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.931981+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_191000","record_id":"REC_0016885","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":3,"smoking_pack_years":14,"primary_tumor_size_cm":6.2,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":16.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.932582+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_323840","record_id":"REC_0016886","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":9.9,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":6.9,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.933042+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_167811","record_id":"REC_0016887","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":4.1,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":24.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.933426+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_470350","record_id":"REC_0016888","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":4.7,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.934009+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_887809","record_id":"REC_0016889","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":2,"smoking_pack_years":21,"primary_tumor_size_cm":4.1,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.934412+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_928663","record_id":"REC_0016890","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":34,"tmb_mutations_per_mb":11.1,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":4.2,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.934809+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_178308","record_id":"REC_0016891","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":29,"primary_tumor_size_cm":3.5,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.935195+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_979516","record_id":"REC_0016892","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None","pd_l1_tps_percent":18,"tmb_mutations_per_mb":8.4,"age_at_diagnosis":79,"sex":"male","ecog_performance_status":2,"smoking_pack_years":78,"primary_tumor_size_cm":5.3,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":26.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.935663+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_564821","record_id":"REC_0016893","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":14.7,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.9,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":20.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.936187+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_779168","record_id":"REC_0016894","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":20,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":0,"smoking_pack_years":29,"primary_tumor_size_cm":6.7,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.936646+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_618202","record_id":"REC_0016895","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":8.7,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":4.1,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.937102+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_190753","record_id":"REC_0016896","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":6.8,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":45.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.937467+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_812922","record_id":"REC_0016897","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":7.3,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.937832+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_330707","record_id":"REC_0016898","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":15.8,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":5.0,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":7.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.938242+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_155018","record_id":"REC_0016899","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":1,"smoking_pack_years":57,"primary_tumor_size_cm":5.2,"metastatic_sites_count":3,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.938625+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_794013","record_id":"REC_0016900","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":15.1,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":7.0,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.939038+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_407630","record_id":"REC_0016901","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":5.7,"age_at_diagnosis":90,"sex":"female","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":7.2,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":34.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.939632+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_511808","record_id":"REC_0016902","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":6.7,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.940066+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_346508","record_id":"REC_0016903","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":5.5,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":7.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.940548+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_995685","record_id":"REC_0016904","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":9.0,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":6.1,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":18.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.940927+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_885041","record_id":"REC_0016905","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":0,"smoking_pack_years":0,"primary_tumor_size_cm":5.8,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.941307+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_344842","record_id":"REC_0016906","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":7.1,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.941668+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_322002","record_id":"REC_0016907","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":1,"smoking_pack_years":28,"primary_tumor_size_cm":5.5,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":40.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.942026+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_362228","record_id":"REC_0016908","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":8.1,"age_at_diagnosis":83,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":5.8,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":7.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.942377+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_836624","record_id":"REC_0016909","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":4.3,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":25.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.942719+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_490203","record_id":"REC_0016910","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":41,"primary_tumor_size_cm":3.9,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.943055+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_646232","record_id":"REC_0016911","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":16.5,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":25,"primary_tumor_size_cm":3.1,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.943421+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_306609","record_id":"REC_0016912","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":16.6,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":5.8,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.943771+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_824126","record_id":"REC_0016913","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":4.9,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.944280+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_317117","record_id":"REC_0016914","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":37,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":6.1,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.944869+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_963594","record_id":"REC_0016915","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":16.4,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":8.4,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.945285+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_998749","record_id":"REC_0016916","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":9.0,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":54,"primary_tumor_size_cm":5.4,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.945629+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_755664","record_id":"REC_0016917","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":4.9,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":2,"smoking_pack_years":7,"primary_tumor_size_cm":4.4,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":21.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.945988+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_856316","record_id":"REC_0016918","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":16.1,"age_at_diagnosis":47,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":5.2,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.946365+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_406740","record_id":"REC_0016919","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":20,"tmb_mutations_per_mb":4.9,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":0,"smoking_pack_years":60,"primary_tumor_size_cm":5.5,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.946742+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_581099","record_id":"REC_0016920","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":30,"tmb_mutations_per_mb":4.3,"age_at_diagnosis":83,"sex":"female","ecog_performance_status":1,"smoking_pack_years":54,"primary_tumor_size_cm":4.5,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.947102+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_369643","record_id":"REC_0016921","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":8.6,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":6.7,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":52.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.947468+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_694049","record_id":"REC_0016922","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":18,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":51,"primary_tumor_size_cm":7.4,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.947841+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_200441","record_id":"REC_0016923","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":16.1,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":3.5,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.948375+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_146083","record_id":"REC_0016924","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":16,"tmb_mutations_per_mb":16.1,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":26,"primary_tumor_size_cm":4.5,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.948804+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_701405","record_id":"REC_0016925","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":4.2,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.949196+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_496398","record_id":"REC_0016926","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":3.3,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.949596+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_443444","record_id":"REC_0016927","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":6.1,"age_at_diagnosis":51,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":5.9,"metastatic_sites_count":8,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":17.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.950202+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_267571","record_id":"REC_0016928","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":10.5,"age_at_diagnosis":48,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":3.2,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.950662+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_802147","record_id":"REC_0016929","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":6.7,"age_at_diagnosis":53,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":3.0,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":17.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.951007+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_633140","record_id":"REC_0016930","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":15.7,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":4.6,"metastatic_sites_count":8,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.951350+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_397898","record_id":"REC_0016931","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":14.9,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.0,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.951705+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_720270","record_id":"REC_0016932","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":14.9,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":5.0,"metastatic_sites_count":3,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.952069+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_507342","record_id":"REC_0016933","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":7.9,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":3,"primary_tumor_size_cm":4.0,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":19.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.952500+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_188811","record_id":"REC_0016934","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":6.8,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":17.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.952885+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_666842","record_id":"REC_0016935","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":9.9,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":6.3,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.953278+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_109317","record_id":"REC_0016936","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":5.1,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.953661+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_592805","record_id":"REC_0016937","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":15,"tmb_mutations_per_mb":14.1,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":4.8,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":29.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.954042+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_663408","record_id":"REC_0016938","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":14.3,"age_at_diagnosis":83,"sex":"male","ecog_performance_status":1,"smoking_pack_years":24,"primary_tumor_size_cm":5.5,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.954395+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_773976","record_id":"REC_0016939","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":12,"tmb_mutations_per_mb":10.3,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":5.1,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.954723+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_658816","record_id":"REC_0016940","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":8.4,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":6.8,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":23.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.955308+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_597591","record_id":"REC_0016941","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":30,"tmb_mutations_per_mb":6.4,"age_at_diagnosis":50,"sex":"male","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":6.1,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.955692+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_618565","record_id":"REC_0016942","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":5.5,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":17.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.956032+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_289023","record_id":"REC_0016943","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":32,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":4.7,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.956537+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_963836","record_id":"REC_0016944","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":34,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":5.7,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":6.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.956934+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_991275","record_id":"REC_0016945","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":13.1,"age_at_diagnosis":51,"sex":"male","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":4.8,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.957356+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_521787","record_id":"REC_0016946","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":16,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":9.3,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":22.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.957725+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_623814","record_id":"REC_0016947","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":30,"tmb_mutations_per_mb":5.7,"age_at_diagnosis":83,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":7.5,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.958111+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_716826","record_id":"REC_0016948","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":5.2,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.958543+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_840344","record_id":"REC_0016949","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":5.3,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":6.9,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.959024+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_584086","record_id":"REC_0016950","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":8.1,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":4.0,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.959477+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_179308","record_id":"REC_0016951","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":18,"tmb_mutations_per_mb":15.5,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":7.2,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.959871+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_448091","record_id":"REC_0016952","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":7.4,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":31.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.960278+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_680218","record_id":"REC_0016953","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":42,"primary_tumor_size_cm":4.8,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":20.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.960946+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_777412","record_id":"REC_0016954","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":15.3,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":6.1,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.961457+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_746105","record_id":"REC_0016955","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":3.7,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":3,"smoking_pack_years":37,"primary_tumor_size_cm":4.0,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.961847+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_472062","record_id":"REC_0016956","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":35,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":5.0,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.962248+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_843551","record_id":"REC_0016957","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":7.3,"age_at_diagnosis":53,"sex":"female","ecog_performance_status":0,"smoking_pack_years":56,"primary_tumor_size_cm":5.5,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.962635+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_535101","record_id":"REC_0016958","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":6.5,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.962975+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_995001","record_id":"REC_0016959","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":16,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":4.5,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.963289+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_542486","record_id":"REC_0016960","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":9.8,"age_at_diagnosis":86,"sex":"female","ecog_performance_status":0,"smoking_pack_years":5,"primary_tumor_size_cm":7.3,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":18.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.963586+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_132439","record_id":"REC_0016961","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":28,"primary_tumor_size_cm":4.2,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.963896+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_860896","record_id":"REC_0016962","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":17.3,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":4.7,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.964376+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_298765","record_id":"REC_0016963","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":16.0,"age_at_diagnosis":74,"sex":"male","ecog_performance_status":3,"smoking_pack_years":16,"primary_tumor_size_cm":4.4,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":23.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.964802+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_116561","record_id":"REC_0016964","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":7.3,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":4.9,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":19.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.965201+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_238422","record_id":"REC_0016965","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":82,"sex":"male","ecog_performance_status":2,"smoking_pack_years":54,"primary_tumor_size_cm":7.5,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":20.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.965603+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_871953","record_id":"REC_0016966","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":10.3,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":4.5,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.966178+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_449544","record_id":"REC_0016967","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":5.6,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":24.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.966649+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_158833","record_id":"REC_0016968","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":53,"sex":"male","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":4.9,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.967125+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_371074","record_id":"REC_0016969","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":15.7,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":5.0,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.967513+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_932421","record_id":"REC_0016970","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":13.5,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":8.6,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.967865+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_323433","record_id":"REC_0016971","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.5,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":3.9,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":22.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.968398+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_731626","record_id":"REC_0016972","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":16.0,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":6.3,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.968829+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_511738","record_id":"REC_0016973","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":15,"tmb_mutations_per_mb":14.5,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":5.0,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":19.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.969226+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_494002","record_id":"REC_0016974","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":16,"tmb_mutations_per_mb":9.9,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":4.8,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.969630+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_330628","record_id":"REC_0016975","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":1.6,"age_at_diagnosis":76,"sex":"male","ecog_performance_status":2,"smoking_pack_years":74,"primary_tumor_size_cm":5.3,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.969990+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_864279","record_id":"REC_0016976","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":8.5,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":27,"primary_tumor_size_cm":6.6,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":24.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.970341+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_910871","record_id":"REC_0016977","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":6.1,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.970665+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_327663","record_id":"REC_0016978","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":17.8,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":6.1,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.971015+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_806849","record_id":"REC_0016979","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":4.1,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.971545+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_365704","record_id":"REC_0016980","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":5.5,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":42,"primary_tumor_size_cm":6.4,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":39.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.971955+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_198769","record_id":"REC_0016981","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":6.5,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.972452+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_105273","record_id":"REC_0016982","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":11.5,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":7.1,"metastatic_sites_count":3,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":6.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.972841+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_462059","record_id":"REC_0016983","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":5.7,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":16.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.973235+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_214013","record_id":"REC_0016984","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":54,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":5.8,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.973602+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_790920","record_id":"REC_0016985","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":2.2,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":45,"primary_tumor_size_cm":6.6,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":21.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.973926+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_191133","record_id":"REC_0016986","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":17.5,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":6.5,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":22.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.974205+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_960778","record_id":"REC_0016987","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":30,"tmb_mutations_per_mb":5.3,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":43,"primary_tumor_size_cm":6.3,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":29.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.974480+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_575916","record_id":"REC_0016988","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":0,"smoking_pack_years":5,"primary_tumor_size_cm":5.0,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.974787+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_964618","record_id":"REC_0016989","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":6.1,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":32,"primary_tumor_size_cm":6.0,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":23.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.975079+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_650596","record_id":"REC_0016990","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":18.6,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":5.5,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.975388+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_486307","record_id":"REC_0016991","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":7.3,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":26.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.975742+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_335331","record_id":"REC_0016992","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":6.6,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.976494+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_676063","record_id":"REC_0016993","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":32,"tmb_mutations_per_mb":6.0,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":73,"primary_tumor_size_cm":5.6,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":41.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.976917+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_190175","record_id":"REC_0016994","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":4.4,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":26.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.977321+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_341786","record_id":"REC_0016995","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":0,"smoking_pack_years":32,"primary_tumor_size_cm":6.4,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.977696+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_226931","record_id":"REC_0016996","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":19,"tmb_mutations_per_mb":4.8,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":3,"smoking_pack_years":53,"primary_tumor_size_cm":6.3,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":19.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.978064+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_392345","record_id":"REC_0016997","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":33,"tmb_mutations_per_mb":8.7,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":4.1,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.978397+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_175307","record_id":"REC_0016998","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":4.7,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.978697+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_152767","record_id":"REC_0016999","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":16,"tmb_mutations_per_mb":8.1,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":3,"smoking_pack_years":21,"primary_tumor_size_cm":5.4,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":19.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.979039+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_985890","record_id":"REC_0017000","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":4.3,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.979404+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_785754","record_id":"REC_0017001","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":13.3,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":7.2,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.979773+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_865000","record_id":"REC_0017002","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":18.9,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":5.6,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.980276+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_950791","record_id":"REC_0017003","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":13.3,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":6.2,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.980714+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_864967","record_id":"REC_0017004","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":7.4,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.0,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":18.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.981103+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_849347","record_id":"REC_0017005","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":5.7,"age_at_diagnosis":90,"sex":"male","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":3.9,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.981703+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_964751","record_id":"REC_0017006","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":32,"tmb_mutations_per_mb":5.5,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":32,"primary_tumor_size_cm":3.5,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":25.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.982148+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_335071","record_id":"REC_0017007","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":17,"tmb_mutations_per_mb":15.5,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":6.0,"metastatic_sites_count":8,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.982543+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_115558","record_id":"REC_0017008","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":4.6,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":20.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.982953+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_740357","record_id":"REC_0017009","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":14.4,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":6.8,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.983323+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_233473","record_id":"REC_0017010","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":15.8,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":4.7,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":16.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.983680+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_514620","record_id":"REC_0017011","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":21,"primary_tumor_size_cm":5.1,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":5.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.984058+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_267189","record_id":"REC_0017012","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":53,"sex":"male","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":4.0,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.984477+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_670275","record_id":"REC_0017013","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":2.7,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.984871+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_334121","record_id":"REC_0017014","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":16.5,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":5.3,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.985243+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_777720","record_id":"REC_0017015","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":5.3,"metastatic_sites_count":8,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.985609+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_770393","record_id":"REC_0017016","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":19.7,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":6.4,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.985988+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_819934","record_id":"REC_0017017","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":35,"tmb_mutations_per_mb":5.5,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":6.6,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.986358+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_656262","record_id":"REC_0017018","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":30,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":5.4,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.986888+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_236998","record_id":"REC_0017019","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":4.3,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":7.3,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.987341+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_940552","record_id":"REC_0017020","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":5.1,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.987774+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_369892","record_id":"REC_0017021","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":5.7,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":23,"primary_tumor_size_cm":4.7,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":16.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.988236+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_755743","record_id":"REC_0017022","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":7.4,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.988653+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_849553","record_id":"REC_0017023","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":4.8,"metastatic_sites_count":8,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":7.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.989039+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_902013","record_id":"REC_0017024","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":10.0,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":5.4,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.989425+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_506534","record_id":"REC_0017025","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":11.1,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":26,"primary_tumor_size_cm":4.7,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":16.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.989779+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_770026","record_id":"REC_0017026","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":21.0,"age_at_diagnosis":54,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":7.1,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.990115+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_839067","record_id":"REC_0017027","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":13.8,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":4.5,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":8.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.990459+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_940819","record_id":"REC_0017028","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":30,"tmb_mutations_per_mb":8.0,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":6.5,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":31.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.990821+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_504219","record_id":"REC_0017029","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":13.8,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":7.2,"metastatic_sites_count":3,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.991187+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_192127","record_id":"REC_0017030","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":5.0,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.991496+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_390304","record_id":"REC_0017031","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":13.3,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":6.0,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":7.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.991935+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_833702","record_id":"REC_0017032","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":3.8,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":47,"primary_tumor_size_cm":4.9,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.992340+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_412277","record_id":"REC_0017033","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":4.8,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":3,"smoking_pack_years":4,"primary_tumor_size_cm":8.0,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.992723+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_504264","record_id":"REC_0017034","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":4.7,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":35,"primary_tumor_size_cm":4.0,"metastatic_sites_count":3,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":6.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.993101+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_323515","record_id":"REC_0017035","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":39,"tmb_mutations_per_mb":15.1,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":5.0,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":17.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.993444+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_648365","record_id":"REC_0017036","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":31,"tmb_mutations_per_mb":10.1,"age_at_diagnosis":79,"sex":"male","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":5.2,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:01.993750+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_781237","record_id":"REC_0017037","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":18.2,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":5.6,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":39.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.994055+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_805535","record_id":"REC_0017038","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":9.0,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":3.8,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.994356+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_796421","record_id":"REC_0017039","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":14.8,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":5,"primary_tumor_size_cm":3.9,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":16.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.994683+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_770439","record_id":"REC_0017040","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":30,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":0,"smoking_pack_years":54,"primary_tumor_size_cm":7.2,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.995010+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_921984","record_id":"REC_0017041","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":3.0,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":6.7,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.995308+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_819810","record_id":"REC_0017042","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":5.9,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":0,"smoking_pack_years":50,"primary_tumor_size_cm":5.6,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":16.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.995605+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_597611","record_id":"REC_0017043","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":9.5,"age_at_diagnosis":53,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":7.3,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":23.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.995907+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_795581","record_id":"REC_0017044","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":3.8,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":6.4,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.996403+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_767895","record_id":"REC_0017045","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":5.0,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.996785+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_971050","record_id":"REC_0017046","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":84,"sex":"female","ecog_performance_status":2,"smoking_pack_years":3,"primary_tumor_size_cm":5.7,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.997134+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_982313","record_id":"REC_0017047","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":7.6,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":4.6,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":27.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.997456+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_871843","record_id":"REC_0017048","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":5.9,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":45,"primary_tumor_size_cm":6.0,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.997806+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_931778","record_id":"REC_0017049","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":15,"tmb_mutations_per_mb":5.5,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":7.0,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.998153+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_765805","record_id":"REC_0017050","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":4.8,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.998526+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_795858","record_id":"REC_0017051","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":36,"tmb_mutations_per_mb":9.7,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":6.5,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":7.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.998898+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_338140","record_id":"REC_0017052","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":20,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":54,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":7.5,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.999262+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_442991","record_id":"REC_0017053","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":4.8,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:01.999638+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_113141","record_id":"REC_0017054","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":4.1,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.000021+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_624430","record_id":"REC_0017055","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":8.0,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":6.3,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.000600+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_148200","record_id":"REC_0017056","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":6.7,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":3.3,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":5.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.000997+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_495462","record_id":"REC_0017057","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":39,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":21,"primary_tumor_size_cm":6.1,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":21.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.001531+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_368775","record_id":"REC_0017058","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":15.5,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":6.6,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":4.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.001917+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_927326","record_id":"REC_0017059","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":7.3,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":42,"primary_tumor_size_cm":2.3,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.002294+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_712274","record_id":"REC_0017060","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":15.0,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":0,"smoking_pack_years":3,"primary_tumor_size_cm":6.8,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.002692+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_419212","record_id":"REC_0017061","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":1,"smoking_pack_years":5,"primary_tumor_size_cm":8.0,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":19.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.003081+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_363473","record_id":"REC_0017062","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":5.4,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.003480+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_550905","record_id":"REC_0017063","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":32,"tmb_mutations_per_mb":14.3,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":5.9,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.003852+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_568001","record_id":"REC_0017064","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":13.3,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":5.8,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":23.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.004286+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_973203","record_id":"REC_0017065","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":6.3,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.004731+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_607044","record_id":"REC_0017066","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":14.9,"age_at_diagnosis":78,"sex":"male","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":4.1,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.005159+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_787710","record_id":"REC_0017067","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":11.0,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":5.5,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.005551+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_138226","record_id":"REC_0017068","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":5,"primary_tumor_size_cm":6.0,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.005941+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_468887","record_id":"REC_0017069","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":9.1,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":5.9,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.006303+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_282794","record_id":"REC_0017070","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":7.8,"metastatic_sites_count":9,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":8.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.006872+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_466775","record_id":"REC_0017071","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":5.9,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":66,"primary_tumor_size_cm":3.8,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.007274+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_453454","record_id":"REC_0017072","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":35,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":26,"primary_tumor_size_cm":5.1,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":28.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.007635+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_160362","record_id":"REC_0017073","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":11.1,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":4.9,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.007998+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_390688","record_id":"REC_0017074","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":16.0,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":5.7,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.008592+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_465449","record_id":"REC_0017075","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":11.0,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":6.6,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.008991+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_743976","record_id":"REC_0017076","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":16.2,"age_at_diagnosis":54,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":6.4,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":22.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.009363+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_852927","record_id":"REC_0017077","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":30,"tmb_mutations_per_mb":9.0,"age_at_diagnosis":77,"sex":"male","ecog_performance_status":2,"smoking_pack_years":69,"primary_tumor_size_cm":4.6,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.009734+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_638907","record_id":"REC_0017078","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":16,"tmb_mutations_per_mb":7.9,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":7.0,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.010101+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_874937","record_id":"REC_0017079","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":4.1,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":23.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.010417+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_633053","record_id":"REC_0017080","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":3.8,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":58,"primary_tumor_size_cm":6.7,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":16.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.010730+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_768119","record_id":"REC_0017081","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":18.7,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":1,"smoking_pack_years":5,"primary_tumor_size_cm":4.4,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.011071+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_913232","record_id":"REC_0017082","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":6.3,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":7.4,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":21.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.011449+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_442806","record_id":"REC_0017083","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":6.4,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":5,"primary_tumor_size_cm":4.1,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.012019+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_481422","record_id":"REC_0017084","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":7.0,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.012490+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_702459","record_id":"REC_0017085","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":4.8,"age_at_diagnosis":53,"sex":"female","ecog_performance_status":0,"smoking_pack_years":68,"primary_tumor_size_cm":4.9,"metastatic_sites_count":8,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":6.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.012861+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_379149","record_id":"REC_0017086","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":17,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":0,"primary_tumor_size_cm":5.0,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.013245+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_707549","record_id":"REC_0017087","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":3,"primary_tumor_size_cm":6.4,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.013624+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_434095","record_id":"REC_0017088","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":18,"tmb_mutations_per_mb":5.1,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":5.7,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.013999+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_382571","record_id":"REC_0017089","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":2,"smoking_pack_years":50,"primary_tumor_size_cm":4.3,"metastatic_sites_count":8,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":5.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.014367+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_532714","record_id":"REC_0017090","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":7.0,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.014743+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_504044","record_id":"REC_0017091","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":1.5,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":5.5,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.015083+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_127235","record_id":"REC_0017092","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":4.3,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":26.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.015466+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_414579","record_id":"REC_0017093","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":3.5,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":1,"smoking_pack_years":43,"primary_tumor_size_cm":4.3,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":18.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.015842+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_563760","record_id":"REC_0017094","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":6.4,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":32,"primary_tumor_size_cm":4.7,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":21.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.016346+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_497756","record_id":"REC_0017095","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":3.4,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.016775+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_412322","record_id":"REC_0017096","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":18,"tmb_mutations_per_mb":9.1,"age_at_diagnosis":90,"sex":"female","ecog_performance_status":2,"smoking_pack_years":29,"primary_tumor_size_cm":6.0,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.017441+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_628944","record_id":"REC_0017097","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":16.6,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":26,"primary_tumor_size_cm":6.0,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":20.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.017843+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_596108","record_id":"REC_0017098","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":9.7,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":4,"primary_tumor_size_cm":5.0,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.018216+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_252534","record_id":"REC_0017099","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":3,"smoking_pack_years":4,"primary_tumor_size_cm":5.4,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.018595+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_242015","record_id":"REC_0017100","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":8.4,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":4.8,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.018942+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_182890","record_id":"REC_0017101","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":10.3,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":6.0,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.019284+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_744233","record_id":"REC_0017102","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":51,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":8.3,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.019622+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_116976","record_id":"REC_0017103","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":18.5,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":6.4,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.020003+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_288432","record_id":"REC_0017104","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":5.1,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":8.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.020508+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_826835","record_id":"REC_0017105","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":3.1,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":22.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.020921+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_465400","record_id":"REC_0017106","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":15.3,"age_at_diagnosis":87,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":4.0,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.021319+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_538958","record_id":"REC_0017107","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":68,"primary_tumor_size_cm":7.2,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.021709+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_703097","record_id":"REC_0017108","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":19,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":1,"smoking_pack_years":61,"primary_tumor_size_cm":3.2,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":18.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.022083+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_498650","record_id":"REC_0017109","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":17.2,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":6.2,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.022587+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_925335","record_id":"REC_0017110","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":83,"sex":"female","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":6.5,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.022939+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_999241","record_id":"REC_0017111","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":15.9,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":4.5,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.023248+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_768932","record_id":"REC_0017112","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":15.3,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":2,"smoking_pack_years":10,"primary_tumor_size_cm":5.6,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":35.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.023541+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_222953","record_id":"REC_0017113","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":16.7,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":3,"smoking_pack_years":14,"primary_tumor_size_cm":7.7,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.023862+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_831140","record_id":"REC_0017114","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":5.9,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":4.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.024265+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_159334","record_id":"REC_0017115","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":90,"sex":"female","ecog_performance_status":3,"smoking_pack_years":20,"primary_tumor_size_cm":6.6,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.024611+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_775371","record_id":"REC_0017116","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":4.1,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":0,"smoking_pack_years":53,"primary_tumor_size_cm":5.1,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.024922+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_729231","record_id":"REC_0017117","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":2.6,"metastatic_sites_count":8,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":7.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.025247+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_219394","record_id":"REC_0017118","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":3.3,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":71,"primary_tumor_size_cm":4.8,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":18.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.025567+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_167699","record_id":"REC_0017119","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":14.0,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":5.6,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.025921+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_404419","record_id":"REC_0017120","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":14.0,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":0,"smoking_pack_years":3,"primary_tumor_size_cm":5.8,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.026297+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_101630","record_id":"REC_0017121","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":18.3,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":4.3,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.026662+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_584697","record_id":"REC_0017122","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":4.7,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":18.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.027201+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_124275","record_id":"REC_0017123","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":8.9,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":50,"primary_tumor_size_cm":6.1,"metastatic_sites_count":3,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":18.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.027596+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_819073","record_id":"REC_0017124","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":7,"primary_tumor_size_cm":4.3,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":5.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.027971+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_610576","record_id":"REC_0017125","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":4.4,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":5.1,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.028475+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_183665","record_id":"REC_0017126","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":18.9,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":27,"primary_tumor_size_cm":3.1,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.028843+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_823832","record_id":"REC_0017127","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":5.9,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":62,"primary_tumor_size_cm":7.0,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":7.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.029217+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_370990","record_id":"REC_0017128","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":1,"primary_tumor_size_cm":6.2,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":69.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.029591+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_590181","record_id":"REC_0017129","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":3.6,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":34,"primary_tumor_size_cm":6.1,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.029989+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_301453","record_id":"REC_0017130","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":9,"primary_tumor_size_cm":4.4,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.030389+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_806498","record_id":"REC_0017131","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":1,"smoking_pack_years":28,"primary_tumor_size_cm":3.8,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":22.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.030777+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_818555","record_id":"REC_0017132","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":17.2,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":3.0,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":21.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.031169+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_685582","record_id":"REC_0017133","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":27,"primary_tumor_size_cm":6.2,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.031560+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_365190","record_id":"REC_0017134","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":16.3,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.4,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.031933+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_521393","record_id":"REC_0017135","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":18.3,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":4.3,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":22.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.032702+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_862044","record_id":"REC_0017136","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":81,"sex":"male","ecog_performance_status":3,"smoking_pack_years":46,"primary_tumor_size_cm":5.8,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.033184+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_872671","record_id":"REC_0017137","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":4.0,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":20.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.033596+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_257402","record_id":"REC_0017138","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":13.8,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":5.4,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.033969+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_529259","record_id":"REC_0017139","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":16,"tmb_mutations_per_mb":4.6,"age_at_diagnosis":79,"sex":"male","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":3.3,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":22.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.034329+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_349566","record_id":"REC_0017140","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":14.4,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":4.1,"metastatic_sites_count":3,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.034674+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_531537","record_id":"REC_0017141","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":56,"primary_tumor_size_cm":6.5,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":6.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.035025+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_471216","record_id":"REC_0017142","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":15.8,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":4.0,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.035406+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_229116","record_id":"REC_0017143","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":16.7,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":4.6,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.035797+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_670054","record_id":"REC_0017144","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":36,"tmb_mutations_per_mb":13.1,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":3.2,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":18.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.036216+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_347670","record_id":"REC_0017145","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":31,"tmb_mutations_per_mb":13.3,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":4.6,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.036951+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_721460","record_id":"REC_0017146","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":28,"primary_tumor_size_cm":2.8,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.037674+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_420475","record_id":"REC_0017147","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":83,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":7.6,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.038066+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_137789","record_id":"REC_0017148","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":19.4,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":6.3,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":16.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.038614+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_340890","record_id":"REC_0017149","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":4.6,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.039143+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_119011","record_id":"REC_0017150","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":6.1,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.5,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.039521+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_527017","record_id":"REC_0017151","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":1,"smoking_pack_years":5,"primary_tumor_size_cm":6.3,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.039915+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_990762","record_id":"REC_0017152","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":77,"sex":"male","ecog_performance_status":1,"smoking_pack_years":55,"primary_tumor_size_cm":4.8,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":6.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.040509+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_574673","record_id":"REC_0017153","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":24,"primary_tumor_size_cm":4.9,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.040963+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_183711","record_id":"REC_0017154","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":5.3,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.041525+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_538614","record_id":"REC_0017155","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":8.3,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":5.7,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":25.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.041933+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_752633","record_id":"REC_0017156","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":9.9,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":5.4,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":6.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.042252+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_618691","record_id":"REC_0017157","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":13.8,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":6.2,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.042575+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_156974","record_id":"REC_0017158","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":4.5,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.043003+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_633766","record_id":"REC_0017159","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":3.2,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.043836+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_305341","record_id":"REC_0017160","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":21.6,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":7.0,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":26.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.044524+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_886505","record_id":"REC_0017161","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":6.7,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":19.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.045286+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_469818","record_id":"REC_0017162","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":50,"primary_tumor_size_cm":5.7,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.046085+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_579540","record_id":"REC_0017163","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":8.3,"age_at_diagnosis":52,"sex":"male","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":5.8,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":20.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.046543+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_913886","record_id":"REC_0017164","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":11.0,"age_at_diagnosis":53,"sex":"male","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":5.4,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":17.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.046939+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_153309","record_id":"REC_0017165","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":16.9,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":7.1,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.047364+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_391598","record_id":"REC_0017166","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":6.0,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.052052+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_363063","record_id":"REC_0017167","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":16,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":77,"sex":"male","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":7.4,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.054783+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_643521","record_id":"REC_0017168","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":6.7,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.055352+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_507154","record_id":"REC_0017169","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":1,"smoking_pack_years":81,"primary_tumor_size_cm":4.4,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.056304+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_331274","record_id":"REC_0017170","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":3.8,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":26,"primary_tumor_size_cm":6.7,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":30.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.056780+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_507387","record_id":"REC_0017171","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":11.0,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":5.3,"metastatic_sites_count":3,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.057164+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_554876","record_id":"REC_0017172","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":23,"primary_tumor_size_cm":6.7,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.057526+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_110149","record_id":"REC_0017173","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":6.7,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.057874+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_645066","record_id":"REC_0017174","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":16.4,"age_at_diagnosis":54,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":4.6,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.058462+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_916898","record_id":"REC_0017175","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":15,"tmb_mutations_per_mb":4.8,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":34,"primary_tumor_size_cm":6.0,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.058881+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_934394","record_id":"REC_0017176","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":5.3,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.059295+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_339406","record_id":"REC_0017177","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":17.1,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":4.2,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.059687+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_304559","record_id":"REC_0017178","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":18.6,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":5.2,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":22.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.060033+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_327163","record_id":"REC_0017179","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":4.9,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":46,"primary_tumor_size_cm":4.1,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":18.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.060677+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_140905","record_id":"REC_0017180","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":15.2,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":5.0,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.061062+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_312876","record_id":"REC_0017181","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":4.6,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.061395+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_746215","record_id":"REC_0017182","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":16,"tmb_mutations_per_mb":10.0,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":6.0,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":21.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.061696+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_998645","record_id":"REC_0017183","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":13,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":6,"primary_tumor_size_cm":5.3,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.061989+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_643641","record_id":"REC_0017184","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":3.6,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":21.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.062295+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_653683","record_id":"REC_0017185","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":2,"smoking_pack_years":33,"primary_tumor_size_cm":6.3,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":22.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.062604+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_127958","record_id":"REC_0017186","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":3,"smoking_pack_years":18,"primary_tumor_size_cm":6.8,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.062918+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_978615","record_id":"REC_0017187","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":3,"primary_tumor_size_cm":5.6,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.063411+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_167365","record_id":"REC_0017188","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":4.7,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.063775+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_703748","record_id":"REC_0017189","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":2.9,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":36,"primary_tumor_size_cm":5.0,"metastatic_sites_count":8,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.064233+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_486244","record_id":"REC_0017190","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":1,"smoking_pack_years":59,"primary_tumor_size_cm":4.3,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":7.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.064654+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_331312","record_id":"REC_0017191","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":14.1,"age_at_diagnosis":51,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":3.2,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.065059+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_961750","record_id":"REC_0017192","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":19.6,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":5.2,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.065422+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_171606","record_id":"REC_0017193","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":2,"smoking_pack_years":21,"primary_tumor_size_cm":7.7,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.065736+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_413407","record_id":"REC_0017194","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":3,"smoking_pack_years":14,"primary_tumor_size_cm":7.3,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.066071+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_141117","record_id":"REC_0017195","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":19,"tmb_mutations_per_mb":5.0,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":33,"primary_tumor_size_cm":6.3,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.066415+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_815996","record_id":"REC_0017196","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":30,"tmb_mutations_per_mb":9.1,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":5.4,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.066797+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_617498","record_id":"REC_0017197","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":38,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":0,"smoking_pack_years":64,"primary_tumor_size_cm":5.4,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.067131+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_353909","record_id":"REC_0017198","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":7.6,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":6.0,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.067461+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_210958","record_id":"REC_0017199","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":6.4,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":6.9,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":27.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.067761+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_297178","record_id":"REC_0017200","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":6.4,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.068371+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_797042","record_id":"REC_0017201","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":9.5,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":24,"primary_tumor_size_cm":5.1,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.068791+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_941123","record_id":"REC_0017202","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":20,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":40,"primary_tumor_size_cm":5.7,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":20.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.069124+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_742432","record_id":"REC_0017203","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":17.7,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":3,"smoking_pack_years":12,"primary_tumor_size_cm":4.0,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.069432+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_804909","record_id":"REC_0017204","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":15.7,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":4.5,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.069743+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_300736","record_id":"REC_0017205","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":14.5,"age_at_diagnosis":86,"sex":"female","ecog_performance_status":2,"smoking_pack_years":2,"primary_tumor_size_cm":6.2,"metastatic_sites_count":8,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.070030+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_670545","record_id":"REC_0017206","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":3.8,"age_at_diagnosis":75,"sex":"male","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":4.6,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.070312+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_643048","record_id":"REC_0017207","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":28,"primary_tumor_size_cm":6.6,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.070614+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_314575","record_id":"REC_0017208","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":5.3,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":4.2,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":6.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.070911+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_352688","record_id":"REC_0017209","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":17.0,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":4.5,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.071216+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_721066","record_id":"REC_0017210","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":7.9,"age_at_diagnosis":86,"sex":"male","ecog_performance_status":2,"smoking_pack_years":10,"primary_tumor_size_cm":5.5,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.071527+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_334586","record_id":"REC_0017211","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":19,"tmb_mutations_per_mb":15.8,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":27,"primary_tumor_size_cm":6.0,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.071846+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_489767","record_id":"REC_0017212","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":6.7,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.072367+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_891306","record_id":"REC_0017213","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":3,"smoking_pack_years":19,"primary_tumor_size_cm":5.7,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":50.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.072922+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_567247","record_id":"REC_0017214","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":52,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":5.4,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":21.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.073322+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_504727","record_id":"REC_0017215","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":6.0,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":4.2,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":6.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.073660+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_858198","record_id":"REC_0017216","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":86,"sex":"female","ecog_performance_status":3,"smoking_pack_years":42,"primary_tumor_size_cm":6.0,"metastatic_sites_count":3,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":16.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.074010+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_781720","record_id":"REC_0017217","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":1,"smoking_pack_years":5,"primary_tumor_size_cm":4.8,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":60.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.074389+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_400478","record_id":"REC_0017218","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":1,"primary_tumor_size_cm":6.4,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":8.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.074722+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_648093","record_id":"REC_0017219","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":4.5,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":5.6,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":16.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.075009+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_996057","record_id":"REC_0017220","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":8.5,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":5.9,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.075282+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_677760","record_id":"REC_0017221","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":18,"tmb_mutations_per_mb":8.6,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":5.8,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.075558+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_255209","record_id":"REC_0017222","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":6.9,"age_at_diagnosis":85,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":6.8,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":23.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.075839+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_312323","record_id":"REC_0017223","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":14.8,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":27,"primary_tumor_size_cm":5.6,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.076279+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_692925","record_id":"REC_0017224","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":16.9,"age_at_diagnosis":83,"sex":"female","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":6.5,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.076630+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_698093","record_id":"REC_0017225","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":3,"smoking_pack_years":38,"primary_tumor_size_cm":6.1,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.076929+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_512159","record_id":"REC_0017226","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":13.8,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":4.7,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":27.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.077364+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_460708","record_id":"REC_0017227","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":3.5,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":32,"primary_tumor_size_cm":5.9,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.077678+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_967510","record_id":"REC_0017228","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":31,"tmb_mutations_per_mb":5.6,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":63,"primary_tumor_size_cm":4.8,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":5.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.077999+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_368353","record_id":"REC_0017229","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":35,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":23,"primary_tumor_size_cm":6.0,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":17.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.078325+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_138565","record_id":"REC_0017230","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":6.4,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":4.7,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":20.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.078637+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_821710","record_id":"REC_0017231","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":5.2,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":4.0,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.078942+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_728070","record_id":"REC_0017232","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":8.6,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":2,"smoking_pack_years":45,"primary_tumor_size_cm":2.9,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.079260+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_891214","record_id":"REC_0017233","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":83,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":7.1,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":6.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.079553+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_913047","record_id":"REC_0017234","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":8.5,"age_at_diagnosis":52,"sex":"male","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":6.0,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.079816+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_533961","record_id":"REC_0017235","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ALK fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":14.1,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":5.0,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":33.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.080142+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_111698","record_id":"REC_0017236","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":17.3,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":5.9,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":5.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.080476+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_106750","record_id":"REC_0017237","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":10.5,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":4.8,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":21.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.080800+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_431497","record_id":"REC_0017238","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":75,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":5.1,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.081144+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_173487","record_id":"REC_0017239","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":79,"sex":"male","ecog_performance_status":3,"smoking_pack_years":18,"primary_tumor_size_cm":4.7,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.081700+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_869315","record_id":"REC_0017240","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":9.5,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":30,"primary_tumor_size_cm":3.3,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":18.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.082145+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_848511","record_id":"REC_0017241","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":4.5,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.082496+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_371487","record_id":"REC_0017242","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":14.7,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":6.0,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.082825+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_301066","record_id":"REC_0017243","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":3.0,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":7.1,"metastatic_sites_count":8,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":19.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.083143+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_138222","record_id":"REC_0017244","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":6.0,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":6.9,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.083485+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_234467","record_id":"REC_0017245","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":17,"tmb_mutations_per_mb":1.5,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":4.9,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.083806+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_171002","record_id":"REC_0017246","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":16.2,"age_at_diagnosis":50,"sex":"male","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":7.0,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":16.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.084877+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_599770","record_id":"REC_0017247","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":5.8,"metastatic_sites_count":8,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.085485+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_108689","record_id":"REC_0017248","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":52,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":6.1,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.085904+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_574179","record_id":"REC_0017249","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":7.6,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":1,"smoking_pack_years":5,"primary_tumor_size_cm":5.5,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":4.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.086290+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_945716","record_id":"REC_0017250","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":49,"sex":"male","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":4.5,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.086639+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_681779","record_id":"REC_0017251","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":14,"tmb_mutations_per_mb":5.6,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":1,"smoking_pack_years":31,"primary_tumor_size_cm":5.7,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.086989+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_283545","record_id":"REC_0017252","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":3.8,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.087497+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_511509","record_id":"REC_0017253","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":16.6,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":5.5,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.087872+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_109438","record_id":"REC_0017254","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":7.2,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.088312+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_429248","record_id":"REC_0017255","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":9,"primary_tumor_size_cm":6.0,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.088700+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_641333","record_id":"REC_0017256","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":4.5,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.089039+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_593637","record_id":"REC_0017257","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":18.7,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":7.5,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.089367+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_654031","record_id":"REC_0017258","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":7.9,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":5.0,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.089695+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_720511","record_id":"REC_0017259","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None","pd_l1_tps_percent":18,"tmb_mutations_per_mb":5.2,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":1,"smoking_pack_years":62,"primary_tumor_size_cm":8.0,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":24.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.090016+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_860900","record_id":"REC_0017260","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":10.5,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":5.1,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.090346+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_934167","record_id":"REC_0017261","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":21.5,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":5.8,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.090661+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_221203","record_id":"REC_0017262","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":4.7,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":22.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.090978+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_570634","record_id":"REC_0017263","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":14.0,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":4.6,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.091285+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_941743","record_id":"REC_0017264","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":14.0,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":4.7,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.091614+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_293647","record_id":"REC_0017265","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":20,"primary_tumor_size_cm":3.9,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.092211+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_785051","record_id":"REC_0017266","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":2.6,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":43.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.092693+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_988308","record_id":"REC_0017267","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":30,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":6.5,"metastatic_sites_count":9,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.093121+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_201582","record_id":"REC_0017268","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":4.3,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":16.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.097259+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_215595","record_id":"REC_0017269","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":4.6,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.097683+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_113197","record_id":"REC_0017270","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":6.0,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":0,"smoking_pack_years":55,"primary_tumor_size_cm":5.3,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.098106+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_465157","record_id":"REC_0017271","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":2.6,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":0,"primary_tumor_size_cm":7.6,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":5.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.098550+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_661296","record_id":"REC_0017272","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":14.9,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":6.1,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":24.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.098950+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_739140","record_id":"REC_0017273","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":23.1,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":4.4,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":22.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.099299+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_140845","record_id":"REC_0017274","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":10.1,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":5.8,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.099603+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_491779","record_id":"REC_0017275","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":30,"tmb_mutations_per_mb":6.4,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":5.3,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":23.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.099926+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_268452","record_id":"REC_0017276","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":14.9,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":20,"primary_tumor_size_cm":6.9,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":6.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.100391+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_596968","record_id":"REC_0017277","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":8.6,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":20.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.100789+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_742820","record_id":"REC_0017278","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":1,"smoking_pack_years":0,"primary_tumor_size_cm":5.4,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.101352+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_535528","record_id":"REC_0017279","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":10.1,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":7.8,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.101777+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_961540","record_id":"REC_0017280","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":15.6,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":3.2,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.102134+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_512439","record_id":"REC_0017281","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":8.9,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":4.8,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.102467+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_624809","record_id":"REC_0017282","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":15.7,"age_at_diagnosis":83,"sex":"male","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":6.0,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":4.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.102802+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_952037","record_id":"REC_0017283","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":14.9,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":5.1,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":21.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.103127+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_718411","record_id":"REC_0017284","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":9.7,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":6.6,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":5.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.103448+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_214517","record_id":"REC_0017285","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":8.7,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":5.7,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":23.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.103774+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_421904","record_id":"REC_0017286","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":5.5,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":36.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.104263+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_741697","record_id":"REC_0017287","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":8.1,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":8,"primary_tumor_size_cm":5.6,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.104669+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_858396","record_id":"REC_0017288","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":4.7,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.105017+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_190275","record_id":"REC_0017289","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":18.1,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":3.6,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":5.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.105367+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_413529","record_id":"REC_0017290","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":5.1,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":3.9,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.105684+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_908482","record_id":"REC_0017291","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":18.3,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":6.3,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.106139+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_284107","record_id":"REC_0017292","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":34,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":4,"primary_tumor_size_cm":5.3,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":16.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.106483+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_289636","record_id":"REC_0017293","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":17.9,"age_at_diagnosis":54,"sex":"male","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":7.0,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.106783+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_323284","record_id":"REC_0017294","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":10.3,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":5.2,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.107080+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_346748","record_id":"REC_0017295","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":4.6,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":8,"primary_tumor_size_cm":4.8,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.107379+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_144059","record_id":"REC_0017296","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":13.3,"age_at_diagnosis":74,"sex":"male","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":6.2,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":19.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.107696+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_158028","record_id":"REC_0017297","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":17,"tmb_mutations_per_mb":8.6,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":38,"primary_tumor_size_cm":3.3,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.107997+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_473763","record_id":"REC_0017298","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":6.0,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":48.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.108426+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_325270","record_id":"REC_0017299","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":20,"tmb_mutations_per_mb":17.7,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":7.5,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.108825+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_819221","record_id":"REC_0017300","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":16.5,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":6.0,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":6.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.109183+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_508784","record_id":"REC_0017301","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":10.3,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":5.6,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.109496+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_295180","record_id":"REC_0017302","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":8.0,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":28,"primary_tumor_size_cm":5.6,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.109801+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_594535","record_id":"REC_0017303","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":6.7,"age_at_diagnosis":47,"sex":"female","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":4.2,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.110094+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_611476","record_id":"REC_0017304","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":4.0,"age_at_diagnosis":49,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":5.2,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.110536+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_664919","record_id":"REC_0017305","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":8.9,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":5.9,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.110864+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_403704","record_id":"REC_0017306","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":6.3,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":6.7,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.111133+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_330157","record_id":"REC_0017307","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":6.9,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.111393+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_209541","record_id":"REC_0017308","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":5.6,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.111672+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_544702","record_id":"REC_0017309","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":8.5,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":4,"primary_tumor_size_cm":6.3,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.111963+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_828947","record_id":"REC_0017310","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":16,"tmb_mutations_per_mb":22.4,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":6.0,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":27.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.113727+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_681675","record_id":"REC_0017311","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":3,"smoking_pack_years":0,"primary_tumor_size_cm":4.9,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.114117+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_122500","record_id":"REC_0017312","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":15.1,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":6.3,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.114498+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_521892","record_id":"REC_0017313","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":8.9,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":3,"smoking_pack_years":49,"primary_tumor_size_cm":6.1,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":20.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.114842+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_936275","record_id":"REC_0017314","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":31,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":7.0,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":18.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.115290+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_479897","record_id":"REC_0017315","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":0,"smoking_pack_years":45,"primary_tumor_size_cm":7.0,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.115665+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_933353","record_id":"REC_0017316","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":16.5,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":6.5,"metastatic_sites_count":3,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.116025+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_275560","record_id":"REC_0017317","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":9.8,"age_at_diagnosis":54,"sex":"female","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":8.9,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.116771+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_557332","record_id":"REC_0017318","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":13.5,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":4.1,"metastatic_sites_count":9,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.117266+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_953670","record_id":"REC_0017319","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":4.4,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":5.1,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.117728+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_391562","record_id":"REC_0017320","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":15.9,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":6.6,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.118201+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_396527","record_id":"REC_0017321","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":13,"tmb_mutations_per_mb":15.6,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":3.2,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.118652+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_510922","record_id":"REC_0017322","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":7.8,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.119047+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_194104","record_id":"REC_0017323","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":18,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":24,"primary_tumor_size_cm":4.4,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":7.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.122541+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_270489","record_id":"REC_0017324","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":13.3,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":2.3,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":7.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.122931+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_913412","record_id":"REC_0017325","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":5.3,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.123251+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_429356","record_id":"REC_0017326","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":8.5,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":5.3,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.123588+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_710514","record_id":"REC_0017327","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":49,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":4.9,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":23.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.123914+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_812569","record_id":"REC_0017328","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.0,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":5.8,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.124365+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_859696","record_id":"REC_0017329","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":15.9,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":26,"primary_tumor_size_cm":5.7,"metastatic_sites_count":3,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":5.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.124767+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_842519","record_id":"REC_0017330","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":20,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":10,"primary_tumor_size_cm":5.0,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.125275+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_290890","record_id":"REC_0017331","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":10.3,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":5.1,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":23.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.125619+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_648401","record_id":"REC_0017332","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":6.7,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":22.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.125949+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_716347","record_id":"REC_0017333","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":32,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":1,"smoking_pack_years":1,"primary_tumor_size_cm":5.0,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":5.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.126317+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_225173","record_id":"REC_0017334","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":5.6,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":18.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.126699+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_888237","record_id":"REC_0017335","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":6.4,"age_at_diagnosis":84,"sex":"female","ecog_performance_status":1,"smoking_pack_years":42,"primary_tumor_size_cm":5.6,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.127070+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_244586","record_id":"REC_0017336","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.8,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":5.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.127492+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_322701","record_id":"REC_0017337","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":5.9,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.128308+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_823196","record_id":"REC_0017338","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":5.1,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":39,"primary_tumor_size_cm":7.0,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.128639+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_171797","record_id":"REC_0017339","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":6.0,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":48.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.128970+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_938723","record_id":"REC_0017340","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.0,"age_at_diagnosis":51,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":5.7,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.129382+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_584788","record_id":"REC_0017341","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":8.1,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.0,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":23.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.129749+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_288706","record_id":"REC_0017342","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":5.7,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":17.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.130089+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_497606","record_id":"REC_0017343","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":7.3,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":30,"primary_tumor_size_cm":5.6,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.130686+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_439942","record_id":"REC_0017344","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":5.0,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":5.2,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":22.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.131256+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_624464","record_id":"REC_0017345","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":4.5,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":21.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.131729+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_403218","record_id":"REC_0017346","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":5.9,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":6.4,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.132294+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_364830","record_id":"REC_0017347","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":16.9,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":3,"smoking_pack_years":3,"primary_tumor_size_cm":7.4,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":20.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.132793+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_699150","record_id":"REC_0017348","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":4.2,"age_at_diagnosis":88,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":4.4,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.133188+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_889708","record_id":"REC_0017349","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":1,"primary_tumor_size_cm":5.8,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.133574+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_184833","record_id":"REC_0017350","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":20,"tmb_mutations_per_mb":5.2,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":38,"primary_tumor_size_cm":6.0,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":18.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.133929+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_778513","record_id":"REC_0017351","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":18.3,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":3,"smoking_pack_years":13,"primary_tumor_size_cm":4.2,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.134273+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_984204","record_id":"REC_0017352","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":13.8,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":5.9,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":19.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.134620+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_344639","record_id":"REC_0017353","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":16.0,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":3.8,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.134956+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_576126","record_id":"REC_0017354","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":4.7,"metastatic_sites_count":10,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.135261+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_153047","record_id":"REC_0017355","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":3.9,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":2,"smoking_pack_years":22,"primary_tumor_size_cm":5.2,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.135589+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_786455","record_id":"REC_0017356","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":14.8,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":5.2,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.136240+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_901524","record_id":"REC_0017357","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":5,"primary_tumor_size_cm":7.9,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.136699+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_282238","record_id":"REC_0017358","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":4.4,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":33,"primary_tumor_size_cm":5.5,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.137071+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_970959","record_id":"REC_0017359","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":16,"tmb_mutations_per_mb":6.3,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":4,"primary_tumor_size_cm":6.2,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.137418+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_895641","record_id":"REC_0017360","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":45,"primary_tumor_size_cm":6.0,"metastatic_sites_count":3,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.137768+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_318284","record_id":"REC_0017361","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":9.7,"age_at_diagnosis":83,"sex":"female","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":7.4,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.138107+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_487007","record_id":"REC_0017362","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":53,"sex":"male","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":4.4,"metastatic_sites_count":8,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":17.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.138451+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_721349","record_id":"REC_0017363","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":18,"tmb_mutations_per_mb":5.6,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":5.1,"metastatic_sites_count":8,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":19.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.138762+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_613224","record_id":"REC_0017364","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":30,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":3.8,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.139101+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_280324","record_id":"REC_0017365","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":16.4,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":5.4,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":23.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.139435+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_763006","record_id":"REC_0017366","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":32,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":42,"sex":"female","ecog_performance_status":0,"smoking_pack_years":49,"primary_tumor_size_cm":4.9,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.139762+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_794092","record_id":"REC_0017367","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":8.6,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":5.0,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.141618+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_422475","record_id":"REC_0017368","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":3.1,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":33,"primary_tumor_size_cm":4.1,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.142149+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_992725","record_id":"REC_0017369","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":83,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":3.9,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.142708+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_155478","record_id":"REC_0017370","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":79,"sex":"male","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.1,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.143110+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_436712","record_id":"REC_0017371","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":10.3,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":5.2,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.143449+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_874809","record_id":"REC_0017372","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":17.6,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":6.0,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.143797+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_724527","record_id":"REC_0017373","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":13.1,"age_at_diagnosis":54,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":5.0,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.144217+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_914075","record_id":"REC_0017374","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":15.7,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":5,"primary_tumor_size_cm":6.0,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":26.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.144596+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_729937","record_id":"REC_0017375","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":22.3,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":4.5,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":5.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.144960+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_974152","record_id":"REC_0017376","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":7.6,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":2,"smoking_pack_years":57,"primary_tumor_size_cm":4.8,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.145298+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_309875","record_id":"REC_0017377","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":20,"tmb_mutations_per_mb":7.3,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":2,"smoking_pack_years":77,"primary_tumor_size_cm":4.8,"metastatic_sites_count":10,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.145666+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_299021","record_id":"REC_0017378","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":14.1,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":7.2,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":23.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.146053+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_288906","record_id":"REC_0017379","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":8.0,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":5.8,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.146431+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_553735","record_id":"REC_0017380","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":8.7,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":7.6,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":4.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.146803+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_456988","record_id":"REC_0017381","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":2.5,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":3.1,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":25.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.147168+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_332711","record_id":"REC_0017382","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":17,"tmb_mutations_per_mb":14.4,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":4.3,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.147805+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_586984","record_id":"REC_0017383","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":2,"smoking_pack_years":21,"primary_tumor_size_cm":4.5,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.148352+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_400402","record_id":"REC_0017384","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":18,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":9,"primary_tumor_size_cm":6.2,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":18.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.148805+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_339618","record_id":"REC_0017385","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":22.9,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":5.1,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.149202+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_690667","record_id":"REC_0017386","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":5.8,"metastatic_sites_count":8,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.154581+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_962114","record_id":"REC_0017387","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":5.5,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.155123+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_929613","record_id":"REC_0017388","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":5.7,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":62,"primary_tumor_size_cm":5.7,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":7.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.155503+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_696609","record_id":"REC_0017389","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":9.8,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":3.2,"metastatic_sites_count":8,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":16.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.155950+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_300503","record_id":"REC_0017390","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":19,"tmb_mutations_per_mb":2.9,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":3,"smoking_pack_years":13,"primary_tumor_size_cm":4.6,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.156728+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_156245","record_id":"REC_0017391","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":5.0,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.157129+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_395415","record_id":"REC_0017392","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":7.4,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":3,"primary_tumor_size_cm":6.1,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.157476+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_998122","record_id":"REC_0017393","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":5.3,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":5.0,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.157814+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_931098","record_id":"REC_0017394","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":14.3,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":5.2,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":21.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.158154+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_317894","record_id":"REC_0017395","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":5.5,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.158720+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_621787","record_id":"REC_0017396","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":9.9,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":23,"primary_tumor_size_cm":8.0,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.159126+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_344606","record_id":"REC_0017397","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":9.0,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":8.4,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":29.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.159527+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_648389","record_id":"REC_0017398","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":14,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":7.0,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.159890+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_311012","record_id":"REC_0017399","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":31,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":5.1,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.160398+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_566921","record_id":"REC_0017400","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":0,"smoking_pack_years":28,"primary_tumor_size_cm":4.5,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.160862+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_457978","record_id":"REC_0017401","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":16.1,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":6.6,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":29.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.161373+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_974284","record_id":"REC_0017402","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":5.5,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.161874+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_319021","record_id":"REC_0017403","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":65,"primary_tumor_size_cm":3.7,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":7.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.162331+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_572408","record_id":"REC_0017404","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":9.5,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":5.3,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.162772+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_579678","record_id":"REC_0017405","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":14,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":6.3,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.163224+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_782627","record_id":"REC_0017406","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":5.1,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.163654+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_130126","record_id":"REC_0017407","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":17.1,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":5.0,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":6.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.164039+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_936402","record_id":"REC_0017408","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":4.6,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":8.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.164756+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_100385","record_id":"REC_0017409","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":16.0,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":5.8,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.165210+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_993907","record_id":"REC_0017410","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":7.9,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":25,"primary_tumor_size_cm":5.7,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":23.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.165633+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_962194","record_id":"REC_0017411","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":7.3,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":41.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.166039+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_855865","record_id":"REC_0017412","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":2.8,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":52,"primary_tumor_size_cm":7.5,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":20.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.166425+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_298633","record_id":"REC_0017413","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":16.4,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":5.0,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.166804+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_987047","record_id":"REC_0017414","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":18,"tmb_mutations_per_mb":5.6,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":4.7,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":24.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.167196+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_808744","record_id":"REC_0017415","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":8.9,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":6.8,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.167603+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_256621","record_id":"REC_0017416","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":21.4,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":8.0,"metastatic_sites_count":3,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.167943+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_192686","record_id":"REC_0017417","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":16.3,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":5.9,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.168536+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_441166","record_id":"REC_0017418","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":5.3,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.171233+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_764421","record_id":"REC_0017419","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":4.5,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.172019+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_320640","record_id":"REC_0017420","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":16.0,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":4.2,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.172599+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_950657","record_id":"REC_0017421","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":15.7,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":2,"smoking_pack_years":27,"primary_tumor_size_cm":4.5,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.173322+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_243476","record_id":"REC_0017422","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":76,"sex":"male","ecog_performance_status":2,"smoking_pack_years":20,"primary_tumor_size_cm":3.3,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.173853+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_968305","record_id":"REC_0017423","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":6.5,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.174223+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_309147","record_id":"REC_0017424","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":5.0,"metastatic_sites_count":8,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.174534+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_416482","record_id":"REC_0017425","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":3.8,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.174839+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_846789","record_id":"REC_0017426","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":4.8,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.175158+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_347142","record_id":"REC_0017427","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":7.0,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.175500+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_469028","record_id":"REC_0017428","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":54,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":6.4,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.175836+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_396094","record_id":"REC_0017429","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":11,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":6.3,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.176230+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_316866","record_id":"REC_0017430","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":14.6,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":2,"smoking_pack_years":7,"primary_tumor_size_cm":6.2,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.176582+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_429702","record_id":"REC_0017431","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":20.4,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":5.3,"metastatic_sites_count":8,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.176932+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_142834","record_id":"REC_0017432","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":18.0,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":7.9,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.177277+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_622142","record_id":"REC_0017433","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":57,"primary_tumor_size_cm":7.7,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.177605+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_242271","record_id":"REC_0017434","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":7.3,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":4.1,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":17.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.178448+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_663632","record_id":"REC_0017435","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":4.5,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":4.5,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":22.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.178844+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_221293","record_id":"REC_0017436","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":51,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":5.0,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.179200+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_104346","record_id":"REC_0017437","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":90,"sex":"male","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":7.9,"metastatic_sites_count":3,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.179539+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_686020","record_id":"REC_0017438","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":35,"tmb_mutations_per_mb":14.9,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":20,"primary_tumor_size_cm":6.7,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.179872+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_180615","record_id":"REC_0017439","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":81,"sex":"male","ecog_performance_status":2,"smoking_pack_years":10,"primary_tumor_size_cm":5.4,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":4.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.180290+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_459455","record_id":"REC_0017440","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":33,"tmb_mutations_per_mb":17.9,"age_at_diagnosis":52,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":7.2,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.180641+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_988375","record_id":"REC_0017441","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":6.3,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.180964+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_517927","record_id":"REC_0017442","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":5.9,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":1,"smoking_pack_years":0,"primary_tumor_size_cm":4.2,"metastatic_sites_count":9,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":16.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.181312+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_309083","record_id":"REC_0017443","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":8.0,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":6.8,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.181652+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_350064","record_id":"REC_0017444","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":16,"tmb_mutations_per_mb":15.8,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":4.5,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":5.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.182052+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_245454","record_id":"REC_0017445","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":16.3,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":4.3,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.182435+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_849339","record_id":"REC_0017446","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":20,"tmb_mutations_per_mb":8.9,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":41,"primary_tumor_size_cm":5.5,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.182787+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_598897","record_id":"REC_0017447","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":15,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":2.6,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.183291+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_905400","record_id":"REC_0017448","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":31,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":28,"primary_tumor_size_cm":5.4,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":24.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.183663+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_607495","record_id":"REC_0017449","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":20,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":3,"smoking_pack_years":25,"primary_tumor_size_cm":6.5,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":17.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.194611+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_557106","record_id":"REC_0017450","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":15.7,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":4.4,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.195641+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_510560","record_id":"REC_0017451","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":75,"sex":"male","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":4.0,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":28.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.197408+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_861333","record_id":"REC_0017452","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":14.9,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":3.7,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.204830+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_259401","record_id":"REC_0017453","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":16.3,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":5.2,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":8.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.205645+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_421150","record_id":"REC_0017454","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":6.4,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":22.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.206504+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_704973","record_id":"REC_0017455","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":8.7,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":7.7,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.207498+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_375717","record_id":"REC_0017456","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":5.0,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":0,"smoking_pack_years":34,"primary_tumor_size_cm":5.7,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.215713+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_502508","record_id":"REC_0017457","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":7.6,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":3.2,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.216845+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_296698","record_id":"REC_0017458","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":9.5,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":1,"smoking_pack_years":3,"primary_tumor_size_cm":5.9,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":47.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.217900+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_809527","record_id":"REC_0017459","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":14.5,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":4.5,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":20.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.218784+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_221270","record_id":"REC_0017460","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":25,"primary_tumor_size_cm":6.9,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.219900+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_357511","record_id":"REC_0017461","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":5.1,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.229004+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_805454","record_id":"REC_0017462","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":4,"primary_tumor_size_cm":5.6,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.229729+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_126548","record_id":"REC_0017463","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":15.0,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":5.2,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.230419+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_470077","record_id":"REC_0017464","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":34,"tmb_mutations_per_mb":8.1,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":64,"primary_tumor_size_cm":5.8,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":17.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.231140+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_198511","record_id":"REC_0017465","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ALK fusion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":83,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":5.5,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":36.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.237019+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_396906","record_id":"REC_0017466","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":11.5,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":6.3,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.238401+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_867930","record_id":"REC_0017467","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":5.6,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":6.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.239445+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_474526","record_id":"REC_0017468","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":16.2,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":3,"smoking_pack_years":2,"primary_tumor_size_cm":4.8,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":21.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.240630+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_708546","record_id":"REC_0017469","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":5.4,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":23.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.241940+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_434578","record_id":"REC_0017470","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":5.5,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":55,"primary_tumor_size_cm":3.0,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":18.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.243114+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_863783","record_id":"REC_0017471","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":2,"smoking_pack_years":21,"primary_tumor_size_cm":3.7,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.243921+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_110307","record_id":"REC_0017472","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":7,"primary_tumor_size_cm":3.9,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":17.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.244865+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_916048","record_id":"REC_0017473","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":12,"tmb_mutations_per_mb":11.1,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":5.2,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.254238+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_487448","record_id":"REC_0017474","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":3.5,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.255098+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_564858","record_id":"REC_0017475","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":14.8,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":6.7,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.256065+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_599155","record_id":"REC_0017476","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":15.3,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":5.4,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.261345+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_868162","record_id":"REC_0017477","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":9.5,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":4.8,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.267209+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_534287","record_id":"REC_0017478","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":17,"tmb_mutations_per_mb":7.9,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":0,"smoking_pack_years":25,"primary_tumor_size_cm":4.2,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.268407+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_804055","record_id":"REC_0017479","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":17.7,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":3.7,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.269318+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_744689","record_id":"REC_0017480","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":17,"tmb_mutations_per_mb":17.4,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":4.8,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":24.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.270158+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_435477","record_id":"REC_0017481","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":6.6,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":45.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.275344+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_550134","record_id":"REC_0017482","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":13.3,"age_at_diagnosis":83,"sex":"male","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":5.8,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":7.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.276484+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_207591","record_id":"REC_0017483","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":6.5,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.277270+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_599519","record_id":"REC_0017484","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":11.5,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":6.0,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":32.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.278077+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_486320","record_id":"REC_0017485","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":89,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":5.8,"metastatic_sites_count":11,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.278794+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_754208","record_id":"REC_0017486","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":16.8,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":5.1,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":24.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.286000+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_657847","record_id":"REC_0017487","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":7.4,"age_at_diagnosis":80,"sex":"male","ecog_performance_status":2,"smoking_pack_years":8,"primary_tumor_size_cm":7.3,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.286777+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_439663","record_id":"REC_0017488","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":16.1,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":4.0,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":4.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.292831+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_237783","record_id":"REC_0017489","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":4.9,"age_at_diagnosis":75,"sex":"male","ecog_performance_status":3,"smoking_pack_years":24,"primary_tumor_size_cm":6.3,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.293622+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_318682","record_id":"REC_0017490","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":33,"tmb_mutations_per_mb":15.1,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":2,"primary_tumor_size_cm":6.5,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":6.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.297573+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_865118","record_id":"REC_0017491","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":49,"sex":"male","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":3.9,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.298466+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_687146","record_id":"REC_0017492","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":14.3,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":5.3,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.299314+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_118503","record_id":"REC_0017493","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":53,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":4.8,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":4.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.301163+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_301986","record_id":"REC_0017494","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":9.1,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":6.8,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.302275+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_554639","record_id":"REC_0017495","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":6.7,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":25,"primary_tumor_size_cm":5.2,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":28.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.303519+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_281657","record_id":"REC_0017496","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":9.7,"age_at_diagnosis":76,"sex":"male","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":6.3,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.304796+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_516356","record_id":"REC_0017497","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":14.0,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":7.1,"metastatic_sites_count":9,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.307260+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_101918","record_id":"REC_0017498","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":8.7,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":5.2,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.308319+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_808885","record_id":"REC_0017499","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":13.1,"age_at_diagnosis":46,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":3.4,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.309380+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_980566","record_id":"REC_0017500","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":17.6,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":4.5,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":25.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.310202+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_165519","record_id":"REC_0017501","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":2,"smoking_pack_years":24,"primary_tumor_size_cm":5.2,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.310988+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_594112","record_id":"REC_0017502","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":6.1,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.311855+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_677024","record_id":"REC_0017503","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":3.8,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":4.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.316046+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_148262","record_id":"REC_0017504","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":13.3,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":3.4,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.317172+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_449420","record_id":"REC_0017505","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":14.3,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":4.6,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":31.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.318196+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_398880","record_id":"REC_0017506","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":8.7,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":70,"primary_tumor_size_cm":5.0,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.319131+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_473926","record_id":"REC_0017507","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":4.2,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":23.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.319945+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_715982","record_id":"REC_0017508","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":5.8,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.320976+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_129341","record_id":"REC_0017509","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":7.1,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":21.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.321775+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_332781","record_id":"REC_0017510","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":31,"tmb_mutations_per_mb":8.4,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":25,"primary_tumor_size_cm":6.1,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.326780+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_180404","record_id":"REC_0017511","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":13.3,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":26,"primary_tumor_size_cm":5.5,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.327741+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_931045","record_id":"REC_0017512","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":31,"tmb_mutations_per_mb":3.0,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":4.5,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":21.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.329156+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_881303","record_id":"REC_0017513","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":18,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":5.0,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.330233+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_911679","record_id":"REC_0017514","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":13.1,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":6.0,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.331209+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_177884","record_id":"REC_0017515","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":9.5,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":6.1,"metastatic_sites_count":8,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.332810+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_506330","record_id":"REC_0017516","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":17.4,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":3.5,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.333856+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_986420","record_id":"REC_0017517","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":4.6,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":43,"primary_tumor_size_cm":4.8,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":31.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.334861+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_662077","record_id":"REC_0017518","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.8,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.335761+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_795186","record_id":"REC_0017519","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":18.1,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":5.8,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.336737+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_606487","record_id":"REC_0017520","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":9.0,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":5.9,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.337626+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_366650","record_id":"REC_0017521","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":85,"sex":"female","ecog_performance_status":2,"smoking_pack_years":4,"primary_tumor_size_cm":5.3,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":4.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.344503+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_318460","record_id":"REC_0017522","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":15.7,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":29,"primary_tumor_size_cm":5.2,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":32.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.345325+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_274539","record_id":"REC_0017523","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":7.6,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":60,"primary_tumor_size_cm":7.4,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.346125+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_708795","record_id":"REC_0017524","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":8.0,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":2,"smoking_pack_years":6,"primary_tumor_size_cm":3.9,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":23.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.346872+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_246045","record_id":"REC_0017525","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":13.3,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":5.0,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.347879+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_214858","record_id":"REC_0017526","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":5.7,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.349022+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_715675","record_id":"REC_0017527","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":13.1,"age_at_diagnosis":54,"sex":"male","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":7.6,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.349823+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_232510","record_id":"REC_0017528","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":5.7,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":23.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.350665+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_640002","record_id":"REC_0017529","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":15.3,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":6.4,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":21.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.351558+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_467103","record_id":"REC_0017530","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":31,"tmb_mutations_per_mb":4.9,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":5.4,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":15.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.352629+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_201777","record_id":"REC_0017531","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":10.0,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":5.4,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.353497+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_723670","record_id":"REC_0017532","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":4.0,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":0,"smoking_pack_years":59,"primary_tumor_size_cm":5.7,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":5.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.354326+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_858765","record_id":"REC_0017533","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":54,"sex":"male","ecog_performance_status":0,"smoking_pack_years":50,"primary_tumor_size_cm":4.6,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":17.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.355157+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_401538","record_id":"REC_0017534","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":5.9,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":6.2,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":43.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.356542+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_420643","record_id":"REC_0017535","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":14.7,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":6.2,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.357683+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_146855","record_id":"REC_0017536","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":7.6,"age_at_diagnosis":43,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":5.9,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.358847+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_300246","record_id":"REC_0017537","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":7.4,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":33,"primary_tumor_size_cm":6.2,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.359916+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_875197","record_id":"REC_0017538","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":11.0,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":4.5,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.362633+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_359497","record_id":"REC_0017539","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":14.3,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":3,"primary_tumor_size_cm":5.5,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.364392+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_167055","record_id":"REC_0017540","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":4.2,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":1,"smoking_pack_years":52,"primary_tumor_size_cm":5.6,"metastatic_sites_count":4,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.365304+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_171592","record_id":"REC_0017541","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":5.5,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":3.2,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.366293+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_526698","record_id":"REC_0017542","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":5.2,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":16.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.367240+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_779935","record_id":"REC_0017543","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":4.4,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":4.0,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":17.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.368492+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_297073","record_id":"REC_0017544","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":35,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":47,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":4.9,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.370865+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_225138","record_id":"REC_0017545","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":6.4,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":39.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.371751+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_866243","record_id":"REC_0017546","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":5.5,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":18.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.372880+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_713287","record_id":"REC_0017547","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.2,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.373954+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_209373","record_id":"REC_0017548","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":21.5,"age_at_diagnosis":85,"sex":"female","ecog_performance_status":2,"smoking_pack_years":20,"primary_tumor_size_cm":4.2,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.375032+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_558821","record_id":"REC_0017549","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":2,"smoking_pack_years":61,"primary_tumor_size_cm":4.4,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.376192+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_589104","record_id":"REC_0017550","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":4.1,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":25.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.382972+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_895151","record_id":"REC_0017551","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":5.0,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":3,"smoking_pack_years":57,"primary_tumor_size_cm":4.4,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.398205+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_591659","record_id":"REC_0017552","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":5.6,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.399042+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_205560","record_id":"REC_0017553","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":6.1,"metastatic_sites_count":3,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.399878+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_731960","record_id":"REC_0017554","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":11,"tmb_mutations_per_mb":10.3,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":3.5,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":16.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.400804+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_304539","record_id":"REC_0017555","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":47,"primary_tumor_size_cm":5.5,"metastatic_sites_count":9,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.401691+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_409407","record_id":"REC_0017556","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":6.3,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":3.2,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.402555+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_942290","record_id":"REC_0017557","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":8.9,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":3.6,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.403431+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_765651","record_id":"REC_0017558","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":0,"smoking_pack_years":27,"primary_tumor_size_cm":4.4,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.404402+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_148338","record_id":"REC_0017559","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":16.2,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":4.5,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":31.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.405331+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_453752","record_id":"REC_0017560","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":6.8,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.406451+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_331935","record_id":"REC_0017561","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":17,"tmb_mutations_per_mb":13.5,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":4.6,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":17.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.407595+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_516595","record_id":"REC_0017562","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":17,"tmb_mutations_per_mb":13.1,"age_at_diagnosis":51,"sex":"male","ecog_performance_status":0,"smoking_pack_years":2,"primary_tumor_size_cm":4.2,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":23.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.416837+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_517032","record_id":"REC_0017563","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":18,"tmb_mutations_per_mb":5.5,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":43,"primary_tumor_size_cm":7.1,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.417727+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_115997","record_id":"REC_0017564","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":16.3,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":4.6,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.419083+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_832556","record_id":"REC_0017565","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":3.8,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":48.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.420291+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_168646","record_id":"REC_0017566","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":5.2,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.422050+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_368686","record_id":"REC_0017567","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":4.8,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":4.5,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":7.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.423221+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_833544","record_id":"REC_0017568","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":1.5,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":36,"primary_tumor_size_cm":5.7,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":20.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.424398+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_996475","record_id":"REC_0017569","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":23,"primary_tumor_size_cm":5.0,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.425426+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_221576","record_id":"REC_0017570","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":79,"sex":"male","ecog_performance_status":2,"smoking_pack_years":4,"primary_tumor_size_cm":3.8,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":29.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.426574+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_813130","record_id":"REC_0017571","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":20,"tmb_mutations_per_mb":3.5,"age_at_diagnosis":54,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":6.0,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.427360+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_121684","record_id":"REC_0017572","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":5.5,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.428189+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_368523","record_id":"REC_0017573","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":14.3,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":3.5,"metastatic_sites_count":8,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.428971+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_296833","record_id":"REC_0017574","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":9.8,"age_at_diagnosis":51,"sex":"male","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":7.8,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.429762+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_331765","record_id":"REC_0017575","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":8.0,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":6.0,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.430523+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_361144","record_id":"REC_0017576","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":19.1,"age_at_diagnosis":53,"sex":"female","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":3.6,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.431324+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_570650","record_id":"REC_0017577","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":63,"primary_tumor_size_cm":5.4,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":26.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.432990+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_348880","record_id":"REC_0017578","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":7.2,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.435793+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_493225","record_id":"REC_0017579","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":9.5,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":3.9,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.436707+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_784625","record_id":"REC_0017580","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":5.0,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":4.0,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.437649+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_536096","record_id":"REC_0017581","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":5.7,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":5.5,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":41.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.440534+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_899008","record_id":"REC_0017582","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":17.1,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":3,"smoking_pack_years":11,"primary_tumor_size_cm":5.6,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":26.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.442677+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_327076","record_id":"REC_0017583","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":10.0,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":7.3,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":7.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.443692+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_492470","record_id":"REC_0017584","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":4.1,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":23.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.444648+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_600141","record_id":"REC_0017585","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":3.4,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":2,"smoking_pack_years":60,"primary_tumor_size_cm":6.1,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":23.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.445506+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_533774","record_id":"REC_0017586","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":5.5,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":1,"smoking_pack_years":71,"primary_tumor_size_cm":7.2,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":22.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.446358+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_968961","record_id":"REC_0017587","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":4.6,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":57,"primary_tumor_size_cm":5.5,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":24.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.447209+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_450546","record_id":"REC_0017588","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":7.4,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":3.7,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":26.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.448751+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_584480","record_id":"REC_0017589","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":5.0,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.449676+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_708654","record_id":"REC_0017590","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None","pd_l1_tps_percent":30,"tmb_mutations_per_mb":4.9,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":63,"primary_tumor_size_cm":6.4,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":45.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.452872+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_784119","record_id":"REC_0017591","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":29,"primary_tumor_size_cm":3.4,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.453704+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_910768","record_id":"REC_0017592","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":18,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":4.6,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":20.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.454579+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_766216","record_id":"REC_0017593","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":2.5,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":24.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.456299+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_212038","record_id":"REC_0017594","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":13.6,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":3.9,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.457459+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_974739","record_id":"REC_0017595","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":6.1,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":36,"primary_tumor_size_cm":4.5,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.458487+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_821800","record_id":"REC_0017596","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":5.2,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":5.8,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.461025+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_785082","record_id":"REC_0017597","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":8.0,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.461934+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_736688","record_id":"REC_0017598","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":7.9,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":46,"primary_tumor_size_cm":7.0,"metastatic_sites_count":3,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.462709+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_583987","record_id":"REC_0017599","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":13.3,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":2,"smoking_pack_years":9,"primary_tumor_size_cm":3.6,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.464535+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_798269","record_id":"REC_0017600","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.1,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":3.5,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.465413+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_230429","record_id":"REC_0017601","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":15.8,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":2.7,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.466272+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_321660","record_id":"REC_0017602","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":31,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":5.0,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.467075+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_356548","record_id":"REC_0017603","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":18.3,"age_at_diagnosis":84,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":4.9,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.470287+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_828793","record_id":"REC_0017604","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":9.9,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":3,"smoking_pack_years":19,"primary_tumor_size_cm":6.4,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.471152+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_275684","record_id":"REC_0017605","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":18,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":10,"primary_tumor_size_cm":5.3,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.474118+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_287131","record_id":"REC_0017606","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":8.1,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":20,"primary_tumor_size_cm":3.6,"metastatic_sites_count":8,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.475311+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_151219","record_id":"REC_0017607","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":16.1,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":3.5,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":20.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.476340+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_816593","record_id":"REC_0017608","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":17,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":74,"sex":"male","ecog_performance_status":1,"smoking_pack_years":71,"primary_tumor_size_cm":8.3,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.477174+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_705755","record_id":"REC_0017609","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":10.1,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":81,"primary_tumor_size_cm":5.3,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":5.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.478032+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_445221","record_id":"REC_0017610","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":31,"tmb_mutations_per_mb":5.9,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":36,"primary_tumor_size_cm":4.9,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.478895+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_114906","record_id":"REC_0017611","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":3.2,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":6.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.479787+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_760928","record_id":"REC_0017612","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":5.4,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.482959+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_833151","record_id":"REC_0017613","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":13.3,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":3,"smoking_pack_years":21,"primary_tumor_size_cm":3.8,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":22.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.486478+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_960455","record_id":"REC_0017614","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":9.0,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":32,"primary_tumor_size_cm":6.3,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":24.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.487594+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_711834","record_id":"REC_0017615","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":14.9,"age_at_diagnosis":54,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":8.9,"metastatic_sites_count":10,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.490440+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_796168","record_id":"REC_0017616","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":1.6,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":30,"primary_tumor_size_cm":7.8,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":20.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.491891+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_534477","record_id":"REC_0017617","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":3.2,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":61,"primary_tumor_size_cm":4.9,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":28.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.493060+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_366880","record_id":"REC_0017618","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":15.0,"age_at_diagnosis":83,"sex":"female","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":6.9,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.493978+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_735330","record_id":"REC_0017619","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":20,"tmb_mutations_per_mb":7.3,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":60,"primary_tumor_size_cm":4.2,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":17.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.494825+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_216997","record_id":"REC_0017620","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":34,"tmb_mutations_per_mb":17.8,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":5.5,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.495724+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_809721","record_id":"REC_0017621","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":54,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":4.5,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.496726+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_445152","record_id":"REC_0017622","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":9.7,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":4.7,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":16.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.497569+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_755757","record_id":"REC_0017623","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":14.1,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":5.7,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":17.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.498404+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_730794","record_id":"REC_0017624","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":18.7,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":6.8,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.499324+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_611041","record_id":"REC_0017625","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":49,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":7.5,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.500813+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_485912","record_id":"REC_0017626","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.5,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":4.6,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":19.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.501765+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_967357","record_id":"REC_0017627","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":74,"sex":"male","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":6.7,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":23.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.502840+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_371155","record_id":"REC_0017628","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":37,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":6.4,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.504444+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_196862","record_id":"REC_0017629","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":6.8,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":21.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.505616+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_573976","record_id":"REC_0017630","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":38,"tmb_mutations_per_mb":3.1,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":1,"smoking_pack_years":71,"primary_tumor_size_cm":4.8,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.506466+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_633572","record_id":"REC_0017631","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":4.4,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":4.9,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.507403+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_395447","record_id":"REC_0017632","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":16.2,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":0,"smoking_pack_years":6,"primary_tumor_size_cm":4.7,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.509442+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_153185","record_id":"REC_0017633","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":16.5,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":6.0,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":18.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.510731+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_881529","record_id":"REC_0017634","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":50,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":4.5,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.511535+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_463415","record_id":"REC_0017635","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":6.7,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":45,"primary_tumor_size_cm":6.5,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":46.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.512491+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_345714","record_id":"REC_0017636","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":3.3,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":20.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.513555+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_297999","record_id":"REC_0017637","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":0,"smoking_pack_years":57,"primary_tumor_size_cm":6.0,"metastatic_sites_count":3,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":26.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.514450+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_458673","record_id":"REC_0017638","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":9.7,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":3.1,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":21.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.515245+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_740497","record_id":"REC_0017639","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":9.0,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":7.4,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":21.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.515992+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_451871","record_id":"REC_0017640","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":5.5,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":3.9,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":19.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.517428+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_105713","record_id":"REC_0017641","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":10.1,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":4.2,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":35.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.518116+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_454746","record_id":"REC_0017642","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":14.9,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":0,"primary_tumor_size_cm":5.4,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":17.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.519333+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_602210","record_id":"REC_0017643","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":7.3,"age_at_diagnosis":78,"sex":"male","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":6.2,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.520963+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_700434","record_id":"REC_0017644","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":5.4,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":4.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.521845+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_262475","record_id":"REC_0017645","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":4.3,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":41,"primary_tumor_size_cm":4.8,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":20.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.522567+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_943464","record_id":"REC_0017646","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":35,"tmb_mutations_per_mb":6.0,"age_at_diagnosis":80,"sex":"male","ecog_performance_status":2,"smoking_pack_years":57,"primary_tumor_size_cm":5.5,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":16.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.523283+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_315439","record_id":"REC_0017647","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":13.7,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":4.8,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":17.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.524624+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_892998","record_id":"REC_0017648","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":15.7,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":5.8,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.525490+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_242234","record_id":"REC_0017649","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":7.4,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":6.0,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.526354+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_978527","record_id":"REC_0017650","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":8.7,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":3,"smoking_pack_years":17,"primary_tumor_size_cm":4.1,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.527123+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_991719","record_id":"REC_0017651","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":33,"tmb_mutations_per_mb":5.1,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":1,"smoking_pack_years":36,"primary_tumor_size_cm":5.3,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.527864+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_724935","record_id":"REC_0017652","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":36,"tmb_mutations_per_mb":6.1,"age_at_diagnosis":83,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":7.2,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.528900+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_382114","record_id":"REC_0017653","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":10.3,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":7.1,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":18.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.529855+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_647955","record_id":"REC_0017654","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":74,"sex":"male","ecog_performance_status":3,"smoking_pack_years":12,"primary_tumor_size_cm":6.0,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.532832+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_123394","record_id":"REC_0017655","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":35,"tmb_mutations_per_mb":15.0,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":2,"smoking_pack_years":7,"primary_tumor_size_cm":5.0,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.534216+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_867599","record_id":"REC_0017656","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":35,"tmb_mutations_per_mb":10.1,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":4.7,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":18.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.534989+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_409759","record_id":"REC_0017657","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":13.5,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":4.4,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":18.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.535702+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_337356","record_id":"REC_0017658","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":18.7,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":3.9,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":22.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.536615+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_875489","record_id":"REC_0017659","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":14.7,"age_at_diagnosis":75,"sex":"male","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":5.2,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.540351+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_956319","record_id":"REC_0017660","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":4.4,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":0,"smoking_pack_years":72,"primary_tumor_size_cm":6.8,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":19.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.541179+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_588321","record_id":"REC_0017661","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":12,"tmb_mutations_per_mb":17.5,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":4.6,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.541969+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_888483","record_id":"REC_0017662","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":10.3,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":3.3,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":26.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.543779+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_755890","record_id":"REC_0017663","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":20,"tmb_mutations_per_mb":5.0,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":56,"primary_tumor_size_cm":7.1,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":17.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.544727+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_455394","record_id":"REC_0017664","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":2.8,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":7.1,"metastatic_sites_count":3,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":10.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.545526+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_775107","record_id":"REC_0017665","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":8.4,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":5.4,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":6.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.546407+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_350990","record_id":"REC_0017666","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":31,"tmb_mutations_per_mb":3.6,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":1,"smoking_pack_years":45,"primary_tumor_size_cm":6.7,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.547975+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_295343","record_id":"REC_0017667","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":6.0,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.549287+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_260695","record_id":"REC_0017668","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":1,"smoking_pack_years":33,"primary_tumor_size_cm":4.4,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.550469+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_207872","record_id":"REC_0017669","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":6.4,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.551879+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_343446","record_id":"REC_0017670","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":9.5,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":6.1,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":19.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.552803+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_859744","record_id":"REC_0017671","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.1,"age_at_diagnosis":51,"sex":"female","ecog_performance_status":0,"smoking_pack_years":5,"primary_tumor_size_cm":7.7,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":17.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.553615+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_398734","record_id":"REC_0017672","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":31,"tmb_mutations_per_mb":15.2,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":6.6,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.554536+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_981350","record_id":"REC_0017673","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.4,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":6.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.555387+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_638798","record_id":"REC_0017674","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":33,"tmb_mutations_per_mb":7.3,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":4.0,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.556233+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_652437","record_id":"REC_0017675","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":54,"sex":"male","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":4.5,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":21.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.556988+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_545754","record_id":"REC_0017676","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":32,"tmb_mutations_per_mb":8.5,"age_at_diagnosis":52,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":7.3,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":25.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.557883+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_668456","record_id":"REC_0017677","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":6.0,"age_at_diagnosis":90,"sex":"female","ecog_performance_status":2,"smoking_pack_years":22,"primary_tumor_size_cm":4.7,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":22.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.558735+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_747906","record_id":"REC_0017678","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"KRAS G12C","pd_l1_tps_percent":18,"tmb_mutations_per_mb":14.1,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":4.0,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":46.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.559723+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_794577","record_id":"REC_0017679","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":15.9,"age_at_diagnosis":49,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":5.7,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":52.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.561319+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_791183","record_id":"REC_0017680","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":9.9,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":3.0,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":19.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.562257+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_612597","record_id":"REC_0017681","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":8.2,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":22.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.563612+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_141850","record_id":"REC_0017682","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":8,"tmb_mutations_per_mb":5.6,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":50,"primary_tumor_size_cm":7.3,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":18.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.564548+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_589252","record_id":"REC_0017683","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":24,"primary_tumor_size_cm":5.2,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.565413+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_804267","record_id":"REC_0017684","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":11.5,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":5.5,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":8.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.566261+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_843920","record_id":"REC_0017685","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":6.1,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.567133+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_422904","record_id":"REC_0017686","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":0,"primary_tumor_size_cm":6.1,"metastatic_sites_count":3,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.568017+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_363775","record_id":"REC_0017687","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":30,"tmb_mutations_per_mb":2.4,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":53,"primary_tumor_size_cm":5.9,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":16.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.568977+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_140288","record_id":"REC_0017688","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":21,"primary_tumor_size_cm":7.3,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.571389+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_243651","record_id":"REC_0017689","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":6.4,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":31,"primary_tumor_size_cm":4.5,"metastatic_sites_count":3,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.572331+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_323048","record_id":"REC_0017690","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":6.2,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.574437+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_992371","record_id":"REC_0017691","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":5.9,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":28.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.575349+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_977502","record_id":"REC_0017692","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":30,"tmb_mutations_per_mb":19.5,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":6.3,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.576321+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_714068","record_id":"REC_0017693","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":30,"tmb_mutations_per_mb":7.4,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":31,"primary_tumor_size_cm":3.3,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":17.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.577197+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_590685","record_id":"REC_0017694","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":3.6,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.578392+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_208059","record_id":"REC_0017695","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":5.3,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":51,"primary_tumor_size_cm":5.5,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.579237+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_581558","record_id":"REC_0017696","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":3,"smoking_pack_years":26,"primary_tumor_size_cm":5.6,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":22.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.580309+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_958247","record_id":"REC_0017697","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":31,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":4.7,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.581268+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_101532","record_id":"REC_0017698","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":8.0,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":6.5,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.582170+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_312029","record_id":"REC_0017699","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":15.7,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":3,"smoking_pack_years":10,"primary_tumor_size_cm":4.1,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.582997+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_841881","record_id":"REC_0017700","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":8.5,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":4.2,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.583863+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_753391","record_id":"REC_0017701","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":7.3,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":5.1,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":22.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.585151+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_101679","record_id":"REC_0017702","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":7.0,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.585990+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_566725","record_id":"REC_0017703","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":15,"tmb_mutations_per_mb":15.8,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":7.6,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":25.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.589527+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_638257","record_id":"REC_0017704","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":4.2,"metastatic_sites_count":8,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.590352+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_352661","record_id":"REC_0017705","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":15.1,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":5.2,"metastatic_sites_count":3,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":6.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.591217+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_574027","record_id":"REC_0017706","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":17,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":73,"sex":"male","ecog_performance_status":1,"smoking_pack_years":36,"primary_tumor_size_cm":4.5,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.591979+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_418430","record_id":"REC_0017707","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":13.6,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":3,"smoking_pack_years":21,"primary_tumor_size_cm":4.7,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.593220+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_918577","record_id":"REC_0017708","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":11.1,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":4.1,"metastatic_sites_count":3,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":20.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.594013+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_807247","record_id":"REC_0017709","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":19,"tmb_mutations_per_mb":6.3,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":1,"smoking_pack_years":67,"primary_tumor_size_cm":6.0,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.594818+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_641985","record_id":"REC_0017710","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":10,"primary_tumor_size_cm":7.2,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":26.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.595679+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_441379","record_id":"REC_0017711","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":15.9,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":1,"smoking_pack_years":25,"primary_tumor_size_cm":6.1,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.598968+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_489834","record_id":"REC_0017712","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":5.5,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.599841+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_711400","record_id":"REC_0017713","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":38,"primary_tumor_size_cm":4.8,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":17.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.601914+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_813563","record_id":"REC_0017714","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":32,"tmb_mutations_per_mb":5.0,"age_at_diagnosis":74,"sex":"male","ecog_performance_status":3,"smoking_pack_years":13,"primary_tumor_size_cm":4.8,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.602764+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_753392","record_id":"REC_0017715","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":34,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":56,"primary_tumor_size_cm":5.2,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.603549+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_310206","record_id":"REC_0017716","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":5.9,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":60,"primary_tumor_size_cm":7.2,"metastatic_sites_count":3,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.604477+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_955622","record_id":"REC_0017717","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":13.3,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":4.4,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.605342+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_316475","record_id":"REC_0017718","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":30,"tmb_mutations_per_mb":13.8,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":5.6,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":15.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.606195+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_212553","record_id":"REC_0017719","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":19.1,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":5.1,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.607367+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_516530","record_id":"REC_0017720","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":16.2,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":3,"primary_tumor_size_cm":5.5,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":44.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.612695+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_977220","record_id":"REC_0017721","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":3.7,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":38,"primary_tumor_size_cm":7.1,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":44.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.613567+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_926460","record_id":"REC_0017722","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":10.3,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":6.7,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":5.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.615018+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_663128","record_id":"REC_0017723","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":17,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":51,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":6.1,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.618703+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_131848","record_id":"REC_0017724","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":18.6,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":4.9,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.619679+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_379778","record_id":"REC_0017725","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":11.0,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":4.5,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.623425+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_684806","record_id":"REC_0017726","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":11.5,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":6.5,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":5.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.624514+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_716257","record_id":"REC_0017727","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":6.4,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":6.9,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":19.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.625492+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_520556","record_id":"REC_0017728","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":19,"tmb_mutations_per_mb":3.9,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":74,"primary_tumor_size_cm":6.6,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":19.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.626284+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_242255","record_id":"REC_0017729","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":19,"tmb_mutations_per_mb":16.1,"age_at_diagnosis":52,"sex":"female","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":4.0,"metastatic_sites_count":3,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.627283+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_723724","record_id":"REC_0017730","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":19,"tmb_mutations_per_mb":3.0,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":6.2,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.628226+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_192583","record_id":"REC_0017731","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":4.5,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":21.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.629135+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_415678","record_id":"REC_0017732","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":16.1,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":4,"primary_tumor_size_cm":5.7,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":23.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.629885+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_184685","record_id":"REC_0017733","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":4.4,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":55,"primary_tumor_size_cm":4.9,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.630960+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_630843","record_id":"REC_0017734","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":4.2,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":5.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.631849+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_295053","record_id":"REC_0017735","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":1,"smoking_pack_years":59,"primary_tumor_size_cm":7.1,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":24.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.632823+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_969661","record_id":"REC_0017736","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":6.7,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":10,"primary_tumor_size_cm":8.0,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.633678+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_967398","record_id":"REC_0017737","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":7.0,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.636546+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_662830","record_id":"REC_0017738","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":31,"tmb_mutations_per_mb":5.2,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":35,"primary_tumor_size_cm":5.5,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":21.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.637422+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_796970","record_id":"REC_0017739","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":35,"tmb_mutations_per_mb":15.4,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":6.4,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":4.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.640162+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_625624","record_id":"REC_0017740","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":2,"primary_tumor_size_cm":5.0,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.641155+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_339662","record_id":"REC_0017741","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":5.7,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":19.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.641937+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_169235","record_id":"REC_0017742","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":10.3,"age_at_diagnosis":83,"sex":"female","ecog_performance_status":1,"smoking_pack_years":4,"primary_tumor_size_cm":6.4,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":27.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.642862+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_677062","record_id":"REC_0017743","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":16.4,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":3.7,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.647761+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_393931","record_id":"REC_0017744","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":6.5,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.651021+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_507538","record_id":"REC_0017745","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":10.1,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":5.5,"metastatic_sites_count":3,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.652003+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_596451","record_id":"REC_0017746","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":22,"tmb_mutations_per_mb":4.8,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":5.3,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":5.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.653351+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_812925","record_id":"REC_0017747","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":13,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":6.0,"metastatic_sites_count":8,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.654160+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_182471","record_id":"REC_0017748","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":15.0,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":4.9,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.654971+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_527308","record_id":"REC_0017749","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":31,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":1,"smoking_pack_years":66,"primary_tumor_size_cm":4.0,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.655767+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_212903","record_id":"REC_0017750","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":10.5,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":2.7,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":56.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.659454+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_880003","record_id":"REC_0017751","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":36,"tmb_mutations_per_mb":15.0,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":5.3,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":24.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.660453+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_262484","record_id":"REC_0017752","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":14.3,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":5.7,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.661373+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_869671","record_id":"REC_0017753","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":5.1,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":6.9,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.662172+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_109287","record_id":"REC_0017754","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":8.5,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":4.0,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.662984+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_459558","record_id":"REC_0017755","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":10.0,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":19,"primary_tumor_size_cm":7.1,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.663817+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_305899","record_id":"REC_0017756","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":4.5,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.664742+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_132080","record_id":"REC_0017757","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":59,"primary_tumor_size_cm":7.5,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.665606+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_335280","record_id":"REC_0017758","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":13,"tmb_mutations_per_mb":2.9,"age_at_diagnosis":47,"sex":"female","ecog_performance_status":0,"smoking_pack_years":59,"primary_tumor_size_cm":6.8,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.666453+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_673726","record_id":"REC_0017759","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":4.6,"age_at_diagnosis":52,"sex":"female","ecog_performance_status":0,"smoking_pack_years":30,"primary_tumor_size_cm":3.3,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.667618+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_813858","record_id":"REC_0017760","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":4.0,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.668707+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_371463","record_id":"REC_0017761","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":85,"sex":"female","ecog_performance_status":2,"smoking_pack_years":2,"primary_tumor_size_cm":5.9,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":21.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.669578+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_615115","record_id":"REC_0017762","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":8.0,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":4.7,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.670418+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_872119","record_id":"REC_0017763","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":14.5,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":5.5,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.671280+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_499447","record_id":"REC_0017764","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":30,"tmb_mutations_per_mb":9.1,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":1,"smoking_pack_years":51,"primary_tumor_size_cm":7.6,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":4.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.672271+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_884410","record_id":"REC_0017765","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":4.5,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.673123+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_735917","record_id":"REC_0017766","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":3.8,"age_at_diagnosis":84,"sex":"female","ecog_performance_status":2,"smoking_pack_years":57,"primary_tumor_size_cm":6.5,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":16.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.673964+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_361983","record_id":"REC_0017767","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":57,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":5.1,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.674822+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_941400","record_id":"REC_0017768","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":4.8,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":7,"primary_tumor_size_cm":5.8,"metastatic_sites_count":3,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.675631+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_496049","record_id":"REC_0017769","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":5.6,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":25.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.676523+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_481515","record_id":"REC_0017770","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":5.5,"metastatic_sites_count":8,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":17.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.677380+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_655101","record_id":"REC_0017771","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":5.1,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":40,"primary_tumor_size_cm":4.7,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":11.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.678174+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_676517","record_id":"REC_0017772","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":5.3,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.679312+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_238478","record_id":"REC_0017773","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":3.3,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":5.1,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.680273+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_692818","record_id":"REC_0017774","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":11.5,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":4.3,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.681149+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_944175","record_id":"REC_0017775","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":16,"primary_tumor_size_cm":5.8,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.682045+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_166594","record_id":"REC_0017776","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":6.3,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":5.7,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":31.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.682874+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_712146","record_id":"REC_0017777","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":19.1,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":2.9,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.683716+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_333017","record_id":"REC_0017778","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":11.3,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":5.4,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":8.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.684677+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_702646","record_id":"REC_0017779","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":3.3,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":1,"smoking_pack_years":61,"primary_tumor_size_cm":5.2,"metastatic_sites_count":8,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.685526+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_437396","record_id":"REC_0017780","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":7.2,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.686375+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_421549","record_id":"REC_0017781","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":24,"primary_tumor_size_cm":7.4,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.687246+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_413282","record_id":"REC_0017782","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":16.1,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":5.6,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.688200+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_961454","record_id":"REC_0017783","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":4.7,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":14.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.689089+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_909815","record_id":"REC_0017784","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":5.9,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":24,"primary_tumor_size_cm":5.3,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.689981+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_903268","record_id":"REC_0017785","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":6.1,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":4.6,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":26.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.691099+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_149047","record_id":"REC_0017786","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":17.6,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":4,"primary_tumor_size_cm":6.1,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":55.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.691997+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_201492","record_id":"REC_0017787","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":7.3,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":6.7,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":21.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.692978+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_897611","record_id":"REC_0017788","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":11.5,"age_at_diagnosis":80,"sex":"male","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":5.3,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.693875+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_819360","record_id":"REC_0017789","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":8.6,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":3.9,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.694720+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_970898","record_id":"REC_0017790","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":23,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":0,"smoking_pack_years":64,"primary_tumor_size_cm":4.3,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":16.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.695544+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_294202","record_id":"REC_0017791","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":4,"primary_tumor_size_cm":6.3,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":25.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.696482+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_889025","record_id":"REC_0017792","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":3,"primary_tumor_size_cm":5.4,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":6.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.697302+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_639504","record_id":"REC_0017793","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":3.0,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":4.3,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":23.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.698144+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_346943","record_id":"REC_0017794","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":6.9,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":73,"primary_tumor_size_cm":6.0,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":19.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.699004+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_886035","record_id":"REC_0017795","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":54,"sex":"male","ecog_performance_status":0,"smoking_pack_years":40,"primary_tumor_size_cm":4.4,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.699848+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_293318","record_id":"REC_0017796","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":5.2,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.700782+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_756698","record_id":"REC_0017797","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":4,"primary_tumor_size_cm":4.4,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.701559+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_184611","record_id":"REC_0017798","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":2.2,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":6.5,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.702712+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_858492","record_id":"REC_0017799","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":11.0,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":5.6,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":5.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.703561+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_780683","record_id":"REC_0017800","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":10,"tmb_mutations_per_mb":11.9,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":0,"smoking_pack_years":4,"primary_tumor_size_cm":4.7,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.704465+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_422628","record_id":"REC_0017801","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":2.2,"age_at_diagnosis":54,"sex":"male","ecog_performance_status":0,"smoking_pack_years":33,"primary_tumor_size_cm":5.2,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":23.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.705322+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_723813","record_id":"REC_0017802","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":13.5,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":0,"smoking_pack_years":32,"primary_tumor_size_cm":6.3,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.706163+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_592795","record_id":"REC_0017803","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":16.0,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.2,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.706977+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_590067","record_id":"REC_0017804","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":6.9,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":22.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.707804+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_794382","record_id":"REC_0017805","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":5.3,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.708710+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_483772","record_id":"REC_0017806","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":20,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":56,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":6.1,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.709528+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_729916","record_id":"REC_0017807","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":5.9,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":30.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.710268+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_114946","record_id":"REC_0017808","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":6.6,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.711038+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_638430","record_id":"REC_0017809","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":3.8,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":27,"primary_tumor_size_cm":6.0,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":4.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.711853+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_197080","record_id":"REC_0017810","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":15.1,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":9,"primary_tumor_size_cm":5.0,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.713307+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_471605","record_id":"REC_0017811","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":14.9,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":2,"smoking_pack_years":7,"primary_tumor_size_cm":5.9,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":36.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.715001+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_788589","record_id":"REC_0017812","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":5.5,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.715892+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_218461","record_id":"REC_0017813","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":6.3,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":3.2,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":18.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.716886+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_284072","record_id":"REC_0017814","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":19.3,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":1,"smoking_pack_years":5,"primary_tumor_size_cm":7.1,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":22.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.717822+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_381732","record_id":"REC_0017815","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":6.9,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":47,"primary_tumor_size_cm":5.8,"metastatic_sites_count":8,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":6.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.718680+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_461982","record_id":"REC_0017816","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":5.0,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":10,"primary_tumor_size_cm":5.9,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":63.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.719533+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_978004","record_id":"REC_0017817","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":4.2,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.720429+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_623279","record_id":"REC_0017818","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":18,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":5.9,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.721301+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_314327","record_id":"REC_0017819","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":30,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":2,"primary_tumor_size_cm":4.5,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.722319+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_734338","record_id":"REC_0017820","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":9.0,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":5.7,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.723333+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_113671","record_id":"REC_0017821","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":24,"tmb_mutations_per_mb":10.3,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":7.4,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.724495+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_413611","record_id":"REC_0017822","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":0,"primary_tumor_size_cm":4.2,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":22.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.725472+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_939903","record_id":"REC_0017823","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":12,"tmb_mutations_per_mb":12.4,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":1,"smoking_pack_years":27,"primary_tumor_size_cm":7.9,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.726446+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_135099","record_id":"REC_0017824","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":14.6,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":6.0,"metastatic_sites_count":9,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.727762+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_329156","record_id":"REC_0017825","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":18.7,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":6.8,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":19.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.729322+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_294988","record_id":"REC_0017826","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":27,"tmb_mutations_per_mb":8.3,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":7.6,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":25.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.730217+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_659285","record_id":"REC_0017827","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":7.5,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":3,"smoking_pack_years":27,"primary_tumor_size_cm":6.2,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.731044+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_387241","record_id":"REC_0017828","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":8.7,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":44,"primary_tumor_size_cm":7.7,"metastatic_sites_count":0,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.731918+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_609256","record_id":"REC_0017829","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":6.8,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":0,"smoking_pack_years":58,"primary_tumor_size_cm":4.5,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.733187+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_568828","record_id":"REC_0017830","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":7.8,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":15,"primary_tumor_size_cm":6.3,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":41.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.734055+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_702139","record_id":"REC_0017831","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":17.2,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":4.6,"metastatic_sites_count":9,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":10.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.734965+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_321426","record_id":"REC_0017832","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":20,"tmb_mutations_per_mb":11.6,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":3.6,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":12.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.735895+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_253855","record_id":"REC_0017833","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":4.2,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":42,"primary_tumor_size_cm":5.6,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.737008+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_288851","record_id":"REC_0017834","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":3.4,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":5.7,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":17.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.738107+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_399473","record_id":"REC_0017835","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":5.4,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":26.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.739027+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_696286","record_id":"REC_0017836","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":7.1,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.739902+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_649813","record_id":"REC_0017837","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":1,"smoking_pack_years":30,"primary_tumor_size_cm":7.6,"metastatic_sites_count":8,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.741186+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_829380","record_id":"REC_0017838","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":11.8,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":3.3,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.742074+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_796954","record_id":"REC_0017839","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":30,"tmb_mutations_per_mb":4.2,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":56,"primary_tumor_size_cm":6.7,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.742876+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_373915","record_id":"REC_0017840","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":6,"primary_tumor_size_cm":5.1,"metastatic_sites_count":9,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.743656+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_478474","record_id":"REC_0017841","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":34,"tmb_mutations_per_mb":17.2,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":23,"primary_tumor_size_cm":3.8,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.744606+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_407023","record_id":"REC_0017842","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":5.6,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":45,"primary_tumor_size_cm":4.0,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.745417+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_567023","record_id":"REC_0017843","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":4.1,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":42,"primary_tumor_size_cm":4.1,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":12.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.746226+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_939291","record_id":"REC_0017844","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":20,"tmb_mutations_per_mb":4.6,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":48,"primary_tumor_size_cm":5.5,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":7.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.747051+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_697248","record_id":"REC_0017845","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":4.2,"age_at_diagnosis":66,"sex":"male","ecog_performance_status":1,"smoking_pack_years":59,"primary_tumor_size_cm":5.3,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.747924+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_393498","record_id":"REC_0017846","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":18,"tmb_mutations_per_mb":20.7,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":6.4,"metastatic_sites_count":5,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":5.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.748975+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_845733","record_id":"REC_0017847","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":35,"tmb_mutations_per_mb":15.6,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":2.6,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.750436+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_403113","record_id":"REC_0017848","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":14.4,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.0,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":6.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.751452+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_256300","record_id":"REC_0017849","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":4.2,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":85,"primary_tumor_size_cm":4.8,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.752616+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_945456","record_id":"REC_0017850","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":10.1,"age_at_diagnosis":54,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":3.9,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":18.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.753984+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_931649","record_id":"REC_0017851","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":3.6,"age_at_diagnosis":78,"sex":"male","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":4.1,"metastatic_sites_count":6,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.754846+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_265346","record_id":"REC_0017852","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":16,"tmb_mutations_per_mb":21.0,"age_at_diagnosis":52,"sex":"female","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":5.3,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":26.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.755706+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_296444","record_id":"REC_0017853","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":3.7,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":19.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.756794+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_462111","record_id":"REC_0017854","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":34,"tmb_mutations_per_mb":15.2,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":6.1,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.757699+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_281548","record_id":"REC_0017855","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":3.2,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":34,"primary_tumor_size_cm":6.0,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":16.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.758498+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_860667","record_id":"REC_0017856","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":5.5,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":5.8,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.759298+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_270805","record_id":"REC_0017857","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":5.2,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.5,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.760353+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_592173","record_id":"REC_0017858","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":18,"tmb_mutations_per_mb":13.8,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":6.2,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.761175+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_207681","record_id":"REC_0017859","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.1,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":1,"primary_tumor_size_cm":5.6,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.761993+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_200798","record_id":"REC_0017860","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":23,"tmb_mutations_per_mb":13.0,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":7.1,"metastatic_sites_count":8,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":13.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.762784+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_861938","record_id":"REC_0017861","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":2,"smoking_pack_years":22,"primary_tumor_size_cm":5.6,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":16.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.763560+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_176864","record_id":"REC_0017862","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":90,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.2,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":7.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.764533+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_411069","record_id":"REC_0017863","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":20,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":65,"primary_tumor_size_cm":6.7,"metastatic_sites_count":8,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.765627+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_398086","record_id":"REC_0017864","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":15.6,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":4.2,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":14.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.766456+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_528732","record_id":"REC_0017865","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":18.9,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":6.0,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":6.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.767264+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_738813","record_id":"REC_0017866","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":17.3,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":2,"smoking_pack_years":3,"primary_tumor_size_cm":7.1,"metastatic_sites_count":3,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.768231+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_468162","record_id":"REC_0017867","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":16,"tmb_mutations_per_mb":10.3,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":6,"primary_tumor_size_cm":6.1,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":4.0,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.769165+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_154601","record_id":"REC_0017868","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":32,"tmb_mutations_per_mb":3.0,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":31,"primary_tumor_size_cm":8.1,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":17.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.770042+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_275114","record_id":"REC_0017869","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":33,"tmb_mutations_per_mb":15.1,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":5.2,"metastatic_sites_count":8,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.770866+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_315030","record_id":"REC_0017870","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":16.2,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":3,"smoking_pack_years":7,"primary_tumor_size_cm":6.4,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":22.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.771714+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_245201","record_id":"REC_0017871","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":16.8,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":22,"primary_tumor_size_cm":5.5,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.772638+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_948929","record_id":"REC_0017872","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":10.4,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":4.9,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":26.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.773438+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_893601","record_id":"REC_0017873","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":13.4,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":3,"smoking_pack_years":11,"primary_tumor_size_cm":4.2,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.774229+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_976090","record_id":"REC_0017874","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":29,"primary_tumor_size_cm":4.8,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.775494+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_949848","record_id":"REC_0017875","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":4.6,"age_at_diagnosis":59,"sex":"male","ecog_performance_status":1,"smoking_pack_years":32,"primary_tumor_size_cm":3.3,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":24.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.776521+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_417605","record_id":"REC_0017876","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":6.4,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":6.9,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":17.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.777865+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_377748","record_id":"REC_0017877","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":4.1,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":4.9,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.778867+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_516511","record_id":"REC_0017878","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":16.6,"age_at_diagnosis":53,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":6.9,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":19.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.779774+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_894027","record_id":"REC_0017879","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":17.2,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":5.8,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":22.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.780644+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_133683","record_id":"REC_0017880","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":6.6,"age_at_diagnosis":83,"sex":"female","ecog_performance_status":2,"smoking_pack_years":28,"primary_tumor_size_cm":4.9,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.781568+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_968228","record_id":"REC_0017881","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":14.5,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":6.0,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.1,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.782671+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_832794","record_id":"REC_0017882","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":16.1,"age_at_diagnosis":51,"sex":"male","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":6.4,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.783414+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_406669","record_id":"REC_0017883","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":3.6,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":5.2,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":21.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.784344+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_470629","record_id":"REC_0017884","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":16.7,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":5.1,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":5.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.785942+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_798633","record_id":"REC_0017885","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":0,"smoking_pack_years":54,"primary_tumor_size_cm":6.6,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":8.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.786973+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_165737","record_id":"REC_0017886","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":11.4,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":7,"primary_tumor_size_cm":3.3,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":21.6,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.789002+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_702103","record_id":"REC_0017887","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":30,"tmb_mutations_per_mb":12.2,"age_at_diagnosis":72,"sex":"male","ecog_performance_status":0,"smoking_pack_years":6,"primary_tumor_size_cm":5.0,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":47.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.790095+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_910715","record_id":"REC_0017888","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":7,"primary_tumor_size_cm":3.6,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.790807+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_585055","record_id":"REC_0017889","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":30,"tmb_mutations_per_mb":5.5,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":4.8,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":14.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.791684+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_991353","record_id":"REC_0017890","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":15.9,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":5,"primary_tumor_size_cm":5.4,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":17.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.792516+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_867243","record_id":"REC_0017891","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":32,"tmb_mutations_per_mb":4.3,"age_at_diagnosis":88,"sex":"female","ecog_performance_status":1,"smoking_pack_years":43,"primary_tumor_size_cm":6.4,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.793296+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_420576","record_id":"REC_0017892","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":4.6,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":0,"smoking_pack_years":48,"primary_tumor_size_cm":7.5,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":25.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.794079+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_821622","record_id":"REC_0017893","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":5.3,"metastatic_sites_count":7,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":7.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.794906+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_745947","record_id":"REC_0017894","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":27,"tmb_mutations_per_mb":5.3,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":54,"primary_tumor_size_cm":3.0,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":12.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.795684+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_864809","record_id":"REC_0017895","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":22,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":6.2,"metastatic_sites_count":2,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":16.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.796658+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_297272","record_id":"REC_0017896","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":6.3,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":17.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.797598+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_525629","record_id":"REC_0017897","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":3,"smoking_pack_years":16,"primary_tumor_size_cm":4.6,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":18.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.798456+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_400254","record_id":"REC_0017898","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":27,"tmb_mutations_per_mb":6.3,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":5.3,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":25.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.799303+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_904796","record_id":"REC_0017899","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":9.6,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":5.3,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.800027+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_352343","record_id":"REC_0017900","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":9.5,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":2,"smoking_pack_years":8,"primary_tumor_size_cm":4.4,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.800798+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_977042","record_id":"REC_0017901","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":9.5,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":6.4,"metastatic_sites_count":3,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.801514+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_496622","record_id":"REC_0017902","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":13.6,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":5.3,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.802525+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_280561","record_id":"REC_0017903","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":15.3,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":4.2,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":27.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.803239+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_197851","record_id":"REC_0017904","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":10.0,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":24,"primary_tumor_size_cm":6.1,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.803937+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_251119","record_id":"REC_0017905","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":11.1,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":0,"primary_tumor_size_cm":6.2,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":22.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.804773+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_414463","record_id":"REC_0017906","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":16.6,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":4.3,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.805524+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_699151","record_id":"REC_0017907","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":8.3,"age_at_diagnosis":79,"sex":"female","ecog_performance_status":2,"smoking_pack_years":18,"primary_tumor_size_cm":3.4,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.806276+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_815257","record_id":"REC_0017908","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":16.2,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":6.5,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.5,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.807010+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_379105","record_id":"REC_0017909","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":7.3,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":1,"smoking_pack_years":74,"primary_tumor_size_cm":6.9,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.807752+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_222689","record_id":"REC_0017910","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":9.8,"age_at_diagnosis":52,"sex":"male","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":6.2,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":25.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.808611+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_762992","record_id":"REC_0017911","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":26,"tmb_mutations_per_mb":6.7,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":38,"primary_tumor_size_cm":4.2,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":5.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.809471+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_111241","record_id":"REC_0017912","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":11.5,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":7,"primary_tumor_size_cm":6.2,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":16.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.810243+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_700149","record_id":"REC_0017913","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":14.0,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":11,"primary_tumor_size_cm":4.6,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":17.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.811040+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_463113","record_id":"REC_0017914","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":9.0,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":4.4,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.811845+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_642126","record_id":"REC_0017915","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":23,"tmb_mutations_per_mb":6.2,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":31,"primary_tumor_size_cm":4.8,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":41.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.813064+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_964648","record_id":"REC_0017916","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":24,"tmb_mutations_per_mb":4.4,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":4.2,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":22.4,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.813954+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_110829","record_id":"REC_0017917","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":29,"tmb_mutations_per_mb":16.9,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":8.2,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":9.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.814773+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_102322","record_id":"REC_0017918","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":25,"tmb_mutations_per_mb":7.4,"age_at_diagnosis":43,"sex":"male","ecog_performance_status":0,"smoking_pack_years":37,"primary_tumor_size_cm":4.0,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":7.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.815625+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_730438","record_id":"REC_0017919","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":8.6,"age_at_diagnosis":65,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":5.6,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":21.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.816494+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_679900","record_id":"REC_0017920","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":14,"primary_tumor_size_cm":5.6,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.817358+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_899986","record_id":"REC_0017921","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":11.0,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":9.0,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":44.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.818215+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_123048","record_id":"REC_0017922","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":16.1,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":9.1,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.819073+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_144942","record_id":"REC_0017923","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":28,"tmb_mutations_per_mb":13.6,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":3.5,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.0,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.819876+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_216254","record_id":"REC_0017924","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":6.3,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":5.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.820788+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_629027","record_id":"REC_0017925","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":81,"sex":"female","ecog_performance_status":2,"smoking_pack_years":17,"primary_tumor_size_cm":7.4,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.821604+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_220326","record_id":"REC_0017926","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":19,"tmb_mutations_per_mb":6.9,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":2,"smoking_pack_years":48,"primary_tumor_size_cm":5.3,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":17.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.822387+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_599613","record_id":"REC_0017927","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":7.0,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":2,"smoking_pack_years":53,"primary_tumor_size_cm":6.5,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":8.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.823218+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_433207","record_id":"REC_0017928","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":6.1,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":6.5,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":31.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.824389+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_867692","record_id":"REC_0017929","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":18,"tmb_mutations_per_mb":7.6,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":0,"smoking_pack_years":58,"primary_tumor_size_cm":5.7,"metastatic_sites_count":3,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.825293+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_602398","record_id":"REC_0017930","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":10.9,"age_at_diagnosis":75,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":5.8,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":18.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.826104+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_448352","record_id":"REC_0017931","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":14.2,"age_at_diagnosis":82,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":5.0,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.826843+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_155748","record_id":"REC_0017932","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":31,"tmb_mutations_per_mb":5.7,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":66,"primary_tumor_size_cm":7.7,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":14.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.827606+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_413647","record_id":"REC_0017933","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":19,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":5,"primary_tumor_size_cm":6.9,"metastatic_sites_count":5,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.828487+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_556385","record_id":"REC_0017934","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":23,"tmb_mutations_per_mb":17.8,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":3.9,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":20.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.829322+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_727551","record_id":"REC_0017935","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":20,"tmb_mutations_per_mb":9.2,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":14,"primary_tumor_size_cm":5.9,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":21.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.830153+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_762110","record_id":"REC_0017936","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":9.0,"age_at_diagnosis":70,"sex":"male","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":6.3,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":8.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.830911+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_759584","record_id":"REC_0017937","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":14,"tmb_mutations_per_mb":11.5,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":6.1,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.831840+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_213381","record_id":"REC_0017938","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":31,"tmb_mutations_per_mb":6.9,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":40,"primary_tumor_size_cm":7.7,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":19.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.832773+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_457608","record_id":"REC_0017939","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":19.4,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":17,"primary_tumor_size_cm":6.2,"metastatic_sites_count":7,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.833623+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_365354","record_id":"REC_0017940","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":28,"tmb_mutations_per_mb":13.6,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":2,"smoking_pack_years":11,"primary_tumor_size_cm":5.8,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":9.7,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.834377+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_752400","record_id":"REC_0017941","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":10.3,"age_at_diagnosis":65,"sex":"male","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":6.0,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":18.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.835440+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_490995","record_id":"REC_0017942","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ALK fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":10.3,"age_at_diagnosis":82,"sex":"male","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":4.4,"metastatic_sites_count":0,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":11.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.836316+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_870212","record_id":"REC_0017943","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":29,"tmb_mutations_per_mb":20.1,"age_at_diagnosis":67,"sex":"male","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":5.1,"metastatic_sites_count":1,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":19.9,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.837131+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_960615","record_id":"REC_0017944","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":8.9,"age_at_diagnosis":68,"sex":"male","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":7.2,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.837889+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_973921","record_id":"REC_0017945","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":26,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":0,"smoking_pack_years":23,"primary_tumor_size_cm":2.9,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":16.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.838600+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_174294","record_id":"REC_0017946","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":14.8,"age_at_diagnosis":54,"sex":"female","ecog_performance_status":0,"smoking_pack_years":21,"primary_tumor_size_cm":5.0,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":25.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.839360+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_568217","record_id":"REC_0017947","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":9.1,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":6.6,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":9.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.840180+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_871413","record_id":"REC_0017948","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":13.1,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":6.5,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.840927+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_596332","record_id":"REC_0017949","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":20,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":32,"primary_tumor_size_cm":6.3,"metastatic_sites_count":1,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":29.8,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.841621+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_810832","record_id":"REC_0017950","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"KRAS G12C","pd_l1_tps_percent":25,"tmb_mutations_per_mb":16.1,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":5.4,"metastatic_sites_count":0,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":20.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.842414+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_343963","record_id":"REC_0017951","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":13.2,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":0,"smoking_pack_years":13,"primary_tumor_size_cm":6.0,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":9.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.843136+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_943678","record_id":"REC_0017952","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":29,"tmb_mutations_per_mb":6.1,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":1,"smoking_pack_years":50,"primary_tumor_size_cm":7.5,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":4.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.843821+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_151547","record_id":"REC_0017953","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":12.9,"age_at_diagnosis":55,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":4.4,"metastatic_sites_count":7,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.844678+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_961761","record_id":"REC_0017954","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":11.1,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":6.0,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.845663+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_407745","record_id":"REC_0017955","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":9,"primary_tumor_size_cm":7.1,"metastatic_sites_count":6,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.846358+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_938613","record_id":"REC_0017956","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":13.5,"age_at_diagnosis":51,"sex":"female","ecog_performance_status":0,"smoking_pack_years":4,"primary_tumor_size_cm":5.5,"metastatic_sites_count":9,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":12.2,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.847049+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_176184","record_id":"REC_0017957","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":22,"tmb_mutations_per_mb":15.6,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":1,"smoking_pack_years":11,"primary_tumor_size_cm":6.0,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.847773+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_231360","record_id":"REC_0017958","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":7.3,"age_at_diagnosis":51,"sex":"female","ecog_performance_status":0,"smoking_pack_years":26,"primary_tumor_size_cm":5.9,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":15.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.848627+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_855902","record_id":"REC_0017959","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":19,"tmb_mutations_per_mb":14.6,"age_at_diagnosis":67,"sex":"female","ecog_performance_status":0,"smoking_pack_years":8,"primary_tumor_size_cm":6.7,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":12.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.849479+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_844810","record_id":"REC_0017960","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":20.0,"age_at_diagnosis":51,"sex":"female","ecog_performance_status":0,"smoking_pack_years":18,"primary_tumor_size_cm":5.1,"metastatic_sites_count":0,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.850303+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_325827","record_id":"REC_0017961","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":18,"tmb_mutations_per_mb":12.6,"age_at_diagnosis":58,"sex":"male","ecog_performance_status":0,"smoking_pack_years":16,"primary_tumor_size_cm":6.6,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":8.3,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.851070+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_831547","record_id":"REC_0017962","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":7.7,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":1,"smoking_pack_years":19,"primary_tumor_size_cm":4.7,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":13.7,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.851824+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_803101","record_id":"REC_0017963","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":26,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":7.7,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.852685+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_184317","record_id":"REC_0017964","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":31,"tmb_mutations_per_mb":15.2,"age_at_diagnosis":56,"sex":"male","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":5.3,"metastatic_sites_count":10,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.853520+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_106876","record_id":"REC_0017965","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":27,"tmb_mutations_per_mb":4.9,"age_at_diagnosis":75,"sex":"male","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":7.2,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":21.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.854287+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_699191","record_id":"REC_0017966","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":18,"tmb_mutations_per_mb":12.7,"age_at_diagnosis":62,"sex":"male","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":5.9,"metastatic_sites_count":6,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.855048+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_570951","record_id":"REC_0017967","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":52,"sex":"female","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":5.1,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":23.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.856016+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_702217","record_id":"REC_0017968","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":5.8,"age_at_diagnosis":57,"sex":"male","ecog_performance_status":1,"smoking_pack_years":57,"primary_tumor_size_cm":3.7,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":10.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.856956+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_996539","record_id":"REC_0017969","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"III","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":7.1,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":0,"primary_tumor_size_cm":5.8,"metastatic_sites_count":0,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":37.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.857709+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_912905","record_id":"REC_0017970","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":4.8,"age_at_diagnosis":76,"sex":"female","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":5.1,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":21.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.858439+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_149471","record_id":"REC_0017971","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":24,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":62,"sex":"female","ecog_performance_status":0,"smoking_pack_years":10,"primary_tumor_size_cm":4.9,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":16.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.859218+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_870041","record_id":"REC_0017972","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":30,"tmb_mutations_per_mb":10.2,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":1,"smoking_pack_years":21,"primary_tumor_size_cm":6.7,"metastatic_sites_count":8,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":10.4,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.859954+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_257918","record_id":"REC_0017973","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":9.8,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":18,"primary_tumor_size_cm":3.6,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":7.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.860772+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_317867","record_id":"REC_0017974","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":21,"tmb_mutations_per_mb":4.2,"age_at_diagnosis":60,"sex":"male","ecog_performance_status":0,"smoking_pack_years":19,"primary_tumor_size_cm":5.8,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":9.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.861516+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_485829","record_id":"REC_0017975","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":70,"sex":"female","ecog_performance_status":2,"smoking_pack_years":10,"primary_tumor_size_cm":3.6,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":27.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.862298+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_998224","record_id":"REC_0017976","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":26,"tmb_mutations_per_mb":10.7,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":7.0,"metastatic_sites_count":8,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.2,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.863051+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_410145","record_id":"REC_0017977","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":20,"tmb_mutations_per_mb":3.7,"age_at_diagnosis":77,"sex":"female","ecog_performance_status":1,"smoking_pack_years":9,"primary_tumor_size_cm":4.8,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":11.5,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.863810+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_178795","record_id":"REC_0017978","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":10.1,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":7.8,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":14.8,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.864682+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_612323","record_id":"REC_0017979","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":31,"tmb_mutations_per_mb":8.7,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":38,"primary_tumor_size_cm":9.2,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":17.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.865465+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_964365","record_id":"REC_0017980","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":17,"tmb_mutations_per_mb":8.9,"age_at_diagnosis":71,"sex":"male","ecog_performance_status":2,"smoking_pack_years":12,"primary_tumor_size_cm":4.2,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.866508+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_633808","record_id":"REC_0017981","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":5.0,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":49,"primary_tumor_size_cm":3.9,"metastatic_sites_count":1,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":5.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.867290+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_158846","record_id":"REC_0017982","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":15.2,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":0,"smoking_pack_years":6,"primary_tumor_size_cm":3.8,"metastatic_sites_count":5,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":4.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.868132+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_796133","record_id":"REC_0017983","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":19,"tmb_mutations_per_mb":10.5,"age_at_diagnosis":53,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":7.0,"metastatic_sites_count":1,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.3,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.868912+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_210153","record_id":"REC_0017984","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":13.9,"age_at_diagnosis":58,"sex":"female","ecog_performance_status":1,"smoking_pack_years":25,"primary_tumor_size_cm":6.4,"metastatic_sites_count":4,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":4.9,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.869711+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_982997","record_id":"REC_0017985","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":32,"tmb_mutations_per_mb":9.4,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":4.9,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.2,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.870454+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_349509","record_id":"REC_0017986","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":21,"tmb_mutations_per_mb":8.2,"age_at_diagnosis":80,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":4.3,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":10.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.871217+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_961976","record_id":"REC_0017987","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":11,"tmb_mutations_per_mb":11.7,"age_at_diagnosis":78,"sex":"female","ecog_performance_status":1,"smoking_pack_years":22,"primary_tumor_size_cm":5.1,"metastatic_sites_count":8,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":6.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.871975+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_759067","record_id":"REC_0017988","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":29,"tmb_mutations_per_mb":3.9,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":16,"primary_tumor_size_cm":4.8,"metastatic_sites_count":7,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":15.9,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.872865+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_467931","record_id":"REC_0017989","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":8.0,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":5.5,"metastatic_sites_count":4,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":4.0,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.873616+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_294036","record_id":"REC_0017990","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":3.8,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":4.2,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":15.4,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.874337+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_188580","record_id":"REC_0017991","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":10.8,"age_at_diagnosis":64,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":4.2,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":21.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.875102+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_184551","record_id":"REC_0017992","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":19,"tmb_mutations_per_mb":9.7,"age_at_diagnosis":69,"sex":"male","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":7.1,"metastatic_sites_count":2,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.875861+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_615049","record_id":"REC_0017993","cancer_type":"Non-small cell lung cancer","histology":"Large cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":19,"tmb_mutations_per_mb":8.6,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":7.2,"metastatic_sites_count":2,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":17.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.876954+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_416827","record_id":"REC_0017994","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":28,"tmb_mutations_per_mb":7.2,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":0,"smoking_pack_years":73,"primary_tumor_size_cm":6.6,"metastatic_sites_count":7,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":4.0,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.877763+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_786419","record_id":"REC_0017995","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":8.8,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":1,"smoking_pack_years":20,"primary_tumor_size_cm":6.7,"metastatic_sites_count":2,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.878478+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_300028","record_id":"REC_0017996","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":25,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":72,"sex":"female","ecog_performance_status":1,"smoking_pack_years":29,"primary_tumor_size_cm":6.8,"metastatic_sites_count":6,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":9.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.879230+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_543188","record_id":"REC_0017997","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":24,"tmb_mutations_per_mb":15.7,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":22,"primary_tumor_size_cm":5.7,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":18.5,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.880021+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_440803","record_id":"REC_0017998","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":18.8,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":14,"primary_tumor_size_cm":6.0,"metastatic_sites_count":3,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":14.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.881000+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_835549","record_id":"REC_0017999","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":21,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":63,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":5.5,"metastatic_sites_count":4,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":11.3,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.881726+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_276823","record_id":"REC_0018000","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":22,"tmb_mutations_per_mb":13.1,"age_at_diagnosis":61,"sex":"male","ecog_performance_status":1,"smoking_pack_years":23,"primary_tumor_size_cm":5.7,"metastatic_sites_count":9,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":13.8,"censored":false,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.882523+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_378864","record_id":"REC_0018001","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"KRAS G12C","pd_l1_tps_percent":17,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":8,"primary_tumor_size_cm":5.2,"metastatic_sites_count":3,"first_line_regimen":"sotorasib 960 mg daily","overall_survival_months":7.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.883293+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_760848","record_id":"REC_0018002","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVA","driver_mutation":"None","pd_l1_tps_percent":21,"tmb_mutations_per_mb":5.4,"age_at_diagnosis":83,"sex":"female","ecog_performance_status":1,"smoking_pack_years":28,"primary_tumor_size_cm":7.3,"metastatic_sites_count":2,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":19.2,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.884040+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_899283","record_id":"REC_0018003","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":5.7,"age_at_diagnosis":61,"sex":"female","ecog_performance_status":1,"smoking_pack_years":17,"primary_tumor_size_cm":5.2,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":12.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.884843+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_248484","record_id":"REC_0018004","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":31,"tmb_mutations_per_mb":11.2,"age_at_diagnosis":71,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":5.2,"metastatic_sites_count":4,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":16.1,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.885605+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_549960","record_id":"REC_0018005","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR L858R","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.5,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":1,"smoking_pack_years":13,"primary_tumor_size_cm":4.7,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":11.6,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.886327+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_765668","record_id":"REC_0018006","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":25,"tmb_mutations_per_mb":12.3,"age_at_diagnosis":68,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":5.7,"metastatic_sites_count":7,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":10.7,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.887333+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_696035","record_id":"REC_0018007","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":21,"tmb_mutations_per_mb":15.9,"age_at_diagnosis":73,"sex":"female","ecog_performance_status":1,"smoking_pack_years":10,"primary_tumor_size_cm":3.9,"metastatic_sites_count":1,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":16.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.888233+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_971278","record_id":"REC_0018008","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":23,"tmb_mutations_per_mb":10.0,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":7.3,"metastatic_sites_count":8,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":13.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.889046+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_235376","record_id":"REC_0018009","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":10.0,"age_at_diagnosis":60,"sex":"female","ecog_performance_status":1,"smoking_pack_years":12,"primary_tumor_size_cm":6.7,"metastatic_sites_count":2,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":11.9,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.889827+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_964887","record_id":"REC_0018010","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVA","driver_mutation":"ROS1 fusion","pd_l1_tps_percent":29,"tmb_mutations_per_mb":11.1,"age_at_diagnosis":74,"sex":"female","ecog_performance_status":2,"smoking_pack_years":13,"primary_tumor_size_cm":4.8,"metastatic_sites_count":1,"first_line_regimen":"entrectinib 600 mg daily","overall_survival_months":23.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.890523+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_578412","record_id":"REC_0018011","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR L858R","pd_l1_tps_percent":18,"tmb_mutations_per_mb":10.6,"age_at_diagnosis":55,"sex":"male","ecog_performance_status":0,"smoking_pack_years":12,"primary_tumor_size_cm":6.6,"metastatic_sites_count":6,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":7.7,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.891198+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_244283","record_id":"REC_0018012","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":22,"tmb_mutations_per_mb":5.9,"age_at_diagnosis":66,"sex":"female","ecog_performance_status":0,"smoking_pack_years":37,"primary_tumor_size_cm":4.7,"metastatic_sites_count":5,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":13.6,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.891867+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_860784","record_id":"REC_0018013","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"EGFR exon 19 deletion","pd_l1_tps_percent":27,"tmb_mutations_per_mb":12.0,"age_at_diagnosis":43,"sex":"female","ecog_performance_status":0,"smoking_pack_years":15,"primary_tumor_size_cm":5.1,"metastatic_sites_count":5,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":13.8,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.892741+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_830377","record_id":"REC_0018014","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None (PD-L1 high)","pd_l1_tps_percent":28,"tmb_mutations_per_mb":6.5,"age_at_diagnosis":69,"sex":"female","ecog_performance_status":1,"smoking_pack_years":15,"primary_tumor_size_cm":6.8,"metastatic_sites_count":6,"first_line_regimen":"pembrolizumab 200 mg q3w","overall_survival_months":7.3,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.893492+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_626005","record_id":"REC_0018015","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":9.3,"age_at_diagnosis":59,"sex":"female","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":5.8,"metastatic_sites_count":8,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":16.1,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.894258+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_772051","record_id":"REC_0018016","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"III","driver_mutation":"EGFR L858R","pd_l1_tps_percent":19,"tmb_mutations_per_mb":9.8,"age_at_diagnosis":53,"sex":"female","ecog_performance_status":0,"smoking_pack_years":9,"primary_tumor_size_cm":6.8,"metastatic_sites_count":0,"first_line_regimen":"osimertinib 80 mg daily","overall_survival_months":54.1,"censored":false,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.895003+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_363420","record_id":"REC_0018017","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","driver_mutation":"None","pd_l1_tps_percent":24,"tmb_mutations_per_mb":4.5,"age_at_diagnosis":64,"sex":"male","ecog_performance_status":0,"smoking_pack_years":51,"primary_tumor_size_cm":4.9,"metastatic_sites_count":4,"first_line_regimen":"carboplatin + paclitaxel + pembrolizumab","overall_survival_months":7.6,"censored":true,"msi_status":"MSS","record_generation_timestamp":"2026-03-15T05:36:02.895751+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}
{"patient_id":"ANODE_848091","record_id":"REC_0018018","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","driver_mutation":"ALK fusion","pd_l1_tps_percent":28,"tmb_mutations_per_mb":12.8,"age_at_diagnosis":63,"sex":"male","ecog_performance_status":0,"smoking_pack_years":20,"primary_tumor_size_cm":5.0,"metastatic_sites_count":5,"first_line_regimen":"alectinib 600 mg BID","overall_survival_months":15.4,"censored":true,"msi_status":"MSI-H","record_generation_timestamp":"2026-03-15T05:36:02.896580+00:00","synthetic_source":"Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied)"}